Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,References,Document Type,Source,EID
"Berhanu W.M., Masunov A.E.","Atomistic mechanism of polyphenol amyloid aggregation inhibitors: Molecular dynamics study of Curcumin, Exifone, and Myricetin interaction with the segment of tau peptide oligomer",2015,"Journal of Biomolecular Structure and Dynamics","33","7",,"1399","1411",,,10.1080/07391102.2014.951689,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928602022&partnerID=40&md5=7d55099e83de3be8536ecc7ae8d092ff","NanoScience Technology Center, Department of Chemistry, University of Central FloridaOrlando, FL, United States","Berhanu, W.M., NanoScience Technology Center, Department of Chemistry, University of Central FloridaOrlando, FL, United States; Masunov, A.E., NanoScience Technology Center, Department of Chemistry, University of Central FloridaOrlando, FL, United States","Amyloid fibrils are highly ordered protein aggregates associated with many diseases affecting millions of people worldwide. Polyphenols such as Curcumin, Exifone, and Myricetin exhibit modest inhibition toward fibril formation of tau peptide which is associated with Alzheimers disease. However, the molecular mechanisms of this inhibition remain elusive. We investigated the binding of three polyphenol molecules to the protofibrils of an amyloidogenic fragment VQIVYK of tau peptide by molecular dynamics simulations in explicit solvent. We find that polyphenols induce conformational changes in the oligomer aggregate. These changes disrupt the amyloid H bonding, perturbing the aggregate. While the structural evolution of the control oligomer with no ligand is limited to the twisting of the β-sheets without their disassembly, the presence of polyphenol molecule pushes the β-sheets apart, and leads to a loosely packed structure where two of four β-sheets dissociate in each of the three cases considered here. The H-bonding capacity of polyphenols is responsible for the observed behavior. The calculated binding free energies and its individual components enabled better understanding of the binding. Results indicated that the contribution from Van der Waals interactions is more significant than electrostatic contribution to the binding. The findings from this study are expected to assist in the development of aggregation inhibitors. Significant binding between polyphenols and aggregate oligomer identified in our simulations confirms the previous experimental observations in which polyphenols refold the tau peptide without forming covalent bonds. © 2014 Taylor & Francis.","aggregation inhibitors; amyloid fibril; binding free energy; Curcumin; Exifone; hydrogen bond; polyphenols; MM-PBSA; molecular dynamic simulation; Myricetin","Akaishi, T., Morimoto, T., Shibao, M., Watanabe, S., Sakai-Kato, K., Abe, K., Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein (2008) Neuroscience Letters, 444, pp. 280-285; Armstrong, A.H., Chen, J., McKoy, A.F., Hecht, M.H., Mutations that replace aromatic side chains promote aggregation of the alzheimer's a beta peptide (2011) Biochemistry, (50), pp. 4058-4067; Bastianetto, S., Krantic, S., Quirion, R., Polyphenols as potential inhibitors of amyloid aggregation and toxicity: Possible significance to alzheimer's disease (2008) Mini-reviews in Medicinal Chemistry, 8, pp. 429-435; Von Bergen, P.F.M., Biernat, P., Heberle, J., Mandelkow, E.-M., Mandelkow, E., Assembly of ? Protein into alzheimer paired helical filaments depends on a local sequence motif (306vqivyk311) forming ? Structure (2000) Proceedings of the National Academy of Sciences, 97, pp. 5129-5134; Berhanu, W.M., Masunov, A.E., Natural polyphenols as inhibitors of amyloid aggregation. Molecular dynamics study of gnnqqny heptapeptide decamer (2010) Biophysical Chemistry, (149), pp. 12-21; Berhanu, W.M., Masunov, A.E., Can molecular dynamics simulations assist in design of specific inhibitors and imaging agents of amyloid aggregation? Structure, stability and free energy predictions for amyloid oligomers of vqivyk, mvggvv and lyqlen (2011) Journal of Molecular Modeling, 17, pp. 2423-2442; Berhanu, W.M., Masunov, A.E., Molecular dynamic simulation of wild type and mutants of the polymorphic amyloid nnqntf segments of elk prion: Structural stability and thermodynamic of association (2011) Biopolymers, 95, pp. 573-590; Berhanu, W.M., Masunov, A.E., Alternative packing modes leading to amyloid polymorphism in five fragments studied with molecular dynamics (2012) Biopolymers, 98, pp. 131-144; Berhanu, W.M., Masunov, A.E., Controlling the aggregation and rate of release in order to improve insulin formulation: Molecular dynamics study of full-length insulin amyloid oligomer models (2012) Journal of Molecular Modeling, 18, pp. 1129-1142; Berhanu, W.M., Masunov, A.E., Unique example of amyloid aggregates stabilized by main chain h-bond instead of the steric zipper: Molecular dynamics study of the amyloidogenic segment of amylin wild-type and mutants (2012) Journal of Molecular Modeling, 18, pp. 891-903; Berhanu, W.M., Masunov, A.E., The atomic level interaction of polyphenols with the amyloid oligomer aggregate, a molecular dynamic guidance for rational drug design (2013) Polyphenols in Human Health and Disease, pp. 59-70. , In R. R. Watson (Ed.). Oxford Academic Press; Berhanu, W.M., Masunov, A.E., Full length amylin oligomer aggregation: Insights from molecular dynamics simulations and implications for design of aggregation inhibitors (2014) Journal of Biomolecular Structure & Dynamics, 32, pp. 1651-1669; Cardenas-Jiron, G.I., Masunov, A., Dannenberg, J.J., Molecular orbital study of crystalline p-benzoquinone (1999) Journal of Physical Chemistry A, 103, pp. 7042-7046; Case, D.A., Darden, T.A., Cheatham, I., Simmerling, T.E., Wang, C., Duke, J., Kollman, P.A., (2010) AMBER 11, , San Francisco, CA University of California San Francisco; Chen, Y., He, Y.J., Wu, M.Y., Yan, G.W., Li, Y.X., Zhang, J., Chen, H.F., Insight into the stability of cross-beta amyloid fibril from molecular dynamics simulation (2010) Biopolymers, 93, pp. 578-586; Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annual Review of Biochemistry, 75, pp. 333-366; Convertino, M., Pellarin, R., Catto, M., Carotti, A., Caflisch, A., 9,10-Anthraquinone hinders beta-aggregation: How does a small molecule interfere with A beta-peptide amyloid fibrillation? (2009) Protein Science, (18), pp. 792-800; Darden, T., York, D., Pedersen, L., Particle mesh ewald-an n.log(n) method for ewald sums in large systems (1993) Journal of Chemical Physics, 98, pp. 10089-10092; De Simone, A., Esposito, L., Pedone, C., Vitagliano, L., Insights into stability and toxicity of amyloid-like oligomers by replica exchange molecular dynamics analyses (2008) Biophysical Journal, 95, pp. 1965-1973; Fabiola, F., Bertram, R., Korostelev, A., Chapman, M.S., An improved hydrogen bond potential: Impact on medium resolution protein structures (2002) Protein Science, 11, pp. 1415-1423; Frisch, M.J.T.G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Montgomery, J.A., Jr., Pople, J.A., (2004) Gaussian 03, , Wallingford CT: Gaussian Inc; Gilson, M.K., Zhou, H.X., Calculation of proteinligand binding affinities (2007) Annual Review of Biophysics and Biomolecular Structure, 36, pp. 21-42; Gohlke, H., Kiel, C., Case, D.A., Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the ras-raf and ras-ralgds complexes (2003) Journal of Molecular Biology, 330, pp. 891-913; Gutierrez, L.J., Enriz, R.D., Baldoni, H.A., Structural and thermodynamic characteristics of the exosite binding pocket on the human bace1: A molecular modeling approach (2010) Journal of Physical Chemistry A, 114, pp. 10261-10269; He, J., Xing, Y.F., Huang, B., Zhang, Y.Z., Zeng, C.M., Tea catechins induce the conversion of preformed lysozyme amyloid fibrils to amorphous aggregates (2009) Journal of Agricultural and Food Chemistry, 57, pp. 11391-11396; Ho, L., Pasinetti, G.M., Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding (2010) Expert Review of Proteomics, (7), pp. 579-589; Ho, L., Yemul, S., Wang, J., Pasinettia, G.M., Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies (2009) Journal of Alzheimers Disease, 16, pp. 433-439; Humphrey, W., Dalke, A., Schulten, K., Vmd: Visual molecular dynamics (1996) Journal of Molecular Graphics, 14, pp. 33-38; Kim, H., Park, B.S., Lee, K.G., Choi, C.Y., Jang, S.S., Kim, Y.H., Lee, S.E., Effects of naturally occurring compounds on fibril formation and oxidative stress of ?-amyloid (2005) Journal of Agricultural and Food Chemistry, 53, pp. 8537-8541; Kollman, P.A., Massova, I., Reyes, C., Kuhn, B., Huo, S.H., Chong, L., Cheatham, T.E., Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models (2000) Accounts of Chemical Research, 33, pp. 889-897; Kuchma, M.H., Komanski, C.B., Colon, J., Teblum, A., Masunov, A.E., Seal, S., Baker, C.H., Phosphate ester hydrolysis of biologically relevant molecules by cerium oxide nanoparticles (2010) Nanomedicine-Nanotechnology Biology and Medicine, 6, pp. 738-744; Landau, M., Sawaya, M.R., Faull, K.F., Laganowsky, A., Jiang, L., Sievers, S.A., Eisenberg, D., Towards a pharmacophore for amyloid (2011) PLoS Biology, (9). , Article Number e1001080; Lemkul, J.A., Bevan, D.R., Destabilizing alzheimer's a 42 protofibrils with morin: Mechanistic insights from molecular dynamics simulations (2010) Biochemistry, (49), pp. 3935-3946; Leonidov, N.B., Zorkii, P.M., Masunov, A.E., Gladkikh, O.P., Belskii, V.K., Dzyabchenko, A.V., Ivanov, S.A., Structure and biononequivalence of methyluracyl polymorphous forms (1993) Zhurnal Fizicheskoi Khimii, 67, pp. 2464-2468; Li, D.W., Mohanty, S., Irback, A., Huo, S.H., Formation and growth of oligomers: A monte carlo study of an amyloid tau fragment (2008) PLoS Computational Biology, 9, p. e1000238; Massova, I., Kollman, P.A., Computational alanine scanning to probe protein?protein interactions: A novel approach to evaluate binding free energies (1999) Journal of the American Chemical Society, 121, pp. 8133-8143; Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T., Hasegawa, M., Small molecule inhibitors of ?-synuclein filament assembly (2006) Biochemistry, 45, pp. 6085-6094; Masunov, A.E., Zorkii, P.M., Geometric characteristics of halogen-halogen intermolecular contacts in organiccrystals (1992) Zhurnal Fizicheskoi Khimii, 66, pp. 60-69; Mikhailov, I.A., Belfield, K.D., Masunov, A.E., Dft-based methods in the design of two-photon operated molecular switches (2009) Journal of Physical Chemistry A, 113, pp. 7080-7089; Masunov, A.E., Grishchenko, S.I., Zorkii, P.M., Effect of specific intermolecular interactions on crystallinestructure-uracyl derivatives and analogs (1993) Zhurnal Fizicheskoi Khimii, 67, pp. 221-239; Miyamoto, S., Kollman, P.A., What determines the strength of noncovalent association of ligands to proteins in aqueous-solution, in (1993) Proceedings of the National Academy of Sciences of the United States of America, 90, pp. 8402-8406; Nishiura, C., Takeuchi, K., Minoura, K., Sumida, M., Taniguchi, T., Tomoo, K., Ishida, T., Importance of tyr310 residue in the third repeat of microtubule binding domain for filament formation of tau protein (2010) Journal of Biochemistry, 147, pp. 405-414; Ono, K., Yamada, M., Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro (2006) Journal of Neurochemistry, 97, pp. 105-115; Plumley, J.A., Dannenberg, J.J., The importance of hydrogen bonding between the glutamine side chains to the formation of amyloid vqivyk parallel ?-sheets: An oniom dft/am1 study (2010) Journal of the American Chemical Society, 132, pp. 1758-1759; Plumley, J.A., Dannenberg, J.J., Comparison of beta-sheets of capped polyalanine with those of the tauamyloid structures vqivyk and vqiink. A density functional theory study (2011) Journal of Physical Chemistry B, 115, pp. 10560-10566; Porat, Y., Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism (2006) Chemical Biology & Drug Design, 67, pp. 27-37; Raman, E.P., Takeda, T., Klimov, D.K., Molecular dynamics simulations of ibuprofen binding to a ? Peptides (2009) Biophysical Journal, 97, pp. 2070-2079; Ryckaert, J.P., Ciccotti, G., Berendsen, H.J.C., Numerical-integration of cartesian equations of motion of a system with constraints-molecular-dynamics of n-alkanes (1977) Journal of Computational Physics, 23, pp. 327-341; Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., Eisenberg, D., Atomic structures of amyloid cross-? Spines reveal varied steric zippers (2007) Nature, 447, pp. 453-457; Shoval, H., Lichtenberg, D., Gazit, E., The molecular mechanisms of the anti-amyloid effects of phenols (2007) Amyloid-Journal of Protein Folding Disorders, 14, pp. 73-87; Takeda, T., Chang, W.L.E., Raman, E.P., Klimov, D.K., Binding of nonsteroidal anti-inflammatory drugs to a ? Fibril (2010) Proteins-Structure Function and Bioinformatics, 78, pp. 2849-2860; Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., Hasegawa, M., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins (2005) Journal of Biological Chemistry, 280, pp. 7614-7623; Toro, C., Thibert, A., De Boni, L., Masunov, A.E., Hernandez, F.E., Fluorescence emission of disperse red 1 in solution at room temperature (2008) Journal of Physical Chemistry B, 112, pp. 929-937; Vitagliano, L., Stanzione, F., De Simone, A., Esposito, L., Dynamics and stability of amyloid-like steric zipper assemblies with hydrophobic dry interfaces (2009) Biopolymers, 91, pp. 1161-1171; Wang, J.M., Wolf, R.M., Caldwell, J.W., Kollman, P.A., Case, D.A., Development and testing of a general amber force field (2004) Journal of Computational Chemistry, 25, pp. 1157-1174; Wang, J., Santa-Maria, I., Ho, L., Ksiezak-Reding, H., Ono, K., Teplow, D.B., Pasinetti, G.M., Grape derived polyphenols attenuate tau neuropathology in a mouse model of alzheimer's disease (2010) Journal of Alzheimers Disease, 22, pp. 653-661; Wiltzius, J.J.W., Landau, M., Nelson, R., Sawaya, M.R., Apostol, M.I., Goldschmidt, L., Eisenberg, D., Molecular mechanisms for protein-encoded inheritance (2009) Nature Structural & Molecular Biology, (16), pp. 973-978; Wu, C., Wang, Z.X., Lei, H.X., Zhang, W., Duan, Y., Dual binding modes of congo red to amyloid protofibril surface observed in molecular dynamics simulations (2007) Journal of the American Chemical Society, 129, pp. 1225-1232; Wu, C., Wang, Z.X., Lei, H.X., Duan, Y., Bowers, M.T., Shea, J.E., The binding of thioflavin t and its neutral analog bta-1 to protofibrils of the alzheimer's disease a16-22 peptide probed by molecular dynamics simulations (2008) Journal of Molecular Biology, 384, pp. 718-729; Yanagisawa, D., Shirai, N., Amatsubo, T., Taguchi, H., Hirao, K., Urushitani, M., Tooyama, I., Relationship between the tautomeric structures of curcumin derivatives and their a-binding activities in the context of therapies for alzheimer's disease (2010) Biomaterials, 31, pp. 4179-4185; Yang, F.S., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Cole, G.M., Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo (2005) Journal of Biological Chemistry, 280, pp. 5892-5901; Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F.M., Fink, A.L., The flavonoid baicalein inhibits fibrillation of synuclein and disaggregates existing fibrils (2004) Journal of Biological Chemistry, 279, pp. 26846-26857; Zhu, J.T.T., Choi, R.C.Y., Chu, G.K.Y., Cheung, A.W.H., Gao, Q.T., Li, J., Tsim, K.W.K., Flavonoids possess neuroprotective effects on cultured pheochromocytoma pc12 cells: A comparison of different flavonoids in activating estrogenic effect and in preventing ?-amyloid-induced cell death (2007) Journal of Agricultural and Food Chemistry, 55, pp. 2438-2445",Article,Scopus,2-s2.0-84928602022
"Gamberini M.T., Rodrigues D.S., Rodrigues D., Pontes V.B.","Effects of the aqueous extract of Pimpinella anisum L. seeds on exploratory activity and emotional behavior in rats using the open field and elevated plus maze tests",2015,"Journal of Ethnopharmacology","168",,,"45","49",,,10.1016/j.jep.2015.03.053,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927537705&partnerID=40&md5=fbc1fa8e3d1fa1fba8f5deb881226b1f","Department of Physiological Sciences of the Santa Casa de Sao Paulo, School of Medical Sciences, R. Dr. Cesario Mota Junior, 112, Vila BuarqueSão Paulo, SP, Brazil; Instituto de Botânica de São Paulo, Centro de Pesquisa Jardim Botânico e Reservas, Av. Miguel Estefano, 3031, Vila Água FundaSão Paulo, SP, Brazil; Santa Casa de Sao Paulo School of Medical Sciences, R. Dr. Cesário Mota Júnior, 61, Vila BuarqueSão Paulo, SP, Brazil; A.C. Camargo Cancer Center, Rua Professor Antônio Prudente, 211, LiberdadeSão Paulo, SP, Brazil","Gamberini, M.T., Department of Physiological Sciences of the Santa Casa de Sao Paulo, School of Medical Sciences, R. Dr. Cesario Mota Junior, 112, Vila BuarqueSão Paulo, SP, Brazil; Rodrigues, D.S., Instituto de Botânica de São Paulo, Centro de Pesquisa Jardim Botânico e Reservas, Av. Miguel Estefano, 3031, Vila Água FundaSão Paulo, SP, Brazil; Rodrigues, D., Santa Casa de Sao Paulo School of Medical Sciences, R. Dr. Cesário Mota Júnior, 61, Vila BuarqueSão Paulo, SP, Brazil; Pontes, V.B., A.C. Camargo Cancer Center, Rua Professor Antônio Prudente, 211, LiberdadeSão Paulo, SP, Brazil","Ethnopharmacological relevance Pimpinella anisum L. is considered one of the first plants used for medicinal purposes. Pharmacological actions of the plant on the central nervous system have been proven but previous analyses have focused on anticonvulsant and neuroprotective actions. In traditional medicine worldwide, the use of Pimpinella is commonly recommended as a tranquilizer, although no scientific information supporting this use is available. Therefore, it was decided to investigate the central actions of the plant to observe behavioral responses, with an emphasis on the emotional component. Aim of study To investigate the effects of the aqueous extract of Pimpinella seeds on exploratory activity and emotional behavior in rats using the open field and elevated plus maze tests. Materials and methods Seeds of Pimpinella were extracted with distilled water, concentrated and freeze-dried yielding the aqueous extract(AE). Rats were divided into four groups: control(water 5 mL/kgo.) and AE 0.5, 1.0 and 2.0 g/kgo. Individual observations were performed in an open field and the parameters locomotor activity, rearing, grooming and defecation were recorded. In elevated plus maze test, rats were divided into four groups: control(water 5 mL/kgo.) and AE 0.5, 1.0 and 2.0 g/kgo. The parameters arm entries, total time spent in open and closed arms; and total number of arrivals at the end of an open or closed arm were recorded for each rat. Results Among the parameters assessed with the open field test, only rearing was reduced in the AE 0.5 g/kg group. When AE 1.0 g/kg was administered, only the initiation of exploratory activity was delayed, without impairing the animals general activity. The highest dose of AE (2.0 g/kg) induced a reduction in the animals habituation during the open field test within the same session, as evidenced by the maintenance of high levels of peripheral locomotion and rearing throughout the test. On the elevated plus maze test, no alterations were observed in the responses of the animals relative to controls for all doses tested. Conclusion These results failed to support anxiety-related central action of the aqueous extract of Pimpinella seeds, invalidating popular beliefs regarding a tranquilizing effect. However, a habituation-related central action of the extract was demonstrated, suggesting action of bioactive compounds on central learning-related areas. The characterization of effects that may interfere with cognitive processes reinforces caution regarding indiscriminate consumption of the plant, especially in individuals with deficits, such as Alzheimers Disease patients. © 2015 Elsevier Ireland Ltd.","Anxiety; Elevated plus maze; Habituation; Open field; Pimpinella anisum L.; Rats","Atta-Ur-Rahman, (2008) Studies in Natural Products Chemistry, 35, pp. 557-559. , 1st ed. Elsevier Science; Boskabady, M.H., Ramazani-Assari, M., Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s) (2001) J. Ethnopharmacol., 74, pp. 83-88; Gamberini, M.T., Bolognesi, M.L., Nasello, A.G., The modulatory role of M2 muscarinic receptor on apomorphine-induced yawning and genital grooming (2012) Neurosci. Lett., 531, pp. 91-95; Gülcin, I., Oktay, M., Kireçic, E., Küfrevioglu Ö., I., Screening of antioxidant and antimicrobial activities of (Pimpinella anisum L.) seed extracts (2003) Food Chem., 83, pp. 371-382; Karimzadeh, F., Hosseini, M., Mangeng, D., Alavi, H., Hassanzadeh, G.R., Bayat, M., Jafarian, M., Gorji, A., Anticonvulsant and neuroprotective effects of Pimpinella anisumin rat brain (2012) BMC Complement. Altern. Med., 12, p. 76; Leussis, M.P., Bolivar, V.J., Habituation in rodents: A review of behavior, neurobiology and genetics (2006) Neurosci. Biobehav. Rev., 30, pp. 1045-1064; Pellow, S., Chopin, P., File, S.E., Briley, M., Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat (1985) J. Neurosci. Methods, 14, pp. 149-167; Pourgholami, M.H., Majzoob, S., Javadi, M., Kamalinejad, M., Fanaee, G.H.R., Sayyah, M., The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice (1999) J. Ethnopharmacol., 66, pp. 211-215; Prut, L., Belzung, C., The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review (2003) Eur. J. Pharmacol., 463, pp. 3-33; Shojaii, A., Fard, M.A., Review of pharmacological properties and chemical constituents of Pimpinella anisum (2012) Int. Sch. Res. Netw. Pharm., 2012, p. 8. , ID 510795; Tepe, A.S., Tepe, B., Tradicional use, biological activity potencial and toxicity of Pimpinella species (2015) Ind. Crops Prod., 69, pp. 153-166; Thiel, C.M., Huston, J.P., Schwarting, R.K., Hippocampal acetylcholine and habituation learning (1998) Neuroscience, 85, pp. 1253-1262",Article,Scopus,2-s2.0-84927537705
"Lloret A., Fuchsberger T., Giraldo E., Vina J.","Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimers disease",2015,"Free Radical Biology and Medicine","83",,,"186","191",,1,10.1016/j.freeradbiomed.2015.02.028,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927602807&partnerID=40&md5=f88045cebafde6f6af70715a912a203a","Department of Physiology, Faculty of Medicine, University of ValenciaValencia, Spain","Lloret, A., Department of Physiology, Faculty of Medicine, University of ValenciaValencia, Spain; Fuchsberger, T., Department of Physiology, Faculty of Medicine, University of ValenciaValencia, Spain; Giraldo, E., Department of Physiology, Faculty of Medicine, University of ValenciaValencia, Spain; Viña, J., Department of Physiology, Faculty of Medicine, University of ValenciaValencia, Spain","Neurofibrillary tangles (aggregates of cytoskeletal Tau protein) and senile plaques (aggregates mainly formed by amyloid β peptide) are two landmark lesions in Alzheimers disease. Some researchers have proposed tangles, whereas others have proposed plaques, as primary lesions. For a long time, these were thought of as independent mechanisms. However, experimental evidence suggests that both lesions are intimately related. We review here some molecular pathways linking amyloid β and Tau toxicities involving, among others, glycogen synthase kinase 3β, p38, Pin1, cyclin-dependent kinase 5, and regulator of calcineurin 1. Understanding amyloid β and Tau toxicities as part of a common pathophysiological mechanism may help to find molecular targets to prevent or even treat the disease. © 2015 Elsevier Inc.","Alzheimers disease; Amyloid β; Dementia p-Tau; Free radicals; Neurodegeneration","Alzheimer, A., Über eine eigenartige Erkrankung der Hirnrinde (1907) Allg. Z. Psychiatr., 64, pp. 146-148; Glabe, C.G., Structural classification of toxic amyloid oligomers (2008) J. Biol. Chem., 283, pp. 29639-29643; Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Klein, W.L., Synaptic targeting by Alzheimers-related amyloid β oligomers (2004) J. Neurosci., 24, pp. 10191-10200; Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L., Laferla, F.M., Intraneuronal Aβ causes the onset of early Alzheimers disease-related cognitive deficits in transgenic mice (2005) Neuron, 45, pp. 675-688; Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-β protein assembly in the brain impairs memory (2006) Nature, 440, pp. 352-357; McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., Masters, C.L., Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimers disease (1999) Ann. Neurol., 46, pp. 860-866; Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline (2000) JAMA, 283, pp. 1571-1577; Deshpande, A., Mina, E., Glabe, C., Busciglio, J., Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons (2006) J. Neurosci., 26, pp. 6011-6018; Zempel, H., Thies, E., Mandelkow, E., Mandelkow, E.M., Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines (2010) J. Neurosci., 30, pp. 11938-11950; Lloret, A., Badia, M.C., Giraldo, E., Ermak, G., Alonso, M.D., Pallardó, F.V., Davies, K.J., Viña, J., Amyloid-β toxicity and Tau hyperphosphorylation are linked via RCAN1 in Alzheimers disease (2011) J. Alzheimers Dis., 27, pp. 701-709; Johansson, S., Jämsä, A., Vasänge, M., Winblad, B., Luthman, J., Cowburn, R.F., Increased Tau phosphorylation at the Ser396 epitope after amyloid β-exposure in organotypic cultures (2006) Neuroreport, 17, pp. 907-911; Chabrier, M.A., Blurton-Jones, M., Agazaryan, A.A., Nerhus, J.L., Martinez-Coria, H., Laferla, F.M., Soluble Aβ promotes wild-type Tau pathology in vivo (2012) J. Neurosci., 32, pp. 17345-17350; Choi, S.H., Kim, Y.H., Hebisch, M., Sliwinski, C., Lee, S., Davanzo, C., Chen, H., Kim, D.Y., A three-dimensional human neural cell culture model of Alzheimers disease (2014) Nature, 515, pp. 274-278; Anandatheerthavarada, H.K., Biswas, G., Robin, M.A., Avadhani, N.G., Mitochondrial targeting and a novel transmembrane arrest of Alzheimers amyloid precursor protein impairs mitochondrial function in neuronal cells (2003) J. Cell Biol., 161, pp. 41-54; Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimers disease brain is associated with mitochondrial dysfunction (2006) J. Neurosci., 26, pp. 9057-9068; Cardoso, S.M., Santana, I., Swedlow, R.H., Oliveira, C.R., Mitochondria dysfunction of Alzheimers disease cybrids enhances Aβ toxicity (2004) J. Neurochem., 89, pp. 1417-1426; Parker, Jr.W.D., Parks, J.K., Cytochrome c oxidase in Alzheimers disease brain: Purification and characterization (1995) Neurology, 45, pp. 482-486; Rhein, V., Song, X., Wiesner, A., Ittner, L.M., Baysang, G., Meier, F., Ozmen, L., Eckert, A., Amyloid-β and Tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimers disease mice (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 20057-20062; Lloret, A., Badía, M.C., Mora, N.J., Ortega, A., Pallardó, F.V., Alonso, M.D., Viña, J., Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimers disease (2008) Free Radic. Biol. Med., 44, pp. 2019-2025; Sultana, R., Butterfield, D.A., Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment (2009) J. Bioenerg. Biomembr., 41, pp. 441-446; Butterfield, D.A., Di Domenico, F., Swomley, A.M., Head, E., Perluigi, M., Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down syndrome and Alzheimers disease brain (2014) Biochem. J., 463, pp. 177-189; Butterfield, D.A., Β amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimers disease (1997) Chem. Res. Toxicol., 10, pp. 495-506; Butterfield, D.A., Drake, J., Pocernich, C., Castegna, A., Evidence of oxidative damage in Alzheimers disease brain: Central role for amyloid β peptide (2001) Trends Mol. Med., 7, pp. 548-554; Butterfield, D.A., The 2013 SFRBM discovery award: Selected discoveries from the Butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment (2014) Free Radic. Biol. Med., 74, pp. 157-174; Lauderback, C.M., Hackett, J.M., Huang, F.F., Keller, J.N., Szweda, L.I., Markesbery, W.R., Butterfield, D.A., The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimers disease brain: The role of Aβ1-42 (2001) J. Neurochem., 78, pp. 413-416; Merkwirth, C., Martinelli, P., Korwitz, A., Morbin, M., Brönneke, H.S., Jordan, S.D., Rugarli, E.I., Langer, T., Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and leads to Tau hyperphosphorylation and neurodegeneration (2012) PLoS Genet., 8, p. e1003021; Llorens-Martín, M., López-Doménech, G., Soriano, E., Avila, J., GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner (2011) PLoS One, 6, p. e27686; Melov, S., Adlard, P.A., Morten, K., Johnson, F., Golden, T.R., Hinerfeld, D., Schilling, B., Bush, A.I., Mitochondrial oxidative stress causes hyperphosphorylation of Tau (2007) PLoS One, 2, p. e536; Fuentes, J.J., Pritchard, M.A., Planas, A.M., Bosch, A., Ferrer, I., Estivill, X., A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart (1995) Hum. Mol. Genet, 4, pp. 1935-1944; Crawford, D.R., Edbauer-Nechamen, C., Schools, G.P., Salmon, S.L., Davies, J.M.S., Davies, K.J.A., Oxidant-modulated gene expression (1995) The Oxygen Paradox, pp. 327-335. , K.J.A. Davies, F. Ursini, CLEUP University Press Padova; Crawford, D.R., Leahy, K.P., Abramova, N., Lan, L., Wang, Y., Davies, K.J., Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress (1997) Arch. Biochem. Biophys., 342, pp. 6-12; Rothermel, B., Vega, R.B., Yang, J., Wu, H., Bassel-Duby, R., Williams, R.S., A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling (2000) J. Biol. Chem., 275, pp. 8719-8725; Davies, K.J.A., Ermak, G., Rothermel, B.A., Pritchard, M., Heitman, J., Ahnn, J., Henrique-Silva, F., Estivill, X., Renaming the DSCR1/Adapt78 gene family as RCAN: Regulators of calcineurin (2007) FASEB J, 21, pp. 3023-3028; Mitchell, A.N., Jayakumar, L., Koleilat, I., Qian, J., Sheehan, C., Bhoiwala, D., Hushmendy, S.F., Crawford, D.R., Brain expression of the calcineurin inhibitor RCAN1 (Adapt78) (2007) Arch. Biochem. Biophys., 467, pp. 185-192; Crawford, D.R., Leahy, K.P., Abramova, N., Lan, L., Wang, Y., Davies, K.J.A., Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress (1997) Arch. Biochem. Biophys., 342, pp. 6-12; Ermak, G., Pritchard, M.A., Dronjak, S., Niu, B., Davies, K.J.A., Do RCAN1 proteins link chronic stress with neurodegeneration? (2011) FASEB J, 25, pp. 3306-3311; Ermak, G., Davies, K.J.A., Chronic high levels of the RCAN1-1L protein may promote neurodegeneration and Alzheimer disease (2013) Free Radic. Biol. Med., 62, pp. 47-51; Norman, S.G., Johnson, G.V., Compromised mitochondrial function results in dephosphorylation of Tau through a calcium-dependent process in rat brain cerebral cortical slices (1994) Neurochem. Res., 19, pp. 1151-1158; Ermak, G., Morgan, T.E., Davies, K.J.A., Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimers disease (2001) J. Biol. Chem., 276, pp. 38787-38794; Harris, C.D., Ermak, G., Davies, K.J.A., RCAN1-1L is overexpressed in neurons of Alzheimers disease patients (2007) FEBS J., 274, pp. 1715-1724; Ermak, G., Davies, K.J.A., DSCR1 (Adapt78) - A Janus gene providing stress protection but causing Alzheimers disease? (2003) IUBMB Life, 55, pp. 29-31; Ermak, G., Sojitra, S., Yin, F., Cadenas, E., Cuervo, A.M., Davies, K.J.A., Chronic expression of RCAN1-1L induces mitochondrial autophagy and a metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells (2012) J. Biol. Chem., 287, pp. 14088-14098; Ermak, G., Harris, C.D., Battocchio, D., Davies, K.J.A., RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3β (2006) FEBS J., 273, pp. 2100-2109; Townsend, M., Mehta, T., Selkoe, D.J., Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway (2007) J. Biol. Chem., 282, pp. 33305-33312; Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Di Domenico, F., Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain (2014) Biochim. Biophys. Acta, 1842, pp. 1144-1153; Lee, H.K., Kumar, P., Fu, Q., Rosen, K.M., Querfurth, H.W., The insulin/Akt signaling pathway is targeted by intracellular β-amyloid (2009) Mol. Biol. Cell., 20, pp. 1533-1544; Ly, P., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Song, W., Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes (2013) J. Clin. Invest., 123, pp. 224-235; Engel, T., Hernández, F., Avila, J., Lucas, J.J., Full reversal of Alzheimers disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3 (2006) J. Neurosci., 26, pp. 5083-5090; Farr, S.A., Ripley, J.L., Sultana, R., Zhang, Z., Niehoff, M.L., Platt, T.L., Murphy, M.P., Butterfield, D.A., Antisense oligonucleotide against GSK-3B in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf-2 and implications for Alzheimers disease (2014) Free Radic. Biol. Med., 67, pp. 387-395; Grune, T., Botzen, D., Engels, M., Voss, P., Kaiser, B., Jung, T., Grimm, S., Davies, K.J.A., Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions (2010) Arch. Biochem. Biophys., 500, pp. 181-188; Poppek, D., Keck, S., Ermak, G., Jung, T., Stolzing, A., Ullrich, O., Grune, T., Davies, K.J.A., Phosphorylation mediates the turnover of the tau protein by the proteasome: Influence of RCAN1 and oxidative stress (2006) Biochem. J., 400, pp. 511-520; Lu, P.J., Wulf, G., Zhou, X.Z., Davies, P., Lu, K.P., The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated Tau protein (1999) Nature, 399, pp. 784-788; Liou, Y.C., Sun, A., Ryo, A., Zhou, X.Z., Yu, Z.X., Huang, H.K., Uchida, T., Lu, K.P., Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration (2003) Nature, 424, pp. 556-561; Sultana, R., Boyd-Kimball, D., Poon, H.F., Cai, J., Pierce, W.M., Klein, J.B., Markesbery, W.R., Butterfield, D.A., Oxidative modification and down-regulation of Pin1 in Alzheimers disease hippocampus: A redox proteomics analysis (2006) Neurobiol. Aging, 27, pp. 918-925; Segat, L., Pontillo, A., Annoni, G., Trabattoni, D., Vergani, C., Clerici, M., Arosio, B., Crovella, S., PIN1 promoter polymorphisms are associated with Alzheimers disease (2007) Neurobiol. Aging, 28, pp. 69-74; Wijsman, E.M., Daw, E.W., Yu, C.E., Payami, H., Steinbart, E.J., Nochlin, D., Conlon, E.M., Schellenberg, G.D., Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2 (2004) Am. J. Hum. Genet., 75, pp. 398-409; Butterfield, D.A., Abdul, H.M., Opii, W., Newman, S.F., Joshi, G., Ansari, M.A., Sultana, R., Pin1 in Alzheimers disease (2006) J. Neurochem., 98, pp. 1697-1706; Zhou, X.Z., Kops, O., Werner, A., Lu, P.J., Shen, M., Stoller, G., Küllertz, G., Lu, K.P., Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and Tau proteins (2000) Mol. Cell, 6, pp. 873-883; Pastorino, L., Sun, A., Lu, P.J., Zhou, X.Z., Balastik, M., Finn, G., Wulf, G., Lu, K.P., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production (2006) Nature, 440, pp. 528-534; Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Caselli, R.J., Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 6820-6825; Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., Demattos, R.B., Patterson, B.W., Fagan, A.M., Holtzman, D.M., Human apoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) Sci. Transl. Med., 3, pp. 89-57; Bales, K.R., Liu, F., Wu, S., Lin, S., Koger, D., Delong, C., Hansen, J.C., Paul, S.M., Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice (2009) J. Neurosci., 29, pp. 6771-6779; Lauderback, C.M., Kanski, J., Hackett, J.M., Maeda, N., Kindy, M.S., Butterfield, D.A., Apolipoprotein e modulates Alzheimers Aβ(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner (2002) Brain Res., 924, pp. 90-97; Osenkowski, P., Ye, W., Wang, R., Wolfe, M.S., Selkoe, D.J., Direct and potent regulation of γ-secretase by its lipid microenvironment (2008) J. Biol. Chem., 283, pp. 22529-22540; Aoki, K., Uchihara, T., Sanjo, N., Nakamura, A., Ikeda, K., Tsuchiya, K., Wakayama, Y., Increased expression of neuronal apolipoprotein e in human brain with cerebral infarction (2003) Stroke, 34, pp. 875-880; Brecht, W.J., Harris, F.M., Chang, S., Tesseur, I., Yu, G.Q., Xu, Q., Dee Fish, J., Huang, Y., Neuron-specific apolipoprotein e4 proteolysis is associated with increased Tau phosphorylation in brains of transgenic mice (2004) J. Neurosci., 24, pp. 2527-2534; Mahley, R.W., Weisgraber, K.H., Huang, Y., Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimers disease (2006) Proc. Natl Acad. Sci. USA, 103, pp. 5644-5651; Zhang, J., Cicero, S.A., Wang, L., Romito-Digiacomo, R.R., Yang, Y., Herrup, K., Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 8772-8777; Cicero, S., Herru, K., Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation (2005) J. Neurosci., 25, pp. 9658-9668; Lew, J., Qi, Z., Huang, Q., Paudel, H., Matsuura, I., Matsshita, M., Zhu, X., Wang, J.I., Structure, function, and regulation of neuronal cdc2-like protein kinase (1995) Neurobiol. Aging, 16, pp. 263-270; Lee, K.Y., Clark, A.W., Rosales, J.L., Chapman, K., Fung, T., Johnston, R., Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain (1999) Neurosci. Res., 34, pp. 21-29; Patrick, G.N., Zukerberg, L., Nikolic, M., Monte, S., Dikkesk, P., Tsai, L.H., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration (2000) Nature, 402, pp. 615-622; Alvarez, A., Munoz, J.P., Maccioni, R.B.A., Cdk5-p35 stable complex is involved in the β-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons (2001) Exp. Cell Res., 264, pp. 266-274; Tseng, H.C., Zhou, Y., Shen, Y., Tsai, L.H.A., Survey of Cdk5 activator p35 and p25 levels in Alzheimers disease brains (2002) FEBS Lett., 523, pp. 58-62; Tsujia, T., Shimohamaa, S., Kimuraa, J., Shimizub, K., M-Calpain (calcium-activated neutral proteinase) in Alzheimers disease brains (1998) Neurosci. Lett., 248, pp. 109-112; Chang, K.H., Pablo, Y., Lee, H.P., Lee, H.G., Smith, M., Shah, K., Cdk5 is a major regulator of p38 cascade: Relevance to neurotoxicity in Alzheimers disease (2010) J. Neurochem., 113, pp. 1221-1229; Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Kumar, S., Green, D., McNulty, D., Landvatter, S.W., A protein kinase involved in the regulation of inflammatory cytokine biosynthesis (1994) Nature, 372, pp. 22-29; Dolado, I., Swat, A., Ajenjo, N., De Vita, G., Cuadrado, A., Nebreda, A.R., P38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis (2007) Cancer Cell, 11, pp. 191-205; Munoz, L., Ammit, A.J., Targeting p38 MAPK pathway for the treatment of Alzheimers disease (2010) Neuropharmacology, 58, pp. 561-568; Pei, J.J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., Cowburn, R.F., Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimers disease brains at different stages of neurofibrillary degeneration (2001) J. Alzheimers Dis., 3, pp. 41-48; Zhu, X., Rottkamp, C.A., Hartzler, A., Sun, Z., Takeda, A., Boux, H., Shimohama, S., Smith, M.A., Activation of MKK6, an upstream activator of p38, in Alzheimers disease (2001) J. Neurochem., 79, pp. 311-318; Hensley, K., Floyd, R.A., Zheng, N.Y., Nael, R., Robinson, K.A., Nguyen, X., Pye, Q.N., Bing, G., P38 kinase is activated in the Alzheimers disease brain (1999) J. Neurochem., 72, pp. 2053-2058; Reynolds, C.H., Nebreda, A.R., Gibb, G.M., Utton, M.A., Anderton, B.H., Reactivating kinase/p38 phosphorylates Tau protein in vitro (1997) J. Neurochem., 69, pp. 191-198; Reynolds, C.H., Betts, J.C., Blackstock, W.P., Nebreda, A.R., Anderton, B.H., Phosphorylation sites on Tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3β (2000) J. Neurochem., 74, pp. 1587-1595; Churcher, I., Tau therapeutic strategies for the treatment of Alzheimers disease (2006) Curr. Top. Med. Chem., 6, pp. 579-595; Feijoo, C., Campbell, D.G., Jakes, R., Goedert, M., Cuenda, A., Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly (2005) J. Cell Sci., 118, pp. 397-408; Goedert, M., Hasegawa, M., Jakes, R., Lawler, S., Cuenda, A., Cohen, P., Phosphorylation of microtubule-associated protein Tau by stress-activated protein kinases (1997) FEBS Lett., 409, pp. 7-62; Kelleher, I., Garwood, C., Hanger, D.P., Anderton, B.H., Noble, W., Kinase activities increase during the development of Tauopathy in hTau mice (2007) J. Neurochem., 103, pp. 2256-2267; Savage, M.J., Lin, Y.G., Ciallella, J.R., Flood, D.G., Scott, R.W., Activation of c-Jun N-terminal kinase and p38 in an Alzheimers disease model is associated with amyloid deposition (2002) J. Neurosci., 22, pp. 3376-3385; Giraldo, E., Lloret, A., Fuchsberger, T., Viña, J., Aβ and Tau toxicities in Alzheimers are linked via oxidative stress-induced p38 activation: Protective role of vitamin e (2014) Redox Biol, 2, pp. 873-877",Review,Scopus,2-s2.0-84927602807
"Thinnes F.P.","Phosphorylation, nitrosation and plasminogen K3 modulation make VDAC-1 lucid as part of the extrinsic apoptotic pathway - Resulting thesis: Native VDAC-1 indispensible for finalisation of its 3D structure",2015,"Biochimica et Biophysica Acta - Biomembranes","1848","6",,"1410","1416",,,10.1016/j.bbamem.2015.02.031,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925881180&partnerID=40&md5=518a55458d7056229980ed7f70377a10","Baumschulenweg 5Göttingen, Germany","Thinnes, F.P., Baumschulenweg 5Göttingen, Germany","Native and recombinant VDAC preparations differ in their acetylation, phosphorylation and nitrosation state; additionally, proteineous modulators are missing in the latter. They thus vary in channel characteristics, as can be taken from comparative black lipid bilayer experiments. Furthermore, the multi-compartment expression makes expect even differing native VDAC-1 molecules. Recent structural work on mammalian VDAC-1 has only used recombinant material, refolded from Escherichia coli inclusion bodies. While this approach established the basic three-dimensional structure of VDAC-1, a ß-barrel set up by nineteen ß-pleated sheets, dissent is on positioning and movements of its free N-terminal helical peptide stretch preceding ß-pleated sheet-1. A synopsis of data concerning posttranslational modifications, cyto-topology and physiology of native VDAC-1, from my point of view, suggests that the finalisation of its three-dimensional structure will need native channel preparations to be studied. Concerning relevance, recent evidence on the regulation of cell membrane-integrated VDAC-1 by posttranslational modifications and proteineous modulators, taken together with experimental demonstrations that VDAC-1 is involved in cell volume regulation, it thus may be part of the extrinsic apoptotic pathway can hopefully help to understand some relevant medical syndromes, e.g. cystic fibrosis, Alzheimer's disease, autism and malaria. © 2015 Elsevier B.V.","Alzheimers disease; Autism; Cystic fibrosis; Malaria; Porin; VRAC","Tewari, D., Ahmed, T., Chirasani, V.R., Singh, P.S., Maji, S.K., Senapati, S., Bera, A.K., Modulation of the mitochondrial voltage dependent anion channel (VDAC) by curcumin (2014) Biochim. Biophys. Acta, 1848, pp. 151-158; Scharstuhl, A., Mutsaers, H.A., Pennings, S.W., Russel, F.G., Wagener, F.A., Involvement of VDAC, Bax and ceramides in the efflux of AIF from mitochondria during curcumin-induced apoptosis (2009) PLoS ONE, 4, p. e6688; Zhang, X., Chen, Q., Wang, Y., Peng, W., Cai, H., Effects of curcumin on ion channels and transporters (2014) Front. Physiol., 5, p. 94; Best, L., Elliott, A.C., Brown, P.D., Curcumin induces electrical activity in rat pancreatic beta-cells by activating the volume-regulated anion channel (2007) Biochem. Pharmacol., 73, pp. 1768-1775; Colombini, M., Mannella, C.A., VDAC, the early days (2012) Biochim. Biophys. Acta, 1818, pp. 1438-1443; Benz, R., Maier, E., Thinnes, F.P., Götz, H., Hilschmann, N., Studies on human porin. VII. The channel properties of the human B-lymphocyte membrane-derived ""porin 31HL"" are similar to those of mitochondrial porins (1992) Biol. Chem. Hoppe Seyler, 373, pp. 295-303; Shoshan-Barmatz, V., Ben-Hail, D., Admoni, L., Krelin, Y., Tripathi, S.S., The mitochondrial voltage-dependent anion channel 1 in tumor cells (2014) Biochim. Biophys. Acta; Hiller, S., Garces, R.G., Malia, T.J., Orekhov, V.Y., Colombini, M., Wagner, G., Solution structure of the integral human membrane protein VDAC-1 in detergent micelles (2008) Science, 321, pp. 1206-1210; Bayrhuber, M., Meins, T., Habeck, M., Becker, S., Giller, K., Villinger, S., Vonrhein, C., Zeth, K., Structure of the human voltage-dependent anion channel (2008) Proc. Natl. Acad. Sci. U. S. A., 105, pp. 15370-15375; Ujwal, R., Cascio, D., Colletier, J.P., Faham, S., Zhang, J., Toro, L., Ping, P., Abramson, J., The crystal structure of mouse VDAC1 at 2.3 Å resolution reveals mechanistic insights into metabolite gating (2008) Proc. Natl. Acad. Sci. U. S. A., 105, pp. 17742-17747; Teijido, O., Ujwal, R., Hillerdal, C.O., Kullman, L., Rostovtseva, T.K., Abramson, J., Affixing N-terminal α-helix to the wall of the voltage-dependent anion channel does not prevent its voltage gating (2012) J. Biol. Chem., 287, pp. 11437-11445; Mertins, B., Psakis, G., Grosse, W., Back, K.C., Salisowski, A., Reiss, P., Koert, U., Essen, L.O., Flexibility of the N-terminal mVDAC1 segment controls the channel's gating behavior (2012) PLoS ONE, 7, p. e47938; Schredelseker, J., Paz, A., López, C.J., Altenbach, C., Leung, C.S., Drexler, M.K., Chen, J.N., Abramson, J., High resolution structure and double electron-electron resonance of the zebrafish voltage-dependent anion channel 2 reveal an oligomeric population (2014) J. Biol. Chem., 289, pp. 12566-12776; Kozuch, J., Weichbrodt, C., Millo, D., Giller, K., Becker, S., Hildebrandt, P., Steinem, C., Voltage-dependent structural changes of the membrane-bound anion channel hVDAC1 probed by SEIRA and electrochemical impedance spectroscopy (2014) Phys. Chem. Chem. Phys., 16, pp. 9546-9955; Gattin, Z., Schneider, R., Laukat, Y., Giller, K., Maier, E., Zweckstetter, M., Griesinger, C., Lange, A., Solid-state NMR, electrophysiology and molecular dynamics characterization of human VDAC2 (2014) J. Biomol. NMR, , (2014 Nov 16. [Epub ahead of print]); Eddy, M.T., Andreas, L., Teijido, O., Su, Y., Clark, L., Noskov, S.Y., Wagner, G., Griffin, R.G., Magic angle spinning nuclear magnetic resonance characterization of voltage-dependent anion channel gating in two-dimensional lipid crystalline bilayers (2015) Biochemistry, 54, pp. 994-1005; Thinnes, F.P., Götz, H., Kayser, H., Benz, R., Schmidt, W.E., Kratzin, H.D., Hilschmann, N., Identification of human porins. I. Purification of a porin from human B-lymphocytes (Porin 31HL) and the topochemical proof of its expression on the plasmalemma of the progenitor cell (1989) Biol. Chem. Hoppe Seyler, 370, pp. 1253-1264. , (German); Kayser, H., Kratzin, H.D., Thinnes, F.P., Götz, H., Schmidt, W.E., Eckart, K., Hilschmann, N., Identification of human porins. II. Characterization and primary structure of a 31-lDa porin from human B lymphocytes (Porin 31HL) (1989) Biol. Chem. Hoppe Seyler, 370, pp. 1265-1278. , (German); Babel, D., Walter, G., Götz, H., Thinnes, F.P., Jürgens, L., König, U., Hilschmann, N., Studies on human porin. VI. Production and characterization of eight monoclonal mouse antibodies against the human VDAC ""porin 31HL"" and their application for histotopological studies in human skeletal muscle (1991) Biol. Chem. Hoppe Seyler, 372, pp. 1027-1034; Thinnes, F.P., Reymann, S., New findings concerning vertebrate porin (1997) Naturwissenschaften, 84, pp. 480-498; Thinnes, F.P., New findings concerning vertebrate porin II - On the relevance of glycine motifs of type-1 VDAC (2013) Mol. Genet. Metab., 108, pp. 212-224. , (Review); König, U., Quantitativer Nachweis und Orientierung des Porin 31HL in normalen und transformierten B-Lymphoczyten (1992) Diploma Thesis Universität Göttingen; Reymann, S., Haase, W., Krick, W., Burckhardt, G., Thinnes, F.P., Endosomes: Another extra-mitochondrial location of type-1 porin/voltage-dependent anion-selective channels (1998) Pflugers Arch., 436, pp. 478-480; Fernandez-Echevarria, C., Díaz, M., Ferrer, I., Canerina-Amaro, A., Marin, R., Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease (2014) Neuroscience, 278, pp. 354-366; Tewari, S.G., Zhou, Y., Otto, B.J., Dash, R.K., Kwok, W.M., Beard, D.A., Markov chain Monte Carlo based analysis of post-translationally modified VDAC gating kinetics (2015) Front. Physiol., 5, p. 513; Li, L., Yao, Y.C., Gu, X.Q., Che, D., Ma, C.Q., Dai, Z.Y., Li, C., Gao, G.Q., Plasminogen kringle 5 induces endothelial cell apoptosis by triggering a voltage-dependent anion channel 1 (VDAC1) positive feedback loop (2014) J. Biol. Chem., 289, pp. 32628-32638; Martel, C., Wang, Z., Brenner, C., VDAC phosphorylation, a lipid sensor influencing the cell fate (2014) Mitochondrion; Colombini, M., The published 3D structure of the VDAC channel: Native or not? (2009) Trends Biochem. Sci., 34, pp. 382-389; Mertins, B., Psakis, G., Essen, L.O., Voltage-dependent anion channels: The wizard of the mitochondrial outer membrane (2014) Biol. Chem., 395, pp. 1435-1442; Marx, V., Structural biology: 'Seeing' crystals the XFEL way (2014) Nat. Methods, 11, pp. 903-908; Neutze, R., Moffat, K., Time-resolved structural studies at synchrotrons and X-ray free electron lasers: Opportunities and challenges (2014) Curr. Opin. Struct. Biol., 22, pp. 651-659; De Pinto, V., Benz, R., Palmieri, F., Interaction of non-classical detergents with the mitochondrial porin. A new purification procedure and characterization of the pore-forming unit (1989) Eur. J. Biochem., 183, pp. 179-187; Stadtmüller, U., Eben-Brunnen, J., Schmid, A., Hesse, D., Klebert, S., Kratzin, H.D., Hesse, J., Hilschmann, N., Mitochondria-derived and extra-mitochondrial human type-1 porin are identical as revealed by amino acid sequencing and electrophysiological characterisation (1999) Biol. Chem., 380, pp. 1461-1466; Thinnes, F.P., Schmid, A., Benz, R., Hilschmann, N., Studies on human porin. III. Does the voltage-dependent anion channel ""porin 31HL"" form part of the chloride channel complex, which is observed in different cells and thought to be affected in cystic fibrosis? (1990) Biol. Chem. Hoppe Seyler, 371, pp. 1047-1050; Jakob, C., Götz, H., Hellmann, T., Hellmann, K.P., Reymann, S., Flörke, H., Thinnes, F.P., Hilschmann, N., Studies on human porin: XIII. The type-1 VDAC 'porin 31HL' biotinylated at the plasmalemma of trypan blue excluding human B lymphocytes (1995) FEBS Lett., 368, pp. 5-9; Eben-Brunnen, J., Reymann, S., Awni, L.A., Cole, T., Hellmann, T., Hellmann, K.P., Paetzold, G., Hilschmann, N., Lentil lectin enriched microsomes from the plasma membrane of the human B-lymphocyte cell line H2LCL carry a heavy load of type-1 porin (1998) Biol. Chem., 379, pp. 1419-1426; Marin, R., Ramírez, C.M., González, M., González-Muñoz, E., Zorzano, A., Camps, M., Alonso, R., Díaz, M., Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons (2007) Mol. Membr. Biol., 24, pp. 148-160; Dermietzel, R., Hwang, T.K., Buettner, R., Hofer, A., Dotzler, E., Kremer, M., Deutzmann, R., Spray, D.C., Cloning and in situ localization of a brain-derived porin that constitutes a large-conductance anion channel in astrocytic plasma membranes (1994) Proc. Natl. Acad. Sci. U. S. A., 91, pp. 499-503; Buettner, R., Papoutsoglou, G., Scemes, E., Spray, D.C., Dermietzel, R., Evidence for secretory pathway localization of a voltage-dependent anion channel isoform (2000) Proc. Natl. Acad. Sci. U. S. A., 97, pp. 3201-3206; Okada, S.F., O'Neal, W.K., Huang, P., Nicholas, R.A., Ostrowski, L.E., Craigen, W.J., Lazarowski, E.R., Boucher, R.C., Voltage-dependent anion channel-1 (VDAC-1) contributes to ATP release and cell volume regulation in murine cells (2004) J. Gen. Physiol., 124, pp. 513-526; Thinnes, F.P., Hellmann, K.P., Hellmann, T., Merker, R., Brockhaus-Pruchniewicz, U., Schwarzer, C., Walter, G., Hilschmann, N., Studies on human porin XXII: Cell membrane integrated human porin channels are involved in regulatory volume decrease (RVD) of HeLa cells (2000) Mol. Genet. Metab., 69, pp. 331-337; Elinder, F., Akanda, N., Tofighi, R., Shimizu, S., Tsujimoto, Y., Orrenius, S., Ceccatelli, S., Opening of plasma membrane voltage-dependent anion channels (VDAC) precedes caspase activation in neuronal apoptosis induced by toxic stimuli (2005) Cell Death Differ., 12, pp. 1134-1140; Akita, T., Okada, Y., Characteristics and roles of the volume-sensitive outwardly rectifying (VSOR) anion channel in the central nervous system (2014) Neuroscience, 275, pp. 211-231; Thinnes, F.P., Burckhardt, G., On a fully closed state of native human type-1 VDAC enriched in Nonidet P40 (2012) Mol. Genet. Metab., 107, pp. 632-633; Weiser, B.P., Salari, R., Eckenhoff, R.G., Brannigan, G., Computational investigation of cholesterol binding sites on mitochondrial VDAC (2014) J. Phys. Chem. B, 118, pp. 9852-9860; Teijido, O., Rappaport, S.M., Chamberlin, A., Noskov, S.Y., Aguilella, V.M., Rostovtseva, T.K., Bezrukov, S.M., Acidification asymmetrically affects voltage-dependent anion channel implicating the involvement of salt bridges (2014) J. Biol. Chem., 289, pp. 23670-23682; De Pinto, V., Prezioso, G., Thinnes, F., Link, T.A., Palmieri, F., Peptide-specific antibodies and proteases as probes of the transmembrane topology of the bovine heart mitochondrial porin (1991) Biochemistry, 30, pp. 10191-10200; De Pinto, V., Tomasello, F., Messina, A., Guarino, F., Benz, R., La Mendola, D., Magrì, A., Pappalardo, G., Determination of the conformation of the human VDAC1 N-terminal peptide, a protein moiety essential for the functional properties of the pore (2007) Chembiochem, 8, pp. 744-756; Tomasello, M.F., Guarino, F., Reina, S., Messina, A., De Pinto, V., The voltage-dependent anion selective channel 1 (VDAC1) topography in the mitochondrial outer membrane as detected in intact cell (2013) PLoS ONE, 8, p. e81522; Geula, S., Ben-Hail, D., Shoshan-Barmatz, V., Structure-based analysis of VDAC1: N-terminus location, translocation, channel gating and association with anti-apoptotic proteins (2012) Biochem. J., 444, pp. 475-485; Stanley, S., Dias, J.A., D'Arcangelis, D., Mannella, C.A., Peptide-specific antibodies as probes of the topography of the voltage-gated channel in the mitochondrial outer membrane of Neurospora crassa (1995) J. Biol. Chem., 270, pp. 16694-16700. , (Mannella); Guo, X.W., Mannella, C.A., Classification of projection images of crystalline arrays of the mitochondrial, voltage-dependent anion-selective channel embedded in aurothioglucose (1992) Biophys. J., 63, pp. 418-427; Thinnes, F.P., On GxxxG in N-terminal stretches of type-1 VDAC/porin: Critical in vertebrate apoptosis, missing in plants (2012) Plant Mol. Biol., 79, pp. 1-3; Flörke, H., Thinnes, F.P., Winkelbach, H., Stadtmüller, U., Paetzold, G., Morys-Wortmann, C., Hesse, D., Kaufmann-Kolle, P., Channel active mammalian porin, purified from crude membrane fractions of human B lymphocytes and bovine skeletal muscle, reversibly binds adenosine triphosphate (ATP) (1994) Biol. Chem. Hoppe Seyler, 375, pp. 513-520; Villinger, S., Giller, K., Bayrhuber, M., Lange, A., Griesinger, C., Becker, S., Zweckstetter, M., Nucleotide interactions of the human voltage-dependent anion channel (2014) J. Biol. Chem., 289, pp. 13397-13406; Komarova, E.Y., Meshalkina, D.A., Aksenov, N.D., Pchelin, I.M., Martynova, E., Margulis, B.A., Guzhova, I.V., The discovery of Hsp70 domain with cell-penetrating activity (2014) Cell Stress Chaperones, 20, pp. 343-354; Bouyer, G., Cueff, A., Egée, S., Kmiecik, J., Maksimova, Y., Glogowska, E., Gallagher, P.G., Thomas, S.L., Erythrocyte peripheral type benzodiazepine receptor/voltage-dependent anion channels are upregulated by Plasmodium falciparum (2011) Blood, 118, pp. 2305-21255; Thinnes, F.P., Opening up of plasmalemma type-1 VDAC to form apoptotic ""find me signal"" pathways is essential in early apoptosis - Evidence from the pathogenesis of cystic fibrosis resulting from failure of apoptotic cell clearance followed by sterile inflammation (2014) Mol. Genet. Metab., 111, pp. 439-444; Asmarinah, A., Paradowska-Dogan, A., Kodariah, R., Tanuhardja, B., Waliszewski, P., Mochtar, C.A., Weidner, W., Hinsch, E., Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells (2014) Int. J. Oncol., 45, pp. 1489-1496; Weiser, B.P., Bu, W., Wong, D., Eckenhoff, R.G., Sites and functional consequence of VDAC-alkylphenol anesthetic interactions (2014) FEBS Lett., 588, pp. 4398-4403",Review,Scopus,2-s2.0-84925881180
"Dienemann C., Coburger I., Mehmedbasic A., Andersen O.M., Than M.E.","Mutants of metal binding site M1 in APP E2 show metal specific differences in binding of heparin but not of sorLA",2015,"Biochemistry","54","15",,"2490","2499",,,10.1021/acs.biochem.5b00111,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928559074&partnerID=40&md5=eb734ce703eac6e7354b97554cfcc51b","Leibniz Institute for Age Research, Protein Crystallography Group, Beutenbergstrasse 11Jena, Germany; Lundbeck Foundation Research Center MIND, Department of Biomedicine, Aarhus University, Ole Worms Allé 3Aarhus C, Denmark","Dienemann, C., Leibniz Institute for Age Research, Protein Crystallography Group, Beutenbergstrasse 11Jena, Germany; Coburger, I., Leibniz Institute for Age Research, Protein Crystallography Group, Beutenbergstrasse 11Jena, Germany; Mehmedbasic, A., Lundbeck Foundation Research Center MIND, Department of Biomedicine, Aarhus University, Ole Worms Allé 3Aarhus C, Denmark; Andersen, O.M., Lundbeck Foundation Research Center MIND, Department of Biomedicine, Aarhus University, Ole Worms Allé 3Aarhus C, Denmark; Than, M.E., Leibniz Institute for Age Research, Protein Crystallography Group, Beutenbergstrasse 11Jena, Germany","The amyloid precursor protein (APP) and its neurotoxic cleavage product Aβ are key players in the development of Alzheimers disease (AD) and appear to be essential for neuronal development and cell homeostasis. Proteolytic processing of APP and its physiological function depend on its interaction with heparin and are influenced by the binding of metal ions and sorLA. We created various mutations of metal binding site M1 residing within the extracellular E2 domain of APP. Using isothermal titration calorimetry and circular dichroism spectroscopy, we analyzed the binding of Cu2+ and Zn2+ to APP E2 and identified two mutations that are most suited for functional studies to dissect ion specific effects of metal binding. The H313A mutation abrogates only copper-based effects, whereas the H382A mutation weakens any metal binding at M1 of APP E2. Subsequently, we tested the effect of Cu2+ and Zn2+ on the binding of heparin and sorLA to APP E2 using a chromatographic technique and surface plasmon resonance. We show that Zn2+ and to a larger degree also Cu2+ enhance the binding of heparin to APP E2, consistent with an extracellular regulation of the function of APP by both metal ions. In contrast, neither ion seemed to affect the interaction between APP E2 and sorLA. This supports an intracellular interaction between the latter two partners that would not sense extracellular variations of metal ions upon synaptic activity. © 2015 American Chemical Society.",,"Jellinger, K.A., Clinicopathological analysis of dementia disorders in the elderly: An update (2006) J. Alzheimers Dis., 9, pp. 61-70; Thies, W., Bleiler, L., 2013 Alzheimers Disease Facts and Figures (2013) Alzheimers Dement., 9, pp. 208-245; Thinakaran, G., Koo, E.H., Amyloid precursor protein trafficking, processing, and function (2008) J. Biol. Chem., 283, pp. 29615-29619; Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Blennow, K., De Leon, M.J., Zetterberg, H., Alzheimers disease (2006) Lancet, 368, pp. 387-403; Golde, T.E., Schneider, L.S., Koo, E.H., Anti-Aβ therapeutics in Alzheimers disease: The need for a paradigm shift (2011) Neuron, 69, pp. 203-213; Lichtenthaler, S.F., Haass, C., Steiner, H., Regulated intramembrane proteolysis: Lessons from amyloid precursor protein processing (2011) J. Neurochem., 117, pp. 779-796; Milward, E.A., Papadopoulos, R., Fuller, S.J., Moir, R.D., Small, D., Beyreuther, K., Masters, C.L., The amyloid protein precursor of Alzheimers disease is a mediator of the effects of nerve growth factor on neurite outgrowth (1992) Neuron, 9, pp. 129-137; Kepp, K.P., Bioinorganic chemistry of Alzheimers disease (2012) Chem. Rev., 112, pp. 5193-5239; Dahms, S.O., Konnig, I., Roeser, D., Guhrs, K.H., Mayer, M.C., Kaden, D., Multhaup, G., Than, M.E., Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain (2012) J. Mol. Biol., 416, pp. 438-452; Von Rotz, R.C., Kohli, B.M., Bosset, J., Meier, M., Suzuki, T., Nitsch, R.M., Konietzko, U., The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor (2004) J. Cell Sci., 117, pp. 4435-4448; Muller, T., Concannon, C.G., Ward, M.W., Walsh, C.M., Tirniceriu, A.L., Tribl, F., Kogel, D., Egensperger, R., Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD) (2007) Mol. Biol. Cell, 18, pp. 201-210; Breen, K.C., Bruce, M., Anderton, B.H., β Amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion (1991) J. Neurosci. Res., 28, pp. 90-100; Soba, P., Eggert, S., Wagner, K., Zentgraf, H., Siehl, K., Kreger, S., Lower, A., Beyreuther, K., Homo- and heterodimerization of APP family members promotes intercellular adhesion (2005) EMBO J., 24, pp. 3624-3634; Ho, A., Sudhof, T.C., Binding of F-spondin to amyloid-β precursor protein: A candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage (2004) Proc. Natl. Acad. Sci. U.S.A., 101, pp. 2548-2553; Koo, E.H., Sisodia, S.S., Archer, D.R., Martin, L.J., Weidemann, A., Beyreuther, K., Fischer, P., Price, D.L., Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport (1990) Proc. Natl. Acad. Sci. U.S.A., 87, pp. 1561-1565; Parvathy, S., Hussain, I., Karran, E.H., Turner, A.J., Hooper, N.M., Cleavage of Alzheimers amyloid precursor protein by α-secretase occurs at the surface of neuronal cells (1999) Biochemistry, 38, pp. 9728-9734; Koo, E.H., Squazzo, S.L., Evidence that production and release of amyloid β-protein involves the endocytic pathway (1994) J. Biol. Chem., 269, pp. 17386-17389; Dries, D.R., Yu, G., Assembly, maturation, and trafficking of the γ-secretase complex in Alzheimers disease (2008) Curr. Alzheimer Res., 5, pp. 132-146; Andersen, O.M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., Von Arnim, C.A., Willnow, T.E., Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein (2005) Proc. Natl. Acad. Sci. U.S.A., 102, pp. 13461-13466; Acevedo, K.M., Hung, Y.H., Dalziel, A.H., Li, Q.X., Laughton, K., Wikhe, K., Rembach, A., Camakaris, J., Copper promotes the trafficking of the amyloid precursor protein (2011) J. Biol. Chem., 286, pp. 8252-8262; Mayer, M.C., Kaden, D., Schauenburg, L., Hancock, M.A., Voigt, P., Roeser, D., Barucker, C., Multhaup, G., Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization (2014) J. Biol. Chem., 289, pp. 19019-19030; Barnham, K.J., Bush, A.I., Metals in Alzheimers and Parkinsons diseases (2008) Curr. Opin. Chem. Biol., 12, pp. 222-228; Budimir, A., Metal ions, Alzheimers disease and chelation therapy (2011) Acta Pharm. (Zagreb, Croatia), 61, pp. 1-14; Bayer, T.A., Cappai, R., Masters, C.L., Beyreuther, K., Multhaup, G., It all sticks together: The APP-related family of proteins and Alzheimers disease (1999) Mol. Psychiatry, 4, pp. 524-528; Coburger, I., Dahms, S.O., Roeser, D., Guhrs, K.H., Hortschansky, P., Than, M.E., Analysis of the overall structure of the multi-domain amyloid precursor protein (APP) (2013) PLoS One, 8, p. 81926; Coburger, I., Hoefgen, S., Than, M.E., The structural biology of the amyloid precursor protein APP: A complex puzzle reveals its multi-domain architecture (2014) Biol. Chem., 395, pp. 485-498; Zheng, H., Koo, E.H., The amyloid precursor protein: Beyond amyloid (2006) Mol. Neurodegener., 1, p. 5; Multhaup, G., Mechler, H., Masters, C.L., Characterization of the high affinity heparin binding site of the Alzheimers disease β A4 amyloid precursor protein (APP) and its enhancement by zinc(II) (1995) J. Mol. Recognit., 8, pp. 247-257; Andersen, O.M., Schmidt, V., Spoelgen, R., Gliemann, J., Behlke, J., Galatis, D., McKinstry, W.J., Willnow, T.E., Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11 (2006) Biochemistry, 45, pp. 2618-2628; Schubert, D., Lacorbiere, M., Saitoh, T., Cole, G., Characterization of an amyloid β precursor protein that binds heparin and contains tyrosine sulfate (1989) Proc. Natl. Acad. Sci. U.S.A., 86, pp. 2066-2069; Hoe, H.S., Lee, H.K., Pak, D.T., The upside of APP at synapses (2012) CNS Neurosci. Ther., 18, pp. 47-56; Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., St George-Hyslop, P., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease (2007) Nat. Genet., 39, pp. 168-177; Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., Destafano, A.L., Hakonarson, H., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimers disease (2013) Nat. Genet., 45, pp. 1452-1458. , European Alzheimers Disease, I. Genetic, Environmental Risk in Alzheimers, D. Alzheimers Disease Genetic, C. Cohorts for, H. Aging Research in Genomic, E. (); Miyashita, A., Koike, A., Jun, G., Wang, L.S., Takahashi, S., Matsubara, E., Kawarabayashi, T., Kuwano, R., SORL1 is genetically associated with late-onset Alzheimers disease in Japanese, Koreans and Caucasians (2013) PLoS One, 8, p. 58618. , Alzheimer Disease Genetics, C; Fjorback, A.W., Seaman, M., Gustafsen, C., Mehmedbasic, A., Gokool, S., Wu, C., Militz, D., Andersen, O.M., Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing (2012) J. Neurosci., 32, pp. 1467-1480; Mehmedbasic, A., Christensen, S.K., Nilsson, J., Ruetschi, U., Gustafsen, C., Poulsen, A.S., Rasmussen, R.W., Andersen, O.M., SorLA complement-type repeat domains protect the amyloid precursor protein against processing (2015) J. Biol. Chem., 290, pp. 3359-3376; Offe, K., Dodson, S.E., Shoemaker, J.T., Fritz, J.J., Gearing, M., Levey, A.I., Lah, J.J., The lipoprotein receptor LR11 regulates amyloid β production and amyloid precursor protein traffic in endosomal compartments (2006) J. Neurosci., 26, pp. 1596-1603; Bhalla, A., Vetanovetz, C.P., Morel, E., Chamoun, Z., Di Paolo, G., Small, S.A., The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport (2012) Neurobiol. Dis., 47, pp. 126-134; Willnow, T.E., Andersen, O.M., Sorting receptor SORLA: A trafficking path to avoid Alzheimer disease (2013) J. Cell Sci., 126, pp. 2751-2760; Keil, C., Huber, R., Bode, W., Than, M.E., Cloning, expression, crystallization and initial crystallographic analysis of the C-terminal domain of the amyloid precursor protein APP (2004) Acta Crystallogr., 60, pp. 1614-1617; Xue, Y., Lee, S., Ha, Y., Crystal structure of amyloid precursor-like protein 1 and heparin complex suggests a dual role of heparin in E2 dimerization (2011) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 16229-16234; Dahms, S.O., Mayer, M., Roeser, D., Multhaup, G., Than, M.E., Interaction of the amyloid precursor protein-like protein 1 (APLP1) E2 domain with heparan sulfate involves two distinct binding modes (2015) Acta Crystallogr., 71, pp. 494-504; Xue, Y., Lee, S., Wang, Y., Ha, Y., Crystal structure of the E2 domain of amyloid precursor protein-like protein 1 in complex with sucrose octasulfate (2011) J. Biol. Chem., 286, pp. 29748-29757; Hoopes, J.T., Liu, X., Xu, X., Demeler, B., Folta-Stogniew, E., Li, C., Ha, Y., Structural characterization of the E2 domain of APL-1, a Caenorhabditis elegans homolog of human amyloid precursor protein, and its heparin binding site (2010) J. Biol. Chem., 285, pp. 2165-2173; Tarohda, T., Yamamoto, M., Amamo, R., Regional distribution of manganese, iron, copper, and zinc in the rat brain during development (2004) Anal. Bioanal. Chem., 380, pp. 240-246; Szewczyk, B., Zinc homeostasis and neurodegenerative disorders (2013) Front. Aging Neurosci., 5, p. 33; Acevedo, K.M., Opazo, C.M., Norrish, D., Challis, L.M., Li, Q.X., White, A.R., Bush, A.I., Camakaris, J., Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells (2014) J. Biol. Chem., 289, pp. 11007-11019; Schmidt, V., Sporbert, A., Rohe, M., Reimer, T., Rehm, A., Andersen, O.M., Willnow, T.E., SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1 (2007) J. Biol. Chem., 282, pp. 32956-32964; Waldron, E., Heilig, C., Schweitzer, A., Nadella, N., Jaeger, S., Martin, A.M., Weggen, S., Pietrzik, C.U., LRP1 modulates APP trafficking along early compartments of the secretory pathway (2008) Neurobiol. Dis., 31, pp. 188-197",Article,Scopus,2-s2.0-84928559074
"Zhang Q., Liu J., Hu X., Wang W., Yuan Z.","In vitro studies on accelerating the degradation and clearance of amyloid-β fibrils by an antiamyloidogenic peptide",2015,"ACS Macro Letters","4","4",,"339","342",,,10.1021/acsmacrolett.5b00033,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928537412&partnerID=40&md5=9394153b7d8dd80cb599f863f60d57c1","Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China","Zhang, Q., Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China; Liu, J., Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China; Hu, X., Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China; Wang, W., Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China; Yuan, Z., Key Laboratory of Functional Polymer Materials, Ministry of Education, Nankai UniversityTianjin, China","The clearance of overloaded amyloid-β (Aβ) species, especially the toxic aggregates, was thought to be an attractive and promising strategy for Alzheimers disease (AD) therapy in the past decade. In this work, an active Aβ inhibitor decapeptide RR was used to transform mature Aβ fibrils (fAβ) into nanorod-like Aβ assemblies (rAβ) as well as loosen the β-structure of rAβ. Compared with fAβ, rAβ could be engulfed by PC12 cells more efficiently and showed a 1.46-fold difference. More importantly, the rAβ was colocated with lysosomes after endocytosis, and in vitro study illustrated that rAβ were easily degraded by lysosome protease cathepsin B when compared with the fibrils. Thus, our study indicated the potential application of RR in Aβ fibrils clearance by a cell-participated and enzyme-mediated pathway. © 2015 American Chemical Society.",,"Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., (2014) Chem. Soc. Rev., 43, p. 6692; Sciacca, M.F., Kotler, S.A., Brender, J.R., Chen, J., Lee, D.-K., Ramamoorthy, A., (2012) Biophys. J., 103, p. 702; Brender, J.R., Salamekh, S., Ramamoorthy, A., (2011) Acc. Chem. Res., 45, p. 454; Vivekanandan, S., Brender, J.R., Lee, S.Y., Ramamoorthy, A., (2011) Biochem. Biophys. Res. Commun., 411, p. 312; Sinha, S., Lopes, D.H.J., Du, Z., Pang, E.S., Shanmugam, A., Lomakin, A., Talbiersky, P., Bitan, G., (2011) J. Am. Chem. Soc., 133, p. 16958; Choi, J.-S., Braymer, J.J., Nanga, R.P., Ramamoorthy, A., Lim, M.H., (2010) Proc. Natl. Acad. Sci. U.S.A., 107, p. 21990; Detoma, A.S., Salamekh, S., Ramamoorthy, A., Lim, M.H., (2012) Chem. Soc. Rev., 41, p. 608; Ramamoorthy, A., Lim, M.H., (2013) Biophys. J., 105, p. 287; Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., Holtzman, D.M., (2006) Nat. Med., 12, p. 856; Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., (2010) Science, 330, p. 1774; Miners, J.S., Baig, S., Palmer, J., Palmer, L.E., Kehoe, P.G., Love, S., (2008) Brain Pathol., 18, p. 240; Li, W., Tang, Y., Fan, Z., Meng, Y., Yang, G., Luo, J., Ke, Z.-J., (2013) Mol. Neurodegener., 8, p. 27; Xiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Cirrito, J.R., (2014) J. Neurosci., 34, p. 9607; Chung, H., Brazil, M.I., Soe, T.T., Maxfield, F.R., (1999) J. Biol. Chem., 274, p. 32301; Koenigsknecht, J., Landreth, G., (2004) J. Neurosci., 24, p. 9838; Crouch, P.J., Tew, D.J., Du, T., Nguyen, D.N., Caragounis, A., Filiz, G., Blake, R.E., Laughton, K., (2009) J. Neurochem., 108, p. 1198; Paresce, D.M., Chung, H., Maxfield, F.R., (1997) J. Biol. Chem., 272, p. 29390; Nielsen, H.M., Mulder, S.D., Beliën, J.A., Musters, R.J., Eikelenboom, P., Veerhuis, R., (2010) Glia, 58, p. 1235; Liu, J., Wang, W., Zhang, Q., Zhang, S., Yuan, Z., (2014) Biomacromolecules, 15, p. 931; Qiu, Y., Liu, Y., Wang, L., Xu, L., Bai, R., Ji, Y., Wu, X., Chen, C., (2010) Biomaterials, 31, p. 7606; Malugin, A., Ghandehari, H., (2010) J. Appl. Toxicol., 30, p. 212; Chafekar, S.M., Malda, H., Merkx, M., Meijer, E.W., Viertl, D., Lashuel, H.A., Baas, F., Scheper, W., (2007) ChemBioChem, 8, p. 1857; Bitan, G., Kirkitadze, M.D., Lomakin, A., Vollers, S.S., Benedek, G.B., Teplow, D.B., (2003) Proc. Natl. Acad. Sci. U.S.A., 100, p. 330; Schmidt, M., Sachse, C., Richter, W., Xu, C., Fändrich, M., Grigorieff, N., (2009) Proc. Natl. Acad. Sci. U.S.A., 106, p. 19813; Sachse, C., Xu, C., Wieligmann, K., Diekmann, S., Grigorieff, N., Fändrich, M., (2006) J. Mol. Biol., 362, p. 347; Schmidt, M., Sachse, C., Richter, W., Xu, C., Fändrich, M., Grigorieff, N., (2009) Proc. Natl. Acad. Sci. U.S.A., 106, p. 19813; Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., Teplow, D.B., (1997) J. Biol. Chem., 272, p. 22364; Urbanc, B., Betnel, M., Cruz, L., Bitan, G., Teplow, D., (2010) J. Am. Chem. Soc., 132, p. 4266; Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., (2003) Science, 300, p. 486; Liu, L., Zhang, L., Niu, L., Xu, M., Mao, X., Yang, Y., Wang, C., (2011) ACS Nano, 5, p. 6001; Zhang, M., Mao, X., Yu, Y., Wang, C.-X., Yang, Y.-L., Wang, C., (2013) Adv. Mater., 25, p. 3780; Li, M., Howson, S.E., Dong, K., Gao, N., Ren, J., Scott, P., Qu, X., (2014) J. Am. Chem. Soc., 136, p. 11655; Saido, T., Leissring, M.A., (2012) Cold Spring Harbor Perspect. Med., p. 006379; Chapman, H.A., Riese, R.J., Shi, G.-P., (1997) Ann. Rev. Physiol., 59, p. 63; Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E.D., Sun, B., Chen, J., Wang, X., Mucke, L., (2006) Neuron, 51, p. 703; Bertini, I., Gonnelli, L., Luchinat, C., Mao, J., Nesi, A., (2011) J. Am. Chem. Soc., 133, p. 16013; Yesuvadian, R., Krishnamoorthy, J., Ramamoorthy, A., Bhunia, A., (2014) Biochem. Biophys. Res. Commun., 447, p. 590; Savelieff, M.G., Liu, Y., Senthamarai, R.R., Korshavn, K.J., Lee, H.J., Ramamoorthy, A., Lim, M.H., (2014) Chem. Commun., 50, p. 5301",Article,Scopus,2-s2.0-84928537412
"Delgado-Cortes M.J., Espinosa-Oliva A.M., Sarmiento M., Arguelles S., Herrera A.J., Maurino R., Villaran R.F., Venero J.L., Machado A., De Pablos R.M.","Synergistic deleterious effect of chronic stress and sodium azide in the mouse hippocampus",2015,"Chemical Research in Toxicology","28","4",,"651","661",,,10.1021/tx5004408,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928124392&partnerID=40&md5=4126bfde799bdce7de236bd89b9a495b","Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Faculty of Pharmacy, University of Sevilla, Profesor García González 2Sevilla, Spain; Institute for Radiation Oncology and Biology, Department of Oncology, University of OxfordOxford, United Kingdom","Delgado-Cortés, M.J., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Espinosa-Oliva, A.M., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Sarmiento, M., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain, Institute for Radiation Oncology and Biology, Department of Oncology, University of OxfordOxford, United Kingdom; Argüelles, S., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Herrera, A.J., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Mauriño, R., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Villarán, R.F., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Venero, J.L., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; Machado, A., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain; De Pablos, R.M., Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of SevillaSevilla, Spain, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Universidad de SevillaSevilla, Spain, Faculty of Pharmacy, University of Sevilla, Profesor García González 2Sevilla, Spain","Alzheimers disease is the most common cause of dementia in the elderly. Although the primary cause of the disease is presently unknown, to date several risk factors have been described. Evidence suggests that one of these risk factors could be chronic stress. The aim of this work is to demonstrate that chronic stress is able to induce Alzheimers disease features after the administration of nontoxic doses of sodium azide. We found that chronic stress increases the levels of several proteins involved in Alzheimers disease pathogenesis, such as presenilin 1, presenilin 2, and S100β, besides inducing the aggregation of Tau, ubiquitin, and β-amyloid proteins in the hippocampus. More important, our work shows a synergistic effect of stress and sodium azide treatment leading to significant neuronal death in the mouse hippocampus. Our results point out that chronic stress is a risk factor contributing to amplify and accelerate Alzheimers disease features in the hippocampus. © 2015 American Chemical Society.",,"Avila, J., Tau aggregation into fibrillar polymers: Taupathies (2000) FEBS Lett., 476, pp. 89-92; Iqbal, K., Grundke-Iqbal, I., Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention (2008) J. Cell. Mol. Med., 12, pp. 38-55; Nitta, A., Fukuta, T., Hasegawa, T., Nabeshima, T., Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration (1997) Jpn. J. Pharmacol., 73, pp. 51-57; Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease (1992) Neurology, 42, pp. 631-639; Mastrogiacomo, F., Bergeron, C., Kish, S.J., Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimers disease (1993) J. Neurochem., 61, pp. 2007-2014; Brand, F.N., Kiely, D.K., Kannel, W.B., Myers, R.H., Family patterns of coronary heart disease mortality: The Framingham Longevity Study (1992) J. Clin. Epidemiol., 45, pp. 169-174; Agarwal, S., Sohal, R.S., Differential oxidative damage to mitochondrial proteins during aging (1995) Mech. Ageing Dev., 85, pp. 55-63; Minati, L., Grisoli, M., Bruzzone, M.G., MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: A conceptual review (2007) J. Geriatr. Psychiatry Neurol., 20, pp. 3-21; Calkins, M.J., Manczak, M., Mao, P., Shirendeb, U., Reddy, P.H., Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimers disease (2011) Hum. Mol. Genet., 20, pp. 4515-4529; Szabados, T., Dul, C., Majtenyi, K., Hargitai, J., Penzes, Z., Urbanics, R., A chronic Alzheimers model evoked by mitochondrial poison sodium azide for pharmacological investigations (2004) Behav. Brain Res., 154, pp. 31-40; Smith, T.S., Bennett, Jr.J.P., Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions (1997) Brain Res., 765, pp. 183-188; Chang, S., Lamm, S.H., Human health effects of sodium azide exposure: A literature review and analysis (2003) Int. J. Toxicol., 22, pp. 175-186; Park, L.C., Zhang, H., Sheu, K.F., Calingasan, N.Y., Kristal, B.S., Lindsay, J.G., Gibson, G.E., Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia (1999) J. Neurochem., 72, pp. 1948-1958; Bennett, M.C., Rose, G.M., Chronic sodium azide treatment impairs learning of the Morris water maze task (1992) Behav. Neural Biol., 58, pp. 72-75; Cada, A., Gonzalez-Lima, F., Rose, G.M., Bennett, M.C., Regional brain effects of sodium azide treatment on cytochrome oxidase activity: A quantitative histochemical study (1995) Metab. Brain Dis., 10, pp. 303-320; Tanzi, R.E., The synaptic Abeta hypothesis of Alzheimer disease (2005) Nat. Neurosci., 8, pp. 977-979; Wilson, R.S., Arnold, S.E., Schneider, J.A., Kelly, J.F., Tang, Y., Bennett, D.A., Chronic psychological distress and risk of Alzheimers disease in old age (2006) Neuroepidemiology, 27, pp. 143-153; Csernansky, J.G., Dong, H., Fagan, A.M., Wang, L., Xiong, C., Holtzman, D.M., Morris, J.C., Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia (2006) Am. J. Psychiatry, 163, pp. 2164-2169; Groeneweg, F.L., Karst, H., De Kloet, E.R., Joels, M., Rapid non-genomic effects of corticosteroids and their role in the central stress response (2011) J. Endocrinol., 209, pp. 153-167; Tsolaki, M., Kounti, F., Karamavrou, S., Severe psychological stress in elderly individuals: A proposed model of neurodegeneration and its implications (2009) Am. J. Alzheimers Dis. Other Dementias, 24, pp. 85-94; Murua, V.S., Molina, V.A., Effects of chronic variable stress and antidepressant drugs on behavioral inactivity during an uncontrollable stress: Interaction between both treatments (1992) Behav. Neural Biol., 57, pp. 87-89; Gamaro, G.D., Manoli, L.P., Torres, I.L., Silveira, R., Dalmaz, C., Effects of chronic variate stress on feeding behavior and on monoamine levels in different rat brain structures (2003) Neurochem. Int., 42, pp. 107-114; Fryer, H.J., Davis, G.E., Manthorpe, M., Varon, S., Lowry protein assay using an automatic microtiter plate spectrophotometer (1986) Anal. Biochem., 153, pp. 262-266; Szabo, S., Tache, Y., Somogyi, A., The legacy of Hans Selye and the origins of stress research: A retrospective 75 years after his landmark brief ""letter"" to the editor of nature (2012) Stress, 15, pp. 472-478; McEwen, B.S., Physiology and neurobiology of stress and adaptation: Central role of the brain (2007) Physiol. Rev., 87, pp. 873-904; Weinstock, M., Shoham, S., Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity (2004) J. Neural Transm., 111, pp. 347-366; Selvatici, R., Previati, M., Marino, S., Marani, L., Falzarano, S., Lanzoni, I., Siniscalchi, A., Sodium azide induced neuronal damage in vitro: Evidence for non-apoptotic cell death (2009) Neurochem. Res., 34, pp. 909-916; Siniscalchi, A., Cavallini, S., Marino, S., Falzarano, S., Franceschetti, L., Selvatici, R., Effects of chemical ischemia on cerebral cortex slices: Focus on mitogen-activated protein kinase cascade (2006) Ann. N.Y. Acad. Sci., 1090, pp. 445-454; Deng, X., Li, M., Ai, W., He, L., Lu, D., Patrylo, P.R., Cai, H., Yan, X., Lipolysaccharide-induced neuroinflammation is associated with Alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in rats (2014) Adv. Alzheimer Dis., 3, pp. 78-93; Mongiat, L.A., Schinder, A.F., Adult neurogenesis and the plasticity of the dentate gyrus network (2011) Eur. J. Neurosci., 33, pp. 1055-1061; Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., Crowther, R.A., Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimers disease (1989) Neuron, 3, pp. 519-526; Lovestone, S., Reynolds, C.H., The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes (1997) Neuroscience, 78, pp. 309-324; Liu, S.J., Zhang, A.H., Li, H.L., Wang, Q., Deng, H.M., Netzer, W.J., Xu, H., Wang, J.Z., Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory (2003) J. Neurochem., 87, pp. 1333-1344; Jessberger, S., Aigner, S., Clemenson, Jr.G.D., Toni, N., Lie, D.C., Karalay, O., Overall, R., Gage, F.H., Cdk5 regulates accurate maturation of newborn granule cells in the adult hippocampus (2008) PLoS Biol., 6, p. 272; Kusakawa, G., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T., Hisanaga, S., Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25 (2000) J. Biol. Chem., 275, pp. 17166-17172; Qu, Z.S., Li, L., Sun, X.J., Zhao, Y.W., Zhang, J., Geng, Z., Fu, J.L., Ren, Q.G., Glycogen synthase kinase-3 regulates production of amyloid-beta peptides and tau phosphorylation in diabetic rat brain (2014) Sci. World J., 2014, p. 878123; Phiel, C.J., Wilson, C.A., Lee, V.M., Klein, P.S., GSK-3alpha regulates production of Alzheimers disease amyloid-beta peptides (2003) Nature, 423, pp. 435-439; Liu, S.J., Zhang, J.Y., Li, H.L., Fang, Z.Y., Wang, Q., Deng, H.M., Gong, C.X., Wang, J.Z., Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain (2004) J. Biol. Chem., 279, pp. 50078-50088; Giese, K.P., GSK-3: A key player in neurodegeneration and memory (2009) IUBMB Life, 61, pp. 516-521; Clodfelder-Miller, B., De Sarno, P., Zmijewska, A.A., Song, L., Jope, R.S., Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3 (2005) J. Biol. Chem., 280, pp. 39723-39731; Dajani, R., Fraser, E., Roe, S.M., Young, N., Good, V., Dale, T.C., Pearl, L.H., Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition (2001) Cell, 105, pp. 721-732; Marshak, D.R., Pesce, S.A., Stanley, L.C., Griffin, W.S., Increased S100 beta neurotrophic activity in Alzheimers disease temporal lobe (1992) Neurobiol. Aging, 13, pp. 1-7; Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.M., Perez-Tur, J., Hutton, M., Younkin, S., Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1 (1996) Nature, 383, pp. 710-713; Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Selkoe, D.J., Mutant presenilins of Alzheimers disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice (1997) Nat. Med., 3, pp. 67-72; Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M.B., Teplow, D.B., Haass, C., Selkoe, D.J., Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins (1997) J. Biol. Chem., 272, pp. 7977-7982; Layfield, R., Lowe, J., Bedford, L., The ubiquitin-proteasome system and neurodegenerative disorders (2005) Essays Biochem., 41, pp. 157-171; Hsu, A.L., Murphy, C.T., Kenyon, C., Regulation of aging and age-related disease by DAF-16 and heat-shock factor (2003) Science, 300, pp. 1142-1145; Morley, J.F., Morimoto, R.I., Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones (2004) Mol. Biol. Cell, 15, pp. 657-664; Hartl, F.U., Bracher, A., Hayer-Hartl, M., Molecular chaperones in protein folding and proteostasis (2011) Nature, 475, pp. 324-332; Proctor, C.J., Lorimer, I.A., Modelling the role of the Hsp70/Hsp90 system in the maintenance of protein homeostasis (2011) PLoS One, 6, p. 22038; Kelly, S., Yenari, M.A., Neuroprotection: Heat shock proteins (2002) Curr. Med. Res. Opin., 18, pp. 55-60; Evans, C.G., Wisen, S., Gestwicki, J.E., Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro (2006) J. Biol. Chem., 281, pp. 33182-33191; Stefani, M., Dobson, C.M., Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution (2003) J. Mol. Med. (Heidelberg, Ger.), 81, pp. 678-699; Jinwal, U.K., Koren, J., Oleary, J.C., Jones, J.R., Abisambra, J.F., Dickey, C.A., Hsp70 ATPase modulators as therapeutics for Alzheimers and other neurodegenerative diseases (2010) Mol. Cell. Pharmacol., 2, pp. 43-46; Broer, L., Ikram, M.A., Schuur, M., Destefano, A.L., Bis, J.C., Liu, F., Rivadeneira, F., Van Duijn, C.M., Association of HSP70 and its co-chaperones with Alzheimers disease (2011) J. Alzheimers Dis., 25, pp. 93-102; Patterson, K.R., Ward, S.M., Combs, B., Voss, K., Kanaan, N.M., Morfini, G., Brady, S.T., Binder, L.I., Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport (2011) Biochemistry, 50, pp. 10300-10310",Article,Scopus,2-s2.0-84928124392
"Martin M.D., Calcul L., Smith C., Jinwal U.K., Fontaine S.N., Darling A., Seeley K., Wojtas L., Narayan M., Gestwicki J.E., Smith G.R., Reitz A.B., Baker B.J., Dickey C.A.","Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic Tau clearance",2015,"ACS Chemical Biology","10","4",,"1099","1109",,,10.1021/cb501013w,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928403118&partnerID=40&md5=699b76c910c77e96035ec40269365f74","Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Department of Pharmaceutical Chemistry, University of California, San FranciscoSan Francisco, CA, United States; ALS Biopharma, LLC, 3805 Old Easton RoadDoylestown, PA, United States; James A. Haley Veterans Hospital, 13000 Bruce B. Downs BoulevardTampa, FL, United States","Martin, M.D., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Calcul, L., Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Smith, C., Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Jinwal, U.K., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Fontaine, S.N., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Darling, A., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Seeley, K., Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Wojtas, L., Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Narayan, M., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States; Gestwicki, J.E., Department of Pharmaceutical Chemistry, University of California, San FranciscoSan Francisco, CA, United States; Smith, G.R., ALS Biopharma, LLC, 3805 Old Easton RoadDoylestown, PA, United States; Reitz, A.B., ALS Biopharma, LLC, 3805 Old Easton RoadDoylestown, PA, United States; Baker, B.J., Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States; Dickey, C.A., Department of Molecular Medicine and Alzheimers Institute, University of South FloridaTampa, FL, United States, Department of Chemistry and Center for Drug Discovery and Innovation, University of South FloridaTampa, FL, United States, James A. Haley Veterans Hospital, 13000 Bruce B. Downs BoulevardTampa, FL, United States","We previously discovered that one specific scalemic preparation of myricanol (1), a constituent of Myrica cerifera (bayberry/southern wax myrtle) root bark, could lower the levels of the microtubule-associated protein tau (MAPT). The significance is that tau accumulates in a number of neurodegenerative diseases, the most common being Alzheimers disease (AD). Herein, a new synthetic route to prepare myricanol using a suitable boronic acid pinacol ester intermediate is reported. An X-ray crystal structure of the isolated myricanol (1) was obtained and showed a co-crystal consisting of (+)-aR,11S-myricanol (2) and (-)-aS,11R-myricanol (3) coformers. Surprisingly, 3, obtained from chiral separation from 1, reduced tau levels in both cultured cells and ex vivo brain slices from a mouse model of tauopathy at reasonable mid-to-low micromolar potency, whereas 2 did not. SILAC proteomics and cell assays revealed that 3 promoted tau degradation through an autophagic mechanism, which was in contrast to that of other tau-lowering compounds previously identified by our group. During the course of structure-activity relationship (SAR) development, we prepared compound 13 by acid-catalyzed dehydration of 1. 13 had undergone an unexpected structural rearrangement through the isomyricanol substitution pattern (e.g., 16), as verified by X-ray structural analysis. Compound 13 displayed robust tau-lowering activity, and, importantly, its enantiomers reduced tau levels similarly. Therefore, the semisynthetic analogue 13 provides a foundation for further development as a tau-lowering agent without its SAR being based on chirality. © 2015 American Chemical Society.",,"Hardy, J., Orr, H., The genetics of neurodegenerative diseases (2006) J. Neurochem., 97, pp. 1690-1699; McKee, A.C., Cantu, R.C., Nowinski, C.J., Hedley-Whyte, E.T., Gavett, B.E., Budson, A.E., Santini, V.E., Stern, R.A., Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury (2009) J. Neuropathol. Exp. Neurol., 68, pp. 709-735; Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration (2013) Lancet. Neurol., 12, pp. 609-622; Lee, V.M., Goedert, M., Trojanowski, J.Q., Neurodegenerative tauopathies (2001) Annu. Rev. Neurosci., 24, pp. 1121-1159; Iqbal, K., Alonso, A.D., Gondal, J.A., Gong, C.X., Haque, N., Khatoon, S., Sengupta, A., Grundke-Iqbal, I., Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach (2000) J. Neural Transm., Suppl., 59, pp. 213-222; Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., Santacruz, K., Guimaraes, A., Ashe, K.H., Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) (2005) J. Neurosci., 25, pp. 10637-10647; Gerson, J.E., Castillo-Carranza, D.L., Kayed, R., Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species (2014) ACS Chem. Neurosci., 5, pp. 752-769; Nygaard, H.B., Van Dyck, C.H., Strittmatter, S.M., Fyn kinase inhibition as a novel therapy for Alzheimers disease (2014) Alzheimers Res. Ther., 6, p. 8; Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Hermine, O., Masitinib as an adjunct therapy for mild-to-moderate Alzheimers disease: A randomised, placebo-controlled phase 2 trial (2011) Alzheimers Res. Ther., 3, p. 16; Blair, L.J., Nordhues, B.A., Hill, S.E., Scaglione, K.M., Fontaine, S.N., Breydo, L., Zhang, B., Dickey, C.A., Accelerated neurodegeneration through chaperone-mediated oligomerization of tau (2013) J. Clin. Invest., 123, pp. 4158-4169; Congdon, E.E., Figueroa, Y.H., Wang, L., Toneva, G., Chang, E., Kuret, J., Conrad, C., Duff, K.E., Inhibition of tau polymerization with a cyanine dye in two distinct model systems (2009) J. Biol. Chem., 284, pp. 20830-20839; Ballatore, C., Crowe, A., Piscitelli, F., James, M., Lou, K., Rossidivito, G., Yao, Y., Iii., B.S.A., Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties (2012) Bioorg. Med. Chem., 20, pp. 4451-4461; Brunden, K.R., Trojanowski, J.Q., Lee, V.M., Advances in tau-focused drug discovery for Alzheimers disease and related tauopathies (2009) Nat. Rev. Drug Discovery, 8, pp. 783-793; Blair, L.J., Zhang, B., Dickey, C.A., Potential synergy between tau aggregation inhibitors and tau chaperone modulators (2013) Alzheimers Res. Ther., 5, p. 41; Jinwal, U.K., Miyata, Y., Jones, J.R., Trotter, J.H., Chang, L., Oleary, J., Morgan, D., Dickey, C.A., Chemical manipulation of hsp70 ATPase activity regulates tau stability (2009) J. Neurosci., 29, pp. 12079-12088; Lee, M.J., Lee, J.H., Rubinsztein, D.C., Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system (2013) Prog. Neurobiol., 105, pp. 49-59; Miyata, Y., Li, X., Lee, H.F., Jinwal, U.K., Srinivasan, S.R., Seguin, S.P., Young, Z.T., Gestwicki, J.E., Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels (2013) ACS Chem. Neurosci., 4, pp. 930-939; Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., Ash, P., Petrucelli, L., The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins (2007) J. Clin. Invest., 117, pp. 648-658; Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Chiosis, G., Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies (2007) Proc. Natl. Acad. Sci. U.S.A., 104, pp. 9511-9516; Erlichman, C., Tanespimycin: The opportunities and challenges of targeting heat shock protein 90 (2009) Expert Opin. Investig. Drugs, 18, pp. 861-868; Sidera, K., Patsavoudi, E., HSP90 inhibitors: Current development and potential in cancer therapy (2014) Recent Pat. Anti-Cancer Drug Discovery, 9, pp. 1-20; Jhaveri, K., Ochiana, S.O., Dunphy, M.P., Gerecitano, J.F., Corben, A.D., Peter, R.I., Janjigian, Y.Y., Chiosis, G., Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions (2014) Expert Opin. Invest. Drugs, 23, pp. 611-628; O'Leary, J.C., III, Li, Q., Marinec, P., Blair, L.J., Congdon, E.E., Johnson, A.G., Jinwal, U.K., Dickey, C.A., Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden (2010) Mol. Neurodegener., 5, p. 45; Congdon, E.E., Wu, J.W., Myeku, N., Figueroa, Y.H., Herman, M., Marinec, P.S., Gestwicki, J.E., Duff, K.E., Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo (2012) Autophagy, 8, pp. 609-622; Rubinsztein, D.C., The roles of intracellular protein-degradation pathways in neurodegeneration (2006) Nature, 443, pp. 780-786; Dolan, P.J., Johnson, G.V., A caspase cleaved form of tau is preferentially degraded through the autophagy pathway (2010) J. Biol. Chem., 285, pp. 21978-21987; Caccamo, A., Majumder, S., Richardson, A., Strong, R., Oddo, S., Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments (2010) J. Biol. Chem., 285, pp. 13107-13120; Majumder, S., Richardson, A., Strong, R., Oddo, S., Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits (2011) PLoS One, 6, p. 25416; Zhu, X.C., Yu, J.T., Jiang, T., Tan, L., Autophagy modulation for Alzheimers disease therapy (2013) Mol. Neurobiol., 48, pp. 702-714; Jones, J.R., Lebar, M.D., Jinwal, U.K., Abisambra, J.F., Blair, L., Oleary, J.C., Davey, Z., Dickey, C.A., The diarylheptanoid (+)-a R,11 S -myricanol and two flavones from bayberry (Myrica cerifera) destabilize the microtubule-associated protein tau (2011) J. Nat. Prod., 74, pp. 38-44; Dai, G.H., Meng, G.M., Tong, Y.L., Chen, X., Ren, Z.M., Wang, K., Yang, F., Growth-inhibiting and apoptosis-inducing activities of myricanol from the bark of Myrica rubra in human lung adenocarcinoma A549 cells (2014) Phytomedicine, 21, pp. 1490-1496; Whiting, D.A., Wood, A.F., Cyclisation of 1,7-diarylheptanoids through oxidative, reductive, and photochemical radical processes: Total synthesies of the m,m-bridged biaryls myricanone and (±)-myricanol, and a related diarylether (1978) Tetrahedron Lett., pp. 2335-2338; Weyer, M.J., Nye, J.J., Ostlund, A.J., Cook, G.R., (2013) Total Synthesis of the Diarylheptanoid (+)-aR,11S-myricanol, , ORGN-182, American Chemical Society, 245th ACS National Meeting & Exposition, New Orleans, LA, United States; Riley, A.P., Prisinzano, T.E., (2012) Studies Toward the Total Synthesis of (+)-aR,11S-myricanol, , ORGN-242, American Chemical Society, 244th ACS National Meeting & Exposition, Philadelphia, PA, United States; Ogura, T., Usuki, T., Total synthesis of acerogenins E, G and K, and centrolobol (2013) Tetrahedron, 69, pp. 2807-2815; Semmelhack, M.F., Helquist, P., Jones, L.D., Keller, L., Mendelson, L.S.R., Smith, J.G., Stauffer, R.D., Reaction of aryl and vinyl halides with zerovalent nickel-preparative aspects and the synthesis of alnusone (1981) J. Am. Chem. Soc., 103, pp. 6460-6471; Joshi, B.S., Pelletier, S.W., Newton, M.G., Lee, D., McGaughey, G.B., Puar, M.S., Extensive 1D, 2D NMR spectra of some [7.0]metacyclophanes and X-ray analysis of (±)-myricanol (1996) J. Nat. Prod., 59, pp. 759-764; Begley, M.J., Campbell, R.V.M., Crombie, L., Tuck, B., Whiting, D.A., Constitution and absolute configuration of meta, meta -bridged, strained biphenyls from Myrica nagi; X-Ray analysis of 16-bromomyricanol (1971) J. Chem. Soc. C, pp. 3634-3642; Abisambra, J., Jinwal, U.K., Miyata, Y., Rogers, J., Blair, L., Li, X., Seguin, S.P., Dickey, C.A., Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau (2013) Biol. Psychiatry, 74, pp. 367-374; Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., Ashe, K.H., Tau suppression in a neurodegenerative mouse model improves memory function (2005) Science, 309, pp. 476-481; Jinwal, U.K., Akoury, E., Abisambra, J.F., Thompson, A.D., Blair, L.J., Jin, Y., Bacon, J., Dickey, C.A., Imbalance of Hsp70 family variants fosters tau accumulation (2013) FASEB J., 27, pp. 1450-1459; Kruger, U., Wang, Y., Kumar, S., Mandelkow, E.M., Autophagic degradation of tau in primary neurons and its enhancement by trehalose (2012) Neurobiol. Aging, 33, pp. 2291-2305; Caccamo, A., De Pinto, V., Messina, A., Branca, C., Oddo, S., Genetic reduction of mammalian target of rapamycin ameliorates Alzheimers disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature (2014) J. Neurosci., 34, pp. 7988-7998; Mizushima, N., Yoshimori, T., Levine, B., Methods in mammalian autophagy research (2010) Cell, 140, pp. 313-326; Pampliega, O., Orhon, I., Patel, B., Sridhar, S., Diaz-Carretero, A., Beau, I., Codogno, P., Cuervo, A.M., Functional interaction between autophagy and ciliogenesis (2013) Nature, 502, pp. 194-200; Abisambra, J.F., Jinwal, U.K., Blair, L.J., Li, Q., Brady, S., Wang, L., Guidi, C.E., Dickey, C.A., Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation (2013) J. Neurosci., 33, pp. 9498-9507; Steelman, L.S., Abrams, S.L., Whelan, J., Bertrand, F.E., Ludwig, D.E., Basecke, J., Libra, M., McCubrey, J.A., Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia (2008) Leukemia, 22, pp. 686-707; Sakurai, N., Yaguchi, Y., Hirakawa, T., Nagai, M., Inoue, T., Two myricanol glycosides from Myrica rubra and revision of the structure of isomyricanone (1991) Phytochemistry, 30, pp. 3077-3079; Baell, J.B., Holloway, G.A., New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays (2010) J. Med. Chem., 53, pp. 2719-2740; Chaput, D., Kirouac, L.H., Bell-Temin, H., Stevens, Jr.S.M., Padmanabhan, J., SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells (2012) Electrophoresis, 33, pp. 3728-3737",Article,Scopus,2-s2.0-84928403118
"Bhowmik D., Das A.K., Maiti S.","Rapid, cell-free assay for membrane-active forms of amyloid-β",2015,"Langmuir","31","14",,"4049","4053",,,10.1021/la502679t,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927726715&partnerID=40&md5=3bc3446095d17dd67b33c12fe630b757","Department of Chemical Sciences, Tata Institute of Fundamental ResearchMumbai, India","Bhowmik, D., Department of Chemical Sciences, Tata Institute of Fundamental ResearchMumbai, India; Das, A.K., Department of Chemical Sciences, Tata Institute of Fundamental ResearchMumbai, India; Maiti, S., Department of Chemical Sciences, Tata Institute of Fundamental ResearchMumbai, India","Small oligomers of amyloid beta (Aβ) are suspected to be the key to Alzheimers disease (AD). However, identifying these toxic species in the background of other similar but nontoxic Aβ aggregates has remained a challenge. Recent studies indicate that Aβ undergoes a global structural transition in an early step of aggregation. This transition is marked by a strong increase in its affinity for cell membranes, which suggests that the resultant oligomers could be the key to Aβ toxicity. Here we use this increased membrane affinity to develop a rapid, quantitative, cell-free assay for these bioactive oligomers. It uses fluorescence correlation spectroscopy of fluorescently labeled Aβ and requires only 30 s of measurement time. We also describe a simpler (though less rapid) assay based on the same principles, which uses a dialysis step followed by conventional fluorescence spectroscopy. Our results potentially provide a much-needed high-throughput assay for AD drug development. © 2014 American Chemical Society.",,"Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Klein, W.L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins (1998) Proc. Natl. Acad. Sci. U.S.A., 95, pp. 6448-6453; Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539; Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, Jr.P.T., Neurodegenerative disease: Amyloid pores from pathogenic mutations (2002) Nature, 418, p. 291; Dubnovitsky, A., Sandberg, A., Rahman, M.M., Benilova, I., Lendel, C., Hard, T., Amyloid-beta Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic (2013) PLoS One, p. 8; Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway (2007) J. Neurosci., 27, pp. 2866-2875; Benilova, I., Karran, E., De Strooper, B., The toxic Abeta oligomer and Alzheimers disease: An emperor in need of clothes (2012) Nat. Neurosci, 15, pp. 349-357; Nag, S., Sarkar, B., Bandyopadhyay, A., Sahoo, B., Sreenivasan, V.K., Kombrabail, M., Muralidharan, C., Maiti, S., Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium (2011) J. Biol. Chem., 286, pp. 13827-13833; Bhowmik, D., Maclaughlin, C.M., Chandrakesan, M., Ramesh, P., Venkatramani, R., Walker, G.C., Maiti, S., PH changes the aggregation propensity of amyloid-beta without altering the monomer conformation (2014) Phys. Chem. Chem. Phys., 16, pp. 885-889; Sarkar, B., Mithu, V.S., Chandra, B., Mandal, A., Chandrakesan, M., Bhowmik, D., Madhu, P.K., Maiti, S., Significant Structural Differences between Transient Amyloid-beta Oligomers and Less-Toxic Fibrils in Regions Known to Harbor Familial Alzheimers Mutations (2014) Angew. Chem., 53, pp. 6888-6892; Sarkar, B., Das, A.K., Maiti, S., Thermodynamically stable amyloid-beta monomers have much lower membrane affinity than the small oligomers (2013) Front. Physiol., 4, p. 84; Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid (2001) J. Biol. Chem., 276, pp. 24985-24990; Wong, P.T., Schauerte, J.A., Wisser, K.C., Ding, H., Lee, E.L., Steel, D.G., Gafni, A., Amyloid-beta Membrane Binding and Permeabilization are Distinct Processes Influenced Separately by Membrane Charge and Fluidity (2009) J. Mol. Biol., 386, pp. 81-96; Bag, N., Ali, A., Chauhan, V.S., Wohland, T., Mishra, A., Membrane destabilization by monomeric hIAPP observed by imaging fluorescence correlation spectroscopy (2013) Chem. Commun., 49, pp. 9155-9157; Van Rooijen, B.D., Claessens, M.M., Subramaniam, V., Membrane interactions of oligomeric alpha-synuclein: Potential role in Parkinsons disease (2010) Curr. Protein Pept. Sci., 11, pp. 334-342; Decker, H., Jurgensen, S., Adrover, M.F., Brito-Moreira, J., Bomfim, T.R., Klein, W.L., Epstein, A.L., Ferreira, S.T., N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimers toxic amyloid-beta peptide oligomers (2010) J. Neurochem., 115, pp. 1520-1529; Dinamarca, M.C., Weinstein, D., Monasterio, O., Inestrosa, N.C., The synaptic protein neuroligin-1 interacts with the amyloid beta-peptide. Is there a role in Alzheimers disease? (2011) Biochemistry, 50, pp. 8127-8137; Yanagisawa, K., Odaka, A., Suzuki, N., Ihara, Y., Gm1 Gangloside-Bound Amyloid Beta-Protein (Ab) - A Possible Form of Preamyloid in Alzheimers-Disease (1995) Nat. Med., 1, pp. 1062-1066; Hertel, C., Terzi, E., Hauser, N., Jakob-Rotne, R., Seelig, J., Kemp, J.A., Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 9412-9416; Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E., Glabe, C.G., Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases (2004) J. Biol. Chem., 279, pp. 46363-46366; Fagan, T., Kagan, B., Nault, L., Hwang, W., Glabe, C., Lal, R., Albensi, B., Sokolov, Y., Alzheimer research forum live discussion: Now you see them, now you dont: The amyloid channel hypothesis (2006) J. Alzheimers Dis., 9, pp. 219-224; Lin, H., Bhatia, R., Lal, R., Amyloid beta protein forms ion channels: Implications for Alzheimers disease pathophysiology (2001) FASEB J., 15, pp. 2433-2444; Tjernberg, L.O., Pramanik, A., Bjorling, S., Thyberg, P., Thyberg, J., Nordstedt, C., Berndt, K.D., Rigler, R., Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy (1999) Chem. Biol., 6, pp. 53-62; Sengupta, P., Garai, K., Sahoo, B., Shi, Y., Callaway, D.J., Maiti, S., The amyloid beta peptide (Abeta(1-40)) is thermodynamically soluble at physiological concentrations (2003) Biochemistry, 42, pp. 10506-10513; Sengupta, P., Balaji, J., Maiti, S., Measuring diffusion in cell membranes by fluorescence correlation spectroscopy (2002) Methods, 27, pp. 374-387; Culbertson, C.T., Jacobson, S.C., Michael Ramsey, J., Diffusion coefficient measurements in microfluidic devices (2002) Talanta, 56, pp. 365-373; White, L.A., Eaton, M.J., Castro, M.C., Klose, K.J., Globus, M.Y., Shaw, G., Whittemore, S.R., Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons (1994) J. Neurosci., 14, pp. 6744-6753; Bokvist, M., Lindstrom, F., Watts, A., Grobner, G., Two types of Alzheimers beta-amyloid (1-40) peptide membrane interactions: Aggregation preventing transmembrane anchoring Versus accelerated surface fibril formation (2004) J. Mol. Biol., 335, pp. 1039-1049; Lemkul, J.A., Bevan, D.R., Lipid composition influences the release of Alzheimers amyloid beta-peptide from membranes (2011) Protein Sci., 20, pp. 1530-1545",Article,Scopus,2-s2.0-84927726715
"Kong X., Zhao Z., Lei X., Zhang B., Dai D., Jiang L.","Interaction of metal ions with the his13-his14 sequence relevant to alzheimers disease",2015,"Journal of Physical Chemistry A","119","14",,"3528","3534",,,10.1021/acs.jpca.5b01443,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927153717&partnerID=40&md5=fa9d8fb7abd82e0b848524cb880dd0cc","State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China; School of Physics and Optoelectronic Technology, Dalian University of TechnologyDalian, China; State Key Laboratory of Fine Chemicals, Dalian University of TechnologyDalian, China","Kong, X., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China; Zhao, Z., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China, School of Physics and Optoelectronic Technology, Dalian University of TechnologyDalian, China; Lei, X., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China; Zhang, B., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China, State Key Laboratory of Fine Chemicals, Dalian University of TechnologyDalian, China; Dai, D., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China; Jiang, L., State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, Liaoning, China","The interaction of a series of metal ions (i.e., groups 1 and 2, first-row transition metals, and groups 11-14) with the His13-His14 sequence relevant to Alzheimers disease has been studied using quantum chemical calculations. Metal ions prefer to occupy three coordination sites at two N<inf>γ</inf> of the imidazole rings and one carbonyl oxygen. Simulated IR spectra reveal that vibrational frequency of C-O stretch affords a sensitive probe for understanding the interaction of His13-His14 with metal ions. The relative strength of the interaction of His13-His14 with the representative metal ions follows the order of K+ < Ca2+ < Zn2+ < Cu2+ < Fe3+ < Al3+, which is closely correlated with the available experimental results, providing a vivid physical picture about how metal ions bind to amyloid β-peptide. IR spectra of the [M·(His13-His14)]n+ complexes could be measured by infrared photodissociation spectroscopic technique and thus afford useful information for the understanding of structure-function relationship and the design of suitable drugs. © 2015 American Chemical Society.",,"Goedert, M., Spillantini, M.G., A Century of Alzheimers Disease (2006) Science, 314, pp. 777-781; Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome (1985) Proc. Natl. Acad. Sci. U.S.A., 82, pp. 4245-4249; Hardy, J., Selkoe, D.J., Medicine: The Amyloid Hypothesis of Alzheimers Disease: Progress and Problems on the Road to Therapeutics (2002) Science, 297, pp. 353-356; Mattson, M.P., Pathways Towards and Away from Alzheimers Disease (2004) Nature, 430, pp. 631-639; Gaggelli, E., Kozlowski, H., Valensin, D., Valensin, G., Copper Homeostasis and Neurodegenerative Disorders (Alzheimers, Prion, and Parkinsons Diseases and Amyotrophic Lateral Sclerosis) (2006) Chem. Rev., 106, pp. 1995-2044; Rauk, A., Why is the Amyloid Beta Peptide of Alzheimers Disease Neurotoxic? (2008) Dalton Trans., pp. 1273-1282; Faller, P., Hureau, C., Bioinorganic Chemistry of Copper and Zinc Ions Coordinated to Amyloid-Beta Peptide (2009) Dalton Trans., pp. 1080-1094; Rauk, A., The Chemistry of Alzheimers Disease (2009) Chem. Soc. Rev., 38, pp. 2698-2715; Miller, Y., Ma, B., Nussinov, R., Polymorphism in Alzheimer A-Beta Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape (2010) Chem. Rev., 110, pp. 4820-4838; Kepp, K.P., Bioinorganic Chemistry of Alzheimers Disease (2012) Chem. Rev., 112, pp. 5193-5239; Mantyh, P.W., Ghilardi, J.R., Rogers, S., Demaster, E., Allen, C.J., Stimson, E.R., Maggio, J.E., Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of Beta-Amyloid Peptide (1993) J. Neurochem., 61, pp. 1171-1174; Bush, A.I., Pettingell, W.H., Multhaup, G., Paradis, M.D., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Tanzi, R.E., Rapid Induction of Alzheimer A-Beta Amyloid Formation by Zinc (1994) Science, 265, pp. 1464-1467; Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., Markesbery, W.R., Copper, Iron and Zinc in Alzheimers Disease Senile Plaques (1998) J. Neurol. Sci., 158, pp. 47-52; Atwood, C.S., Moir, R.D., Huang, X.D., Scarpa, R.C., Bacarra, N.M.E., Romano, D.M., Hartshorn, M.K., Bush, A.I., Dramatic Aggregation of Alzheimer A-Beta by Cu(II) is Induced by Conditions Representing Physiological Acidosis (1998) J. Biol. Chem., 273, pp. 12817-12826; Hung, Y.H., Bush, A.I., Cherny, R.A., Copper in the Brain and Alzheimers Disease (2010) J. Biol. Inorg. Chem., 15, pp. 61-76; Huang, X.D., Atwood, C.S., Hartshorn, M.A., Multhaup, G., Goldstein, L.E., Scarpa, R.C., Cuajungco, M.P., Moir, R.D., The A-Beta Peptide of Alzheimers Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction (1999) Biochemistry, 38, pp. 7609-7616; Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Shimohama, S., Oxidative Damage is the Earliest Event in Alzheimer Disease (2001) J. Neuropathol. Exp. Neurol., 60, pp. 759-767; Dong, J., Atwood, C.S., Anderson, V.E., Siedlak, S.L., Smith, M.A., Perry, G., Carey, P.R., Metal Binding and Oxidation of Amyloid-Beta within Isolated Senile Plaque Cores: Raman Microscopic Evidence (2003) Biochemistry, 42, pp. 2768-2773; Curtain, C.C., Ali, F., Volitakis, I., Cherny, R.A., Norton, R.S., Beyreuther, K., Barrow, C.J., Barnham, K.J., Alzheimers Disease Amyloid-Beta Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-Penetrating Structure Containing Superoxide Dismutase-Like Subunits (2001) J. Biol. Chem., 276, pp. 20466-20473; Hou, L., Zagorski, M.G., NMR Reveals Anomalous Copper(II) Binding to the Amyloid A-Beta Peptide of Alzheimers Disease (2006) J. Am. Chem. Soc., 128, pp. 9260-9261; Gaggelli, E., Janicka-Klos, A., Jankowska, E., Kozlowski, H., Migliorini, C., Molteni, E., Valensin, D., Wieczerzak, E., NMR Studies of the Zn2+ Interactions with Rat and Human Beta-Amyloid (1-28) Peptides in Water-Micelle Environment (2008) J. Phys. Chem. B, 112, pp. 100-109; Guilloreau, L., Damian, L., Coppel, Y., Mazarguil, H., Winterhalter, M., Faller, P., Structural and Thermodynamical Properties of Cu-II Amyloid-Beta 16/28 Complexes Associated with Alzheimers Disease (2006) J. Biol. Inorg. Chem., 11, pp. 1024-1038; Parthasarathy, S., Long, F., Miller, Y., Xiao, Y., McElheny, D., Thurber, K., Ma, B., Ishii, Y., Molecular-Level Examination of Cu2+ Binding Structure for Amyloid Fibrils of 40-Residue Alzheimers Beta by Solid-State NMR Spectroscopy (2011) J. Am. Chem. Soc., 133, pp. 3390-3400; Drew, S.C., Masters, C.L., Barnham, K.J., Alanine-2 Carbonyl is an Oxygen Ligand in Cu2+ Coordination of Alzheimers Disease Amyloid-Beta Peptide - Relevance to N-Terminally Truncated Forms (2009) J. Am. Chem. Soc., 131, pp. 1195-1207; Morante, S., The Role of Metals in Beta-Amyloid Peptide Aggregation: X-Ray Spectroscopy and Numerical Simulations (2008) Curr. Alzheimer Res., 5, pp. 508-524; Faller, P., Hureau, C., Impact of Metallic Ions in Alzheimers Disease: Insights from XAS Spectroscopy (2011) Actual. Chim., pp. 88-90; El Khoury, Y., Dorlet, P., Faller, P., Hellwig, P., New Insights into the Coordination of Cu(II) by the Amyloid-B (16) Peptide from Fourier Transform IR Spectroscopy and Isotopic Labeling (2011) J. Phys. Chem. B, 115, pp. 14812-14821; Miller, Y., Ma, B., Nussinov, R., Zinc Ions Promote Alzheimer A-Beta Aggregation via Population Shift of Polymorphic States (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 9490-9495; Ali-Torres, J., Rodriguez-Santiago, L., Sodupe, M., Rauk, A., Structures and Stabilities of Fe2+/3+ Complexes Relevant to Alzheimers Disease: An Ab Initio Study (2011) J. Phys. Chem. A, 115, pp. 12523-12530; Ali-Torres, J., Marechal, J.-D., Rodriguez-Santiago, L., Sodupe, M., Three Dimensional Models of Cu2+-A-Beta(1-16) Complexes from Computational Approaches (2011) J. Am. Chem. Soc., 133, pp. 15008-15014; Raffa, D.F., Gomez-Balderas, R., Brunelle, P., Rickard, G.A., Rauk, A., Ab Initio Model Studies of Copper Binding to Peptides Containing a His-His Sequence: Relevance to the Beta-Amyloid Peptide of Alzheimers Disease (2005) J. Biol. Inorg. Chem., 10, pp. 887-902; Okumura, M., Yeh, L.I., Lee, Y.T., The Vibrational Predissociation Spectroscopy of Hydrogen Cluster Ions (1985) J. Chem. Phys., 83, pp. 3705-3706; Bieske, E.J., Dopfer, O., High-Resolution Spectroscopy of Cluster Ions (2000) Chem. Rev., 100, pp. 3963-3998; Von Helden, G., Van Heijnsbergen, D., Meijer, G., Resonant Ionization Using IR Light: A New Tool to Study the Spectroscopy and Dynamics of Gas-Phase Molecules and Clusters (2003) J. Phys. Chem. A, 107, pp. 1671-1688; Lisy, J.M., Infrared Studies of Ionic Clusters: The Influence of Yuan T. Lee (2006) J. Chem. Phys., 125, pp. 1323021-13230219; Rizzo, T.R., Stearns, J.A., Boyarkin, O.V., Spectroscopic Studies of Cold, Gas-Phase Biomolecular Ions (2009) Int. Rev. Phys. Chem., 28, pp. 481-515; Polfer, N.C., Oomens, J., Vibrational Spectroscopy of Bare and Solvated Ionic Complexes of Biological Relevance (2009) Mass Spectrom. Rev., 28, pp. 468-494; Fridgen, T.D., Infrared Consequence Spectroscopy of Gaseous Protonated and Metal Ion Cationized Complexes (2009) Mass Spectrom. Rev., 28, pp. 586-607; Garand, E., Kamrath, M.Z., Jordan, P.A., Wolk, A.B., Leavitt, C.M., McCoy, A.B., Miller, S.J., Johnson, M.A., Determination of Noncovalent Docking by Infrared Spectroscopy of Cold Gas-Phase Complexes (2012) Science, 335, pp. 694-698; Wolk, A.B., Leavitt, C.M., Garand, E., Johnson, M.A., Cryogenic Ion Chemistry and Spectroscopy (2014) Acc. Chem. Res., 47, pp. 202-210; TURBOMOLE, , V6.3 2011; University of Karlsruhe and Forschungszentrum Karlsruhe GmbH: Karlsruhe, Germany, 2011; Savoca, M., Wende, T., Jiang, L., Langer, J., Meijer, G., Dopfer, O., Asmis, K.R., Infrared Spectra and Structures of Silver-PAH Cation Complexes (2011) J. Phys. Chem. Lett., 2, pp. 2052-2056; Hurlburt, P.K., Anderson, O.P., Strauss, S.H., Ag(CO)B(OTeF<inf>5</inf>)<inf>4</inf>: The 1ST Isolable Silver Carbonyl (1991) J. Am. Chem. Soc., 113, pp. 6277-6278; Hurlburt, P.K., Rack, J.J., Luck, J.S., Dec, S.F., Webb, J.D., Anderson, O.P., Strauss, S.H., Nonclassical Metal-Carbonyls: Ag(CO)+ and Ag(CO)<inf>2</inf>+ (1994) J. Am. Chem. Soc., 116, pp. 10003-10014; Rack, J.J., Webb, J.D., Strauss, S.H., Cu(CO)<inf>n</inf>+ Complex Ions in the Solid State (n = 1, 2, 3) (1996) Inorg. Chem., 35, pp. 277-278; Lupinetti, A.J., Frenking, G., Strauss, S.H., Nonclassical Metal Carbonyls: Appropriate Definitions with a Theoretical Justification (1998) Angew. Chem., Int. Ed., 37, pp. 2113-2116; Velasquez, J., III, Njegic, B., Gordon, M.S., Duncan, M.A., IR Photodissociation Spectroscopy and Theory of Au+(CO)<inf>n</inf> Complexes: Nonclassical Carbonyls in the Gas Phase (2008) J. Phys. Chem. A, 112, pp. 1907-1913; Goldman, A.S., Kroghjespersen, K., Why Do Cationic Carbon Monoxide Complexes Have High C-O Stretching Force Constants and Short C-O Bonds? Electrostatic Effects, Not Sigma-Bonding (1996) J. Am. Chem. Soc., 118, pp. 12159-12166; Lupinetti, A.J., Fau, S., Frenking, G., Strauss, S.H., Theoretical Analysis of the Bonding between CO and Positively Charged Atoms (1997) J. Phys. Chem. A, 101, pp. 9551-9559; Frenking, G., Loschen, C., Krapp, A., Fau, S., Strauss, S.H., Electronic Structure of CO: An Exercise in Modern Chemical Bonding Theory (2007) J. Comput. Chem., 28, pp. 117-126; Chen, M., Zhang, Q., Zhou, M., Andrada, D.M., Frenking, G., Carbon Monoxide Bonding with BeO and BeCO<inf>3</inf>: Surprisingly High CO Stretching Frequency of OCBeCO<inf>3</inf> (2015) Angew. Chem., Int. Ed., 54, pp. 124-128; Shieh, C.C., Coghlan, M., Sullivan, J.P., Gopalakrishnan, M., Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities (2000) Pharmacol. Rev., 52, pp. 557-593; Rauer, H., Lanigan, M.D., Pennington, M.W., Aiyar, J., Ghanshani, S., Cahalan, M.D., Norton, R.S., Chandy, K.G., Structure-Guided Transformation of Charybdotoxin Yields an Analog that Selectively Targets Ca2+-Activated over Voltage-Gated K+ Channels (2000) J. Biol. Chem., 275, pp. 1201-1208; Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Nicotera, P., Glutamate-Induce Neuronal Death: A Succession of Necrosis or Apoptosis Depending on Mitochondrial-Function (1995) Neuron, 15, pp. 961-973; You, H., Tsutsui, S., Hameed, S., Kannanayakal, T.J., Chen, L., Xia, P., Engbers, J.D.T., Zamponi, G.W., A-Beta Neurotoxicity Depends on Interactions between Copper Ions, Prion Protein, and N-Methyl-D-Aspartate Receptors (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 1737-1742; Burnet, F.M., A Possible Role of Zinc in the Pathology of Dementia (1981) Lancet, 1, pp. 186-188; Bitanihirwe, B.K.Y., Cunningham, M.G., Zinc: The Brains Dark Horse (2009) Synapse, 63, pp. 1029-1049; Hozumi, I., Hasegawa, T., Honda, A., Ozawa, K., Hayashi, Y., Hashimoto, K., Yamada, M., Kimura, A., Patterns of Levels of Biological Metals in CSF Differ among Neurodegenerative Diseases (2011) J. Neurol. Sci., 303, pp. 95-99; Koh, J.Y., Suh, S.W., Gwag, B.J., He, Y.Y., Hsu, C.Y., Choi, D.W., The Role of Zinc in Selective Neuronal Death after Transient Global Cerebral Ischemia (1996) Science, 272, pp. 1013-1016; Rae, T.D., Schmidt, P.J., Pufahl, R.A., Culotta, V.C., Ohalloran, T.V., Undetectable Intracellular Free Copper: The Requirement of a Copper Chaperone for Superoxide Dismutase (1999) Science, 284, pp. 805-808; Opazo, C., Huang, X.D., Cherny, R.A., Moir, R.D., Roher, A.E., White, A.R., Cappai, R., Bush, A.I., Metalloenzyme-Like Activity of Alzheimers Disease Beta-Amyloid: Cu-Dependent Catalytic Conversion of Dopamine, Cholesterol, and Biological Reducing Agents to Neurotoxic H<inf>2</inf>O<inf>2</inf> (2002) J. Biol. Chem., 277, pp. 40302-40308; Sarell, C.J., Wilkinson, S.R., Viles, J.H., Substoichiometric Levels of Cu2+ Ions Accelerate the Kinetics of Fiber Formation and Promote Cell Toxicity of Amyloid-Beta from Alzheimer Disease (2010) J. Biol. Chem., 285, pp. 41533-41540; Pedersen, J.T., Ostergaard, J., Rozlosnik, N., Gammelgaard, B., Heegaard, N.H.H., Cu(II) Mediates Kinetically Distinct, Non-Amyloidogenic Aggregation of Amyloid-Beta Peptides (2011) J. Biol. Chem., 286, pp. 26952-26963; Ponka, P., Beaumont, C., Richardson, D.R., Function and Regulation of Transferrin and Ferritin (1998) Semin. Hematol., 35, pp. 35-54; Friedman, A., Arosio, P., Finazzi, D., Koziorowski, D., Galazka-Friedman, J., Ferritin As an Amportant Player in Neurodegeneration (2011) Parkinsonism & Related Disorders, 17, pp. 423-430; Bader, B., Nuebling, G., Mehle, A., Nobile, S., Kretzschmar, H., Giese, A., Single Particle Analysis of Tau Oligomer Formation Induced by Metal Ions and Organic Solvents (2011) Biochem. Biophys. Res. Commun., 411, pp. 190-196; Chen, W.-T., Liao, Y.-H., Yu, H.-M., Cheng, I.H., Chen, Y.-R., Distinct Effects of Zn2+, Cu2+, Fe3+, and Al3+ on Amyloid-Beta Stability, Oligomerization, and Aggregation (2011) J. Biol. Chem., 286, pp. 9646-9656; House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., Exley, C., Aluminium, Iron, Zinc and Copper Influence the in vitro Formation of Amyloid Fibrils of A-Beta(42) in a Manner Which May Have Consequences for Metal Chelation Therapy in Alzheimers Disease (2004) J. Alzheimers Dis., 6, pp. 291-301; Exley, C., Aluminium and Iron, but Neither Copper Nor Zinc, are Key to the Precipitation of Beta-Sheets of A-Beta(42) in Senile Plaque Cores in Alzheimers Disease (2006) J. Alzheimers Dis., 10, pp. 173-177; Scott, L.E., Orvig, C., Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease (2009) Chem. Rev., 109, pp. 4885-4910; Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Kim, Y.S., Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Beta-Amyloid Accumulation in Alzheimers Disease Transgenic Mice (2001) Neuron, 30, pp. 665-676; Faux, N.G., Ritchie, C.W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Zetterberg, H., PBT2 Rapidly Improves Cognition in Alzheimers Disease: Additional Phase II Analyses (2010) J. Alzheimers Dis., 20, pp. 509-516; Walker, N.R., Walters, R.S., Duncan, M.A., Frontiers in the Infrared Spectroscopy of Gas Phase Metal Ion Complexes (2005) New J. Chem., 29, pp. 1495-1503; Garand, E., Wende, T., Goebbert, D.J., Bergmann, R., Meijer, G., Neumark, D.M., Asmis, K.R., Infrared Spectroscopy of Hydrated Bicarbonate Anion Clusters: HCO<inf>3</inf>-(H<inf>2</inf>O)<inf>1-10</inf> (2010) J. Am. Chem. Soc., 132, pp. 849-856; Wende, T., Wanko, M., Jiang, L., Meijer, G., Asmis, K.R., Rubio, A., Spectroscopic Characterization of Solvent-Mediated Folding in Dicarboxylate Dianions (2011) Angew. Chem., Int. Ed., 50, pp. 3807-3810; Wang, G., Chi, C., Cui, J., Xing, X., Zhou, M., Infrared Photodissociation Spectroscopy of Mononuclear Iron Carbonyl Anions (2012) J. Phys. Chem. A, 116, pp. 2484-2489",Article,Scopus,2-s2.0-84927153717
"Hubbs J.L., Fuller N.O., Austin W.F., Shen R., Ma J., Gong Z., Li J., McKee T.D., Loureiro R.M.B., Tate B., Dumin J.A., Ives J., Bronk B.S.","Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators",2015,"Bioorganic and Medicinal Chemistry Letters","25","7",,"1621","1626",,,10.1016/j.bmcl.2015.01.051,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925057498&partnerID=40&md5=a68f43c92bc15d9ff699e05599248667","Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; WuXi AppTec Co., Ltd, 288 Fute Zhong RoadShanghai, China","Hubbs, J.L., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Fuller, N.O., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Austin, W.F., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Shen, R., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Ma, J., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Gong, Z., WuXi AppTec Co., Ltd, 288 Fute Zhong RoadShanghai, China; Li, J., WuXi AppTec Co., Ltd, 288 Fute Zhong RoadShanghai, China; McKee, T.D., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Loureiro, R.M.B., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Tate, B., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Dumin, J.A., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Ives, J., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States; Bronk, B.S., Satori Pharmaceuticals, Inc., 281 Albany StreetCambridge, MA, United States","Early lead compounds in this gamma secretase modulator series were found to potently inhibit CYP3A4 and other human CYP isoforms increasing their risk of causing drug-drug-interactions (DDIs). Using structure-activity relationships and CYP3A4 structural information, analogs were developed that minimized this DDI potential. Three of these new analogs were further characterized by rat PK, rat PK/PD and rat exploratory toxicity studies resulting in selection of SPI-1865 (14) as a preclinical development candidate. © 2015 Elsevier Ltd. All rights reserved.","Alzheimers disease; Amyloid-beta; Cytochrome P450 3A4; Drugdrug-interactions; Gamma secretase modulator; Natural product; Semisynthesis; Sterol","Hall, A., Patel, T.R., (2014) Prog. Med. Chem., 53, p. 101; Pettersson, M., Stepan, A.F., Kaufmann, G.W., Johnson, D.S., (2013) Expert Opin. Ther. Pat., 23, p. 1349; Findeis, M.A., Schroeder, F.C., McKee, T.D., Yager, D., Fraering, P.C., Creaser, S.P., Austin, W.F., Eckman, C.B., (2012) ACS Chem. Neurosci., 3, p. 941; Fuller, N.O., Hubbs, J.L., Austin, W.F., Creaser, S.P., McKee, T.D., Loureiro, R.M.B., Tate, B., Bronk, B.S., (2012) ACS Med. Chem. Lett., 3, p. 908; Hubbs, J.L., Fuller, N.O., Austin, W.F., Shen, R., Creaser, S.P., McKee, T.D., Loureiro, R.M.B., Bronk, B.S., (2012) J. Med. Chem., 55, p. 9270; Austin, W.F., Hubbs, J.L., Fuller, N.O., Creaser, S.P., McKee, T.D., Loureiro, R.M.B., Findeis, M.A., Bronk, B.S., (2013) Med. Chem. Commun., 4, p. 569; Lin, A.H., Lu, A.Y.H., (1998) Clin. Pharmacokinet., 35, p. 361; Ekroos, M., Sjögren, T., (2006) Proc. Natl. Acad. Sci. U.S.A., 103, p. 13682; Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., Thorton, S.J., (2008) Nat. Rev. Drug Disc., 7, p. 84; Loureiro, R.M., Dumin, J.A., McKee, T.D., Austin, W.F., Fuller, N.O., Hubbs, J.H., Shen, R., Tate, B., (2013) Alzheimers Res. Ther., 5, p. 19; The development of SPI-1865 was halted",Article,Scopus,2-s2.0-84925057498
"Beduer A., Joris P., Mosser S., Fraering P.C., Renaud P.","Detection of Alzheimer's disease amyloid-beta plaque deposition by deep brain impedance profiling",2015,"Journal of Neural Engineering","12","2", 024001,"","",,,10.1088/1741-2560/12/2/024001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924402180&partnerID=40&md5=18097035e45f6865d63a63be45f6af85","Microsystems Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL)Lausanne, Switzerland; Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Brain Mind Institute, School of Life SciencesLausanne, Switzerland","Béduer, A., Microsystems Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL)Lausanne, Switzerland; Joris, P., Microsystems Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL)Lausanne, Switzerland; Mosser, S., Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Brain Mind Institute, School of Life SciencesLausanne, Switzerland; Fraering, P.C., Laboratory of Molecular and Cellular Biology of Alzheimer's Disease, Brain Mind Institute, School of Life SciencesLausanne, Switzerland; Renaud, P., Microsystems Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL)Lausanne, Switzerland","Objective. Alzheimer disease (AD) is the most common form of neurodegenerative disease in elderly people. Toxic brain amyloid-beta (Aß) aggregates and ensuing cell death are believed to play a central role in the pathogenesis of the disease. In this study, we investigated if we could monitor the presence of these aggregates by performing in situ electrical impedance spectroscopy measurements in AD model mice brains. Approach. In this study, electrical impedance spectroscopy measurements were performed post-mortem in APPPS1 transgenic mice brains. This transgenic model is commonly used to study amyloidogenesis, a pathological hallmark of AD. We used flexible probes with embedded micrometric electrodes array to demonstrate the feasibility of detecting senile plaques composed of Aß peptides by localized impedance measurements. Main results. We particularly focused on deep brain structures, such as the hippocampus. Ex vivo experiments using brains from young and old APPPS1 mice lead us to show that impedance measurements clearly correlate with the percentage of Aβ plaque load in the brain tissues. We could monitor the effects of aging in the AD APPPS1 mice model. Significance. We demonstrated that a localized electrical impedance measurement constitutes a valuable technique to monitor the presence of Aβ-plaques, which is complementary with existing imaging techniques. This method does not require prior Aβ staining, precluding the risk of variations in tissue uptake of dyes or tracers, and consequently ensuring reproducible data collection. © 2015 IOP Publishing Ltd.","Alzheimer's disease; APPPS1 model; Aβ plaques; impedance spectroscopy; microelectrodes array; mouse brain; neural probe","Amit, M., Cheng, G., Hamley, I.W., Ashkenasy, N., Conductance of amyloid beta based peptide filaments: Structure-function relations (2012) Soft Matter, 8, pp. 8690-8696; Ball, M.J., Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. a quantitative study (1977) Acta Neuropathol. (Berl.), 37, pp. 111-118; Ball, M.J., Fisman, M., Hachinski, V., Blume, W., Fox, A., Kral, V.A., Kirshen, A.J., Merskey, H., A new definition of Alzheimer's disease: A hippocampal dementia (1985) Lancet, 1, pp. 14-16; Bloudek, L.M., Spackman, D.E., Blankenburg, M., Sullivan, S.D., Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease (2011) J. Alzheimers Dis., 26, pp. 627-645; Bolmont, T., Bouwens, A., Pache, C., Dimitrov, M., Berclaz, C., Villiger, M., Wegenast-Braun, B.M., Fraering, P.C., Label-free imaging of cerebral β-amyloidosis with extended-focus optical coherence microscopy (2012) J. Neurosci., 32, pp. 14548-14556; Béduer, A., Joris, P., Mosser, S., Delattre, V., Fraering, P.C., Renaud, P., Accurate resistivity mouse brain mapping using microelectrode arrays (2014) Biosens. Bioelectron., 60, pp. 143-153; Cheung, K.C., Renaud, P., Tanila, H., Djupsund, K., Flexible polyimide microelectrode array for in vivo recordings and current source density analysis (2007) Biosens. Bioelectron., 22, pp. 1783-1790; Gordon, M.N., Holcomb, L.A., Jantzen, P.T., Dicarlo, G., Wilcock, D., Boyett, K.W., Connor, K., Morgan, D., Time course of the development of alzheimer-like pathology in the doubly transgenic PS1+APP mouse (2002) Exp. Neurol., 173, pp. 183-195; Hardy, J.A., Higgins, G.A., Alzheimer's disease: The amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; Holcomb, L., Gordon, M.N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Morgan, D., Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes (1998) Nat. Med., 4, pp. 97-100; Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., Memory-related neural systems in Alzheimer's disease: An anatomic study (1990) Neurology, 40, pp. 1721-1730; Kasi, H., Meissner, R., Babalian, A., Van Lintel, H., Bertsch, A., Renaud, P., Direct localised measurement of electrical resistivity profile in rat and embryonic chick retinas using a microprobe (2011) J. Electr. Bioimpedance, 1, pp. 84-92; Killiany, R.J., Hyman, B.T., Gomez-Isla, T., Moss, M.B., Kikinis, R., Jolesz, F., Tanzi, R., Albert, M.S., MRI measures of entorhinal cortex versus hippocampus in preclinical AD (2002) Neurology, 58, pp. 1188-1196; Mercanzini, A., Reddy, S., Velluto, D., Colin, P., Maillard, A., Bensadoun, J.-C., Bertsch, A., Renaud, P., Controlled release drug coatings on flexible neural probes (2007) 29th Annual Int. Conf. of the IEEE Engineering in Medicine and Biology Society (Lyon, France), pp. 6612-6615; Metz, S., Bertsch, A., Bertrand, D., Renaud, P., Flexible polyimide probes with microelectrodes and embedded microfluidic channels for simultaneous drug delivery and multi-channel monitoring of bioelectric activity (2004) Biosens. Bioelectron., 19, pp. 1309-1318; Metz, S., Bertsch, A., Renaud, P., Partial release and detachment of microfabricated metal and polymer structures by anodic metal dissolution (2005) J. Microelectromech. Syst., 14, pp. 383-391; Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., De Leon, M.J., Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging (2010) J. Alzheimers Dis., 20, pp. 843-854; Nestor, P.J., Scheltens, P., Hodges, J.R., Advances in the early detection of Alzheimer's disease (2004) Nat. Med., 10, pp. 34-S41; Newman, J., Resistance for flow of current to a disk (1966) J. Electrochem. Soc., 113, pp. 501-502; Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., Blennow, K., Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry (2006) J. Proteome Res., 5, pp. 1010-1016; Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M.E., Gengler, S., Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology (2006) EMBO Rep., 7, pp. 940-946; Seoane, F., Lindecrantz, K., Olsson, T., Kjellmer, I., Flisberf, A., Bagenholm, R., Spectroscopy study of the dynamics of the transencephalic electrical impedance in the perinatal brain during hypoxia (2005) Physiol. Meas., 26 (5), pp. 849-863; Spires-Jones, T.L., Hyman, B.T., The intersection of amyloid beta and tau at synapses in Alzheimer's disease (2014) Neuron, 82, pp. 756-771; Yan, P., Bero, A.W., Cirrito, J.R., Xiao, Q., Hu, X., Wang, Y., Gonzales, E., Lee, J.-M., Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice (2009) J. Neurosci., 29, pp. 10706-10714",Article,Scopus,2-s2.0-84924402180
"Butler C.R., Brodney M.A., Beck E.M., Barreiro G., Nolan C.E., Pan F., Vajdos F., Parris K., Varghese A.H., Helal C.J., Lira R., Doran S.D., Riddell D.R., Buzon L.M., Dutra J.K., Martinez-Alsina L.A., Ogilvie K., Murray J.C., Young J.M., Atchison K., Robshaw A., Gonzales C., Wang J., Zhang Y., Oneill B.T.","Discovery of a series of efficient, centrally efficacious bace1 inhibitors through structure-based drug design",2015,"Journal of Medicinal Chemistry","58","6",,"2678","2702",,1,10.1021/jm501833t,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925957189&partnerID=40&md5=d5b128f3872578407658b9be7f8b9ff7","Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Center of Chemistry Innovation and Excellence, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Departamento de Inovacao, Eurofarma Laboratorios S.A., Avenida Vereador José Diniz, 3465Campo Belo, SP, Brazil; WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade ZoneShanghai, China","Butler, C.R., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Brodney, M.A., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Beck, E.M., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Barreiro, G., Departamento de Inovacao, Eurofarma Laboratorios S.A., Avenida Vereador José Diniz, 3465Campo Belo, SP, Brazil; Nolan, C.E., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Pan, F., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Vajdos, F., Center of Chemistry Innovation and Excellence, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Parris, K., Center of Chemistry Innovation and Excellence, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Varghese, A.H., Center of Chemistry Innovation and Excellence, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Helal, C.J., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Lira, R., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Doran, S.D., Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Riddell, D.R., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Buzon, L.M., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Dutra, J.K., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Martinez-Alsina, L.A., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Ogilvie, K., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Murray, J.C., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Young, J.M., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States; Atchison, K., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Robshaw, A., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Gonzales, C., Neuroscience Research Unit, Pfizer Worldwide Research and Development, 610 Main StreetCambridge, MA, United States; Wang, J., WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade ZoneShanghai, China; Zhang, Y., WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade ZoneShanghai, China; Oneill, B.T., Neuroscience Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point RoadGroton, CT, United States","The identification of centrally efficacious β-secretase (BACE1) inhibitors for the treatment of Alzheimers disease (AD) has historically been thwarted by an inability to maintain alignment of potency, brain availability, and desired absorption, distribution, metabolism, and excretion (ADME) properties. In this paper, we describe a series of truncated, fused thioamidines that are efficiently selective in garnering BACE1 activity without simultaneously inhibiting the closely related cathepsin D or negatively impacting brain penetration and ADME alignment, as exemplified by 36. Upon oral administration, these inhibitors exhibit robust brain availability and are efficacious in lowering central Amyloid β (Aβ) levels in mouse and dog. In addition, chronic treatment in aged PS1/APP mice effects a decrease in the number and size of Aβ-derived plaques. Most importantly, evaluation of 36 in a 2-week exploratory toxicology study revealed no accumulation of autofluorescent material in retinal pigment epithelium or histology findings in the eye, issues observed with earlier BACE1 inhibitors. © 2015 American Chemical Society.",,"Hardy, J., Allsop, D., Amyloid Deposition as the Central Event in the Aetiology of Alzheimers Disease (1991) Trends Pharmacol. Sci., 12, p. 383; Tanzi, R.E., Bertram, L., Twenty Years of the Alzheimers Disease Amyloid Hypothesis: A Genetic Perspective (2005) Cell, 120, p. 545; De Strooper, B., Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process (2010) Physiol. Rev., 90, pp. 465-494; Vassar, R., Kovacs, D.M., Yan, R., Wong, P.C., The beta-Secretase Enzyme BACE in Health and Alzheimers Disease: Regulation, Cell Biology, Function, and Therapeutic Potential (2009) J. Neurosci., 29, pp. 12787-12794; Marks, N., Berg, M.J., BACE and gamma-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis (2010) Neurochem. Res., 35, pp. 181-210; Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Stefansson, K., A Mutation in APP Protects against Alzheimers Disease and Age-Related Cognitive Decline (2012) Nature, 488 (7409), pp. 96-99; Evin, G., Hince, C., BACE1 as a Therapeutic Target in Alzheimers Disease: Rationale and Current Status (2013) Drugs Aging, 30, pp. 755-764; Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B.M., Dillard, L.W., Singh, S.B., Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimers Disease (2013) J. Med. Chem., 56, pp. 4156-4180; Woltering, T.J., Wostl, W., Hilpert, H., Rogers-Evans, M., Pinard, E., Mayweg, A., Gobel, M., Narquizian, R., BACE1 Inhibitors: A Head Group Scan on a Series of Amides (2013) Bioorg. Med. Chem. Lett., 23, pp. 4239-4243; Brodney, M.A., Barreiro, G., Ogilvie, K., Hajos-Korcsok, E., Murray, J., Vajdos, F., Ambroise, C., Oneill, B.T., Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimers Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors (2012) J. Med. Chem., 55, pp. 9224-9239; Johnson, T.W., Richardson, P.F., Bailey, S., Brooun, A., Burke, B.J., Collins, M.R., Cui, J.J., Edwards, M.P., Discovery of (10 R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2 H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations (2014) J. Med. Chem., 57, pp. 4720-4744; May, P.C., Dean, R.A., Lowe, S.L., Martenyi, F., Sheehan, S.M., Boggs, L.N., Monk, S.A., Audia, J.E., Robust Central Reduction of Amyloid-beta in Humans with an Orally Available, Non-Peptidic beta-Secretase Inhibitor (2011) J. Neurosci., 31, pp. 16507-16516; Muller, S., Dennemarker, J., Reinheckel, T., Specific Functions of Lysosomal Proteases in Endocytic and Autophagic Pathways (2012) Biochim. Biophys. Acta, Proteins Proteomics, 1824 (1), pp. 34-43; Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R., Bruck, W., Saftig, P., Gartner, J., Cathepsin D Deficiency Is Associated with a Human Neurodegenerative Disorder (2006) Am. J. Hum. Genet., 78, pp. 988-998; Tamura, Y., Suzuki, S., Tada, Y., Yonezawa, S., Fujikoshi, C., Matsumoto, S., Kooriyama, Y., Ueno, T., (2010) Aminodihydrothiazine Derivatives Substituted with A Cyclic Group, , U.S. Patent Application 2010/0075957 A1, March 25; Oehlrich, D., Prokopcova, H., Gijsen, H.J., The Evolution of Amidine-Based Brain Penetrant BACE1 Inhibitors (2014) Bioorg. Med. Chem. Lett., 24, pp. 2033-2045; Hitchcock, S.A., Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds (2012) J. Med. Chem., 55, pp. 4877-4895; Wager, T.T., Hou, X., Verhoest, P.R., Villalobos, A., Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach to Enable Alignment of Druglike Properties (2010) ACS Chem. Neurosci., 1, pp. 435-449; Wager, T.T., Chandrasekaran, R.Y., Hou, X., Troutman, M.D., Verhoest, P.R., Villalobos, A., Will, Y., Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes (2010) ACS Chem. Neurosci., 1, pp. 420-434; Hori, A., Kato, T., (2014), U.S. Patent Application, US 08637504 B2Robak, M.T., Herbage, M.A., Ellman, J.A., Synthesis and Applications of tert -Butanesulfinamide (2010) Chem. Rev. (Washington, DC, U.S.), 110, pp. 3600-3740; Motoki, T., Takeda, K., Kita, Y., Takaishi, M., Suzuki, Y., Ishida, T., (2010) Novel Fused Aminodihydrothiazine Derivative, , U.S. Patent Application 2010/0093999 A1, April 15; Ghosez, L., -Chloroenamines: New Reagents for Organic Synthesis (1972) Angew. Chem., Int. Ed. Engl., 11, pp. 852-853; Castro-Pineiro, J.L., Hall, A., Madin, A., Vo, N.-T., (2011) Fused Aminodihydropyrimidone Derivatives, , WO2011009897A1, January 27; Zhu, H., Waters Role in Compound Design for Drug Discovery (2013) UGM & Conference 2013 North America, , In; Hashimura, K., Tomita, S., Hiroya, K., Ogasawara, K., A Stereocontrolled Route to Both Enantiomers of the Necine Base Dihydroxyheliotridane via Intramolecular 1,3-Dipolar Addition Using the Same Chiral Precursor (1995) J. Chem. Soc., Chem. Commun., 229, p. 1; Alam, M., Wise, C., Baxter, C.A., Cleator, E., Walkinshaw, A., Development of a Robust Procedure for the Copper-Catalyzed Ring-Opening of Epoxides with Grignard Reagents (2012) Org. Process Res. Dev., 16, pp. 435-441; Tahtaoui, C., Demailly, A., Guidemann, C., Joyeux, C., Schneider, P., Enantioselective Synthesis of Iclaprim Enantiomers - A Versatile Approach to 2-Substituted Chiral Chromenes (2010) J. Org. Chem., 75, pp. 3781-3785; Lu, Y., Riddell, D., Hajos-Korcsok, E., Bales, K., Wood, K.M., Nolan, C.E., Robshaw, A.E., Pettersson, M., Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses (2012) J. Pharmacol. Exp. Ther., 342, pp. 366-375; Svoboda, K., Yasuda, R., Principles of Two-Photon Excitation Microscopy and Its Applications to Neuroscience (2006) Neuron, 50, pp. 823-839; Pan, F., Gan, W.-B., Two-Photon Imaging of Dendritic Spine Development in the Mouse Cortex (2008) Dev. Neurobiol., 68, pp. 771-778; Eketjall, S., Janson, J., Jeppsson, F., Svanhagen, A., Kolmodin, K., Gustavsson, S., Radesater, A.-C., Falting, J., AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different in Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice (2013) J. Neurosci., 33, pp. 10075-10084; Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Bohrmann, B., Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice (2014) J. Neurosci., 34, pp. 11621-11630; Farah, M.H., Pan, B.H., Hoffman, P.N., Ferraris, D., Tsukamoto, T., Nguyen, T., Wong, P.C., Griffin, J.W., Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System (2011) J. Neurosci., 31, pp. 5744-5754; Otsu, N.A., Threshold Selection Method from Gray-Level Histograms (1979) IEEE Transactions on Systems, Man and Cybernetics, 9, pp. 62-66; Maintz, J.B.A., Viergever, M.A., A Survey of Medical Image Registration (1998) Med. Image Anal., 2, pp. 1-36; Kalvass, J.C., Maurer, T.S., Influence of Nonspecific Brain and Plasma Binding on CNS Exposure: Implications for Rational Drug Discovery (2002) Biopharm. Drug Dispos., 23, p. 327; Tomasselli, A.G., Paddock, D.J., Emmons, T.L., Mildner, A.M., Leone, J.W., Lull, J.M., Cialdella, J.I., Benson, T.E., High Yield Expression of Human BACE Constructs in Eschericia coli for Refolding, Purification, and High Resolution Diffracting Crystal Forms (2008) Protein Pept. Lett., 15, p. 131; Patel, S., Vuillard, L., Cleasby, A., Murray, C.W., Yon, J., Apo and Inhibitor Complex Structures of BACE (beta-Secretase) (2004) J. Mol. Biol., 343, pp. 407-416; Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., Bricogne, G., Data Processing and Analysis with the AutoPROC Tool Box (2011) Acta Crystallogr., Sect. D, 67, pp. 293-302; Kabsch, W., XDS (2010) Acta Crystallogr., Sect. D, 66, pp. 125-132; French, S., Wilson, K., On the Treatment of Negative Intensity Observations (1978) Acta Crystallogr., 34, pp. 517-525; (1994) Acta Crystallogr., Sect. D, 50, pp. 760-763. , Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography; Murshudov, G.N., Vagin, A.A., Dodson, E.J., Refinement of Macromolecular Structures by the Maximum-Likelihood Method (1997) Acta Crystallogr., 53, p. 240; Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Womack, T.O., (2011) BUSTER, , Global Phasing Ltd: Cambridge, UK; (2014), Maestro, 9.7; Schrodinger: New York, NY(2014) Desmond Molecular Dynamics System, , 3.7; D. E. Shaw Research: New York; (2014) Maestro-Desmond Interoperability Tools, , 3.7; Schrodinger: New York; Banks, J.L., Beard, H.S., Cao, Y., Cho, A.E., Damm, W., Farid, R., Felts, A.K., Levy, R.M., Integrated Modeling Program, Applied Chemical Theory (IMPACT) (2005) J. Comput. Chem., 26, pp. 1752-1780; Martyna, G.J., Klein, M.L., Tuckerman, M., Nosé-Hoover Chains: The Canonical Ensemble via Continuous Dynamics (1992) J. Chem. Phys., 97, pp. 2635-2643; Essmann, U., Perera, L., Berkowitz, M.L., Darden, T., Lee, H., Pedersen, L.G., A Smooth Particle Mesh Ewald Method (1995) J. Chem. Phys., 103, pp. 8577-8593; Humphreys, D.D., Friesner, R.A., Berne, B.J., A Multiple-Time-Step Molecular Dynamics Algorithm for Macromolecules (1994) J. Phys. Chem., 98, pp. 6885-6892",Article,Scopus,2-s2.0-84925957189
"Dugger J.W., Webb L.J.","Fibrillar structures formed by covalently bound, short, β-stranded peptides on self-assembled monolayers",2015,"Langmuir","31","11",,"3441","3450",,,10.1021/la5049369,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925637997&partnerID=40&md5=e1e2bbe42e906ee324500f6eeba900ad","Department of Chemistry, Institute for Cell and Molecular Biology, University of Texas at Austin, 1 University Station, A5300Austin, TX, United States","Dugger, J.W., Department of Chemistry, Institute for Cell and Molecular Biology, University of Texas at Austin, 1 University Station, A5300Austin, TX, United States; Webb, L.J., Department of Chemistry, Institute for Cell and Molecular Biology, University of Texas at Austin, 1 University Station, A5300Austin, TX, United States","The ability to maintain or reproduce biomolecular structures on inorganic substrates has the potential to impact diverse fields such as sensing and molecular electronics, as well as the study of biological self-assembly and structure-function relationships. Because the structure and self-assembly of biomolecules are exquisitely sensitive to their local chemical and electrostatic environment, the goal of reproducing or mimicking biological function in an abiological environment, including at a surface, is challenging. However, simple and well-characterized chemical modifications of prepared surfaces can be used to tune surface chemistry, structure, electrostatics, and reactivity of inorganic materials to facilitate biofunctionalization and function. Here, we describe the covalent attachment of 13-residue β-stranded peptides containing alkyne groups to a flat gold surface functionalized with an azide-terminated self-assembled monolayer through a Huisgen cycloaddition, or ""click"", reaction. The chemical composition and structural morphology of these surfaces were characterized using X-ray photoelectron spectroscopy, grazing incidence angle reflection-absorption infrared spectroscopy, surface circular dichroism, and atomic force microscopy. The surface-bound β-strands self-assemble into antiparallel β-sheets to form fibrillar structures 24.9 ± 1.6 nm in diameter and 2.83 ± 0.74 nm in height on the reactive surface. The results herein provide a platform for studying and controlling the self-assembly process of biomolecules into larger supermolecular structures while allowing tunable control through chemical functionalization of the surface. Interest in the mechanisms of formation of fibrillar structures has most commonly been associated with neurodegenerative diseases, such as Alzheimers and Parkinsons, but fibrils may actually represent the thermodynamic low-energy conformation of a much larger class of peptides and proteins. The protocol developed here is an important step toward uncovering not only the factors that dictate self-assembly but also the mechanisms by which this fibrillar class of superstructures forms. © 2015 American Chemical Society.",,"Raigoza, A.F., Dugger, J.W., Webb, L.J., Review: Recent Advances and Current Challenges in Scanning Probe Microscopy of Biomolecular Surfaces and Interfaces (2013) ACS Appl. Mater. Interfaces, 5, pp. 9249-9261; Gong, J.-R., Yan, H.-J., Yuan, Q.-H., Xu, L.-P., Bo, Z.-S., Wan, L.-J., Controllable Distribution of Single Molecules and Peptides within Oligomer Template Investigated by STM (2006) J. Am. Chem. Soc., 128, pp. 12384-12385; Acar, H., Garifullin, R., Guler, M.O., Self-Assembled Template-Directed Synthesis of One-Dimensional Silica and Titania Nanostructures (2011) Langmuir, 27, pp. 1079-1084; Jedlicka, S.S., Rickus, J.L., Zemlyanov, D., Controllable Surface Expression of Bioactive Peptides Incorporated into a Silica Thin Film Matrix (2010) J. Phys. Chem. C, 114, pp. 342-344; Della Pia, E.A., Chi, Q., Macdonald, J.E., Ulstrup, J., Jones, D.D., Elliott, M., Fast Electron Transfer through a Single Molecule Natively Structured Redox Protein (2012) Nanoscale, 4, pp. 7106-7113; Pollheimer, P., Taskinen, B., Scherfler, A., Gusenkov, S., Creus, M., Wiesauer, P., Zauner, D., Gruber, H.J., Reversible Biofunctionalization of Surfaces with a Switchable Mutant of Avidin (2013) Bioconjugate Chem., 24, pp. 1656-1668; Zhang, H., Lee, K.-B., Li, Z., Biofunctionalized Nanoarrays of Inorganic Structures Prepared by Dip-Pen Nanolithography (2003) Nanotechnology, 14, pp. 1113-1117; Leung, B.O., Wang, J., Brash, J.L., Hitchcock, A.P., Imaging Hydrated Albumin on a Polystyrene-Poly(methyl methacrylate) Blend Surface with X-ray Spectromicroscopy (2009) Langmuir, 25, pp. 13332-13335; Zheng, H., Du, X., Enhanced Binding and Biosensing of Carbohydrate-Functionalized Monolayers to Target Proteins by Surface Molecular Imprinting (2009) J. Phys. Chem. B, 113, pp. 11330-11337; Millo, D., Pandelia, M.-E., Utesch, T., Wisitruangsakul, N., Lubitz, W., Hildebrandt, P., Zebger, I., Spectroelectrochemical Study of the [Nife] Hydrogenase from Desulfovibrio vulgaris Miyazaki F in Solution and Immobilized on Biocompatible Gold Surfaces (2009) J. Phys. Chem. B, 113, pp. 15344-15351; Gallardo, I.F., Webb, L.J., Tethering Hydrophobic Peptides to Functionalized Self-Assembled Monolayers on Gold through Two Chemical Linkers Using the Huisgen Cycloaddition (2010) Langmuir, 26, pp. 18959-18966; Gallardo, I.F., Webb, L.J., Demonstration of α-Helical Structure of Peptides Tethered to Gold Surfaces Using Surface Infrared and Circular Dichroic Spectroscopies (2012) Langmuir, 28, pp. 3510-3515; Raigoza, A.F., Webb, L.J., Molecularly Resolved Images of Peptide-Functionalized Gold Surfaces by Scanning Tunneling Microscopy (2012) J. Am. Chem. Soc., 134, pp. 19354-19357; Cherny, I., Gazit, E., Amyloids: Not only Pathological Agents but Also Ordered Nanomaterials (2008) Angew. Chem., Int. Ed., 47, pp. 4062-4069; Li, C., Bolisetty, S., Mezzenga, R., Hybrid Nanocomposites of Gold Single-Crystal Platelets and Amyloid Fibrils with Tunable Fluorescence, Conductivity, and Sensing Properties (2013) Adv. Mater., 25, pp. 3694-3700; Reynolds, N.P., Styan, K.E., Easton, C.D., Li, Y., Waddington, L., Lara, C., Forsythe, J.S., Muir, B.W., Nanotopographic Surfaces with Defined Surface Chemistries from Amyloid Fibril Networks Can Control Cell Attachment (2013) Biomacromolecules, 14, pp. 2305-2316; Cinar, G., Ceylan, H., Urel, M., Erkal, T.S., Tekin, E.D., Tekinay, A.B., Dana, A., Guler, M.O., Amyloid Inspired Self-Assembled Peptide Nanofibers (2012) Biomacromolecules, 13, pp. 3377-3387; Giraldo, R., Amyloid Assemblies: Protein Legos at a Crossroads in Bottom-up Synthetic Biology (2010) ChemBioChem, 11, pp. 2347-2357; Lednev, I.K., Amyloid Fibrils: The Eighth Wonder of the World in Protein Folding and Aggregation (2014) Biophys. J., 106, pp. 1433-1435; Makin, O.S., Atkins, E., Sikorski, P., Johansson, J., Serpell, L.C., Molecular Basis for Amyloid Fibril Formation and Stability (2005) Proc. Natl. Acad. Sci. U. S. A., 102, pp. 315-320; Rambaran, R.N., Serpell, L.C., Amyloid Fibrils: Abnormal Protein Assembly (2008) Prion, 2, pp. 112-117; Knowles, T.P.J., Vendruscolo, M., Dobson, C.M., The Amyloid State and Its Association with Protein Misfolding Diseases (2014) Nat. Rev. Mol. Cell Bio., 15, pp. 384-396; Thirumalai, D., Reddy, G., Protein Thermodynamics: Are Native Proteins Metastable? (2011) Nat. Chem., 3, pp. 910-911; Trovato, A., Chiti, F., Maritan, A., Seno, F., Insight into the Structure of Amyloid Fibrils from the Analysis of Globular Proteins (2006) PLoS Comput. Biol., 2, pp. 1608-1618; Ricchiuto, P., Brukhno, A.V., Auer, S., Protein Aggregation: Kinetics Versus Thermodynamics (2012) J. Phys. Chem. B, 116, pp. 5384-5390; Baldwin, A.J., Knowles, T.P.J., Tartaglia, G.G., Fitzpatrick, A.W., Devlin, G.L., Shammas, S.L., Mossuto, M.F., Dobson, C.M., Metastability of Native Proteins and the Phenomenon of Amyloid Formation (2011) J. Am. Chem. Soc., 133, pp. 14160-14163; Dong, J., Canfield, J.M., Mehta, A.K., Shokes, J.E., Tian, B., Childers, W.S., Simmons, J.A., Lynn, D.G., Engineering Metal Ion Coordination to Regulate Amyloid Fibril Assembly and Toxicity (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 13313-13318; Pinotsi, D., Buell, A.K., Galvagnion, C., Dobson, C.M., Kaminski Schierle, G.S., Kaminski, C.F., Direct Observation of Heterogeneous Amyloid Fibril Growth Kinetics Via Two-Color Super-Resolution Microscopy (2014) Nano Lett., 14, pp. 339-345; Kallberg, Y., Gustafsson, M., Persson, B., Thyberg, J., Johansson, J., Prediction of Amyloid Fibril-Forming Proteins (2001) J. Biol. Chem., 276, pp. 12945-12950; Zhao, Y., Wang, J., Deng, L., Zhou, P., Wang, S., Wang, Y., Xu, H., Lu, J.R., Tuning the Self-Assembly of Short Peptides Via Sequence Variations (2013) Langmuir, 29, pp. 13457-13464; Zurdo, J., Guijarro, J.I., Jiménez, J.L., Saibil, H.R., Dobson, C.M., Dependence on Solution Conditions of Aggregation and Amyloid Formation by an SH3 Domain (2001) J. Mol. Biol., 311, pp. 325-340; Fändrich, M., Schmidt, M., Grigorieff, N., Recent Progress in Understanding Alzheimers β-Amyloid Structures (2011) Trends Biochem. Sci., 36, pp. 338-345; Härd, T., Amyloid Fibrils-Formation, Polymorphism and Inhibition (2014) J. Phys. Chem. Lett., 5, pp. 607-614; Toyama, B.H., Weissman, J.S., Amyloid Structure: Conformational Diversity and Consequences (2011) Annu. Rev. Biochem., 80, pp. 557-585; Miller, Y., Ma, B., Nussinov, R., The Unique Alzheimers β-Amyloid Triangular Fibril Has a Cavity Along the Fibril Axis under Physiological Conditions (2011) J. Am. Chem. Soc., pp. 2742-2748; Takai, E., Ohashi, G., Ueki, R., Yamada, Y., Fujita, J.-I., Shiraki, K., Scanning Electron Microscope Imaging of Amyloid Fibrils (2014) Am. J. Biochem. Biotechnol., 10, pp. 31-39; Pashuck, E.T., Stupp, S.I., Direct Observation of Morphological Transformation from Twisted Ribbons into Helical Ribbons (2010) J. Am. Chem. Soc., 132, pp. 8819-8821; Meyerson, J.R., Rao, P., Kumar, J., Chittori, S., Banerjee, S., Pierson, J., Mayer, M.L., Subramaniam, S., Self-Assembled Monolayers Improve Protein Distribution on Holey Carbon Cryo-EM Supports (2014) Sci. Rep., 4, p. 7084; Degrado, W.F., Lear, J.D., Induction of Peptide Conformation at Apolar/Water Interfaces. 1. A Study with Model Peptides of Defined Hydrophobic Periodicity (1985) J. Am. Chem. Soc., 107, pp. 7684-7689; Chan, T.R., Hilgraf, R., Sharpless, K.B., Fokin, V.V., Polytriazoles as Copper(I)-Stabilizing Ligands in Catalysis (2004) Org. Lett., 6, pp. 2853-2855; Fears, K.P., Petrovykh, D.Y., Photiadis, S.J., Clark, T.D., Circular Dichroism Analysis of Cyclic β-Helical Peptides Adsorbed on Planar Fused Quartz (2013) Langmuir, 29, pp. 10095-10101; Shimizu, M., Kobayashi, K., Morii, H., Mitsui, K., Knoll, W., Nagamune, T., Secondary Structure Analyses of Protein Films on Gold Surfaces by Circular Dichroism (2003) Biochem. Biophys. Res. Commun., 310, pp. 606-611; Hostetler, M.J., Stokes, J.J., Murray, R.W., Infrared Spectroscopy of Three-Dimensional Self-Assembled Monolayers: N -Alkanethiolate Monolayers on Gold Cluster Compounds (1996) Langmuir, 7463, pp. 3604-3612; Radhakrishnan, C., Lo, M.K.F., Warrier, M.V., Monbouquette, H.G., Photocatalytic Reduction of an Azide-Terminated Self-Assembled Monolayer Using CDS Quantum Dots (2006) Langmuir, 22, pp. 5018-5024; Barth, A., Zscherp, C., What Vibrations Tell Us about Proteins (2002) Q. Rev. Biophys., 35, pp. 369-430; Cerf, E., Sarroukh, R., Tamamizu-Kato, S., Breydo, L., Derclaye, S., Dufrêne, Y.F., Narayanaswami, V., Raussens, V., Antiparallel Beta-Sheet: A Signature Structure of the Oligomeric Amyloid β-Peptide (2009) Biochem. J., 421, pp. 415-423; Kitagawa, K., Morita, T., Kimura, S., Observation of Single Helical Peptide Molecule Incorporated into Alkanethiol Self-Assembled Monolayer on Gold by Scanning Tunneling Microscopy (2004) J. Phys. Chem. B, 108, pp. 15090-15095; Zou, Y., Li, Y., Hao, W., Hu, X., Ma, G., Parallel B-Sheet Fibril and Antiparallel β-Sheet Oligomer: New Insights into Amyloid Formation of Hen Egg White Lysozyme under Heat and Acidic Condition from FTIR Spectroscopy (2013) J. Phys. Chem. B, 117, pp. 4003-4013; Berthelot, K., Ta, H.P., Géan, J., Lecomte, S., Cullin, C., In Vivo and in Vitro Analyses of Toxic Mutants of Het-S: FTIR Antiparallel Signature Correlates with Amyloid Toxicity (2011) J. Mol. Biol., 412, pp. 137-152; Miyazawa, T., Blout, E.R., The Infrared Spectra of Polypeptides in Various Conformations: Amide i and II Bands (1961) J. Am. Chem. Soc., 83, pp. 712-719; Byler, D.M., Susi, H., Examination of the Secondary Structure of Proteins by Deconvolved FTIR Spectra (1986) Biopolymers, 25, pp. 469-487; Shivu, B., Seshadri, S., Li, J., Oberg, K.A., Uversky, V.N., Fink, A.L., Distinct β-Sheet Structure in Protein Aggregates Determined by ATR-FTIR Spectroscopy (2013) Biochemistry, 52, pp. 5176-5183; Moulder, J.F., Stickle, W.F., Sobol, P.E., Bomben, K.D., (1992) Handbook of X-ray Photoelectron Spectroscopy, , Physical Electronics, Inc. Chanhassen, MN; Chen, Y.H., Yang, J.T., Chau, K.H., Determination of the Helix and Beta Form of Proteins in Aqueous Solution by Circular Dichroism (1974) Biochemistry, 13, pp. 3350-3359; Parson, W.W., (2007) Modern Optical Spectroscopy, , Springer: Berlin; Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M., Robinson, C.V., Formation of Insulin Amyloid Fibrils Followed by FTIR Simultaneously with Cd and Electron Microscopy (2000) Protein Sci., 9, pp. 1960-1967; Gal, N., Morag, A., Kolusheva, S., Winter, R., Landau, M., Jelinek, R., Lipid Bilayers Significantly Modulate Cross-Fibrillation of Two Distinct Amyloidogenic Peptides (2013) J. Am. Chem. Soc., 135, pp. 13582-13589; Zhu, M., Souillac, P.O., Ionescu-Zanetti, C., Fink, A.L., Surface-Catalyzed Amyloid Fibril Formation (2002) J. Biol. Chem., 277, pp. 50914-50922; Wang, Z., Fu, L., Yan, E.C.Y., C-H Stretch for Probing Kinetics of Self-Assembly into Macromolecular Chiral Structures at Interfaces by Chiral Sum Frequency Generation Spectroscopy (2013) Langmuir, 29, pp. 4077-4083; Lynn, D.G., Meredith, S.C., Review: Model Peptides and the Physicochemical Approach to β-Amyloids (2000) J. Struct. Biol., 130, pp. 153-173; Shen, L., Adachi, T., Vanden Bout, D., Zhu, X.-Y., A Mobile Precursor Determines Amyloid-β Peptide Fibril Formation at Interfaces (2012) J. Am. Chem. Soc., 134, pp. 14172-14178; Wang, Z., Han, X., He, N., Chen, Z., Brooks, C.L., Molecular Structures of C- and N-Terminus Cysteine Modified Cecropin P1 Chemically Immobilized onto Maleimide-Terminated Self-Assembled Monolayers Investigated by Molecular Dynamics Simulation (2014) J. Phys. Chem. B, 118, pp. 5670-5680; Shen, L., Ulrich, N.W., Mello, C.M., Chen, Z., Determination of Conformation and Orientation of Immobilized Peptides and Proteins at Buried Interfaces (2014) Chem. Phys. Lett., 619, pp. 247-255; Wang, Z., Han, X., He, N., Chen, Z., Brooks, C.L., Environmental Effect on Surface Immobilized Biological Molecules (2014) J. Phys. Chem. B, 118, pp. 12176-12185; Adamcik, J., Mezzenga, R., Study of Amyloid Fibrils via Atomic Force Microscopy (2012) Curr. Opin. Colloid Interface Sci., 17, pp. 369-376; Mandel-Gutfreund, Y., Gregoret, L.M., On the Significance of Alternating Patterns of Polar and Non-Polar Residues in β-Strands (2002) J. Mol. Biol., 323, pp. 453-461",Article,Scopus,2-s2.0-84925637997
"Tofoleanu F., Brooks B.R., Buchete N.-V.","Modulation of alzheimers aβ protofilament-membrane interactions by lipid headgroups",2015,"ACS Chemical Neuroscience","6","3",,"446","455",,,10.1021/cn500277f,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925104747&partnerID=40&md5=70e87630344453e295bc344f29aa1651","Laboratory of Computational Biology, Biochemistry and Biophysics Center, National Institutes of HealthBethesda, MD, United States; School of Physics and Complex, Adaptive Systems Laboratory, University College DublinBelfield-Dublin 4, Ireland","Tofoleanu, F., Laboratory of Computational Biology, Biochemistry and Biophysics Center, National Institutes of HealthBethesda, MD, United States; Brooks, B.R., Laboratory of Computational Biology, Biochemistry and Biophysics Center, National Institutes of HealthBethesda, MD, United States; Buchete, N.-V., School of Physics and Complex, Adaptive Systems Laboratory, University College DublinBelfield-Dublin 4, Ireland","The molecular pathogenesis of Alzheimers disease (AD) is complex and sparsely understood. The relationship between ADs amyloid β (Aβ) peptides and neuronal membranes is central to Aβs cytotoxicity and is directly modulated by the composition of the lipid headgroups. Molecular studies of the insertion of model Aβ40 protofilaments in lipid bilayers revealed strong interactions that affect the structural integrity of both the membranes and the ordered amyloid aggregates. In particular, electrostatics plays a crucial role in the interaction between Aβ protofilaments and palmytoil-oleoyl-phosphatidylethanolamine (POPE) lipids, a common component of neuronal plasma membranes. Here, we use all-atom molecular dynamics and steered molecular dynamics simulations to systematically compare the effects that POPE and palmytoil-oleoyl-phosphatidylcholine (POPC) headgroups have on the Aβ-lipid interactions. We find that Aβ protofilaments exhibit weaker electrostatic interactions with POPC headgroups and establish significantly shorter-lived contacts with the POPC bilayer. This illustrates the crucial yet complex role of electrostatic and hydrogen bonding interactions in modulating the anchoring and insertion of Aβ peptides into lipid bilayers. Our study reveals the atomistic details behind the barrier created by the lipid headgroup region in impeding solution-aggregated fibrillar oligomers to spontaneously insert into POPC bilayers, in contrast to the POPE case. While the biological reality is notoriously more complex (e.g., including other factors such as cholesterol), our results evidence a simple experimentally and computationally testable case for probing the factors that control the insertion of Aβ oligomeric aggregates in neuronal cell membranes-a process central to their neurotoxicity. © 2015 American Chemical Society.","Alzheimers disease; amyloid peptide-lipid membrane interactions; amyloid β-peptide fibrils; Aβ fibrillar oligomers; molecular dynamics simulations; toxic amyloid channels","Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M.P., Ding, K., Ihara, Y., Mutant presenilin 2 transgenic mice: A large increase in the levels of Aβ 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin (2000) J. Biol. Chem., 275, pp. 27901-27908; Zhang, S., Iwata, K., Lachenmann, M.J., Peng, J.W., Li, S., Stimson, E.R., Lu, Y., Lee, J.P., The Alzheimers peptide Aβ adopts a collapsed coil structure in water (2000) J. Struct. Biol., 130, pp. 130-141; Vivekanandan, S., Brender, J.R., Lee, S.Y., Ramamoorthy, A., A partially folded structure of amyloid-β(1-40) in an aqueous environment (2011) Biochem. Biophys. Res. Commun., 411, pp. 312-316; Danielsson, J., Jarvet, J., Damberg, P., Graslund, A., The Alzheimer β-peptide shows temperature-dependent transitions between left-handed 3(1)-helix, beta-strand and random coil secondary structures (2005) FEBS J., 272, pp. 3938-3949; Niu, Z., Zhao, W., Zhang, Z., Xiao, F., Tang, X., Yang, J., The Molecular Structure of Alzheimer β-Amyloid Fibrils Formed in the Presence of Phospholipid Vesicles (2014) Angew. Chem., Int. Ed., 53, pp. 9294-9297; Morriss-Andrews, A., Brown, F.L.H., Shea, J.-E., A Coarse-Grained Model for Peptide Aggregation on a Membrane Surface (2014) J. Mol. Biol., 118, pp. 8420-8432; Hertel, C., Terzi, E., Hauser, N., Jakobrotne, R., Seelig, J., Kemp, J.A., Inhibition of the electrostatic interaction between β-amyloid peptide and membranes prevents beta-amyloid-induced toxicity (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 9412-9416; Zhao, H.X., Tuominen, E.K.J., Kinnunen, P.K.J., Formation of amyloid fibers triggered by phosphatidylserine-containing membranes (2004) Biochemistry, 43, pp. 10302-10307; Kubo, S., Nemani, V.M., Chalkley, R.J., Anthony, M.D., Hattori, N., Mizuno, Y., Edwards, R.H., Fortin, D.L., A combinatorial code for the interaction of alpha-synuclein with membranes (2005) J. Biol. Chem., 280, pp. 31664-31672; Bokvist, M., Lindstrom, F., Watts, A., Grobner, G., Two types of Alzheimers β-amyloid (1-40) peptide membrane interactions: Aggregation preventing transmembrane anchoring versus accelerated surface fibril formation (2004) J. Mol. Biol., 335, pp. 1039-1049; Aisenbrey, C., Borowik, T., Bystrom, R., Bokvist, M., Lindstrom, F., Misiak, H., Sani, M.A., Grobner, G., How is protein aggregation in amyloidogenic diseases modulated by biological membranes? (2008) Eur. Biophys. J., 37, pp. 247-255; Lau, T.L., Ambroggio, E.E., Tew, D.J., Cappai, R., Masters, C.L., Fidelio, G.D., Barnham, K.J., Separovic, F., Amyloid-β peptide disruption of lipid membranes and the effect of metal ions (2006) J. Mol. Biol., 356, pp. 759-770; De Planque, M.R.R., Raussens, V., Contera, S.A., Rijkers, D.T.S., Liskamp, R.M.J., Ruysschaert, J.M., Ryan, J.F., Watts, A., β-sheet structured β-amyloid(1-40) perturbs phosphatidylcholine model membranes (2007) J. Mol. Biol., 368, pp. 982-997; Wong, P.T., Schauerte, J.A., Wisser, K.C., Ding, H., Lee, E.L., Steel, D.G., Gafni, A., Amyloid-β Membrane Binding and Permeabilization are Distinct Processes Influenced Separately by Membrane Charge and Fluidity (2009) J. Mol. Biol., 386, pp. 81-96; Hane, F., Drolle, E., Gaikwad, R., Faught, E., Leonenko, Z., Amyloid-β Aggregation on Model Lipid Membranes: An Atomic Force Microscopy Study (2011) J. Alzheimers Dis., 26, pp. 485-494; Sasahara, K., Morigaki, K., Shinya, K., Effects of membrane interaction and aggregation of amyloid β-peptide on lipid mobility and membrane domain structure (2013) Phys. Chem. Chem. Phys., 15, pp. 8929-8939; Engel, M.F.M., Khemtemourian, L., Kleijer, C.C., Meeldijk, H.J.D., Jacobs, J., Verkleij, A.J., De Kruijff, B., Hoppener, J.W.M., Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 6033-6038; Williams, T.L., Day, I.J., Serpell, L.C., The Effect of Alzheimers Aβ Aggregation State on the Permeation of Biomimetic Lipid Vesicles (2010) Langmuir, 26, pp. 17260-17268; Kremer, J.J., Murphy, R.M., Kinetics of adsorption of β-amyloid peptide Aβ(1-40) to lipid bilayers (2003) J. Biochem. Biophys. Methods, 57, pp. 159-169; Poojari, C., Strodel, B., Stability of Transmembrane Amyloid β-Peptide and Membrane Integrity Tested by Molecular Modeling of Site-Specific Aβ 42 Mutations (2013) PLoS One, 8, p. 78399; Tofoleanu, F., Buchete, N.-V., Molecular Interactions of Alzheimers Aß Protofilaments with Lipid Membranes (2012) J. Mol. Biol., 421, pp. 572-586; Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F., Tycko, R., A structural model for Alzheimers β-amyloid fibrils based on experimental constraints from solid state NMR (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 16742-16747; Petkova, A.T., Yau, W.M., Tycko, R., Experimental constraints on quaternary structure in Alzheimers β-amyloid fibrils (2006) Biochemistry, 45, pp. 498-512; Buchete, N.-V., Tycko, R., Hummer, G., Molecular Dynamics Simulations of Alzheimers β-Amyloid Protofilaments (2005) J. Mol. Biol., 353, pp. 804-821; Vance, J.E., Tasseva, G., Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells (2013) Biochim. Biophys. Acta, 1831, pp. 543-554; Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimers amyloid β-peptide (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; Campioni, S., Mannini, B., Zampagni, M., Pensalfini, A., Parrini, C., Evangelisti, E., Relini, A., Chiti, F., A causative link between the structure of aberrant protein oligomers and their toxicity (2010) Nat. Chem. Biol., 6, pp. 140-147; Buchete, N.V., Hummer, G., Structure and dynamics of parallel β-sheets, hydrophobic core, and loops in Alzheimers Aβ fibrils (2007) Biophys. J., 92, pp. 3032-3039; Glabe, C.G., Amyloid Oligomer Structures and Toxicity (2009) Open Biol. J., 2, pp. 222-227; Murzyn, K., Rog, T., Pasenkiewicz-Gierula, M., Phosphatidylethanolamine-phosphatidylglycerol bilayer as a model of the inner bacterial membrane (2005) Biophys. J., 88, pp. 1091-1103; Pasenkiewicz-Gierula, M., Murzyn, K., Rog, T., Czaplewski, C., Molecular dynamics simulation studies of lipid bilayer systems (2000) Acta Biochim. Polym., 47, pp. 601-611; Kandasamy, S.K., Larson, R.G., Binding modes of protegrin-1, a β-strand antimicrobial peptide, in lipid bilayers (2007) Mol. Simul., 33, pp. 799-807; Shai, Y., Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides (1999) Biochim. Biophys. Acta, Biomembr., 1462, pp. 55-70; Urbanc, B., Betnel, M., Cruz, L., Li, H., Fradinger, E.A., Monien, B.H., Bitan, G., Structural Basis for Aβ(1-42) Toxicity Inhibition by Aβ C-Terminal Fragments: Discrete Molecular Dynamics Study (2011) J. Mol. Biol., 410, pp. 316-328; Giacomelli, C.E., Norde, W., Conformational changes of the amyloid β-peptide (1-40) adsorbed on solid surfaces (2005) Macromol. Biosci., 5, pp. 401-407; Dominguez, L., Meredith, S.C., Straub, J.E., Thirumalai, D., Transmembrane Fragment Structures of Amyloid Precursor Protein Depend on Membrane Surface Curvature (2014) J. Am. Chem. Soc., 136, pp. 854-857; Di Scala, C., Troadec, J.D., Lelievre, C., Garmy, N., Fantini, J., Chahinian, H., Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide (2014) J. Neurochem., 128, pp. 186-195; Sciarretta, K.L., Gordon, D.J., Petkova, A.T., Tycko, R., Meredith, S.C., Aβ40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid (2005) Biochemistry, 44, pp. 6003-6014; Reddy, G., Straub, J.E., Thirumalai, D., Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Aβ peptides with implications for rates of fibril formation (2009) J. Phys. Chem. B, 113, pp. 1162-1172; Tofoleanu, F., Buchete, N.V., Alzheimer A beta peptide interactions with lipid membranes Fibrils, oligomers and polymorphic amyloid channels (2012) Prion, 6, pp. 339-345; Ladiwala, A.R., Litt, J., Kane, R., Aucoin, D., Smith, S., Ranjan, S., Davis, J., Tessier, P., Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity (2012) J. Biol. Chem., 287, pp. 24765-24773; Sparr, E., Engel, M.F.M., Sakharov, D.V., Sprong, M., Jacobs, J., De Kruijff, B., Hoppener, J.W.M., Killian, J.A., Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers (2004) FEBS Lett., 577, pp. 117-120; Butterfield, S.M., Lashuel, H.A., Amyloidogenic protein-membrane interactions: Mechanistic insight from model systems (2010) Angew. Chem., Int. Ed., 49, pp. 5628-5654; Andreetto, E., Yan, L.M., Tatarek-Nossol, M., Velkova, A., Frank, R., Kapurniotu, A., Identification of Hot Regions of the Aβ-IAPP Interaction Interface as High-Affinity Binding Sites in both Cross- and Self-Association (2010) Angew. Chem., Int. Ed., 49, pp. 3081-3085; Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., Differences between amyloid-β aggregation in solution and on the membrane: Insights into elucidation of the mechanistic details of Alzheimers disease (2014) Chem. Soc. Rev., 43, pp. 6692-6700; Jang, H., Connelly, L., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane (2013) J. Chem. Theory Comput., 9, pp. 822-833; Jang, H., Arce, F., Ramachandran, S., Kagan, B., Lal, R., Nussinov, R., Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity (2013) J. Phys. Chem. B, 117, pp. 11518-11529; Straub, J.E., Thirumalai, D., Membrane-Protein Interactions Are Key to Understanding Amyloid Formation (2014) J. Phys. Chem. Lett., 5, pp. 633-635; Song, Y., Mittendorf, K.F., Lu, Z., Sanders, C.R., Impact of bilayer lipid composition on the structure and topology of the transmembrane amyloid precursor c99 protein (2014) J. Am. Chem. Soc., 136, pp. 4093-4096; Fantini, J., Yahi, N., Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: Common mechanisms in neurodegenerative diseases (2010) Expert. Rev. Mol. Med., 12, p. 27; Fantini, J., Yahi, N., Garmy, N., Cholesterol accelerates the binding of Alzheimers β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation (2013) Front. Physiol., 4, p. 120; Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Interactions of amyloid β-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid (2002) Biochemistry, 41, pp. 7385-7390; Atilla-Gokcumen, G.E., Muro, E., Relat-Goberna, J., Sasse, S., Bedigian, A., Coughlin, M., Garcia-Manyes, S., Eggert, U.S., Dividing Cells Regulate Their Lipid Composition and Localization (2014) Cell, 156, pp. 428-439; Muro, E., Atilla-Gokcumen, G.E., Eggert, U.S., Lipids in cell biology: How can we understand them better? (2014) Mol. Biol. Cell, 25, pp. 1819-1823; Kale, L., Skeel, R., Bhandarkar, M., Brunner, R., Gursoy, A., Krawetz, N., Phillips, J., Schulten, K., NAMD2: Greater scalability for parallel molecular dynamics (1999) J. Comput. Phys., 151, pp. 283-312; Mackerell, A.D., All-atom empirical potential for molecular modeling and dynamics studies of proteins (1998) J. Phys. Chem. B, 102, pp. 3586-3616; Feller, S.E., Zhang, Y.H., Pastor, R.W., Brooks, B.R., Constant-Pressure Molecular-Dynamics Simulation - The Langevin Piston Method (1995) J. Chem. Phys., 103, pp. 4613-4621; Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., Comparison of Simple Potential Functions for Simulating Liquid Water (1983) J. Chem. Phys., 79, pp. 926-935; Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics (1996) J. Mol. Graphics, 14, p. 33; Kelly, C.M., Northey, T., Ryan, K., Brooks, B.R., Kholkin, A.L., Rodriguez, B.J., Buchete, N.-V., Conformational dynamics and aggregation behavior of piezoelectric diphenylalanine peptides in an external electric field (2015) Biophys. Chem., 196, pp. 16-24; Grubmuller, H., Heymann, B., Tavan, P., Ligand Binding: Molecular Mechanics Calculation of the Streptavidin-Biotin Rupture Force (1996) Science, 271, pp. 997-999; Izrailev, S., Stepaniants, S., Balsera, M., Oono, Y., Schulten, K., Molecular dynamics study of unbinding of the avidin-biotin complex (1997) Biophys. J., 72, pp. 1568-1581; Raman, E.P., Takeda, T., Barsegov, V., Klimov, D.K., Mechanical Unbinding of Aß Peptides from Amyloid Fibrils (2007) J. Mol. Biol., 373, pp. 785-800; Heinig, M., Frishman, D., STRIDE: A web server for secondary structure assignment from known atomic coordinates of proteins (2004) Nucleic Acids Res., 32, pp. 500-W502",Article,Scopus,2-s2.0-84925104747
"Hooshyar Yousefi B., Manook A., Grimmer T., Arzberger T., Von Reutern B., Henriksen G., Drzezga A., Forster S., Schwaiger M., Wester H.-J.","Characterization and first human investigation of FIBT, a novel fluorinated aβ plaque neuroimaging pet radioligand",2015,"ACS Chemical Neuroscience","6","3",,"428","437",,,10.1021/cn5001827,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925143377&partnerID=40&md5=a5bc892729d06cc734b40739fc5d086f","Department of Pharmaceutical Radiochemistry, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Department of Pharmaceutical Radiochemistry, Technische Universität München, Walter-Meissner Strasse 3Garching, Germany; Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Centre for Neuropathology and Prion Research, Ludwig-Maximilians Universität MünchenMunich, Germany; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians Universität MünchenMunich, Germany","Hooshyar Yousefi, B., Department of Pharmaceutical Radiochemistry, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany, Department of Pharmaceutical Radiochemistry, Technische Universität München, Walter-Meissner Strasse 3Garching, Germany; Manook, A., Department of Pharmaceutical Radiochemistry, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany, Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Grimmer, T., Centre for Neuropathology and Prion Research, Ludwig-Maximilians Universität MünchenMunich, Germany; Arzberger, T., Department of Psychiatry and Psychotherapy, Ludwig-Maximilians Universität MünchenMunich, Germany; Von Reutern, B., Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Henriksen, G., Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Drzezga, A., Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Förster, S., Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Schwaiger, M., Department of Nuclear Medicine, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany; Wester, H.-J., Department of Pharmaceutical Radiochemistry, Department of Psychiatry and Psychotherapy, Technische Universität MünchenMunich, Germany","Imidazo[2,1-b]benzothiazoles (IBTs) are a promising novel class of amyloid positron emission tomography (PET) radiopharmaceuticals for diagnosis of neurodegenerative disorders like Alzheimers disease (AD). Their good in vivo imaging properties have previously been shown in preclinical studies. Among IBTs, fluorinated [18F]FIBT was selected for further characterization and advancement toward use in humans. [18F]FIBT characteristics were analyzed in relation to Pittsburgh compound B (PiB) as reference ligand. [18F]FIBT and [3H]PiB were coinjected to an APP/PS1 mouse for ex vivo dual-label autoradiographic correlation. Acute dose toxicity of FIBT was examined in two groups of healthy mice. Preexisting in vivo stability and biodistribution studies in mice were complemented with analogous studies in rats. [18F]FIBT was titrated against postmortem human AD brain homogenate in a saturation binding assay previously performed with [3H]PiB. Binding of [18F]FIBT to human AD brain was further analyzed by in vitro incubation of human AD brain sections in comparison to [11C]PiB in relation to standard immunohistochemistry. Finally, [18F]FIBT was administered to two human subjects for a dynamic 90 min PET/MR brain investigation. Ex vivo autoradiography confirmed good uptake of [18F]FIBT to mouse brain and its excellent correlation to [3H]PiB binding. No toxicity of FIBT could be found in mice at a concentration of 33.3 nmol/kg. As in mice, [18F]FIBT was showing high in vivo stability in rats and comparable regional brain biodistribution dynamics to [3H]PiB. Radioligand saturation binding confirmed at least one high-affinity binding component of [18F]FIBT around 1 nM. Good binding of FIBT relative to PiB was further confirmed in binding assays and autoradiographies using post-mortem AD brain. First use of [18F]FIBT in humans successfully yielded clinical [18F]FIBT PET/MR images with very good contrast. In summary, [18F]FIBT has been characterized to be a new lead compound with improved binding characteristics and pharmacokinetics on its own as well as in comparison to PiB. A pilot human PET investigation provided high-quality images with a plausible tracer distribution pattern. Detailed clinical investigations are needed to confirm these first results and to explore the specific qualities of [18F]FIBT PET for dementia imaging in relation to established ligands. © 2014 American Chemical Society.","18F-labeled radiopharmaceutical; Alzheimers disease; amyloid-beta; autoradiography; binding assay; FIBT; PET; PiB","Henriksen, G., Yousefi, B., Drzezga, A., Wester, H.-J., Development and evaluation of compounds for imaging of ?-amyloid plaque by means of positron emission tomography (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 75-81; Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G.M., Barrio, J.R., Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimers disease (2001) J. Neurosci., 21 (24), p. 189; Noda, A., Murakami, Y., Nishiyama, S., Fukumoto, D., Miyoshi, S., Tsukada, H., Nishimura, S., Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP (2008) Synapse, 62 (6), pp. 472-475; Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W.E., Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents (2003) J. Med. Chem., 46 (13), pp. 2740-2754; Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Barrio, J.R., PET of brain amyloid and tau in mild cognitive impairment (2006) N. Engl. J. Med., 355 (25), pp. 2652-2663; Kung, M.P., Hou, C., Zhuang, Z.P., Cross, A.J., Maier, D.L., Kung, H.F., Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice (2004) Eur. J. Nucl. Med. Mol. Imaging, 31 (8), pp. 1136-1145; Kung, M.P., Hou, C., Zhuang, Z.P., Zhang, B., Skovronsky, D., Trojanowski, J.Q., Lee, V.M., Kung, H.F., IMPY: An improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques (2002) Brain Res., 956 (2), pp. 202-210; Yousefi, B.H., Manook, A., Drzezga, A., Von Reutern, B., Schwaiger, M., Wester, H.J., Henriksen, G., Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging beta-amyloid plaques in Alzheimers disease (2011) J. Med. Chem., 54 (4), pp. 949-956; Yousefi, B.H., Drzezga, A., Reutern, B.V., Manook, A., Schwaiger, M., Wester, H.-J., Henriksen, G., A novel 18F-labeled imidazo[2,1-b]benzothiazole (IBT) for high-contrast PET imaging of ?-amyloid plaques (2011) ACS Med. Chem. Lett., 2 (9), pp. 673-677; Manook, A., Yousefi, B.H., Willuweit, A., Platzer, S., Reder, S., Voss, A., Huisman, M., Drzezga, A., Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimers disease (2012) PLoS One, 7 (3), p. 31310; Irwin, D.J., Lee, V.M., Trojanowski, J.Q., Parkinsons disease dementia: Convergence of alpha-synuclein, tau and amyloid-beta pathologies (2013) Nat. Rev. Neurosci., 14 (9), pp. 626-636; Willuweit, A., Velden, J., Godemann, R., Manook, A., Jetzek, F., Tintrup, H., Kauselmann, G., Von Der Kammer, H., Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimers disease (2009) PLoS One, 4 (11), p. 7931; Von Reutern, B., Grunecker, B., Yousefi, B.H., Henriksen, G., Czisch, M., Drzezga, A., Voxel-Based Analysis of Amyloid-Burden Measured with [(11)C]PiB PET in a Double Transgenic Mouse Model of Alzheimers Disease (2013) Mol. Imaging Biol., 15 (5), pp. 576-584; Johnston, M., Zakharov, A., Papaiconomou, C., Salmasi, G., Armstrong, D., Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species (2004) Cerebrospinal Fluid Res., 1 (1), p. 2; Klunk, W.E., Lopresti, B.J., Ikonomovic, M.D., Lefterov, I.M., Koldamova, R.P., Abrahamson, E.E., Debnath, M.L., Mathis, C.A., Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimers disease brain but not in transgenic mouse brain (2005) J. Neurosci., 25 (46), pp. 10598-10606; Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., Joliot, M., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain (2002) NeuroImage, 15 (1), pp. 273-289; Ikoma, Y., Edison, P., Ramlackhansingh, A., Brooks, D.J., Turkheimer, F.E., Reference region automatic extraction in dynamic [(11)C]PIB (2013) J. Cereb. Blood Flow Metab., 33 (11), pp. 1725-1731; Lopresti, B.J., Klunk, W.E., Mathis, C.A., Hoge, J.A., Ziolko, S.K., Lu, X., Meltzer, C.C., Price, J.C., Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis (2005) J. Nucl. Med., 46 (12), pp. 1959-1972; Johnson, K.A., Gregas, M., Becker, J.A., Kinnecom, C., Salat, D.H., Moran, E.K., Smith, E.E., Greenberg, S.M., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy (2007) Ann. Neurol., 62 (3), pp. 229-234; Barthel, H., Luthardt, J., Becker, G., Patt, M., Hammerstein, E., Hartwig, K., Eggers, B., Sabri, O., Individualized quantification of brain beta-amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimers disease and healthy controls (2011) Eur. J. Nucl. Med. Mol. Imaging, 38 (9), pp. 1702-1714",Article,Scopus,2-s2.0-84925143377
"Zhao J., Wang P., Li H., Gao Z.","Nitration of Y10 in Aβ1-40: Is It a compensatory reaction against oxidative/nitrative stress and Aβ aggregation?",2015,"Chemical Research in Toxicology","28","3",,"401","407",,,10.1021/tx500353s,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924908696&partnerID=40&md5=89dbca92f28915b82bd35a1a8861bdff","School of Chemistry and Chemical Engineering, Huazhong University of Science and TechnologyWuhan, China; Hubei Key Laboratory of Bioinorganic Chemistry and Materia MedicaWuhan, China","Zhao, J., School of Chemistry and Chemical Engineering, Huazhong University of Science and TechnologyWuhan, China, Hubei Key Laboratory of Bioinorganic Chemistry and Materia MedicaWuhan, China; Wang, P., School of Chemistry and Chemical Engineering, Huazhong University of Science and TechnologyWuhan, China, Hubei Key Laboratory of Bioinorganic Chemistry and Materia MedicaWuhan, China; Li, H., School of Chemistry and Chemical Engineering, Huazhong University of Science and TechnologyWuhan, China, Hubei Key Laboratory of Bioinorganic Chemistry and Materia MedicaWuhan, China; Gao, Z., School of Chemistry and Chemical Engineering, Huazhong University of Science and TechnologyWuhan, China, Hubei Key Laboratory of Bioinorganic Chemistry and Materia MedicaWuhan, China","Amyloid β peptide (Aβ) aggregation is considered to be a crucial pathological biomarker of Alzheimers disease (AD). It was found that Aβ and heme can form an Aβ-heme complex, which results in increased heme pseudoperoxidase activity. Recently, we found that increasing pseudoperoxidase activity induces elevated tyrosine nitration on Aβ in the presence of nitrite and hydrogen peroxide. However, the nature of tyrosine nitration of Aβ and its physiologic significance are still unknown. In this study, we revealed that Aβ1-40 can be nitrated in vitro by binding to heme in the presence of nitrite and hydrogen peroxide. Moreover, we found that tyrosine nitration had little effect on Aβ1-40s binding activity with heme. A TMB assay also revealed that the peroxidase activity of the heme-Aβ1-40Y10(3N)T (tyrosine 10 was replaced with 3-nitrtotyrosine in Aβ1-40) complex was moderately increased compared with that of the heme-Aβ1-40 complex. Furthermore, Thioflavin T fluorescence and transmission electron microscopic characterization indicated that tyrosine nitration significantly decreased the aggregation of Aβ1-40. In addition, a cytotoxicity test verified that wild-type Aβ1-40 was more cytotoxic than that of Aβ1-40Y10(3N)T. These results suggest that nitration of Aβ1-40 might be an Aβ detoxicant process and a compensatory reaction to nitrative stress. Our findings may lead to a detailed understanding of the function of Aβ1-40 and may be helpful in preventing and curing AD. © 2014 American Chemical Society.",,"Behrouz, N., Defossez, A., Delacourte, A., Mazzuca, M., The immunohistochemical evidence of amyloid diffuse deposits as a pathological hallmark in Alzheimers disease (1991) J. Gerontol., 46, pp. 209-B212; Tran, M.H., Yamada, K., Nakajima, A., Mizuno, M., He, J., Kamei, H., Nabeshima, T., Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction (2003) Mol. Psychiatry, 8, pp. 407-412; Guix, F.X., Ill-Raga, G., Bravo, R., Nakaya, T., De Fabritiis, G., Coma, M., Miscione, G.P., Munoz, F.J., Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation (2009) Brain, 132, pp. 1335-1345; Caraman, M., Tangpong, J., Keller, J.N., Murphy, M.P., Markesbery, W.R., Kiningham, K.K., St. Clair, D.K., Beta-amyloid mediated nitration of manganese superoxide dismutase: Implication for oxidative stress in a APPNLH/NLH × PS-1P264L/P264L double knock-in mouse model of Alzheimers disease (2006) Am. J. Pathol., 168, pp. 1608-1618; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimers disease (2009) Nat. Chem., 1, pp. 326-331; Hardy, J.A., Higgins, G.A., Alzheimers disease: The amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; Gazit, E., From green bacteria to human dementia: A novel model for discovering amyloid assembly inhibitors (2006) ACS Chem. Biol., 1, pp. 417-419; Gregory, G.C., Halliday, G.M., What is the dominant Aβ species in human brain tissue? A review (2005) Neurotoxic. Res., 7, pp. 29-41; Mattson, M.P., Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives (1997) Physiol. Rev., 77, pp. 1081-1132; Li, F., Calingasan, N.Y., Yu, F., Mauck, W.M., Toidze, M., Almeida, C.G., Takahashi, R.H., Gouras, G.K., Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice (2004) J. Neurochem., 89, pp. 1308-1312; Nishida, Y., Yokota, T., Takahashi, T., Uchihara, T., Jishage, K., Mizusawa, H., Deletion of vitamin e enhances phenotype of Alzheimer disease model mouse (2006) Biochem. Biophys. Res. Commun., 350, pp. 530-536; Nunomura, A., Castellani, R.J., Zhu, X., Moreira, P.I., Perry, G., Smith, M.A., Involvement of oxidative stress in Alzheimer disease (2006) J. Neuropathol. Exp. Neurol., 65, pp. 631-641; Abello, N., Kerstjens, H.A., Postma, D.S., Bischoff, R., Protein tyrosine nitration: Selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins (2009) J. Proteome Res., 8, pp. 3222-3238; Pacher, P., Beckman, J.S., Liaudet, L., Nitric oxide and peroxynitrite in health and disease (2007) Physiol. Rev., 87, pp. 315-424; De Filippis, V., Frasson, R., Fontana, A., 3-Nitrotyrosine as a spectroscopic probe for investigating protein protein interactions (2006) Protein Sci., 15, pp. 976-986; Zamyatnin, A.A., Protein volume in solution (1972) Prog. Biophys. Mol. Biol., 24, pp. 107-123; Sultana, R., Poon, H.F., Cai, J., Pierce, W.M., Merchant, M., Klein, J.B., Markesbery, W.R., Butterfield, D.A., Identification of nitrated proteins in Alzheimers disease brain using a redox proteomics approach (2006) Neurobiol. Dis., 22, pp. 76-87; Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Lee, V.M., Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions (2000) Science, 290, pp. 985-989; Alkam, T., Nitta, A., Mizoguchi, H., Itoh, A., Murai, R., Nagai, T., Yamada, K., Nabeshima, T., The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid beta in mice (2008) J. Pharmacol. Exp. Ther., 327, pp. 137-147; Atamna, H., Boyle, K., Amyloid-beta peptide binds with heme to form a peroxidase: Relationship to the cytopathologies of Alzheimers disease (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 3381-3386; Atamna, H., Frey, W.H., Ko, N., Human and rodent amyloid-beta peptides differentially bind heme: Relevance to the human susceptibility to Alzheimers disease (2009) Arch. Biochem. Biophys., 487, pp. 59-65; Yuan, C., Yi, L., Yang, Z., Deng, Q., Huang, Y., Li, H., Gao, Z., Amyloid beta-heme peroxidase promoted protein nitrotyrosination: Relevance to widespread protein nitration in Alzheimers disease (2012) J. Biol. Inorg. Chem., 17, pp. 197-207; Van Der Vliet, A., Eiserich, J.P., Halliwell, B., Cross, C.E., Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity (1997) J. Biol. Chem., 272, pp. 7617-7625; Rojas, N.R., Kamtekar, S., Simons, C.T., McLean, J.E., Vogel, K.M., Spiro, T.G., Farid, R.S., Hecht, M.H., De novo heme proteins from designed combinatorial libraries (1997) Protein Sci., 6, pp. 2512-2524; Paoli, M., Marles-Wright, J., Smith, A., Structure-function relationships in heme-proteins (2002) DNA Cell Biol., 21, pp. 271-280; Dawson, J.H., Probing structure-function relations in heme-containing oxygenases and peroxidases (1988) Science, 240, pp. 433-439; Fukuyama, K., Kunishima, N., Amada, F., Kubota, T., Matsubara, H., Crystal structures of cyanide- and triiodide-bound forms of Arthromyces ramosus peroxidase at different pH values. Perturbations of active site residues and their implication in enzyme catalysis (1995) J. Biol. Chem., 270, pp. 21884-21892; Kummer, M.P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Heneka, M.T., Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation (2011) Neuron, 71, pp. 833-844; Josephy, P.D., Eling, T., Mason, R.P., The horseradish peroxidase-catalyzed oxidation of 3,5,3,5-tetramethylbenzidine. Free radical and charge-transfer complex intermediates (1982) J. Biol. Chem., 257, pp. 3669-3675; Bartolini, M., Bertucci, C., Bolognesi, M.L., Cavalli, A., Melchiorre, C., Andrisano, V., Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: Elucidation of inhibitors mechanism of action (2007) ChemBioChem, 8, pp. 2152-2161; Sánchez, L., Madurga, S., Pukala, T., Vilaseca, M., López-Iglesias, C., Robinson, C.V., Giralt, E., Carulla, N.L., Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties (2011) J. Am. Chem. Soc., 133, pp. 6505-6508; Levine, H.R., Quantification of beta-sheet amyloid fibril structures with thioflavin T (1999) Methods Enzymol., 309, pp. 274-284; Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays (1983) J. Immunol. Methods, 65, pp. 55-63; Pereira, C., Santos, M.S., Oliveira, C., Involvement of oxidative stress on the impairment of energy metabolism induced by Aβ peptides on PC12 cells: Protection by antioxidants (1999) Neurobiol. Dis., 6, pp. 209-219; Haughey, N.J., Nath, A., Chan, S.L., Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimers disease (2002) J. Neurochem., 83, pp. 1509-1524; Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Smith, M.A., Oxidative damage is the earliest event in Alzheimer disease (2001) J. Neuropathol. Exp. Neurol., 60, pp. 759-767; Nunomura, A., Chiba, S., Lippa, C.F., Neuronal RNA oxidation is a prominent feature of familial Alzheimers disease (2004) Neurobiol. Dis., 17, pp. 108-113; Gazit, E., A possible role for π-stacking in the self-assembly of amyloid fibrils (2002) FASEB J., 16, pp. 77-83; Yuan, C., Gao, Z., Aβ interacts with both the iron center and the porphyrin ring of heme: Mechanism of hemes action on Aβ aggregation and disaggregation (2013) Chem. Res. Toxicol., 26, pp. 262-269; Zhao, L.N., Mu, Y., Chew, L.Y., Heme prevents amyloid beta peptide aggregation through hydrophobic interaction based on molecular dynamics simulation (2013) Phys. Chem. Chem. Phys., 15, pp. 14098-14106; Lee, C., Ham, S., Characterizing amyloid-beta protein misfolding from molecular dynamics simulations with explicit water (2011) J. Comput. Chem., 32, pp. 349-355; Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356",Article,Scopus,2-s2.0-84924908696
"Lu N., Li J., Tian R., Peng Y.-Y.","Key roles for tyrosine 10 in Aβ-heme complexes and its relevance to oxidative stress",2015,"Chemical Research in Toxicology","28","3",,"365","372",,,10.1021/tx5003035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924856808&partnerID=40&md5=09f53f50759ad914c181750499a82a67","Key Laboratory of Functional Small Organic Molecule, Ministry of Education, College of Life Science, China; Key Laboratory of Green Chemistry, Jiangxi Province and College of Chemistry and Chemical Engineering, Jiangxi Normal University, 99 Ziyang RoadNanchang, Jiangxi, China","Lu, N., Key Laboratory of Functional Small Organic Molecule, Ministry of Education, College of Life Science, China; Li, J., Key Laboratory of Green Chemistry, Jiangxi Province and College of Chemistry and Chemical Engineering, Jiangxi Normal University, 99 Ziyang RoadNanchang, Jiangxi, China; Tian, R., Key Laboratory of Green Chemistry, Jiangxi Province and College of Chemistry and Chemical Engineering, Jiangxi Normal University, 99 Ziyang RoadNanchang, Jiangxi, China; Peng, Y.-Y., Key Laboratory of Functional Small Organic Molecule, Ministry of Education, College of Life Science, China, Key Laboratory of Green Chemistry, Jiangxi Province and College of Chemistry and Chemical Engineering, Jiangxi Normal University, 99 Ziyang RoadNanchang, Jiangxi, China","Amyloid β-peptide (Aβ) aggregation in the brain, known as amyloid plaques, is a pathological feature of Alzheimers disease (AD). Recent studies show that heme binds to the His residue of Aβ with the iron center and subsequently forms an Aβ-heme complex, which can inhibit Aβ aggregation. Although Tyr-10 was not the residue binding heme, the key roles for Tyr-10 in Aβ-heme complexes and its potential biological relevance to AD etiology under oxidative stress were not sufficiently evaluated. Here, we used wild-type and Tyr-10-mutated human Aβ peptides and studied the impact of the mutation on Aβ-heme peroxidase activity, heme-bound Aβ aggregation, and oxidation and nitration under oxidative and nitrative stresses. Our results indicate that the mutation of Tyr-10 in Aβ16 and Aβ40 decreased the peroxidase activity of Aβ-heme complexes and that the mutation of Tyr-10 could inhibit Aβ40 self-assembly aggregation. Under oxidative (H2O2) and nitrative (H2O2/NaNO2) stress conditions, the Aβ40-heme complexes caused oxidation and nitration of the Aβ Tyr-10 residue through promoting peroxidase-like reactions, which were different from the classic inhibitive effect of heme on Aβ aggregation. To our knowledge, this is the first time that the formation of a heme-to-protein cross-linked Aβ40-heme complex under oxidative stress has been reported; in addition, the mutation of Tyr-10 could inhibit the cross-link formation. Therefore, Tyr-10 is pivotal in Aβ-heme complexes and plays key roles in Aβ aggregation under oxidative and nitrative stresses, demonstrating a novel significance of Tyr-10 as well as Aβ-heme complexes in the pathology of AD. © 2014 American Chemical Society.",,"Rauk, A., The chemistry of Alzheimers disease (2009) Chem. Soc. Rev., 38, pp. 2698-2715; Selkoe, D.J., Alzheimers disease: Genes, proteins, and therapy (2001) Phys. Rev., 81, pp. 741-766; Hamley, I.W., The amyloid beta peptide: A chemists perspective. Role in Alzheimers and fibrillization (2012) Chem. Rev., 112, pp. 5147-5192; Atamna, H., Frey, W.H.I.I., A role for heme in Alzheimers disease: Heme binds amyloid β and has altered metabolism (2004) Proc. Natl. Acad. Sci. U.S.A., 101, pp. 11153-11158; Atamna, H., Boyle, K., Amyloid-β peptide binds with heme to form a peroxidase: Relationship to the cytopathologies of Alzheimers disease (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 3381-3386; Bao, Q., Luo, Y., Li, W., Sun, X., Zhu, C., Li, P., Huang, Z.-X., Tan, X., The mechanism for heme to prevent Aβ1-40 aggregation and its cyotoxicity (2011) J. Biol. Inorg. Chem., 16, pp. 809-816; Yuan, C., Gao, Z., Aβ interacts with both the iron center and the porphyrin ring of heme: Mechanism of hemes action on Aβ aggregation and disaggregation (2013) Chem. Res. Toxicol., 26, pp. 262-269; Atamna, H., Frey, W.H.I.I., Ko, N., Human and rodent amyloid-β peptides differentially bind heme: Relevance to the human susceptibility to Alzheimers disease (2009) Arch. Biochem. Biophys., 487, pp. 59-65; Pramanik, D., Dey, S.G., Active site environment of heme-bound amyloid β peptide associated with Alzheimers disease (2011) J. Am. Chem. Soc., 133, pp. 81-87; Zhou, Y., Wang, J., Liu, L., Wang, R., Lai, X., Xu, M., Interaction between amyloid-β peptide and heme probed by electrochemistry and atomic force microscopy (2013) ACS Chem. Neurosci., 4, pp. 535-539; Pramanik, D., Ghosh, G., Mukherjee, S., Dey, S.G., Interaction of amyloid β peptides with redox active heme cofactor: Relevance to Alzheimers disease (2013) Coordin. Chem. Rev., 257, pp. 81-92; Pramanik, D., Ghosh, C., Dey, S.G., Heme-Cu bound Aβ peptides: Spectroscopic characterization, reactivity, and relevance to Alzheimers disease (2011) J. Am. Chem. Soc., 133, pp. 15545-15552; Kummer, M.P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Heneka, M.T., Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation (2011) Neuron, 71, pp. 833-844; Atwood, C.S., Perry, G., Zeng, H., Kato, Y., Jones, W.D., Ling, K.Q., Huang, X., Bush, A.I., Copper mediates dityrosine cross-linking of Alzheimers amyloid-beta (2004) Biochemistry, 43, pp. 560-568; Zhu, X., Su, B., Wang, X., Smith, M.A., Perry, G., Causes of oxidative stress in Alzheimer disease (2007) Cell. Mol. Life Sci., 64, pp. 2202-2210; Yuan, C., Yi, L., Yang, Z., Deng, Q., Huang, Y., Li, H., Gao, Z., Amyloid beta-heme peroxidase promoted protein nitrotyrosination: Relevance to widespread protein nitration in Alzheimers disease (2012) J. Biol. Inorg. Chem., 17, pp. 197-207; Yuan, C., Li, H., Gao, Z., Amyloid beta modulated the selectivity of heme-catalyzed protein tyrosine nitration: An alternative mechanism for selective protein nitration (2012) J. Biol. Inorg. Chem., 17, pp. 1083-1091; Hensley, K., Maidt, M.L., Yu, Z., Sang, H., Markesbery, W.R., Floyd, R.A., Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation (1998) J. Neurosci., 18, pp. 8126-8132; Thiabaud, G., Pizzocaro, S., Garcia-Serres, R., Latour, J.M., Monzani, E., Casella, L., Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress (2013) Angew. Chem., Int. Ed., 52, pp. 8041-8044; Sohn, O.S., Fiala, E.S., Analysis of nitrite/nitrate in biological fluids: Denitrification of 2-nitropropane in F344 rats (2000) Anal. Biochem., 279, pp. 202-208; Reeder, B.J., Cutruzzola, F., Bigotti, M.G., Watmough, N.J., Wilson, M.T., Histidine and not tyrosine is required for the peroxide-induced formation of haem to protein cross-linked myoglobin (2007) IUBMB Life, 59, pp. 477-489; Huang, Y., Shuai, Y., Li, H., Gao, Z., Tyrosine residues play an important role in heme detoxification by serum albumin (2014) Biochim. Biophys. Acta, 1840, pp. 970-976; Grinberg, L.N., Obrien, P.J., Hrkal, Z., The effects of heme-binding proteins on the peroxidative and catalatic activities of hemin (1999) Free Radical Biol. Med., 27, pp. 214-219; Paoli, M., Marles-Wright, J., Smith, A., Structure-function relationships in heme-proteins (2002) DNA Cell Biol., 21, pp. 271-280; Butterfield, D.A., Lange, M.L., Multifunctional roles of enolase in Alzheimers disease brain: Beyond altered glucose metabolism (2009) J. Neurochem., 111, pp. 915-933; Radi, R., Nitric oxide, oxidants, and protein tyrosine nitration (2004) Proc. Natl. Acad. Sci. U.S.A., 101, pp. 4003-4008; Reeder, B.J., Cutruzzola, F., Bigotti, M.G., Hider, R.C., Wilson, M.T., Tyrosine as a redox-active center in electron transfer to ferryl heme in globins (2008) Free Radical Biol. Med., 44, pp. 274-283; Lu, N., Li, J., Tian, R., Peng, Y.-Y., Key roles of Arg5, Tyr10 and His residues in Aβ-heme peroxidase: Relevance to Alzheimers disease (2014) Biochem. Biophys. Res. Commun.",Article,Scopus,2-s2.0-84924856808
"Choi B.-K., Kim J.-Y., Cha M.-Y., Mook-Jung I., Shin Y.-K., Lee N.K.","β-Amyloid and α-synuclein cooperate to block snare-dependent vesicle fusion",2015,"Biochemistry","54","9",,"1831","1840",,,10.1021/acs.biochem.5b00087,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924386284&partnerID=40&md5=1839ec4ad3d0631daef0f4268917c587","School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and TechnologyPohang, South Korea; Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversitySeoul, South Korea; Department of Biochemistry, Biophysics and Molecular Biology, Iowa State UniversityAmes, IA, United States; Department of Physics, Pohang University of Science and TechnologyPohang, South Korea","Choi, B.-K., School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and TechnologyPohang, South Korea; Kim, J.-Y., Department of Physics, Pohang University of Science and TechnologyPohang, South Korea; Cha, M.-Y., Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversitySeoul, South Korea; Mook-Jung, I., Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National UniversitySeoul, South Korea; Shin, Y.-K., Department of Biochemistry, Biophysics and Molecular Biology, Iowa State UniversityAmes, IA, United States; Lee, N.K., School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and TechnologyPohang, South Korea, Department of Physics, Pohang University of Science and TechnologyPohang, South Korea","Alzheimers disease (AD) and Parkinsons disease (PD) are caused by β-amyloid (Aβ) and α-synuclein (αS), respectively. Ample evidence suggests that these two pathogenic proteins are closely linked and have a synergistic effect on eliciting neurodegenerative disorders. However, the pathophysiological consequences of Aβ and αS coexistence are still elusive. Here, we show that large-sized αS oligomers, which are normally difficult to form, are readily generated by Aβ42-seeding and that these oligomers efficiently hamper neuronal SNARE-mediated vesicle fusion. The direct binding of the Aβ-seeded αS oligomers to the N-terminal domain of synaptobrevin-2, a vesicular SNARE protein, is responsible for the inhibition of fusion. In contrast, large-sized Aβ42 oligomers (or aggregates) or the products of αS incubated without Aβ42 have no effect on vesicle fusion. These results are confirmed by examining PC12 cell exocytosis. Our results suggest that Aβ and αS cooperate to escalate the production of toxic oligomers, whose main toxicity is the inhibition of vesicle fusion and consequently prompts synaptic dysfunction. © 2015 American Chemical Society.",,"Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., De Silva, H.A., Kittel, A., Saitoh, T., The precursor protein of non-A beta component of Alzheimers disease amyloid is a presynaptic protein of the central nervous system (1995) Neuron, 14, pp. 467-475; Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies (1997) Nature, 388, pp. 839-840; Irwin, D.J., Lee, V.M., Trojanowski, J.Q., Parkinsons disease dementia: Convergence of alpha-synuclein, tau and amyloid-beta pathologies (2013) Nat. Rev. Neurosci., 14, pp. 626-636; Armstrong, R.A., Cairns, N.J., Lantos, P.L., Beta-Amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies (1997) Neurosci. Lett., 227, pp. 193-196; Hamilton, R.L., Lewy bodies in Alzheimers disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry (2000) Brain Pathol., 10, pp. 378-384; Leverenz, J.B., Fishel, M.A., Peskind, E.R., Montine, T.J., Nochlin, D., Steinbart, E., Raskind, M.A., Tsuang, D., Lewy body pathology in familial Alzheimer disease: Evidence for disease- and mutation-specific pathologic phenotype (2006) Arch. Neurol., 63, pp. 370-376; Tsuang, D.W., Riekse, R.G., Purganan, K.M., David, A.C., Montine, T.J., Schellenberg, G.D., Steinbart, E.J., Leverenz, J.B., Lewy body pathology in late-onset familial Alzheimers disease: A clinicopathological case series (2006) J. Alzheimers Dis., 9, pp. 235-242; Rosenberg, C.K., Pericak-Vance, M.A., Saunders, A.M., Gilbert, J.R., Gaskell, P.C., Hulette, C.M., Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation (2000) Acta Neuropathol., 100, pp. 145-152; Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., Mucke, L., Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimers disease and Parkinsons disease (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 12245-12250; Clinton, L.K., Blurton-Jones, M., Myczek, K., Trojanowski, J.Q., Laferla, F.M., Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline (2010) J. Neurosci., 30, pp. 7281-7289; Marsh, S.E., Blurton-Jones, M., Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies (2012) Alzheimer Res. Ther., 4, p. 11; Morales, R., Moreno-Gonzalez, I., Soto, C., Cross-seeding of misfolded proteins: Implications for etiology and pathogenesis of protein misfolding diseases (2013) PLoS Pathog., 9, p. 1003537; Ono, K., Takahashi, R., Ikeda, T., Yamada, M., Cross-seeding effects of amyloid beta-protein and alpha-synuclein (2012) J. Neurochem., 122, pp. 883-890; Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, Jr.L., Eckman, C., Golde, T.E., Younkin, S.G., An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants (1994) Science, 264, pp. 1336-1340; Mandal, P.K., Pettegrew, J.W., Masliah, E., Hamilton, R.L., Mandal, R., Interaction between Abeta peptide and alpha synuclein: Molecular mechanisms in overlapping pathology of Alzheimers and Parkinsons in dementia with Lewy body disease (2006) Neurochem. Res., 31, pp. 1153-1162; Tsigelny, I.F., Crews, L., Desplats, P., Shaked, G.M., Sharikov, Y., Mizuno, H., Spencer, B., Masliah, E., Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimers and Parkinsons diseases (2008) PloS One, 3, p. 3135; Laferla, F.M., Green, K.N., Oddo, S., Intracellular amyloid-beta in Alzheimers disease (2007) Nat. Rev. Neurosci., 8, pp. 499-509; Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Stefani, M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases (2002) Nature, 416, pp. 507-511; Lotharius, J., Brundin, P., Pathogenesis of Parkinsons disease: Dopamine, vesicles and alpha-synuclein (2002) Nat. Rev. Neurosci., 3, pp. 932-942; Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annu. Rev. Biochem., 75, pp. 333-366; Kim, H.Y., Cho, M.K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., Fernandez, C.O., Zweckstetter, M., Structural properties of pore-forming oligomers of alpha-synuclein (2009) J. Am. Chem. Soc., 131, pp. 17482-17489; Lorenzen, N., Nielsen, S.B., Buell, A.K., Kaspersen, J.D., Arosio, P., Vad, B.S., Paslawski, W., Otzen, D.E., The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation (2014) J. Am. Chem. Soc., 136, pp. 3859-3868; Larsen, K.E., Schmitz, Y., Troyer, M.D., Mosharov, E., Dietrich, P., Quazi, A.Z., Savalle, M., Sulzer, D., Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis (2006) J. Neurosci., 26, pp. 11915-11922; Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., Lindquist, S., The Parkinsons disease protein alpha-synuclein disrupts cellular Rab homeostasis (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 145-150; Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, F.A., Edwards, R.H., Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis (2010) Neuron, 65, pp. 66-79; Murphy, D.D., Rueter, S.M., Trojanowski, J.Q., Lee, V.M., Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons (2000) J. Neurosci., 20, pp. 3214-3220; Yavich, L., Tanila, H., Vepsalainen, S., Jakala, P., Role of alpha-synuclein in presynaptic dopamine recruitment (2004) J. Neurosci., 24, pp. 11165-11170; Dewitt, D.C., Rhoades, E., Alpha-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers (2013) Biochemistry, 52, pp. 2385-2387; Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., Sudhof, T.C., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010) Science, 329, pp. 1663-1667; Diao, J., Burre, J., Vivona, S., Cipriano, D.J., Sharma, M., Kyoung, M., Sudhof, T.C., Brunger, A.T., Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2 (2013) ELife, 2, p. 00592; Choi, B.K., Choi, M.G., Kim, J.Y., Yang, Y., Lai, Y., Kweon, D.H., Lee, N.K., Shin, Y.K., Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 4087-4092; Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J.I., Smith, S.O., Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils (2010) Nat. Struct. Mol. Biol., 17, pp. 561-567; Sudhof, T.C., Rothman, J.E., Membrane Fusion: Grappling with SNARE and SM Proteins (2009) Science, 323, pp. 474-477; Jahn, R., Scheller, R.H., SNAREs - Engines for membrane fusion (2006) Nat. Rev. Mol. Cell. Biol., 7, pp. 631-643; Weber, T., Zemelman, B.V., McNew, J.A., Westermann, B., Gmachl, M., Parlati, F., Sollner, T.H., Rothman, J.E., SNAREpins: Minimal machinery for membrane fusion (1998) Cell, 92, pp. 759-772; Lai, Y., Kim, S., Varkey, J., Lou, X., Song, J.K., Diao, J., Langen, R., Shin, Y.K., Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding (2014) Biochemistry, 53, pp. 3889-3896; Sudhof, T.C., The synaptic vesicle cycle (2004) Annu. Rev. Neurosci., 27, pp. 509-547; Kyoung, M., Srivastava, A., Zhang, Y., Diao, J., Vrljic, M., Grob, P., Nogales, E., Brunger, A.T., In vitro system capable of differentiating fast Ca2+-triggered content mixing from lipid exchange for mechanistic studies of neurotransmitter release (2011) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 304-313; Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M., Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes (1998) J. Biol. Chem., 273, pp. 9443-9449; Jo, E., McLaurin, J., Yip, C.M., St George-Hyslop, P., Fraser, P.E., Alpha-Synuclein membrane interactions and lipid specificity (2000) J. Biol. Chem., 275, pp. 34328-34334; Eliezer, D., Kutluay, E., Bussell, Jr.R., Browne, G., Conformational properties of alpha-synuclein in its free and lipid-associated states (2001) J. Mol. Biol., 307, pp. 1061-1073; Comellas, G., Lemkau, L.R., Zhou, D.H., George, J.M., Rienstra, C.M., Structural intermediates during alpha-synuclein fibrillogenesis on phospholipid vesicles (2012) J. Am. Chem. Soc., 134, pp. 5090-5099; Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., Lansbury, Jr.P.T., Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinsons disease (2001) Biochemistry, 40, pp. 7812-7819; Kim, J.Y., Choi, B.K., Choi, M.G., Kim, S.A., Lai, Y., Shin, Y.K., Lee, N.K., Solution single-vesicle assay reveals PIP(2)-mediated sequential actions of synaptotagmin-1 on SNAREs (2012) EMBO J., 31, pp. 2144-2155; Sakono, M., Zako, T., Amyloid oligomers: Formation and toxicity of Abeta oligomers (2010) FEBS J., 277, pp. 1348-1358; Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Relkin, N.R., Intraneuronal Abeta42 accumulation in human brain (2000) J. Pathol., 156, pp. 15-20; Chui, D.H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Tabira, T., Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation (1999) Nat. Med., 5, pp. 560-564; Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Gouras, G.K., Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology (2002) J. Pathol., 161, pp. 1869-1879; Clifford, P.M., Zarrabi, S., Siu, G., Kinsler, K.J., Kosciuk, M.C., Venkataraman, V., Dandrea, M.R., Nagele, R.G., Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons (2007) Brain Res., 1142, pp. 223-236; Sharma, M., Burre, J., Sudhof, T.C., Proteasome inhibition alleviates SNARE-dependent neurodegeneration (2012) Sci. Transl. Med., 4, p. 147ra113; Hirsch, E., Graybiel, A.M., Agid, Y.A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinsons disease (1988) Nature, 334, pp. 345-348; Halliday, G.M., McRitchie, D.A., Cartwright, H., Pamphlett, R., Hely, M.A., Morris, J.G., Midbrain neuropathology in idiopathic Parkinsons disease and diffuse Lewy body disease (1996) J. Clin. Neurosci., 3, pp. 52-60; Conway, K.A., Rochet, J.C., Bieganski, R.M., Lansbury, Jr.P.T., Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct (2001) Science, 294, pp. 1346-1349; Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., Galatis, D., Sharples, R.A., Hill, A.F., Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway (2005) FASEB J., 19, pp. 1377-1379; Rekas, A., Knott, R.B., Sokolova, A., Barnham, K.J., Perez, K.A., Masters, C.L., Drew, S.C., Pham, C.L., The structure of dopamine induced alpha-synuclein oligomers (2010) Eur. Biophys. J., 39, pp. 1407-1419; Uversky, V.N., Li, J., Fink, A.L., Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinsons disease and heavy metal exposure (2001) J. Biol. Chem., 276, pp. 44284-44296; Binolfi, A., Rasia, R.M., Bertoncini, C.W., Ceolin, M., Zweckstetter, M., Griesinger, C., Jovin, T.M., Fernandez, C.O., Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement (2006) J. Am. Chem. Soc., 128, pp. 9893-9901",Article,Scopus,2-s2.0-84924386284
"Blount J.W., Redan B.W., Ferruzzi M.G., Reuhs B.L., Cooper B.R., Harwood J.S., Shulaev V., Pasinetti G., Dixon R.A.","Synthesis and quantitative analysis of plasma-targeted metabolites of catechin and epicatechin",2015,"Journal of Agricultural and Food Chemistry","63","8",,"2233","2240",,,10.1021/jf505922b,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924266566&partnerID=40&md5=b6ee2165fa3107891f75b3eae51e4309","Department of Biological Sciences, University of North Texas, 1155 Union Circle #305220Denton, TX, United States; Department of Nutrition Science, Purdue University, 700 W. State StreetWest Lafayette, IN, United States; Department of Food Science, Purdue University, 745 Agriculture Mall DriveWest Lafayette, IN, United States; Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230New York, NY, United States; James J. Peters Veterans Affairs Medical CenterBronx, NY, United States; Bindley Bioscience Center Metabolite Profiling Facility, Purdue University, 1203 W. State StreetWest Lafayette, IN, United States; Purdue Interdepartmental NMR Facility, Purdue University, 560 Oval DriveWest Lafayette, IN, United States; Department of Chemistry, Purdue University, 560 Oval DriveWest Lafayette, IN, United States","Blount, J.W., Department of Biological Sciences, University of North Texas, 1155 Union Circle #305220Denton, TX, United States; Redan, B.W., Department of Nutrition Science, Purdue University, 700 W. State StreetWest Lafayette, IN, United States; Ferruzzi, M.G., Department of Nutrition Science, Purdue University, 700 W. State StreetWest Lafayette, IN, United States, Department of Food Science, Purdue University, 745 Agriculture Mall DriveWest Lafayette, IN, United States; Reuhs, B.L., Department of Nutrition Science, Purdue University, 700 W. State StreetWest Lafayette, IN, United States; Cooper, B.R., Bindley Bioscience Center Metabolite Profiling Facility, Purdue University, 1203 W. State StreetWest Lafayette, IN, United States; Harwood, J.S., Purdue Interdepartmental NMR Facility, Purdue University, 560 Oval DriveWest Lafayette, IN, United States, Department of Chemistry, Purdue University, 560 Oval DriveWest Lafayette, IN, United States; Shulaev, V., Department of Biological Sciences, University of North Texas, 1155 Union Circle #305220Denton, TX, United States; Pasinetti, G., Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230New York, NY, United States, James J. Peters Veterans Affairs Medical CenterBronx, NY, United States; Dixon, R.A., Department of Biological Sciences, University of North Texas, 1155 Union Circle #305220Denton, TX, United States","Grape seed polyphenolic extract (GSPE) rich in the flavan-3-ols (+)-catechin and (-)-epicatechin beneficially modulates Alzheimers Disease phenotypes in animal models. The parent molecules in the extract are converted to a series of methylated and glucuronidated derivatives. To fully characterize these metabolites and establish a robust quantitative assay of their levels in biological fluids, we have implemented a partial synthetic approach utilizing chemical methylation followed by enzymatic glucuronidation. Liquid chromatography/time-of-flight mass spectrometry (LC-TOF-MS) and nuclear magnetic resonance (NMR) spectroscopy were used to assign unequivocal structures to the compounds. An analytical method using solid-phase extraction and LC-MS/MS in selective reaction monitoring mode (SRM) was validated for their quantitation in plasma. These studies provide a basis for improvements in future work on the bioavailability, metabolism, and mechanism of action of metabolites derived from dietary flavan-3-ols in a range of interventions. © 2015 American Chemical Society.","catechin; glucuronosylation; O-methylation; phase II metabolites; semisynthesis; structure determination; two-site validation","Ishikawa, T., Suzukawa, M., Ito, T., Yoshida, H., Ayaori, M., Nishiwaki, M., Yonemura, A., Nakamura, H., Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification (1997) Am. J. Clin. Nutr., 66, pp. 261-266; Guo, W., Kong, E., Meydani, M., Dietary polyphenols, inflammation, and cancer (2009) Nutr. Cancer, 61, pp. 807-810; Dixon, R.A., Natural products and disease resistance (2001) Nature, 411, pp. 843-847; Wang, J., Ferruzzi, M.G., Ho, L., Blount, J., Janle, E., Arrieta-Cruz, I., Sharma, V., Pasinetti, G.M., Brain-targeted proanthocyanidin metabolites for Alzheimers disease treatment (2012) J. Neurosci., 32, pp. 5144-5150; Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Pasinetti, G.M., Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimers disease (2008) J. Neurosci., 28, pp. 6388-6392; Sharma, V., Zhang, C., Pasinetti, G.M., Dixon, R.A., Fractionation of grape seed proanthocyanidins for bioactivity assessment (2010) Recent Advances in Phytochemistry: Biological Activity of Phytochemicals, 41, pp. 33-46. , Gang, D. R. Springer: New York, Vol; Blount, J.W., Ferruzzi, M.G., Raftery, D., Pasinetti, G.M., Dixon, R.A., Enzymatic synthesis of substituted epicatechins for bioactivity studies in neurological disorders (2011) Biochem. Biophys. Res. Commun., 417, pp. 457-461; Ćirić, A., Prosen, H., Jelikić-Stankov, M., Aurłević, P., Evaluation of matrix effect in determination of some bioflavonoids in food samples by LC-MS/MS method (2012) Talanta, 99, pp. 780-790; Gonzalez-Manzano, S., Gonzalez-Paramas, A., Santos-Buelga, C., Duenas, M., Preparation and characterization of catechin sulfates, glucuronides, and methylethers with metabolic interest (2009) J. Agric. Food Chem., 57, pp. 1231-1238; Baba, S., Osakabe, N., Natsume, M., Muto, Y., Takizawa, T., Terao, J., In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats (2001) J. Nutr., 131, pp. 2885-2891; Baba, S., Osakabe, N., Natsume, M., Yasuda, A., Takizawa, T., Cocoa powder enhances the level of antioxidative activity in rat plasma (2000) Br. J. Nutr., 84, pp. 673-680; Feng, W., Metabolism of green tea catechins: An overview (2006) Curr. Drug Metab., 7, pp. 755-809; Spencer, J., Schroeter, H., Rechner, A., Rice-Evans, C., Bioavailability of flavan-3-ols and procyanidins: Gastrointestinal tract influences and their relevance to bioactive forms in vivo (2001) Antioxid. Redox Signaling, 3, pp. 1023-1039; Abd-El-Mohsen, M., Kuhnle, G., Rechner, A., Schroeter, H., Rose, S., Jenner, P., Rice-Evans, C., Uptake and metabolism of epicatechin and its access to the brain after oral ingestion (2002) Free Radical Biol. Med., 33, pp. 1693-1702; Piskula, M., Terao, J., Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues (1998) J. Nutr., 128, pp. 1172-1178; Spencer, J., Role of flavonoids in the diet metabolism of tea flavonoids in the gastrointestinal tract. Proceedings of the third international scientific symposium on tea and human health (2003) J. Nutr., 133, pp. 3255S-3261S; Tsang, C., Auger, C., Mullen, W., Bornet, A., Rouanet, J.M., Crozier, A., Teissedre, P.L., The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats (2005) Br. J. Nutr., 94, pp. 170-181; Urpi-Sarda, M., Monagas, M., Khana, N., Lloracha, L., Lamuela-Raventósa, R.M., Jáureguib, O., Estruch, R., Andrés-Lacueva, C., Targeted metabolic profiling of phenolics in urine and plasma after regular consumption of cocoa by liquid chromatography-tandem mass spectrometry (2009) J. Chromatogr. A, 1216 (43), pp. 7258-7267; Roura, E., Andres-Lacueva, C., Estruch, R., Lourdes Mata Bilbao, M., Izquierdo-Pulido, M., Lamuela-Raventos, R.M., The effects of milk as a food matrix for polyphenols on the excretion profile of cocoa (-)-epicatechin metabolites in healthy human subjects (2008) Br. J. Nutr., 100, pp. 846-851; Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS (2003) Anal. Chem., 75, pp. 3019-3030; Li, L., Liang, S., Du, F., Li, C., Simultaneous quantification of multiple licorice flavonoids in rat plasma (2007) J. Am. Soc. Mass Spectrom., 18, pp. 778-782; Gardana, C., Guarnieri, S., Riso, P., Simonetti, P., Porrini, M., Flavanone plasma pharmacokinetics from blood orange juice in human subjects (2007) Br. J. Nutr., 98, pp. 165-172; Horwitz, W., Albert, R., The Horwitz ratio (HorRat): A useful index of method performance with respect to precision (2006) J. AOAC Int., 89, pp. 1095-1109; Zhang, M., Jagdmann, Jr.G.E., Van Zandt, M., Sheeler, R., Beckett, P., Schroeter, H., Chemical synthesis and characterization of epicatechin glucuronides and sulfates: Bioanalytical standards for epicatechin metabolite identification (2013) J. Nat. Prod., 76, pp. 157-169; Natsume, M., Osakabe, N., Oyama, M., Sasaki, M., Baba, S., Nakamura, Y., Osawa, T., Terao, J., Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: Differences between human and rat (2003) Free Radical Biol. Med., 34, pp. 840-849; He, X.-Z., Li, W.-S., Blount, J.W., Dixon, R.A., Regioselective synthesis of plant flavonoid glycosides in E. Coli (2008) Appl. Microbiol. Biotechnol., 80, pp. 253-260; Ottaviani, J.I., Momma, T.Y., Kuhnle, G.K., Keen, C.L., Schroeter, H., Structurally related (-)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized authentic standards (2012) Free Radical Biol. Med., 52, pp. 1403-1412",Article,Scopus,2-s2.0-84924266566
"Ashish N., Toga A.W.","Medical data transformation using rewriting",2015,"Frontiers in Neuroinformatics","9","FEB", 1,"1","8",,,10.3389/fninf.2015.00001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923291133&partnerID=40&md5=12d8093abfe241aebf3c842d72120e91","Laboratory of Neuroimaging, Institute for Neuroimaging and Neuroinformatics, Keck School of Medicine of USC, University of Southern CaliforniaLos Angeles, CA, United States","Ashish, N., Laboratory of Neuroimaging, Institute for Neuroimaging and Neuroinformatics, Keck School of Medicine of USC, University of Southern CaliforniaLos Angeles, CA, United States; Toga, A.W., Laboratory of Neuroimaging, Institute for Neuroimaging and Neuroinformatics, Keck School of Medicine of USC, University of Southern CaliforniaLos Angeles, CA, United States","This paper presents a system for declaratively transforming medical subjects' data into a common data model representation. Our work is part of the ""GAAIN"" project on Alzheimer's disease data federation across multiple data providers. We present a general purpose data transformation system that we have developed by leveraging the existing state-of-the-art in data integration and query rewriting. In this work we have further extended the current technology with new formalisms that facilitate expressing a broader range of data transformation tasks, plus new execution methodologies to ensure efficient data transformation for disease datasets. © 2015 Ashish and Toga.","Alzheimer's disease datasets; Data integration; Data mapping; Query rewriting","Ashish, N., Ambite, J.L., Muslea, M., Turner, J.A., Neuroscience data integration through mediation: An (F)BIRN case study (2010) Front. Neuroinform, 4, p. 118; Azami, I.E., Malki, M., Tahon, C., Integrating hospital information systems in healthcare institutions: A mediation architecture (2012) J. Med. Syst, 36, pp. 3123-3134; Beekly, D.L., Ramos, E.M., Lee, W.W., Deitrich, W.D., Jacka, M.E., Wu, J., The National Alzheimer’s Coordinating Center (NACC) database: The uniform data set (2007) Alzheimer Dis. Assoc. Disord, 21, pp. 249-258; Beeri, C., Levy, A.Y., Rousset, M., Rewriting queries using views in description logics. ACMPrinc (1997) Database Syst, 1997, pp. 99-108; Bodenreider, O., Biomedical ontologies in action: Role in knowledge management, data integration and decision support (2008) Yearb. Med. Inform, 2008, pp. 67-69; Detwiler, L.T., Suciu, D., Franklin, J.D., Moore, E.B., Poliakov, A.V., Lee, E.S., Distributed XQuery-based integration and visualization of multimodality brain mapping data. Front (2009) Neuroinform, 3, p. 2009; (2014) Global Alzheimer's Association Interactive Network, , http://www.gaain.org; Garcia-Molina, H., Ullman, J., Widom, J., (2009) Database Systems: The Completebook, , 2nd Edn. Prentice Hall; Gardner, D., Knuth, K.H., Abato, M., Erdr, S.M., White, T., Debellis, R., Model formulation: Common data model for neuroscience data and data model exchange (2001) J. Am. Med. Inform. Assoc, 8, pp. 17-33; Hall, D., Huerta, M.F., McAuliffe, M.J., Farber, G.K., Sharing heterogeneous data: The national database for autism research (2012) Neuroinformatics, 10, pp. 331-339; Ives, Z., Halevy, A., Doan, A., (2012) Principles of Data Integration, , Morgan Kaufmann; Louie, B., Mork, P., Martin-Sanchez, F., Halevy, A.Y., Tarczy-Hornoch, P., Data integration and genomic medicine J. Biomed. Inform, 40, pp. 5-16; (2014) The Laboratory Ofneuroimaging, , http://www.loni.usc.edu; Madhavan, J., Bernstein, P.A., Doan, A., Halevy, A., Corpus-based schema matching (2005) Proceedings Ofthe21sticde Conference (Tokyo), pp. 57-68; Marenco, L., Wang, R., Bandrowski, A., Grethe, J.S., Shepherd, G.M., Miller, P., Extending the NIF DISCO framework to automate complex workflow. Front (2014) Neuroinform, 8, p. 58; Mueller, S.G., Weiner, M.W., Thal, L.J., Peterson, R.C., Jack, C., Jagust, W., Alzheimer’s disease neuroimaging initiative Neuroimag. Clin. North Am, 15, 869p; Nguyen, K., Boxwala, A., Farzaneh, S., Patel, K., Ashish, N., A mediation technology architecture for clinical databases integration (2012) 2Nd AHIC Conference, , Toronto, ON); Ogunyem, O., Meeke, D., Ki, H.E., Ashis, N., Farzane, S., Boxwal, A., Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems (2013) Med. Care, 51, pp. S45-S52; Pinto, F.D., Lembo, D., Lenzerini, M., Mancini, R., Poggi, A., Rosati, R., Optimizing query rewriting in ontology-based data access (2013) EDBT, 2013, pp. 561-572; Poldrack, R.A., Barch, D.M., Mitchell, J., Wager, T., Wagner, A.D., Devlin, J.T., Toward open sharing of task-based fMRI data: The OpenfMRI project. Front (2013) Neuroinform, 7, p. 12; Sadalage, P., Fowler, M., (2013) Nosql Distilled: A Briefguide to the Emerging World Ofpolyglot Persistence, , Pearson Education",Article,Scopus,2-s2.0-84923291133
"More S.S., Vince R.","Hyperspectral imaging signatures detect amyloidopathy in alzheimers mouse retina well before onset of cognitive decline",2015,"ACS Chemical Neuroscience","6","2",,"306","315",,,10.1021/cn500242z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923253222&partnerID=40&md5=df5439eb6dd349ce696619187fd21641","Center for Drug Design, University of Minnesota, 516 Delaware Street S.E.Minneapolis, MN, United States","More, S.S., Center for Drug Design, University of Minnesota, 516 Delaware Street S.E.Minneapolis, MN, United States; Vince, R., Center for Drug Design, University of Minnesota, 516 Delaware Street S.E.Minneapolis, MN, United States","Amyloidopathic disorders such as Alzheimers disease present symptomology years after the entrenchment of amyloidogenic imbalance. The pathologic α-helix → β-strand conversion of amyloid β1-42 and amyloid β1-40 peptides causes neuronal death in the vicinity. Symptomology often presents only after significant neurodegeneration. This thus warrants early detection of amyloidopathy in Alzheimers disease. Nonexistent modalities for direct identification and quantitation of soluble amyloid aggregates or (proto)fibrils forced us to undertake the development of a spectrophotometric technique to support ongoing drug design. Key requirements were independence from the need for extraneous staining, unambiguous amyloid aggregate detection, and minimal influence of interpretative errors. A Cytoviva instrument pivotal to this study captures scattering of light of visible-near-infrared (VNIR, 400-1000 nm) wavelengths within each pixel of the microscopic view field. We thus assembled a scattering intensity pattern database that provided ""signatures"" of amyloid aggregates. Comparison of unknown samples against this database enabled direct detection of amyloid aggregates. The technique was found useful for monitoring retinal and brain amyloidopathy in an ongoing preclinical anti-AD study, attesting to the techniques sensitivity and specificity. Interestingly, the technique was found applicable not just to excised brain tissue but also to isolated mouse retina. With the retina being heralded widely as a (diagnostic) extension of the CNS and retinal amyloidopathy occurring well before that in the brain, this development raises a possibility for the first direct retinal imaging diagnosis of early asymptomatic Alzheimers disease. © 2014 American Chemical Society.","advanced glycation end products; Alzheimers disease; Hyperspectral imaging (HSI); methylglyoxal; β-amyloid peptide","Herczenik, E., Gebbink, M.F., Molecular and cellular aspects of protein misfolding and disease (2008) FASEB J., 22, pp. 2115-2133; Yerbury, J.J., Stewart, E.M., Wyatt, A.R., Wilson, M.R., Quality control of protein folding in extracellular space (2005) EMBO Rep., 6, pp. 1131-1136; Moore, R.A., Taubner, L.M., Priola, S.A., Prion protein misfolding and disease (2009) Curr. Opin. Struct. Biol., 19, pp. 14-22; Bruce, A., Bray, D., Hopkin, K., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P., Protein Structure and Function (2010) Essential Cell Biology, pp. 120-170. , 3 rd ed. pp, Garland Science, Taylor and Francis Group, New York; Selkoe, D.J., Folding proteins in fatal ways (2003) Nature, 426, pp. 900-904; Costanzo, M., Zurzolo, C., The cell biology of prion-like spread of protein aggregates: Mechanisms and implication in neurodegeneration (2013) Biochem. J., 452, pp. 1-17; Selkoe, D.J., Cell biology of protein misfolding: The examples of Alzheimers and Parkinsons diseases (2004) Nat. Cell Biol., 6, pp. 1054-1061; Lesne, S.E., Sherman, M.A., Grant, M., Kuskowski, M., Schneider, J.A., Bennett, D.A., Ashe, K.H., Brain amyloid-beta oligomers in ageing and Alzheimers disease (2013) Brain, 136, pp. 1383-1398; Modler, A.J., Gast, K., Lutsch, G., Damaschun, G., Assembly of amyloid protofibrils via critical oligomers-A novel pathway of amyloid formation (2003) J. Mol. Biol., 325, pp. 135-148; Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., Teplow, D.B., Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate (1997) J. Biol. Chem., 272, pp. 22364-22372; Yoshimura, Y., Lin, Y., Yagi, H., Lee, Y.H., Kitayama, H., Sakurai, K., So, M., Goto, Y., Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 14446-14451; Roychaudhuri, R., Yang, M., Hoshi, M.M., Teplow, D.B., Amyloid beta-protein assembly and Alzheimers disease (2009) J. Biol. Chem., 284, pp. 4749-4753; Kagan, B.L., Hirakura, Y., Azimov, R., Azimova, R., Lin, M.C., The channel hypothesis of Alzheimers disease: Current status (2002) Peptides, 23, pp. 1311-1315; Miller, Y., Ma, B., Tsai, C.J., Nussinov, R., Hollow core of Alzheimers Aβ42 amyloid observed by cryoEM is relevant at physiological pH (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 14128-14133; Li, J.J., Dolios, G., Wang, R., Liao, F.F., Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression (2014) PLoS One, 9, p. 90770; Tomiyama, T., Involvement of beta-amyloid in the etiology of Alzheimers disease (2010) Brain Nerve, 62, pp. 691-699; Vellas, B., Carrillo, M.C., Sampaio, C., Brashear, H.R., Siemers, E., Hampel, H., Schneider, L.S., Aisen, P., Designing drug trials for Alzheimers disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force (2013) Alzheimers Dementia, 9, pp. 438-444; Verdooner, S., (2013) Apparatus and Method for Imaging An Eye, , International Patent WO201111602A2; Groenning, M., Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status (2010) J. Chem. Biol., 3, pp. 1-18; Zovo, K., Helk, E., Karafin, A., Tougu, V., Palumaa, P., Label-free high-throughput screening assay for inhibitors of Alzheimers amyloid-beta peptide aggregation based on MALDI MS (2010) Anal. Chem., 82, pp. 8558-8565; McKoy, A.F., Chen, J., Schupbach, T., Hecht, M.H., A novel inhibitor of amyloid β (Aβ) peptide aggregation: From high throughput screening to efficacy in an animal model of Alzheimers disease (2012) J. Biol. Chem., 287, pp. 38992-39000; Ahn, B.W., Song, D.U., Jung, Y.D., Chay, K.O., Chung, M.A., Yang, S.Y., Shin, B.A., Detection of β-amyloid peptide aggregation using DNA electrophoresis (2000) Anal. Biochem., 284, pp. 401-405; Hu, X., Crick, S.L., Bu, G., Frieden, C., Pappu, R.V., Lee, J.M., Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide (2009) Proc. Natl. Acad. Sci. U. S. A., 106, pp. 20324-20329; Li, J., Kanekiyo, T., Shinohara, M., Zhang, Y., Ladu, M.J., Xu, H., Bu, G., Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein e Isoforms (2012) J. Biol. Chem., 287, pp. 44593-44601; Quinten, M., Stier, J., Absorption of Scattered Light in Colloidal Systems of Aggregated Particles (1995) Colloid Polym. Sci., 273, pp. 233-241; Veloso, A.J., Yoshikawa, H., Cheng, X.R., Tamiya, E., Kerman, K., Optical Trapping for the Characterization of Amyloid-Beta Aggregation Kinetics (2011) Analyst, 136, pp. 4164-4167; Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., Cerami, A., Advanced glycation end products contribute to amyloidosis in Alzheimers disease (1994) Proc. Natl. Acad. Sci. U. S. A., 91, pp. 4766-4770; Tilton, R.G., Chang, K., Hasan, K.S., Smith, S.R., Petrash, J.M., Misko, T.P., Moore, W.M., Williamson, J.R., Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation (1993) Diabetes, 42, pp. 221-232; Subratty, A.H., Aukburally, N., Jowaheer, V., Joonus, N., Vitamin C and urea inhibit the formation of advanced glycation end products in vitro (2010) Nutr. Food Sci., 40, pp. 456-465; Esler, W.P., Stimson, E.R., Jennings, J.M., Ghilardi, J.R., Mantyh, P.W., Maggio, J.E., Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro (1996) J. Neurochem., 66, pp. 723-732; Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A.V., Miller, C.A., Ko, M.K., Black, K.L., Schwartz, M., Farkas, D.L., Identification of amyloid plaques in retinas from Alzheimers patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model (2011) Neuroimage, 54, pp. 204-S217; Berisha, F., Feke, J.T., Trempe, C.L., McMeel, J.W., Schepens, C.L., Retinal abnormalities in early Alzheimers disease (2007) Invest. Ophthalmol. Vis. Sci., 48, pp. 2285-2289; Blanks, J.C., Schmidt, S.Y., Torigoe, Y., Porrello, K.V., Hinton, D.R., Blanks, R.H., Retinal pathology in Alzheimers disease. II. Regional neuron loss and glial changes in GCL (1996) Neurobiol. Aging, 17, pp. 385-395; Paquet, C., Boissonnot, M., Roger, F., Dighiero, P., Gil, R., Hugon, J., Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimers disease (2007) Neurosci. Lett., 420, pp. 97-99; Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M.G., Pierelli, F., Morphological and functional retinal impairment in Alzheimers disease patients (2001) Clin. Neurophysiol., 112, pp. 1860-1867; Drexler, W., Morgner, U., Ghanta, R.K., Kartner, F.X., Schuman, J.S., Fujimoto, J.G., Ultrahigh-resolution ophthalmic optical coherence tomography (2001) Nat. Med., 7, pp. 502-507; More, S.S., Vartak, A.P., Vince, R., Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimers disease (2013) ACS Chem. Neurosci., 4, pp. 330-338; Morris, R., Developments of a water-maze procedure for studying spatial learning in the rat (1984) J. Neurosci. Methods, 11, pp. 47-60; Aikio, M., (2001) Hyperspectral Prism-grating-prism Imaging Spectrograph, , Ph.D. Thesis, University of Oulu, Publ. 435, VTT Publications, Espoo, Finland; Robila, S.A., An analysis of spectral metrics for hyperspectral image processing (2004) Geoscience and Remote Sensing Symposium, IGARSS 04. Proceedings. 2004, 5, pp. 3233-3236. , IEEE International, Piscataway, NJ; Zhang, J., Zhu, W., Wang, L., Jiang, N., Evaluation of similarity measure methods for hyperspectral remote sensing data (2012) Geoscience and Remote Sensing Symposium (IGARSS), 2012, pp. 4138-4141. , IEEE International, Piscataway, NJ; Pitulescu, M.E., Schmidt, I., Benedito, R., Adams, R.H., Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice (2010) Nat. Protoc., 5, pp. 1518-1534",Article,Scopus,2-s2.0-84923253222
"Peng J., Xu W., Teoh C.L., Han S., Kim B., Samanta A., Er J.C., Wang L., Yuan L., Liu X., Chang Y.-T.","High-efficiency in vitro and in vivo detection of Zn2+ by dye-assembled upconversion nanoparticles",2015,"Journal of the American Chemical Society","137","6",,"2336","2342",,,10.1021/ja5115248,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923253099&partnerID=40&md5=93b8cfe66dc6a510d8391906b809a2d8","Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Department of Chemistry, National University of SingaporeSingapore, Singapore; Institute of Materials Research and Engineering, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Center for Functional Materials, NUS (Suzhou) Research InstituteSuzhou, Jiangsu, China","Peng, J., Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Xu, W., Department of Chemistry, National University of SingaporeSingapore, Singapore; Teoh, C.L., Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Han, S., Department of Chemistry, National University of SingaporeSingapore, Singapore; Kim, B., Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Samanta, A., Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore; Er, J.C., Department of Chemistry, National University of SingaporeSingapore, Singapore; Wang, L., Department of Chemistry, National University of SingaporeSingapore, Singapore; Yuan, L., Department of Chemistry, National University of SingaporeSingapore, Singapore; Liu, X., Department of Chemistry, National University of SingaporeSingapore, Singapore, Institute of Materials Research and Engineering, Agency for Science, Technology and Research (A STAR)Singapore, Singapore, Center for Functional Materials, NUS (Suzhou) Research InstituteSuzhou, Jiangsu, China; Chang, Y.-T., Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A STAR)Singapore, Singapore, Department of Chemistry, National University of SingaporeSingapore, Singapore","Development of highly sensitive and selective sensing systems of divalent zinc ion (Zn2+) in organisms has been a growing interest in the past decades owing to its pivotal role in cellular metabolism, apoptosis, and neurotransmission. Herein, we report the rational design and synthesis of a Zn2+ fluorescent-based probe by assembling lanthanide-doped upconversion nanoparticles (UCNPs) with chromophores. Specifically, upconversion luminescence (UCL) can be effectively quenched by the chromophores on the surface of nanoparticles via a fluorescence resonant energy transfer (FRET) process and subsequently recovered upon the addition of Zn2+, thus allowing for quantitative monitoring of Zn2+. Importantly, the sensing system enables detection of Zn2+ in real biological samples. We demonstrate that this chromophore-UCNP nanosystem is capable of implementing an efficient in vitro and in vivo detection of Zn2+ in mouse brain slice with Alzheimers disease and zebrafish, respectively. © 2015 American Chemical Society.",,"Nolan, E.M., Lippard, S.J., (2009) Acc. Chem. Res., 42, p. 193; Burdette, S.C., Lippard, S.J., (2003) Proc. Natl. Acad. Sci. U.S.A., 100, p. 3605; Walkup, G.K., Burdette, S.C., Lippard, S.J., Tsien, R.Y., (2000) J. Am. Chem. Soc., 122, p. 5644; Kimura, E., Aoki, S., Kikuta, E., Koike, T., (2003) Proc. Natl. Acad. Sci. U.S.A., 100, p. 3731; Atwood, C.S., Moir, R.D., Huang, X., Scarpa, R.C., Bacarra, N.M.E., Romano, D.M., Hartshorn, M.A., Bush, A.I., (1998) J. Biol. Chem., 273, p. 12817; Xu, Z., Baek, K.-H., Kim, H.N., Cui, J., Qian, X., Spring, D.R., Shin, I., Yoon, J., (2009) J. Am. Chem. Soc., 132, p. 601; Qian, F., Zhang, C.L., Zhang, Y.M., He, W.J., Gao, X., Hu, P., Guo, Z.J., (2009) J. Am. Chem. Soc., 131, p. 1460; Datta, B.K., Mukherjee, S., Kar, C., Ramesh, A., Das, G., (2013) Anal. Chem., 85, p. 8369; Wang, H., Sun, C.L., Yue, Y.H., Yin, F.F., Jiang, J.Q., Wu, H.R., Zhang, H.L., (2013) Analyst, 138, p. 5576; Wong, B.A., Friedle, S., Lippard, S.J., (2009) J. Am. Chem. Soc., 131, p. 7142; Xu, Z., Yoon, J., Spring, D.R., (2010) Chem. Soc. Rev., 39, p. 1996; Burdette, S.C., Walkup, G.K., Spingler, B., Tsien, R.Y., Lippard, S.J., (2001) J. Am. Chem. Soc., 123, p. 7831; Guo, Z., Kim, G.-H., Shin, I., Yoon, J., (2012) Biomaterials, 33, p. 7818; Meng, X.M., Wang, S.X., Li, Y.M., Zhu, M.Z., Guo, Q.X., (2012) Chem. Commun., 48, p. 4196; Satapathy, R., Wu, Y.H., Lin, H.C., (2012) Org. Lett., 14, p. 2564; Wang, Z.L., Hao, J.H., Chan, H.L.W., (2010) J. Mater. Chem., 20, p. 3178; Chatterjee, D.K., Yong, Z., (2008) Nanomedicine (London, U.K.), 3, p. 73; Shen, J., Sun, L.D., Yan, C.H., (2008) Dalton Trans., p. 5687; Zhang, F., Shi, Y.F., Sun, X.H., Zhao, D.Y., Stucky, G.D., (2009) Chem. Mater., 21, p. 5237; Chen, G., Ohulchanskyy, T.Y., Liu, S., Law, W.-C., Wu, F., Swihart, M.T., Ågren, H., Prasad, P.N., (2012) ACS Nano, 6, p. 2969; Hou, Z.Y., Li, C.X., Ma, P.A., Cheng, Z.Y., Li, X.J., Zhang, X., Dai, Y.L., Lin, J., (2012) Adv. Funct. Mater., 22, p. 2713; Wang, G.F., Peng, Q., Li, Y.D., (2011) Acc. Chem. Res., 44, p. 322; He, M., Huang, P., Zhang, C.L., Chen, F., Wang, C., Ma, J.B., He, R., Cui, D.X., (2011) Chem. Commun., 47, p. 9510; Ju, Q., Tu, D.T., Liu, Y.S., Li, R.F., Zhu, H.M., Chen, J.C., Chen, Z., Chen, X.Y., (2011) J. Am. Chem. Soc., 134, p. 1323; Wang, F., Liu, X.G., (2009) Chem. Soc. Rev., 38, p. 976; Zhou, J., Liu, Z., Li, F.Y., (2012) Chem. Soc. Rev., 41, p. 1323; Zhang, F., Haushalter, R.C., Haushalter, R.W., Shi, Y.F., Zhang, Y.C., Ding, K.L., Zhao, D.Y., Stucky, G.D., (2011) Small, 7, pp. 1972-1976; Auzel, F., (2004) Chem. Rev., 104, p. 139; Lehmann, O., Kompe, K., Haase, M., (2004) J. Am. Chem. Soc., 126, p. 14935; Park, Y.I., Kim, H.M., Kim, J.H., Moon, K.C., Yoo, B., Lee, K.T., Lee, N., Hyeon, T., (2012) Adv. Mater., 24, p. 5755; Zhang, F., Braun, G.B., Shi, Y.F., Zhang, Y.C., Sun, X.H., Reich, N.O., Zhao, D.Y., Stucky, G., (2010) J. Am. Chem. Soc., 132, p. 2850; Sivakumar, S., Boyer, J.C., Bovero, E., Van Veggel, F.C.J.M., (2009) J. Mater. Chem., 19, p. 2392; He, G.S., Tan, L.S., Zheng, Q., Prasad, P.N., (2008) Chem. Rev., 108, p. 1245; Dong, C.H., Van Veggel, F.C.J.M., (2009) ACS Nano, 3, p. 123; Liu, J., Liu, Y., Bu, W., Bu, J., Sun, Y., Du, J., Shi, J., (2014) J. Am. Chem. Soc., 136, p. 9701; Wang, J., Deng, R.R., Macdonald, M.A., Chen, B.L., Yuan, J.K., Wang, F., Chi, D.Z., Liu, X.G., (2014) Nat. Mater., 13, p. 157; Xie, X.J., Gao, N.Y., Deng, R.R., Sun, Q., Xu, Q.H., Liu, X.G., (2013) J. Am. Chem. Soc., 135, p. 12608; Shen, J., Chen, G.Y., Vu, A.-M., Fan, W., Bilsel, O.S., Chang, C.-C., Han, G., (2013) Adv. Opt. Mater., 1, p. 644; Min, Y.Z., Li, J.M., Liu, F., Yeow, E.K.L., Xing, B.G., (2014) Angew. Chem., 126, p. 1030; Tian, G., Gu, Z.J., Zhou, L.J., Yin, W.Y., Liu, X.X., Yan, L., Jin, S., Zhao, Y.L., (2012) Adv. Mater., 24, p. 1226; Lai, J.P., Zhang, Y.X., Pasquale, N., Lee, K.-B., (2014) Angew. Chem., Int. Ed., 53, p. 14419; Zhang, P., Rogelj, S., Nguyen, K., Wheeler, D., (2006) J. Am. Chem. Soc., 128, p. 12410; Kumar, M., Zhang, P., (2009) Langmuir, 25, p. 6024; Achatz, D.E., Meier, R.J., Fischer, L.H., Wolfbeis, O.S., (2010) Angew. Chem., Int. Ed., 50, p. 260; Yao, L.M., Zhou, J., Liu, J.L., Feng, W., Li, F.Y., (2012) Adv. Funct. Mater., 22, p. 2667; Liu, J.L., Liu, Y., Liu, Q., Li, C.Y., Sun, L.N., Li, F.Y., (2011) J. Am. Chem. Soc., 133, p. 15276; Zhao, L.Z., Peng, J.J., Chen, M., Liu, Y., Yao, L.M., Feng, W., Li, F.Y., (2014) ACS Appl. Mater. Interfaces, 6, p. 11190; Mader, H.S., Wolfbeis, O.S., (2010) Anal. Chem., 82, p. 5002; Liu, Q., Peng, J.J., Sun, L.N., Li, F.Y., (2011) ACS Nano, 5, p. 8040; Liu, Y., Chen, M., Cao, T.Y., Sun, Y., Li, C.Y., Liu, Q., Yang, T.S., Li, F.Y., (2013) J. Am. Chem. Soc., 135, p. 9869; Wang, F., Deng, R.R., Wang, J., Wang, Q.X., Han, Y., Zhu, H.M., Chen, X.Y., Liu, X.G., (2011) Nat. Mater., 10, p. 968; Boyer, J.C., Manseau, M.P., Murray, J.I., Van Veggel, F.C.J.M., (2010) Langmuir, 26, p. 1157; Zhao, L.Z., Peng, J.J., Huang, Q., Li, C.Y., Chen, M., Sun, Y., Lin, Q.N., Li, F.Y., (2013) Adv. Funct. Mater., 24, p. 363; Bogdan, N., Vetrone, F., Ozin, G.A., Capobianco, J.A., (2011) Nano Lett., 11, p. 835; Cheng, L., Yang, K., Chen, Q., Liu, Z., (2012) ACS Nano, 6, p. 5605; Cirrito, J., Extracellular Amyloid-β Protein Dynamics in Alzheimers Disease (2013) Microdialysis in Drug Development, pp. 163-178. , Müller, M. Springer: New York, Chapter 9; Adlard, P.A., Bush, A.I., (2006) J. Alzheimers Dis., 10, p. 145; Crichton, R.R., Dexter, D.T., Ward, R.J., (2008) Coord. Chem. Rev., 252, p. 1189; Barnham, K.J., Bush, A.I., (2008) Curr. Opin. Chem. Biol., 12, p. 222; Bush, A.I., Pettingell, W.H., De Paradis, M., Tanzi, R.E., Wasco, W., (1994) J. Biol. Chem., 269, p. 26618; Reshmi, R., Ren, M., Maria, D.Y., Gemma, C., Mark, A.S., George, P., Barry, H., Frank, W., (2009) Biochem. Biophys. Res. Commun., 382, p. 91; Emily, L.Q., Dylan, W.D., Christopher, J.C., (2008) Chem. Rev., 108, p. 1517; Hutchinson, R.W., Cox, A.G., McLeod, C.W., Marshall, P.S., Harper, A., Dawson, E.L., Howlett, D.R., (2005) Anal. Biochem., 346, p. 225; Brustein, E., Marandi, N., Kovalchuk, Y., Drapeau, P., Konnerth, A., (2003) Pfluegers Arch., 446, p. 766; Grant, K.A., Raible, D.W., Piotrowski, T., (2005) Neuron, 45, p. 69; Wang, F., Wang, J., Liu, X.G., (2010) Angew. Chem., Int. Ed., 49, p. 7456",Article,Scopus,2-s2.0-84923253099
"Yuyama K., Sun H., Usuki S., Sakai S., Hanamatsu H., Mioka T., Kimura N., Okada M., Tahara H., Furukawa J.-I., Fujitani N., Shinohara Y., Igarashi Y.","A potential function for neuronal exosomes: Sequestering intracerebral amyloid-β peptide",2015,"FEBS Letters","589","1",,"84","88",,1,10.1016/j.febslet.2014.11.027,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84918776208&partnerID=40&md5=23bc9af162aef89f4eec2b4007ac765b","Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Division of Molecular Interaction, Institute for Genetic Medicine, Hokkaido UniversitySapporo, Japan; Section of Cell Biology and Pathology, Department of Alzheimer's Disease Research, National Center for Geriatrics and GerontologyObu, Japan; Department of Cellular and Molecular Biology, Graduate School of Biomedical Science, Hiroshima UniversityHiroshima, Japan; Laboratory of Medical and Functional Glycomics, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan","Yuyama, K., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Sun, H., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Usuki, S., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Sakai, S., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Hanamatsu, H., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Mioka, T., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan, Division of Molecular Interaction, Institute for Genetic Medicine, Hokkaido UniversitySapporo, Japan; Kimura, N., Section of Cell Biology and Pathology, Department of Alzheimer's Disease Research, National Center for Geriatrics and GerontologyObu, Japan; Okada, M., Department of Cellular and Molecular Biology, Graduate School of Biomedical Science, Hiroshima UniversityHiroshima, Japan; Tahara, H., Department of Cellular and Molecular Biology, Graduate School of Biomedical Science, Hiroshima UniversityHiroshima, Japan; Furukawa, J.-I., Laboratory of Medical and Functional Glycomics, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Fujitani, N., Laboratory of Medical and Functional Glycomics, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Shinohara, Y., Laboratory of Medical and Functional Glycomics, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan; Igarashi, Y., Laboratory of Biomembrane and Biofunctional Chemistry, Graduate School of Advanced Life Science, Hokkaido UniversitySapporo, Japan","Elevated amyloid-β peptide (Aβ) in brain contributes to Alzheimer's disease (AD) pathogenesis. We demonstrated the presence of exosome-associated Aβ in the cerebrospinal fluid (CSF) of cynomolgus monkeys and APP transgenic mice. The levels of exosome-associated Aβ notably decreased in the CSF of aging animals. We also determined that neuronal exosomes, but not glial exosomes, had abundant glycosphingolipids and could capture Aβ. Infusion of neuronal exosomes into brains of APP transgenic mice decreased Aβ and amyloid depositions, similarly to what reported previously on neuroblastoma-derived exosomes. These findings highlight the role of neuronal exosomes in Aβ clearance, and suggest that their downregulation might relate to Aβ accumulation and, ultimately, the development of AD pathology. © 2014 Federation of European Biochemical Societies.","Alzheimers disease; Amyloid-b peptide; APP transgenic mouse; Cerebrospinal fluid; Cynomolgus monkey; Exosome","Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., Simons, K., Alzheimer's disease beta-amyloid peptides are released in association with exosomes (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 11172-11177; Vingtdeux, V., Hamdane, M., Loyens, A., Gele, P., Drobeck, H., Begard, S., Galas, M.C., Sergeant, N., Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies (2007) J. Biol. Chem., 282, pp. 18197-18205; Yuyama, K., Sun, H., Mitsutake, S., Igarashi, Y., Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia (2012) J. Biol. Chem., 287, pp. 10977-10989; Yuyama, K., Sun, H., Sakai, S., Mitsutake, S., Okada, M., Tahara, H., Furukawa, J., Igarashi, Y., Decreased amyloid-beta pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice (2014) J. Biol. Chem., 289, pp. 24488-24498; Tsuchida, J., Yoshida, T., Sankai, T., Yasutomi, Y., Maternal behavior of laboratory-born, individually reared long-tailed macaques (Macaca fascicularis) (2008) J. Am. Assoc. Lab. Anim. Sci.: JAALAS, 47, pp. 29-34; Demattos, R.B., Bales, K.R., Parsadanian, M., O'Dell, M.A., Foss, E.M., Paul, S.M., Holtzman, D.M., Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease (2002) J. Neurochem., 81, pp. 229-236; Gottfried-Blackmore, A., Sierra, A., Jellinck, P.H., McEwen, B.S., Bulloch, K., Brain microglia express steroid-converting enzymes in the mouse (2008) J. Steroid Biochem. Mol. Biol., 109, pp. 96-107; Liu, H.T., Tashmukhamedov, B.A., Inoue, H., Okada, Y., Sabirov, R.Z., Roles of two types of anion channels in glutamate release from mouse astrocytes under ischemic or osmotic stress (2006) Glia, 54, pp. 343-357; Heuer, E., Rosen, R.F., Cintron, A., Walker, L.C., Nonhuman primate models of Alzheimer-like cerebral proteopathy (2012) Curr. Pharm. Des., 18, pp. 1159-1169; Oikawa, N., Kimura, N., Yanagisawa, K., Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition (2010) Brain Res., 1315, pp. 137-149; Kimura, N., Yanagisawa, K., Terao, K., Ono, F., Sakakibara, I., Ishii, Y., Kyuwa, S., Yoshikawa, Y., Age-related changes of intracellular Abeta in cynomolgus monkey brains (2005) Neuropathol. Appl. Neurobiol., 31, pp. 170-180; Thery, C., Exosomes: Secreted vesicles and intercellular communications (2011) F1000 Biol, Rep., 3, p. 15; Kimura, N., Inoue, M., Okabayashi, S., Ono, F., Negishi, T., Dynein dysfunction induces endocytic pathology accompanied by an increase in Rab GTPases: A potential mechanism underlying age-dependent endocytic dysfunction (2009) J. Biol. Chem., 284, pp. 31291-31302; Kimura, N., Okabayashi, S., Ono, F., Dynein dysfunction disrupts beta-amyloid clearance in astrocytes through endocytic disturbances (2014) Neuroreport, 25, pp. 514-520; Cataldo, A.M., Barnett, J.L., Pieroni, C., Nixon, R.A., Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis (1997) J. Neurosci., 17, pp. 6142-6151; Cataldo, A.M., Petanceska, S., Terio, N.B., Peterhoff, C.M., Durham, R., Mercken, M., Mehta, P.D., Nixon, R.A., Abeta localization in abnormal endosomes: Association with earliest Abeta elevations in AD and Down syndrome (2004) Neurobiol. Aging, 25, pp. 1263-1272; Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Jackson, B., McKee, A.C., Hall, G.F., Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease (2012) J. Biol. Chem., 287, pp. 3842-3849",Article,Scopus,2-s2.0-84918776208
"Wobst H.J., Sharma A., Diamond M.I., Wanker E.E., Bieschke J.","The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios",2015,"FEBS Letters","589","1",,"77","83",,,10.1016/j.febslet.2014.11.026,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84918784359&partnerID=40&md5=05fbd3f4359b6b2c3ddd2b7804759f67","AstraZeneca-Tufts Lab for Basic and Translational MedicineBoston, MA, United States; Max Delbrück Center for Molecular MedicineBerlin, Germany; Washington University in St. LouisSaint Louis, MO, United States; Department of Neurology and Neurotherapeutics, University of Texas, Southwestern Medical Center, United States","Wobst, H.J., AstraZeneca-Tufts Lab for Basic and Translational MedicineBoston, MA, United States, Max Delbrück Center for Molecular MedicineBerlin, Germany; Sharma, A., Department of Neurology and Neurotherapeutics, University of Texas, Southwestern Medical Center, United States; Diamond, M.I., Department of Neurology and Neurotherapeutics, University of Texas, Southwestern Medical Center, United States; Wanker, E.E., Max Delbrück Center for Molecular MedicineBerlin, Germany; Bieschke, J., Max Delbrück Center for Molecular MedicineBerlin, Germany, Washington University in St. LouisSaint Louis, MO, United States","The accumulation of amyloid-beta (Aβ) and tau aggregates is a pathological hallmark of Alzheimer's disease. Both polypeptides form fibrillar deposits, but several lines of evidence indicate that Aβ and tau form toxic oligomeric aggregation intermediates. Depleting such structures could thus be a powerful therapeutic strategy. We generated a fragment of tau (His-K18ΔK280) that forms stable, toxic, oligomeric tau aggregates in vitro. We show that (-)-epigallocatechin gallate (EGCG), a green tea polyphenol that was previously found to reduce Aβ aggregation, inhibits the aggregation of tau K18ΔK280 into toxic oligomers at ten- to hundred-fold substoichiometric concentrations, thereby rescuing toxicity in neuronal model cells. © 2014 Federation of European Biochemical Societies.","(-)-Epigallocatechin gallate; Aggregation inhibitors; Alzheimers disease; Polyphenol; Tau oligomers; Tau protein","Masters, C.L., Amyloid plaque core protein in Alzheimer disease and down syndrome (1985) Proc. Natl. Acad. Sci. U.S.A., 82, pp. 4245-4249; Grundke-Iqbal, I., Microtubule-associated protein tau. A component of Alzheimer paired helical filaments (1986) J. Biol. Chem., 261, pp. 6084-6089; Kosik, K.S., Joachim, C.L., Selkoe, D.J., Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease (1986) Proc. Natl. Acad. Sci. U.S.A., 83, pp. 4044-4048; Tanzi, R.E., Amyloid beta protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus (1987) Science, 235, pp. 880-884; Giannetti, A.M., Fibers of tau fragments, but not full length tau, exhibit a cross beta-structure: Implications for the formation of paired helical filaments (2000) Protein Sci. Publ. Protein Soc., 9, pp. 2427-2435; Goedert, M., Ghetti, B., Spillantini, M.G., Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process (2000) Ann. N. Y. Acad. Sci., 920, pp. 74-83; Goedert, M., Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans (1996) Nature, 383, pp. 550-553; Friedhoff, P., Schneider, A., Mandelkow, E.M., Mandelkow, E., Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution (1998) Biochemistry, 37, pp. 10223-10230; Barghorn, S., Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias (2000) Biochemistry, 39, pp. 11714-11721; Bieschke, J., Natural compounds may open new routes to treatment of amyloid diseases (2013) Neurotherapeutics, 10, pp. 429-439; Pickhardt, M., Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells (2005) J. Biol. Chem., 280, pp. 3628-3635; Taniguchi, S., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins (2005) J. Biol. Chem., 280, pp. 7614-7623; Rambold, A.S., Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP (2008) J. Neurochem., 107, pp. 218-229; Meng, F., Abedini, A., Plesner, A., Verchere, C.B., Raleigh, D.P., The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity (2010) Biochemistry, 49, pp. 8127-8133; Hauber, I., Hohenberg, H., Holstermann, B., Hunstein, W., Hauber, J., The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 9033-9038; Ferreira, N., Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity (2009) FEBS Lett., 583, pp. 3569-3576; Ferreira, N., Saraiva, M.J., Almeida, M.R., Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation (2011) FEBS Lett., 585, pp. 2424-2430; Sheynis, T., Aggregation modulators interfere with membrane interactions of β2-microglobulin fibrils (2013) Biophys. J., 105, pp. 745-755; Ehrnhoefer, D.E., EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers (2008) Nat. Struct. Mol. Biol., 15, pp. 558-566; Cao, P., Raleigh, D.P., Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols (2012) Biochemistry, 51, pp. 2670-2683; Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimer's disease: Bioavailability, metabolism, and cellular and molecular mechanisms (2008) J. Agric. Food Chem., 56, pp. 4855-4873; Singh, M., Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles (2011) J. Biomed. Nanotechnol., 7, p. 202; Bieschke, J., EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 7710-7715; Nesterenko, M.V., Tilley, M., Upton, S.J., A simple modification of Blum's silver stain method allows for 30 minute detection of proteins in polyacrylamide gels (1994) J. Biochem. Biophys. Methods, 28, pp. 239-242; Levine, H., Quantification of beta-sheet amyloid fibril structures with thioflavin T (1999) Methods Enzymol., 309, pp. 274-284; Kayed, R., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis (2003) Science, 300, pp. 486-489; Flach, K., Tau oligomers impair artificial membrane integrity and cellular viability (2012) J. Biol. Chem., 287, pp. 43223-43233; Paz, M.A., Flückiger, R., Boak, A., Kagan, H.M., Gallop, P.M., Specific detection of quinoproteins by redox-cycling staining (1991) J. Biol. Chem., 266, pp. 689-692; Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; Shankar, G.M., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) Nat. Med., 14, pp. 837-842; Walsh, D.M., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539; Lasagna-Reeves, C.A., Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau (2012) Sci. Rep., 2, p. 700; Lasagna-Reeves, C.A., Identification of oligomers at early stages of tau aggregation in Alzheimer's disease (2012) FASEB J., 26, pp. 1946-1959; Guzmán-Martinez, L., Farías, G.A., MacCioni, R.B., Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs (2013) Front. Neurol., 4, p. 167; Castillo-Carranza, D.L., Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles (2014) J. Neurosci., 34, pp. 4260-4272; Davidowitz, E., Chatterjee, I., Moe, J., Targeting tau oligomers for therapeutic development for Alzheimer's disease and tauopathies (2008) Curr. Top. Biotechnol., 4, pp. 47-64; Palhano, F.L., Lee, J., Grimster, N.P., Kelly, J.W., Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils (2013) J. Am. Chem. Soc., 135, pp. 7503-7510; Cortez, L., Sim, V., The therapeutic potential of chemical chaperones in protein folding diseases (2014) Prion, 8; Ignatova, Z., Gierasch, L.M., Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 13357-13361; Tatzelt, J., Prusiner, S.B., Welch, W.J., Chemical chaperones interfere with the formation of scrapie prion protein (1996) EMBO J., 15, pp. 6363-6373; Torrente, M.P., Shorter, J., The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins (2014) Prion, 7",Article,Scopus,2-s2.0-84918784359
"Lin L., Ni B., Lin H., Zhang M., Li X., Yin X., Qu C., Ni J.","Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review",2015,"Journal of Ethnopharmacology","159",,,"158","183",,,10.1016/j.jep.2014.11.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84912535919&partnerID=40&md5=0f16b1240802ba86354b1376c3a10a8b","School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China","Lin, L., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Ni, B., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Lin, H., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Zhang, M., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Li, X., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Yin, X., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Qu, C., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China; Ni, J., School of Chinese Materia Medica, Beijing University of Chinese MedicineBeijing, China","Conclusion Therapeutic potential of Polygonum multiflorum has been demonstrated in the conditions like Alzheimers disease, Parkinsons disease, hyperlipidaemia, inflammation and cancer, which is attributed to the presence of various stilbenes, quinones, flavonoids, phospholipids and other compounds in the drug. On the other hand, the adverse effects (hepatotoxicity, nephrotoxicity, and embryonic toxicity) of this plant were caused by the quinones, such as emodin and rhein. Thus more pharmacological and toxicological mechanisms on main active compounds are necessary to be explored, especially the combined anthraquinones (Emodin-8-O-β-d-glucopyranoside, Physcion-8-O-β-d-glucopyranoside, etc.) and the variety of stilbenes.Ethnopharmacological relevance Polygonum multiflorum Thunb., which is known as Heshouwu (in Chinese) in China. It is traditionally valued and reported for hair-blacking, liver and kidney-tonifying and anti-aging effects as well as low toxicity. The aim of this review is to provide comprehensive information on the botany, traditional uses, phytochemistry, pharmacological research and toxicology of Polygonum multiflorum, based on the scientific literature. Moreover, trends and perspectives for future investigation of this plant are discussed. It will build up a new foundation for further study on Polygonum multiflorum.Results Polygonum multiflorum is widely distributed throughout the world and has been used as a traditional medicine for centuries in China. The ethnomedical uses of Polygonum multiflorum have been recorded in many provinces of China and Japan for nine species of adulterants in six families. More than 100 chemical compounds have been isolated from this plant, and the major components have been determined to be stilbenes, quinones, flavonoids and others. Crude extracts and pure compounds of this plant are used as effective agents in pre-clinical and clinical practice due to their anti-aging, anti-hyperlipidaemia, anti-cancer and anti-inflammatory effects and to promote immunomodulation, neuroprotection, and the curing of other diseases. However, these extracts can also lead to hepatotoxicity, nephrotoxicity and embryonic toxicity. Pharmacokinetic studies have demonstrated that the main components of Polygonum multiflorum, such as 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucopyranoside and emodin are distributed among many organs and tissues.Materials and methods A systematic review of the literature on Polygonum multiflorum was performed using several resources, including classic books on Chinese herbal medicine and various scientific databases, such as PubMed, SciFinder, the Web of Science, Science Direct, China Knowledge Resource Integrated (CNKI). © 2014 Elsevier Ireland Ltd. All rights reserved.","Botany; Pharmacology and toxicology; Phytochemistry; Polygonum multiflorum Thunb; Traditional usages","Achenbach, H., Lowell, M., Waibel, R., Gupta, M., Solis, P., New lignin glucosides from Stemmadenia minima (1992) Planta Medica, 58, pp. 270-272; Bai, P., (2013) The Clinical Efficacy of Compound Radix Tribulus Decoction for Treatment on Vitiligo and Its Effect of Tyrosinase Activity, , Shandong Traditional Chinese Medicine University Jinan; Bhadauria, M., Dose-dependent hepatoprotective effect of emodin against acetaminophen-induced acute damage in rats (2010) Experimental and Toxicologic Pathology, 62, pp. 627-635; Birgitte, B.O., Marina, B.P., Barbara, G., Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: A study on its mechanism of action (2007) The International Journal of Biochemistry & Cell Biology, 39, pp. 227-237; Cai, L.F., Zhong, G.Y., Zhang, Q., Qu, X.Y., Quality evaluation of raw and prepared radix polygonui multiflori from different producing areas and markets (2011) Traditional Chinese Drug Research & Clinical Pharmacology, 22, pp. 204-208; Chan, Y.C., Cheng, F.C., Wang, M.F., Beneficial effects of different Polygonum multiflorum Thunb. extracts on memory and hippocampus morphology (2002) Journal of Nutritional Science and Vitaminology, 48, pp. 491-497; Chan, Y.C., Wang, M.F., Chang, H.C., Polygonum multiflorum extracts improve cognitive performance in senescence accelerated mice (2003) American Journal of Chinese Medicine, 31, pp. 171-179; Chang, M.H., Huang, F.J., Chan, W.H., Emodin induces embryonic toxicity in mouse blastocysts through apoptosis (2012) Toxicology, 299, pp. 25-32; Chen, G.H., Pan, G.H., Shen, S.X., Meng, X.F., Zhou, R.H., Effect of heshouwu and roucongrong compound on immunological function of elderly patients with kidney deficiency and blood stasis (2006) Chinese Journal of Clinical Rehabilitation, 10, pp. 13-15; Chen, J.Y., Chen, L., Chen, S.X., An, Z.B., Tong, Y.X., Identification index of Polygonum multiflorum thunb and its Adulterants (I.Plant, Macrostructure) (1999) Lishizhen Medicine and Materia Medica Research, 10, pp. 44-45; Chen, J.Y., Tong, Y.X., An, Z.B., Chen, L., Gel electrophoresis identification of radix polygoni multiflori and its adulterants (1998) Journal of Chinese Medicinal Materials, 21, pp. 71-72; Chen, L., (2013) Study on the Curative Effect of Peibu Ganshen Compound in Treating Parkinsons Disease and Intestinal Dysfunction, , Beijing University of Chinese Medicine Beijing; Chen, L.L., Huang, X.J., Li, M.M., Ou, G.M., Zhao, B.X., Chen, M.F., Zhang, Q.W., Ye, W.C., Polygonflavanol A, a novel flavonostilbene glycoside from the roots of Polygonum multiflorum (2012) Phytochemistry Letters, 5, pp. 756-760; Chen, Q., Zhang, S.Z., Ying, H.Z., Daic, X.Y., Li, X.X., Yu, C.H., Ye, H.C., Chemical characterization and immunostimulatory effects of a polysaccharide from Polygoni Multiflori Radix Praeparata in cyclophosphamide-induced anemic mice (2012) Carbohydrate Polymers, 88, pp. 1476-1482; Chen, Q.T., Zhou, L.H., Xu, W., Huang, Z.H., Qiu, X.H., Content changes of 5 components in Polygohum muhiflorum during processing (2012) Chinese Journal of Experimental Traditional Medical Formulae, 18, pp. 66-71; Chen, Q.T., Zhuo, L.H., Xu, W., Huang, Z.H., Qiu, X.H., The content change of 5 kinds of chemical components in Polygonum multiflorum Thunb during the processing (2012) Chinese Journal of Experimental Traditional Medical Formulae, 18, pp. 66-71; Chen, W.S., Fan, W., Yang, G.J., Qiao, C.Z., Chen, H.S., Yuan, Y., Studies on the chemical constituents of radix Polygoni multiflori preparata (1999) Academic Journal of Second Military Medical University, 20, pp. 438-440; Chen, W.S., Liu, W.Y., Yang, G.J., Zhang, W.D., Chu, Z.Y., Chen, H.S., Qiao, C.Z., Structural elucidation of a new tetrahydroxystilbene of radix polygoni multiflori preparata and study on its cardiovascular activity (2000) Acta Pharmaceutica Sinica, 35, pp. 906-908; Chen, W.S., Xu, J.P., Li, L., Qiao, C.Z., Studies on nootropic activity and mechanism of emodin-8-O-β-d-glucopyranoside (2001) Chinese Traditional and Herbal Drugs, 32, pp. 39-41; Chen, W.S., Yang, G.J., Zhang, W.D., Chen, H.S., Qiao, C.Z., A new fatty ketone of radix Polygoni multiflori preparata (2000) China Journal of Chinese Materia Medica, 25, pp. 476-477; Chen, W.S., Yang, G.J., Zhang, W.D., Chen, H.S., Qiao, C.Z., Studies on two new phospholipids of radix Polygoni multiflori preparata (2001) Chinese Pharmaceutical Journal, 36, pp. 155-157; Chen, W.S., Yang, G.J., Zhang, W.D., Qiao, C.Z., Chen, H.S., Two new compounds of radix polygoni multiflori preparata (2000) Acta Pharmaceutica Sinica, 35, pp. 273-276; Chen, W.S., Zhang, W.D., Qiao, C.Z., Analysis of the constituents of essential oil from radix Polygoni multiflori preparata (2001) Journal of Chinese Medicinal Materials, 23, pp. 684-685; Chen, Y., Wang, M., Rosen, R.T., Ho, C.T., 2,2-Diphenyl-1-picrylhydrazyl radical-scavenging active components from Polygonum multiflorum thunb (1999) Journal of Agricultural and Food Chemistry, 47, pp. 2226-2228; Cheng, R.Y., Zhou, J.L., Identification of fleece-flower root cut crude drug and spurious breed airpotato yam in crude drug (2005) Journal of Anhui Traditional Chinese Medical College, 24, p. 24; Cheng, R.Y., Zhou, J.L., Identification of fleece-flower root cut crude drug and spurious breed airpotato yam in crude drug (2005) Journal of Anhui TCM College, 24, pp. 52-53; Cheung, F.W., Leung, A.W., Liu, W.K., Che, C.T., Tyrosinase inhibitory activity of a glucosylated hydroxystilbene in mouse melan-A melanocytes (2014) Journal of Natural Products, 77, pp. 1270-1274; Chiu, T.H., Lai, W.W., Hsia, T.C., Yang, J.S., Lai, T.Y., Wu, P.P., Ma, C.Y., Chung, J.G., Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells (2009) Anticancer Research, 29, pp. 4503-4512; (1996) Science of Processing Chinese Materia Medica, p. 235. , Committee on the programming teaching material for higher TCM education (1996) Shanghai Science and Technology Press Shanghai; Da, H.Y., Jiang, Z.Z., Wang, C.F., Zhang, L.Y., Liu, G.Q., The toxic effects of rhein and emodin on human renal tubular epithelial cells in vitro (2009) Chinese Traditional and Herbal Drugs, 40, pp. 102-105; Deng, X.C., Huang, J.N., Lian, Z.W., Sun, G.B., Song, W., Proliferative effects of different extract of Polygonum multiflorum thunberg on spleen lymphocytes in mice (2008) Chinese Journal of Modern Drug Application, 2, pp. 1-3; Dong, H.H., Slain, D., Cheng, J., Ma, W.H., Liang, W.F., Eighteen cases of liver injury following ingestion of Polygonum multiflorum (2014) Complementary Therapies in Medicine, 22, pp. 70-74; Du, C.H., Hai, Q.S., Yan, Y., Yuan, H.X., Zhao, R.H., Zhao, S.L., Wang, X.H., Preliminary study on the processing mechanism of Polygonum multiflorum Thunb by microbial fermentation (2012) Natural Product Research & Development, 24, pp. 212-215; (1998) Flora of China, 25, pp. 102-103. , Editorial Board of Flora of China Science Publishing House Beijing; (2010) Chinese Pharmacopoeia, pp. 164-165. , Editorial Committee of Chinese Pharmacopoeia 2010 ed. Medical Science and Technology Press Beijing, China; Fahad, A., Simon, R.W., Stott, R., Barker, A., Stem cells and the treatment of Parkinsons disease (2014) Experimental Neurology, 260, pp. 3-11; Fresno Vara, J.A., Casado, E., De Castro, J., Cejas, P., Belda-Iniesta, C., González-Barón, M., PI3K/Akt signalling pathway and cancer (2004) Cancer Treatment, 30, pp. 193-204; Fu, W.H., HPLC determination of the main chemical ingredients content in polygonum multiflorum during the processing (2013) Asia-Pacific Traditional Medicine, 9, pp. 50-51; Gao, X., Hu, Y.J., Fu, L.C., Blood lipid-regulation of stilbene glycoside from Polygonum multiflorum (2007) China Journal of Chinese Materia Medica, 32, pp. 323-326; Ge, C.L., Liu, Y., Polysaccharide from Polygonum multiflorum Thunb potentiates the immunological function in immunosuppressed mice (2007) Chinese Journal of New Drugs, 16, pp. 2040-2042; Ge, L.W., Wu, Z.C., Zhang, Z.F., Zhang, M., Identification of fallopia multiflora and its adulterants (2011) Chinese Wild Plant Resources, 30, pp. 64-68; Guo, J.M., Xiao, B.X., Liu, Q., Zhang, S., Liu, D.H., Gong, Z.H., Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation (2007) Acta Pharmacologica Sinica, 28, pp. 1991-1995; Guo, Y.Q., Chen, D.X., Guo, M., Quality identification on the authenticity of fleece-flower root (2007) Journal of Traditional Chinese Medicine University of Hunan, 27, pp. 71-73; He, E.H., Sun, W.J., Physical and chemical identification of radix polygoni multiflori and its adulterants (2010) Aerospace Medicine, 21, pp. 380-381; Ho, T.Y., Wu, S.L., Chen, J.C., Li, C.C., Hsiang, C.Y., Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction (2007) Antiviral Research, 74, pp. 92-101; Hsu, C.M., Hsu, Y.A., Tsai, Y., Shieh, F.K., Huang, S.H., Wan, L., Tsai, F.J., Emodin inhibits the growth of hepatoma cells: Finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells (2010) Biochemical and Biophysical Research Communications, 392, pp. 473-478; Hu, X.Q., Fang, H.L., Quan, Z.B., Geng, Z.Y., Experimental study of Radix Plygoni Multiflori peparata on livers biochemical matters (2007) Journal of Shaanxi College of Traditional Chinese Medicine, 30, pp. 63-64; Hu, X.Q., Li, Y.L., Lin, F., Effect of polygonum multiflorum and polygonum multiflorum preparation on immunoglobulin in rats (2009) Tianjin Journal of Traditional Chinese Medicine, 26, pp. 139-141; Hu, X.Q., Yang, H.L., Zhang, X.Q., Miao, Y.X., Geng, Z.Y., Experimental study on the toxicology of prepared Radix Polygoni Multiflori to the rats liver (2006) Journal of Shaanxi College of Traditional Chinese Medicine, 29, pp. 40-42; Hu, X.Q., Yang, X.Q., Xing, Y.R., Miao, Y.X., Fang, H.L., Study on liver injury induced by prepared Radix Polygoni Multiflori (2006) Shaanxi Journal of Traditional Chinese Medicine, 27, pp. 625-626; Huang, C., Wang, Y.Z., Wang, J., Yao, W.J., Chen, X.F., Zhang, W., TSG (2,3,4′,5-tetrahydroxystilbene 2-O-β-d-glucoside) suppresses induction of pro-inflammatory factors by attenuating the binding activity of nuclear factor-κB in microglia (2013) Journal of Neuroinflammation, 10, pp. 129-141; Huang, C.H., Homg, L.Y., Chen, C.F., Wu, R.T., Chinese herb Radix Polygoni Multiflori as a therapeutic drug for liver cirrhosis in mice (2007) Journal of Ethnopharmacology, 114, pp. 199-206; Huang, W., Zhang, Y.N., Sun, R., Comparative study on acute toxicity of different components of Polygonum multiflorum in mice (2010) Chinese Journal of Pharmacovigilance, 7, pp. 705-707; Huang, W., Zhang, Y.N., Sun, R., Experimental study on the ""dose- time- toxicity"" relationship of acute hepatotoxicity induced by different components from Polygonum multiflorum in mice (2011) Chinese Journal of Pharmacovigilance, 8, pp. 193-197; Jang, J.Y., Kim, H.N., Kim, Y.R., Choi, Y.W., Choi, Y.H., Lee, J.H., Shin, H.K., Choi, B.T., Hexane extract from Polygonum multiflorum attenuates glutamate-induced apoptosis in primary cultured cortical neurons (2013) Journal of Ethnopharmacology, 145, pp. 261-268; Jung, K.A., Min, H.J., Yoo, S.S., Kim, H.J., Choi, S.N., Ha, C.Y., Kim, H.J., Shim, S.G., Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of polygonum multiflorum thunb (2011) Gut Liver, 5, pp. 493-499; Kato, T., Morita, Y., Anthraquinones components in Rumex acetosa L (1987) Shoy Akugaku Zasshi, 41, pp. 67-74; Kim, H.N., Kim, Y.R., Jang, J.Y., Choi, Y.W., Baek, J.U., Hong, J.W., Choi, Y.H., Choi, B.T., Neuroprotective effects of Polygonum multiflorum extract against glutamate-induced oxidative toxicity in HT22 hippocampal cells (2013) Journal of Ethnopharmacology, 150, pp. 108-115; Lan, M., (1959) Diannan Bencao, p. 111. , (1959) ed. Peoples Medical Publishing House Beijing; Lang, A.E., Lozano, A.M., Parkinsons disease. First of two parts (1998) New England Journal of Medicine, 339, pp. 1044-1053; Lee, B.H., Huang, Y.Y., Duh, P.D., Wu, S.C., Hepatoprotection of emodin and Polygonum multiflorum against CCl(4)-induced liver injury (2012) Pharmaceutical Biology, 50, pp. 351-359; Lee, S.V., Choi, K.H., Choi, Y.W., Hong, J.W., Baek, J.U., Choi, B.T., Shin, H.K., Hexane extracts of Polygonum multiflorum improve tissue and functional outcome following focal cerebral ischemia in mice (2014) Molecular Medicine Reports, 9, pp. 1415-1421; Li, C.L., Ma, J., Zheng, L., Li, H.J., Li, P., Determination of emodin in L-02 cells and cell culture media with liquid chromatography-mass spectrometry: Application to a cellular toxicokinetic study (2012) Journal of Pharmaceutical and Biomedical Analysis, 71, pp. 71-78; Li, C.R., Cai, F., Yang, Y.Q., Zhao, X.Y., Wang, C., Li, J., Jia, Y.L., Liu, Q., Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: Involvement of SIRT1 and TGF-β1 pathway (2010) European Journal of Pharmacology, 649, pp. 382-389; Li, D.P., Zhang, N.S., Cao, Y.G., Zhang, W., Su, G.L., Sun, Y., Liu, Z.C., Yang, Z.T., Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-kB and MAPKs signal pathways (2013) European Journal of Pharmacology, 705, pp. 79-85; Li, J., Xu, G.J., Xu, L.S., Jin, R.L., Studies on the traditional Chinese medicine Shouwu II. botanical origins and applied drugs (1995) Chinese Traditional and Herbal Drugs, 26, pp. 33-35; Li, J.B., Lin, M., Study on the chemical constituents of polygonum multiflorum Thunb (1993) Chinese Traditional and Herbal Drugs, 3, pp. 115-118; Li, J.K., Jiang, Z.T., Li, R., Tan, J., Investigation of antioxidant activities and free radical scavenging of flavonoids in leaves of polygonum multiflorum thumb (2012) China Food Additives, 2, pp. 69-74; Li, L., Zhang, L., Zhang, R.Y., Effects of tetrahydroxystilbene glucoside on multiple targets of Alzheimers disease in seven Alzheimerlike animal models (2010) Alzheimers & Dementia, 6, pp. 579-S580. , (Poster Presentations); Li, N., Chen, Z., Mao, X., Yu, J., Zhao, R., Effects of lipid regulation using raw and processed radix Polygoni multiflori in rats fed a high-Fat diet (2012) Evidence-Based Complementary and Alternative Medicine, , (Article ID 329171); Li, Q., Zhao, K.J., Zhao, Y.L., Wang, J.B., Fang, F., Lv, Y., Ma, Z.J., Xiao, X.H., High dosage administration of Polygonum multiflorum alcohol extract caused the multi-organ injury in rats (2013) Global Traditional Chinese Medicine, 6, pp. 1-7; Li, S.G., Chen, L.L., Huang, X.J., Zhao, B.X., Wang, Y., Ye, W.C., Five new stilbene glycosides from the roots of Polygonum multiflorum (2013) Journal of Asian Natural Products Research, 15, pp. 1145-1151; Li, T.H., Luo, S.F., Yang, S.Y., 58 cases of Xiaohuoluo pill in treating knee osteoarthritis (2012) Henan Traditional Chinese Medicine, 32, pp. 489-490; Li, W.X., Zhang, Q., Wang, G.R., Lin, X.L., Peng, Y.T., Study on liver injury induced by different processing of prepared Radix Polygoni multiflori (2012) Guangming Journal of Chinese Medicine, 27, pp. 595-597; Li, W.X., Zhang, Q., Wang, G.R., Lin, X.L., Peng, Y.T., Quality standard of Polygonum by different processing methods (2012) China Medical Herald, 9, pp. 41-47; Li, W.X., Zhang, Q., Wang, G.R., Lin, X.L., Peng, Y.T., Study on the quality standard of high-pressure steamed radix polygoni multiflori at different time (2012) Guide of China Medicine, 10, pp. 396-397; Li, X., Matsumoto, K., Murakami, Y., Tezuka, Y., Wu, Y., Kadota, S., Neuroprotective effects of Polygonum multiflorumon nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice (2005) Pharmacology, Biochemistry and Behavior, 82, pp. 345-352; Li, X.B., Li, Y., Chen, J.Z., Sum, J., Li, X.F., Sun, X., Kang, X.G., Tetrahydroxystilbene glucoside attenuates MPP+-induced apoptosis in PC12 cells by inhibiting ROS generation and modulating JNK activation (2010) Neuroscience Letters, 483, pp. 1-5; Li, X.E., Liu, J.Z., Liao, S.T., Xu, L.X., Wei, X.Y., Chemical constituents from tubers of Polygonum multiflorum Thunb (2006) Journal of Tropical and Subtropical Botany, 17, pp. 617-620; Li, Z., Hang, Y.Y., Zhou, Y.F., Germplasm appraisements of Plolygonum Multiflorum from main producing areas in China by content of tetrahydroxystilbene (2003) Chemistry and Industry of Forest Products, 23, pp. 37-41; Li, Z.C., Jin, Z.J., Cui, S., Hong, Y.J., Experimental study on the active situs of radix polygoni multiflori to reduce blood lipid and their dose-effect relation (2008) China Practical Medicine, 3, pp. 3-5; Liang, Y., Tian, W.X., Ma, X.F., Chemical cnstituents of Caulis Polygoni Multiflori(the stem of Polygonum multiflorum Thunb.) (2009) Journal of Shenyang Pharmaceutical University, 26, pp. 536-538; Lim, K.M., Kwon, J.H., Kim, K., Noh, J.Y., Kang, S., Park, J.M., Lee, M.Y., Chung, J.H., Emodin inhibits tonic tension through suppressing PKCδ-mediated inhibition of myosin phosphatase in isolated rat thoracic aorta (2014) British Journal of Pharmacology, 171, pp. 4300-4310; Lin, C.C., Chang, C.H., Yang, J.J., Namba, T., Hattori, M., Hepatoprotective effects of emodin from Ventilago leiocarpa (1996) Journal of Ethnopharmacoiogy, 52, pp. 107-111; Lin, H.Q., Ho, M.T., Lau, L.S., Wong, K.K., Shaw, P.C., Wan, D.C., Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimers disease (2008) Chemico-Biological Interactions, 175, pp. 352-354; Lin, J.G., Chen, G.W., Li, T.M., Chouh, S.T., Tan, T.W., Chung, J.G., Aloe-emodin induces apoptosis in T24 human bladder cancer cells through the p53 dependent apoptotic pathway (2006) The Jouranl of Urology, 175, pp. 343-347; Lin, S.P., Chu, P.M., Tsai, S.Y., Wu, M.H., Hou, Y.C., Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats (2012) Journal of Ethnopharmacology, 144, pp. 671-676; Liu, Z.L., Li, F.L., Song, Z.Q., Lv, A.P., Changes before and after processing of Radix Polygoni Multiflori HPLC fingerprints (2005) Chinese Traditional and Herbal Drugs, 36, pp. 1644-1646; Liu, Z.L., Song, Z.Q., Zhang, L., Li, S.L., Influence of process methods on contents of chemical component Radix Polygoni Multiflori (2005) China Journal of Chinese Materia Medica, 30, pp. 336-340; Liu, C.J., Zhang, Q.H., Lin, J., Effect of the root of Polygonum multiflorum Thunb and its processed products on fat accumulation in the liver of mice (1992) China Journal of Chinese Materia Medica, 17, pp. 595-596; Liu, J.B., Gao, X.G., Lian, T., Zhao, A.Z., Li, K.Z., Apoptosis of human hepatoma HepG2 cells induced by emodin in vitro (2003) Chinese Journal of Cancer, 22, pp. 1280-1283; Liu, L., Li, L., Zhao, L., Zhang, L., Li, Y.L., Ye, C.F., Effects of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside on learning and memory abilities of rats with chronic cerebral ischemia (2008) Chinese Journal of Pharmacology and Toxicology, 22, pp. 108-115; Liu, M.H., Jing, X.B., Cai, X.B., Chen, S.Z., Cai, J.Y., The mechanism about the inhibition effects of emodin on the proliferation of EC-109 cell in esophageal cancer (2009) Journal of Shantou University Medical College, 22, pp. 12-14; Liu, S.Q., Wang, L., Yue, L., Influence of high pressure processing on contents of active ingredients from Polygoni multiflori radix (2013) Chinese Journal of Experimental Traditional Medical Formulae, 19, pp. 37-40; Liu, W., Zheng, Z.J., Liu, X., Gao, S., Ye, L., Yang, Z., Hu, M., Liu, Z.Q., Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide (2011) Journal of Pharmaceutical and Biomedical Analysis, 54, pp. 1157-1162; Liu, Z.J., Li, L., Ye, C.F., Wang, Y.Q., The effects of tetrahydroxylstilbene on learning and memory ability and NMDA-receptor binding to [3H]MK801 in forebrain of ischemia-reperfusion gerbils (2004) Chinese New Drugs Journal, 13, pp. 223-226; Liu, Z.L., Chao, Z.M., Li, L.F., Song, Z.Q., Wang, C., Lv, S., HPLC-ELSD determination of the content change of monosaccharides and disaccharides in polygonum multiflorum during the processing (2008) Chinese Journal of Experimental Traditional Medical Formulae, 14, pp. 6-8; Liu, Z.L., Li, F.L., Song, Z.Q., Zhang, L., Quality Evaluation of Radix Polygoni Multiflori (2007) Journal of Chinese Medicinal Materials, 30, pp. 278-281; Liu, Z.L., Li, L.F., Chao, Z.M., Lv, S.Y., Wang, C., Li, L.F., Content analysis of the newly generated component in radix polygoni multiflori after processing (2008) China Journal of Chinese Materia Medica, 33, pp. 2326-2329; Liu, Z.L., Li, L.F., Chao, Z.M., Song, Z.Q., Wang, C., Zhang, L., Study on chemical constituents of radix polygoni multiflori after processing (2009) Natural Product Research & Development, 21, pp. 239-241. , (248); Liu, Z.L., Li, L.F., Song, Z.Q., Wang, C., Zhang, L., Chao, Z.M., New chemical constituents from radix polygoni multiflori after processing (2007) Journal of Chinese Medicinal Materials, 30, pp. 1505-1507; Liu, Z.L., Song, Z.Q., Chao, Z.M., Wang, C., Lv, S.Y., Wang, C., Li, L.F., HPLC analysis of the content change of gallic acid and catechin which antioxidant constituents in radix polygoni multiflori before and after processing (2009) Chinese Traditional Patent Medicine, 31, pp. 1392-1394; Liu, Z.L., Song, Z.Q., Zhang, L., Li, S.L., The impact of different processing methods on the component content of polygonum multiflorum (2005) China Journal of Chinese Materia Medica, 30, pp. 336-340; Long, C.O., Dougherty, J., Whats new in Alzheimers disease? (2003) Home Health Nurse, 21, pp. 8-14; Lu, X.L., Li, J.S., Zhang, T., Wu, T., Identification of unknown unqualified polygonum mulitflorum system (2012) Chinese Archives of Traditional Chinese Medicine, 30, pp. 1087-1088; Luo, W., Liu, B., Wang, W., Shi, R.B., HPLC fingerprint chromatogram of Polygonum multiflorum Thunb (2008) Journal of Beijing University of Traditional Chinese Medicine, 31, pp. 557-560; Lv, G.Y., Lou, Z.H., Chen, S.H., Gu, H., Shan, L.T., Pharmacokinetics and tissue distribution of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats (2011) Journal of Ethnopharmacology, 137, pp. 449-456; Lv, J.S., Meng, D.S., Xiang, M.F., Feng, Y.Y., Preliminary study on the Anti-inflammatory effect of Polygonum multiflorum (2001) China Pharmacy, 12, pp. 712-714; Lv, L.H., Cheng, Y.H., Zheng, T.S., Li, X.M., Zhai, R., Purification, antioxidant activity and antiglycation of polysaccharides from Polygonum multiflorum Thunb (2014) Carbohydrate Polymers, 99, pp. 765-773; Lv, L.S., Gu, X.H., Tang, J., Ho, C.T., Antioxidant activity of stilbene glycoside from Polygonum multiflorum Thunb in vivo (2007) Food Chemistry, 104, pp. 1678-1681; Ma, J., Zheng, L., Deng, T., Cui, L.L., He, Y.S., Li, H.J., Li, P., Stilbene glucoside inhibits the glucuronidation of emodin in rats through the down-regulation of UDP-glucuronosyltransferases 1A8: Application to a drug-drug interaction study in Radix Polygoni Multiflori (2013) Journal of Ethnopharmacology, 147, pp. 335-340; Ma, Y.M., Du, H.Q., Effect of Shouwushen (SWS) on Ability of learning and memory in mice (2001) Pharmacology and Clinics of Chinese Materia Medica, 17, pp. 35-37; Ma, Y.S., Weng, S.W., Lin, M.W., Lu, C.C., Chiang, J.H., Yang, J.S., Lai, K.C., Chung, J.G., Antitumor effects of emodin on LS1034 human colon cancer cellsin vitro and in vivo: Roles of apoptotic cell death and LS1034 tumor xenografts model (2012) Food and Chemical Toxicology, 50, pp. 1271-1278; Masaldan, S., Iyer, V.V., Exploration of effects of emodin in selected cancer cell lines: Enhanced growth inhibition by ascorbic acid and regulation of LRP1 and AR under hypoxia-like conditions (2014) Journal of Applied Toxicology, 34, pp. 95-104; Min, H.J., Jung, K.A., Kim, H.J., Kim, T.H., Jung, W.T., Lee, O.K., Twelve cases of toxic hepatitis related to the root of Polygonum multiflorum Thunb (2008) Journal of Hepatology, 48, p. 356. , (Posters); (2001) The Toxicology and Carcinogenesis Studies of Emodin in F344/N Rats and B6C3F1 Mice, , National Toxiclogy Program. NTP technical report (Report No. 01-3952) NIH Publication (PP1-278); Nie, X.P., Liu, Z.G., Study overview of the processing of polygonum multiflorum thumb (2002) Shangdong Pharmaceutical Industry, 21, p. 24; Niu, J.H., A severe liver damage case induced by Shou Wu Pian though oral administration (1996) Chinese Journal of New Drugs and Clinical Remedies, 15, p. 382; Nonaka, G.I., Miwa, N., Nishioka, I., Stilbene glycoside gallates and proanthocyanidins from Polygonum multiflorum (1982) Phytochemistry, 21, pp. 429-432; Obeso, J.A., Rodriguez-Oroz, M.C., Goetz, C.G., Marin, C., Kordower, J.H., Rodriguez, M., Hirsch, E.C., Halliday, G., Missing pieces in the Parkinsons disease puzzle (2010) Nature Medicine, 16, pp. 653-661; Park, G.J., Mann, S.P., Ngu, M.C., Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum (2001) Journal of Gastroenterology and Hepatology, 16, pp. 115-117; Pecere, T., Gazzola, M.V., Mucignat, C., Parolin, C., Vecchia, F.D., Cavaggioni, A., Basso, G., Palu, G., Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors (2000) Cancer Research, 60, pp. 2800-2804; Qin, F.H., Xie, S.S., Zhang, W.R., Long, Z.Z., Liu, F.J., Study on the immune function influence by Polygonum multiflorum in mice (1990) Immunological Journal, 6, pp. 252-254; Qin, R., Li, X.B., Li, G., Tao, L.Z., Li, Y., Sun, J., Kang, X.G., Chen, J.Z., Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP+: The involvement of PI3K/Akt pathway activation (2011) Toxicology Letters, 202, pp. 1-7; Qiu, X.H., Huang, Z.H., Content comparative analysis of water soluble saccharides in radix polygoni multiflori before and after its processing (2006) China Pharmacy, 17, pp. 954-956; Qiu, X.H., Zeng, W.H., On Processing Technique of Radix Polygoni Multiflori (2006) China Pharmacy, 17, pp. 1270-1273; Qiu, X.H., Zhang, J., Huang, Z.H., Zhu, D.Y., Xu, W., Profiling of phenolic constituents in Polygonum multiflorum Thunb. by combination of ultra-high-pressure liquid chromatography with linear ion trap-Orbitrap mass spectrometry (2013) Journal of Chromatography A, 1292, pp. 121-131; Rao, G.X., Xue, Y.M., Hui, T.T., Wang, W.J., Zhang, Q.L., Studies on the chemical constituents of the leaves of Polygonum multiflorum (2009) Journal of Chinese Medicinal Materials, 32, pp. 891-893; Shi, G.B., Study on the influence of concoction over active ingredients in Polygonum multiflorum (2003) Chinese Hospital Pharmacy Journal, 23, pp. 95-97; Song, S.J., Li, F.F., Yue, H., Yin, Z.W., Study on the anti-aging effects of radix Polygonum multiflorum (2003) Journal of Hebei Medical University, 24, pp. 90-91; Steele, M.L., Truong, J., Govindaraghavan, S., Ooi, L., Sucher, N.J., Münch, G., Cytoprotective properties of traditional Chinese medicinal herbal extracts in hydrogen peroxide challenged human U373 astroglia cells (2013) Neurochemistry International, 62, pp. 522-529; Su, Y., Wang, Q.H., Wang, C.F., Chan, K., Sun, Y.P., Kuang, H.X., The treatment of Alzheimers disease using Chinese Medicinal Plants: From disease models to potential clinical applications (2014) Journal of Ethnopharmacology, 152, pp. 403-423; Sun, F.L., Zhang, L., Zhang, R.Y., Li, L., Tetrahydroxystilbene glucoside protects human neuroblastoma SH-SY5Y cellsagainst MPP+-induced cytotoxicity (2011) European Journal of Pharmacology, 660, pp. 283-290; Sun, G.B., Guo, B.J., Li, X.E., Huang, J.N., Xue, H.B., Sun, X.B., The effect of anthraquinone glycoside from Polygonum multiflorum Thunb on cellular immunological function in mice (2006) Pharmacology and Clinics of Chinese Materia Medica, 22, pp. 30-32; Sun, J.H., (2004) Studies on the Pharmacokinetics and Metaboliteof Stilbene Glycoside, , Heibei Medical University ShijiaZhuang; Sun, J.L., Huang, X.L., Wu, H.Q., Huang, F., HPLC/IT-MS analysis of glycosides in Radix polygoni multiflori (2009) Natural Product Research & Development, 21, pp. 806-812; Sun, Q.H., Bai, Q., The differentiation on Polygonum multiflorum thumb and its forgery human-Like Polygonum multiflorum thunb (Musa basjoo Sieb. et Zucc) (1996) Journal of North Sichuan Medical College, 11, pp. 54-56; Sun, Q.H., Bai, Q., The differentiation on polygonum mulitflorum thunb and its forgery (1996) Journal of North Sichuan Medical College, 11, pp. 44-46; Sun, S.F., The processing method of Polygonum multiflorum Thunb (1996) China Journal of Chinese Materia Medica, 21, p. 360; Sun, X.H., Sun, Y.W., Li, H., Sun, W., Influence of main component of Heshouwu such as emodin, rhein and toluylene glycoside onhepatic cells and hepatomacarcinoma cell (2010) Modern Journal of Integrated Traditional Chinese and Western Medicine, 19, pp. 1315-1319; Sun, Y.N., Cui, L., Li, W., Yan, X.T., Yang, S.Y., Kang, J.I., Kang, H.K., Kim, Y.H., Promotion effect of constituents from the root of Polygonum multiflorumon on hair growth (2013) Bioorganic & Medicinal Chemistry Letters, 23, pp. 4801-4805; Tabolacci, C., Lentini, A., Mattioli, P., Provenzano, B., Oliverio, S., Carlomosti, F., Beninati, S., Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells (2010) Life Sciences, 87, pp. 316-324; Tian, Y.H., Zhang, L.Y., Yang, Y.Q., Li, J., Li, M., Yu, Q.L., Optimization of processing technologies for steamed Polygonum multiflorum by colligation score (2007) Journal of Guiyang College of Traditional Chinese Medicine, 29, pp. 15-17; Toth, P.P., Drug treatment of hyperlipidaemia: A guide to the rational use of lipid-lowering drugs (2010) Drugs, 70, pp. 1363-1379; Um, M.Y., Choi, W.H., Aan, J.Y., Kim, S.R., Ha, T.Y., Protective effect of Polygonum multiflorumThunb on amyloid β-peptide 25-35 induced cognitive deficits in mice (2006) Journal of Ethnopharmacology, 104, pp. 144-148; Wang, C.F., Wu, X.D., Chen, M., Duan, W.G., Sun, L.X., Yan, M., Zhang, L.Y., Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells (2007) Toxicology, 231, pp. 120-128; Wang, C.Y., (2005) Studies on Antihyperlipidemic Effects and Pharmacokinetics of Stilbene Glycoside from Radix Polygoni Multiflori, , Hebei Medical University Shijiazhuang; Wang, C.Y., Gu, J.M., Liu, W.N., Yang, W., Zhang, L.T., Studies on pharmacokinetics and tissue distribution of stilbene glycoside in the hyperlipide miamodel rats (2009) Chinese Journal of Pharmaceutical Analysis, 29, pp. 1073-1078; Wang, H.Y., Li, S.X., Ma, Y.Z., Clinical observation of tuber fleeceflower root injection in the treatment of hair loss (2001) Journal of Traditional Chinese Medicine and Chinese Materia Medica of Jilin, 1, p. 35; Wang, J.K., Gao, Y.M., Chen, H.L., The determination of stilbene glucoside in Fleece-flower root raw product and four kinds of processed products (2004) Studies of Trace Elements and Health, 21, pp. 27-28; Wang, M.J., Zhao, R.H., Wang, W.G., Mao, X.J., Yu, J., Lipid regulation effects of Polygoni Multiflori Radix, its processed products and its major substances on steatosis human liver cell line L02 (2012) Journal of Ethnopharmacology, 139, pp. 287-293; Wang, Q.X., (2007) Study on the Toxicity and Its Mechanism Sofrhubarbandits Major Constituents, , Academy of Military Medical Sciences Beijing; Wang, Q.X., Wu, C.Q., Yang, H.L., Jing, S.F., Jin, C., Xiao, X.H., Liao, M.Y., Cytotoxicity of free anthraquinone from Radix et Rhizoma Rhei to HK-2 Cells (2007) Chinese Journal of New Drugs, 16, pp. 189-199; Wang, T., Gu, J., Wu, P.F., Wang, F., Xiong, Z., Yang, Y.J., Wu, W.N., Chen, J.G., Protection by tetrahydroxystilbene glucoside against cerebral ischemia: Involvement of JNK, SIRT1, and NF-κB pathways and inhibition of intracellular ROS/RNS generation (2009) Free Radical Biology and Medicine, 47, pp. 229-240; Wang, T., Yang, Y.J., Wu, P.F., Wang, W., Hu, Z.L., Long, L.H., Xie, N., Chen, J.G., Tetrahydroxystilbene glucoside, a plant-derived cognitive enhancer, promotes hippocampal synaptic plasticity (2011) European Journal of Pharmacology, 650, pp. 206-214; Wang, W., He, Y., Lin, P., Li, Y., Sun, R., Gu, W., Yu, J., Zhao, R., In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism (2014) Journal of Ethnopharmacology, 153, pp. 763-770; Wang, W., Sun, Y., Li, X., Li, H., Chen, Y., Tian, Y., Yi, J., Wang, J., Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression (2011) Oncology Reports, 26, pp. 1143-1148; Wang, W.J., Zhang, W.M., Dong, X.L., Zhao, R.H., Rao, G.X., Studies on chemical constituents of Polygonum multiflorun from Yunnan (2005) Journal of Yunnan College of Traditional Chinese Medicine, 28, pp. 10-12; Wang, X.L., (2012) The Study of Anti-aging Mechanism of Zishen Yigan Fang in Vivo and Vitro, , Hubei University of Chinese Medicine Wuhan; Wang, X.M., Zhao, L.B., Han, T.Z., Chen, S.F., Wang, J.L., Protective effects of 2,3,5,4′-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice (2008) European Journal of Pharmacology, 578, pp. 339-348; Way, T.D., Huang, J.T., Chou, C.H., Huang, C.H., Yang, M.H., Ho, C.T., Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the β-catenin and Akt pathways (2014) European Journal of Cancer, 50, pp. 366-378; Wu, X.M., Effect of emodin on combined hyperlipidemia familial in rats (2008) Anhui Medical and Pharmaceutical Journal, 12, pp. 1026-1028; Wu, X.Q., Chen, X.Z., Huang, Q.C., Fang, D.M., Li, G.Y., Zhang, G.L., Toxicity of raw and processed roots of Polygonum multiflorum (2012) Fitoterapia, 83, pp. 469-475; Wu, Y.W., Zhang, D.K., Yu, C.Y., Yiganning granule on liver injury animal model research of protecting liver and reducing enzyme and immune function (2001) Journal of Hunan College of Traditional Chinese Medicine, 21, pp. 14-15; Wu, Z., Zhang, M., Zhang, C.F., Wang, Z.T., Study on Quality Evaluation for 36 Samples of Radix Polygonui Multiflori by HPLC-Fingerprints (2006) Chinese Pharmaceutical Journal, 41, pp. 257-260; Xia, C.L., Li, L.X., Identification of radix polygoni multiflori and silvervine fleeceflower root (2003) LiShiZhen Medicine and Materia Medica Research, 14, p. 540; Xiang, J.H., Han, P.K., Efficacy of Qishu decoction on 120 NSCLC patients with leucopenia after-Chemotherapy experienced prescription (2013) Gansu Medical Journal, 32, pp. 171-173; Xiang, K., Liu, G., Zhou, Y.J., Hao, H.Z., Yin, Z., He, A.D., Da, X.W., Ming, Z.Y., 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside (THSG) attenuates human platelet aggregation, secretion and spreading in vitro (2014) Thrombosis Research, 133, pp. 211-217; Xiao, K., Xuan, L.J., Xu, Y.M., Bai, D.L., Novel stilbene glycosides from Polygonum multiflorum (2002) Acta Botanica Sinica, 44, pp. 1491-1494; Xiao, P.G., Xing, S.T., Wang, L.W., Immunological aspects of Chinese medicinal plants as anti-ageing drugs (1993) Journal of Ethnopharmacology, 38, pp. 167-175; Xie, W.D., Zhao, Y.N., Du, L.J., Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia (2012) Journal of Ethnopharmacology, 140, pp. 345-367; Xu, D.J., Tao, Y., Wang, S.X., Cheng, W.S., Zhong, X.F., You, B.H., Effect of high pressure processing onstilbene glycoside and phosphatidylcholine in Polygoni Multiflori Radix (2011) Chinese Traditional and Herbal Drugs, 42, pp. 78-80; Xu, G.J., (1986) Microscopic Identification of Chinese Medicinal Materials Powder, pp. 102-103. , (1986) ed. Peoples Health Publishing House Beijing, China; Xu, M.L., Zheng, M.S., Lee, Y.K., Moon, D.C., Lee, C.S., Woo, M.H., Jeong, B.S., Son, J.K., A new stilbene glucoside from the roots of Polygonum multiflorum Thunb (2006) Archives of Pharmacal Research, 29, pp. 946-951; Xu, X.L., Zhu, Q.Y., Zhao, C., Wang, F., Zhou, Z.Y., Hu, Y.E., Zhang, W., The effect of 2,3,4′,5-tetrahydroxystilbene-2-O-β-d-glucoside on pressure overload-induced cardiac remodeling in rats and its possible mechanism (2014) Planta Medica, 80, pp. 130-138; Xu, Y.L., Dong, Q., Hu, F.Z., Simultaneous quantitative determination of eight active components in Polygonum multiflorum thunb by RP-HPLC (2009) Journal of Chinese Pharmaceutical Sciences, 18, pp. 358-361; Xu, Z.H., Yi, J.J., Mechanism of the protection of stilbene glycoside which is the effective component of tuber fleece flower root on nerve cells (2013) Asia-Pacific Traditional Medicine, 9, pp. 61-62; Xue, Y.M., Ma, S., Lang, X.F., Zhang, T., Zhao, S.L., Zhao, R.H., Rao, G.X., Determination of Anthraquinone in Polygonum Multiflorum from Different Regions of Yunnan (2004) Journal of Yunnan College of Traditional Chinese Medicine, 27, pp. 42-45; Yamaguchi, A., Hiroi, T., Miyazaki, M., Synthesis of some new phydroxyphenylpropane monomer (1969) Mokuzai Gakkaishi, 15, pp. 256-261; Yan, S.L., Su, Y.F., Chen, L., Que, M., Gao, X.M., Chang, J.B., Polygonumosides A-D, stilbene derivatives from processed roots of Polygonum multiflorum (2014) Journal of Natural Products., 77, pp. 397-401; Yang, J., Song, J.F., Li, P.Y., Study on the quality standard of Chinese traditional medicine processing excipient of black bean juice (2008) China Association of Chinese Medicine - Processing Branch, pp. 281-283; Yang, P.Y., Almofti, M.R., Lu, L., Kang, H., Zhang, J., Li, T.J., Rui, Y.C., Chen, W.S., Reduction of atherosclerosisin cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum (2005) Journal of Pharmacological Sciences, 99, pp. 294-300; Yang, X.P., Liu, T.Y., Qin, X.Y., Yu, L.C., Potential protection of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside against staurosporine-induced toxicity on cultured rat hippocampus neurons (2014) Neuroscience Letters, 576, pp. 79-83; Yang, X.W., Gu, Z.M., Ma, C.M., Hattori, M., Namba, T., A New indole derivative isolated from the root of tuber fleeceflower (Polygonum multiflorum) (1998) Chinese Traditional and Herbal Drugs, 1, pp. 5-11; Yang, Y.Z., The new ingredients of Polygonum multiflorum thunb: Hydroxyl on stilbene glucoside (1976) Foreign Medical Reference. SCI, 3, p. 247; Yang, Z.X., Zhang, G.C., 48 cases of Yiganning granules in treating chronic hepatitis B (1999) Hunan Journal of Traditional Chinese Medicine, 15, p. 13; Yao, W.J., Fan, W.J., Huang, C., Zhong, H., Chen, X.F., Zhang, W., Proteomic analysis for anti-atherosclerotic effect of tetrahydroxystilbene glucoside in rats (2013) Biomedicine & Pharmacotherapy, 67, pp. 140-145; Ye, Q.H., An acute toxic hepatopathy case induced by Radix Polygoni Multiflori (1996) Chinese Journal of Integrative Medicine, 16, p. 732; Yi, T., Leung, K.S., Lu, G.H., Zhang, H., Chan, K., Identification and determination of the major constituents in traditional Chinese medicinal plant Polygonum multiflorum thunb by HPLC coupled with PAD and ESI/MS (2007) Phytochemical Analysis, 18, pp. 181-187; Yin, X.R., Gong, X., Jiang, R., Kuang, G., Wang, B., Zhang, L., Xu, G., Wan, J.Y., Emodin ameliorated lipopolysaccharide-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in d-galactosamine-sensitized mice (2014) International Immunopharmacology, 23, pp. 66-72; Yon, J.M., Lin, C., Oh, K.W., Baek, H.S., Lee, B.J., Yun, Y.W., Nam, S.Y., Emodin prevents ethanol-induced developmental anomalies in cultured mouse fetus through multiple activities (2013) Birth Defects Research B: Developmental and Reproductive Toxicology, 98, pp. 268-275; Yoshizaki, M., Fujino, H., Arise, A., Ohmura, K., Arrisawa, M., Morita, N., Polygoacetophenoside, a new acetophenone glucoside from Polygonum multiflorum 1 (1987) Planta Medica, 53, pp. 273-275; Yu, G.Q., The processing history of Polygonum multiflorum (2014) Journal of North Pharmacy, 11, pp. 63-64; Yu, J., Xie, J., Mao, X.J., Wang, M.J., Li, N., Wang, J., Zhaori, G.T., Zhao, R.H., Hepatoxicity of major constituents and extractions of Radix Polygoni Multiflori and Radix Polygoni Multiflori Praeparata (2011) Journal of Ethnopharmacology, 137, pp. 1291-1299; Yu, J.Q., Bao, W., Lei, J.C., Emodin regulates apoptotic pathway in human liver cancer cells (2013) Phytotherapy Research, 27, pp. 251-257; Yu, R.M., Zhou, L.B., Yan, C.Y., Duan, G.Y., Zhao, Y., Two new coumarin glucosides biosynthesized by transgenic hairy roots of Polygonum multiflorum (2008) Chinese Chemical Letters, 19, pp. 76-78; Yuan, X.W., Deng, Z.H., Ye, L.X., Luo, Y.C., Preparation and clinical curative effect observation of Zhentongdieda wine (2004) Journal of Chinese Medicinal Materials, 27, pp. 544-545; Zeng, C., Xiao, J.H., Chang, M.J., Wang, J.L., Beneficial effects of THSG on acetic acid-induced experimental colitis: Involvement of upregulation of PPAR-γ and inhibition of the Nf-Κb inflammatory pathway (2011) Molecules, 16, pp. 8552-8568; Zhai, R., Lv, L.S., Jin, B.Q., Hypolipidemic effect of the polysaccharide from polygonum multiflorum (2010) Food and Machinery, 26, pp. 87-101; Zhang, C.M., (2008) The Study of Effects of Buyanghuanw Pill Jiajian Fang and Madopar on Parkinsons Disease, , Shandong Traditional Chinese Medicine University Jinan; Zhang, H.Y., Shi, X.G., Analysis of rDNA ITS sequences in root tuber of Polygonum multiflorum from various habitats (2007) Chinese Traditional and Herbal Drugs, 38, pp. 911-914; Zhang, L., Li, L., Li, Y.L., Mechanism of the protection of stilbene glycoside which is the effective component of tuber fleece flower root on nerve cells (2004) Chinese Journal of Clinical Rehabilitation, 8, pp. 118-120; Zhang, L., Lin, L., Xing, Y., Effects of tetrahydroxystilbene glucoside on mapks signaltransduction pathway in APP transgenic model of Alzheimers disease (2010) Alzheimers & Dementia, 7, pp. 668-S669. , (Poster presentations); Zhang, L., Ma, W.F., Li, J., He, J., Zhang, P., Zheng, F., Zhang, B.L., Chang, Y.X., Influence of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration by LC-ESI-MS/MS (2013) Journal of Ethnopharmacology, 148, pp. 246-253; Zhang, L., Xing, Y., Ye, C.F., Ai, H.X., Wei, H.F., Li, L., Learning-memory deficit with aging in APP transgenic mice of Alzheimers disease and intervention by using tetrahydroxystilbene glucoside (2006) Behavioural Brain Research, 173, pp. 246-254; Zhang, L.L., Huang, L.H., Chen, L.W., Hao, D.J., Chen, J.Z., Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinsons disease (2013) Toxicology Letters, 222, pp. 155-163; Zhang, T., Lv, G.Y., Chen, S.H., Yu, X.J., Comparative study of pre and post processed Polygonum multiforum anthraquinones content (2009) Journal of Zhejiang Chinese Medical University, 33, pp. 872-873; Zhang, Y.L., Yang, Y.Q., Gao, Y.M., Comparison the content of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside of wild and cultivated Radix Polygoni Multiflori from different areas of Guizhou (2003) China Journal of Chinese Materia Medica, 28, pp. 786-787; Zhang, Y.Z., Shen, J.F., Xu, J.Y., Xiao, J.H., Wang, J.L., Inhibitory effects of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside on experimental inflammation and cyclooxygenase 2 activity (2007) Journal of Asian Natural Products Research, 9, pp. 355-363; Zhang, Z.G., Lv, T.S., Yao, Q.Q., Studies on the anthraquinone chemical constituents of radix Polygoni multiflori (2006) Chinese Traditional and Herbal Drugs, 37, pp. 1311-1313; Zhang, Z.G., Lv, T.S., Yao, Q.Q., Studies on the non-anthraquinone chemical constituents of radix Polygoni multiflori (2006) China Journal of Chinese Materia Mediea, 31, pp. 1027-1029; Zhang, Z.Y., Miao, M.S., Gu, L.Y., Study on the immune function influence by polysaccharide from Polygonum multiflorum Peparata in mice (2008) Traditional Chinese Medicinal Research, 21, pp. 18-19; Zhao, G.Q., Li, F.F., Li, C.G., Zhang, Y., Zeng, Y., Meng, X.L., Experimental studies on the anti-inflammatory and analgesic effects of Gou-pi plaster (2011) Pharmacy and Clinics of Chinese Materia Medica, 2, pp. 27-29; Zhao, H.N., Chen, L.L., Huang, X.J., Wang, Y., Li, Y.L., Ye, W.C., A new chromone glycoside from roots of Polygonum multiflorum (2014) China Journal of Chinese Materia Medica, 39, pp. 1441-1444; Zhao, H.Y., Xu, X.R., Chen, Y.L., Chen, H.N., Cheng, J.Y., Liu, Y., Study on the identification of radix polygoni multiflori and its adulterants of rodgersia aesculifolia (1998) ShiZhen Journal of Traditional Chinese Medicine Research, 9, pp. 147-148; Zhao, Y.L., Zhou, G.D., Yang, H.B., Wang, J.B., Shan, L.M., Li, R.S., Xiao, X.H., Rhein protects against acetaminophen-induced hepatic and renal toxicity (2011) Food and Chemical Toxicology, 49, pp. 1705-1710; Zheng, C.J., Zhao, S.J., Zhao, Z.H., Ge, J., Molecular identification of fallopia multiflora by PCR-RFLP based on rDNA ITS sequence (2009) Journal of South China University of Technology, 37, pp. 74-78; Zheng, G.H., (2010) Study on the Radix Polygoni Multiflori Pieces Quality Standards and Fingerprint, , Hubei University of Chinese Medicine Wuhan; Zhou, C.H., Effects of processing on the content of effective components in Radix Polygoni Multiflori (2005) TCM Research, 18, pp. 18-19; Zhou, L.X., Lin, M., Li, J.B., Li, S.Z., Chemical studies on the ethyl acetate insoluble fraction of the roots of Polygonum mutifloum thunb (1994) Acta Pharmaceutica Sinica, 29, pp. 107-110; Zhou, R.H., (1993) Science of Chinese Medicinal Material Resources, pp. 265-269. , Chinese Medical Science and Technology Press Beijing; Zhou, W.Q., 82 cases of Sanshen pill in treating male erectile dysfunction (2010) Chinese Medicine Modern Distance Education of China, 8, p. 176; Zhou, X.X., Yang, Q., Xie, Y.H., Sun, J.Y., Qiu, P.C., Cao, W., Wang, S.W., Protective effect of tetrahydroxystilbene glucoside against d-galactose induced aging process in mice (2013) Phytochemistry Letters, 6, pp. 372-378; Zhou, Y., Luo, C.J., Deng, Z.J., The processing history research of Radix Polygoni multiflori (2010) China Medical Herald, 7, pp. 9-10; Zhu, Q.Z., Chen, W., Zhang, L.S., Evaluation of in vitro genotoxicity of emodinanrhein (2011) Carcinogenesis,Teratogenesis, and Mutagenesis, 23, pp. 65-67; Zhu, S.M., Clinical observation of treating pregnancy constipation with Polygonum multiflorum granule therapy in 52 cases (2011) Zhejiang Journal of Traditional Chinese Medicine, 46, pp. 129-130; Zuo, Y.G., Wang, C.J., Lin, Y.J., Guo, J.W., Deng, Y.W., Simultaneous determination of anthraquinones in radix Polygoni multiflori by capillary gas chromatography coupled with flame ionization and mass spectrometric detection (2008) Journal of Chromatography A, 1200, pp. 43-48",Review,Scopus,2-s2.0-84912535919
"Trujano-Ortiz L.G., Gonzalez F.J., Quintanar L.","Redox cycling of copper-amyloid β 1-16 peptide complexes is highly dependent on the coordination mode",2015,"Inorganic Chemistry","54","1",,"4","6",,,10.1021/ic501941a,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920482228&partnerID=40&md5=585177e389f398ae25f222e02122bfb6","Departamento de Química, Centro de Investigación y de Estudios Avanzados (Cinvestav), Avenida Instituto Politecnico Nacional, 2508, San Pedro ZacatencoCiudad de México, D.F, Mexico","Trujano-Ortiz, L.G., Departamento de Química, Centro de Investigación y de Estudios Avanzados (Cinvestav), Avenida Instituto Politecnico Nacional, 2508, San Pedro ZacatencoCiudad de México, D.F, Mexico; González, F.J., Departamento de Química, Centro de Investigación y de Estudios Avanzados (Cinvestav), Avenida Instituto Politecnico Nacional, 2508, San Pedro ZacatencoCiudad de México, D.F, Mexico; Quintanar, L., Departamento de Química, Centro de Investigación y de Estudios Avanzados (Cinvestav), Avenida Instituto Politecnico Nacional, 2508, San Pedro ZacatencoCiudad de México, D.F, Mexico","Copper (Cu)-amyloid β (Aβ) interactions play a role in the etiology of Alzheimers disease. This work presents a spectroscopic and electrochemical study of two physiologically relevant Aβ-CuII complexes, as a function of pH and relative Cu-Aβ(1-16) concentrations. Our results reveal that these coordination modes display distinct redox behaviors and provide experimental evidence for the existence of an intermediate CuI species. A mechanism for the redox cycling of these complexes is proposed, providing further insight into the redox relevance of Aβ-Cu interactions. © 2014 American Chemical Society.",,"Glenner, G.G., Wong, C.W., (1984) Biochem. Biophys. Res. Commun., 120, pp. 885-890; Bush, A.I., (2003) Trends Neurosci., 26, pp. 207-214; Kozlowski, H., (2009) Coord. Chem. Rev., 253, pp. 2665-2685; Faller, P., (2014) Acc. Chem. Res., 47, pp. 2252-2259; Karr, J.W., (2004) J. Am. Chem. Soc., 126, pp. 13534-13538; Hureau, C., (2012) Coord. Chem. Rev., 256, pp. 2164-2174; Hureau, C., Dorlet, P., (2012) Coord. Chem. Rev., 256, pp. 2175-2187; Alies, B., (2013) Anal. Chem., 85, pp. 1501-1508; Alies, B., (2011) Inorg. Chem., 50, pp. 1192-11201; Balland, V., (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 17113-17118; Jiang, D., (2007) Biochemistry, 46, pp. 9270-9282; Bonomo, R.P., (2000) Chem. - Eur. J., 6, pp. 4195-4202; Zhou, F., Milhauser, G.L., (2012) Coord. Chem. Rev., 256, pp. 2285-2296; Alí-Torres, J., (2014) J. Phys. Chem. B, 118, pp. 4840-4850; Quintanar, L., (2013) Coord. Chem. Rev., 257, pp. 429-444; Rivillas-Acevedo, L., (2011) Inorg. Chem., 50, pp. 1956-1972; Hureau, C., (2009) J. Biol. Inorg. Chem., 14, pp. 995-1000; Shearer, J., (2010) Chem. Commun., 46, pp. 9137-9139; Shearer, J., Szalai, V.A., (2008) J. Am. Chem. Soc., 130, pp. 17826-17835; Furlan, S., (2012) J. Phys. Chem. B, 116, pp. 11899-11910; Que, E.L., (2008) Chem. Rev., 108, pp. 1517-1549; Scheiber, I.F., (2014) Prog. Neurobiol., 116, pp. 33-57; Alies, B., (2012) Inorg. Chem., 51, pp. 12988-13000; Yates, C.M., (1990) J. Neurochem., 55, pp. 1624-1630",Article,Scopus,2-s2.0-84920482228
"Schutz A.K., Vagt T., Huber M., Ovchinnikova O.Y., Cadalbert R., Wall J., Guntert P., Bcockmann A., Glockshuber R., Meier B.H.","Atomic-resolution three-dimensional structure of amyloid b fibrils bearing the osaka mutation",2015,"Angewandte Chemie - International Edition","54","1",,"331","335",,1,10.1002/anie.201408598,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920175943&partnerID=40&md5=3b5dd4feada7bce96e2e345e23c69d7b","Physical Chemistry, ETZ Zürich, Vladimir-Prelog-Weg 2Zurich, Switzerland; Institute of Molecular Biology and Biophysics, ETH Zurich, Otto-Stern-Weg 5Zurich, Switzerland; Brookhaven National Laboratory, Building 463, 50 Bell AvenueUpton, NY, United States; Institute of Biophysical Chemistry, Center for Biomolecular Magnetic Resonance, Goethe University Frankfurt am Main, Germany; Institut de Biologie et Chimie des Protéines, UMR 5086 CNRS, Université de Lyon, 7 passage du VercorsLyon, France","Schütz, A.K., Physical Chemistry, ETZ Zürich, Vladimir-Prelog-Weg 2Zurich, Switzerland; Vagt, T., Institute of Molecular Biology and Biophysics, ETH Zurich, Otto-Stern-Weg 5Zurich, Switzerland; Huber, M., Physical Chemistry, ETZ Zürich, Vladimir-Prelog-Weg 2Zurich, Switzerland; Ovchinnikova, O.Y., Institute of Molecular Biology and Biophysics, ETH Zurich, Otto-Stern-Weg 5Zurich, Switzerland; Cadalbert, R., Physical Chemistry, ETZ Zürich, Vladimir-Prelog-Weg 2Zurich, Switzerland; Wall, J., Brookhaven National Laboratory, Building 463, 50 Bell AvenueUpton, NY, United States; Güntert, P., Institute of Biophysical Chemistry, Center for Biomolecular Magnetic Resonance, Goethe University Frankfurt am Main, Germany; Bcöckmann, A., Institut de Biologie et Chimie des Protéines, UMR 5086 CNRS, Université de Lyon, 7 passage du VercorsLyon, France; Glockshuber, R., Institute of Molecular Biology and Biophysics, ETH Zurich, Otto-Stern-Weg 5Zurich, Switzerland; Meier, B.H., Physical Chemistry, ETZ Zürich, Vladimir-Prelog-Weg 2Zurich, Switzerland","Despite its central importance for understanding the molecular basis of Alzheimers disease (AD), high-resolution structural information on amyloid β-peptide (Aβ) fibrils, which are intimately linked with AD, is scarce. We report an atomic-resolution fibril structure of the Aβ1-40 peptide with the Osaka mutation (E22Δ), associated with early-onset AD. The structure, which differs substantially from all previously proposed models, is based on a large number of unambiguous intra- and intermolecular solid-state NMR distance restraints. © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA,Weinheim.","Alzheimer's disease; Amyloids; Solid-state nmr spectroscopy; Structure elucidation","Hardy, J., Selkoe, D., (2002) Science, 297, pp. 353-356; Hardy, J., Higgins, G., (1992) Science, 256, pp. 184-185; Wasmer, C., Lange, A., Van Melckebeke, H., Siemer, A.B., Riek, R., Meier, B.H., (2008) Science, 319, pp. 1523-1526; Van Melckebeke, H., Wasmer, C., Lange, A., Ab, E., Loquet, A., Bcöckmann, A., Meier, B.H., (2010) J. Am. Chem. Soc., 132, pp. 13765-13775; Fitzpatrick, A.W.P., Debelouchina, G.T., Bayro, M.J., Clare, D.K., Caporini, M.A., Bajaj, V.S., Jaroniec, C.P., Müller, S.A., (2013) Proc. Natl. Acad. Sci. USA, 110, pp. 5468-5473; Tycko, R., Wickner, R.B., (2013) Acc. Chem. Res., 46, pp. 1487-1496; Petkova, A., Ishii, Y., Balbach, J., Antzutkin, O., Leapman, R., Delaglio, F., Tycko, R., (2002) Proc. Natl. Acad. Sci. USA, 99, pp. 16742-16747; Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., Riek, R., (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 17342-17347; Bertini, I., Gonnelli, L., Luchinat, C., Mao, J., Nesi, A., (2011) J. Am. Chem. Soc., 133, pp. 16013-16022; Paravastu, A.K., Leapman, R.D., Yau, W.-M., Tycko, R., (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 18349-18354; Ahmed, M., Ovchinnikova, O.Y., Laganowsky, A., Finder, V.H., Davis, J., Liu, C., Aucoin, D., Sato, T., (2010) Nat. Struct. Mol. Biol., 17, pp. 561-567; Lopez Del Amo, J.-M., Schmidt, M., Fink, U., Dasari, M., Fändrich, M., Reif, B., (2012) Angew. Chem. Int. Ed., 51, pp. 6136-6139; (2012) Angew. Chem., 124, pp. 6240-6243; Petkova, A., Yau, W., Tycko, R., (2006) Biochemistry, 45, pp. 498-512; Lu, J.-X., Qiang, W., Yau, W.-M., Schwieters, C.D., Meredith, S.C., Tycko, R., (2013) Cell, 154, pp. 1257-1268; Niu, Z., Zhao, W., Zhang, Z., Xiao, F., Tang, X., Yang, J., (2014) Angew. Chem. Int. Ed., 53, pp. 9294-9297; (2014) Angew. Chem., 126, pp. 9448-9451; Qiang, W., Yau, W.-M., Luo, Y., Mattson, M.P., Tycko, R., (2012) Proc. Natl. Acad. Sci. USA, 109, pp. 4443-4448; Guo, J.L., Covell, D.J., Daniels, J.P., Iba, M., Stieber, A., Zhang, B., Riddle, D.M., Trojanowski, J.Q., (2013) Cell, 154, pp. 103-117; Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P.H., Habenstein, B., Madiona, K., Meier, B.H., (2013) Nat. Commun., 4, p. 2575; Toyama, B.H., Kelly, M.J.S., Gross, J.D., Weissman, J.S., (2007) Nature, 449, pp. 233-237; Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Ataka, S., (2008) Ann. Neurol., 63, pp. 377-387; Ovchinnikova, O.Y., Finder, V.H., Vodopivec, I., Nitsch, R.M., Glockshuber, R., (2011) J. Mol. Biol., 408, pp. 780-791; Inayathullah, M., Teplow, D.B., (2011) Amyloid, 18, pp. 98-107; Huber, M., Ovchinnikova, O.Y., Schütz, A.K., Glockshuber, R., Meier, B.H., Bcöckmann, A., (2014) Biomol. NMR Assignments; Lange, A., Luca, S., Baldus, M., (2002) J. Am. Chem. Soc., 124, pp. 9704-9705; De Paepe, G., Lewandowski, J.R., Loquet, A., Bcöckmann, A., Griffin, R.G., (2008) J. Chem. Phys., 129, p. 245101; De Paepe, G., Lewandowski, J.R., Loquet, A., Eddy, M., Megy, S., Bcöckmann, A., Griffin, R.G., (2011) J. Chem. Phys., 134, p. 095101; Takegoshi, K., Nakamura, S., Terao, T., (2003) J. Chem. Phys., 118, pp. 2325-2341; Güntert, P., Mumenthaler, C., Wüthrich, K., (1997) J. Mol. Biol., 273, pp. 283-298; Shen, Y., Delaglio, F., Cornilescu, G., Bax, A., Biomol, J., (2009) NMR, 44, pp. 213-223; Tycko, R., (2011) Annu. Rev. Phys. Chem., 62, pp. 279-299; Spirig, T., Ovchinnikova, O.Y., Vagt, T., Glockshuber, R., (2014) Neurodegenerative Diseases, 14, pp. 151-159; Schütz, A.K., Soragni, A., Hornemann, S., Aguzzi, A., Ernst, M., Bcöckmann, A., Meier, B.H., (2011) Angew. Chem. Int. Ed., 50, pp. 5956-5960; (2011) Angew. Chem., 123, pp. 6078-6082",Article,Scopus,2-s2.0-84920175943
"Heinonen T., Gaus W.","Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract",2015,"Toxicology","327",,,"95","115",,1,10.1016/j.tox.2014.10.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84916624177&partnerID=40&md5=4c5b5beea9d5c1e82bffef2075e84f7b","School of Medicine, University of Tampere, Medisiinarin katu 3, Finland; Institute for Epidemiology and Biometry, Medical Faculty, University of Ulm, Germany","Heinonen, T., School of Medicine, University of Tampere, Medisiinarin katu 3, Finland; Gaus, W., Institute for Epidemiology and Biometry, Medical Faculty, University of Ulm, Germany","Ginkgo biloba is one of the most widely used herbal remedies in Europe and the US. It may be purchased in different types of formulations, but most of the clinical studies have been performed with the controlled G. biloba extract EGb761®. Indications include Alzheimers disease, cardiovascular disease, dementia, memory loss, and cerebral ischemia. The pharmacological modes of action cover antioxidant effects, radical scavenging, inhibition of platelet activating factor, alterations in membrane fluidity (signal transduction), and inhibition of glucocorticoid synthesis. Due to the widespread and long-term use of G. biloba - about a million doses of EGb761® are sold per day - tolerability and safety are a crucial issue. Based on broad and long-term clinical use of G. biloba extracts, it is regarded as well tolerated in man.Cross matching, a tool we introduced, combines different fields of knowledge and types of data to a consolidated result. In this article, we combine toxicological and clinical data and utilize other sources of information to assess tolerability and safety of G. biloba. It is well known that because of biological differences between animals and man or even between animal species, animal experiments do not necessarily mimic the effects in humans. Therefore, for adequate risk assessment, the relevance of non-clinical toxicological findings should be correlated with human data. The cross matching of toxicological data and results from clinical studies is possible because many toxicological and clinical studies are available on G. biloba. We give an in depth analysis of the modes of action in animals and describe toxicological studies with regard to metabolism, pharmacokinetics, genotoxicity, as well as carcinogenicity (e.g., the Technical Report TR 578 of the US National Toxicology Program). In addition, 75 clinical trials with high methodological quality are summarized. They included a total of 7115 patients treated with G. biloba. Based on this extensive amount of information, the broad variety of investigations, and their accordance we conclude that G. biloba extract is well tolerated and safe for humans. © 2014 The Authors.","Adverse drug reaction; Carcinogenicity; Clinical studies; Cross matching; EGb761®, CAS 122933-57-7; Ginkgo biloba","Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Bethem, J., Zuang, V., Andersen, K.E., Zaldivvar, J.-M., Alternative (non animal) methods for cosmetics testing: current status and future prospects - 2010 (2011) Arch. Toxicol., 85 (5), pp. 367-485; Altmann, D.G., Bland, J.M., Statistics notes: absence of evidence is not evidence of absence (1995) BMJ, 311, p. 485. , http://dx.doi.org/10.1136/bmj.311.7003.485; Amieva, H., Meillon, C., Helmer, C., Barberger-Gateau, P., Dartigues, J.F., Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study (2013) PloS One, 8 (1), p. e52755; Arrigo, A., Cattaneo, S., Clinical and psychometric evaluation of Ginkgo biloba extract in chronic cerebro-vascular diseases (1985) Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment, pp. 85-89. , John Libbey Eurotext Ltd., London, Paris, A. Agnoli, J.R. Rapin, V. Scapagnini, W.V. Weitbrecht (Eds.); Arrigo, A., Behandlung der chronischen zerebrovascularen Insuffizienz mit Ginkgo biloba-Extrakt [Treatment of chronic cerebrovascular insufficency with Ginkgo biloba extract] (1986) Therapiewoche, 36, pp. 5208-5218; Arrowsmith, J., Miller, P., Trial watch: phase II and phase III attrition rates 2011-2012 (2013) Nat. Rev. Drug Discov., 12 (8), p. 569; Attia, A., Rapp, S.R., Case, L.D., D'Agostino, R., Lesser, G., Naughton, M., McMullen, K., Shaw, E.G., Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood (2012) J. Neurooncol., 109 (2), pp. 357-363; Augustin, P., Tanakan en geriatrie. Etude Clinique et psychometrique chez 189 malades d'hospice [Tanakan in geriatric medicine. Clinical and psychometric study in 189 patients in a long stay ficility] (1976) Psychol. Med., 8, pp. 123-130; Bachinskaya, N., Hörr, R., Ihl, R., Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb761. Findings from a randomized controlled trial (2011) Neuropsych. Dis. Treat., 7, pp. 209-215; Barton, D.L., Burger, K., Novotny, P.J., Fitch, T.R., Kohli, S., Soori, G., Wilwerding, M.B., Loprinzi, C.L., The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 (2013) Support Care Cancer, 21, pp. 1185-1192; Basketter, D.A., Clewell, H., Kimber, I., Rossi, A., Blaauboer, B., Burrier, R., Daneshian, M., Hartung, T., A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing-t3 report (2012) Altex, 29 (1), pp. 3-91; Bauer, U., 6-month double blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency (1984) Arzneimittelforschung/Drug Res., 34 (6), pp. 716-720; Beer, S., Komatsubara, K., Bellowin, D.I., Kurobe, M., Sylvester, K., Felsher, D.W., Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis (2008) PloS One, 3, p. e2493; Bhagwat, S., Haytowitz, D.B., Holden, J.M., (2011) USDA Database for the Flavonoid Content of Selected Foods, , http://www.ars.usda.gov/nutrientdata, U.S. Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Nutrient Data Laboratory 10300, Baltimore, Release 3; Bibber, A., Koch, E., Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS (1999) Planta Med., 65 (2), pp. 192-193; Biggs, M.L., Sorkin, B.C., Nahin, R.L., Kuller, L.H., Fitzpatrick, A.L., Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo evaluation of memory (GEM) study (2010) Pharmacoepidem. Drug Safety, 19, pp. 694-698; Birks, J., Grimley-Evans, J., Ginkgo biloba for cognitive impairment and dementia (2009) Cochrane database Syst. Rev., , arxiv:/CD003120; Bischoff, S.C., Quercetin: potentials in the prevention and therapy of disease (2008) Curr. Opin. Clin. Nutr. Metab. Care, 11 (6), pp. 733-740; Blume, J., Kieser, M., Hölscher, U., Placebokontrollierte Blindstudie zur Wirksamkeit von Ginkgo biloba-Spezialextrakt EGb761 bei austrainierten Patienten mit claudicatio intermittens [Placebo controlled blind study on efficacy of Ginkgo biloba special extract EGb761 in trained patients with claudication intermittens] (1996) Eur. J. Vascular Med. (VASA), 25, pp. 265-274; Blume, J., Kieser, M., Hölscher, U., Ginkgo-Spezialextract EGb761 bei pAVK [Ginkgo special extract EGb761 for peripheral arterial occlusive disease] (1998) Fortschr. Med., 116 (35-36), pp. 36-37; Boiko, A.N., Lebedeva, A.V., Shchukin, I.A., Soldatov, M.A., Ismailov, A.M., Shykhkerimov, R.K., Otcheskaya, O.V., Khozova, A.A., Possibilities of medical correction of moderate cognitive impairment (2013) J. Neurol. Psych., 2, pp. 28-32. , (English Translation of the Russian Journal); Boots, A.W., Kubben, N., Haenen, R.M.M., Bast, A., Oxidized quercetin reeacht with thiols rather thant with ascorbate: implication for quercetin supplementation (2003) Biochem. Biophys. Res. Commun., 308, pp. 560-565; Brüchert, E., Heinrich, S.E., Ruf-Kohler, P., Wirksamkeit von LI 1370 bei älteren Patienten mit Hirnleistungsschwäche. Multizentrische Doppelblindstudie des Fachverbands Deutscher Allgemeinärzte [Efficacy of LI 1370 in elderly patients with mild dementia. Multicenter double-blind study of the German Association of General Practitioners] (1991) Münch. Med. Wschr., 133 (1), pp. 9-14; Brautigam, M.R.H., Blommaert, F.A., Verleye, G., Castermans, J., Steur, E.N.H.J., Kleijnen, J., Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized placebo-controlled study (1998) Phytomedicine, 5, pp. 425-434; Bredie, S.J.H., Jong, M.C., No significant effect of Ginkgo biloba special extract EGb761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial (2012) J. Cardiovasc. Pharm., 59, pp. 215-221; Bulling, B., Bary von, S., Behandlung der chronischen peripheren arteriellen Verschlusskrankheit mit physikalischem Training und Ginkgo biloba-extrakt 761 [Treatment of chronical peripheral arterial occlusive disease with physical training and Ginkgo biloba extract 761] (1991) Med. Welt, 42, pp. 702-708; Chang, T.K.H., Chen, J., Yeung, E.Y.H., Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP 1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP 1B1 (2006) Toxicol. Appl. Pharm., 213, pp. 18-26; Chang, Y.-C., Tsai, M.-H., Sheu, W.H.-H., Hsieh, S.-C., Chiang, A.-N., The therapeutic potential and mechanisms of action of quercetin in relation to lipopolysaccharide-induced sepsis in vitro and in vivo (2013) PLoS One, , November 19; Chartres, J.-P., Bonnan, P., Martin, G., Réduction de posologie de médicaments psychotropes chez des personnes âgées vivant en institution. Etude à double-insu chez des patients prenant soit de l'extrait de Ginkgo biloba 761 soit du placebo [Reduction of the dosage of psychotropic drugs in elderly institutionalised peop (1987) Psychol. Méd., 19, pp. 1365-1375; Choksi, N.Y., Jahnke, G.D., Hilaire, C., Shelby, M., Role of thyroid hormones in human and laboratory animal reproductive health (2003) Birth Defects Res. B, 68, pp. 479-491; Dardano, A., Ballardin, M., Ferdeghini, M., Lazzeri, E., Traino, C., Caraccio, N., Mariani, G., Monzani, F., Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy (2007) J. Clin. Endocrinol. Metab., 92, pp. 4286-4289; Dardano, A., Ballardin, M., Caraccio, N., Boni, G., Traino, C., Mariani, G., Ferdeghini, M., Monzani, F., The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131 (2012) Thyroid, 22 (3), pp. 318-324; De Feudis, F.V., Drieu, K., Ginkgo biloba extract (EGb761) and CNS functions: basic studies and clinical applications (2000) Curr. Drug Target, 1, pp. 25-58; DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Ginkgo biloba for prevention of dementia: a randomized controlled trial (2008) JAMA, 300 (19), pp. 2253-2262; DeVries, J.H.M., Janssen, P., Hollman, P.C.H., vanStaveren, W.A., Katan, M.B., Consumption of quercetin and kaempferol in free-living subjects eating a variety of diets (1997) Cancer Lett., 114, pp. 141-144; Deng, Y., Bi, H.-C., Zhao, L.-Z., He, F., Liu, Y.-Q., Yu, J.-J., Ou, Z.-M., Zhou, S.-F., Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb761 in rats (2008) Xenobiotica, 38 (5), pp. 465-481; Diamond, B.J., Bailey, M.R., Ginkgo biloba. Indications, mechanisms and safety (2013) Psych. Clin. North Am., 36, pp. 73-83; Diehm, C., Heinrich, F., Mörl, H., Placebokontrollierte, multizentrische, randomisierte, doppelblinde Pilotstudie zur Prüfung der Wirksamkeit des Ginkgo biloba-Extrakts EGb761 bei Patienten mit peripherer arterieller Verschlusskrankheit im Stadium IIb nach Fontaine (1990), [Placebo-controlled, multicentre, randomised, double-blind pilot study examining the effectivemess of Ginkgo biloba extract EGb761 in patients with Fontaine stage IIb peripheral arterial disease]. Internal Report. Dr. Willmar Schwabe GmbH & Co. KGDrabæk, H., Petersen, J.R., Wiinberg, N., Winter-Hansen, K.F., Mehlsen, J., Effekten af Ginkgo biloba-ekstrakt hos patienter med claudicatio intermittens [Effect of Ginkgo biloba extract on lower limb symptoms and cognitive function in patients with intermittent claudication] (1996) Ugeskr Læger, 158, pp. 3928-3931; Drew, S., Davies, E., Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial (2001) BMJ, 322, pp. 73-75; DuPont, M.S., Day, R.N., Bennett, R.N., Mellon, F.A., Kroon, P.A., Absorption of kaempferol from endlive, a source of kaempferol-3-glucuronide, in humans (2004) Eur. J. Clin. Nutr., 58, pp. 947-954; Duarte, S.I., Rodrigues, A.S., Gaspar, J., Maia, R., Laires, A., Rueff, J., Involvement of rat cytochrome 1A1 in the biotransformation of kaempferol to quercetin: relevance to the genotoxicity of kaempferol (1997) Mutagenesis, 12, pp. 383-390; Duche, J.C., Barre, J., Guonot, P., Duchier, J., Cournot, A., Tillement, J.P., Effect of Ginkgo biloba extract on microsomal enzyme induction (1989) Int. J. Clin. Pharm. Res., 9, pp. 165-168; Eckmann von, F., Schlag, H., Kontrollierte doppelblindstudie zum wirksamkeitsnachweis von Tebonin forte bei patienten mit zerebrovaskulärer insuffizienz [Controlled double-blind study to prove efficacy of Tebonin forte in patients with cerebral insufficiency] (1982) Fortschr. Med., 100, pp. 1474-1478; Eckmann von, F., Hirnleistungsstörungen-Behandlung mit Ginkgo biloba-Extrakt. Zeitpunkt des Wirkungseintritts in einer Doppelblindstudie mit 60 stationären Patienten [Cerebral insufficiency-treatment with Ginkgo biloba extract. Time of onset of effect in a double-blind study with 60 inpatients] (1990) Fortschr. Med., 108, pp. 557-560; (2014) Assessment report on Ginkgo biloba L., folium. European Medicines Agency.; Emerit, I., Oganesian, N., Sarkisian, T., Arutyunyan, R., Pogosian, A., Asrian, K., Levi, A., Cernjavski, L., Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract (1995) Radiat. Res., 144, pp. 198-205; Emerit, I., Alaoui-Youssefi, A., Cernjavski, L., Levy, A., Oganessian, N., Pogossian, A., Arutyunyan, R., Sarkisian, T., Ginkgo biloba extract (EGb761) and adaption to radiation (1997) Advantages in Ginkgo biloba Extract Research. Adaptive effects of Ginkgo biloba Extract (EGb761), 6, pp. 21-29. , Elsevier, Paris; Ginkgo folium; Ginkgo leaf (2003) ESCOP Monographs, pp. 178-210. , Thieme-Verlag; Ginkgo dry extract, refined and quantified (2008), pp. 3461-3463. , Monograph 6.1.Evans, J.R., Ginkgo biloba extract for age-related macular degeneration (2013) Cochrane Database Syst. Rev., , arxiv:/CD001775; Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers (2005) U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Pharmacology and Toxicology.; Fies, P., Dienel, A., Ginkgoextrakt bei eingeschränktem Sehvermögen-Behandlung mit dem Spezialextrakt EGb761 bei Beeinträchtigung aufgrund seniler trockener Makuladegeneration [Extract of Ginkgo for reduced sight - Treatment of senile macula degeneration with the special extract EGb761] (2002) Wien. Med. Wochenschr., 152, pp. 423-426; Findlay, K.A.B., Kaptein, E., Visser, T.J., Burchell, B., Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man (2000) J. Clin. Endocrinol. Metab., 85 (8), pp. 2879-2883; Fourtillan, J.B., Brisson, A.M., Girault, J., Ingrand, I., Decourt, J.P., Drieu, K., Jouenne, P., Biber, A., Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb761) (1995) Therapie, 50 (2), pp. 137-144; Fowler, P., Smith, K., Young, J., Jeffrey, L., Kirkland, D., Pfuhler, S., Carmichael, P., Reduction of misleading (false) positive results in mammalian cellm genotoxicity assays. I. Choice of cell type (2012) Mutat. Res., 742, pp. 11-25; Gardner, C.D., Taylor-Piliae, R.E., Kiazand, A., Nicholus, J., Rigby, A.J., Farquhar, J.W., Effect of Ginkgo biloba (EGb761) on treadmill walking time among adults with peripheral artery disease (2008) J. Cardiopulm. Rehabil., 28, pp. 258-265; Garg, R.K., Nag, D., Agrawal, A., A double blind placebo controlled trial of Ginkgo biloba extract in acute cerebral ischaemia (1995) J. Assoc. Phys. I (JAPI), 43, pp. 760-763; Gaudineau, C., Beckerman, R., Welbourn, S., Auclair, K., Inhibition of human P-450 enzymes by multiple constituents of the Ginkgo biloba extract (2004) Biochem. Biophys. Res. Commun., 318, pp. 1072-1078; Gavrilova, S.I., Preuss, U.W., Wong, J.W.M., Hörr, R., Kaschel, R., Bachinskaya, N., Efficacy and safety of Ginkgo biloba extract EGb761 in mild cognitive impairment with neuropsychiatric symptoms: a randomised, placebo-controlled, double-blind, multi-center trial (2014) Int. J. Geriatr .Psych.; Graessel, E., Einfluss von Ginkgo biloba Extrakt auf die geistige Leistungsfähigkeit. Doppelblindstudie unter computerisierten Messbedingungen bei patienten mit Zerebralinsuffizienz [Effect of Ginkgo biloba extract on mental performance. Double-blind study using computerized measurements conditions in patients with cerebral insufficiency] (1992) Fortschr. Med., 110, pp. 73-76; Guo, L., Mei, N., Liao, W., Chan, P.-C., Fu, P., Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and myc-centered network (2010) OMICS, 14 (1), pp. 75-90; Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Cui, Y., Ang, C.Y., Cytochrome P-450 phenotypic ratios for predicting herb-drug interactions in humans (2002) Clin. Pharmacol. Ther., 72 (3), pp. 276-287; Haan, J., Hörr, R., Delay in progression of dependency and need of care of care of dementia patients treated with Ginkgo biloba extract EGb761 (2004) Wien. Med. Wochenschr., 154, pp. 511-514; Haase, J., Halama, P., Hörr, R., Wirksamkeit kurzdauernder Infusionsbehandlungen mit Ginkgo biloba-Spezialextrakt EGb761 bei Demenz vom vaskularen und Alzheimer-Typ [Effectiveness of brief infusions with Ginkgo biloba special extract EGb761 in dementia of the vascular and Alzheimer type] (1996) Z. Gerontol. Geriatr., 29, pp. 302-309; Halama, P., Bartsch, G., Meng, G., Hirnleistungsstörungen vascularer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo biloba-Extrakt [Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Ginkgo biloba extract] (1988) Fortschr. Med., 106 (19), pp. 408-412; Halama, P., Bartsch, G., Meng, G., Cerebrovascular insufficiency - placebo-controlled, randomized, double blind-trial on the effect of Ginkgo biloba-extract (1988) Fortschr. Med., 106 (19), pp. 54-60; Hartmann, A., Frick, M., Wirkung eines Ginkgo-spezial-Extrakts auf psychometrische Parameter bei Patienten mit vascular bedingter Demenz [The effectiveness of a Ginkgo special extract on psychometric parameters for patients with vascular dementia] (1991) Münch. Med. Wochenschr., 133, pp. 23-25; Harwood, M., Danielewska-Nikiel, B., Borzelleca, J.F., Flamm, G.W., Williams, G.M., Lines, T.C., A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties (2007) Food Chem. Tox., 45, pp. 2179-2205; Hasanzadeh, E., Mohammadi, M.-R., Ghanizadeh, A., Rezazadeh, S.-A., Tabrizi, M., Rezaei, F., Akhondzadeh, S., A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders (2012) Child Psychiat. Human Dev., 43, pp. 674-682; Heinonen, T., Louekari, K., Tähti, H., Need for harmonized strategies and improved. Assessment of carcinogenic and genotoxic potencies of chemical substances (2014) J. Transl. Toxicol., 1 (1), pp. 76-87; Hellum, B.H., Hu, Z., Nilsen, O.G., The induction of CYP 1A2, CYP 2D6 and CYP 3A4 by six trade herbal products in cultured primary human hepatocytes (2007) Basic Clin. Pharmacol., 100, pp. 23-30; Herrschaft, H., Nacu, A., Likhachev, S., Sholomov, I., Hörr, R., Schlaefke, S., Ginkgo biloba extract EGb761 in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240mg (2012) J. Psychiat. Res., 46, pp. 716-723; Heywood, R., Clinical toxicity-could it have been predicted? Post-marketing experience (1990) Animal Toxicity Studies: Their Relevance for Man, pp. 57-67. , Quay, Lancaster, C.E. Lumley, S. Walker (Eds.); Hill, R.N., Crisp, T.M., Hurley, P.M., Rosenthal, S.L., Singh, D.V., Risk assessment of thyroid follicular cell tumors (1998) Environ. Health Perspect., 106 (8), pp. 447-457; Hilton, M.P., Zimmermann, E.F., Hunt, W.T., Ginkgo biloba for tinnitus (2013) Cochrane Database Syst. Rev., , arxiv:/CD003852; Hoenerhoff, M.J., Pandiri, A.R., Snyder, S.A., Hong, H.-H.L., Ton, T.-V., Peddada, S., Shockeley, K., Sills, R.C., Hepatocellular carcinomas in B6C3F1 mice treated with Ginkgo biloba extract for two years differ from spontaneous liver tumors in cancer gene mutations and genomic pathways (2013) Toxicol. Pathol., 41 (6), pp. 826-841; Hofferberth, B., Einfluss von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Messergebnisse bei Patienten mit hirnorganischem Psychosyndrom. Eine Doppelblindstudie gegen Placebo [Effect of Ginkgo biloba extract on neurophysiological and psychometric measurements results in patients with psychotic organic brain syndrome. A double-blind study against placebo] (1989) Arzneimittelforschung, 39, pp. 918-922; Hofferberth, B., Ginkgo biloba-Spezialextrakt bei Patienten mit hirnorganischem Syndrom. Prüfung der Wirksamkeit mit neurophysiologischen und psychometrischen Methoden [Ginkgo biloba special extract treatment in patients with cerebro-organic syndrome. Study on the efficacy with neurophysiological and psychometrical methods] (1991) Münch. Med. Wochenschr., 133, pp. 30-33; Hofferberth, B., The efficacy of EGb761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation (1994) Human Psychopharmacol., 9, pp. 215-222; Hollman, P.C.H., Katan, M.B., Dietary favonoids: intake, health effects and bioavailability (1999) Food Chem. Toxicol., 37, pp. 937-942; Hollman, P.C.H., van Trijp, J.M.P., Buysman, M., van der Gaag, M.S., Mengelers, M.J.B., deVries, J.H.M., Katan, M.B., Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man (1997) FEBS Lett., 418, pp. 152-156; Hood, A., Liu, Y.P., Gattone, V.H., Klaassen, C.D., Sensitivity of thyroid gland growth to thyroid stimulating hormone (TSH) in rats treated with antithyroid drugs (1999) Toxicol. Sci., 49 (2), pp. 263-271; Hood, A., Allen, M.L., Liu, Y., Liu, J., Klaassen, C.D., Induction of T4 UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers (2003) Toxicol. Appl. Pharm., 188 (1), pp. 6-13; Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances (1999) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 73, pp. 498-515. , IARC, Paris, France; ICH harmonised tripartite guideline. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1), Step 4 (2011) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; Ihl, R., Bachinskaya, N., Korczyn, A.D., Vakhapova, V., Tribanek, M., Hörr, R., Napryeyenko, O., Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb761 in dementia with neuropsychiatric features (2011) Int. J. Geriatr. Psychiat., 26, pp. 1186-1194; Israël, L., Dell'Accio, E., Martin, G., Hugonot, R., Extrait de Ginkgo biloba et exercises d'entrainement de la memoire. Evaluation comparative chez des personnes agees ambulatories [Ginkgo biloba extract and exercises for memory training. A comparative evaluation with elderly ambulatory persons] (1987) Psychol. Mëd., 19, pp. 1431-1439; Issing, W., Klein, P., Weiser, M., The homeopathic preparation Vertigoheel® versus Ginkgo biloba in the treatment of vertigo in an elderly population: a double-blinded, randomized, controlled clinical trial (2005) J. Altern. Complement. Med., 11, pp. 155-160; Jancova, P., Anzenbacher, P., Anzenbacherova, E., Phase II drug metabolizing enzymes (2010) Biomed. Papers Med. Fac. Univ. Palacky Olomouc Czech. Repub., 154 (2), pp. 103-116; Joseph, P., Long, D.J., Klein-Szanto, A.J., Jaiswal, A.K., Role of NAD(P)H:quinone oxidoreductase I (DT diaphorase) in protection against quinone toxicity (2000) Biochem. Pharmacol., 60 (2), pp. 207-2014; Kade, F., Miller, W., Dose-dependent effects of Ginkgo biloba extract on cerebral, mental and physical efficiency-a placebo controlled double blind study. (1993)Kanowski, S., Hörr, R., Ginkgo biloba extract EGb761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial (2003) Pharmacopsychiatry, 36 (6), pp. 297-303; Kanowski, S., Herrmann, W.M., Stephan, K., Wierich, W., Hörr, R., Proof of efficacy of the Ginkgo biloba special extract EGb761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia (1996) Pharmacopsychiatry, 29 (2), pp. 47-56; Kiewert, C., Kumar, V., Hildmann, O., Rueda, M., Hartmann, J., Naik, R.S., Klein, J., Role of GABAergic antagonism in the neuroprotective effects of bilobalide (2007) Brain Res., 1128 (1), pp. 70-78; Klaassen, C.D., Hood, A.M., Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism (2001) Toxicol. Pathol., 29 (1), pp. 34-40; Klepser, T.B., Klepser, M.E., Unsafe and potentially safe herbal therapies (1999) Am. J. Health Syst. Pharm., 56, pp. 125-138; Knight, A., Bailey, J., Balcombe, J., Animal carcinogenicity studies: 1. Poor human predictivity (2006) Altern. Lab. Anim., 34, pp. 19-27; Kressmann, S., Muller, W.E., Blume, H.H., Pharmaceutical quality of different Ginkgo biloba brands (2002) J. Pharm. Pharmacol., 54, pp. 661-669; Lacarelle, B., Rahmani, R., de Sousa, G., Durand, A., Placidi, M., Cano, J.P., Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes (1991) Fund. Clin. Pharmacol., 5 (7), pp. 567-582; Larson, A.J., Symons, D., Jalili, T., Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms (2012) Adv. Nutr., 3, pp. 39-46; Lau, A.J., Chang, T.K., Inhibition of human CYP 2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols (2009) Drug Metab. Dispos., 37 (9), pp. 1931-1937; Le Bars, P.L., Response patterns of EGb761 in Alzheimer's disease: influence of neuropsychological profiles (2003) Pharmacopsychiatry, 36 (1), pp. 50-55; Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, A.F., A placebo-controlled, double blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group (1997) JAMA, 278 (16), pp. 1327-1332; Le Bars, P.L., Kieser, M., Itil, K.Z., A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extraxt EGb761 in dementia (2000) Dement. Geriatr. Cogn. Disord., 11 (4), pp. 230-237; Le Bars, P.L., Velasco, F.M., Ferguson, J.M., Dessain, E.C., Kieser, M., Hörr, R., Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb761 in Alzheimer's disease (2002) Neuropsychobiology, 45 (1), pp. 19-26; Lebuisson, D.A., Leroy, L., Rigal, G., Traitement des dégénérescences maculaires séniles par l'extrait de Ginkgo biloba. Etude preliminaries á double insu face au placebo [Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind study versus placebo] (1986) La Presse Méd., 15, pp. 1556-1558. , English translation In: E.W. Fünfgeld (Ed.), 1988. Rökan (Ginkgo biloba) Recent Results in Pharmacology and Clinic. Springer Berlin, Heidelberg, New York 231-236; Lichtblau, D., Berger, J.M., Nakanishi, K., Efficient extraction of ginkgolides and bilobalide from Ginkgo biloba leaves (2002) J. Nat. Prod., 65 (10), pp. 1501-1504; Linhao, L., Stanton, J.D., Tolson, A.H., Luo, Y., Wang, H., Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through Pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways (2009) Pharm. Res., 26 (4), pp. 872-882; Liu, X.-P., Goldring, C.E.P., Wang, H.-Y., Copple, I.M., Kitteringham, N.R., Park, B.K., Extract of Ginkgo biloba induces glutathione-S-transferase subunit-P1 in vitro (2009) Phytomedicine, 16 (5), pp. 451-455; Lovera, J.F., Kim, E., Heriza, E., Fitzpatrick, M., Hunziker, J., Turner, A.P., Adams, J., Bourdette, D., Ginkgo biloba does not improve cognitive function in MS. A randomized placebo-controlled trial (2012) Neurology, 79, pp. 1278-1284; Maeda, J., Kijima, A., Inoue, K., Ishii, Y., Ichimura, R., Takasu, S., Kuroda, K., Yoshida, M., In vivo genotoxicity of Ginkgo biloba extract in Gpt delta mice and constitutive androstane receptor knockout mice (2014) Toxicol. Sci., , First published online: 13.05.14; Mancini, M., Agozzino, B., Bompani, R., Effecti clinico-terapeutici dell'estratto di Ginkgo biloba (EGb) in confronto a placebo, affetti da demenza psicorganica senile su base arteriosclerotica [Clinical and therapeutic effects of Ginkgo biloba extract (EGb) compared to placebo in the treatment of patients affected by senile psychorganic dementia on an arteriosclerotic basic] (1993) Gazz. Med. Italiana Arch. Sci. Med., 152 (3), pp. 69-80; Markowitz, J.S., Donovan, J.L., Lindsay, D.C., Sipkes, L., Chavin, K.D., Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers (2003) J. Clin. Psychopharm., 2 (6), pp. 576-581; Martignoni, M., Geny, M.M., Groothuis, G.M.M., de Kanter, R., Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction (2006) Exp. Opin. Drug Metab. Toxicol., 2 (6), pp. 875-894; Maurer, K., Ihl, R., Dierks, T., Frölich, L., Clinical efficacy of Ginkgo biloba special extract EGb761 in dementia of the Alzheimer type (1997) J. Psychiat. Res., 31 (6), pp. 645-655; Mauri, P.L., Iemoli, L., Gardana, C., Riso, P., Simonetti, P., Porrini, M., Pietta, P.G., Liquid chromatography electrospray ionization mass spectrometric characterization of avonol glycosides in tomato extracts and human plasma (1999) Rapid Commun. Mass Spectrom., 13, pp. 924-931; Maurici, D., Aardema, M., Corvi, R., Kleber, M., Krul, C., Laurent, C., Loprieno, N., Vanparys, P., Carcinogenicity (2005) Altern. Lab. Anim., 33, pp. 177-182; Mauro, V.F., Mauro, L.S., Kleshinski, J.F., Khuder, S.A., Wang, Y., Erhardt, P.W., Impact of Ginkgo Biloba on the pharmacokinetics of digoxin (2003) Am. J. Ther., 10 (4), pp. 247-251; Mazza, M., Capuano, A., Bria, P., Mazza, S., Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study (2006) Eur. J. Neurol., 13, pp. 981-985; McCarney, R., Fisher, P., Iliffe, S., van Haselen, R., Griffin, M., van der Meulen, J., Warner, J., Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomized, parallel-group, double-blind, placebo-controlled trial (2008) Int. J. Geriatr. Psychiat., 23 (12), pp. 1222-1230; Metodiewa, D., Jaiswal, A.K., Cenas, N., Dickancaite, E., Segura-Aguilar, J., Quercetin may act as cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product (1999) Free Radical Biol. Med., 26 (1-2), pp. 107-116; Michel, P.F., (1986) Ginkgo Biloba: L'arbre Qui a Vaincu le Temps [Ginkgo biloba, a tree defeat the time], , Due Felin, Paris; Middleton, E., Biological properties of plant flavonoids: an overview (1996) Int. J. Pharm., 34, pp. 344-348; Mohutsky, M.A., Anderson, G.D., Miller, J.W., Elmer, G.W., Ginkgo biloba: evaluation of CYP 2C9 drug interactions in vitro and in vivo (2006) Am. J. Ther., 13, pp. 24-31; Morgenstern, C., Biermann, E., Tinnitus-Langzeittherapie mit Ginkgo-Spezialextrakt EGb761 [Long term therapy of tinnitus with Ginkgo special extract EGb761] (1997) Fortschritr. Med., 115 (29), pp. 57-58; Mouren, X., Chaillard, P., Schwartz, F., Study of the antiischemic action of EGb761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination (1994) Angiology, 45, p. 413; Napryeyenko, O., Borzenko, I., Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomized placebo-controlled, double-blind clinical study (2007) Arzneim. Forsch. (Drug Res.), 57, pp. 4-11; Napryeyenko, O., Sonnik, G., Tartakovsky, I., Efficacy and tolerability of Ginkgo biloba extract EGb761 by type of dementia: analyses of a randomized controlled trial (2009) J. Neurol. Sci., 283, pp. 224-229; Nicolaï, S.P.A., Kruidenier, L.M., Bendermacher, B.L.W., Prins, M.H., Stokmans, R.A., Broos, P.P.H.L., Teijink, J.A.W., Ginkgo biloba for intermittent claudication (2013) Cochrane Database Syst. Rev., , arxiv:/CD006888; (2007) Toxicity testing for assessment of environmental agents, , The National Academic Press, Washington DC; NTP technical report 578. Toxicology and carcinogenesis studies of Ginkgo biloba extract (CAS No. 90045-36-6) in F344/N rats and B6C3F1/N mice (gavage studies) (2013) National Toxicology program, , P.O. Box 12233 research Triangle Park, NC 27709; Okamoto, T., Safety of quercetin for clinical application (review) (2005) Int. J. Mol. Med., 16 (2), pp. 275-278; Oliveira, E.J., Watson, D.G., In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes (2000) FEBS Lett., 471, pp. 1-6; Oliveira, E.J., Watson, D.G., Grant, M.H., Metabolism of querceting and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasma (2002) Xenobiotica, 32 (4), pp. 279-287; Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Heller, A., Concordance of the toxicity of pharmaceuticals in humans and in animals (2000) Regul. Toxicol. Pharm., 32 (1), pp. 56-67; Oswald, W.D., Hörr, R., Oswald, B., Steger, W., Sappa, J., Zur Verbesserung fluider, kognitiver Leistungen mit Ginkgo biloba-Spezialextrakt EGb761 bei Patienten mit leichten bis mittelschweren Hirnleistungsstörungen im Alter [Increase of fluid cognitive factors with Ginkgo biloba special extract EGb761 in elderly patients with mild to moderate organic brain syndrome] (1997) Zeitschr Gerontopsychol. Psychiat., 10 (3), pp. 133-146; Paganga, G., RiceEvans, C.A., The identification of favonoids as glycosides in human plasma (1997) FEBS Lett., 401, pp. 78-82; Paulke, A., Nöldner, M., Schubert-Zsilavecz, M., Wurglics, M., St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral doses (2008) Pharmazie, 63, pp. 296-302; Pereira, E., Barros, L., Ferreira, C.F.R., Chemical characterization of Ginkgo biloba L. and antioxidant properties of its extracts and dietary supplements (2013) Ind. Corp products, 51, pp. 244-248; Peters, H., Kieser, M., Hölscher, U., Demonstration of the efficacy of Ginkgo biloba special extract EGb761 on intermittent claudication - A placebo controlled, double-blind multicenter trial (1998) Eur. J. Vascular Med. (VASA), 27, pp. 106-110; Pidoux, B., Bastien, C., Niddam, S., Clinical and quantitative EEG double-blind study of Ginkgo biloba extract (GBE) (1983) J. Cerebral Blood Flow Metab., 3, pp. 556-557; Rai, G.S., Shovlin, C., Wesnes, K.A., A double-blind, placebo controlled study of Ginkgo biloba extract (Tanakan) in elderly out-patients with mild to moderate memory impairment (1991) Curr. Med. Res. Opin., 12 (6), pp. 350-355; Rajaraman, G., Yang, G., Chen, J., Chang, T.K.H., Modulation of CYP 1B1 and CYP 1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells (2009) Can. J. Physiol. Pharm., 87, pp. 674-683; Rangel-Ordónez, M., Nöldner, M., Schubert-Zsilavecz, M., Wurglics, M., Plasma levels and distribution of flavonoids in rat brain after single and repeated dose of standard Ginkgo biloba extract EGb761® (2010) Planta Med., 76, pp. 1683-1690; Rejali, D., Sivakumar, A., Balaji, N., Ginkgo biloba does not benefit patients with tinnitus a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials (2004) Clin. Otolaryngol., 29, pp. 226-231; (1994), Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. September(1988), Mouse Micronucleus Test on J-121. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. August 26(1988), J-121 Metaphase chromosome analysis of human lymphocytes cultured in vitro. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. November 2An assessment of the mutagenic potential of J-121 using the mouse lymphoma TK locus assay (1989), Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. May 12Mutagenicity study of Ginkgo biloba extract 501282080/EXCH. 249 in mammalian cells (V79) in the in vitro gene mutation assay (HPRT TEST) (2009), Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. February 4Micronucleus Test of Ginkgo biloba Extract EGb761 in Bone Marrow Cells of the Mouse by Oral Administration (2008), Internal Rreport of Dr. Willmar Schwabe, GmbH & Co. KG. November 11(2013), Micronucleus test of Ginkgo biloba extract EGb761® and Ginkgo biloba extract NTP in bone marrow cells of the NMRI mouse following oral administration - According to Council Regulation (EC) No. 440/2008 B.12 and OECD Guideline 474. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. June 13(1991), Dr. R. Heywood. Ginkgo Extract EGb761 A 104 week (dietary) carcinogenicity study in the rat. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. September(1999), EGb761. Bacterial mutation assay. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. 5 August(2000), EGb761. Toxicokinetic study by oral gavage administration to CD rats for 7 days. Internal Report of Dr. Willmar Schwabe, GmbH & Co. KG. 6 MarchResende, F.A., Vilegas, W., Dos Santos, L.C., Varanda, E.A., Mutagenicity of flavonoids assayed by bacterial reverse mutation (Ames) test (2012) Molecules, 17 (5), pp. 5255-5268; (2007), Updates and information from Rex pathology laboratory. Issue number 130Robak, J., Gryglewski, R.J., Flavonoids are scavengers of superoxide anions (1988) Biochem. Pharmacol., 37 (5), pp. 837-841; Robben-Bathe, P., Häring, B., Hauns, B., Kuhlmann, J., Maier-Lenz, H., Meng, G., Unger, C., Phase II study with 5-FU+ Ginkgo biloba extract in 5FU pretreated patients with advanced colorectal cancer (1996) Ann. Hematol., 73, p. 73; Robertson, S.M., Davey, R.T., Voell, J., Formentini, E., Alfaro, R.M., Penzak, S.R., Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects (2008) Curr. Med. Res. Opin., 24 (2), pp. 591-599; Salz, H., Zur Wirksamkeit eines Ginkgo biloba-Präparats bei arteriellen Durchblutungsstörungen der unteren Extremitäten. Therapie der Gegenwart [Efficacy of a Ginkgo biloba preparation for circulatory disorders of the lower extremities] (1980) Monatsschr. Prakt. Med., 119, pp. 1345-1356; Sampaio, A.L., Dias, M.A., Venosa, A.R., Tauil, P.L., Alencar, E., Oliveira, C.A.C.P., The effect of Ginkgo Biloba (EGb761) as an otoprotector against cisplatin ototoxicity (2013) Otolaryngol. Head Neck Surgery, 149, pp. 222-223; Saper, R.B., (2014), http://www.uptodate.com/contents/clinical-use-of-ginkgo-biloba, Clinical use of Ginkgo biloba. UpToDate, IncSasaki, K., Hatta, S., Wada, K., Ueda, N., Yoshimura, T., Endo, T., Sakata, M., Haga, M., Effects of extract of Ginkgo biloba leaves and its constituents on carcinogen-metabolizing enzymne activities and glutathione levels in mouse liver (2002) Life Sci., 70, pp. 1657-1667; Schmidt, U., Rabinovici, K., Lande, S., Einfluss eines Ginkgo-Spezialextrakts auf die Befindlichkeit bei zerebraler Insuffizienz [Effect of a Ginkgo biloba special extract on well-being in cerebral insufficiency] (1991) Münch. Med. Wochenschr., 133, pp. 15-18; Schneider, L.S., DeKosky, S.T., Farlow, M.R., Tariot, P.N., Hörr, R., Kieser, M., A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type (2005) Curr. Alzheimer Res., 2, pp. 541-551; Scholtyssek, H., Damerau, W., Wessel, R., Schimke, I., Antioxidative activity of ginkgolides against superoxide in an aprotic environment (1997) Chem.-Biol. Interact., 106 (3), pp. 183-190; Schoop, W., Breddin, K., Diehm, C., Gruß, J., Held, K., Horsch, S., Rieger, H., Wuppermann, T., Klinische Prüfung mit Ginkgo biloba-Spezialextract EGb761 bei Patienten mit peripherer arterieller Verschlusskrankheit im Stadium IIb nach Fontaine im Vergleich zu Placebo [Clinical trial with Ginkgo biloba special extract EGb761 in patients with peripheral arterial occlusive disease of stage IIb (Fontaine) in comparison to placebo] (1997) Eur. J.Vascular Med. (VASA), 26, p. 160; Scripnikov, A., Khomenko, A., Napryeyenko, O., Effects of Ginkgo biloba extract EGb761 on neuropsychiatric symptoms of dementia: findings from a randomized controlled trial (2007) Wien. Med. Wochenschr., 157 (13-14), pp. 295-300; Sheweita, S.A., Drug-metabolizing enzymes: mechanisms and functions (2000) Curr. Drug Metab., 1, pp. 107-132; Shinozuka, K., Umegaki, K., Kubota, Y., Tanaka, N., Mizuno, H., Yamauchi, J., Nakamura, K., Kunitomo, M., Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats (2002) Life Sci., 70, pp. 2783-2792; Sierpina, V.S., Wollschlaeger, B., Blumenthal, M., Ginkgo biloba (2003) Am. Fam. Physician, 68 (5), pp. 923-926; Sugiyama, T., Kubota, Y., Shinozuka, K., Yamada, S., Yamada, K., Umegaki, K., Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract (2004) Food Chem. Toxicol., 42 (6), pp. 953-957; Taillandier, J., Ammar, A., Rabourdin, J.P., Ribeyre, J.P., Pichon, J., Niddam, S., Pierart, H., Traitement des troubles du vieillissement cérébral par l'extrait de Ginkgo biloba. Edude longitudionale multicentique à double insu face au placebo [Ginkgo biloba extract in the treatment of cerebral disorders due to aging. A longitudinal multicentric, double-blind, drug versus placebo trial] (1986) Presse Méd., 15, pp. 1583-1587; Taki, Y., Yamazaki, Y., Shimura, F., Yamada, S., Umegaki, K., Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in tars (2009) J. Pharmacol. Sci., 109, pp. 459-462; Taki, Y., Yokotani, K., Yamada, S., Shinozuka, K., Kubota, Y., Watanabe, Y., Umegaki, K., Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice (2012) Phytomedicine, 19, pp. 177-182; Thomson, G.J.L., Vohra, R.K., Carr, M.H., Walker, M.G., A clinical trial of Ginkgo biloba extract in patients with intermittent claudication (1990) Int. Angiol., 9 (2), pp. 75-78; Ude, C., Schubert-Zsilavecz, M., Wurglics, M., Ginkgo biloba extracts: A review of the pharmacokinetics of the active ingredients (2013) Clin. Pharmacokinet., 52 (9), pp. 727-749; Ulbricht, C., Chao, W., Costa, D., Rusie-Seamon, E., Weissner, W., Woods, J., Clinical evidence of herb-drug interactions: A systematic review by the natural standard research collaboration (2008) Curr. Durg Metab., 9 (10), pp. 1063-1120; Umegaki, K., Saito, K., Kubota, Y., Sanada, H., Yamada, K., Shinozuka, K., Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats (2002) Jpn. J. Pharm., 90, pp. 345-351; Umegaki, K., Taki, Y., Endoh, K., Taku, K., Tanabe, H., Shinozuka, K., Sugiyama, T., Bilobalide in Gingko biloba extract is a major substance inducing hepatic CYPs (2007) J. Pharm. Pharmacol., 59, pp. 871-877; van Dongen, M.C.J.M., van Rossum, E., Kessels, A.G.H., Sielhorst, H.J.G., Knipschild, P.G., The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial (2000) J. Am. Geriatr. Soc., 48, pp. 1183-1194; van Dongen, M.C.J.M., Efficacy of Ginkgo biloba in dementia and cognitive decline (1999) Ph.D. Thesis, , Department of Epidemiology, Maastricht University; van der Logt, E.M., Roelofs, H.M., Nagengast, F.M., Peters, W.H., Induction of rat hepatic and intestinal UDP-glucurononsyltransferase by naturally occurring dietary anticarcinogens (2003) Carcinogenesis, 24, pp. 1651-1656; Vardy, J.L., Dhillon, H.M., Clarke, S.J., Potential pharmacocinetic interactions with Ginkgo biloba in women receiving hormonal treatment for early breast cancer (2011) Asia-Pac. J. Clin. Oncol., 7, p. 121. , poster 217; Vardy, J.L., Dhillon, H.N., McLachlan, A., Bell, M.L., Cysique, L., Warby, A., Boyle, F., Tattersall, M.H.N., Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled randomised phase III trial (2011) Asia-Pac. J. Clin. Oncol., 74, p. 154. , poster 326; Vesper, G., Hänsgen, K.-D., Efficacy of Ginkgo biloba in 90 outpatients with cerebral insufficiency caused by old age. Results of a placebo-controlled double-blind trial (1994) Phytomedicine, 1, pp. 9-16; Vorberg, G., Schenk, N., Schmidt, U., Wirksamkeit eines neuen Ginkgo biloba-Extrakts bei 100 Patienten mit zerebraler Insuffizienz [Efficacy of a new Ginkgo bioba extract in 100 patients with cerebral insufficiency] (1989) Herz+Gefäße, 9 (7), pp. 396-401; Wang, F.M., Yao, T.W., Zeng, S., Disposition of quercetin and kaempferol in human following an oral administration of Ginkgo biloba extract tablets (2003) Eur. J. Drug. Metab. Pharmacokinet., 28 (3), pp. 173-177; Wang, J., Zhou, S., Roger Bronks, R., Graham, J., Myers, S., Supervised exercise training combined with Ginkgo biloba treatment for patients with peripheral arterial disease (2007) Clin. Rehab., 21, pp. 579-586; Wang, D., Liang, Y., Chen, W., Xie, L., Wang, G., Liu, X., Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro (2008) Acta Pharm. Sinica, 29 (3), pp. 376-384; Ward, J.M., Value of rodent carcinogenesis bioassays (2008) Toxicol. Appl. Pharm., 226, p. 212; Weitbrecht von, W.-U., Jansen, W., Doubleblind and comparative (Ginkgo biloba versus placebo) therapeutic study in geriatic patients with primary degenerative dementia - a preliminary evaluation (1985) Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment, pp. 91-99. , John Libby Eurotext Ltd., London, Paris, A. Aggnoli, J.R. Rapin, V. Scapagnini (Eds.); Weitbrecht von, W.-U., Jansen, W., Primär degenerative Demenz: Therapie mit Ginkgo biloba-Extrakt. Plazebo-kontrollierte Doppelblind- und Vergeichsstudie [Primary degenerative dementia: therapy with Ginkgo biloba extract. Placebo-controlled double-blind and comparative study] (1986) Fortschr. Med., 104 (9), pp. 199-202; Wesnes, K., Simmons, D., Rook Simpson, M.P., A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly (1987) Human Psychopharm. Clin. Exp., 2 (3), pp. 159-169; Williams, E.D., Mechanisms and pathogenesis of thyroid cancer in animals and man (1995) Mutat. Res., 33, pp. 123-129; Woelkart, K., Feizlmayr, E., Dittrich, P., Beubler, E., Pinl, F., Suter, A., Bauer, R., Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans (2010) Phytother. Res., 24 (3), pp. 445-450; Wohlmuth, H., Savage, K., Dowell, A., Muatt, P., Adulteration of Ginkgo biloba products and a simple method to improve its detection (2014) Phytomedicine, 21 (6), pp. 912-918; Wu, X., Qian, Z., Ke, Y., Du, F., Zhu, L., Ginkgolide B preconditioning protects neurons against ischaemia-induced apoptosis (2009) J. Cell Mol. Med., 13 (11-12), pp. 4474-4483; Xu, A.H., Chen, H.S., Sun, B.C., Xiang, X.-R., Chu, Y.-F., Zhai, F., Jia, L.-C., Therapeutic mechanism of Ginkgo biloba exocarp polysaccharides on gastic cancer (2003) World J. Gastroenterol., 9, pp. 2424-2427; Ye, B., Aponte, M., Dai, Y., Li, L., Ho, M.-C.D., Vitonis, A., Edwards, D., Cramer, D.W., Ginkgo biloba and ovarian cancer prevention. Epidemiological and biological evidence (2007) Cancer lett., 251, pp. 43-52; Zadoyan, G., Rokitta, D., Klement, S., Dienel, A., Hörr, R., Gramatte, T., Fuhr, U., Effect of Ginkgo biloba special extract EGb761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers (2012) Eur. J. Clin. Pharmacol., 68 (5), pp. 553-560; Zeng, X., Liu, M., Yang, Y., Li, Y., Asplund, K., Ginkgo biloba for acute ischaemic stroke (2009) Cochrane Database Syst. Rev., , arxiv:/CD003691",Review,Scopus,2-s2.0-84916624177
"Berry J.M., Williams H.L., Thomas K.D., Blair J.","Perceptions of competence: Age moderates views of healthy aging and Alzheimers disease",2015,"Experimental Aging Research","41","2",,"157","176",,,10.1080/0361073X.2015.1001653,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924182203&partnerID=40&md5=7ef27274f1bb6f0108d1c4c8fece8fee","Department of Psychology, University of Richmond, 28 Westhampton WayRichmond, VA, United States","Berry, J.M., Department of Psychology, University of Richmond, 28 Westhampton WayRichmond, VA, United States; Williams, H.L., Department of Psychology, University of Richmond, 28 Westhampton WayRichmond, VA, United States; Thomas, K.D., Department of Psychology, University of Richmond, 28 Westhampton WayRichmond, VA, United States; Blair, J., Department of Psychology, University of Richmond, 28 Westhampton WayRichmond, VA, United States","Background/Study Context: Older adults have more complex and differentiated views of aging than do younger adults, but less is known about age-related perceptions of Alzheimers disease. This study investigated age-related perceptions of competence of an older adult labeled as ""in good health"" (healthy) or ""has Alzheimers disease"" (AD), using a person-perception paradigm. It was predicted that older adults would provide more differentiated assessments of the two targets than would younger adults.Methods: Younger (n = 86; 18-36 years) and older (n = 66; 61-95 years) adults rated activities of daily living (ADL), instrumental activities of daily living (IADL), and memory abilities of a female target aged 75 years, described as healthy or with AD. Data on anxiety about aging, knowledge of and experience with aging and AD, knowledge of memory aging, and positive and negative biases toward aging and AD were also collected.Results: Older adults perceived the healthy target as more capable of cognitively effortful activities (e.g., managing finances) and as possessing better memory abilities than the AD target. As predicted, these differences were greater than differences between targets perceived by younger adults. The interaction effect remained significant after statistically controlling for relevant variables, including education and gender. Additionally, exploratory analyses revealed that older adults held less positively biased views of AD than younger adults, but negatively biased views were equivalent between age groups.Conclusion: The results demonstrate that mere labels of ""healthy"" and ""Alzheimers disease"" produce significant and subtle age differences in perceived competencies of older adults, and that biases towards AD vary by age group and valence. Our findings extend the person-perception paradigm to an integrative analysis of aging and AD, are consistent with models of adult development, and complement current research and theory on stereotypes of aging. Future directions for research on perceptions of aging are suggested. © 2015 Taylor and Francis Group, LLC.",,"Anderson, L.A., Day, K.L., Beard, R.L., Reed, P.S., Wu, B., The publics perceptions about cognitive health and Alzheimers disease among the US population: A national review (2009) The Gerontologist, 49, pp. S3-S11; Brewer, M.B., Lui, L., Categorization of the elderly by the elderly: Effects of perceivers category membership (1984) Personality and Social Psychology Bulletin, 10, pp. 585-595; Carpenter, B.D., Balsis, S., Otilingam, P.G., Hanson, P.K., Gatz, M., The Alzheimers Disease Knowledge Scale: Development and psychometric properties (2009) The Gerontologist, 49, pp. 236-247; Carpenter, B.D., Zoller, S.M., Balsis, S., Otilingam, P.G., Gatz, M., Demographic and contextual factors related to knowledge about Alzheimers disease (2011) American Journal of Alzheimers Disease and Other Dementias, 26, pp. 121-126; Chasteen, A.L., The role of age and age-related attitudes in perceptions of elderly individuals (2000) Basic and Applied Social Psychology, 22, pp. 147-156; Cherry, K.E., West, R.L., Reese, C.M., Santa Maria, M.P., Yassuda, M., The knowledge of memory aging questionnaire (2000) Educational Gerontology, 26, pp. 195-219; Corner, L., Bond, J., Being at risk of dementia: Fears and anxieties of older adults (2004) Journal of Aging Studies, 18, pp. 143-155; Dieckmann, L., Zarit, S.H., Zarit, J.M., Gatz, M., The Alzheimers disease knowledge test (1988) The Gerontologist, 28, pp. 402-408; Erber, J.T., Prager, I.G., Age and memory: Perceptions of forgetful young and older adults (1999) Social Cognition and Aging, pp. 197-217. , T. M. Hess. & F. Blanchard-Fields. (Eds.) New York, NY: Academic Press; Erber, J.T., Szuchman, L.T., Rothberg, S.T., Everyday memory failure: Age differences in appraisal and attribution (1990) Psychology and Aging, 5, pp. 236-241; Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., Ferris, S., An inventory to assess activities of daily living for clinical trials in Alzheimers disease. the Alzheimers Disease Cooperative Study (1997) Alzheimer Disease and Associated Disorders, 11, pp. S33-S39; Harris, D.K., Changas, P.S., Palmore, E.B., Palmores first Facts on Aging Quiz in a multiple-choice format (1996) Educational Gerontology, 22, pp. 575-589; Heckhausen, J., Dixon, R.A., Baltes, P.B., Gains and losses in development throughout adulthood as perceived by different adult age groups (1989) Developmental Psychology, 25, pp. 109-121; Hess, T.M., Auman, C., Colcombe, S.J., Rahhal, T.A., The impact of stereotype threat on age differences in memory performance (2003) The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 58, pp. 3-11; Hess, T.M., Emery, L., Queen, T.L., Task demands moderate stereotype threat effects on memory performance (2009) The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 64, pp. 482-486; Hummert, M.L., Age stereotypes and aging (2011) Handbook of the Psychology of Aging (7th Ed.), pp. 249-262. , K. W. Schaie. & S. L. Willis. (Eds.); Hummert, M.L., Garstka, T.A., Obrien, L.T., Greenwald, A.G., Mellott, D.S., Using the implicit association test to measure age differences in implicit social cognitions (2002) Psychology and Aging, 17, pp. 482-495; Hummert, M.L., Garstka, T.A., Shaner, J.L., Strahm, S., Stereotypes of the elderly held by young, middle-aged, and elderly adults (1994) Journal of Gerontology, 49, pp. 240-249; Jackson, E.M., Cherry, K.E., Smitherman, E.A., Hawley, K.S., Knowledge of memory aging and Alzheimers disease in college students and mental health professionals (2008) Aging & Mental Health, 12, pp. 258-266; Katz, S., Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living (1983) Journal of the American Geriatrics Society, 31, pp. 721-727; Kessler, E.-M., Schwender, C., Giving dementia a face? the portrayal of older people with dementia in German weekly news magazines between the years 2000 and 2009 (2012) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 67 B, pp. 261-270; Kite, M.E., Stockdale, G.D., Whitley, B.E., Johnson, B.T., Attitudes toward younger and older adults: An updated meta-analytic review (2005) Journal of Social Issues, 61, pp. 241-266; Kornadt, A.E., Rothermund, K., Internalization of age stereotypes into the self-concept via future self-views: A general model and domain-specific differences (2012) Psychology and Aging, 27, pp. 164-172; Kotter-Grühn, D., Hess, T.M., The impact of age stereotypes on self-perceptions of aging across the adult lifespan (2012) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 67 B, pp. 563-571; Laplante, M.P., The classic measure of disability in activities of daily living is biased by age but an expanded IADL/ADL measure is not (2010) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 65 B, pp. 720-732; Lasher, K.P., Faulkender, P.J., Measurement of aging anxiety: Development of the anxiety about aging scale (1993) International Journal of Aging and Human Development, 37, pp. 247-259; Levy, B.R., Mind matters: Cognitive and physical effects of aging self-stereotypes (2003) The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 58, pp. 203-211; Levy, B.R., Stereotype embodiment: A psychosocial approach to aging (2009) Current Directions in Psychological Science, 18, pp. 332-336; Levy, B., Ashman, O., Dror, I., To be or not to be: The effects of aging stereotypes on the will to live (2000) Omega: Journal of Death and Dying, 40, pp. 409-420; Levy, B.R., Hausdorff, J.M., Hencke, R., Wei, J.Y., Reducing cardiovascular stress with positive self-stereotypes of aging (2000) The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 55, pp. 205-213; Levy, B.R., Slade, M.D., Kasl, S.V., Longitudinal benefit of positive self-perceptions of aging on functional health (2002) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 57 B, pp. P409-P417; Levy, B.R., Slade, M.D., Kunkel, S.R., Kasl, S.V., Longevity increased by positive self-perceptions of aging (2002) Journal of Personality and Social Psychology, 83, pp. 261-270; Levy, B.R., Zonderman, A.B., Slade, M.D., Ferrucci, L., Memory shaped by age stereotypes over time (2012) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 67 B, pp. 432-436; Lineweaver, T.T., Berger, A.K., Hertzog, C., Expectations about memory change across the life span are impacted by aging stereotypes (2009) Psychology and Aging, 24, p. 169; Linville, P.W., Fischer, G.W., Salovey, P., Perceived distributions of the characteristics of in-group and out-group members: Empirical evidence and a computer simulation (1989) Journal of Personality and Social Psychology, 57, pp. 165-188; Luszcz, M.A., Fitzgerald, K.M., Understanding cohort differences in cross-generational, self, and peer perceptions (1986) Journal of Gerontology, 41, pp. 234-240; Marques, J.M., Yzerbyt, V.Y., Leyens, J.P., The black sheep effect"": Extremity of judgments towards ingroup members as a function of group identification (1988) European Journal of Social Psychology, 18, pp. 1-16; McArthur, L.Z., Judging a book by its cover: A cognitive analysis of the relationship between physical appearance and stereotyping (1982) Cognitive Social Psychology, pp. 149-211. , A. Hastorf. & A. Isen. (Eds.) New York: Elsevier/North Holland; Meisner, B.A., A meta-analysis of positive and negative age stereotype priming effects on behavior among older adults (2012) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 67 B, pp. 13-17; Montepare, J.M., Zebrowitz, L.A., Person perception comes of age: The salience and significance of age in social judgments (1998) Advances in Experimental Social Psychology, 30, pp. 93-161. , M. P. Zanna. (Ed.) New York: Academic Press; Montepare, J.M., Zebrowitz, L.A., A social-developmental view of ageism (2002) Ageism: Stereotyping and Prejudice Against Older Persons, pp. 77-125. , T. D. Nelson. (Ed.) Cambridge, MA: The MIT Press; Moser, C., Spagnoli, J., Santos-Eggimann, B., Self-perception of aging and vulnerability to adverse outcomes at the age of 65-70 years (2011) The Journals of Gerontology: Series B: Psychological Sciences and Social Sciences, 66 B, pp. 675-680; North, M.S., Fiske, S.T., An inconvenienced youth? Ageism and its potential intergenerational roots (2012) Psychological Bulletin, 138, pp. 982-997; Ohanlon, A.M., Camp, C.J., Osofsky, H.J., Knowledge of and attitudes toward aging in young, middle-aged, and older college students: A comparison of two measures of knowledge of aging (1993) Educational Gerontology, 19, pp. 753-766; Park, B., Rothbart, M., Perception of out-group homogeneity and levels of social categorization: Memory for the subordinate attributes of in-group and out-group members (1982) Journal of Personality and Social Psychology, 42, pp. 1051-1068; Reese, C.M., Cherry, K.E., Copeland, A.L., Knowledge of normal versus pathological memory aging in younger and older adults (2000) Aging, Neuropsychology, and Cognition, 7, pp. 1-8; Smith, E.R., Collins, E.C., Contextualizing person perception: Distributed social cognition (2009) Psychological Review, 116, pp. 343-364; Sontag, S., The double standard of aging (1979) Psychology of Women, pp. 462-478. , J. Williams. (Ed.) New York: Academic Press; Weiss, D., Lang, F.R., They are old but ""i"" feel younger: Age-group dissociation as a self-protective strategy in old age (2012) Psychology and Aging, 27, pp. 153-163; Werner, P., Knowledge about symptoms of Alzheimers disease: Correlates and relationship to help-seeking behavior (2003) International Journal of Geriatric Psychiatry, 18, pp. 1029-1036; Werner, P., Social distance towards a person with Alzheimers disease (2005) International Journal of Geriatric Psychiatry, 20, pp. 182-188; Werner, P., Lay perceptions regarding the competence of persons with Alzheimers disease (2006) International Journal of Geriatric Psychiatry, 21, pp. 674-680; Zebrowitz, L.A., Franklin, R.G., Jr., Hillman, S., Boc, H., Older and younger adults first impressions from faces: Similar in agreement but different in positivity (2012) Psychology and Aging, 28 (1), pp. 202-212. , Advance online publication",Article,Scopus,2-s2.0-84924182203
"Ji H., Dai D., Wang Y., Jiang D., Zhou X., Lin P., Ji X., Li J., Zhang Y., Yin H., Chen R., Zhang L., Xu M., Duan S., Wang Q.","Association of BDNF and BCHE with Alzheimers disease Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls",2015,"Experimental and Therapeutic Medicine","9","5",,"1831","1840",,,10.3892/etm.2015.2327,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925068248&partnerID=40&md5=d29502a322faa306f744d2348a1bd7ed","Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Department of Neurology, The 148 Central Hospital of PLAZibo, Shandong, China; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong UniversityShanghai, China","Ji, H., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Dai, D., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Wang, Y., Department of Neurology, The 148 Central Hospital of PLAZibo, Shandong, China; Jiang, D., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Zhou, X., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Lin, P., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Ji, X., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Li, J., Department of Neurology, The 148 Central Hospital of PLAZibo, Shandong, China; Zhang, Y., Department of Neurology, The 148 Central Hospital of PLAZibo, Shandong, China; Yin, H., Department of Neurology, The 148 Central Hospital of PLAZibo, Shandong, China; Chen, R., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Zhang, L., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Xu, M., Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong UniversityShanghai, China; Duan, S., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China; Wang, Q., Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo UniversityNingbo, Zhejiang, China","Alzheimer's disease (AD) is a common neurodegenerative disorder that can destroy the memory of sufferers and lead to distress for the individual and society. Brain-derived neurotrophic factor (BDNF) and butyrylcholinesterase (BCHE) are two genes associated with β-amyloid plaques and neurofibrillary tangles that are two key factors in the pathophysiology of AD. The aim of the current meta-analysis was to evaluate the association between BDNF Val66Met (rs6265), BDNF C270T (rs2030324) and BCHE-K (rs1803274) polymorphisms and AD. A comprehensive meta-analysis was performed using the online database PubMed without a time limitation. A total of 56 articles evaluating 12,563 cases and 12,622 controls were selected for the current meta-analysis. The results showed a moderate association of the BDNF C270T polymorphism with the risk of AD in Asians under a dominant model (P=0.03; odds ratio, 1.88; 95% confidence interval, 1.08-3.27). No other significant association was found during the meta-analysis for the other two polymorphisms (P>0.05). The current meta-analysis suggests that BDNF C270T is a risk factor for AD in Asians. This meta-analysis has been, to the best of our knowledge, the most comprehensive meta-analysis of BDNF Val66Met, BDNF C270T and BCHE-K to date. © 2015 Spandidos Publications. All rights reserved.","Alzheimers disease; Asians; BCHE-K; BDNF c270T; BDNF val66Met; Meta-analysis","Mucke, L., Neuroscience: Alzheimer's disease (2009) Nature, 461, pp. 895-897; Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., Forecasting the global burden of Alzheimer’s disease (2007) Alzheimers Dement, 3, pp. 186-191; Armstrong, R.A., What causes Alzheimer's disease (2013) Folia Neuropathol, 51, pp. 169-188; Bertram, L., Tanzi, R.E., Genome-wide association studies in Alzheimer's disease (2009) Hum Mol Genet, 18, pp. R137-R145; Scacchi, R., Gambina, G., Moretto, G., Corbo, R.M., Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine (2009) Am J Med Genet B Neuropsychiatr Genet, 150 B, pp. 502-507; Borroni, B., Costanzi, C., Padovani, A., Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease (2010) Curr Alzheimer Res, 7, pp. 158-164; Serretti, A., Olgiati, P., De Ronchi, D., Genetics of Alzheimer's disease. A rapidly evolving field (2007) J Alzheimers Dis, 12, pp. 73-92; Maisonpierre, P.C., Le Beau, M.M., Espinosa, R., Ip, N.Y., Belluscio, L., De La Monte, S.M., Squinto, S., Yancopoulos, G.D., Human and rat brain-derived neurotrophic factor and neurotrophin-3: Gene structures, distributions, and chromosomal localizations (1991) Genomics, 10, pp. 558-568; Ferrer, I., Marín, C., Rey, M.J., Ribalta, T., Goutan, E., Blanco, R., Tolosa, E., Martí, E., BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies (1999) J Neuropathol Exp Neurol, 58, pp. 729-739; Aicardi, G., Argilli, E., Cappello, S., Santi, S., Riccio, M., Thoenen, H., Canossa, M., Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor (2004) Proc Natl Acad Sci USA, 101, pp. 15788-15792; Poo, M.M., Neurotrophins as synaptic modulators (2001) Nat Rev Neurosci, 2, pp. 24-32; Ventriglia, M., Bocchio Chiavetto, L., Benussi, L., Binetti, G., Zanetti, O., Riva, M.A., Gennarelli, M., Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease (2002) Mol Psychiatry, 7, pp. 136-137; Saarela, M.S., Lehtimaki, T., Rinne, J.O., Huhtala, H., Rontu, R., Hervonen, A., Roytta, M., Mattila, K.M., No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer's or Parkinson's disease (2006) Folia Neuropathol, 44, pp. 12-16; Fehér, A., Juhász, A., Rimanóczy, A., Kálmán, J., Janka, Z., Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease (2009) Alzheimer Dis Assoc Disord, 23, pp. 224-228; Pivac, N., Nikolac, M., Nedic, G., Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease (2011) Prog Neuropsychopharmacol Biol Psychiatry, 35, pp. 356-362; Matsushita, S., Arai, H., Matsui, T., Yuzuriha, T., Urakami, K., Masaki, T., Higuchi, S., Brain-derived neurotrophic factor gene polymorphisms and Alzheimer's disease (2005) J Neural Transm, 112, pp. 703-711; Olin, D., Macmurray, J., Comings, D.E., Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism (2005) Neurosci Lett, 381, pp. 275-278; Kunugi, H., Ueki, A., Otsuka, M., Isse, K., Hirasawa, H., Kato, N., Nabika, T., Nanko, S., A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease (2001) Mol Psychiatry, 6, pp. 83-86; Nishimura, M., Kuno, S., Kaji, R., Kawakami, H., Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy (2005) Mov Disord, 20, pp. 1031-1033; Allderdice, P.W., Gardner, H.A., Galutira, D., Lockridge, O., Ladu, B.N., McAlpine, P.J., The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26 (1991) Genomics, 11, pp. 452-454; Arpagaus, M., Kott, M., Vatsis, K.P., Bartels, C.F., La Du, B.N., Lockridge, O., Structure of the gene for human butyrylcholinesterase. Evidence for a single copy (1990) Biochemistry, 29, pp. 124-131; Perry, E., McKeith, I., Ballard, C., Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies (2003) Neurology, 60, pp. 1852-1853; Arendt, T., Brückner, M.K., Lange, M., Bigl, V., Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms (1992) Neurochem Int, 21, pp. 381-396; Carson, K.A., Geula, C., Mesulam, M.M., Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue (1991) Brain Res, 540, pp. 204-208; Darvesh, S., Cash, M.K., Reid, G.A., Martin, E., Mitnitski, A., Geula, C., Butyrylcholinesterase is associated with ß-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease (2012) J Neuropathol Exp Neurol, 71, pp. 2-14; Nacmias, B., Piccini, C., Bagnoli, S., Tedde, A., Cellini, E., Bracco, L., Sorbi, S., Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer's disease (2004) Neurosci Lett, 367, pp. 379-383; Combarros, O., Infante, J., Llorca, J., Berciano, J., Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer's disease (2004) Dement Geriatr Cogn Disord, 18, pp. 55-58; Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C.R., Irizarry, M.C., Ingelsson, M., Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms (2005) Exp Neurol, 194, pp. 91-96; Desai, P., Nebes, R., Dekosky, S.T., Kamboh, M.I., Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression (2005) Neurosci Lett, 379, pp. 229-234; Vepsäläinen, S., Castren, E., Helisalmi, S., Iivonen, S., Mannermaa, A., Lehtovirta, M., Hänninen, T., Hiltunen, M., Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer's disease (2005) J Neurol, 252, pp. 423-428; Bodner, S.M., Berrettini, W., Van Deerlin, V., Bennett, D.A., Wilson, R.S., Trojanowski, J.Q., Arnold, S.E., Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease (2005) Am J Med Genet B Neuropsychiatr Genet, 134 B, pp. 1-5; Li, Y., Rowland, C., Tacey, K., The BDNF Val66Met polymorphism is not associated with late onset Alzheimer's disease in three case-control samples (2005) Mol Psychiatry, 10, pp. 809-810; Forero, D.A., Benítez, B., Arboleda, G., Yunis, J.J., Pardo, R., Arboleda, H., Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia (2006) Neurosci Res, 55, pp. 334-341; Zhang, H., Ozbay, F., Lappalainen, J., Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence (2006) Am J Med Genet B Neuropsychiatr Genet, 141 B, pp. 387-393; Huang, R., Huang, J., Cathcart, H., Smith, S., Poduslo, S.E., Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease (2007) J Med Genet, 44; Boiocchi, C., Maggioli, E., Zorzetto, M., Sinforiani, E., Cereda, C., Ricevuti, G., Cuccia, M., Brain-derived neurotrophic factor gene variants and Alzheimer disease: An association study in an Alzheimer disease Italian population (2013) Rejuvenation Res, 16, pp. 57-66; Cozza, A., Melissari, E., Iacopetti, P., Mariotti, V., Tedde, A., Nacmias, B., Conte, A., Pellegrini, S., SNPs in neurotrophin system genes and Alzheimer's disease in an Italian population (2008) J Alzheimers Dis, 15, pp. 61-70; Tsai, S.J., Hong, C.J., Liu, H.C., Liu, T.Y., Hsu, L.E., Lin, C.H., Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset (2004) Neuropsychobiology, 49, pp. 10-12; Bian, J.T., Zhang, J.W., Zhang, Z.X., Zhao, H.L., Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland China (2005) Neurosci Lett, 387, pp. 11-16; Akatsu, H., Yamagata, H.D., Kawamata, J., Kamino, K., Takeda, M., Yamamoto, T., Miki, T., Kosaka, K., Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan (2006) Dement Geriatr Cogn Disord, 22, pp. 216-222; Tsai, S.J., Hong, C.J., Liu, H.C., Liu, T.Y., Liou, Y.J., The brain-derived neurotrophic factor gene as a possible susceptibility candidate for Alzheimer's disease in a Chinese population (2006) Dement Geriatr Cogn Disord, 21, pp. 139-143; He, X.M., Zhang, Z.X., Zhang, J.W., Zhou, Y.T., Tang, M.N., Wu, C.B., Hong, Z., Lack of association between the BDNF gene Val66Met polymorphism and Alzheimer disease in a Chinese Han population (2007) Neuropsychobiology, 55, pp. 151-155; Riemenschneider, M., Schwarz, S., Wagenpfeil, S., Diehl, J., Müller, U., Förstl, H., Kurz, A., A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein (2002) E Epsilon4 Allele. Mol Psychiatry, 7, pp. 782-785; Nishimura, A.L., Oliveira, J.R., Mitne-Neto, M., Guindalini, C., Nitrini, R., Bahia, V.S., De Brito-Marques, P.R., Zatz, M., Lack of association between the brain-derived neurotrophin factor (C-270T) polymorphism and late-onset Alzheimer's disease (LOAD) in Brazilian patients (2004) J Mol Neurosci, 22, pp. 257-260; Cousin, E., Macé, S., Rocher, C., No replication of genetic association between candidate polymorphisms and Alzheimer's disease (2011) Neurobiol Aging, 32, pp. 1443-1451; Combarros, O., Riancho, J.A., Infante, J., Sañudo, C., Llorca, J., Zarrabeitia, M.T., Berciano, J., Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk (2005) Dement Geriatr Cogn Disord, 20, pp. 153-157; Raygani, A.V., Zahrai, M., Soltanzadeh, A., Doosti, M., Javadi, E., Pourmotabbed, T., Analysis of association between butyrylcholinesterase K variant and apolipoprotein (2004) E Genotypes in Alzheimer's Disease. Neurosci Lett, 371, pp. 142-146; Alvarez-Arcaya, A., Combarros, O., Llorca, J., Sánchez-Guerra, M., Berciano, J., Fernández-Viadero, C., Peña, N., The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women (2000) Acta Neurol Scand, 102, pp. 350-353; McIlroy, S.P., Crawford, V.L., Dynan, K.B., McGleenon, B.M., Vahidassr, M.D., Lawson, J.T., Passmore, A.P., Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland (2000) J Med Genet, 37, pp. 182-185; Wiebusch, H., Poirier, J., Sévigny, P., Schappert, K., Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease (1999) Hum Genet, 104, pp. 158-163; Lehmann, D.J., Johnston, C., Smith, A.D., Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease (1997) Hum Mol Genet, 6, pp. 1933-1936; Simão-Silva, D.P., Bertolucci, P.H., De Labio, R.W., Payão, S.L., Furtado-Alle, L., Souza, R.L., Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population (2013) Chem Biol Interact, 203, pp. 358-360; Mateo, I., Llorca, J., Infante, J., Rodríguez-Rodríguez, E., Berciano, J., Combarros, O., Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk (2008) Eur J Neurol, 15, pp. 219-222; Déniz-Naranjo, M.C., Muñoz-Fernández, C., Alemany-Rodríguez, M.J., Del Carmen Pérez-Vieitez, M., Aladro-Benito, Y., Irurita-Latasa, J., Sánchez-García, F., Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain) (2007) Neurosci Lett, 427, pp. 34-38; Piccardi, M., Congiu, D., Squassina, A., Manconi, F., Putzu, P.F., Mereu, R.M., Chillotti, C., Del Zompo, M., Alzheimer's disease: Case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample (2007) Am J Med Genet B Neuropsychiatr Genet, 144 B, pp. 895-899; Prince, J.A., Feuk, L., Sawyer, S.L., Gottfries, J., Ricksten, A., Nägga, K., Bogdanovic, N., Brookes, A.J., Lack of replication of association findings in complex disease: An analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease (2001) Eur J Hum Genet, 9, pp. 437-444; Mattila, K.M., Rinne, J.O., Röyttä, M., Laippala, P., Pietilä, T., Kalimo, H., Koivula, T., Lehtimäki, T., Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology (2000) J Med Genet, 37, pp. 766-770; Tilley, L., Morgan, K., Grainger, J., Marsters, P., Morgan, L., Lowe, J., Xuereb, J., Kalsheker, N., Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease (1999) Eur J Hum Genet, 7, pp. 659-663; Grubber, J.M., Saunders, A.M., Crane-Gatherum, A.R., Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K) (1999) Neurosci Lett, 269, pp. 115-119; Kehoe, P.G., Williams, H., Holmans, P., Wilcock, G., Cairns, N.J., Neal, J., Owen, M.J., The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease (1998) J Med Genet, 35, pp. 1034-1035; Hiltunen, M., Mannermaa, A., Helisalmi, S., Koivisto, A., Lehtovirta, M., Ryynänen, M., Riekkinen, P., Soininen, H., Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients (1998) Neurosci Lett, 250, pp. 69-71; Crawford, F., Fallin, D., Suo, Z., Abdullah, L., Gold, M., Gauntlett, A., Duara, R., Mullan, M., The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations (1998) Neurosci Lett, 249, pp. 115-118; Singleton, A.B., Smith, G., Gibson, A.M., Woodward, R., Perry, R.H., Ince, P.G., Edwardson, J.A., Morris, C.M., No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease (1998) Hum Mol Genet, 7, pp. 937-939; Brindle, N., Song, Y., Rogaeva, E., Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease (1998) Hum Mol Genet, 7, pp. 933-935; Russ, C., Powell, J., Lovestone, S., Holmes, C., K variant of butyrycholinesterase and late-onset Alzheimer's disease (1998) Lancet, 351, p. 881; Helbecque, N., The butyrylcholinesterase K variant is not associated with Alzheimer's (1998) Alzheimers Rep, 1, pp. 309-313; Laws, S.M., Evidence that the butyrylcholinesterase K variant can protect against late-onset Alzheimer's disease (1999) Alzheimers Rep, 2, pp. 219-223; Bi, S., Zhang, Y., Wu, J., Wang, D., Zhao, Q., Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer's disease in Chinese (2001) Chin Med Sci J, 16, pp. 71-75; Lee, D.W., Liu, H.C., Liu, T.Y., Chi, C.W., Hong, C.J., No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese (2000) Am J Med Genet, 96, pp. 167-169; Yamamoto, Y., Yasuda, M., Mori, E., Maeda, K., Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease (1999) J Neurol Neurosurg Psychiatry, 67, pp. 94-96; Ki, C.S., Na, D.L., Kim, J.W., Kim, H.J., Kim, D.K., Yoon, B.K., No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease (1999) Am J Med Genet, 88, pp. 113-115; Yamada, M., Sodeyama, N., Itoh, Y., Suematsu, N., Otomo, E., Matsushita, M., Mizusawa, H., Butyrylcholinesterase K variant and cerebral amyloid angiopathy (1998) Stroke, 29, pp. 2488-2490; Xu, X., Wang, Y., Wang, L., Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer's disease (2013) Plos One, 8; Dai, D., Wang, Y., Wang, L., Polymorphisms of DRD2 and DRD3 genes and Parkinson’s disease: A meta-analysis (2014) Biomed Rep, 2, pp. 275-281; Zhou, J., Huang, Y., Huang, R.S., A case-control study provides evidence of association for a common SNP rs974819 in PDGFD to coronary heart disease and suggests a sex-dependent effect (2012) Thromb Res, 130, pp. 602-606; Excoffier, L., Laval, G., Schneider, S., Arlequin (Version 3.0): An integrated software package for population genetics data analysis (2005) Evol Bioinform Online, 1, pp. 47-50; Gibson, E., Fenster, A., Ward, A.D., The impact of registration accuracy on imaging validation study design: A novel statistical power calculation (2013) Med Image Anal, 17, pp. 805-815; Coory, M.D., Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified (2010) Int J Epidemiol, 39, pp. 932-933; Kawalec, P., Mikrut, A., Wisniewska, N., Pilc, A., The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: A systematic review and meta-analysis (2013) Clin Rheumatol, 32, pp. 1415-1424; McHughen, S.A., Rodriguez, P.F., Kleim, J.A., Kleim, E.D., Marchal Crespo, L., Procaccio, V., Cramer, S.C., BDNF val66met polymorphism influences motor system function in the human brain (2010) Cereb Cortex, 20, pp. 1254-1262; Pezawas, L., Verchinski, B.A., Mattay, V.S., Callicott, J.H., Kolachana, B.S., Straub, R.E., Egan, M.F., Weinberger, D.R., The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology (2004) J Neurosci, 24, pp. 10099-10102; Fukumoto, N., Fujii, T., Combarros, O., Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: New data and meta-analysis (2010) Am J Med Genet B Neuropsychiatr Genet, 153 B, pp. 235-242; Nagata, T., Shinagawa, S., Nukariya, K., Ochiai, Y., Kawamura, S., Agawa-Ohta, M., Kasahara, H., Yamada, H., Association between brain-derived neurotrophic factor (BDNF) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease (2011) Psychogeriatrics, 11, pp. 141-149; Guillozet, A.L., Smiley, J.F., Mash, D.C., Mesulam, M.M., Butyrylcholinesterase in the life cycle of amyloid plaques (1997) Ann Neurol, 42, pp. 909-918; Lehmann, D.J., Nagy, Z., Litchfield, S., Borja, M.C., Smith, A.D., Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease (2000) Hum Genet, 106, pp. 447-452; Lehmann, D.J., Williams, J., McBroom, J., Smith, A.D., Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups (2001) Neuroscience, 108, pp. 541-554",Article,Scopus,2-s2.0-84925068248
"Jorgensen K., Kristensen M.K., Waldemar G., Vogel A.","The six-item Clock Drawing Test-reliability and validity in mild Alzheimers disease",2015,"Aging, Neuropsychology, and Cognition","22","3",,"301","311",,,10.1080/13825585.2014.932325,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923621655&partnerID=40&md5=e5c714f71573d9daf3c6c7f470746ea2","Department of Neurology, Danish Dementia Research Centre, RigshospitaletCopenhagen, Denmark; Department of Mental Health, Odense University ClinicOdense, Denmark","Jørgensen, K., Department of Neurology, Danish Dementia Research Centre, RigshospitaletCopenhagen, Denmark; Kristensen, M.K., Department of Mental Health, Odense University ClinicOdense, Denmark; Waldemar, G., Department of Neurology, Danish Dementia Research Centre, RigshospitaletCopenhagen, Denmark; Vogel, A., Department of Neurology, Danish Dementia Research Centre, RigshospitaletCopenhagen, Denmark","This study presents a reliable, short and practical version of the Clock Drawing Test (CDT) for clinical use and examines its diagnostic accuracy in mild Alzheimers disease versus elderly nonpatients. Clock drawings from 231 participants were scored independently by four clinical neuropsychologists blind to diagnostic classification. The interrater agreement of individual scoring criteria was analyzed and items with poor or moderate reliability were excluded. The classification accuracy of the resulting scoring system-the six-item CDT-was examined. We explored the effect of further reducing the number of scoring items on classification accuracy and estimated classification accuracy associated with performances deviating from the optimal cutoff score. At a cutoff of 5/6, the six-item CDT had a sensitivity (SN) of 0.65 and a specificity of 0.80. Stepwise removal of up to three items reduced SN slightly. Classification accuracy associated with a score of four or less out of six was very high. © 2014 Taylor and Francis.","Alzheimer's disease; Clock Drawing Test; cognitive screening; dementia; dementia screening","Cacho, J., Garcia-Garcia, R., Fernandez-Calvo, B., Gamazo, S., Rodriguez-Perez, R., Almeida, A., Contador, I., Improvement pattern in the clock drawing test in early Alzheimers disease (2005) European Neurology, 53, pp. 140-145; Chiu, Y.C., Li, C.L., Lin, K.N., Chiu, Y.F., Liu, H.C., Sensitivity and specificity of the clock drawing test, incorporating Rouleau scoring system, as a screening instrument for questionable and mild dementia: Scale development (2008) International Journal of Nursing Studies, 45, pp. 75-84; Connor, D.J., Seward, J.D., Bauer, J.A., Golden, K.S., Salmon, D.P., Performance of three clock scoring systems across different ranges of dementia severity (2005) Alzheimer Disease & Associated Disorders, 19, pp. 119-127; Esteban-Santillan, C., Praditsuwan, R., Ueda, H., Geldmacher, D.S., Clock drawing test in very mild Alzheimers disease (1998) Journal of American Geriatrics Society, 46, pp. 1266-1269; Forti, P., Olivelli, V., Rietti, E., Maltoni, B., Ravaglia, G., Diagnostic performance of an executive clock drawing task (CLOX) as a screening test for mild cognitive impairment in elderly persons with cognitive complaints (2010) Dementia and Geriatric Cognitive Disorders, 30, pp. 20-27; Freedman, M., Leach, L., Kaplan, E., Delis, D., Shulman, K.I., (1994) Clock-drawing: A Neuropsychological Analysis, , New York, NY: Oxford University Press; Heinik, J., Solomesh, I., Berkman, P., Correlation between the CAMCOG, the MMSE, and three clock drawing tests in a specialized outpatient psychogeriatric service (2004) Archives of Gerontology and Geriatrics, 38, pp. 77-84; Kitabayashi, Y., Ueda, H., Narumoto, J., Nakamura, K., Kita, H., Fukui, K., Qualitative analyses of clock drawings in Alzheimers disease and vascular dementia (2001) Psychiatry and Clinical Neurosciences, 55, pp. 485-491; Korner, E.A., Lauritzen, L., Nilsson, F.M., Lolk, A., Christensen, P., Simple scoring of the clock-drawing test for dementia screening (2012) Danish Medical Journal, 59, p. A4365; Lee, H., Swanwick, G.R., Coen, R.F., Lawlor, B.A., Use of the clock drawing task in the diagnosis of mild and very mild Alzheimers disease (1996) International Psychogeriatrics, 8, pp. 469-476; Lee, K.S., Kim, E.A., Hong, C.H., Lee, D.W., Oh, B.H., Cheong, H.K., Clock drawing test in mild cognitive impairment: Quantitative analysis of four scoring methods and qualitative analysis (2008) Dementia and Geriatric Cognitive Disorders, 26, pp. 483-489; Lessig, M.C., Scanlan, J.M., Nazemi, H., Borson, S., Time that tells: Critical clock-drawing errors for dementia screening (2008) International Psychogeriatrics, 20, pp. 459-470; Leyhe, T., Milian, M., Muller, S., Eschweiler, G.W., Saur, R., The minute hand phenomenon in the clock test of patients with early Alzheimer disease (2009) Journal of Geriatric Psychiatry and Neurology, 22, pp. 119-129; Leyhe, T., Saur, R., Eschweiler, G.W., Milian, M., Clock test deficits are associated with semantic memory impairment in Alzheimer disease (2009) Journal of Geriatric Psychiatry and Neurology, 22, pp. 235-245; Lin, K.N., Wang, P.N., Chen, C., Chiu, Y.H., Kuo, C.C., Chuang, Y.Y., Liu, H., The three-item clock-drawing test: A simplified screening test for Alzheimers disease (2003) European Neurology, 49, pp. 53-58; Mainland, B.J., Amodeo, S., Shulman, K.I., Multiple clock drawing scoring systems: Simpler is better (2013) International Journal of Geriatric Psychiatry, 29, pp. 127-136; Mathuranath, P.S., Nestor, P.J., Berrios, G.E., Rakowicz, W., Hodges, J.R., A brief cognitive test battery to differentiate Alzheimers disease and frontotemporal dementia (2000) Neurology, 55, pp. 1613-1620; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimers disease (1984) Neurology, 34, pp. 939-944; Mendez, M.F., Ala, T., Underwood, K.L., Development of scoring criteria for the clock drawing task in Alzheimers disease (1992) Journal of American Geriatrics Society, 40, pp. 1095-1099; Nyborn, J.A., Himali, J.J., Beiser, A.S., Devine, S.A., Du, Y., Kaplan, E., Au, R., The Framingham heart study clock drawing performance: Normative data from the offspring cohort (2013) Experimental Aging Research, 39, pp. 80-108; Pfeffer, R.I., Kurosaki, T.T., Harrah, C.H., Jr., Chance, J.M., Filos, S., Measurement of functional activities in older adults in the community (1982) Journal of Gerontology, 37, pp. 323-329; Pinto, E., Peters, R., Literature review of the clock drawing test as a tool for cognitive screening (2009) Dementia and Geriatric Cognitive Disorders, 27, pp. 201-213; Powlishta, K.K., Von Dras, D.D., Stanford, A., Carr, D.B., Tsering, C., Miller, J.P., Morris, J.C., The clock drawing test is a poor screen for very mild dementia (2002) Neurology, 59, pp. 898-903; Sackett, D.L., The rational clinical examination. A primer on the precision and accuracy of the clinical examination (1992) JAMA: The Journal of the American Medical Association, 267, pp. 2638-2644; Scanlan, J., Borson, S., The mini-cog: Receiver operating characteristics with expert and naive raters (2001) International Journal of Geriatric Psychiatry, 16, pp. 216-222; Shulman, K.I., Clock-drawing: Is it the ideal cognitive screening test? (2000) International Journal of Geriatric Psychiatry, 15, pp. 548-561; Shulman, K.I., Shedletsky, R., Silver, I.L., The challenge of time: Clock-drawing and cognitive function in the elderly (1986) International Journal of Geriatric Psychiatry, 1, pp. 135-140; Stokholm, J., Vogel, A., Johannsen, P., Waldemar, G., Validation of the Danish Addenbrookes Cognitive Examination as a screening test in a memory clinic (2009) Dementia and Geriatric Cognitive Disorders, 27, pp. 361-365; Stopford, C.L., Snowden, J.S., Thompson, J.C., Neary, D., Variability in cognitive presentation of Alzheimers disease (2008) Cortex, 44, pp. 185-195; Strauss, E., Sherman, E.M.S., Spreen, O., A compendium of neuropsychological tests (2006) Administration, Norms, and Commentary (3rd Ed.), , New York, NY: Oxford University Press; Tuokko, H., Hadjistavropoulos, T., Rae, S., Orourke, N., A comparison of alternative approaches to the scoring of clock drawing (2000) Archives of Clinical Neuropsychology, 15, pp. 137-148; Vogel, A., Gade, A., Stokholm, J., Waldemar, G., Semantic memory impairment in the earliest phases of Alzheimers disease (2005) Dementia and Geriatric Cognitive Disorders, 19, pp. 75-81; Wolf-Klein, G.P., Silverstone, F.A., Levy, A.P., Brod, M.S., Screening for Alzheimers disease by clock drawing (1989) Journal of American Geriatrics Society, 37, pp. 730-734; Yamamoto, S., Mogi, N., Umegaki, H., Suzuki, Y., Ando, F., Shimokata, H., Iguchi, A., The clock drawing test as a valid screening method for mild cognitive impairment (2004) Dementia and Geriatric Cognitive Disorders, 18, pp. 172-179",Article,Scopus,2-s2.0-84923621655
"Borges S.D.M., Radanovic M., Forlenza O.V.","Fear of falling and falls in older adults with mild cognitive impairment and Alzheimers disease",2015,"Aging, Neuropsychology, and Cognition","22","3",,"312","321",,,10.1080/13825585.2014.933770,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924018978&partnerID=40&md5=2fbf54cb4de8132c943968a27f02b788","Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Saõ PauloSaõ Paulo, Brazil","Borges, S.D.M., Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Saõ PauloSaõ Paulo, Brazil; Radanovic, M., Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Saõ PauloSaõ Paulo, Brazil; Forlenza, O.V., Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Saõ PauloSaõ Paulo, Brazil","Cognitive impairment and fear of falling are risk factors for falls in older adults. Recurrent falls are more prevalent in older adults with cognitive impairment. We examined the number of previous falls, self-reported fear of falling, and the Falls Efficacy Scale-International (FES-I) in 104 older adults [26 with mild Alzheimers disease (AD), 42 with mild cognitive impairment (MCI) and 36 cognitively healthy]. Older adults with AD and MCI had a higher number of falls (1.1 ± 1.2 and 1.5 ± 1.5, respectively) compared to the control group (0.3 ± 0.5, P <.001). Older adults with MCI more often reported fear of falling (74%) than patients with AD (31%) (P ≤.002) and scored higher on the FES-I (29.7 and 23.8, respectively, P ≤.01). The prevalence of falls in older adults with MCI and AD is higher than in subjects cognitively healthy. Older adults with MCI and AD differ in terms of reported fear of falling and falls self-efficacy. © 2014 Taylor and Francis.","Alzheimer's disease; falls; fear of falling; mild cognitive impairment","Allan, L.M., Ballard, C.G., Rowan, E.N., Kenny, R.A., Baune, B., Incidence and prediction of falls in dementia: A prospective study in older people (2009) PLoS One, 4, p. e5521; Arfken, C.L., Lach, H.W., Birge, S.J., Miller, J.P., The prevalence and correlates of fear of falling in elderly persons living in the community (1994) American Journal of Public Health, 84, pp. 565-570; Bandura, A., Self-efficacy mechanism in human agency (1982) American Psychologist, 37, pp. 122-147; Beauchet, O., Fantino, B., Allali, G., Muir, S.W., Montero-Odasso, M., Annweiler, C., Timed up and go test and risk of falls in older adults: A systematic review (2011) The Journal of Nutrition, Health & Aging, 10, pp. 933-938; Brucki, S.M.D., Nitrini, P., Caramelli, P., Bertolucci, P.H.F., Okamoto, I.H., Sugestões para o uso do mini-exame do estado mental no Brasil (2003) Arquivos de Neuro-Psiquiatria, 61, pp. 777-781; Buchner, D.M., Larson, E.B., Falls and fractures in patients with Alzheimer type dementia (1987) JAMA, 257, pp. 1492-1495; Camargos, F.F.O., Dias, R.C., Dias, J.M.D., Freire, M.T.F., Adaptacąõ transcultural e avaliacąõ das propriedades psicométricas da Falls Efficacy Scale-International em idosos brasileiros (FES-I-BRASIL) (2010) Revista Brasileira de Fisioterapia, 14, pp. 237-243; Cameron, I.D., Stafford, B., Cumming, R.G., Birks, C., Kurrle, S.E., Lockwood, K., Salkeld, G., Hip protectors improve falls self-efficacy (2000) Age Ageing, 29, pp. 57-62; Cho, K.H., Bok, S.K., Kim, Y.J., Hwang, S.L., Effect of lower limb strength on falls and balance of the elderly (2012) Annals of Rehabilitation Medicine, 36, pp. 386-393; Clément, F., Belleville, S., Gauthier, S., Cognitive complaint in mild cognitive impairment and Alzheimers disease (2008) Journal of the International Neuropsychological Society, 14, pp. 222-232; Coelho, F.G., Stella, F., Andrade, L.P., Barbieri, F.A., Santos-Galduróz, R.F., Gobbi, S., Gobbi, L.T., Gait and risk of falls associated with frontal cognitive functions at different stages of Alzheimers disease (2012) Aging, Neuropsychology, and Cognition, 19, pp. 644-656; Delbaere, K., Crombez, G., Vanderstraeten, G., Willems, T., Cambier, D., Fear-related avoidance of activities falls and physical frailty. A prospective community-based cohort study (2004) Age Ageing, 33, pp. 368-373; Delbaere, K., Kochan, N.A., Close, J.C., Menant, J.C., Sturnieks, D.L., Brodaty, H., Lord, S.R., Mild cognitive impairment as a predictor of falls in community-dwelling older people (2012) The American Journal of Geriatric Psychiatry, 20, pp. 845-853; Erzigkeit, H., The development of the SKT project (1991) Dementia: Molecules, Methods and Measures, pp. 101-108. , I. Hindmarch, H. Hippius, & G. K. Wilcock. (Eds.) Chichester: Wiley; Farias, S.T., Mungas, D., Jagust, W., Degree of discrepancy between self and other-reported everyday functioning by cognitive status: Dementia, mild cognitive impairment, and healthy elders (2005) International Journal of Geriatric Psychiatry, 20, pp. 827-834; Flaks, M.K., Yassuda, M.S., Regina, A.C.B., Cid, C.G., Camargo, C.H.P., Gattaz, W.F., Forlenza, O.V., The short cognitive performance test (SKT): A preliminary study of its psychometric properties in Brazil (2005) International Psychogeriatrics, 18, pp. 121-133; Folstein, M.F., Folstein, S.E., McHugh, P.R., Minimental state: A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Gagnon, N., Flint, A.J., Naglie, G., Devins, G.M., Affective correlates of fear of falling in elderly persons (2005) The American Journal of Geriatric Psychiatry, 13, pp. 7-14; Galeone, F., Pappalardo, S., Chieffi, S., Iavarone, A., Carlomagno, S., Anosognosia for memory deficit in amnestic mild cognitive impairment and Alzheimers disease (2011) International Journal of Geriatric Psychiatry, 26, pp. 695-701; Goncąlves, D.F.F., Ricci, N.A., Coimbra, A.M.V., Equilíbrio funcional de idosos da comunidade: Comparacąõ em relacąõ ao histórico de quedas (2009) Reviews Bras Fisioter, 13, pp. 316-323; Hauer, K., Lamb, S.E., Jørstad, E.C., Todd, C., Becker, C., Systematic review of definitions and methods of measuring falls in randomised controlled fall prevention trials (2006) Age Ageing, 35, pp. 5-10. , Profane-Group; Hauer, K., Yardley, L., Beyer, N., Kempen, G., Dias, N., Campbell, M., Todd, C., Validation of the falls efficacy scale and falls efficacy scale international in geriatric patients with and without cognitive impairment: Results of self-report and interview-based questionnaires (2010) Gerontology, 56, pp. 190-199; Hauer, K.A., Kempen, G.I., Schwenk, M., Yardley, L., Beyer, N., Todd, C., Zijlstra, G.A., Validity and sensitivity to change of the falls efficacy scales international to assess fear of falling in older adults with and without cognitive impairment (2011) Gerontology, 57, pp. 462-472; Isaacs, B., Kennie, A.T., The set test as an aid to the detection of dementia in old people (1973) The British Journal of Psychiatry, 123, pp. 467-470; Jørstad, E.C., Hauer, K., Becker, C., Lamb, S.E., Measuring the psychological outcomes of falling: A systematic review (2005) Journal of the American Geriatrics Society, 53, pp. 501-510. , ProFaNE Group; Kalbe, E., Salmon, E., Perani, D., Holthoff, V., Sorbi, S., Elsner, A., Herholz, K., Anosognosia in very mild Alzheimers disease but not in mild cognitive impairment (2005) Dementia and Geriatric Cognitive Disorders, 19, pp. 349-356; Kato-Narita, E.M., Radanovic, M., Characteristics of falls in mild and moderate Alzheimers disease (2009) Dement Neuropsychology, 3, pp. 337-343. , http://www.demneuropsy.com.br/imageBank/PDF/v3n4a13-ing.pdf, Retrived from; Kwan, M.M., Close, J.C., Wong, A.K., Lord, S.R., Falls incidence, risk factors, and consequences in Chinese older people: A systematic review (2011) Journal of the American Geriatrics Society, 59, pp. 536-543; Lamb, S.E., Jørstad-Stein, E.C., Hauer, K., Becker, C., Development of a common outcome data set for fall injury prevention trials: The prevention of Falls Network Europe Consensus (2005) Journal of the American Geriatrics Society, 53, pp. 1618-1622. , ProFaNE Group; Lawrence, R.H., Tennstedt, S.L., Kasten, L.E., Shih, J., Howland, J., Jette, A.M., Intensity and correlates of fear of falling and hurting oneself in the next year: Baseline findings from a royal center fear of falling intervention (1998) Journal of Aging and Health, 10, pp. 267-286; Legters, K., Fear of falling (2002) Physical Therapy, 82, pp. 264-272; Liu-Ambrose, T.Y., Ashe, M.C., Graf, P., Beattie, B.L., Khan, K.M., Increased risk of falling in older community-dwelling women with mild cognitive impairment (2008) Physical Therapy, 88, pp. 1482-1491; Maia, A.L., Godinho, C., Ferreira, E.D., Almeida, V., Schuh, A., Kaye, J., Chaves, M.L., Aplicacąõ da versaõ brasileira da escala de avaliacąõ clínica da demência (clinical dementia rating-CDR) em amostras de pacientes com demência (2006) Arquivos de Neuro-Psiquiatria, 64, pp. 485-489; Martin, K.L., Blizzard, L., Srikanth, V.K., Wood, A., Thomson, R., Sanders, L.M., Callisaya, M.L., Cognitive function modifies the effect of physiological function on the risk of multiple falls - A population-based study (2013) The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 68, pp. 1091-1097; Matioli, M.N., Caramelli, P., Limitations in differentiating vascular dementia from Alzheimers disease with brief cognitive tests (2010) Arquivos de Neuro-Psiquiatria, 68, pp. 185-188; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimers disease (1984) Neurology, 34, pp. 939-944; Meguro, K., Subjective memory complaints are not sine qua non as diagnostic criteria for MCI: The Tajiri project (2006) Acta Neurologica Taiwanica, 15, pp. 55-57. , PMID:16599289; Morris, M., Osborne, D., Hill, K., Kendig, H., Lundgren-Lindquist, B., Browning, C., Reid, J., Predisposing factors for occasional and multiple falls in older Australians who live at home (2004) Australian Journal of Physiotherapy, 50, pp. 153-159; Muir, S.W., Gopaul, K., Montero Odasso, M.M., The role of cognitive impairment in fall risk among older adults: A systematic review and meta-analysis (2012) Age Ageing, 41, pp. 299-308; Orfei, M.D., Varsi, A.E., Blundo, C., Celia, E., Casini, A.R., Caltagirone, C., Spalletta, G., Anosognosia in mild cognitive impairment and mild Alzheimers disease: Frequency and neuropsychological correlates (2010) The American Journal of Geriatric Psychiatry, 18, pp. 1133-1140; Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Winblad, B., Current concepts in mild cognitive impairment (2001) Archives of Neurology, 58, pp. 1985-1992; Podsiadlo, D., Richardson, S., The timed up & go"": A test of basic functional mobility for frail elderly persons (1991) Journal of the American Geriatrics Society, 39, pp. 142-148; Royal, D.R., Mahurin, R.K., Gray, K.F., Beside assessment of executive impairment: The executive interview (1992) Journal of the American Geriatrics Society, 40, pp. 1221-1226; Salvà, A., Roqué, M., Rojano, X., Inzitari, M., Andrieu, S., Schiffrin, E.J., Vellas, B., Falls and risk factors for falls in community-dwelling adults with dementia (NutriAlz Trial) (2012) Alzheimer Disease & Associated Disorders, 26, pp. 74-80; Scheffer, A.C., Schuurmans, M.J., Van Dijk, N., Van Der Hooft, T., De Rooij, S.E., Fear of falling: Measurement strategy, prevalence, risk factors and consequences among older persons (2007) Age Ageing, 37, pp. 19-24; Schwenk, M., Lauenroth, A., Stock, C., Moreno, R.R., Oster, P., McHugh, G., Hauer, K., Definitions and methods of measuring and reporting on injurious falls in randomised controlled fall preventions trials: A systematic review (2012) BMC Medical Research Methodology, 12, p. 50; Shaw, F.E., Prevention of falls in older people with dementia (2007) Journal of Neural Transmission, 114, pp. 1259-1264; Shaw, F.E., Bond, J., Richardson, D.A., Dawson, P., Steen, I.N., McKeith, I.G., Kenny, I.G., Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: Randomised controlled trial (2003) BMJ, 326, pp. 73-77; Sheridan, P.L., Hausdorff, J.M., The role of higher-level cognitive function in gait: Executive dysfunction contributes to fall risk in Alzheimers disease (2007) Dementia and Geriatric Cognitive Disorders, 24, pp. 125-137; Shimada, H., Suzukawa, M., Ishizaki, T., Kobayashi, K., Kim, H., Suzuki, T., Relationship between subjective fall risk assessment and falls and fall-related fractures in frail elderly people (2011) BMC Geriatrics, 11, p. 40; Shumaway-Cook, A., Brauer, S., Woollacott, M., Predicting the probability for falls in community-dwelling older adults using the timed up & go test (2000) Physical Therapy, 80, pp. 896-903. , http://ptjournal.apta.org/content/80/9/896, Retrieved from; Spalletta, G., Girardi, P., Caltagirone, C., Orfei, M.D., Anosognosia and neuropsychiatric symptoms and disorders in mild Alzheimer disease and mild cognitive impairment (2012) Journal of Alzheimers Disease: JAD, 29, pp. 761-772; Suttanon, P., Hill, K.D., Said, C.M., Logiudice, D., Lautenschlager, N.T., Dodd, K.J., Balance and mobility dysfunction and falls risk in older people with mild to moderate Alzheimer disease (2012) American Journal of Physical Medicine & Rehabilitation, 1, pp. 12-23; Tinetti, M.E., Doucette, J., Claus, E., Marottoli, R., Risk factors for serious injury during falls by older persons in the community (1995) Journal of the American Geriatrics Society, 43, pp. 1214-1221; Tinetti, M.E., Powell, L., 4 Fear of falling and low self-efficacy: A cause of dependence in elderly persons (1993) Journal of Gerontology, 48, pp. 35-38; Tinetti, M.E., Richman, D., Powel, L., Falls efficacy as a measure of fear of falling (1990) Journal of Gerontology: Psychological Sciences, 45, pp. 239-243; Tinetti, M.E., Speechley, M., Ginter, S.F., Risk factors for falls among elderly persons living in the community (1988) New England Journal of Medicine, 319, pp. 1701-1707; Tinetti, M.E., Williams, C.S., Falls, injuries due to falls, and the risk of admission to a nursing home (1997) The New England Journal of Medicine, 337, pp. 1279-1284; Uemura, K., Shimada, H., Makizako, H., Doi, T., Tsutsumimoto, K., Yoshida, D., Suzuki, T., Effects of mild and global cognitive impairment on the prevalence of fear of falling in community-dwelling older adults (2014) Maturitas, 78, pp. 62-66; Uemura, K., Shimada, H., Makizako, H., Yoshida, D., Doi, T., Tsutsumimoto, K., Suzuki, T., A lower prevalence of self-reported fear of falling is associated with memory decline among older adults (2012) Gerontology, 58, pp. 413-418; Van Der Mussele, S., Le Bastard, N., Vermeiren, Y., Saerens, J., Somers, N., Mariën, P., Engelborghs, S., Behavioral symptoms in mild cognitive impairment as compared with Alzheimers disease and healthy older adults (2013) International Journal of Geriatric Psychiatry, 28, pp. 265-275; Van Dijk, P.T., Meulenberg, O.G., Van De Sande, H.J., Habbema, J.D., Falls in dementia patients (1993) The Gerontologist, 33, pp. 200-204; (2010) Falls, , http://www.who.int/mediacentre/factsheets/fs344/es, World Health Organization (WHO) Retrieved November 2, 2012, from; Yardley, L., Beyer, N., Hauer, K., Kempen, G., Piot-Ziegler, C., Todd, C., Development and initial validation of the falls efficacy scale international (FES-I) (2005) Age and Ageing, 34, pp. 614-619; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M.B., Leirer, V.O., Development and validation of a geriatric depression screening scale: A preliminary report (1982) Journal of Psychiatric Research, 17, pp. 37-49",Article,Scopus,2-s2.0-84924018978
"Martis E.A.F., Chandarana R.C., Shaikh M.S., Ambre P.K., Dsouza J.S., Iyer K.R., Coutinho E.C., Nandan S.R., Pissurlenkar R.R.S.","Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimers disease",2015,"Journal of Biomolecular Structure and Dynamics","33","5",,"1107","1125",,,10.1080/07391102.2014.931824,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923571825&partnerID=40&md5=83362707ba2cb94756386f9bc093f59a","Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; UM-DAE-Center for Excellence in Basic SciencesKalina, Santacruz E, Mumbai, India; Chemworx, Creative Industries PremisesKalina, Santacruz E, Mumbai, India","Martis, E.A.F., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Chandarana, R.C., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Shaikh, M.S., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Ambre, P.K., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Dsouza, J.S., UM-DAE-Center for Excellence in Basic SciencesKalina, Santacruz E, Mumbai, India; Iyer, K.R., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Coutinho, E.C., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India; Nandan, S.R., Chemworx, Creative Industries PremisesKalina, Santacruz E, Mumbai, India; Pissurlenkar, R.R.S., Department of Pharmaceutical Chemistry, Molecular Simulations Group, Bombay College of PharmacyKalina, Santacruz E, Mumbai, India","There is a need for continued development of acetylcholinesterase (AChE) inhibitors that could prolong the life of acetylcholine in the synaptic cleft and also prevent the aggregation of amyloid peptides associated with Alzheimers disease. The lack of a 3D-QSAR model which specifically deconvulates the type of interactions and quantifies them in terms of energies has motivated us to report a CoRIA model vis-à-vis the standard 3D-QSAR methods, CoMFA and CoMSIA. The CoRIA model was found to be statistically superior to the CoMFA and CoMSIA models and it could efficiently extract key residues involved in ligand recognition and binding to AChE. These interactions were quantified to gauge the magnitude of their contribution to the biological activity. In order to validate the CoRIA model, a pharmacophore map was first constructed and then used to virtually screen public databases, from which novel scaffolds were cherry picked that were not present in the training set. The biological activities of these novel molecules were then predicted by the CoRIA, CoMFA, and CoMSIA models. The hits identified were purchased and their biological activities were measured by the Ellmans method for AChE inhibition. The predicted activities are in unison with the experimentally measured biological activities. © 2014 Taylor & Francis.","3D-QSAR; acetylcholinesterase inhibitors; Alzheimer's disease; CoRIA; G/PLS; pharmacophore modeling; virtual screening","Abuhamdah, S., Habash, M., Taha, M.O., Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors (2013) Journal of Computer-Aided Molecular Design, 27, pp. 1075-1092; Accerlys Inc., (2011) Discovery Studio v3., , 1. San Diego, USA; Alvarez, A., Opazo, C., Alarcón, R., Garrido, J., Inestrosa, N.C., Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragments by forming a complex with the growing fibrils (1997) Journal of Molecular Biology, 272, pp. 348-361; Ambre, P.K., Pissurlenkar, R.R., Coutinho, E.C., Iyer, R.P., Identification of new checkpoint kinase-1 (Chk1) inhibitors by docking, 3D-QSAR, and pharmacophore-modeling methods (2012) Canadian Journal of Chemistry, 90, pp. 675-692; Ambure, P., Kar, S., Roy, K., Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents (2014) Biosystems, 116, pp. 10-20; Ambure, P., Roy, K., Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents (2014) Expert Opinion on Drug Discovery, 9, pp. 697-723; Ambure, P., Roy, K., Exploring structural requirements of leads for improving activity and selectivity against CDK5/p25 in Alzheimer's disease: An in silico approach (2014) RSC Advances, 4, pp. 6702-6709; Archontis, J.M.H.A.G., (2012) MM-GB(PB)SA Calculations of Protein-ligand Binding Free Energies, pp. 171-190. , L. Wang (Ed.), Molecular dynamics -Studies of synthetic and biological macromolecules . Croatia: InTech Open Access Publishers; Balasubramanian, P.K., Balupuri, A., Kothandan, G., Cho, S.J., In silico study of 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl) ethanones derivatives as CCR1 antagonist: Homology modeling, docking and 3D-QSAR approach (2014) Bioorganic & Medicinal Chemistry Letters, 24, pp. 928-933; Bartolini, M., Bertucci, C., Cavrini, V., Andrisano, V., β-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies (2003) Biochemical Pharmacology, 65, pp. 407-416; Belluti, F., Bartolini, M., Bottegoni, G., Bisi, A., Cavalli, A., Andrisano, V., Rampa, A., Benzophenone-based derivatives: A novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesteraseinduced beta-amyloid aggregation (2011) European Journal of Medicinal Chemistry, 46, pp. 1682-1693; Bourne, Y., Palmer Taylor, Z.R., Marchot, P., Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site (2003) The EMBO Journal, 22, pp. 1-12; Bush, B.L., Nachbar, R.B., Jr., Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA (1993) Journal of Computer-Aided Molecular Design, 7, pp. 587-619; Correa-Basurto, J., Bello, M., Rosales-Hernández, M., Hernández-Rodríguez, M., Nicolás-Vázquez, I., Rojo-Domínguez, A., Trujillo-Ferrara, J.G., QSAR, docking, dynamic simulation and quantum mechanics studies to explore the recognition properties of cholinesterase binding sites (2014) Chemico-Biological Interactions, 209, pp. 1-13; Cramer, R.D., Bunce, J.D., Patterson, D.E., Frank, I.E., Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies (1988) Quantitative Structure-Activity Relationships, 7, pp. 18-25; Datar, P.A., Khedkar, S.A., Malde, A.K., Coutinho, E.C., Comparative residue interaction analysis (CoRIA): A 3D-QSAR approach to explore the binding contributions of active site residues with ligands (2006) Journal of Computer-Aided Molecular Design, 20, pp. 343-360; Delano, W.L., (2002) PyMOL v0.99, , DeLano Scientific, San Carlos, CA, 700; Dhaked, D.K., Verma, J., Saran, A., Coutinho, E.C., Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA) (2009) Journal of Molecular Modeling, 15, pp. 233-245; Dvir, H., Silman, I., Harel, M., Rosenberry, T.L., Sussman, J.L., Acetylcholinesterase: From 3D structure to function (2010) Chemico-Biological Interactions, 187, pp. 10-22; Ellman, G.L., Courtney, K.D., Valentino, A., A new and rapid colorimetric determination of acetylcholinesterase activity (1961) Biochemical Pharmacology, 7, pp. 88-95; Friesner, R.A., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Shenkin, P.S., Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy (2004) Journal of Medicinal Chemistry, 47, pp. 1739-1749; Ghose, A.K., Crippen, G.M., Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships I. Partition coefficients as a measure of hydrophobicity (1986) Journal of Computational Chemistry, 7, pp. 565-577; Ghose, A.K., Pritchett, A., Crippen, G.M., Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships III: Modeling hydrophobic interactions (1988) Journal of Computational Chemistry, 9, pp. 80-90; Golbraikh, A., Tropsha, A., Beware of q2 (2002) Journal of Molecular Graphics and Modelling, 20, p. 269; Guo, J., Hurley, M.M., Wright, J.B., Lushington, G.H., A docking score function for estimating ligand-protein interactions: Application to acetylcholinesterase inhibition (2004) Journal of Medicinal Chemistry, 47, pp. 5492-5500; Halgren, T.A., Murphy, R.B., Friesner, R.A., Beard, H.S., Frye, L.L., Pollard, W., Banks, J.L., Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening (2004) Journal of Medicinal Chemistry, 47, pp. 1750-1759; Han, S.H., Hulette, C., Saunders, A.M., Einstein, G., Pericak-Vance, M., Strittmatter, W.J., Roses, A.D., Apolipoprotein e is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls (1994) Experimental Neurology, 128, pp. 13-26; Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P.H., Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase (1993) Proceedings of the National Academy of Sciences, 90, p. 9031; Hassan, M., Bielawski, J.P., Hempel, J.C., Waldman, M., Optimization and visualization of molecular diversity of combinatorial libraries (1996) Molecular Diversity, 2, pp. 64-74; Huang, N., Shoichet, B.K., Irwin, J.J., Benchmarking sets for molecular docking (2006) Journal of Medicinal Chemistry, 49, pp. 6789-6801; Huang, W., Tang, L., Shi, Y., Huang, S., Xu, L., Sheng, R., Wu, P., Searching for the multi-target-directed ligands against Alzheimer's disease: Discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities (2011) Bioorganic & Medicinal Chemistry, 19, pp. 7158-7167; Inestrosa, N.C., Alarcón, R., Molecular interactions of acetylcholinesterase with senile plaques (1998) Journal of Physiology-Paris, 92, pp. 341-344; Inestrosa, N., Alvarez, A., Calderon, F., Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments (1996) Molecular Psychiatry, 1, pp. 359-361; Inestrosa, N.C., Dinamarca, M.C., Alvarez, A., Amyloid-cholinesterase interactions (2008) FEBS Journal, 275, pp. 625-632; Irwin, J.J., Shoichet, B.K., ZINC -A free database of commercially available compounds for virtual screening (2005) Journal of Chemical Information and Modeling, 45, pp. 177-182; Jack, C.R., Jr., Petersen, R.C., Xu, Y.C., O'brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment (1999) Neurology, 52, pp. 1397-1397; Jiang, Y.-R., Yang, Y.-Y., Chen, Y.-L., Liang, Z.-J., CoMFA, CoMSIA and HQSAR studies of acetylcholinesterase inhibitors (2013) Current Computer Aided-Drug Design, 9, pp. 385-395; Jin, Z., Yang, L., Xu, H., Huang, E., Wan, D.C., Li, S., Lin, H.Q., Synthesis and biological activity of 3,6-diaryl-7H-thiazolo[3,2-b][1,2,4]triazin-7-one derivatives as novel acetylcholinesterase inhibitors (2010) Science China Chemistry, 53, pp. 2297-2303; Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., Comparison of simple potential functions for simulating liquid water (1983) The Journal of Chemical Physics, 79, pp. 926-935; Jorgensen, W.L., Maxwell, D.S., Tirado-Rives, J., Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids (1996) Journal of the American Chemical Society, 118, pp. 11225-11236; Kellogg, G.E., Semus, S.F., Abraham, D.J., HINT: A new method of empirical hydrophobic field calculation for CoMFA (1991) Journal of Computer-Aided Molecular Design, 5, pp. 545-552; Kryger, G., Silman, I., Sussman, J.L., Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica (1998) Journal of Physiology-Paris, 92, pp. 191-194; Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs (1999) Structure, 7, pp. 297-307; Kubinyi, H., (1993) 3D Qsar in Drug Design: Theory Methods and Applications, 1. , Dordrecht: Kluwer Academic Publishers; Kumar, V., Chadha, N., Tiwari, A.K., Sehgal, N., Mishra, A.K., Prospective atom-based 3D-QSAR model prediction, pharmacophore generation, and molecular docking study of carbamate derivatives as dual inhibitors of AChE and MAO-B for Alzheimer's disease (2014) Medicinal Chemistry Research, 23, pp. 1114-1122; Li, Y.-P., Weng, X., Ning, F.-X., Ou, J.-B., Hou, J.-Q., Luo, H.-B., Li, D., 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method (2013) Journal of Molecular Graphics and Modelling, 41, pp. 61-67; Mark, P., Nilsson, L., Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K (2001) The Journal of Physical Chemistry A, 105, pp. 9954-9960; Martín-Santamaría, S., Muñoz-Muriedas, J., Luque, F.J., Gago, F., Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis (2004) Journal of Medicinal Chemistry, 47, pp. 4471-4482; Mohamed, T., Yeung, J.C., Rao, P.P., Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation (2011) Bioorganic & Medicinal Chemistry Letters, 21, pp. 5881-5887; Nemukhin, A.V., Lushchekina, S.V., Bochenkova, A.V., Golubeva, A.A., Varfolomeev, S.D., Characterization of a complete cycle of acetylcholinesterase catalysis by ab initio QM/MM modeling (2008) Journal of Molecular Modeling, 14, pp. 409-416; Palakurti, R., Sriram, D., Yogeeswari, P., Vadrevu, R., Multiple e-pharmacophore modeling combined with high-throughput virtual screening and docking to identify potential inhibitors of β-secretase(BACE1) (2013) Molecular Informatics, 32, pp. 385-398; Pratim Roy, P., Paul, S., Mitra, I., Roy, K., On two novel parameters for validation of predictive QSAR models (2009) Molecules, 14, pp. 1660-1701; Rachinsky, T.L., Camp, S., Li, Y., Ekström, T.J., Newton, M., Taylor, P., Molecular cloning of mouse acetylcholinesterase: Tissue distribution of alternatively spliced mRNA species (1990) Neuron, 5, pp. 317-327; Recanatini, M., Cavalli, A., Belluti, F., Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structurebased CoMFA of tacrine analogues (2000) Journal of Medicinal Chemistry, 43, pp. 2007-2018; Ripoll, D.R., Faerman, C.H., Axelsen, P.H., Silman, I., Sussman, J.L., An electrostatic mechanism for substrate guidance down the aromatic gorge of acetylcholinesterase (1993) Proceedings of the National Academy of Sciences, 90, pp. 5128-5132; Rogers, D., Hopfinger, A., Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships (1994) Journal of Chemical Information and Modeling, 34, pp. 854-866; Roy, K., Chakraborty, P., Mitra, I., Ojha, P.K., Kar, S., Das, R.N., (2013) RmSquare Calculator, , http://aptsoftware.co.in/rmsquare/, Retrieved from; Roy, K., Chakraborty, P., Mitra, I., Ojha, P.K., Kar, S., Das, R.N., Some case studies on application of ""rm 2"" metrics for judging quality of quantitative structure-activity relationship predictions: Emphasis on scaling of response data (2013) Journal of Computational Chemistry, 34, pp. 1071-1082; Roy, K., Mitra, I., On the use of the metric rm 2 as an effective tool for validation of QSAR models in computational drug design and predictive toxicology (2012) Mini-Reviews in Medicinal Chemistry, 12, pp. 491-504; Samadi, A., Chioua, M., Bolea, I., De Los Ríos, C., Iriepa, I., Moraleda, I., Bastida, A., Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease (2011) European Journal of Medicinal Chemistry, 46, pp. 4665-4668; Schmechel, D., Saunders, A., Strittmatter, W., Crain, B., Hulette, C., Joo, S., Pericak-Vance, M.A., Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein e genotype in late-onset Alzheimer disease (1993) Proceedings of the National Academy of Sciences, 90, pp. 9649-9653; Schrödinger LLC. (2012a). Epik v2.3, New York, NYSchrödinger LLC. (2012b). Impact v5.8, New York, NYSchrödinger LLC. (2012c). LigPrep, v2.5, New York, NYSchrödinger LLC. (2012d). MacroModel version 9.9, New York, NYSchrödinger LLC. (2012e). Maestro v 9.3.5, New York, NYSchrödinger LLC. (2012f). Prime v 3.1 , New York, NYSchrödinger LLC. (2012 g). QikProp v3.5 , New York, NYShan, W.-J., Huang, L., Zhou, Q., Meng, F.-C., Li, X.-S., Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation (2011) European Journal of Medicinal Chemistry, 46, pp. 5885-5893; Shaw, D.E., A fast, scalable method for the parallel evaluation of distance-limited pairwise particle interactions (2005) Journal of Computational Chemistry, 26, pp. 1318-1328; Sopkova-De Oliveira Santos, J., Lesnard, A., Agondanou, J.-H., Dupont, N., Godard, A.-M., Stiebing, S., Rochais, C., Virtual screening discovery of new acetylcholinesterase inhibitors issued from CERMN chemical library (2010) Journal of Chemical Information and Modeling, 50, pp. 422-428; Sugimoto, H., Yamanish, Y., Iimura, Y., Kawakami, Y., Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors (2000) Current Medicinal Chemistry, 7, pp. 303-339; Sussman, J.L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., Silman, I., Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein (1991) Science, 253, pp. 872-879; Tong, W., Collantes, E.R., Chen, Y., Welsh, W.J., A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors (1996) Journal of Medicinal Chemistry, 39, pp. 380-387; Tripos Accociates Inc. (2005). Sybyl v7.1, St. Louis, MOTripos Accociates Inc. (2010). Sybyl-X 2.0, St. Louis, MOVerma, J., Khedkar, V.M., Prabhu, A.S., Khedkar, S.A., Malde, A.K., Coutinho, E.C., A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants (2008) Journal of Computer-Aided Molecular Design, 22, pp. 91-104; Wellenzohn, B., Tonmunphean, S., Khalid, A., Choudhary, M.I., Rode, B.M., 3D-QSAR Studies on natural acetylcholinesterase inhibitors of Sarcococca saligna by comparative molecular field analysis (CoMFA) (2003) Bioorganic and Medicinal Chemistry Letters, 13, pp. 4375-4380; Wildman, S.A., Crippen, G.M., Prediction of physicochemical parameters by atomic contributions (1999) Journal of Chemical Information and Modeling, 39, pp. 868-873; Wu, Z.P., Wu, X.W., Shen, T., Li, Y.P., Cheng, X., Gu, L.Q., Huang, Z.-S., Synthesis and acetylcholinesterase and butyrylcholinesterase inhibitory activities of 7-alkoxyl substituted indolizinoquinoline-5,12-dione derivatives (2012) Archiv der Pharmazie, 345, pp. 175-184; Zheng, F., Zhan, M., Huang, X., Abdul Hameed, M.D.M., Zhan, C.-G., Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches (2014) Bioorganic & Medicinal Chemistry, 22, pp. 538-549",Article,Scopus,2-s2.0-84923571825
"Goncalves C., Pinho M.S., Cruz V., Pais J., Gens H., Oliveira F., Santana I., Rente J., Santos J.M.","The Portuguese version of Addenbrooke's cognitive examination-revised (ACE-R) in the diagnosis of subcortical vascular dementia and Alzheimers disease",2015,"Aging, Neuropsychology, and Cognition","22","4",,"473","485",,,10.1080/13825585.2014.984652,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927799324&partnerID=40&md5=0f8b0417a9ffc9e8d3f4366119306fa7","Faculty of Psychology and Educational Sciences, University of CoimbraCoimbra, Portugal; Neurology Department, Entre O Douro e O Vouga Hospital CenterSanta-Maria-da-Feira, Portugal; Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal; Neurology Department, Baixo Vouga Hospital CenterAveiro, Portugal","Gonçalves, C., Faculty of Psychology and Educational Sciences, University of CoimbraCoimbra, Portugal; Pinho, M.S., Faculty of Psychology and Educational Sciences, University of CoimbraCoimbra, Portugal; Cruz, V., Neurology Department, Entre O Douro e O Vouga Hospital CenterSanta-Maria-da-Feira, Portugal; Pais, J., Neurology Department, Entre O Douro e O Vouga Hospital CenterSanta-Maria-da-Feira, Portugal; Gens, H., Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal; Oliveira, F., Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal; Santana, I., Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal; Rente, J., Neurology Department, Baixo Vouga Hospital CenterAveiro, Portugal; Santos, J.M., Neurology Department, Baixo Vouga Hospital CenterAveiro, Portugal","The aim of this study was to investigate the accuracy of the Portuguese version of Addenbrookes Cognitive Examination-Revised (ACE-R) in detecting and differentiating early stage subcortical vascular dementia (SVD) from early stage Alzheimers disease (AD). Ninety-two subjects (18 SVD patients, 36 AD patients, and 38 healthy controls) were assessed using the ACE-R. Between-groups differences were evaluated using the Quades rank analysis of covariance. The diagnostic accuracy and discriminatory ability of the ACE-R were examined via receiver operating characteristic (ROC) analysis. The ACE-R was able to successfully discriminate between patients and healthy subjects. The mean ACE-R total scores differed between SVD and AD patients; there were also significant differences in attention and orientation and in memory measures between the groups. An optimal cut-off of 72/73 was found for the detection of AD (sensitivity: 97%; specificity: 92%) and SVD (sensitivity: 100%; specificity: 92%). © 2014 Taylor & Francis.","Addenbrooke's Cognitive Examination-Revised; Alzheimer's disease; Dementia; Screening; Subcortical vascular dementia","Alexopoulos, P., Greim, B., Nadler, K., Martens, U., Krecklow, B., Domes, G., Kurz, A., Validation of the Addenbrooke's cognitive examination for detecting early Alzheimer's disease and mild vascular dementia in a German population (2006) Dementia and Geriatric Cognitive Disorders, 22, pp. 385-391; Alexopoulos, P., Mioshi, E., Greim, B., Kurz, A., Brief assessment of cognitive mental status in German: The Addenbrooke's cognitive examination (ACE) and the Addenbrooke's cognitive examination revised (ACE-R) (2007) European Journal of Geriatrics, 9, pp. 175-180; Almkvist, O., Fratiglioni, L., Aguero-Torres, H., Viitanem, M., Back-Man, L., Cognitive support at episodic encoding and retrieval: Similar patterns of utilization in community-based samples of Alzheimer's disease and vascular dementia patients (1999) Journal of Clinical and Experimental Neuropsychology, 21, pp. 816-830; Baillon, S., Muhommad, S., Marudkar, M., Suribhatla, S., Dennis, M., Spreadbury, C., Lindesay, J., Neuropsychological performance in Alzheimer's disease and vascular dementia: Comparisons in a memory clinic population (2003) International Journal of Geriatric Psychiatry, 18, pp. 602-608; Bak, T., Mioshi, E., A cognitive bedside assessment beyond the MMSE: The Addendrooke's cognitive examination (2007) Practical Neurology, 7, pp. 245-249; Barreto, J., Leuschner, A., Santos, F., Sobral, M., Geriatric depression scale (2007) Escalas e Testes Na Demência, pp. 65-67. , Grupo de Estudos de Envelhecimento Cerebral e Demência (Eds.),. Lisboa: Novartis; Boustani, M., Peterson, B., Hanson, L., Harris, H., Harris, R., Lohr, K., Screening for dementia in primary care: A summary of the evidence for the US preventive services task force (2003) Annals of Internal Medicine, 138, pp. 927-936; Brookes, R., Hannesdottir, K., Lawrence, R., Morris, R., Markus, H., Brief memory and executive test: Evaluation of a new screening test for cognitive impairment due to small vessel disease (2012) Age and Ageing, 41, pp. 212-218; Carew, T., Lamar, M., Cloud, B., Grossman, M., Libon, D., Impairment in category fluency in ischemic vascular dementia (1997) Neuropsychology, 11, pp. 400-412; Carvalho, V., Barbosa, M., Caramelli, P., Brazilian version of the Addenbrooke cognitive examination-revised in the diagnosis of mild Alzheimer disease (2010) Cognitive and Behavioral Neurology, 23, pp. 8-13; Carvalho, V., Caramelli, P., Brazilian adaptation of the Addenbrooke's cognitive examination-revised (ACE-R) (2007) Dementia & Neuropsychologica, 2, pp. 212-216; Chui, H., Subcortical ischemic vascular dementia (SIVD) (2007) Neurologic Clinics, 25, pp. 717-740; Crossley, M., D'arcy, C., Rawson, N., Letter and category fluency in community-dwelling Canadian seniors: A comparison of normal participants to those with dementia of the Alzheimer or vascular type (1997) Journal of Clinical and Experimental Neuropsychology, 19, pp. 52-62; Desmond, D., Erkinjuntti, T., Sano, M., Cummings, J., Bowler, J., Pasquier, F., Hachinski, V., The cognitive syndrome of vascular dementia: Implications for clinical trials (1999) Alzheimer Disease and Associated Disorders, 13, pp. S21-S29; Dudas, R., Berrios, G., Hodges, J., The Addenbrooke's cognitive examination (ACE) in the differential diagnosis of early dementias versus affective disorder (2005) The American Journal of Geriatric Psychiatry, 13, pp. 218-226; Dufouil, C., Clayton, D., Brayne, C., Chi, L., Dening, T., Paykel, E.S., Huppert, F.A., Population norms for the MMSE in the very old: Estimates based on longitudinal data (2000) Neurology, 55, pp. 1609-1613; Erkinjuntti, T., Cerebrovascular disease, vascular cognitive impairment and dementia (2005) Psychiatry, 4, pp. 48-51; Erkinjuntti, T., Inzitari, D., Pantoni, L., Wallin, A., Scheltens, P., Rockwood, K., Desmond, D., Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials: Is a focus on subcortical vascular dementia a solution? (2000) Annals of the New York Academy of Sciences, 903, pp. 262-272; Fahlander, K., Wahlin, A., Almkvist, O., Backman, L., Cognitive functioning in Alzheimer's disease and vascular dementia: Further evidence for similar patterns of deficits (2002) Journal of Clinical and Experimental Neuropsychology, 24, pp. 734-744; Firmino, H., Simões, M.R., Pinho, S., Cerejeira, J., Martins, C., (2009) Avaliação Cognitiva de Addenbrooke. Experimental Portuguese Version of the Addenbrooke's Cognitive Examination-revised (ACE-R; J. Hodges, E. Mioshi, 2005), , Manual. Psychological Service. Coimbra: Faculty of Psychology and Educational Sciences of University of Coimbra; Folstein, M., Folstein, S., McHugh, P., Mini-mental state A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Freitas, S., Simões, M.R., Alves, L., Santana, I., Montreal cognitive assessment (MOCA): Normative study for the Portuguese population (2011) Journal of Clinical and Experimental Neuropsychology, 33, pp. 989-996; Galton, C., Erzinçlioglu, S., Sahakian, B., Antoun, N., Hodges, J., A comparison of the Addenbrooke's cognitive examination (ACE), conventional neuropsychological assessment, and simple MRI-based medial temporal lobe evaluation in the early diagnosis of Alzheimer's disease (2005) Cognitive and Behavioral Neurology, 18, pp. 144-150; Graham, N., Emery, T., Hodges, J., Distinctive cognitive profiles in Alzheimer's disease and subcortical dementia (2004) Journal of Neurology, Neurosurgery and Psychiatry, 75, pp. 61-71; Guerreiro, M., Silva, A.P., Botelho, M.A., Leitão, O., Garcia, C., Adaptation to the Portuguese population of the translation of mini mental state examination (MMSE) (1994) Revista Portuguesa de Neurologia, 1, p. 9; Jefferson, A., Cosentino, S., Ball, S., Bogdanoff, B., Leopold, N., Kaplan, E., Libon, D., Errors produced on the mini-mental state examination and neuropsychological test performance in Alzheimer's disease, ischemic vascular dementia, and Parkinson's disease (2002) The Journal of Neuropsychiatry and Clinical Neurosciences, 14, pp. 311-320; Kwak, Y.T., Yang, Y., Kim, G.W., Korean Addenbrooke's cognitive examination revised (K-ACER) for differential diagnosis of Alzheimer's disease and subcortical ischemic vascular dementia (2010) Geriatrics & Gerontology International, 10, pp. 295-301; Lagaay, A.M., Van Der Meij, J.C., Hijmans, W., Validation of medical history taking as part of a population based survey in subjects aged 85 and over (1992) BMJ, 304, pp. 1091-1092; Mathuranath, P.S., Nestor, P.J., Berrios, G.E., Rakowicz, W., Hodges, J.R., A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia (2000) Neurology, 55, pp. 1613-1620; Matioli, M., Caramelli, P., Limitations in differentiating vascular dementia from Alzheimer's disease with brief cognitive tests (2010) Arquivos de Neuropsiquiatria, 68, pp. 185-188; Mendonça, A., Guerreiro, M., (2007) Escalas e Testes Na Demência [Scales and Tests in Dementia], , (Grupo de estudos de envelhecimento cerebral e demência). Lisboa: Novartis; Mioshi, E., Dawson, K., Mitchell, J., Arnold, R., Hodges, J., The Addenbrooke's cognitive examination revised (ACE-R): A brief cognitive test battery for dementia screening (2006) International Journal of Geriatric Psychiatry, 21, pp. 1078-1085; Morgado, J., Rocha, C., Maruta, C., Guerreiro, M., Martins, I., Novos valores normativos do mini-mental state examination (2009) Sinapse, 9, pp. 19-25; O'connor, D.W., Pollitt, P.A., Hyde, J.B., Brook, C.P., Reis, B.B., Roth, M., Do general practitioners miss dementia in elderly patients? (1988) BMJ, 297, pp. 1107-1110; O'sullivan, M., Morris, R.G., Markus, H.S., Brief cognitive assessment for patients with cerebral small vessel disease (2005) Journal of Neurology, Neurosurgery and Psychiatry, 76, pp. 1140-1145; Prins, N., Van Dijk, E., Den Heijer, T., Vermeer, S., Jolles, J., Koudstaal, P., Breteler, M., Cerebral small-vessel disease and decline in information processing speed, executive function and memory (2005) Brain, 128, pp. 2034-2041; Reed, B., Mungas, D., Kramer, J., Ellis, W., Vinters, H., Zarow, C., Chui, H.C., Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease (2007) Brain, 130, pp. 731-739; Ridha, B., Rossor, M., The mini-mental state examination (2005) Practical Neurology, 5, pp. 298-303; Roca, M., Torralva, T., López, P., Marengo, J., Cetkovich, M., Manes, F., Diferenciación entre demencias en estadio inicial y depression utilizando la version española del Addenbrooke's cognitive examination (2008) Revista de Neurologia, 46, pp. 340-343; Román, G., Clinical forms of vascular dementia (2005) Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management, pp. 7-22. , In R. H. Paul, R. Cohen, B. Ott, & S. Salloway (Eds.),. Totowa, NJ: Human Press; Román, G., Erkinjuntti, T., Wallin, A., Pantoni, L., Chui, H., Subcortical ischaemic vascular dementia (2002) The Lancet Neurology, 1, pp. 426-436; Rosser, A., Hodges, J., Initial letter and semantic category fluency in Alzheimer's disease, Huntington's disease, and progressive supranuclear palsy (1994) Journal of Neurology, Neurosurgery, and Psychiatry, 57, pp. 1389-1394; Sarasola, D., De Luján-Calcagno, M., Sabe, L., Crivelli, L., Torralva, T., Roca, M., Manes, F., El Addenbrooke's cognitive examination en español para el diagnóstico de demencia y para la diferenciación entre enfermedad de Alzheimer y demencia frontotemporal (2005) Revista de Neurologia, 41, pp. 717-721; Spreen, O., Strauss, E., (1998) A Compendium of Neuropsychological Tests. Administration, Norms and Commentary (2nd Ed.), , New York, NY: Oxford University Press; Tekin, S., Cummings, J.L., Frontal-subcortical neuronal circuits and clinical neuropsychiatry: An update (2002) Journal of Psychosomatic Research, 53, pp. 647-654; Valcour, V.G., Masaki, K.H., Curb, J.D., Blanchette, P.L., The detection of dementia in the primary care setting (2000) Archives of Internal Medicine, 160, pp. 2964-2968; Villardita, C., Alzheimer's disease compared with cerebrovascular dementia (1993) Neuropsychological Similarities and Differences. Acta Neurologica Scandinavica, 87, pp. 299-308; Vuorinen, E., Laine, M., Rinne, J., Common pattern of language impairment in vascular dementia and in Alzheimer disease (2000) Alzheimer Disease and Associated Disorders, 14, pp. 81-86; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V., Development and validation of a geriatric depression screening scale: A preliminary report (1983) Journal of Psychiatric Research, 17, pp. 37-49",Article,Scopus,2-s2.0-84927799324
"Bi Oh S., Suh N., Kim I., Lee J.-Y.","Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimers disease",2015,"Brain Research","1597",,,"159","167",,,10.1016/j.brainres.2014.11.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923238811&partnerID=40&md5=ae621f001f439a051938a04558f5dfe8","Asan Institute for Life Sciences, Asan Medical CenterSeoul, South Korea; Department of Neurology, University of Ulsan College of MedicineSeoul, South Korea","Bi Oh, S., Asan Institute for Life Sciences, Asan Medical CenterSeoul, South Korea; Suh, N., Asan Institute for Life Sciences, Asan Medical CenterSeoul, South Korea; Kim, I., Asan Institute for Life Sciences, Asan Medical CenterSeoul, South Korea; Lee, J.-Y., Asan Institute for Life Sciences, Asan Medical CenterSeoul, South Korea, Department of Neurology, University of Ulsan College of MedicineSeoul, South Korea","Plasminogen activators (PAs), which convert plasminogen into the fibrinolytic protease plasmin, may initiate the degradation of amyloid-β (Aβ) to suppress the amyloid pathogenesis. In that way, tissue plasminogen activator (tPA)-mediated plasmin activation could maintain a low level of Aβ deposition to delay the pathogenesis of Alzheimers disease (AD). In a previous study, we reported that tPA/plasmin proteolytic activity is attenuated throughout the brain during aging or with Aβ accumulation but clustered intense around the amyloid plaques in AD brain. The present study demonstrates that the altered proteolytic activity primarily results from the competition between the expressions of tPA and plasminogen activator inhibitor-1 (PAI-1) in the brains of Tg2576 Aβ-transgenic mice, as revealed by immunohistochemistry and immunoblot assays. Compared with that in the brains of younger Tg2576 mice, tPA protein is generally reduced throughout the brain in older Tg2576 mice but elevated near amyloid plaques. In contrary, PAI-1 expression increases during aging or Aβ deposition with its clusters surrounding amyloid plaques. No significant alteration in the expression of urokinase plasminogen activator (uPA) is detected. These results suggest reciprocal feedback influences between tPA, PAI-1 and Aβ during aging and amyloid pathogenesis in AD brain; tPA-mediated plasmin activity is declined throughout the brain causing Aβ deposition during aging, and the Aβ deposits locally attract the cluster of tPA and/or PAI-1 around their deposits to competitively determine tPA/plasmin-mediated Aβ proteolysis. © 2014 Elsevier B.V. All rights reserved.","Amyloid degrading enzymes; Amyloid pathogenesis; Amyloid plaques; Plasmin","Alonso, D.F., Farias, E.F., Famulari, A.L., Dominguez, R.O., Kohan, S., De Lustig, E.S., Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia (1996) J. Neurol Sci., 139, pp. 83-88; Beringer, D.X., Fischer, M.J., Meeldijk, J.D., Van Donselaar, E.G., De Mol, N.J., Kroon-Batenburg, L.M., Tissue-type plasminogen activator binds to Abeta and AIAPP amyloid fibrils with multiple domains (2013) Amyloid, 20, pp. 113-121; Cacquevel, M., Launay, S., Castel, H., Benchenane, K., Cheenne, S., Buee, L., Moons, L., Vivien, D., Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms (2007) Neurobiol. Dis., 27, pp. 164-173; Cho, E., Lee, K.J., Seo, J.W., Byun, C.J., Chung, S.J., Suh, D.C., Carmeliet, P., Lee, J.Y., Neuroprotection by urokinase plasminogen activator in the hippocampus (2012) Neurobiol. Dis., 46, pp. 215-224; Davis, J., Wagner, M.R., Zhang, W., Xu, F., Van Nostrand, W.E., Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells (2003) J. Biol. Chem., 278, pp. 19054-19061; Ertekin-Taner, N., Ronald, J., Feuk, L., Prince, J., Tucker, M., Younkin, L., Hella, M., Younkin, S.G., Elevated amyloid beta protein (Abeta42) and late onset Alzheimers disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene (2005) Hum. Mol. Genet., 14, pp. 447-460; Exley, C., Korchazhkina, O.V., Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures (2001) Neuroreport, 12, pp. 2967-2970; Finckh, U., Van Hadeln, K., Muller-Thomsen, T., Alberici, A., Binetti, G., Hock, C., Nitsch, R.M., Gal, A., Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2 (2003) Neurogenetics, 4, pp. 213-217; Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G., Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice (1996) Science, 274, pp. 99-102; Kingston, I.B., Castro, M.J., Anderson, S., In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues (1995) Nat. Med, 1, pp. 138-142; Kranenburg, O., Bouma, B., Kroon-Batenburg, L.M., Reijerkerk, A., Wu, Y.P., Voest, E.E., Gebbink, M.F., Tissue-type plasminogen activator is a multiligand cross-beta structure receptor (2002) Curr. Biol., 12, pp. 1833-1839; Krystosek, A., Seeds, N.W., Plasminogen activator secretion by granule neurons in cultures of developing cerebellum (1981) P. Natl. Acad. Sci. USA., 78, pp. 7810-7814; Ledesma, M.D., Da Silva, J.S., Crassaerts, K., Delacourte, A., De Strooper, B., Dotti, C.G., Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimers disease brains (2000) EMBO Rep., 1, pp. 530-535; Lee, J.Y., Kweon, H.S., Cho, E., Byun, H.R., Kim, D.H., Kim, Y.H., Han, P.L., Koh, J.Y., Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimers disease (2007) Neurosci. Lett., 423, pp. 82-87; Lee, J.Y., Cho, E., Seo, J.W., Hwang, J.J., Koh, J.Y., Alteration of the cerebral zinc pool in a mouse model of Alzheimer disease (2012) J. Neuropath. Exp. Neur., 71, pp. 211-222; Liu, R.M., Van Groen, T.K.A., Cao, D., Kadisha, I., Ballinger, C., Wang, L., Carroll, S.L., Li, L., Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimers disease (2011) Neurobiol. Aging, 32, pp. 1079-1089; Maas, C., Schiks, B., Strangi, R.D., Hackeng, T.M., Bouma, B.N., Gebbink, M.F., Bouma, B., Identification of fibronectin type i domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs (2008) Amyloid, 15, pp. 166-180; Melchor, J.P., Pawlak, R., Strickland, S., The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration (2003) J. Neurosci., 23, pp. 8867-8871; Miller, D.L., Papayannopoulos, I.A., Styles, J., Bobin, S.A., Lin, Y.Y., Biemann, K., Iqbal, K., Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimers disease (1993) Arch. Biochem. Biophys., 301, pp. 41-52; Nathalie, P., Jean-Noel, O., Processing of amyloid precursor protein and amyloid peptide neurotoxicity (2008) Curr. Alz. Res., 5, pp. 92-99; Oh, S.B., Byun, C.J., Yun, J.H., Jo, D.G., Carmeliet, P., Koh, J.Y., Lee, J.Y., Tissue plasminogen activator arrests Alzheimers disease pathogenesis (2014) Neurobiol. Aging, 35, pp. 511-519; Qian, Z., Gilbert, M.E., Colicos, M.A., Kandel, E.R., Kuhl, D., Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation (1993) Nature, 361, pp. 453-457; Riemenschneider, M., Konta, L., Friedrich, P., Schwarz, S., Taddei, K., Neff, F., Padovani, A., Kurz, A., A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimers disease (2006) Hum. Mol. Genet., 15, pp. 2446-2456; Roussel, B.D., Macrez, R., Jullienne, A., Agin, V., Maubert, E., Dauphinot, L., Potier, M.C., Vivien, D., Age and albumin D site-binding protein control tissue plasminogen activator levels: Neurotoxic impact (2009) Brain, 132, pp. 2219-2230; Siao, C.J., Fernandez, S.R., Tsirka, S.E., Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury (2003) J. Neurosci., 23, pp. 3234-3242; Teesalu, T., Kulla, A., Simisker, A., Siren, V., Lawrence, D.A., Asser, T., Vaheri, A., Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system (2004) Thromb. Haemostasis, 92, pp. 358-368; Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Estus, S., The plasmin system is induced by and degrades amyloid-beta aggregates (2000) J. Neurosci., 20, pp. 3937-3946; Tucker, H.M., Kihiko-Ehmann, M., Estus, S., Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen (2002) J. Neurosci. Res., 70, pp. 249-255; Van Nostrand, W.E., Porter, M., Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity (1999) Biochemistry, 38, pp. 11570-11576; Wnendt, S., Wetzels, I., Gunzler, W.A., Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase (1997) Thromb. Res., 85, pp. 217-224",Article,Scopus,2-s2.0-84923238811
"Nguyen M., Rechignat L., Robert A., Meunier B.","The necessity of having a tetradentate ligand to extract Copper(II) ions from amyloids",2015,"ChemistryOpen","4","1",,"27","31",,,10.1002/open.201402075,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923293193&partnerID=40&md5=4404dd94e8f9f4c6934903649cea2e98","Laboratoire de Chimie de Coordination, Centre National de la Recherche Scientifique (CNRS), 205 route de NarbonneToulouse cedex 4, France; Department of Chemical Engineering, Guangdong University of Technology, Education Mega Center, 100 Waihuan Xi RdGuangzhou, China","Nguyen, M., Laboratoire de Chimie de Coordination, Centre National de la Recherche Scientifique (CNRS), 205 route de NarbonneToulouse cedex 4, France; Rechignat, L., Laboratoire de Chimie de Coordination, Centre National de la Recherche Scientifique (CNRS), 205 route de NarbonneToulouse cedex 4, France; Robert, A., Laboratoire de Chimie de Coordination, Centre National de la Recherche Scientifique (CNRS), 205 route de NarbonneToulouse cedex 4, France; Meunier, B., Laboratoire de Chimie de Coordination, Centre National de la Recherche Scientifique (CNRS), 205 route de NarbonneToulouse cedex 4, France, Department of Chemical Engineering, Guangdong University of Technology, Education Mega Center, 100 Waihuan Xi RdGuangzhou, China","The accumulation of redox-active metal ions, in particular copper, in amyloid plaques is considered to the cause of the intensive oxidation damage to the brain of patients with Alzheimers disease (AD). Drug candidates based on a bis(8-aminoquinoline) tetradentate ligand are able to efficiently extract Cu2+ from copper-loaded amyloids (Cu-Aβ). Contrarily, in the presence of a bidentate hydroxyquinoline, such as clioquinol, the copper is not released from Aβ, but remains sequestrated within a Aβ-Cu-clioquinol ternary complex that has been characterized by mass spectrometry. Facile extraction of copper(II) at a low amyloid/ligand ratio is essential for the re-introduction of copper in regular metal circulation in the brain. As, upon reduction, the Cu+ is easily released from the bis(8-aminoquinoline) ligand unable to accommodate CuI, it should be taken by proteins with an affinity for copper. So, the tetradentate bis(8-aminoquinoline) described here might act as a regulator of copper homeostasis. © 2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.","Alzheimers disease; chelating agents; copper homeostasis; medicinal chemistry; therapeutic agents","Maurer, K., Volk, S., Gerbaldo, H., (1997) Lancet, 349, pp. 1546-1549; Hershey, C.O., Hershey, L.A., Varnes, A., Vibhakar, S.D., Lavin, P., Strain, W.H., (1983) Neurology, 33, pp. 1350-1353; Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., Markesbery, W.R., (1998) J. Neurol. Sci., 158, pp. 47-52; Atwood, C.S., Moir, R.D., Huang, X., Scarpa, R.C., Bacarra, N.M.E., Romano, D.M., Hartshorn, M.A., Bush, A.I., (1998) J. Biol. Chem., 273, pp. 12817-12826; Telpoukhovskaia, M.A., Orvig, C., (2013) Chem. Soc. Rev., 42, pp. 1836-1846; Gabbita, S.P., Lovell, M.A., Markesbery, W.R., (1998) J. Neurochem., 71, pp. 2034-2040; Citron, M., (2010) Nat. Rev. Drug Discovery, 9, pp. 387-398; Patten, D.A., Germain, M., Kelly, M.A., Slack, R.S., (2010) J. Alzheimer's Dis., 20, p. 357. , SS 367; Faller, P., Hureau, C., (2012) Chem. Eur. J., 18, pp. 15910-15920; Cassagnes, L.E., Hervé, V., Nepveu, F., Hureau, C., Faller, P., Collin, F., (2013) Angew. Chem. Int. Ed., 52, pp. 11110-11113; (2013) Angew. Chem., 125, pp. 11316-11319; Ceccom, J., Coslédan, F., Halley, H., Francès, B., Lassalle, J.M., Meunier, B., (2012) PLoS One, 7, p. 43105; Nguyen, M., Robert, A., Sournia-Saquet, A., Vendier, L., Meunier, B., (2014) Chem. Eur. J., 20, pp. 6771-6785; Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Bush, A.I., (2001) Neuron, 30, pp. 665-676; Alies, B., Renaglia, E., Rõzga, M., Bal, W., Faller, P., Hureau, C., (2013) Anal. Chem., 85, pp. 1501-1508; Sarell, C.J., Syme, C.D., Rigby, S.E.J., Viles, J.H., (2009) Biochemistry, 48, pp. 4388-4402; Dorlet, P., Gambarelli, S., Faller, P., Hureau, C., (2009) Angew. Chem. Int. Ed., 48, pp. 9273-9276; (2009) Angew. Chem., 121, pp. 9437-9440; Kenche, V.B., Zawisza, I., Masters, C.L., Bal, W., Barnham, K.J., Drew, S.C., (2013) Inorg. Chem., 52, pp. 4303-4318; Ferrada, E., Arancibia, V., Loeb, B., Norambuena, E., Olea-Azar, C., Huidobro-Toro, J.P., (2007) Neurotoxicology, 28, pp. 445-449; Opazo, C., Luza, S., Villemagne, V.L., Volitakis, I., Rowe, C., Barnham, K.J., Strozyk, D., Bush, A.I., (2006) Aging Cell, 5, pp. 69-79; Jiang, D., Li, X., Williams, R., Patel, S., Men, L., Wang, Y., Zhou, F., (2009) Biochemistry, 48, pp. 7939-7947",Article,Scopus,2-s2.0-84923293193
"Shamirian S., Nalbandian A., Khare M., Castellani R., Kim R., Kimonis V.E.","Early-onset Alzheimers and cortical vision impairment in a woman with valosin-containing protein disease associated with 2 APOE e4/APOE e4 genotype",2015,"Alzheimer Disease and Associated Disorders","29","1",,"90","93",,,10.1097/WAD.0b013e318298e54f,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924255712&partnerID=40&md5=b816618c76296af53b21cf316d7303e8","Department of Pediatrics, Division of Genetics and Metabolism, University of California, 101 The City Drive SouthOrange, CA, United States; Department of Pathology, University of California Medical CenterOrange, CA, United States; Department of Pathology, University of Maryland, School of MedicineBaltimore, MD, United States","Shamirian, S., Department of Pediatrics, Division of Genetics and Metabolism, University of California, 101 The City Drive SouthOrange, CA, United States; Nalbandian, A., Department of Pediatrics, Division of Genetics and Metabolism, University of California, 101 The City Drive SouthOrange, CA, United States; Khare, M., Department of Pediatrics, Division of Genetics and Metabolism, University of California, 101 The City Drive SouthOrange, CA, United States; Castellani, R., Department of Pathology, University of Maryland, School of MedicineBaltimore, MD, United States; Kim, R., Department of Pathology, University of California Medical CenterOrange, CA, United States; Kimonis, V.E., Department of Pediatrics, Division of Genetics and Metabolism, University of California, 101 The City Drive SouthOrange, CA, United States","Hereditary inclusion body myopathy is a heterogeneous group of disorders characterized by rimmed vacuoles and by the presence of filamentous cytoplasmic and intranuclear inclusions. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia is a progressive autosomal dominant disorder associated with a mutation in valosin-containing protein (VCP) with typical onset of symptoms in the 30s. APOE e4 is a major risk factor for late-onset Alzheimer disease, a progressive neurodegenerative disorder that affects memory, thinking, behavior, and emotion as a result of the excessive buildup and decreased clearance of b-amyloid proteins resulting in the appearance of neuritic plaques and neurofibrillary tangles. In conclusion, we report a unique patient with an APOE e4/APOE e4 genotype and atypical VCP disease associated with early Alzheimer disease and severe vision impairment. Future studies will elucidate the interaction of VCP mutations and APOE e4 alleles in understanding common mechanisms in AD and VCP disease. © 2013 Wolters Kluwer Health, Inc. All rights reserved.","Alzheimer disease (AD); APOE e4 allele; frontotemporal dementia and Paget disease of bone (IBMPFD); inclusion body myopathy; TAR DNA-binding protein-43 (TDP-43); tau protein; ubiquitin (Ub); valosin-containing protein (VCP)","Nalbandian, A., Donkervoort, S., Dec, E., The multiple faces of valosin-containing protein-associated diseases: Inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis (2011) J Mol Neurosci, 45, pp. 522-531; Kimonis, V.E., Mehta, S.G., Fulchiero, E.C., Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia (2008) Am J Med Genet A, 146, pp. 745-757; Weihl, C.C., Temiz, P., Miller, S.E., TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia (2008) J Neurol Neurosurg Psychiatry, 79, pp. 1186-1189; Chan, N., Le Shieh C, P., Valosin-containing protein mutation and Parkinson's disease (2012) Parkinsonism Relat Disord, 18, pp. 107-109; Watts, G.D., Wymer, J., Kovach, M.J., Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein (2004) Nat Genet, 36, pp. 377-381; Kimonis, V., Donkervoort, S., Watts, G., Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia Gene Reviewst [Internet], p. 1993. , http://www.ncbi.nlm.nih.gov/books/NBK1476, 2007 May 25 [Updated 2011 Jul 28]. In: Pagon RA, Bird TD, Dolan CR, et al, eds. Seattle (WA): University of Washington, Seattle Available at; Corder, E.H., Saunders, A.M., Strittmatter, W.J., Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families (1993) Science, 261, pp. 921-923; Strittmatter, W.J., Saunders, A.M., Schmechel, D., Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease (1993) Proc Natl Acad Sci USA, 90, pp. 1977-1981; Mehta, S.G., Watts, G.D., Adamson, J.L., APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD) (2007) Genet Med, 9, pp. 9-13; Kaleem, M., Zhao, A., Hamshere, M., Identification of a novel valosin-containing protein polymorphism in late-onset Alzheimer's disease (2007) Neurodegener Dis, 4, pp. 376-381; Halawani, D., Tessier, S., Anzellotti, D., Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: A novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation (2010) J Neurosci, 30, pp. 6132-6142; Griciuc, A., Aron, L., Piccoli, G., Clearance of rhodopsin(P23H) aggregates requires the ERAD effector VCP (1803) Biochim Biophys Acta, pp. 424-434",Article,Scopus,2-s2.0-84924255712
"Harris P.W.R., Squire C., Young P.G., Brimble M.A.","Chemical synthesis of γ-secretase activating protein using pseudo-glutamines as ligation sites",2015,"Biopolymers - Peptide Science Section","104","1",,"37","45",,,10.1002/bip.22600,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922459784&partnerID=40&md5=12de606d035baa216206246329b8a59e","School of Chemical Sciences, University of Auckland, 23 Symonds StreetAuckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019Auckland, New Zealand; School of Biological Sciences, University of Auckland, 3A Symonds StreetAuckland, New Zealand","Harris, P.W.R., School of Chemical Sciences, University of Auckland, 23 Symonds StreetAuckland, New Zealand, Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019Auckland, New Zealand, School of Biological Sciences, University of Auckland, 3A Symonds StreetAuckland, New Zealand; Squire, C., Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019Auckland, New Zealand, School of Biological Sciences, University of Auckland, 3A Symonds StreetAuckland, New Zealand; Young, P.G., School of Biological Sciences, University of Auckland, 3A Symonds StreetAuckland, New Zealand; Brimble, M.A., School of Chemical Sciences, University of Auckland, 23 Symonds StreetAuckland, New Zealand, Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019Auckland, New Zealand, School of Biological Sciences, University of Auckland, 3A Symonds StreetAuckland, New Zealand","The chemical synthesis of analogue of a novel γ-secretase activating protein, which may play a pivotal role in the formation of amyloid peptides, the precursor to Alzheimer's disease, is described. The linear polypeptide sequence, consisting of 121 amino acids was assembled from four unprotected peptide building blocks using a convergent ligation-based synthesis. A strategic mutation of three glutamine residues to cysteine enabled the ligations, and the cysteines were subsequently converted to pseudoglutamines, to mimic the native glutamine. The full length unfolded protein was obtained in milligram amounts and was demonstrated to be homogeneous by liquid chromatography and mass spectrometry. © 2014 Wiley Periodicals, Inc.","Alzheimers; Ligation; Pseudoglutamine; γ-secretase","(2014) 2014 Alzheimer's Disease Facts and Figures, , Alzheimers Association: Chicago; Hardy, J., Selkoe, D.J., (2002) Science, 297, pp. 353-356; Crump, C.J., Johnson, D.S., Li, Y.M., (2013) Biochemistry, 52, pp. 3197-3216; He, G., Luo, W.J., Li, P., Remmers, C., Netzer, W.J., Hendrick, J., Bettayeb, K., Greengard, P., (2010) Nature, 467, pp. 95-U129; Netzer, W.J., Dou, F., Cai, D.M., Veach, D., Jean, S., Li, Y.M., Bornamann, W.G., Greengard, P., (2003) Proc Natl Acad Sci USA, 100, pp. 12444-12449; Hussain, I., Fabregue, J., Anderes, L., Ousson, S., Borlat, F., Eligert, V., Berger, S., Beher, D., (2013) J Biol Chem, 288, pp. 2521-2531; Olsson, B., Legros, L., Guilhot, F., Strömberg, K., Smith, J., Livesey, F.J., Wilson, D.H., Blennow, K., (2014) Alzheimers Dement, 10, pp. S374-S380; Deatherage, C.L., Hadziselimovic, A., Sanders, C.R., (2012) Biochemistry, 51, pp. 5153-5159; Harris, P.W.R., Yang, S.H., Brimble, M.A., (2011) Tetrahedron Lett, 52, pp. 6024-6026; Harris, P.W.R., Lee, D.J., Brimble, M.A., (2012) J Pept Sci, 18, pp. 549-555; Hackeng, T.M., Griffin, J.H., Dawson, P.E., (1999) Proc Natl Acad Sci USA, 96, pp. 10068-10073; Schnolzer, M., Alewood, P., Jones, A., Alewood, D., Kent, S.B.H., (2007) Int J Pept Res Ther, 13, pp. 31-44; Vilaseca, M., Nicolas, E., Capdevila, F., Giralt, E., (1998) Tetrahedron, 54, pp. 15273-15286; Harris, P.W.R., Williams, G.M., Shepherd, P., Brimble, M.A., (2008) Int J Pept Res Ther, 14, pp. 387-392; Harris, P.W.R., Kowalczyk, R., Yang, S.-H., Williams, G.M., Brimble, M.A., (2014) J Pept Sci, 20, pp. 186-190; Dawson, P.E., Muir, T.W., Clark-Lewis, I., Kent, S.B.H., (1994) Science, 266, pp. 776-779; Kent, S.B.H., (2009) Chem Soc Rev, 38, pp. 338-351; Siman, P., Karthikeyan, S.V., Brik, A., (2012) Org Lett, 14, pp. 1520-1523; Wong, C.T.T., Tung, C.L., Li, X., (2013) Mol Biosyst, 9, pp. 826-833; Torbeev, V.Y., Kent, S.B.H., (2007) Angew Chem Int Ed Engl, 46, pp. 1667-1670; Bang, D., Pentelute, B.L., Kent, S.B.H., (2006) Angew Chem Int Ed Engl, 45, pp. 3985-3988; Lee, J., Kwon, Y., Pentelute, B.L., Bang, D., (2011) Bioconjugate Chem, 22, pp. 1645-1649; Villain, M., Vizzavona, J., Rose, K., (2001) Chem Biol, 8, pp. 673-679; Mende, F., Seitz, O., (2011) Angew Chem Int Ed Engl, 50, pp. 1232-1240; Harris, P.W.R., Brimble, M.A., (2013) Peptide Science, 100, pp. 356-365; Johnson, E.C.B., Kent, S.B.H., (2006) J Am Chem Soc, 128, pp. 6640-6646; Melnyk, R.A., Partridge, A.W., Yip, J., Wu, Y.Q., Goto, N.K., Deber, C.M., (2003) Biopolymers, 71, pp. 675-685; Wade, J.D., Mathieu, M.N., Macris, M., Tregear, G.W., (2000) Lett Pept Sci, 7, pp. 107-112; Subirós-Funosas, R., El-Faham, A., Albericio, F., (2011) Tetrahedron, 67, pp. 8595-8606; Gates, Z.P., Stephan, J.R., Lee, D.J., Kent, S.B.H., (2013) Chem Commun (Cambridge U K), 49, pp. 786-788",Article,Scopus,2-s2.0-84922459784
"Bajda M., Filipek S.","Study of early stages of amyloid Aβ13-23 formation using molecular dynamics simulation in implicit environments",2015,"Computational Biology and Chemistry","56",,,"13","18",,,10.1016/j.compbiolchem.2015.02.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924072684&partnerID=40&md5=5be310eeb51a5ac8ad84b572f778eb00","Faculty of Chemistry, University of Warsaw, Pasteura 1Warsaw, Poland; Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University, Medyczna 9Cracow, Poland","Bajda, M., Faculty of Chemistry, University of Warsaw, Pasteura 1Warsaw, Poland, Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University, Medyczna 9Cracow, Poland; Filipek, S., Faculty of Chemistry, University of Warsaw, Pasteura 1Warsaw, Poland","β-amyloid aggregation and formation of senile plaques is one of the hallmarks of Alzheimer's disease (AD). It leads to degeneration of neurons and decline of cognitive functions. The most aggregative and toxic form of β-amyloid is Aβ1-42 but in experiments, the shorter forms able to form aggregates are also used. The early stages of amyloid formation are of special interest due to the influence of this peptide on progression of AD. Here, we employed nine helices of undecapeptide Aβ13-23 and studied progress of amyloid formation using 500 ns molecular dynamics simulation and implicit membrane environment. The small β-sheets emerged very early during simulation as separated two-strand structures and a presence of the membrane facilitated this process. Later, the larger β-sheets were formed. However, the ninth helix which did not form paired structure stayed unchanged till the end of MD simulation. Paired helix-helix interactions seemed to be a driving force of β-sheet formation at early stages of amyloid formation. Contrary, the specific interactions between α-helix and β-sheet can be very stable and be stabilized by the membrane. © 2015 Elsevier Ltd. All rights reserved.","Aggregation; Alzheimers disease; Implicit environment; MD simulation; β-Amyloid","Alptuzun, V., Prinz, M., Horr, V., Scheiber, J., Radacki, K., Fallarero, A., Vuorela, P., Erciyas, E., Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases (2010) Bioorg. Med. Chem., 18, pp. 2049-2059; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Robinson, C.V., Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease (2009) Nat. Chem., 1, pp. 326-331; Cecchini, M., Curcio, R., Pappalardo, M., Melki, R., Caflisch, A., A molecular dynamics approach to the structural characterization of amyloid aggregation (2006) J. Mol. Biol., 357, pp. 1306-1321; http://www.charmm-gui.org, Charmm GUI, 2012Chasseigneaux, S., Allinquant, B., Functions of Abeta, sAPPalpha and sAPPbeta: Similarities and differences (2012) J. Neurochem., 120, pp. 99-108; Cohen, S.I., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., Knowles, T.P., Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Nat. Acad. Sci. U. S. A., 110, pp. 9758-9763; Crescenzi, O., Tomaselli, S., Guerrini, R., Salvadori, S., D'Ursi, A.M., Temussi, P.A., Picone, D., Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain (2002) Eur. J. Biochem., 269, pp. 5642-5648; Davis, C.H., Berkowitz, M.L., Interaction between amyloid-β (1-42) peptide and phospholipid bilayers: A molecular dynamics study (2009) Biophys. J., 96, pp. 785-797; Davis, C.H., Berkowitz, M.L., Structure of the amyloid-β (1-42) monomer absorbed to model phospholipid bilayers: A molecular dynamics study (2009) J. Phys. Chem. B, 113, pp. 14480-14486; (2006) Pymol 0.99rc6, , Palo Alto, CA, USA: DeLano Scientific LLC; Dubnovitsky, A., Sandberg, A., Rahman, M.M., Benilova, I., Lendel, C., Hard, T., Amyloid-beta protofibrils: Size, morphology and synaptotoxicity of an engineered mimic (2013) PLOS One, 8, p. e66101; Gandy, S., Dekosky, S.T., Toward the treatment and prevention of Alzheimer's disease: Rational strategies and recent progress (2013) Annu. Rev. Med., 64, pp. 367-383; Gazit, E., A possible role for pi-stacking in the self-assembly of amyloid fibrils (2002) FASEB J., 16, pp. 77-83; Gazit, E., Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool (2005) FEBS J., 272, pp. 5971-5978; Giannozzi, P., Jansen, K., La Penna, G., Minicozzi, V., Morante, S., Rossi, G., Stellato, F., Zn induced structural aggregation patterns of beta-amyloid peptides by first-principle simulations and XAS measurements (2012) Metallomics, 4, pp. 156-165; Gu, L., Guo, Z., Alzheimer's Abeta42 and Abeta40 peptides form interlaced amyloid fibrils (2013) J. Neurochem., 126, pp. 305-311; Guo, J.L., Lee, V.M., Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles (2011) J. Biol. Chem., 286, pp. 15317-15331; (2008) Chemistry at HARvard Macromolecular Mechanics, , Charmm c34b2; Hochdorffer, K., Marz-Berberich, J., Nagel-Steger, L., Epple, M., Meyer-Zaika, W., Horn, A.H., Sticht, H., Schrader, T., Rational design of beta-sheet ligands against Abeta42-induced toxicity (2011) J. Am. Chem. Soc., 133, pp. 4348-4358; Ignasik, M., Bajda, M., Guzior, N., Prinz, M., Holzgrabe, U., Malawska, B., Design, synthesis and evaluation of novel 2-(aminoalkyl)-isoindoline-1,3-dione derivatives as dual-binding site acetylcholinesterase inhibitors (2012) Arch. Pharm., 345, pp. 509-516; Karlsson, D., Fallarero, A., Brunhofer, G., Guzik, P., Prinz, M., Holzgrabe, U., Erker, T., Vuorela, P., Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation (2012) Eur. J. Pharm. Sci., 45, pp. 169-183; Kirkitadze, M.D., Condron, M.M., Teplow, D.B., Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis (2001) J. Mol. Biol., 312, pp. 1103-1119; Lazaridis, T., Effective energy function for proteins in lipid membranes (2003) Proteins, 52, pp. 176-192; Lazaridis, T., Implicit solvent simulations of peptide interactions with anionic lipid membranes (2005) Proteins, 58, pp. 518-527; Lee, C., Ham, S., Characterizing amyloid-beta protein misfolding from molecular dynamics simulations with explicit water (2011) J. Comput. Chem., 32, pp. 349-355; Lemkul, J.A., Bevan, D.R., Aggregation of Alzheimer's amyloid beta-peptide in biological membranes: A molecular dynamics study (2013) Biochemistry, 52, pp. 4971-4980; Lu, J.X., Qiang, W., Yau, W.M., Schwieters, C.D., Meredith, S.C., Tycko, R., Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue (2013) Cell, 154, pp. 1257-1268; Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., Riek, R., 3D structure of Alzheimer's amyloid-beta(1-42) fibrils (2005) Proc. Nat. Acad. Sci. U. S. A., 102, pp. 17342-17347; Miller, Y., Ma, B., Nussinov, R., Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states (2010) Proc. Nat. Acad. Sci. U. S. A., 107, pp. 9490-9495; Minicozzi, V., Chiaraluce, R., Consalvi, V., Giordano, C., Narcisi, C., Punzi, P., Rossi, G.C., Morante, S., Computational and experimental studies on beta-sheet breakers targeting Abeta1-40 fibrils (2014) J. Biol. Chem., 289, pp. 11242-11252; Musiek, E.S., Holtzman, D.M., Origins of Alzheimer's disease: Reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement (2012) Curr. Opin. Neurol., 25, pp. 715-720; Naldi, M., Fiori, J., Pistolozzi, M., Drake, A.F., Bertucci, C., Wu, R., Mlynarczyk, K., Andrisano, V., Amyloid beta-peptide 25-35 self-assembly and its inhibition: A model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment (2012) ACS Chem. Neurosci., 3, pp. 952-962; Nikolic, A., Baud, S., Rauscher, S., Pomes, R., Molecular mechanism of beta-sheet self-organization at water-hydrophobic interfaces (2011) Proteins, 79, pp. 1-22; O'Brien, R.J., Wong, P.C., Amyloid precursor protein processing and Alzheimer's disease (2011) Annu. Rev. Neurosci., 34, pp. 185-204; Ono, K., Condron, M.M., Teplow, D.B., Structure-neurotoxicity relationships of amyloid beta-protein oligomers (2009) Proc. Nat. Acad. Sci. U. S. A., 106, pp. 14745-14750; Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B.P., Logroscino, G., Santamato, A., Greco, A., Pilotto, A., Interacting with gamma-secretase for treating Alzheimer's disease: From inhibition to modulation (2011) Curr. Med. Chem., 18, pp. 5430-5447; http://www.rcsb.org, Protein Data Bank, 2012Prinz, M., Parlar, S., Bayraktar, G., Alptuzun, V., Erciyas, E., Fallarero, A., Karlsson, D., Forster, C., 1,4-substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-beta aggregation crossing the blood-brain barrier (2013) Eur. J. Pharm. Sci., 49, pp. 603-613; Sathya, M., Premkumar, P., Karthick, C., Moorthi, P., Jayachandran, K.S., Anusuyadevi, M., BACE1 in Alzheimer's disease (2012) Clin. Chim. Acta, 414, pp. 171-178; Shao, H., Jao, S., Ma, K., Zagorski, M.G., Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease (1999) J. Mol. Biol., 285, pp. 755-773; Shea, J.E., Urbanc, B., Insights into Abeta aggregation: A molecular dynamics perspective (2012) Curr. Top. Med. Chem., 12, pp. 2596-2610; Silva, K.I., Saxena, S., Zn(II) ions substantially perturb Cu(II) ion coordination in amyloid-beta at physiological pH (2013) J. Phys. Chem. B, 117, pp. 9386-9394; Stellato, F., Menestrina, G., Serra, M.D., Potrich, C., Tomazzolli, R., Meyer-Klaucke, W., Morante, S., Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes (2006) Eur. Biophys. J., 35, pp. 340-351; Tan, J., Evin, G., Beta-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis (2012) J. Neurochem., 120, pp. 869-880; Tomaselli, S., Esposito, V., Vangone, P., Van Nuland, N.A., Bonvin, A.M., Guerrini, R., Tancredi, T., Picone, D., The alpha-to-beta conformational transition of Alzheimer's abeta-(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of beta conformation seeding (2006) ChemBioChem, 7, pp. 257-267; Tycko, R., Solid-state NMR studies of amyloid fibril structure (2011) Annu. Rev. Phys. Chem., 62, pp. 279-299; (2011) Vmd 1.9, , Urbana-Champaign, IL, USA: University of Illinois; Urbanc, B., Cruz, L., Teplow, D.B., Stanley, H.E., Computer simulations of Alzheimer's amyloid beta-protein folding and assembly (2006) Curr. Alzheimer Res., 3, pp. 493-504; Wang, Q., Zhao, C., Zhao, J., Wang, J., Yang, J.C., Yu, X., Zheng, J., Comparative molecular dynamics study of Abeta adsorption on the self-assembled monolayers (2010) Langmuir, 26, pp. 3308-3316; Williams, T.L., Serpell, L.C., Membrane and surface interactions of Alzheimer's Abeta peptide - Insights into the mechanism of cytotoxicity (2011) FEBS J., 278, pp. 3905-3917; Yu, X., Wang, Q., Lin, Y., Zhao, J., Zhao, C., Zheng, J., Structure, orientation, and surface interaction of Alzheimer amyloid-beta peptides on the graphite (2012) Langmuir, 28, pp. 6595-6605; Zhao, J., Wang, Q., Liang, G., Zheng, J., Molecular dynamics simulations of low-ordered Alzheimer beta-amyloid oligomers from dimer to hexamer on self-assembled monolayers (2011) Langmuir, 27, pp. 14876-14887; Zheng, J., Jang, H., Ma, B., Tsai, C.J., Nussinov, R., Modeling the Alzheimer Abeta17-42 fibril architecture: Tight intermolecular sheet-sheet association and intramolecular hydrated cavities (2007) Biophys. J., 93, pp. 3046-3057",Article,Scopus,2-s2.0-84924072684
"Chae Y.J., Lee H.J., Jeon J.H., Kim I.-B., Choi J.-S., Sung K.-W., Hahn S.J.","Effects of donepezil on hERG potassium channels",2015,"Brain Research","1597",,,"77","85",,,10.1016/j.brainres.2014.11.057,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923241696&partnerID=40&md5=746dfae789b064a9f975a63db0d7fc59","Department of Physiology, College of Medicine, Catholic University of Korea, 222 Banpo-daeroSeoul, Seocho-gu, South Korea; Department of Pharmacology, College of Medicine, Catholic University of KoreaSeoul, South Korea; Department of Anatomy, College of Medicine, Catholic University of KoreaSeoul, South Korea; College of Pharmacy, Integrated Research Institute of Pharmaceutical, Catholic University of Korea, 43-1 Yeokgok 2-dongWonmi-gu, Bucheon, Gyeonggi-do, South Korea","Chae, Y.J., Department of Physiology, College of Medicine, Catholic University of Korea, 222 Banpo-daeroSeoul, Seocho-gu, South Korea; Lee, H.J., Department of Pharmacology, College of Medicine, Catholic University of KoreaSeoul, South Korea; Jeon, J.H., Department of Anatomy, College of Medicine, Catholic University of KoreaSeoul, South Korea; Kim, I.-B., Department of Anatomy, College of Medicine, Catholic University of KoreaSeoul, South Korea; Choi, J.-S., College of Pharmacy, Integrated Research Institute of Pharmaceutical, Catholic University of Korea, 43-1 Yeokgok 2-dongWonmi-gu, Bucheon, Gyeonggi-do, South Korea; Sung, K.-W., Department of Pharmacology, College of Medicine, Catholic University of KoreaSeoul, South Korea; Hahn, S.J., Department of Physiology, College of Medicine, Catholic University of Korea, 222 Banpo-daeroSeoul, Seocho-gu, South Korea","Donepezil is a potent, selective inhibitor of acetylcholinesterase, which is used for the treatment of Alzheimer's disease. Whole-cell patch-clamp technique and Western blot analyses were used to study the effects of donepezil on the human ether-a-go-go-related gene (hERG) channel. Donepezil inhibited the tail current of the hERG in a concentration-dependent manner with an IC50 of 1.3 μM. The metabolites of donepezil, 6-ODD and 5-ODD, inhibited the hERG currents in a similar concentration-dependent manner; the IC50 values were 1.0 and 1.5 μM, respectively. A fast drug perfusion system demonstrated that donepezil interacted with both the open and inactivated states of the hERG. A fast application of donepezil during the tail currents inhibited the open state of the hERG in a concentration-dependent manner with an IC50 of 2.7 μM. Kinetic analysis of donepezil in an open state of the hERG yielded blocking and unblocking rate constants of 0.54 μM-1s-1 and 1.82 s-1, respectively. The block of the hERG by donepezil was voltage-dependent with a steep increase across the voltage range of channel activation. Donepezil caused a reduction in the hERG channel protein trafficking to the plasma membrane at low concentration, but decreased the channel protein expression at higher concentrations. These results suggest that donepezil inhibited the hERG at a supratherapeutic concentration, and that it did so by preferentially binding to the activated (open and/or inactivated) states of the channels and by inhibiting the trafficking and expression of the hERG channel protein in the plasma membrane. © 2014 Elsevier B.V. All rights reserved.","Alzheimers disease; Channel trafficking; Donepezil; hERG","Chae, Y.J., Jeon, J.H., Lee, H.J., Kim, I.B., Choi, J.S., Sung, K.W., Hahn, S.J., Escitalopram block of hERG potassium channels (2014) N-S. Arch. Pharmacol., 387, pp. 23-32; Chiesa, N., Rosati, B., Arcangeli, A., Olivotto, M., Wanke, E., A novel role for HERG K+ channels: Spike-frequency adaptation (1997) J. Physiol., 501, pp. 313-318; Choi, J.S., Choi, B.H., Ahn, H.S., Kim, M.J., Rhie, D.J., Yoon, S.H., Jo, S., Hahn J.S, K.W., Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells (2003) Biochem. Pharmacol., 66, pp. 2125-2132; Dooley, M., Lamb, H.M., Donepezil: A review of its use in Alzheimers disease (2000) Drug Aging, 16, pp. 199-226; Fischer, F., Vonderlin, N., Seyler, C., Zitron, E., Schernus, B., Katus, H., Scholz, E., Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels (2013) N-S. Arch. Pharmacol., 386, pp. 795-804; Ganapathi, S.B., Kester, M., Elmslie, K.S., State-dependent block of HERG potassium channels by R-roscovitine: Implications for cancer therapy (2009) Am. J. Physiol. Cell Physiol, 296, pp. C701-C710; Guasti, L., Cilia, E., Crociani, O., Hofmann, G., Polvani, S., Becchetti, A., Wanke, E., Arcangeli, A., Expression pattern of the ether-a-go-go-related (ERG) family proteins in the adult mouse central nervous system: Evidence for coassembly of different subunits (2005) J. Comp. Neurol., 491, pp. 157-174; Huffaker, S.J., Chen, J., Nicodemus, K.K., Sambataro, F., Yang, F., Mattay, V., Lipska, B.K., Weinberger, D.R., A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia (2009) Nat. Med., 15, pp. 509-518; Jeon, J.H., Paik, S.S., Chun, M.H., Oh, U., Kim, I.B., Presynaptic localization and possible function of calcium-activated chloride channel anoctamin 1 in the mammalian retina (2013) PLoS One, 8, p. e67989; Kosasa, T., Kuriya, Y., Matsui, K., Yamanishi, Y., Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimers disease, on cholinesterase activity in rats (2000) Eur. J. Pharmacol., 389, pp. 173-179; Kraliz, D., Singh, S., Selective blockade of the delayed rectifier potassium current by tacrine in Drosophila (1997) J. Neurobiol., 32, pp. 1-10; Lavretsky, E.P., Jarvik, L.F., A group of potassium-channel blockers-acetylcholine releasers: New potentials for Alzheimer disease? A review (1992) J. Clin. Psychopharmacol., 12, pp. 110-118; Li, Y., Hu, G.Y., Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons (2002) Neurosci. Lett., 324, pp. 25-28; Pan, Y., Xu, X., Wang, X., Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons (2003) Br. J. Pharmacol., 140, pp. 907-912; Pan, Y.P., Xu, X.H., Wang, X.L., Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons (2003) Neurosci. Lett., 336, pp. 37-40; Paul, A.A., Witchel, H.J., Hancox, J.C., Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine (2002) Br. J. Pharmacol., 136, pp. 717-729; Rajamani, S., Eckhardt, L.L., Valdivia, C.R., Klemens, C.A., Gillman, B.M., Anderson, C.L., Holzem, K.M., January, C.T., Drug-induced long QT syndrome: HERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine (2006) Br. J. Pharmacol., 149, pp. 481-489; Rajamani, S., Shryock, J.C., Belardinelli, L., Rapid kinetic interactions of ranolazine with HERG K+ current (2008) J. Cardiovasc. Pharmacol., 51, pp. 581-589; Rogawski, M.A., Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons (1987) Eur. J. Pharmacol., 142, pp. 169-172; Rogers, S.L., Doody, R.S., Mohs, R.C., Friedhoff, L.T., Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group (1998) Arch. Intern. Med., 158, pp. 1021-1031; Rogers, S.L., Friedhoff, L.T., Long-term efficacy and safety of donepezil in the treatment of Alzheimers disease: An interim analysis of the results of a US multicentre open label extension study (1998) Eur. Neuropsychopharmacol., 8, pp. 67-75; Sanguinetti, M.C., Jiang, C., Curran, M.E., Keating, M.T., A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel (1995) Cell, 81, pp. 299-307; Sanguinetti, M.C., Tristani-Firouzi, M., HERG potassium channels and cardiac arrhythmia (2006) Nature, 440, pp. 463-469; Snyders, D.J., Structure and function of cardiac potassium channels (1999) Cardiovasc. Res., 42, pp. 377-390; Solntseva, E.I., Bukanova, J.V., Marchenko, E., Skrebitsky, V.G., Donepezil is a strong antagonist of voltage-gated calcium and potassium channels in molluscan neurons (2007) Comp. Biochem. Physiol. C Toxicol. Pharmacol., 144, pp. 319-326; Sugimoto, H., Yamanishi, Y., Iimura, Y., Kawakami, Y., Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors (2000) Curr. Med. Chem., 7, pp. 303-339; Takaya, T., Okamoto, M., Yodoi, K., Hata, K., Kijima, Y., Nakajima, H., Nishikawa, Y., Kawashima, S., Torsades de Pointes with QT prolongation related to donepezil use (2009) J. Cardiol., 54, pp. 507-511; Tanaka, A., Koga, S., Hiramatsu, Y., Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes (2009) Intern. Med., 48, pp. 1219-1223; Thomas, D., Gut, B., Wendt-Nordahl, G., Kiehn, J., The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels (2002) J. Pharmacol. Exp. Ther., 300, pp. 543-548; Vandenberg, J.I., Perry, M.D., Perrin, M.J., Mann, S.A., Ke, Y., Hill, A.P., HERG K+ channels: Structure, function, and clinical significance (2012) Physiol. Rev., 92, pp. 1393-1478; Vigneault, P., Bourgault, S., Kaddar, N., Caillier, B., Pilote, S., Patoine, D., Simard, C., Drolet, B., Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current (2012) Eur. J. Pharmacol., 681, pp. 68-74; Wilkinson, D.G., The pharmacology of donepezil: A new treatment of Alzheimers disease (1999) Expert Opin. Pharmacother., 1, pp. 121-135; Wiseman, E.J., Jarvik, L.F., Potassium channel blockers: Could they work in Alzheimer disease? (1991) Alz. Dis. Assoc. Dis., 5, pp. 25-30; Witchel, H.J., Pabbathi, V.K., Hofmann, G., Paul, A.A., Hancox, J.C., Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents (2002) FEBS Lett., 512, pp. 59-66; Yu, B., Hu, G.Y., Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons (2005) Eur. J. Pharmacol., 508, pp. 15-21; Zhong, C.B., Zhang, W., Wang, X.L., [Effects of donepezil on the delayed rectifier-like potassium current in pyramidal neurons of rat hippocampus and neocortex] (2002) Yao Xue Xue Bao, 37, pp. 415-418",Article,Scopus,2-s2.0-84923241696
"Karch C.M., Goate A.M.","Alzheimer's disease risk genes and mechanisms of disease pathogenesis",2015,"Biological Psychiatry","77","1",,"43","51",,5,10.1016/j.biopsych.2014.05.006,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920703987&partnerID=40&md5=86e628c47b7fede608081525788736c0","Department of Psychiatry, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States","Karch, C.M., Department of Psychiatry, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States; Goate, A.M., Department of Psychiatry, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States","We review the genetic risk factors for late-onset Alzheimer's disease (AD) and their role in AD pathogenesis. More recent advances in understanding of the human genome - technologic advances in methods to analyze millions of polymorphisms in thousands of subjects - have revealed new genes associated with AD risk, including ABCA7, BIN1, CASS4, CD33, CD2AP, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB5-DBR1, INPP5D, MS4A, MEF2C, NME8, PICALM, PTK2B, SLC24H4-RIN3, SORL1, and ZCWPW1. Emerging technologies to analyze the entire genome in large data sets have also revealed coding variants that increase AD risk: PLD3 and TREM2. We review the relationship between these AD risk genes and the cellular and neuropathologic features of AD. Understanding the mechanisms underlying the association of these genes with risk for disease will provide the most meaningful targets for therapeutic development to date. © 2015 Society of Biological Psychiatry.","Alzheimers Disease; Amyloid Precursor Protein; Cholesterol Metabolism; Endocytosis; Genome-Wide Association Studies; Immune Response","Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Holtzman, D.M., Morris, J.C., Goate, A.M., Alzheimer's disease: The challenge of the second century (2011) Sci Transl Med, 3, p. 77sr71; Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) Nat Genet, 41, pp. 1088-1093; Naj, A.C., Jun, G., Beecham, G.W., Wang, L.-S., Vardarajan, B.N., Buros, J., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease (2011) Nat Genet, 43, pp. 436-441; Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M.M., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease (2011) Nat Genet, 43, pp. 429-435; Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease (2013) Nat Genet, 45, pp. 1452-1458; Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M.F., Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE (2008) Am J Hum Genet, 83, pp. 623-632; Kim, M., Suh, J., Romano, D., Truong, M.H., Mullin, K., Hooli, B., Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity (2009) Hum Mol Genet, 18, pp. 3987-3996; Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., TREM2 variants in Alzheimer's disease (2013) N Engl J Med, 368, pp. 117-127; Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Variant of TREM2 associated with the risk of Alzheimer's disease (2013) N Engl J Med, 368, pp. 107-116; Cruchaga, C., Karch, C.M., Jin, S.C., Benitez, B.A., Cai, Y., Guerreiro, R., Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease (2014) Nature, 505, pp. 550-554; Zhang, B., Gaiteri, C., Bodea, L.G., Wang, Z., McElwee, J., Podtelezhnikov, A.A., Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease (2013) Cell, 153, pp. 707-720; Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease (2009) Nat Genet, 41, pp. 1094-1099; Cruchaga, C., Kauwe, J.S.K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease (2010) PLoS Genet, 6, p. e1001101; Cruchaga, C., Kauwe, J.S., Harari, O., Jin, S.C., Cai, Y., Karch, C.M., GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease (2013) Neuron, 78, pp. 256-268; Kauwe, J.S.K., Cruchaga, C., Bertelsen, S., Mayo, K., Latu, W., Nowotny, P., Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels (2010) J Alzheimers Dis, 21, pp. 833-842; Kauwe, J.S.K., Cruchaga, C., Karch, C.M., Sadler, B., Lee, M., Mayo, K., Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease (2011) PLoS One, 6, p. e15918; Kauwe, J.S.K., Cruchaga, C., Mayo, K., Fenoglio, C., Bertelsen, S., Nowotny, P., Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition (2008) Proc Natl Acad Sci U S A, 105, pp. 8050-8054; Biffi, A., Anderson, C.D., Desikan, R.S., Sabuncu, M., Cortellini, L., Schmansky, N., Genetic variation and neuroimaging measures in Alzheimer disease (2010) Arch Neurol, 67, pp. 677-685; Shulman, J.M., Chen, K., Keenan, B.T., Chibnik, L.B., Fleisher, A., Thiyyagura, P., Genetic susceptibility for Alzheimer disease neuritic plaque pathology (2013) JAMA Neurol, 70, pp. 1150-1157; Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2013) Alzheimers Dement, 9, pp. e111-e194; Guerreiro, R.J., Gustafson, D.R., Hardy, J., The genetic architecture of Alzheimer's disease: Beyond APP, PSENs and APOE (2012) Neurobiol Aging, 33, pp. 437-456; Thinakaran, G., Koo, E.H., Amyloid precursor protein trafficking, processing, and function (2008) J Biol Chem, 283, pp. 29615-29619; Mattson, M.P., Cheng, B., Culwell, A.R., Esch, F.S., Lieberburg, I., Rydel, R.E., Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein (1993) Neuron, 10, pp. 243-254; Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A., The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice (2007) J Neurosci, 27, pp. 7817-7826; Cruchaga, C., Haller, G., Chakraverty, S., Mayo, K., Vallania, F.L., Mitra, R.D., Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families (2012) PLoS One, 7, p. e31039; Benitez, B.A., Karch, C.M., Cai, Y., Jin, S.C., Cooper, B., Carrell, D., The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-epsilon4 carriers (2013) PLoS Genet, 9, p. e1003685; Jin, S.C., Pastor, P., Cooper, B., Cervantes, S., Benitez, B.A., Razquin, C., Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort (2012) Alzheimers Res Ther, 4, p. 34; Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline (2012) Nature, 488, pp. 96-99; Kuhn, P.H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J.W., ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons (2010) EMBO J, 29, pp. 3020-3032; Suh, J., Choi, S.H., Romano, D.M., Gannon, M.A., Lesinski, A.N., Kim, D.Y., ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function (2013) Neuron, 80, pp. 385-401; Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families (1993) Science, 261, pp. 921-923; Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Binding of human apolipoprotein e to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease (1993) Proc Natl Acad Sci U S A, 90, pp. 8098-8102; Mahley, R.W., Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology (1988) Science, 240, pp. 622-630; Kim, J., Basak, J.M., Holtzman, D.M., The role of apolipoprotein e in Alzheimer's disease (2009) Neuron, 63, pp. 287-303; Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., Demattos, R.B., Patterson, B.W., Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance (2011) Sci Transl Med, 3, p. 89ra57; Verghese, P.B., Castellano, J.M., Garai, K., Wang, Y., Jiang, H., Shah, A., ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions (2013) Proc Natl Acad Sci U S A, 110, pp. E1807-E1816; Bales, K.R., Verina, T., Dodel, R.C., Du, Y., Altstiel, L., Bender, M., Lack of apolipoprotein e dramatically reduces amyloid beta-peptide deposition (1997) Nat Genet, 17, pp. 263-264; Fryer, J.D., Simmons, K., Parsadanian, M., Bales, K.R., Paul, S.M., Sullivan, P.M., Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model (2005) J Neurosci, 25, pp. 2803-2810; Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadanian, M., Sartorius, L.J., Apolipoprotein e isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease (2000) Proc Natl Acad Sci U S A, 97, pp. 2892-2897; Fagan, A.M., Watson, M., Parsadanian, M., Bales, K.R., Paul, S.M., Holtzman, D.M., Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease (2002) Neurobiol Dis, 9, pp. 305-318; Rebeck, G.W., Reiter, J.S., Strickland, D.K., Hyman, B.T., Apolipoprotein e in sporadic Alzheimer's disease: Allelic variation and receptor interactions (1993) Neuron, 11, pp. 575-580; Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging (2010) Ann Neurol, 67, pp. 122-131; Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) Proc Natl Acad Sci U S A, 106, pp. 6820-6825; Jones, S.E., Jomary, C., Clusterin (2002) Int J Biochem Cell Biol, 34, pp. 427-431; Rizzi, F., Caccamo, A.E., Belloni, L., Bettuzzi, S., Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells (2009) J Cell Physiol, 219, pp. 314-323; Szymanski, M., Wang, R., Bassett, S.S., Avramopoulos, D., Alzheimer's risk variants in the clusterin gene are associated with alternative splicing (2011) Transl Psychiatry 1.pii, p. e18; Xing, Y.Y., Yu, J.T., Cui, W.Z., Zhong, X.L., Wu, Z.C., Zhang, Q., Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease (2012) J Alzheimers Dis, 29, pp. 515-519; Schurmann, B., Wiese, B., Bickel, H., Weyerer, S., Riedel-Heller, S.G., Pentzek, M., Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration (2011) J Alzheimers Dis, 25, pp. 421-424; Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease (2010) Arch Gen Psychiatry, 67, pp. 739-748; Schrijvers, E.M., Koudstaal, P.J., Hofman, A., Breteler, M.M., Plasma clusterin and the risk of Alzheimer disease (2011) JAMA, 305, pp. 1322-1326; Kiddle, S.J., Sattlecker, M., Proitsi, P., Simmons, A., Westman, E., Bazenet, C., Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study (2014) J Alzheimers Dis, 38, pp. 515-531; Karch, C.M., Jeng, A.T., Nowotny, P., Cady, J., Cruchaga, C., Goate, A.M., Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains (2012) PLoS One, 7, p. e50976; Allen, M., Zou, F., Chai, H.S., Younkin, C.S., Crook, J., Pankratz, V.S., Novel late-onset Alzheimer disease loci variants associate with brain gene expression (2012) Neurology, 79, pp. 221-228; May, P.C., Lampert-Etchells, M., Johnson, S.A., Poirier, J., Masters, J.N., Finch, C.E., Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat (1990) Neuron, 5, pp. 831-839; Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B., Ghiso, J., Apolipoprotein J (clusterin) and Alzheimer's disease (2000) Microsc Res Tech, 50, pp. 305-315; Matsubara, E., Frangione, B., Ghiso, J., Characterization of apolipoprotein J-Alzheimer's A beta interaction (1995) J Biol Chem, 270, pp. 7563-7567; Oda, T., Wals, P., Osterburg, H.H., Johnson, S.A., Pasinetti, G.M., Morgan, T.E., Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress (1995) Exp Neurol, 136, pp. 22-31; Matsubara, E., Soto, C., Governale, S., Frangione, B., Ghiso, J., Apolipoprotein J and Alzheimer's amyloid beta solubility (1996) Biochem J, 316 (2), pp. 671-679; Demattos, R.B., O'Dell, M.A., Parsadanian, M., Taylor, J.W., Harmony, J.A.K., Bales, K.R., Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease (2002) Proc Natl Acad Sci U S A, 99, pp. 10843-10848; Demattos, R.B., Cirrito, J.R., Parsadanian, M., May, P.C., O'Dell, M.A., Taylor, J.W., ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo (2004) Neuron, 41, pp. 193-202; Kim, W.S., Weickert, C.S., Garner, B., Role of ATP-binding cassette transporters in brain lipid transport and neurological disease (2008) J Neurochem, 104, pp. 1145-1166; Ikeda, Y., Abe-Dohmae, S., Munehira, Y., Aoki, R., Kawamoto, S., Furuya, A., Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release (2003) Biochem Biophys Res Commun, 311, pp. 313-318; Vasquez, J.B., Fardo, D.W., Estus, S., ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status (2013) Neurosci Lett, 556, pp. 58-62; Kim, W.S., Guillemin, G.J., Glaros, E.N., Lim, C.K., Garner, B., Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells (2006) Neuroreport, 17, pp. 891-896; Kim, W.S., Fitzgerald, M.L., Kang, K., Okuhira, K., Bell, S.A., Manning, J.J., Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels (2005) J Biol Chem, 280, pp. 3989-3995; Kim, W.S., Li, H., Ruberu, K., Chan, S., Elliott, D.A., Low, J.K., Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease (2013) J Neurosci, 33, pp. 4387-4394; Chan, S.L., Kim, W.S., Kwok, J.B., Hill, A.F., Cappai, R., Rye, K.A., ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro (2008) J Neurochem, 106, pp. 793-804; Jehle, A.W., Gardai, S.J., Li, S., Linsel-Nitschke, P., Morimoto, K., Janssen, W.J., ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages (2006) J Cell Biol, 174, pp. 547-556; Tanaka, N., Abe-Dohmae, S., Iwamoto, N., Fitzgerald, M.L., Yokoyama, S., HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7 (2011) Atherosclerosis, 217, pp. 407-414; Tanaka, N., Abe-Dohmae, S., Iwamoto, N., Yokoyama, S., Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system (2011) J Atheroscler Thromb, 18, pp. 274-281; Wildsmith, K.R., Holley, M., Savage, J.C., Skerrett, R., Landreth, G.E., Evidence for impaired amyloid beta clearance in Alzheimer's disease (2013) Alzheimers Res Ther, 5, p. 33; Krych-Goldberg, M., Moulds, J.M., Atkinson, J.P., Human complement receptor type 1 (CR1) binds to a major malarial adhesin (2002) Trends Mol Med, 8, pp. 531-537; Liu, D., Niu, Z.X., The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35) (2009) Immunopharmacol Immunotoxicol, 31, pp. 524-535; Eikelenboom, P., Stam, F.C., Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study (1982) Acta Neuropathol, 57, pp. 239-242; Shen, Y., Li, R., McGeer, E.G., McGeer, P.L., Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain (1997) Brain Res, 769, pp. 391-395; Terai, K., Walker, D.G., McGeer, E.G., McGeer, P.L., Neurons express proteins of the classical complement pathway in Alzheimer disease (1997) Brain Res, 769, pp. 385-390; Gasque, P., Ischenko, A., Legoedec, J., Mauger, C., Schouft, M.T., Fontaine, M., Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells (1993) J Biol Chem, 268, pp. 25068-25074; Hosokawa, M., Klegeris, A., Maguire, J., McGeer, P.L., Expression of complement messenger RNAs and proteins by human oligodendroglial cells (2003) Glia, 42, pp. 417-423; McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., Activation of the classical complement pathway in brain tissue of Alzheimer patients (1989) Neurosci Lett, 107, pp. 341-346; Shen, Y., Lue, L., Yang, L., Roher, A., Kuo, Y., Strohmeyer, R., Complement activation by neurofibrillary tangles in Alzheimer's disease (2001) Neurosci Lett, 305, pp. 165-168; Schifferli, J.A., Paccaud, J.P., Two isotypes of human C4, C4A and C4B have different structure and function (1989) Complement Inflamm, 6, pp. 19-26; Gibson, N.C., Waxman, F.J., Relationship between immune complex binding and release and the quantitative expression of the complement receptor, type 1 (CR1, CD35) on human erythrocytes (1994) Clin Immunol Immunopathol, 70, pp. 104-113; Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes (2006) Neurobiol Aging, 27, pp. 1733-1739; Velazquez, P., Cribbs, D.H., Poulos, T.L., Tenner, A.J., Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis (1997) Nat Med, 3, pp. 77-79; Crocker, P.R., Hartnell, A., Munday, J., Nath, D., The potential role of sialoadhesin as a macrophage recognition molecule in health and disease (1997) Glycoconj J, 14, pp. 601-609; Malik, M., Simpson, J.F., Parikh, I., Wilfred, B.R., Fardo, D.W., Nelson, P.T., CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing (2013) J Neurosci, 33, pp. 13320-13325; Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta (2013) Neuron, 78, pp. 631-643; Linnartz, B., Neumann, H., Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx (2013) Glia, 61, pp. 37-46; Tateno, H., Li, H., Schur, M.J., Bovin, N., Crocker, P.R., Wakarchuk, W.W., Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity (2007) Mol Cell Biol, 27, pp. 5699-5710; Howie, D., Nolan, K.F., Daley, S., Butterfield, E., Adams, E., Garcia-Rueda, H., MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation (2009) J Immunol, 183, pp. 4197-4204; Zuccolo, J., Bau, J., Childs, S.J., Goss, G.G., Sensen, C.W., Deans, J.P., Phylogenetic analysis of the MS4A and TMEM176 gene families (2010) PLoS One, 5, p. e9369; Rohn, T.T., The triggering receptor expressed on myeloid cells 2: ""tREM-ming"" the inflammatory component associated with Alzheimer's disease (2013) Oxid Med Cell Longev, 2013, p. 860959; Colonna, M., TREMs in the immune system and beyond (2003) Nat Rev Immunol, 3, pp. 445-453; Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype (2002) Am J Hum Genet, 71, pp. 656-662; Guerreiro, R.J., Lohmann, E., Bras, J.M., Gibbs, J.R., Rohrer, J.D., Gurunlian, N., Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement (2013) JAMA Neurol, 70, pp. 78-84; Giraldo, M., Lopera, F., Siniard, A.L., Corneveaux, J.J., Schrauwen, I., Carvajal, J., Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease (2013) Neurobiol Aging, 34, p. 2077. , e11-e18; Bertram, L., Parrado, A.R., Tanzi, R.E., TREM2 and neurodegenerative disease (2013) N Engl J Med, 369, p. 1565; Benitez, B.A., Cruchaga, C., TREM2 and neurodegenerative disease (2013) N Engl J Med, 369, pp. 1567-1568; Pottier, C., Wallon, D., Rousseau, S., Rovelet-Lecrux, A., Richard, A.C., Rollin-Sillaire, A., TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease (2013) J Alzheimers Dis, 35, pp. 45-49; Guerreiro, R., Hardy, J., TREM2 and neurodegenerative disease (2013) N Engl J Med, 369, pp. 1569-1570; Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W.W., TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease (2013) Mol Neurodegener, 8, p. 19; Cady, J., Koval, E.D., Benitez, B.A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis (2014) JAMA Neurol, 71, pp. 449-453; Rajagopalan, P., Hibar, D.P., Thompson, P.M., TREM2 and neurodegenerative disease (2013) N Engl J Med, 369, pp. 1565-1567; Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N.T., Neumann, H., Walter, J., Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) by ectodomain shedding and gamma-secretase dependent intramembranous cleavage (2013) J Biol Chem, 288, pp. 33027-33036; Ren, G., Vajjhala, P., Lee, J.S., Winsor, B., Munn, A.L., The BAR domain proteins: Molding membranes in fission, fusion, and phagy (2006) Microbiol Mol Biol Rev, 70, pp. 37-120; Ramjaun, A.R., McPherson, P.S., Multiple amphiphysin II splice variants display differential clathrin binding: Identification of two distinct clathrin-binding sites (1998) J Neurochem, 70, pp. 2369-2376; McMahon, H.T., Wigge, P., Smith, C., Clathrin interacts specifically with amphiphysin and is displaced by dynamin (1997) FEBS Lett, 413, pp. 319-322; Tsutsui, K., Maeda, Y., Seki, S., Tokunaga, A., CDNA cloning of a novel amphiphysin isoform and tissue-specific expression of its multiple splice variants (1997) Biochem Biophys Res Commun, 236, pp. 178-183; Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K.V., Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology (2013) Mol Psychiatry, 18, pp. 1225-1234; Yang, S., Liu, T., Li, S., Zhang, X., Ding, Q., Que, H., Comparative proteomic analysis of brains of naturally aging mice (2008) Neuroscience, 154, pp. 1107-1120; Meunier, B., Quaranta, M., Daviet, L., Hatzoglou, A., Leprince, C., The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170) (2009) Eur J Cell Biol, 88, pp. 91-102; Pant, S., Sharma, M., Patel, K., Caplan, S., Carr, C.M., Grant, B.D., AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling (2009) Nat Cell Biol, 11, pp. 1399-1410; Wigge, P., McMahon, H.T., The amphiphysin family of proteins and their role in endocytosis at the synapse (1998) Trends Neurosci, 21, pp. 339-344; Di Paolo, G., Sankaranarayanan, S., Wenk, M.R., Daniell, L., Perucco, E., Caldarone, B.J., Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice (2002) Neuron, 33, pp. 789-804; Galderisi, U., Di Bernardo, G., Cipollaro, M., Jori, F.P., Piegari, E., Cascino, A., Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein (1999) J Cell Biochem, 74, pp. 313-322; Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingam, M., Green, M.R., Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7 (2008) Cell, 132, pp. 363-374; Wixler, V., Laplantine, E., Geerts, D., Sonnenberg, A., Petersohn, D., Eckes, B., Identification of novel interaction partners for the conserved membrane proximal region of alpha-integrin cytoplasmic domains (1999) FEBS Lett, 445, pp. 351-355; Xiao, Q., Gil, S.C., Yan, P., Wang, Y., Han, S., Gonzales, E., Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis (2012) J Biol Chem, 287, pp. 21279-21289; Baig, S., Joseph, S.A., Tayler, H., Abraham, R., Owen, M.J., Williams, J., Distribution and expression of picalm in Alzheimer disease (2010) J Neuropathol Exp Neurol, 69, pp. 1071-1077; Harel, A., Wu, F., Mattson, M.P., Morris, C.M., Yao, P.J., Evidence for CALM in directing VAMP2 trafficking (2008) Traffic, 9, pp. 417-429; Wendland, B., Emr, S.D., Riezman, H., Protein traffic in the yeast endocytic and vacuolar protein sorting pathways (1998) Curr Opin Cell Biol, 10, pp. 513-522; Zhang, B., Koh, Y.H., Beckstead, R.B., Budnik, V., Ganetzky, B., Bellen, H.J., Synaptic vesicle size and number are regulated by a clathrin adaptor protein required for endocytosis (1998) Neuron, 21, pp. 1465-1475; Duce, J.A., Tsatsanis, A., Cater, M.A., James, S.A., Robb, E., Wikhe, K., Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease (2010) Cell, 142, pp. 857-867; Treusch, S., Hamamichi, S., Goodman, J.L., Matlack, K.E., Chung, C.Y., Baru, V., Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast (2011) Science, 334, pp. 1241-1245; Tian, Y., Chang, J.C., Fan, E.Y., Flajolet, M., Greengard, P., Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy (2013) Proc Natl Acad Sci U S A, 110, pp. 17071-17076; Dustin, M.L., Olszowy, M.W., Holdorf, A.D., Li, J., Bromley, S., Desai, N., A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts (1998) Cell, 94, pp. 667-677; Shulman, J.M., Chipendo, P., Chibnik, L.B., Aubin, C., Tran, D., Keenan, B.T., Functional screening of Alzheimer pathology genome-wide association signals in Drosophila (2011) Am J Hum Genet, 88, pp. 232-238; Cormont, M., Meton, I., Mari, M., Monzo, P., Keslair, F., Gaskin, C., CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl (2003) Traffic, 4, pp. 97-112; Yamazaki, T., Masuda, J., Omori, T., Usui, R., Akiyama, H., Maru, Y., EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility (2009) J Cell Sci, 122, pp. 243-255; Martinez, A., Otal, R., Sieber, B.A., Ibanez, C., Soriano, E., Disruption of ephrin-A/EphA binding alters synaptogenesis and neural connectivity in the hippocampus (2005) Neuroscience, 135, pp. 451-461; Lai, K.O., Ip, N.Y., Synapse development and plasticity: Roles of ephrin/Eph receptor signaling (2009) Curr Opin Neurobiol, 19, pp. 275-283; Sakamoto, A., Sugamoto, Y., Tokunaga, Y., Yoshimuta, T., Hayashi, K., Konno, T., Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells (2011) J Int Med Res, 39, pp. 522-527; Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease (2007) Nat Genet, 39, pp. 168-177; Lee, J.H., Cheng, R., Honig, L.S., Vonsattel, J.P., Clark, L., Mayeux, R., Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease (2008) Neurology, 70, pp. 887-889; Spoelgen, R., Von Arnim, C.A., Thomas, A.V., Peltan, I.D., Koker, M., Deng, A., Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme (2006) J Neurosci, 26, pp. 418-428; Offe, K., Dodson, S.E., Shoemaker, J.T., Fritz, J.J., Gearing, M., Levey, A.I., The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments (2006) J Neurosci, 26, pp. 1596-1603; Schmidt, V., Sporbert, A., Rohe, M., Reimer, T., Rehm, A., Andersen, O.M., SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1 (2007) J Biol Chem, 282, pp. 32956-32964; Dodson, S.E., Andersen, O.M., Karmali, V., Fritz, J.J., Cheng, D., Peng, J., Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: Evidence for a proximal role in Alzheimer's disease (2008) J Neurosci, 28, pp. 12877-12886; Scherzer, C.R., Offe, K., Gearing, M., Rees, H.D., Fang, G., Heilman, C.J., Loss of apolipoprotein e receptor LR11 in Alzheimer disease (2004) Arch Neurol, 61, pp. 1200-1205; Dodson, S.E., Gearing, M., Lippa, C.F., Montine, T.J., Levey, A.I., Lah, J.J., LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease (2006) J Neuropathol Exp Neurol, 65, pp. 866-872; Sager, K.L., Wuu, J., Leurgans, S.E., Rees, H.D., Gearing, M., Mufson, E.J., Neuronal LR11/sorLA expression is reduced in mild cognitive impairment (2007) Ann Neurol, 62, pp. 640-647; Munck, A., Bohm, C., Seibel, N.M., Hashemol Hosseini, Z., Hampe, W., Hu-K4 is a ubiquitously expressed type 2 transmembrane protein associated with the endoplasmic reticulum (2005) FEBS J, 272, pp. 1718-1726; McDermott, M., Wakelam, M.J., Morris, A.J., Phospholipase D (2004) Biochem Cell Biol, 82, pp. 225-253; Cai, D., Zhong, M., Wang, R., Netzer, W.J., Shields, D., Zheng, H., Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons (2006) Proc Natl Acad Sci U S A, 103, pp. 1936-1940; Cai, D., Netzer, W.J., Zhong, M., Lin, Y., Du, G., Frohman, M., Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation (2006) Proc Natl Acad Sci U S A, 103, pp. 1941-1946; Jin, J.K., Ahn, B.H., Na, Y.J., Kim, J.I., Kim, Y.S., Choi, E.K., Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease (2007) Neurobiol Aging, 28, pp. 1015-1027; Oliveira, T.G., Chan, R.B., Tian, H., Laredo, M., Shui, G., Staniszewski, A., Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits (2010) J Neurosci, 30, pp. 16419-16428; Guerreiro, R., Bras, J., Hardy, J., SnapShot: Genetics of Alzheimer's disease (2013) Cell, 155. , 968-968.e961",Review,Scopus,2-s2.0-84920703987
"Joshi Y.B., Giannopoulos P.F., Pratico D.","The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease",2015,"Trends in Pharmacological Sciences","36","3",,"181","186",,,10.1016/j.tips.2015.01.005,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923926629&partnerID=40&md5=559de45c492f73559ff972a529b376d9","Department of Pharmacology and Center for Translational Medicine, Temple University School of MedicinePhiladelphia, PA, United States","Joshi, Y.B., Department of Pharmacology and Center for Translational Medicine, Temple University School of MedicinePhiladelphia, PA, United States; Giannopoulos, P.F., Department of Pharmacology and Center for Translational Medicine, Temple University School of MedicinePhiladelphia, PA, United States; Praticò, D., Department of Pharmacology and Center for Translational Medicine, Temple University School of MedicinePhiladelphia, PA, United States","Alzheimer's disease (AD) is a chronic neurodegenerative condition characterized by progressive memory loss. Mutations in genes involved in the production of amyloid-β (Aβ) are linked to the early-onset variant of AD. However, the most common form, sporadic AD, is considered to be the result of an interaction between environmental risk factors and various genes. Among them, recent work has highlighted the potential role that the 12/15-lipoxygenase (12/15LO) pathway may play in AD pathogenesis. 12/15LO is widely distributed in the central nervous system, and its levels are upregulated in patients with AD or mild cognitive impairments. Studies using animal models have implicated 12/15LO in the molecular pathology of AD, including the metabolism of Aβ and tau, synaptic integrity, and cognitive functions. We provide an overview of this pathway and its relevance to AD pathogenesis, discuss the mechanism(s) involved, and provide an assessment of how targeting 12/15LO could lead to novel AD therapeutics. © 2015 Elsevier Ltd.","12/15-lipoxygenase; Alzheimers disease; amyloid b; synapse; behavior; tau protein; therapeutics.; transgenic mouse models","Ivanov, I., Molecular enzymology of lipoxygenases (2010) Arch. Biochem. Biophys., 503, pp. 161-174; Kuhn, H., Mammalian lipoxygenases and their biological relevance (2014) Biochim. Biophys. Acta, , Published online October 12, 2014. http://dx.doi.org/10.1016/j.bbalip.2014.10.002; Skrzypczak-Jankun, E., Human lipoxygenase: Developments in its structure, function, relevance to diseases and challenges in drug development (2012) Curr. Med. Chem., 19, pp. 5122-5127; Joo, Y.C., Oh, D.K., Lipoxygenases: Potential starting biocatalysts for the synthesis of signaling compounds (2012) Biotechnol. Adv., 30, pp. 1524-1532; Kuhn, H., Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications (2002) Prostaglandins Other Lipid Mediat., 68-69, pp. 263-290; Berger, M., Simultaneous expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase in rabbits (1998) J. Mol. Biol., 278, pp. 935-948; Watanabe, T., Molecular cloning of a 12-lipoxygenase cDNA from rat brain (1993) Eur. J. Biochem., 212, pp. 605-612; Nishiyama, M., Localization of arachidonate 12-lipoxygenase in canine brain tissue (1992) J. Neurochem., 58, pp. 1395-1400; Natarajan, R., Nadler, J.L., Lipid inflammatory mediators in diabetic vascular disease (2004) Arterioscler. Thromb. Vasc. Biol., 24, pp. 1542-1548; Haeggström, J.Z., Funk, C.D., Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease (2011) Chem. Rev., 111, pp. 5866-5898; Thies, W., Bleiler, L., 2013 Alzheimer's disease facts and figures (2013) Alzheimers Dement., 9, pp. 208-245; Tan, C.C., Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis (2014) J. Alzheimers Dis., 41, pp. 615-631; Caraci, F., Clinical pharmacology of novel anti-Alzheimer disease modifying medications (2013) Curr. Top. Med. Chem., 13, pp. 1853-1863; Giannopoulos, P.F., Pratico, D., Alzheimer's disease (2014) Diet and Nutrition in Dementia and Cognitive Decline, pp. 13-21. , C.R. Martin, V.R. Preddy, Elsevier; Ono, K., Yamada, M., Low-n oligomers as therapeutic targets of Alzheimer's disease (2011) J. Neurochem., 117, pp. 19-28; Hanger, D.P., Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localization of the kinase (1992) Neurosci. Lett., 147, pp. 58-62; Baumann, K., Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 (1993) FEBS Lett., 336, pp. 417-424; Pei, J.J., Distribution of active glycogen cynthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes (1999) J. Neuropathol. Exp. Neurol., 58, pp. 1010-1019; Uderhardt, S., Kronke, G., 12/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance (2012) J. Mol. Med., 90, pp. 1247-1256; Sultana, C., Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte-like HL-60 cells is linked to protein kinase C activation (1996) J. Cell Physiol., 167, pp. 477-487; Reddy, M.A., The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects (2002) J. Biol. Chem., 277, pp. 9920-9928; Cyrus, T., Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice (2001) Circulation, 103, pp. 2277-2282; McDuffie, M., Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes (2008) Diabetes, 57, pp. 199-208; Sears, D.D., 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice (2009) PLoS ONE, 4, p. e7250; Reilly, K.B., 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo (2004) J. Biol. Chem., 279, pp. 9440-9450; Strosznajder, J.B., Lipoxygenases and poly(ADP-ribose) polymerase in amyloid beta cytotoxicity (2011) Neurochem. Res., 36, pp. 839-848; Nishiyama, M., Arachidonate 12-lipoxygenase is localized in neurons, glial cells, and endothelial cells of the canine brain (1993) J. Histochem. Cytochem., 41, pp. 111-117; Li, Y., A role for 12-lipoxygenase in nerve cell death casued by glutathione depletion (1997) Neuron, 19, pp. 453-463; Chinnici, C.M., Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice (2005) Am. J. Pathol., 167, pp. 1371-1377; Praticò, D., Oxidative stress hypothesis in Alzheimer's disease: A reappraisal (2008) Trends Pharm. Sci., 29, pp. 609-615; Pratico, D., 12/15-lipoxygenase is increased in Alzheimer's disease: Possible involvement in brain oxidative stress (2004) Am. J. Pathol., 164, pp. 1655-1662; Yao, Y., Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment (2005) Ann. Neurol., 58, pp. 623-626; Tajima, Y., Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease (2013) Lipids Health Dis., 12, p. 68; Succol, F., Pratico, D., A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism (2007) J. Neurochem., 103, pp. 380-387; Yang, H., Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase (2010) Biol. Psychiatry, 68, pp. 922-929; Chu, J., Transcriptional regulation of beta-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments (2012) Ann. Neurol., 71, pp. 57-67; Giannopoulos, P.F., The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo (2013) Aging Cell, 12, pp. 1082-1090; Oddo, S., Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction (2003) Neuron, 39, pp. 409-421; Chu, J., Pharmacologic blockade of 12/15-Lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple transgenic mouse (2015) Mol. Psychiatry., , http://dx/doi/org/10.1038/mp.2014.170, Published online January 6, 2015; Normandin, M., Involvement of the 12-lipoxygenase pathway of arachidonic acid metabolism in homosynaptic long-term depression of the rat hippocampus (1996) Brain Res., 730, pp. 40-46; Feinmark, S.J., 12-lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses (2003) J. Neurosci., 23, pp. 11427-11435; Decostanzo, A.J., 12-Lipoxygenase regulates hippocampal long-term potentiation by modulating L-type Ca2+ channels (2010) J. Neurosci., 30, pp. 1822-1831; Lo, E.H., Mechanisms, challenges and opportunities in stroke (2003) Nat. Rev. Neurosci., 4, pp. 399-415; Hardingham, G.E., Lipton, S.A., Regulation of neuronal oxidative and nitrosative stress by endogenous protective pathways and disease processes (2011) Antioxid. Redox Signal., 14, pp. 1421-1424; Moskowitz, M.A., The science of stroke: Mechanisms in search of treatments (2010) Neuron, 67, pp. 181-198; Niizuma, K., Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival (2009) J. Neurochem., 109, pp. 133-138; Saito, A., Oxidative stress and neuronal death/survival signaling in cerebral ischemia (2005) Mol. Neurobiol., 31, pp. 105-116; Leblanc, A.C., The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death (2005) Curr. Alzheimer Res., 2, pp. 389-402; Lebeau, A., Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide (2004) Cell Death Differ., 11, pp. 875-884; Gamblin, T.C., Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 10032-10037; Nakagomi, T., Effect of cyclooxygenase and lipoxygenase inhibitors on delayed neuronal death in the gerbil hippocampus (1989) Stroke, 20, pp. 925-929; Jin, G., Protecting against cerebrovascular injury: Contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia (2008) Stroke, 39, pp. 2538-2543; Van Leyen, K., Baicalein and 12/15-lipoxygenase in the ischemic brain (2006) Stroke, 37, pp. 3014-3018; Yigitkanli, K., Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke (2013) Ann. Neurol., 73, pp. 129-135; Sun, L., Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: Inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption (2012) Brain Res., 1473, pp. 227-235; Pallast, S., Increased nuclear apoptosis-inducing factor after transient focal ischemia: A 12/15-lipoxygenase-dependent organelle damage pathway (2010) J. Cereb. Blood Flow Metab., 30, pp. 1157-1167; Lapchak, P.A., Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes (2010) Neuroscience, 150, pp. 585-591",Review,Scopus,2-s2.0-84923926629
"Baron S., Ulstein I., Werheid K.","Psychosocial interventions in Alzheimer's disease and amnestic mild cognitive impairment: Evidence for gender bias in clinical trials",2015,"Aging and Mental Health","19","4",,"290","305",,1,10.1080/13607863.2014.938601,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921612430&partnerID=40&md5=de48c5eab4b25cc0b64c8bf6a0682b96","Department of Psychology, Humboldt University BerlinBerlin, Germany; Department of Psychiatry of Old Age, Oslo University HospitalOslo, Norway","Baron, S., Department of Psychology, Humboldt University BerlinBerlin, Germany; Ulstein, I., Department of Psychiatry of Old Age, Oslo University HospitalOslo, Norway; Werheid, K., Department of Psychology, Humboldt University BerlinBerlin, Germany","Background: Alzheimer's disease (AD) affects twice as many women as men. Gender differences in symptom profile, living conditions, coping style and response might affect the outcome of psychosocial interventions (PSIs).Objectives: Our aim was to review gender differences in the available high-quality phase III trials on PSI in AD and amnestic mild cognitive impairment (aMCI) by considering the gender ratio in the investigated samples.Design: Randomized controlled trials published in 2000-2012 were stepwise analyzed by statistically testing the representativeness of the gender ratio and examining reported gender differences.Results: Forty-five studies (62% of 73 studies) reported gender ratios for each subsample and were included. In these studies, females were underrepresented in the control groups. In the 14 studies (19%) reporting analyses of gender differences, women were underrepresented in both intervention and control groups. However, in the six studies (8%) reporting significant gender differences in outcome, gender distribution was in accordance with prevalence rates.Conclusion: Current evidence is insufficient for reliable conclusions on gender differences in PSI outcome in AD and aMCI, as 81% of the available clinical trials either not reported the gender ratio of their samples, or underrepresent females. Further research is needed addressing gender differences, and clinical trials should routinely control for gender bias. © 2014 Taylor and Francis.","Alzheimers disease; dementia; gender differences; mild cognitive impairment; psychosocial interventions","Acevedo, A., Loewenstein, Loewenstein, D.A., Nonpharmacological cognitive interventions in aging and dementia (2007) Journal of Geriatric Psychiatry and Neurology, 20, pp. 239-249; (2013) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association. (5th ed.). Arlington, AV: American Psychiatric Publishing; Andersen, K., Launer, L.J., Dewey, M.E., Letenneur, L., Ott, A., Copeland, J.R., Hofman, A., Gender differences in the incidence of AD and vascular dementia: The EURODEM studies (1999) Neurology, 53, pp. 1992-1997; Avison, W.R., McAlpine, McAlpine, D.D., Gender differences in symptoms of depression among adolescents (1992) Journal of Health and Social Behavior, 33, pp. 77-96; Ayalon, L., Gum, A.M., Feliciano, L., Arean, P.A., Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: A systematic review (2006) Archives of Internal Medicine, 166, pp. 2182-2188; Baker, L.D., Frank, L.L., Foster-Schubert, K., Green, P.S., Wilkinson, C.W., McTierman, A., Craft, S., Effects of aerobic exercise on mild cognitive impairment: A controlled trial (2010) Archives of Neurology, 67, pp. 71-79; Barnes, L.L., Wilson, R.S., Bienias, J.L., Schneider, J.A., Evans, D.A., Bennett, D.A., Sex differences in the clinical manifestations of Alzheimer disease pathology (2005) Archives of General Psychiatry, 62, pp. 685-691; Beinhoff, U., Tumani, H., Brettschneider, J., Bittner, D., Riepe, M.W., Gender-specificities in Alzheimer's disease and mild cognitive impairment (2008) Journal of Neurology, 255, pp. 117-122; Bonsignore, M., Barkow, K., Heun, R., Possible influence of selection bias on gender differences in the risk of Alzheimer's disease (2002) Archives of Women's Mental Health, 5, pp. 73-77; Breuil, V., De Rotrou, J., Forette, F., Tortrat, D., Ganansia-Ganem, A., Frambourt, A., Boller, F., Cognitive stimulation of patients with dementia: Preliminary results (1994) International Journal of Geriatric Psychiatry, 9, pp. 211-217; Buchanan, R.J., Wang, S., Ju, H., Graber, D., Analyses of gender differences in profiles of nursing home residents with Alzheimer's disease (2004) Gender Medicine, 1, pp. 48-59; Burgener, S.C., Yang, Y., Gilbert, R., Marsh-Yant, S., The effects of a multimodal intervention on outcomes of persons with early-stage dementia (2008) American Journal of Alzheimer's Disease and Other Dementias, 23, pp. 382-394; Burns, A., Guthrie, E., Marino-Francis, F., Busby, C., Morris, J., Russel, E., Byrne, J., Brief psychotherapy in Alzheimer's disease: Randomised controlled trial (2005) British Journal of Psychiatry, 187, pp. 143-147; Cahn-Weiner, D.A., Malloy, P.F., Rebok, G.W., Ott, B.R., Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients (2003) Applied Neuropsychology, 10, pp. 215-223; Clare, L., Linden, D.E.J., Woods, R.T., Whitkaer, R., Evans, S.J., Parkinson, C.H., Rugg, M.D., Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: A single-blind randomized controlled trial of clinical efficacy (2010) American Journal of Geriatric Psychiatry, 18, pp. 928-939; Clare, L., Woods, R.T., Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer's disease: A review (2004) Neuropsychological Rehabilitation, 14, pp. 385-401; Clarkin, J.F., Levy, K.N., The influence of client variables on psychotherapy (2004) Bergin and Garfield's Handbook of Psychotherapy and Behavior Change, pp. 194-226. , In M.J. Lambert (Ed.),. New York, NY: Wiley; Cohen, J., (1988) Statistical Power Analysis for the Behavioral Sciences, , Hillsdale, NJ: Lawrence Erlbaum; Cooke, M.L., Moyle, W., Shum, D.H.K., Harrison, S.D., Murfield, J.E., A randomized controlled trial exploring the effect of music on agitated behaviours and anxiety in older people with dementia (2010) Aging & Mental Health, 14, pp. 905-916; Copeland, J.R., McCracken, C.F., Dewey, M.E., Wilson, K.C., Doran, M., Gilmore, C., Larkin, B.A., Undifferentiated dementia, Alzheimer's disease and vascular dementia: Age-and gender-related incidence in Liverpool. The MRC-ALPHA study (1999) British Journal of Psychiatry, 175, pp. 433-438; Darcy, C., Siddique, C.M., Psychological distress among Canadian adolescents (1984) Psychological Medicine, 14, pp. 615-628; Davis, R.N., Massman, P.J., Doody, R.S., Cognitive intervention in Alzheimer disease: A randomized placebo-controlled study (2001) Alzheimer Disease & Associated Disorders, 15, pp. 1-9; Eloniemi-Sulkava, U., Notkola, I.L., Hentinen, M., Kivela, S.L., Sivenius, J., Sulkava, R., Effects of supporting community-living demented patients and their caregivers: A randomized trial (2001) Journal of the American Geriatrics Society, 49, pp. 1282-1287; Eloniemi-Sulkava, U., Saarenheimo, M., Laakkonen, M.-L., Pietilä, M., Savikko, N., Kautiainen, H., Pitkälä, K.H., Family care as collaboration: Effectiveness of a multicomponent support program for elderly couples with dementia. Randomized controlled intervention study (2009) Journal of the American Geriatrics Society, 57, pp. 2200-2208; Finnema, E., Droës, R.-M., Ettema, T., Ooms, M., Ader, H., Ribbe, M., Van Tilburg, W., The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: A randomized clinical trial (2005) International Journal of Geriatric Psychiatry, 20, pp. 330-343; Gambassi, G., Lapane, K.L., Landi, F., Sgadari, A., Mor, V., Bernabei, R., Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease (1999) Neurology, 53, pp. 508-516; Gijsbers Van Wijk, C.M.T., Kolk, A.M., Sex differences in physical symptoms: The contribution of symptom perception theory (1997) Social Science & Medicine, 45, pp. 231-246; Gitlin, L.N., Corcoran, M., Winter, L., Boyce, A., Hauck, W.W., A randomized, controlled trial of a home environmental intervention: Effect on efficacy and upset in caregivers and on daily function of persons with dementia (2001) The Gerontologist, 41, pp. 4-14; Gitlin, L.N., Winter, L., Burke, J., Chernett, N., Dennis, M.P., Hauck, W.W., Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: A randomized pilot study (2008) American Journal of Geriatric Psychiatry, 16, pp. 229-239; Gitlin, L.N., Winter, L., Corcoran, M., Dennis, M.P., Schinfeld, S., Hauck, W.W., Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH initiative (2003) The Gerontologist, 43, pp. 532-546; Gormley, N., Lyons, D., Howard, R., Behavioural management of aggression in dementia: A randomized controlled trial (2001) Age and Ageing, 30, pp. 141-145; Graff, M.J.L., Vernooij-Dassen, M.J.M., Thijssen, M., Dekker, J., Hoefnagels, W.H.L., Rikkert, M.G.M., Community based occupational therapy for patients with dementia and their care givers: Randomised controlled trial (2006) British Medical Journal, 333, pp. 1196-1199; Grandmaison, E., Simard, M., A critical review of memory stimulation programs in Alzheimer's disease (2003) The Journal of Neuropsychiatry and Clinical Neurosciences, 15, pp. 130-144; Groen, G., Wunderlich, A.P., Spitzer, M., Tomczak, R., Riepe, M.W., Brain activation during human navigation: Gender-different neural networks as substrate of performance (2000) Nature and Neuroscience, 3, pp. 404-408; Guetin, S., Portet, F., Picot, M.C., Pommie, C., Messaoudi, M., Djabelkir, L., Touchon, J., Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: Randomised, controlled study (2009) Dementia and Geriatric Cognitive Disorders, 28, pp. 36-46; Hartman, J.M., Forsen, J.W., Wallace, M.S., Neely, J.G., Tutorials in clinical research: Part IV: Recognizing and controlling bias (2002) Laryngoscope, 112, pp. 23-31; Hebert, L.E., Scherr, P.A., McCann, J.J., Beckett, L.A., Evans, D.A., Is the risk of developing Alzheimer's disease greater for women than for men? (2001) American Journal of Epidemiology, 153, pp. 132-136; Herlitz, A., Airaksinen, E., Nordstrom, E., Sex differences in episodic memory: The impact of verbal and visuospatial ability (1999) Neuropsychology, 13, pp. 590-597; Herlitz, A., Nilsson, L.G., Backman, L., Gender differences in episodic memory (1997) Memory and Cognition, 25, pp. 801-811; Hy, L.X., Keller, D.M., Prevalence of AD among whites: A summary by levels of severity (2000) Neurology, 55, pp. 198-204; Kawashima, R., Okita, K., Yamazaki, R., Tajima, N., Yoshida, H., Taira, M., Sugimoto, K., Reading aloud and arithmetic calculation improve frontal function of people with dementia (2005) Journal of Gerontology: Medical Sciences, 60, pp. 380-384; Kinsella, G.J., Mullaly, E., Rand, E., Ong, B., Burton, C., Price, S., Storey, E., Early intervention for mild cognitive impairment: A randomised controlled trial (2009) Journal of Neurology, Neurosurgery and Psychiatry, 80, pp. 730-736; Kurz, A., Thöne-Otto, A., Cramer, B., Egert, S., Frölich, L., Gertz, H.-J., Werheid, K., CORDIAL: Cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: A multicenter, randomized, controlled trial (2012) Alzheimer Disease & Associated Disorders, 26, pp. 246-253; Lapane, K.L., Gambassi, G., Landi, F., Sgadari, A., Mor, V., Bernabei, R., Gender differences in predictors of mortality in nursing home residents with AD (2001) Neurology, 56, pp. 650-654; Lautenschlager, N.T., Cox, K.L., Flicker, L., Foster, J.K., Van Bockxmeer, F.M., Xiao, J., Almeida, O.P., Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial (2008) Journal of the American Medical Association, 300, pp. 1027-1037; Lewin, C., Wolgers, G., Herlitz, A., Sex differences favoring women in verbal but not in visuospatial episodic memory (2001) Neuropsychology, 15, pp. 165-173; Littbrand, H., Lundin-Olsson, L., Gustafson, Y., Rosendahl, E., The effect of a high-intensity functional exercise program on activities of daily living: A randomized controlled trial in residential care facilities (2009) Journal of the American Geriatrics Society, 57, pp. 1741-1749; Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C.G., Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia (2005) American Journal of Psychiatry, 162, pp. 1996-2021; Lobo, A., Launer, L.J., Fratiglioni, L., Andersen, K., Di Carlo, A., Breteler, M.M., Hofman, A., Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts (2000) Neurology, 54, pp. 4-9; Loewenstein, D.A., Acevedo, A., Czaja, S.J., Duara, R., Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors (2004) American Journal of Geriatric Psychiatry, 12, pp. 395-402; Logsdon, R.G., McCurry, S.M., Teri, L., Evidence-based psychological treatments for disruptive behaviors in individuals with dementia (2007) Psychology and Aging, 22, pp. 28-36; Logsdon, R.G., Pike, K.C., McCurry, S.M., Hunter, P., Maher, J., Snyder, L., Teri, L., Early-stage memory loss support groups: Outcomes from a randomized controlled clinical trial (2010) Journal of Gerontology: Psychological Sciences, 65, pp. 691-697; Marriott, A., Donaldson, C., Tarrier, N., Burns, A., Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease (2000) British Journal of Psychiatry, 176, pp. 557-562; McCallion, P., Toseland, R.W., Freeman, K., An evaluation of a family visit education program (1999) Journal of the American Geriatrics Society, 47, pp. 203-214; Moher, D., Altman, D.G., Liberati, A., Tetzlaff, J., PRISMA statement (2011) Epidemiology, 22, p. 128. , doi: 10.1097/EDE.0b013e3181fe7825; Neiser, M., Barolin, G.S., Gender-spezifische Aspekte in der Psychotherapie [Gender specific aspects in psychotherapy] (2009) Wiener Medizinische Wochenschrift, 159 (1112), pp. 281-287; Ober, C., Loisel, D.A., Gilad, Y., Sex-specific genetic architecture of human disease (2008) Nature Reviews Genetics, 9, pp. 911-922; Oertelt-Prigione, S., Regitz-Zagrosek, Regitz-Zagrosek, V., Women's cardiovascular health prevention is key (2009) Archives of Internal Medicine, 169, pp. 1740-1741; Ogrodniczuk, J.S., Men, women, and their outcome in psychotherapy (2006) Psychotherapy Research, 16, pp. 453-462; Ogrodniczuk, J.S., Piper, W.E., Joyce, A.S., McCallum, M., Patient gender differences in outcome for two forms of dynamically-oriented individual psychotherapy (2000) Panel Presentation at the Annual Meeting of the Society for Psychotherapy Research, , Chicago, IL; Ogrodniczuk, J.S., Piper, W.E., Joyce, A.S., McCallum, M., Effect of patient gender on outcome in two forms of short-term individual psychotherapy (2001) Journal of Psychotherapy Practice Research, 10, pp. 69-78; Ogrodniczuk, J.S., Staats, H., Psychotherapie und Geschlechtszugehörigkeit: Brauchen Männer und Frauen unterschiedliche Behandlungen? [Psychotherapy and gender-identity: Need men and women different treatments?] (2002) Zeitschrift für Psychosomatische Medizin und Psychotherapie, 48, pp. 270-285; Olazaran, J., Muniz, R., Reisberg, B., Pena-Casanova, J., Del Ser, T., Cruz-Jentoft, A.J., Sevilla, C., Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease (2004) Neurology, 63, pp. 2348-2353; Onder, G., Zanetti, O., Giacobini, E., Frisoni, G.B., Bartorelli, L., Carbone, G., Bernabei, R., Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: Randomised controlled trial (2005) The British Journal of Psychiatry, 187, pp. 450-455; Ott, B.R., Cognition and behavior in patients with Alzheimer's disease (1999) The Journal of Gender Specific Medicine, 2, pp. 63-69; Ott, B.R., Lapane, K.L., Gambassi, G., Group, S.S., Gender differences in the treatment of behavior problems in Alzheimer's disease (2000) Neurology, 54, pp. 427-432; Ott, B.R., Tate, C.A., Gordon, N.M., Heindel, W.C., Gender differences in the behavioral manifestations of Alzheimer's disease (1996) Journal of the American Geriatrics Society, 44, pp. 583-587; Parker, G., Blanch, B., Crawford, J., Does gender influence response to differing psychotherapies by those with unipolar depression? (2011) Journal of Affective Disorders, 130, pp. 17-20; Parker, G., Crawford, J., Personality and self-reported treatment effectiveness in depression (2009) Australian and New Zealand Journal of Psychiatry, 43, pp. 518-525; Parsons, T.D., Larson, P., Kratz, K., Thiebaux, M., Bluestein, B., Buckwalter, J.G., Rizzo, A.A., Sex differences in mental rotation and spatial rotation in a virtual environment (2004) Neuropsychologia, 42, pp. 555-562; Pinquart, M., Sorensen, S., Gender differences in caregiver stressors, social resources, and health: An updated meta-analysis (2006) Journal of Gerontology: Psychological Sciences and Social Sciences, 61, pp. 33-45; Raglio, A., Bellelli, G., Traficante, D., Gianotti, M., Ubezio, M.C., Gentile, S., Trabucchi, M., Efficacy of music therapy treatment based on cycles of sessions: A randomised controlled trial (2010) Aging & Mental Health, 14, pp. 900-904; Riecher-Roessler, A., Psychische Erkrankungen bei Frauen: Einige Argumente für eine geschlechtssensible Psychiatrie und Psychotherapie (2000) Zeitschrift für Psychosomatische Medizin und Psychotherapie, 14, pp. 129-139. , Mental disorders in women: Some arguments for gender-sensitive psychiatry and psychotherapy; Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., Andrieu, S., Vellas, Vellas, B., Exercise program for nursing home residents with Alzheimer's disease: A 1-year randomized, controlled trial (2007) Journal of the American Geriatrics Society, 55, pp. 158-165; Schrijnemaekers, V., Van Rosum, E., Candel, M., Frederiks, C., Derix, M., Sielhorst, H., Van Den Brandt, P., Effects of emotion-oriented care on elderly people with cognitive impairment and behavioral problems (2002) International Journal of Geriatric Psychiatry, 17, pp. 926-937; Schut, H.A.W., Stroebe, M.S., Van Den Bout, J., De Keijser, J., Intervention for the bereaved: Gender differences in the efficacy of two counselling programmes (1997) British Journal of Clinical Psychology, 36, pp. 63-72; Schwartz, C.E., Fox, B.H., Who says yes? Identifying selection biases in a psychosocial intervention study of multiple sclerosis (1995) Social Science & Medicine, 40, pp. 359-370; Sloane, P.D., Hoeffer, B., Mitchell, M., McMenzie, D., Barrick, A.L., Rader, J., Koch, G.G., Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: A randomized, controlled trial (2004) Journal of the American Geriatrics Society, 52, pp. 1795-1804; Smits, C.H.M., De Lange, J., Droes, R.M., Meiland, F., Vernooij-Dassen, M., Pot, A.M., Effects of combined intervention programmes for people with dementia living at home and their caregivers: A systematic review (2007) International Journal of Geriatric Psychiatry, 22, pp. 1181-1193; Sowers, J.R., Diabetes in the elderly and in women: Cardiovascular risks (2004) Cardiology Clinics, 22, pp. 541-551; Spector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterworth, M., Orrell, M., Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial (2003) British Journal of Psychiatry, 183, pp. 248-254; Spek, V., Nyklicek, I., Cuijpers, P., Pop, V., Predictors of outcome of group and internet-based cognitive behavior therapy (2008) Journal of Affective Disorders, 105, pp. 137-145; Steinberg, M., Leoutsakos, J.M.S., Podewils, L.J., Lyketsos, C.G., Evaluation of a home-based exercise program in the treatment of Alzheimer's disease: The maximizing independence in dementia (MIND) study (2009) International Journal of Geriatric Psychiatry, 24, pp. 680-685; Tarraga, L., Boada, M., Modinos, G., Espinosa, A., Diego, S., Morera, A., Becker, J.T., A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease (2006) Journal of Neurology, Neurosurgery and Psychiatry, 77, pp. 1116-1121; Teri, L., Behavioral treatment of depression in patients with dementia (1994) Alzheimer Disease & Associated Disorders, 8, pp. 66-74; Teri, L., Borson, S., Kiyak, H.A., Yamagishi, M., Behavioral disturbance, cognitive dysfunction, and functional skill: Prevalence and relationship in Alzheimer's disease (1989) Journal of the American Geriatrics Society, 37, pp. 784-790; Teri, L., Gibbons, L.E., McCurry, S.M., Logsdon, R.G., Buchner, D.M., Barlow, W.E., Larson, E.B., Exercise plus behavioral management in patients with Alzheimer disease: A randomized controlled trial (2003) Journal of the American Medical Association, 290, pp. 2015-2022; Teri, L., Logsdon, R.G., Uomoto, J., McCurry, S.M., Behavioral treatment of depression in dementia patients: A controlled clinical trial (1997) Journal of Gerontology: Psychological Sciences, 52, pp. 159-166; Teri, L., McKenzie, G., Lafazia, D., Psychosocial treatment of depression in older adults with dementia (2005) Clinical Psychology: Science and Practice, 12, pp. 303-316; Toseland, R.W., Diehl, M., Freeman, K., Manzanares, T., Naleppa, M., McCallion, P., The impact of validation group therapy on nursing home residents with dementia (1997) Journal of Applied Gerontology, 16, pp. 31-50; Troyer, A.K., Murphy, K.J., Anderson, N.D., Moscovitch, M., Craik, F.I.M., Changing everyday memory behaviour in amnestic mild cognitive impairment: A randomised controlled trial (2008) Neuropsychological Rehabilitation, 18, pp. 65-88; Tsolaki, M., Kounti, F., Agogiatou, C., Poptsi, E., Bakoglidou, E., Zafeiropoulou, Vasiloglou, M., Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment (2010) Neurodegenerative Diseases, 8, pp. 1-8; Ueki, A., Shinjo, H., Shimode, H., Nakajima, T., Morita, Y., Factors associated with mortality in patients with early-onset Alzheimer's disease: A five-year longitudinal study (2001) International Journal of Geriatric Psychiatry, 16, pp. 810-815; Ulstein, I.D., Sandvik, L., Wyller, T.B., Engedal, K., A one-year randomized controlled psychosocial intervention study among family carers of dementia patients: Effects on patients and carers (2007) Dementia and Geriatric Cognitive Disorders, 24, pp. 469-475; Van De Winckel, A., Feys, H., De Weerdt, W., Dom, R., Cognitive and behavioural effects of music-based exercises in patients with dementia (2004) Clinical Rehabilitation, 18, pp. 253-260; Van Mierlo, L.D., Van Der Roest, H.G., Meiland, F.J.M., Droes, R.M., Personalized dementia care: Proven effectiveness of psychosocial interventions in subgroups (2010) Ageing Research Reviews, 9, pp. 163-183; Van Uffelen, J.G., Chin Paw A, M.J.M., Hopman-Rock, M., Van Mechelen, W., The effect of walking and vitamin B supplementation on quality of life in community-dwelling adults with mild cognitive impairment: A randomized, controlled trial (2007) Quality of Life Research, 16, pp. 1137-1146; Van Uffelen, J.G., Chin Paw A, M.J., Van Mechelen, W., Hopman-Rock, M., Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial (2008) British Journal of Sports and Medicine, 42, pp. 344-351; Vas, C.J., Panikker, D., Noronha, S., Deshpande, N., Kulkarni, L., Prevalence of dementia in an urban Indian population (2001) International Psychogeriatrics, 13, pp. 439-450; Verkaik, R., Van Weert, J.C., Francke, A.L., The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: A systematic review (2005) International Journal of Geriatric Psychiatry, 20, pp. 301-314; Vina, J., Lloret, A., Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide (2010) Journal of Alzheimer's Disease, 20, pp. 527-533; Wang, W., Wu, S., Cheng, X., Dai, H., Ross, K., Du, X., Yin, W., Prevalence of Alzheimer's disease and other dementing disorders in an urban community of Beijing, China (2000) Neuroepidemiology, 19, pp. 194-200; Welsh, K.A., Butters, N., Hughes, J.P., Mohs, R.C., Heyman, A., Detection and staging of dementia in Alzheimer's disease: Use of the neuropsychological measures developed for the consortium to establish a registry for Alzheimer's disease (1992) Archives of Neurology, 49, pp. 448-452; Wilz, G., Adler, C., Gunzelmann, T., Gruppenarbeit mit Angehörigen von Demenzkranken (2001) Ein Therapeutischer Leitfaden [Group Therapy with Relatives of Patients with Dementia. A Therapeutical Manual], , Göttingen: Hogrefe; Wizemann, T., Pardue, M., (2001) Exploring the Biological Contributions to Human Health: Does Sex Matter?, , Washington, DC: National Academic Press",Review,Scopus,2-s2.0-84921612430
"Magini A., Polchi A., Tozzi A., Tancini B., Tantucci M., Urbanelli L., Borsello T., Calabresi P., Emiliani C.","Abnormal cortical lysosomal β-hexosaminidase and β-galactosidase activity at post-synaptic sites during Alzheimer's disease progression",2015,"International Journal of Biochemistry and Cell Biology","58",,,"62","70",,1,10.1016/j.biocel.2014.11.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84918770418&partnerID=40&md5=3f469ce7dbd68386e4cf3418269395da","Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy; Department of Medical and Biological Sciences (DSMB), University of Udine, P.le S. Maria della Misericordia 15Perugia, Italy; Deparment of Medicine, University of Perugia, S. Maria della Misericordia HospitalPerugia, Italy; IRCCS S. Lucia FoundationRome, Italy; IRCCS Institute for Pharmacological Research Mario Negri, Via La Masa 19Milan, Italy; CEMIN-Center of Excellence for Innovative Nanostructured MaterialPerugia, Italy","Magini, A., Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy, Department of Medical and Biological Sciences (DSMB), University of Udine, P.le S. Maria della Misericordia 15Perugia, Italy; Polchi, A., Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy; Tozzi, A., Deparment of Medicine, University of Perugia, S. Maria della Misericordia HospitalPerugia, Italy, IRCCS S. Lucia FoundationRome, Italy; Tancini, B., Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy; Tantucci, M., Deparment of Medicine, University of Perugia, S. Maria della Misericordia HospitalPerugia, Italy; Urbanelli, L., Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy; Borsello, T., IRCCS Institute for Pharmacological Research Mario Negri, Via La Masa 19Milan, Italy; Calabresi, P., Deparment of Medicine, University of Perugia, S. Maria della Misericordia HospitalPerugia, Italy, IRCCS S. Lucia FoundationRome, Italy; Emiliani, C., Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del GiochettoPerugia, Italy, CEMIN-Center of Excellence for Innovative Nanostructured MaterialPerugia, Italy","A critical role of endosomal-lysosomal system alteration in neurodegeneration is supported by several studies. Dysfunction of the lysosomal compartment is a common feature also in Alzheimer's disease. Altered expression of lysosomal glycohydrolases has been demonstrated not only in the brain and peripheral tissues of Alzheimer's disease patients, but also in presymptomatic subjects before degenerative phenomenon becomes evident. Moreover, the presence of glycohydrolases associated to the plasma membrane have been widely demonstrated and their alteration in pathological conditions has been documented. In particular, lipid microdomains-associated glycohydrolases can be functional to the maintenance of the proper glycosphingolipids pattern, especially at cell surface level, where they are crucial for the function of cell types such as neurons. In this study we investigated the localization of β-hexosaminidase and β-galactosidase glycohydrolases, both involved in step by step degradation of the GM1 to GM3 gangliosides, in lipid microdomains from the cortex of both an early and advanced TgCRND8 mouse model of Alzheimer's disease. Throughout immunoprecipitation experiments of purified cortical lipid microdomains, we demonstrated for the first time that β-hexosaminidase and β-galactosidase are associated with post-synaptic vesicles and that their activities are increased at both the early and the advanced stage of Alzheimer's disease. The early increase of lipid microdomain-associated β-hexosaminidase and β-galactosidase activities could have relevant implications for the pathophysiology of the disease since their possible pharmacological manipulation could shed light on new reliable targets and biological markers of Alzheimer's disease. © 2014 Elsevier Ltd.","Alzheimers diseasea; Membrane microdomains; Plasma membrane glycohydrolases","Adamec, E., Mohan, P.S., Cataldo, A.M., Vonsattel, J.P., Nixon, R.A., Up-regulation of the lysosomal system in experimental models of neuronal injury: Implications for Alzheimer's disease (2000) Neuroscience, 100, pp. 663-675; Aureli, M., Loberto, N., Chigorno, V., Prinetti, A., Sonnino, S., Remodeling of sphingolipids by plasma membrane associated enzymes (2011) Neurochem Res, 36, pp. 1636-1644; Aureli, M., Bassi, R., Loberto, N., Regis, S., Prinetti, A., Chigorno, V., Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts (2012) J Inherit Metab Dis, 35, pp. 1081-1091; Aureli, M., Samarani, M., Loberto, N., Bassi, R., Murdica, V., Prioni, S., The glycosphingolipid hydrolases in the central nervous system (2014) Mol Neurobiol, 50, pp. 76-87; Bertram, L., Tanzi, R.E., Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses (2008) Nat Rev Neurosci, 9, pp. 768-778; Blennow, K., De Leon, M.J., Zetterberg, H., Alzheimer's disease (2006) Lancet, 368, pp. 387-403; Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal Biochem, 72, pp. 248-254; Cataldo, A.M., Barnett, J.L., Berman, S.A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system (1995) Neuron, 14, pp. 671-680; Cataldo, A.M., Hamilton, D.J., Barnett, J.L., Paskevich, P.A., Nixon, R.A., Properties of the endosomal-lysosomal system in the human central nervous system: Disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease (1996) J Neurosci, 16, pp. 186-199; Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695 (2001) J Biol Chem, 276, pp. 21562-21570; Crespo, P.M., Demichelis, V.T., Daniotti, J.L., Neobiosynthesis of glycosphingolipids by plasma membrane-associated glycosyltransferases (2010) J Biol Chem, 285, pp. 29179-29190; Ehehalt, R., Keller, P., Haass, C., Thiele, C., Simons, K., Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts (2003) J Cell Biol, 160, pp. 113-123; Emiliani, C., Beccari, T., Tabilio, A., Orlacchio, A., Hosseini, R., Stirling, J.L., An enzyme with properties similar to those of beta-Nacetylhexosaminidase S is expressed in the promyelocytic cell line HL-60 (1990) Biochem J, 267, pp. 111-117; Emiliani, C., Martino, S., Stirling, J.L., Orlacchio, A., Influence of cell differentiation and protein kinase C activation on sub-cellular distribution of beta-N-acetylhexosaminidases of HL60 cells (1995) Physiol Chem Phys Med NMR, 27, pp. 369-376; Emiliani, C., Urbanelli, L., Racanicchi, L., Orlacchio, A., Pelicci, G., Sorbi, S., Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation (2003) J Biol Chem, 278, pp. 38453-38460; Gylys, K.H., Fein, J.A., Yang, F., Wiley, D.J., Miller, C.A., Cole, G.M., Synaptic changes in Alzheimer's Disease increased amyloid-β and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence (2004) Am J Pathol, 165, pp. 1809-1817; Isacson, O., Seo, H., Lin, L., Albeck, D., Granholm, A.C., Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh (2002) Trends Neurosci, 25, pp. 79-84; Kakio, A., Nishimoto, S.I., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Cholesterol dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid (2001) J Biol Chem, 276, pp. 24985-24990; Magini, A., Mencarelli, S., Tancini, B., Ciccarone, V., Urbanelli, L., Hasilik, A., Identification and characterization of mature β-hexosaminidases associated with human placenta lysosomal membrane (2008) Biosci Rep, 28, pp. 229-237; Magini, A., Urbanelli, L., Ciccarone, V., Tancini, B., Polidoro, M., Timperio, A.M., Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile (2010) J Alzheimers Dis, 21, pp. 431-444; Magini, A., Polchi, A., Tancini, B., Urbanelli, L., Hasilik, A., Emiliani, C., Glycohydrolases β-hexosaminidase and β-galactosidase are associated with lipid microdomains of Jurkat T-lymphocytes (2012) Biochimie, 94, pp. 684-694; Magini, A., Polchi, A., Urbanelli, L., Cesselli, D., Beltrami, A., Tancini, B., TFEB activation promotes the recruitment of lysosomal glycohydrolases β-hexosaminidase and β-galactosidase to the plasma membrane (2013) Biochem Biophys Res Commun, 440, pp. 251-257; Magini, A., Polchi, A., Tancini, B., Urbanelli, L., Di Cristina, M., Mannucci, R., Methods to discriminate the distribution of acidic glycohydrolases between the endosomal-lysosomal systems and the plasma membrane (2014) Methods Enzymol, 534, pp. 25-45; Mahuran, D.J., Biochemical consequences of mutations causing the GM2 gangliosidoses (1999) Biochim Biophys Acta, 1455, pp. 105-138; Mathews, P.M., Guerra, C.B., Jiang, Y., Grbovic, O.M., Kao, B.H., Schmidt, S.D., Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: Role for altered lysosomal hydrolase distribution in beta-amyloidogenesis (2002) J Biol Chem, 277, pp. 5299-5307; Medina, D.L., Fraldi, A., Bouche, V., Annunziata, F., Mansueto, G., Spampanato, C., Transcriptional activation of lysosomal exocytosis promotes cellular clearance (2011) Dev Cell, 21, pp. 421-430; Mencarelli, S., Cavalieri, C., Magini, A., Tancini, B., Basso, L., Lemansky, P., Identification of plasma membrane associated mature betahexosaminidase A, active towards GM2 ganglioside, in human fibroblasts (2005) FEBS Lett, 579, pp. 5501-5506; Mizuno, T., Nakata, M., Naiki, H., Michikawa, M., Wang, R., Haass, C., Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture (1999) J Biol Chem, 274, pp. 15110-15114; Nixon, R.A., Cataldo, A.M., Lysosomal system pathways: Genes to neurodegeneration in Alzheimer's disease (2006) J Alzheimers Dis, 9, pp. 277-289; Nixon, R.A., Mathews, P.M., Cataldo, A.M., The neuronal endosomal-lysosomal system in Alzheimer's disease (2001) J. Alzheimers Dis, 3, pp. 97-107; Okada, S., O'Brien, J.S., Generalized gangliosidosis: Beta-galactosidase deficiency (1968) Science, 160, pp. 1002-1004; Orlacchio, A., Martino, S., Sarchielli, P., Gallai, V., Emiliani, C., Beta-N-acetylhexosaminidase in peripheral blood lymphocytes and monocytes in the different forms and stages of multiplesclerosis (1998) J Neurochem, 71, pp. 1168-1176; Parihar, M.S., Hemnani, T., Alzheimer's disease pathogenesis and therapeutic interventions (2004) J Clin Neurosci, 11, pp. 456-467; Ploia, C., Antoniou, X., Sclip, A., Grande, V., Cardinetti, D., Colombo, A., JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models (2011) J Alzheimers Dis, 26, pp. 315-329; Sardiello, M., Palmieri, M., Di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., A gene network regulating lysosomal biogenesis and function (2009) Science, 325, pp. 473-477; Sclip, A., Antoniou, X., Colombo, A., Camici, G.G., Pozzi, L., Cardinetti, D., C-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model (2011) J Biol Chem., 286, pp. 43871-43880; Sclip, A., Tozzi, A., Abaza, A., Cardinetti, D., Colombo, I., Calabresi, P., C-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo (2014) Cell Death Dis, 23, p. 1019; Selkoe, D.J., Alzheimer's disease is a synaptic failure (2002) Science, 298, pp. 789-791; Settembre, C., Di Malta, C., Polito, V.A., Garcia Arencibia, M., Vetrini, F., Erdin, S., TFEB links autophagy to lysosomal biogenesis (2011) Science, 332, pp. 1429-1433; Settembre, C., Zoncu, R., Medina, D.L., Vetrini, F., Erdin, S., Erdin, S., A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB (2012) EMBO J, 31, pp. 1095-1108; Sonnino, S., Aureli, M., Loberto, N., Chigorno, V., Prinetti, A., Fine tuning of cell functions through remodelling of glycosphingolipids by plasma membrane-associated glycohydrolases (2010) FEBS Lett, 584, pp. 1914-1922; Tamboli, I.Y., Hampel, H., Tien, N.T., Tolksdorf, K., Breiden, B., Mathews, P.M., Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Aβ generation (2011) J Neurosci, 2, pp. 1837-1849; Tancini, B., Magini, A., Latterini, L., Urbanelli, L., Ciccarone, V., Elisei, F., Occurrence of an anomalous endocytic compartment in fibroblasts from Sandhoff disease patients (2010) Mol Cell Biochem, 335, pp. 273-282; Tancini, B., Magini, A., Bortot, B., Polchi, A., Urbanelli, L., Sonnino, S., β-Hexosaminidase over-expression affects lysosomal glycohydrolases expression and glycosphingolipid metabolism in mammalian cells (2012) Mol Cell Biochem, 363, pp. 109-118; Tozzi, A., Sclip, A., Tantucci, M., De Iure, A., Ghiglieri, V., Costa, C., Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease (2014) Neurobiol Aging, , [Epub ahead of print]; Urbanelli, L., Emiliani, C., Massini, C., Persichetti, E., Orlacchio, A., Pelicci, G., Cathepsin D expression is decreased in Alzheimer's disease fibroblasts (2008) Neurobiol Aging, 29, pp. 12-22; Valaperta, R., Chigorno, V., Basso, L., Prinetti, A., Bresciani, R., Preti, A., Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts (2006) FASEB J, 20, pp. 1227-1229; Walkley, S.U., Pathogenic cascades in lysosomal disease - Why so complex? (2009) J Inherit Metab Dis, 32, pp. 181-189",Article,Scopus,2-s2.0-84918770418
"Flores-Rodriguez P., Angel O.-T.M., Cardenas-Aguayo M.C., Pedro L.-A.J., Meraz-Rios M.A., Pintos A.V., Harrington C.R., Wischik C.M., Mena R., Floran-Garduno B., Luna-Munoz J.","The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease",2015,"Frontiers in Neuroscience","9","JAN", 33,"","",,,10.3389/fnins.2015.00033,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921784768&partnerID=40&md5=19527ee4ad0ea8984c6fc4b4b2b04ea2","Department of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico; Department of Cell Biology, CINVESTAV-IPN, Mexico; Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico; Department of Brain Bank-LaNSE, CINVESTAV-IPN, Mexico; School of Medicine and Dentistry, University of AberdeenAberdeen, United Kingdom","Flores-Rodríguez, P., Department of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico; Angel, O.-T.M., Department of Cell Biology, CINVESTAV-IPN, Mexico; Cárdenas-Aguayo, M.C., Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico; Pedro, L.-A.J., Department of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico; Meraz-Ríos, M.A., Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico; Pintos, A.V., Department of Brain Bank-LaNSE, CINVESTAV-IPN, Mexico; Harrington, C.R., School of Medicine and Dentistry, University of AberdeenAberdeen, United Kingdom; Wischik, C.M., School of Medicine and Dentistry, University of AberdeenAberdeen, United Kingdom; Mena, R., Department of Cell Biology, CINVESTAV-IPN, Mexico; Florán-Garduño, B., Department of Cell Biology, CINVESTAV-IPN, Mexico; Luna-Muñoz, J., Department of Brain Bank-LaNSE, CINVESTAV-IPN, Mexico","We previously demonstrated that, in the early stages of tau processing inAlzheimer's disease, the N-terminal part of the molecule undergoes acharacteristic cascade of phosphorylation and progressive misfolding of theproteins resulting in a structural conformation detected by Alz-50. In thisimmunohistochemical study of AD brain tissue, we have found that C-terminaltruncation of tau at Asp-421 was an early event in tau aggregation and analyzedthe relationship between phospho-dependent tau epitopes located at the Cterminuswith truncation at Glu-391. The aim of this study was to determinewhether C-terminal truncation may trigger events leading to the assembly ofinsoluble PHFs from soluble tau aggregates present in pre-tangle cells. Ourfindings suggest that there is a complex interaction between phosphorylatedand truncated tau species. A model is presented here in which truncated tauprotein represents an early neurotoxic species while phosphorylated tauspecies may provide a neuroprotective role in Alzheimer's disease. © 2015 Flores-rodríguez, Ontiveros-torres, Cárdenas-aguayo, Luna-arias, Meraz-ríos, Viramontes-pintos, Harrington, M_wischik, Florán, Mena and Luna-muñoz.","Alzheimers disease; Neurofibrillary tangles; Neurotoxicity; PHFs; Tau oligomers; Tau protein; Truncation","Abraha, A., Ghoshal, N., Gamblin, T.C., Cryns, V., Berry, R.W., Kuret, J., Binder, L.I., C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease (2000) J Cell Sci, 113, pp. 3737-3745; Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., Iqbal, K., Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments (2001) Proc Natl Acad Sci U S A, 98, pp. 6923-6928; Alonso, A.C., Grundke-Iqbal, I., Iqbal, K., Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules (1996) Nat Med, 2, pp. 783-787; Arendt, T., Stieler, J., Strijkstra, A.M., Hut, R.A., Rudiger, J., Van Der Zee, E.A., Harkany, T., Hartig, W., Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals (2003) J Neurosci, 23, pp. 6972-6981; Augustinack, J.C., Schneider, A., Mandelkow, E.M., Hyman, B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease (2002) Acta Neuropathol, 103, pp. 26-35; Basurto-Islas, G., Luna-Munoz, J., Guillozet-Bongaarts, A.L., Binder, L.I., Mena, R., Garcia-Sierra, F., Accumulation of aspartic acid421-and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease (2008) Journal of neuropathology and experimental neurology, 67, pp. 470-483; Berry, R.W., Abraha, A., Lagalwar, S., Lapointe, N., Gamblin, T.C., Cryns, V.L., Binder, L.I., Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment (2003) Biochemistry, 42, pp. 8325-8331; Binder, L.I., Frankfurter, A., Rebhun, L.I., The distribution of tau in the mammalian central nervous system (1985) The Journal of cell biology, 101, pp. 1371-1378; Bondareff, W., Wischik, C.M., Novak, M., Amos, W.B., Klug, A., Roth, M., Molecular analysis of neurofibrillary degeneration in Alzheimer's disease (1990) An immunohistochemical study. Am J Pathol, 137, pp. 711-723; Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski, J.Q., Lee, V.M., Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding (1993) Neuron, 10, pp. 1089-1099; Bretteville, A., Planel, E., Tau aggregates: toxic inert or protective species? (2008) J Alzheimers Dis, 14, pp. 431-436; Buee-Scherrer, V., Condamines, O., Mourton-Gilles, C., Jakes, R., Goedert, M., Pau, B., Delacourte, A., AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease (1996) Brain Res Mol Brain Res, 39, pp. 79-88; Bussiere, T., Hof, P.R., Mailliot, C., Brown, C.D., Caillet-Boudin, M.L., Perl, D.P., Buee, L., Delacourte, A., Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration (1999) Acta Neuropathol, 97, pp. 221-230; Carmel, G., Mager, E.M., Binder, L.I., Kuret, J., The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology (1996) J Biol Chem, 271, pp. 32789-32795; Castellani, R.J., Nunomura, A., Lee, H.G., Perry, G., Smith, M.A., Phosphorylated tau: toxic, protective, or none of the above (2008) J Alzheimers Dis, 14, pp. 377-383; Congdon, E.E., Duff, K.E., Is tau aggregation toxic or protective? (2008) J Alzheimers Dis, 14, pp. 453-457; Fasulo, L., Ugolini, G., Cattaneo, A., Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K (2005) J Alzheimers Dis, 7, pp. 3-13; Fasulo, L., Ugolini, G., Visintin, M., Bradbury, A., Brancolini, C., Verzillo, V., Novak, M., Cattaneo, A., The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis (2000) J Neurochem, 75, pp. 624-633; Fasulo, L., Visintin, M., Novak, M., Cattaneo, A., Tau truncation in Alzheimer's disease: encompassing PHF core tau induces apoptosis ina COS cells (1998) Alzheimes's reports, 1, pp. 25-32; Galvan, M., David, J.P., Delacourte, A., Luna, J., Mena, R., Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2 (2001) J Alzheimers Dis, 3, pp. 417-425; Gamblin, T.C., Berry, R.W., Binder, L.I., Modeling tau polymerization in vitro: a review and synthesis (2003) Biochemistry, 42, pp. 15009-15017; Gamblin, T.C., Berry, R.W., Binder, L.I., Tau polymerization: role of the amino terminus (2003) Biochemistry, 42, pp. 2252-2257; Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Cryns, V.L., Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease (2003) Proc Natl Acad Sci U S A, 100, pp. 10032-10037; Garcia-Sierra, F., Ghoshal, N., Quinn, B., Berry, R.W., Binder, L.I., Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease (2003) J Alzheimers Dis, 5, pp. 65-77; Garcia-Sierra, F., Mondragon-Rodriguez, S., Basurto-Islas, G., Truncation of tau protein and its pathological significance in Alzheimer's disease (2008) J Alzheimers Dis, 14, pp. 401-409; Goedert, M., Spillantini, M.G., Cairns, N.J., Crowther, R.A., Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms (1992) Neuron, 8, pp. 159-168; Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Reynolds, M.R., Horowitz, P.M., Fu, Y., Wang, T., Cahill, M.E., Binder, L.I., Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease (2005) Neurobiol Aging, 26, pp. 1015-1022; Horowitz, P.M., Lapointe, N., Guillozet-Bongaarts, A.L., Berry, R.W., Binder, L.I., N-terminal fragments of tau inhibit full-length tau polymerization in vitro (2006) Biochemistry, 45, pp. 12859-12866; Jicha, G.A., Berenfeld, B., Davies, P., Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease (1999) J Neurosci Res, 55, pp. 713-723; Jicha, G.A., Bowser, R., Kazam, I.G., Davies, P., Alz-50. and MC-1 a new monoclonal antibody raised to paired helical filaments recognize conformational epitopes on recombinant tau (1997) J Neurosci Res, 48, pp. 128-132; Jicha, G.A., Lane, E., Vincent, I., Otvos Jr., L., Hoffmann, R., Davies, P., A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease (1997) J Neurochem, 69, pp. 2087-2095; Jicha, G.A., Weaver, C., Lane, E., Vianna, C., Kress, Y., Rockwood, J., Davies, P., cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease (1999) J Neurosci, 19, pp. 7486-7494; Liu, F., Iqbal, K., Grundke-Iqbal, I., Rossie, S., Gong, C.X., Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease (2005) The Journal of biological chemistry, 280, pp. 1790-1796; Luna-Munoz, J., Chavez-Macias, L., Garcia-Sierra, F., Mena, R., Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease (2007) J Alzheimers Dis, 12, pp. 365-375; Luna-Munoz, J., Garcia-Sierra, F., Falcon, V., Menendez, I., Chavez-Macias, L., Mena, R., Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease (2005) J Alzheimers Dis, 8, pp. 29-41; Mckhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944; Mena, R., Edwards, P., Perez-Olvera, O., Wischik, C.M., Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease (1995) Acta Neuropathol, 89, pp. 50-56; Mena, R., Edwards, P.C., Harrington, C.R., Mukaetova-Ladinska, E.B., Wischik, C.M., Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease (1996) Acta Neuropathol, 91, pp. 633-641; Mena, R., Wischik, C.M., Novak, M., Milstein, C., Cuello, A.C., A progressive deposition of paired helical filaments (PHF) in the brain characterizes the evolution of dementia in Alzheimer's disease An immunocytochemical study with a monoclonal antibody against the PHF core. (1991) J Neuropathol Exp Neurol, 50, pp. 474-490; Mena, R.L.-M.J., Stages of pathological tau-protein processing in Alzheimer's disease: From soluble aggregation to polymetization into insoluble tau-PHFs (2009) Currents Hypotheses and Research Milestones, pp. 79-91. , ed. R.B.M.a. G. Perry.); Mondragon-Rodriguez, S., Basurto-Islas, G., Santa-Maria, I., Mena, R., Binder, L.I., Avila, J., Smith, M.A., Garcia-Sierra, F., Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease (2008) Int J Exp Pathol, 89, pp. 81-90; Morsch, R., Simon, W., Coleman, P.D., Neurons may live for decades with neurofibrillary tangles (1999) J Neuropathol Exp Neurol, 58, pp. 188-197; Novak, M., Truncated tau protein as a new marker for Alzheimer's disease (1994) Acta Virol, 38, pp. 173-189; Novak, M., Kabat, J., Wischik, C.M., Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament (1993) Embo J, 12, pp. 365-370; Nunomura, A., Takeda, A., Moreira, P.I., Castellanir, J., Hyoung-Gon, L., Zhu, X., Smith, M.A., Perry, G., Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer's disease (2009) Current hypotheses and reseach milestones in Alzheimer's disease, pp. 103-124. , ed. G.P. Ricardo B. Maccioni. (Miami Florida USA: Springer); Preuss, U., Doring, F., Illenberger, S., Mandelkow, E.M., Cell cycledependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells (1995) Molecular biology of the cell, 6, pp. 1397-1410; Rissman, R.A., Poon, W.W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M.P., Laferla, F.M., Cotman, C.W., Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology (2004) J Clin Invest, 114, pp. 121-130; Schneider, A., Biernat, J., Von Bergen, M., Mandelkow, E., Mandelkow, E.M., Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments (1999) Biochemistry, 38, pp. 3549-3558; Stieler, J.T., Bullmann, T., Kohl, F., Barnes, B.M., Arendt, T., PHF-like tau phosphorylation in mammalian hibernation is not associated with p25-formation (2009) J Neural Transm, 116, pp. 345-350; Stieler, J.T., Bullmann, T., Kohl, F., Toien, O., Bruckner, M.K., Hartig, W., Barnes, B.M., Arendt, T., The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation PLoS One, 6; Su, B., Wang, X., Drew, K.L., Perry, G., Smith, M.A., Zhu, X., Physiological regulation of tau phosphorylation during hibernation (2008) J Neurochem, 105, pp. 2098-2108; Uchihara, T., Nakamura, A., Yamazaki, M., Mori, O., Evolution from pretangle neurons to neurofibrillary tangles monitored by thiazin red combined with Gallyas method and double immunofluorescence (2001) Acta Neuropathol, 101, pp. 535-539; Wang, J.Z., Liu, F., Microtubule-associated protein tau in development, degeneration and protection of neurons (2008) Prog Neurobiol, 85, pp. 148-175; Weaver, C.L., Espinoza, M., Kress, Y., Davies, P., Conformational change as one of the earliest alterations of tau in Alzheimer's disease (2000) Neurobiol Aging, 21, pp. 719-727; Wischik, C.M., Edwards, P.C., Lai, R.Y., Gertz, H.N., Xuereb, J.H., Paykel, E.S., Brayne, C., Mena, R., Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease (1995) Neurobiol Aging, 16, pp. 409-417. , discussion 418-431; Wischik, C.M., Edwards, P.C., Lai, R.Y., Roth, M., Harrington, C.R., Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines (1996) Proc Natl Acad Sci U S A, 93, pp. 11213-11218; Wischik, C.M., Novak, M., Edwards, P.C., Klug, A., Tichelaar, W., Crowther, R.A., Structural characterization of the core of the paired helical filament of Alzheimer disease (1988) Proc Natl Acad Sci U S A, 85, pp. 4884-4888; Wischik, C.M., Novak, M., Thogersen, H.C., Edwards, P.C., Runswick, M.J., Jakes, R., Walker, J.E., Klug, A., Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease (1988) Proc Natl Acad Sci U S A, 85, pp. 4506-4510; Zhang, Y., Tian, Q., Zhang, Q., Zhou, X., Liu, S., Wang, J.Z., Hyperphosphorylation of microtubule-associated tau protein plays dual role in neurodegeneration and neuroprotection (2009) Pathophysiology: the official journal of the International Society for Pathophysiology/ISP, 16, pp. 311-316; Zilkova, M., Zilka, N., Kovac, A., Kovacech, B., Skrabana, R., Skrabanova, M., Novak, M., Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model (2011) Journal of Alzheimer's disease: JAD, 23, pp. 161-169",Article,Scopus,2-s2.0-84921784768
"Cooley S.A., Cabeen R.P., Laidlaw D.H., Conturo T.E., Lane E.M., Heaps J.M., Bolzenius J.D., Baker L.M., Salminen L.E., Scott S.E., Paul R.H.","Posterior brain white matter abnormalities in older adults with probable mild cognitive impairment",2015,"Journal of Clinical and Experimental Neuropsychology","37","1",,"61","69",,,10.1080/13803395.2014.985636,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924624755&partnerID=40&md5=73528fcb62e1fe4fc6974c4ca08f7f87","Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Computer Science Department, Brown UniversityProvidence, RI, United States; Mallinckrodt Institute of Radiology, Washington University School of MedicineSaint Louis, MO, United States; Vanderbilt University Medical CenterNashville, TN, United States; Missouri Institute of Mental HealthSaint Louis, MO, United States","Cooley, S.A., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Cabeen, R.P., Computer Science Department, Brown UniversityProvidence, RI, United States; Laidlaw, D.H., Computer Science Department, Brown UniversityProvidence, RI, United States; Conturo, T.E., Mallinckrodt Institute of Radiology, Washington University School of MedicineSaint Louis, MO, United States; Lane, E.M., Vanderbilt University Medical CenterNashville, TN, United States; Heaps, J.M., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States, Missouri Institute of Mental HealthSaint Louis, MO, United States; Bolzenius, J.D., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Baker, L.M., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Salminen, L.E., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Scott, S.E., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States; Paul, R.H., Department of Psychology, University of Missouri-Saint Louis, Stadler Hall 442B, One University BoulevardSaint Louis, MO, United States, Missouri Institute of Mental HealthSaint Louis, MO, United States","Objective: Much of the mild cognitive impairment (MCI) neuroimaging literature has exclusively focused on regions associated with Alzheimers disease. Little research has examined white matter abnormalities of other brain regions, including those associated with visual processing, despite evidence that other brain abnormalities appear in these regions in early disease stages. Method: Diffusion tensor imaging (DTI) was utilized to examine participants (n = 44) that completed baseline imaging as part of a longitudinal healthy aging study. Participants were divided into two groups based on scores from the Montreal Cognitive Assessment (MoCA), a brief screening tool for MCI. Participants who scored <26 were defined as ""probable MCI"" while those who scored ≥26 were labeled cognitively healthy. Two DTI indices were analyzed including fractional anisotropy (FA) and mean diffusivity (MD). DTI values for white matter in the lingual gyrus, cuneus, pericalcarine, fusiform gyrus, and all four lobes were compared using multivariate analysis of variance (MANOVA). Regression analyses examined the relationship between DTI indices and total MoCA score. Results: Results revealed significantly lower FA in the probable MCI group in the cuneus, fusiform, pericalcarine, and occipital lobe, and significantly higher MD in the temporal lobe. Fusiform FA and temporal lobe MD were significantly related to total MoCA score after accounting for age and education. Conclusions: Results indicate that there are posterior white matter microstructural changes in individuals with probable MCI. These differences demonstrate that white matter abnormalities are evident among individuals with probable MCI in regions beyond those commonly associated with Alzheimers disease and anterior brain aging patterns. © 2014 Taylor & Francis.","Aging; Diffusion tensor imaging; Fractional anisotropy; Mild cognitive impairment; Occipital lobe","Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease (2011) Alzheimer's & Dementia, 7 (3), pp. 270-279; Alexander, A.L., Lee, J.E., Lazar, M., Field, A.S., Diffusion tensor imaging of the brain (2007) Neurotherapeutics, 4 (3), pp. 316-329; Artero, S., Tiemeier, H., Prins, N., Sabatier, R., Breteler, M., Ritchie, K., Neuroanatomical localisation and clinical correlates of white matter lesions in the elderly (2004) Journal of Neurology, Neurosurgery & Psychiatry, 75 (9), pp. 1304-1308; Benjamani, Y., Hochberg, Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing (1995) Journal of the Royal Statistical Society, 57 (1), pp. 289-300; Binnewijzend, M.A., Kuijer, J.P., Benedictus, M.R., Van Der Flier, W.M., Wink, A.M., Wattjes, M.P., Barkhof, F., Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: A marker for disease severity (2013) Neuroradiology, 267 (1), pp. 221-230; Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes (1991) Acta Neuropathologica, 82 (4), pp. 239-259; Farias, S.T., Mungas, D., Reed, B.R., Harvey, D., Decarli, C., Progression of mild cognitive impairment to dementia in clinc-vs. Communitybased cohorts (2010) Archives of Neurology, 66 (9), pp. 1151-1157; Fellgiebel, A., Müller, M.J., Willie, P., Dellani, P., Scheurich, A., Schmidt, G., Stoeter, P., Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment (2005) Neurobiology of Aging, 26 (8), pp. 1193-1198; Fellgiebel, A., Wille, P., Müller, M.J., Winterer, G., Scheurich, A., Vucurevic, G., Stoeter, P., Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: A diffusion tensor imaging study (2004) Dementia and Geriatric Cognitive Disorders, 18 (1), pp. 101-108; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state. A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12 (3), pp. 189-198; Head, D., Buckner, R.L., Shimony, J.S., Williams, L.E., Akbudak, E., Conturo, T.E., Snyder, A.Z., Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: Evidence from diffusion tensor imaging (2004) Cerebral Cortex, 14 (4), pp. 410-423; Huang, J., Friedland, R.P., Auchus, A.P., Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer's disease: Preliminary evidence of axonal degeneration in the temporal lobe (2007) American Journal of Neuroradiology, 28 (10), pp. 1943-1948; Jenkinson, M., Bannister, P.R., Brady, J.M., Smith, S.M., Improved optimization for the robust and accurate linear registration and motion correction of brain images (2002) NeuroImage, 17 (2), pp. 825-841; Jenkinson, M., Smith, S.M., A global optimisation method for robust affine registration of brain images (2001) Medical Image Analysis, 5 (2), pp. 143-156; Kennedy, K.M., Raz, N., Pattern of normal age-related regional differences in white matter microstructure is modified by vascular risk (2009) Brain Research, 1297, pp. 41-56; Lawton, M.P., Brody, E.M., Assessment of older people: Self-maintaining and instrumental activities of daily living (1969) The Gerontologist, 9, pp. 179-185; Le Bihan, D., Mangin, J.F., Poupon, C., Clark, C.A., Pappata, S., Molko, N., Chabriat, H., Diffusion tensor imaging: Concepts and applications (2001) Journal of Magnetic Resonance Imaging, 13 (4), pp. 534-546; Lopez, O.L., Jagust, W.J., Dekosky, S.T., Becker, J.T., Fitzpatrick, A., Dulberg, C., Kuller, L.H., Prevalence and classification of mild cognitive impairment in the cardiovascular health study cognition study, Part 1 (2003) Archives of Neurology, 60 (10), pp. 1385-1389; Luis, C.A., Keegan, A.P., Mullan, M., Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US (2009) International Journal of Geriatric Psychiatry, 24 (2), pp. 197-201; Mapstone, M., Steffenella, T.N., Duffy, C.J., A visuospatial variant of mild cognitive impairment: Getting lost between aging and AD (2003) Neurology, 60 (5), pp. 802-808; McKee, A.C., Au, R., Cabral, H.J., Kowall, N.W., Seshadri, S., Kubilus, C.A., Wolf, P.A., Visual association pathology in preclinical Alzheimer disease (2006) Journal of Neuropathology and Experimental Neurology, 65 (6), pp. 621-630; Medina, D., Detoledo-Morrell, L., Urresta, F., Gabrieli, J., Moseley, M., Fleischman, D., Stebbins, G.T., White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study (2006) Neurobiology of Aging, 27, pp. 663-672; Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Clifford, J., Jagust, W., Beckett, L., The Alzheimer's disease neuroimaging initiative (2008) Neuroimaging Clinics of NorthAmerica, 15 (4), pp. 869-877; Nasreddine, Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Chertkow, H., The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment (2005) Journal of the American Geriatrics Society, 53 (4), pp. 695-699; Paul, R., Lane, E.M., Tate, D.F., Heaps, J., Romo, D.M., Akbudak, E., Conturo, T.E., Neuroimaging signatures and cognitive correlates of the Montreal Cognitive Assessment screen in a nonclinical elderly sample (2011) Archives of Clinical Neuropsychology, 26, pp. 454-460; Petersen, R.C., Mild cognitive impairment (2011) The New England Journal of Medicine, 364 (23), pp. 2227-2234; Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Winblad, B., Current concepts in mild cognitive impairment (2001) Archives of Neurology, 58 (12), pp. 1985-1992; Petersen, R.C., Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.H., Pankratz, V.S., Rocca, W.A., Prevalence of mild cognitive impairment is higher in men (2010) Neurology, 75 (10), pp. 889-897; Plassman, B.L., Langa, K.L., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M., Wallace, R.B., Prevalence of cognitive impairment without dementia in the United States (2008) Annals of Internal Medicine, 148 (6), pp. 427-434; Randolph, C., Tierney, M.C., Mohr, E., Chase, T.N., The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity (1998) Journal of Clinical and Experimental Psychology, 20 (3), pp. 310-319; Raz, N., Rodrigue, K.M., Kennedy, M., Acker, J.D., Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults (2007) Neuropsychology, 21 (2), pp. 149-157; Rose, S.E., McMahon, K.L., Janke, A.L., O'Dowd, B., De Zubicaray, G., Strudwick, M., Chalk, J.B., Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment (2006) Journal of Neurology, Neurosurgery & Psychiatry with Practical Neurology, 77 (10), pp. 1122-1128; Scola, E., Bozzali, M., Agosta, F., Magnani, G., Franceschi, M., Sormani, M., Falini, A., A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up (2010) Journal of Neurology, Neurosurgery & Psychiatry, 81, pp. 798-805; Smith, T., Gildeh, N., Holmes, C., The Montreal Cognitive Assessment: Validity and utility in a memory clinic setting (2007) Canadian Journal of Psychiatry, 52 (5), pp. 329-332; Stebbins, G.T., Murphy, C.M., Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment (2009) Behavioural Neurology, 21 (1), pp. 39-49; Sullivan, E.V., Pfefferbaum, A., Diffusion tensor imaging and aging (2006) Neuroscience and Biobehavioral Reviews., 30 (6), pp. 749-761; Zhang, Y., Schuff, N., Jahng, G.H., Bayne, W., Mori, S., Schad, L., Weiner, M.W., Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer's disease (2007) Neurology, 68 (1), pp. 13-19",Article,Scopus,2-s2.0-84924624755
"Lopez-Alvarez J., Zea Sevilla M.A., Aguera Ortiz L., Fernandez Blazquez M.A., Valenti Soler M., Martinez-Martin P.","Effect of anticholinergic drugs on cognitive impairment in the elderly [Efecto de los fármacos anticolinérgicos en el rendimiento cognitivo de las personas mayores]",2015,"Revista de Psiquiatria y Salud Mental","8","1",,"35","43",,,10.1016/j.rpsm.2013.11.003,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84925682829&partnerID=40&md5=a1c90244362770f9d4555d00327d217f","Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos IIIMadrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos IIIMadrid, Spain","López-Álvarez, J., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain; Zea Sevilla, M.A., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain; Agüera Ortiz, L., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos IIIMadrid, Spain; Fernández Blázquez, M.Á., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain; Valentí Soler, M., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain; Martínez-Martín, P., Unidad de Investigación Enfermedad Alzheimer, Fundación CIEN, Centro Alzheimer Fundación Reina SofíaMadrid, Spain, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos IIIMadrid, Spain","The use of anticholinergic drugs is common in the elderly, even in people with cognitive impairment. A systematic search was conducted in PubMed (anticholinergic effects, anticholinergic and dementia) to define the effects of anticholinergic drugs in the elderly. We emphasized the search in patterns of use, the combined use with AChEIs, the measurement of the Serum Anticholinergic Activity, and the short-term and long-term cognitive effects. The conclusions are that the use of anticholinergic drugs is common in the elderly, even more so than the medical prescription of AChEIs in Alzheimer's disease. The use of anticholinergic drugs may result in cognitive impairment. In long-term use it may generate a worsening of cognitive functions. It can lead to a wrong diagnosis of mild cognitive impairment or dementia, and they can also initiate signs of dementia. Greater cognitive effects appear when there is a previous deficit, but cognitive effects from anticholinergic drugs disappear in severe dementia. The presence of ApoE E4 increases the vulnerability for cognitive impairment when these drugs are employed. © 2013 SEP y SEPB.","Alzheimers disease; Dementia; Mild cognitive impairment; Serum anticholinergic activity","Potamianos, G., Kellet, J.M., Anti-cholinergic drugs and memory: The effects of benzhexol on memory in a group of geriatric patients (1982) Br J Psychiatry, 140, pp. 470-472; Tune, L.E., Anticholinergic effects of medication in elderly patients (2001) J Clin Psychiatry, 62, pp. 11-14; Lechevallier-Michel, N., Molimard, M., Dartigues, J.F., Fabrigoule, C., Fourrier-Réglat, A., Drugs with anticholinergic properties and cognitive performance in the elderly: Results from the PAQUID Study (2005) Br J Clin Pharmacol, 59, pp. 143-151; Roe, C.M., Anderson, M.J., Spivack, B., Use of anticholinergic medications by older adults with dementia (2002) J Am Geriatr Soc, 50, pp. 836-842; Harrison, B.E., Therrien, B., Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss (2007) J Gerontol Nurs, 33, pp. 11-20; Bartus, R.T., Dean, R.L., III, Beer, B., Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction (1982) Science, 217, pp. 408-414; Bottiggi, K.A., Salazar, J.C., Yu, L., Caban-Holt, A.M., Ryan, M., Mendionde, M.S., Long-term cognitive impact of anticholinergic medications in older adults (2006) Am J Geriatr Psychiatry, 14, pp. 980-984; Moore, A.R., O'Keeffe, S.T., Drug-induced cognitive impairment in the elderly (1999) Drugs Aging, 15, pp. 15-28; Catterson, M.L., Preskorn, S.H., Martin, R.L., Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology (1997) Psychiatr Clin North Am, 20, pp. 205-218; Lu, C.J., Tune, L.E., Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease (2003) Am J Geriatr Psychiatry, 11, pp. 458-461; Carnahan, R.M., Lund, B.C., Perry, P.J., Chrischilles, E.A., The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? (2004) J Am Geriatr Soc, 52, pp. 2082-2087; Pitkala, K.H., Strandberg, T.E., Tilvis, R.S., Inappropriate drug prescribing in home-dwelling, elderly patients: A population-based survey (2002) Arch Intern Med, 162, pp. 1707-1712; Campbell, N., Boustani, M., Limbil, T., Ott, C., Fox, C., Maidment, I., The cognitive impact of anticholinergics. A clinical review (2009) Clin Interv Aging, 4, pp. 225-233; Jessen, F., Kaduszkiewicz, H., Daerr, M., Bickel, H., Pentzek, M., Riedel-Heller, S., Anticholinergic drug use and risk for dementia: Target for dementia prevention (2010) Eur Arch Psychiatry Clin Neurosci, 260, pp. S111-S115; Chew, M.L., Mulsant, B.H., Pollock, B.G., Lehman, M.E., Greenspan, A., Mahmoud, R.A., Anticholinergic activity of 107 medications commonly used by older adults (2008) J Am Geriatr Soc, 56, pp. 1333-1341; Hori, K., Konishi, K., Watanabe, K., Uchida, H., Tsuboi, T., Moriyasu, M., Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer's disease (2011) Neuropsychobiology, 63, pp. 147-153; Plaschke, K., Kopitz, J., Mattern, J., Martin, E., Teschendorf, P., Increased cortisol levels and anticholinergic activity in cognitively unimpaired patients (2010) J Neuropsychiatry Clin Neurosci, 22, pp. 433-441; Fox, C., Livingston, G., Maidment, I.D., Coulton, S., Smithard, D.G., Boustani, M., The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study (2011) Age Ageing, 40, pp. 730-735; Thomas, C., Hestermann, U., Kopitz, J., Plaschke, K., Oster, P., Driessen, M., Serum anticholinergic activity and cerebral cholinergic dysfunction: An EEG study in frail elderly with and without delirium (2008) BMC Neurosci, 9, p. 86; Wawruch, M., Macugova, A., Kostkova, L., Luha, J., Dukat, A., Murin, J., The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients (2012) Pharmacoepidemiol Drug Saf, 21, pp. 170-176; Carnahan, R.M., Lund, B.C., Perry, P.J., Pollock, B.G., Culp, K.R., The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity (2006) J Clin Pharmacol, 46, pp. 1481-1486; Rudolph, J.L., Salow, M.J., Angelini, M.C., McGlinchey, R.E., The anticholinergic risk scale and anticholinergic adverse effects in older persons (2008) Arch Intern Med, 168, pp. 508-513; Hilmer, S.N., Mager, D.E., Simonsick, E.M., Cao, Y., Ling, S.M., Windham, B.G., A drug burden index to define the functional burden of medications in older people (2007) Arch Intern Med, 167, pp. 781-787; Hilmer, S.N., Mager, D.E., Simonsick, E.M., Sing, S.M., Windham, B.G., Harris, T.B., Drug burden index score and functional decline in older people (2009) Am J Med, 122, pp. 1142-1149; Tune, L., Carr, S., Hoag, E., Cooper, T., Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium (1992) Am J Psychiatry, 149, pp. 1393-1394; García-Gollarte, F., Baleriola-Júlvez, J., Ferrero-López, I., Cruz-Jentoft, A.J., Inappropriate drug prescription at nursing home admission (2012) J Am Med Dir Assoc, 13. , 83.e9-15; Blazer, D.G., II, Federspiel, C.F., Ray, W.A., Schaffner, W., The risk of anticholinergic toxicity in the elderly: A study of prescribing practices in two populations (1983) J Gerontol, 38, pp. 31-35; Chatterjee, S., Mehta, S., Sherer, J.T., Aparasu, R.R., Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: Analysis of data from the 2004 National Nursing Home Survey (2010) Drugs Aging, 27, pp. 987-997; Bhattacharya, R., Chatterjee, S., Carnahan, R.M., Aparasu, R.R., Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia (2011) Am J Geriatr Pharmacother, 9, pp. 434-441; Robinson, M., Rowett, D., Leverton, A., Mabbott, V., Changes in utilization of anticholinergic drugs after initiation of cholinesterase inhibitors (2009) Pharmacoepidemiol Drug Saf, 18, pp. 659-664; Crow, T.J., Grove-White, I.G., An analysis of the learning deficit following hyoscine administration to man (1973) Br J Pharmacol, 49, pp. 322-327; Nakra, B.R., Margolis, R.B., Gfeller, J.D., Grossberg, G.T., Sata, L.S., The effect of a single low dose of trihexyphenidyl on memory functioning in the healthy elderly (1992) Int Psychogeriatr, 4, pp. 207-214; Gnjidic, D., Le Couteur, D.G., Naganathan, V., Cumming, R.G., Creasey, H., Waite, L.M., Effects of drug burden index on cognitive function in older men (2012) J Clin Psychopharmacol, 32, pp. 273-277; Fortin, M.P., Rouch, I., Dauphinot, V., Gédéon, C., Genthon, S., Bonnefoy, M., Effects of anticholinergic drugs on verbal episodic memory function in the elderly: A retrospective, cross-sectional study (2011) Drugs Aging, 28, pp. 195-204; Rovner, B.W., David, A., Lucas-Blaustein, M.J., Conklin, B., Filipp, L., Tune, L., Self-care capacity and anticholinergic drug levels in nursing home patients (1988) Am J Psychiatry, 145, pp. 107-109; Konishi, K., Hori, K., Uchida, H., Watanabe, K., Tominaga, I., Kimura, M., Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease (2010) Psychogeriatrics, 10, pp. 34-38; Sittironnarit, G., Ames, D., Bush, A.I., Faux, N., Flicker, L., Foster, J., Effect of anticholinergic drugs on cognitive function in older Australians: Results from the AIBL study (2011) Dement Geriatr Cogn Disord, 31, pp. 173-178; Chew, M.L., Mulsant, B.H., Pollock, B.G., Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia (2005) Am J Geriatr Psychiatry, 13, pp. 535-538; Mulsant, B.H., Pollock, B.G., Kirshner, M., Shen, C., Dodge, H., Ganguli, M., Serum anticholinergic activity in a community-based sample of older adults: Relationship with cognitive performance (2003) Arch Gen Psychiatry, 60, pp. 198-203; Ancelin, M.L., Artero, S., Portet, F., Dupuy, A.M., Touchon, J., Ritchie, K., Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study (2006) BMJ, 332, pp. 455-459; Carrière, I., Fourrier-Reglat, A., Dartigues, J.F., Rouaud, O., Pasquier, F., Ritchie, K., Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-City Study (2009) Arch Intern Med, 169, pp. 1317-1324; Whalley, L.J., Sharma, S., Fox, H.C., Murray, A.D., Staff, R.T., Duthie, A.C., Anticholinergic drugs in late life: Adverse effects on cognition but not on progress to dementia (2012) J Alzheimers Dis, 30, pp. 253-261; Han, L., Agostini, J.V., Allore, H.G., Cumulative anticholinergic exposure is associated with poor memory and executive function in older men (2008) J Am Geriatr Soc, 56, pp. 2203-2210; Fox, C., Richardson, K., Maidment, I.D., Savva, G.M., Matthews, F.E., Smithard, D., Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study (2011) J Am Geriatr Soc, 59, pp. 1477-1483; Uusvaara, J., Pitkala, K.H., Tienari, P.J., Kautiainen, H., Tilvis, R.S., Strandberg, T.E., Association between anticholinergic drugs and apolipoprotein e epsilon 4 allele and poorer cognitive function in older cardiovascular patients: A cross-sectional study (2009) J Am Geriatr Soc, 57, pp. 427-431; Pomara, N., Willoughby, L.M., Wesnes, K., Sidtis, J.J., Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: A controlled pilot study (2004) Neuropsychopharmacology, 29, pp. 403-409; Boudreau, D.M., Yu, O., Gray, S.L., Raebel, M.A., Johnson, J., Larson, E.B., Concomitant use of cholinesterase inhibitors and anticholinergics: Prevalence and outcomes (2011) J Am Geriatr Soc, 59, pp. 2069-2076; Bottiggi, K.A., Salazar, J.C., Yu, L., Caban-Holt, A.M., Ryan, M., Schmitt, F.A., Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: Impact on cognitive and physical functioning in Alzheimer disease (2007) Am J Geriatr Psychiatry, 15, pp. 357-359; Jedenius, E., Johnell, K., Fastborn, J., Strömqvist, J., Winblad, B., Andreasen, N., Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population (2011) Scand J Prim Health Care, 29, pp. 181-186",Review,Scopus,2-s2.0-84925682829
"Parasuraman P., Suresh R.","Design and insilico molecular prediction of flavone-fusedthiazole analogues as Acetyl Cholinesterase and β-Secretase inhibitor in the treatment of Alzheimer’s disease",2015,"International Journal of PharmTech Research","7","1",,"125","131",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920475348&partnerID=40&md5=6ae4de8e4cdadab0ec634c789332e1e4","Department of Pharmacy, FEAT, Annamalai UniversityAnnamalai Nagar, Chidambaram, TamilNadu, India","Parasuraman, P., Department of Pharmacy, FEAT, Annamalai UniversityAnnamalai Nagar, Chidambaram, TamilNadu, India; Suresh, R., Department of Pharmacy, FEAT, Annamalai UniversityAnnamalai Nagar, Chidambaram, TamilNadu, India","The objective of this study is to evaluate the Acetyl Cholinesterase and β-Secretase inhibitory activity of designed flavone-fused-thiazole analogues using insilico docking studies. Insilico docking studies were carried out using Schrodinger software based on GLIDE (Grid-based Ligand Docking with Energetics). Acetyl Cholinesterase inhibitors, including Donepezil, Tacrine, Galantamine and Rivastigamine are being used currently in the treatment of Alzheimer’s disease and used as standards in the present study. The docking scores of flavone-fused-thiazole analogues were varied between -0.16 and -7.5 against Acetyl Cholinesterase and -1.6 and -9.3 for β-Secretase. Test compound (PS206) 1-(2-oxobutyl)-3-(5-(3, 6, 7-trihydroxy-5, 8- dimethoxy-4-oxo-4H-chromen-2-yl) benzo[d] thiazol-2-yl) urea was found to be more significant when compared with the standard docking score. These molecular docking analyses could lead to the further development of potent inhibitors for the treatment of Alzheimer’s disease. Further investigations on the above compounds are necessary to develop potential chemical entities for the prevention and treatment of Alzheimer’s disease. © 2014, International Journal of PharmTech Research. All rights reserved.","Acetyl Cholinesterase; Alzheimers disease; Flavone-fusedthiazole; Insilico drug design; MTDL; β-Secretase","Aurn, K.G., Nagaswamy, K., Jordan, T., Recent developments of structure based β-secretase inhibitors for alzheimer's disease (2005) Curr Top Med Chem, 5, pp. 1609-1622; Tao, G., Doug, W.H., Development of β-SECRETASE1 inhibitors for alzheimer's disease (2006) Curr Med Chem, 13, pp. 1811-1829; Toews, M.L., Bylund, D.B., Pharmacologic principles for combination therapy (2005) Proc Am Thorac Soc, 2, pp. 282-289; Cavalli, A., Bolognesi, M.L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., Multi-target-directed ligands to combat neurodegenerative diseases (2008) J Med Chem, 51, pp. 347-372; Small, G., Dubois, B., A review of compliance to treatment in alzheimer’s disease: Potential benefits of a transdermal patch (2007) Curr Med Res Opin, 23, pp. 2705-2713; Morphy, R., Rankovic, Z., Designing multiple ligands - medicinal chemistry strategies and challenges (2009) Curr Pharm Design, 15, pp. 587-600; Bolognesi, M.L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., MelchiorreC. Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against alzheimer's disease (2007) J Med Chem, 50, pp. 6446-6449; Zhu, Y.P., Xiao, K., Ma, L.P., Xiong, B., Fu, Y., Yu, H.P., Wang, W.D., Shen, J.K., Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase (2009) Bioorg Med Chem, 17, pp. 1600-1613; Morphy, R., Rankovic, Z., Designing multiple ligands - medicinal chemistry strategies and challenges (2009) Curr Pharm Design, 15, pp. 587-600; Choi, M.M., Kim, E.A., Hahn, H.G., Nam, K.D., Yang, S.J., Choi, S.Y., Kim, T.U., Huh, J.W., Protective effect of benzothiazole derivative KHG21834 on amyloid -induced neurotoxicity in PC12 cells and cortical and mesencephalic neurons (2007) Toxicol, 239, pp. 156-166; Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Flavonols and flavones as β-SECRETASE- 1 inhibitors: Structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features (2008) Biochim Biophys Acta, 1780, pp. 819-825; Parasuraman, P., Suresh, R., Premnath, D., Balancing anti-amyloid and anti-cholinesterase capacity in a single chemical entity: In-silico drug design (2014) Int J Pharm Pharm Sci, 6 (2), p. 571",Article,Scopus,2-s2.0-84920475348
"Busche M.A., Konnerth A.","Neuronal hyperactivity - A key defect in Alzheimer's disease?",2015,"BioEssays",,,,"","",,,10.1002/bies.201500004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924875387&partnerID=40&md5=bf8ccd37b2d3d930c2001ead55e0b491","Institute of NeuroscienceTechnische Universität MünchenMünchenGermany; Department of Psychiatry and PsychotherapyTechnische Universität MünchenMünchenGermany; Munich Cluster for Systems Neurology (SyNergy) and Center for Integrated Protein Sciences (CIPSM)Technische Universität MünchenMunichGermany","Busche, M.A., Institute of NeuroscienceTechnische Universität MünchenMünchenGermany, Department of Psychiatry and PsychotherapyTechnische Universität MünchenMünchenGermany, Munich Cluster for Systems Neurology (SyNergy) and Center for Integrated Protein Sciences (CIPSM)Technische Universität MünchenMunichGermany; Konnerth, A., Institute of NeuroscienceTechnische Universität MünchenMünchenGermany, Munich Cluster for Systems Neurology (SyNergy) and Center for Integrated Protein Sciences (CIPSM)Technische Universität MünchenMunichGermany","Traditionally, the impairment of cognitive functions in Alzheimeŕs disease (AD) is thought to result from a reduction in neuronal and synaptic activities, and ultimately cell death. Here, we review recent in vivo evidence from mouse models and human patients indicating that, particularly in early stages of AD, neuronal circuits are hyperactive instead of hypoactive. Functional analyses at many levels, from single neurons to neuronal populations to large-scale networks, with a variety of electrophysiological and imaging techniques have revealed two forms of AD-related hyperactivity and provided first insights into the synaptic mechanisms. The unexpected finding that hyperactivity is an early neuronal dysfunction represents a major conceptual shift in our understanding of AD that may have important implications for the development of therapeutic approaches. © 2015 WILEY Periodicals, Inc.","Alzheimer's disease; Amyloid-ß; Biomedicine; Brain imaging; Mouse models; Neuronal dysfunction; Neuronal hyperactivity",,Article in Press,Scopus,2-s2.0-84924875387
"Verhulsdonk S., Hellen F., Hoft B., Supprian T., Lange-Asschenfeldt C.","Attention and CERAD test performances in cognitively impaired elderly subjects",2015,"Acta Neurologica Scandinavica","131","6",,"364","371",,,10.1111/ane.12346,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926294866&partnerID=40&md5=622f8f29f47e32a83fa341918876aa35","Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany","Verhülsdonk, S., Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany; Hellen, F., Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany; Höft, B., Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany; Supprian, T., Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany; Lange-Asschenfeldt, C., Department of Psychiatry and Psychotherapy, Division of Geriatric Psychiatry, Medical Faculty, Heinrich Heine UniversityDüsseldorf, Germany","Objectives: Attention plays a fundamental role in cognitive performance and is closely interrelated with all major cognitive domains. In this retrospective study, we correlated different measures of attention with standard cognitive parameters in 85 cognitively impaired elderly individuals presenting with cognitive complaints to a memory clinic. Materials and Methods: Z-scores of all relevant cognitive parameters of a extended Consortium to Establish a Registry for Alzheimer's disease (CERAD-Plus) neuropsychological battery were correlated with tonic and phasic alertness, inhibition, and divided attention, assessed by a computerized test battery of attention. The pooled sample consisted of 36 patients with the diagnosis of mild AD, 30 patients with mild cognitive impairment, and 19 patients with major depressive disorder. Results: Subjects of all diagnostic groups exhibited normal results in all subtests of attention. Reaction times of neither the tonic nor the phasic alertness task were correlated with any parameter of memory and global cognition. However, significant correlations were obtained between reaction times in the alertness tasks and the trail-making tests. Omissions in the divided attention task yielded the strongest correlations with deficits in cognitive performance, particularly in the verbal learning tasks, the Boston naming test, and the trail-making tests. Conclusions: Our data demonstrate the relative independency of the CERAD-Plus on the variability of attention and particularly alertness suggesting its robustness in psychiatric memory clinic settings. Moreover, CERAD-Plus subtests correlated considerably with failure rates in divided attention, suggesting that impairment in divided attention tasks may be early markers of cognitive impairment. © 2014 John Wiley & Sons A/S.","Alzheimer's disease; Depression; Mild cognitive impairment; Neuropsychology","Sturm, W., Willmes, K., On the functional neuroanatomy of intrinsic and phasic alertness (2001) NeuroImage, 14, pp. 76-84; Van Zomeren, A.H., Brouwer, W.H., (1994) Clinical neuropsychology of attention, , New York: Oxford University Press; Harrison, T.L., Mullet, H.G., Whiffen, K.N., Ousterhout, H., Einstein, G.O., Prospective memory: effects of divided attention on spontaneous retrieval (2014) Mem Cognit, 42, pp. 212-224; Naveh-Benjamin, M., Guez, J., Hara, Y., Brubaker, M.S., Lowenschuss-Erlich, I., The effects of divided attention on encoding processes under incidental and intentional learning instructions: underlying mechanisms? (2014) Q J Exp Psychol (Hove), 67, pp. 1682-1696; Reppermund, S., Zihl, J., Lucae, S., Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation (2007) Biol Psychiatry, 62, pp. 400-406; Lupien, S.J., Maheu, F., Tu, M., Fiocco, A., Schramek, T.E., The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition (2007) Brain Cogn, 65, pp. 209-237; Mc Guiness, B., Barrett, S.L., Craig, D., Lawson, J., Passmore, A.P., Attention deficits in Alzheimer's disease and vascular dementia (2010) J Neurol Neurosurg Psychiatry, 81, pp. 157-159; Zihl, J., Reppermund, S., Thum, S., Unger, K., Neuropsychological profiles in MCI and in depression: differential cognitive dysfunction patterns or similar final common pathway disorder? (2010) J Psychiatr Res, 44, pp. 647-654; Foldi, N.S., Lobosco, J.J., Schaefer, L.A., The effect of attentional dysfunction in Alzheimer's disease: theoretical and practical implications (2002) Semin Speech Lang, 23, pp. 139-150; Dannhauser, T.M., Walker, Z., Stevens, T., Lee, L., Seal, M., Shergill, S.S., The functional anatomy of divided attention in amnestic mild cognitive impairment (2005) Brain, 128, pp. 1418-1427; Johns, E.K., Phillips, N.A., Belleville, S., The profile of executive functioning in amnestic mild cognitive impairment: disproportionate deficits in inhibitory control (2012) J Int Neuropsychol Soc, 18, pp. 541-555; Logie, R.H., Cocchini, G., Delia, S.S., Baddeley, A.D., Is there a specific executive capacity for dual task coordination? Evidence from Alzheimer's disease (2004) Neuropsychology, 18, pp. 504-513; Lonie, J.A., Tierney, K.M., Herrmann, L.L., Dual task performance in early Alzheimer's disease, amnestic mild cognitive impairment and depression (2009) Psychol Med, 39, pp. 23-31; Perry, R.J., Hodges, J.R., Attention and executive deficits in Alzheimer's disease. A critical review (1999) Brain, 122, pp. 383-404; Mc Khann, G.M., Knopman, D.S., Chertkow, H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 263-269; Winblad, B., Palmer, K., Kivipelto, M., Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment (2004) J Intern Med, 256, pp. 240-246; Karrasch, M., Sinerva, E., Gronholm, P., Rinne, J., Laine, M., CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease (2005) Acta Neurol Scand, 111, pp. 172-179; Sotaniemi, M., Pulliainen, V., Hokkanen, L., CERAD-neuropsychological battery in screening mild Alzheimer's disease (2012) Acta Neurol Scand, 125, pp. 16-23; Karrasch, M., Laatu, S., Martikainen, K., Marttila, R., CERAD test performance and cognitive impairment in Parkinson's disease (2013) Acta Neurol Scand, 128, pp. 409-413; Folstein, M.F., Folstein, S.E., Mc Hugh, P.R., Mini-mental state. A practical method for grading the cognitive state of patients for the clinician (1975) J Psychiatr Res, 12, pp. 189-198; Zimmermann, P., Fimm, B., A test battery for attentional performance (2002) Applied neuropsychology of attention: theory, diagnosis, and rehabilitation, pp. 110-151. , Leclerq M, Zimmermann P, eds. New York: Psychology Press; Berres, M., Zehnder, A., Blasi, S., Monsch, A.U., Evaluation of diagnostic scores with adjustment for covariates (2008) Stat Med, 27, pp. 1777-1790; Logue, S.F., Gould, T.J., The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition (2014) Pharmacol Biochem Behav, 12 C, pp. 45-54; Mc Cabe, D.P., Roediger, H.L., Mc Daniel, M.A., Balota, D.A., Hambrick, D.Z., The relationship between working memory capacity and executive functioning: evidence for a common executive attention construct (2010) Neuropsychology, 24, pp. 222-243; Posner, M.I., Attentional networks and consciousness (2012) Front Psychol, 3, p. 64; Szabadi, E., Functional neuroanatomy of the central noradrenergic system (2013) J Psychopharmacol, 27, pp. 659-693; Posner, M., Measuring alertness (2008) Ann N Y Acad Sci, 1129, pp. 193-199; Chun, M.M., Turk-Browne, N.B., Interactions between attention and memory (2007) Curr Opin Neurobiol, 17, pp. 177-184; Posner, M.I., Fan, J., (2008) Attention as an organ system. Topics in Integrative Neuroscience: from cells to cognition, pp. 31-61. , Cambridge: Cambridge University Press; Kusnir, F., Chica, A.B., Mitsumasu, M.A., Bartolomeo, P., Phasic auditory alerting improves visual conscious perception (2011) Conscious Cogn, 20, pp. 1201-1210; Matthias, E., Bublak, P., Müller, H.J., Schneider, W.X., Krummenacher, J., Finke, K., The influence of alertness on spatial and nonspatial components of visual attention (2010) J Exp Psychol Hum Percept Perform, 36, pp. 38-56; Tucha, L., Tucha, O., Laufkotter, R., Walitza, S., Klein, H.E., Lange, K.W., Neuropsychological assessment of attention in adults with different subtypes of attention-deficit/hyperactivity disorder (2008) J Neural Transm, 115, pp. 269-278; Rieger, M., Mayer, G., Gauggel, S., Attention deficits in patients with narcolepsy (2003) Sleep, 26, pp. 36-43; Sprengelmeyer, R., Lange, H., Homberg, V., The pattern of attentional deficits in Huntington's disease (1995) Brain, 118, pp. 145-152; Tinnefeld, M., Treitz, F.H., Haase, C.G., Wilhelm, H., Daum, I., Faustmann, P.M., Attention and memory dysfunctions in mild multiple sclerosis (2005) Eur Arch Psychiatry Clin Neurosci, 255, pp. 319-326; Johannsen, P., Jakobsen, J., Bruhn, P., Gjedde, A., Cortical responses to sustained and divided attention in Alzheimer's disease (1999) NeuroImage, 10, pp. 269-281",Article,Scopus,2-s2.0-84926294866
"Hughes M.L., Lowe D.A., Shine H.E., Carpenter B.D., Balsis S.","Using the alzheimer's association web site to improve knowledge of alzheimer's disease in health care providers",2015,"American Journal of Alzheimer's Disease and other Dementias","30","1",,"98","100",,,10.1177/1533317514559827,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922607640&partnerID=40&md5=cf1065e5c530f536c00aa69507fb3e32","Department of Psychology, Texas A and M UniversityCollege Station, TX, United States; Department of Psychology, Washington University in St LouisSt Louis, MO, United States","Hughes, M.L., Department of Psychology, Texas A and M UniversityCollege Station, TX, United States; Lowe, D.A., Department of Psychology, Texas A and M UniversityCollege Station, TX, United States; Shine, H.E., Department of Psychology, Texas A and M UniversityCollege Station, TX, United States; Carpenter, B.D., Department of Psychology, Washington University in St LouisSt Louis, MO, United States; Balsis, S., Department of Psychology, Texas A and M UniversityCollege Station, TX, United States","Background: The purpose of the current study was to investigate whether an informative Web site is effective at producing higher scores for an individuals knowledge of Alzheimers disease (AD) relative to those who do not visit a Web site. Methods: A total of 552 participants completed the study on Amazons Mechanical Turk; half were randomly assigned to visit alz.org, while a control group did not. Both groups were given the AD Knowledge Scale (ADKS) to assess their knowledge of AD. Results: Participants who visited alz.org scored significantly higher on the ADKS than those in the control group. Participants who were health care workers demonstrated higher scores than others in the experimental condition. Findings indicate that the Alzheimers Association Web site is effective at producing higher scores for AD knowledge relative to no Web site at all and that it is especially helpful for health care workers compared to those who are not health care workers. © The Author(s) 2014 Reprints and permission: sagepub.com/journalsPermissions.nav.","ADKS; Alzheimer's Association; Alzheimer's disease; Alzheimer's Disease Knowledge Scale; dementia","Hebert, L.E., Weuve, J., Scherr, P.A., Evans, D.A., Alzheimer disease in the United States (2010-2050) estimated using the 2010 census (2013) Neurology, 80 (19), pp. 1778-1783; Whalley, L.J., Smyth, K.A., Human culture and the future dementia epidemic (2013) Neurology, 80 (20), pp. 1-2; De, B., Yaffe, K., The projected effect of risk factor reduction on Alzheimer's disease prevalence (2011) Lancet Neurol, 10 (9), pp. 819-828; Carpenter, B.D., Balsis, S., Otilingam, P.G., Hanson, P.K., Gatz, M., The Alzheimer's disease knowledge scale: Development and psychometric properties (2009) Gerontologist, 49 (2), pp. 236-247; Bargh, J.A., Ferguson, M.J., Beyond behaviorism: On the automaticity of higher mental processes (2000) Psychol Bull, 126 (6), pp. 925-945; Bargh, J.A., Attention and automaticity in the processing of self-relevant information (1982) J Pers Soc Psychol, 43 (3), pp. 425-436",Article,Scopus,2-s2.0-84922607640
"Sun Y.-P., Liu J.-P.","Blockade of emodin on amyloid-β 25-35-induced neurotoxicity in A β PP/PS1 mice and PC12 cells through activation of the class III phosphatidylinositol 3-kinase/beclin-1/B-cell lymphoma 2 pathway",2015,"Planta Medica","81","2",,"108","115",,,10.1055/s-0034-1383410,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921777959&partnerID=40&md5=d735db17f13df45a69c2d857d6d58fb2","Department of Pharmacology, Xian Medical University, 1st, Xinwang RoadWeiyang District, Xian, China; Department of Pharmacology, Shaanxi University of Chinese MedicineXianyang, China","Sun, Y.-P., Department of Pharmacology, Xian Medical University, 1st, Xinwang RoadWeiyang District, Xian, China; Liu, J.-P., Department of Pharmacology, Shaanxi University of Chinese MedicineXianyang, China","Autophagy plays an important role in the pathogenesis of Alzheimers disease. In the present study, the blockade mechanism of emodin on amyloid-β 25-35-induced neurotoxicity was explored. Cell viability of PC12 cells was evaluated by the MTT assay and neuro damage by the lactate dehydrogenase leakage assay. Gene silencing by small interfering RNA, cDNA constructs and transfection, as well as Western blot were performed to assess protein expression levels. AβPP/PS1 mice were administered orally with emodin (50 mg/kg/day), and LC3-II positive cells in their brain cortex sections were detected by immunohistochemical staining. Emodin could significantly inhibit the LC3-I/LC3-II conversion ratio and cell viability while decreasing the lactate dehydrogenase level in AβPP/PS1 mice and PC12 cells. LC3II positive cells in the cortex were decreased significantly by the treatment with both emodin and 3-methyladenine. Furthermore, emodin and 3-methyladenine could increase B-cell lymphoma 2 while decreasing Beclin-1 and hVps34 expressions, which were induced by amyloid-β 25-35. Small interfering gene silencing Beclin-1 and B-cell lymphoma 2 confirmed this signaling pathway. We also found that the phosphatidylinositol 3-kinase inhibitor LY294002 could block LC3-I/LC3-II conversion and increase B-cell lymphoma 2 while decreasing hVps34 and Beclin-1 expressions. The results suggest that the blockade of emodin on amyloid-β 25-35-induced autophagy may occur via the activation of the class III phosphatidylinositol 3-kinase/Beclin-1/B-cell lymphoma 2 pathway. Our results provide confirmatory evidence for the application of emodin in the prevention and treatment of Alzheimers disease. © Georg Thieme Verlag KG Stuttgart New York.","autophagy; class III PI3 K/Beclin-1/Bcl-2 pathways; emodin","Steele, J.W., Gandy, S., Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model (2013) Autophagy, 9, pp. 617-618; Marwarha, G., Ghribi, O., Leptin signaling and Alzheimers disease (2012) Am J Neurodegener Dis, 1, pp. 245-265; Wang, H., Ma, J., Tan, Y., Wang, Z., Sheng, C., Chen, S., Ding, J., Amyloid-beta1-42 induces reactive oxygen species-mediated autophagic cell death in U87 and SH-SY5Y cells (2010) J Alzheimers Dis, 21, pp. 597-610; Resende, R., Marques, S.C., Ferreiro, E., Simões, I., Oliveira, C.R., Pereira, C.M., Effect of α-synuclein on amyloid β-induced toxicity: Relevance to Lewy body variant of Alzheimer disease (2013) Neurochem Res, 38, pp. 797-806; Zhi-Kun, S., Hong-Qi, Y., Zhi-Quan, W., Jing, P., Zhen, H., Sheng-Di, C., Erythropoietin prevents PC12 cells from beta-amyloid-induced apoptosis via PI3K-Akt pathway (2012) Transl Neurodegener, 1, p. 7; Li, X., Fan, Z., The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex (2010) Cancer Res, 70, pp. 5942-5952; Wang, Q., Zhu, J., Zhang, K., Jiang, C., Wang, Y., Yuan, Y., Bian, J., Liu, Z., Induction of cytoprotective autophagy in PC-12 cells by cadmium (2013) Biochem Biophys Res Commun, 438, pp. 186-192; Zhu, S., Wang, Y., Wang, X., Li, J., Hu, F., Emodin inhibits ATP-induced IL-1β secretion, ROS production and phagocytosis attenuation in rat peritoneal macrophages via antagonizing P2X7 receptor (2014) Pharm Biol, 52, pp. 51-57; Yiu, C.Y., Chen, S.Y., Yang, T.H., Chang, C.J., Yeh, D.B., Chen, Y.J., Lin, T.P., Inhibition of Epstein-Barr virus lytic cycle by an ethyl acetate subfraction separated from Polygonum cuspidatum root and its major component, emodin (2014) Molecules, 19, pp. 1258-1272; Pickhardt, M., Gazova, Z., Von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E.M., Mandelkow, E., Anthraquinones inhibit tau aggregation and dissolve Alzheimers paired helical filaments in vitro and in cells (2005) J Biol Chem, 280, pp. 3628-3635; Liu, T., Jin, H., Sun, Q.R., Xu, J.H., Hu, H.T., Neuroprotective effects of emodin in rat cortical neurons against beta-amyloid-induced neurotoxicity (2010) Brain Res, 1347, pp. 149-160; Wang, X., Zou, Y., Sun, A., Xu, D., Niu, Y., Wang, S., Wang, K., Ge, J., Emodin induces growth arrest and death of human vascular smooth muscle cells through reactive oxygen species and p-53 (2007) J Cardiovasc Pharmacol, 49, pp. 253-260; Wang, Y., Pan, W.L., Liang, W.C., Law, W.K., Tsz-Ming Ip, D., Ng, T.B., Miu-Yee Waye, M., Chi-Cheong Wan, D., Acetylshikonin, a novel AChE inhibitor, inhibits apoptosis via upregulation of heme oxygenase-1 expression in SH-SY5Y cells (2013) Evid Based Complement Alternat Med, 2013, p. 937370; Du, B., Zhang, Z., Li, N., Madecassoside prevents Aβ25-35-induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway (2014) Int Immunopharmacol, 20, pp. 221-228; Xue, Z., Zhang, S., Huang, L., He, Y., Fang, R., Fang, Y., Increased expression of Beclin-1-dependent autophagy protects against beta-amyloid-induced cell injury in PC12 cells (2013) J Mol Neurosci, 51, pp. 180-186; McFarland, A.J., Grant, G.D., Perkins, A.V., Flegg, C., Davey, A.K., Allsopp, T.J., Renshaw, G., Anoopkumar-Dukie, S., Paradoxical role of 3-methyladenine in pyocyanin-induced toxicity in 1321N1 astrocytoma and SH-SY5Y neuroblastoma cells (2013) Int J Toxicol, 32, pp. 209-218; Molejon, M.I., Ropolo, A., Re, A.L., Boggio, V., Vaccaro, M.I., The VMP1-Beclin 1 interaction regulates autophagy induction (2013) Sci Rep, 3, p. 1055; Hung, S.Y., Huang, W.P., Liou, H.C., Fu, W.M., Autophagy protects neuron from Abeta-induced cytotoxicity (2009) Autophagy, 5, pp. 502-510; Yang, Y., Chen, S., Zhang, J., Li, C., Sun, Y., Zhang, L., Zheng, X., Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells (2014) J Alzheimers Dis, 40, pp. 929-939; Moreira, P.I., Santos, R.X., Zhu, X., Lee, H.G., Smith, M.A., Casadesus, G., Perry, G., Autophagy in Alzheimers disease (2010) Expert Rev Neurother, 10, pp. 1209-1218; Mauthe, M., Jacob, A., Freiberger, S., Hentschel, K., Stierhof, Y.D., Codogno, P., Proikas-Cezanne, T., Resveratrol-mediated autophagy requires WIPI-1-regulated LC3 lipidation in the absence of induced phagophore formation (2011) Autophagy, 7, pp. 1448-1461; Trenti, A., Grumati, P., Cusinato, F., Orso, G., Bonaldo, P., Trevisi, L., Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2 (2014) Biochem Pharmacol, 89, pp. 197-209; Zeng, M., Wei, X., Wu, Z., Li, W., Li, B., Fei, Y., He, Y., Liu, X., Reactive oxygen species contribute to simulated ischemia/reperfusion-induced autophagic cell death in human umbilical vein endothelial cells (2014) Med Sci Monit, 20, pp. 1017-1023; Lindqvist, L.M., Heinlein, M., Huang, D.C., Vaux, D.L., Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak (2014) Proc Natl Acad Sci U S A, 111, pp. 8512-8517; Fan, J., Zhang, Z., Chao, X., Gu, J., Cai, W., Zhou, W., Yin, G., Li, Q., Ischemic preconditioning enhances autophagy but suppresses autophagic cell death in rat spinal neurons following ischemia-reperfusion (2014) Brain Res, 1562, pp. 76-86; Nopparat, C., Porter, J.E., Ebadi, M., Govitrapong, P., 1-Methyl-4-phenylpyridinium-induced cell death via autophagy through a Bcl-2/Beclin 1 complex-dependent pathway (2014) Neurochem Res, 39, pp. 225-232; Luo, C.L., Li, B.X., Li, Q.Q., Chen, X.P., Sun, Y.X., Bao, H.J., Dai, D.K., Zhao, Z.Q., Autophagy is involved in traumatic brain injury-induced cell death and contributes to functional outcome deficits in mice (2011) Neuroscience, 184, pp. 54-63; Zhang, X.D., Wang, Y., Wu, J.C., Lin, F., Han, R., Han, F., Fukunaga, K., Qin, Z.H., Down-regulation of Bcl-2 enhances autophagy activation and cell death induced by mitochondrial dysfunction in rat striatum (2009) J Neurosci Res, 87, pp. 3600-3610; Yu, J.Q., Bao, W., Lei, J.C., Emodin regulates apoptotic pathway in human liver cancer cells (2013) Phytother Res, 27, pp. 251-257; Yang, W., Luo, Y., Tang, R., Zhang, H., Ye, Y., Xiang, L., Qi, J., Neuritogenic monoglyceride derived from the constituent of a marine fish for activating the PI3K/ERK/CREB signalling pathways in PC12 cells (2013) Int J Mol Sci, 14, pp. 24200-24210; Kong, M., Ba, M., Protective effects of diazoxide against Aβ25-35-induced PC12 cell apoptosis due to prevention of endoplasmic reticulum stress (2012) Neuroreport, 23, pp. 493-497; Grudzinski, I.P., Bystrzejewski, M., Cywinska, M.A., Kosmider, A., Poplawska, M., Cieszanowski, A., Ostrowska, A., Cytotoxicity evaluation of carbon-encapsulated iron nanoparticles in melanoma cells and dermal fibroblasts (2013) J Nanopart Res, 15, p. 1835; Wang, J., Feng, X., Zeng, Y., Fan, J., Wu, J., Li, Z., Liu, X., Yang, X., Lipopolysaccharide (LPS)-induced autophagy is involved in the restriction of Escherichia coli in peritoneal mesothelial cells (2013) BMC Microbiol, 13, p. 255; Wen, Y.D., Sheng, R., Zhang, L.S., Han, R., Zhang, X., Zhang, X.D., Han, F., Qin, Z.H., Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways (2008) Autophagy, 4, pp. 762-769; Yang, H., Xie, Z., Wei, L., Yang, H., Yang, S., Zhu, Z., Wang, P., Bi, J., Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse model (2013) Stem Cell Res Ther, 4, p. 76",Article,Scopus,2-s2.0-84921777959
"Somani G., Kulkarni C., Shinde P., Shelke R., Laddha K., Sathaye S.","In vitro acetylcholinesterase inhibition by psoralen using molecular docking and enzymatic studies",2015,"Journal of Pharmacy and Bioallied Sciences","7","1",,"32","36",,,10.4103/0975-7406.148775,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922061120&partnerID=40&md5=4b03f7b4cd179f2689d660f3ba0842c5","Departments of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, India; Medicinal Natural Products Research Laboratory, India; Medicinal Chemistry Research Laboratory, Institute of Chemical Technology, Centre of Excellence-Government of MaharashtraMumbai, MH, India","Somani, G., Departments of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, India; Kulkarni, C., Departments of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, India; Shinde, P., Medicinal Natural Products Research Laboratory, India; Shelke, R., Medicinal Chemistry Research Laboratory, Institute of Chemical Technology, Centre of Excellence-Government of MaharashtraMumbai, MH, India; Laddha, K., Medicinal Natural Products Research Laboratory, India; Sathaye, S., Departments of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, India","Alzheimers disease (AD) has increased at an alarming rate and is now a worldwide health problem. Inhibitors of acetylcholinesterase (AChE) leading to inhibition of acetylcholine breakdown constitute the main therapeutic strategy for AD. Psoralen was investigated as inhibitor of AChE enzyme in an attempt to explore its potential for the management of AD. Materials and Methods: Psoralen was isolated from powdered Psoralea corylifolia fruits. AChE enzyme inhibitory activity of different concentrations of psoralen was investigated by use of in vitro enzymatic and molecular docking studies. Further, the enzyme kinetics were studied using Lineweaver-Burk plot. Results: Psoralen was found to inhibit AChE enzyme activity in a concentration-dependent manner. Kinetic studies showed psoralen inhibits AChE in a competitive manner. Molecular docking study revealed that psoralen binds well within the binding site of the enzyme showing interactions such as π-π stacking and hydrogen bonding with residues present therein. Conclusion: The result of AChE enzyme inhibitory activity of the psoralen in this study is promising. It could be further explored as a potential candidate for further development of new drugs against AD.","Acetylcholinesterase enzyme; docking; psoralen","Zheng, X.Y., Zhang, Z.J., Chou, G.X., Wu, T., Cheng, X.M., Ch, W., Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC-bioautographic assay (2009) Arch Pharm Res, 32, pp. 1245-1251; (2012) Alzheimer Disease International: Global Knowledge Research, , http://www.alz.co.uk, UK [Last accessed on 2013 Jun 09]; (2011) The Hindu: Online Edition of Indian National Newspaper, Alzheimers Will Be on the Rise in India, , http://www.hindu.com/seta/2011/04/21/stories/2011042155291700.htm, India April 21 [Last accessed on 2013 Jun 09]; Anand, P., Singh, B., Singh, N., A review on coumarins as acetylcholinesterase inhibitors for Alzheimers disease (2012) Bioorg Med Chem, 20, pp. 1175-1180; Mukherjee, P.K., Kumar, V., Mal, M., Houghton, P.J., Acetylcholinesterase inhibitors from plants (2007) Phytomedicine, 14, pp. 289-300; Wu, C.R., Chang, C.L., Hsieh, P.Y., Lin, L.W., Ching, H., Psoralen and isopsoralen, two coumarins of Psoraleae Fructus, can alleviate scopolamine-induced amnesia in rats (2007) Planta Med, 73, pp. 275-278; Ellman, G.L., Courtney, K.D., Andres, V., Jr., Feather-Stone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity (1961) Biochem Pharmacol, 7, pp. 88-95; Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-Alzheimer drugs (1999) Structure, 7, pp. 297-307; Fadaeinasab, M., Hadi, A.H., Kia, Y., Basiri, A., Murugaiyah, V., Cholinesterase enzymes inhibitors from the leaves of Rauvolfia reflexa and their molecular docking study (2013) Molecules, 18, pp. 3779-3788; Wang, Y., Hong, C., Zhou, C., Xu, D., Qu, H.B., Screening antitumor compounds psoralen and isopsoralen from Psoralea corylifolia L. Seeds (2011) Evid Based Complement Alternat Med, 2011, p. 363052; Stern, R.S., Nichols, K.T., Väkevä, L.H., Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). the PUVA Follow-Up Study (1997) N Engl J Med, 336, pp. 1041-1045; Budzynska, B., Kruk-Slomka, M., Skalicka-Wozniak, K., Biala, G., Glowniak, K., The effects of imperatorin on anxiety and memory-related behavior in male Swiss mice (2012) Exp Clin Psychopharmacol, 20, pp. 325-332; Kim, J.K., Bae, H., Kim, M.J., Choi, S.J., Cho, H.Y., Hwang, H.J., Inhibitory effect of Poncirus trifoliate on acetylcholinesterase and attenuating activity against trimethyltin-induced learning and memory impairment (2009) Biosci Biotechnol Biochem, 73, pp. 1105-1112; Lagatolla, C., Dolzani, L., Granzotto, M., Monti-Bragadin, C., Genotoxic activity of 4,4,5-trimethylazapsoralen on plasmid DNA (1998) Teratog Carcinog Mutagen, 18, pp. 239-248; Stern, R.S., Liebman, E.J., Väkevä, L., Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study (1998) J Natl Cancer Inst, 90, pp. 1278-1284; Shen, L.L., Liu, G.X., Tang, Y., Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors (2007) Acta Pharmacol Sin, 28, pp. 2053-2063; Kong, L.D., Tan, R.X., Woo, A.Y., Cheng, C.H., Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: Implications for the treatment of affective disorders (2001) Pharmacol Toxicol, 88, pp. 75-80; Inestrosa, N.C., Alvarez, A., Pérez, C.A., Moreno, R.D., Vicente, M., Linker, C., Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimers fibrils: Possible role of the peripheral site of the enzyme (1996) Neuron, 16, pp. 881-891; Bartolini, M., Bertucci, C., Cavrini, V., Andrisano, V., Beta-amyloid aggregation induced by human acetylcholinesterase: Inhibition studies (2003) Biochem Pharmacol, 65, pp. 407-416",Article,Scopus,2-s2.0-84922061120
"Cavallo F., Aquilano M., Arvati M.","An ambient assisted living approach in designing domiciliary services combined with innovative technologies for patients with alzheimer's disease: A case study",2015,"American Journal of Alzheimer's Disease and other Dementias","30","1",,"69","77",,,10.1177/1533317514539724,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922647348&partnerID=40&md5=53687ba238de53a35312fc1ca472d77a","BioRobotics Institute - Scuola Superiore SantAnna, Viale Rinaldo Piaggio 34Pontedera (PI), Italy; A.S.P. e F. Azienda Servizi Alla Persona e Alla FamigliaMantova, Italy","Cavallo, F., BioRobotics Institute - Scuola Superiore SantAnna, Viale Rinaldo Piaggio 34Pontedera (PI), Italy; Aquilano, M., BioRobotics Institute - Scuola Superiore SantAnna, Viale Rinaldo Piaggio 34Pontedera (PI), Italy; Arvati, M., A.S.P. e F. Azienda Servizi Alla Persona e Alla FamigliaMantova, Italy","Background: Alzheimers disease (AD) is one of the most disabling diseases to affect large numbers of elderly people worldwide. Because of the characteristics of this disease, patients with AD require daily assistance from service providers both in nursing homes and at home. Domiciliary assistance has been demonstrated to be cost effective and efficient in the first phase of the disease, helping to slow down the course of the illness, improve the quality of life and care, and extend independence for patients and caregivers. In this context, the aim of this work is to demonstrate the technical effectiveness and acceptability of an innovative domiciliary smart sensor system for providing domiciliary assistance to patients with AD which has been developed with an Ambient Assisted Living (AAL) approach. Methods: The design, development, testing, and evaluation of the innovative technological solution were performed by a multidisciplinary team. In all, 15 sociomedical operators and 14 patients with AD were directly involved in defining the endusers needs and requirements, identifying design principles with acceptability and usability features and evaluating the technological solutions before and after the real experimentation. Results: A modular technological system was produced to help caregivers continuously monitor the health status, safety, and daily activities of patients with AD. During the experimentation, the acceptability, utility, usability, and efficacy of this system were evaluated as quite positive. Conclusion: The experience described in this article demonstrated that AAL technologies are feasible and effective nowadays and can be actively used in assisting patients with AD in their homes. The extensive involvement of caregivers in the experimentation allowed to assess that there is, through the use of the technological system, a proven improvement in care performance and efficiency of care provision by both formal and informal caregivers and consequently an increase in the quality of life of patients, their relatives, and their caregivers. © The Author(s) 2014 Reprints and permission: sagepub.com/journalsPermissions.nav.","Alzheimer disease; ambient assisted living; ambient intelligence; domiciliary assistance; smart environments","(2012), http://www.alz.co.uk/research/statistics.html, Alzheimer's Disease International(2012), http://www.alzheimer-europe.org, Alzheimer Europe(2012) Alzheimer's Disease Facts and Figures 2008], , http://www.alz.org, American Alzheimer's Association; Mittelman, M.S., Ferris, S.H., Shulman, E., Steinberg, G., Levin, B., A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial (1996) JAMA, 276 (21), pp. 1725-1731; Irwin, M., Hanger, R., Patterson, T.L., Semple, S., Ziegler, M., Grant, I., Alzheimer caregiver stress: Basal natural killer cell activity, pituitary-adrenal cortical function, and sympathetic tone (1997) Ann Behav Med, 19 (2), pp. 83-90; Rodriguez, G., De Leo, C., Girtler, N., Vitali, P., Grossi, E., Nobili, F., Psychological and social aspects in management of Alzheimer's patients: An inquiry among caregivers (2003) Neurol Sci, 24 (5), pp. 329-335; European Project Funded under the Work Programme 2005-2006 of the IST Priority in the European 6th Framework Programme for Research and Technological Development, , http://www.cogknow.eu/, COGKNOW; Nugent, C., Mulvenna, M., Moelaert, F., Home based assistive technologies for people with mild dementia (2007) ICOST, 4541, pp. 63-69; Zhang, D., Hariz, M., Mokhtari, M., (2008) Assisting Elders with Mild Dementia Staying at Home. Proceedings of the 6th Annual IEEE International Conference on Pervasive Computing and Communications; 2008 Mar 17-21; Hong Kong, China, pp. 692-697. , Piscataway, NJ: IEEE;; Demiris, G., Hensel, B.K., Technologies for an aging society: A systematic review of smart home applications (2008) Yearb Med Inform, pp. 33-40; Carrillo, M.C., Dishman, E., Plowman, T., Everyday technologies for Alzheimer's diseases care: Research findings, directions, and challenges (2009) Alzheimers Dement, 5 (6), pp. 479-488; (2013), http://www.psychologie.uni-heidelberg.de/ae/apa/research/sentra.html, Project SenTraCheng, H.T., Zhuang, W., Bluetooth-enabled in-home patient monitoring system: Early detection of Alzheimer's disease (2010) IEEE Wireless Comm, 17 (1), pp. 74-79; Ma, R., Kelly, A., Horne, C., Reducing dangerous nighttime events in person with dementia by using a nighttime monitoring system (2009) Alzheimers Dement, 5 (5), pp. 419-426; Donnelly, M., Nugent, C., McClean, S., A mobile multimedia technology to aid those with Alzheimer's disease (2010) IEEE Mobile Ubiquitous Multimedia, 17 (2), pp. 42-51; Lin, C., Lin, P., Lu, P., Hsieh, G., Lee, W., Lee, R., A healthcare integration system for disease assessment and safety monitoring of dementia patients (2008) Technol Biomed, 12 (5), pp. 579-586; Taub, D.M., Leeb, S.B., Lupton, E.C., Hinman, R.T., Zeisel, J., Blacker, S., The escort system: A safety monitor for people living with Alzheimer's disease (2011) IEEE Pervasive Computing, 10 (2), pp. 68-76; Van Den Broek, G., Cavallo, F., Wehrmann, C., AALIANCE Ambient Assisted Living Roadmap, , Amsterdam, Netherlands: Ambient Intelligence and Smart Environments IOS Press; March 2010;; (2011) Fondazione Cariverona, , http://www.fondazionecariverona.org/, Site web; (2011), http://www.aspefmantova.it/, Azienda Servizi alla Persona e alla Famiglia (ASPeF), Site webMahoney, D.F., Purtilo, R.B., Webbe, F.M., In-home monitoring of persons with dementia: Ethical guidelines for technology research and development (2007) Alzheimers Dement, 3 (3), pp. 217-226; Cook, A.M., Hussey, S.M., (2002) Assistive Technologies: Principles and Practices. 2nd Ed, , St. Louis: Mosby Inc;; Aquilano, M., Salatino, C., Carrozza, M.C., (2007) Assistive Technology: A New Approach to Evaluation. Proceedings of the IEEE 10th International Conference on Rehabilitation Robotics; 2007 Jun 12-15; Noordwijk, the Netherlands, pp. 809-819. , Piscataway, NJ: IEEE;; (2012), http://www.zigbee.org, ZigBee AllianceParnetti, L., Calabresi, P., Spatial cognition in Parkinson's disease and neurodegenerative dementias (2006) Cogn Process, 7 (1), pp. 77-S78; Mozaz, M., Garaigordobil, M., Gonzalez Rothi, L.J., Anderson, J.V., Crucian, G.P., Heilman, K.M., Posture recognition in Alzheimer's disease (2006) Brain Cogn, 62 (3), pp. 241-245; Manckoundia, P., Moure, F., Fitzenmeyer, P., Papaxanthis, C., Comparison of motor strategies in sit-to-stand and back-to-sit motions between healthy and Alzheimer's disease elderly subjects (2006) Neuroscience, 137 (2), pp. 385-392; Sarne-Fleischmann, V., Tractinsky, N., Development and evaluation of a personalised multimedia system for reminiscence therapy in Alzheimer's patients (2008) Int J Social Humanistic Computing, 1 (1), pp. 81-96; Pittiglio, L., Use of reminiscence therapy in patients with Alzheimer's disease (2000) Lippincotts Case Manag, 5 (6), pp. 216-220; Cohene, T., Baecker, R.M., Marziali, E., Mindy, S., (2007) Universal Usability, pp. 357-387. , Lazar J, ed. New York: John Wiley & Sons;; Clare, L., Woods, R.T., Moniz Cook, E.D., Orrell, M., Spector, A., Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia (2003) Cochrane Database Syst Rev, (4); Norberg, A., Melin, E., Asplunda, K., Reactions to music, touch and object presentation in the final stage of dementia: An exploratory study (2003) Int J Nurs Stud, 40 (5), pp. 473-479; Cuddy, L.L., Duffin, J., Music, memory, and Alzheimer's disease: Is music recognition spared in dementia, and how can it be assessed? (2005) Med Hypotheses, 64 (2), pp. 229-235; Kang, H.G., Mahoney, D.F., Hoenig, H., In situ monitoring of health in older adults: Technologies and issues (2010) J Am Geriatr Soc, 58 (8), pp. 1579-1586; Landau, R., Werner, S., Ethical aspects of using GPS for tracking people with dementia: Recommendations for practice (2012) Int Psychogeriatr, 3 (24), pp. 358-366",Article,Scopus,2-s2.0-84922647348
"Castelletto V., Hamley I.W., Reza M., Ruokolainen J.","Interactions between lipid-free apolipoprotein-AI and a lipopeptide incorporating the RGDS cell adhesion motif",2015,"Nanoscale","7","1",,"171","178",,,10.1039/c4nr05072j,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920040854&partnerID=40&md5=1d1de2711d91d161b18dc52b2c9a5e98","Department of Chemistry, University of Reading, WhiteknightsReading, United Kingdom; Department of Applied Physics, Aalto University, School of Science, P.O. Box 15100Aalto, Finland; National Physical Laboratory, Hampton RdTeddington-Middlesex, United Kingdom","Castelletto, V., Department of Chemistry, University of Reading, WhiteknightsReading, United Kingdom, National Physical Laboratory, Hampton RdTeddington-Middlesex, United Kingdom; Hamley, I.W., Department of Chemistry, University of Reading, WhiteknightsReading, United Kingdom; Reza, M., Department of Applied Physics, Aalto University, School of Science, P.O. Box 15100Aalto, Finland; Ruokolainen, J., Department of Applied Physics, Aalto University, School of Science, P.O. Box 15100Aalto, Finland","The interaction of a designed bioactive lipopeptide C16-GGGRGDS, comprising a hexadecyl lipid chain attached to a functional heptapeptide, with the lipid-free apoliprotein, Apo-AI, is examined. This apolipoprotein is a major component of high density lipoprotein and it is involved in lipid metabolism and may serve as a biomarker for cardiovascular disease and Alzheimers' disease. We find via isothermal titration calorimetry that binding between the lipopeptide and Apo-AI occurs up to a saturation condition, just above equimolar for a 10.7 μM concentration of Apo-AI. A similar value is obtained from circular dichroism spectroscopy, which probes the reduction in α-helical secondary structure of Apo-AI upon addition of C16-GGGRGDS. Electron microscopy images show a persistence of fibrillar structures due to self-assembly of C16-GGGRGDS in mixtures with Apo-AI above the saturation binding condition. A small fraction of spheroidal or possibly ""nanodisc"" structures was observed. Small-angle X-ray scattering (SAXS) data for Apo-AI can be fitted using a published crystal structure of the Apo-AI dimer. The SAXS data for the lipopeptide/Apo-AI mixtures above the saturation binding conditions can be fitted to the contribution from fibrillar structures coexisting with flat discs corresponding to Apo-AI/lipopeptide aggregates. This journal is © The Royal Society of Chemistry.",,"Rogers, D.P., Roberts, L.M., Lebowitz, J., Engler, J.A., Brouillette, C.G., (1998) Biochemistry, 37, p. 945; Hamley, I.W., (2012) Chem. Rev., 112, p. 5147; Nagao, K., Hata, M., Tanaka, K., Takechi, Y., Nguyen, D., Dhanasekaran, P., (2014) Biochim. Biophys. Acta, Bioenerg., 1841, p. 80; Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., Hussain, M.M., Murthy, H.M.K., (2006) Proc. Natl. Acad. Sci. U. S. A., 103, p. 2126; Davidson, W.S., Hazlett, T., Mantulin, W.W., Jonas, A., (1996) Proc. Natl. Acad. Sci. U. S. A., 93, p. 13605; Borhani, D.W., Roger, D.P., Engler, J.A., Brouillette, C.G., (1997) Proc. Natl. Acad. Sci. U. S. A., 94, p. 12291; Fang, Y., Gursky, O., Atkinson, D., (2003) Biochemistry, 42, p. 13260; Nath, A., Atkins, W.M., Sligar, S.G., (2007) Biochemistry, 46, p. 2059; Franceschini, G., Vecchio, G., Gianfranceschi, G., Magani, D., Sirtori, C.R., (1985) J. Biol. Chem., 260, p. 6321; Saito, H., Dhanasekaran, P., Nguyen, D., Deridder, E., Holvoet, P., Lund-Katz, S., (2004) J. Biol. Chem., 279, p. 20974; Lux, S.E., Shrager, R.I., Hirz, R., Gotto, A.M., (1972) J. Biol. Chem., 247, p. 2598; Saito, H., Lund-Katz, S., Phillips, M.C., (2004) Progr. Lipid Res., 43, p. 350; Jonas, A., Wald, J.H., Toohill, K.L.H., Krul, E.S., Kezdy, K.E., (1990) J. Biol. Chem., 265, p. 22123; Segrest, J.P., Jones, M.K., Klon, A.E., Sheldahl, C.J., Hellinger, M., De Loof, H., (1999) J. Biol. Chem., 274, p. 31755; Castelletto, V., Gouveia, R.M., Connon, C.J., Hamley, I.W., Seitsonen, J., Nykanen, A., (2014) Biomat. Sci., 2, p. 362; Gouveia, R.M., Castelletto, V., Hamley, I.W., Connon, C.J., (2014) Adv. Healthcare Mater., , Submitted; Webber, M.J., Tongers, J., Renault, M.-A., Roncalli, J.G., Losordo, D.W., Stupp, S.I., (2010) Acta Biomater., 6, p. 3; Harrington, D.A., Cheng, E.Y., Guler, M.O., Lee, L.K., Donovan, J.L., Claussen, R.C., (2006) J. Biomed. Mat. Res., Part A, 78, p. 157; Castelletto, V., Gouveia, R., Connon, C.J., Hamley, I.W., (2013) Faraday Discuss., 166, p. 381; Hartgerink, J.D., Beniash, E., Stupp, S.I., (2002) Proc. Natl. Acad. Sci. U. S. A., 99, p. 5133; Atsas, (1995) Crysol - Version 2.8; Svergun, D., Barberato, C., Koch, M.H.J., (1995) J. Appl. Crystallogr., 28, p. 768; Mei, X., Atkinson, D., (2011) J. Biol. Chem., 286, p. 38570; Pabst, G., Rappolt, M., Amenitsch, H., Laggner, P., (2000) Phys. Rev. E: Stat. Phys., Plasmas, Fluids, Relat. Interdiscip. Top., 62, p. 4000; Caillé, A., (1972) C. R. Acad. Sci. Paris, 274, p. 891; Zhang, R., Suter, R.M., Nagle, J.F., (1994) Phys. Rev. E: Stat. Phys., Plasmas, Fluids, Relat. Interdiscip. Top., 50, p. 5047; O'Brien, R., Haq, I., Applications of Biocalorimetry: Binding, Stability and Enzyme Kinetics (2004) Biocalorimetry 2, pp. 3-34. , in, ed. J. E. Ladbury and M. Doyle, Wiley & Sons, London; Kono, M., Okumura, Y., Tanaka, M., Nguyen, D., Dhanasekaran, P., Lund-Katz, S., (2008) Biochemistry, 47, p. 11340; Arnulphi, C., Sanchez, S.A., Tricerri, M.A., Gratton, E., Jonas, A., (2005) Biophys. J., 89, p. 285; Derksen, A., Gantz, D., Small, D.M., (1996) Biophys. J., 70, p. 330; Calabresi, L., Vecchio, G., Longhi, R., Gianazza, E., Palm, G., Wadensten, H., (1994) J. Biol. Chem., 269, p. 32168; Castelletto, V., Hamley, I.W., Perez, J., Abezgauz, L., Danino, D., (2010) Chem. Commun., 46, p. 9185; Hamley, I.W., Nutt, D.R., Brown, G.D., Miravet, J.F., Escuder, B., Rodriguez-Llansola, F., (2010) J. Phys. Chem. B, 114, p. 940; Peters-Libeu, C.A., Newhouse, Y., Hall, S.C., Witkowska, H.E., Weisgraber, K.H., (2007) J. Lipid Res., 48, p. 1035; Vitello, L.B., Scanu, A.M., (1976) J. Biol. Chem., 251, p. 1131; Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., Hussain, M.M., Murthy, K.H.M., (2006) Proc. Natl. Acad. Sci. U. S. A., 103, p. 2126; Creighton, T.E., (1992) Protein Folding, , W W. H. Freeman, New York",Article,Scopus,2-s2.0-84920040854
"Chadha N., Tiwari A.K., Kumar V., Lal S., Milton M.D., Mishra A.K.","Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: Probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis",2015,"Journal of Biomolecular Structure and Dynamics","33","5",,"978","990",,,10.1080/07391102.2014.921793,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923626094&partnerID=40&md5=8a86ccb91c106ed1934b717a9926ae88","Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S. K. Mazumdar RoadDelhi, India; Department of Chemistry, University of DelhiDelhi, India; Department of Zoology, University of DelhiDelhi, India; Department of Physics, B.S. College, Magadh UniversityBihar, India","Chadha, N., Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S. K. Mazumdar RoadDelhi, India, Department of Chemistry, University of DelhiDelhi, India; Tiwari, A.K., Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S. K. Mazumdar RoadDelhi, India; Kumar, V., Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S. K. Mazumdar RoadDelhi, India, Department of Zoology, University of DelhiDelhi, India; Lal, S., Department of Physics, B.S. College, Magadh UniversityBihar, India; Milton, M.D., Department of Chemistry, University of DelhiDelhi, India; Mishra, A.K., Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S. K. Mazumdar RoadDelhi, India","Neuropathological cascades leading to reduced cholinergic transmission in Alzheimers disease led to development of AChE-inhibitors. Although lethal dose of some inhibitors cause interruption with AChE mediated mechanism but reversible AChE inhibitors can assist in protection from inhibition of AChE and hence in an aim to probe potential molecules as anticholinesterase and as reactivators, computationally structure-based approach has been exploited in this work for designing new 2-amino-3-pyridoixime-dipeptides conjugates. We have combined MD simulations with flexible ligand docking approach to determine binding specificity of 2-amino-3-pyridoixime dipeptides towards AChE (PDB 2WHP). PAS residues are found to be responsible for oxime-dipeptides binding along with π-π interactions with Trp86 and Tyr286, hydrogen bonding with side chains of Asp74 and Tyr341 (Gscore -10.801 and MM-GBSA free energy -34.89 kcal/mol). The docking results depicted complementary multivalent interactions along with good binding affinity as predicted from MM-GBSA analysis. The 2-amino-3-pyridoxime-(Arg-Asn) AChE systems subjected to MD simulations under explicit solvent systems with NPT and NVT ensemble. MD simulations uncovered dynamic behavior of 2-amino-3-pyridoxime-(Arg-Asn) and exposed its mobile nature and competence to form strong long range-order contacts towards active site residues to approach inhibited serine residue and facilitated via large contribution from hydrogen bonding and water bridges along with slow and large movements of adjacent important residues. In an effort to evaluate the complete potential surface profile, 2-amino-3-pyridoxime induced reactivation pathway of sarin-serine adduct has been investigated by the DFT approach at the vacuum MO6/6-311G (d, p) level along with the Poisson-Boltzmann solvation model and found to be of relatively low energy barrier. The pKa evaluation has revealed the major deprotonated 2-amino-3-pyridoixime species having pKa of 6.47 and hence making 2-amino-3-pyridoxime-(Arg-Asn) potential anticholinesterase and reactivator for AChE under the physiological pH. © 2014 Taylor & Francis.","acetylcholinesterase; Alzheimer's disease; DFT; molecular dynamics; oxime","Acharya, J., Dubey, D.K., Kaushik, P.M., In vitro reactivation potency of novel symmetrical bis-pyridinium oximes for electric eel acetylcholinesterase inhibited by nerve agent sarin (2011) Toxicology in Vitro, 25, pp. 2135-2139; Acharya, J., Rana, H., Kaushik, P.M., Synthesis and in vitro evaluation of xylene linked carbamoyl bis-pyridinium monooximes as reactivators of organophosphorus (OP) inhibited electric eel acetylcholinesterase (AChE) (2011) European Journal of Medicinal Chemistry, 46, pp. 3926-3933; Bajgar, J., Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, prophylaxis and treatment (2004) Advances in Clinical Chemistry, 38, pp. 151-216; Bharate, S.B., Guo, L., Reeves, T.E., Cerasoli, D.M., Thompson, C.M., Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase (2010) Bioorganic & Medicinal Chemistry, 18, pp. 787-794; Bui, M.J., Tai, K., McCammon, J.A., Acetylcholinesterase: Enhanced fluctuations and alternative routes to the active site in the complex with fasciculin-2 (2004) Journal of the American Chemical Society, 126, pp. 7198-7205; Chadha, N., Tiwari, A.K., Kumar, V., Milton, M.D., Mishra, A.K., In silico thermodynamics stability change analysis involved in BH4 responsive mutations in phenylalanine hydroxylase: QM/MM and MD simulations analysis (2014) Journal of Biomolecular Structure and Dynamics, , http://dx.doi.org/10.1080/07391102.2014.897258, Retrieved from; Cummings, J.L., Alzheimer's disease (2004) The New England Journal of Medicine, 351, pp. 56-67; Shaw, D.E., (2011) Desmond Molecular Dynamics System, Version 3.1, Maestro-Desmond Interoperability Tools, Version 3.0, , Research, New York, NY Schrödinger: New York, NY; Delfino, R.T., Figueroa-Villar, J.D., Nucleophilic reactivation of sarin-inhibited acetylcholinesterase: A molecular modeling study (2009) The Journal of Physical Chemistry B, 113, pp. 8402-8411; Ekström, F., Hörnberg, A., Artursson, E., Hammarström, L.G., Schneider, G., Structure of HI-6-sarin-acetylcholinesterase determined by X-ray crystallography and molecular dynamics simulation: Reactivator mechanism and design (2009) PLoS ONE, 4, p. e5957; Inestrosa, N.C., Alvarez, A., Perez, C.A., Moreno, R.D., Vicente, M., Linker, C., Casanueva, O.I., Garrido, Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme (1996) Neuron Journal, 16, pp. 881-891; Jacquemin, D., Perpète, E.A., Ciofini, I., Adamo, C., Valero, R., Zhao, Y., Truhlar, D.G., On the performances of the M06 family of density functionals for electronic excitation energies (2010) Journal of Chemical Theory and Computation, 6, pp. 2071-2085; Kuca, K., Jun, D., Musilek, K., Structural requirements of acetylcholinesterase reactivators (2006) Mini-Reviews in Medicinal Chemistry, 6, pp. 269-277; Kua, K., Racakova, V., Jun, D., Bajgar, J., Structure-activity relationship of acetylcholinesterase reactivators antidotes against nerve agents (2007) Letters in Organic Chemistry, 4, pp. 212-217; MarVin 5.0.0, (2008) ChemAxon: Calculator Plugins Were Used for Structure Property Prediction and Calculation, , http://www.chemaxon.com, Budapest. Retrieved from; Maxwell, D.M., Koplovitz, I., Worek, F., Sweeney, R.E., A structure-activity analysis of the variation in oxime efficacy against nerve agents (2008) Toxicology and Applied Pharmacology, 231, pp. 157-164; Musilek, K., Komloova, M., Holas, O., Horova, A., Pohanka, M., Gunn-Moore, F., Dohnal, V., Kuca, K., Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage-preparation, in vitro screening and molecular docking (2011) Bioorganic & Medicinal Chemistry, 19, pp. 754-762; Musilek, K., Kua, K., Jun, D., Dohnal, V., Dolezal, M., Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase (2006) Bioorganic & Medicinal Chemistry Letters, 16, pp. 622-627; Nurulain, S.M., Efficacious oxime for organophosphorus poisoning: A minireview (2011) Tropical Journal of Pharmaceutical Research, 10, pp. 341-349; Quinn, D.M., Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states (1987) Chem. Rev, 87, pp. 955-979; Racchi, M., Mazzucchelli, M., Porrello, E., Lanni, C., Govoni, S., Acetylcholinesterase inhibitors: Novel activities of old molecules (2004) Pharmacological Research, 50, pp. 441-451; Radi, Z., Taylor, P., Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex (2001) Journal of Biological Chemistry, 276, pp. 4622-4633; Ramalho, T.C., França, T.C.C., Rennó, M.N., Guimarães, A.P., Da Cunha, E.F.F., Kua, K., Development of new acetylcholinesterase reactivators: Molecular modeling versus in vitro data (2010) Chemico-Biological Interactions, 185, pp. 73-77; Rosenberry, T.L., Acetylcholinesterase (1975) Advances in Enzymology, 43, pp. 103-218. , A. Meister (Ed.) ). New York, NY: Wiley; Schrödinger, L., New York, NY. (2013). Prime version 2.4, Jaguar version 8.1, Desmond version 3.1, Lig prep version 2.9, Glide version 6Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., Singh, D., Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection (2013) European Journal of Medicinal Chemistry, 70, pp. 165-188; Tai, K., Shen, T., Börjesson, U., Philippopoulos, M., McCammon, J.A., Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase (2001) Biophysical Journal, 81, pp. 715-724; Taylor, P., Lappi, S., Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding (1975) Biochemistry, 14, pp. 1989-1997; Tiwari, A.K., Singh, V.R., Sinha, D., Datta, A., Sehgal, N., Chuttani, K., Mishra, A.K., Design and Docking Studies of [Diethylenetriaminepentaacetic acid-(amino acid)2] with acetylcholine receptor as a molecular imaging agent for single-photon emission computed tomographic application (2012) Molecular Imaging, 3, pp. 240-250; Wang, J., Gu, J., Leszczynski, J., Phosphonylation mechanisms of sarin and acetylcholinesterase: A model DFT study (2006) The Journal of Physical Chemistry B, 110, pp. 7567-7573; Wang, J., Gu, J., Leszczynski, J., Feliks, M., Sokalski, W.A., Oxime-induced reactivation of sarin-inhibited AChE: A theoretical mechanisms study (2007) The Journal of Physical Chemistry B, 111, pp. 2404-2408; Xu, Y., Shen, J., Luo, X., Silman, I., Sussman, L.J., Chen, K., Jiang, H., How does huperzine a enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations (2003) Journal of the American Chemical Society, 125, pp. 11340-11349; Zhao, Y., Truhlar, D.G., The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals (2008) Theoretical Chemistry Accounts, 120, pp. 215-241",Article,Scopus,2-s2.0-84923626094
"Zeng Y., Zhang J., Zhu Y., Zhang J., Shen H., Lu J., Pan X., Lin N., Dai X., Zhou M., Chen X.","Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease",2015,"Journal of Neurochemistry","133","1",,"38","52",,,10.1111/jnc.13056,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924528671&partnerID=40&md5=473d482b00bd2157e682c9e06007fc25","Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China; Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China","Zeng, Y., Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China, Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Zhang, J., Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China, Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Zhu, Y., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Zhang, J., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Shen, H., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Lu, J., Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China, Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Pan, X., Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China, Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Lin, N., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Dai, X., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Zhou, M., Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China; Chen, X., Department of Neurology and Geriatrics, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan RoadFuzhou, Fujian, China, Key Laboratory of Brain Aging and Neurodegenerative Disease, Fujian Key Laboratory of Molecular Neurology, Fujian Medical UniversityFuzhou, China","Alzheimer's disease (AD) is characterized by early impairments in memory and progressive neurodegeneration. Disruption of synaptic plasticity processes that underlie learning and memory contribute partly to this pathophysiology. Tripchlorolide (T4), an extract from a traditional Chinese herbal Tripterygium wilfordii Hook F, has been shown to be neuroprotective in animal models of Parkinson's disease and to improve cognitive deficits in senescence-accelerated mouse P8. In this study, we investigated the effect of T4 on cognitive decline and synaptic plasticity in five times familial AD (5XFAD) mice co-expressing mutated amyloid precursor protein and presenilin-1. Five-month-old 5XFAD mice and wild type littermates were intraperitoneally injected with T4, 5 μg/kg or 25 μg/kg, every other day for 60 days. T4 treatment significantly improved spatial learning and memory, alleviated synaptic ultrastructure degradation, up-regulated expression of synapse-related proteins, including synaptophysin, post-synaptic density-95, N-methyl-D-aspartate receptor subunit 1, phosphorylation of calcium/calmodulin dependent protein kinase II α, and phosphorylation of cyclic AMP-response element binding protein, and promoted activation of the phophoinositide-3-kinase-Akt-mammalian target of rapamycin signaling pathway in 5XFAD mice. Accumulation of amyloid β (Aβ) may contribute to synapse dysfunction and memory impairment in AD. We found that T4 treatment significantly reduced cerebral Aβ deposits and lowered Aβ levels in brain homogenates. These effects coincided with a reduction in cleavage of β-carboxyl-terminal amyloid precursor protein (APP) fragment, levels of soluble APPβ, and protein expression of β-site APP cleaving enzyme 1. Taken together, our findings identify T4 as a potent negative regulator of brain Aβ levels and show that it significantly ameliorates synaptic degeneration and cognitive deficits in a mouse model of AD. Tripchlorolide (T4), a traditional Chinese herbal compound, was shown to be neuroprotective, but the underlying mechanisms remain unclear. The present study demonstrates that T4 alleviates cognitive decline in five times familial AD (5XFAD) mice. T4 acts against cognition impairment through downregulating BACE1 activity, reducing Aβ deposits, upregulating synapse-related proteins expression, in particular the PI3K-Akt-mTOR signaling pathway. The findings suggest that T4 may be a promising novel therapeutic option for treating AD. Akt = protein kinase B; Aβ = amyloid β; AD = Alzheimeŕs disease; BACE1 = beta-secretase 1; PI3K = phosphatidylinositol 3-kinase; mTOR = mammalian target of rapamycin Tripchlorolide (T4), a traditional Chinese herbal compound, was shown to be neuroprotective, but the underlying mechanisms remain unclear. The present study demonstrates that T4 alleviates cognitive decline in five times familial AD (5XFAD) mice. T4 acts against cognition impairment through downregulating BACE1 activity, reducing Aβ deposits, upregulating synapse-related proteins expression, in particular the PI3K-Akt-mTOR signaling pathway. The findings suggest that T4 may be a promising novel therapeutic option for treating AD. Akt = protein kinase B; Aβ = amyloid β; AD = Alzheimeŕs disease; BACE1 = beta-secretase 1; PI3K = phosphatidylinositol 3-kinase; mTOR = mammalian target of rapamycin © 2015 International Society for Neurochemistry.","Alzheimer's disease; amyloid β; cognition; synaptic plasticity; transgenic mice; tripchlorolide","Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., Eldar-Finkelman, H., Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies (2013) J. Biol. Chem., 288, pp. 1295-1306; Bitan, G., Kirkitadze, M.D., Lomakin, A., Vollers, S.S., Benedek, G.B., Teplow, D.B., Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways (2003) Proc. Natl Acad. Sci. USA, 100, pp. 330-335; Blennow, K., De, L.M.Z.H., Alzheimer's disease (2006) Lancet, 368, pp. 387-403; Blundell, J., Kouser, M., Powell, C.M., Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation (2008) Neurobiol. Learn. Mem., 90, pp. 28-35; Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., BACE1 is the major beta-secretase for generation of Abeta peptides by neurons (2001) Nat. Neurosci., 4, pp. 233-234; Cheli, V., Adrover, M., Blanco, C., Ferrari, C., Cornea, A., Pitossi, F., Epstein, A.L., Jerusalinsky, D., Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning (2006) J. Neurochem., 97, pp. 68-73; Chen, T.J., Wang, D.C., Chen, S.S., Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons (2009) J. Neurosci. Res., 87, pp. 2297-2307; Chen, Y., Mao, Y., Zhou, D., Hu, X., Wang, J., Ma, Y., Environmental enrichment and chronic restraint stress in ICR mice: Effects on prepulse inhibition of startle and Y-maze spatial recognition memory (2010) Behav. Brain Res., 212, pp. 49-55; Costa-Mattioli, M., Sossin, W.S., Klann, E., Sonenberg, N., Translational control of long-lasting synaptic plasticity and memory (2009) Neuron, 61, pp. 10-26; D'Hooge, R., De Deyn, P.P., Applications of the Morris water maze in the study of learning and memory (2001) Brain Res. Brain Res. Rev., 36, pp. 60-90; Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., Haass, C., Reconstitution of gamma-secretase activity (2003) Nat. Cell Biol., 5, pp. 486-488; Ennaceur, A., Delacour, J., A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data (1988) Behav. Brain Res., 31, pp. 47-59; Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., Ward, P.J., Cleavage of amyloid beta peptide during constitutive processing of its precursor (1990) Science, 248, pp. 1122-1124; Findeis, M.A., The role of amyloid beta peptide 42 in Alzheimer's disease (2007) Pharmacol. Ther., 116, pp. 266-286; Fukumoto, H., Cheung, B.S., Hyman, B.T., Irizarry, M.C., Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease (2002) Arch. Neurol., 59, pp. 1381-1389; Garelick, M.G., Kennedy, B.K., TOR on the brain (2011) Exp. Gerontol., 46, pp. 155-163; Gong, R., Park, C.S., Abbassi, N.R., Tang, S.J., Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons (2006) J. Biol. Chem., 281, pp. 18802-18815; Gu, W.Z., Chen, R., Brandwein, S., McAlpine, J., Burres, N., Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: Triptolide and tripdiolide (1995) Int. J. Immunopharmacol., 17, pp. 351-356; Henderson, V.W., Mack, W., Williams, B.W., Spatial disorientation in Alzheimer's disease (1989) Arch. Neurol., 46, pp. 391-394; Hoeffer, C.A., Klann, E., MTOR signaling: At the crossroads of plasticity, memory and disease (2010) Trends Neurosci., 33, pp. 67-75; Holcomb, L.A., Gordon, M.N., Jantzen, P., Hsiao, K., Duff, K., Morgan, D., Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits (1999) Behav. Genet., 29, pp. 177-185; Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L., Evin, G., Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease (2002) Ann. Neurol., 51, pp. 783-786; Hong, Z., Wang, G., Gu, J., Pan, J., Bai, L., Zhang, S., Chen, S.D., Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice (2007) Eur. J. Neurosci., 26, pp. 1500-1508; Jankowsky, J.L., Slunt, H.H., Gonzales, V., Jenkins, N.A., Copeland, N.G., Borchelt, D.R., APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1 (2004) Neurobiol. Aging, 25, pp. 885-892; Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., Wirths, O., Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease (2012) Neurobiol. Aging, 33, pp. e29-e40. , 196; Kelly, M.T., Crary, J.F., Sacktor, T.C., Regulation of protein kinase Mzeta synthesis by multiple kinases in long-term potentiation (2007) J. Neurosci., 27, pp. 3439-3444; Kennedy, M.B., Beale, H.C., Carlisle, H.J., Washburn, L.R., Integration of biochemical signalling in spines (2005) Nat. Rev. Neurosci., 6, pp. 423-434; Kimura, R., Ohno, M., Impairments in remote memory stabilization precede hippocampal synaptic andcognitive failures in 5XFAD Alzheimer mouse model (2009) Neurobiol. Dis., 33, pp. 229-235; Klyubin, I., Cullen, W.K., Hu, N.W., Rowan, M.J., Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory (2012) Mol. Brain, 5, p. 25; Lafay-Chebassier, C., Paccalin, M., Page, G., Barc-Pain, S., Perault-Pochat, M.C., Gil, R., Pradier, L., Hugon, J., MTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease (2005) J. Neurochem., 94, pp. 215-225; Laird, F.M., Cai, H., Savonenko, A.V., BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions (2005) J. Neurosci., 25, pp. 11693-11709; Lee, C.C., Huang, C.C., Wu, M.Y., Hsu, K.S., Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway (2005) J. Biol. Chem., 280, pp. 18543-18550; Li, F.Q., Cheng, X.X., Liang, X.B., Wang, X.H., Xue, B., He, Q.H., Wang, X.M., Han, J.S., Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons (2003) Exp. Neurol., 179, pp. 28-37; Li, L., Xu, B., Zhu, Y., Chen, L., Sokabe, M., Chen, L., DHEA prevents Abeta25-35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling (2010) Neuropharmacology, 59, pp. 323-333; Lichtenthaler, S.F., Alpha-secretase in Alzheimer's disease: Molecular identity, regulation and therapeutic potential (2011) J. Neurochem., 116 (1), pp. 10-21; Lin, N., Pan, X.D., Chen, A.Q., Zhu, Y.G., Wu, M., Zhang, J., Chen, X.C., Tripchlorolide improves age-associated cognitive deficits by reversing hippocampal synaptic plasticity impairment and NMDA receptor dysfunction in SAMP8 mice (2014) Behav. Brain Res., 258, pp. 8-18; Luo, Y., Bolon, B., Damore, M.A., Fitzpatrick, D., Liu, H., Zhang, J., Yan, Q., Citron, M., BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time (2003) Neurobiol. Dis., 14, pp. 81-88; Ma, M.X., Chen, Y.M., He, J., Zeng, T., Wang, J.H., Effects of morphine and its withdrawal on Y-maze spatial recognition memory in mice (2007) Neuroscience, 147, pp. 1059-1065; Ma, T., Hoeffer, C.A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M.T., Tampellini, D., Gouras, G.K., Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease (2010) PLoS ONE, 5, p. e12845; Nakazawa, K., Quirk, M.C., Chitwood, R.A., Requirement for hippocampal CA3 NMDA receptors in associative memory recall (2002) Science, 297, pp. 211-218; Oakley, H., Cole, S.L., Logan, S., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss intransgenic mice with five familial Alzheimer's disease mutations: Potentialfactors in amyloid plaque formation (2006) J. Neurosci., 26, pp. 10129-10140; Ohno, M., Failures to reconsolidate memory in a mouse model of Alzheimer's disease (2009) Neurobiol. Learn. Mem., 92, pp. 455-459; Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W.L., Vassar, R., Disterhoft, J.F., Temporal memory deficits in Alzheimer's mouse models: Rescue by genetic deletion of BACE1 (2006) Eur. J. Neurosci., 23, pp. 251-260; Ohno, M., Cole, S.L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J.F., Vassar, R., BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice (2007) Neurobiol. Dis., 26, pp. 134-145; Pan, X.D., Chen, X.C., [Advances in the study of immunopharmacological effects and mechanisms of extracts of Tripterygium wilfordii Hook. f. in neuroimmunologic disorders] (2008) Yao Xue Xue Bao =. Acta Pharm. Sin., 43, pp. 1179-1185; Pan, X.D., Chen, X.C., Zhu, Y.G., Zhang, J., Huang, T.W., Chen, L.M., Ye, Q.Y., Huang, H.P., Neuroprotective role of tripchlorolide on inflammatory neurotoxicity induced by lipopolysaccharide-activated microglia (2008) Biochem. Pharmacol., 76, pp. 362-372; Pan, X.D., Chen, X.C., Zhu, Y.G., Chen, L.M., Zhang, J., Huang, T.W., Ye, Q.Y., Huang, H.P., Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling (2009) Glia, 57, pp. 1227-1238; Parsons, R.G., Gafford, G.M., Helmstetter, F.J., Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons (2006) J. Neurosci., 26, pp. 12977-12983; Peng, S., Zhang, Y., Zhang, J., Wang, H., Ren, B., Glutamate receptors and signal transduction in learning and memory (2011) Mol. Biol. Rep., 38, pp. 453-460; Rockenstein, E., Mallory, M., Mante, M., Sisk, A., Masliaha, E., Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42) (2001) J. Neurosci. Res., 66, pp. 573-582; Saura, C.A., Valero, J., The role of CREB signaling in Alzheimer's disease and other cognitive disorders (2011) Rev. Neurosci., 22, pp. 153-169; Selkoe, D.J., Alzheimer's disease is a synaptic failure (2002) Science, 298, pp. 789-791; Shankar, G.M., Walsh, D.M., Alzheimer's disease: Synaptic dysfunction and Abeta (2009) Mol. Neurodegener., 4, p. 48; Shankar, G.M., Li, S., Mehta, T.H., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) Nat. Med., 14, pp. 837-842; Stoica, L., Zhu, P.J., Huang, W., Zhou, H., Kozma, S.C., Costa-Mattioli, M., Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex i (mTORC1) blocks long-term synaptic plasticity and memory storage (2011) Proc. Natl Acad. Sci. USA, 108, pp. 3791-3796; Vincent, B., Govitrapong, P., Activation of the alpha-secretase processing of AbetaPP as a therapeutic approach in Alzheimer's disease (2011) J. Alzheimers Dis., 24, pp. 75-94; Vingtdeux, V., Marambaud, P., Identification and biology of α-secretase (2012) J. Neurochem., 120, pp. 34-45; Vorhees, C.V., Williams, M.T., Morris water maze: Procedures for assessing spatial and related forms of learning and memory (2006) Nat. Protoc., 1, pp. 848-858; Wietrzych, M., Meziane, H., Sutter, A., Ghyselinck, N., Chapman, P.F., Chambon, P., Krezel, W., Working memory deficits in retinoid X receptor gamma-deficient mice (2005) Learn. Mem., 12, pp. 318-326; Yang, L.B., Lindholm, K., Yan, R., Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease (2003) Nat. Med., 9, pp. 3-4; Yoon, S.O., Park, D.J., Ryu, J.C., JNK3 perpetuates metabolic stress induced by Abeta peptides (2012) Neuron, 75, pp. 824-837; Yu, D.Q., Zhang, D.M., Wang, H.B., Liang, X.T., Structure modification of triptolide, a diterpenoid from Tripterygium wilfordii (1992) Yao Xue Xue Bao = Acta Pharm. Sin., 27, pp. 830-836; Zhang, X.M., Cai, Y., Xiong, K., Cai, H., Luo, X.G., Feng, J.C., Clough, R.W., Yan, X.X., Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: Implications for neuritic plaque development (2009) Eur. J. Neurosci., 30, pp. 2271-2283; Zhao, J., Fu, Y., Yasvoina, M., Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis (2007) J. Neurosci., 27, pp. 3639-3649",Article,Scopus,2-s2.0-84924528671
"Hill E.H., Zhang Y., Evans D.G., Whitten D.G.","Enzyme-specific sensors via aggregation of charged p-phenylene ethynylenes",2015,"ACS Applied Materials and Interfaces","7","9",,"5550","5560",,,10.1021/acsami.5b00185,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924587942&partnerID=40&md5=87d6fd624005444d7669d99b8c63617f","Center for Biomedical Engineering, Department of Chemical and Biological Engineering, University of New MexicoAlbuquerque, NM, United States; Nanoscience and Microsystems Engineering Program, Department of Chemistry and Chemical Biology, University of New MexicoAlbuquerque, NM, United States","Hill, E.H., Center for Biomedical Engineering, Department of Chemical and Biological Engineering, University of New MexicoAlbuquerque, NM, United States, Nanoscience and Microsystems Engineering Program, Department of Chemistry and Chemical Biology, University of New MexicoAlbuquerque, NM, United States; Zhang, Y., Center for Biomedical Engineering, Department of Chemical and Biological Engineering, University of New MexicoAlbuquerque, NM, United States; Evans, D.G., Nanoscience and Microsystems Engineering Program, Department of Chemistry and Chemical Biology, University of New MexicoAlbuquerque, NM, United States; Whitten, D.G., Center for Biomedical Engineering, Department of Chemical and Biological Engineering, University of New MexicoAlbuquerque, NM, United States","Chemical and biological sensors are sought for their ability to detect enzymes as biomarkers for symptoms of various disorders, or the presence of chemical pollutants or poisons. p-Phenylene ethynylene oligomers with pendant charged groups have been recently shown to have ideal photophysical properties for sensing. In this study, one anionic and one cationic oligomer are combined with substrates that are susceptible to enzymatic degradation by phospholipases or acetylcholinesterases. The photophysical properties of the J-aggregated oligomers with the substrate are ideal for sensing, with fluorescence quantum yields of the sensors enhanced between 30 and 66 times compared to the oligomers without substrate. The phospholipase sensor was used to monitor the activity of phospholipase A1 and A2 and obtain kinetic information, though phospholipase C did not degrade the sensor. The acetylcholinesterase sensor was used to monitor enzyme activity and was also used to detect the inhibition of acetylcholinesterase by three different inhibitors. Phospholipase A2 is a biomarker for heart and circulatory disease, and acetylcholinesterase is a biomarker for Alzheimers, and indicative of exposure to certain pesticides and nerve agents. This work shows that phenylene ethynylene oligomers can be tailored to enzyme-specific sensors by careful selection of substrates that induce formation of a molecular aggregate, and that the sensing of enzymes can be extended to enzyme kinetics and detection of inhibition. Furthermore, the aggregates were studied through all-atom molecular dynamics, providing a molecular-level view of the formation of the molecular aggregates and their structure. © 2015 American Chemical Society.","biomarkers; biosensing; chemical sensing; enzyme sensing; fluorescence quenching; molecular aggregation","Altintas, Z., Tothill, I., Biomarkers and Biosensors for the Early Diagnosis of Lung Cancer (2013) Sens. Actuators, B, 188, pp. 988-998; Pandey, S., Singh, A., Dubey, A.P., Mishra, T.K., Kapoor, S., Estimation of Biomarkers Chitotriosidase and CCL18/PARC in Gaucher Patients: Indian Experience (2014) Indian J. Clin. Biochem., pp. 1-5; Ramos, D., Martins, E.G., Viana-Gomes, D., Casimiro-Lopes, G., Salerno, V.P., Biomarkers of Oxidative Stress and Tissue Damage Released by Muscle and Liver after a Single Bout of Swimming Exercise (2013) Appl. Physiol. Nutr. Metab., 38, pp. 507-511; Abildgaard, U., Heimdal, K., Pathogenesis of the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count (HELLP): A Review (2013) Eur. J. Obstet. Gynecol. Reprod. Biol., 166, pp. 117-123; Vilella, F., Ramirez, L., Berlanga, O., Martinez, S., Alama, P., Meseguer, M., Simon, C., PGE2 and PGF2α Concentrations in Human Endometrial Fluid as Biomarkers for Embryonic Implantation (2013) J. Clin. Endocrinol. Metab., 98, pp. 4123-4132; Antoine, D.J., Lewis, P.S., Goldring, C.E., Park, B.K., Are We Closer to Finding Biomarkers for Identifying Acute Drug-induced Liver Injury? (2013) Biomarkers Med., 7, pp. 383-386; Altintas, Z., Tothill, I., Biomarkers and Biosensors for the Early Diagnosis of Lung Cancer (2013) Sens. Actuators, B, 188, pp. 988-998; Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., Calabresi, P., Cerebrospinal Fluid Biomarkers in Parkinson Disease (2013) Nat. Rev. Neurol., 9, pp. 131-140; Rostami, R., Aghasi, M.R., Mohammadi, A., Nourooz-Zadeh, J., Enhanced Oxidative stress in Hashimotos Thyroiditis: Inter-relationships to Biomarkers of Thyroid Function (2013) Clin. Biochem., 46, pp. 308-312; Shao, Y., Wang, J., Wu, H., Liu, J., Aksay, I.A., Lin, Y., Graphene based Electrochemical Sensors and Biosensors: A Review (2010) Electroanalysis, 22, pp. 1027-1036; Jacobs, C.B., Peairs, M.J., Venton, B.J., Review: Carbon Nanotube based Electrochemical Sensors for Biomolecules (2010) Anal. Chim. Acta, 662, pp. 105-127; Vashist, S.K., Zheng, D., Al-Rubeaan, K., Luong, J.H., Sheu, F.S., Advances in Carbon Nanotube based Electrochemical Sensors for Bioanalytical Applications (2011) Biotechnol. Adv., 29, pp. 169-188; Pinto, M.R., Schanze, K.S., Amplified Fluorescence Sensing of Protease Activity with Conjugated Polyelectrolytes (2004) Proc. Natl. Acad. Sci. U.S.A., 101, pp. 7505-7510; Feng, F., Liu, L., Yang, Q., Wang, S., Water-Soluble Conjugated Polymers for Fluorescent-Enzyme Assays (2010) Macromol. Rapid Commun., 31, pp. 1405-1421; Li, K., Liu, B., Water-soluble Conjugated Polymers as the Platform for Protein Sensors (2010) Polym. Chem., 1, pp. 252-259; Golub, E., Niazov, A., Freeman, R., Zatsepin, M., Willner, I., Photoelectrochemical Biosensors Without External Irradiation: Probing Enzyme Activities and DNA Sensing Using Hemin/G-Quadruplex-Stimulated Chemiluminescence Resonance Energy Transfer (CRET) Generation of Photocurrents (2012) J. Phys. Chem. C, 116, pp. 13827-13834; Ji, X., Yao, Y., Li, J., Yan, X., Huang, F., A Supramolecular Cross-linked Conjugated Polymer Network for Multiple Fluorescent Sensing (2012) J. Am. Chem. Soc., 135, pp. 74-77; Dai, N., Kool, E.T., Fluorescent DNA-based Enzyme Sensors (2011) Chem. Soc. Rev., 40, pp. 5756-5770; Zhou, Z., Corbitt, T.S., Parthasarathy, A., Tang, Y., Ista, L.K., Schanze, K.S., Whitten, D.G., End-Only"" Functionalized Oligo(phenylene ethynylene)s: Synthesis, Photophysical and Biocidal Activity (2010) J. Phys. Chem. Lett., 1, pp. 3207-3212; Liu, Y., Ogawa, K., Schanze, K.S., Conjugated Polyelectrolytes as Fluorescent Sensors (2009) J. Photochem. Photobiol., C, 10, pp. 173-190; Tang, Y., Hill, E.H., Zhou, Z., Evans, D.G., Schanze, K.S., Whitten, D.G., Synthesis, Self-assembly, and Photophysical Properties of Cationic Oligo(p -phenyleneethynylene)s (2011) Langmuir, 27, pp. 4945-4955; Hill, E.H., Sanchez, D., Evans, D.G., Whitten, D.G., Structural Basis for Aggregation Mode of oligo- p -Phenylene Ethynylenes with Ionic Surfactants (2013) Langmuir, 29, pp. 15732-15737; Hill, E.H., Zhang, Y., Whitten, D.G., Aggregation of Cationic p -phenylene ethynylenes on Laponite Clay in Aqueous Dispersions and Solid Films (2014) J. Colloid Interface Sci., , DOI; Hill, E.H., Evans, D.G., Whitten, D.G., The Influence of Structured Interfacial Water on the Photoluminescence of Carboxyester-terminated Oligo- p -Phenylene Ethynylenes (2014) J. Phys. Org. Chem., 27, pp. 252-257; Qureshi, A., Gurbuz, Y., Niazi, J.H., Biosensors for Cardiac Biomarkers Detection: A Review (2012) Sens. Actuators, B, 171, pp. 62-76; Packard, C.J., Oreilly, D.S., Caslake, M.J., McMahon, A.D., Ford, I., Cooney, J., Lowe, G.D., Lipoprotein-associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease (2000) N. Engl. J. Med., 343, pp. 1148-1155; Ballantyne, C.M., Hoogeveen, R.C., Bang, H., Coresh, J., Folsom, A.R., Heiss, G., Sharrett, A.R., Lipoprotein-associated Phospholipase A2, High-sensitivity C-reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study (2004) Circulation, 109, pp. 837-842; Hurt-Camejo, E., Camejo, G., Peilot, H., Öörni, K., Kovanen, P., Phospholipase A2 in Vascular Disease (2001) Circ. Res., 89, pp. 298-304; Sudhir, K., Lipoprotein-associated Phospholipase A2, a Novel Inflammatory Biomarker and Independent Risk Predictor for Cardiovascular Disease (2005) J. Clin. Endocrinol. Metab., 90, pp. 3100-3105; Mallat, Z., Lambeau, G., Tedgui, A., Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease Roles as Biological Effectors and Biomarkers (2010) Circulation, 122, pp. 2183-2200; Packard, C.J., Lipoprotein-associated Phospholipase A2 as a Biomarker of Coronary Heart Disease and a Therapeutic Target (2009) Curr. Opin. Cardiol., 24, pp. 358-363; Torres, M.A., Barros, M.P., Campos, S.C., Pinto, E., Rajamani, S., Sayre, R.T., Colepicolo, P., Biochemical Biomarkers in Algae and Marine Pollution: A Review (2008) Ecotoxicol. Environ. Saf., 71, pp. 1-15; Carvalho, S.M., Belzunces, L.P., Carvalho, G.A., Brunet, J.L., Badiou-Beneteau, A. Enzymatic Biomarkers as Tools to Assess Environmental Quality: A Case Study of Exposure of the Honeybee Apis mellifera to Insecticides (2013) Environ. Toxicol. Chem., 32, pp. 2117-2124; Rickwood, C.J., Galloway, T.S., Acetylcholinesterase Inhibition as a Biomarker of Adverse Effect: A Study of Mytilus edulis Exposed to the Priority Pollutant Chlorfenvinphos (2004) Aquat. Toxicol., 67, pp. 45-56; Strelitz, J., Engel, L.S., Keifer, M.C., Blood Acetylcholinesterase and Butyrylcholinesterase as Biomarkers of Cholinesterase Depression among Pesticide Handlers (2014) Occup. Environ. Med., 71, pp. 842-847; Mdegela, R.H., Mosha, R.D., Sandvik, M., Skaare, J.U., Assessment of Acetylcholinesterase Activity in Clarias gariepinus as a Biomarker of Organophosphate and Carbamate Exposure (2010) Ecotoxicology, 19, pp. 855-863; Lionetto, M.G., Caricato, R., Calisi, A., Giordano, M.E., Schettino, T., Acetylcholinesterase as a Biomarker in Environmental and Occupational Medicine: New Insights and Future Perspectives (2013) BioMed. Res. Int., 2013, pp. 1-8; Pundir, C.S., Chauhan, N., Acetylcholinesterase Inhibition-based Biosensors for Pesticide Determination: A Review (2012) Anal. Biochem., 429, pp. 19-31; Payne, J.F., Mathieu, A., Melvin, W., Fancey, L.L., Acetylcholinesterase, an Old Biomarker with a New Future? Field Trials in Association with Two Urban Rivers and a Paper Mill in Newfoundland (1996) Mar. Pollut. Bull., 32, pp. 225-231; Hall, R.J., Shenkin, S.D., Maclullich, A.M., A Systematic Literature Review of Cerebrospinal Fluid Biomarkers in Delirium (2011) Dementia Geriatr. Cognit. Disord., 32, pp. 79-93; Shenhar-Tsarfaty, S., Berliner, S., Bornstein, N.M., Soreq, H., Cholinesterases as Biomarkers for Parasympathetic Dysfunction and Inflammation-related Disease (2013) J. Mol. Neurosci., 53, pp. 298-305; Henry, M.S., Passmore, A.P., Todd, S., McGuinness, B., Craig, D., Johnston, J.A., The Development of Effective Biomarkers for Alzheimers Disease: A Review (2013) Int. J. Geriatr. Psychiatry, 28, pp. 331-340; Birks, J., Cholinesterase Inhibitors for Alzheimers Disease (2006) Cochrane Database Syst. Rev., p. 005593; Sinha, N., Firbank, M., Obrien, J.T., Biomarkers in Dementia with Lewy Bodies: A Review (2012) Int. J. Geriatr. Psychiatry, 27, pp. 443-453; Tan, C., Pinto, M.R., Schanze, K.S., Photophysics, Aggregation and Amplified Quenching of a Water-soluble poly(Phenylene ethynylene) (2002) Chem. Commun., pp. 446-447; Williams, A.T.R., Winfield, S.A., Miller, J.N., Relative Fluorescence Quantum Yields using a Computer-controlled Luminescence Spectrometer (1983) Analyst, 108, pp. 1067-1071; Goutelle, S., Maurin, M., Rougier, F., Barbaut, X., Bourguignon, L., Ducher, M., Maire, P., The Hill Equation: A Review of its Capabilities in Pharmacological Modelling (2008) Fundam. Clin. Pharmacol., 22, pp. 633-648; Case, D.A., Babin, V., Berryman, J.T., Betz, R.M., Cai, Q., Cerutti, D.S., Cheatham, T.E., III, Kollman, P.A., (2014) AMBER 14, , University of California: San Francisco; Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., Case, D.A., Development and Testing of a General AMBER Force Field (2004) J. Comput. Chem., 25, pp. 1157-1174; Dickson, C.J., Madej, B.D., Skjevik, A.A., Betz, R.M., Teigen, K., Gould, I.R., Walker, R.C., Lipid14: The Amber Lipid Force Field (2014) J. Chem. Theory Comput., 10, pp. 865-879; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Fox, D.J., (2009) Gaussian 09, , Revision C.1; Gaussian, Inc. Wallingford CT; Bayly, C.I., Cieplak, P., Cornell, W., Kollman, P.A., A Well-behaved Electrostatic Potential based Method using Charge Restraints for Deriving Atomic Charges: The RESP Model (1993) J. Phys. Chem., 97, pp. 10269-10280; Cieplak, P., Cornell, W.D., Bayly, C., Kollman, P.A., Application of the Multimolecule and Multiconformational RESP Methodology to Biopolymers: Charge Derivation for DNA, RNA, and Proteins (1995) J. Comput. Chem., 16, pp. 1357-1377; Martínez, L., Andrade, R., Birgin, E.G., Martínez, J.M., PACKMOL: A Package for Building Initial Configurations for Molecular Dynamics Simulations (2009) J. Comput. Chem., 30, pp. 2157-2164; Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., Comparison of Simple Potential Functions for Simulating Liquid Water (1983) J. Chem. Phys., 79, p. 926; Darden, T.A., York, D., Pedersen, L.G., Particle mesh Ewald: An N• log(N) Method for Ewald Sums in Large Systems (1993) J. Chem. Phys., 98, pp. 10089-10092; Martyna, G.J., Tobias, D.J., Klein, M.L., Constant Pressure Molecular Dynamics Algorithms (1994) J. Chem. Phys., 101, pp. 4177-4189; Feller, S.E., Zhang, Y., Pastor, R.W., Brooks, B.R., Constant Pressure Molecular Dynamics Simulation: The Langevin Piston Method (1995) J. Chem. Phys., 103, pp. 4613-4621; Salomon-Ferrer, R., Goetz, A.W., Poole, D., Le Grand, S., Walker, R.C., Routine Microsecond Molecular Dynamics Simulations with AMBER - Part II: Particle Mesh Ewald (2013) J. Chem. Theory Comput., 9, pp. 3878-3888; Le Grand, S., Goetz, A.W., Walker, R.C., SPFP: Speed without Compromise - A Mixed Precision Model for GPU Accelerated Molecular Dynamics Simulations (2013) Comput. Phys. Commun., 184, pp. 374-380; Roe, D.R., Cheatham, T.E., Ptraj, I.I.I., And CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data (2013) J. Chem. Theory Comput., 9, pp. 3084-3095; Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera - A Visualization System for Exploratory Research and Analysis (2004) J. Comput. Chem., 25, pp. 1605-1617; Yuan, W., Quinn, D.M., Sigler, P.B., Gelb, M.H., Kinetic and Inhibition Studies of Phospholipase A2 with Short-chain Substrates and Inhibitors (1990) Biochemistry, 29, pp. 6082-6094; Richmond, G.S., Smith, T.K., Phospholipases A1 (2011) Int. J. Mol. Sci., 12, pp. 588-612; Otzen, D.E., Blans, K., Wang, H., Gilbert, G.E., Rasmussen, J.T., Lactadherin Binds to Phosphatidylserine-containing Vesicles in a Two-step Mechanism Sensitive to Vesicle Size and Composition (2012) Biochim. Biophys. Acta, Biomembr., 1818, pp. 1019-1027; Spano, F.C., Excitons in Conjugated Oligomer Aggregates, Films, and Crystals (2006) Annu. Rev. Phys. Chem., 57, pp. 217-243",Article,Scopus,2-s2.0-84924587942
"Hensley K., Denton T.T.","Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement",2015,"Free Radical Biology and Medicine","78",,,"123","134",,,10.1016/j.freeradbiomed.2014.10.581,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84919352181&partnerID=40&md5=562d2822a896e97c1f054bfca90a1e9a","Department of Pathology and Department of Neurosciences, University of Toledo Health Science Campus, 3000 Arlington AvenueToledo, OH, United States; Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, P.O. Box 1495Spokane, WA, United States","Hensley, K., Department of Pathology and Department of Neurosciences, University of Toledo Health Science Campus, 3000 Arlington AvenueToledo, OH, United States; Denton, T.T., Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, P.O. Box 1495Spokane, WA, United States","Scientific appreciation for the subtlety of brain sulfur chemistry has lagged, despite understanding that the brain must maintain high glutathione (GSH) to protect against oxidative stress in tissue that has both a high rate of oxidative respiration and a high content of oxidation-prone polyunsaturated fatty acids. In fact, the brain was long thought to lack a complete transsulfuration pathway (TSP) for cysteine synthesis. It is now clear that not only does the brain possess a functional TSP, but brain TSP enzymes catalyze a rich array of alternative reactions that generate novel species including the gasotransmitter hydrogen sulfide (H2S) and the atypical amino acid lanthionine (Lan). Moreover, TSP intermediates can be converted to unusual cyclic ketimines via transamination. Cell-penetrating derivatives of one such compound, lanthionine ketimine (LK), have potent antioxidant, neuroprotective, neurotrophic, and antineuroinflammatory actions and mitigate diverse neurodegenerative conditions in preclinical rodent models. This review will explore the source and function of alternative TSP products, and lanthionine-derived metabolites in particular. The known biological origins of lanthionine and its ketimine metabolite will be described in detail and placed in context with recent discoveries of a GSH- and LK-binding brain protein called LanCL1 that is proving essential for neuronal antioxidant defense; and a related LanCL2 homolog now implicated in immune sensing and cell fate determinations. The review will explore possible endogenous functions of lanthionine metabolites and will discuss the therapeutic potential of lanthionine ketimine derivatives for mitigating diverse neurological conditions including Alzheimers disease, stroke, motor neuron disease, and glioma. © 2014 Elsevier Inc.","anCL1; anCL2; anthionine; euroinflammation; lutathione; reeradical; RMP2; Transsulfuration; utophagy; ydrogensulfide","Stryer, L., (1988), Biochemistry, third edDominy, J.E., Stipanuk, M.H., New roles for cysteine and transsulfuration enzymes: Production of H2S, a neuromodulator and smooth muscle relaxant (2004) Nutr. Rev., 62, pp. 348-353; Kabil, O., Motl, N., Banerjee, R., H2S and its role in redox signaling (2014) Biochim. Biophys. Acta, 1844, pp. 1355-1366; Singh, S., Padovani, D., Leslie, R.A., Chiku, T., Banerjee, R., Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions (2009) J. Biol. Chem., 284, pp. 22457-22466; Hensley, K., Emerging biological importance of central nervous system lanthionines (2010) Molecules, 15, pp. 5581-5594; Qabazard, B., Li, L., Gruber, J., Peh . M, T., Ng . L, F., Dinesh Kumar, S., Rose, P., Moore . P, K., Hydrogen sulfide is an endogenous regulator of aging in Caenorhabditis elegans (2013) Antioxid. Redox Signal, , [Epub ahead of press]; Kabil, H., Kabil, O., Banerjee, R., Harshman, L.G., Pletcher, S.D., Increased transsulfuration mediates longevity and dietary restriction in Drosophila (2011) Proc. Natl. Acad. Sci. USA, 108, pp. 16831-16836; Uthus, E.O., Bron-Borg, H.M., Methionine flux to transsulfuration is enhanced in the long living Ames dwarf mouse (2006) Mech. Ageing Dev., 127, pp. 444-450; Albertini, E., Koziel, R., Durr, A., Neuhaus, M., Jansen-Durr, P., Cystathionine beta synthase modulates senescence of human endothelial cells (2012) Aging (Albany NY), 4, pp. 664-673; Selhub, J., Troen, A., Rosenberg, I.H., B vitamins and the aging brain (2010) Nutr. Rev., 68 (SUPPL. 2), pp. 112-S118; Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., Dagostino, R.B., Wilson, P.W., Wolf, P.A., Plasma homocysteine as a risk factor for dementia and Alzheimers disease (2002) N. Engl. J. Med., 346, pp. 476-483; Selhub, J., The many facets of hyperhomocysteinemia: Studies from the Framingham cohorts (2006) J. Nutr., 136, pp. 1726S-1730S; Aitken, S.M., Kirsch, J.F., The enzymology of cystathionine biosynthesis: Strategies for the control of substrate and reaction specificity (2005) Arch. Biochem. Biophys., 433, pp. 166-175; Seiflein, T.A., Lawrence, J.G., Two transsulfuration pathways in Klebsiella pneumoniae (2006) J. Bacteriol., 188, pp. 5762-5774; Fowler, B., Homocysteine: Overview of biochemistry, molecular biology, and role in disease processes (2005) Semin. Vasc. Med, 5, pp. 77-86; Obeid, R., Herrmann, W., Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia (2006) FEBS Lett., 580, pp. 2994-3005; Mattson, M.P., Shea, T.B., Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders (2003) Trends Neurosci., 26, pp. 137-146; Vitvitsky, V., Thomas, M., Ghorpade, A., Gendelman, H.E., Banerjee, R., A functional transsulfuration pathway in the brain links to glutathione homeostasis (2006) J. Biol. Chem., 281, pp. 35785-35793; McBean, G.J., The transsulfuration pathway: A source of cysteine for glutathione in astrocytes (2012) Amino Acids, 42, pp. 199-205; Taoka, S., West, M., Banerjee, R., Characterization of the heme and pyridoxal phosphate cofactors of human cystathionine beta-synthase reveals nonequivalent active sites (1999) Biochemistry, 38, pp. 2738-2744; Banerjee, R., Evande, R., Kabil, O., Ojha, S., Taoka, S., Reaction mechanism and regulation of cystathione beta-synthase (2003) Biochem. Biophys. Acta, 1647, pp. 30-35; Banerjee, R., Zou, C.G., Redox regulation and reaction mechanism of human cystathionine-beta synthase: A PLP-dependent hemesensor protein (2005) Arch. Biochem. Biophys., 433, pp. 144-156; Carballal, S., Cuevasanta, E., Marmisolle, I., Kabil, O., Gherasim, C., Ballou, D.P., Banerjee, R., Alvarez, B., Kinetics of reversible reductive carbonylation of heme in human cystathionine β-synthase Biochemistry, 52, pp. 4553-4562; Chiku, T., Padovani, D., Zhu, W., Singh, S., Vitvitsky, V., Banerjee, R., H2S biogenesis by human cystathionine γ-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia (2009) J. Biol. Chem., 284, pp. 11601-11612; Tallan . H, H., Moore, S., Stein, W.H., L-cystathionine in human brain Biol. Chem, 230, pp. 707-716; Martin, J.A., Pereda, J., Martinez-Lopez, I., Escrig, R., Miralles, V., Pallardo, F.V., Vento, M., Sastrea, J., Oxidative stress is a signal to up-regulate gamma cystathionase in the fetal-to-neonatal transition in rats (2007) Cell. Mol. Biol., 53, pp. 1010-OL1014; Hwang, S.Y., Sarna, L.K., Siow, Y.L., Karmin, O., High-fat diet stimulates hepatic cystathionine β-synthase and cystathionine -lyase expression (2013) Can. J. Physiol. Pharmacol., 91, pp. 913-919; Ratnam, S., Maclean, K.N., Jacobs, R.L., Brosnan, M.E., Kraus, J.P., Brosnan, J.T., Hormonal regulation of cystathionine beta-synthase expression in liver (2002) J. Biol. Chem., 277, pp. 42912-42918; Li, L., Hsu, A., Moore, P.K., Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulfide in the cardiovascular system and in inflammation - A tale of three gases! (2009) Pharmacol. Ther., 123, pp. 386-400; Kimura, H., Hydrogen sulfide: Its production, release and function (2011) Amino Acids, 41, pp. 113-121; Krejsa, C.M., Franklin, C.C., White, C.C., Ledbetter, J.A., Schieven, G.L., Kavanagh, T.J., Rapid activation of glutamate cysteine ligase following oxidative stress (2010) J. Biol. Chem., 285, pp. 16116-16124; Kabil, O., Zhou, Y., Banerjee, R., Human cystathionine β-synthase is a target for sumoylation (2006) Biochemistry, 45, pp. 13528-13536; Jhee, K.-H., Kruger, W.D., The role of cystathionine β-synthase in homocysteine metabolism (2005) Antioxid. Redox Signal., 7, pp. 813-822; Paul, B.D., Snyder, S.H., H2S signaling through protein sulfhydration and beyond (2012) Nat. Rev. Mol. Cell. Biol., 13, pp. 499-507; Li, Q., Lancaster, J.R., Jr., Chemical foundation of hydrogen sulfide biology (2013) Nitric Oxide, 35, pp. 21-34; Kimura, H., Physiological role of hydrogen sulfide and polysulfide in the central nervous system (2014) Neurochem. Int., 63, pp. 492-497; Toohey, J.I., Cooper, A.J.L., Thiosulfoxide (sulfane) sulfur: New chemistry and new regulatory roles in biology (2014) Molecules, 19, pp. 12789-12813; Braunstein, A.E., Goryachenkova, E.V., The beta-replacement-specific pyridoxal-P-dependent lyases (1984) Adv. Enzymol. Relat. Areas Mol. Biol., 56, pp. 1-89; Townsend, D.M., Lushchak, V.I., Cooper, A.J., A comparison of reversible versus irreversible protein glutathionylation (2014) Adv. Cancer Res., 122, pp. 177-198; Cavallini, D., Ricci, G., Federri, G., The ketimine derivatives of thialysine, lanthionine, cystathionine, cysteine: Preparation and properties (1983) Sulfur Amino Acids: Biochemical and Clinical Aspects, pp. 355-364. , R. Alan, New York Liss Inc; Cavallini, D., Ricci, G., Dupre, S., Pecci, L., Costa, M., Matarese, R.M., Pensa, B., Fontana, M., Sulfur-containing cyclic ketimines and imino acids. A novel family of endogenous products in search for a role (1991) Eur. J. Biochem., 202, pp. 217-223; Cooper, A.J., Anders, M.W., Glutamine transaminase K and cysteine conjugate β-lyase (1990) Ann. N. Y. Acad. Sci., 585, pp. 118-127; Cooper, A.J.L., The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants (2004) Neurochem. Int., 44, pp. 557-577; Ricci, G., Vesci, L., Nardini, M., Arduini, A., Storto, S., Rosato, N., Cavallini, D., Detection of 2 H-1,4-thiazine-5,6-dihydro-3,5-dicarboxylic acid (lanthionine ketimine) in the bovine brain by a fluorometric assay (1989) Biochim. Biophys. Acta, 990, pp. 211-215; Fontana, M., Ricci, G., Solinas, S.P., Antonucci, A., Serao, I., Dupre, S., Cavallini, D., [35S]Lanthionine ketimine binding to bovine brain membranes (1990) Biochem. Biophys. Res. Commun., 171, pp. 480-486; Fontana, M., Brunori, A., Costa, M., Antonucci, A., Detection of cystathionine ketimine and lanthionine ketimine in human brain (1997) Neurochem. Res., 22, pp. 821-844; Moroni, F., Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites (1999) Eur. J. Pharmacol., 375, pp. 87-100; Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: When physiology meets pathology (2012) Nat. Rev. Neurosci., 13, pp. 465-477; Malherbe, P., Alberati-Giani, D., Kohler, C., Cesura, A.M., Identification of a mitochondrial form of kynurenine aminotransferase/glutamine transaminase K from rat brain (1995) FEBS Lett., 367, pp. 141-144; Pinto, J.T., Krasnikov, B.F., Alcutt, S., Jones, M.E., Dorai, T., Villar, M.T., Artigues, A., Cooper, A.J., Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate β-lyase activity and can transaminate L-selenomethionine (2014) J. Biol. Chem., 114 M, p. 591461. , ([Epub ahead of print]); Macone, A., Matarese, R.M., Gentili, V., Antonucci, A., Dupre, S., Nardini, M., Effect of aminoethylcysteine ketimine decarboxylated dimer, a natural sulfur compound present in human plasma, on tert-butyl hydroperoxide-induced oxidative stress in human monocytic U937 cells (2004) Free Radic. Res., 38, pp. 704-714; Macone, A., Fontana, M., Barba, M., Botta, B., Nardini, M., Girga, F., Calcaterra, A., Matarese, R.M., Antioxidant properties of aminoethylcysteine ketimine decarboxylated dimer: A review (2012) Int. J. Mol. Sci, 12, pp. 3072-3084; Tsikas, D., Evans, C.E., Denton, T.T., Mitschke, A., Gutzki, F.-M., Pinto, J.T., Khomenko, T., Cooper, A.J.L., Stable-isotope GC-MS/MS determination of aminoethylcysteine ketimine decarboxylated dimer in biological samples (2012) Anal. Biochem., 430, pp. 4-15; Leeson, P.D., Baker, R., Carling, R.W., Curtis, N.R., Moore, K.W., Williams, B.J., Foster, A.C., Marshall, G.R., Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor (1991) J. Med. Chem., 34, pp. 1243-1252; Sapko, M.T., Guidetti, P., Yu, P., Tagle, D.A., Pellicciari, R., Schwarcz, R., Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntingtons disease (2005) Exp. Neurol., 197, pp. 31-40; Stone, T.W., Darlington, L.G., The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders (2013) Br. J. Pharmacol., 169, pp. 121-127; Stone, T.W., Stoy, N., Darlington, L.G., An expanding range of targets for kynurenine metabolites of tryptophan (2013) Trends. Pharmacol. Sci., 34, pp. 136-143; Hensley, K., Christov, A., Kamat, S., Zhang, X.C., Jackson, K.W., Snow, S., Post, J., Proteomic Identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures (2010) J. Neurosci., 30, pp. 2979-2988; Hensley, K., Christov, A., Venkova, K., Gunning, W., Park, J., Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications (2011) Mol. Neurobiol., 43, pp. 180-191; Nada, S.E., Raghava, A., Tulsulkar, J., Hensley, K., Shah, Z.A., A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia (2012) Neurochem. Int., 61, pp. 1357-1363; Khanna, R., Wilson, S.M., Brittain, J.M., Weimer, J., Sultana, R., Butterfield, D.A., Hensley, K., Opening Pandoras jar: A primer on the putative roles of collapsin response mediator protein 2 (CRMP2) in a panoply of neurodegenerative, sensory and motor neuron, and central disorders (2012) Future Neurol, 7, pp. 749-771; Hubbard, C., Benda, E., Hardin, T., Baxter, T., St. John, E., Obrien, S., Hensley, K., Holgado, A., Lanthionine ketimine ethyl ester partially rescues neuro-developmental defects in unc-33 (DPYSL2/CRMP2) mutants (2013) J. Neurosci. Res., 91, pp. 1183-1190; Hensley, K., Venkova, K., Christov, A., Johnson, M., Eslami, P., Gabbitta, S.P., Harris-White, M., A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3xTg-AD mouse model of Alzheimers disease (2013) J. Neuropathol. Exp. Neurol., 72, pp. 955-969; Floyd, R., Castro, H.C., Neto, F., Zimmerman, G.A., Hensley, K., Towner, R., Nitrone-based therapeutics for neurodegenerative diseases. Their use alone or in combination with lanthionines (2013) Free Radic. Biol. Med., 51, pp. 931-941; Chatterjee, C., Paul, M., Xie, L., Van Der Donk, W.A., Biosynthesis and mode of action of lantibiotics (2005) Chem. Rev., 105, pp. 633-683; Willey, J.M., Van Der Donk, W.A., Lanthionines: Peptides of diverse structure and function (2007) Annu. Rev. Microbiol., 61, pp. 47-501; Chung, C., Kurien, B.T., Mehta, P., Mhatre, M.C., Mou, S., Pye, Q.N., Stewart, C.A., Hensley, K., Identification of lanthionine synthase C-like protein 1 (LanCL1) as a prominent glutathione binding protein expressed in the mammalian central nervous system (2007) Biochemistry, 46, pp. 3262-3269; Zhang, W., Wang, L., Liu, Y., Xu, J., Zhu, G., Cang, H., Li, X., Zhang, X., Structure of human lanthionine synthetase C-like protein-1 and its interaction with Eps8 and glutathione (2009) Genes Dev., 23, pp. 1387-1392; Huang, C., Chen, M., Pang, D., Bi, D., Zou, Y., Zia, X., Yang, W., Xiao, B., Developmental and activity-dependent expression of LanCL1 confers antioxidant activity required for neuronal survival Dev. Cell, 30, pp. 479-487; Zhong, W.X., Wang, Y.B., Peng, L., Ge, X.Z., Zhang, J., Liu, S.S., Zhang, X.N., Luo, J.H., Lanthionine synthetase C-like protein 1 interacts with and inhibits cystathionine β-synthase: A target for neuronal antioxidant defense (2012) J. Biol. Chem., 287, pp. 34189-34201; Law, I.K., Liu, L., Xu, A., Lam, K.S., Vanhoutte, P.M., Che, C.M., Leung, P.T., Wang, Y., Identification and characterization of proteins interacting with SIRT1 and SIRT3: Implications in the anti-aging and metabolic effects of sirtuins (2009) Proteomics, 9, pp. 2444-2456; Mayer, H., Salzer, U., Breuss, J., Ziegler, S., Marchler-Bauer, A., Prohaska, R., Isolation, molecular characterization, and tissue-specific expression of a novel putative G protein-coupled receptor (1998) Biochim. Biophys. Acta, 1395, pp. 301-308; Mayer, H., Bauer, H., Breuss, J., Ziegler, S., Prohaska, R., Characterization of rat LanCL1, a novel member of the lanthionine synthase C-like protein family, highly expressed in testis and brain (2001) Gene, 269, pp. 73-80; Blisnick, T., Vincensin, L., Barale, J.C., Namane, A., Braun, B.C., LanCL1, an erythrocyte protein recruited to the Maurers clefts during plasmodium falciparum development (2005) Mol. Biochem. Parisitol, 141, pp. 39-47; Jones, B.C., Miller, D.B., Ocallaghan, J.P., Lu, L., Unger, E.L., Alam, G., Williams, R.W., Systems analysis of genetic variation in MPTP neurotoxicity in mice (2013) Neurotoxicology, 27, pp. 26-34; Meister, A., Anderson, M.E., Glutathione (1983) Annu. Rev. Biochem., 52, pp. 711-760; Dringen, R., Metabolism and functions of glutathione in brain (2000) Prog. Neurobiol., 62, pp. 649-671; Langlinger, C., Salzer, U., Prohaska, R., Myristoylation of human LanC-like protein-2 (LANCL2) is essential for the interaction with the plasma membrane and the increase in cellular sensitivity to Adriamycin (2006) Biochim. Biophys. Acta, 1758, pp. 1759-1767; Lu, P., Bevan, D.R., Lewis, S.N., Hontecillas, R., Bassaganya-Riera, J., Molecular modeling of lanthionine synthetase component C-like protein 2: A potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics (2011) J. Mol. Model., 17, pp. 543-553; Bassaganya-Riera, J., Guri, A.J., Lu, P., Climent, M., Carbo, A., Sobral, B.W., Horne, W.T., Hontecillas, R., Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma (2011) J. Biol. Chem., 286, pp. 2505-2516; Lu, P., Hontecillas, R., Horne, W.T., Carbo, A., Viladomiu, M., Pedragosa, M., Bevan, D.R., Bassaganya-Riera, J., Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein-2 (2012) PLoS One, 7 (4), p. 34643; Sturla, L., Fresia, C., Guida, L., Bruzzone, S., Scarfi, S., Usai, C., Fruscione, F., Zocci, E., LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells (2009) J. Biol. Chem., 284, pp. 28045-28057; Sturla, L., Fresia, C., Guida, L., Grozio, A., Vigliarola, T., Mannino, E., Millo, E., Zocci, E., Binding of abscisic acid to human LANCL2 (2011) Biochem. Biophys. Res. Commun., 415, pp. 390-395; Park, S., James, C.D., Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism (2003) Cancer Res., 63, pp. 723-727; Zeng, M., Van Der Donk, W.A., Chen, J., Lantibiotic cyclase-like protein 2 (LanCL2) is a novel regulator of Akt (2014) Mol. Biol. Cell, , (pii: mbc.E14-01-0004. [Epub ahead of print]); Vadlakona, L., Dash, A., Pasupuleti, M., Anil Kumar, K., Reddanna, P., The paradox of Akt-mTOR interactions (2013) Front. Oncol, 3, p. 165; Boushey, C.J., Beresford, S.A., Omenn, G.S., Motulsky, A.G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes (1995) JAMA, 274, pp. 1049-1057; Hermann, W., Quast, S., Ullrich, M., Schultze, H., Bodis, M., Geisel, J., Hyperhomocysteinemia in high-aged subjects: Relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation Atherosclerosis, 144, pp. 91-101; Obeid, R., Schorr, H., Eckert, R., Hermann, W., Vitamin B12 status in the elderly as judged by available biochemical markers (2004) Clin. Chem., 50, pp. 238-241; McCully, K.S., Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis (1969) Am. J. Pathol., 56, pp. 111-128; Mudd, S.H., Skovby, F., Levy, H.L., Pettigrew, K.D., Wicken, B., Pyeritz, R.E., Andria, G., Cerone, R., The natural history of homocystinuria due to cystathionine beta-synthase deficiency (1985) Am. J. Hum. Genet., 37, pp. 1-31; Obeid, R., Hermann, W., Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia (2006) FEBS Lett., 580, pp. 2994-3005; Vafai, S.B., Stock, J.B., Protein phosphatase 2 A methylation: A link between elevated plasma homocysteine and Alzheimers disease (2002) FEBS Lett., 518, pp. 1-4; Wang, J.F., Li, Y., Song, J.N., Pang, H.G., Role of hydrogen sulfide in secondary neuronal injury (2014) Neurochem. Int., 64, pp. 37-47; Garcia-Bereguiain, M.A., Samhan-Arias, A.K., Martin-Romero, F.J., Gutierrez-Merino, C., Hydrogen sulfide raises cytosolic calcium in neurons through activation of L-type Ca2+ channels (2008) Antioxid. Redox Signal., 10, pp. 31-42; Lee, S.W., Hu, Y.S., Hu, L.F., Dawe, G.S., Moore, P.K., Wong, P.T., Blan, J.S., Hydrogen sulfide regulates calcium homeostasis in microglial cells (2006) Glia, 54, pp. 116-124",Review,Scopus,2-s2.0-84919352181
"Duim W.C., Jiang Y., Shen K., Frydman J., Moerner W.E.","Super-resolution fluorescence of huntingtin reveals growth of globular species into short fibers and coexistence of distinct aggregates",2014,"ACS Chemical Biology","9","12",,"2767","2778",,,10.1021/cb500335w,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84919702871&partnerID=40&md5=183650376a77b3252434362c9854b975","Department of Chemistry, Stanford UniversityStanford, CA, United States; Department of Applied Physics, Stanford UniversityStanford, CA, United States; Department of Biology, Stanford UniversityStanford, CA, United States; Department of Biological Sciences, University of Southern CaliforniaLos Angeles, CA, United States; Program in Cellular and Molecular Medicine, Boston Childrens HospitalBoston, MA, United States","Duim, W.C., Department of Chemistry, Stanford UniversityStanford, CA, United States, Department of Biological Sciences, University of Southern CaliforniaLos Angeles, CA, United States; Jiang, Y., Department of Chemistry, Stanford UniversityStanford, CA, United States, Department of Applied Physics, Stanford UniversityStanford, CA, United States, Program in Cellular and Molecular Medicine, Boston Childrens HospitalBoston, MA, United States; Shen, K., Department of Biology, Stanford UniversityStanford, CA, United States; Frydman, J., Department of Biology, Stanford UniversityStanford, CA, United States; Moerner, W.E., Department of Chemistry, Stanford UniversityStanford, CA, United States","Polyglutamine-expanded huntingtin, the protein encoded by HTT mutations associated with Huntingtons disease, forms aggregate species in vitro and in vivo. Elucidation of the mechanism of growth of fibrillar aggregates from soluble monomeric protein is critical to understanding the progression of Huntingtons disease and to designing therapeutics for the disease, as well as for aggregates implicated in Alzheimers and Parkinsons diseases. We used the technique of multicolor single-molecule, super-resolution fluorescence imaging to characterize the growth of huntingtin exon 1 aggregates. The huntingtin exon 1 aggregation followed a pathway from exclusively spherical or globular species of ∼80 nm to fibers ∼1 μm in length that increased in width, but not length, over time with the addition of more huntingtin monomers. The fibers further aggregated with one another into aggregate assemblies of increasing size. Seeds created by sonication, which were comparable in shape and size to the globular species in the pathway, were observed to grow through multidirectional elongation into fibers, suggesting a mechanism for growth of globular species into fibers. The single-molecule sensitivity of our approach made it possible to characterize the aggregation pathway across a large range of size scales, from monomers to fiber assemblies, and revealed the coexistence of different aggregate species (globular species, fibers, fiber assemblies) even at late time points. © 2014 American Chemical Society.",,"A novel gene containing a trinucleotide repeat that is expanded and unstable on huntington disease chromosomes (1993) Cell, 72, pp. 971-983. , The Huntingtons Disease Collaborative Research Group. (); Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C., Saiki, S., Rose, C., Krishna, G., Rubinsztein, D.C., Huntingtons disease: From pathology and genetics to potential therapies (2008) Biochem. J., 412, pp. 191-209; Difiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., Aronin, N., Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain (1997) Science, 277, pp. 1990-1993; Nagai, Y., Inui, T., Popiel, H.A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Toda, T., A toxic monomeric conformer of the polyglutamine protein (2007) Nat. Struct. Mol. Biol., 14, pp. 332-340; Miller, J., Arrasate, M., Brooks, E., Libeu, C.P., Legleiter, J., Hatters, D., Curtis, J., Finkbeiner, S., Identifying polyglutamine protein species in situ that best predict neurodegeneration (2011) Nat. Chem. Biol., 7, pp. 925-934; Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., Hartl, F.U., Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation (2004) Mol. Cell, 15, pp. 95-105; Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., Finkbeiner, S., Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death (2004) Nature, 431, pp. 805-810; Pieri, L., Madiona, K., Bousset, L., Melki, R., Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells (2012) Biophys. J., 102, pp. 2894-2905; Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M., Ross, C.A., Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization (2002) J. Biol. Chem., 277, pp. 41032-41037; Ross, C.A., Poirier, M.A., Wanker, E.E., Amzel, M., Polyglutamine fibrillogenesis: The pathway unfolds (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 1-3; Legleiter, J., Mitchell, E., Lotz, G.P., Sapp, E., Ng, C., Difiglia, M., Thompson, L.M., Muchowski, P.J., Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo (2010) J. Biol. Chem., 285, pp. 14777-14790; Burke, K.A., Godbey, J., Legleiter, J., Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy (2011) Methods, 53, pp. 275-284; Thakur, A.K., Jayaraman, M., Mishra, R., Thakur, M., Chellgren, V.M., Byeon, I.-J.L., Anjum, D.H., Wetzel, R., Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism (2009) Nat. Struct. Mol. Biol., 16, pp. 380-389; Tam, S., Spiess, C., Auyeung, W., Joachimiak, L., Chen, B., Poirier, M.A., Frydman, J., The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation (2009) Nat. Struct. Mol. Biol., 16, pp. 1279-1285; Kim, M.W., Chelliah, Y., Kim, S.W., Otwinowski, Z., Bezprozvanny, I., Secondary structure of huntingtin amino-terminal region (2009) Structure, 17, pp. 1205-1212; Sivanandam, V.N., Jayaraman, M., Hoop, C.L., Kodali, R., Wetzel, R., Van Der Wel, Patrick, C.A., The aggregation-enhancing huntingtin N-terminus is helical in amyloid fibrils (2011) J. Am. Chem. Soc., 133, pp. 4558-4566; Kelley, N.W., Huang, X., Tam, S., Spiess, C., Frydman, J., Pande, V.S., The predicted structure of the headpiece of the huntingtin protein and its implications on huntingtin aggregation (2009) J. Mol. Biol., 388, pp. 919-927; Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G.P., Wanker, E.E., Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntingtons disease pathology (1999) Proc. Natl. Acad. Sci. U. S. A., 96, pp. 4604-4609; Sathasivam, K., Lane, A., Legleiter, J., Warley, A., Woodman, B., Finkbeiner, S., Paganetti, P., Bates, G.P., Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of huntingtons disease (2010) Hum. Mol. Genet., 19, pp. 65-78; Suhr, S.T., Senut, M., Whitelegge, J.P., Faull, K.F., Cuizon, D.B., Gage, F.H., Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression (2001) J. Cell Biol., 153, pp. 283-294; Muchowski, P.J., Wacker, J.L., Modulation of neurodegeneration by molecular chaperones (2005) Nat. Rev. Neurosci., 6, pp. 11-22; Tam, S., Geller, R., Spiess, C., Frydman, J., The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions (2006) Nat. Cell Biol., 8, pp. 1155-1162; Behrends, C., Langer, C.A., Boteva, R., Böttcher, U.M., Stemp, M.J., Schaffar, G., Rao, B.V., Hartl, F.U., Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers (2006) Mol. Cell, 23, pp. 887-897; Kitamura, A., Kubota, H., Pack, C., Matsumoto, G., Hirayama, S., Takahashi, Y., Kimura, H., Nagata, K., Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state (2006) Nat. Cell Biol., 8, pp. 1163-1169; Inoue, Y., Kishimoto, A., Hirao, J., Yoshida, M., Taguchi, H., Strong growth polarity of yeast prion fiber revealed by single fiber imaging (2001) J. Biol. Chem., 276, pp. 35227-35230; Collins, S.R., Douglass, A., Vale, R.D., Weissman, J.S., Mechanism of prion propagation: Amyloid growth occurs by monomer addition (2004) PLoS Biol., 2, p. 321; Ban, T., Hamada, D., Hasegawa, K., Naiki, H., Goto, Y., Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence (2003) J. Biol. Chem., 278, pp. 16462-16465; Andersen, C.B., Yagi, H., Manno, M., Martorana, V., Ban, T., Christiansen, G., Otzen, D.E., Rischel, C., Branching in amyloid fibril growth (2009) Biophys. J., 96, pp. 1529-1536; Ban, T., Hoshino, M., Takahashi, S., Hamada, D., Hasegawa, K., Naiki, H., Goto, Y., Direct observation of Aβ amyloid fibril growth and inhibition (2004) J. Mol. Biol., 344, pp. 757-767; Liang, Y., Lynn, D.G., Berland, K.M., Direct observation of nucleation and growth in amyloid self-assembly (2010) J. Am. Chem. Soc., 132, pp. 6306-6308; Huang, B., Babcock, H., Zhuang, X., Breaking the diffraction barrier: Super-resolution imaging of cells (2010) Cell, 143, pp. 1047-1058; Thompson, M.A., Lew, M.D., Moerner, W.E., Extending microscopic resolution with single-molecule imaging and active control (2012) Annu. Rev. Biophys., 41, pp. 321-342; Duim, W.C., Chen, B., Frydman, J., Moerner, W.E., Sub-diffraction imaging of huntingtin protein aggregates by fluorescence blink-microscopy and atomic force microscopy (2011) ChemPhysChem., 12, pp. 2387-2390; Sahl, S.J., Weiss, L.E., Duim, W.C., Frydman, J., Moerner, W.E., Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species (2012) Sci. Rep., 2, pp. 1-7; Caron, N.S., Hung, C.L., Atwal, R.S., Truant, R., Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions (2014) Hum. Mol. Genet., 23, pp. 2324-2338; Kaminski Schierle, G.S., Van De Linde, S., Erdelyi, M., Esbjorner, E.K., Klein, T., Rees, E., Bertoncini, C.W., Kaminski, C.F., In situ measurements of the formation and morphology of intracellular beta-amyloid fibrils by super-resolution fluorescence imaging (2011) J. Am. Chem. Soc., 133, pp. 12902-12905; Roberti, M.J., Folling, J., Celej, M.S., Bossi, M., Jovin, T.M., Jares-Erijman, E.A., Imaging nanometer-sized α-synuclein aggregates by superresolution fluorescence localization microscopy (2012) Biophys. J., 102, pp. 1598-1607; Ries, J., Udayar, V., Soragni, A., Hornemann, S., Nilsson, K.P., Riek, R., Hock, C., Rajendran, L., Superresolution imaging of amyloid fibrils with binding-activated probes (2013) ACS Chem. Neurosci., 4, pp. 1057-1061; Pinotsi, D., Buell, A.K., Galvagnion, C., Dobson, C.M., Kaminski Schierle, G.S., Kaminski, C.F., Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy (2014) Nano Lett., 14, pp. 339-345; Dalal, V., Bhattacharya, M., Narang, D., Sharma, P.K., Mukhopadhyay, S., Nanoscale fluorescence imaging of single amyloid fibrils (2012) J. Phys. Chem. Lett., 3, pp. 1783-1787; Shahmoradian, S.H., Galaz-Montoya, J.G., Schmid, M.F., Cong, Y., Ma, B., Spiess, C., Frydman, J., Chiu, W., TRiCs tricks inhibit huntingtin aggregation (2013) ELife, 2, p. 00710; Heilemann, M., Van De Linde, S., Schüttpelz, M., Kasper, R., Seefeldt, B., Mukherjee, A., Tinnefeld, P., Sauer, M., Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes (2008) Angew. Chem., Int. Ed., 47, pp. 6172-6176; Dempsey, G.T., Vaughan, J.C., Chen, K.H., Bates, M., Zhuang, X., Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging (2011) Nat. Methods, 8, pp. 1027-1036; Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Bates, G.P., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice (1996) Cell, 87, pp. 493-506; Lee, S., Shin, J.Y., Lee, A., Bustamante, C., Counting single photoactivatable fluorescent molecules by photoactivated localization microscopy (PALM) (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 17436-17441; Annibale, P., Vanni, S., Scarselli, M., Rothlisberger, U., Radenovic, A., Quantitative photo activated localization microscopy: Unraveling the effects of photoblinking (2011) PLoS One, 6, p. 22678; Durisic, N., Laparra-Cuervo, L., Sandoval-Alvarez, A., Borbely, J.S., Lakadamyali, M., Single-molecule evaluation of fluorescent protein photoactivation efficiency using an in vivo nanotemplate (2014) Nat. Methods, 11, pp. 156-162; Shroff, H., Galbraith, C.G., Galbraith, J.A., Betzig, E., Live-cell photoactivated localization microscopy of nanoscale adhesion dynamics (2008) Nat. Methods, 5, pp. 417-423; Jones, S.A., Shim, S., He, J., Zhuang, X., Fast, three-dimensional super-resolution imaging of live cells (2011) Nat. Methods, 8, pp. 499-505; Lunkes, A., Mandel, J., A cellular model that recapitulates major pathogenic steps of huntingtons disease (1998) Hum. Mol. Genet., 7, pp. 1355-1361; Williams, T.L., Serpell, L.C., Membrane and surface interactions of alzheimers abeta peptide - Insights into the mechanism of cytotoxicity (2011) FEBS J., 278, pp. 3905-3917; Difiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Aronin, N., Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons (1995) Neuron, 14, pp. 1075-1081; Atwal, R.S., Xia, J., Pinchev, D., Taylor, J., Epand, R.M., Truant, R., Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity (2007) Hum. Mol. Genet., 16, pp. 2600-2615; Kegel, K.B., Sapp, E., Alexander, J., Valencia, A., Reeves, P., Li, X., Masso, N., Difiglia, M., Polyglutamine expansion in huntingtin alters its interaction with phospholipids (2009) J. Neurochem., 110, pp. 1585-1597; Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annu. Rev. Biochem., 75, pp. 333-366; Eichner, T., Radford, S., A diversity of assembly mechanisms of a generic amyloid fold (2011) Mol. Cell, 43, pp. 8-18; Fischer, H., Polikarpov, I., Craievich, A.F., Average protein density is a molecular-weight-dependent function (2004) Protein Sci., 13, pp. 2825-2828; Bolte, S., Cordelieres, F.P., A guided tour into subcellular colocalization analysis in light microscopy (2006) J. Microsc., 224, pp. 213-232; Dani, A., Huang, B., Bergan, J., Dulac, C., Zhuang, X., Superresolution imaging of chemical synapses in the brain (2010) Neuron, 68, pp. 843-856; Biteen, J.S., Thompson, M.A., Tselentis, N.K., Bowman, G.R., Shapiro, L., Moerner, W.E., Super-resolution imaging in live caulobacter crescentus cells using photoswitchable EYFP (2008) Nat. Methods, 5, pp. 947-949; Ptacin, J.L., Lee, S.F., Garner, E.C., Toro, E., Eckart, M., Comolli, L.R., Moerner, W.E., Shapiro, L., A spindle-like apparatus guides bacterial chromosome segregation (2010) Nat. Cell Biol., 12, pp. 791-798",Article,Scopus,2-s2.0-84919702871
"Pacifico S., Piccolella S., Marciano S., Galasso S., Nocera P., Piscopo V., Fiorentino A., Monaco P.","LC-MS/MS profiling of a mastic leaf phenol enriched extract and its effects on H2O2 and Aβ(25-35) oxidative injury in SK-B-NE(C)-2 Cells",2014,"Journal of Agricultural and Food Chemistry","62","49",,"11957","11966",,,10.1021/jf504544x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84916596723&partnerID=40&md5=101b15c3f0870ac25ff1a8b5bb01d5de","Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy","Pacifico, S., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Piccolella, S., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Marciano, S., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Galasso, S., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Nocera, P., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Piscopo, V., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Fiorentino, A., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy; Monaco, P., Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Via Vivaldi 43Caserta, Italy","The development of polyphenol neuroprotective nutraceuticals useful for functional foods could be a valuable strategy for counteracting oxidative stress relative diseases as Alzheimers Disease (AD). Oxidative stress is one of the AD earliest event and seems to play a central role in Aβ generation, neuroinflammation, and neuronal apoptosis. In order to counteract AD neurodegeneration, the inhibition of the vicious cycle of Aβ generation and oxidation is an attractive therapeutic strategy, and antiamyloidogenic and antioxidant plant drugs could represent an alternative and valid approach. In this context, an alcoholic extract (Pl-M) from deterpenated Pistacia lentiscus L. leaves was investigated for its phenol composition through LC-ESI-MS/MS analysis. Besides the identified metabolites, ten compounds were reported for the first time as constituents of Pistacia lentiscus leaves. Through DPPH, ABTS, and ORAC methods, the antioxidant potential of the extract was initially investigated. In order to evaluate the preparation of a safe and no toxic extract, MTT, SRB, and LDH assays toward SH-5YSY, and SK-N-BE(2)-C human neuronal cell lines, as well as on C6 mouse glial cell line, were performed. Evaluating the protective effects from oxidant injury in SK-N-BE(2)-C cells cotreated with the plant complex and H2O2, or Aβ(25-35) fragment, it was observed that Pl-M extract exerted a significant cytoprotective response in both the oxidized cell systems. In particular, Pl-M extract was able to reduce by nearly 50% the Aβ(25-35) induced toxicity at 25.0 μg/mL dose level, whereas it counteracted almost completely the cytotoxic action at 100.0 μg/mL. Data obtained allow us to hypothesize the use of Pistacia lentiscus leaves, a broadly available and renewable source, as an alternative strategy for the enrichment of food matrices with polyphenol bioactives. The present study put the basis for bioavailability and preclinical studies, able to define Pl-M extract safety and efficacy. © 2014 American Chemical Society.","antioxidant activity; LC-MS/MS metabolic fingerprinting; neuroprotection; Pistacia lentiscus; polyphenols","De Flora, S., Quaglia, A., Bennicelli, C., Vercelli, M., The epidemiological revolution of the 20th century (2005) FASEB J., 19, pp. 892-897; Prince, M.J., Jackson, J., (2013) World Alzheimer Report 2013, , Alzheimers Disease International. Alzheimers Disease International: London; Prince, M.J., Jackson, J., (2012) World Alzheimer Report 2012, , Alzheimers Disease International. Alzheimers Disease International: London; Ramesh, B.N., Rao, T.S., Prakasam, A., Sambamurti, K., Rao, K.S., Neuronutrition and Alzheimers disease (2010) J. Alzheimers Dis., 19, pp. 1123-1139; Mattson, M.P., Pathways towards and away from Alzheimers disease (2004) Nature, 430, pp. 631-639; Cai, Z., Zhao, B., Ratka, A., Oxidative stress and β-amyloid protein in Alzheimers disease (2011) Neuromol. Med., 13, pp. 223-250; Tamagno, E., Guglielmotto, M., Monteleone, D., Tabaton, M., Amyloid-β production: Major link between oxidative stress and BACE1 (2012) Neurotox. Res., 22, pp. 208-219; Ono, K., Hasegawa, K., Naiki, H., Yamada, M., Curcumin has potent anti-amyloidogenic effects for Alzheimers β-amyloid fibrils in vitro (2004) J. Neurosci. Res., 75, pp. 742-750; Marambaud, P., Zhao, H., Davies, P., Resveratrol promotes clearance of Alzheimers disease amyloid-β peptides (2005) J. Biol. Chem., 280, pp. 37377-37382; Rezai-Zadeh, K., Arendash, G.W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., Shytle, R.D., Tan, J., Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice (2008) Brain Res., 1214, pp. 177-187; Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimers disease: Bioavailability, metabolism, and cellular and molecular mechanisms (2008) J. Agric. Food Chem., 56, pp. 4855-4873; Abuznait, A.H., Qosa, H., Busnena, B.A., El Sayed, K.A., Kaddoumi, A., Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimers Disease: In vitro and in vivo studies (2013) ACS Chem. Neurosci., 4, pp. 973-982; Shytle, R.D., Tan, J., Bickford, P.C., Rezai-Zadeh, K., Hou, L., Zeng, J., Sanberg, P.R., Roschek, B., Jr., Optimized turmeric extract reduces β-amyloid and phosphorylated Tau protein burden in Alzheimers transgenic mice (2012) Curr. Alzheimer Res., 9, pp. 500-506; Shi, C., Liu, J., Wu, F., Yew, D.T., Ginkgo biloba extract in Alzheimers disease: From action mechanisms to medical practice (2010) Int. J. Mol. Sci., 11, pp. 107-123; Gupta, V.B., Indi, S.S., Rao, K.S., Garlic extract exhibits antiamyloidogenic activity on amyloid-β fibrillogenesis: Relevance to Alzheimers disease (2009) Phytother. Res., 23, pp. 111-115; Pacifico, S., Gallicchio, M., Lorenz, P., Duckstein, S.M., Potenza, N., Galasso, S., Marciano, S., Monaco, P., Neuroprotective potential of Laurus nobilis antioxidant polyphenol-enriched leaf extracts (2014) Chem. Res. Toxicol., 27, pp. 611-626; Nahida, Ansari, S.H., Siddiqui, A.N., Pistacia lentiscus: A review on phytochemistry and pharmacological properties (2012) Int. J. Pharm. Pharm. Sci., 4 (SUPPLEMENT. 4), pp. 16-20; Romani, A., Pinelli, P., Galardi, C., Mulinacci, N., Tattini, M., Identification and quantification of galloyl derivatives, flavonoid glycosides, and anthocyanins in leaves of Pistacia lentiscus L (2002) Phytochem. Anal., 13, pp. 79-86; Vaya, J., Mahmood, S., Flavonoid content in leaf extracts of the fig (Ficus carica L.), carob (Ceratonia siliqua L.), and pistachio (Pistacia lentiscus L.) (2006) Biofactors, 28, pp. 169-175; Rodrìguez-Perez, C., Quirantes-Pinè, R., Amessis-Ouchemoukh, N., Khodir, M., Segura-Carretero, A., Fernàndez-Gutierrez, A., A metabolite profiling approach allows the identification of new compounds from Pistacia lentiscus leaves. J (2013) Pharm. Biomed. Anal., 77, pp. 167-174; Pacifico, S., Gallicchio, M., Fiorentino, A., Fischer, A., Meyer, U., Stintzing, F.C., Antioxidant properties and cytotoxic effects on human cancer cell lines of aqueous fermented and lipophilic quince (Cydonia oblonga Mill.) preparations (2012) Food Chem. Toxicol., 50, pp. 4130-4135; Pacifico, S., Gallicchio, M., Lorenz, P., Potenza, N., Galasso, S., Marciano, S., Fiorentino, A., Monaco, P., Apolar Laurus nobilis leaf extracts induce cytotoxicity and apoptosis towards three nervous system cell lines (2013) Food Chem. Toxicol., 62, pp. 628-637; Essa, M.M., Vijayan, R.K., Castellano-Gonzalez, G., Memon, M.A., Braidy, N., Guillemin, G.J., Neuroprotective effect of natural products against Alzheimers disease (2012) Neurochem. Res., 37, pp. 1829-1842; Flores, P., Hellin, P., Fenoll, J., Determination of organic acid in fruits and vegetables by liquid chromatography with tandem-mass spectroscopy (2012) Food Chem., 132, pp. 1049-1054; Pacifico, S., Di Maro, A., Petriccione, M., Galasso, S., Piccolella, S., Di Giuseppe, A.M.A., Scortichini, M., Monaco, P., Chemical composition, nutritional value and antioxidant properties of autochthonous Prunus avium cultivars from Campania Region (2014) Food Res. Int., 64, pp. 188-199; Clifford, M.N., Stoupi, S., Kuhnert, N., Profiling and characterization by LC-MSn of the galloylquinic acids of green tea, tara tannin, and tannic acid (2007) J. Agric. Food Chem., 55, pp. 2797-2807; Abu-Reidah, I.M., Ali-Shtayeh, M.S., Jamous, R.M., Arráez-Román, D., Segura-Carretero, A., HPLC-DAD-ESI-MS/MS screening of bioactive components from Rhus coriaria L. (Sumac) fruits (2015) Food Chem., 166, pp. 179-191; Dou, J., Lee, V.S.Y., Tzen, J.T.C., Lee, M.-R., Identification and comparison of phenolic compounds in the preparation of oolong tea manufactured by semifermentation and drying processes (2007) J. Agric. Food Chem., 55, pp. 7462-7468; Jaiswal, R., Jayasinghe, L., Kuhnerta, N., Identification and characterization of proanthocyanidins of 16 members of the Rhododendron genus (Ericaceae) by tandem LC-MS (2012) J. Mass. Spectrom., 47, pp. 502-515; Miketova, P., Schram, K.H., Whitney, J., Li, M., Huang, R., Kerns, E., Valcic, S., Klohr, S., Tandem mass spectrometry studies of green tea catechins. Identification of three minor components in the polyphenolic extract of green tea (2000) J. Mass Spectrom., 35, pp. 860-869; Mizooku, Y., Yoshikawa, M., Tsuneyoshi, T., Arakawa, R., Analysis of oxidized epigallocatechin gallate by liquid chromatography/mass spectrometry (2003) Rapid Commun. Mass Spectrom., 17, pp. 1915-1918; Vanholme, R., Storme, V., Vanholme, B., Sundin, L., Christensen, J.H., Goeminne, G., Halpin, C., Boerjan, W., A systems biology view of responses to lignin biosynthesis perturbations in Arabidopsis (2012) Plant Cell., 24, pp. 3506-3529; Hou, A.J., Peng, L.J., Liu, Y.Z., Lin, Z.W., Sun, H.D., Two new gallotannins from Pistacia weinmannifolia (2000) Chin. Chem. Lett., 11, pp. 53-56; Romani, A., Pinelli, P., Galardi, C., Mulinacci, N., Tattini, M., Identification and quantification of galloyl derivatives, flavonoid glycosides, and anthocyanins in leaves of Pistacia lentiscus L (2002) Phytochem. Anal., 13, pp. 79-86; Cuyckens, F., Claeys, M., Determination of the glycosylation site in flavonoid mono- O -glycosides by collision-induced dissociation of electrospray-generated deprotonated and sodiated molecules (2005) J. Mass Spectrom., 40, pp. 364-372; March, R.E., Lewars, E.G., Stadey, C.J., Miao, X.-S., Zhao, X., Metcalfe, C.D., A comparison of flavonoid glycosides by electrospray tandem mass spectrometry (2006) Int. J. Mass Spectrom., 248, pp. 61-85; Guimarães, R., Barros, L., Duenãs, M., Carvalho, A.M., Queiroz, M.J.R.P., Santos-Buelga, C., Ferreira, I.C.F.R., Characterization of phenolic compounds in wild fruits from Northeastern Portugal (2013) Food Chem., 141, pp. 3721-3730; Shearman, M.S., Hawtin, S.R., Tailor, V.J., The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides (1995) J. Neurochem., 65, pp. 218-227; Liu, Y., Schubert, D., Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis (1997) J. Neurochem., 69, pp. 2285-2293; Howes, M.J., Perry, E., The role of phytochemicals in the treatment and prevention of dementia (2011) Drugs Aging, 28, pp. 439-468; Williams, P., Sorribas, A., Howes, M.J.R., Natural products as a source of Alzheimers drug leads (2011) Nat. Prod. Rep., 28, pp. 48-77; Howes, M.J., Houghton, P.J., Ethnobotanical treatment strategies against Alzheimers disease (2012) Curr. Alzheimer Res., 9, pp. 67-85; Bastianetto, S., Yao, Z.X., Papadopoulos, V., Quirion, R., Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity (2006) Eur. J. Neurosci., 23, pp. 55-64; Kim, J.K., Choi, S.J., Cho, H.Y., Hwang, H.J., Kim, Y.J., Lim, S.T., Kim, C.J., Shin, D.H., Protective effects of kaempferol (3,4?,5,7-tetrahydroxyflavone) against amyloid β peptide (Aβ)-induced neurotoxicity in ICR mice (2010) Biosci. Biotechnol. Biochem., 74, pp. 397-401; Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., Yamada, M., Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimers disease (2003) J. Neurochem., 87, pp. 172-181; Commenges, D., Scotet, V., Renaud, S., Jacqumin-Gadda, H., Barberger-Gateau, P., Dartigues, J.F., Intake of flavonoids and risk of dementia (2000) Eur. J. Epidemiol., 16, pp. 357-363; Ramassamy, C., Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets (2008) Eur. J. Pharmacol., 545, pp. 51-64; Levites, Y., Amit, T., Youdim, M., Mandel, S., Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (?)-epigallocatechin 3-gallate neuroprotective action (2002) J. Biol. Chem., 277, pp. 30574-30580; Orhan, I., Kartal, M., Tosun, F., Sener, B., Screening of various phenolic acids and flavonoid derivatives for their anticholinesterase potential (2007) Z. Naturforsch C, 62, pp. 829-832; Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimers disease: Bioavailability, metabolism, and cellular and molecular mechanisms (2008) J. Agric. Food Chem., 56, pp. 4855-4873; Del Rio, D., Rodrigues-Mateos, A., Spencer, J.P., Tognolini, M., Borges, G., Grozier, A., Dietary (poly)phenolics in human health: Structures, bioavailability, and evidence of protective effects against chronic diseases (2013) Antioxid. Redox. Signal., 18, pp. 1818-1892; Shahrzad, S., Bitsch, I., Determination of gallic acid and its metabolites in human plasma and urine by high-performance liquid chromatography (1998) J. Chromatogr. B, 705, pp. 87-95; Lee, M.J., Maliakal, P., Chen, L., Meng, X., Bondoc, F.Y., Prabhu, S., Lambert, G., Yang, C.S., Pharmacokinetics of tea catechins after ingestion of green tea and (?)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability (2002) Cancer Epidemiol Biomarkers Prev., 11, pp. 1025-1032; Kohri, T., Nanjo, F., Suziki, M., Seto, R., Matsumoto, N., Yamakawa, M., Hojo, H., Chung, F.L., Synthesis of (?)-[4-3H]epigallocatechin gallate and its metabolic fate in rats after intravenous administration (2001) J. Agric. Food Chem., 49, pp. 1042-1048; Smith, T.J., Green tea polyphenols in drug discovery-A success or failure? (2011) Expert. Opin. Drug Discovery, 6, pp. 589-595; Youdim, K.A., Dobbie, S.M., Kuhnle, G., Proteggente, A.R., Abbott, J.N., Rice-Evans, C., Interaction between flavonoids and the blood-brain barrier: In vitro studies (2003) J. Neurochem., 85, pp. 180-192; Suganuma, M., Okabe, S., Oniyama, M., Tada, Y., Ito, H., Fujiki, H., Wide distribution of [3H](?)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue (1998) Carcinogenesis, 19, pp. 1771-1776; Farbood, Y., Sarkaki, A., Hashemi, S., Mansouri, M.T., Dianat, M., The effects of gallic acid on pain and memory following transient global ischemia/reperfusion in Wistar rats (2013) Avicenna J. Phytomed., 3, pp. 329-340; Janle, E.M., Lila, M.A., Grannan, M., Wood, L., Higgins, A., Yousef, G.G., Rogers, R.B., Weaver, C.M., Pharmacokinetics and tissue distribution of 14C-labeled grape polyphenols in the periphery and the central nervous system following oral administration (2010) J. Med. Food., 13, pp. 926-933; Youdim, K.A., Qaiser, M.Z., Begley, D.J., Rice-Evance, C.A., Abbott, N.J., Flavonoid permeability across an in situ model of blood-brain barrier (2004) Free Radic. Biol. Med., 36, pp. 592-604; Vauzour, D., Vafeiadou, K., Rodrigues-Mateos, A., Rendeiro, C., Spencer, J.P.E., The neuroprotective potential of flavonoids: A multiplicity of effects (2008) Genes Nutr., 3, pp. 115-126; Schaffer, S., Halliwell, B., Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations (2012) Genes Nutr., 7, pp. 99-109",Article,Scopus,2-s2.0-84916596723
"Pan-Montojo F.J., Reichmann H.","Aetiology of parkinson's disease: Braak revisited",2014,"Aktuelle Neurologie","41","10",,"573","578",,,10.1055/s-0034-1387475,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928539102&partnerID=40&md5=25e5d288582afdfee1178e690c0d508b","Neurologische Klinik und Poliklinik, Klinikum der Universität, Marchioninistr. 15München, Germany; Klinik und Poliklinik für Neurologie, Klinikum Carl Gustav CarusDresden, Germany","Pan-Montojo, F.J., Neurologische Klinik und Poliklinik, Klinikum der Universität, Marchioninistr. 15München, Germany; Reichmann, H., Klinik und Poliklinik für Neurologie, Klinikum Carl Gustav CarusDresden, Germany","Movement disorders belong to the most complicated neurodegenerative diseases. The aetiology of these disorders is only partially understood and most probably multi-factorial. The treatment in these cases is normally restricted to the symptoms and has many side effects. Parkinson's disease is the most frequent movement disorder and the second most frequent neurodegenerative disease after Alzheimers disease. It is slowly progressive and affects different regions from the central and peripheral nervous systems. In this review, we would like to give the reader an overview of the latest studies done in this field. We believe that the new findings regarding the role of alpha-synuclein in the progression of Parkinsons disease will lead to new, more specific causal therapies. © Georg Thieme Verlag KG Stuttgart New York.","alpha-synuclein; Braaks pathological staging; Parkinsons disease","Checkoway, H., Nelson, L.M., Epidemiologic approaches to the study of Parkinson's disease etiology (1999) Epidemiology, 10, pp. 327-336; Twelves, D., Perkins, K.S., Counsell, C., Systematic review of incidence studies of Parkinson's disease (2003) Mov Disord, 18, pp. 19-31; De Rijk, M.C., Launer, L.J., Berger, K., Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group (2000) Neurology, 54, pp. S21-23; Gasser, T., Genetics of Parkinson's disease (1998) Clin Genet, 54, pp. 259-265; Bekris, L.M., Mata, I.F., Zabetian, C.P., The genetics of Parkinson disease (2010) J Geriatr Psychiatry Neurol, 23, pp. 228-242; Ben-Shlomo, Y., The epidemiology of Parkinson's disease (1997) Baillieres Clin Neurol, 6, pp. 55-68; Tanner, C.M., Ben-Shlomo, Y., Epidemiology of Parkinson's disease (1999) Advances Neurol, 80, pp. 153-159; Baldi, I., Cantagrel, A., Lebailly, P., Association between Parkinson's disease and exposure to pesticides in southwestern France (2003) Neuroepidemiology, 22, pp. 305-310; Freire, C., Koifman, S., Pesticide exposure and Parkinson's disease: Epidemiological evidence of association (2012) Neurotoxicology, 33, pp. 947-971; Gorell, J.M., Johnson, C.C., Rybicki, B.A., The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living (1998) Neurology, 50, pp. 1346-1350; Kamel, F., Tanner, C., Umbach, D., Pesticide exposure and self-reported Parkinson's disease in the agricultural health study (2007) Am J Epidemiol, 165, pp. 364-374; Rajput, A.H., Uitti, R.J., Stern, W., Early onset Parkinson's disease in Saskatchewan - Environmental considerations for etiology (1986) Can J Neurol Sci, 13, pp. 312-316; Behari, M., Srivastava, A.K., Das, R.R., Risk factors of Parkinson's disease in Indian patients (2001) J Neurol Sci, 190, pp. 49-55; Liou, H.H., Tsai, M.C., Chen, C.J., Environmental risk factors and Parkinson's disease: A case-control study in Taiwan (1997) Neurology, 48, pp. 1583-1588; Seidler, A., Hellenbrand, W., Robra, B.P., Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany (1996) Neurology, 46, pp. 1275-1284; Semchuk, K.M., Love, E.J., Lee, R.G., Parkinson's disease and exposure to agricultural work and pesticide chemicals (1992) Neurology, 42, pp. 1328-1335; Tanner, C.M., Kamel, F., Ross, G.W., Rotenone, paraquat, and Parkinson's disease (2011) Environ Health Perspect, 119, pp. 866-872; Priyadarshi, A., Khuder, S.A., Schaub, E.A., Environmental risk factors and Parkinson's disease: A metaanalysis (2001) Environ Res, 86, pp. 122-127; Lai, B.C., Marion, S.A., Teschke, K., Occupational and environmental risk factors for Parkinson's disease (2002) Parkinsonism Relat Disord, 8, pp. 297-309; Doder, M., Jahanshahi, M., Turjanski, N., Parkinson's syndrome after closed head injury: A single case report (1999) J Neurol Neurosurg Psychiatry, 66, pp. 380-385; Nayernouri, T., Posttraumatic parkinsonism (1985) Surg Neurol, 24, pp. 263-264; Goldman, S.M., Tanner, C.M., Oakes, D., Head injury and Parkinson's disease risk in twins (2006) Ann Neurol, 60, pp. 65-72; Jafari, S., Etminan, M., Aminzadeh, F., Head injury and risk of Parkinson disease: A systematic review and meta-analysis (2013) Mov Disord, 28, pp. 1222-1229; Liu, B., Hong, J.S., Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention (2003) J Pharmacol Exp Ther, 304, pp. 1-7; Ghaemi, M., Rudolf, J., Schmulling, S., FDG- and Dopa-PET in postencephalitic parkinsonism (2000) J Neural Transm, 107, pp. 1289-1295; Abbott, R.D., Petrovitch, H., White, L.R., Frequency of bowel movements and the future risk of Parkinson's disease (2001) Neurology, 57, pp. 456-462; Baron, J.A., Cigarette smoking and Parkinson's disease (1986) Neurology, 36, pp. 1490-1496; Ascherio, A., Zhang, S.M., Hernan, M.A., Prospective study of caffeine consumption and risk of Parkinson's disease in men and women (2001) Ann Neurol, 50, pp. 56-63; Weisskopf, M.G., O'Reilly, E., Chen, H., Plasma urate and risk of Parkinson's disease (2007) Am J Epidemiol, 166, pp. 561-567; Forno, L.S., Neuropathology of Parkinson's disease (1996) J Neuropathol Exp Neurol, 55, pp. 259-272; Spillantini, M.G., Schmidt, M.L., Lee, V.M., Alpha-synuclein in Lewy bodies (1997) Nature, 388, pp. 839-840; Braak, H., Del Tredici, K., Rub, U., Staging of brain pathology related to sporadic Parkinson's disease (2003) Neurobiol Aging, 24, pp. 197-211; Braak, H., Ghebremedhin, E., Rub, U., Stages in the development of Parkinson's disease-related pathology (2004) Cell Tissue Res, 318, pp. 121-134; Wakabayashi, K., Takahashi, H., Neuropathology of autonomic nervous system in Parkinson's disease (1997) Eur Neurol, 38, pp. 2-7. , 02; Braak, H., De Vos, R.A., Bohl, J., Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology (2006) Neurosci Lett, 396, pp. 67-72; Del Tredici, K., Hawkes, C.H., Ghebremedhin, E., Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease (2010) Acta Neuropathol, 119, pp. 703-713; Orimo, S., Amino, T., Itoh, Y., Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease (2005) Acta Neuropathol, 109, pp. 583-588; Wolters, E., Braak, H., Parkinson's disease: Premotor clinico-pathological correlations (2006) J Neural Transm Suppl, 70, pp. 309-319; Shulman, L.M., Taback, R.L., Bean, J., Comorbidity of the nonmotor symptoms of Parkinson's disease (2001) Mov Disord, 16, pp. 507-510; Chaudhuri, K.R., Martinez-Martin, P., Quantitation of non-motor symptoms in Parkinson's disease (2008) Eur J Neurol, 15, pp. 2-7. , 02; Haehner, A., Hummel, T., Hummel, C., Olfactory loss may be a first sign of idiopathic Parkinson's disease (2007) Mov Disord, 22, pp. 839-842; Sommer, U., Hummel, T., Cormann, K., Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT (2004) Mov Disord, 19, pp. 1196-1202; Ponsen, M.M., Stoffers, D., Wolters, E., Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease (2010) J Neurol Neurosurg Psychiatry, 81, pp. 396-399; Stiasny-Kolster, K., Doerr, Y., Moller, J.C., Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT (2005) Brain, 128, pp. 126-137; Fleming, L., Mann, J.B., Bean, J., Parkinson's disease and brain levels of organochlorine pesticides (1994) Ann Neurol, 36, pp. 100-103; Manning-Bog, A.B., McCormack, A.L., Li, J., The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein (2002) J Biol Chem, 277, pp. 1641-1644; Alam, M., Schmidt, W.J., Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats (2002) Behav Brain Res, 136, pp. 317-324; Uversky, V.N., Li, J., Fink, A.L., Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease (2001) FEBS Lett, 500, pp. 105-108; Huang, C.C., Lu, C.S., Chu, N.S., Progression after chronic manganese exposure (1993) Neurology, 43, pp. 1479-1483; Needleman, H., Landrigan, P.J., Toxins at the pump (1996) New York Times, p. 15; Richardson, J.R., Roy, A., Shalat, S.L., Beta-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease (2011) Neurotoxicology, 32, pp. 640-645; Champy, P., Hoglinger, G.U., Feger, J., Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: Possible relevance for atypical parkinsonism in Guadeloupe (2004) J Neurochem, 88, pp. 63-69; Betarbet, R., Sherer, T.B., Mackenzie, G., Chronic systemic pesticide exposure reproduces features of Parkinson's disease (2000) Nat Neurosci, 3, pp. 1301-1306; Hoeglinger, G.U., Feger, J., Prigent, A., Chronic systemic complex i inhibition induces a hypokinetic multisystem degeneration in rats (2003) J Neurochem, 84, pp. 491-502; Pan-Montojo, F., Anichtchik, O., Dening, Y., Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice (2010) PLoS One, 5, p. e8762; Pan-Montojo, F., Schwarz, M., Winkler, C., Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice (2012) Scientific Rep, 2, p. 898; Desplats, P., Lee, H.J., Bae, E.J., Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein (2009) Proc Natl Acad Sci U S A, 106, pp. 13010-13015; Li, J.Y., Englund, E., Holton, J.L., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation (2008) Nat Med, 14, pp. 501-503; Angot, E., Steiner, J.A., Lema Tome, C.M., Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons in Vivo (2012) PLoS One, 7, p. e39465; Luk, K.C., Kehm, V., Carroll, J., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012) Science, 338, pp. 949-953; Braidy, N., Gai, W.P., Xu, Y.H., Alpha-Synuclein Transmission and Mitochondrial Toxicity in Primary Human Foetal Enteric Neurons in Vitro (2014) Neurotox Res, 25, pp. 170-182; Klegeris, A., Giasson, B.I., Zhang, H., Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells (2006) FASEB J, 20, pp. 2000-2008; Valente, E.M., Salvi, S., Ialongo, T., PINK1 mutations are associated with sporadic early-onset parkinsonism (2004) Ann Neurol, 56, pp. 336-341; Esteves, A.R., Arduino, D.M., Silva, D.F., Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD (2011) Parkinsons Dis, 2011, pp. 693-761; Freeman, D., Cedillos, R., Choyke, S., Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis (2013) PLoS One, 8, p. e62143; Chinta, S.J., Mallajosyula, J.K., Rane, A., Mitochondrial alpha-synuclein accumulation impairs complex i function in dopaminergic neurons and results in increased mitophagy in vivo (2010) Neurosci Lett, 486, pp. 235-239; Braidy, N., Gai, W.P., Xu, Y.H., Alpha-synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons in vitro (2014) Neurotox Res, 25, pp. 170-182; Gao, H.M., Kotzbauer, P.T., Uryu, K., Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration (2008) J Neurosci, 28, pp. 7687-7698; Gao, H.M., Zhang, F., Zhou, H., Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease (2011) Environm Health Perspect, 119, pp. 807-814; Frank-Cannon, T.C., Tran, T., Ruhn, K.A., Parkin deficiency increases vulnerability to inflammation-related nigral degeneration (2008) J Neurosci, 28, pp. 10825-10834; Norris, E.H., Uryu, K., Leight, S., Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model (2007) Am J Pathol, 170, pp. 658-666; Manning-Bog, A.B., McCormack, A.L., Purisai, M.G., Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration (2003) J Neurosci, 23, pp. 3095-3099; Kahle, P.J., Waak, J., Gasser, T., DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders (2009) Free Radical Biology & Medicine, 47, pp. 1354-1361; Masliah, E., Dumaop, W., Galasko, D., Distinctive patterns of DNA methylation associated with Parkinson disease: Identification of concordant epigenetic changes in brain and peripheral blood leukocytes (2013) Epigenetics, 8, pp. 1030-1038; Iacobazzi, V., Castegna, A., Infantino, V., Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool (2013) Mol Genet Metabol, 110, pp. 25-34; Marques, S., Outeiro, T.F., Epigenetics in Parkinson's and Alzheimer's diseases (2013) Sub-cell Biochem, 61, pp. 507-525; Zhu, M., Han, S., Fink, A.L., Oxidized quercetin inhibits alpha-synuclein fibrillization (2013) Biochim Biophys Acta, 1830, pp. 2872-2881; Horvath, I., Sellstedt, M., Weise, C., Modulation of alpha-synuclein fibrillization by ring-fused 2-pyridones: Templation and inhibition involve oligomers with different structure (2013) Arch Biochem Biophys, 532, pp. 84-90; Decressac, M., Mattsson, B., Weikop, P., TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity (2013) Proc Natl Acad Sci U S A, 110, pp. E1817-1826; Shaltiel-Karyo, R., Davidi, D., Frenkel-Pinter, M., Differential inhibition of alpha-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract (2012) Biochim Biophys Acta, 1820, pp. 1628-1635; Lorenzen, N., Nielsen, S.B., Yoshimura, Y., How Epigallocatechin Gallate Can Inhibit alpha-Synuclein Oligomer Toxicity in Vitro (2014) J Biol Chem, 289, pp. 21299-21310; Wagner, J., Ryazanov, S., Leonov, A., Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinsons disease (2013) Acta Neuropathol, 125, pp. 795-813; Jackrel, M.E., Desantis, M.E., Martinez, B.A., Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events (2014) Cell, 156, pp. 170-182; McLean, P.J., Kawamata, H., Shariff, S., TorsinA and heat shock proteins act as molecular chaperones: Suppression of alpha-synuclein aggregation (2002) J Neurochem, 83, pp. 846-854; Du, Y., Wang, F., Zou, J., Histone deacetylase 6 regulates cytotoxic alpha-synuclein accumulation through induction of the heat shock response (2014) Neurobiol Aging, 35, pp. 2316-2328; Faria, C., Jorge, C.D., Borges, N., Inhibition of formation of alpha-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease (2013) Biochim Biophys Acta, 1830, pp. 4065-4072; Games, D., Valera, E., Spencer, B., Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models (2014) J Neurosci, 34, pp. 9441-9454; Spencer, B., Emadi, S., Desplats, P., ESCRT-mediated Uptake and Degradation of Brain-targeted alpha-synuclein Single Chain Antibody Attenuates Neuronal Degeneration in Vivo (2014) Mol Ther, pp. 1753-1767; Tran, H.T., Chung, C.H., Iba, M., Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration (2014) Cell Rep, 7, pp. 2054-2065; Lindstrom, V., Fagerqvist, T., Nordstrom, E., Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice (2014) Neurobiol Dis, 69, pp. 134-143; Sanchez-Guajardo, V., Annibali, A., Jensen, P.H., Alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model (2013) J Neuropathol Exp Neurol, 72, pp. 624-645; Besong-Agbo, D., Wolf, E., Jessen, F., Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease (2013) Neurology, 80, pp. 169-175; Janetzky, B., Hauck, S., Youdim, M.B., Unaltered aconitase activity, but decreased complex i activity in substantia nigra pars compacta of patients with Parkinson's disease (1994) Neurosci Lett, 169, pp. 126-128; Schapira, A.H., Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal (1994) Mov Disord, 9, pp. 125-138; Menke, T., Gille, G., Reber, F., Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential (2003) BioFactors, 18, pp. 65-72; Sandoval-Acuna, C., Ferreira, J., Speisky, H., Polyphenols and mitochondria: An update on their increasingly emerging ROS-scavenging independent actions (2014) Arch Biochem Biophys, 559 C, pp. 75-90; Caruana, M., Neuner, J., Hogen, T., Polyphenolic compounds are novel protective agents against lipid membrane damage by alpha-synuclein aggregates in vitro (2012) Biochim Biophys Acta, 1818, pp. 2502-2510; Geed, M., Garabadu, D., Ahmad, A., Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats (2014) Pharmal Biochem Behav, 117, pp. 92-103; Rousseau, E., Michel, P.P., Hirsch, E.C., The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis (2013) Mol Pharmacol, 84, pp. 888-898; Toyoda, Y., Erkut, C., Pan-Montojo, F., Products of the Parkinson's disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival (2014) Biology Open; Storch, A., Jost, W.H., Vieregge, P., Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease (2007) Arch Neurol, 64, pp. 938-944",Article,Scopus,2-s2.0-84928539102
"Wang R., Wang J., Li S., Yu H., Deng B., Wei X.","Multiple feature extraction and classification of electroencephalograph signal for Alzheimers' with spectrum and bispectrum",2014,"Chaos","25","1", 013110,"","",,,10.1063/1.4906038,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84923673619&partnerID=40&md5=8a80e15a3cb9867f14c70bc8c46357b1","School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China","Wang, R., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China; Wang, J., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China; Li, S., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China; Yu, H., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China; Deng, B., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China; Wei, X., School of Electrical Engineering and Automation, Tianjin UniversityTianjin, China","In this paper, we have combined experimental neurophysiologic recording and statistical analysis to investigate the nonlinear characteristic and the cognitive function of the brain. Spectrum and bispectrum analyses are proposed to extract multiple effective features of electroencephalograph (EEG) signals from Alzheimer's disease (AD) patients and further applied to distinguish AD patients from the normal controls. Spectral analysis based on autoregressive Burg method is first used to quantify the power distribution of EEG series in the frequency domain. Compared to the control group, the relative power spectral density of AD group is significantly higher in the theta frequency band, while lower in the alpha frequency bands. In addition, median frequency of spectrum is decreased, and spectral entropy ratio of these two frequency bands undergoes drastic changes at the P3 electrode in the central-parietal brain region, implying that the electrophysiological behavior in AD brain is much slower and less irregular. In order to explore the nonlinear high order information, bispectral analysis which measures the complexity of phase-coupling is further applied to P3 electrode in the whole frequency band. It is demonstrated that less bispectral peaks appear and the amplitudes of peaks fall, suggesting a decrease of non-Gaussianity and nonlinearity of EEG in ADs. Notably, the application of this method to five brain regions shows higher concentration of the weighted center of bispectrum and lower complexity reflecting phase-coupling by bispectral entropy. Based on spectrum and bispectrum analyses, six efficient features are extracted and then applied to discriminate AD from the normal in the five brain regions. The classification results indicate that all these features could differentiate AD patients from the normal controls with a maximum accuracy of 90.2%. Particularly, different brain regions are sensitive to different features. Moreover, the optimal combination of features obtained by discriminant analysis may improve the classification accuracy. These results demonstrate the great promise for scape EEG spectral and bispectral features as a potential effective method for detection of AD, which may facilitate our understanding of the pathological mechanism of the disease. © 2015 AIP Publishing LLC.",,"Dauwels, J., Vialatte, F., Cichocki, A., (2010) Curr. Alzheimer Res., 7, p. 487; Mattson, M.P., (2004) Nature, 430, p. 634; Dauwels, J., Srinivasan, K., Ramasubba Reddy, M., Musha, T., Vialatte, F.B., Latchoumane, C., Jeong, J., Cichocki, A., Int. J. Alzheimer's Dis., 2011, p. 539621; Kowalski, J.W., Gawel, M., Pfeffer, A., Barcikowska, M., (2001) J. Clin. Neurophysiol., 18, p. 570; Adeli, H., Ghosh Dastidar, S., Dadmehr, N., (2005) Clin. EEG Neurosci., 36, p. 131; Gueguen, B., Derouesne, C., Bourdel, M.C., Guillou, S., Landre, E., Gaches, J., (1991) Neurophysiol. Clin., 21, p. 357; Czigler, B., Csikos, D., Hidasi, Z., Gaal, Z.A., Csibri, E., Kiss, E., Salacz, P., Molnar, M., (2008) Int. J. Psychophysiol., 68, p. 75; Dauwels, J., Vialatte, F., Musha, T., Cichocki, A., (2010) Neuroimage, 49, p. 668; Wang, R., Wang, J., Yu, H., Wei, X., Yang, C., Deng, B., (2014) Chaos, 24, p. 033136; Akin, M., Kiymik, M.K., (2000) J. Med. Syst., 24, p. 247; Bennys, K., Rondouin, G., Vergnes, C., Touchon, J., (2001) Neurophysiol. Clin., 31, p. 153; Jeong, J.S., (2004) Neurophysiol. Clin., 115, p. 1490; Gianotti, L.R.R., Kuenig, G., Lehmann, D., Faber, P.L., Pascual-Marqui, R.D., Kochi, K., Schreiter-Gasser, U., (2007) Neurophysiol. Clin., 118, p. 186; Zhou, S.M., Gan, J.Q., Sepulveda, F., (2008) Inf. Sci., 178, p. 1629; Sankari, Z., Adeli, H., Adeli, A., (2011) Neurophysiol. Clin., 122, p. 897; Escudero, J., Abasolo, D., Hornero, R., Espino, P., Lopez, M., (2006) Physiol. Meas., 27, p. 1091; Abasolo, D., Hornero, R., Espino, P., Poza, J., Sanchez, C.I., de la Rosa, R., (2005) Neurophysiol. Clin., 116, p. 1826; Abasolo, D., Hornero, R., Espino, P., Alvarez, D., Poza, J., (2006) Physiol. Meas., 27, p. 241; Stam, C.J., Jones, B.F., Manshanden, I., van Walsum, A.M.V.C., Montez, T., Verbunt, J.P.A., de Munck, J.C., Scheltens, P., (2006) Neuroimage, 32, p. 1335; Goshvarpour, A., Goshvarpour, A., Rahati, S., Saadatian, V., (2012) Iran. J. Psychiatry Behav. Sci., 6, p. 48; Schack, B., Vath, N., Petsche, H., Geissler, H.G., Moller, E., (2002) Int. J. Psychophysiol., 44, p. 143; Lay-Ekuakille, A., Vergallo, P., Griffo, G., Conversano, F., Casciaro, S., Urooj, S., Bhateja, V., Trabacca, A., (2014) IEEE Trans. Instrum. Meas., 63, p. 1440; Acharya, U.R., Sree, S.V., Alvin, A.P.C., Yanti, R., Suri, J.S., (2012) Int. J. Neural Syst., 22, p. 1250002; Cooper, J.E., (1995) Br. J. Psychiatry, 166, p. 4; Kay, S.M., (1988) Prentice Hall, p. 240. , (Academic, New Jersey), p. 240; Chua, K.C., Chandran, V., Acharya, U.R., Lim, C.M., (2010) Med. Eng. Phys., 32, p. 679; McBridea, J.C., Zhao, X., Munro, N.B., Smith, C.D., Jicha, G.A., Hively, L., Broster, L.S., Jiang, Y., (2014) Comput. Methods Programs Biomed., 114, p. 153; Nikias, C.L., Raghuveer, M.R., (1987) Proc. IEEE, 75, p. 869; Zhang, J.W., Zheng, C.X., Xie, A., (2000) IEEE Trans. Biomed. Eng., 47, p. 352; Cabin, R.J., Mitchell, R.J., (2000) Bull. Ecol. Soc. Am., 81, p. 246; Zweig, M.H., Campbell, G., (1993) Clin. Chem., 39, p. 561; Jelles, B., Scheltens, P., van der Flier, W.M., Jonkman, E.J., da Silva, F.H.L., Stam, C.J., (2008) Clin. Neurophysiol., 119, p. 837; Dauwels, J., Srinivasan, K., Reddy, M.R., Cichocki, A., (2013) IEEE J. Biomed. Health. Inform., 17, p. 708; Stam, C.J., Montez, T., Jones, B.F., Rombouts, S.A., van der Made, Y., Pijnenburg, Y.A., Scheltens, P., (2005) Clin. Neurophysiol., 116, p. 708; Stam, C.J., Jones, B.F., Nolte, G., Breakspear, M., Scheltens, P., (2006) Cereb. Cortex, 17, p. 92; Sanz-Arigita, E.J., Schoonheim, M.M., Damoiseaux, J.S., Rombouts, S.A., Maris, E., Barkhof, F., Scheltens, P., Stam, C.J., (2010) PLoS ONE, 5, p. e13788; Ponomareva, N.V., Selesneva, N.D., Jarikov, G.A., (2003) Neuropsychobiology, 48, p. 152; van der Hiele, K., Vein, A.A., Reijntjes, R.H.A.M., Westendorp, R.G.J., Bollen, E.L.E.M., van Buchern, M.A., van Dijk, J.G., Middelkoop, H.A.M., (2007) Clin. Neurophysiol., 118, p. 1931; Molnar, M., Csuhaj, R., Horvath, S., Vastagh, I., Gaal, Z.A., Czigler, B., Balint, A., Nagy, Z., (2006) Clin. Neurophysiol., 117, p. 771; Moretti, D.V., Fracassi, C., Pievani, M., Geroldi, C., Binetti, G., Zanetti, O., Sosta, K., Frisoni, G.B., (2009) Clin. Neurophysiol., 120, p. 295; Baraniuk, R.G., Flandrin, P., Janssen, A., Michel, O.J.J., (2001) IEEE Trans. Inf. Theory, 47, p. 1391; Bruna, R., Poza, J., Gomez, C., Garcia, M., Fernandez, A., Hornero, R., (2012) J. Neural Eng., 9, p. 036007; Gomez, C., Hornero, R., Abasolo, D., Fernandez, A., Escudero, J., (2007) Comput. Methods Programs Biomed., 87, p. 239; Yuvaraj, R., Murugappan, M., Ibrahim, N.M., Omar, M.I., Sundaraj, K., Mohamad, K., Palaniappan, R., Satiyan, M., (2014) J. Integr. Neurosci., 13, p. 89; Chua, K.C., Chandran, V., Acharya, R., Lim, C.M., (2008), p. 3824Tirel, O., Wodey, E., Harris, R., Bansard, J.Y., Ecoffey, C., Senhadji, L., (2006) Br. J. Anaesth., 96, p. 480; Huang, L., Zhao, J., Singare, S., Wang, J., Wang, Y., (2007) Med. Eng. Phys., 29, p. 1; Chua, K.C., Chandran, V., Acharya, U.R., Lim, C.M., (2008) J. Med. Eng. Technol., 32, p. 145; Besthorn, C., Zerfass, R., Geiger-Kabisch, C., Sattel, H., Daniel, S., Schreiter-Gasser, U., Förstl, H., (1997) Electroencephalogr. Clin. Neurophysiol., 103, p. 241; Abásolo, D., Hornero, R., Gómez, C., Garcia, M., López, M., (2006) Med. Eng. Phys., 28, p. 315; Wang, R.F., Wang, J., Yu, H.T., Wei, X.W., Yang, C., Deng, B., Power spectral density and coherence analysis of Alzheimer's EEG Cognit. Neurodynamics",Article,Scopus,2-s2.0-84923673619
"Sharma A.K., Kim J., Prior J.T., Hawco N.J., Rath N.P., Kim J., Mirica L.M.","Small bifunctional chelators that do not disaggregate amyloid β fibrils exhibit reduced cellular toxicity",2014,"Inorganic Chemistry","53","21",,"11367","11376",,,10.1021/ic500926c,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908611174&partnerID=40&md5=930610b427da4c996d97686cad9341bc","Department of Chemistry, Washington University, One Brookings DriveSt. Louis, MO, United States; Department of Neurology, Washington University, School of MedicineSt. Louis, MO, United States; Department of Chemistry and Biochemistry, University of Missouri-St. Louis, One University BoulevardSt. Louis, MO, United States","Sharma, A.K., Department of Chemistry, Washington University, One Brookings DriveSt. Louis, MO, United States; Kim, J., Department of Neurology, Washington University, School of MedicineSt. Louis, MO, United States; Prior, J.T., Department of Chemistry, Washington University, One Brookings DriveSt. Louis, MO, United States; Hawco, N.J., Department of Chemistry, Washington University, One Brookings DriveSt. Louis, MO, United States; Rath, N.P., Department of Chemistry and Biochemistry, University of Missouri-St. Louis, One University BoulevardSt. Louis, MO, United States; Kim, J., Department of Neurology, Washington University, School of MedicineSt. Louis, MO, United States; Mirica, L.M., Department of Chemistry, Washington University, One Brookings DriveSt. Louis, MO, United States","Multifunctional metal chelators that can modulate the amyloid β (Aβ) peptide aggregation and its interaction with metal ions such as copper and zinc hold considerable promise as therapeutic agents for Alzheimers disease (AD). However, specific rather than systemic metal chelation by these compounds is needed in order to limit any side effects. Reported herein are two novel small bifunctional chelators, 2-[2-hydroxy-4-(diethylamino)phenyl]benzothiazole (L1) and 2-(2-hydroxy-3-methoxyphenyl)benzothiazole (L2), in which the metal-binding donor atoms are integrated within a molecular framework derived from the amyloid-binding fluorescent dye thioflavin T (ThT). The metal-binding properties of L1 and L2 were probed by pH spectrophotometric titrations to determine their pKa values and the corresponding metal complex stability constants, and the isolated metal complexes were structurally characterized. The amyloid-fibril-binding properties of L1 and L2 were investigated by fluorescence titrations and ThT competition assays. Interestingly, L1 and L2 do not lead to the formation of neurotoxic Aβ42 oligomers in the presence or absence of metal ions, as observed by native gel electrophoresis, Western blotting, and transmission electron microscopy. In addition, L1 and L2 were able to reduce the cell toxicity of preformed Aβ42 oligomers and of the copper-stabilized Aβ42 oligomers. Given their ability to reduce the toxicity of soluble Aβ42 and Cu-Aβ42 species, L1 and L2 are promising lead compounds for the development of chemical agents that can control the neurotoxicity of soluble Aβ42 species in AD. © 2014 American Chemical Society.",,"(2013), www.alz.org, Alzheimers Disease Facts and Figures: Annual ReportFerri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Scazufca, M., (2005) Lancet, 366, pp. 2112-2117; Jakob-Roetne, R., Jacobsen, H., (2009) Angew. Chem., Int. Ed., 48, pp. 3030-3059; Hardy, J., Selkoe, D.J., (2002) Science, 297, pp. 353-356; Walsh, D.M., Selkoe, D.J., (2007) J. Neurochem., 101, pp. 1172-1184; Haass, C., Selkoe, D.J., (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Klein, W.L., (1998) Proc. Natl. Acad. Sci. U.S.A., 95, pp. 6448-6453; Gong, Y.S., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L., (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 10417-10422; McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Golde, T., (2005) Neuron, 47, pp. 191-199; Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., De Strooper, B., (2010) EMBO J., 29, pp. 3408-3420; Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., Markesbery, W.R., (1998) J. Neurol. Sci., 158, pp. 47-52; Bush, A.I., Pettingell, W.H., Multhaup, G., Paradis, M.D., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Tanzi, R.E., (1994) Science, 265, pp. 1464-1467; Atwood, C.S., Moir, R.D., Huang, X.D., Scarpa, R.C., Bacarra, N.M.E., Romano, D.M., Hartshorn, M.K., Bush, A.I., (1998) J. Biol. Chem., 273, pp. 12817-12826; Hureau, C., Faller, P., (2009) Biochimie, 91, p. 1212; Zhu, X., Su, B., Wang, X., Smith, M., Perry, G., (2007) Cell. Mol. Life Sci., 64, pp. 2202-2210; Crichton, R.R., Dexter, D.T., Ward, R.J., (2008) Coord. Chem. Rev., 252, pp. 1189-1199; House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., Exley, C., (2004) J. Alzheimers Dis., 6, pp. 291-301; Exley, C., (2006) J. Alzheimers Dis., 10, pp. 173-177; Exley, C., (2012) Coord. Chem. Rev., 256, pp. 3114-3114; Sharma, A.K., Pavlova, S.T., Kim, J., Finkelstein, D., Hawco, N.J., Rath, N.P., Kim, J., Mirica, L.M., (2012) J. Am. Chem. Soc., 134, pp. 6625-6636; Sharma, A.K., Pavlova, S.T., Kim, J., Kim, J., Mirica, L.M., (2013) Metallomics, 5, pp. 1529-1536; Zhang, Y., Rempel, D.L., Zhang, J., Sharma, A.K., Mirica, L.M., Gross, M.L., (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 14604-14609; Rodríguez-Rodríguez, C., Telpoukhovskaia, M., Orvig, C., (2012) Coord. Chem. Rev., 256, pp. 2308-2332; Braymer, J.J., Detoma, A.S., Choi, J.-S., Ko, K.S., Lim, M.H., (2011) Int. J. Alzheimers Dis., 2011, p. 623051; Choi, J.-S., Braymer, J.J., Nanga, R.P.R., Ramamoorthy, A., Lim, M.H., (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 21990-21995; Scott, L.E., Orvig, C., (2009) Chem. Rev., 109, pp. 4885-4910; Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K.A., Kremsky, J.N., Lai, L., Li, X.H., Huang, X.D., (2004) Exp. Gerontol., 39, pp. 1641-1649; Liu, Y.Z., Kochi, A., Pithadia, A.S., Lee, S., Nam, Y., Beck, M.W., He, X.M., Lim, M.H., (2013) Inorg. Chem., 52, pp. 8121-8130; Pithadia, A.S., Lim, M.H., (2012) Curr. Opin. Chem. Biol., 16, pp. 67-73; Pithadia, A.S., Kochi, A., Soper, M.T., Beck, M.W., Liu, Y.Z., Lee, S., Detoma, A.S., Lim, M.H., (2012) Inorg. Chem., 51, pp. 12959-12967; Hindo, S.S., Mancino, A.M., Braymer, J.J., Liu, Y.H., Vivekanandan, S., Ramamoorthy, A., Lim, M.H., (2009) J. Am. Chem. Soc., 131, p. 16663; Scott, L.E., Telpoukhovskaia, M., Rodriguez-Rodriguez, C., Merkel, M., Bowen, M.L., Page, B.D.G., Green, D.E., Orvig, C., (2011) Chem. Sci., 2, p. 642; Rodriguez-Rodriguez, C., De Groot, N.S., Rimola, A., Alvarez-Larena, A., Lloveras, V., Vidal-Gancedo, J., Ventura, S., Gonzalez-Duarte, P., (2009) J. Am. Chem. Soc., 131, pp. 1436-1451; Braymer, J.J., Detoma, A.S., Choi, J.-S., Ko, K.S., Lim, M.H., (2011) Int. J. Alzheimers Dis., 2011, p. 623051; (2008), Bruker Analytical X-ray: Madison, WISheldrick, G.M., (2008) Acta Crystallogr., 64, pp. 112-122; Gans, P., Sabatini, A., Vacca, A., (1999) Ann. Chim., p. 45; Alderighi, L., (1999) Coord. Chem. Rev., 184, p. 311; Klein, W.L., (2002) Neurochem. Int., 41, pp. 345-352; Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., (2001) Adv. Drug Delivery Rev., 46, pp. 3-26; Storr, T., Merkel, M., Song-Zhao, G.X., Scott, L.E., Green, D.E., Bowen, M.L., Thompson, K.H., Orvig, C., (2007) J. Am. Chem. Soc., 129, pp. 7453-7463; Huang, C.Y., (1982) Methods Enzymol., 87, p. 509; Talmard, C., Bouzan, A., Faller, P., (2007) Biochemistry, 46, pp. 13658-13666; Klunk, W.E., Wang, Y.M., Huang, G.F., Debnath, M.L., Holt, D.P., Mathis, C.A., (2001) Life Sci., 69, pp. 1471-1484; Levine, H., (1999) Methods Enzymol., 309, pp. 274-284; Lockhart, A., Ye, L., Judd, D.B., Merritt, A.T., Lowe, P.N., Morgenstern, J.L., Hong, G.Z., Brown, J., (2005) J. Biol. Chem., 280, pp. 7677-7684; Haass, C., Selkoe, D.J., (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; Mold, M., Ouro-Gnao, L., Wieckowski, B.M., Exley, C., (2013) Sci. Rep., 3; House, E., Mold, M., Collingwood, J., Baldwin, A., Goodwin, S., Exley, C., (2009) J. Alzheimers Dis., 18, pp. 811-817; Bush, A.I., (2002) Neurobiol. Aging, 23, pp. 1031-1038; Huang, X.D., Cuajungco, M.P., Atwood, C.S., Hartshorn, M.A., Tyndall, J.D.A., Hanson, G.R., Stokes, K.C., Bush, A.I., (1999) J. Biol. Chem., 274, pp. 37111-37116; Dahlgren, K.N., Manelli, A.M., Stine, W.B., Baker, L.K., Krafft, G.A., Ladu, M.J., (2002) J. Biol. Chem., 277, pp. 32046-32053; Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Mucke, L., (1999) Proc. Natl. Acad. Sci. U.S.A., 96, pp. 3228-3233; Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., (2006) Nature, 440, pp. 352-357; Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J.I., Smith, S.O., (2011) Nat. Struct. Mol. Biol., 17, pp. 561-567",Article,Scopus,2-s2.0-84908611174
"Gerben S.R., Lemkul J.A., Brown A.M., Bevan D.R.","Comparing atomistic molecular mechanics force fields for a difficult target: A case study on the Alzheimers amyloid β-peptide",2014,"Journal of Biomolecular Structure and Dynamics","32","11",,"1817","1832",,2,10.1080/07391102.2013.838518,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84905701176&partnerID=40&md5=7f994e489699f315913453cb36058bc3","Department of Biochemistry, Virginia Tech, 111 Engel Hall, Blacksburg, VA, 24061, United States","Gerben, S.R., Department of Biochemistry, Virginia Tech, 111 Engel Hall, Blacksburg, VA, 24061, United States; Lemkul, J.A., Department of Biochemistry, Virginia Tech, 111 Engel Hall, Blacksburg, VA, 24061, United States; Brown, A.M., Department of Biochemistry, Virginia Tech, 111 Engel Hall, Blacksburg, VA, 24061, United States; Bevan, D.R., Department of Biochemistry, Virginia Tech, 111 Engel Hall, Blacksburg, VA, 24061, United States","Macromolecular function arises from structure, and many diseases are associated with misfolding of proteins. Molecular simulation methods can augment experimental techniques to understand misfolding and aggregation pathways with atomistic resolution, but the reliability of these predictions is a function of the parameters used for the simulation. There are many biomolecular force fields available, but most are validated using stably folded structures. Here, we present the results of molecular dynamics simulations on the intrinsically disordered amyloid β-peptide (Aβ), whose misfolding and aggregation give rise to the symptoms of Alzheimers disease. Because of the link between secondary structure changes and pathology, being able to accurately model the structure of Aβ would greatly improve our understanding of this disease, and it may facilitate application of modeling approaches to other protein misfolding disorders. To this end, we compared five popular atomistic force fields (AMBER03, CHARMM22 + CMAP, GROMOS96 53A6, GROMOS96 54A7, and OPLS-AA) to determine which could best model the structure of Aβ. By comparing secondary structure content, NMR shifts, and radius of gyration to available experimental data, we conclude that AMBER03 and CHARMM22 + CMAP over-stabilize helical structure within Aβ, with CHARMM22 + CMAP also producing elongated Aβ structures, in conflict with experimental findings. OPLS-AA, GROMOS96 53A6, and GROMOS96 54A7 produce very similar results in terms of helical and β-strand content, calculated NMR shifts, and radii of gyration that agree well with experimental data. © 2013 © 2013 Taylor & Francis.","force field; molecular dynamics; molecular mechanics; protein folding; simulation","2013 Alzheimer's disease facts and figures (2013) Alzheimer's &Dementia, 9, pp. 1-68; Ball, K.A., Phillips, A.H., Nerenberg, P.S., Fawzi, N.L., Wemmer, D.E., Head-Gordon, T., Homogeneous and heterogeneous tertiary structure ensembles of amyloid-β peptides (2011) Biochemistry, 50, pp. 7612-7628; Ball, K.A., Phillips, A.H., Wemmer, D.E., Head-Gordon, T., Differences in β-strand populations of monomeric Aβ40 and Aβ42 (2013) Biophysical Journal, 104, pp. 2714-2724; Best, R.B., Buchete, N.-V., Hummer, G., Are current molecular dynamics force fields too helical? (2008) Biophysical Journal, 95, pp. L07-L09; Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annual Review of Biochemistry, 75, pp. 333-366; Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Ashe, K.H., Natural oligomers of the amyloid-β protein specifically disrupt cognitive function (2005) Nature Neuroscience, 8, pp. 79-84; Coles, M., Bicknell, W., Watson, A.A., Fairlie, D.P., Craik, D.J., Solution structure of amyloid β-peptide(1-40) in a water-micelle environment (1998) Is the Membrane-spanning Domain Where We Think It Is?. Biochemistry, 37, pp. 11064-11077; Danielsson, J., Andersson, A., Jarvet, J., Gräslund, A., 15N relaxation study of the amyloid β-peptide: Structural propensities and persistence length (2006) Magnetic Resonance in Chemistry, 44, pp. S114-S121; Darden, T., York, D., Pedersen, L., Particle mesh Ewald: An N• log(N) method for Ewald sums in large systems (1993) Journal of Chemical Physics, 98, pp. 10089-10092; Daura, X., Gademann, K., Jaun, B., Seebach, D., Van Gunsteren, W.F., Peptide folding: When simulation meets experiment (1999) Angewandte Chemie International Edition, 38, pp. 236-240; Daura, X., Mark, A.E., Van Gunsteren, W.F., Parametrization of aliphatic CHn united atoms of GROMOS96 force field (1998) Journal of Computational Chemistry, 19, pp. 535-547; Duan, Y., Wu, C., Chowdhury, S., Lee, M.C., Xiong, G., Zhang, W., Kollman, P., A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations (2003) Journal of Computational Chemistry, 24, pp. 1999-2012; Essmann, U., Perera, L., Berkowitz, M.L., Darden, T., Lee, H., Pedersen, L.G., A smooth particle mesh Ewald method (1995) Journal of Chemical Physics, 103, pp. 8577-8593; Foloppe, N., MacKerell Jr., A.D., All-atom empirical force field for nucleic acids: I (2000) Parameter Optimization Based on Small Molecule and Condensed Phase Macromolecular Target Data. Journal of Computational Chemistry, 21, pp. 86-104; Gu, L., Liu, C., Guo, Z., Structural insights into Aβ42 oligomers using site-directed spin labeling (2013) Journal of Biological Chemistry, 288, pp. 18673-18683; Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons form the Alzheimer's amyloid β-peptide (2007) Nature Reviews: Molecular Cell Biology, 8, pp. 101-112; Hardy, J.A., Higgins, G.A., Alzheimer's disease: The amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; Harper, J.D., Lansbury, P.T., Models of amyloid seeding in Alzheimer's disease and Scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins (1997) Annual Review of Biochemistry, 66, pp. 385-407; Hess, B., P-LINCS: A parallel linear constraint solver for molecular simulation (2008) Journal of Chemical Theory and Computation, 4, pp. 116-122; Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation (2008) Journal of Chemical Theory and Computation, 4, pp. 435-447; Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., Simmerling, C., Comparison of multiple Amber force fields and development of improved protein backbone parameters (2006) Proteins: Structure Function, and Bioinformatics, 65, pp. 712-725; Hou, L., Shao, H., Zhang, Y., Li, H., Menon, N.K., Neuhaus, E.B., Zagorski, M.G., Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation (2004) Journal of the American Chemical Society, 126, pp. 1992-2005; Jarrett, J.T., Lansbury, P.T., Seeding ""One-Dimensional Crystallization"" of amyloid: A pathogenic mechanism in Alzheimer's disease and Scrapie? (1993) Cell, 73, pp. 1055-1058; Kabsch, W., Sander, C., Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features (1983) Biopolymers, 22, pp. 2577-2637; Kaminski, G.A., Friesner, R.A., Tirado-Rives, J., Jorgensen, W.L., Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides (2001) Journal of Physical Chemistry B, 105, pp. 6474-6487; Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis (2003) Science, 300, pp. 486-489; Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E., Glabe, C.G., Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases (2004) Journal of Biological Chemistry, 279, pp. 46363-46366; Kirkitadze, M.D., Condron, M.M., Teplow, D.B., Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis (2001) Journal of Molecular Biology, 312, pp. 1103-1119; Kohlhoff, K.J., Robustelli, P., Cavalli, A., Salvatella, X., Vendruscolo, M., Fast and accurate predictions of protein NMR chemical shifts from interatomic distances (2009) Journal of the American Chemical Society, 131, pp. 13894-13895; Lee, C., Ham, S., Characterizing amyloid-beta protein misfolding from molecular dynamics simulations with explicit water (2011) Journal of Computational Chemistry, 32, pp. 349-355; Luttmann, E., Fels, G., All-atom molecular dynamics studies of the full-length β-amyloid peptides (2006) Chemical Physics, 323, pp. 138-147; MacKerell Jr., A.D., Banavali, N., Foloppe, N., Development and current status of the CHARMM force field for nucleic acids (2001) Biopolymers, 56, pp. 257-265; MacKerell Jr., A.D., Feig, M., Brooks, C.L., Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations (2004) Journal of Computational Chemistry, 25, pp. 1400-1415; MacKerell Jr., A.D., Brooks, B.R., Brooks, C.L., Nilsson, L., Roux, B., Won, Y., Karplus, M., CHARMM: The energy function and its parameterization with an overview of the program (1998) Encyclopedia of Computational Chemistry, pp. 271-277. , In P. V. Schleyer, N. L. Allinger, T. Clark, J. Gasteiger, P. A. Kollman, H. F. Shaefer III, &P. R. Schreiner (Eds.)Chichester: Wiley; Miyamoto, S., Kollman, P.A., SETTLE: An analytical version of the SHAKE and RATTLE algorithms for rigid water models (1992) Journal of Computational Chemistry, 13, pp. 952-962; Nag, S., Sarkar, B., Bandyopadhyay, A., Sahoo, B., Sreenivasan, V.K.A., Kombrabail, M., Maiti, S., Nature of the amyloid-β monomer and the monomer-oligomer equilibrium (2011) Journal of Biological Chemistry, 286, pp. 13827-13833; Nosé, S., Klein, M.L., Constant pressure molecular dynamics for molecular systems (1983) Molecular Physics, 50, pp. 1055-1076; Olubiyi, O.O., Strodel, B., Structures of the amyloid β-peptides Aβ1-40 and Aβ1-42 as influenced by pH and a Dpeptide (2012) Journal of Physical Chemistry B, 116, pp. 3280-3291; Oostenbrink, C., Villa, A., Mark, A.E., Van Gunsteren, W.F., A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS forcefield parameter sets 53A5 and 53A6 (2004) Journal of Computational Chemistry, 25, pp. 1656-1676; Pan, J., Han, J., Borchers, C.H., Konermann, L., Structure and dynamics of small soluble Aβ(1-40) oligomers studied by top-down hydrogen exchange mass spectrometry (2012) Biochemistry, 51, pp. 3694-3703; Parrinello, M., Rahman, A., Polymorphic transitions in single crystals: A new molecular dynamics method (1981) Journal of Applied Physics, 52, pp. 7182-7190; Piana, S., Lindorff-Larsen, K., Shaw, D.E., How robust are protein folding simulations with respect to force field parameterization? (2011) Biophysical Journal, 100, pp. L47-L49; Project, E., Nachliel, E., Gutman, M., Force fielddependent structural divergence revealed during long time simulations of calbindin d9k (2010) Journal of Computational Chemistry, 31, pp. 1864-1872; Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Lindahl, E., GROMACS 4.5: A highthroughput and highly parallel open source molecular simulation toolkit (2013) Bioinformatics, 29, pp. 845-854; Rosenman, D.J., Connors, C., Chen, W., Wang, C., García, A.E., Aβ monomers transiently sample oligomer and fibril-like configurations: Ensemble characterization using a combined MD/NMR approach (2013) Journal of Molecular Biology, 425, pp. 3338-3359; Roychaudhuri, R., Yang, M., Hoshi, M.M., Teplow, D.B., Amyloid β-protein assembly and Alzheimer disease (2009) Journal of Biological Chemistry, 284, pp. 4749-4753; Saitô, H., Conformation-dependent 13C chemical shifts: A new means of conformational characterization as obtained by high-resolution solid-state 13C NMR (1986) Magnetic Resonance in Chemistry, 24, pp. 835-852; Schmid, N., Eichenberger, A.P., Choutko, A., Riniker, S., Winger, M., Mark, A.E., Van Gunsteren, W.F., Definition and testing of the GROMOS force-field versions 54A7 and 54B7 (2011) European Biophysics Journal, 40, pp. 843-856; Scott, W.R.P., Hünenberger, P.H., Tironi, I.G., Mark, A.E., Billeter, S.R., Fennen, J., Van Gunsteren, W.F., The GROMOS biomolecular simulation program package (1999) Journal of Physical Chemistry A, 103, pp. 3596-3607; Sgourakis, N.G., Yan, Y., McCallum, S.A., Wang, C., Garcia, A.E., The Alzheimer's peptide Aβ40 and Aβ42 adopt distinct conformations in water: A combined MD/ NMR study (2007) Journal of Molecular Biology, 368, pp. 1448-1457; Soto, C., Castaño, E.M., Frangione, B., Inestrosa, N.C., The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation (1995) Journal of Biological Chemistry, 270, pp. 3063-3067; Tycko, R., Insights into the amyloid folding problem from solid-state NMR (2003) Biochemistry, 42, pp. 3151-3159; Van Gunsteren, W.F., Berendsen, H.J.C., A leapfrog algorithm for stochastic dynamics (1988) Molecular Simulation, 1, pp. 173-185; Vuister, G.W., Bax, A., Quantitative J correlation: A new approach for measuring homonuclear three-bond J (HNHα) coupling constants in 15N-enriched proteins (1993) Journal of the American Chemical Society, 115, pp. 7772-7777; Wang, Y., Jardetzky, O., Probability-based protein secondary structure identification using combined NMR chemical-shift data (2002) Protein Science, 11, pp. 852-861; Wickstrom, L., Okur, A., Simmerling, C., Evaluating the performance of the ff99SB force field based on NMR scalar coupling data (2009) Biophysical Journal, 97, pp. 853-856; Wishart, D.S., Sykes, B.D., The 13C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data (1994) Journal of Biomolecular NMR, 4, pp. 171-180; Wishart, D.S., Sykes, B.D., Richards, F.M., The chemical shift index: A fast and simple method for the assignment of protein secondary structure through NMR spectroscopy (1992) Biochemistry, 31, pp. 1647-1651; Yan, Y., McCallum, S.A., Wang, C., M35 oxidation induces Aβ40-like structural and dynamical changes in Aβ42 (2008) Journal of the American Chemical Society, 130, pp. 5394-5395; Yang, M., Teplow, D.B., Amyloid β-protein monomer folding: Free-energy surfaces reveal alloform-specific differences (2008) Journal of Molecular Biology, 384, pp. 450-464; Zhang, S., Iwata, K., Lachenmann, M.J., Peng, J.W., Li, S., Lee, J.P., The Alzheimer's peptide Aβ adopts a collapsed coil structure in water (2000) Journal of Structural Biology, 130, pp. 130-141",Article,Scopus,2-s2.0-84905701176
"Lan J.-S., Xie S.-S., Li S.-Y., Pan L.-F., Wang X.-B., Kong L.-Y.","Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease",2014,"Bioorganic and Medicinal Chemistry","22","21",,"6089","6104",,,10.1016/j.bmc.2014.08.035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908407171&partnerID=40&md5=decf15f78aae39deec3a826b45632d2f","State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China","Lan, J.-S., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China; Xie, S.-S., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China; Li, S.-Y., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China; Pan, L.-F., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China; Wang, X.-B., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China; Kong, L.-Y., State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia XiangNanjing, China","A series of tacrine-(β-carboline) hybrids (11a-q) were designed, synthesized and evaluated as multifunctional cholinesterase inhibitors against Alzheimer's disease (AD). In vitro studies showed that most of them exhibited significant potency to inhibit acetylcholinesterase (eeAChE and hAChE), butyrylcholinesterase (BuChE) and self-induced β-amyloid (Aβ) aggregation, Cu2+-induced Aβ (1-42) aggregation, and to chelate metal ions. Especially, 11l presented the greatest ability to inhibit cholinesterase (IC50, 21.6 nM for eeAChE, 63.2 nM for hAChE and 39.8 nM for BuChE), good inhibition of Aβ aggregation (65.8% at 20 μM) and good antioxidant activity (1.57 trolox equivalents). Kinetic and molecular modeling studies indicated that 11l was a mixed-type inhibitor, binding simultaneously to the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE. In addition, 11l could chelate metal ions, reduce PC12 cells death induced by oxidative stress and penetrate the blood-brain barrier (BBB). These results suggested that 11l might be an excellent multifunctional agent for AD treatment. © 2014 Elsevier Ltd. All rights reserved.","Alzheimers disease; Antioxidant; Metal chelator; Tacrine; β-Amyloid aggregation; β-Carboline","Palmer, A.M., (2011) Trends. Pharmacol. Sci., 32, p. 141; Schelterns, P., Feldman, H., (2003) Lancet Neurol., 2, p. 539; Xie, Q., Wang, H., Xia, Z., Lu, M., Zhang, W., Wang, X., Fu, W., Li, W., (2008) J. Med. Chem., 51, p. 2027; Bartus, R.T., Dean, R.L., Beer, B., Lippa, A.S., (1982) Science, 217, p. 408; Munoz-Torrero, D., (2008) Curr. Med. Chem., 15, p. 2433; Greig, N.H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H.W., Perry, T., Lee, B., Lahiri, D.K., (2001) Curr. Med. Res. Opin., 17, p. 159; Luo, W., Li, Y.-P., He, Y., Huang, S.-L., Tan, J.-H., Ou, T.-M., Li, D., Huang, Z.-S., (2011) Bioorg. Med. Chem., 19, p. 763; Bourne, Y., Taylor, P., Radić, Z., Marchot, P., (2003) EMBO J., 22, p. 1; Harel, M., Sonoda, L.K., Silman, I., Sussman, J.L., Rosenberry, T.L., (2008) J. Am. Chem. Soc., 130, p. 7856; Chen, Y., Sun, J., Fang, L., Liu, M., Peng, S., Liao, H., Lehmann, J., Zhang, Y., (2012) J. Med. Chem., 55, p. 4309; Reyes, A.E., Chacón, M.A., Dinamarca, M.C., Cerpa, W., Morgan, C., Inestrosa, N.C., (2004) Am. J. Pathol., 164, p. 2163; Fernaíndez-Bachiller, M.I., Monjas, L., Rodríguez-Franco, M.I., (2012) J. Med. Chem., 55, p. 1303; Özturan Özer, E., Unsal Tan, O., Ozadali, K., Küçükkilinç, T., Balkan, A., Uçar, G., (2013) Bioorg. Med. Chem. Lett., 23, p. 440; Guillozet, A., Mesulam, M.M., Smiley, J., Mash, D., (1997) Ann. Neurol., 42, p. 909; Ansari, M.A., Scheff, S.W., (2010) J. Neuropathol. Exp. Neurol., 69, p. 155; Nunomura, A., Castellani, R.J., Zhu, X., Moreira, P.I., Perry, G., Smith, M.A., (2006) J. Neuropathol. Exp. Neurol., 65, p. 631; Tan, D.-X., Manchester, L.C., Sainz, R., Mayo, J.C., Alvares, F.L., Reiter, R.J., (2003) Expert Opin. Ther. Pat., 13, p. 1513; Klatte, E.T., Scharre, D.W., Nagaraja, H.N., Davis, R.A., Beversdorf, D.Q., (2003) Alzheimer Dis. Assoc. Disord., 17, p. 113; Yankner, B.A., Dawes, L.R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M.L., Neve, R.L., (1989) Science, 245, p. 417; Hardy, J., Selkoe, D.J., (2002) Science, 297, p. 353; Paul, S., Planque, S., Nishiyama, Y., (2010) Rejuvenation Res., 13, p. 179; Liu, G., Huang, W., Moir, R.D., Vanderburg, C.R., Lai, B., Peng, Z., Tanzi, R.E., Huang, X., (2006) J. Struct. Biol., 155, p. 45; Barnham, K.J., Bush, A.I., (2008) Curr. Opin. Chem. Biol., 12, p. 222; Price, K.A., Crouch, P.J., White, A.R., (2007) Recent Pat. CNS Drug Discov., 2, p. 180; Huang, L., Luo, Z., He, F., Lu, J., Li, X., (2010) Bioorg. Med. Chem., 18, p. 4475; Chen, X., Tikhonova, G., Decke, M., (2011) Bioorg. Med. Chem., 19, p. 1222; Zhu, J., Wu, C., Li, X., Wu, G., Xie, S., Hu, Q., Deng, Z., Hong, X., (2013) Bioorg. Med. Chem., 21, p. 4218; Chen, X., Decker, M., (2013) Curr. Med. Chem., 20, p. 1673; Wang, Y., Wang, F., Yu, J.-P., Jiang, F.-C., Guan, X.-L., Wang, C.-M., Li, L., Chen, J.-G., (2012) Bioorg. Med. Chem., 20, p. 6513; Decker, M., Kraus, B., Heilmann, J., (2008) Bioorg. Med. Chem., 16, p. 4252; Mohamed, T., Pn Rao, P., (2011) Curr. Med. Chem., 18, p. 4299; Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., Lewis, K.W., (1994) Jama, 271, p. 992; Gracon, S.I., Knapp, M.J., Berghoff, W.G., Pierce, M., Dejong, R., Lobbestael, S.J., Symons, J., Kraemer, D., (1998) Alzheimer Dis. Assoc. Disord., 12, p. 93; Rodríguez-Franco, M.I., Fernández-Bachiller, M.I., Pérez, C., Hernández-Ledesma, B., Bartolomé, B., (2006) J. Med. Chem., 49, p. 459; Fernaíndez-Bachiller A. M, I., Pérez, C., González-Munoz, G.C., Conde, S., López, M.G., Villarroya, M., Garciía, A.G., Rodriíguez-Franco A. M, I., (2010) J. Med. Chem., 53, p. 4927; Fang, L., Appenroth, D., Decker, M., Kiehntopf, M., Roegler, C., Deufel, T., Fleck, C., Lehmann, J., (2008) J. Med. Chem., 51, p. 713; Airaksinen, M., Kari, I., (1981) Med. Biol., 59, p. 21; Adayev, T., Wegiel, J., Hwang, Y.-W., (2011) Arch. Biochem. Biophys., 507, p. 212; Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., Dunckley, T., (2011) PLoS One, 6, p. 19264; Schott, Y., Decker, M., Rommelspacher, H., Lehmann, J., (2006) Bioorg. Med. Chem. Lett., 16, p. 5840; Rook, Y., Schmidtke, K.-U., Gaube, F., Schepmann, D., Wünsch, B., Heilmann, J.R., Lehmann, J., Winckler, T., (2010) J. Med. Chem., 53, p. 3611; Herraiz, T., Galisteo, J., (2002) Free Radical Res., 36, p. 923; Herraiz, T., Galisteo, J., Chamorro, C., (2003) J. Agric. Food Chem., 51, p. 2168; Matsutomo, T., Stark, T.D., Hofmann, T., (2013) J. Agric. Food Chem., 61, p. 3059; Xie, S.-S., Wang, X.-B., Li, J.-Y., Yang, L., Kong, L.-Y., (2013) Eur. J. Med. Chem., 64, p. 540; Li, S.-Y., Wang, X.-B., Xie, S.-S., Jiang, N., Wang, K.D., Yao, H.-Q., Sun, H.-B., Kong, L.-Y., (2013) Eur. J. Med. Chem., 69, p. 632; Li, S.-Y., Jiang, N., Xie, S.-S., Wang, K.D., Wang, X.-B., Kong, L.-Y., (2014) Org. Biomol. Chem., 12, p. 801; Brossi, A., Focella, A., Teitel, S., (1973) J. Med. Chem., 16, p. 418; Lippke, K.P., Schunack, W.G., Wenning, W., Mueller, W.E., (1983) J. Med. Chem., 26, p. 499; Cain, M., Weber, R.W., Guzman, F., Cook, J.M., Barker, S.A., Rice, K.C., Crawley, J.N., Skolnick, P., (1982) J. Med. Chem., 25, p. 1081; Han, Y.F., Li, C.P.-L., Chow, E., Wang, H., Pang, Y.-P., Carlier, P.R., (1999) Bioorg. Med. Chem., 7, p. 2569; Bi, W., Bi, Y., Xue, P., Zhang, Y., Gao, X., Wang, Z., Li, M., Li, X., (2011) Eur. J. Med. Chem., 46, p. 2441; Ellman, G.L., Courtney, K.D., Featherstone, R.M., (1961) Biochem. Pharmacol., 7, p. 88; Rizzo, S., Riviere, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Monti, J.-P., (2008) J. Med. Chem., 51, p. 2883; Muzammil, S., Armstrong, A., Kang, L., Jakalian, A., Bonneau, P., Schmelmer, V., Amzel, L., Freire, (2007) J. Virol., 81, p. 5144; Bartolini, M., Bertucci, C., Bolognesi, M.L., Cavalli, A., Melchiorre, C., Andrisano, V., (2007) Chem. Biol. Chem., 8, p. 2152; Bolognesi, M.L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., Melchiorre, C., (2007) J. Med. Chem., 50, p. 6446; Huang, W., Lv, D., Yu, H., Sheng, R., Kim, S.C., Wu, P., Luo, K., Hu, Y., (2010) Bioorg. Med. Chem., 18, p. 5610; Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H.-B., Yan, M., Huang, L., Li, X., (2013) J. Med. Chem., 56, p. 5843; Magliaro, B.C., Saldanha, C.J., (2009) Brain Res., 1283, p. 14; Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., (2003) Eur. J. Med. Chem., 38, p. 223; Miller, N.J., Rice-Evans, C.A., (1997) Free Radical Res., 26, p. 195; Reinke, A.A., Gestwicki, J.E., (2007) Chem. Biol. Drug Des., 70, p. 206",Article,Scopus,2-s2.0-84908407171
"Ramachandran G., Milan-Garces E.A., Udgaonkar J.B., Puranik M.","Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation",2014,"Biochemistry","53","41",,"6550","6565",,,10.1021/bi500528x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908087790&partnerID=40&md5=04ec01c1915ff65025208232262cd4d7","National Centre for Biological Sciences, Tata Institute of Fundamental ResearchBangalore, India","Ramachandran, G., National Centre for Biological Sciences, Tata Institute of Fundamental ResearchBangalore, India; Milán-Garcés, E.A., National Centre for Biological Sciences, Tata Institute of Fundamental ResearchBangalore, India; Udgaonkar, J.B., National Centre for Biological Sciences, Tata Institute of Fundamental ResearchBangalore, India; Puranik, M., National Centre for Biological Sciences, Tata Institute of Fundamental ResearchBangalore, India","The aggregation of the microtubule-associated protein, tau, into amyloid fibrils is a hallmark of neurodegenerative diseases such as the tauopathies and Alzheimers disease. Since monomeric tau is an intrinsically disordered protein and the polymeric fibrils possess an ordered cross-β core, the aggregation process is known to involve substantial conformational conversion besides growth. The aggregation mechanism of tau in the presence of inducers such as heparin, deciphered using probes such as thioflavin T/S fluorescence, light scattering, and electron microscopy assays, has been shown to conform to ligand-induced nucleation-dependent polymerization. These probes do not, however, distinguish between the processes of conformational conversion and fibril growth. In this study, UV resonance Raman spectroscopy is employed to look directly at signatures of changes in secondary structure and side-chain packing during fibril formation by the four repeat functional domain of tau in the presence of the inducer heparin, at pH 7 and at 37 °C. Changes in the positions and intensities of the amide Raman bands are shown to occur in two distinct stages during the fibril formation process. The first stage of UVRR spectral changes corresponds to the transformation of monomer into early fibrillar aggregates. The second stage corresponds to the transformation of these early fibrillar aggregates into the final, ordered, mature fibrils and during this stage; the processes of conformational conversion and the consolidation of the fibril core occur simultaneously. Delineation of these secondary structural changes accompanying the formation of tau fibrils holds significance for the understanding of generic and tau-specific principles of amyloid assembly. © 2014 American Chemical Society.",,"Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., Kirschner, M.W., A protein factor essential for microtubule assembly (1975) Proc. Natl. Acad. Sci. U. S. A., 72, pp. 1858-1862; Schweers, O., Schonbrunn-Hanebeck, E., Marx, A., Mandelkow, E., Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure (1994) J. Biol. Chem., 269, pp. 24290-24297; Mukrasch, M.D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., Griesinger, C., Mandelkow, E., Zweckstetter, M., Structural polymorphism of 441-residue tau at single residue resolution (2009) PLoS Biol., 7. , e34; Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimers disease and related disorders (2007) Nat. Rev. Neurosci., 8, pp. 663-672; Ramachandran, G., Udgaonkar, J.B., Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimers disease and the tauopathies (2013) Biochemistry, 52, pp. 4107-4126; Lee, G., Cowan, N., Kirschner, M., The primary structure and heterogeneity of tau protein from mouse brain (1988) Science, 239, pp. 285-288; Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.M., Mandelkow, E., Domains of tau protein and interactions with microtubules (1994) Biochemistry, 33, pp. 9511-9522; Wischik, C.M., Novak, M., Edwards, P.C., Klug, A., Tichelaar, W., Crowther, R.A., Structural characterization of the core of the paired helical filament of Alzheimer disease (1988) Proc. Natl. Acad. Sci. U. S. A., 85, pp. 4884-4888; Friedhoff, P., Von Bergen, M., Mandelkow, E.M., Davies, P., Mandelkow, E., A nucleated assembly mechanism of Alzheimer paired helical filaments (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 15712-15717; Goedert, M., Jakes, R., Spillantini, M.G., Hasegawa, M., Smith, M.J., Crowther, R.A., Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans (1996) Nature, 383, pp. 550-553; Wilson, D.M., Binder, L.I., Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. in vitro evidence for a common effector of pathogenesis in Alzheimers disease (1997) Am. J. Pathol., 150, pp. 2181-2195; Chirita, C.N., Necula, M., Kuret, J., Anionic micelles and vesicles induce tau fibrillization in vitro (2003) J. Biol. Chem., 278, pp. 25644-25650; King, M.E., Ahuja, V., Binder, L.I., Kuret, J., Ligand-dependent tau filament formation: Implications for Alzheimers disease progression (1999) Biochemistry, 38, pp. 14851-14859; Ramachandran, G., Udgaonkar, J.B., Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein (2011) J. Biol. Chem., 286, pp. 38948-38959; Congdon, E.E., Kim, S., Bonchak, J., Songrug, T., Matzavinos, A., Kuret, J., Nucleation-dependent tau filament formation: The importance of dimerization and an estimation of elementary rate constants (2008) J. Biol. Chem., 283, pp. 13806-13816; Necula, M., Kuret, J., A static laser light scattering assay for surfactant-induced tau fibrillization (2004) Anal. Biochem., 333, pp. 205-215; Ramachandran, G., Udgaonkar, J.B., Evidence for the Existence of a Secondary Pathway for Fibril Growth during the Aggregation of Tau (2012) J. Mol. Biol., 421, pp. 296-314; Berriman, J., Serpell, L.C., Oberg, K.A., Fink, A.L., Goedert, M., Crowther, R.A., Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 9034-9038; Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., Thompson, M.J., Eisenberg, D., Atomic structures of amyloid cross-beta spines reveal varied steric zippers (2007) Nature, 447, pp. 453-457; Margittai, M., Langen, R., Template-assisted filament growth by parallel stacking of tau (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 10278-10283; Daebel, V., Chinnathambi, S., Biernat, J., Schwalbe, M., Habenstein, B., Loquet, A., Akoury, E., Lange, A., β-Sheet Core of Tau Paired Helical Filaments Revealed by Solid-State NMR (2012) J. Am. Chem. Soc., 134, pp. 13982-13989; Andronesi, O.C., Von Bergen, M., Biernat, J., Seidel, K., Griesinger, C., Mandelkow, E., Baldus, M., Characterization of Alzheimers-like paired helical filaments from the core domain of tau protein using solid-state NMR spectroscopy (2008) J. Am. Chem. Soc., 130, pp. 5922-5928; Tompa, P., Structural disorder in amyloid fibrils: Its implication in dynamic interactions of proteins (2009) FEBS J., 276, pp. 5406-5415; Seshadri, S., Khurana, R., Fink, A.L., Fourier transform infrared spectroscopy in analysis of protein deposits (1999) Methods Enzymol., 309, pp. 559-576; Woody, R.W., Circular dichroism (1995) Methods Enzymol., 246, pp. 34-71; Manning, M.C., Underlying assumptions in the estimation of secondary structure content in proteins by circular dichroism spectroscopy - A critical review (1989) J. Pharm. Biomed. Anal., 7, pp. 1103-1119; Soldi, G., Bemporad, F., Torrassa, S., Relini, A., Ramazzotti, M., Taddei, N., Chiti, F., Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state (2005) Biophys. J., 89, pp. 4234-4244; Shashilov, V.A., Lednev, I.K., 2D correlation deep UV resonance raman spectroscopy of early events of lysozyme fibrillation: Kinetic mechanism and potential interpretation pitfalls (2008) J. Am. Chem. Soc., 130, pp. 309-317; Chi, Z., Chen, X.G., Holtz, J.S., Asher, S.A., UV resonance Raman-selective amide vibrational enhancement: Quantitative methodology for determining protein secondary structure (1998) Biochemistry, 37, pp. 2854-2864; Huang, C.Y., Balakrishnan, G., Spiro, T.G., Protein secondary structure from deep-UV resonance Raman spectroscopy (2006) J. Raman Spectrosc., 37, pp. 277-282; Sikirzhytski, V., Topilina, N.I., Takor, G.A., Higashiya, S., Welch, J.T., Uversky, V.N., Lednev, I.K., Fibrillation mechanism of a model intrinsically disordered protein revealed by 2D correlation deep UV resonance Raman spectroscopy (2012) Biomacromolecules, 13, pp. 1503-1509; Barghorn, S., Mandelkow, E., Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments (2002) Biochemistry, 41, pp. 14885-14896; Jayanth, N., Ramachandran, S., Puranik, M., Solution structure of the DNA damage lesion 8-oxoguanosine from ultraviolet resonance Raman spectroscopy (2009) J. Phys. Chem. A, 113, pp. 1459-1471; Gonzalez-Montalban, N., Makarava, N., Savtchenko, R., Baskakov, I.V., Relationship between conformational stability and amplification efficiency of prions (2011) Biochemistry, 50, pp. 7933-7940; Popova, L.A., Kodali, R., Wetzel, R., Lednev, I.K., Structural variations in the cross-beta core of amyloid beta fibrils revealed by deep UV resonance Raman spectroscopy (2010) J. Am. Chem. Soc., 132, pp. 6324-6328; Fodor, S.P.A., Copeland, R.A., Grygon, C.A., Spiro, T.G., Deep-Ultraviolet Raman Excitation Profiles and Vibronic Scattering Mechanisms of Phenylalanine, Tyrosine, and Tryptophan (1989) J. Am. Chem. Soc., 111, pp. 5509-5518; Wang, Y., Purrello, R., Jordan, T., Spiro, T.G., UVRR Spectroscopy of the Peptide Bond. 1. Amide S, a Nonhelical Structure Marker, is a CαH Bending Mode (1991) J. Am. Chem. Soc., 113, pp. 6359-6368; Mikhonin, A.V., Ahmed, Z., Ianoul, A., Asher, S.A., Assignments and conformational dependencies of the amide III peptide backbone UV resonance Raman bands (2004) J. Phys. Chem. B, 108, pp. 19020-19028; Xu, M., Shashilov, V., Lednev, I.K., Probing the cross-β core structure of amyloid fibrils by hydrogen-deuterium exchange deep ultraviolet resonance Raman spectroscopy (2007) J. Am. Chem. Soc., 129, pp. 11002-11003; Maiti, N.C., Apetri, M.M., Zagorski, M.G., Carey, P.R., Anderson, V.E., Raman spectroscopic characterization of secondary structure in natively unfolded proteins: α-Synuclein (2004) J. Am. Chem. Soc., 126, pp. 2399-2408; Jiji, R.D., Balakrishnan, G., Hu, Y., Spiro, T.G., Intermediacy of poly(l -proline) II and β-strand conformations in poly(l -lysine) β-sheet formation probed by temperature-jump/UV resonance Raman spectroscopy (2006) Biochemistry, 45, pp. 34-41; Roach, C.A., Simpson, J.V., Jiji, R.D., Evolution of quantitative methods in protein secondary structure determination via deep-ultraviolet resonance Raman spectroscopy (2012) Analyst, 137, pp. 555-562; Oladepo, S.A., Xiong, K., Hong, Z., Asher, S.A., Handen, J., Lednev, I.K., UV resonance Raman investigations of peptide and protein structure and dynamics (2012) Chem. Rev., 112, pp. 2604-2628; Takeuchi, H., Harada, I., Ultraviolet resonance Raman-spectroscopy of X-Proline bonds - A new marker band of hydrogen-bonding at the imide C-O site (1990) J. Raman Spectrosc., 21, pp. 509-515; Jordan, T., Mukerji, I., Wang, Y., Spiro, T.G., UV resonance Raman spectroscopy and hydrogen bonding of the proline peptide bond (1996) J. Mol. Struct., 379, pp. 51-64; Austin, J.C., Jordan, T., Spiro, T.G., (1993) Ultraviolet Resonance Raman Studies of Proteins and Related Model Compounds, , Wiley & Sons Ltd. New York; Ramachandran, G., Udgaonkar, J.B., Difference in fibril core stability between two tau four-repeat domain proteins: A hydrogen-deuterium exchange coupled to mass spectrometry study (2013) Biochemistry, 52, pp. 8787-8789; Naiki, H., Higuchi, K., Hosokawa, M., Takeda, T., Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1 (1989) Anal. Biochem., 177, pp. 244-249; Levine, H., III, Thioflavine T interaction with synthetic Alzheimers disease beta-amyloid peptides: Detection of amyloid aggregation in solution (1993) Protein Sci., 2, pp. 404-410; Biancalana, M., Makabe, K., Koide, A., Koide, S., Molecular mechanism of thioflavin-T binding to the surface of beta-rich peptide self-assemblies (2009) J. Mol. Biol., 385, pp. 1052-1063; Kitts, C.C., Vanden Bout, D.A., Near-field scanning optical microscopy measurements of fluorescent molecular probes binding to insulin amyloid fibrils (2009) J. Phys. Chem. B, 113, pp. 12090-12095; Chirita, C.N., Congdon, E.E., Yin, H., Kuret, J., Triggers of full-length tau aggregation: A role for partially folded intermediates (2005) Biochemistry, 44, pp. 5862-5872; Mukrasch, M.D., Biernat, J., Von Bergen, M., Griesinger, C., Mandelkow, E., Zweckstetter, M., Sites of tau important for aggregation populate β-structure and bind to microtubules and polyanions (2005) J. Biol. Chem., 280, pp. 24978-24986; Mukrasch, M.D., Markwick, P., Biernat, J., Bergen, M., Bernado, P., Griesinger, C., Mandelkow, E., Blackledge, M., Highly populated turn conformations in natively unfolded tau protein identified from residual dipolar couplings and molecular simulation (2007) J. Am. Chem. Soc., 129, pp. 5235-5243; Von Bergen, M., Barghorn, S., Muller, S.A., Pickhardt, M., Biernat, J., Mandelkow, E.M., Davies, P., Mandelkow, E., The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis (2006) Biochemistry, 45, pp. 6446-6457; Margittai, M., Langen, R., Side chain-dependent stacking modulates tau filament structure (2006) J. Biol. Chem., 281, pp. 37820-37827; Song, S., Asher, S.A., UV resonance Raman studies of peptide conformation in poly(l -lysine), poly(l -glutamic acid), and model complexes: The basis for protein secondary structure determinations (1989) J. Am. Chem. Soc., 111, pp. 4295-4305; Copeland, R.A., Spiro, T.G., Secondary structure determination in proteins from deep (192-223-nm) ultraviolet Raman spectroscopy (1987) Biochemistry, 26, pp. 2134-2139; Chen, X.G., Asher, S.A., Schweitzer-Stenner, R., Mirkin, N.G., Krimm, S., UV Raman Determination of the π⋯π∗ Excited State Geometry of N -Methylacetamide: Vibrational Enhancement Pattern (1995) J. Am. Chem. Soc., 117, pp. 2884-2895; Wang, Y., Purrello, R., Georgiou, S., Spiro, T.G., UVRR spectroscopy of the peptide bond. 2. Carbonyl H-bond effects on the ground- and excited-state structures of N -methylacetamide (1991) J. Am. Chem. Soc., 113, pp. 6368-6377; Balakrishnan, G., Hu, Y., Spiro, T.G., His26 protonation in cytochrome c triggers microsecond β-sheet formation and heme exposure: Implications for apoptosis (2012) J. Am. Chem. Soc., 134, pp. 19061-19069; Sikirzhytski, V., Topilina, N.I., Higashiya, S., Welch, J.T., Lednev, I.K., Genetic engineering combined with deep UV resonance Raman spectroscopy for structural characterization of amyloid-like fibrils (2008) J. Am. Chem. Soc., 130, pp. 5852-5853; Wang, M., Jiji, R.D., Spectroscopic detection of beta-sheet structure in nascent Abeta oligomers (2011) J. Biophotonics, 4, pp. 637-644; Barghorn, S., Davies, P., Mandelkow, E., Tau paired helical filaments from Alzheimers disease brain and assembled in vitro are based on β-structure in the core domain (2004) Biochemistry, 43, pp. 1694-1703; Asher, S.A., Mikhonin, A.V., Bykov, S., UV Raman demonstrates that α-helical polyalanine peptides melt to polyproline II conformations (2004) J. Am. Chem. Soc., 126, pp. 8433-8440; Shi, Z., Chen, K., Liu, Z., Kallenbach, N.R., Conformation of the backbone in unfolded proteins (2006) Chem. Rev., 106, pp. 1877-1897; Fitzkee, N.C., Fleming, P.J., Gong, H., Panasik, N., Jr., Street, T.O., Rose, G.D., Are proteins made from a limited parts list? (2005) Trends Biochem. Sci., 30, pp. 73-80; Syme, C.D., Blanch, E.W., Holt, C., Jakes, R., Goedert, M., Hecht, L., Barron, L.D., A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins (2002) Eur. J. Biochem., 269, pp. 148-156; Von Bergen, M., Barghorn, S., Biernat, J., Mandelkow, E.M., Mandelkow, E., Tau aggregation is driven by a transition from random coil to beta sheet structure (2005) Biochim. Biophys. Acta, 1739, pp. 158-166; Zhu, H.L., Fernandez, C., Fan, J.B., Shewmaker, F., Chen, J., Minton, A.P., Liang, Y., Quantitative characterization of heparin binding to Tau protein: Implication for inducer-mediated Tau filament formation (2010) J. Biol. Chem., 285, pp. 3592-3599; Carlson, S.W., Branden, M., Voss, K., Sun, Q., Rankin, C.A., Gamblin, T.C., A complex mechanism for inducer mediated tau polymerization (2007) Biochemistry, 46, pp. 8838-8849; Elbaum-Garfinkle, S., Rhoades, E., Identification of an aggregation-prone structure of tau (2012) J. Am. Chem. Soc., 134, pp. 16607-16613; Wegmann, S., Scholer, J., Bippes, C.A., Mandelkow, E., Muller, D.J., Competing interactions stabilize pro- and anti-aggregant conformations of human Tau (2011) J. Biol. Chem., 286, pp. 20512-20524; Von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E.M., Mandelkow, E., Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure (2000) Proc. Natl. Acad. Sci. U. S. A., 97, pp. 5129-5134; Mikhonin, A.V., Bykov, S.V., Myshakina, N.S., Asher, S.A., Peptide secondary structure folding reaction coordinate: Correlation between UV Raman amide III frequency, Ramachandran angle, and hydrogen bonding (2006) J. Phys. Chem. B, 110, pp. 1928-1943; Chirgadze, Y.N., Nevskaya, N.A., Infrared spectra and resonance interaction of amide-I vibration of the antiparallel-chain pleated sheet (1976) Biopolymers, 15, pp. 607-625; Apetri, M.M., Maiti, N.C., Zagorski, M.G., Carey, P.R., Anderson, V.E., Secondary structure of alpha-synuclein oligomers: Characterization by raman and atomic force microscopy (2006) J. Mol. Biol., 355, pp. 63-71; Xiong, K., Punihaole, D., Asher, S.A., UV resonance Raman spectroscopy monitors polyglutamine backbone and side chain hydrogen bonding and fibrillization (2012) Biochemistry, 51, pp. 5822-5830; Chang, S., Yang, W., Spiro, T.G., Saturation effects on ultraviolet resonance Raman intensities - Excimer/YAG laser comparison and aromatic amino-acid cross-sections (1990) J. Raman Spectrosc., 21, pp. 435-440; Chi, Z.H., Asher, S.A., UV Raman determination of the environment and solvent exposure of Tyr and Trp residues (1998) J. Phys. Chem. B, 102, pp. 9595-9602; Moore, C.L., Huang, M.H., Robbennolt, S.A., Voss, K.R., Combs, B., Gamblin, T.C., Goux, W.J., Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation (2011) Biochemistry, 50, pp. 10876-10886; Kurouski, D., Deckert-Gaudig, T., Deckert, V., Lednev, I.K., Structure and Composition of Insulin Fibril Surfaces Probed by TERS (2012) J. Am. Chem. Soc., 134, pp. 13323-13329; Toyama, B.H., Weissman, J.S., Amyloid structure: Conformational diversity and consequences (2011) Annu. Rev. Biochem., 80, pp. 557-585; Kumar, S., Udgaonkar, J.B., Mechanisms of amyloid fibril formation by proteins (2010) Curr. Sci. India, 98, pp. 639-656; Goldsbury, C., Frey, P., Olivieri, V., Aebi, U., Muller, S.A., Multiple assembly pathways underlie amyloid-beta fibril polymorphisms (2005) J. Mol. Biol., 352, pp. 282-298; Kumar, S., Mohanty, S.K., Udgaonkar, J.B., Mechanism of formation of amyloid protofibrils of barstar from soluble oligomers: Evidence for multiple steps and lateral association coupled to conformational conversion (2007) J. Mol. Biol., 367, pp. 1186-1204; Kumar, S., Udgaonkar, J.B., Conformational conversion may precede or follow aggregate elongation on alternative pathways of amyloid protofibril formation (2009) J. Mol. Biol., 385, pp. 1266-1276; Jayaraman, M., Mishra, R., Kodali, R., Thakur, A.K., Koharudin, L.M., Gronenborn, A.M., Wetzel, R., Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties (2012) Biochemistry, 51, pp. 2706-2716; Morris, A.M., Watzky, M.A., Finke, R.G., Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature (2009) Biochim. Biophys. Acta, 1794, pp. 375-397; Carulla, N., Caddy, G.L., Hall, D.R., Zurdo, J., Gairi, M., Feliz, M., Giralt, E., Dobson, C.M., Molecular recycling within amyloid fibrils (2005) Nature, 436, pp. 554-558; Sanchez, L., Madurga, S., Pukala, T., Vilaseca, M., Lopez-Iglesias, C., Robinson, C.V., Giralt, E., Carulla, N., Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties (2011) J. Am. Chem. Soc., 133, pp. 6505-6508; Kuret, J., Chirita, C.N., Congdon, E.E., Kannanayakal, T., Li, G., Necula, M., Yin, H., Zhong, Q., Pathways of tau fibrillization (2005) Biochim. Biophys. Acta, 1739, pp. 167-178; Sievers, S.A., Karanicolas, J., Chang, H.W., Zhao, A., Jiang, L., Zirafi, O., Stevens, J.T., Eisenberg, D., Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation (2011) Nature, 475, pp. 96-100",Article,Scopus,2-s2.0-84908087790
"Prakash A., Kumar A.","Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in β-amyloid induced Alzheimers disease",2014,"European Journal of Pharmacology","741",,,"104","111",,,10.1016/j.ejphar.2014.07.036,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906966961&partnerID=40&md5=8bc2998c1d507f856bc7959d2e23b736","Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab UniversityChandigarh, India","Prakash, A., Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab UniversityChandigarh, India; Kumar, A., Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab UniversityChandigarh, India","Lycopene has attracted significant research interest due to its beneficial therapeutic effects, which include anti-oxidant, neuro-protective and anti-cancer effects, but the mechanisms of its beneficial action are not clear so far. The present study was carried out to elucidate the neuroprotective effect of lycopene against the β-amyloid induced cognitive impairment and mitochondria oxidative damage in rats. β-amyloid (β-A1-42) was administered through intracerebroventricular (ICV) by using stereotaxic instrument in male Wistar rats. Lycopene (2.5 and 5 mg/kg) was administrated for three weeks. Behavioral performances were conducted during the study. The rats were sacrificed on the 21st day following the last behavioral test and cytoplasmic fractions of hippocampus were prepared for the quantification of acetylcholinesterase, oxidative stress parameter, mitochondrial enzymes, and inflammatory mediator like TNF-α, Il-6 activities, caspase-3 and BDNF. ICV β-A1-42resulted in poor memory retention in Morris water maze and caused marked oxidative stress as indicated by significant increase in oxidative, mitochondria damage, TNF-α, IL-6 and Caspase-3 activity. We also found that β-A1-42induced animal altered BDNF level than control animals. Chronic administration of lycopene resulted in an improvement in memory retention, attenuation of mitochondrial-oxidative damage, reduced neuro-inflammation and restoration of BDNF level in β-A1-42treated rats. These studies indicated that lycopene helps to protect β-A1-42induced cognitive dysfunction and modulates amyloidogenesis. © 2014 Elsevier B.V.","Alzheimers disease; Anti-oxidant; BDNF β-amyloid; Lycopene","Anand, R., Gill, K.D., Mahdi, A.A., Therapeutics of Alzheimers disease: Past, present and future (2014) Neuropharmacology, 76 (PART A), pp. 27-50; Aydin, S., Tokac, M., Taner, G., Arikok, A.T., Dundar, H.Z., Ozkardes, A.B., Taslipinar, M.Y., Basaran, N., Antioxidant and antigenotoxic effects of lycopene in obstructive jaundice (2013) J. Surg. Res., 182, pp. 285-295; Bezprozvanny, I., Mattson, M.P., Neuronal calcium mishandling and the pathogenesis of Alzheimers disease (2008) Trends Neurosci., 31, pp. 454-463; Burchell, V.S., Gandhi, S., Deas, E., Wood, N.W., Abramov, A.Y., Plun-Favreau, H., Targeting mitochondrial dysfunction in neurodegenerative disease: Part i (2010) Expert Opin. Ther. Targets, 14, pp. 369-385; Burchell, V.S., Gandhi, S., Deas, E., Wood, N.W., Abramov, A.Y., Targeting mitochondrial dysfunction in neurodegenerative disease: Part II (2010) Expert Opin. Ther. Targets, 14, pp. 497-511; Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., Rizzuto, R., Mitochondria, calcium and cell death: A deadly triad in neurodegeneration (2009) Biochim. Biophys. Acta, 1787, pp. 335-344; D'Amelio, M., Cavallucci, V., Cecconi, F., Neuronal caspase-3 signaling: Not only cell death (2010) Cell Death Differ., 17, pp. 1104-1114; Ding, J., Yu, H.L., Ma, W.W., Xi, Y.D., Zhao, X., Yuan, L.H., Feng, J.F., Xiao, R., Soy isoflavone attenuates brain mitochondrial oxidative stress induced by beta-amyloid peptides 1-42 injection in lateral cerebral ventricle (2013) J. Neurosci. Res., 91, pp. 562-567; Diogenes, M.J., Costenla, A.R., Lopes, L.V., Jeronimo-Santos, A., Sousa, V.C., Fontinha, B.M., Ribeiro, J.A., Sebastiao, A.M., Enhancement of LTP in aged rats is dependent on endogenous BDNF (2011) Neuropsychopharmacology, 36, pp. 1823-1836; Du, H., Yan, S.S., Mitochondrial permeability transition pore in Alzheimers disease: Cyclophilin D and amyloid beta (2010) Biochim. Biophys. Acta, 1802, pp. 198-204. , (77); Ellman, G.L., Tissue sulfhydryl groups (1959) Arch. Biochem. Biophys., 82, pp. 70-77; Ellman, G.L., Courtney, K.D., Andres, V., Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity (1961) Biochem. Pharmacol., 7, pp. 88-91; Federico, A., Cardaioli, E., Da Pozzo, P., Formichi, P., Gallus, G.N., Radi, E., Mitochondria, oxidative stress and neurodegeneration (2012) J. Neurol. Sci., 322, pp. 254-262; Ferrer, I., Krupinski, J., Goutan, E., Marti, E., Ambrosio, S., Arenas, E., Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat (2001) Acta Neuropathol., 101, pp. 229-238; Friedman, M., Anticarcinogenic, cardioprotective, and other health benefits of tomato compounds lycopene, alpha-tomatine, and tomatidine in pure form and in fresh and processed tomatoes (2013) J. Agric. Food Chem., 61, pp. 9534-9550; Gandhi, S., Abramov, A.Y., Mechanism of oxidative stress in neurodegeneration (2012) Oxid. Med. Cell. Longev., 2012, p. 428010; Gilbert, B.J., The role of amyloid beta in the pathogenesis of Alzheimers disease (2013) J. Clin. Pathol., 66, pp. 362-366; Gornall, A.G., Bardawill, C.J., David, M.M., Determination of serum proteins by means of the biuret reaction (1949) J. Biol. Chem., 177, pp. 751-766; Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., Analysis of nitrate, nitrite, and [N-15]-labeled nitrate in biological-fluids (1982) Anal. Biochem., 126, pp. 131-138; Hayashi, T., Saito, A., Okuno, S., Ferrand-Drake, M., Dodd, R.L., Nishi, T., Maier, C.M., Chan, P.H., Oxidative damage to the endoplasmic reticulum is implicated in ischemic neuronal cell death (2003) J. Cereb. Blood Flow Metab., 23, pp. 1117-1128; Jeong, J.H., Jeong, H.R., Jo, Y.N., Kim, H.J., Shin, J.H., Heo, H.J., Ameliorating effects of aged garlic extracts against Abeta-induced neurotoxicity and cognitive impairment (2013) BMC Complement. Altern. Med., 13, p. 268; King, T.E., Preparation of succinate dehydrogenase and reconstitution of succinate oxidase (1967) Methods in Enzymology, 10, pp. 322-331. , W. Ronald, M.E.P. Estabrook, Academic Press New York, United States; King, T.E., Howard, R.L., Preparations and properties of soluble NADH dehydrogenases from cardiac muscle (1967) Methods in Enzymology, pp. 275-294. , W. Ronald, M.E.P. Estabrook, Academic Press New York, United States; Kobayashi, M., Sakamoto, Y., Singlet oxygen quenching ability of astaxanthin esters from the green alga Haematococcus pluvialis (1999) J. Biotechnol. Lett., 21, pp. 265-269; Kono, Y., Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide-dismutase (1978) Arch. Biochem. Biophys., 186, pp. 189-195; Liu, Y., Peterson, D.A., Kimura, H., Schubert, D., Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction (1997) J. Neurochem., 69, pp. 581-593; Luck, H., Catalase (1978) Methods of Enzymatic Analysis, pp. 885-893. , H.U. Bergmeyer, Academic Press New York, United States; Manczak, M., Park, B., Jung, Y., Reddy, P.H., Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochondrial dysfunction and oxidative damage (2004) Neuromol. Med., 5, pp. 147-162; Maurice, T., Lockhart, B.P., Privat, A., Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction (1996) Brain Res., 706, pp. 181-193; Muirhead, K.E.A., Borger, E., Aitken, L., Conway, S.J., Gunn-Moore, F.J., The consequences of mitochondrial amyloid beta-peptide in Alzheimers disease (2010) Biochem. J., 426, pp. 255-270; Nathalie, P., Jean-Noel, O., Processing of amyloid precursor protein and amyloid peptide neurotoxicity (2008) Curr. Alzheimer Res., 5, pp. 92-99; Numakawa, T., Adachi, N., Richards, M., Chiba, S., Kunugi, H., Brain-derived neurotrophic factor and glucocorticoids: Reciprocal influence on the central nervous system (2013) Neuroscience, 239, pp. 157-172; O'Bryant, S.E., Hobson, V., Hall, J.R., Waring, S.C., Chan, W., Massman, P., Lacritz, L., Diaz-Arrastia, R., Brain-derived neurotrophic factor levels in Alzheimers disease (2009) J. Alzheimers Dis., 17, pp. 337-341; Park, K.M., Bowers, W.J., Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction (2010) Cell Signal., 22, pp. 977-983; Prakash, A., Kumar, A., Lycopene protects against memory impairment and mito-oxidative damage induced by colchicine in rats: An evidence of nitric oxide signaling (2013) Eur. J. Pharmacol., 721, pp. 373-381; Prakash, A.K., Kumar, A., Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats (2009) J. Pharm. Pharmacol., 61, pp. 1665-1672; Readnower, R.D., Sauerbeck, A.D., Sullivan, P.G., Mitochondria, amyloid beta, and Alzheimers disease (2011) Int. J. Alzheimers Dis., 2011, p. 104545; Reddy, P.H., Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimers disease? (2013) Biochim. Biophys. Acta, 1832, pp. 67-75; Reddy, P.H., Beal, M.F., Are mitochondria critical in the pathogenesis of Alzheimers disease? (2005) Brain Res. Brain Res. Rev., 49, pp. 618-632; Ruan, C.-J., Zhang, L., Chen, D.-H., Li, Z., Du, G.-H., Sun, L., Effects of trans-2,4-dimethoxystibene against the neurotoxicity induced by Aβ25-35 both in vitro and in vivo (2010) Neurosci. Res., 67, pp. 209-214; Saadipour, K., Yang, M., Lim, Y., Georgiou, K., Sun, Y., Keating, D., Liu, J., Zhou, X.F., Amyloid beta1-42 (Abeta42) up-regulates the expression of sortilin via the p75(NTR) /RhoA signaling pathway (2013) J. Neurochem., 127, pp. 152-162; Saxena, G., Patro, I.K., Nath, C., ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor (2011) Behav. Brain Res., 224, pp. 50-57; Seo, J.Y., Masamune, A., Shimosegawa, T., Kim, H., Protective effect of lycopene on oxidative stress-induced cell death of pancreatic acinar cells (2009) Ann. N. Y. Acad. Sci., 1171, pp. 570-575; Sharma, P., Jha, A.B., Dubey, R.S., Pessarakli, M., Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions (2012) J. Bot., , (Article ID 217037); Sottocasa, G.L., Kuylenstierna, B., Ernster, L., Bergstrand, A., An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study (1967) J. Cell Biol., 32, pp. 415-438; Sun, H., Zhang, J., Zhang, L., Liu, H., Zhu, H., Yang, Y., Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats (2010) Curr. Neurovasc. Res., 7, pp. 268-280; Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Beta-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways (2005) J. Neurochem., 92, pp. 628-636; Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Koylu, E., Yalcin, A., Nicotinamide treatment reduces the levels of oxidative stress, apoptosis and PARP-1 activity in Abeta(1-42) induced rat model of Alzheimers disease (2013) Free Radic. Res., 48, pp. 146-158; Wang, H., Yu, Y., Chen, W., Cui, Y., Luo, T., Ma, J., Jiang, X.C., Qin, S., PLTP deficiency impairs learning and memory capabilities partially due to alteration of amyloid-β metabolism in old mice (2014) J. Alzheimers Dis., 39, pp. 79-88; Wills, E.D., Mechanisms of lipid peroxide formation in animal tissues (1966) Biochem. J., 99, pp. 667-676; Yi, F., He, X., Wang, D., Lycopene protects against MPP(+)-induced cytotoxicity by maintaining mitochondrial function in SH-SY5Y cells (2013) Neurochem. Res., 38, pp. 1747-1757",Article,Scopus,2-s2.0-84906966961
"Garai K., Verghese P.B., Baban B., Holtzman D.M., Frieden C.","The binding of apolipoprotein e to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation",2014,"Biochemistry","53","40",,"6323","6331",,3,10.1021/bi5008172,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908032605&partnerID=40&md5=300889abd4336b115d5f51336e603fd8","Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 South Euclid AvenueSt. Louis, MO, United States; Department of Neurology, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States; TIFR Centre for Interdisciplinary Sciences, 21 Brundavan ColonyNarsingi, Hyderabad, India; C2N Diagnostics, Center for Emerging TechnologiesSt. Louis, MO, United States","Garai, K., Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 South Euclid AvenueSt. Louis, MO, United States, TIFR Centre for Interdisciplinary Sciences, 21 Brundavan ColonyNarsingi, Hyderabad, India; Verghese, P.B., Department of Neurology, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States, C2N Diagnostics, Center for Emerging TechnologiesSt. Louis, MO, United States; Baban, B., Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 South Euclid AvenueSt. Louis, MO, United States; Holtzman, D.M., Department of Neurology, Hope Center for Neurological Disorders, Washington University School of MedicineSt. Louis, MO, United States; Frieden, C., Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 South Euclid AvenueSt. Louis, MO, United States","Deposition of amyloid-β (Aβ) in Alzheimers disease (AD) is strongly correlated with the APOE genotype. However, the role of apolipoprotein E (apoE) in Aβ aggregation has remained unclear. Here we have used different apoE preparations, such as recombinant protein or protein isolated from cultured astrocytes, to examine the effect of apoE on the aggregation of both Aβ1-40 and Aβ1-42. The kinetics of aggregation, measured by the loss of fluorescence of tetramethylrhodamine-labeled Aβ, is shown to be dramatically slowed by the presence of substoichiometric concentrations of apoE. Using these concentrations, we conclude that apoE binds primarily to and affects the growth of oligomers that lead to the nuclei required for fibril growth. At higher apoE concentrations, the protein also binds to Aβ fibrils, resulting in fibril stabilization and a slower rate of fibril growth. The aggregation of Aβ1-40 is dependent on the apoE isoform, being the most dramatic for apoE4 and less so for apoE3 and apoE2. Our results indicate that the detrimental role of apoE4 in AD could be related to apoE-induced stabilization of the soluble but cytotoxic oligomeric forms and intermediates of Aβ, as well as fibril stabilization. © 2014 American Chemical Society.",,"Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D., Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease (1993) Proc. Natl. Acad. Sci. U.S.A., 90, pp. 1977-1981; Corder, E.H., Saunders, A.M., Pericak-Vance, M.A., Roses, A.D., There is a pathologic relationship between ApoE-ε4 and Alzheimers disease (1995) Arch. Neurol., 52, pp. 650-651; Ma, J., Yee, A., Brewer, H.B., Jr., Das, S., Potter, H., Amyloid-associated proteins 1-antichymotrypsin and apolipoprotein e promote assembly of Alzheimer β-protein into filaments (1994) Nature, 372, pp. 92-94; Wisniewski, T., Frangione, B., Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid (1992) Neurosci. Lett., 135, pp. 235-238; Wisniewski, T., Castano, E.M., Golabek, A., Vogel, T., Frangione, B., Acceleration of Alzheimers fibril formation by apolipoprotein e in vitro (1994) Am. J. Pathol., 145, pp. 1030-1035; Evans, K.C., Berger, E.P., Cho, C.G., Weisgraber, K.H., Lansbury, P.T., Jr., Apolipoprotein e is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease (1995) Proc. Natl. Acad. Sci. U.S.A., 92, pp. 763-767; Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadanian, M., Sartorius, L.J., Mackey, B., Paul, S.M., Apolipoprotein e isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimers disease (2000) Proc. Natl. Acad. Sci. U.S.A., 97, pp. 2892-2897; Belinson, H., Lev, D., Masliah, E., Michaelson, D.M., Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits (2008) J. Neurosci., 28, pp. 4690-4701; Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K.W., Takeda, S., Banerji, A.O., Mitani, A., Hyman, B.T., Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide (2012) J. Neurosci., 32, pp. 15181-15192; Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.Y., Karlo, J.C., Zinn, A.E., Casali, B.T., Landreth, G.E., ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models (2012) Science, 335, pp. 1503-1506; Verghese, P.B., Castellano, J.M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Holtzman, D.M., ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 1807-E1816; Biere, A.L., Ostaszewski, B., Stimson, E.R., Hyman, B.T., Maggio, J.E., Selkoe, D.J., Amyloid β-Peptide is Transported on Lipoproteins and Albumin in Human Plasma (1996) J. Biol. Chem., 271, pp. 32916-32922; Fagan, A.M., Younkin, L.H., Morris, J.C., Fryer, J.D., Cole, T.G., Younkin, S.G., Holtzman, D.M., Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein e genotype (2000) Ann. Neurol., 48, pp. 201-210; Tai, L.M., Bilousova, T., Jungbauer, L., Roeske, S.K., Youmans, K.L., Yu, C., Poon, W.W., Ladu, M.J., Levels of soluble apolipoprotein E/amyloid-β complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples (2013) J. Biol. Chem., 288, pp. 5914-5916; Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., Ikeda, K., Apolipoprotein e immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers disease and kuru plaque amyloid in Creutzfeldt-Jakob disease (1991) Brain Res., 541, pp. 163-166; Ladu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., Frail, D.E., Isoform-specific binding of apolipoprotein e to β-amyloid (1994) J. Biol. Chem., 269, pp. 23403-23406; Cerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J.M., Raussens, V., High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimers disease (2011) FASEB J., 25, pp. 1585-1595; Ly, S., Altman, R., Petrlova, J., Lin, Y., Hilt, S., Huser, T., Laurence, T.A., Voss, J.C., Binding of apolipoprotein e inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy (2013) J. Biol. Chem., 288, pp. 11628-11635; Hatters, D.M., Peters-Libeu, C.A., Weisgraber, K.H., Apolipoprotein e structure: Insights into function (2006) Trends Biochem. Sci., 31, pp. 445-454; Chen, J., Li, Q., Wang, J., Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions (2011) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 14813-14818; Peters-Libeu, C.A., Newhouse, Y., Hall, S.C., Witkowska, H.E., Weisgraber, K.H., Apolipoprotein E-dipalmitoylphosphatidylcholine particles are ellipsoidal in solution (2007) J. Lipid Res., 48, pp. 1035-1044; Garai, K., Sahoo, B., Kaushalya, S.K., Desai, R., Maiti, S., Zinc lowers amyloid-β toxicity by selectively precipitating aggregation intermediates (2007) Biochemistry, 46, pp. 10655-10663; Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Ashe, K.H., Natural oligomers of the amyloid-β protein specifically disrupt cognitive function (2005) Nat. Neurosci., 8, pp. 79-84; Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., Selkoe, D.J., Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration (2011) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 5819-5824; Carter, D.B., The interaction of amyloid-β with ApoE (2005) Subcell. Biochem., 38, pp. 255-272; Garai, K., Frieden, C., Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 3321-3326; Garai, K., Mustafi, S.M., Baban, B., Frieden, C., Structural differences between apolipoprotein E3 and E4 as measured by 19F NMR (2010) Protein Sci., 19, pp. 66-74; Garai, K., Baban, B., Frieden, C., Dissociation of apoE oligomers to monomers is required for high affinity binding to phospholipid vesicles (2011) Biochemistry, 50, pp. 2550-2558; Zhang, Y., Vasudevan, S., Sojitrawala, R., Zhao, W., Cui, C., Xu, C., Fan, D., Wang, J., A monomeric, biologically active, full-length human apolipoprotein e (2007) Biochemistry, 46, pp. 10722-10732; Schneeweis, L.A., Koppaka, V., Lund-Katz, S., Phillips, M.C., Axelsen, P.H., Structural Analysis of Lipoprotein e Particles (2005) Biochemistry, 44, pp. 12525-12534; Huang, R.Y.C., Garai, K., Frieden, C., Gross, M.L., Hydrogen/Deuterium Exchange and Electron-Transfer Dissociation Mass Spectrometry Determine the Interface and Dynamics of Apolipoprotein e Oligomerization (2011) Biochemistry, 50, pp. 9273-9282; Xue, W.F., Radford, S.E., An imaging and systems modeling approach to fibril breakage enables prediction of amyloid behavior (2013) Biophys. J., 105, pp. 2811-2819; Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., Mintun, M.A., APOE predicts amyloid-β but not tau Alzheimer pathology in cognitively normal aging (2010) Ann. Neurol., 67, pp. 122-131; Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M.B., Holtzman, D.M., Zlokovic, B.V., ApoE isoform-specific disruption of amyloid β peptide clearance from mouse brain (2008) J. Clin. Invest., 118, pp. 4002-4013; Ladu, M.J., Shah, J.A., Reardon, C.A., Getz, G.S., Bu, G., Hu, J., Guo, L., Van Eldik, L.J., Apolipoprotein e and apolipoprotein e receptors modulate Aβ-induced glial neuroinflammatory responses (2001) Neurochem. Int., 39, pp. 427-434; Bien-Ly, N., Gillespie, A.K., Walker, D., Yoon, S.Y., Huang, Y., Reducing human apolipoprotein e levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice (2012) J. Neurosci., 32, pp. 4803-4811; Sadowski, M.J., Pankiewicz, J., Scholtzova, H., Mehta, P.D., Prelli, F., Quartermain, D., Wisniewski, T., Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimers disease (2006) Proc. Natl. Acad. Sci. U.S.A., 103, pp. 18787-18792; Lee, J., Culyba, E.K., Powers, E.T., Kelly, J.W., Amyloid-β forms fibrils by nucleated conformational conversion of oligomers (2011) Nat. Chem. Biol., 7, pp. 602-609; Knowles, T.P., Waudby, C.A., Devlin, G.L., Cohen, S.I., Aguzzi, A., Vendruscolo, M., Terentjev, E.M., Dobson, C.M., An analytical solution to the kinetics of breakable filament assembly (2009) Science, 326, pp. 1533-1537; Cohen, S.I., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., Knowles, T.P., Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 9758-9763; Xue, W.-F., Hellewell, A.L., Gosal, W.S., Homans, S.W., Hewitt, E.W., Radford, S.E., Fibril Fragmentation Enhances Amyloid Cytotoxicity (2009) J. Biol. Chem., 284, pp. 34272-34282; Webster, S., Rogers, J., Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation (1996) J. Neurosci. Res., 46, pp. 58-66; Chauhan, A., Pirttila, T., Mehta, P., Chauhan, V.P., Wisniewski, H.M., Effect of cerebrospinal fluid from normal and Alzheimers patients with different apolipoprotein e phenotypes on in vitro aggregation of amyloid β-protein (1996) J. Neurol. Sci., 141, pp. 54-58; Beffert, U., Poirier, J., ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation (1998) NeuroReport, 9, pp. 3321-3323; Castano, E.M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R.A., Soto, C., Frangione, B., Fibrillogenesis in Alzheimers disease of amyloid β peptides and apolipoprotein e (1995) Biochem. J., 306 (PART 2), pp. 599-604; Bitan, G., Lomakin, A., Teplow, D.B., Amyloid β-protein oligomerization: Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins (2001) J. Biol. Chem., 276, pp. 35176-35184; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimers disease (2009) Nat. Chem., 1, pp. 326-331; Koffie, R.M., Hashimoto, T., Tai, H.C., Kay, K.R., Serrano-Pozo, A., Joyner, D., Hou, S., Spires-Jones, T.L., Apolipoprotein E4 effects in Alzheimers disease are mediated by synaptotoxic oligomeric amyloid-β (2012) Brain, 135, pp. 2155-2168; Kim, J., Eltorai, A.E., Jiang, H., Liao, F., Verghese, P.B., Kim, J., Stewart, F.R., Holtzman, D.M., Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) J. Exp. Med., 209, pp. 2149-2156; Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Roses, A.D., Binding of human apolipoprotein e to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease (1993) Proc. Natl. Acad. Sci. U.S.A., 90, pp. 8098-8102; Tanaka, M., Vedhachalam, C., Sakamoto, T., Dhanasekaran, P., Phillips, M.C., Lund-Katz, S., Saito, H., Effect of Carboxyl-Terminal Truncation on Structure and Lipid Interaction of Human Apolipoprotein E4 (2006) Biochemistry, 45, pp. 4240-4247; Hoshino, T., Mahmood, I., Mori, K., Matsuzaki, K., Binding and Aggregation Mechanism of Amyloid β-Peptides onto the GM1 Ganglioside-Containing Lipid Membrane (2013) J. Phys. Chem. B, 117, pp. 8085-8094; Frieden, C., Garai, K., Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimers disease (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 8913-8918",Article,Scopus,2-s2.0-84908032605
"Ulens C., Spurny R., Thompson A.J., Alqazzaz M., Debaveye S., Han L., Price K., Villalgordo J.M., Tresadern G., Lynch J.W., Lummis S.C.R.","The prokaryote ligand-gated ion channel ELIC captured in a pore blocker-bound conformation by the Alzheimer's disease drug memantine",2014,"Structure","22","10",,"1399","1407",,1,10.1016/j.str.2014.07.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908159544&partnerID=40&md5=79571ea0171ddc928e3c6ddcdfc72c0c","Laboratory of Structural Neurobiology, KU LeuvenLeuven, Belgium; Department of Biochemistry, University of CambridgeCambridge, United Kingdom; Queensland Brain Institute, University of QueenslandBrisbane, QLD, Australia; VillaPharma ResearchMurcia, Spain; Molecular Sciences, Janssen R and DBeerse, Belgium","Ulens, C., Laboratory of Structural Neurobiology, KU LeuvenLeuven, Belgium; Spurny, R., Laboratory of Structural Neurobiology, KU LeuvenLeuven, Belgium; Thompson, A.J., Department of Biochemistry, University of CambridgeCambridge, United Kingdom; Alqazzaz, M., Department of Biochemistry, University of CambridgeCambridge, United Kingdom; Debaveye, S., Laboratory of Structural Neurobiology, KU LeuvenLeuven, Belgium; Han, L., Queensland Brain Institute, University of QueenslandBrisbane, QLD, Australia; Price, K., Department of Biochemistry, University of CambridgeCambridge, United Kingdom; Villalgordo, J.M., VillaPharma ResearchMurcia, Spain; Tresadern, G., Molecular Sciences, Janssen R and DBeerse, Belgium; Lynch, J.W., Queensland Brain Institute, University of QueenslandBrisbane, QLD, Australia; Lummis, S.C.R., Department of Biochemistry, University of CambridgeCambridge, United Kingdom","Pentameric ligand-gated ion channels (pLGIC) catalyze the selective transfer of ions across the cell membrane in response to a specific neurotransmitter. A variety of chemically diverse molecules, including the Alzheimers drug memantine, block ion conduction at vertebrate pLGICs by plugging the channel pore. We show that memantine has similar potency in ELIC, a prokaryotic pLGIC, when it contains an F16S pore mutation. X-ray crystal structures, using both memantine and its derivative, Br-memantine, reveal that the ligand is localized at the extracellular entryway of the channel pore, and the pore is in a more closed conformation than wild-type ELIC in both the presence and absence of memantine. However, using voltage clamp fluorometry we observe fluorescence changes in opposite directions during channel activation and pore block, revealing an additional conformational transition not apparent from the crystal structures. These results have important implications for drugs such as memantine, which block channel pores. © 2014 Elsevier Ltd. All rights reserved.",,"Adams, P.R., Voltage jump analysis of procaine action at frog end-plate (1977) J. Physiol., 268, pp. 291-318; Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Grosse-Kunstleve, R.W., PHENIX: A comprehensive Python-based system for macromolecular structure solution (2010) Acta Crystallogr. D Biol. Crystallogr., 66, pp. 213-221; Alqazzaz, M., Thompson, A.J., Price, K.L., Breitinger, H.-G., Lummis, S.C.R., Cys-loop receptor channel blockers also block GLIC (2011) Biophys. J., 101, pp. 2912-2918; Aracava, Y., Pereira, E.F.R., Maelicke, A., Albuquerque, E.X., Memantine blocks alpha7∗ nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons (2005) J. Pharmacol. Exp. Ther., 312, pp. 1195-1205; Bocquet, N., Nury, H., Baaden, M., Le Poupon, C., Changeux, J.-P., Delarue, M., Corringer, P.-J., X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation (2009) Nature, 457, pp. 111-114; Bouzat, C., New insights into the structural bases of activation of Cys-loop receptors (2012) J. Physiol. Paris, 106, pp. 23-33; Buisson, B., Bertrand, D., Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor (1998) Mol. Pharmacol., 53, pp. 555-563; Chen, V.B., Arendall, W.B., III, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, D.C., MolProbity: All-atom structure validation for macromolecular crystallography (2010) Acta Crystallogr. D Biol. Crystallogr., 66, pp. 12-21; Dahan, D.S., Dibas, M.I., Petersson, E.J., Auyeung, V.C., Chanda, B., Bezanilla, F., Dougherty, D.A., Lester, H.A., A fluorophore attached to nicotinic acetylcholine receptor beta M2 detects productive binding of agonist to the alpha delta site (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 10195-10200; Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of Coot (2010) Acta Crystallogr. D Biol. Crystallogr., 66, pp. 486-501; Gonzalez-Gutierrez, G., Lukk, T., Agarwal, V., Papke, D., Nair, S.K., Grosman, C., Mutations that stabilize the open state of the Erwinia chrisanthemi ligand-gated ion channel fail to change the conformation of the pore domain in crystals (2012) Proc. Natl. Acad. Sci. USA, 109, pp. 6331-6336; Hibbs, R.E., Gouaux, E., Principles of activation and permeation in an anion-selective Cys-loop receptor (2011) Nature, 474, pp. 54-60; Hilf, R.J.C., Dutzler, R., X-ray structure of a prokaryotic pentameric ligand-gated ion channel (2008) Nature, 452, pp. 375-379; Hilf, R.J.C., Dutzler, R., Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel (2009) Nature, 457, pp. 115-118; Hilf, R.J.C., Bertozzi, C., Zimmermann, I., Reiter, A., Trauner, D., Dutzler, R., Structural basis of open channel block in a prokaryotic pentameric ligand-gated ion channel (2010) Nat. Struct. Mol. Biol., 17, pp. 1330-1336; Kabsch, W., XDS (2010) Acta Crystallogr. D Biol. Crystallogr., 66, pp. 125-132; Oliver, D., Ludwig, J., Reisinger, E., Zoellner, W., Ruppersberg, J.P., Fakler, B., Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells (2001) Mol. Pharmacol., 60, pp. 183-189; Pan, J., Chen, Q., Willenbring, D., Yoshida, K., Tillman, T., Kashlan, O.B., Cohen, A., Tang, P., Structure of the pentameric ligand-gated ion channel ELIC cocrystallized with its competitive antagonist acetylcholine (2012) Nat. Commun., 3, p. 714; Pless, S.A., Dibas, M.I., Lester, H.A., Lynch, J.W., Conformational variability of the glycine receptor M2 domain in response to activation by different agonists (2007) J. Biol. Chem., 282, pp. 36057-36067; Prevost, M.S., Sauguet, L., Nury, H., Van Renterghem, C., Huon, C., Poitevin, F., Baaden, M., Corringer, P.-J., A locally closed conformation of a bacterial pentameric proton-gated ion channel (2012) Nat. Struct. Mol. Biol., 19, pp. 642-649; Price, K.L., Lummis, S.C.R., FlexStation examination of 5-HT3 receptor function using Ca2+ - And membrane potential-sensitive dyes: Advantages and potential problems (2005) J. Neurosci. Methods, 149, pp. 172-177; Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., Parsons, C.G., The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner (2001) Neurosci. Lett., 306, pp. 81-84; Rogawski, M.A., Wenk, G.L., The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease (2003) CNS Drug Rev., 9, pp. 275-308; Sauguet, L., Shahsavar, A., Poitevin, F., Huon, C., Menny, A., Nemecz À., Haouz, A., Delarue, M., Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation (2014) Proc. Natl. Acad. Sci. USA, 111, pp. 966-971; Schnell, J.R., Chou, J.J., Structure and mechanism of the M2 proton channel of influenza A virus (2008) Nature, 451, pp. 591-595; Sine, S.M., End-plate acetylcholine receptor: Structure, mechanism, pharmacology, and disease (2012) Physiol. Rev., 92, pp. 1189-1234; Smart, O.S., Neduvelil, J.G., Wang, X., Wallace, B.A., Sansom, M.S., HOLE: A program for the analysis of the pore dimensions of ion channel structural models (1996) J Mol Graph, 14, pp. 354-360; Spurny, R., Ramerstorfer, J., Price, K., Brams, M., Ernst, M., Nury, H., Verheij, M., Bertrand, S., Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines (2012) Proc. Natl. Acad. Sci. USA, 109, pp. 3028-E3034; Spurny, R., Billen, B., Howard, R.J., Brams, M., Debaveye, S., Price, K.L., Weston, D.A., Bertrand, S., Multisite binding of a general anesthetic to the prokaryotic pentameric Erwinia chrysanthemi ligand-gated ion channel (ELIC) (2013) J. Biol. Chem., 288, pp. 8355-8364; Stouffer, A.L., Acharya, R., Salom, D., Levine, A.S., Di Costanzo, L., Soto, C.S., Tereshko, V., Degrado, W.F., Structural basis for the function and inhibition of an influenza virus proton channel (2008) Nature, 451, pp. 596-599; Thompson, A.J., Alqazzaz, M., Ulens, C., Lummis, S.C.R., The pharmacological profile of ELIC, a prokaryotic GABA-gated receptor (2012) Neuropharmacology, 63, pp. 761-767; Wang, Q., Pless, S.A., Lynch, J.W., Ligand- and subunit-specific conformational changes in the ligand-binding domain and the TM2-TM3 linker of alpha1 beta2 gamma2 GABAA receptors (2010) J. Biol. Chem., 285, pp. 40373-40386; Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., McCoy, A., Overview of the CCP4 suite and current developments (2011) Acta Crystallogr. D Biol. Crystallogr., 67, pp. 235-242; Zimmermann, I., Dutzler, R., Ligand activation of the prokaryotic pentameric ligand-gated ion channel ELIC (2011) PLoS Biol., 9, p. 1001101; Zimmermann, I., Marabelli, A., Bertozzi, C., Sivilotti, L.G., Dutzler, R., Inhibition of the prokaryotic pentameric ligand-gated ion channel ELIC by divalent cations (2012) PLoS Biol., 10, p. 1001429",Article,Scopus,2-s2.0-84908159544
"Cheng C.","Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis",2014,"The journals of gerontology. Series A, Biological sciences and medical sciences","69","10",,"1299","1305",,1,10.1093/gerona/glu073,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922222735&partnerID=40&md5=101edcd04ecb6afa183708ba8f57326a","Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Department of Psychiatry and; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan. Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan; Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan; Department of Psychiatry and Department of Neuropsychiatry, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Department of Psychiatry and Department of Psychiatry, National Yang-Ming University, Taipei, Taiwan. Center for Neuropsychiatric research, National Health Research Institutes, Miaoli, Taiwan. thlan@ym.edu.tw","Cheng, C., Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Department of Psychiatry and, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan. Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan, Department of Psychiatry and Department of Neuropsychiatry, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, Department of Psychiatry and Department of Psychiatry, National Yang-Ming University, Taipei, Taiwan. Center for Neuropsychiatric research, National Health Research Institutes, Miaoli, Taiwan. thlan@ym.edu.tw","BACKGROUND: Type 2 diabetes (T2D) has been shown to increase dementia risk, but few studies evaluated the relationship between antidiabetic treatment and dementia.METHODS: We followed up 67,731 participants who were nondemented, nondiabetic, aged 65 or over at baseline from January 2004 to December 2009, to observe the onset of T2D (median follow-up 2.4 years), and to compare the risk of the development of dementia associated with particular types of antidiabetic medication among participants with T2D who had solely one type of antidiabetic agents throughout the follow-up period (median follow-up for participants with T2D 3.1 years).RESULTS: The hazard ratio for dementia diagnosis in the new-onset T2D participants compared with the non-T2D participants was 1.56 (95%CI: 1.39-2.18). The relative rate of dementia was 5.31 (95% CI: 1.89-14.96) for participants taking thiazolidinediones (n = 28) and 1.22 (95% CI: 0.78-1.91) for those taking sulfonylureas (n = 796) compared to those taking metformin (n = 1,033). The risk of dementia was higher in ever (n = 841) versus never users (n = 4,579) of thiazolidinediones: 1.44 (95% CI: 1.12-1.86).CONCLUSIONS: Diabetes is associated with an increased risk of dementia. The risk effect becomes weaker provided that participants take sulfonylureas or metformin rather than thiazolidinediones for a longer period. © The Author 2014. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.","Alzheimers; Cognition.; Diabetes; Drug related; Medication; Risk factors",,Article,Scopus,2-s2.0-84922222735
"Do T.D., Economou N.J., Chamas A., Buratto S.K., Shea J.-E., Bowers M.T.","Interactions between amyloid-β and tau fragments promote aberrant aggregates: Implications for amyloid toxicity",2014,"Journal of Physical Chemistry B","118","38",,"11220","11230",,,10.1021/jp506258g,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907588691&partnerID=40&md5=5b647fe2554625fdb08aa29dd3846d03","Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States; Department of Physics, University of CaliforniaSanta Barbara, CA, United States","Do, T.D., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States; Economou, N.J., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States; Chamas, A., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States; Buratto, S.K., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States; Shea, J.-E., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States, Department of Physics, University of CaliforniaSanta Barbara, CA, United States; Bowers, M.T., Department of Chemistry and Biochemistry, University of CaliforniaSanta Barbara, CA, United States","We have investigated at the oligomeric level interactions between Aβ(25-35) and Tau(273-284), two important fragments of the amyloid-β and Tau proteins, implicated in Alzheimers disease. We are able to directly observe the coaggregation of these two peptides by probing the conformations of early heteroligomers and the macroscopic morphologies of the aggregates. Ion-mobility experiment and theoretical modeling indicate that the interactions of the two fragments affect the self-assembly processes of both peptides. Tau(273-284) shows a high affinity to form heteroligomers with existing Aβ(25-35) monomer and oligomers in solution. The configurations and characteristics of the heteroligomers are determined by whether the population of Aβ(25-35) or Tau(273-284) is dominant. As a result, two types of aggregates are observed in the mixture with distinct morphologies and dimensions from those of pure Aβ(25-35) fibrils. The incorporation of some Tau into β-rich Aβ(25-35) oligomers reduces the aggregation propensity of Aβ(25-35) but does not fully abolish fibril formation. On the other hand, by forming complexes with Aβ(25-35), Tau monomers and dimers can advance to larger oligomers and form granular aggregates. These heteroligomers may contribute to toxicity through loss of normal function of Tau or inherent toxicity of the aggregates themselves. © 2014 American Chemical Society.",,"Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., Hof, P.R., Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative Disorders (2000) Brain Res. Rev., 33, pp. 95-130; Binder, L.I., Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Berry, R.W., Tau, Tangles, and Alzheimers Disease (2005) Biochim. Biophys. Acta, 1739, pp. 216-223; Wolfe, M.S., Tau Mutations in Neurodegenerative Diseases (2009) J. Biol. Chem., 284, pp. 6021-6025; Goedert, M., Spillantini, M.G., Tau Mutations in Frontotemporal Dementia Ftdp-17 and Their Relevance for Alzheimers Disease (2000) Biochim. Biophys. Acta, 1502, pp. 110-121; Hardy, J., Selkoe, D.J., The Amyloid Hypothesis of Alzheimers Disease: Progress and Problems on the Road to Therapeutics (2002) Science, 297, pp. 353-356; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid-β Protein Oligomerization and the Importance of Tetramers and Dodecamers in the Aetiology of Alzheimers Disease (2009) Nat. Chem., 1, pp. 326-331; Laganowsky, A., Liu, C., Sawaya, M.R., Whitelegge, J.P., Park, J., Zhao, M.L., Pensalfini, A., Eisenberg, D., Atomic View of a Toxic Amyloid Small Oligomer (2012) Science, 335, pp. 1228-1231; Gotz, J., Chen, F., Van Dorpe, J., Nitsch, R.M., Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ 42 Fibrils (2001) Science, 293, pp. 1491-1495; Lee, H.G., Zhu, X.W., Castellani, R.J., Nunomura, A., Perry, G., Smith, M.A., Amyloid-β in Alzheimer Disease: The Null Versus the Alternate Hypotheses (2007) J. Pharmacol. Exp. Ther., 321, pp. 823-829; Giannakopoulos, P., Herrmann, F.R., Bussiere, T., Bouras, C., Kovari, E., Perl, D.P., Morrison, J.H., Hof, P.R., Tangle and Neuron Numbers, but Not Amyloid Load, Predict Cognitive Status in Alzheimers Disease (2003) Neurology, 60, pp. 1495-1500; Williams, T.L., Serpell, L.C., Membrane and Surface Interactions of Alzheimers Aβ Peptide - Insights into the Mechanism of Cytotoxicity (2011) FEBS J., 278, pp. 3905-3917; Bokvist, M., Lindstrom, F., Watts, A., Grobner, G., Two Types of Alzheimers β-Amyloid (1-40) Peptide Membrane Interactions: Aggregation Preventing Transmembrane Anchoring Versus Accelerated Surface Fibril Formation (2004) J. Mol. Biol., 335, pp. 1039-1049; Laferla, F.M., Green, K.N., Oddo, S., Intracellular Amyloid-β in Alzheimers Disease (2007) Nat. Rev. Neurosci., 8, pp. 499-509; Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Vabulas, R.M., Amyloid-Like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions (2011) Cell, 144, pp. 67-78; King, M.E., Kan, H.M., Baas, P.W., Erisir, A., Glabe, C.G., Bloom, G.S., Tau-Dependent Microtubule Disassembly Initiated by Prefibrillar β-Amyloid (2006) J. Cell Biol., 175, pp. 541-546; Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., McGowan, E., Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP (2001) Science, 293, pp. 1487-1491; Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., Selkoe, D.J., Soluble Amyloid β-Protein Dimers Isolated from Alzheimer Cortex Directly Induce Tau Hyperphosphorylation and Neuritic Degeneration (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 5819-5824; Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., Mandelkow, E.M., Amyloid-β Oligomers Induce Synaptic Damage Via Tau-Dependent Microtubule Severing by TTLL6 and Spastin (2013) EMBO J., 32, pp. 2920-2937; Zheng, W.H., Bastianetto, S., Mennicken, F., Ma, W., Kar, S., Amyloid-β Peptide Induces Tau Phosphorylation and Loss of Cholinergic Neurons in Rat Primary Septal Cultures (2002) Neuroscience, 115, pp. 201-211; Ma, Q.L., Yang, F., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Cole, G.M., β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate Via C-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin (2009) J. Neurosci., 29, pp. 9078-9089; Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., Ikeuchi, T., Hyperphosphorylation of Tau Induced by Naturally Secreted Amyloid-B at Nanomolar Concentrations is Modulated by Insulin-Dependent AKT-GSK3β Signaling Pathway (2012) J. Biol. Chem., 287, pp. 35222-35233; Ittner, L.M., Gotz, J., Amyloid-Beta and Tau - A Toxic Pas de Deux in Alzheimers Disease (2011) Nat. Rev. Neurosci., 12, pp. 65-72; Guo, J.-P., Arai, T., Miklossy, J., McGeer, P.L., Aβ and Tau Form Soluble Complexes That May Promote Self Aggregation of Both into the Insoluble Forms Observed in Alzheimers Disease (2006) Proc. Natl. Acad. Sci. U. S. A., 103, pp. 1953-1958; Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., Ferreira, A., Tau is Essential to β-Amyloid-Induced Neurotoxicity (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 6364-6369; Busciglio, J., Lorenzo, A., Yeh, J., Yankner, B.A., β-Amyloid Fibrils Induce Tau-Phosphorylation and Loss of Microtubule-Binding (1995) Neuron, 14, pp. 879-888; Ferreira, A., Lu, Q., Orecchio, L., Kosik, K.S., Selective Phosphorylation of Adult Tau Isoforms in Mature Hippocampal Neurons Exposed to Fibrillar Aβ (1997) Mol. Cell. Neurosci., 9, pp. 220-234; Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., Yamaguchi, H., Activation of Tau Protein Kinase I/Glycogen Synthase Kinase-3beta by Amyloid-β Peptide (25-35) Enhances Phosphorylation of Tau in Hippocampal Neurons (1998) Neurosci. Res., 31, pp. 317-323; Wei, G., Jewett, A.I., Shea, J.E., Structural Diversity of Dimers of the Alzheimer Amyloid-β(25-35) Peptide and Polymorphism of the Resulting Fibrils (2010) Phys. Chem. Chem. Phys., 12, pp. 3622-3629; Wei, G.H., Shea, J.E., Effects of Solvent on the Structure of the Alzheimer Amyloid-β (25-35) Peptide (2006) Biophys. J., 91, pp. 1638-1647; Larini, L., Gessel, M.M., Lapointe, N.E., Do, T.D., Bowers, M.T., Feinstein, S.C., Shea, J.E., Initiation of Assembly of Tau(273-284) and Its K280 Mutant: An Experimental and Computational Study (2013) Phys. Chem. Chem. Phys., 15, pp. 8916-8928; Larini, L., Shea, J.E., Role of B-Hairpin Formation in Aggregation: The Self-Assembly of the Amyloid-β (25-35) Peptide (2012) Biophys. J., 103, pp. 576-586; Bleiholder, C., Do, T.D., Wu, C., Economou, N.J., Bernstein, S.S., Buratto, S.K., Shea, J.-E., Bowers, M.T., Ion Mobility Spectrometry Reveals the Mechanism of Amyloid Formation of Aβ(25-35) and Its Modulation by Inhibitors at the Molecular Level: Epigallocatechin Gallate and Scyllo-Inositol (2013) J. Am. Chem. Soc., 135, pp. 16926-16937; Kittner, M., Knecht, V., Disordered Versus Fibril-Like Amyloid-β (25-35) Dimers in Water: Structure and Thermodynamics (2010) J. Phys. Chem. B, 114, pp. 15288-15295; Clementi, M.E., Marini, S., Coletta, M., Orsini, F., Giardina, B., Misiti, F., Aβ(31-35) and Aβ(25-35) Fragments of Amyloid Beta-Protein Induce Cellular Death through Apoptotic Signals: Role of the Redox State of Methionine-35 (2005) FEBS Lett., 579, pp. 2913-2918; Pike, C.J., Walencewiczwasserman, A.J., Kosmoski, J., Cribbs, D.H., Glabe, C.G., Cotman, C.W., Structure-Activity Analyses of β-Amyloid Peptides - Contributions of the Beta-25-35 Region to Aggregation and Neurotoxicity (1995) J. Neurochem., 64, pp. 253-265; Moore, C.L., Huang, M.H., Robbennolt, S.A., Voss, K.R., Combs, B., Gamblin, T.C., Goux, W.J., Secondary Nucleating Sequences Affect Kinetics and Thermodynamics of Tau Aggregation (2011) Biochemistry, 50, pp. 10876-10886; Li, W.K., Lee, V.M.Y., Characterization of Two VQIXXK Motifs for Tau Fibrillization in Vitro (2006) Biochemistry, 45, pp. 15692-15701; Goux, W.J., Kopplin, L., Nguyen, A.D., Leak, K., Rutkofsky, M., Shanmuganandam, V.D., Sharma, D., Kirschner, D.A., The Formation of Straight and Twisted Filaments from Short Tau Peptides (2004) J. Biol. Chem., 279, pp. 26868-26875; Von Bergen, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E.M., Mandelkow, E., Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure (2001) J. Biol. Chem., 276, pp. 48165-48174; Miller, Y., Ma, B., Nussinov, R., Synergistic Interactions between Repeats in Tau Protein and Aβ Amyloids May Be Responsible for Accelerated Aggregation Via Polymorphic States (2011) Biochemistry, 50, pp. 5172-5181; Levy, S.F., Leboeuf, A.C., Massie, M.R., Jordan, M.A., Wilson, L., Feinstein, S.C., Three- and Four-Repeat Tau Regulate the Dynamic Instability of Two Distinct Microtubule Subpopulations in Qualitatively Different Manners. Implications for Neurodegeneration (2005) J. Biol. Chem., 280, pp. 13520-13528; Colletiera, J.-P., Laganowskya, A., Landau, M., Zhao, M., Soriaga, A.B., Goldschmidt, L., Flot, D., Eisenberg, D., Molecular Basis for Amyloid-β Polymorphism (2011) Proc. Natl. Acad. Sci. U. S. A., 108, pp. 16938-16943; Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., Thompson, M.J., Eisenberg, D., Atomic Structures of Amyloid Cross-β Spines Reveal Varied Steric Zippers (2007) Nature, 447, pp. 453-457; Kemper, P.R., Dupuis, N.F., Bowers, M.T., A New, Higher Resolution, Ion Mobility Mass Spectrometer (2009) Int. J. Mass. Spectrom., 287, pp. 46-57; Mason, E.A., (1988) Transport Properties of Ions in Gases, , 99 th ed. John Wiley & Sons: New York; Do, T.D., Economou, N.J., Lapointe, N.E., Kincannon, W.M., Bleiholder, C., Feinstein, S.C., Teplow, D.B., Bowers, M.T., Factors That Drive Peptide Assembly and Fibril Formation: Experimental and Theoretical Analysis of Sup35 NNQQNY Mutants (2013) J. Phys. Chem. B, 117, pp. 8436-8446; Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., Gromacs 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation (2008) J. Chem. Theory Comput., 4, pp. 435-437; Spoel, D.V.D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., Berendsen, H.J.C., Gromacs: Fast, Flexible, and Free (2005) J. Comput. Chem., 26, pp. 1701-1718; Damm, W., Halgren, T.A., Murphy, R.B., Smondyrev, A.M., Friesner, R.A., Jorgensen, W.L., OPLS-2002: A New Version of the OPLS-AA Force Field (2002) Abstr. Pap. Am. Chem. Soc., 224, pp. 471-U471; Halgren, T.A., Murphy, R.B., Jorgensen, W.L., Friesner, R.A., Extending the OPLS-AA Force Field for Ligand Functionality (2000) Abstr. Pap. Am. Chem. Soc., 220, pp. 277-U277; Jorgensen, W.L., Tirado-Rives, J., The Opls Potential Functions for Proteins. Energy Minimizations for Crystals of Cyclic Peptides and Crambin (1988) J. Am. Chem. Soc., 110, pp. 1657-1666; Kaminski, G.A., Friesner, R.A., Tirado-Rives, J., Jorgensen, W.L., OPLS-AA/L Force Field for Proteins: Using Accurate Quantum Mechanical Data (2000) Abstr. Pap. Am. Chem. Soc., 220, pp. 279-U279; Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., Comparison of Simple Potential Functions for Simulating Liquid Water (1983) J. Chem. Phys., 79, pp. 926-935; Mesleh, M.F., Hunter, J.M., Shvartsburg, A.A., Schatz, G.C., Jarrold, M.F., Structural Information from Ion Mobility Measurements: Effects of the Long Range Potential (1996) J. Phys. Chem. A, 100, pp. 16082-16086; Shvartsburg, A.A., Jarrold, M.F., An Exact Hard-Spheres Scattering Model for the Mobilities of Polyatomic Ions (1996) Chem. Phys. Lett., 261, pp. 86-91; Bleiholder, C., Dupuis, N.F., Wyttenbach, T., Bowers, M.T., Ion Mobility-Mass Spectrometry Reveals a Conformational Conversion from Random Assembly to β-Sheet in Amyloid Fibril Formation (2011) Nat. Chem., 3, pp. 172-177; Sugita, Y., Okamoto, Y., Replica-Exchange Molecular Dynamics Method for Protein Folding (1999) Chem. Phys. Lett., 314, pp. 141-151; Anderson, S.E., Bleiholder, C., Brocker, E.R., Stang, P.J., Bowers, M.T., Novel, A., Projection Approximation Algorithm for the Fast and Accurate Computation of Molecular Collision Cross Sections (III): Application to Supramolecular Coordination-Driven Assemblies with Complex Shapes (2012) Int. J. Mass. Spectrom., 330, pp. 78-84; Bleiholder, C., Contreras, S., Bowers, M.T., Novel, A., Projection Approximation Algorithm for the Fast and Accurate Computation of Molecular Collision Cross Sections (IV). Application to Polypeptides (2013) Int. J. Mass. Spectrom., 354, pp. 275-280; Wiltzius, J.J.W., Landau, M., Nelson, R., Sawaya, M.R., Apostol, M.I., Goldschmidt, L., Soriaga, A.B., Eisenberg, D., Molecular Mechanisms for Protein-Encoded Inheritance (2009) Nat. Struct. Mol. Biol., 16, pp. 973-U998; Do, T.D., Lapointe, N.E., Sangwan, S., Teplow, D.B., Feinstein, S.C., Sawaya, M.R., Eisenberg, D.S., Bowers, M.T., Factors That Drive Peptide Assembly from Native to Amyloid Structures: Experimental and Theoretical Analysis of [Leu-5]-Enkephalin Mutants (2014) J. Phys. Chem. B, 118, pp. 7247-7256; Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Takashima, A., Granular Tau Oligomers as Intermediates of Tau Filaments (2007) Biochemistry, 46, pp. 3856-3861",Article,Scopus,2-s2.0-84907588691
"Leandro G.S., Sykora P., Bohr V.A.","The impact of base excision DNA repair in age-related neurodegenerative diseases",2015,"Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis",,,,"","",,,10.1016/j.mrfmmm.2014.12.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921960935&partnerID=40&md5=ce15d614bdcd9678781af73782a8b7df","Laboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program (NIA IRP), Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224, United States; Department of Genetics, Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, SP 14049-900, Brazil","Leandro, G.S., Laboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program (NIA IRP), Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224, United States, Department of Genetics, Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto, SP 14049-900, Brazil; Sykora, P., Laboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program (NIA IRP), Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224, United States; Bohr, V.A., Laboratory of Molecular Gerontology, National Institute on Aging, Intramural Research Program (NIA IRP), Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224, United States","The aging process and several age-related neurodegenerative disorders have been linked to elevated levels of DNA damage induced by ROS and deficiency in DNA repair mechanisms. DNA damage induced by ROS is a byproduct of cellular respiration and accumulation of damage over time, is a fundamental aspect of a main theory of aging. Mitochondria have a pivotal role in generating cellular oxidative stress, and mitochondrial dysfunction has been associated with several diseases. DNA base excision repair is considered the major pathway for repair of oxidized bases in DNA both in the nuclei and in mitochondria, and in neurons this mechanism is particularly important because non-diving cells have limited back-up DNA repair mechanisms. An association between elevated oxidative stress and a decrease in BER is strongly related to the aging process and has special relevance in age-related neurodegenerative diseases. Here, we review the role of DNA repair in aging, focusing on the implications of the DNA base excision repair pathways and how alterations in expression of these DNA repair proteins are related to the aging process and to age-related neurodegenerative diseases. © 2015.","Aging; Alzheimers disease; DNA repair; Neurodegeneration; Oxidative damage; Oxidative stress",,Article in Press,Scopus,2-s2.0-84921960935
"Xue X., Wang L.-R., Sato Y., Jiang Y., Berg M., Yang D.-S., Nixon R.A., Liang X.-J.","Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of alzheimers disease",2015,"Nano Letters","14","9",,"5110","5117",,,10.1021/nl501839q,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84914160024&partnerID=40&md5=fc60200f62218c4ce36dd1f00647efaa","CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of ChinaBeijing, China; Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States; Department of Psychiatry, New York University Langone Medical CenterNew York, NY, United States; Department of Cell Biology, New York University Langone Medical CenterNew York, NY, United States; CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology of ChinaBeijing, China","Xue, X., CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of ChinaBeijing, China, Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States; Wang, L.-R., CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology of ChinaBeijing, China; Sato, Y., Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States, Department of Psychiatry, New York University Langone Medical CenterNew York, NY, United States; Jiang, Y., Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States, Department of Psychiatry, New York University Langone Medical CenterNew York, NY, United States; Berg, M., Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States; Yang, D.-S., Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States, Department of Psychiatry, New York University Langone Medical CenterNew York, NY, United States; Nixon, R.A., Center for Dementia Research, Nathan Kline Institute, 140 Old Orangeburg RoadOrangeburg, NY, United States, Department of Psychiatry, New York University Langone Medical CenterNew York, NY, United States, Department of Cell Biology, New York University Langone Medical CenterNew York, NY, United States; Liang, X.-J., CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of ChinaBeijing, China","Defective autophagy in Alzheimers disease (AD) promotes disease progression in diverse ways. Here, we demonstrate impaired autophagy flux in primary glial cells derived from CRND8 mice that overexpress mutant amyloid precursor protein (APP). Functionalized single-walled carbon nanotubes (SWNT) restored normal autophagy by reversing abnormal activation of mTOR signaling and deficits in lysosomal proteolysis, thereby facilitating elimination of autophagic substrates. These findings suggest SWNT as a novel neuroprotective approach to AD therapy. © 2014 American Chemical Society.","Alzheimers disease; autophagy; primary glia; Single-walled carbon nanotubes","Rubinsztein, D.C., Codogno, P., Levine, B., (2012) Nat. Rev. Drug Discovery, 11 (9), pp. 709-730; Hochfeld, W.E., Lee, S., Rubinsztein, D.C., (2013) Acta Pharmacol. Sin., 34 (5), pp. 600-604; Nixon, R.A., (2013) Nat. Med., 19 (8), pp. 983-997; Keefer, E.W., Botterman, B.R., Romero, M.I., Rossi, A.F., Gross, G.W., (2008) Nat. Nanotechnol., 3 (7), pp. 434-439; Skakalova, V., Kaiser, A.B., Dettlaff-Weglikowska, U., Hrncarikova, K., Roth S.O, (2005) J. Phys. Chem. B, 109 (15), pp. 7174-7181; Randeniya, L.K., Bendavid, A., Martin, P.J., Tran, C.D., (2010) Small, 6 (16), pp. 1806-1811; Kim, P., Shi, L., Majumdar, A., McEuen, P.L., (2001) Phys. Rev. Lett., 87 (21), p. 215502; Treacy, M.M., Krishnan, A., Yianilos, P.N., (2000) Microsc. Microanal., 6 (4), pp. 317-323; Nardelli, M.B., I, Y.B., Bernholc, J., (1997) Phys. Rev. B, 57, pp. 4277-4280; Kyle, S., Saha, S., (2014) Adv. Healthcare Mater.; Akhter, S., Ahmad, I., Ahmad, M.Z., Ramazani, F., Singh, A., Rahman, Z., Ahmad, F.J., Kok, R.J., (2013) Curr. Cancer Drug Targets, 13 (4), pp. 362-378; Bokara, K.K., Kim, J.Y., Lee, Y.I., Yun, K., Webster, T.J., Lee, J.E., (2013) Anat. Cell Biol., 46 (2), pp. 85-92; Uo, M., Akasaka, T., Watari, F., Sato, Y., Tohji, K., (2011) Dent. Mater. J., 30 (3), pp. 245-263; Vardharajula, S., Ali, S.Z., Tiwari, P.M., Eroglu, E., Vig, K., Dennis, V.A., Singh, S.R., (2012) Int. J. Nanomed., 7, pp. 5361-5374; Liu, H.L., Zhang, Y.L., Yang, N., Zhang, Y.X., Liu, X.Q., Li, C.G., Zhao, Y., Yang, P., (2011) Cell Death Dis., 2, p. 159; Park, E.J., Zahari, N.E., Lee, E.W., Song, J., Lee, J.H., Cho, M.H., Kim, J.H., (2014) Toxicol. in Vitro; Yu, K.N., Kim, J.E., Seo, H.W., Chae, C., Cho, M.H., (2013) J. Toxicol. Environ. Health, Part A, 76 (23), pp. 1282-1292; Tsukahara, T., Matsuda, Y., Usui, Y., Haniu, H., (2013) Biochem. Biophys. Res. Commun., 440 (2), pp. 348-353; Bari, S., Chu, P.P., Lim, A., Fan, X., Gay, F.P., Bunte, R.M., Lim, T.K., Hwang, W.Y., (2013) Nanomedicine, 9 (8), pp. 1304-1316; Lee, H.J., Park, J., Yoon, O.J., Kim, H.W., Lee Do, Y., Kim Do, H., Lee, W.B., Kim, S.S., (2011) Nat. Nanotechnol, 6 (2), pp. 121-125; Boya, P., Reggiori, F., Codogno, P., (2013) Nat. Cell Biol., 15 (7), pp. 713-720; Kundu, M., Thompson, C.B., (2008) Annu. Rev. Pathol., 3, pp. 427-455; Shacka, J.J., Roth, K.A., Zhang, J., (2008) Front Biosci., 13, pp. 718-736; Klionsky, D.J., Abeliovich, H., Agostinis, P., Agrawal, D.K., Aliev, G., Askew, D.S., Baba, M., Ballabio, A., (2008) Autophagy, 4 (2), pp. 151-175; Holtzman, D.M., Morris, J.C., Goate, A.M., (2011) Sci. Transl. Med., 3 (77), p. 77sr71; Zhu, Z., Yan, J., Jiang, W., Yao, X.G., Chen, J., Chen, L., Li, C., Shen, X., (2013) J. Neurosci., 33 (32), pp. 13138-13149; Marambaud, P., Zhao, H., Davies, P., (2005) J. Biol. Chem., 280 (45), pp. 37377-37382; Rubinsztein, D.C., Marino, G., Kroemer, G., (2011) Cell, 146 (5), pp. 682-695; Di Malta, C., Fryer, J.D., Settembre, C., Ballabio, A., (2012) Autophagy, 8 (12), pp. 1871-1872; Von Bernhardi, R., (2007) Neurotoxic. Res., 12 (4), pp. 215-232; Mandrekar, S., Jiang, Q., Lee, C.Y., Koenigsknecht-Talboo, J., Holtzman, D.M., Landreth, G.E., (2009) J. Neurosci., 29 (13), pp. 4252-4262; Bolmont, T., Haiss, F., Eicke, D., Radde, R., Mathis, C.A., Klunk, W.E., Kohsaka, S., Calhoun, M.E., (2008) J. Neurosci., 28 (16), pp. 4283-4292; Kraft, A.W., Hu, X., Yoon, H., Yan, P., Xiao, Q., Wang, Y., Gil, S.C., Restivo, J.L., (2013) FASEB J., 27 (1), pp. 187-198; Wang, L.R., Xue, X., Hu, X.M., Wei, M.Y., Zhang, C.Q., Ge, G.L., Liang, X.J., (2014) Small; Chen, G., Ke, Z., Xu, M., Liao, M., Wang, X., Qi, Y., Zhang, T., Shi, X., (2012) Autophagy, 8 (11), pp. 1577-1589; Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R., French, J., (2001) J. Biol. Chem., 276 (24), pp. 21562-21570; Yang, D.S., Stavrides, P., Mohan, P.S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S.D., Jiang, Y., (2011) Brain, 134 (PART 1), pp. 258-277; Hyde, L.A., Kazdoba, T.M., Grilli, M., Lozza, G., Brusa, R., Zhang, Q., Wong, G.T., Parker, E.M., (2005) Behav. Brain Res., 160 (2), pp. 344-355; Wang, L., Zhang, L., Xue, X., Ge, G., Liang, X., (2012) Nanoscale, 4 (13), pp. 3983-3989; Berger, Z., Ravikumar, B., Menzies, F.M., Oroz, L.G., Underwood, B.R., Pangalos, M.N., Schmitt, I., Okane, C.J., (2006) Hum. Mol. Genet., 15 (3), pp. 433-442; Tanida, I., Minematsu-Ikeguchi, N., Ueno, T., Kominami, E., (2005) Autophagy, 1 (2), pp. 84-91; Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Aguirre-Ghiso, J.A., (2012) Autophagy, 8 (4), pp. 445-544; Wolfe, D.M., Lee, J.H., Kumar, A., Lee, S., Orenstein, S.J., Nixon, R.A., (2013) Eur. J. Neurosci, 37 (12), pp. 1949-1961; Rong, Y., Liu, M., Ma, L., Du, W., Zhang, H., Tian, Y., Cao, Z., Zhang, C., (2012) Nat. Cell Biol., 14 (9), pp. 924-934; Rubinsztein, D.C., Nixon, R.A., (2010) Proc. Natl. Acad. Sci. U.S.A., 107 (49), p. 181. , author reply E182; Caccamo, A., Majumder, S., Richardson, A., Strong, R., Oddo, S., (2010) J. Biol. Chem., 285 (17), pp. 13107-13120; Lee, C.M., Huang, S.T., Huang, S.H., Lin, H.W., Tsai, H.P., Wu, J.Y., Lin, C.M., Chen, C.T., (2011) Nanomedicine, 7 (1), pp. 107-114; Seleverstov, O., Zabirnyk, O., Zscharnack, M., Bulavina, L., Nowicki, M., Heinrich, J.M., Yezhelyev, M., Bader, A., (2006) Nano Lett., 6 (12), pp. 2826-2832; Zhang, Y., Zheng, F., Yang, T., Zhou, W., Liu, Y., Man, N., Zhang, L., Zhang, Y., (2012) Nat. Mater., 11 (9), pp. 817-826; Yu, L., Lu, Y., Man, N., Yu, S.H., Wen, L.P., (2009) Small, 5 (24), pp. 2784-2787; Fabbro, A., Villari, A., Laishram, J., Scaini, D., Toma, F.M., Turco, A., Prato, M., Ballerini, L., (2012) ACS Nano, 6 (3), pp. 2041-2055; Cellot, G., Cilia, E., Cipollone, S., Rancic, V., Sucapane, A., Giordani, S., Gambazzi, L., Scaini, D., (2009) Nat. Nanotechnol, 4 (2), pp. 126-133; Fan, L., Feng, C., Zhao, W., Qian, L., Wang, Y., Li, Y., (2012) Nano Lett., 12 (7), pp. 3668-3673; Yang, D.S., Stavrides, P., Mohan, P.S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S.D., Jiang, Y., (2011) Autophagy, 7 (7), pp. 788-789; Sardiello, M., Palmieri, M., Di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Polishchuk, R.S., (2009) Science, 325 (5939), pp. 473-477; Settembre, C., Di Malta, C., Polito, V.A., Garcia Arencibia, M., Vetrini, F., Erdin, S., Erdin, S.U., Colella, P., (2011) Science, 332 (6036), pp. 1429-1433; Meng, L., Chen, R., Jiang, A., Wang, L., Wang, P., Li, C.Z., Bai, R., Chen, C., (2013) Small, 9 (910), pp. 1786-1798; Lee, J.H., Yu, W.H., Kumar, A., Lee, S., Mohan, P.S., Peterhoff, C.M., Wolfe, D.M., Sovak, G., (2010) Cell, 141 (7), pp. 1146-1158; Nixon, R.A., Yang, D.S., (2012) Cold Spring Harbor Perspect. Biol., 4, p. 10; Shvedova, A.A., Kapralov, A.A., Feng, W.H., Kisin, E.R., Murray, A.R., Mercer, R.R., St Croix, C.M., Konduru, N.V., (2012) PLoS One, 7 (3), p. 30923; Ali-Boucetta, H., Kostarelos, K., (2013) Adv. Drug Delivery Rev., 65 (15), pp. 2111-2119; Al-Jamal, K.T., Gherardini, L., Bardi, G., Nunes, A., Guo, C., Bussy, C., Herrero, M.A., Kostarelos, K., (2011) Proc. Natl. Acad. Sci. U.S.A., 108 (27), pp. 10952-10957",Article,Scopus,2-s2.0-84914160024
"Abraham J.N., Kedracki D., Prado E., Gourmel C., Maroni P., Nardin C.","Effect of the interaction of the amyloid β (1-42) peptide with short single-stranded synthetic nucleotide sequences: Morphological characterization of the inhibition of fibrils formation and fibrils disassembly",2014,"Biomacromolecules","15","9",,"3253","3258",,1,10.1021/bm501004q,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907500655&partnerID=40&md5=66fc1f07954d4bc59612d32f32c73b91","Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland; School of Medicine, Institute of Inflammation and Repair, University of Manchester, Oxford RoadManchester, United Kingdom","Abraham, J.N., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland; Kedracki, D., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland; Prado, E., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland; Gourmel, C., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland, School of Medicine, Institute of Inflammation and Repair, University of Manchester, Oxford RoadManchester, United Kingdom; Maroni, P., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland; Nardin, C., Faculty of Sciences, Department of Inorganic and Analytical Chemistry, University of Geneva, Quai Ernest Ansermet 30Geneva 4, Switzerland","The formation of extracellular neuritic plaques in the brain of individuals who suffered from Alzheimers disease (AD) is a major pathological hallmark. These plaques consist of filamentous aggregates of the amyloid beta (1-42) (Aβ42) proteins. Prevention or reduction of the formation of these fibrils is foreseen as a potential therapeutic approach. In this context, we investigated the interactions between the Aβ42 protein and polyions, in particular short single stranded synthetic nucleotide sequences. The experimental outcomes reported herein provide evidence of the inhibition of amyloid fibril genesis as well as disassembly of existing fibers through electrostatic interaction between the Aβ42 protein and the polyions. Since the polyions and the Aβ42 protein are oppositely charged, the formation of (micellar) inter polyelectrolyte complexes (IPECs) is likely to occur. Since the abnormal deposition of amyloid fibers is an archetype of AD, the outcomes of these investigations, supported by atomic force microscopy imaging in the dry and liquid states, as well as circular dichroism and Fourier transform infrared spectroscopy, are of high interest for the development of future strategies to cure a disease that concerns an ever aging population. © 2014 American Chemical Society.",,"Teplow, D.B., (1998) Amyloid: Int. J. Exp. Clin. Invest., 5, pp. 121-142; Härd, T.J., (2014) Phys. Chem. Lett., 5, pp. 607-614; Lednev, I.K., (2014) Biophys. J., 106, pp. 1433-1435; Hamley, I.W., (2007) Angew. Chem., Int. Ed., 46, pp. 8128-8147; Adler, J., Scheidt, H.A., Krüger, M., Thomas, L., Huster, D., (2014) Phys. Chem. Chem. Phys., 16, pp. 7461-7471; Auer, S., (2014) J. Phys. Chem. B, 118, pp. 5289-5299; Rawat, A., Nagaraj, R., (2014) Curr. Top. Med. Chem., 14, pp. 740-746; Morris, R., Mucke, L., (2006) Nature, 440, pp. 284-285; Glabe, C.G., (2009) Open Biol. J., 2, pp. 222-227; Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J.I., Smith, S.O., (2010) Nat. Struct. Mol. Biol., 17, pp. 561-567; Klimov, D.K., Thirumalai, D., (2003) Structure, 11, pp. 295-307; Liao, M.Q., Tzeng, Y.J., Chang, L.Y., Huang, H.B., Lin, T.H., Chyan, C.L., Chen, Y.C., (2007) FEBS Lett., 581, pp. 1161-1165; Hamodrakas, S.J., Liappa, C., Iconomidou, V.A., (2007) Int. J. Biol. Macromol., 41, pp. 295-300; Caughey, B., Lansbury, P.T., (2003) Ann. Rev. Neurosci., 26, pp. 267-298; Glabe, C.G., (2006) Neurobiol. Aging, 27, pp. 570-575; Stine, W.B., Dahlgren, K.N., Krafft, G.A., Ladu, M.J., (2003) J. Biol. Chem., 278, pp. 11612-11622; Jeong, J.S., Ansaloni, A., Mezzenga, R., Lashuel, H.A., Dietler, G., (2013) J. Mol. Biol., 425, pp. 1765-1781; Adamcik, J., Jung, J.-M., Flakowski, J., De Los Rios, P., Dietler, G., Mezzenga, R., (2010) Nat. Nanotechnol., 5, pp. 423-428; Drolle, E., Hane, F., Lee, B., Leonenko, Z., (2014) Drug Metab. Rev., 46, pp. 207-223; Lin, S.Y., Chu, H.L., (2003) Int. J. Biol. Macromol., 32, pp. 173-177; Armstrong, A.H., Chen, J., McKoy, A.F., Hecht, M.H., (2011), pp. 4058-4067Yin, J., Chen, R., Liu, C., (2009) Front. Biosci., pp. 5084-5106; Macedo, B., Millen, T.A., Braga, C.A.C.A., Gomes, M.P.B., Ferreira, P.S., Kraineva, J., Winter, R., Cordeiro, Y., (2012) Biochemistry, 51, pp. 5402-5413; Nandi, P.K., Nicole, J.-C., (2004) J. Mol. Biol., 344, pp. 827-837; Neddenriep, B., Calciano, A., Conti, D., Sauve, E., Paterson, M., Bruno, E., (2011) Open Biotechnol. J., 5, pp. 39-46; Luo, J., Abrahams, J.P., (2014) Chemistry, 20, pp. 2410-2419; Mäger, I., Roberts, T.C., Wood, M.J., El Andaloussi, S., (2014) Mol. Ther., 22, pp. 485-486; Pujadas, L., Rossi, D., Andrés, R., Teixeira, C.M., Serra-Vidal, B., Parcerisas, A., Maldonado, R., Soriano, E., (2014) Nat. Commun.; Hochberg, G.K.A., Ecroyd, H., Liu, C., Cox, D., Cascio, D., Sawaya, M.R., Collier, M.P., Laganowsky, A., (2014) Proc. Natl. Acad. Sci. U.S.A., 111, pp. 1562-E1570; Calamai, M., Kumita, J.R., Mifsud, J., Parrini, C., Ramazzotti, M., Ramponi, G., Taddei, N., Dobson, C.M., (2006) Biochemistry, 45, pp. 12806-12815; Barrantes, A., Camero, S., Garcia-Lucas, A., Navarro, P.J., Benitez, M.J., Jimenez, J.S., (2012) Curr. Alzheimer Res., 9, pp. 924-934; Barrantes, A., Rejas, M.T., Benitez, M.J., Jimenez, J.S., (2007) J. Alzheimers Dis., 12, pp. 345-355; Udomprasert, A., Bongiovanni, M.N., Sha, R., Sherman, W.B., Wang, T., Arora, P.S., Canary, J.W., Seeman, N.C., (2014) Nat. Nanotechnol., pp. 1-5; Schnitzler, T., Herrmann, A., (2012) Acc. Chem. Res., 45, pp. 1419-1430; Gour, N., Kedracki, D., Safir, I., Ngo, K.X., Vebert-Nardin, C., (2012) Chem. Commun., 48, pp. 5440-5442; Pergushov, D.V., Muller, A.H., Schacher, F.H., (2012) Chem. Soc. Rev., 41, pp. 6888-6901; Voets, I.K., De Keizer, A., Cohen Stuart, M.A., (2009) Adv. Colloid Interface Sci., pp. 147-148; Bayo-Puxan, N., Dufresne, M.H., Felber, A.E., Castagner, B., Leroux, J.C., (2011) J. Controlled Release, 156, pp. 118-127; Assarsson, A., Hellstrand, E., Cabaleiro-Lago, C., Linse, S., (2014) ACS Chem. Neurosci., 5, pp. 266-274; Ghosh, D., Dutta, P., Chakraborty, C., Singh, P.K., Anoop, A., Jha, N.N., Jacob, R.S., Maji, S.K., (2014) Langmuir, 30, pp. 3775-3786; Gress, A., Völkel, A., Schlaad, H., (2007) Macromolecules, 40, pp. 7928-7933; Hoogenboom, R., (2009) Angew. Chem., Int. Ed., 48, pp. 7978-7994; Sigurdsson, E.M., Calero, M., Gasset, M., (2012) Amyloid Proteins: Methods and Protocols, 849, p. 548. , 2 nd ed. Springer: New York; Sarroukh, R., Goormaghtigh, E., Ruysschaert, J.M., Raussens, V., (2013) Biochim. Biophys. Acta, 10 (38), p. 5; Kong Jilie, Y.S., (2007) Acta Biochim. Biophys. Sin., 39 (8), pp. 549-559; Goormaghtigh, E., Cabiaux, V., Ruysschaert, J.M., (1994) Subcell. Biochem., 23, pp. 329-362; Lin, S.-Y., Chu, H.-L., Wei, Y.-S., (2003) J. Biomol. Struct. Dyn., 20 (4), pp. 595-601; Cerf, E., Sarroukh, R., Tamamizu-Kato, S., Breydo, L., Derclaye, S., Dufrene, Y.F., Narayanaswami, V., Raussens, V., (2009) Biochem. J., 421 (3), pp. 415-423; Gan, H., Li, Y., Liu, H., Wang, S., Li, C., Yuan, M., Liu, X., Zhu, D., (2007) Biomacromolecules, 8, pp. 1723-1729",Article,Scopus,2-s2.0-84907500655
"Chojnacki J.E., Liu K., Yan X., Toldo S., Selden T., Estrada M., Rodriguez-Franco M.I., Halquist M.S., Ye D., Zhang S.","Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H- indol-3-yl)-ethyl]-Amide as a neuroprotectant for Alzheimers Disease by Hybridization of Curcumin and Melatonin",2014,"ACS Chemical Neuroscience","5","8",,"690","699",,4,10.1021/cn500081s,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906266231&partnerID=40&md5=3c153cf5f668ae7f9fa70c20c1bcee37","Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, United States; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, United States; Department of Physics, Virginia Commonwealth University, Richmond, VA 23298, United States; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, United States; Instituto de Química Médica - Consejo Superior de Investigaciones Científicas, C/Juan de la Cierva, 3 - 28006-Madrid, Spain","Chojnacki, J.E., Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, United States; Liu, K., Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, United States; Yan, X., Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, United States; Toldo, S., Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, United States; Selden, T., Department of Physics, Virginia Commonwealth University, Richmond, VA 23298, United States; Estrada, M., Instituto de Química Médica - Consejo Superior de Investigaciones Científicas, C/Juan de la Cierva, 3 - 28006-Madrid, Spain; Rodríguez-Franco, M.I., Instituto de Química Médica - Consejo Superior de Investigaciones Científicas, C/Juan de la Cierva, 3 - 28006-Madrid, Spain; Halquist, M.S., Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, United States; Ye, D., Department of Physics, Virginia Commonwealth University, Richmond, VA 23298, United States; Zhang, S., Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, United States","In our effort to develop effective neuroprotectants as potential treatments for Alzheimer""s disease (AD), hybrid compounds of curcumin and melatonin, two natural products that have been extensively studied in various AD models, were designed, synthesized, and biologically characterized. A lead hybrid compound (7) was discovered to show significant neuroprotection with nanomolar potency (EC<inf>50</inf> = 27.60 ± 9.4 nM) in MC65 cells, a cellular AD model. Multiple in vitro assay results established that 7 exhibited moderate inhibitory effects on the production of amyloid-β oligomers (AβOs) in MC65 cells, but not on the aggregation of Aβ species. It also exhibited significant antioxidative properties. Further mechanistic studies demonstrated that 7""s antioxidant effects correlate well with its neuroprotective potency for MC65 cells, and these effects might be due to its interference with the interactions of AβOs within the mitochondria of MC65 cells. Furthermore, 7 was confirmed to cross the blood-brain barrier (BBB) and deliver a sufficient amount to brain tissue after oral administration. Collectively, these results strongly support the hybridization approach as an efficient strategy to help identify novel scaffolds with a desired pharmacology, and strongly encourage further optimization of 7 to develop more potent neuroprotectants for AD. © 2014 American Chemical Society.","Alzheimer""s disease; curcumin; hybridization; melatonin; Neuroprotectants","2013 Alzheimer""s Disease Facts and Figures (2013) Alzheimer;s Dementia, 9, p. 208. , Alzheimer""s Association () - 245; Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer""s disease: Progress and problems on the road to therapeutics (2002) Science (New York, N.Y.), 297, pp. 353-356; Kirkitadze, M.D., Bitan, G., Teplow, D.B., Paradigm shifts in Alzheimer""s disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies (2002) J. Neurosci. Res., 69, pp. 567-577; Walsh, D.M., Selkoe, D.J., A beta oligomers - A decade of discovery (2007) J. Neurochem., 101, pp. 1172-1184; Selkoe, D.J., Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior (2008) Behav. Brain Res., 192, pp. 106-113; Bush, A.I., Drug development based on the metals hypothesis of Alzheimer""s disease (2008) J. Alzheimer""s Dis., 15, pp. 223-240; Zhu, X., Su, B., Wang, X., Smith, M.A., Perry, G., Causes of oxidative stress in Alzheimer disease (2007) Cell. Mol. Life Sci., 64, pp. 2202-2210; Viegas-Junior, C., Danuello, A., Da Silva Bolzani, V., Barreiro, E.J., Fraga, C.A., Molecular hybridization: A useful tool in the design of new drug prototypes (2007) Curr. Med. Chem., 14, pp. 1829-1852; Tietze, L.F., Bell, H.P., Chandrasekhar, S., Natural product hybrids as new leads for drug discovery (2003) Angew. Chem., Int. Ed., 42, pp. 3996-4028; Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Cole, G.M., Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo (2005) J. Biol. Chem., 280, pp. 5892-5901; Kim, J., Lee, H.J., Lee, K.W., Naturally occurring phytochemicals for the prevention of Alzheimer""s disease (2010) J. Neurochem., 112, pp. 1415-1430; The antiapoptotic activity of melatonin in neurodegenerative diseases (2009) CNS Neurosci. Ther., 15, pp. 345-357; Rosales-Corral, S.A., Acuna-Castroviejo, D., Coto-Montes, A., Boga, J.A., Manchester, L.C., Fuentes-Broto, L., Korkmaz, A., Reiter, R.J., Alzheimer""s disease: Pathological mechanisms and the beneficial role of melatonin (2012) J. Pineal Res., 52, pp. 167-202; Frautschy, S.A., Cole, G.M., Why pleiotropic interventions are needed for Alzheimer""s disease (2010) Mol. Neurobiol., 41, pp. 392-409; Pevet, P., Melatonin and biological rhythms (2000) Biol. Signals Recept., 9, pp. 203-212; Carpentieri, A., Diaz De Barboza, G., Areco, V., Peralta Lopez, M., Tolosa De Talamoni, N., New perspectives in melatonin uses (2012) Pharmacol. Res., 65, pp. 437-444; Zhou, J.N., Liu, R.Y., Kamphorst, W., Hofman, M.A., Swaab, D.F., Early neuropathological Alzheimer""s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels (2003) J. Pineal Res., 35, pp. 125-130; Hatfield, C.F., Herbert, J., Van Someren, E.J., Hodges, J.R., Hastings, M.H., Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer""s dementia (2004) Brain, 127, pp. 1061-1074; Rosales-Corral, S., Acuna-Castroviejo, D., Tan, D.X., Lopez-Armas, G., Cruz-Ramos, J., Munoz, R., Melnikov, V.G., Reiter, R.J., Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: A protective role for melatonin (2012) Oxid. Med. Cell. Longevity, 2012, p. 843649; Pandi-Perumal, S.R., Bahammam, A.S., Brown, G.M., Spence, D.W., Bharti, V.K., Kaur, C., Hardeland, R., Cardinali, D.P., Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes (2013) Neurotoxic. Res., 23, pp. 267-300; Hardeland, R., Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment (2012) Aging Dis., 3, pp. 194-225; Esatbeyoglu, T., Huebbe, P., Ernst, I.M., Chin, D., Wagner, A.E., Rimbach, G., Curcumin - From molecule to biological function (2012) Angew. Chem., Int. Ed., 51, pp. 5308-5332; Wong, Y.-S., Peuchmaur, M.A., Marechal, E., Botte, C., Vial, H.J., Saidani, N., (2009) Preparation of Novel Polyspirane Compounds for Treating Malaria or Toxoplasmosis, p. 122. , pp, Université Joseph Fourier, Grenoble, France; Sopher, B.L., Fukuchi, K., Kavanagh, T.J., Furlong, C.E., Martin, G.M., Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death (1996) Mol. Chem. Neuropathol., 29, pp. 153-168; Lenhart, J.A., Ling, X., Gandhi, R., Guo, T.L., Gerk, P.M., Brunzell, D.H., Zhang, S., ""clicked"" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: Design, synthesis, and biological characterization (2010) J. Med. Chem., 53, pp. 6198-6209; Liu, K., Gandhi, R., Chen, J., Zhang, S., Bivalent ligands targeting multiple pathological factors involved in Alzheimer""s disease (2012) ACS Med. Chem. Lett., 3, pp. 942-946; McClain, D.E., Kalinich, J.F., Ramakrishnan, N., Trolox inhibits apoptosis in irradiated MOLT-4 lymphocytes (1995) FASEB J., 9, pp. 1345-1354; Aruoma, O.I., Halliwell, B., Hoey, B.M., Butler, J., The antioxidant action of N-Acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid (1989) Free Radicals Biol. Med., 6, pp. 593-597; Atkuri, K.R., Mantovani, J.J., Herzenberg, L.A., Herzenberg, L.A., N-Acetylcysteine - A safe antidote for cysteine/glutathione deficiency (2007) Curr. Opin. Pharmacol., 7, pp. 355-359; Lezoualch, F., Skutella, T., Widmann, M., Behl, C., Melatonin prevents oxidative stress-induced cell death in hippocampal cells (1996) NeuroReport, 7, pp. 2071-2077; Ishimura, A., Ishige, K., Taira, T., Shimba, S., Ono, S., Ariga, H., Tezuka, M., Ito, Y., Comparative study of hydrogen peroxide- and 4-hydroxy-2-nonenal-induced cell death in HT22 cells (2008) Neurochem. Int., 52, pp. 776-785; Reale, M., Pesce, M., Priyadarshini, M., Kamal, M.A., Patruno, A., Mitochondria as an easy target to oxidative stress events in Parkinson""s disease (2012) CNS Neurol. Disord.: Drug Targets, 11, pp. 430-438; Hirst, J., King, M.S., Pryde, K.R., The production of reactive oxygen species by complex i (2008) Biochem. Soc. Trans., 36, pp. 976-980; Martin, L.J., Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis (2010) IDrugs, 13, pp. 568-580; Nazarewicz, R.R., Dikalova, A., Bikineyeva, A., Ivanov, S., Kirilyuk, I.A., Grigorev, I.A., Dikalov, S.I., Does scavenging of mitochondrial superoxide attenuate cancer prosurvival signaling pathways? (2013) Antioxid. Redox. Signaling, 19, pp. 344-349; Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP, and ROS: A mitochondrial love-hate triangle (2004) Am. J. Physiol.: Cell. Physiol., 287, pp. 817-833; Umeda, T., Maekawa, S., Kimura, T., Takashima, A., Tomiyama, T., Mori, H., Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice (2014) Acta Neuropathol., 127, pp. 685-698; De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Klein, W.L., Alzheimer""s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers (2008) Neurobiol. Aging, 29, pp. 1334-1347; Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., Selkoe, D.J., Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration (2011) Proc. Natl. Acad. Sci. U.S.A., 108, pp. 5819-5824; Klein, W.L., Synaptotoxic amyloid-beta oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer""s disease? (2013) J. Alzheimer""s Dis., 33 (SUPPL. 1), pp. 49-65; Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., High throughput artificial membrane permeability assay for blood-brain barrier (2003) Eur. J. Med. Chem., 38, pp. 223-232; Fernandez-Bachiller, M.I., Perez, C., Monjas, L., Rademann, J., Rodriguez-Franco, M.I., New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer""s disease, with cholinergic, antioxidant, and beta-Amyloid-reducing properties (2012) J. Med. Chem., 55, pp. 1303-1317; Stine, Jr.W.B., Dahlgren, K.N., Krafft, G.A., Ladu, M.J., In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis (2003) J. Biol. Chem., 278, pp. 11612-11622",Article,Scopus,2-s2.0-84906266231
"Viet M.H., Nguyen P.H., Derreumaux P., Li M.S.","Effect of the english familial disease mutation (H6R) on the monomers and dimers of Aβ40 and Aβ42",2014,"ACS Chemical Neuroscience","5","8",,"646","657",,3,10.1021/cn500007j,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84905376515&partnerID=40&md5=f8a4f0acbc8741d8213a2bc6cf986e40","Institute of Physics, Polish Academy of Sciences, Al. Lotnikow 32/46, 02-668 Warsaw, Poland; Laboratoire de Biochimie Theorique, UPR 9080 CNRS, Universite Paris 7, 13 rue Pierre et Marie Curie, 75005 Paris, France; Laboratoire de Biochimie Theorique, UPR 9080 CNRS, Universite Denis Diderot, Paris Sorbonne Cité 13 rue Pierre et Marie Curie, 75005 Paris, France; Institut Universitaire de France, Bvd Saint Michel, 75005 Paris, France; Institute for Computational Science and Technology, Quang Trung Software City, Tan Chanh Hiep Ward, District 12, Ho Chi Minh City, Viet Nam","Viet, M.H., Institute of Physics, Polish Academy of Sciences, Al. Lotnikow 32/46, 02-668 Warsaw, Poland; Nguyen, P.H., Laboratoire de Biochimie Theorique, UPR 9080 CNRS, Universite Paris 7, 13 rue Pierre et Marie Curie, 75005 Paris, France; Derreumaux, P., Laboratoire de Biochimie Theorique, UPR 9080 CNRS, Universite Denis Diderot, Paris Sorbonne Cité 13 rue Pierre et Marie Curie, 75005 Paris, France, Institut Universitaire de France, Bvd Saint Michel, 75005 Paris, France; Li, M.S., Institute of Physics, Polish Academy of Sciences, Al. Lotnikow 32/46, 02-668 Warsaw, Poland, Institute for Computational Science and Technology, Quang Trung Software City, Tan Chanh Hiep Ward, District 12, Ho Chi Minh City, Viet Nam","The self-Assembly of the amyloid beta (Aβ) peptides into senile plaques is the hallmark of Alzheimer""s disease. Recent experiments have shown that the English familial disease mutation (H6R) speeds up the fibril formation process of alloforms Aβ40 and Aβ42 peptides altering their toxicity to cells. We used all-Atom molecular dynamics simulations at microsecond time scales with the OPLS-AA force field and TIP4P explicit water model to study the structural dynamics of the monomer and dimer of H6R sequences of both peptides. The reason behind the self-Assembly acceleration is common that upon mutation the net charge is reduced leading to the weaker repulsive interaction between chains that facilitates the peptide association. In addition, our estimation of the solvation free energy shows that the mutation enhances the hydrophobicity of both peptides speeding up their aggregation. However, we can show that the acceleration mechanisms are different for different peptides: the rate of fibril formation of Aβ42 increases due to increased β-structure at the C-terminal in both monomer and dimer and enhanced stability of salt bridge Asp23-Lys28 in monomer, while the enhancement of turn at residues 25-29 and reduction of coil in regions 10-13, 26-19, and 30-34 would play the key role for Aβ40. Overall, our study provides a detailed atomistic picture of the H6R-mediated conformational changes that are consistent with the experimental findings and highlights the important role of the N-terminal in Aβ peptide aggregation. © 2014 American Chemical Society.","Alzheimers disease; Amyloid simulations; amyloid-β proteins; dimer; H6R mutation; molecular dynamics; monomer","Henderson, A.S., Jorm, A.F., (2002) Dementia, , Chapter 1, John Wiley & Sons Ltd. New York; Hardy, J., Selkoe, D.J., Medicine - The amyloid hypothesis of Alzheimer""s disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Citron, M., Strategies for disease modification in Alzheimer""s disease (2004) Nat. Rev. Neurosci., 5, pp. 677-685; Aguzzi, A., Oconnor, T., Protein aggregation diseases: Pathogenicity and therapeutic perspectives (2010) Nat. Rev. Drug Discovery, 9, pp. 237-248; Lue, L.F., Kou, Y.M., Roher, A.E., Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer""s disease (1999) Am. J. Pathol., 155, pp. 853-862; Querfurth, H.W., Laferla, F.M., Mechanisms of disease Alzheimer""s disease (2010) N. Engl. J. Med., 362, pp. 329-344; Cummings, J.L., Alzheimer""s Disease (2004) N. Engl. J. Med., 351, pp. 56-67; Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis (2003) Science, 300, pp. 486-489; Caughey, B., Lansbury, P.T., Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders (2003) Annu. Rev. Neurosci., 26, pp. 267-298; Walsh, D.M., Selkoe, D.J., Aβ oligomers - A decade of discovery (2007) J. Neurochem., 101, pp. 1172-1184; Chebaro, Y., Derreumaux, P., Targeting the early steps of Aβ16-22 protofibril disassembly by N-methylated inhibitors: A numerical study (2009) Proteins, 75, pp. 442-452; Anand, P., Nandel, F.S., Hansmann, U.H.E., The Alzheimer beta-Amyloid (A beta(1-39)) dimer in an implicit solvent (2008) J. Chem. Phys., 129, p. 195102; Berhanu, W.M., Hansmann, U.H.E., Structure and dynamics of amyloid-beta segmental polymorphisms (2012) PLoS One, 7, p. 41479; Wu, C., Bowers, M.T., Shea, J.E., Molecular structures of quiescently grown and brain-derived polymorphic fibrils of the Alzheimer amyloid A beta(9-40) peptide: A comparison to agitated fibrils (2010) PloS Comput. Biol., 6, p. 1000693; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer""s disease (2009) Nat. Chem., 1, pp. 326-331; Hendriks, L., Van Duijin, C.M., Cras, P., Cruts, M., Hul, W.V., Van Harskamp, F., Warren, A., Broekhoven, C.V., Presenil dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-Amyloid precursor protein gene (1992) Nat. Genet., 1, pp. 218-221; Levy, E., Carman, M.D., Fernandez-Madrid, I.J., Power, M.D., Lieberburg, I., Van Duinen, S.G., Bots, G.T.A.M., Frangione, B., Mutation of the Alzheimer""s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type (1990) Science, 1, pp. 1124-1126; Bugiani, O., Padovani, A., Magoni, M., Andora, G., Sgarzi, M., Savoiardo, M., Bizzi, A., Tagliavini, F., An Italian type of HCHWA (1998) Neurobiol. Aging, 19, p. 238; Kamino, K., Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region (1992) Am. J. Hum. Genet., 51, pp. 998-1014; Grabowski, T.J., Cho, H.S., Vonsattel, J.P., Rebeck, G.W., Greenberg, S.M., Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (2001) Ann. Nerol., 49, pp. 697-705; Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Mori, H., A new amyloid beta variant favoring oligomerization in Alzheimer""s-type dementia (2008) Ann. Neurol., 63, pp. 377-387; Massi, F., Straub, J.E., Probing the origins of increased activity of the E22Q ""dutch"" mutant Alzheimer""s beta-Amyloid peptide (2001) Biophys. J., 81, pp. 697-709; Cote, S., Derreumaux, P., Mousseau, N., Distinct morphologies for amyloid beta protein monomer: Aβ1-40, Aβ1-42, and Aβ1-40(D23N) (2011) J. Chem. Theor. Comp, 7, pp. 2584-2592; Lin, Y.-S., Pande, V.S., Effects of familial mutations on the monomer structure of Aβ42 (2012) Biophys. J., 103, pp. 47-L49; Huet, A., Derreumaux, P., Impact of the mutation A21G (Flemish variant) on Alzheimer""s β-Amyloid dimers by molecular dynamics simulations (2006) Biophys. J., 91, pp. 3829-3840; Coskuner, O., Wise-Scira, O., Perry, G., Kitahara, T., The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms (2013) ACS Chem. Neurosci., 4, pp. 310-320; Mitternacht, S., Staneva, I., Hard, T., Irback, A., Comparing the folding free-energy landscapes of Aβ42 variants with different aggregation properties (2010) Proteins, 78, pp. 2600-2608; Mitternacht, S., Staneva, I., Hard, T., Irback, A., Monte Carlo study of the formation and conformational properties of dimers of A beta 42 variants (2011) J. Mol. Biol., 410, pp. 357-367; Petkova, A.T., Yau, W.M., Tycko, R., Experimental constraints on quaternary structure in Alzheimer""s β-Amyloid Fibrils (2006) Biochemistry, 45, pp. 498-512; Paravastu, A.K., Leapman, R.D., Yau, W.M., Tycko, R., Molecular structural basis for polymorphism in Alzheimer""s β-Amyloid fibrils (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 18349-18354; Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Doeli, H., Schubert, D., Riek, R., 3D structure of Alzheimer""s amyloid-β(1-42) fibrils (2005) Proc. Natl. Acad. Sci. U.S.A., 102, pp. 17342-17347; Bertini, I., Gonnelli, L., Luchinat, C., Mao, J.F., Nesi, A., A new structural model of A beta(40) fibrils (2011) J. Am. Chem. Soc., 133, pp. 16013-16022; Scheidt, H.A., Morgado, I., Rothemund, S., Huster, D., Dynamics of amyloid beta fibrils revealed by solid-state NMR (2012) J. Biol. Chem., 287, pp. 2017-2021; Lu, J.X., Qiang, W., Yau, W.M., Schwieters, C.D., Meredith, S.C., Tycko, R., Molecular structure of beta-Amyloid fibrils in Alzheimer""s disease brain tissue (2013) Cell, 154, pp. 1257-1268; Janssen, J.C., Beck, J.A., Campbell, T.A., Dickinson, A., Fox, N.C., Harvey, R.J., Houlden, H., Collinge, J., Early onset familial Alzheimer""s disease: Mutation frequency in 31 families (2003) Neurology, 60, pp. 235-239; Hori, Y., Hashimoto, T., Wakutani, Y., Urakami, K., Nakashima, K., Condron, M.M., Tsubuki, S., Iwatsubo, T., The Tottori (D7N) and English (H6R) familial Alzheimer Disease mutations accelerate Aβ fibril formation without inscreasing protofibril formation (2007) J. Biol. Chem., 282, pp. 4916-4923; Chen, W.T., Hong, C.J., Lin, Y.T., Chang, W.H., Huang, H.T., Liao, J.Y., Chang, Y.J., Cheng, I.H., Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-Zinc/Copper assemblies (2012) PLoS One, 7, p. 35807; Wakutani, Y., Watanabe, K., Adachi, Y., Wada-Isoe, K., Urakami, K., Ninomiya, H., Saido, T.C., Nakashima, K., Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer""s disease (2004) J. Neurol., Neurosurg. Psychiatry, 75, pp. 1039-1042; Ono, K., Condron, M.M., Teplow, D.B., Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity (2010) J. Biol. Chem., 285, pp. 23186-23197; Fede, G.D., Catania, M., Morbin, M., Rossi, G., Suardi, S., Mazzoleni, G., Merlin, M., Tagliavini, F., Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis (2009) Science, 323, pp. 1473-1477; Lv, Z.J., Roychaudhuri, R., Condron, M.M., Teplow, D.B., Lyubchenko, Y.L., Mechanism of amyloid beta-protein dimerization determined using single-molecule AFM force spectroscopy (2013) Sci. Rep., 3, p. 02880; Nguyen, P.H., Tarus, B., Derreumaux, P., Familial Alzheimer A2V Mutation Reduces the Intrinsic Disorder and Completely Changes the Free Energy Landscape of the Aβ1-28 Monomer (2013) J. Phys. Chem. B, 118, pp. 501-510; Viet, M.H., Nguyen, P.H., Ngo, S.T., Li, M.S., Derreumaux, P., Effect of the Tottori Familial Disease Mutation (D7N) on the Monomers and Dimers of Aβ40 and Aβ42 (2013) ACS Chem. Neurosci., 4, pp. 1446-1457; Reddy, G., Straub, J.E., Thirumalai, D., Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Aβ peptides with implications for rates of fibril formation (2009) J. Phys. Chem. B, 113, pp. 1162-1172; Li, M.S., Co, N.T., Hu, C.K., Straub, J.E., Thirumalai, D., Determination of factors governing fibrillogenesis of polypeptide chains using lattice models (2010) Phys. Rev. Lett., 105, p. 218101; Sciarretta, K.L., Gordon, D.J., Petkova, A.T., Tycko, R., Meredith, S.C., Aβ40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid (2005) Biochemistry, 44, pp. 6003-6014; Bellesia, G., Shea, J.-E., Effect of β-sheet propensity on peptide aggregation (2009) J. Chem. Phys., 130, p. 145103; Nam, H.B., Kouza, M., Zung, H., Li, M.S., Relationship between population of the fibril-prone conformation in the monomeric state and oligomer formation times of peptides: Insights from all-Atom simulations (2010) J. Chem. Phys., 132, p. 165104; Gessel, M.M., Bernstein, S., Kemper, M., Teplow, D.B., Bowers, M.T., Familial Alzheimer""s Disease mutations differentially alter amyloid β-protein oligomerization (2012) ACS Chem. Neurosci., 3, pp. 909-918; Mesleh, M.F., Hunter, J.M., Shvartsburg, A.A., Schatz, G.C., Jarrold, M.F., Structural information from ion mobility measurements: Effects of the long range potential (1996) J. Phys. Chem., 100, p. 16082; Baumketner, A., Bernstein, S.L., Wyttenbach, T., Bitan, G., Teplow, D.B., Bowers, M.T., Shea, J.E., Amyloid β-protein monomer structure: A computational and experimental study (2006) Protein Sci., 15, pp. 420-428; Kollman, P., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Cheatham I T, E., Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models (2000) Acc. Chem. Res., 33, pp. 889-897; Nguyen, T.T., Mai, B.K., Li, M.S., Study of tamiflu sensitivity to variants of A/H5N1 virus using different force fields (2011) J. Chem. Inf. Model., 51, pp. 2266-2276; Viet, M.H., Li, M.S., Amyloid peptide Aβ40 inhibits aggregation of Aβ42: Evidence from molecular dynamics simulations (2012) J. Chem. Phys., 136, p. 245105; Sharp, K.A., Honig, B., Electrostatic interactions in macromolecules: Theory and applications. Annu. Rev. Biophys (1990) Biophys. Chem., 19, pp. 301-332; Baker, N.A., Sept, D., Joseph, S., Holst, M.J., McCammon, J.A., Electrostatics of nanosystems: Application to microtubules and the ribosome (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 10037-10041; Shrake, A., Rupley, J.A., Environment and exposure to solvent of protein atoms-lysozyme and insulin (1973) J. Mol. Biol., 79, pp. 351-371; Sitkoff, D., Sharp, K.A., Honig, B., Accurate calculation of hydration free energies using macroscopic solvent models (1994) J. Phys. Chem., 97, pp. 1978-1988; Maji, S.K., Loo, R.R.O., Inayathullah, M., Spring, S.M., Vollers, S.S., Condron, M.M., Bitan, G., Teplow, D.B., Amino Acid Position-specific Contributions to Amyloid beta-Protein Oligomerization (2009) J. Biol. Chem., 284, pp. 23580-23591; Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., Simmerling, C., Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters (2006) Proteins: Struct., Funct., Bioinf., 65, pp. 712-725; Jorgensen, J.W., Chandrasekhar, J., Madura, J.D., Imprey, R.W., Klein, M.L., Comparison of simple potential functions for simulating liquid water (1983) J. Chem. Phys., 79, p. 926; Van Gunsteren, W.F., Billeter, S.R., Eising, A.A., Hunenberger, P.H., Kruger, P., Mark, A.E., Scott, W.R.P., Tironi, I.G., (1996) Biomolecular Simulation: The GROMOS96 Manual and User Guide, , Vdf Hochschulverlag AG an der ETH Zurich, Zurich; Nguyen, T.T., Viet, M.H., Li, M.S., Effects of water models on binding affinity: Evidence from all-Atom simulation of binding of tamiflu to A/H5N1 neuraminidase (2014) Sci. World J., 2014, p. 536084; Coles, M., Bicknell, W., Watson, A.A., Fairlie, D.P., Craik, D.J., Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? (1998) Biochemistry, 37, pp. 11064-11077; Tomaselli, S., Esposito, V., Vangone, P., Van Nuland, N.A., Bonvin, A.M., Guerrini, R., Tancredi, T., Picone, D., The α-to-β conformational transition of Alzheimer""s Aβ-(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of β conformation seeding (2006) ChemBioChem, 7, pp. 257-267; Kaminski, G.A., Friesner, R.A., Evaluation and reparametrization of the OPSL-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides (2001) J. Phys. Chem. B, 105, pp. 6474-6487; Jorgensen, W.L., Madura, J.D., (1985) Mol. Phys., 56, pp. 1381-1392; PyMOL: The PyMOL Molecular Graphics System, , Version 1.3, Schrodinger, LLC; Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation (2008) J. Chem. Theory Comput., 4, pp. 435-447; Sgourakis, N.G., Yan, Y.L., McCallum, S.A., Wang, C.Y., Garcia, A.E., The Alzheimer""s peptides Aβ40 and 42 adopt distinct conformations in water: A combined MD/NMR study (2007) J. Mol. Biol., 368, pp. 1448-1457; Nguyen, P.H., Derreumaux, P., Li, M.S., Effects of all-Atom force fields on amyloid oligomerization: Replica exchange molecular dynamics simulations of the Aβ16-22 dimer and trimer (2011) Phys. Chem. Chem. Phys., 13, p. 9778; Hockney, R.W., Goel, S.P., Eastwood, J., Quit high resolution computer models of plasma (1974) J. Comput. Phys., 14, pp. 148-158; Hess, B., Bekker, H., Berendsen, H.J.C., Fraaije, J.G.E.M., LINCS: A linear constraint solver for molecular simulations (1997) J. Comput. Chem., 18, pp. 1463-1472; Bussi, G., Donadio, D., Parrinello, M., Canonical sampling through velocity rescaling (2007) J. Chem. Phys., 126, p. 014101; Berendsen, H.J.C., Postma, J.P.M., Vangunsteren, W.F., Dinola, A., Haak, J.R., Molecular-dynamics with coupling to an external bath (1984) J. Chem. Phys., 81, pp. 3684-3690; Darden, T., York, D., Pedersen, L., Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems (1993) J. Chem. Phys., 98, pp. 10089-10092; Heinig, M., Frishman, D., STRIDE: A Web server for secondary structure assignment from known atomic coordinates of proteins (2004) Nucleic Acids Res., 32, pp. 500-502; Mu, Y., Nguyen, P.H., Stock, G., Energy landscape of a small peptide revealed by dihedral angle principal component analysis (2005) Proteins, 58, pp. 45-52; Chong, S.-H., Ham, S., Atomic-level investigations on the amyloid-β dimerization process and its driving forces in water (2012) Phys. Chem. Chem. Phys., 14, pp. 1573-1575",Article,Scopus,2-s2.0-84905376515
"Savelieff M.G., Detoma A.S., Derrick J.S., Lim M.H.","The ongoing search for small molecules to study metal-Associated amyloid-β species in alzheimers disease",2014,"Accounts of Chemical Research","47","8",,"2475","2482",,5,10.1021/ar500152x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906261439&partnerID=40&md5=4fc19f41f3bfd7aa5571f69eed2ab95f","Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, United States; Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, United States; Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), Ulsan 689-798, South Korea","Savelieff, M.G., Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, United States; Detoma, A.S., Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, United States; Derrick, J.S., Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, United States; Lim, M.H., Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, United States, Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), Ulsan 689-798, South Korea","ConspectusThe development of a cure for Alzheimers disease (AD) has been impeded by an inability to pinpoint the root cause of this disorder. Although numerous potential pathological factors have been indicated, acting either individually or mutually, the molecular mechanisms leading to disease onset and progression have not been clear. Amyloid-β (Aβ), generated from proteolytic processing of the amyloid precursor protein (APP), and its aggregated forms, particularly oligomers, are suggested as key pathological features in AD-Affected brains. Historically, highly concentrated metals are found colocalized within Aβ plaques. Metal binding to Aβ (metal-Aβ) generates/stabilizes potentially toxic Aβ oligomers, and produces reactive oxygen species (ROS) in vitro (redox active metal ions; plausible contribution to oxidative stress). Consequently, clarification of the relationship between Aβ, metal ions, and toxicity, including oxidative stress via metal-Aβ, can lead to a deeper understanding of AD development.To probe the involvement of metal-Aβ in AD pathogenesis, rationally designed and naturally occurring molecules have been examined as chemical tools to target metal-Aβ species, modulate the interaction between the metal and Aβ, and subsequently redirect their aggregation into nontoxic, off-pathway unstructured aggregates. These ligands are also capable of attenuating the generation of redox active metal-Aβ-induced ROS to mitigate oxidative stress. One rational design concept, the incorporation approach, installs a metal binding site into a framework known to interact with Aβ. This approach affords compounds with the simultaneous ability to chelate metal ions and interact with Aβ. Natural products capable of Aβ interaction have been investigated for their influence on metal-induced Aβ aggregation and have inspired the construction of synthetic analogues. Systematic studies of these synthetic or natural molecules could uncover relationships between chemical structures, metal/Aβ/metal-Aβ interactions, and inhibition of Aβ/metal-Aβ reactivity (i.e., aggregation modes of Aβ/metal-Aβ; associated ROS production), suggesting mechanisms to refine the design strategy.Interdisciplinary investigations have demonstrated that the designed molecules and natural products control the aggregation pathways of metal-Aβ species transforming their size/conformation distribution. The aptitude of these molecules to impact metal-Aβ aggregation pathways, either via inhibition of Aβ aggregate formation, most importantly of oligomers, or disaggregation of preformed fibrils, could originate from their formation of complexes with metal-Aβ. Potentially, these molecules could direct metal-Aβ size/conformational states into alternative nontoxic unstructured oligomers, and control the geometry at the Aβ-ligated metal center for limited ROS formation to lessen the overall toxicity induced by metal-Aβ. Complexation between small molecules and Aβ/metal-Aβ has been observed by nuclear magnetic resonance spectroscopy (NMR) and ion mobility-mass spectrometry (IM-MS) pointing to molecular level interactions, validating the design strategy. In addition, these molecules exhibit other attractive properties, such as antioxidant capacity, prevention of ROS production, potential blood-brain barrier (BBB) permeability, and reduction of Aβ-/metal-Aβ-induced cytotoxicity, making them desirable tools for unraveling AD complexity. In this Account, we summarize the recent development of small molecules, via both rational design and the selection and modification of natural products, as tools for investigating metal-Aβ complexes, to advance our understanding of their relation to AD pathology. © 2014 American Chemical Society.",,"2013 Alzheimers disease facts and figures (2013) Alzheimers Dementia, 9, pp. 208-215. , Alzheimers Association; Jakob-Roetne, R., Jacobsen, H., Alzheimers disease: From pathology to therapeutic approaches (2009) Angew. Chem., Int. Ed., 48, pp. 3030-3059; Hamley, I.W., The amyloid beta peptide: A chemists perspective. Role in Alzheimers and fibrillization (2012) Chem. Rev., 112, pp. 5147-5192; Rodríguez-Rodríguez, C., Telpoukhovskaia, M., Orvig, C., The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases (2012) Coord. Chem. Rev., 256, pp. 2308-2332; Savelieff, M.G., Lee, S., Liu, Y., Lim, M.H., Untangling amyloid-β, tau, and metals in Alzheimers disease (2013) ACS Chem. Biol., 8, pp. 856-865; Kepp, K.P., Bioinorganic chemistry of Alzheimers disease (2012) Chem. Rev., 112, pp. 5193-5239; Rauk, A., The chemistry of Alzheimers disease (2009) Chem. Soc. Rev., 38, pp. 2698-2715; Faller, P., Hureau, C., Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide (2009) Dalton Trans., pp. 1080-1094; Pithadia, A.S., Lim, M.H., Metal-Associated amyloid-β species in Alzheimers disease (2012) Curr. Opin. Chem. Biol., 16, pp. 67-73; Pedersen, J.T., Teilum, K., Heegaard, N.H.H., Østergaard, J., Adolph, H.-W., Hemmingsen, L., Rapid formation of a preoligomeric peptide-metal-peptide complex following copper(II) binding to amyloid β peptides (2011) Angew. Chem., Int. Ed., 50, pp. 2532-2535; Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane, S., Mastwyk, M., Macgregor, L., Kiers, L., Masters, C.L., Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial (2003) Arch. Neurol., 60, pp. 1685-1691; Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Maters, C.L., Ritchie, C.W., Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimers disease: A phase IIa, double-blind, randomized, placebo-controlled trial (2008) Lancet Neurol., 7, pp. 779-786; Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Bush, A.I., Treatment with a copper-zinc chelator markedly and rapidly inhibits β-Amyloid accumulation in Alzheimers disease transgenic mice (2001) Neuron, 30, pp. 665-676; Adlard, P.A., Cherny, R.A., Finkelstein, D.I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Bush, A.I., Rapid restoration of cognition in Alzheimers transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ (2008) Neuron, 59, pp. 43-55; Detoma, A.S., Salamekh, S., Ramamoorthy, A., Lim, M.H., Misfolded proteins in Alzheimers disease and type II diabetes (2012) Chem. Soc. Rev., 41, pp. 608-621; Braymer, J.J., Detoma, A.S., Choi, J.-S., Ko, K.S., Lim, M.H., Recent development of bifunctional small molecules to study metal-Amyloid-β species in Alzheimers disease (2011) Int. J. Alzheimers Dis., p. 623051; Choi, J.-S., Braymer, J.J., Nanga, R.P.R., Ramamoorthy, A., Lim, M.H., Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 21990-21995; Lee, S., Zheng, X., Krishnamoorthy, J., Savelieff, M.G., Park, H.M., Brender, J.R., Kim, J.H., Lim, M.H., Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzehimers disease (2014) J. Am. Chem. Soc., 136, pp. 299-310; Savelieff, M.G., Liu, Y., Senthamarai, R.R.P., Korshavn, K.J., Lee, H.J., Ramamoorthy, A., Lim, M.H., A small molecule that displays marked reactivity toward copper- versus zinc-Amyloid-β implicated in Alzheimers disease (2014) Chem. Commun., 50, pp. 5301-5303; Liu, Y., Kochi, A., Pithadia, A.S., Lee, S., Nam, Y., Beck, M.W., He, X., Lim, M.H., Tuning reactivity of diphenylpropynone derivatives with metal-Associated amyloid-β species via structural modifications (2013) Inorg. Chem., 52, pp. 8121-8130; Hindo, S.S., Mancino, A.M., Braymer, J.J., Liu, Y., Vivekanandan, S., Ramamoorthy, A., Lim, M.H., Small molecule modulators of copper-induced Aβ aggregation (2009) J. Am. Chem. Soc., 131, pp. 16663-16665; Braymer, J.J., Choi, J.-S., Detoma, A.S., Wang, C., Nam, K., Kampf, J.W., Ramamoorthy, A., Lim, M.H., Development of bifunctional stilbene derivatives for targeting and modulating metal-Amyloid-β species (2011) Inorg. Chem., 50, pp. 10724-10734; Choi, J.-S., Braymer, J.J., Park, S.K., Mustafa, S., Chae, J., Lim, M.H., Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation (2011) Metallomics, 3, pp. 284-291; Pithadia, A.S., Kochi, A., Soper, M.T., Beck, M.W., Liu, Y., Lee, S., Detoma, A.S., Lim, M.H., Reactivity of diphenylpropynone derivatives toward metal-Associated amyloid-β species (2012) Inorg. Chem., 51, pp. 12959-12967; Rodríguez-Rodríguez, C., Sánchez De Groot, N., Rimola, A., Álvarez-Larena, A., Lloveras, V., Vidal-Gancedo, J., Ventura, S., González-Duarte, P., Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimers disease (2009) J. Am. Chem. Soc., 131, pp. 1436-1451; Scott, L.E., Telpoukhovskaia, M., Rodríguez-Rodríguez, C., Merkel, M., Bowen, M.L., Page, B.D.G., Green, D.E., Orvig, C., N -Aryl-substituted 3-(β- d -glucopyranosyloxy)-2-methyl-4(1 H)-pyridinones as agents for Alzheimers therapy (2011) Chem. Sci., 2, pp. 642-648; Jones, M.R., Service, E.L., Thompson, J.R., Wang, M.C.P., Kimsey, I.J., Detoma, A.S., Ramamoorthy, A., Storr, T., Dual-function triazole-pyridine derivatives as inhibitors of metal-induced amyloid-β aggregation (2012) Metallomics, 4, pp. 910-920; Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (2001) Adv. Drug Delivery Rev., 46, pp. 3-26; Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Wanker, E.E., EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers (2008) Nat. Struct. Mol. Biol., 15, pp. 558-566; Ono, M., Watanabe, H., Watanabe, R., Haratake, M., Nakayama, M., Saji, H., Diphenylpropynone derivatives as probes for imaging β-Amyloid plaques in Alzheimers brains (2011) Bioorg. Med. Chem. Lett., 21, pp. 117-120; Koleva, Y.K., Madden, J.C., Cronin, M.T.D., Formation of categories from structure-Activity relationships to allow read-Across for risk assessment: Toxicity of α,β-unsaturated carbonyl compounds (2008) Chem. Res. Toxicol., 21, pp. 2300-2312; Knekt, P., Kumpulainen, J., Jarvinen, R., Rissanen, H., Heliovaara, M., Reunanen, A., Hakulinen, T., Aromaa, A., Flavonoid intake and risk of chronic diseases (2002) Am. J. Clin. Nutr., 76, pp. 560-568; Grant, W.B., Dietary links to Alzheimers disease (1997) Alzheimers Dis. Rev., 2, pp. 42-55; Hirohata, M., Hasegawa, K., Tsutsumi-Yasuhara, S., Ohhashi, Y., Ookoshi, T., Ono, K., Yamada, M., Naiki, H., The anti-Amyloidogenic effect is exerted against Alzheimers β-Amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure (2007) Biochemistry, 46, pp. 1888-1899; Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Tan, J., Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice (2005) J. Neurosci., 25, pp. 8807-8814; Esparza, I., Salinas, Í., Santamaría, C., García-Mina, J.M., Fernández, J.M., Electrochemical and theoretical complexation studies for Zn and Cu with individual polyphenols (2005) Anal. Chim. Acta, 543, pp. 267-274; Detoma, A.S., Choi, J.-S., Braymer, J.J., Lim, M.H., Myricetin: A naturally occurring regulator of metal-induced amyloid-β aggregation and neurotoxicity (2011) ChemBioChem, 12, pp. 1198-1201; Hyung, S.-J., Detoma, A.S., Brender, J.R., Lee, S., Vivekanandan, S., Kochi, A., Choi, J.-S., Lim, M.H., Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-Associated amyloid-β species (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 3743-3748; Cheng, X.R., Hau, B.Y.H., Veloso, A.J., Martic, S., Kraatz, H.-B., Kerman, K., Surface plasmon resonance imaging of amyloid-β aggregation kinetics in the presence of epigallocatechin gallate and metals (2013) Anal. Chem., 85, pp. 2049-2055; Zhang, B., Cheng, X.R., Da Silva, I.S., Hung, V.W.S., Veloso, A.J., Angnes, L., Kerman, K., Electroanalysis of the interaction between (-)-epigallocatechin-3-gallate (EGCG) and amyloid-β in the presence of copper (2013) Metallomics, 5, pp. 259-264; He, X., Park, H.M., Hyung, S.-J., Detoma, A.S., Kim, C., Ruotolo, B.T., Lim, M.H., Exploring the reactivity of flavonoid compounds with metal-Associated amyloid-β species (2012) Dalton Trans., 41, pp. 6558-6566",Article,Scopus,2-s2.0-84906261439
"Xie B., Li X., Dong X.-Y., Sun Y.","Insight into the inhibition effect of acidulated serum albumin on amyloid β-protein fibrillogenesis and cytotoxicity",2014,"Langmuir","30","32",,"9789","9796",,1,10.1021/la5025197,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906224657&partnerID=40&md5=538cf8d48a86b72fdc61022237215563","Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China; Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China","Xie, B., Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China; Li, X., Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China; Dong, X.-Y., Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China; Sun, Y., Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China","Alzheimers disease (AD) is the most prevalent form of dementia, and aggregation of amyloid β-proteins (Aβ) into soluble oligomers and fibrils has been implicated in the pathogenesis of AD. Herein we developed acidulated serum albumin for the inhibition of Aβ42 fibrillogenesis. Bovine serum albumin (BSA) was modified with diglycolic anhydride, leading to the coupling of 14.5 more negative charges (carboxyl groups) on average on each protein surface. The acidulated BSA (A-BSA) was characterized and confirmed to keep the tertiary structure and stability of BSA. Extensive biophysical and biological analyses showed that A-BSA significantly inhibited Aβ42 fibrillogenesis and mitigated amyloid cytotoxicity. As compared to the Aβ42-treated group (cell viability, 50%), the cell viability increased to 88% by the addition of equimolar A-BSA. The inhibitory effect was remarkably higher than that of BSA at the same concentration. On the basis of the experimental findings, a mechanistic model was proposed. The model considers that Aβ42 is bound to the A-BSA surface by hydrophobic interactions, but the widely distributed negative charges on the A-BSA surface give rise to electrostatic repulsions to the bound Aβ42 that is also negatively charged. The two well-balanced opposite forces make Aβ42 adopt extended conformations instead of the β-sheet structure that is necessary for the on-pathway fibrillogenesis, even when the protein is released off the surface. Thus, A-BSA greatly slows down the fibrillation and changes the fibrillogenesis pathway, leading to the formation of less toxic aggregates. The findings and the mechanistic model offer new insights into the development of more potent inhibitors of Aβ fibrillogenesis and cytotoxicity. © 2014 American Chemical Society.",,"Selkoe, D.J., Alzheimers disease: Genes, proteins, and therapy (2001) Physiol. Rev., 81, p. 26; Vitiello, G., Di Marino, S., Dursi, A.M., Derrico, G., Omega-3 fatty acids regulate the interaction of the Alzheimers abeta(25-35) peptide with lipid membranes (2013) Langmuir, 29, pp. 14239-14245; Jakob-Roetne, R., Jacobsen, H., Alzheimers disease: From pathology to therapeutic approaches (2009) Angew. Chem., Int. Ed., 48, pp. 3030-3059; Sehgal, N., Gupta, A., Valli, R.K., Joshi, S.D., Mills, J.T., Hamel, E., Khanna, P., Ravindranath, V., Withania somnifera reverses Alzheimers disease pathology by enhancing low-density lipoprotein receptor-related protein in liver (2012) Proc. Natl. Acad. Sci. U.S.A., 109, p. 6; Brambilla, D., PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: Toward engineering of functional nanomedicines for Alzheimers disease (2012) ACS Nano, 6, pp. 5897-5908; Thapa, A., Vernon, B.C., De La Pena, K., Soliz, G., Moreno, H.A., Lopez, G.P., Chi, E.Y., Membrane-mediated neuroprotection by curcumin from amyloid-beta-peptide- induced toxicity (2013) Langmuir, 29, pp. 11713-11723; Liao, Y.H., Chang, Y.J., Yoshiike, Y., Chang, Y.C., Chen, Y.R., Negatively charged gold nanoparticles inhibit Alzheimers amyloid-beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity (2012) Small, 8, pp. 3631-3639; Tanzi, R.E., Bertram, L., Twenty years of the Alzheimers disease amyloid hypothesis: A genetic perspective (2005) Cell, 120, pp. 545-555; Richman, M., Perelman, A., Gertler, A., Rahimipour, S., Effective targeting of Abeta to macrophages by sonochemically prepared surface-modified protein microspheres (2013) Biomacromolecules, 14, pp. 110-116; Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Stefansson, K., A mutation in APP protects against Alzheimers disease and age-related cognitive decline (2012) Nature, 488, pp. 96-99; Jiang, D., Rauda, I., Han, S., Chen, S., Zhou, F., Aggregation pathways of the amyloid beta(1-42) peptide depend on its colloidal stability and ordered beta-sheet stacking (2012) Langmuir, 28, pp. 12711-12721; Zhang, Y.W., Thompson, R., Zhang, H., Xu, H., APP processing in Alzheimers disease (2011) Mol. Brain, 4, p. 3; Yu, X., Wang, Q., Lin, Y., Zhao, J., Zhao, C., Zheng, J., Structure, orientation, and surface interaction of Alzheimer amyloid-beta peptides on the graphite (2012) Langmuir, 28, pp. 6595-6605; Stanyon, H.F., Viles, J.H., Human Serum albumin can regulate amyloid-beta peptide fiber growth in the brain interstitium: Implications for Alzheimer disease (2012) J. Biol. Chem., 287, pp. 28163-28168; Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.Y., Karlo, J.C., Zinn, A.E., Casali, B.T., Landreth, G.E., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models (2012) Science, 335, pp. 1503-1506; Yoo, S.I., Yang, M., Brender, J.R., Subramanian, V., Sun, K., Joo, N.E., Jeong, S.H., Kotov, N.A., Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: Functional similarities with proteins (2011) Angew. Chem., Int. Ed., 50, pp. 5110-5115; Adessi, C., Frossard, M.J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Soto, C., Pharmacological profiles of peptide drug candidates for the treatment of Alzheimers disease (2003) J. Biol. Chem., 278, pp. 13905-13911; Sciarretta, K.L., Gordon, D.J., Meredith, S.C., Peptide-based inhibitors of amyloid assembly (2006) Methods Enzymol., 413, pp. 273-312; Palhano, F.L., Lee, J., Grimster, N.P., Kelly, J.W., Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils (2013) J. Am. Chem. Soc., 135, pp. 7503-7510; Necula, M., Kayed, R., Milton, S., Glabe, C.G., Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct (2007) J. Biol. Chem., 282, pp. 10311-10324; Chan, H.M., Xiao, L., Yeung, K.M., Ho, S.L., Zhao, D., Chan, W.H., Li, H.W., Effect of surface-functionalized nanoparticles on the elongation phase of beta-amyloid (1-40) fibrillogenesis (2012) Biomaterials, 33, pp. 4443-4450; Xiao, L., Zhao, D., Chan, W.H., Choi, M.M., Li, H.W., Inhibition of beta 1-40 amyloid fibrillation with N-acetyl-L-cysteine capped quantum dots (2010) Biomaterials, 31, pp. 91-98; Kerr, M.L., Gasperini, R., Gibbs, M.E., Hou, X., Shepherd, C.E., Strickland, D.K., Foa, L., Small, D.H., Inhibition of Abeta aggregation and neurotoxicity by the 39-kDa receptor-associated protein (2010) J. Neurochem., 112, pp. 1199-1209; Milojevic, J., Raditsis, A., Melacini, G., Human serum albumin inhibits Abeta fibrillization through a ""monomer-competitor"" mechanism (2009) Biophys. J., 97, pp. 2585-2594; Palivan, C.G., Fischer-Onaca, O., Delcea, M., Itel, F., Meier, W., Protein-polymer nanoreactors for medical applications (2012) Chem. Soc. Rev., 41, pp. 2800-2823; Klonoff-Cohen, H., Barrett-Connor, E.L., Edelstein, S.L., Albumin levels as a predictor of mortality in the healthy elderly (1992) J. Clin. Epidemiol., 45, pp. 207-212; Inhee, C., Lee, P., Rapid, L., Detection of Aβ aggregation and inhibition by dual functions of gold nanoplasmic particles: Catalytic activator and optical reporter (2013) ACS Nano, 7, p. 10; Kuo, Y.M., Kokjohn, T.A., Kalback, W., Luehrs, D., Galasko, D.R., Chevallier, N., Koo, E.H., Roher, A.E., Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma (2000) Biochem. Biophys. Res. Commun., 268, pp. 750-756; Rozga, M., Kloniecki, M., Jablonowska, A., Dadlez, M., Bal, W., The binding constant for amyloid Abeta40 peptide interaction with human serum albumin (2007) Biochem. Biophys. Res. Commun., 364, pp. 714-718; Elovaara, I., Palo, J., Erkinjuntti, T., Sulkava, R., Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimers disease and multi-infarct dementia (1987) Eur. J. Neurol., 26, pp. 229-234; Kay, A.D., May, C., Papadopoulos, N.M., Costello, R., Atack, J.R., Luxenberg, J.S., Cutler, N.R., Rapoport, S.I., CSF and serum concentrations of albumin and IgG in Alzheimers disease (1987) Neurobiol. Aging, 8, pp. 21-25; Mahmoudi, M., Quinlan-Pluck, F., Monopoli, M.P., Sheibani, S., Vali, H., Dawson, K.A., Lynch, I., Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid beta protein fibrillation in solution (2013) ACS Chem. Neurosci., 4, pp. 475-485; Kim, S.T., Saha, K., Kim, C., Rotello, V.M., The role of surface functionality in determining nanoparticle cytotoxicity (2013) Acc. Chem. Res., 46, pp. 681-691; Santa-María, I., Hernández, F., Moreno, F.J., Avila, J., Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-β-peptide aggregation (2007) Neurosci. Lett., 429, pp. 91-94; Xu, Y., Takai, M., Ishihara, K., Protein adsorption and cell adhesion on cationic, neutral, and anionic 2-methacryloyloxyethyl phosphorylcholine copolymer surfaces (2009) Biomaterials, 30, pp. 4930-4938; Gu, M., Kilduff, J.E., Belfort, G., High throughput atmospheric pressure plasma-induced graft polymerization for identifying protein-resistant surfaces (2012) Biomaterials, 33, pp. 1261-1270; Powers, D., J. Trypsin purification by affinity binding to small unilamellar liposomes (1990) Biotechnol. Bioeng., 36, p. 14; Bujacz, A., Structures of bovine, equine and leporine serum albumin (2012) Acta Crystallogr., Sect. D, 68, pp. 1278-12789; Khurana, R., Coleman, C., Ionescu-Zanetti, C., Carter, S.A., Krishna, V., Grover, R.K., Roy, R., Singh, S., Mechanism of thioflavin T binding to amyloid fibrils (2005) J. Struct. Biol., 151, pp. 229-238; Shearman, M.S., Toxicity of protein aggregates in PC12 cells: 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide assay (1999) Methods Enzymol., 309, pp. 716-723; Zhang, C., Wan, X., Zheng, X., Shao, X., Liu, Q., Zhang, Q., Qian, Y., Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimers disease mice (2014) Biomaterials, 35, pp. 456-465; Chen, Q., Yang, L., Zheng, C., Zheng, W., Zhang, J., Zhou, Y., Liu, J., Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Abeta-peptide associated with Alzheimers disease (2014) Nanoscale, 6, pp. 6886-6897; Veloso, A.J., Kerman, K., Modulation of fibril formation by a beta-sheet breaker peptide ligand: An electrochemical approach (2012) Bioelectrochemistry, 84, pp. 49-52; Giordano, C., Sansone, A., Masi, A., Masci, A., Mosca, L., Chiaraluce, R., Pasquo, A., Consalvi, V., Inhibition of amyloid peptide fragment Aβ25-35 fibrillogenesis and toxicity by N-terminal β-amino acid-containing esapeptides: Is taurine moiety essential for in vivo effects? (2012) Chem. Biol. Drug. Des., 79, pp. 30-37; Zhang, W., Du, Y., Bai, M., Xi, Y., Li, Z., Miao, J., S14G-humanin inhibits Abeta1-42 fibril formation, disaggregates preformed fibrils, and protects against Abeta-induced cytotoxicity in vitro (2013) J. Pept. Sci., 19, pp. 159-165; Jan, A., Hartley, D.M., Lashuel, H.A., Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimers disease research (2010) Nat. Protoc., 5, pp. 1186-1209; Kim, T., Vidal, G.S., Djurisic, M., William, C.M., Birnbaum, M.E., Garcia, K.C., Hyman, B.T., Shatz, C.J., Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimers model (2013) Science, 341, pp. 1399-1404; Li, H., Du, Z., Lopes, D.H., Fradinger, E.A., Wang, C., Bitan, G., C-terminal tetrapeptides inhibit Abeta42-induced neurotoxicity primarily through specific interaction at the N-terminus of Abeta42 (2011) J. Med. Chem., 54, pp. 8451-8460; Monji, A., Tashiro, K.-I., Yoshida, I., Kaname, H., Hayashi, Y., Matsuda, K., Tashiro, N., Laminin inhibits both Aβ40 and Aβ42 fibril formation but does not affect Aβ40 or Aβ42-induced cytotoxicity in PC12 cells (1999) Neurosci. Lett., 266, pp. 85-88; Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Lindman, S., Minogue, A.M., Thulin, E., Walsh, D.M., Linse, S., Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles (2008) J. Am. Chem. Soc., 130, pp. 15437-15443; Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., Riek, R., 3D structure of Alzheimers amyloid-beta(1-42) fibrils (2005) P. Natl. Acad. Sci. U.S.A., 102, pp. 17342-17347; Pellarin, R., Caflisch, A., Interpreting the Aggregation Kinetics of Amyloid Peptides (2006) J. Mol. Biol., 360, pp. 882-892; Wood, S.J., Maleeff, B., Hart, T., Wetzel, R., Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimers amyloid peptide Aβ (1996) J. Mol. Biol., 256, pp. 870-877; Algamal, M., Milojevic, J., Jafari, N., Zhang, W., Melacini, G., Mapping the interactions between the Alzheimers Abeta-peptide and human serum albumin beyond domain resolution (2013) Biophys. J., 105, pp. 1700-1709; Yang, C., Li, J.Y., Li, Y., Zhu, X.L., The effect of solvents on the conformations of amyloid beta-peptide (1-42) studied by molecular dynamics simulation (2009) J. Mol. Struct., 895, pp. 1-8; Zhang, L., Zhao, G., Sun, Y., Effects of ligand density on hydrophobic charge induction chromatography: Molecular dynamics simulation (2010) J. Phys. Chem. B, 114, pp. 2203-2211; Zhang, L., Zhao, G., Sun, Y., Molecular insight into protein conformational transition in hydrophobic charge induction chromatography: A molecular dynamics simulation (2009) J. Phys. Chem. B, 113, pp. 6873-6880",Article,Scopus,2-s2.0-84906224657
"Matsuzaki K.","How do membranes initiate alzheimers disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters",2014,"Accounts of Chemical Research","47","8",,"2397","2404",,3,10.1021/ar500127z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906239240&partnerID=40&md5=6c7c7c51e9938045e45354622b35a707","Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan","Matsuzaki, K., Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan","ConspectusAlzheimers disease (AD), a severe neurodegenerative disorder, causes more than half of dementia cases. According to the popular ""Aβ hypothesis"" to explain the mechanism of this disease, amyloid β-peptides (Aβ) of 39-43 amino acid residues aggregate and deposit onto neurons, igniting the neurotoxic cascade of the disease. Therefore, researchers studying AD would like to elucidate the mechanisms by which essentially water-soluble but hydrophobic Aβ aggregates under pathological conditions.Most researchers have investigated the aggregation of Aβ in aqueous solution, and they concluded that the final aggregation product, the amyloid fibrils, were less toxic than the component peptide oligomers. They consequently shifted their interests to more toxic ""soluble oligomers"", structures that form as intermediates or off-pathway products during the aggregation process. Some researchers have also investigated artificial oligomers prepared under nonphysiological conditions.In contrast to these ""in solution"" studies, we have focused on ""membrane- mediated"" amyloidogenesis. In an earlier study, other researchers identified a specific form of Aβ that was bound to monosialoganglioside GM1, a sugar lipid, in brains of patients who exhibited the early pathological changes associated with AD. This Account summarizes 15 years of our research on this topic. We have found that Aβ specifically binds to GM1 that occurs in clusters, but not when it is uniformly distributed. Clustering is facilitated by cholesterol. Upon binding, Aβ changes its conformation from a random coil to an α-helix-rich structure. A CH-π interaction between the aromatic side chains of Aβ and carbohydrate moieties appended to GM1 appears to be important for binding. In addition, as Aβ accumulates and reaches its first threshold concentration (Aβ/GM1 = ∼0.013), aggregated β-sheets of ∼15 molecules appear and coexist with the helical form.However, this β-structure is stable and does not form larger aggregates. When the disease progresses further and the Aβ/GM1 ratio exceeds ∼0.044, the β-structure converts to a second β-structure that can seed aggregates. The seed recruits monomers from the aqueous phase to form toxic amyloid fibrils that have larger surface hydrophobicity and can contain antiparallel β-sheets. In contrast, amyloid fibrils formed in aqueous solution are less toxic and have parallel β-sheets. The less polar environments of GM1 clusters play an important role in the formation of these toxic fibrils.Membranes that contain GM1 clusters not only accelerate the aggregation of Aβ by locally concentrating Aβ molecules but also generate amyloid fibrils with unique structures and significant cytotoxicity. The inhibition of this aggregation cascade could be a promising strategy for the development of AD-modulating therapies. © 2014 American Chemical Society.",,"Selkoe, D.J., Alzheimers disease: Genes, proteins, and therapy (2001) Physiol. Rev., 81, pp. 741-766; Citron, M., Alzheimers disease: Treatments in discovery and development (2002) Nat. Neurosci., 5, pp. 1055-1057; Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ 42(43) (1994) Neuron, 13, pp. 45-53; Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline (2000) JAMA, J. Am. Med. Assoc., 283, pp. 1571-1577; Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schenk, D., Isolation and quantification of soluble Alzheimers β-peptide from biological fluids (1992) Nature, 359, pp. 325-327; Hardy, J.A., Higgins, G.A., Alzheimers disease: The amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; Onuallain, B., Shivaprasad, S., Kheterpal, I., Wetzel, R., Thermodynamics of Aβ(1-40) amyloid fibril elongation (2005) Biochemistry, 44, pp. 10709-12718; Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., Bateman, R.J., Decreased clearance of CNS β-Amyloid in Alzheimers disease (2010) Science, 330, p. 1774; Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Klein, W.L., Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 6448-6453; Bush, A.I., Pettingell, W.H., Multhaup, G., Dparadis, M., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Tanzi, R.E., Rapid induction of Alzheimer Aβ amyloid formation by zinc (1994) Science, 265, pp. 1464-1467; Matsuzaki, K., Physicochemical interactions of amyloid β-peptide with lipid bilayers (2007) Biochim. Biophys. Acta, 1768, pp. 1935-1942; Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., Differences between amyloid-β aggregation in solution and on the membrane: Insights into elucidation of the mechanistic details of Alzheimers disease (2014) Chem. Soc. Rev., , http//dx.doi.org/10.1039/C3CS60431D; Sciacca, M.F., Kotler, S.A., Brender, J.R., Chen, J., Lee, D.K., Ramamoorthy, A., Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation (2012) Biophys. J., 103, pp. 702-710; Butterfield, S.M., Lashuel, H.A., Amyloidogenic protein-membrane interactions: Mechanistic insight from model systems (2010) Angew. Chem., Int. Ed., 49, pp. 5628-5654; Brender, J.R., Salamekh, S., Ramamoorthy, A., Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective (2012) Acc. Chem. Res., 45, pp. 454-462; Sciacca, M.F., Brender, J.R., Lee, D.K., Ramamoorthy, A., Phosphatidylethanolamine enhances amyloid fiber-dependent membrane fragmentation (2012) Biochemistry, 51, pp. 7676-7684; Yanagisawa, K., Odaka, A., Suzuki, N., Ihara, Y., GM1 ganglioside-bound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimers disease (1995) Nat. Med., 1, pp. 1062-1066; Matsuzaki, K., Kato, K., Yanagisawa, K., Aβ polymerization through interaction with membrane gangliosides (2010) Biochim. Biophys. Acta, 1801, pp. 868-877; Matsuzaki, K., Formation of toxic amyloid fibrils by amyloid β-protein on ganglioside clusters (2011) Int. J. Alzheimers Res., 2011, p. 956104; Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid (2001) J. Biol. Chem., 276, pp. 24985-24990; Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Interactions of amyloid β-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid (2002) Biochemistry, 41, pp. 7385-7390; Ogawa, M., Tsukuda, M., Yamaguchi, T., Ikeda, K., Okada, T., Yano, Y., Hoshino, M., Matsuzaki, K., Ganglioside-mediated aggregation of amyloid β-proteins (Aβ): Comparison between Aβ-(1-42) and Aβ-(1-40) (2011) J. Neurochem., 116, pp. 851-857; Ikeda, K., Matsuzaki, K., Driving force of binding of amyloid β-protein to lipid bilayers (2008) Biochem. Biophys. Res. Commun., 370, pp. 525-529; Arispe, N., Rojas, E., Pollard, H.B., Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum (1993) Proc. Natl. Acad. Sci. U. S. A., 90, pp. 567-571; Lau, T.-L., Ambroggio, E.E., Tew, D.J., Cappi, R., Masters, C.L., Fidelio, G.D., Barnham, K.J., Separovic, F., Amyloid-β peptide disruption of lipid membranes and the effect of metal ions (2006) J. Mol. Biol., 356, pp. 759-770; Ma, K., Clancy, E.L., Zhang, Y., Ray, D.G., Wollenberg, K., Zagorski, M.G., Residue-specific pKa measurements of the β-peptide and mechanism of pH-induced amyloid formation (1999) J. Am. Chem. Soc., 121, pp. 8698-8706; Zhang, S., Lee, J.P., Selectively 2H-labeled Glu/Asp: Application to pKa measurements in Aβ amyloid peptides (2000) J. Peptide Res., 55, pp. 1-6; Simons, K., Ikonen, E., Functional rafts in cell membranes (1997) Nature, 385, pp. 569-572; Mori, K., Mahmood, M.I., Neya, S., Matsuzaki, K., Hoshino, T., Formation of GM1 ganglioside clusters on the lipid membrane containing sphingomyelin and cholesterol (2012) J. Phys. Chem. B, 116, pp. 5111-5121; Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M., Matsuzaki, K., Formation of toxic Aβ(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: Polymorphisms in Aβ(1-40) fibrils (2008) J. Mol. Biol., 382, pp. 1066-1074; Law, A., Gauthier, S., Quirion, R., Say NO to Alzheimers disease: The putative links between nitric oxide and dementia of the Alzheimers type (2001) Brain Res. Rev., 35, pp. 73-96; Igbavboa, U., Avdulov, N.A., Schroeder, F., Wood, W.G., Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes in mice (1996) J. Neurochem., 66, pp. 1717-1725; Hayashi, H., Igbavboa, U., Hamanaka, H., Kobayashi, M., Fujita, S.C., Wood, W.G., Yanagisawa, K., Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice (2002) NeuroReport, 13, pp. 383-386; Yamamoto, N., Matsubara, T., Sato, T., Yanagisawa, K., Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid β-protein fibrillogenesis (2008) Biochim. Biophys. Acta, 1778, pp. 2717-2726; Gylys, K.H., Fein, J.A., Yang, F., Miller, C.A., Cole, G.M., Increased cholesterol in Aβ-positive nerve terminals from Alzheimers disease cortex (2007) Neurobiol Aging, 28, pp. 8-17; Molander-Melin, M., Blennow, K., Bogdanovic, N., Dellheden, B., Mansson, J.E., Fredman, P., Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; Increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains (2005) J. Neurochem., 92, pp. 171-182; Refolo, L.M., Pappolla, M.A., Malester, B., Lafrancois, J., Bryant-Thomas, T., Wang, R., Tint, G.S., Duff, K., Hypercholesterolemia accelerates the Alzheimers amyloid pathology in a transgenic mouse model (2000) Neurobiol. Disease, 7, pp. 321-331; Wolozin, B., A fluid connection: Cholesterol and Aβ (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 5371-5373; Marx, J., Bad for the heart, bad for the mind? (2001) Science, 294, pp. 508-509; Wakabayashi, M., Okada, T., Kozutsumi, Y., Matsuzaki, K., GM1 ganglioside-mediated accumulation of amyloid β-protein on cell membranes (2005) Biochem. Biophys. Res. Commun., 328, pp. 1019-1023; Wakabayashi, M., Matsuzaki, K., Formation of amyloids by Aβ-(1-42) on NGF-differentiated PC12 cells: Roles of gangliosides and cholesterol (2007) J. Mol. Biol., 371, pp. 924-933; De Planque, M.R., Raussens, V., Contera, S.A., Rijkers, D.T., Liskamp, R.M., Ruysschaert, J.M., Ryan, J.F., Watts, A., β-Sheet structured β-Amyloid(1-40) perturbs phosphatidylcholine model membranes (2007) J. Mol. Biol., 368, pp. 982-997; Hoshino, T., Mahmood, M.I., Mori, K., Matsuzaki, K., Binding and aggregation mechanism of amyloid β-peptides onto the GM1 ganglioside-containing lipid membrane (2013) J. Phys. Chem. B, 117, pp. 8085-8094; Ikeda, K., Yamaguchi, T., Fukunaga, S., Hoshino, M., Matsuzaki, K., Mechanism of amyloid β-protein aggregation mediated by GM1 ganglioside clusters (2011) Biochemistry, 50, pp. 6433-6440; Sani, M.A., Gehman, J.D., Separovic, F., Lipid matrix plays a role in Aβ fibril kinetics and morphology (2011) FEBS Lett., 585, pp. 749-754; Fukunaga, S., Ueno, H., Yamaguchi, T., Yano, Y., Hoshino, M., Matsuzaki, K., GM1 cluster mediates formation of toxic Aβ fibrils by providing hydrophobic environments (2012) Biochemistry, 51, pp. 8125-8131; Petkova, A.T., Leapman, R.D., Guo, Z., Yau, W.-M., Mattson, M.P., Tycko, R., Self-propagating, molecular-level polymorphism in Alzheimers β-Amyloid fibrils (2005) Science, 307, pp. 262-265; Liu, Y., Schubert, D., Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis (1997) J. Neurochem., 69, pp. 2285-2293; Liu, Y., Schubert, D., Steroid hormones block amyloid fibril-induced 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) formazan exocytosis: Relationship to neurotoxicity (1998) J. Neurochem., 71, pp. 2322-2329; Liu, Y., Dargusch, R., Banh, C., Miller, C.A., Schubert, D., Detecting bioactive amyloid β peptide species in Alzheimers disease (2004) J. Neurochem., 91, pp. 648-656; Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., Yamamoto, N., Yanagisawa, K., A seed for Alzheimer amyloid in the brain (2004) J. Neurosci., 24, pp. 4894-4902; Yamamoto, N., Yokoseki, T., Shibata, M., Yamaguchi, H., Yanagisawa, K., Suppression of Aβ deposition in brain by peripheral administration of Fab fragments of anti-seed antibody (2005) Biochem. Biophys. Res. Commun., 335, pp. 45-47; Petkova, A.T., Ishii, Y., Balbach, J.J., Antzukin, O.N., Leapman, R.D., Delaglio, F., Tycko, R., A structural model for Alzheimers β-Amyloid fibrils based on experimental constrains from solid state NMR (2002) Proc. Natl. Acad. Sci. U. S. A., 99, pp. 16742-16747; Miyazawa, T., Perturbation treatment of the characteristic vibrations of polypeptide chains in various configurations (1960) J. Chem. Phys., 32, pp. 1647-1652; Miyazawa, T., Blout, E.R., The infrared spectra of polypeptides in various conformations: Amide i and II bands (1961) J. Am. Chem. Soc., 83, pp. 712-719; Jackson, M., Mantsch, H.H., The use and misuse of FTIR spectroscopy in the determination of protein structure (1995) Crit. Rev. Biochem. Mol. Biol., 30, pp. 95-120; Cerf, E., Sarroukh, R., Tamamizu-Kato, S., Breydo, L., Derclaye, S., Dufrêne, Y.F., Narayanaswami, V., Raussens, V., Antiparallel β-sheet: A signature structure of the oligomeric amyloid β-peptide (2009) Biochem. J., 421, pp. 415-423; Sarroukh, R., Cerf, E., Derclaye, S., Dufrêne, Y.F., Goormaghtigh, E., Ruysschaert, J.M., Raussens, V., Transformation of amyloid β(1-40) oligomers into fibrils is characterized by a major change in secondary structure (2011) Life Sci., 68, pp. 1429-1438; Qiang, W., Yau, W.-M., Luo, Y., Mattson, M.P., Tycko, R., Antiparallel β-sheet architecture in Iowa-mutant β-Amyloid fobrils (2012) Proc. Natl. Acad. Sci. U. S. A., 109, pp. 4443-4448; Dahlgren, K.N., Manelli, A.M., Stine Jr., W.B., Baker, L.K., Krafft, G.A., Ladu, M.J., Oligomeric and fibrillar species of amyloid-b peptides differentially affect neuronal viability (2002) J. Biol. Chem., 277, pp. 32046-32053; Grace, E.A., Rabiner, C.A., Busciglio, J., Characterization of neuronal dystrophy induced by fibrillar amyloid β: Implications for Alzheimers disease (2002) Neuroscience, 114, pp. 265-273; Jana, A., Pahan, K., Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimers disease (2004) J. Biol. Chem., 279, pp. 51451-51459; Tsai, J., Grutzendler, J., Duff, K., Gan, W.-B., Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches (2004) Nat. Neurosci., 7, pp. 1181-1183; Deshpande, A., Mina, E., Glabe, C., Busciglio, J., Different conformations of β amyloid induce neurotoxicity by distinct mechasnism in human cortical neurons (2006) J. Neurosci., 26, pp. 6011-6018; Walsh, D.M., Kyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539; Chromy, B.A., Nowak, R.J., Lambert, M.P., Viola, K.L., Chang, L., Velasco, P.T., Jones, B.W., Klein, W.L., Self-Assembly of Aβ1-42 into globular neurotoxins (2003) Biochemistry, 42, pp. 12749-12760; Hoshi, M., Sato, M., Matsumoto, S., Nogichi, A., Yasutake, K., Yoshida, N., Sato, K., Spherical aggregates of β-Amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 6370-6375; Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis (2003) Science, 300, pp. 486-489; Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Hillen, H., Globular amyloid β-peptide1-42 oligomer - A homogenous and stable neuropathological protein in Alzheimers disease (2005) J. Neurochem., 95, pp. 834-847; Demuro, A., Mina, E., Kayed, R., Milton, S.C., Parker, I., Glabe, C.G., Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers (2005) J. Biol. Chem., 280, pp. 17294-17300; Lesné, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-β protein assembly in the brain impairs memory (2006) Nature, 440, pp. 352-357; Noguchi, A., Matsumura, S., Dezawa, M., Tada, M., Yanazawa, M., Ito, A., Akioka, M., Hoshi, M., Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains (2009) J. Biol. Chem., 284, pp. 32859-32905; Matsuzaki, K., Horikiri, C., Interactions of amyloid β-peptide (1-40) with ganglioside-containing membranes (1999) Biochemistry, 38, pp. 4137-4142; Engel, M.F., Khemtémourian, L., Kleijer, C.C., Meeldijk, H.J., Jacobs, J., Verkleij, A.J., De Kruijff, B., Höppener, J.W., Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane (2008) Proc. Natl. Acad. Sci. U. S. A., 105, pp. 6033-6038; Yuyama, K., Yanagisawa, K., Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimers disease (2009) J. Neurochem., 109, pp. 1250-1260; Matsuzaki, K., Noguch, T., Wakabayashi, M., Ikeda, K., Okada, T., Ohashi, Y., Hoshino, M., Naiki, H., Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes (2007) Biochim. Biophys. Acta, 1768, pp. 122-130; Kimura, N., Yanagisawa, K., Endosomal accumulation of GM1 ganglioside-bound amyloid β-protein in neurons of aged monkey brains (2007) Neuroreport, 18, pp. 1669-1673",Article,Scopus,2-s2.0-84906239240
"Faller P., Hureau C., La Penna G.","Metal ions and intrinsically disordered proteins and peptides: From Cu/Zn amyloid-β to general principles",2014,"Accounts of Chemical Research","47","8",,"2252","2259",,7,10.1021/ar400293h,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906263191&partnerID=40&md5=be6147af236dc16b89b5fcb351be86ff","CNRS, LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, Toulouse F-31077 Cedex 4, France; Université de Toulouse, UPS, INPT, Toulouse F-31077 Cedex 4, France; CNR - National Research Council of Italy, ICCOM - Institute for Chemistry of Organo-metallic Compounds, via Madonna del Piano 10, I-50019 Sesto Fiorentino, Firenze, Italy","Faller, P., CNRS, LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, Toulouse F-31077 Cedex 4, France, Université de Toulouse, UPS, INPT, Toulouse F-31077 Cedex 4, France; Hureau, C., CNRS, LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, Toulouse F-31077 Cedex 4, France, Université de Toulouse, UPS, INPT, Toulouse F-31077 Cedex 4, France; La Penna, G., CNR - National Research Council of Italy, ICCOM - Institute for Chemistry of Organo-metallic Compounds, via Madonna del Piano 10, I-50019 Sesto Fiorentino, Firenze, Italy","ConspectusThe interaction of d-block metal ions (Cu, Zn, Fe, etc.) with intrinsically disordered proteins (IDPs) has gained interest, partly due to their proposed roles in several diseases, mainly neurodegenerative. A prominent member of IDPs is the peptide amyloid-β (Aβ) that aggregates into metal-enriched amyloid plaques, a hallmark of Alzheimers disease, in which Cu and Zn are bound to Aβ.IDPs are a class of proteins and peptides that lack a unique 3D structure when the protein is isolated. This disordered structure impacts their interaction with metal ions compared with structured metalloproteins. Metalloproteins either have a preorganized metal binding site or fold upon metal binding, resulting in defined 3D structure with a well-defined metal site. In contrast, for Aβ and likely most of the other IDPs, the affinity for Cu(I/II) and Zn(II) is weaker and the interaction is flexible with different coordination sites present. Coordination of Cu(I/II) with Aβ is very dynamic including fast Cu-exchange reactions (milliseconds or less) that are intrapeptidic between different sites as well as interpeptidic.This highly dynamic metal-IDP interaction has a strong impact on reactivity and potential biological role: (i) Due to the low affinity compared with classical metalloproteins, IDPs likely bind metals only at special places or under special conditions. For Aβ, this is likely in the neurons that expel Zn or Cu into the synapse and upon metal dysregulation occurring in Alzheimers disease. (ii) Amino acid substitutions (mutations) on noncoordinating residues can change drastically the coordination sphere. (iii) Considering the Cu/Zn-Aβ aberrant interaction, therapeutic strategies can be based on removal of Cu/Zn or precluding their binding to the peptide. The latter is very difficult due to the multitude of metal-binding sites, but the fast k off facilitates removal. (iv) The high flexibility of the Cu-Aβ complex results in different conformations with different redox activity. Only some conformations are able to produce reactive oxygen species. (v) Other, more specific catalysis (like enzymes) is very unlikely for Cu/Zn-Aβ. (vi) The Cu/Zn exchange reactions with Aβ are faster than the aggregation process and can hence have a strong impact on this process.In conclusion, the coordination chemistry is fundamentally different for most of IDPs compared with the classical, structured metalloproteins or with (bio)-inorganic complexes. The dynamics is a key parameter to understand this interaction and its potential biological impact. © 2014 American Chemical Society.",,"Uversky, V.N., Unusual biophysics of intrinsically disordered proteins (2013) Biochim. Biophys. Acta, 1834 (5), pp. 932-951; Abelein, A., Abrahams, J.P., Danielsson, J., Gräslund, A., Jarvet, J., Luo, J., Tiiman, A., Wärmländer, S.K.T.S., The hairpin conformation of the amyloid-β peptide is an important structural motif along the aggregation pathway (2014) J. Biol. Inorg. Chem., 19, pp. 623-634. , 10.1007/s00775-014-1131-8; Vivekanandan, S., Brender, J.R., Lee, S.Y., Ramamoorthy, A., A partially folded structure of amyloid-beta(1-40) in an aqueous environment (2011) Biochem. Biophys. Res. Commun., 411 (2), pp. 312-316; Drew, S.C., Barnham, K.J., The heterogeneous nature of Cu(2+) interactions with Alzheimers amyloid-β peptide (2011) Acc. Chem. Res., 44 (11), pp. 1146-1155; Hureau, C., Dorlet, P., Coordination of redox active metal ions to the APP protein and to the amyloid-β peptides involved in Alzheimer disease. Part 2: How Cu(II) binding sites depend on changes in the Aβ sequences (2012) Coord. Chem. Rev., 256 (1920), pp. 2175-2187; Durand, J., Meloni, G., Talmard, C., Vasak, M., Faller, P., Zinc release of Zn(7)-metallothionein-3 induces fibrillar type amyloid-beta aggregates (2010) Metallomics, 2 (11), pp. 741-744; Meloni, G., Sonois, V., Delaine, T., Guilloreau, L., Gillet, A., Teissié, J., Faller, P., Vasak, M., Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity (2008) Nat. Chem. Biol., 4 (6), pp. 366-372; Crow, J.P., Sampson, J.B., Zhuang, Y., Thompson, J.A., Beckman, J.S., Decreased zinc affinity of amyotrophic lateral sclerosis-Associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite (1997) J. Neurochem., 69 (5), pp. 1936-1944; Alies, B., Renaglia, E., Rozga, M., Bal, W., Faller, P., Hureau, C., Cu(II) affinity for the Alzheimers peptide: Tyrosine fluorescence studies revisited (2013) Anal. Chem., 85, pp. 1501-1508; Jiang, D., Zhang, L., Grant, G.P., Dudzik, C.G., Chen, S., Patel, S., Hao, Y., Zhou, F., The Elevated copper binding strength of amyloid-beta aggregates allows the sequestration of copper from albumin: A pathway to accumulation of copper in senile plaques (2013) Biochemistry, 52 (3), pp. 547-556; Banci, L., Bertini, I., Ciofi-Baffoni, S., Kozyreva, T., Zovo, K., Palumaa, P., Affinity gradients drive copper to cellular destinations (2010) Nature, 465 (7298), pp. 645-648; Rae, T.D., Schmidt, P.J., Pufahl, R.A., Culotta, V.C., Ohalloran, T.V., Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase (1999) Science, 284 (5415), pp. 805-808; Alies, B., Badei, B., Faller, P., Hureau, C., Reevaluation of copper(I) affinity for amyloid-β peptides by competition with ferrozine, an unusual copper(I) indicator (2012) Chemistry, 18, pp. 1161-1167; Krezel, A., Maret, W., Dual nanomolar and picomolar Zn(II) binding properties of metallothionein (2007) J. Am. Chem. Soc., 129 (35), pp. 10911-10921; Talmard, C., Bouzan, A., Faller, P., Zinc binding to amyloid-β: Isothermal titration calorimetry and Zn competition experiments with Zn sensors (2007) Biochemistry, 46, pp. 13658-13666; Pedersen, J.T., Hureau, C., Hemmingsen, L., Heegaard, N.H., Ostergaard, J., Vasak, M., Faller, P., Rapid exchange of metal between Zn7-metallothionein-3 and amyloid-β peptide promotes amyloid-related structural changes (2012) Biochemistry, 51 (8), pp. 1697-1706; Noy, D., Solomonov, I., Sinkevich, O., Arad, T., Kjaer, K., Sagi, I., Zinc-Amyloid β interactions on a millisecond time-scale stabilize non-fibrillar Alzheimer-related species (2008) J. Am. Chem. Soc., 130 (4), pp. 1376-1383; Faller, P., Copper and zinc binding to amyloid-beta: Coordination, dynamics, aggregation, reactivity and metal-ion transfer (2009) ChemBioChem, 10 (18), pp. 2837-2845; Hureau, C., Balland, V., Coppel, Y., Solari, P.L., Fonda, E., Faller, P., Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-β complexes (2009) J. Biol. Inorg. Chem., pp. 995-1000; Pedersen, J.T., Teilum, K., Heegaard, N.H.H., Østergaard, J., Adolph, H.-W., Hemmingsen, L., Rapid formation of a preoligomeric peptide-metal-peptide complex following copper(II) binding to amyloid β peptides (2011) Angew. Chem., Int. Ed., 50 (11), pp. 2532-2535; Tycko, R., Molecular structure of amyloid fibrils: Insights from solid-state NMR (2006) Q. Rev. Biophys., 39 (1), pp. 1-55; Gunderson, W.A., Hernandez-Guzman, J., Karr, J.W., Sun, L., Szalai, V.A., Warncke, K., Local structure and global patterning of Cu2+ binding in fibrillar amyloid-β [Aβ(1-40)] protein (2012) J. Am. Chem. Soc., 134 (44), pp. 18330-18337; Parthasarathy, S., Long, F., Miller, Y., Xiao, Y., McElheny, D., Thurber, K., Ma, B., Ishii, Y., Molecular-level examination of Cu2+ binding structure for amyloid fibrils of 40-residue Alzheimers β by solid-state NMR spectroscopy (2011) J. Am. Chem. Soc., 133 (10), pp. 3390-3400; Peck, K.L., Clewett, H.S., Schmitt, J.C., Shearer, J., Copper ligation to soluble oligomers of the English mutant of the amyloid-beta peptide yields a linear Cu(I) site that is resistant to O2 oxidation (2013) Chem. Commun., 49 (42), pp. 4797-4799; Drew, S.C., Kok, W.M., Hutton, C.A., Barnham, K.J., Cu2+ Coordination of Covalently Cross-linked beta-Amyloid Dimers (2013) Appl. Magn. Reson., 44 (8), pp. 927-939; Colvin, R.A., Holmes, W.R., Fontaine, C.P., Maret, W., Cytosolic zinc buffering and muffling: Their role in intracellular zinc homeostasis (2010) Metallomics, 2 (5), pp. 306-317; Madsen, E., Gitlin, J.D., Copper and iron disorders of the brain (2007) Annu. Rev. Neurosci., 30, pp. 317-337; James, S.A., Volitakis, I., Adlard, P.A., Duce, J.A., Masters, C.L., Cherny, R.A., Bush, A.I., Elevated labile Cu is associated with oxidative pathology in Alzheimer disease (2012) Free Radical Biol. Med., 52 (2), pp. 298-302; Bush, A.I., Metal complexing agents as therapies for Alzheimers disease (2002) Neurobiol. Aging, 23 (6), pp. 1031-1038; Detoma, A.S., Salamekh, S., Ramamoorthy, A., Lim, M.H., Misfolded proteins in Alzheimers disease and type II diabetes (2012) Chem. Soc. Rev., 41 (2), pp. 608-621; Eury, H., Bijani, C., Faller, P., Hureau, C., CuII coordination amyloid-β: Murine versus human peptide (2011) Angew. Chem., Int. Ed., 50 (4), pp. 901-905; Alies, B., Bijani, C., Sayen, S., Guillon, E., Faller, P., Hureau, C., Copper coordination to native N-terminally modified versus full-length amyloid-beta: Second-sphere effects determine the species present at physiological pH (2012) Inorg. Chem., 51 (23), pp. 12988-13000; Valensin, D., Gabbiani, C., Messori, L., Metal compounds as inhibitors of β-Amyloid aggregation. Perspectives for an innovative metalloptherapeutics on Alzheimer Disease (2012) Coord. Chem. Rev., 1920 (256), pp. 2357-2366; Sasaki, I., Bijani, C., Ladeira, S., Bourdon, V., Faller, P., Hureau, C., Interference of a new cyclometallated Pt compound with Cu binding to amyloid-β peptide (2012) Dalton Trans., 41, pp. 6404-6407; Balland, V., Hureau, C., Savéant, J.-M., Electrochemical and homogeneous electron transfers to the Alzheimer amyloid-β copper complex follow a preorganization mechanism (2010) Proc. Natl. Acad. Sci. U. S. A., 107 (48), pp. 17113-17118; Furlan, S., Hureau, C., Faller, P., La Penna, G., Modeling copper binding to the amyloid-β peptide at different pH: Toward a molecular mechanism for Cu reduction (2012) J. Phys. Chem. B, 116 (39), pp. 11899-11910; Cassagnes, L.E., Herve, V., Nepveu, F., Hureau, C., Faller, P., Collin, F., The catalytically active copper-Amyloid-beta state: Coordination site responsible for reactive oxygen species production (2013) Angew. Chem., Int. Ed., 52 (42), pp. 11110-11113; La Penna, G., Hureau, C., Andreussi, O., Faller, P., Identifying, by first-principles simulations, Cu[amyloid-β] species making Fenton-type reactions in Alzheimers disease (2013) J. Phys. Chem. B, 117 (51), pp. 16455-16467; Ciregna, D., Monzani, E., Thiabaud, G., Pizzocaro, S., Casella, L., Copper-beta-Amyloid peptides exhibit neither monooxygenase nor superoxide dismutase activities (2013) Chem. Commun., 49 (38), pp. 4027-4029; Faller, P., Hureau, C., Berthoumieu, O., Role of metal ions in the self-Assembly of the Alzheimers amyloid-β peptide (2013) Inorg. Chem., 52, pp. 12193-12206; Alies, B., Solari, P.L., Hureau, C., Faller, P., Dynamics of Zn-binding as a key feature in the formation of amyloid fibrils (2012) Inorg. Chem., 51 (1), pp. 701-708; Barnham, K.J., Kenche, V.B., Ciccotosto, G.D., Smith, D.P., Tew, D.J., Liu, X., Perez, K., Cappai, R., Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimers disease (2008) Proc. Natl. Acad. Sci. U. S. A., 105 (19), pp. 6813-6818; Binolfi, A., Quintanar, L., Bertoncini, C.W., Griesinger, C., Fernández, C.O., Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinsons disease (2012) Coord. Chem. Rev., 256 (1920), pp. 2188-2201; Kozlowski, H., Luczkowski, M., Remelli, M., Valensin, D., Copper, zinc and iron in neurodegenerative diseases (Alzheimers disease, Parkinsons disease and prion diseases) (2012) Coord. Chem. Rev., 256 (1920), pp. 2129-2141; Zhou, B., Hao, Y., Wang, C., Li, D., Liu, Y.N., Zhou, F., Conversion of natively unstructured alpha-synuclein to its alpha-helical conformation significantly attenuates production of reactive oxygen species (2013) J. Inorg. Biochem., 118, p. 68",Article,Scopus,2-s2.0-84906263191
"Silva K.I., Michael B.C., Geib S.J., Saxena S.","ESEEM analysis of multi-histidine Cu(II)-coordination in model complexes, peptides, and amyloid-β",2014,"Journal of Physical Chemistry B","118","30",,"8935","8944",,2,10.1021/jp500767n,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84905393641&partnerID=40&md5=8e382ca5108f3437d998dd48b46fd82f","Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States","Silva, K.I., Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States; Michael, B.C., Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States; Geib, S.J., Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States; Saxena, S., Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States","We validate the use of ESEEM to predict the number of 14N nuclei coupled to a Cu(II) ion by the use of model complexes and two small peptides with well-known Cu(II) coordination. We apply this method to gain new insight into less explored aspects of Cu(II) coordination in amyloid-β (Aβ). Aβ has two coordination modes of Cu(II) at physiological pH. A controversy has existed regarding the number of histidine residues coordinated to the Cu(II) ion in component II, which is dominant at high pH (∼8.7) values. Importantly, with an excess amount of Zn(II) ions, as is the case in brain tissues affected by Alzheimers disease, component II becomes the dominant coordination mode, as Zn(II) selectively substitutes component I bound to Cu(II). We confirm that component II only contains single histidine coordination, using ESEEM and set of model complexes. The ESEEM experiments carried out on systematically 15N-labeled peptides reveal that, in component II, His 13 and His 14 are more favored as equatorial ligands compared to His 6. Revealing molecular level details of subcomponents in metal ion coordination is critical in understanding the role of metal ions in Alzheimers disease etiology. © 2014 American Chemical Society.",,"Malmström, B.G., Leckner, J., The Chemical Biology of Copper (1998) Curr. Opin. Chem. Biol., 2, pp. 286-292; Deschampsa, P., Kulkarnia, P.P., Gautam-Basakb, M., Sarkar, B., The Saga of Copper(II)- l -Histidine (2005) Coord. Chem. Rev., 249, pp. 895-909; Viles, J.H., Metal Ions and Amyloid Fiber Formation in Neurodegenerative Diseases. Copper, Zinc and Iron in Alzheimers, Parkinsons and Prion Diseases (2012) Coord. Chem. Rev., 256, pp. 2271-2284; Faller, P., Hureau, C., Bioinorganic Chemistry of Copper and Zinc Ions Coordinated to Amyloid-β Peptide (2009) Dalton Trans., pp. 1080-1094; Binolfi, A.S., Lamberto, G.R., Duran, R., Quintanar, L., Bertoncini, C.W., Souza, J.M., Cerveñansky, C., Fernández, C.O., Site-Specific Interactions of Cu(II) with α and β-Synuclein: Bridging the Molecular Gap between Metal Binding and Aggregation (2008) J. Am. Chem. Soc., 130, pp. 11801-11812; Binolfi, A., Rodriguez, E.E., Valensin, D., Damelio, N., Ippoliti, E., Obal, G., Duran, R., Zweckstetter, M., Bioinorganic Chemistry of Parkinsons Disease: Structural Determinants for the Copper-Mediated Amyloid Formation of Alpha-Synuclein (2010) Inorg. Chem., 49, pp. 10668-10679; Drew, S.C., Leong, S.L., Pham, C.L.L., Tew, D.J., Masters, C.L., Miles, L.A., Cappai, R., Barnham, K.J., Cu2+ Binding Modes of Recombinant α-Synuclein: Insights from EPR Spectroscopy (2008) J. Am. Chem. Soc., 130, pp. 7766-7773; Bortolus, M., Bisaglia, M., Zoleo, A., Fittipaldi, M., Benfatto, M., Bubacco, L., Maniero, A.L., Structural Characterization of a High Affinity Mononuclear Site in the Copper(II)-α-Synuclein Complex (2010) J. Am. Chem. Soc., 132, pp. 18057-18066; Dudzik, C.G., Walter, E.D., Millhauser, G.L., Coordination Features and Affinity of the Cu2+ Site in the α-Synuclein Protein of Parkinsons Disease (2011) Biochemistry, 50, pp. 1771-1777; Binolfia, A., Quintanarb, L., Bertoncinic, C.W., Griesingerd, C., Fernández, C.O., Bioinorganic Chemistry of Copper Coordination to Alpha-Synuclein: Relevance to Parkinsons Disease (2012) Coord. Chem. Rev., 256, pp. 2188-2201; Rasia, R.M., Bertoncini, C.W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., Griesinger, C., Fernández, C.O., Structural Characterization of Copper(II) Binding to α-Synuclein: Insights into the Bioinorganic Chemistry of Parkinsons Disease (2005) Proc. Natl. Acad. Sci., 102, pp. 4294-4299; Aronoff-Spencer, E., Burns, C.S., Avdievich, N.I., Gerfen, G.J., Peisach, J., Antholine, W.E., Ball, H.L., Millhauser, G.L., Identification of the Cu2+ Binding Sites in the N-Terminal Domain of the Prion Protein by Epr and Cd Spectroscopy (2000) Biochemistry, 39, pp. 13760-13771; Burns, C.S., Aronoff-Spencer, E., Legname, G., Prusiner, S.B., Antholine, W.E., Gerfen, G.J., Peisach, J., Millhauser, G.L., Copper Coordination in the Full-Length, Recombinant Prion Protein (2003) Biochemistry, 42, pp. 6794-6803; Klewpatinond, M., Davie, P., Bowen, S., Brown, D.R., Viles, J.H., Deconvoluting the Cu2+ Binding Modes of Full-Length Prion Protein (2007) J. Biol. Chem., 283, pp. 1870-1881; Millhauser, G.L., Copper and the Prion Protein: Methods, Structures, Function,and Disease (2007) Annu. Rev. Phys. Chem., 58, pp. 299-320; Walter, E.D., Stevens, D.J., Visconte, M.P., Millhauser, G.L., The Prion Protein Is a Combined Zinc and Copper Binding Protein: Zn 2+ Alters the Distribution of Cu2+ Coordination Modes (2007) J. Am. Chem. Soc., 129, pp. 15440-15441; Chattopadhyay, M., Walter, E.D., Newell, D.J., Jackson, P.J., Aronoff-Spencer, E., Peisach, J., Gerfen, G.J., Millhauser, G.L., The Octarepeat Domain of the Prion Protein Binds Cu(II) with Three Distinct Coordination Modes at pH 7.4 (2005) J. Am. Chem. Soc., 127, pp. 12647-12656; Jackson, G.S., Murray, I., Hosszu, L.L.P., Gibbs, N., Waltho, J.P., Clarke, A.R., Collinge, J., Location and Properties of Metal-Binding Sites on the Human Prion Protein (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 8531-8535; Jones, C.E., Klewpatinond, M., Abdelraheim, S.R., Brown, D.R., Viles, J.H., Probing Cu2+ Binding to the Prion Protein Using Diamagnetic Ni2+ and 1H NMR: The Unstructured N Terminus Facilitates the Coordination of Six Cu2+ Ions at Physiological Concentrations (2005) J. Mol. Biol., 346, pp. 1393-1407; Stellato, F., Spevacek, A., Proux, O., Minicozzi, V., Millhauser, G., Morante, S., Zinc Modulates Copper Coordination Mode in Prion Protein Octa-Repeat Subdomains (2011) Eur. Biophys J., 40, pp. 1259-1270; Morante, S., González-Iglesias, R., Potrich, C., Meneghini, C., Meyer-Klaucke, W., Menestrina, G., Gasset, M., Inter- and Intra-Octarepeat Cu(II) Site Geometries in the Prion Protein Implications in Cu(II) Binding Cooperativity and Cu(II)-Mediated Assemblies (2004) J. Biol. Chem., 279, pp. 11753-11759; Furlan, S., Penna, G.L., Guerrieri, F., Morante, S., Rossi, G.C., Ab Initio Simulations of Cu Binding Sites on the N-Terminal Region of Prion Protein (2007) J. Biol. Inorg. Chem., 12, pp. 571-583; Guerrieri, F., Minicozzi, V., Morante, S., Rossi, G., Furlan, S., Penna, G.L., Modeling the Interplay of Glycine Protonation and Multiple Histidine Binding of Copper in the Prion Protein Octarepeat Subdomains (2009) J. Biol. Inorg. Chem., 14, pp. 361-374; Quintanar, L., Rivillas-Acevedo, L., Grande-Aztatzi, R., Gómez-Castro, C.Z., Arcos-López, T., Vela, A., Copper Coordination to the Prion Protein: Insights from Theoretical Studies (2013) Coord. Chem. Rev., 257, pp. 429-444; Syme, C.D., Nadal, R.C., Rigby, S.E., Viles, J.H., Copper Binding to the Amyloid-β (Aβ) Peptide Associated with Alzheimers Disease: Folding, Coordination Geometry, pH Dependence, Stoichiometry, and Affinity of Aβ-(1-28): Insights from a Range of Complementary Spectroscopic Techniques (2004) J. Biol. Chem., 279, pp. 18169-18177; Guilloreau, L., Damian, L., Coppel, Y., Mazarguil, H., Winterhalter, M., Faller, P., Structural and Thermodynamical Properties of Cuii Amyloid-β16/28 Complexes Associated with Alzheimers Disease (2006) J. Biol. Inorg. Chem., 11, pp. 1024-1038; Shin, B.-K., Saxena, S., Direct Evidence That All Three Histidine Residues Coordinate to Cu(II) in Amyloid-β(1-16) (2008) Biochemistry, 47, pp. 9117-9123; Morante, S., The Role of Metals in β-Amyloid Peptide Aggregation: X-Ray Spectroscopy and Numerical Simulations (2008) Curr. Alzheimers Res., 5, pp. 508-524; Faller, P., Hureau, C., Impact of Metallic Ions in Alzheimers Disease: Insights from XAS Spectroscopy (2011) Actual. Chim., pp. 356-357; Youssef, E.K., Pierre, D., Peter, F., Petra, H., New Insights into the Coordination of Cu(II) by the Amyloid-β 16 Peptide from Fourier Transform Ir Spectroscopy and Isotopic Labeling (2011) J. Phys. Chem. B, 115, pp. 14812-14821; Hureau, C., Coppel, Y., Dorlet, P., Solari, P.L., Sayen, S., Guillon, E., Sabater, L., Faller, P., Deprotonation of the Asp1-Ala2 Peptide Bond Induces Modification of the Dynamic Copper(II) Environment in the Amyloid-β Peptide near Physiological pH (2009) Angew. Chem., Int. Ed., 48, pp. 9522-9525; Kowalik-Jankowska, T., Ruta, M., Wisniewska, K., Ankiewicz, L., Coordination Abilities of the 1-16 and 1-28 Fragments of B-Amyloid Peptide Towards Copper(II) Ions: A Combined Potentiometric and Spectroscopic Study (2003) J. Inorg. Biochem., 95, pp. 270-282; Lu, Y., Prudent, M., Qiao, L., Mendeza, M.A., Girault, H.H., Copper(I) and Copper(II) Binding to β-Amyloid 16 (Aβ16) Studied by Electrospray Ionization Mass Spectrometry (2010) Metallomics, 2, pp. 474-479; Raffa, D.F., Gómez-Balderas, R., Brunelle, P., Rickard, G.A., Rauk, A., Ab Initio Model Studies of Copper Binding to Peptides Containing a His-His Sequence: Relevance to the β-Amyloid Peptide of Alzheimers Disease (2005) J. Biol. Inorg. Chem., 10, pp. 887-902; Rauk, A., Why Is the Amyloid Beta Peptide of Alzheimers Disease Neurotoxic? (2008) Dalton Trans., pp. 1273-1282; Drew, S.C., Noble, C.J., Masters, C.L., Hanson, G.R., Barnham, K.J., Pleomorphic Copper Coordination by Alzheimers Disease Amyloid-β Peptide (2009) J. Am. Chem. Soc., 131, pp. 1195-1207; Dorlet, P., Gambarelli, S., Faller, P., Hureau, C., Pulse EPR Spectroscopy Reveals the Coordination Sphere of Copper(II) Ions in the 1-16 Amyloid-β Peptide: A Key Role of the First Two N-Terminus Residues (2009) Angew. Chem., Int. Ed., 48, pp. 9273-9276; Shin, B.-K., Saxena, S., Substantial Contribution of the Two Imidazole Rings of the His13-His14 Dyad to Cu(II) Binding in Amyloid-β(1-16) at Physiological pH and Its Significance (2011) J. Phys. Chem. A, 115, pp. 9590-9602; Silva, K.I., Saxena, S., Zn(II) Ions Substantially Perturb Cu(II) Ion Coordination in Amyloid-β at Physiological pH (2013) J. Phys. Chem. B, 117, pp. 9386-9394; Drew, S.C., Noble, C.J., Masters, C.L., Hanson, G.R., Barnham, K.J., Pleomorphic Copper Coordination by Alzheimers Disease Amyloid-β Peptide (2009) J. Am. Chem. Soc., 131, pp. 1195-1207; Gunderson, W.A., Hernández-Guzmán, J., Karr, J.W., Sun, L., Szalai, V.A., Warncke, K., Local Structure and Global Patterning of Cu2+ Binding in Fibrillar Amyloid-β [Aβ(1-40)] Protein (2012) J. Am. Chem. Soc., 134, pp. 18330-18337; Hureau, C., Coordination of Redox Active Metal Ions to the Amyloid Precursor Protein and to Amyloid-β Peptides Involved in Alzheimer Disease. Part 1: An Overview (2012) Coord. Chem. Rev., 256, pp. 2164-2174; Dorlet, P., Gambarelli, S., Faller, P., Hureau, C., Pulse EPR Spectroscopy Reveals the Coordination Sphere of Copper(II) Ions in the 1-16 Amyloid-β Peptide: A Key Role of the First Two N-Terminus Residues (2009) Angew. Chem., Int. Ed., 48, pp. 9273-9276; Jun, S., Gillespie, J.R., Shin, B.K., Saxena, S., The Second Cu(II)-Binding Site in a Proton-Rich Environment Interferes with the Aggregation of Amyloid-Beta(1-40) into Amyloid Fibrils (2009) Biochemistry, 48, pp. 10724-10732; Alies, B., Sasaki, I., Sayen, S., Guillon, E., Faller, P., Hureau, C., Zn Impacts Cu Coordination to Amyloid-β, the Alzheimers Peptide, but Not the Ros Production and the Associated Cell Toxicity (2013) Chem. Commun., 49, pp. 2130-2132; Lovell, M.A., Robertsona, J.D., Teesdaleb, W.J., Campbell, J.L., Markesbery, W.R., Copper, Iron and Zinc in Alzheimers Disease Senile Plaques (1998) J. Neurol. Sci., 158, pp. 47-52; McCracken, J., Desai, P.R., Papadopoulos, N.J., Villafranca, J.J., Peisach, J., Electron Spin-Echo Studies of the Copper(II) Binding Sites in Dopamine β-Hydroxylase (1988) Biochemistry, 27, pp. 4133-4137; Goldfarb, D., Fauth, J.-M., Tor, Y., Shanzer, A., Study of Cu(II) Binding to Chiral Tripodal Ligands by Electron Spin Echo Spectroscopy (1991) J. Am. Chem. Soc., 113, pp. 1941-1948; Fransson, G., Lundberg, B.K.S., Metal Complexes with Mixed Ligands, 4. The Crystal Structure of Tetrakisimidazole Cu(II) Sulphate, Cu(C3H4N 2)4so4 (1972) Acta Chem. Scand., 26, pp. 3969-3976; Abuhijleh, A.L., Woods, C., Ahmed, I.Y., Synthesis and Molecular Structure of Monomeric Copper(II) Acetates with 2-Methylimidazole and 1,2-Dimethylimidazole (1990) Inorg. Chim. Acta, 190, pp. 11-17; Sato, M., Nagae, S., Ohmae, K., Nakaya, J.-I., Preparation and Crystal Structure of an Imidazolate: Bridged Polynuclear Complex [{Cu(Im)(Dien)}N][ClO4]N (Dien = Diethylenetriamine), and Its Properties in Dimethyl Sulfoxide Solution (1986) J. Chem. Soc., Dalton Trans., p. 1949; Merrifield, R.B., Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide (1963) J. Am. Chem. Soc., 85, pp. 2149-2154; Fields, G.B., Noble, R.L., Solid Phase Peptide Synthesis Utilizing 9-Fluorenylmethoxycarbonyl Amino Acids (1990) Int. J. Pept. Protein Res., 35, pp. 161-214; Fauth, J.M., Schweiger, A., Braunschweiler, L., Forrer, J., Ernst, R.R., Elimination of Unwanted Echoes and Reduction of Deadtime in Three-Pulse Electron Spin-Echo Spectroscopy (1986) J. Magn. Reson., 66, p. 74; Gemperle, C., Aebli, G., Schweiger, A., Ernst, R.R., Phase Cycling in Pulse EPR (1990) J. Magn. Reson., 88, p. 241; Guilloreau, L., Combalbert, S., Sournia-Saquet, A., Mazarguil, H., Faller, P., Redox Chemistry of Copper-Amyloid-β: Thegeneration of Hydroxyl Radical in the Presenceof Ascorbate Is Linked to Redox-Potentials and Aggregation State (2007) ChemBioChem, 8, pp. 1317-1325; Burns, C.S., Aronoff-Spencer, E., Dunham, C.M., Lario, P., Avdiech, N.I., Antholine, W.E., Olmstead, M.M., Peisach, J., Molecular Features of the Copper Binding Sites in the Octarepeat Domain of the Prion Protein (2002) Biochemistry, 41, pp. 3991-4001; Deligiannakis, Y., Louloudib, M., Hadjiliadis, N., Electron Spin Echo Envelope Modulation (ESEEM) Spectroscopy as a Tool to Investigate the Coordination Environment of Metal Centers (2000) Coord. Chem. Rev., 201, pp. 1-112; Peisach, J., Blumberg, W.E., Structural Implications Derived from the Analysis of EPR Spectra of Natural and Artificial Copper Proteins (1974) Arch. Biochem. Biophys., 165, pp. 691-708; Hernández-Guzmán, J., Sun, L., Mehta, A.K., Dong, J., Lynn, D.G., Warncke, K., Copper(II)-Bis-Histidine Coordination Structure in a Fibrillar Amyloid β-Peptide Fragment and Model Complexes Revealed by Electron Spin Echo Envelope Modulation Spectroscopy (2013) ChemBioChem, 14, pp. 1762-1771; McCracken, J., Pember, S., Benkovic, S.J., Villafranca, J.J., Miller, R.J., Peisach, J., Electron Spin-Echo Studies of the Copper Binding Site in Phenylalanine Hydroxylase from Chromobacterium Violaceum (1988) J. Am. Chem. Soc., 110, pp. 1069-1074; Burns, C.S., Aronoff-Spencer, E., Dunham, C.M., Lario, P., Avdievich, N.I., Antholine, W.E., Olmstead, M.M., Peisach, Molecular Features of the Copper Binding Sites in the Octarepeat Domain of the Prion Protein (2002) Biochemistry, 41, pp. 3991-4001; Shin, B.-K., Saxena, S., Insight into Potential Cu(II)-Binding Motifs in the Four Pseudorepeats of Tau Protein (2011) J. Phys. Chem. B, 115, pp. 15067-15078; McCracken, J., Peisach, J., Cote, C.E., McGuirl, M.A., Dooley, D.M., Pulsed EPR Studies of the Semiquinone State of Copper-Containing Amine Oxidases (1992) J. Am. Chem. Soc., 114, pp. 3715-3720; Mims, W.B., Envelope Modulation in Spin-Echo Experiments (1972) Phys. Rev. B, 5, pp. 2409-2419; Lai, A., Flanagan, H.L., Singel, D.J., Multifrequency Electron Spin Echo Envelope Modulation in S = 1/2, i = 1/2 Systems: Analysis of the Spectral Amplitudes, Line Shapes, and Linewidths (1988) J. Chem. Phys., 89, pp. 7161-7166; Tang, X.S., Diner, B.A., Larsen, B.S., Gilchrist, Jr.M.L., Lorigan, G.A., Britt, R.D., Identification of Histidine at the Catalytic Site of the Photosynthetic Oxygen-Evolving Complex (1994) Proc. Natl. Acad. Sci. U.S.A., 91, pp. 704-708; Singh, V., Zhu, Z., Davidson, V.L., McCracken, J., Characterization of the Tryptophan Tryptophyl-Semiquinone Catalytic Intermediate of Methylamine Dehydrogenase by Electron Spin-Echo Envelope Modulation Spectroscopy (2000) J. Am. Chem. Soc., 122, pp. 931-938; Stoll, S., Calle, C., Mitrikas, G., Schweiger, A., Peak Suppression in Eseem Spectra of Multinuclear Spin Systems (2005) J. Magn. Reson., 177, pp. 93-101; Ma, K., Clancy, E.L., Zhang, Y., Ray, D.G., Wollenberg, K., Zagorski, M.G., Residue-Specific p K a Measurements of the β-Peptide and Mechanism of pH-Induced Amyloid Formation (1999) J. Am. Chem. Soc., 121, pp. 8698-8706; Zhang, X., Tian, Y., Li, Z., Tian, X., Sun, H., Liu, H., Moore, A., Ran, C., Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimers Disease (2013) J. Am. Chem. Soc., 135, pp. 16397-16409; Drew, S.C., Masters, C.L., Barnham, K.J., Alanine-2 Carbonyl Is an Oxygen Ligand in Cu2+ Coordination of Alzheimers Disease Amyloid-B Peptide: Relevance to N-Terminally Truncated Forms (2009) J. Am. Chem. Soc., 131, pp. 8760-8761",Article,Scopus,2-s2.0-84905393641
"Richardson J.C., Hunter J.","'Recent advances in the treatment of Alzheimers': Therapeutic strategies",2014,"Drug Discovery Today: Therapeutic Strategies",,,,"","",,,10.1016/j.ddstr.2014.06.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904520150&partnerID=40&md5=6959018cd08bb0e256efc974652329ff","Neurosciences Therapeutic Area, GlaxoSmithKline R and D, Gunnels Wood Road, Stevenage SG1 2NY, UK; Biotechnology and Biological Sciences Research Council, Polaris House, North Star Avenue, Swindon SN2 1UH, UK","Richardson, J.C., Neurosciences Therapeutic Area, GlaxoSmithKline R and D, Gunnels Wood Road, Stevenage SG1 2NY, UK; Hunter, J., Biotechnology and Biological Sciences Research Council, Polaris House, North Star Avenue, Swindon SN2 1UH, UK",[No abstract available],,,Article in Press,Scopus,2-s2.0-84904520150
"Di Scala C., Chahinian H., Yahi N., Garmy N., Fantini J.","Interaction of Alzheimer's β-amyloid peptides with cholesterol: Mechanistic insights into amyloid pore formation",2014,"Biochemistry","53","28",,"4489","4502",,1,10.1021/bi500373k,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904700172&partnerID=40&md5=df83220fc42bd4f2b60528f3ec55c749","EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France","Di Scala, C., EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France; Chahinian, H., EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France; Yahi, N., EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France; Garmy, N., EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France; Fantini, J., EA-4674, Faculté des Sciences de Saint-Jérôme, Aix-Marseille Université, 13013 Marseille, France","Brain cholesterol plays a critical role in Alzheimer's disease and other neurodegenerative diseases. The molecular mechanisms linking cholesterol to neurotoxicity have remained elusive for a long time, but recent data have allowed the identification of functional cholesterol-binding domains in several amyloidogenic proteins involved in neurodegenerative diseases, including Alzheimers disease. In this review, we analyze the cholesterol binding properties of β-amyloid (Aβ) peptides and the impact of these interactions on amyloid pore formation. We show that although the cholesterol-binding domains of Aβ peptides and of transmembrane precursor C99 are partially overlapping, they involve distinct amino acid residues, so that cholesterol has a greater affinity for Aβ than for C99. Synthetic 22-35 and 25-35 fragments of Aβ retained the ability of the full-length peptide 1-42 to bind cholesterol and to form zinc-sensitive, calcium-permeable amyloid pores in cultured neural cells. Studies with mutant peptides allowed the identification of key residues involved in cholesterol binding and channel formation. Cholesterol promoted the insertion of Aβ in the plasma membrane, induced α-helical structuration, and forced the peptide to adopt a tilted topology that favored the oligomerization process. Bexarotene, an amphipathic drug currently considered as a potential candidate medication for the treatment of neurodegenerative diseases, competed with cholesterol for binding to Aβ and prevented oligomeric channel formation. These studies indicate that it is possible to prevent the generation of neurotoxic oligomers by targeting the cholesterol-binding domain of Aβ peptides. This original strategy could be used for the treatment of Alzheimers and other neurodegenerative diseases that involve cholesterol-dependent toxic oligomers. © 2014 American Chemical Society.",,"Wood, W.G., Li, L., Muller, W.E., Eckert, G.P., Cholesterol as a causative factor in Alzheimers disease: A debatable hypothesis (2014) J. Neurochem., 129, pp. 559-572; Kivipelto, M., Helkala, E.L., Laakso, M.P., Hanninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Nissinen, A., Midlife vascular risk factors and Alzheimers disease in later life: Longitudinal, population based study (2001) BMJ [Br. Med. J.], 322, pp. 1447-1451; Pappolla, M.A., Bryant-Thomas, T.K., Herbert, D., Pacheco, J., Fabra Garcia, M., Manjon, M., Girones, X., Refolo, L.M., Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology (2003) Neurology, 61, pp. 199-205; McGuinness, B., Ohare, J., Craig, D., Bullock, R., Malouf, R., Passmore, P., Cochrane review on Statins for the treatment of dementia (2013) International Journal of Geriatric Psychiatry, 28, pp. 119-126; Silva, T., Teixeira, J., Remiao, F., Borges, F., Alzheimers disease, cholesterol, and statins: The junctions of important metabolic pathways (2013) Angew. Chem., Int. Ed., 52, pp. 1110-1121; Simons, M., Keller, P., Dichgans, J., Schulz, J.B., Cholesterol and Alzheimers disease: Is there a link? (2001) Neurology, 57, pp. 1089-1093; Abramov, A.Y., Ionov, M., Pavlov, E., Duchen, M.R., Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: Implications for Alzheimers disease (2011) Aging Cell, pp. 595-603; Fantini, J., Garmy, N., Mahfoud, R., Yahi, N., Lipid rafts: Structure, function and role in HIV, Alzheimers and prion diseases (2002) Expert Rev. Mol. Med., 4, pp. 1-22; Posse De Chaves, E., Sipione, S., Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction (2010) FEBS Lett., 584, pp. 1748-1759; Van Echten-Deckert, G., Walter, J., Sphingolipids: Critical players in Alzheimers disease (2012) Prog. Lipid Res., 51, pp. 378-393; Hartmann, T., Kuchenbecker, J., Grimm, M.O., Alzheimers disease: The lipid connection (2007) J. Neurochem., 103 (SUPPL. 1), pp. 159-170; Martins, I.J., Berger, T., Sharman, M.J., Verdile, G., Fuller, S.J., Martins, R.N., Cholesterol metabolism and transport in the pathogenesis of Alzheimers disease (2009) J. Neurochem., 111, pp. 1275-1308; Laufs, U., Gertz, K., Dirnagl, U., Bohm, M., Nickenig, G., Endres, M., Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice (2002) Brain Res., 942, pp. 23-30; Mohmmad Abdul, H., Wenk, G.L., Gramling, M., Hauss-Wegrzyniak, B., Butterfield, D.A., APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: Implications for Alzheimers disease (2004) Neurosci. Lett., 368, pp. 148-150; Harris, J.R., Milton, N.G., Cholesterol in Alzheimers disease and other amyloidogenic disorders (2010) Subcell. Biochem., 51, pp. 47-75; Yanagisawa, K., Role of gangliosides in Alzheimers disease (2007) Biochim. Biophys. Acta, 1768, pp. 1943-1951; Yanagisawa, K., Pathological significance of ganglioside clusters in Alzheimers disease (2011) J. Neurochem., 116, pp. 806-812; Greenwald, J., Riek, R., Biology of amyloid: Structure, function, and regulation (2010) Structure, 18, pp. 1244-1260; Dasilva, K.A., Shaw, J.E., McLaurin, J., Amyloid-β fibrillogenesis: Structural insight and therapeutic intervention (2010) Exp. Neurol., 223, pp. 311-321; Kanekiyo, T., Xu, H., Bu, G., ApoE and Aβ in Alzheimers disease: Accidental encounters or partners? (2014) Neuron, 81, pp. 740-754; Yanagisawa, K., Cholesterol and amyloid β fibrillogenesis (2005) Subcell. Biochem., 38, pp. 179-202; Li, H., Papadopoulos, V., Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern (1998) Endocrinology, 139, pp. 4991-4997; Baier, C.J., Fantini, J., Barrantes, F.J., Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor (2011) Sci. Rep., 1, p. 69; Fantini, J., Barrantes, F.J., How cholesterol interacts with membrane proteins: An exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains (2013) Front. Physiol., 4, p. 31; Fantini, J., Barrantes, F.J., Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function (2009) Biochim. Biophys. Acta, 1788, pp. 2345-2361; Rosenhouse-Dantsker, A., Noskov, S., Durdagi, S., Logothetis, D.E., Levitan, I., Identification of novel cholesterol-binding regions in Kir2 channels (2013) J. Biol. Chem., 288, pp. 31154-31164; Levitan, I., Singh, D.K., Rosenhouse-Dantsker, A., Cholesterol binding to ion channels (2014) Front. Physiol., 5, p. 65; Nishio, M., Umezawa, Y., Fantini, J., Weiss, M.S., Chakrabarti, P., CH/π hydrogen bonds in biological macromolecules (2014) Phys. Chem. Chem. Phys., 16, pp. 12648-12683; Lahdo, R., Coillet-Matillon, S., Chauvet, J.P., De La Fourniere-Bessueille, L., The amyloid precursor protein interacts with neutral lipids (2002) Eur. J. Biochem., 269, pp. 2238-2246; Seelig, A., Local anesthetics and pressure: A comparison of dibucaine binding to lipid monolayers and bilayers (1987) Biochim. Biophys. Acta, 899, pp. 196-204; Thakur, G., Pao, C., Micic, M., Johnson, S., Leblanc, R.M., Surface chemistry of lipid raft and amyloid Abeta (1-40) Langmuir monolayer (2011) Colloids Surf., B, 87, pp. 369-377; Fantini, J., Carlus, D., Yahi, N., The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain (2011) Biochim. Biophys. Acta, 1808, pp. 2343-2351; Hammache, D., Yahi, N., Pieroni, G., Ariasi, F., Tamalet, C., Fantini, J., Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: Implications for the role of glycolipids as potential HIV-1 fusion cofactors (1998) Biochem. Biophys. Res. Commun., 246, pp. 117-122; Aubert-Jousset, E., Garmy, N., Sbarra, V., Fantini, J., Sadoulet, M.O., Lombardo, D., The combinatorial extension method reveals a sphingolipid binding domain on pancreatic bile salt-dependent lipase: Role in secretion (2004) Structure, 12, pp. 1437-1447; Chakrabandhu, K., Huault, S., Garmy, N., Fantini, J., Stebe, E., Mailfert, S., Marguet, D., Hueber, A.O., The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand (2008) Cell Death Differ., 15, pp. 1824-1837; Taieb, N., Maresca, M., Guo, X.J., Garmy, N., Fantini, J., Yahi, N., The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif (2009) Cancer Lett., 278, pp. 164-173; Hamel, S., Fantini, J., Schweisguth, F., Notch ligand activity is modulated by glycosphingolipid membrane composition in Drosophila melanogaster (2010) J. Cell Biol., 188, pp. 581-594; Chattopadhyay, A., Paila, Y.D., Shrivastava, S., Tiwari, S., Singh, P., Fantini, J., Sphingolipid-binding domain in the serotonin(1A) receptor (2012) Adv. Exp. Med. Biol., 749, pp. 279-293; Heuss, S.F., Tarantino, N., Fantini, J., Ndiaye-Lobry, D., Moretti, J., Israel, A., Logeat, F., A glycosphingolipid binding domain controls trafficking and activity of the mammalian notch ligand delta-like 1 (2013) PLoS One, 8, p. 74392; Hammache, D., Pieroni, G., Yahi, N., Delezay, O., Koch, N., Lafont, H., Tamalet, C., Fantini, J., Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3 (1998) J. Biol. Chem., 273, pp. 7967-7971; Fantini, J., Hammache, D., Pieroni, G., Yahi, N., Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion (2000) Glycoconjugate J., 17, pp. 199-204; Fantini, J., Maresca, M., Hammache, D., Yahi, N., Delezay, O., Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: Activation of signal transduction pathways and perturbations of intestinal absorption and secretion (2000) Glycoconjugate J., 17, pp. 173-179; Hammache, D., Pieroni, G., Maresca, M., Ivaldi, S., Yahi, N., Fantini, J., Reconstitution of sphingolipid-cholesterol plasma membrane microdomains for studies of virus-glycolipid interactions (2000) Methods Enzymol., 312, pp. 495-506; Mahfoud, R., Mylvaganam, M., Lingwood, C.A., Fantini, J., A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction (2002) J. Lipid Res., 43, pp. 1670-1679; Fantini, J., How sphingolipids bind and shape proteins: Molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains (2003) Cell. Mol. Life Sci., 60, pp. 1027-1032; Fantini, J., Garmy, N., Yahi, N., Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: Application to HpaA, a protein involved in the adhesion of Helicobacter pylori to gastrointestinal cells (2006) Biochemistry, 45, pp. 10957-10962; Mahfoud, R., Garmy, N., Maresca, M., Yahi, N., Puigserver, A., Fantini, J., Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins (2002) J. Biol. Chem., 277, pp. 11292-11296; Taieb, N., Yahi, N., Fantini, J., Rafts and related glycosphingolipid-enriched microdomains in the intestinal epithelium: Bacterial targets linked to nutrient absorption (2004) Adv. Drug Delivery Rev., 56, pp. 779-794; Levy, M., Garmy, N., Gazit, E., Fantini, J., The minimal amyloid-forming fragment of the islet amyloid polypeptide is a glycolipid-binding domain (2006) FEBS J., 273, pp. 5724-5735; Fantini, J., Interaction of proteins with lipid rafts through glycolipid-binding domains: Biochemical background and potential therapeutic applications (2007) Curr. Med. Chem., 14, pp. 2911-2917; Yahi, N., Aulas, A., Fantini, J., How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimers β amyloid peptide (Aβ1-40) (2010) PLoS One, 5, p. 9079; Mazargui, H., Leveque, C., Bartnik, D., Fantini, J., Gouget, T., Melone, M.A., Funke, S.A., Perrone, L., A synthetic amino acid substitution of Tyr10 in Aβ peptide sequence yields a dominant negative variant in amyloidogenesis (2012) Aging Cell, 11, pp. 530-541; Fantini, J., Yahi, N., The driving force of α-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: Key role of ganglioside- and cholesterol-binding domains (2013) Adv. Exp. Med. Biol., 991, pp. 15-26; Fantini, J., Yahi, N., Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: Key role of tyrosine 39 in membrane insertion (2011) J. Mol. Biol., 408, pp. 654-669; Beel, A.J., Sakakura, M., Barrett, P.J., Sanders, C.R., Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimers disease relationships? (2010) Biochim. Biophys. Acta, 1801, pp. 975-982; Barrett, P.J., Song, Y., Van Horn, W.D., Hustedt, E.J., Schafer, J.M., Hadziselimovic, A., Beel, A.J., Sanders, C.R., The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol (2012) Science, 336, pp. 1168-1171; Beel, A.J., Mobley, C.K., Kim, H.J., Tian, F., Hadziselimovic, A., Jap, B., Prestegard, J.H., Sanders, C.R., Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): Does APP function as a cholesterol sensor? (2008) Biochemistry, 47, pp. 9428-9446; Wolozin, B., A fluid connection: Cholesterol and Aβ (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 5371-5373; Chauhan, N.B., Membrane dynamics, cholesterol homeostasis, and Alzheimers disease (2003) J. Lipid Res., 44, pp. 2019-2029; Johnson, R.M., Rath, A., Melnyk, R.A., Deber, C.M., Lipid solvation effects contribute to the affinity of Gly-xxx-Gly motif-mediated helix-helix interactions (2006) Biochemistry, 45, pp. 8507-8515; Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Hartmann, T., Simvastatin strongly reduces levels of Alzheimers disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 5856-5861; Kojro, E., Gimpl, G., Lammich, S., Marz, W., Fahrenholz, F., Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 (2001) Proc. Natl. Acad. Sci. U.S.A., 98, pp. 5815-5820; Arispe, N., Doh, M., Plasma membrane cholesterol controls the cytotoxicity of Alzheimers disease AβP(1-40) and (1-42) peptides (2002) FASEB J., 16, pp. 1526-1536; Avdulov, N.A., Chochina, S.V., Igbavboa, U., Warden, C.S., Vassiliev, A.V., Wood, W.G., Lipid binding to amyloid β-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids (1997) J. Neurochem., 69, pp. 1746-1752; Harris, J.R., Cholesterol binding to amyloid-β fibrils: A TEM study (2008) Micron, 39, pp. 1192-1196; Qiu, L., Buie, C., Reay, A., Vaughn, M.W., Cheng, K.H., Molecular dynamics simulations reveal the protective role of cholesterol in β-amyloid protein-induced membrane disruptions in neuronal membrane mimics (2011) J. Phys. Chem. B, 115, pp. 9795-9812; Yu, X., Zheng, J., Cholesterol promotes the interaction of Alzheimer β-amyloid monomer with lipid bilayer (2012) J. Mol. Biol., 421, pp. 561-571; Di Scala, C., Yahi, N., Lelievre, C., Garmy, N., Chahinian, H., Fantini, J., Biochemical identification of a linear cholesterol-binding domain within Alzheimers β amyloid peptide (2013) ACS Chem. Neurosci., 4, pp. 509-517; Di Scala, C., Troadec, J.D., Lelievre, C., Garmy, N., Fantini, J., Chahinian, H., Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide (2014) J. Neurochem., 128, pp. 186-195; Fantini, J., Di Scala, C., Yahi, N., Troadec, J.D., Sadelli, K., Chahinian, H., Garmy, N., Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimers β-amyloid peptides (2014) ACS Chem. Neurosci., 5, pp. 216-224; Mobley, D.L., Cox, D.L., Singh, R.R., Maddox, M.W., Longo, M.L., Modeling amyloid β-peptide insertion into lipid bilayers (2004) Biophys. J., 86, pp. 3585-3597; Uversky, V.N., Intrinsic disorder in proteins associated with neurodegenerative diseases (2009) Front. Biosci., Landmark Ed., 14, pp. 5188-5238; Fantini, J., Yahi, N., Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: Common mechanisms in neurodegenerative diseases (2010) Expert Rev. Mol. Med., 12, p. 27; Kallberg, Y., Gustafsson, M., Persson, B., Thyberg, J., Johansson, J., Prediction of amyloid fibril-forming proteins (2001) J. Biol. Chem., 276, pp. 12945-12950; Ji, S.R., Wu, Y., Sui, S.F., Cholesterol is an important factor affecting the membrane insertion of β-amyloid peptide (Aβ1-40), which may potentially inhibit the fibril formation (2002) J. Biol. Chem., 277, pp. 6273-6279; Cecchi, C., Stefani, M., The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity (2013) Biophys. Chem., 182, pp. 30-43; Lashuel, H.A., Lansbury, Jr.P.T., Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? (2006) Q. Rev. Biophys., 39, pp. 167-201; Zhao, L.N., Long, H., Mu, Y., Chew, L.Y., The Toxicity of Amyloid β Oligomers (2012) Int. J. Mol. Sci., 13, pp. 7303-7327; Kagan, B.L., Azimov, R., Azimova, R., Amyloid peptide channels (2004) J. Membr. Biol., 202, pp. 1-10; Ono, K., Yamada, M., Low-n oligomers as therapeutic targets of Alzheimers disease (2011) J. Neurochem., 117, pp. 19-28; Lin, H., Bhatia, R., Lal, R., Amyloid β protein forms ion channels: Implications for Alzheimers disease pathophysiology (2001) FASEB J., 15, pp. 2433-2444; Arispe, N., Pollard, H.B., Rojas, E., Zn2+ interaction with Alzheimer amyloid β protein calcium channels (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 1710-1715; Strandberg, E., Killian, J.A., Snorkeling of lysine side chains in transmembrane helices: How easy can it get? (2003) FEBS Lett., 544, pp. 69-73; Gleason, N.J., Vostrikov, V.V., Greathouse, D.V., Koeppe, R.E.I.I., Buried lysine, but not arginine, titrates and alters transmembrane helix tilt (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 1692-1695; Shafrir, Y., Durell, S., Arispe, N., Guy, H.R., Models of membrane-bound Alzheimers Aβ peptide assemblies (2010) Proteins, 78, pp. 3473-3487; Durell, S.R., Guy, H.R., Arispe, N., Rojas, E., Pollard, H.B., Theoretical models of the ion channel structure of amyloid β-protein (1994) Biophys. J., 67, pp. 2137-2145; Jang, H., Zheng, J., Nussinov, R., Models of β-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process (2007) Biophys. J., 93, pp. 1938-1949; Jang, H., Arce, F.T., Capone, R., Ramachandran, S., Lal, R., Nussinov, R., Misfolded amyloid ion channels present mobile β-sheet subunits in contrast to conventional ion channels (2009) Biophys. J., 97, pp. 3029-3037; Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B.L., Nussinov, R., Lal, R., Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimers disease and Down syndrome (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 6538-6543; Arispe, N., Diaz, J., Durell, S.R., Shafrir, Y., Guy, H.R., Polyhistidine peptide inhibitor of the Aβ calcium channel potently blocks the Aβ-induced calcium response in cells. Theoretical modeling suggests a cooperative binding process (2010) Biochemistry, 49, pp. 7847-7853; Strodel, B., Lee, J.W., Whittleston, C.S., Wales, D.J., Transmembrane structures for Alzheimers Aβ(1-42) oligomers (2010) J. Am. Chem. Soc., 132, pp. 13300-13312; Qiu, L., Lewis, A., Como, J., Vaughn, M.W., Huang, J., Somerharju, P., Virtanen, J., Cheng, K.H., Cholesterol modulates the interaction of β-amyloid peptide with lipid bilayers (2009) Biophys. J., 96, pp. 4299-4307; Micelli, S., Meleleo, D., Picciarelli, V., Gallucci, E., Effect of sterols on β-amyloid peptide (AβP 1-40) channel formation and their properties in planar lipid membranes (2004) Biophys. J., 86, pp. 2231-2237; Meleleo, D., Notarachille, G., Gallucci, E., Micelli, S., Cholesterol modulates amyloid beta peptide 1-42 channel formation in planar lipid membranes (2009) New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2009, Medimond International Proceedings, p. 167. , Fisher, A. and Hanin, I. MEDIMOND S.r.l. Bologna, Italy -171; Lal, R., Lin, H., Quist, A.P., Amyloid β ion channel: 3D structure and relevance to amyloid channel paradigm (2007) Biochim. Biophys. Acta, 1768, pp. 1966-1975; Diaz, J.C., Linnehan, J., Pollard, H., Arispe, N., Histidines 13 and 14 in the Aβ sequence are targets for inhibition of Alzheimers disease Aβ ion channel and cytotoxicity (2006) Biol. Res., 39, pp. 447-460; Zhu, M., Han, S., Zhou, F., Carter, S.A., Fink, A.L., Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy (2004) J. Biol. Chem., 279, pp. 24452-24459; Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., Riek, R., 3D structure of Alzheimers amyloid-β(1-42) fibrils (2005) Proc. Natl. Acad. Sci. U.S.A., 102, pp. 17342-17347; Jang, H., Zheng, J., Lal, R., Nussinov, R., New structures help the modeling of toxic amyloid β ion channels (2008) Trends Biochem. Sci., 33, pp. 91-100; Zhou, X., Xu, J., Free cholesterol induces higher β-sheet content in Aβ peptide oligomers by aromatic interaction with Phe19 (2012) PLoS One, 7, p. 46245; Yuyama, K., Yanagisawa, K., Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid β-protein (2010) Neurosci. Lett., 481, pp. 168-172; Coles, M., Bicknell, W., Watson, A.A., Fairlie, D.P., Craik, D.J., Solution structure of amyloid β-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? (1998) Biochemistry, 37, pp. 11064-11077; Shao, H., Jao, S., Ma, K., Zagorski, M.G., Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimers disease (1999) J. Mol. Biol., 285, pp. 755-773; Wong, P.T., Schauerte, J.A., Wisser, K.C., Ding, H., Lee, E.L., Steel, D.G., Gafni, A., Amyloid-β membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity (2009) J. Mol. Biol., 386, pp. 81-96; Zhorov, B.S., Ananthanarayanan, V.S., Structural model of a synthetic Ca2+ channel with bound Ca2+ ions and dihydropyridine ligand (1996) Biophys. J., 70, pp. 22-37; Gondre-Lewis, M.C., Petrache, H.I., Wassif, C.A., Harries, D., Parsegian, A., Porter, F.D., Loh, Y.P., Abnormal sterols in cholesterol-deficiency diseases cause secretory granule malformation and decreased membrane curvature (2006) J. Cell Sci., 119, pp. 1876-1885; Ivankin, A., Kuzmenko, I., Gidalevitz, D., Cholesterol mediates membrane curvature during fusion events (2012) Phys. Rev. Lett., 108, p. 238103; Yesylevskyy, S.O., Demchenko, A.P., Kraszewski, S., Ramseyer, C., Cholesterol induces uneven curvature of asymmetric lipid bilayers (2013) Sci. World J., 2013, p. 965230; Barenholz, Y., Cholesterol and other membrane active sterols: From membrane evolution to ""rafts"" (2002) Prog. Lipid Res., 41, pp. 1-5; Kawahara, M., Kuroda, Y., Molecular mechanism of neurodegeneration induced by Alzheimers β-amyloid protein: Channel formation and disruption of calcium homeostasis (2000) Brain Res. Bull., 53, pp. 389-397; Kawahara, M., Kuroda, Y., Intracellular calcium changes in neuronal cells induced by Alzheimers β-amyloid protein are blocked by estradiol and cholesterol (2001) Cell. Mol. Neurobiol., 21, pp. 1-13; Mirzabekov, T.A., Lin, M.C., Kagan, B.L., Pore formation by the cytotoxic islet amyloid peptide amylin (1996) J. Biol. Chem., 271, pp. 1988-1992; Yeagle, P.L., Modulation of membrane function by cholesterol (1991) Biochimie, 73, pp. 1303-1310; Curtain, C.C., Ali, F.E., Smith, D.G., Bush, A.I., Masters, C.L., Barnham, K.J., Metal ions, pH, and cholesterol regulate the interactions of Alzheimers disease amyloid-β peptide with membrane lipid (2003) J. Biol. Chem., 278, pp. 2977-2982; Zhou, Y., Richardson, J.S., Cholesterol protects PC12 cells from β-amyloid induced calcium disordering and cytotoxicity (1996) NeuroReport, 7, pp. 2487-2490; Yip, C.M., Elton, E.A., Darabie, A.A., Morrison, M.R., McLaurin, J., Cholesterol, a modulator of membrane-associated Aβ-fibrillogenesis and neurotoxicity (2001) J. Mol. Biol., 311, pp. 723-734; Lin, M.C., Kagan, B.L., Electrophysiologic properties of channels induced by Aβ25-35 in planar lipid bilayers (2002) Peptides, 23, pp. 1215-1228; Fantini, J., Yahi, N., Garmy, N., Cholesterol accelerates the binding of Alzheimers β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation (2013) Front. Physiol., 4, p. 120; Schnaar, R.L., Gerardy-Schahn, R., Hildebrandt, H., Sialic acids in the brain: Gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration (2014) Physiol. Rev., 94, pp. 461-518; Radhakrishnan, A., Anderson, T.G., McConnell, H.M., Condensed complexes, rafts, and the chemical activity of cholesterol in membranes (2000) Proc. Natl. Acad. Sci. U.S.A., 97, pp. 12422-12427; Rondelli, V., Fragneto, G., Motta, S., Del Favero, E., Brocca, P., Sonnino, S., Cantu, L., Ganglioside GM1 forces the redistribution of cholesterol in a biomimetic membrane (2012) Biochim. Biophys. Acta, 1818, pp. 2860-2867; Zakharov, S.D., Hulleman, J.D., Dutseva, E.A., Antonenko, Y.N., Rochet, J.C., Cramer, W.A., Helical α-synuclein forms highly conductive ion channels (2007) Biochemistry, 46, pp. 14369-14379; Di Pasquale, E., Fantini, J., Chahinian, H., Maresca, M., Taieb, N., Yahi, N., Altered ion channel formation by the Parkinsons-disease-linked E46K mutant of α-synuclein is corrected by GM3 but not by GM1 gangliosides (2010) J. Mol. Biol., 397, pp. 202-218; Glabe, C.G., Structural classification of toxic amyloid oligomers (2008) J. Biol. Chem., 283, pp. 29639-29643; Esparza, T.J., Zhao, H., Cirrito, J.R., Cairns, N.J., Bateman, R.J., Holtzman, D.M., Brody, D.L., Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls (2013) Ann. Neurol., 73, pp. 104-119; Shirwany, N.A., Payette, D., Xie, J., Guo, Q., The amyloid β ion channel hypothesis of Alzheimers disease (2007) Neuropsychiatr. Dis. Treat., 3, pp. 597-612; Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.Y., Karlo, J.C., Zinn, A.E., Casali, B.T., Landreth, G.E., ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models (2012) Science, 335, pp. 1503-1506; Price, A.R., Xu, G., Siemienski, Z.B., Smithson, L.A., Borchelt, D.R., Golde, T.E., Felsenstein, K.M., Comment on ""apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"" (2013) Science, 340, pp. 924-e; Laferla, F.M., Preclinical success against Alzheimers disease with an old drug (2012) N. Engl. J. Med., 367, pp. 570-572; Fitz, N.F., Cronican, A.A., Lefterov, I., Koldamova, R., Comment on ""apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"" (2013) Science, 340, pp. 924-c; Landreth, G.E., Cramer, P.E., Lakner, M.M., Cirrito, J.R., Wesson, D.W., Brunden, K.R., Wilson, D.A., Response to comments on ""apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"" (2013) Science, 340, pp. 924-g; Tesseur, I., Lo, A.C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., De Strooper, B., Comment on ""apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"" (2013) Science, 340, pp. 924-e; Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J.K., Rajapaksha, T.W., Ulrich, J., Jucker, M., Sisodia, S.S., Comment on ""apoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"" (2013) Science, 340, pp. 924-f; Laclair, K.D., Manaye, K.F., Lee, D.L., Allard, J.S., Savonenko, A.V., Troncoso, J.C., Wong, P.C., Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice (2013) Mol. Neurodegener., 8, p. 18; Gandy, S., Dekosky, S.T., Toward the treatment and prevention of Alzheimers disease: Rational strategies and recent progress (2013) Annu. Rev. Med., 64, pp. 367-383; Jang, H., Connelly, L., Arce, F.T., Ramachandran, S., Lal, R., Kagan, B.L., Nussinov, R., Alzheimers disease: Which type of amyloid-preventing drug agents to employ? (2013) Phys. Chem. Chem. Phys., 15, pp. 8868-8877; McFarland, K., Spalding, T.A., Hubbard, D., Ma, J.N., Olsson, R., Burstein, E.S., Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinsons disease (2013) ACS Chem. Neurosci., 4, pp. 1430-1438; Malchiodi-Albedi, F., Paradisi, S., Matteucci, A., Frank, C., Diociaiuti, M., Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts (2011) Int. J. Alzheimers Dis., 2011, p. 906964; Pollard, H.B., Rojas, E., Arispe, N., A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid β protein (AβP) in phospholipid bilayer membranes (1993) Ann. N.Y. Acad. Sci., 695, pp. 165-168; Arispe, N., Pollard, H.B., Rojas, E., β-Amyloid Ca2+-channel hypothesis for neuronal death in Alzheimer disease (1994) Mol. Cell. Biochem., 140, pp. 119-125; Shaikh, S.A., Li, J., Enkavi, G., Wen, P.C., Huang, Z., Tajkhorshid, E., Visualizing functional motions of membrane transporters with molecular dynamics simulations (2013) Biochemistry, 52, pp. 569-587; Brooks, B.R., Mackerell Jr., A.D., Nilsson, L., Petrella, R.J., Roux, B., Won, Y., Archontis, G., Karplus, M., CHARMM: The biomolecular simulation program (2009) J. Comput. Chem., 30, pp. 1545-1614; Singh, R.P., Brooks, B.R., Klauda, J.B., Binding and release of cholesterol in the Osh4 protein of yeast (2009) Proteins, 75, pp. 468-477; Yao, Z.X., Brown, R.C., Teper, G., Greeson, J., Papadopoulos, V., 22R-Hydroxycholesterol protects neuronal cells from β-amyloid- induced cytotoxicity by binding to β-amyloid peptide (2002) J. Neurochem., 83, pp. 1110-1119; Ashley, R.H., Harroun, T.A., Hauss, T., Breen, K.C., Bradshaw, J.P., Autoinsertion of soluble oligomers of Alzheimers Aβ(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface (2006) BMC Struct. Biol., 6, p. 21; Thinnes, F.P., Concerning a Clue on the Enigma of ""amyloid Made"" versus ""amyloid Regulated"" Channels in Cell Membranes: A Comment on M. A. Mukhamedyarov et al., Neuroscience and Behavioral Physiology, Vol. 43, No. 4, pp 479-484 (2013) (2014) Neuroscience and Behavioral Physiology, 44, pp. 125-126; Thinnes, F.P., On a solution to the riddle of ""amyloid made"" versus ""amyloid regulated"" > channels in cell membranes (2013) Letter to the Editor of JAD, , September 1, 2013; Soscia, S.J., Kirby, J.E., Washicosky, K.J., Tucker, S.M., Ingelsson, M., Hyman, B., Burton, M.A., Moir, R.D., The Alzheimers disease-associated amyloid β-protein is an antimicrobial peptide (2010) PLoS One, 5, p. 9505; Last, N.B., Miranker, A.D., Common mechanism unites membrane poration by amyloid and antimicrobial peptides (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 6382-6387; Kagan, B.L., Jang, H., Capone, R., Teran Arce, F., Ramachandran, S., Lal, R., Nussinov, R., Antimicrobial properties of amyloid peptides (2012) Mol. Pharmaceutics, 9, pp. 708-717; Yanagisawa, K., Fantini, J., Chakrabartty, A., Eckert, A., Aβ behavior on neuronal membranes: Aggregation and toxicities (2011) Int. J. Alzheimers Dis., 2011, p. 286536; Kakio, A., Nishimoto, S.I., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid (2001) J. Biol. Chem., 276, pp. 24985-24990; Matsubara, T., Iijima, K., Yamamoto, N., Yanagisawa, K., Sato, T., Density of GM1 in nanoclusters is a critical factor in the formation of a spherical assembly of amyloid β-protein on synaptic plasma membranes (2013) Langmuir, 29, pp. 2258-2264; Kakio, A., Nishimoto, S., Kozutsumi, Y., Matsuzaki, K., Formation of a membrane-active form of amyloid β-protein in raft-like model membranes (2003) Biochem. Biophys. Res. Commun., 303, pp. 514-518; Hicks, D.A., Nalivaeva, N.N., Turner, A.J., Lipid rafts and Alzheimers disease: Protein-lipid interactions and perturbation of signaling (2012) Front. Physiol., 3, p. 189; Malchiodi-Albedi, F., Contrusciere, V., Raggi, C., Fecchi, K., Rainaldi, G., Paradisi, S., Matteucci, A., Diociaiuti, M., Lipid raft disruption protects mature neurons against amyloid oligomer toxicity (2010) Biochim. Biophys. Acta, 1802, pp. 406-415; Barenholz, Y., Sphingomyelin and cholesterol: From membrane biophysics and rafts to potential medical applications (2004) Subcell. Biochem., 37, pp. 167-215",Article,Scopus,2-s2.0-84904700172
"Lee J., Gillman A.L., Jang H., Ramachandran S., Kagan B.L., Nussinov R., Teran Arce F.","Role of the fast kinetics of pyroglutamate-modified amyloid-β oligomers in membrane binding and membrane permeability",2014,"Biochemistry","53","28",,"4704","4714",,,10.1021/bi500587p,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904647914&partnerID=40&md5=241bfc054358ffb319e5339eac9c69b2","Department of Bioengineering, University of California at San Diego, San Diego, CA 92093, United States; Department of Mechanical, Aerospace Engineering and Material Science Program, University of California at San Diego, San Diego, CA 92093, United States; Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick, MD 21702, United States; Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, United States; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel","Lee, J., Department of Mechanical, Aerospace Engineering and Material Science Program, University of California at San Diego, San Diego, CA 92093, United States; Gillman, A.L., Department of Bioengineering, University of California at San Diego, San Diego, CA 92093, United States; Jang, H., Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick, MD 21702, United States; Ramachandran, S., Department of Bioengineering, University of California at San Diego, San Diego, CA 92093, United States, Department of Mechanical, Aerospace Engineering and Material Science Program, University of California at San Diego, San Diego, CA 92093, United States; Kagan, B.L., Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, United States; Nussinov, R., Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick, MD 21702, United States, Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Teran Arce, F., Department of Bioengineering, University of California at San Diego, San Diego, CA 92093, United States, Department of Mechanical, Aerospace Engineering and Material Science Program, University of California at San Diego, San Diego, CA 92093, United States","Membrane permeability to ions and small molecules is believed to be a critical step in the pathology of Alzheimers disease (AD). Interactions of oligomers formed by amyloid-β (Aβ) peptides with the plasma cell membrane are believed to play a fundamental role in the processes leading to membrane permeability. Among the family of Aβs, pyroglutamate (pE)-modified Aβ peptides constitute the most abundant oligomeric species in the brains of AD patients. Although membrane permeability mechanisms have been studied for full-length Aβ1-40/42 peptides, these have not been sufficiently characterized for the more abundant AβpE3-42 fragment. Here we have compared the adsorbed and membrane-inserted oligomeric species of AβpE3-42 and Aβ1-42 peptides. We find lower concentrations and larger dimensions for both species of membrane-associated AβpE3-42 oligomers. The larger dimensions are attributed to the faster self-assembly kinetics of AβpE3-42, and the lower concentrations are attributed to weaker interactions with zwitterionic lipid headgroups. While adsorbed oligomers produced little or no significant membrane structural damage, increased membrane permeabilization to ionic species is understood in terms of enlarged membrane-inserted oligomers. Membrane-inserted AβpE3-42 oligomers were also found to modify the mechanical properties of the membrane. Taken together, our results suggest that membrane-inserted oligomers are the primary species responsible for membrane permeability. © 2014 American Chemical Society.",,"Hardy, J.A., Higgins, G.A., Alzheimers Disease: The Amyloid Cascade Hypothesis (1992) Science, 256, pp. 184-185; Detoma, A.S., Salamekh, S., Ramamoorthy, A., Lim, M.H., Misfolded proteins in Alzheimers disease and type II diabetes (2012) Chem. Soc. Rev., 41, pp. 608-621; Thinakaran, G., Koo, E.H., Amyloid Precursor Protein Trafficking, Processing, and Function (2008) J. Biol. Chem., 283, pp. 29615-29619; Sipe, J.D., Cohen, A.S., Review: History of the amyloid fibril (2000) J. Struct. Biol., 130, pp. 88-98; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimers disease (2009) Nat. Chem., 1, pp. 326-331; Bernstein, S.L., Wyttenbach, T., Baumketner, A., Shea, J.E., Bitan, G., Teplow, D.B., Bowers, M.T., Amyloid β-protein: Monomer structure and early aggregation states of Aβ42 and its Pro(19) alloform (2005) J. Am. Chem. Soc., 127, pp. 2075-2084; Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease (2006) Annu. Rev. Biochem., 75, pp. 333-366; Eisenberg, D., Jucker, M., The Amyloid State of Proteins in Human Diseases (2012) Cell, 148, pp. 1188-1203; Glabe, C.G., Structural Classification of Toxic Amyloid Oligomers (2008) J. Biol. Chem., 283, pp. 29639-29643; Jang, H., Zheng, J., Lal, R., Nussinov, R., New structures help the modeling of toxic amyloid β ion channels (2008) Trends Biochem. Sci., 33, pp. 91-100; Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, Jr.P.T., Neurodegenerative disease: Amyloid pores from pathogenic mutations (2002) Nature, 418, p. 291; Lashuel, H.A., Lansbury, Jr.P.T., Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? (2006) Q. Rev. Biophys., 39, pp. 167-201; Lin, H.A.I., Bhatia, R., Lal, R., Amyloid β protein forms ion channels: Implications for Alzheimers disease pathophysiology (2001) FASEB J., 15, pp. 2433-2444; Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Lal, R., Amyloid ion channels: A common structural link for protein-misfolding disease (2005) Proc. Natl. Acad. Sci. U.S.A., 102, pp. 10427-10432; Kagan, B.L., Hirakura, Y., Azimov, R., Azimova, R., Lin, M.C., The channel hypothesis of Alzheimers disease: Current status (2002) Peptides, 23, pp. 1311-1315; Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J.S., Taddei, N., Stefani, M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases (2002) Nature, 416, pp. 507-511; Butterfield, S.M., Lashuel, H.A., Amyloidogenic Protein-Membrane Interactions: Mechanistic Insight from Model Systems (2010) Angew. Chem., Int. Ed., 49, pp. 5628-5654; Jawhar, S., Wirths, O., Bayer, T.A., Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease (2011) J. Biol. Chem., 286, pp. 38825-38832; Nussbaum, J.M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Bloom, G.S., Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β (2012) Nature, 485, pp. 651-655; Kirkitadze, M.D., Bitan, G., Teplow, D.B., Paradigm shifts in Alzheimers disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies (2002) J. Neurosci. Res., 69, pp. 567-577; Stroud, J.C., Liu, C., Teng, P.K., Eisenberg, D., Toxic fibrillar oligomers of amyloid-β have cross-β structure (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 7717-7722; Saido, T.C., Yamaoharigaya, W., Iwatsubo, T., Kawashima, S., Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain (1996) Neurosci. Lett., 215, pp. 173-176; Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., Schettini, G., Pyroglutamate-modified amyloid β-peptides: A β N3(pE)-strongly affect cultured neuron and astrocyte survival (2002) J. Neurochem., 82, pp. 1480-1489; Saido, T.C., Iwatsubo, T., Mann, D.M.A., Shimada, H., Ihara, Y., Kawashima, S., Dominant and Differential Deposition of Distinct β-Amyloid Peptide Species, a-β(N3(Pe)), in Senile Plaques (1995) Neuron, 14, pp. 457-466; Di Paolo, G., Kim, T.W., Linking lipids to Alzheimers disease: Cholesterol and beyond (2011) Nat. Rev. Neurosci., 12, pp. 284-296; Relini, A., Cavalleri, O., Rolandi, R., Gliozzi, A., The two-fold aspect of the interplay of amyloidogenic proteins with lipid membranes (2009) Chem. Phys. Lipids, 158, pp. 1-9; Teran Arce, F., Jang, H., Ramachandran, S., Landon, P.B., Nussinov, R., Lal, R., Polymorphism of amyloid β peptide in different environments: Implications for membrane insertion and pore formation (2011) Soft Matter, 7, pp. 5267-5273; Miller, Y., Ma, B., Nussinov, R., Polymorphism in Alzheimer Aβ Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape (2010) Chem. Rev., 110, pp. 4820-4838; Jang, H., Connelly, L., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane (2013) J. Chem. Theory Comput., 9, pp. 822-833; Matsuzaki, K., Horikiri, C., Interactions of amyloid β-peptide (1-40) with ganglioside-containing membranes (1999) Biochemistry, 38, pp. 4137-4142; Matsuzaki, K., Kato, K., Yanagisawa, K., Aβ polymerization through interaction with membrane gangliosides (2010) Biochim. Biophys. Acta, 1801, pp. 868-877; Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., Differences between amyloid-β aggregation in solution and on the membrane: Insights into elucidation of the mechanistic details of Alzheimers disease (2014) Chem. Soc. Rev., pp. 101039/C3CS60431D; Jang, H., Connelly, L., Teran Arce, F., Ramachandran, S., Lal, R., Kagan, B., Nussinov, R., Alzheimers disease: Which type of amyloid-preventing drug agents to employ? (2013) Phys. Chem. Chem. Phys., 15, pp. 8868-8877; Jang, H., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs (2014) Chem. Soc. Rev., pp. 101039/C3CS60459D; Williams, T.L., Serpell, L.C., Membrane and surface interactions of Alzheimers Aβ peptide: Insights into the mechanism of cytotoxicity (2011) FEBS J., 278, pp. 3905-3917; Teran Arce, F., Jang, H., Connelly, L., Ramachandran, S., Kagan, B.L., Nussinov, R., Lal, R., Structure-Function Studies of Amyloid Pores in Alzheimers Disease as a Case Example of Neurodegenerative Diseases (2014) Bio-nanoimaging: Protein Misfolding and Aggregation, pp. 397-408. , (Uversky, V. and Lyubchenko, Y. Eds.) pp, Elsevier, Amsterdam; Hallock, K.J., Lee, D.-K., Ramamoorthy, A., MSI-78, an Analogue of the Magainin Antimicrobial Peptides, Disrupts Lipid Bilayer Structure via Positive Curvature Strain (2003) Biophys. J., 84, pp. 3052-3060; Brender, J.R., Heyl, D.L., Samisetti, S., Kotler, S.A., Osborne, J.M., Pesaru, R.R., Ramamoorthy, A., Membrane disordering is not sufficient for membrane permeabilization by islet amyloid polypeptide: Studies of IAPP(20-29) fragments (2013) Phys. Chem. Chem. Phys., 15, pp. 8908-8915; Sciacca, M.F.M., Kotler, S.A., Brender, J.R., Chen, J., Lee, D.K., Ramamoorthy, A., Two-Step Mechanism of Membrane Disruption by Aβ through Membrane Fragmentation and Pore Formation (2012) Biophys. J., 103, pp. 702-710; Soderberg, M., Edlund, C., Alafuzoff, I., Kristensson, K., Dallner, G., Lipid-Composition in Different Regions of the Brain in Alzheimers Disease Senile Dementia of Alzheimers Type (1992) J. Neurochem., 59, pp. 1646-1653; Wells, K., Farooqui, A.A., Liss, L., Horrocks, L.A., Neural membrane phospholipids in Alzheimer disease (1995) Neurochem. Res., 20, pp. 1329-1333; Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V.N., Fink, A.L., Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism (2001) Biochemistry, 40, pp. 6036-6046; Connelly, L., Teran Arce, F., Jang, H., Capone, R., Kotler, S.A., Ramachandran, S., Kagan, B.L., Lal, R., Atomic Force Microscopy and MD Simulations Reveal Pore-Like Structures of All- d -Enantiomer of Alzheimers β-Amyloid Peptide: Relevance to the Ion Channel Mechanism of AD Pathology (2012) J. Phys. Chem. B, 116, pp. 1728-1735; Jang, H., Teran Arce, F., Ramachandran, S., Capone, R., Azimova, R., Kagan, B.L., Nussinov, R., Lal, R., Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimers disease and Down syndrome (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 6538-6543; Liu, F., Teran Arce, F., Ramachandran, S., Lal, R., Nanomechanics of hemichannel conformations: Connexin flexibility underlying channel opening and closing (2006) J. Biol. Chem., 281, pp. 23207-23217; Bustamante, C., Vesenka, J., Tang, C.L., Rees, W., Guthold, M., Keller, R., Circular DNA molecules imaged in air by scanning force microscopy (1992) Biochemistry, 31, pp. 22-26; Arimon, M., Díez-Pérez, I., Kogan, M.J., Durany, N., Giralt, E., Sanz, F., Fernàndez-Busquets, X., Fine structure study of Aβ1-42 fibrillogenesis with atomic force microscopy (2005) FASEB J., 19, pp. 1344-1346; Hutter, J.L., Bechhoefer, J., Calibration of Atomic-Force Microscope Tips (1993) Rev. Sci. Instrum., 64, pp. 1868-1873; Tien, H.T., Carbone, S., Dawidowicz, E.A., Formation of ""black"" Lipid Membranes by Oxidation Products of Cholesterol (1966) Nature, 212, pp. 718-719; Mueller, P., Rudin, D.O., Ti Tien, H., Wescott, W.C., Reconstitution of Cell Membrane Structure in vitro and its Transformation into an Excitable System (1962) Nature, 194, pp. 979-980; Schlenzig, D., Manhart, S., Cinar, Y., Kleinschmidt, M., Hause, G., Willbold, D., Funke, S.A., Demuth, H.-U., Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides (2009) Biochemistry, 48, pp. 7072-7078; Pifer, P.M., Yates, E.A., Legleiter, J., Point Mutations in Aβ Result in the Formation of Distinct Polymorphic Aggregates in the Presence of Lipid Bilayers (2011) PLoS One, 6, p. 16248; Yip, C.M., Darabie, A.A., McLaurin, J., Aβ42-peptide assembly on lipid bilayers (2002) J. Mol. Biol., 318, pp. 97-107; Yip, C.M., Elton, E.A., Darabie, A.A., Morrison, M.R., McLaurin, J., Cholesterol, a modulator of membrane-associated Aβ-fibrillogenesis and neurotoxicity (2001) J. Mol. Biol., 311, pp. 723-734; Yip, C.M., McLaurin, J., Amyloid-β peptide assembly: A critical step in fibrillogenesis and membrane disruption (2001) Biophys. J., 80, pp. 1359-1371; Williams, T.L., Johnson, B.R.G., Urbanc, B., Jenkins, A.T.A., Connell, S.D.A., Serpell, L.C., Aβ42 oligomers, but not fibrils, simultaneously bind to and cause damage to ganglioside-containing lipid membranes (2011) Biochem. J., 439, pp. 67-77; Gillman, A.L., Jang, H., Lee, J., Ramachandran, S., Kagan, B.L., Nussinov, R., Teran Arce, F., Activity and Architecture of Pyroglutamate Modified Amyloid-β (AβpE3-42) Pores (2014) J. Phys. Chem. B, 118, pp. 7335-7344; Tosatto, L., Andrighetti, A.O., Plotegher, N., Antonini, V., Tessari, I., Ricci, L., Bubacco, L., Serra, M.D., α-Synuclein pore forming activity upon membrane association (2012) Biochim. Biophys. Acta, 1818, pp. 2876-2883; Sansom, M.S.P., Structure and Function of Channel-Forming Peptaibols (1993) Q. Rev. Biophys., 26, pp. 365-421; Dufrene, Y.F., Barger, W.R., Green, J.B.D., Lee, G.U., Nanometer-scale surface properties of mixed phospholipid monolayers and bilayers (1997) Langmuir, 13, pp. 4779-4784; Kunneke, S., Kruger, D., Janshoff, A., Scrutiny of the failure of lipid membranes as a function of headgroups, chain length, and lamellarity measured by scanning force microscopy (2004) Biophys. J., 86, pp. 1545-1553; Garcia-Manyes, S., Oncins, G., Sanz, F., Effect of temperature on the nanomechanics of lipid bilayers studied by force spectroscopy (2005) Biophys. J., 89, pp. 4261-4274; Garcia-Manyes, S., Oncins, G., Sanz, F., Effect of ion-binding and chemical phospholipid structure on the nanomechanics of lipid bilayers studied by force spectroscopy (2005) Biophys. J., 89, pp. 1812-1826; Garcia-Manyes, S., Oncins, G., Sanz, F., Effect of pH and ionic strength on phospholipid nanomechanics and on deposition process onto hydrophilic surfaces measured by AFM (2006) Electrochim. Acta, 51, pp. 5029-5036; Nussio, M.R., Oncins, G., Ridelis, I., Szili, E., Shapter, J.G., Sanz, F., Voelcker, N.H., Nanomechanical characterization of phospholipid bilayer islands on flat and porous substrates: A force spectroscopy study (2009) J. Phys. Chem. B, pp. 10339-10347; Garcia-Manyes, S., Redondo-Morata, L., Oncins, G., Sanz, F., Nanomechanics of Lipid Bilayers: Heads or Tails? (2010) J. Am. Chem. Soc., 132, pp. 12874-12886; Redondo-Morata, L., Giannotti, M.I., Sanz, F., AFM-Based Force-Clamp Monitors Lipid Bilayer Failure Kinetics (2012) Langmuir, 28, pp. 6403-6410; Redondo-Morata, L., Oncins, G., Sanz, F., Force Spectroscopy Reveals the Effect of Different Ions in the Nanomechanical Behavior of Phospholipid Model Membranes: The Case of Potassium Cation (2012) Biophys. J., 102, pp. 66-74; Oncins, G., Picas, L., Hernandez-Borrell, J., Garcia-Manyes, S., Sanz, F., Thermal response of Langmuir-Blodgett films of dipalmitoylphosphatidylcholine studied by atomic force microscopy and force spectroscopy (2007) Biophys. J., 93, pp. 2713-2725; Cherny, I., Gazit, E., Amyloids: Not only pathological agents but also ordered nanomaterials (2008) Angew. Chem., Int. Ed., 47, pp. 4062-4069; Suzuki, Y., Brender, J.R., Soper, M.T., Krishnamoorthy, J., Zhou, Y., Ruotolo, B.T., Kotov, N.A., Marsh, E.N.G., Resolution of Oligomeric Species during the Aggregation of Aβ1-40 Using 19F NMR (2013) Biochemistry, 52, pp. 1903-1912; Vivekanandan, S., Brender, J.R., Lee, S.Y., Ramamoorthy, A., A partially folded structure of amyloid-β(1-40) in an aqueous environment (2011) Biochem. Biophys. Res. Commun., 411, pp. 312-316; Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F., Head, E., Hall, J., Glabe, C., Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer (2009) J. Biol. Chem., 284, pp. 4230-4237; Conway, K.A., Harper, J.D., Lansbury, P.T., Fibrils Formed in Vitro from α-Synuclein and Two Mutant Forms Linked to Parkinsons Disease are Typical Amyloid (2000) Biochemistry, 39, pp. 2552-2563; Janson, J., Ashley, R.H., Harrison, D., McIntyre, S., Butler, P.C., The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles (1999) Diabetes, 48, pp. 491-498; Arispe, N., Pollard, H.B., Rojas, E., Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AβP-(1-40)] in bilayer membranes (1993) Proc. Natl. Acad. Sci. U.S.A., 90, pp. 10573-10577; Arispe, N., Rojas, E., Pollard, H.B., Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum (1993) Proc. Natl. Acad. Sci. U.S.A., 90, pp. 567-571; Connelly, L., Jang, H., Teran Arce, F., Ramachandran, S., Kagan, B.L., Nussinov, R., Lal, R., Effects of Point Substitutions on the Structure of Toxic Alzheimers β-Amyloid Channels: Atomic Force Microscopy and Molecular Dynamics Simulations (2012) Biochemistry, 51, pp. 3031-3038; Mustata, M., Capone, R., Jang, H., Teran Arce, F., Ramachandran, S., Lal, R., Nussinov, R., K3 Fragment of Amyloidogenic β2-Microglobulin Forms Ion Channels: Implication for Dialysis Related Amyloidosis (2009) J. Am. Chem. Soc., 131, pp. 14938-14945; Brulet, P., McConnell, H.M., Lateral Hapten Mobility and Immunochemistry of Model Membranes (1976) Proc. Natl. Acad. Sci. U.S.A., 73, pp. 2977-2981; Byfield, F.J., Aranda-Espinoza, H., Romanenko, V.G., Rothblat, G.H., Levitan, I., Cholesterol depletion increases membrane stiffness of aortic endothelial cells (2004) Biophys. J., 87, pp. 3336-3343; Demel, R.A., Dekruyff, B., Function of Sterols in Membranes (1976) Biochim. Biophys. Acta, 457, pp. 109-132; Evans, E., Needham, D., Physical-Properties of Surfactant Bilayer-Membranes: Thermal Transitions, Elasticity, Rigidity, Cohesion, and Colloidal Interactions (1987) J. Phys. Chem., 91, pp. 4219-4228; Needham, D., Nunn, R.S., Elastic-Deformation and Failure of Lipid Bilayer-Membranes Containing Cholesterol (1990) Biophys. J., 58, pp. 997-1009; Redondo-Morata, L., Giannotti, M.I., Sanz, F., Influence of Cholesterol on the Phase Transition of Lipid Bilayers: A Temperature-Controlled Force Spectroscopy Study (2012) Langmuir, 28, pp. 12851-12860; Stockton, G.W., Smith, I.C.P., Deuterium Nuclear Magnetic-Resonance Study of Condensing Effect of Cholesterol on Egg Phosphatidylcholine Bilayer Membranes. 1. Perdeuterated Fatty-Acid Probes (1976) Chem. Phys. Lipids, 17, pp. 251-263; Xu, X.L., London, E., The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation (2000) Biochemistry, 39, pp. 843-849; Canale, C., Seghezza, S., Vilasi, S., Carrotta, R., Bulone, D., Diaspro, A., Biagio, P.L.S., Dante, S., Different effects of Alzheimers peptide Aβ(1-40) oligomers and fibrils on supported lipid membranes (2013) Biophys. Chem., 182, pp. 23-29; Dante, S., Hauss, T., Steitz, R., Canale, C., Dencher, N.A., Nanoscale structural and mechanical effects of β-amyloid (1-42) on polymer cushioned membranes: A combined study by neutron reflectometry and AFM force spectroscopy (2011) Biochim. Biophys. Acta, 1808, pp. 2646-2655; Jang, H., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Familial Alzheimers disease Osaka mutant (ΔE22) β-barrels suggest an explanation for the different Aβ1-40/42 preferred conformational states observed by experiment (2013) J. Phys. Chem. B, 117, pp. 11518-11529; Jang, H., Zheng, J., Nussinov, R., Models of β-Amyloid Ion Channels in the Membrane Suggest That Channel Formation in the Bilayer Is a Dynamic Process (2007) Biophys. J., 93, pp. 1938-1949; Jang, H., Teran Arce, F., Ramachandran, S., Capone, R., Lal, R., Nussinov, R., Structural convergence among diverse, toxic β-sheet ion channels (2010) J. Phys. Chem. B, 114, pp. 9445-9451; Jang, H., Teran Arce, F., Ramachandran, S., Capone, R., Lal, R., Nussinov, R., β-Barrel Topology of Alzheimers β-Amyloid Ion Channels (2010) J. Mol. Biol., 404, pp. 917-934",Article,Scopus,2-s2.0-84904647914
"Pasquini L., Scherr M., Tahmasian M., Meng C., Myers N.E., Ortner M., Muhlau M., Kurz A., Forstl H., Zimmer C., Grimmer T., Wohlschlager A.M., Riedl V., Sorg C.","Link between hippocampus' raised local and eased global intrinsic connectivity in AD",2014,"Alzheimer's and Dementia",,,,"","",,,10.1016/j.jalz.2014.02.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904235396&partnerID=40&md5=a9963805e35f7028bf8d5b42510738c0","Department of Neuroradiology, Technische Universität München, Munich, Germany; TUM-Neuroimaging Center, Technische Universität München, Munich, Germany; Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University Salzburg, Salzburg, Austria; Department of Nuclear Medicine, Technische Universität München, Munich, Germany; Department of Experimental Psychology, Oxford University, Oxford, United Kingdom; Department of Psychiatry, Technische Universität München, Munich, Germany; Department of Neurology of Klinikum rechts der Isar, Technische Universität München, Munich, Germany","Pasquini, L., Department of Neuroradiology, Technische Universität München, Munich, Germany, TUM-Neuroimaging Center, Technische Universität München, Munich, Germany; Scherr, M., TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University Salzburg, Salzburg, Austria; Tahmasian, M., Department of Neuroradiology, Technische Universität München, Munich, Germany, TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Nuclear Medicine, Technische Universität München, Munich, Germany; Meng, C., Department of Neuroradiology, Technische Universität München, Munich, Germany; Myers, N.E., TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Experimental Psychology, Oxford University, Oxford, United Kingdom; Ortner, M., Department of Psychiatry, Technische Universität München, Munich, Germany; Mühlau, M., TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Neurology of Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Kurz, A., Department of Psychiatry, Technische Universität München, Munich, Germany; Förstl, H., Department of Psychiatry, Technische Universität München, Munich, Germany; Zimmer, C., Department of Neuroradiology, Technische Universität München, Munich, Germany; Grimmer, T., Department of Psychiatry, Technische Universität München, Munich, Germany; Wohlschläger, A.M., Department of Neuroradiology, Technische Universität München, Munich, Germany, TUM-Neuroimaging Center, Technische Universität München, Munich, Germany; Riedl, V., Department of Neuroradiology, Technische Universität München, Munich, Germany, TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Nuclear Medicine, Technische Universität München, Munich, Germany; Sorg, C., Department of Neuroradiology, Technische Universität München, Munich, Germany, TUM-Neuroimaging Center, Technische Universität München, Munich, Germany, Department of Psychiatry, Technische Universität München, Munich, Germany","Background: The hippocampus (HP) is part of the default mode network (DMN), and both are key targets of Alzheimer's disease (AD). Because of widespread network degeneration, it has been suggested that increasing HP disconnection from the DMN may lead to progressive disinhibition of intra-HP synchronized activity. Methods: To analyze HP local (i.e., within HP) and global (i.e., within DMN) intrinsic functional connectivity (local/global intrinsic functional connectivity [iFC]), healthy controls and patients with mild cognitive impairment and AD dementia were assessed by spatial high and normal resolution resting-state functional magnetic resonance imaging. Results: Although patients' parietal local-iFC was reduced and positively correlated with reduced global-iFC within the DMN, HP local connectivity was progressively increased and negatively correlated with HP decreased global connectivity. Increased intra-HP connectivity was associated with impaired memory. Conclusion: Our result demonstrates a link between increased local and reduced global hippocampal connectivity in AD. Increased intra-HP synchrony may contribute to distinct symptoms such as memory impairment or more speculatively epileptic seizure. © 2014 The Alzheimers Association.","Alzheimer's disease; Default mode network; High-resolution resting-state fMRI; Hippocampus; Independent component analysis; Intrinsic functional connectivity; Mild cognitive impairment; Synchrony",,Article in Press,Scopus,2-s2.0-84904235396
"Dominguez L., Foster L., Meredith S.C., Straub J.E., Thirumalai D.","Structural heterogeneity in transmembrane amyloid precursor protein Homodimer is a consequence of environmental selection",2014,"Journal of the American Chemical Society","136","27",,"9619","9626",,,10.1021/ja503150x,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903973868&partnerID=40&md5=eb3f141b9143b3cdd135746feef9dfbb","Department of Chemistry, Boston University, Boston, MA 02215, United States; Department of Biochemistry and Molecular Biology, Department of Pathology, University of Chicago, Chicago, IL 60637, United States; Department of Chemistry and Biochemistry, Biophysics Program, University of Maryland, College Park, MD, United States","Dominguez, L., Department of Chemistry, Boston University, Boston, MA 02215, United States; Foster, L., Department of Chemistry, Boston University, Boston, MA 02215, United States; Meredith, S.C., Department of Biochemistry and Molecular Biology, Department of Pathology, University of Chicago, Chicago, IL 60637, United States; Straub, J.E., Department of Chemistry, Boston University, Boston, MA 02215, United States; Thirumalai, D., Department of Chemistry and Biochemistry, Biophysics Program, University of Maryland, College Park, MD, United States","The 99 amino acid C-terminal fragment of amyloid precursor protein (C99), consisting of a single transmembrane (TM) helix, is known to form homodimers. Homodimers can be processed by γ-secretase to produce amyloid-ß (Aß) protein, which is implicated in Alzheimers disease (AD). While knowledge of the structure of C99 homodimers is of great importance, experimental NMR studies and simulations have produced varying structural models, including right-handed and left-handed coiled-coils. In order to investigate the structure of this critical protein complex, simulations of the C9915-55 homodimer in POPC membrane bilayer and DPC surfactant micelle environments were performed using a multiscale approach that blends atomistic and coarse-grained models. The C9915-55 homodimer adopts a dominant right-handed coiled-coil topology consisting of three characteristic structural states in a bilayer, only one of which is dominant in the micelle. Our structural study, which provides a self-consistent framework for understanding a number of experiments, shows that the energy landscape of the C99 homodimer supports a variety of slowly interconverting structural states. The relative importance of any given state can be modulated through environmental selection realized by altering the membrane or micelle characteristics. © 2014 American Chemical Society.",,"Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., Kametani, F., Ihara, Y., (2005) J. Neurosci., 25, pp. 436-445; Zhao, G., Tan, J., Mao, G., Cui, M.-Z., Xu, X., (2007) J. Neurochem., 100, pp. 1234-1246; Kienlen-Campard, P., Tasiaux, B., Van Hees, J., Li, M., Huysseune, S., Sato, T., Fei, J.Z., Smith, S.O., (2008) J. Biol. Chem., 283, pp. 7733-7744; Munter, L.-M., Botev, A., Richter, L., Hildebrand, P.W., Althoff, V., Weise, C., Kaden, D., Multhaup, G., (2010) J. Biol. Chem., 285, p. 21636; Sato, T., Tang, T.-C., Reubins, G., Fei, J.Z., Fujimoto, T., Kienlen-Campard, P., Constantinescu, S.N., Smith, S.O., (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 1421-1426; Munter, L.-M., Voigt, P., Harmeier, A., Kaden, D., Gottschalk, K.E., Weise, C., Pipkorn, R., Multhaup, G., (2007) EMBO J., 26, pp. 1702-1712; Scheuermann, S., Hambsch, B., Hesse, L., Stumm, J., Schmidt, C., Beher, D., Bayer, T.A., Multhaup, G., (2001) J. Biol. Chem., 276, pp. 33923-33929; Gorman, P., Kim, S., Guo, M., Melnyk, R., McLaurin, J., Fraser, P., Bowie, J., Chakrabartty, A., (2008) BMC Neurosci., 9, p. 17; Eggert, S., Midthune, B., Cottrell, B., Koo, E.H., (2009) J. Biol. Chem., 284, pp. 28943-28952; Goo, J.H., Park, W.J., (2004) DNA Cell Biol., 23, pp. 59-65; Lu, J.-X., Yau, W.-M., Tycko, R., (2011) Biophys. J., 100, pp. 711-719; Dominguez, L., Meredith, S.C., Straub, J.E., Thirumalai, D., (2014) J. Am. Chem. Soc., 136, pp. 854-857; Barrett, P.J., Song, Y., Van Horn, W.D., Hustedt, E.J., Schafer, J.M., Hadziselimovic, A., Beel, A.J., Sanders, C.R., (2012) Science, 336, pp. 1168-1171; Khalifa, N.B., Van Hees, J., Tasiaux, B., Huysseune, S., Smith, S.O., Constantinescu, S.N., Octave, J.-N., Kienlen-Campard, P., (2010) Cell Adhes. Migrat., 4, pp. 268-272; Song, Y., Hustedt, E.J., Brandon, S., Sanders, C.R., (2013) Biochemistry, 52, pp. 5051-5064; Song, Y., Mittendorf, K.F., Lu, Z., Sanders, C.R., (2014) J. Am. Chem. Soc., 136, pp. 4093-4096; Miyashita, N., Straub, J.E., Thirumalai, D., Sugita, Y., (2009) J. Am. Chem. Soc., 131, pp. 3438-3439; Pester, O., Barrett, P.J., Hornburg, D., Hornburg, P., Pröbstle, R., Widmaier, S., Kutzner, C., Langosch, D., (2013) J. Am. Chem. Soc., 135, pp. 1317-1329; Wang, H., Barreyro, L., Provasi, D., Djemil, I., Torres-Arancivia, C., Filizola, M., Ubarretxena-Belandia, I., (2011) J. Mol. Biol., 408, pp. 879-895; Mackenzie, K.R., Prestegard, J.H., Engelman, D.M., (1997) Science, 276, pp. 131-133; Nadezhdin, K.D., Bocharova, O.V., Bocharov, E.V., Arseniev, A.S., (2012) FEBS Lett., 586, pp. 1687-1692; Chen, W., Gamache, E., Rosenman, D.J., Xie, J., Lopez, M.M., Li, Y.-M., Wang, C., (2014) Nat. Commun., 5. , 3037; Monticelli, L., Kandasamy, S.K., Periole, X., Larson, R.G., Tieleman, D.P., Marrink, S.-J., (2008) J. Chem. Theor. Comput., 4, pp. 819-834; Marrink, S.J., Risselada, H.J., Yefimov, S., Tieleman, D.P., De Vries, A.H., (2007) J. Phys. Chem. B, 111, pp. 7812-7824; Marrink, S.J., De Vries, A.H., Tieleman, D.P., (2009) Biochim. Biophys. Acta-Biomembranes, 1788, pp. 149-168; Bond, P.J., Holyoake, J., Ivetac, A., Khalid, S., Sansom, M.S., (2007) J. Struct. Biol., 157, pp. 593-605; Braun, R., Engelman, D.M., Schulten, K., (2004) Biophys. J., 87, pp. 754-763; Cuthbertson, J.M., Bond, P.J., Sansom, M.S., (2006) Biochemistry, 45, pp. 14298-14310; Psachoulia, E., Fowler, P.W., Bond, P.J., Sansom, M.S., (2008) Biochemistry, 47, pp. 10503-10512; Berendsen, H.J., Postma, J.P.M., Van Gunsteren, W.F., Dinola, A., Haak, J., (1984) J. Chem. Phys., 81, p. 3684; Rotkiewicz, P., Skolnick, J., (2008) J. Comput. Chem., 29, pp. 1460-1465; Jo, S., Kim, T., Im, W., (2007) PLoS One, 2, p. 880; Jo, S., Kim, T., Iyer, V.G., Im, W., (2008) J. Comput. Chem., 29, pp. 1859-1865; Cheng, X., Jo, S., Lee, H.S., Klauda, J.B., Im, W., (2013) J. Chem. Inf. Model., 53, pp. 2171-2180; Mackerell, A.D., Bashford, D., Bellott, M., Dunbrack, R., Evanseck, J., Field, M.J., Fischer, S., Ha, (1998) J. Phys. Chem. B, 102, pp. 3586-3616; Klauda, J.B., Venable, R.M., Freites, J.A., Oconnor, J.W., Tobias, D.J., Mondragon-Ramirez, C., Vorobyov, I., Pastor, R.W., (2010) J. Phys. Chem. B, 114, pp. 7830-7843; Huang, J., Mackerell, A.D., (2013) J. Comput. Chem., 34, pp. 2135-2145; Abel, S., Dupradeau, F.-Y., Marchi, M., (2012) J. Chem. Theor. Comput., 8, pp. 4610-4623; Hoover, W.G., (1985) Phys. Rev. A, 31, p. 1695; Essmann, U., Perera, L., Berkowitz, M.L., Darden, T., Lee, H., Pedersen, L.G., (1995) J. Chem. Phys., 103, pp. 8577-8593; Hess, B., Bekker, H., Berendsen, H.J., Fraaije, J.G., (1997) J. Comput. Chem., 18, pp. 1463-1472; Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., Berendsen, H.J., (2005) J. Comput. Chem., 26, pp. 1701-1718; Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., (2008) J. Chem. Theor. Comput., 4, pp. 435-447; Kabsch, W., Sander, C., (1983) Biopolymers, 22, pp. 2577-2637; Joosten, R.P., Te Beek, T.A., Krieger, E., Hekkelman, M.L., Hooft, R.W., Schneider, R., Sander, C., Vriend, G., (2011) Nucleic Acids Res., 39, pp. 411-D419; Michaud-Agrawal, N., Denning, E.J., Woolf, T.B., Beckstein, O., (2011) J. Comput. Chem., 32, pp. 2319-2327; Bansal, M., Kumart, S., Velavan, R., (2000) J. Biomol. Struct. Dyn., 17, pp. 811-819; Humphrey, W., Dalke, A., Schulten, K., (1996) J. Mol. Graph., 14, pp. 33-38; Crick, F.H.C., (1953) Acta Crystallogr., 6, pp. 689-697; Strelkov, S.V., Burkhard, P., (2002) J. Struct. Biol., 137, pp. 54-64; Lupas, A.N., Gruber, M., (2005) Fibrous Proteins: Coiled-Coils, Collagen and Elastomers, 70, p. 37. , In; Parry, D. A. D. Squire, J. M. Advances in Protein Chemistry; Academic Press: San Diego, CA - 38; Beel, A.J., Mobley, C.K., Kim, H.J., Tian, F., Hadziselimovic, A., Jap, B., Prestegard, J.H., Sanders, C.R., (2008) Biochemistry, 47, pp. 9428-9446; Franzin, C.M., Teriete, P., Marassi, F.M., (2007) J. Am. Chem. Soc., 129, pp. 8078-8079; Mineev, K., Bocharov, E., Volynsky, P., Goncharuk, M., Tkach, E., Ermolyuk, Y.S., Schulga, A., Arseniev, A., (2011) Acta Natur., 3, p. 90; Stangl, M., Veerappan, A., Kroeger, A., Vogel, P., Schneider, D., (2012) Biophys. J., 103, pp. 2455-2464; Fisher, L.E., Engelman, D.M., Sturgis, J.N., (1999) J. Mol. Biol., 293, pp. 639-651; Fisher, L.E., Engelman, D.M., Sturgis, J.N., (2003) Biophys. J., 85, pp. 3097-3105; White, S.H., Wimley, W.C., (1999) Annu. Rev. Biophys. Biomol. Struct., 28, p. 319. , 365",Article,Scopus,2-s2.0-84903973868
"Papp K.V., Amariglio R.E., Dekhtyar M., Roy K., Wigman S., Bamfo R., Sherman J., Sperling R.A., Rentz D.M.","Development of a psychometrically equivalent short form of the face-name associative memory exam for use along the early alzheimers disease trajectory",2014,"Clinical Neuropsychologist","28","5",,"771","785",,,10.1080/13854046.2014.911351,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84906315807&partnerID=40&md5=38ec09acc8d8ab135dc6c5f63776f844","Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States; Department of Neurology, Harvard Medical School, Boston, MA, United States; Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, United States; Department of Neurobiology, Harvard Colleges, Cambridge, MA, United States; Department of Neurology, Massachusetts General Hospital, Boston, MA, United States","Papp, K.V., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States, Department of Neurology, Harvard Medical School, Boston, MA, United States; Amariglio, R.E., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States, Department of Neurology, Harvard Medical School, Boston, MA, United States; Dekhtyar, M., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States; Roy, K., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States; Wigman, S., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, United States; Bamfo, R., Department of Neurobiology, Harvard Colleges, Cambridge, MA, United States; Sherman, J., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States; Sperling, R.A., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States, Department of Neurology, Harvard Medical School, Boston, MA, United States, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, United States, Department of Neurology, Massachusetts General Hospital, Boston, MA, United States; Rentz, D.M., Center for Alzheimer Research and Treatment, 221 Longwood Avenue BL-104, Boston, MA 02115, United States, Department of Neurology, Harvard Medical School, Boston, MA, United States, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, United States, Department of Neurology, Massachusetts General Hospital, Boston, MA, United States","Neuropsychologists are developing more challenging and specific tests to detect early and subtle changes in cognition related to preclinical Alzheimers disease (AD). The 16-item Face-Name Associative Memory Exam (FNAME-16) is a challenging paired associative memory test able to detect subtle memory changes associated with biomarker evidence of preclinical AD. However, as individuals progress along the AD trajectory, measures that are sensitive at the preclinical stage may become too challenging by the stage of Mild Cognitive Impairment (MCI). Our goal was to develop a modified version of the face-name and face-occupation paired associative memory task (FNAME-12) with fewer stimuli and additional learning trials suitable for use in MCI. We administered the FNAME-12A, an alternate version FNAME 12B, the original FNAME-16, and a series of other neuropsychological measures to 65 clinically normal (CN) older adults (aged 65 to 85) and a subsample characterized by MCI (n = 18). The FNAME-12 exhibited psychometric equivalence with the FNAME-16 (r =.77, p <.001) and was correlated with other measures of episodic and semantic memory. The alternate form, FNAME-12B, was highly correlated with FNAME-12A (r =.76, p <.001). Mean performance on the FNAME 12A, stratified by education, was generated. The task could be completed by our MCI group yet remained challenging in the CN group, providing evidence for its utility along the AD trajectory. © 2014 Taylor & Francis.","Associative memory; Mild Cognitive Impairment; Neuropsychology; Preclinical Alzheimer's disease; Test development","Amariglio, R.E., Frishe, K., Olson, L.E., Wadsworth, L.P., Lorius, N., Sperling, R.A., Rentz, D.M., Validation of the Face-Name Associative Memory Exam in cognitively normal older individuals (2012) Journal of Clinical and Experimental Neuropsychology, 34, pp. 580-587. , doi:10.1080/13803395.2012.666230; Andersen, K., Launer, L.J., Dewey, M.E., Letenneur, L., Ott, A., Copeland, J.R.M., Hofman, A., Gender differences in the incidence of AD and vascular dementia (1999) Neurology, 53, p. 1992. , doi:10.1212/WNL.53.9.1992; Benton, A., Varney, N., Hamsher De, S.K., Spreen, O., (1983) Contributions to Neuropsychological Assessment, , Oxford, UK: Oxford University Press; Binder, J.R., Desai, R.H., The neurobiology of semantic memory (2011) Trends in Cognitive Science, 15, pp. 527-536. , doi:10.1016/j.tics.2011.10.001; Blackwell, A.D., Sahakian, B.J., Vesey, R., Semple, J.M., Robbins, T.W., Hodges, J.R., Detecting dementia: Novel neuropsychological markers of preclinical Alzheimer's disease (2004) Dementia and Geriatric Cognitive Disorders, 17, pp. 42-48. , doi:10.1159/000074081; Celone, K.A., Calhoun, V.D., Dickerson, B.C., Atri, A., Chua, E.F., Miller, S.L., Sperling, R.A., Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: An independent component analysis (2006) Journal of Neuroscience, 26, pp. 10222-10231. , doi:10.1523/JNEUROSCI.2250-06.2006; Dejager, C.A., Milwain, E., Budge, M., Early detection of isolated memory deficits in the elderly: The need for more sensitive neuropsychological tests (2002) Psychological Medicine, 32, pp. 483-491. , doi:10.1017/S003329170200524X; Didic, M., Barbeau, E.J., Felician, O., Tramoni, E., Guedj, E., Poncet, M., Ceccaldi, M., Which memory system is impaired first in Alzheimer's disease? (2011) Journal of Alzheimer's Disease, 27, pp. 11-22. , doi:10.3233/JAD-2011-110557; Dudas, R.B., Clague, F., Thompson, S.A., Graham, K.S., Hodges, J.R., Episodic and semantic memory in mild cognitive impairment (2005) Neuropsychologia, 43, pp. 1266-1276. , doi:10.1016/j.neuropsychologia.2004.12.005; Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'agostino, R.B., The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort (2000) Archives of Neurology, 57, p. 808. , doi:10.1001/archneur.57.6.808; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state"" (1975) A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, pp. 189-198. , doi:0022-3956(75)90026-6; Fowler, K.S., Saling, M.M., Conway, E.L., Semple, J.M., Louis, W.J., Paired associate performance in the early detection of DAT (2002) Journal of the International Neuropsychological Society, 8, pp. 58-71. , doi:10.1017/S1355617701020069; Giffard, B., Desgranges, B., Nore-Mary, F., Lalevee, C., Beaunieux, H., De La Sayette, V., Eustache, F., The dynamic time course of semantic memory impairment in Alzheimer's disease: Clues from hyperpriming and hypopriming effects (2002) Brain, 125, pp. 2044-2057. , doi:10.1093/brain/awf209; Grober, E., Buschke, H., Genuine memory deficits in dementia (1987) Developmental Neuropsychology, 3, pp. 13-36. , doi:10.1080/87565648709540361; Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., Kawas, C., Gorlyn, M., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease (2008) Journal of the International Neuropsychological Society, 14, p. 266. , doi:10.1017/S1355617708080302; Konkel, A., Cohen, N.J., Relational memory and the hippocampus: Representations and methods (2009) Frontiers in Neuroscience, 3, p. 166. , doi:10.3389/neuro.01.023.2009; Lindeboom, J., Schmand, B., Tulner, L., Walstra, G., Jonker, C., Visual association test to detect early dementia of the Alzheimer type (2002) Journal of Neurology, Neurosurgery & Psychiatry, 73, pp. 126-133. , doi:10.1136/jnnp.73.2.126; Masur, D.M., Fuld, P.A., Blau, A.D., Thal, L.J., Levin, H.S., Aronson, M.K., Distinguishing normal and demented elderly with the selective reminding test (1989) Journal of Clinical and Experimental Neuropsychology, 11, pp. 615-630. , doi:10.1080/01688638908400920; Monsch, A.U., Bondi, M.W., Butters, N., Salmon, D.P., Katzman, R., Thal, L.J., Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type (1992) Archives of Neurology, 49, pp. 1253-1258. , doi:10.1001/archneur.1992.00530360051017; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; O'brien, J.L., O'keefe, K.M., Laviolette, P.S., Deluca, A.N., Blacker, D., Dickerson, B.C., Sperling, R.A., Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline (2010) Neurology, 74, pp. 1969-1976. , doi:10.1212/WNL.0b013e3181e3966e; Parra, M.A., Abrahams, S., Logie, R.H., Mendez, L.G., Lopera, F., Della Sala, S., Visual short-term memory binding deficits in familial Alzheimer's disease (2010) Brain, 133, pp. 2702-2713. , doi:10.1093/brain/awq148; Pike, K.E., Ellis, K.A., Villemagne, V.L., Good, N., Chételat, G., Ames, D., Rowe, C.C., Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study (2011) Neuropsychologia, 49, pp. 2384-2390. , doi:10.1016/j.neuropsychologia. 2011.04.012; Price, J.L., McKeel Jr., D.W., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Morris, J.C., Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease (2009) Neurobiol Aging, 30, pp. 1026-1036. , doi:10.1016/j.neurobiolaging.2009. 04.002; Reitan, R., (1979) Manual for Administration of Neuropsychological Test Batteries for Adults and Children, , Tuscon, AZ: Reitan Neuropsychology Laboratories; Rentz, D.M., Amariglio, R.E., Becker, J.A., Frey, M., Olson, L.E., Frishe, K., Sperling, R.A., Face-name associative memory performance is related to amyloid burden in normal elderly (2011) Neuropsychologia, 49, pp. 2776-2783. , doi:10.1016/j.neuropsychologia.2011.06.006; Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Johnson, K.A., Cognition, reserve, and amyloid deposition in normal aging (2010) Annals of Neurology, 67, pp. 353-364. , doi:10.1002/ana.21904; Rentz, D.M., Parra, M., Amariglio, R.E., Stern, Y., Sperling, R.A., Ferris, S., Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: A selective review (2013) Alzheimer's Research & Therapy, 5, p. 58. , doi:10.1186/alzrt222; Sperling, R.A., Chua, E., Cocchiarella, A., Rand-Giovannetti, E., Poldrack, R., Schacter, D.L., Albert, M., Putting names to faces: Successful encoding of associative memories activates the anterior hippocampal formation (2003) Neuroimage, 20, pp. 1400-1410. , doi:10.1016/S1053-8119(03)00391-4; Sperling, R.A., Jack, C.R., Aisen, P.S., Testing the right target and right drug at the right stage (2011) Science Translational Medicine, 3, pp. 111cm33. , doi:10.1126/scitranslmed.3002609; Sperling, R.A., Laviolette, P.S., O'keefe, K., O'brien, J., Rentz, D.M., Pihlajamaki, M., Johnson, K.A., Amyloid deposition is associated with impaired default network function in older persons without dementia (2009) Neuron, 63, pp. 178-188. , doi:10.1016/j.neuron.2009.07.003; Stark, S.M., Yassa, M.A., Lacy, J.W., Stark, C.E., A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment (2013) Neuropsychologia, 51, pp. 2442-2449. , doi:10.1016/j.neuropsych; Werheid, K., Clare, L., Are faces special in Alzheimer's disease? Cognitive conceptualization, neural correlates, and diagnostic relevance of impaired memory for faces and names (2007) Cortex, 43, pp. 898-906. , doi:10.1016/S0010-9452(08)70689-0; Wiggs, C.L., Weisberg, J., Martin, A., Neural correlates of semantic and episodic memory retrieval (1998) Neuropsychologia, 37, pp. 103-118. , doi:/10.1016/S0028-3932(98)00044-X",Article,Scopus,2-s2.0-84906315807
"Pinsetta F.R., Taft C.A., De Paula Da Silva C.H.T.","Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimers disease",2014,"Journal of Biomolecular Structure and Dynamics","32","7",,"1047","1063",,3,10.1080/07391102.2013.803441,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84899969869&partnerID=40&md5=06bc4b4a3eb27a036cb46582dba0abd9","Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. do Café, Ribeirão Preto, SP 14040-903, Brazil; Centro Brasileiro de Pesquisas Fisicas, Rua Dr. Xavier Sigaud, Urca 22290-180, Rio de Janeiro, Brazil","Pinsetta, F.R., Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. do Café, Ribeirão Preto, SP 14040-903, Brazil; Taft, C.A., Centro Brasileiro de Pesquisas Fisicas, Rua Dr. Xavier Sigaud, Urca 22290-180, Rio de Janeiro, Brazil; De Paula Da Silva, C.H.T., Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. do Café, Ribeirão Preto, SP 14040-903, Brazil","Alzheimers disease (AD) is characterized microscopically by the presence of amyloid plaques, which are accumulations of beta-amyloid protein inter-neurons, and neurofibrillary tangles formed predominantly by highly phosphorylated forms of the microtubule-associated protein, tau, which form tangled masses that consume neuronal cell body, possibly leading to neuronal dysfunction and ultimately death. p38α mitogen-activated protein kinase (MAPK) has been implicated in both events associated with AD, tau phosphorylation and inflammation. p38α MAPK pathway is activated by a dual phosphorylation at Thr180 and Tyr182 residues. Drug design of p38α MAPK inhibitors is mainly focused on small molecules that compete for Adenosine triphosphate in the catalytic site. Here, we used different approaches of structure- and ligand-based drug design and medicinal chemistry strategies based on a selected p38α MAPK structure deposited in the Protein Data Bank in complex with inhibitor, as well as others reported in literature. As a result of the virtual screening experiments performed here, as well as molecular dynamics, molecular interaction fields studies, shape and electrostatic similarities, activity and toxicity predictions, and pharmacokinetic and physicochemical properties, we have selected 13 compounds that meet the criteria of low or no toxicity potential, good pharmacotherapeutic profile, predicted activities, and calculated values comparable with those obtained for the reference compounds, while maintaining the main interactions observed for the most potent inhibitors. © 2013 © 2013 Taylor & Francis.","Alzheimer's disease; drug design; p38 alpha MAPK","Allen, F.H., The Cambridge Structural Database: A quarter of a million crystal structures and rising (2002) Acta Crystallographica. Section B Structural Science, 58, pp. 380-388; Alonso, H., Bliznyuk, A.A., Gready, J.E., Combining docking and molecular dynamic simulations in drug design (2006) Medicinal Research Reviews, 26, pp. 531-568; Banerjee, A., Koziol-White, C., Panettieri Jr., R., P38 MAPK inhibitors IKK2 inhibitors and TNF inhibitors in COPD (2012) Current Opinion in Pharmacology, 12, pp. 287-292; Benfenati, E., Gini, G., Computational predictive programs (expert systems) in toxicology (1997) Toxicology, 119, pp. 213-225; Berchtold, N.C., Cotman, C.W., Evolution in the conceptualization of dementia and Alzheimer's disease: Disease (1998) Neurobiology of Aging, 19, pp. 173-189; Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The protein data bank (2000) Nucleic Acids Research, 28, pp. 235-242; Boström, J., Greenwood, J.R., Gottfries, J., Assessing the performance of OMEGA with respect to retrieving bioactive conformations (2003) Journal of Molecular Graphics and Modelling, 21, pp. 449-462; Brooijmans, N., Kuntz, I.D., Molecular recognition and docking algorithms (2003) Annual Review of Biophysics and Biomolecular Structure, 32, pp. 335-373; Chico, L.K., Van Eldik, L.J., Watterson, D.M., Targeting protein kinases in central nervous system disorders (2009) Nature Reviews Drug Discovery, 8, pp. 892-909; Citron, M., [beta]-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge (2004) Trends in Pharmacological Sciences, 25, pp. 92-97; Cole, S.L., Vassar, R., The Alzheimer's disease betasecretase Enzyme BACE1 (2007) Molecular Neurodegeneration, 2, pp. 22-32; Dalrymple, S.A., P38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease (2002) Journal of Molecular Neuroscience, 19, pp. 295-304; (2004), DEREK10.0. Leeds: LHASA Limited(2012), Discovery Studio. ersao 3.5. San Diego CA: Accelrys IncDvir, H., Jiang, H.L., Wong, D.M., Harel, M., Chetrit, M., He, X.C., Sussman, J.L., X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: Structural e vidence for an active site rearrangement (2002) Biochemistry, (41), pp. 10810-10818; Eldridge, M.D., Murray, C.W., Auton, T.R., Paolini, G.V., Mee, R.P., Empirical scoring functions: I. The develop ment of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes (1997) Journal of Computer-Aided Molecular Design, 11, pp. 425-445; (2007), EON. Versao 2.0.1. Santa Fe NM: Openeyes Scientific SoftwareGiacobini, E., Cholinergic foundations of Alzheimer's disease therapy (1998) Journal of Physiology-Paris, 92, pp. 283-290; (2009), GLIDE. Versao 5.5. New York NY: Schrödinger LLC(2009), GOLD. Versao 5.1. Cambridge: Cambridge Crystallographic DatacenterGompel, M., Leost, M., De Kier Joffe, E.B., Puricelli, L., Franco, L.H., Palermo, J., Meijer, L., Meridianins a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum (2004) Bioorganic & Medicinal Chemistry Letters, 14, pp. 1703-1710; Goodford, P.J., A computat ional procedure for determining energetically favorable binding sites on biologically important macromolecules (1985) Journal of Medicinal Chemistry, 28, pp. 849-857; Grant, J.A., Gallardo, M.A., Pickup, B.T., A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape (1996) Journal of Computational Chemistry, 17, pp. 1653-1666; Grant, J.A., Pickup, B.T., Sykes, M.J., Kitchen, C.A., Nicholls, A., A simple formula for dielectric polarisation energies: The Sheffield Solvation Model (2007) Chemical Physics Letters, 44, pp. 163-166; (2006), GRID. Versao 22. London: Molecular Discovery LtdGuex, N., Peitsch, M.C., SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling (1997) Electrophoresis, 18, pp. 2714-2723; Haigh, J.A., Pickup, B.T., Grant, J.A., Nicholls, A., Small molecule shape-fingerprints (2005) Journal of Chemical Information and Modeling, 45, pp. 673-684; Halperin, I., Ma, B., Wolfson, H., Nussinov, R., Principles of docking: An overview of search algorithms and a guide to scoring functions (2002) Proteins, 47, pp. 409-443; Heinig, M., Frishman, D., STRIDE: A web server for secondary structure assignment from known atomic coordinates of proteins (2004) Nucleic Acids Research, 32. , (Web Server issue) W500-2; Hert, J., Willett, P., Wilton, D.J., Acklin, P., Azzaoui, K., Jacoby, E., Schuffenhauer, A., Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures (2004) Journal of Chemical Information and Computer Sciences, 44, pp. 1177-1185; (2000) Molecular Simulations, , Insight II. San Diego CA; Irwin, J.J., Sterling, T., Mysinger, M.M., Bolstad, E.S., Coleman, R.G., ZINC: A free tool to discover chemistry for biology (2005) Journal of Chemical Information and Modeling; Irwin, J.J., Shoichet, B.K., ZINC-A free database of commercially available compounds for virtual screening (2005) Journal of Chemical Information and Modeling, 45, pp. 177-182; Johnson, G.V., Bailey, C.D., The p38 MAP kinase signaling pathway in Alzheimer's disease (2003) Experimental Neurology, 183, pp. 263-271; Kirchmair, J., Wolber, G., Laggner, C., Langer, T., Comparative performance assessment of the conformational model generators omega and catalyst: A large-scale survey on the retrieval of protein-bound ligand conformations (2006) Journal of Chemical Information and Modeling, 46, pp. 1848-1861; Koes, D.R., Camacho, C.J., ZINCPharmer: Pharmacophore search of the ZINC database (2012) Nucleic Acids Research, 40, pp. W409-W414. , (Web Server issue; Kuglstatter, A., Stahl, M., Peters, J.U., Huber, W., Stihle, M., Schlatte, D., Hennig, M., Tyramine fragment binding to BACE-1 (2008) Bioorganic & Medicinal Chemistry Letters, (18), pp. 1304-1311; Kumar, A., Ghosh, I., Mapping selectivity and specificity of active site of plasmepsins from Plasmodium falciparum using molecular interaction field approach (2007) Protein and Peptide Letters, 14, pp. 569-574; Kuret, J., Johnson, G.S., Cha, D., Christenson, E.R., Demaggio, A.J., Hoekstra, M.F., Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain (1997) J Ournal of Neurochemistry, 69, pp. 2506-2521; Laurie, A.T., Jackson, R.M., Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites (2005) Bioinformatics, 21, pp. 1908-1916; Lee, M.R., Dominguez, C., MAP Kinase p38Inhibitors: Clinical results and an intimate look at their interactions with p38 protein (2005) Current Medicinal Chemistry, 12, pp. 2979-2994; Lengauer, T., Bioinformatics: From genomes to drugs (2002) Methods and Principles in Medicinal Chemistry, 1. , Weinheim Wiley-VHC Verlag; Liu, X., Ouyang, S., Yu, B., Liu, Y., Huang, K., Gong, J., Jiang, H., PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach (2010) Nucleic Acids Research, 38, pp. W609-W614; Lu, Q., Wang, C., Pan, R., Ao X, G., Wei, Z., Xia, Y., Dai, Y., Histamine synergistically promotes bFGF-induced angiogenesis by enhancing VEGF production via H1 receptor (2013) Journal of Cellular Biochemistry, 114, pp. 1009-1019; Martin, K.J., Arthur, J.S., Selective kinase inhibitors as tools for neuroscience research (2012) Neuropharmacology, 63, pp. 1227-1237; Matos, K.S., Da Cunha, E.F., Da Silva Gonçalves, A., Wilter, A., Kua, K., França, T.C., Ramalho, T.C., First principles calculations of thermodynamics and kinetic parameters and molecular dynamics simulations of acetylcholinesterase reactivators Can mouse data provide new insights into humans (2012) Journal of Biomolecular Structure & Dynamics, 30, pp. 546-558; Mohan, C.G., Gandhi, T., Garg, D., Shinde, R., Computer-assisted methods in chemical toxicity prediction (2007) Mini Reviews in Medicinal Chemistry, 7, pp. 499-507; Mohan, V., Gibbs, A.C., Cummings, M.D., Jaeger, E.P., Desjarlais, R.L., Docking: Successes and challenges (2005) Current Pharmaceutical Design, 11, pp. 3233-3333; Muchmore, S.W., Souers, A.J., Akritopoulou-Zanze, I., The use of three-dimensional shape and electrostatic similarity searching in the identification of a melaninconcentrating hormone receptor 1 antagonist (2006) Chemical Biology & Drug de Sign, 67, pp. 174-176; Mucke, L., Neuroscience: Alzheimer's disease (2009) Nature, 461, pp. 895-902; Muster, W., Breidenbach, A., Fischer, H., Kirchner, S., Müller, L., Pähle, R.A., Computational toxicology in drug development (2008) Drug Discovery Today, 13, pp. 303-310; Nwaka, S., Hudson, A., Innovative lead discovery strategies for tropical diseases (2006) Nature Reviews Drug Discovery, 5, pp. 941-955; (2006), Omega.Versao 2.0. Santa Fe NM: Openeyes Scientific SoftwarePerry, J.J., Harris, R.M., Moiani, D., Olson, A.J., Tainer, J.A., P38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses (2009) Journal of Molecular Biology, 391, pp. 1-11; Pinsetta, F.R., Taft, C.A., Silva, C.H.T.P., Rational design of novel potential p38 MAPK inhibitors with drug-like properties using pharmacophore and similarity-based virtual screening procedures (2013) Current Bioactive Compounds, (13), pp. 3-13; Polgar, T., Keseru, G.M., Virtual screening for betasecretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228 (2005) Journal of Medicinal Chemistry, 48, pp. 3749-3755; (2011), QikProp.V ersion 3.4. New York NY: Schrödinger LLCReichman, W.E., Current pharmacologic options for patients with Alzheimer's disease (2003) Annals of General Hospital Psychiatry, 2, p. 1; Schneidma N-Duhovny, D., Dror, O., Inbar, Y., Nussinov, R., Wolfson, H.J., PharmaGist: A webserver for ligandbased pharmacophore detection (2008) Nucleic Acids Research, 36, pp. W223-W228; Scior, T., Bender, A., Tresadern, G., Medina-Franco, J.L., Martí Nez-Mayorga, K., Langer, T., Cuanalo-Contreras, K., Agrafiotis, D.K., Recognizing pitfalls in virtual screening: A critical review (2012) Journal of Chemical in Formation and Modeling, 52, pp. 867-881; Shintani, E.Y., Uchida, K.M., Donepezil: An anticholinesterase inhibitor for Alzheimer's disease (1997) American Journal of Health-System Pharmacy, 54, pp. 2805-2815; Simard, J.R., Grütter, C., Pawar, V., Aust, B., Wolf, A., Rabiller, M., Rauh, D., High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha (2009) Journal of the American Chemical Society, 131 (51), pp. 18478-18488; Singh, T.J., Grundke-Iqbal, I., Iqbal, K., Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state (1995) Journal of Neurochemistry, 64, pp. 1420-1423; Sutherland, J.J., Nandigam, R.K., Erickson, J.A., Vieth, M., Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy (2007) Journal of Chemical Information and Modeling, 47, pp. 2293-2302; Aft C A, T., Silva, C.H.T.P., Comments on the paper Levinthal's question revisited and answered (2013) Journal of Biomolecular Structure & Dynamics, , doi:10.1080/07391102.2012.748540 The PyMOL Molecular Graphics System Ve rsion 1.2r3pre Schrödinger LL; Tuccinardi, T., Ortore, G., Santos, M.A., Marques, S.M., Nuti, E., Rossello, A., Martinelli, A., Multitemplate alignment method for the development of a reliab le 3DQSAR model for the analysis of MMP3 inhibitors (2009) Journal of Chemical Information and Modeling, 49, pp. 1715-1724; Weiner, M.W., Dementia in (2012) further insights into Alzheimer disease pathogenesis (2012) Nature Reviews, (9), pp. 65-66; Yasuda, S., Sugiura, H., Tanaka, H., Takigami, S., Yamagata, K., P38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases (2011) Central Nervous System Agents in Medicinal Chemistry, (11), pp. 45-59; Zhang, Y.Y., Mei, Z.Q., Wu, J.W., Wang, Z.X., Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphoryl ation states (2008) Journal of Biological Chemistry, 283, pp. 26591-26601",Article,Scopus,2-s2.0-84899969869
"Gillman A.L., Jang H., Lee J., Ramachandran S., Kagan B.L., Nussinov R., Teran Arce F.","Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores",2014,"Journal of Physical Chemistry B","118","26",,"7335","7344",,2,10.1021/jp5040954,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903756361&partnerID=40&md5=1a78c07c8e09124a99ed8537f521c9e1","Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States; Department of Mechanical and Aerospace Engineering and Material Science Program, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States; Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States; Department of Psychiatry, David Geffen School of Medicine, University of California, 760 Westwood Plaza, San Diego, CA 90024, United States; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel","Gillman, A.L., Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States; Jang, H., Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States; Lee, J., Department of Mechanical and Aerospace Engineering and Material Science Program, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States; Ramachandran, S., Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States, Department of Mechanical and Aerospace Engineering and Material Science Program, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States; Kagan, B.L., Department of Psychiatry, David Geffen School of Medicine, University of California, 760 Westwood Plaza, San Diego, CA 90024, United States; Nussinov, R., Cancer and Inflammation Program, National Cancer Institute at Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States, Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Teran Arce, F., Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States, Department of Mechanical and Aerospace Engineering and Material Science Program, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States","Among the family of Aβ peptides, pyroglutamate-modified Aβ (AβpE) peptides are particularly associated with cytotoxicity in Alzheimers disease (AD). They represent the dominant fraction of Aβ oligomers in the brains of AD patients, but their accumulation in the brains of elderly individuals with normal cognition is significantly lower. Accumulation of AβpE plaques precedes the formation of plaques of full-length Aβ (Aβ1-40/42). Most of these properties appear to be associated with the higher hydrophobicity of AβpE as well as an increased resistance to enzymatic degradation. However, the important question of whether AβpE peptides induce pore activity in lipid membranes and their potential toxicity compared with other Aβ pores is still open. Here we examine the activity of AβpE pores in anionic membranes using planar bilayer electrical recording and provide their structures using molecular dynamics simulations. We find that AβpE pores spontaneously induce ionic current across the membrane and have some similar properties to the other previously studied pores of the Aβ family. However, there are also some significant differences. The onset of Aβ pE3-42 pore activity is generally delayed compared with Aβ1-42 pores. However, once formed, AβpE3-42 pores produce increased ion permeability of the membrane, as indicated by a greater occurrence of higher conductance electrical events. Structurally, the lactam ring of AβpE peptides induces a change in the conformation of the N-terminal strands of the AβpE3-42 pores. While the N-termini of wild-type Aβ1-42 peptides normally reside in the bulk water region, the N-termini of AβpE3-42 peptides tend to reside in the hydrophobic lipid core. These studies provide a first step to an understanding of the enhanced toxicity attributed to AβpE peptides. © 2014 American Chemical Society.",,"Tanzi, R.E., Bertram, L., Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective (2005) Cell, 120 (4), pp. 545-555. , DOI 10.1016/j.cell.2005.02.008; Iversen, L.L., Mortishiresmith, R.J., Pollack, S.J., Shearman, M.S., The Toxicity In-Vitro of Beta-Amyloid Protein (1995) Biochem. J., 311, pp. 1-16; Jakob-Roetne, R., Jacobsen, H., Alzheimers Disease: From Pathology to Therapeutic Approaches (2009) Angew. Chem., Int. Ed., 48 (17), pp. 3030-3059; Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics (2002) Science, 297 (5580), pp. 353-356. , DOI 10.1126/science.1072994; Hardy, J.A., Higgins, G.A., Alzheimers Disease: The Amyloid Cascade Hypothesis (1992) Science, 256 (5054), pp. 184-185; Thinakaran, G., Koo, E.H., Amyloid Precursor Protein Trafficking, Processing, and Function (2008) J. Biol. Chem., 283 (44), pp. 29615-29619; Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B.L., Nussinov, R., Lal, R., Truncated B-Amyloid Peptide Channels Provide An Alternative Mechanism for Alzheimers Disease and Down Syndrome (2010) Proc. Natl. Acad. Sci. U.S.A., pp. 6538-6543; Jawhar, S., Wirths, O., Bayer, T.A., Pyroglutamate Amyloid-B (Aβ): A Hatchet Man in Alzheimer Disease (2011) J. Biol. Chem., 286 (45), pp. 38825-38832; Saido, T.C., Iwatsubo, T., Mann, D.M.A., Shimada, H., Ihara, Y., Kawashima, S., Dominant and Differential Deposition of Distinct Beta-Amyloid Peptide Species, A-Beta(N3(Pe)), in Senile Plaques (1995) Neuron, 14 (2), pp. 457-466; Saido, T.C., Yamao-Harigaya, W., Iwatsubo, T., Kawashima, S., Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain (1996) Neuroscience Letters, 215 (3), pp. 173-176. , DOI 10.1016/S0304-3940(96)12970-0; Piccini, A., Russo, C., Gliozzi, A., Relini, A., Vitali, A., Borghi, R., Giliberto, L., Tabaton, M., β-amyloid is different in normal aging and in Alzheimer disease (2005) Journal of Biological Chemistry, 280 (40), pp. 34186-34192. , DOI 10.1074/jbc.M501694200; Tabaton, M., Piccini, A., Role of water-soluble amyloid-β in the pathogenesis of Alzheimer's disease (2005) International Journal of Experimental Pathology, 86 (3), pp. 139-145. , DOI 10.1111/j.0959-9673.2005.00428.x; Arispe, N., Pollard, H.B., Rojas, E., Giant multilevel cation channels formed by Alzheimer disease amyloid β- protein [AβP-(1-40)] in bilayer membranes (1993) Proceedings of the National Academy of Sciences of the United States of America, 90 (22), pp. 10573-10577. , DOI 10.1073/pnas.90.22.10573; Arispe, N., Rojas, E., Pollard, H.B., Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum (1993) Proceedings of the National Academy of Sciences of the United States of America, 90 (2), pp. 567-571. , DOI 10.1073/pnas.90.2.567; Capone, R., Quiroz, F.G., Prangkio, P., Saluja, I., Sauer, A.M., Bautista, M.R., Turner, R.S., Mayer, M., Amyloid-Beta-Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving A Controversy (2009) Neurotoxic. Res., 16 (1), pp. 1-13; Prangkio, P., Yusko, E.C., Sept, D., Yang, J., Mayer, M., Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate A Connection between Pore Formation and Cytotoxicity (2012) PLoS One, 7, p. 10; Demuro, A., Smith, M., Parker, I., Single-Channel Ca2+ Imaging Implicates Aβ1-42 Amyloid Pores in Alzheimers Disease Pathology (2011) J. Cell Biol., 195 (3), pp. 515-524; Kagan, B.L., Azimov, R., Azimova, R., Amyloid peptide channels (2004) Journal of Membrane Biology, 202 (1), pp. 1-10. , DOI 10.1007/s00232-004-0709-4; Kagan, B.L., Hirakura, Y., Azimov, R., Azimova, R., Lin, M.-C., The channel hypothesis of Alzheimer's disease: Current status (2002) Peptides, 23 (7), pp. 1311-1315. , DOI 10.1016/S0196-9781(02)00067-0, PII S0196978102000670; Kim, H.Y., Cho, M.K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., Fernandez, C.O., Lange, A., Structural Properties of Pore-Forming Oligomers of Alpha-Synuclein (2009) J. Am. Chem. Soc., 131 (47), pp. 17482-17489; Jang, H., Connelly, L., Arce, F.T., Ramachandran, S., Lal, R., Kagan, B., Nussinov, R., Alzheimers Disease: Which Type of Amyloid-Preventing Drug Agents to Employ? (2013) Phys. Chem. Chem. Phys., 15, pp. 8868-8877; Jang, H., Connelly, L., Arce, F.T., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Mechanisms for the Insertion of Toxic, Fibril-Like Beta-Amyloid Oligomers into the Membrane (2013) J. Chem. Theory Comput., 9 (1), pp. 822-833; Lin, H., Bhatia, R., Lal, R., Amyloid β protein forms ion channels: Implications for Alzheimer's disease pathophysiology (2001) FASEB Journal, 15 (13), pp. 2433-2444. , DOI 10.1096/fj.01-0377com; Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Lal, R., Amyloid ion channels: A common structural link for protein-misfolding disease (2005) Proceedings of the National Academy of Sciences of the United States of America, 102 (30), pp. 10427-10432. , DOI 10.1073/pnas.0502066102; Connelly, L., Arce, F.T., Jang, H., Capone, R., Kotler, S.A., Ramachandran, S., Kagan, B.L., Lal, R., Atomic Force Microscopy and MD Simulations Reveal Pore-Like Structures of All-D-Enantiomer of Alzheimers B-Amyloid Peptide: Relevance to the Ion Channel Mechanism of AD Pathology (2012) J. Phys. Chem. B, 116 (5), pp. 1728-1735; Capone, R., Jang, H., Kotler, S.A., Connelly, L., Arce, F.T., Ramachandran, S., Kagan, B.L., Lal, R., All-D-Enantiomer of Beta-Amyloid Peptide Forms Ion Channels in Lipid Bilayers (2012) J. Chem. Theory Comput., 8 (3), pp. 1143-1152; Lin, M.-C.A., Kagan, B.L., Electrophysiologic properties of channels induced by Aβ25-35 in planar lipid bilayers (2002) Peptides, 23 (7), pp. 1215-1228. , DOI 10.1016/S0196-9781(02)00057-8, PII S0196978102000578; Arce, F.T., Jang, H., Ramachandran, S., Landon, P.B., Nussinov, R., Lal, R., Polymorphism of Amyloid B Peptide in Different Environments: Implications for Membrane Insertion and Pore Formation (2011) Soft Matter, 7 (11), pp. 5267-5273; Jang, H., Arce, F.T., Capone, R., Ramachandran, S., Lal, R., Nussinov, R., Misfolded Amyloid Ion Channels Present Mobile B-Sheet Subunits in Contrast to Conventional Ion Channels (2009) Biophys. J., 97 (11), pp. 3029-3037; Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Lal, R., Nussinov, R., Structural Convergence among Diverse, Toxic B-Sheet Ion Channels (2010) J. Phys. Chem. B, 114 (29), pp. 9445-9451; Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Lal, R., Nussinov, R., B-Barrel Topology of Alzheimers B-Amyloid Ion Channels (2010) J. Mol. Biol., 404 (5), pp. 917-934; Connelly, L., Jang, H., Arce, F.T., Ramachandran, S., Kagan, B.L., Nussinov, R., Lal, R., Effects of Point Substitutions on the Structure of Toxic Alzheimers B-Amyloid Channels: Atomic Force Microscopy and Molecular Dynamics Simulations (2012) Biochemistry, 51 (14), pp. 3031-3038; Connelly, L., Jang, H., Teran Arce, F., Capone, R., Kotler, S.A., Ramachandran, S., Kagan, B.L., Lal, R., Atomic Force Microscopy and MD Simulations Reveal Pore-Like Structures of All-D-Enantiomer of Alzheimers B-Amyloid Peptide: Relevance to the Ion Channel Mechanism of AD Pathology (2012) J. Phys. Chem. B, 116 (5), pp. 1728-1735; Butterfield, S.M., Lashuel, H.A., Amyloidogenic Protein-Membrane Interactions: Mechanistic Insight from Model Systems (2010) Angew. Chem., Int. Ed., 49, pp. 5628-5654; Williams, T.L., Serpell, L.C., Membrane and Surface Interactions of Alzheimers A Beta Peptide - Insights into the Mechanism of Cytotoxicity (2011) FEBS J., 278 (20), pp. 3905-3917; Sciacca, M.F.M., Kotler, S.A., Brender, J.R., Chen, J., Lee, D.K., Ramamoorthy, A., Two-Step Mechanism of Membrane Disruption by A Beta Through Membrane Fragmentation and Pore Formation (2012) Biophys. J., 103 (4), pp. 702-710; Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.U., Bayer, T.A., Intraneuronal Pyroglutamate-Abeta 3-42 Triggers Neurodegeneration and Lethal Neurological Deficits in A Transgenic Mouse Model (2009) Acta Neuropathol., 118 (4), pp. 487-496; Soderberg, M., Edlund, C., Alafuzoff, I., Kristensson, K., Dallner, G., Lipid-Composition in Different Regions of the Brain in Alzheimers-Disease Senile Dementia of Alzheimers Type (1992) J. Neurochem., 59 (5), pp. 1646-1653; Wells, K., Farooqui, A.A., Liss, L., Horrocks, L.A., Neural membrane phospholipids in Alzheimer disease (1995) Neurochemical Research, 20 (11), pp. 1329-1333. , DOI 10.1007/BF00992508; Nitsch, R.M., Blusztajn, J.K., Pittas, A.G., Slack, B.E., Growdon, J.H., Wurtman, R.J., Evidence for A Membrane Defect in Alzheimer-Disease Brain (1992) Proc. Natl. Acad. Sci. U.S.A., 89 (5), pp. 1671-1675; Svennerholm, L., Gottfries, C.-G., Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II) (1994) Journal of Neurochemistry, 62 (3), pp. 1039-1047; Mueller, P., Rudin, D.O., Tien, H.T., Wescott, W.C., Reconstitution of Cell Membrane Structure in Vitro and Its Transformation into An Excitable System (1962) Nature, 194 (4832), pp. 979-980; Capone, R., Jang, H., Kotler, S.A., Kagan, B.L., Nussinov, R., Lal, R., Probing Structural Features of Alzheimers Amyloid-Beta Pores in Bilayers Using Site-Specific Amino Acid Substitutions (2012) Biochemistry, 51 (3), pp. 776-785; Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Doeli, H., Schubert, D., Riek, R., 3D Structure of Alzheimers Amyloid-B(1-42) Fibrils (2005) Proc. Natl. Acad. Sci. U. S. A., 102 (48), pp. 17342-17347; Petkova, A.T., Yau, W.-M., Tycko, R., Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils (2006) Biochemistry, 45 (2), pp. 498-512. , DOI 10.1021/bi051952q; Zirah, S., Kozin, S.A., Mazur, A.K., Blond, A., Cheminant, M., Segalas-Milazzo, I., Debey, P., Rebuffat, S., Structural changes of region 1-16 of the Alzheimer disease amyloid β-peptide upon zinc binding and in vitro aging (2006) Journal of Biological Chemistry, 281 (4), pp. 2151-2161. , http://www.jbc.org/cgi/reprint/281/4/2151, DOI 10.1074/jbc.M504454200; Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., Karplus, M., Charmm - A Program for Macromolecular Energy, Minimization, and Dynamics Calculations (1983) J. Comput. Chem., 4 (2), pp. 187-217; Hanwell, M.D., Curtis, D.E., Lonie, D.C., Vandermeersch, T., Zurek, E., Hutchison, G.R., Avogadro: An Advanced Semantic Chemical Editor, Visualization, and Analysis Platform (2012) J. Cheminform, 4 (1), p. 17; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Petersson, G.A., (2009) Gaussian 09, , revision B.01; Gaussian, Inc. Wallingford CT; Schulz, G.E., The structure of bacterial outer membrane proteins (2002) Biochimica et Biophysica Acta - Biomembranes, 1565 (2), pp. 308-317. , DOI 10.1016/S0005-2736(02)00577-1, PII S0005273602005771; Capone, R., Jang, H., Kotler, S.A., Kagan, B.L., Nussinov, R., Lal, R., Probing Structural Features of Alzheimers Amyloid-B Pores in Bilayers Using Site-Specific Amino Acid Substitutions (2012) Biochemistry, 51 (3), pp. 776-785; Jang, H., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Disordered Amyloidogenic Peptides May Insert into the Membrane and Assemble into Common Cyclic Structural Motifs (2014) Chem. Soc. Rev., , 10.1039/C3CS60459D; Jang, H., Zheng, J., Lal, R., Nussinov, R., New Structures Help the Modeling of Toxic Amyloidβ Ion Channels (2008) Trends Biochem. Sci., 33 (2), pp. 91-100; Jang, H., Zheng, J., Nussinov, R., Models of β-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process (2007) Biophysical Journal, 93 (6), pp. 1938-1949. , http://www.biophysj.org/cgi/reprint/93/6/1938, DOI 10.1529/biophysj.107.110148; Jang, H., Arce, F.T., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Familial Alzheimers Disease Osaka Mutant (δE22) B-Barrels Suggest An Explanation for the Different Aβ(1-40/42) Preferred Conformational States Observed by Experiment (2013) J. Phys. Chem. B, 117 (39), pp. 11518-11529; Mustata, M., Capone, R., Jang, H., Arce, F.T., Ramachandran, S., Lal, R., Nussinov, R., K3 Fragment of Amyloidogenic Beta(2)-Microglobulin Forms Ion Channels: Implication for Dialysis Related Amyloidosis (2009) J. Am. Chem. Soc., 131 (41), pp. 14938-14945; Zhao, J., Luo, Y., Jang, H.B., Yu, X., Wei, G.H., Nussinov, R., Zheng, J., Probing Ion Channel Activity of Human Islet Amyloid Polypeptide (Amylin) (2012) Biochim. Biophys. Acta, Biomembr., 1818 (12), pp. 3121-3130; Capone, R., Mustata, M., Jang, H., Arce, F.T., Nussinov, R., Lal, R., Antimicrobial Protegrin-1 Forms Ion Channels: Molecular Dynamic Simulation, Atomic Force Microscopy, and Electrical Conductance Studies (2010) Biophys. J., 98 (11), pp. 2644-2652; Jang, H., Ma, B., Lal, R., Nussinov, R., Models of Toxic Beta-Sheet Channels of Protegrin-1 Suggest A Common Subunit Organization Motif Shared with Toxic Alzheimer Beta-Amyloid Ion Channels (2008) Biophys. J., 95 (10), pp. 4631-4642; Gupta, K., Jang, H., Harlen, K., Puri, A., Nussinov, R., Schneider, J.P., Blumenthal, R., Mechanism of Membrane Permeation Induced by Synthetic Beta-Hairpin Peptides (2013) Biophys. J., 105 (9), pp. 2093-2103; Woolf, T.B., Roux, B., Molecular dynamics simulation of the gramicidin channel in a phospholipid bilayer (1994) Proceedings of the National Academy of Sciences of the United States of America, 91 (24), pp. 11631-11635. , DOI 10.1073/pnas.91.24.11631; Klauda, J.B., Venable, R.M., Freites, J.A., Oconnor, J.W., Tobias, D.J., Mondragon-Ramirez, C., Vorobyov, I., Pastor, R.W., Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types (2010) J. Phys. Chem. B, 114 (23), pp. 7830-7843; Durell, S.R., Brooks, B.R., Bennaim, A., Solvent-Induced Forces between Two Hydrophilic Groups (1994) J. Phys. Chem., 98, pp. 2198-2202; Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Schulten, K., Scalable molecular dynamics with NAMD (2005) Journal of Computational Chemistry, 26 (16), pp. 1781-1802. , DOI 10.1002/jcc.20289; Jang, H., Teran Arce, F., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., Familial Alzheimers Disease Osaka Mutant (Deltae22) Beta-Barrels Suggest An Explanation for the Different Abeta1-40/42 Preferred Conformational States Observed by Experiment (2013) J. Phys. Chem. B, 117 (39), pp. 11518-11529; Allen, T.W., Andersen, O.S., Roux, B., Energetics of ion conduction through the gramicidin channel (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (1), pp. 117-122. , DOI 10.1073/pnas.2635314100; Nussbaum, J.M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Bloom, G.S., Prion-Like Behaviour and Tau-Dependent Cytotoxicity of Pyroglutamylated Amyloid-Beta (2012) Nature, 485 (7400), pp. 651-655; Jang, H., Arce, F.T., Mustata, M., Ramachandran, S., Capone, R., Nussinov, R., Lal, R., Antimicrobial Protegrin-1 Forms Amyloid-Like Fibrils with Rapid Kinetics Suggesting A Functional Link (2011) Biophys. J., 100 (7), pp. 1775-1783; Bleicken, S., Wagner, C., Garcia-Saez, A.J., Mechanistic Differences in the Membrane Activity of Bax and Bcl-Xl Correlate with Their Opposing Roles in Apoptosis (2013) Biophys. J., 104 (2), pp. 421-431; Smart, O.S., Goodfellow, J.M., Wallace, B.A., The pore dimensions of gramicidin A (1993) Biophysical Journal, 65 (6), pp. 2455-2460",Article,Scopus,2-s2.0-84903756361
"Gupta M.K., Jayaram S., Madugundu A.K., Chavan S., Advani J., Pandey A., Thongboonkerd V., Sirdeshmukh R.","Chromosome-centric human proteome project: Deciphering proteins associated with glioma and neurodegenerative disorders on chromosome 12",2014,"Journal of Proteome Research","13","7",,"3178","3190",,1,10.1021/pr500023p,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903722482&partnerID=40&md5=439d9d402eb6160b75caf66c408fd79f","Institute of Bioinformatics, International Tech Park, Bangalore 560066, India; Manipal University, Madhav Nagar, Manipal 576104, India; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand; Center for Research, Complex Systems Science, Mahidol University, Bangkok 10700, Thailand; Mazumdar Shaw Centre for Translational Research, Narayana Health, Bangalore 560099, India","Gupta, M.K., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India, Manipal University, Madhav Nagar, Manipal 576104, India; Jayaram, S., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India, Manipal University, Madhav Nagar, Manipal 576104, India; Madugundu, A.K., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India; Chavan, S., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India, Manipal University, Madhav Nagar, Manipal 576104, India; Advani, J., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India; Pandey, A., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Thongboonkerd, V., Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Bangkok 10700, Thailand, Center for Research, Complex Systems Science, Mahidol University, Bangkok 10700, Thailand; Sirdeshmukh, R., Institute of Bioinformatics, International Tech Park, Bangalore 560066, India, Mazumdar Shaw Centre for Translational Research, Narayana Health, Bangalore 560099, India","In line with the aims of the Chromosome-centric Human Proteome Project (C-HPP) to completely annotate proteins of each chromosome and biology/disease driven HPP (B/D-HPP) to decipher their relation to diseases, we have generated a nonredundant catalogue of protein-coding genes for Chromosome 12 (Chr. 12) and further annotated proteins associated with major neurological disorders. Integrating high level proteomic evidence from four major databases (neXtProt, Global Proteome Machine (GPMdb), PeptideAtlas, and Human Protein Atlas (HPA)) along with Ensembl data resource resulted in the identification of 1066 protein coding genes, of which 171 were defined as ""missing proteins"" based on the weak or complete absence of experimental evidence. With functional annotations using DAVID and GAD, about 40% of the proteins could be grouped as brain related with implications in cancer or neurological disorders. We used published and unpublished high confidence mass spectrometry data from our group and other literature consisting of more than 5000 proteins derived from clinical specimens from patients with human gliomas, Alzheimers disease, and Parkinsons disease and mapped it onto Chr. 12. We observed a total of 202 proteins mapping to human Chr. 12, 136 of which were differentially expressed in these disease conditions as compared to the normal. Functional grouping indicated their association with cell cycle, cell-to-cell signaling, and other important processes and networks, whereas their disease association analysis confirmed neurological diseases and cancer as the major group along with psycological disorders, with several overexpressed genes/proteins mapping to 12q13-15 amplicon region. Using multiple strategies and bioinformatics tools, we identified 103 differentially expressed proteins to have secretory potential, 17 of which have already been reported in direct analysis of the plasma or cerebrospinal fluid (CSF) from the patients and 21 of them mapped to cancer associated protein (CAPs) database that are amenable to selective reaction monitoring (SRM) assays for targeted proteomic analysis. Our analysis also reveals, for the first time, mass spectrometric evidence for two ""missing proteins"" from Chr. 12, namely, synaptic vesicle 2-related protein (SVOP) and IQ motif containing D (IQCD). The analysis provides a snapshot of Chr. 12 encoded proteins associated with gliomas and major neurological conditions and their secretability which can be used to drive efforts for clinical applications. © 2014 American Chemical Society.","""missing proteins""; Alzheimers disease; B/D-HPP; CHPP; chromosome 12; glioma; Parkinsons disease; secretory proteins","Paik, Y.K., Jeong, S.K., Omenn, G.S., Uhlen, M., Hanash, S., Cho, S.Y., Lee, H.J., Hancock, W.S., The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome (2012) Nat. Biotechnol., 30 (3), pp. 221-223; Legrain, P., Aebersold, R., Archakov, A., Bairoch, A., Bala, K., Beretta, L., Bergeron, J., Omenn, G.S., The human proteome project: Current state and future direction (2011) Mol. Cell. Proteomics, 10 (7), p. 111. , 009993; Aebersold, R., Bader, G.D., Edwards, A.M., Van Eyk, J.E., Kussmann, M., Qin, J., Omenn, G.S., The biology/disease-driven human proteome project (B/D-HPP): Enabling protein research for the life sciences community (2013) J. Proteome Res., 12 (1), pp. 23-27; Scherer, S.E., Muzny, D.M., Buhay, C.J., Chen, R., Cree, A., Ding, Y., Dugan-Rocha, S., Davy-Carroll, L., The finished DNA sequence of human chromosome 12 (2006) Nature, 440 (7082), pp. 346-351; Mejia-Guerrero, S., Quejada, M., Gokgoz, N., Gill, M., Parkes, R.K., Wunder, J.S., Andrulis, I.L., Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma (2010) Genes Chromosomes Cancer, 49 (6), pp. 518-525; Forus, A., Florenes, V.A., Maelandsmo, G.M., Meltzer, P.S., Fodstad, O., Myklebost, O., Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: Some amplica do not include MDM2 (1993) Cell Growth Differ., 4 (12), pp. 1065-1070; Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P.S., Collins, V.P., Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2 (1994) Cancer Res., 54 (16), pp. 4299-4303; Reifenberger, G., Ichimura, K., Reifenberger, J., Elkahloun, A.G., Meltzer, P.S., Collins, V.P., Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets (1996) Cancer Res., 56 (22), pp. 5141-5145; Crespo, I., Tao, H., Nieto, A.B., Rebelo, O., Domingues, P., Vital, A.L., Patino Mdel, C., Tabernero, M.D., Amplified and homozygously deleted genes in glioblastoma: Impact on gene expression levels (2012) PLoS One, 7 (9), p. 46088; Reifenberger, G., Reifenberger, J., Ichimura, K., Collins, V.P., Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site (1995) Cancer Res., 55 (4), pp. 731-734; Rogaeva, E., Premkumar, S., Song, Y., Sorbi, S., Brindle, N., Paterson, A., Duara, R., St George-Hyslop, P.H., Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity (1998) JAMA, 280 (7), pp. 614-618; Pericak-Vance, M.A., Bass, M.P., Yamaoka, L.H., Gaskell, P.C., Scott, W.K., Terwedow, H.A., Menold, M.M., Haines, J.L., Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12 (1997) JAMA, 278 (15), pp. 1237-1241; Scott, W.K., Grubber, J.M., Conneally, P.M., Small, G.W., Hulette, C.M., Rosenberg, C.K., Saunders, A.M., Pericak-Vance, M.A., Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: Potential genetic and phenotypic heterogeneity (2000) Am. J. Hum. Genet., 66 (3), pp. 922-932; Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Ross, C.A., Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration (2005) Proc. Natl. Acad. Sci. U. S. A., 102 (51), pp. 18676-18681; Hall, A.V., Antoniou, H., Wang, Y., Cheung, A.H., Arbus, A.M., Olson, S.L., Lu, W.C., Marsden, P.A., Structural organization of the human neuronal nitric oxide synthase gene (NOS1) (1994) J. Biol. Chem., 269 (52), pp. 33082-33090; Abkevich, V., Camp, N.J., Hensel, C.H., Neff, C.D., Russell, D.L., Hughes, D.C., Plenk, A.M., Cannon-Albright, L., Predisposition locus for major depression at chromosome 12q22-12q23.2 (2003) Am. J. Hum. Genet., 73 (6), pp. 1271-1281; Gaudet, P., Argoud-Puy, G., Cusin, I., Duek, P., Evalet, O., Gateau, A., Gleizes, A., Lane, L., NeXtProt: Organizing protein knowledge in the context of human proteome projects (2013) J. Proteome Res., 12 (1), pp. 293-298; Desiere, F., Deutsch, E.W., King, N.L., Nesvizhskii, A.I., Mallick, P., Eng, J., Chen, S., Aebersold, R., The PeptideAtlas project (2006) Nucleic Acids Res., 34 (DATABASE ISSUE), pp. 655-658; Lane, L., Bairoch, A., Beavis, R.C., Deutsch, E.W., Gaudet, P., Lundberg, E., Omenn, G.S., Metrics for the Human Proteome Project 2013-2014 and strategies for finding missing proteins (2014) J. Proteome Res., 13 (1), pp. 15-20; Marko-Varga, G., Omenn, G.S., Paik, Y.K., Hancock, W.S., A first step toward completion of a genome-wide characterization of the human proteome (2013) J. Proteome Res., 12 (1), pp. 1-5; Paik, Y.K., Omenn, G.S., Uhlen, M., Hanash, S., Marko-Varga, G., Aebersold, R., Bairoch, A., Hancock, W.S., Standard guidelines for the chromosome-centric human proteome project (2012) J. Proteome Res., 11 (4), pp. 2005-2013; Keshava Prasad, T.S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., Telikicherla, D., Pandey, A., Human Protein Reference Database - 2009 update (2009) Nucleic Acids Res., 37 (DATABASE ISSUE), pp. 767-772; Polisetty, R.V., Gautam, P., Gupta, M.K., Sharma, R., Uppin, M.S., Challa, S., Ankathi, P., Sirdeshmukh, R., Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: A grade III malignant glioma (2013) J. Proteome Res., 12 (7), pp. 3128-3138; Huttenhain, R., Soste, M., Selevsek, N., Rost, H., Sethi, A., Carapito, C., Farrah, T., Aebersold, R., Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics (2012) Sci. Transl. Med., 4 (142), pp. 142ra94; Polisetty, R.V., Gautam, P., Sharma, R., Harsha, H.C., Nair, S.C., Gupta, M.K., Uppin, M.S., Sirdeshmukh, R., LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions (2012) Mol. Cell. Proteomics, 11 (6), p. 111. , 013565; Desouza, L.V., Matta, A., Karim, Z., Mukherjee, J., Wang, X.S., Krakovska, O., Zadeh, G., Siu, K.M., Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme (2013) Mol. Cancer, 12, p. 74; Gimenez, M., Souza, V.C., Izumi, C., Barbieri, M.R., Chammas, R., Oba-Shinjo, S.M., Uno, M., Rosa, J.C., Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin (2010) Proteomics, 10 (15), pp. 2812-2821; Collet, B., Guitton, N., Saikali, S., Avril, T., Pineau, C., Hamlat, A., Mosser, J., Quillien, V., Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach (2011) Proteome Sci., 9 (1), p. 16; Li, J., Zhuang, Z., Okamoto, H., Vortmeyer, A.O., Park, D.M., Furuta, M., Lee, Y.S., Weil, R.J., Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers (2006) Neurology, 66 (5), pp. 733-736; Melchior, K., Tholey, A., Heisel, S., Keller, A., Lenhof, H.P., Meese, E., Huber, C.G., Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches (2009) J. Proteome Res., 8 (10), pp. 4604-4614; An, J.H., Lee, S.Y., Jeon, J.Y., Cho, K.G., Kim, S.U., Lee, M.A., Identification of gliotropic factors that induce human stem cell migration to malignant tumor (2009) J. Proteome Res., 8 (6), pp. 2873-2881; Chumbalkar, V.C., Subhashini, C., Dhople, V.M., Sundaram, C.S., Jagannadham, M.V., Kumar, K.N., Srinivas, P.N., Sirdeshmukh, R., Differential protein expression in human gliomas and molecular insights (2005) Proteomics, 5 (4), pp. 1167-1177; Shi, M., Bradner, J., Bammler, T.K., Eaton, D.L., Zhang, J., Ye, Z., Wilson, A.M., Pan, C., Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression (2009) Am. J. Pathol., 175 (1), pp. 54-65; Van Dijk, K.D., Berendse, H.W., Drukarch, B., Fratantoni, S.A., Pham, T.V., Piersma, S.R., Huisman, E., Van De Berg, W.D., The proteome of the locus ceruleus in Parkinsons disease: Relevance to pathogenesis (2012) Brain Pathol., 22 (4), pp. 485-498; Begcevic, I., Kosanam, H., Martinez-Morillo, E., Dimitromanolakis, A., Diamandis, P., Kuzmanov, U., Hazrati, L.N., Diamandis, E.P., Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimers disease and age-matched control brains (2013) Clin. Proteomics, 10 (1), p. 5; Melanson, J.E., Avery, S.L., Pinto, D.M., High-coverage quantitative proteomics using amine-specific isotopic labeling (2006) Proteomics, 6 (16), pp. 4466-4474; Schonberger, S.J., Edgar, P.F., Kydd, R., Faull, R.L., Cooper, G.J., Proteomic analysis of the brain in Alzheimers disease: Molecular phenotype of a complex disease process (2001) Proteomics, 1 (12), pp. 1519-1528; Tsuji, T., Shimohama, S., Analysis of the proteomic profiling of brain tissue in Alzheimers disease (2001) Dis. Markers, 17 (4), pp. 247-257; Castegna, A., Thongboonkerd, V., Klein, J.B., Lynn, B., Markesbery, W.R., Butterfield, D.A., Proteomic identification of nitrated proteins in Alzheimers disease brain (2003) J. Neurochem., 85 (6), pp. 1394-1401; Khalil, A.A., Biomarker discovery: A proteomic approach for brain cancer profiling (2007) Cancer Sci., 98 (2), pp. 201-213; Gautam, P., Nair, S.C., Gupta, M.K., Sharma, R., Polisetty, R.V., Uppin, M.S., Sundaram, C., Sirdeshmukh, R., Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis (2012) PLoS One, 7 (9), p. 46153; Khwaja, F.W., Reed, M.S., Olson, J.J., Schmotzer, B.J., Gillespie, G.Y., Guha, A., Groves, M.D., Van Meir, E.G., Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients (2007) J. Proteome Res., 6 (2), pp. 559-570; Zhang, X., Yin, X., Yu, H., Liu, X., Yang, F., Yao, J., Jin, H., Yang, P., Quantitative proteomic analysis of serum proteins in patients with Parkinsons disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry (2012) Analyst, 137 (2), pp. 490-495; Abdi, F., Quinn, J.F., Jankovic, J., McIntosh, M., Leverenz, J.B., Peskind, E., Nixon, R., Zhang, J., Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders (2006) J. Alzheimers Dis., 9 (3), pp. 293-348; Lehnert, S., Jesse, S., Rist, W., Steinacker, P., Soininen, H., Herukka, S.K., Tumani, H., Otto, M., ITRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinsons disease dementia (2012) Exp. Neurol., 234 (2), pp. 499-505; Ringman, J.M., Schulman, H., Becker, C., Jones, T., Bai, Y., Immermann, F., Cole, G., Wan, H.I., Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations (2012) Arch. Neurol., 69 (1), pp. 96-104; Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H.L., Hooper, C., Lovestone, S., Proteome-based plasma biomarkers for Alzheimers disease (2006) Brain, 129 (PART 11), pp. 3042-3050; Blalock, E.M., Geddes, J.W., Chen, K.C., Porter, N.M., Markesbery, W.R., Landfield, P.W., Incipient Alzheimers disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses (2004) Proc. Natl. Acad. Sci. U. S. A., 101 (7), pp. 2173-2178; Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Hayes, D.N., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 (2010) Cancer Cell, 17 (1), pp. 98-110; Dong, H., Luo, L., Hong, S., Siu, H., Xiao, Y., Jin, L., Chen, R., Xiong, M., Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma (2010) BMC Syst. Biol., 4, p. 163; Mathivanan, S., Fahner, C.J., Reid, G.E., Simpson, R.J., ExoCarta 2012: Database of exosomal proteins, RNA and lipids (2012) Nucleic Acids Res., 40 (DATABASE ISSUE), pp. 1241-1244; Schutzer, S.E., Liu, T., Natelson, B.H., Angel, T.E., Schepmoes, A.A., Purvine, S.O., Hixson, K.K., Bergquist, J., Establishing the proteome of normal human cerebrospinal fluid (2010) PLoS One, 5 (6), p. 10980; Farrah, T., Deutsch, E.W., Omenn, G.S., Campbell, D.S., Sun, Z., Bletz, J.A., Mallick, P., Aebersold, R., A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas (2011) Mol. Cell. Proteomics, 10 (9), p. 110. , 006353; Buttenschon, H.N., Foldager, L., Flint, T.J., Olsen, I.M., Deleuran, T., Nyegaard, M., Hansen, M.M., Mors, O., Support for a bipolar affective disorder susceptibility locus on chromosome 12q24.3 (2010) Psychiatr. Genet., 20 (3), pp. 93-101; Claes, L., Audenaert, D., Deprez, L., Van Paesschen, W., Depondt, C., Goossens, D., Del-Favero, J., De Jonghe, P., Novel locus on chromosome 12q22-q23.3 responsible for familial temporal lobe epilepsy associated with febrile seizures (2004) J. Med. Genet., 41 (9), pp. 710-714; Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., Obata, F., A new locus for Parkinsons disease (PARK8) maps to chromosome 12p11.2-q13.1 (2002) Ann. Neurol., 51 (3), pp. 296-301; Lucae, S., Salyakina, D., Barden, N., Harvey, M., Gagne, B., Labbe, M., Binder, E.B., Muller-Myhsok, B., P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder (2006) Hum. Mol. Genet., 15 (16), pp. 2438-2445; Beecham, G.W., Martin, E.R., Li, Y.J., Slifer, M.A., Gilbert, J.R., Haines, J.L., Pericak-Vance, M.A., Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease (2009) Am. J. Hum. Genet., 84 (1), pp. 35-43; Deangelis, L.M., Brain tumors (2001) N. Engl. J. Med., 344 (2), pp. 114-123; Maher, E.A., Furnari, F.B., Bachoo, R.M., Rowitch, D.H., Louis, D.N., Cavenee, W.K., Depinho, R.A., Malignant glioma: Genetics and biology of a grave matter (2001) Genes Dev., 15 (11), pp. 1311-1333; Rothstein, J.D., Paving new pathways (2002) Nat. Med., 8 (9), pp. 938-940; Sontheimer, H., A role for glutamate in growth and invasion of primary brain tumors (2008) J. Neurochem., 105 (2), pp. 287-295; Lee, S.G., Kim, K., Kegelman, T.P., Dash, R., Das, S.K., Choi, J.K., Emdad, L., Fisher, P.B., Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity (2011) Cancer Res., 71 (20), pp. 6514-6523; Liu, Y., Melin, B.S., Rajaraman, P., Wang, Z., Linet, M., Shete, S., Amos, C.I., Bondy, M.L., Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma (2012) Hum. Genet., 131 (9), pp. 1507-1517; Collins, V.P., Gene amplification in human gliomas (1995) Glia, 15 (3), pp. 289-296; Fischer, U., Keller, A., Leidinger, P., Deutscher, S., Heisel, S., Urbschat, S., Lenhof, H.P., Meese, E., A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma (2008) Mol. Cancer Res., 6 (4), pp. 576-584; Fischer, U., Meltzer, P., Meese, E., Twelve amplified and expressed genes localized in a single domain in glioma (1996) Hum. Genet., 98 (5), pp. 625-628; Polisetty, R.V., Gupta, M.K., Nair, S.C., Ramamoorthy, K., Tiwary, S., Shiras, A., Chandak, G.R., Sirdeshmukh, R., Glioblastoma cell secretome: Analysis of three glioblastoma cell lines reveal 148 non-redundant proteins (2011) J. Proteomics, 74 (10), pp. 1918-1925; Gupta, M.K., Polisetty, R.V., Ramamoorthy, K., Tiwary, S., Kaur, N., Uppin, M.S., Shiras, A., Sirdeshmukh, R., Secretome analysis of Glioblastoma cell line - HNGC-2 (2013) Mol. Biosyst., 9 (6), pp. 1390-1400; Butterfield, D.A., Lange, M.L., Multifunctional roles of enolase in Alzheimers disease brain: Beyond altered glucose metabolism (2009) J. Neurochem., 111 (4), pp. 915-933; Palumbo, B., Siepi, D., Sabalich, I., Tranfaglia, C., Parnetti, L., Cerebrospinal fluid neuron-specific enolase: A further marker of Alzheimers disease? (2008) Funct. Neurol., 23 (2), pp. 93-96; Blacker, D., Wilcox, M.A., Laird, N.M., Rodes, L., Horvath, S.M., Go, R.C., Perry, R., Tanzi, R.E., Alpha-2 macroglobulin is genetically associated with Alzheimer disease (1998) Nat. Genet., 19 (4), pp. 357-360; Kanekiyo, T., Cirrito, J.R., Liu, C.C., Shinohara, M., Li, J., Schuler, D.R., Holtzman, D.M., Bu, G., Neuronal Clearance of Amyloid-beta by Endocytic Receptor LRP1 (2013) J. Neurosci., 33 (49), pp. 19276-19283; Song, H., Li, Y., Lee, J., Schwartz, A.L., Bu, G., Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9 (2009) Cancer Res., 69 (3), pp. 879-886; Tajes, M., Guivernau, B., Ramos-Fernandez, E., Bosch-Morato, M., Palomer, E., Guix, F.X., Munoz, F.J., The pathophysiology of triose phosphate isomerase dysfunction in Alzheimers disease (2013) Histol. Histopathol., 28 (1), pp. 43-51; Liu, K.W., Feng, H., Bachoo, R., Kazlauskas, A., Smith, E.M., Symes, K., Hamilton, R.L., Cheng, S.Y., SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans (2011) J. Clin. Invest., 121 (3), pp. 905-917; Bentires-Alj, M., Paez, J.G., David, F.S., Keilhack, H., Halmos, B., Naoki, K., Maris, J.M., Neel, B.G., Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia (2004) Cancer Res., 64 (24), pp. 8816-8820; Robertson, J., Beaulieu, J.M., Doroudchi, M.M., Durham, H.D., Julien, J.P., Mushynski, W.E., Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha (2001) J. Cell Biol., 155 (2), pp. 217-226",Article,Scopus,2-s2.0-84903722482
"Humphrey J.M.","Selective New Small-Molecule Inhibitors of Phosphodiesterase 1",2014,"Phosphodiesterases and Their Inhibitors","61",,,"155","164",,,10.1002/9783527682348.ch10,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926257031&partnerID=40&md5=2f88977a7e526bd0c62c7a41fa1d1a7c","Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern Point RoadGroton, CT, United States","Humphrey, J.M., Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern Point RoadGroton, CT, United States","Although PDE1 was the first discovered and is perhaps the most studied phosphodiesterase, a lack of potent and selective small molecules inhibitors suitable for use as chemical probes has hampered elucidation of biological processed linked to the enzyme. Recent advances have led to the discovery of new synthetic inhibitor molecules that hold promise in filling this void. These compounds are presented with chemical structures and PDE selectivity data where available, in addition to routes for their chemical synthesis and select information on binding modes. © 2014 Wiley-VCH Verlag GmbH & Co. KGaA. All rights reserved.","Alzheimers Disease; Calcium-calmodulin; Calmodulin; Cognition; Imidazole; Isozyme; Neuroplasticity; PDE1; Phosphodiesterase; Phosphorylation; Quinazoline; Schizophrenia; Small-molecule inhibitors","Blokland, A., Menniti, F.S., Prickaerts, J., (2012) Expert Opinion on Therapeutic Patents, 22, p. 349; Sharma, R.K., Hickie, R.A., (1996) Phosphodiesterase Inhibitors, p. 65. , Academic; Kakkar, R., Raju, R.V.S., Sharma, R.K., (1999) Cellular and Molecular Life Sciences, 55, p. 1164; Bender, A.T., (2007) Cyclic Nucleotide Phosphodiesterases in Health and Disease, p. 35. , CRC Press; Wang, J.H., Sharma, R.K., Mooibroek, M.J., Calmodulin-stimulated cyclic nucleotide phosphodiesterases (1990) Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, 2, pp. 19-59. , J. Beavo andM.D. Houslay), Wiley Series in Molecular Pharmacology of Cell Regulation, John Wiley & Sons, Ltd, Chichester, UK; Surapisitchat, J., Beavo, J.A., (2011) Transduction Mechanisms in Cellular Signaling, p. 375. , Elsevier Inc; Cheung, Y., (1970) Biochemical and Biophysical Research Communications, 38, p. 533; Kakiuchi, S., Yamazaki, R., (1970) Biochemical and Biophysical Research Communications, 41, p. 1104; Bender, A., (2006) Cyclic Nucleotide Phosphodiesterases in Health and Disease, p. 35. , J.A. Beavo, S.H. Francis, and M.D. Houslay), CRC Press; Sonnenburg, W.K., Seger, D., Kwak, K.S., Huang, J., Charbonneau, H., Beavo, J.A., (1995) The Journal of Biological Chemistry, 270, p. 30989; Yan, C., Bentley, J., Sonnenburg, W., Beavo, J., (1994) The Journal of Neuroscience, 14, p. 973; Yan, C., Zhao, A.Z., Bentley, J.K., Loughney, K., Ferguson, K., Beavo, J.A., (1995) Proceedings of the National Academy of Sciences of the United States of America, 92, p. 9677; Beavo, J.A., Francis, S.H., Houslay, M.D., (2007) Cyclic Nucleotide Phosphodiesterases in Health and Disease, , CRC Press; Medina, A.E., (2011) Front Neuropharmacology, 5, p. 21; Lugnier, C., (2006) Pharmacology & Therapeutics, 109, p. 366; Bereczki, D., Fekete, I., (1999) European Journal of Clinical Pharmacology, 55, p. 349; Jha, M.K., Rahman, M.H., Sheikh, H., (2012) International Journal of Pharmaceutical Sciences and Research, 3, p. 346; Bonoczk, P., Gulyas, B., Adam-Vizi, V., Nemes, A., Karpati, E., Kiss, B., Kapas, M., Vas, A., (2000) Brain Research Bulletin, 53, p. 245; Medina, A.E., (2010) Proceedings of the National Academy of Sciences of the United States of America, 107, p. 9921; Jakovljevic, V.L., Canovic, P.S., Andjelkovic, N.V., Djuric, D.M., (2006) Acta Physiologica Academiae Scientiarum Hungaricae, 93, p. 251; Terrett, N.K., Bell, A.S., Brown, D., Ellis, P., (1996) Bioorganic & Medicinal Chemistry Letters, 6, p. 1819; Holland, A., Jackson, D., Chaplen, P., Lunt, E., Marshall, S., Pain, D., Wooldridge, K., (1975) European Journal of Medicinal Chemistry: Chim Ther, 10, p. 447; Francis, S.H., Sekhar, K.R., Ke, H., Corbin, J.D., (2011) Handbook of Experimental Pharmacology, 200, p. 93; Ukena, D., Schudt, C., Sybrecht, G.W., (1993) Biochemical Pharmacology, 45, p. 847; Daly, J.W., Padgett, W.L., Shamim, M.T., (1986) Journal ofMedicinal Chemistry, 29, p. 1305; Schenke, T., Haning, H., Niewohner, U., Rosentreter, U., Bischoff, E., Schlemmer, K.-H., Keldenich, J., (2000) 9-(Dialkylamino)purinone derivatives useful as phosphodiesterase inhibitors, p. 45. , WO2000011002A1, to Bayer Aktiengesellschaft, Germany; Silver, P.J., Dundore, R.L., Bode, D.C., de Garavilla, L., Buccholz, R.A., van Aller, G., Hamel, L.T., Singh, B., (1994) Journal of Pharmacology and Experimental Therapeutics, 271, p. 1143; Daugan, A., Grondin, P., Ruault, C., de Gouville, A.-C.L.M., Coste, H., Linget, J.M., Kirilovsky, J., Labaudiniere, R., (2003) Journal of Medicinal Chemistry, 46, p. 4533; de Saenz, T.I., Angulo, J., Cuevas, P., Fernandez, A., Moncada, I., Allona, A., Lledo, E., Bischoff, E., (2001) International Journal of Impotence Research, 13, p. 282; Bell, A.S., Terrett, N.K., (1999) Pfizer Inc., USA; Pfizer Limited, p. 78; Puzzo, D., Staniszewski, A., Deng, S.X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Arancio, O., Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-b load in an Alzheimer's disease mouse model (2009) Journal of Neuroscience, 29, pp. 8075-8086; Cai, Y., Miller, C.L., Nagel, D.J., Jeon, K.-I., Lim, S., Gao, P., Knight, P.A., Yan, C., (2011) Arteriosclerosis, Thrombosis, and Vascular Biology, 31, p. 616; Nagel, D.J., Aizawa, T., Jeon, K.-I., Liu, W., Mohan, A., Wei, H., Miano, J.M., Yan, C., (2006) Circulation Research, 98, p. 777; Miller, C.L., Oikawa, M., Cai, Y., Wojtovich, A.P., Nagel, D.J., Xu, X., Xu, H., Yan, C., Preparation of imidazo[1,2-a]pyrazolo [4,3-e]pyrimidin-4(5H)-ones as PDE1 inhibitors useful in treatment and prevention of diseases (2009) Circulation Research, 105, p. 956; Li, P., Zheng, H., Zhao, J., Wennogle, L.P., (2012) Fused pyrazolo[3,4-e] pyrimidinones as PDE-1 inhibitors, their preparation, pharmaceutical compositions, and use in therapy, p. 48. , WO2012171016A1, to Intra-Cellular Therapies, Inc., USA; Li, P., Zheng, H., Zhao, J., Wennogle, L.P., (2011) Preparation of imidazopyrazolopyrimidines and pyrimidopyrazolopyrimidines as therapeutic PDE1 inhibitors, p. 98. , WO2011153129A1, to Intra-Cellular Therapies, Inc., USA; Li, P., Wennogle, L.P., (2010), p. 83. , WO2010065151A1, to Intra-Cellular Therapies, Inc., USAYang, E.X., Chappie, T.A., Humphrey, J.M., Menniti, F.S., (2009) Abstracts of Papers, 238th ACS National Meeting, pp. MEDI-078. , Washington, DC, US, August 16-20; Humphrey, J.M., Arnold, E.P., Yang, E.X., Head, J., Lebel, L.A., Menitti, F.S., (2010) Abstracts of Papers, 239th ACS National Meeting, , San Francisco, CA, US, March 21-25, MEDI-56. Language: English, Database: CAPLUS; Chappie, T.A., Humphrey, J.M., Allen, M.P., Estep, K.G., Fox, C.B., Lebel, L.A., Liras, S., Yang, F.V., (2007) Journal of Medicinal Chemistry, 50, p. 182",Book Chapter,Scopus,2-s2.0-84926257031
"Wang L., Li X., Song J., Jiang T., Wu X., Zhou S.","Comparisons of cognitive function and serum S-100B level between diabetic and non-diabetic patients after the implantation of carotid artery stent (CAS)",2014,"Neuroscience Letters","570",,,"58","62",,,10.1016/j.neulet.2014.04.009,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84899692113&partnerID=40&md5=f211b3f09663b632fb47583fabd95ce8","Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China","Wang, L., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Li, X., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Song, J., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Jiang, T., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Wu, X., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Zhou, S., Department of Radiology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China","To investigate cognitive function improvement in diabetic and non-diabetic patients after the implantation of Carotid Artery Stent (CAS), 128 patients suffering severe carotid stenosis were successfully enrolled in this study. Tests including, the Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Clock Drawing Test (CDT), Hasegawa's Dementia Scale-Revised (HDS-R) and the serum levels of S-100B, were all measured at baseline for 3 months after the implantation of CAS. The baseline characteristics were similar between the patients with and without diabetes. 3 months after the implantation, significant improvements in MMSE (24.8. ± 2.2 vs. 25.2. ± 2.1, p= 0.003), MoCA (25.6. ± 2.0 vs. 26.1. ± 1.9, p= 0.000), ADAS-Cog (6.5. ± 1.3 vs. 6.1. ± 1.3, p= 0.000), and CDT (3.3. ± 0.7 vs. 3.5. ± 0.7, p= 0.034) were observed in the non-diabetic group. In contrast, there was no significant improvement in any of the cognitive test for the diabetic group. Another interesting discovery was the CAS procedure significantly decreased the S-100B level in the non-diabetic group (0.11. ± 0.04. ng/mL vs. 0.10. ± 0.04. ng/mL, p= 0.000), but similar phenomena were not discovered in the diabetic group. In this light, the change of the S-100B level was negatively correlated with the results in the MMSE (p< 0.01) and the MoCA (p< 0.01) tests, and positively correlated with the result in ADAS-Cog (p< 0.05) test. Our findings suggest that the CAS-induced beneficial effects on cognitive function might have a correlation relationship with the serum level of S-100B. © 2014.","Alzheimers disease; Carotid artery stent; Diabetic patients; Non-diabetic patients","Sztriha, L.K., Nemeth, D., Sefcsik, T., Vecsei, L., Carotid stenosis and the cognitive function (2009) J Neurol Sci, 283, pp. 36-40; Rocque, B.G., Jackson, D., Varghese, T., Hermann, B., Mccormick, M., Kliewer, M., Mitchell, C., Dempsey, R.J., Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements (2012) J Neurol Sci, 322, pp. 20-24; Takaiwa, A., Hayashi, N., Kuwayama, N., Akioka, N., Kubo, M., Endo, S., Changes in cognitive function during the 1-year period following endarterectomy and stenting of patients with high-grade carotid artery stenosis (2009) Acta Neurochir (Wien), 151, pp. 1593-1600; Turk, A.S., Chaudry, I., Haughton, V.M., Hermann, B.P., Rowley, H.A., Pulfer, K., Aagaard-Kienitz, B., Strother, C.M., Effect of carotid artery stenting on cognitive function in patients with carotid artery stenosis: preliminary results (2008) Am J Neuroradiol, 29, pp. 265-268; Gaudet, J.G., Meyers, P.M., Mckinsey, J.F., Lavine, S.D., Gray, W., Mitchell, E., Connolly, E.S., Heyer, E.J., Incidence of moderate to severe cognitive dysfunction in patients treated with carotid artery stenting (2009) Neurosurgery, 65, pp. 325-329. , discussion 329-330; Aleksic, M., Huff, W., Hoppmann, B., Heckenkamp, J., Pukrop, R., Brunkwall, J., Cognitive function remains unchanged after endarterectomy of unilateral internal carotid artery stenosis under local anaesthesia (2006) Eur J Vasc Endovasc Surg, 31, pp. 616-621; Chen, Y.H., Lin, M.S., Lee, J.K., Chao, C.L., Tang, S.C., Chao, C.C., Chiu, M.J., Kao, H.L., Carotid stenting improves cognitive function in asymptomatic cerebral ischemia (2012) Int J Cardiol, 157, pp. 104-107; Schmieder, R.E., Schmidt, B.M., Raff, U., Bramlage, P., Dörfler, A., Achenbach, S., Schwab, J., Kolominsky-Rabas, P., Cerebral microangiopathy in treatment-resistant hypertension (2011) J Clin Hypertens (Greenwich), 13, pp. 582-587; Qiu, C., Cotch, M.F., Sigurdsson, S., Garcia, M., Klein, R., Jonasson, F., Klein, B.E., Launer, L.J., Retinal and cerebral microvascular signs and diabetes: the age, gene/environment susceptibility-Reykjavik study (2008) Diabetes, 57, pp. 1645-1650; Connolly, E.S., Winfree, C.J., Rampersad, A., Sharma, R., Mack, W.J., Mocco, J., Solomon, R.A., Heyer, E.J., Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotid endarterectomy (2001) Neurosurgery, 49, pp. 1076-1082. , discussion 1082-1073; Mussack, T., Hauser, C., Klauss, V., Tató, F., Rieger, J., Ruppert, V., Jochum, M., Hoffmann, U., Serum S-100B protein levels during and after successful carotid artery stenting or carotid endarterectomy (2006) J Endovasc Ther, 13, pp. 39-46; Scarcello, E., Morrone, F., Piro, P., Tarsitano, S., Intrieri, F., Vaccarella, S., Guerra, E., de Franciscis, S., Protein S-100B as biochemical marker of brain ischemic damage after treatment of carotid stenosis (2011) Ann Vasc Surg, 25, pp. 975-978; Sahlein, D.H., Heyer, E.J., Rampersad, A., Winfree, C.J., Solomon, R.A., Benvenisty, A.I., Quest, D.O., Connolly, E.S., Failure of intraoperative jugular bulb S-100B and neuron-specific enolase sampling to predict cognitive injury after carotid endarterectomy (2003) Neurosurgery, 53, pp. 1243-1249. , discussion 1249-1250; Mussack, T., Klauss, V., Ruppert, V., Gippner-Steppert, C., Biberthaler, P., Schiemann, U., Hoffmann, U., Jochum, M., Rapid measurement of S-100B serum protein levels by Elecsys S100 immunoassay in patients undergoing carotid artery stenting or endarterectomy (2006) Clin Biochem, 39, pp. 349-356; Kao, H.L., Lin, M.S., Wang, C.S., Lin, Y.H., Lin, L.C., Chao, C.L., Jeng, J.S., Chen, S.C., Feasibility of endovascular recanalization for symptomatic cervical internal carotid artery occlusion (2007) J Am Coll Cardiol, 49, pp. 765-771; Lal, B.K., Younes, M., Cruz, G., Kapadia, I., Jamil, Z., Pappas, P.J., Cognitive changes after surgery vs stenting for carotid artery stenosis (2011) J Vasc Surg, 54, pp. 691-698; Altinbas, A., van Zandvoort, M.J., Van Den Berg, E., Jongen, L.M., Algra, A., Moll, F.L., Nederkoorn, P.J., van der Worp, H.B., Cognition after carotid endarterectomy or stenting: a randomized comparison (2011) Neurology, 77, pp. 1084-1090; Goldberg, J.B., Goodney, P.P., Kumbhani, S.R., Roth, R.M., Powell, R.J., Likosky, D.S., Brain injury after carotid revascularization: outcomes, mechanisms, and opportunities for improvement (2011) Ann Vasc Surg, 25, pp. 270-286; Grunwald, I.Q., Papanagiotou, P., Reith, W., Grunwald, I.Q., Papanagiotou, P., Reith, W., Backens, M., Krick, C.M., Influence of carotid artery stenting on cognitive function (2010) Neuroradiology, 52, pp. 61-66; Murata, K., Fujiki, M., Ooba, H., Murata, K., Fujiki, M., Ooba, H., Kubo, T., Mori, H., Cognitive alteration after carotid revascularization is correlated with cortical GABA(B)-ergic modulations (2011) Neurosci Lett, 500, pp. 151-156; Ishihara, H., Oka, F., Shirao, S., Sadahiro, H., Osaki, M., Suzuki, M., Cognitive outcome differences on the side of carotid artery stenting (2013) J Vasc Surg, 57, pp. 125-130",Article,Scopus,2-s2.0-84899692113
"Babri S., Mohaddes G., Feizi I., Mohammadnia A., Niapour A., Alihemmati A., Amani M.","Effect of troxerutin on synaptic plasticity of hippocampal dentate gyrus neurons in a β-amyloid model of Alzheimers disease: An electrophysiological study",2014,"European Journal of Pharmacology","732","1",,"19","25",,1,10.1016/j.ejphar.2014.03.018,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897363947&partnerID=40&md5=0df3da34a317cb1fc2b9384abeaa81ee","Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Department of Basic Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Department of Anatomical Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Department of Histology and Embryology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Physiology, School of Medicine, Ardabil University of Medical Sciences, P.O. Box, 56189-53142 Ardabil, Iran","Babri, S., Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Mohaddes, G., Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Feizi, I., Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Mohammadnia, A., Department of Basic Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Niapour, A., Department of Anatomical Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran; Alihemmati, A., Department of Histology and Embryology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Amani, M., Department of Physiology, School of Medicine, Ardabil University of Medical Sciences, P.O. Box, 56189-53142 Ardabil, Iran","Alzheimers disease (AD) is a neurodegenerative disorder with a progressive cognitive decline and memory loss. Multiple pathogenetic factors including aggregated β-amyloid (Aβ), neurofibrillary tangles (NFTs), cholinergic dysfunction and oxidative stress are involved in AD. Aβ, a major constituent of the senile plaques, is a potent neurotoxic peptide and has a pivotal role in cognitive deficit and reduced synaptic plasticity in AD. In the present study we examined the protective effect of troxerutin, as a multipotent bioflavonoid, on Aβ (1-42)-induced impairment of evoked field potential in hippocampal DG neurons. Male Wistar rats were divided into four groups including Aβ (42-1), Aβ (1-42), Aβ (1-42) plus troxerutin and Aβ (42-1) plus troxerutin groups. Aβ was injected intracerebroventricularly (i.c.v.) into right lateral ventricle and after two weeks the evoked field potential recorded from perforant path-DG synapses to assess paired pulse paradigm and long term potentiation (LTP). Administration of Aβ (1-42) drastically attenuated the LTP of DG neurons, while there was no significant difference in evoked field potentials between Aβ (1-42) plus troxerutin group with respect to Aβ (42-1) group. This study revealed that troxerutin improves the synaptic failure induced by Aβ peptide and can be introduced as a promising multi-potent pharmacological agent in prevention or treatment of AD in the future. © 2014 Elsevier B.V.","Alzheimers disease; Dentate gyrus; Synaptic plasticity; Troxerutin; β-Amyloid","Akbari, E., Motamedi, F., Davoodi, F.G., Noorbakhshnia, M., Ghanbarian, E., Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats (2011) Behav. Brain Res., 216, pp. 375-380; Babri, S., Amani, M., Mohaddes, G., Alihemmati, A., Ebrahimi, H., Effect of aggregated β-amyloid (1-42) on synaptic plasticity of hippocampal dentate gyrus granule cells in vivo (2012) BioImpacts, 2, pp. 189-194; Babri, S., Amani, M., Mohaddes, G., Alihemmati, A., Ebrahimi, H., Protective effects of troxerutin on β-Amyloid (1-42)-induced impairments of spatial learning and memory in rats (2012) Neurophysiology, 44, pp. 387-393; Babri, S., Amani, M., Mohaddes, G., Mirzaei, F., Mahmoudi, F., Effects of intrahippocampal injection of ghrelin on spatial memory in PTZ-induced seizures in male rats (2013) Neuropeptides, 47, pp. 355-360; Brzyska, M., Elbaum, D., Dysregulation of calcium in Alzheimers disease (2003) Acta Neurobiol. Exp., 63, pp. 171-184; Campanucci, V.A., Krishnaswamy, A., Cooper, E., Mitochondrial reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors and induce long-term depression of fast nicotinic synaptic transmission (2008) Journal of Neuroscience, 28 (7), pp. 1733-1744. , http://www.jneurosci.org/cgi/reprint/28/7/1733, DOI 10.1523/JNEUROSCI.5130-07.2008; D'andrea, M.R., Nagele, R.G., Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimers disease pyramidal neurons (2006) Curr. Pharm. Des., 12, pp. 677-684; Dall'Igna, O.P., Fett, P., Gomes, M.W., Souza, D.O., Cunha, R.A., Lara, D.R., Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice (2007) Experimental Neurology, 203 (1), pp. 241-245. , DOI 10.1016/j.expneurol.2006.08.008, PII S001448860600478X; Debanne, D., Guerineau, N.C., Gähwiler, B., Thompson, S.M., Paired-pulse facilitation and depression at unitary synapses in rat hippocampus: Quantal fluctuation affects subsequent release (1996) J. Physiol., 491, pp. 163-176; Drever, B.D., Riedel, G., Platt, B., The cholinergic system and hippocampal plasticity (2011) Behav. Brain Res., 221, pp. 505-514; Dziewczapolski, G., Glogowski, C.M., Masliah, E., Heinemann, S.F., Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimers disease (2009) J. Neurosci., 29, pp. 8805-8815; Fan, S.-H., Zhang, Z.-F., Zheng, Y.-L., Lu, J., Wu, D.-M., Shan, Q., Hu, B., Wang, Y.-Y., Troxerutin protects the mouse kidney from d-galactose-caused injury through anti-inflammation and anti-oxidation (2009) Int. Immunopharmacol., 9, pp. 91-96; Francis, P.T., Ramírez, M.J., Lai, M.K., Neurochemical basis for symptomatic treatment of Alzheimers disease (2010) Neuropharmacology, 59, pp. 221-229; Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., Malinow, R., Ampar removal underlies aβ-induced synaptic depression and dendritic spine loss (2006) Neuron, 52 (5), pp. 831-843. , DOI 10.1016/j.neuron.2006.10.035, PII S0896627306008725; Irimajiri, R., Michalewski, H.J., Golob, E.J., Starr, A., Cholinesterase inhibitors affect brain potentials in amnestic mild cognitive impairment (2007) Brain Research, 1145 (1), pp. 108-116. , DOI 10.1016/j.brainres.2007.01.120, PII S0006899307002752; Jedlicka, P., Hoon, M., Papadopoulos, T., Vlachos, A., Winkels, R., Poulopoulos, A., Betz, H., Varoqueaux, F., Increased dentate gyrus excitability in neuroligin-2-deficient mice in vivo (2011) Cereb. Cortex, 21, pp. 357-367; Jiang, L., Sun, S., Nedergaard, M., Kang, J., Paired-pulse modulation at individual GABAergic synapses in rat hippocampus (2000) Journal of Physiology, 523 (2), pp. 425-439; Levine, H., Thioflavine t interaction with synthetic alzheimers disease β-amyloid peptides: Detection of amyloid aggregation in solution (1993) Protein Sci., 2, pp. 404-410; Li, J., Wang, C., Zhang, J.H., Cai, J.-M., Cao, Y.-P., Sun, X.-J., Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimers disease by reduction of oxidative stress (2010) Brain Res., 1328, pp. 152-161; Li, R.-S., Wang, X.-B., Hu, X.-J., Kong, L.-Y., Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimers disease (2013) Bioorg. Med. Chem. Lett., 23, pp. 2636-2641; Lisman, J., Schulman, H., Cline, H., The molecular basis of CaMKII function in synaptic and behavioural memory (2002) Nature Reviews Neuroscience, 3 (3), pp. 175-190. , DOI 10.1038/nrn753; Lu, J., Wu, D.-M., Zheng, Z.-H., Zheng, Y.-L., Hu, B., Zhang, Z.-F., Troxerutin protects against high cholesterol-induced cognitive deficits in mice (2011) Brain, 134, pp. 783-797; Lu, J., Wu, D., Hu, B., Cheng, W., Zheng, Y., Zhang, Z., Ye, Q., Wang, Y., Chronic administration of troxerutin protects mouse brain against d-galactose-induced impairment of cholinergic system (2010) Neurobiol. Learn. Mem., 93, pp. 157-164; Lynch, M.A., Long-term potentiation and memory (2004) Physiological Reviews, 84 (1), pp. 87-136. , DOI 10.1152/physrev.00014.2003; Marhic, C., Clinical and rheological efficacy of troxerutin in obstetric gynecology (1991) Revue francaise de gynecologie et d'obstetrique, 86, pp. 209-212; Namgung, U., Valcourt, E., Routtenberg, A., Long-term potentiation in vivo in the intact mouse hippocampus (1995) Brain Res., 689, pp. 85-92; Nimmrich, V., Reymann, K., Strassburger, M., Schöder, U., Gross, G., Hahn, A., Schoemaker, H., Möller, A., Inhibition of calpain prevents NMDA? Induced cell death and β? Amyloid? Induced synaptic dysfunction in hippocampal slice cultures (2010) Br. J. Pharmacol., 159, pp. 1523-1531; Nordberg, A., Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications (2001) Biological Psychiatry, 49 (3), pp. 200-210. , DOI 10.1016/S0006-3223(00)01125-2, PII S0006322300011252; Parri, H.R., Hernandez, C.M., Dineley, K.T., Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimers disease (2011) Biochem. Pharmacol., 82, pp. 931-942; Paxinos, G., Watson, C., (2007) The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition, , Academic London; Pyrzanowska, J., Piechal, A., Blecharz-Klin, K., Joniec-Maciejak, I., Zobel, A., Widy-Tyszkiewicz, E., Influence of long-term administration of rutin on spatial memory as well as the concentration of brain neurotransmitters in aged rats (2012) Pharmacol. Rep., 64, pp. 808-816; Querfurth, H.W., Laferla, F.M., Mechanisms of disease (2010) N. Engl. J. Med., 362, pp. 329-344; Reisi, P., Babri, S., Alaei, H., Sharifi, M.R., Mohaddes, G., Lashgari, R., Effects of treadmill running on short-term pre-synaptic plasticity at dentate gyrus of streptozotocin-induced diabetic rats (2008) Brain Res., 1211, pp. 30-36; Reisi, P., Babri, S., Alaei, H., Sharifi, M.R., Mohaddes, G., Noorbakhsh, S.M., Lashgari, R., Treadmill running improves long-term potentiation (LTP) defects in streptozotocin-induced diabetes at dentate gyrus in rats (2010) Pathophysiology, 17, pp. 33-38; Selkoe, D.J., Alzheimers disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein (2001) J. Alzheimers Dis., 3, pp. 75-80; Selkoe, D.J., Alzheimers disease is a synaptic failure (2002) Science, 298, pp. 789-791; Selkoe, D.J., Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior (2008) Behav. Brain Res., 192, pp. 106-113; Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, A.C., Greengard, P., Regulation of NMDA receptor trafficking by amyloid-β (2005) Nature Neuroscience, 8 (8), pp. 1051-1058. , DOI 10.1038/nn1503; Thiels, E., Barrionuevo, G., Berger, T.W., Excitatory stimulation during postsynaptic inhibition induces long-term depression in hippocampus in vivo (1994) Journal of Neurophysiology, 72 (6), pp. 3009-3016; Tran, M.H., Yamada, K., Nabeshima, T., Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits: A minireview (2002) Peptides, 23 (7), pp. 1271-1283. , DOI 10.1016/S0196-9781(02)00062-1, PII S0196978102000621; Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416 (6880), pp. 535-539. , DOI 10.1038/416535a; Wang, H.-W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Trommer, B.L., Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus (2002) Brain Research, 924 (2), pp. 133-140. , DOI 10.1016/S0006-8993(01)03058-X, PII S000689930103058X; Wang, H.-W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Trommer, B.L., Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus (2002) Brain Research, 924 (2), pp. 133-140. , DOI 10.1016/S0006-8993(01)03058-X, PII S000689930103058X; Williams, R.J., Spencer, J.P., Flavonoids, cognition, and dementia: Actions, mechanisms, and potential therapeutic utility for alzheimer disease (2012) Free Radic. Biol. Med., 52, pp. 35-45; Wu, M., He, Y., Guo, F., Qi, J., [Alpha] 4 [beta] 2 nicotinic acetylcholine receptors are required for the amyloid [beta] protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo (2008) Brain Res. Bull., 77, pp. 84-90; Wu, M., He, Y., Guo, F., Qi, J., α4β2 Nicotinic acetylcholine receptors are required for the amyloid β protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo (2008) Brain Res. Bull., 77, pp. 84-90; Youdim, K.A., Dobbie, M.S., Kuhnle, G., Proteggente, A.R., Abbott, N.J., Rice-Evans, C., Interaction between flavonoids and the blood-brain barrier: In vitro studies (2003) Journal of Neurochemistry, 85 (1), pp. 180-192; Yun, S.H., Gamkrelidze, G., Stine, W.B., Sullivan, P.M., Pasternak, J.F., LaDu, M.J., Trommer, B.L., Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus (2006) Neuroscience Letters, 403 (1-2), pp. 162-165. , DOI 10.1016/j.neulet.2006.04.065, PII S0304394006005192; Zhao, D., Watson, J.B., Xie, C.-W., Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation (2004) Journal of Neurophysiology, 92 (5), pp. 2853-2858. , DOI 10.1152/jn.00485.2004; Zucker, R.S., Regehr, W.G., Short-term synaptic plasticity (2002) Annual Review of Physiology, 64, pp. 355-405. , DOI 10.1146/annurev.physiol.64.092501.114547",Article,Scopus,2-s2.0-84897363947
"Mittag J.J., Milani S., Walsh D.M., Radler J.O., McManus J.J.","Simultaneous measurement of a range of particle sizes during Aβ1-42 fibrillogenesis quantified using fluorescence correlation spectroscopy",2014,"Biochemical and Biophysical Research Communications","448","2",,"195","199",,1,10.1016/j.bbrc.2014.04.088,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901635545&partnerID=40&md5=d3da3043a95efca0101d948341068034","Ludwig-Maximilians-Universität, Fakultät für Physik and CeNS, Geschwister-Scholl-Platz 1, 80539 München, Germany; Laboratory for Neurodegenerative Research, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, MA 02115, United States; Department of Chemistry, National University of Ireland Maynooth, Maynooth, Co. Kildare, Ireland","Mittag, J.J., Ludwig-Maximilians-Universität, Fakultät für Physik and CeNS, Geschwister-Scholl-Platz 1, 80539 München, Germany; Milani, S., Ludwig-Maximilians-Universität, Fakultät für Physik and CeNS, Geschwister-Scholl-Platz 1, 80539 München, Germany; Walsh, D.M., Laboratory for Neurodegenerative Research, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, MA 02115, United States; Rädler, J.O., Ludwig-Maximilians-Universität, Fakultät für Physik and CeNS, Geschwister-Scholl-Platz 1, 80539 München, Germany; McManus, J.J., Department of Chemistry, National University of Ireland Maynooth, Maynooth, Co. Kildare, Ireland","Low molecular weight oligomers of amyloid beta (Aβ) are important drivers of Alzheimer's disease. A decrease in Aβ monomer levels in human cerebrospinal fluid (CSF) is observed in Alzheimers' patients and is a robust biomarker of the disease. It has been suggested that the decrease in monomer levels in CSF is due to the formation of Aβ oligomers. A robust technique capable of identifying Aβ oligomers in CSF is therefore desirable. We have used fluorescence correlation spectroscopy and a five Gaussian distribution model (5GDM) to monitor the aggregation of Aβ1-42 in sodium phosphate buffer and in artificial cerebrospinal fluid (ACSF). In buffer, several different sized components (monomer, oligomers, protofibrils and fibrils) can be identified simultaneously using 5GDM. In ACSF, the faster kinetics of fibrillogenesis leads to the formation of fibrils on very short timescales. This analysis method can also be used to monitor the aggregation of other proteins, nanoparticles or colloids, even in complex biological fluids. © 2014 Elsevier Inc. All rights reserved.","Aggregation; Alzheimer's disease; Amyloid beta; Fluorescence correlation spectroscopy; Oligomerization; Protein folding disease","Masters, C.L., Simms, G., Weinman, N.A., Amyloid plaque core protein in Alzheimer disease and Down syndrome (1985) Proc. Natl. Acad. Sci. U.S.A., 82, pp. 4245-4249; Zhao, L.N., Long, H., Mu, Y., The toxicity of amyloid beta oligomers (2012) Int. J. Mol. Sci., 13, pp. 7303-7327; Walsh, D.M., Selkoe, D.J., A beta oligomers - A decade of discovery (2007) J. Neurochem., 101, pp. 1172-1184; Benilova, I., Karran, E., De Strooper, B., The toxic Abeta oligomer and Alzheimer's disease: An emperor in need of clothes (2012) Nat. Neurosci., 15, pp. 349-357; Walsh, D.M., Hartley, D.M., Kusumoto, Y., Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates (1999) J. Biol. Chem., 274, pp. 25945-25952; Hoshi, M., Sato, M., Matsumoto, S., Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 6370-6375; Barghorn, S., Nimmrich, V., Striebinger, A., Globular amyloid beta-peptide oligomer - A homogenous and stable neuropathological protein in Alzheimer's disease (2005) J. Neurochem., 95, pp. 834-847; Lesne, S., Koh, M.T., Kotilinek, L., A specific amyloid-beta protein assembly in the brain impairs memory (2006) Nature, 440, pp. 352-357; Shankar, G.M., Li, S., Mehta, T.H., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) Nat. Med., 14, pp. 837-842; Lambert, M., Barlow, A., Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins (1998) Proc. Natl. Acad. Sci. U.S.A., 95, pp. 6448-6453; Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry (2006) J. Proteome Res., 5, pp. 1010-1016; De Strooper, B., Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process (2010) Physiol. Rev., 90, pp. 465-494; Holtzman, D.M., CSF biomarkers for Alzheimer's disease: Current utility and potential future use (2011) Neurobiol. Aging, 32 (SUPPL. 1), pp. S4-S9; Bateman, R.J., Xiong, C., Benzinger, T.L., Dominantly inherited Alzheimer, clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N. Engl. J. Med., 367, pp. 795-804; Peder Buchhave, L.M., Henrik Zetterberg, K.B., Wallin, A.K., Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5-10 years before the onset of Alzheimer dementia (2012) Arch. Gen. Psychiatry, 69, pp. 98-106; Pryor, N.E., Moss, M.A., Hestekin, C.N., Unraveling the early events of amyloid-beta protein (Abeta) aggregation: Techniques for the determination of Abeta aggregate size (2012) Int. J. Mol. Sci., 13, pp. 3038-3072; Paredes, J.M., Casares, S., Ruedas-Rama, M.J., Early amyloidogenic oligomerization studied through fluorescence lifetime correlation spectroscopy (2012) Int. J. Mol. Sci., 13, pp. 9400-9418; Kumar, S., Rezaei-Ghaleh, N., Terwel, D., Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease (2011) EMBO J., 30, pp. 2255-2265; Munishkina, L.A., Fink, A.L., Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins (2007) Biochim. Biophys. Acta, 1768, pp. 1862-1885; Liang, Y., Lynn, D.G., Berland, K.M., Direct observation of nucleation and growth in amyloid self-assembly (2010) J. Am. Chem. Soc., 132, pp. 6306-6308; Hellstrand, E., Boland, B., Walsh, D.M., Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process (2010) ACS Chem. Neurosci., 1, pp. 13-18; Cohen, S.I., Linse, S., Luheshi, L.M., Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Natl. Acad. Sci. U.S.A., 110, pp. 9758-9763; Nag, S., Sarkar, B., Bandyopadhyay, A., Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium (2011) J. Biol. Chem., 286, pp. 13827-13833; Takahashi, Y., Okamoto, Y., Popiel, H.A., Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy (2007) J. Biol. Chem., 282, pp. 24039-24048; Nath, S., Meuvis, J., Hendrix, J., Early aggregation steps in alpha-synuclein as measured by FCS and FRET: Evidence for a contagious conformational change (2010) Biophys. J., 98, pp. 1302-1311; Rhoades, E., Ramlall, T.F., Webb, W.W., Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy (2006) Biophys. J., 90, pp. 4692-4700; Garai, K., Sahoo, B., Sengupta, P., Quasihomogeneous nucleation of amyloid beta yields numerical bounds for the critical radius, the surface tension, and the free energy barrier for nucleus formation (2008) J. Chem. Phys., 128, p. 045102; Wiesehan, K., Stohr, J., Nagel-Steger, L., Inhibition of cytotoxicity and amyloid fibril formation by a d-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide (2008) Protein Eng. Des. Sel., 21, pp. 241-246; Hossain, S., Grande, M., Ahmadkhanov, G., Binding of the Alzheimer amyloid beta-peptide to neuronal cell membranes by fluorescence correlation spectroscopy (2007) Exp. Mol. Pathol., 82, pp. 169-174; Sarkar, B., Das, A.K., Maiti, S., Thermodynamically stable amyloid-beta monomers have much lower membrane affinity than the small oligomers (2013) Front. Physiol., 4, p. 84; Tjernberg, L.O., Pramanik, A., Bjorling, S., Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy (1999) Chem. Biol., 6, pp. 53-62; Sengupta, P., Garai, K., Sahoo, B., The amyloid beta peptide (A beta(1-40)) is thermodynamically soluble at physiological concentrations (2003) Biochemistry-US, 42, pp. 10506-10513; Amyloid (1-42), HiLyte Fluor™ 488-labeled Product Data Sheet, , Anaspec Inc; Cizas, P., Budvytyte, R., Morkuniene, R., Size-dependent neurotoxicity of beta-amyloid oligomers (2010) Arch. Biochem. Biophys., 496, pp. 84-92; Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dual effect of amino modified polystyrene nanoparticles on amyloid beta protein fibrillation (2010) ACS Chem. Neurosci., 1, pp. 279-287; Finder, V.H., Glockshuber, R., Amyloid-beta aggregation (2007) Neurodegener. Dis., 4, pp. 13-27; Sengupta, P., Garai, K., Balaji, J., Measuring size distribution in highly heterogeneous systems with fluorescence correlation spectroscopy (2003) Biophys. J., 84, pp. 1977-1984; Pal, N., Dev Verma, S., Singh, M.K., Fluorescence correlation spectroscopy: An efficient tool for measuring size, size-distribution and polydispersity of microemulsion droplets in solution (2011) Anal. Chem., 83, pp. 7736-7744; Jan, A., Hartley, D.M., Lashuel, H.A., Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research (2010) Nat. Protoc., 5, pp. 1186-1209; Funke, S.A., Detection of soluble amyloid-beta oligomers and insoluble high-molecular-weight particles in CSF: Development of methods with potential for diagnosis and therapy monitoring of Alzheimer's disease (2011) Int. J. Alzheimers Dis., 2011, p. 151645; Kumar, S., Walter, J., Phosphorylation of amyloid beta (Aâ) peptides - A trigger for formation of toxic aggregates in Alzheimer's disease (2011) Aging (N.Y.), 3, pp. 1-10; Sachse, C., Elektronenmikroskopie an Alzheimer-Fibrillen (2009) Bioforum, 32, pp. 26-28; Fandrich, M., Oligomeric intermediates in amyloid formation: Structure determination and mechanisms of toxicity (2012) J. Mol. Biol., 421, pp. 427-440; Salvadores, N., Shahnawaz, M., Scarpini, E., Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer's disease (2014) Cell Rep., pp. 1-8",Article,Scopus,2-s2.0-84901635545
"Yoon J.-H., Youn K., Ho C.-T., Karwe M.V., Jeong W.-S., Jun M.","P -coumaric acid and ursolic acid from corni fructus attenuated β-amyloid25-35-induced toxicity through regulation of the NF-κB signaling pathway in PC12 cells",2014,"Journal of Agricultural and Food Chemistry","62","21",,"4911","4916",,2,10.1021/jf501314g,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901642245&partnerID=40&md5=2abd5c1535abb8acc176e2fb92a152da","Department of Food Science and Nutrition, Dong-A University, Busan 604-714, South Korea; Department of Food Science, Rutgers University, New Brunswick, NJ 08901, United States; Department of Food and Life Science, College of Biomedical Science and Engineering, Inje University, Gimhae 621-749, South Korea","Yoon, J.-H., Department of Food Science and Nutrition, Dong-A University, Busan 604-714, South Korea; Youn, K., Department of Food Science and Nutrition, Dong-A University, Busan 604-714, South Korea; Ho, C.-T., Department of Food Science, Rutgers University, New Brunswick, NJ 08901, United States; Karwe, M.V., Department of Food Science, Rutgers University, New Brunswick, NJ 08901, United States; Jeong, W.-S., Department of Food and Life Science, College of Biomedical Science and Engineering, Inje University, Gimhae 621-749, South Korea; Jun, M., Department of Food Science and Nutrition, Dong-A University, Busan 604-714, South Korea","Neuroinflammatory responses induced by amyloid-beta peptide (Aβ) are important causes in the pathogenesis of Alzheimers disease (AD). Blockade of Aβ has emerged as a possible therapeutic approach to control the onset of AD. This study investigated the neuroprotective effects and molecular mechanisms of p-coumaric acid (p-CA) and ursolic acid (UA) from Corni fructus against Aβ25-35-induced toxicity in PC12 cells. p-CA and UA significantly inhibited the expression of iNOS and COX-2 in Aβ 25-35-injured PC12 cells. Blockade of nuclear translocation of the p65 subunit of nuclear factor κB (NF-κB) and phosphorylation of IκB- was also observed after p-CA and UA treatment. For the upstream kinases, UA exclusively reduced ERK1/2, p-38, and JNK phosphorylation, but p-CA suppressed ERK1/2 and JNK phosphorylation. Both compounds comprehensively inhibited NF-κB activity, but possibly with different upstream pathways. The results provide new insight into the pharmacological modes of p-CA and UA and their potential therapeutic application to AD. © 2014 American Chemical Society.","Alzheimers disease; amyloid β peptide; Corni fructus; COX-2; iNOS; IκB; MAPKs; NFκB; p-coumaric acid; ursolic acid","Selkoe, D.J., Translating cell biology into therapeutic advances in Alzheimers disease (1999) Nature, 399, pp. 23-A31; Hardy, J., Amyloid the presenilins and Alzheimers disease (1997) Trends Neurosci., 20, pp. 154-159; Szaingurten-Solodkin, I., Hadad, N., Levy, R., Regulatory role of cytosolic phospholipase A2 in NADPH oxidase activity and in inducible nitric oxide synthase induction by aggregated Aβ1-42 in microglia (2009) Glia, 57, pp. 1727-1740; Int Veld, B.A., Ruitenberg, A., Hofman, A., Launer, L.J., Van Duijn, C.M., Stijnen, T., Breteler, M.M.B., Stricker, B.H.C., Nonsteroidal anti-inflammatory drugs and the risk of Alzheimers disease (2001) N. Engl. J. Med., 22, pp. 1515-1521; Kaltschmidt, B., Uherek, M., Volk, B., Baeuerie, P.A., Kaltschmidt, C., Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimers disease (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 2642-2647; Yun, K.J., Koh, D.J., Kim, S.H., Park, S.J., Ryu, J.H., Kim, D.G., Lee, J.Y., Lee, K.T., Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-κB inactivation (2008) J. Agric. Food Chem., 56, pp. 10265-10272; Tsai, S.J., Lin, C.Y., Mong, M.C., Ho, M.W., Yin, M.C., S -Ethyl cysteine and S -propyl cysteine alleviate β-amyloid induced cytotoxicity in nerve growth factor differentiated PC12 cells (2010) J. Agric. Food Chem., 58, pp. 7104-7108; Nolan, G.P., Ghosh, S., Liou, H.C., Tempst, P., Baltimore, D., DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide (1991) Cell, 64, pp. 961-969; Saklatvala, J., Inflammatory signaling in cartilage: MAPK and NF-κB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis (2007) Drug Targets, 8, pp. 305-313; Davis, R., The mitogen-activated protein kinase signal transduction pathway (1993) J. Biol. Chem., 268, pp. 14553-14556; Su, B., Karin, M., Mitogen-activated protein kinase cascades and regulation of gene expression (1996) Curr. Opin. Immunol., 8, pp. 402-411; Ichijo, H., From receptors to stress-activated MAP kinases (1999) Oncogene, 18, pp. 6087-6093; Hwang, D., Jang, B.C., Yu, G., Boudreau, M., Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide (1997) Biochem. Pharmacol., 54, pp. 87-96; Gao, D., Li, N., Li, Q., Li, J., Han, Z., Fan, Y., Liu, Z., Study of the extraction, purification and antidiabetic potential of ursolic acid from Cornus officinalis Sieb. et Zucc (2008) Therapy, 5, pp. 697-705; Park, C.H., Noh, J.S., Tanaka, T., Yokozawa, T., Effects of morroniside isolated from Corni fructus on renal lipids and inflammation in type 2 diabetic mice (2010) J. Pharm. Pharmacol., 62, pp. 374-380; Youn, K., Jun, M., Effects of key compounds isolated from Corni fructus on BACE1 inhibition (2012) Phytother. Res., 26, pp. 1714-1718; Hong, S.Y., Jeong, W.S., Jun, M., Protective effects of the key compounds isolated from Corni fructus against β-amyloid-induced neurotoxicity in PC12 cells (2012) Molecules, 17, pp. 10831-10845; Jang, J.H., Surh, Y.J., Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells (2001) Mutat. Res., 496, pp. 181-190; Zhu, J.T., Choi, R.C., Chu, G.K., Cheung, A.W., Gao, Q.T., Li, J., Jiang, Z.Y., Tsim, K.W., Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: A comparison of different flavonoids in activating estrogenic effect and in preventing β-amyloid-induced cell death (2007) J. Agric. Food. Chem., 55, pp. 2438-2445; Qu, M., Li, L., Chen, C., Li, M., Pei, L., Chu, F., Yang, J., Zhou, Z., Protective effects of lycopene against amyloid β-induced neurotoxicity in cultured rat cortical neurons (2011) Neurosci. Lett., 505, pp. 286-290; Luo, S., Lan, T., Liao, W., Zhao, M., Yang, H., Genistein inhibits Aβ25-35-induced neurotoxicity in PC12 cells via PKC signaling pathway (2012) Neurochem. Res., 37, pp. 2787-2794; Zhang, X., Cao, J., Zhong, L., Hydroxytyrosol inhibits pro-inflammatory cytokines, iNOS, and COX-2 expression in human monocytic cells (2009) Naunyn. Schmiedebergs Arch. Pharmacol., 379, pp. 581-586; Mattson, M.P., Camandola, S., NFκB in neuronal plasticity and neurodegenerative disorders (2001) J. Clin. Invest., 107, pp. 247-254; Fang, M., Wang, J., Han, S., Hu, Z., Zhan, J., Ling, S., Rudd, J.A., Geng, Y., Protective effects of -conotoxin on amyloid-β-induced damage in PC12 cells (2011) Toxicol. Lett., 206, pp. 325-338; Lentsch, A.B., Ward, P.A., The NFκB/IκB system in acute inflammation (2000) Arch. Immunol. Ther. Exp. (Warsz.), 48, pp. 59-63; Lee, S.Y., Lee, J.W., Lee, H., Yoo, H.S., Yun, Y.P., Oh, K.W., Ha, T.Y., Hong, J.T., Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NFκB and ERK/p38 MAP kinase pathway through antioxidant mechanisms (2005) Mol. Brain Res., 140, pp. 45-54; Yan, S.D., Zhu, H., Fu, J., Yan, S.F., Roher, A., Tourtellotte, W.W., Rajavashisth, T., Schmidt, A.M., Amyloid-β peptide-receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimers disease (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 5296-5301; Rosales-Corral, S., Tan, D.X., Reiter, R.J., Valdivia-Velázquez, M., Acosta-Marti'nez, J.P., Ortiz, G.G., Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo (2004) J. Neuroimmunol., 150, pp. 20-28; Chen, F., Castranova, V., Shi, X., Demers, L.M., New insights into the role of nuclear factor-κB, aubiquitous transcription factor in the initiation of diseases (1999) Clin. Chem., 45, pp. 7-17; Heras, B., Hortelano, S., Molecular basis of the anti-inflammatory effects of terpenoids (2009) Inflamm. Allergy Drug Targets, 8, pp. 28-39; Luceri, C., Giannini, L., Lodovici, M., Antonucci, E., Abbate, R., P -Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo (2007) Br. J. Nutr., 97, pp. 458-463; Luceri, C., Guglielmi, F., Lodovici, M., Giannini, L., Messerini, L., Dolara, P., Plant phenolic 4-coumaric acid protects against intestinal inflammation in rats (2004) Scand. J. Gastroenterol., 39, pp. 1128-1133; Lee, C.H., Wu, S.L., Chen, J.C., Li, C.C., Lo, H.Y., Cheng, W.Y., Lin, J.G., Ho, T.Y., Eriobotrya japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-κB signaling pathway in lung epithelial cells (2008) Am. J. Chin. Med., 36, pp. 1185-1198; Lu, J., Wu, D., Zheng, Y., Hu, B., Zhang, Z., Ye, Q., Liu, C., Wang, Y., Ursolic acid attenuates d -galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/ NFκB pathway activation (2010) Cereb. Cortex, 20, pp. 2540-2548; Lee, A., Chen, T.L., Shih, C.M., Huang, C.Y., Tsao, N.W., Chang, N.C., Chen, Y.H., Lin, F.Y., Ursolic acid induces allograft inflammatory factor-1 expression via a nitric oxide-related mechanism and increases neovascularization (2010) J. Agric. Food Chem., 58 (24), pp. 12941-12949; Najid, A., Simon, A., Cook, J., Chable-Robinovitch, H., Delage, C., Chulia, A.J., Rugaud, M., Characterization of ursolic acid as a lipoxygenase and cyclooxygenase inhibitor using macrophages, platelets and differentiated HL60 leukemic cells (1992) FEBS Lett., 299, pp. 213-217; Suh, N., Honda, T., Finlay, H.J., Barchowsky, A., Williams, C., Benoit, N.E., Xie, Q.W., Sporn, M.B., Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages (1998) Cancer Res., 58, pp. 717-723; Li, Y., Xing, D., Chen, Q., Chen, W.R., Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NFκB using ursolic acid (2009) Int. J. Cancer, 127, pp. 462-473; Yeh, C.T., Wu, C.H., Yen, G.C., Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling (2010) Mol. Nutr. Food Res., 54, pp. 1285-1295; Chen, Q., Luo, S., Zhang, Y., Development of a liquid chromatography-mass spectrometry method for the determination of ursolic acid in rat plasma and tissue: Application to the pharmacokinetic and tissue distribution study (2011) Anal. Bioanal. Chem., 399, pp. 2877-2884",Article,Scopus,2-s2.0-84901642245
"Lemaire P., Leclere M.","Strategy selection in Alzheimer patients: A study in arithmetic",2014,"Journal of Clinical and Experimental Neuropsychology","36","5",,"507","516",,,10.1080/13803395.2014.911248,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901847427&partnerID=40&md5=1633dcf866625244ab1eabed8fe1ada4","Centre National de la Recherche Scientifique, Aix-Marseille Université, 3 Place Victor Hugo, Case D, 13331 Marseille, France; Institut Universitaire de France, France","Lemaire, P., Centre National de la Recherche Scientifique, Aix-Marseille Université, 3 Place Victor Hugo, Case D, 13331 Marseille, France, Institut Universitaire de France, France; Leclère, M., Centre National de la Recherche Scientifique, Aix-Marseille Université, 3 Place Victor Hugo, Case D, 13331 Marseille, France","Objective: We compared Alzheimers disease (AD) patients and elderly controls abilities to select the best strategy on each item and determined whether AD patients tended to repeat the same strategy across consecutive items more often than controls. Method: A total of 60 participants (30 healthy older adults, HOA; 30 AD patients) were asked to select the best rounding strategy to estimate products of multiplication problems (e.g., estimating 42 × 76 by rounding operands down or up, like doing 40 × 70 = 2800 or 50 × 80 = 3200). We identified strategies used on each problem and measured solution latencies and percentage errors with each strategy as a function of problem characteristics. Results: Older adults and AD patients were able to use both available strategies. However, AD patients were less able to select the best strategy than HOA, especially on problems for which selecting the best strategy was most difficult. Moreover, AD patients significantly repeated the preceding strategies across successive problems more often than HOA. Conclusions: Our findings have important implications for further our understanding of dementia-related differences in strategic aspects of cognitive performance. © 2014 © 2014 Taylor & Francis.","Alzheimer's disease; Arithmetic; Cognition; Cognitive strategies; Perseveration; Problem solving; Strategy repetition; Strategy selection","Allen, P.A., Bucur, B., Lemaire, P., Duverne, S., Ogrocki, P.K., Sanders, R.E., Influence of probable Alzheimer's disease on multiplication verification and production (2005) Aging, Neuropsychology, and Cognition, 12 (1), pp. 1-31. , DOI 10.1080/13825580490521322; Ardiale, E., Hodzik, S., Lemaire, P., Aging and strategy switch costs: A study in arithmetic problem solving (2012) L'Année Psychologique, 12 (1), pp. 345-360; Arnaud, L., Lemaire, P., Allen, P., Michel, B.F., Strategic aspects of young, healthy older adults', and Alzheimer patients' arithmetic performance (2008) Cortex, 44 (2), pp. 119-130. , DOI 10.1016/j.cortex.2006.03.001, PII S0010945207000184; Ashcraft, M.H., Battaglia, J., Cognitive arithmetic: Evidence for retrieval and decision processes in mental addition (1978) Journal of Experimental Psychology: Human Memory and Learning, 4, pp. 527-538; Belleville, S., Bherer, L., Lepage, E., Chertkow, H., Gauthier, S., Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment (2008) Neuropsychologia, 46 (8), pp. 2225-2233; Bherer, L., Belleville, S., Hudon, C., The decline executive function during aging normal, in Alzheimer's disease and in the frontotemporal dementia (2004) Psychologie et Neuropsychiatrie du Vieillissement, 2 (3), pp. 1-9; Bouazzaoui, B., Isingrini, M., Fay, S., Angel, L., Vanneste, S., Clarys, D., Taconnat, L., Aging and self-reported internal and external strategy uses: The role of executive functioning (2010) Acta Psychologica, 135 (1), pp. 59-66; Campbell, J.I.D., (2005) Handbook of Mathematical Cognition, , New York, NY: Psychology Press; Castel, A.D., Balota, D.A., McCabe, D.P., Memory efficiency and the strategic control of attention at encoding: Impairments of value-directed remembering in Alzheimer's disease (2009) Neuropsychology, 23 (3), pp. 297-306; Collette, F., Adam, S., Van Der Linden, M., Attention and memory: Relationships among attentional and memory deficits during early phase of dementia (1999) « Attention la Mémoire »: Les Rapports Entre les Troubles Attentionnels et les Troubles Mnésiques À la Phase Précoce des Démences, , B. Michel, J. F. Camus, & H. Allain (Eds.), Marseille: Solal; Cullen, B., Coen, R.F., Lynch, C.A., Cunningham, C.J., Coakley, D., Robetson, I.H., Lawlor, B.A., Repetitive behaviour in Alzheimer's disease: Description, correlates and functions (2005) International Journal of Geriatric Psychiatry, 20 (7), pp. 686-693. , DOI 10.1002/gps.1344; Dalla Barba, G., Wong, C., Encoding specificity and intrusions in Alzheimer's disease and amnesia (1995) Brain and Cognition, 27, pp. 1-16; Dalrymple-Alford, J.C., Kalders, A.S., Jones, R.D., Watson, R.W., A central executive deficit in patients with Parkinson's disease (1994) Journal of Neurology Neurosurgery and Psychiatry, 57 (3), pp. 360-367; Deloche, G., Hannequin, D., Carlomagno, S., Angiel, A., Dordain, M., Pasquier, F., Seron, X., Calculation and number processing in mild Alzheimer's disease (1995) Journal of Clinical Experimental Neuropsychology, 17, pp. 634-639; Deltour, J.J., (1993) Echelle de Vocabulaire de Mill Hill de J.C. Raven. Adaptation Française et Normes Européennes du Mill Hill et du Standard Progressive Matrices de Raven (PM38) [French Adapatation and European Norms for Raven's Matrices and Mill-Hill Tests], , Braine-le-Château: Editions l'application des techniques modernes; Diamond, A., Executive functions (2013) Annual Review of Psychology, 64 (1), pp. 135-168; Dirkx, E., Craik, F.I., Age-related differences in memory as a function of imagery processing (1992) Psychology and Aging, 7, pp. 352-358; (1996) Manuel Diagnostic et Statistique des Troubles Mentaux, , DSM, Masson, Paris: Author; Duverne, S., Lemaire, P., Aging and arithmetic (2005) The Handbook of Mathematical Cognition, pp. 397-412. , J. I. D. Campbell (Ed.), New York, NY: Psychology Press; Duverne, S., Lemaire, P., Michel, B.F., Alzheimer's disease disrupts arithmetic fact retrieval processes but not arithmetic strategy selection (2003) Brain and Cognition, 52 (3), pp. 302-318. , DOI 10.1016/S0278-2626(03)00168-4; Duverne, S., Lemaire, P., Vandierendonck, A., Do working-memory executive components mediate the effects of age on strategy selection or on strategy execution? Insights from arithmetic problem solving (2008) Psychological Research, 72, pp. 27-38; Faust, M.E., Balota, D.A., Spieler, D.H., Building episodic connections: Changes in episodic priming with age and dementia (2001) Neuropsychology, 15 (4), pp. 626-637. , DOI 10.1037; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Gallo, D.A., Sullivan, A.L., Daffner, K.R., Schacter, D.L., Budson, A.E., Associative recognition in Alzheimer's disease: Evidence for impaired recall-to-reject (2004) Neuropsychology, 18 (3), pp. 556-563. , DOI 10.1037/0894-4105.18.3.556; Gandini, D., Lemaire, P., Michel, B.-F., Approximate quantification in young, healthy older adults, and Alzheimer patients (2009) Brain & Cognition, 70, pp. 53-61; Grafman, J., Kampen, D., Rosenberg, J., Salazar, A.M., Boller, F., The progressive breakdown of number processing and calculation ability: A case study (1989) Cortex, 25 (1), pp. 121-133; Hodzik, S., Lemaire, P., Inhibition and shifting capacities mediate adults' age-related differences in strategy selection and repertoire (2011) Acta Psychologica, 137 (3), pp. 335-344; Jurado, M.B., Rosselli, M., The elusive nature of executive functions: A review of our current understanding (2007) Neuropsychology Review, 17 (3), pp. 213-233. , DOI 10.1007/s11065-007-9040-z, Special Issue-Alcohol and Drug Dependence: Brain Mechanisms and Behavioral Impact; Lemaire, P., Cognitive strategy variations during aging (2010) Current Direction in Psychological Science, 19, pp. 363-369; Lemaire, P., Arnaud, L., Lecacheur, M., Adults' age-related differences in adaptivity of strategy choices: Evidence from computational estimation (2004) Psychology and Aging, 19 (3), pp. 467-481. , DOI 10.1037/0882-7974.19.3.467; Lemaire, P., Hinault, T., Age-related differences in sequential modulations of poorer-strategy effects (2013) Experimental Psychology, 11, pp. 1-10; Lemaire, P., Lecacheur, M., Strategy with cost in arithmetic problem solving (2010) Memory & Cognition, 38 (3), pp. 322-332; Lemaire, P., Lecacheur, M., Age-related changes in children's executive functions and strategy selection: A study in computational estimation (2011) Cognitive Development, 26 (3), pp. 282-294; Lemaire, P., Leclère, M., Strategy repetition in young and older adults: A study in arithmetic (2014) Developmental Psychology, 50 (2), pp. 460-468; Mantovan, M.C., Delazer, M., Ermani, M., Denes, G., The breakdown of calculation procedures in Alzheimer's disease (1999) Cortex, 35 (1), pp. 21-38; McKhann, G., Drachman, D., Folstein, M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease (1984) Neurology, 34 (7), pp. 939-944; Paolo, A.M., Axelrod, B.N., Troster, A.I., Blackwell, K.T., Koller, W.C., Utility of a Wisconsin Card Sorting Test short form in persons with Alzheimer's and Parkinson's disease (1996) Journal of Clinical and Experimental Neuropsychology, 18 (6), pp. 892-897; Raven, J.C., (1951) Guide to Using Progressive Matrices (1947), Sets A, Ab, B, , London: Lewis; Taillan, J., Ardiale, E., Lemaire, P., Relationships between strategy switching and strategy switch costs in young and older adults. A study in arithmetic problem solving Experimental Aging Research, , (in press); Terada, S., Sato, S., Honda, H., Kishimoto, Y., Takeda, N., Oshima, E., Uchitomi, Y., Perseverative errors on the Wisconsin Card Sorting Test and brain perfusion imaging in mild Alzheimer's disease (2011) International Psychogeriatrics, 23 (10), pp. 1552-1559; Uittenhove, K., Lemaire, P., Strategy sequential difficulty effects in Alzheimer patients: A study in arithmetic (2013) Journal of Clinical and Experimental Neuropsychology, 35 (1), pp. 83-89; West, R.L., An application of prefrontal cortex function theory to cognitive aging (1996) Psychological Bulletin, 120 (2), pp. 272-292",Article,Scopus,2-s2.0-84901847427
"Ammar M., Smadja C., Phuong Ly G.T., Tandjigora D., Vigneron J., Etcheberry A., Taverna M., Dufour-Gergam E.","Chemical engineering of self-assembled alzheimers peptide on a silanized silicon surface",2014,"Langmuir","30","20",,"5863","5872",,,10.1021/la500695y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901407946&partnerID=40&md5=b0a669e43f5acafe1eb30990751595ff","Université Paris Sud, Institut DElectronique Fondamentale, UMR 8622, Orsay F-91405, France; CNRS, Orsay F-91405, France; Université Paris Sud, Faculté de Pharmacie, UMR CNRS 8612, Chatenay-Malabry F-92296, France; Université Saint-Quentin en Yvelines, Institut Lavoisier de Versailles, UMR 8180, Versailles F-78035, France","Ammar, M., Université Paris Sud, Institut DElectronique Fondamentale, UMR 8622, Orsay F-91405, France, CNRS, Orsay F-91405, France; Smadja, C., Université Paris Sud, Faculté de Pharmacie, UMR CNRS 8612, Chatenay-Malabry F-92296, France; Phuong Ly, G.T., Université Paris Sud, Faculté de Pharmacie, UMR CNRS 8612, Chatenay-Malabry F-92296, France; Tandjigora, D., Université Paris Sud, Institut DElectronique Fondamentale, UMR 8622, Orsay F-91405, France, CNRS, Orsay F-91405, France; Vigneron, J., Université Saint-Quentin en Yvelines, Institut Lavoisier de Versailles, UMR 8180, Versailles F-78035, France; Etcheberry, A., Université Saint-Quentin en Yvelines, Institut Lavoisier de Versailles, UMR 8180, Versailles F-78035, France; Taverna, M., Université Paris Sud, Faculté de Pharmacie, UMR CNRS 8612, Chatenay-Malabry F-92296, France; Dufour-Gergam, E., Université Paris Sud, Institut DElectronique Fondamentale, UMR 8622, Orsay F-91405, France, CNRS, Orsay F-91405, France","The aim of this work is to develop a sensitive and specific immune-sensing platform dedicated to the detection of potential biomarkers of Alzheimers disease (AD) in biological fluids. Accordingly, a controlled and adaptive surface functionalization of a silicon wafer with 7-octenyltrichlorosilane has been performed. The surface has extensively been characterized by atomic force microscopy (AFM; morphology) and X-ray photoelectron spectroscopy (XPS; chemical composition) and contact angle measurements. The wettability of the grafted chemical groups demonstrated the gradual trend from hydrophilic to hydrophobic surface during functionalization. XPS evidenced the presence of silanes on the surface after silanization, and even carboxylic groups as products from the oxidation step of the functionalization process. The characterization results permitted us to define an optimal protocol to reach a high-quality grafting yield. The issue of the quality of controlled chemical preparation on bioreceiving surfaces was also investigated by the recognition of one AD biomarker, the amyloid peptide Aβ 1-42. We have therefore evaluated the biological activity of the grafted anti Aβ antibodies onto this silanized surface by fluorescent microscopy. In conclusion, we have shown, both qualitatively and quantitatively, the uniformity of the optimized functionalization on slightly oxidized silicon surfaces, providing a reliable and chemically stable procedure to determine specific biomarkers of Alzheimer disease. This work opens the route to the integration of controlled immune-sensing applications on lab-on-chip systems. © 2014 American Chemical Society.",,"Buchapudi, K.R., Huang, X., Yang, X., Ji, H., Thundat, T., Microcantilever biosensors for chemicals and bioorganisms (2011) Analyst, 136, pp. 1539-1556; Hervas, M., Lopez, M.A., Escarpa, A., Electrochemical immunosensing on board microfluidic chip platforms (2012) Trends Anal. Chem., 31, pp. 109-127; Seitz, O., Fernandes, P.G., Tian, R., Karnik, N., Wen, H.C., Stiegler, H., Chapman, R.A., Chabal, Y.J., Control and stability of self-assembled monolayers under biosensing conditions (2011) J. Mater. Chem., 21, pp. 4384-4392; Mäkilä, E., Bimb, M., Kaasalainen, M., Herranz, B., Airaksinen, A., Heinonen, M., Kukk, E., Salonen, J., Amine Modification of Thermally Carbonized Porous Silicon with Silane Coupling Chemistry (2012) Langmuir, 26, pp. 14045-14054; Rusmini, F., Zhong, Z., Feijen, J., Protein Immobilization Strategies for Protein Biochips (2007) Biomacromolecules, 8, pp. 1775-1789; Howarter, J., Youngblood, J.P., Coatings Based on Side-chain Ether-Linked Poly(ethylene glycol) and Fluorocarbon Polymers for the Control of Marine Biofouling (2006) Langmuir, 22, pp. 11142-11147; Pallandre, A., De Lambert, B., Attia, R., Jonas, A., Viovy, J.L., Surface treatment and characterization: Perspectives to electrophoresis and lab-on-chips (2006) Electrophoresis, 27, pp. 584-610; Wirth, M.J., Fatunmbi, H.O., Horizontal Polymerization of Mixed Trif unctional Silanes on Silica. 2. Application to Chromatographic Silica Gel (1993) Anal. Chem., 65, pp. 822-826; Sander, L.S., Wise, S.A., Synthesis and Characterization of Polymeric Phases for Liquid Chromatography C18 Stationary (1984) Anal. Chem., 56, pp. 504-510; De Smet, L., Ullien, D., Mescher, M., Sudhölter, E.J.R., Organic Surface Modification of Silicon Nanowire-Based Sensor Devices (2011) Nanowires: Implementations Appl., 13, pp. 267-288; Kurth, D.G., Bein, T., Surface Reactions on Thin Layers of Silane Coupling (1993) Langmuir, 9, pp. 2965-2973; Xiao, X., Hu, J., Charych, D.H., Salmeron, M., Frictional Properties of Alkylsilane Molecules Self-Assembled on Mica Studied by Atomic Force Microscopy (1996) Langmuir, 12, pp. 235-237; Talaei, S., Frey, O., Van Der Wal, P.D., De Rooij, N.F., Koudelka-Hep, M., Hybrid microfluidic cartridge formed by irreversible bonding of SU-8 and PDMS for multi-layer flow applications (2009) Procedia Chem., 1, pp. 381-384; Fairbank, R.W.P., Wirth, M.J., Role of surface-adsorbed water in the horizontal polymerization of trichlorosilanes (1999) J. Chromatogr. A, 830, pp. 285-292; Flinn, D.H., Guzonas, D.A., Yoon, R.-H., Characterization of silica surfaces hydrophobized by octadecyltrichlorosilane (1994) Colloids Surf., A, 87, pp. 163-176; McGovern, M.E., Kallury, K.M.R., Thompson, M., Role of Solvent on the Silanization of Glass with. Octadecyltrichlorosilane (1994) Langmuir, 10, pp. 3607-3614; Cloarec, J.P., Chevolot, Y., Laurenceau, E., Phaner-Goutorbe, M., Souteyrand, E., A multidisciplinary approach for molecular diagnostics based on biosensors and microarrays (2008) ITBM-RBM, 29, pp. 105-127; Inoue, Y., Ishihara, K., Reduction of protein adsorption on well-characterized polymer brush layers with varying chemical structures (2010) Colloids Surf., B, 81, pp. 350-357; Boussert, S., Diez-Perez, I., Kogan, M.J., De Oliveira, E., Giralt, E., An Intramolecular O-N Migration Reaction on Gold Surfaces: Toward the Preparation of Well-Defined Amyloid Surfaces (2009) ACS Nano, 3, pp. 3091-3097; Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., Garcia-Alloza, M., De Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Hyman, B.T., Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimers disease (2008) Nature, 451, pp. 720-725; Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Goldstein, L.S.B., Probing sporadic and familial Alzheimers disease using induced pluripotent stem cells (2012) Nature, 481, pp. 216-222; Sagiv, J., Organized monolayers by adsorption I. Formation and structure of oleophobic mixed monolayers on solid surface (1980) J. Am. Chem. Soc., 102, pp. 92-98; Ulman, A., Formation and Structure of Self-Assembled Monolayers (1996) Chem. Rev., 96, pp. 1533-1554; Ulman, A., (1991) Introduction to Ultra-thin Organic Films: From Langmuir Blodgett to Self-Assembly, , Academic Press: San Diego, CA, USA; Müller, A., Chetham, A.K., (2007) Nanomaterials Chemistry, 5, pp. 177-179. , Wiley: New York; Faucheux, N., Schweiss, R., Lützow, K., Werner, C., Groth, T., Self-assembled monolayers with different terminating groups as model substrates for cell adhesion studies (2004) Biomaterials, 25, pp. 2721-2730; Zou, J., Kauzlarich, S.M., Functionalization of silicon nanoparticles via silanization: Alkyl, halide and ester (2008) J. Cluster Sci., 19, pp. 341-355; Cai, K., Frant, M., Bossert, J., Hildebrand, G., Liefeith, K., Jandt, K.D., Surface functionalized titanium thin films: Zeta-potential, protein adsorption and cell proliferation (2006) Colloid Surf., B, 50, pp. 1-8; Wasserman, S.R., Tao, Y.T., Whitesides, G.M., Structure and reactivity of alkylsiloxane monolayers formed by reaction of alkyltrichlorosilanes on silicon substrates (1989) Langmuir, 5, pp. 1074-1087; Schreiber, F., Self-assembled monolayers: From simple model systems to biofunctionalized interfaces (2004) J. Phys.: Condens. Matter, 16, pp. 881-R900; Dugas, V., Chevalier, Y., Surface hydroxylation and silane grafting on fumed and thermal silica (2003) J. Colloid Interface Sci., 264, pp. 354-361; Popat, K.C., Johnson, R.W., Desai, T.A., Characterization of vapor deposited thin silane films on silicon substrates for biomedical microdevices (2002) Surf. Coat. Technol., 154, pp. 253-261; Von Muhlen, M.G., Brault, N.D., Knudsen, S.K., Jiang, S., Manalis, S.R., Label-Free Biomarker Sensing in Undiluted Serum with Suspended Microchannel Resonators (2010) Anal. Chem., 82, pp. 1905-1910; Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., Differences between amyloid-β aggregation in solution and on the membrane: Insights into elucidation of the mechanistic details of Alzheimers disease (2014) Chem. Soc. Rev., , (in press) 10.1039/c3cs60431d; Ammar, M., Smadja, C., Phuong, L., Azzouz, M., Vigneron, J., Etcheberry, A., Taverna, M., Dufour-Gergam, E., A new controlled concept of immune-sensing platform for specific detection of Alzheimers biomarkers (2013) Biosens. Bioelectron., 40, pp. 329-335; Wagner, M., Wolf, S., Reischies, F.M., Daerr, M., Wolfsgruber, S., Jessen, F., Popp, J., Wiltfang, J., Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease (2012) Neurology, 74, pp. 379-386; Gagni, P., Sola, L., Cretich, M., Chiari, M., Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform (2013) Biosens. Bioelectron., 47, pp. 490-495",Article,Scopus,2-s2.0-84901407946
"Gomez-Gallego M., Gomez-Garcia J., Ato-Garcia M.","Confirmatory factor analysis of the quality of life in alzheimers disease scale in patients with alzheimers disease",2014,"Experimental Aging Research","40","3",,"266","279",,,10.1080/0361073X.2014.896664,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84899828981&partnerID=40&md5=434dd171fe6a89f0c186106ba8a97bb9","Department of Neuroscience, Catholic University of Murcia, Campus of Jerónimos, 135 Murcia 30107, Spain; Department of Quantitative Methods, University of Murcia, Campus of Espinardo, Murcia, Spain; Department of Psychobiology, University of Murcia, Campus of Espinardo, Murcia, Spain","Gómez-Gallego, M., Department of Neuroscience, Catholic University of Murcia, Campus of Jerónimos, 135 Murcia 30107, Spain; Gomez-García, J., Department of Quantitative Methods, University of Murcia, Campus of Espinardo, Murcia, Spain; Ato-García, M., Department of Psychobiology, University of Murcia, Campus of Espinardo, Murcia, Spain","Background/Study Context: Quality of life (QoL) has become an important outcome measure in clinical trials for Alzheimers disease (AD). The Quality of Life in Alzheimers Disease (QoL-AD) Scale is widely used for assessing QoL of patients with AD. This research aims to determine the factor structure of the QoL-AD Scale in AD patients.Methods: One hundred thirty-nine patients with mild-to-moderate AD were administered the QoL-AD Scale. Based on the model proposed for healthy people, confirmatory factor models were built using modification indices and residual analysis to improve the model fit.Results: Confirmatory factor analysis indicated poor fit for both the initial model and the single-factor model. Two models showed a good fit: a three-factor model (perceived health, perceived environment and perceived functional ability) and a two-factor model (perceived physical health and perceived psychological health). Because no differences in fit were found between both models, the authors proposed the more parsimonious solution as the best model.Conclusion: These results provide evidence supporting the construct validity of the QoL-AD Scale. This instrument seems to measure the perception of two related constructs (behavioral competence and environment) and could be used together with instruments measuring psychological well-being and the perception of health. © 2014 Taylor & Francis Group, LLC.",,"Akaike, H., Factor analysis and AIC (1987) Psychometrika, 52, pp. 317-332; Balinsky, B., An analysis of the mental factors of various age groups from nine to sixty (1941) Genetic Psychology Monographs, 23, pp. 191-234; Bentler, P.M., Comparative fit indexes in structural models (1990) Psychological Bulletin, 107, pp. 238-246; Bentler, P.M., (2001) EQS 6 Structural Equations Program Manual, , Encino, CA: Multivariate Software; Bentler, P.M., (2005) EQS 6 Structural Equations Program Manual, , Encino, CA: Multivariate Software; Bernstein, I.H., Garbin, C., Teng, G., (1988) Applied Multivariate Analysis, , New York: Springer-Verlag; Bozdogan, H., Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions (1987) Psychometrika, 52, pp. 345-370; Akaike, H., Factor analysis and AIC (1987) Psychometrika, 52, pp. 317-332; Balinsky, B., An analysis of the mental factors of various age groups from nine to sixty (1941) Genetic Psychology Monographs, 23, pp. 191-234; Bentler, P.M., Comparative fit indexes in structural models (1990) Psychological Bulletin, 107, pp. 238-246; Bentler, P.M., (2001) EQS 6 Structural Equations Program Manual, , Encino, CA: Multivariate Software; Bentler, P.M., (2005) EQS 6 Structural Equations Program Manual, , Encino, CA: Multivariate Software; Bernstein, I.H., Garbin, C., Teng, G., (1988) Applied Multivariate Analysis, , New York: Springer-Verlag; Bozdogan, H., Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions (1987) Psychometrika, 52, pp. 345-370; With dementia rate their own quality of life? International Psychogeriatrics, 20, pp. 482-493; Logsdon, R.G., Gibbons, L.E., McCurry, S.M., Teri, L., Assessing quality of life in older adults with cognitive impairment (2002) Psychosomatic Medicine, 64, pp. 510-519; MacCallum, R.C., Browne, M.W., Cai, L., Testing differences between nested covariance structure models: Power analysis and null hypotheses (2006) Psychological Methods, 11, pp. 19-35; Mardia, K.V., Measures of multivariate skewness and kurtosis with applications (1970) Biometrika, 57, pp. 519-530; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of alzheimer's disease: Report of the nincdsadrda work group under the auspices of department of health and human services task force on alzheimer's disease (1984) Neurology, 34, pp. 939-944; Mougias, A.A., Politis, A., Lyketsos, C.G., Mavreas, V.G., Quality of life in dementia patients in Athens, Greece: Predictive factors and the role of caregiver-related factors (2011) International Psychogeriatrics, 23, pp. 395-403; Nunnaly, J., Bernstein, I., (1994) Psychometric Theory, , New York: McGraw-Hill; Rabins, P.V., Measuring quality of life in dementia: Purposes, goals, challenges and progress (2007) International Psychogeriatrics, 19, pp. 401-407; Reisberg, B., Ferris, S., De Leon, M., Crook, T., The Global Deterioration Scale for assessment of primary degenerative dementia (1982) American Journal of Psychiatry, 139, pp. 1136-1139; Revell, A.J., Caskie, G.I., Willis, S.L., Schaie, K.W., Factor structure and invariance of the quality of life in alzheimer's disease (qol-Ad) scale (2009) Experimental Aging Research, 35, pp. 250-267; Schumacker, R.E., Lomax, R.G., (2004) A Beginner's Guide to Structural Equation Modeling, , Mahwah, NJ: Lawrence Erlbaum Associates; Sloane, P.D., Zimmerman, S., Williams, C.S., Reed, P.S., Gill, K.S., Preisser, J.S., Evaluating the quality of life of long-Term care residents with dementia (2005) The Gerontologist, 1, pp. 37-49; Steiger, J.H., Lind, J.C., Statistically-based tests for the number of common factors (1980) Paper Presented at the Annual Spring Meeting of the Psychometric Society in Iowa City, May 30, 1980; Thorgrimsen, L., Whose quality of life is it anyway? the validity and reliability of the quality of life-Alzheimer disease (qol-Ad) scale (2003) Alzheimer Disease and Associated Disorders, 17, pp. 201-208; Vogel, A., Bhattacharya, S., Waldorff, F.B., Waldemar, G., Proxyrated quality of life in Alzheimer's disease: A three-year longitudinal study (2012) International Psychogeriatrics, 24, pp. 82-89; Yuan, K.H., Bentler, E.M., Structural equation modeling with robust covariances (1998) Sociological Methodology, 28, pp. 363-396; Zumbo, B.D., Zimmerman, D.W., Is the selection of statistical methods governed by level of measurement? (1993) Canadian Psychology, 34, pp. 390-400",Article,Scopus,2-s2.0-84899828981
"Conicella A.E., Fawzi N.L.","The C-terminal threonine of Aβ43 nucleates toxic aggregation via structural and dynamical changes in monomers and protofibrils",2014,"Biochemistry","53","19",,"3095","3105",,4,10.1021/bi500131a,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901008835&partnerID=40&md5=da958288720e695672850cd15c8af3c1","Graduate Program in Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, United States; Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI 02912, United States","Conicella, A.E., Graduate Program in Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, United States; Fawzi, N.L., Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI 02912, United States","Recent studies suggest that deposition of amyloid β (Aβ) into oligomeric aggregates and fibrils, hallmarks of Alzheimers disease, may be initiated by the aggregation of Aβ species other than the well-studied 40- and 42-residue forms, Aβ40 and Aβ42, respectively. Here we report on key structural, dynamic, and aggregation kinetic parameters of Aβ43, extended by a single threonine at the C-terminus relative to Aβ42. Using aggregation time course experiments, electron microscopy, and a combination of nuclear magnetic resonance measurements including backbone relaxation, dark-state exchange saturation transfer, and quantification of chemical shift differences and scalar coupling constants, we demonstrate that the C-terminal threonine in Aβ43 increases the rate and extent of protofibril aggregation and confers slow C-terminal motions in the monomeric and protofibril-bound forms of Aβ43. Relative to the neighboring residues, the hydrophilic Thr43 of Aβ43 favors direct contact with the protofibril surface more so than the C-terminus of Aβ40 or Aβ42. Taken together, these results demonstrate the potential of a small chemical modification to affect the properties of Aβ structure and aggregation, providing a mechanism for the potential role of Aβ43 as a primary nucleator of Aβ aggregates in Alzheimers disease. © 2014 American Chemical Society.",,"Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., Davies, P., Correlations of synaptic and pathological markers with cognition of the elderly (1995) Neurobiol. Aging, 16, pp. 285-298. , 298-304 (discussion); McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., Masters, C.L., Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimers disease (1999) Ann. Neurol., 46, pp. 860-866; Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Teplow, D.B., Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates (1999) J. Biol. Chem., 274, pp. 25945-25952; Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Rogers, J., Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimers disease (1999) Am. J. Pathol., 155, pp. 853-862; Benilova, I., Karran, E., De Strooper, B., The toxic Aβ oligomer and Alzheimers disease: An emperor in need of clothes (2012) Nat. Neurosci., 15, pp. 349-357; Zhao, G., Mao, G., Tan, J., Dong, Y., Cui, M.Z., Kim, S.H., Xu, X., Identification of a new presenilin-dependent -cleavage site within the transmembrane domain of amyloid precursor protein (2004) J. Biol. Chem., 279, pp. 50647-50650; Steiner, H., Fluhrer, R., Haass, C., Intramembrane proteolysis by γ-secretase (2008) J. Biol. Chem., 283, pp. 29627-29631; Jarrett, J.T., Berger, E.P., Lansbury, Jr.P.T., The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimers disease (1993) Biochemistry, 32, pp. 4693-4697; Borchelt, D.R., Thinakaran, G., Eckman, C.B., Lee, M.K., Davenport, F., Ratovitsky, T., Prada, C.M., Sisodia, S.S., Familial Alzheimers disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo (1996) Neuron, 17, pp. 1005-1013; Yan, Y., Liu, J., McCallum, S.A., Yang, D., Wang, C., Methyl dynamics of the amyloid-β peptides Aβ40 and Aβ42 (2007) Biochem. Biophys. Res. Commun., 362, pp. 410-414; Yan, Y., Wang, C., Aβ42 is more rigid than Aβ40 at the C terminus: Implications for Aβ aggregation and toxicity (2006) J. Mol. Biol., 364, pp. 853-862; Riek, R., Guntert, P., Dobeli, H., Wipf, B., Wuthrich, K., NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, Aβ(1-40)(ox) and Aβ(1-42)(ox) (2001) Eur. J. Biochem., 268, pp. 5930-5936; Lu, J.X., Qiang, W., Yau, W.M., Schwieters, C.D., Meredith, S.C., Tycko, R., Molecular structure of β-amyloid fibrils in Alzheimers disease brain tissue (2013) Cell, 154, pp. 1257-1268; Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D., Riek, R., 3D structure of Alzheimers amyloid-β(1-42) fibrils (2005) Proc. Natl. Acad. Sci. U.S.A., 102, pp. 17342-17347; Zhang, R., Hu, X., Khant, H., Ludtke, S.J., Chiu, W., Schmid, M.F., Frieden, C., Lee, J.M., Interprotofilament interactions between Alzheimers Aβ1-42 peptides in amyloid fibrils revealed by cryoEM (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 4653-4658; Abelein, A., Kaspersen, J.D., Nielsen, S.B., Jensen, G.V., Christiansen, G., Pedersen, J.S., Danielsson, J., Graslund, A., Formation of dynamic soluble surfactant-induced amyloid β peptide aggregation intermediates (2013) J. Biol. Chem., 288, pp. 23518-23528; Ladiwala, A.R., Litt, J., Kane, R.S., Aucoin, D.S., Smith, S.O., Ranjan, S., Davis, J., Tessier, P.M., Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity (2012) J. Biol. Chem., 287, pp. 24765-24773; Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J.I., Smith, S.O., Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils (2010) Nat. Struct. Mol. Biol., 17, pp. 561-567; Carulla, N., Zhou, M., Arimon, M., Gairi, M., Giralt, E., Robinson, C.V., Dobson, C.M., Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 7828-7833; Scheidt, H.A., Morgado, I., Huster, D., Solid-state NMR reveals a close structural relationship between amyloid-β protofibrils and oligomers (2012) J. Biol. Chem., 287, pp. 22822-22826; Bertini, I., Gallo, G., Korsak, M., Luchinat, C., Mao, J., Ravera, E., Formation kinetics and structural features of β-amyloid aggregates by sedimented solute NMR (2013) ChemBioChem, 14, pp. 1891-1897; Narayanan, S., Reif, B., Characterization of chemical exchange between soluble and aggregated states of β-amyloid by solution-state NMR upon variation of salt conditions (2005) Biochemistry, 44, pp. 1444-1452; Dasari, M., Espargaro, A., Sabate, R., Lopez Del Amo, J.M., Fink, U., Grelle, G., Bieschke, J., Reif, B., Bacterial inclusion bodies of Alzheimers disease β-amyloid peptides can be employed to study native-like aggregation intermediate states (2011) ChemBioChem, 12, pp. 407-423; Krishnamoorthy, J., Brender, J.R., Vivekanandan, S., Jahr, N., Ramamoorthy, A., Side-chain dynamics reveals transient association of Aβ(1-40) monomers with amyloid fibers (2012) J. Phys. Chem. B, 116, pp. 13618-13623; Fawzi, N.L., Ying, J., Ghirlando, R., Torchia, D.A., Clore, G.M., Atomic-resolution dynamics on the surface of amyloid-β protofibrils probed by solution NMR (2011) Nature, 480, pp. 268-272; Jawhar, S., Wirths, O., Bayer, T.A., Pyroglutamate amyloid-β (Aβ): A hatchet man in Alzheimer disease (2011) J. Biol. Chem., 286, pp. 38825-38832; Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., Matsuba, Y., Saido, T.C., Potent amyloidogenicity and pathogenicity of Aβ43 (2011) Nat. Neurosci., 14, pp. 1023-1032; Welander, H., Franberg, J., Graff, C., Sundstrom, E., Winblad, B., Tjernberg, L.O., Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains (2009) J. Neurochem., 110, pp. 697-706; Sandebring, A., Welander, H., Winblad, B., Graff, C., Tjernberg, L.O., The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease (2013) PLoS One, 8, p. 55847; Zou, K., Liu, J., Watanabe, A., Hiraga, S., Liu, S., Tanabe, C., Maeda, T., Komano, H., Aβ43 is the earliest-depositing Aβ species in APP transgenic mouse brain and is converted to Aβ41 by two active domains of ACE (2013) Am. J. Pathol., 182, pp. 2322-2331; Vandersteen, A., Masman, M.F., De Baets, G., Jonckheere, W., Van Der Werf, K., Marrink, S.J., Rozenski, J., Broersen, K., Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide pool (2012) J. Biol. Chem., 287, pp. 36732-36743; Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., Bax, A., NMRPipe: A multidimensional spectral processing system based on UNIX pipes (1995) J. Biomol. NMR, 6, pp. 277-293; Fawzi, N.L., Ying, J., Torchia, D.A., Clore, G.M., Probing exchange kinetics and atomic resolution dynamics in high-molecular-weight complexes using dark-state exchange saturation transfer NMR spectroscopy (2012) Nat. Protoc., 7, pp. 1523-1533; Fawzi, N.L., Phillips, A.H., Ruscio, J.Z., Doucleff, M., Wemmer, D.E., Head-Gordon, T., Structure and dynamics of the Aβ(21-30) peptide from the interplay of NMR experiments and molecular simulations (2008) J. Am. Chem. Soc., 130, pp. 6145-6158; Kragelj, J., Ozenne, V., Blackledge, M., Jensen, M.R., Conformational propensities of intrinsically disordered proteins from NMR chemical shifts (2013) ChemPhysChem, 14, pp. 3034-3045; Maltsev, A.S., Ying, J., Bax, A., Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties (2012) Biochemistry, 51, pp. 5004-5013; Rosenman, D.J., Connors, C.R., Chen, W., Wang, C., Garcia, A.E., Aβ monomers transiently sample oligomer and fibril-like configurations: Ensemble characterization using a combined MD/NMR approach (2013) J. Mol. Biol., 425, pp. 3338-3359; Minor, Jr.D.L., Kim, P.S., Measurement of the β-sheet-forming propensities of amino acids (1994) Nature, 367, pp. 660-663; Zhang, H., Neal, S., Wishart, D.S., RefDB: A database of uniformly referenced protein chemical shifts (2003) J. Biomol. NMR, 25, pp. 173-195; Fawzi, N.L., Ying, J., Torchia, D.A., Clore, G.M., Kinetics of amyloid β monomer-to-oligomer exchange by NMR relaxation (2010) J. Am. Chem. Soc., 132, pp. 9948-9951; Hou, L., Shao, H., Zhang, Y., Li, H., Menon, N.K., Neuhaus, E.B., Brewer, J.M., Zagorski, M.G., Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation (2004) J. Am. Chem. Soc., 126, pp. 1992-2005; Fawzi, N.L., Okabe, Y., Yap, E.H., Head-Gordon, T., Determining the critical nucleus and mechanism of fibril elongation of the Alzheimers Aβ(1-40) peptide (2007) J. Mol. Biol., 365, pp. 535-550; Ball, K.A., Phillips, A.H., Wemmer, D.E., Head-Gordon, T., Differences in β-strand populations of monomeric Aβ40 and Aβ42 (2013) Biophys. J., 104, pp. 2714-2724; Ball, K.A., Phillips, A.H., Nerenberg, P.S., Fawzi, N.L., Wemmer, D.E., Head-Gordon, T., Homogeneous and heterogeneous tertiary structure ensembles of amyloid-β peptides (2011) Biochemistry, 50, pp. 7612-7628; Hu, X., Crick, S.L., Bu, G., Frieden, C., Pappu, R.V., Lee, J.M., Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-β peptide (2009) Proc. Natl. Acad. Sci. U.S.A., 106, p. 20324",Article,Scopus,2-s2.0-84901008835
"Asti M., Ferrari E., Croci S., Atti G., Rubagotti S., Iori M., Capponi P.C., Zerbini A., Saladini M., Versari A.","Synthesis and characterization of 68Ga-labeled curcumin and curcuminoid complexes as potential radiotracers for imaging of cancer and alzheimers disease",2014,"Inorganic Chemistry","53","10",,"4922","4933",,4,10.1021/ic403113z,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901058224&partnerID=40&md5=2f775dc3fd4cb0dea0c9867415b7dcb5","Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Department of Chemical and Geological Sciences, University of Modena, via Campi, 183, 41125 Modena, Italy; Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy","Asti, M., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Ferrari, E., Department of Chemical and Geological Sciences, University of Modena, via Campi, 183, 41125 Modena, Italy; Croci, S., Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Atti, G., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Rubagotti, S., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Iori, M., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Capponi, P.C., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Zerbini, A., Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Saladini, M., Department of Chemical and Geological Sciences, University of Modena, via Campi, 183, 41125 Modena, Italy; Versari, A., Nuclear Medicine Unit, Oncology and Advanced Technologies Department, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy","Curcumin (CUR) and curcuminoids complexes labeled with fluorine-18 or technetium-99m have recently shown their potential as diagnostic tools for Alzheimers disease. Gallium-68 is a positron-emitting, generator-produced radionuclide, and its properties can be exploited in situ in medical facilities without a cyclotron. Moreover, CUR showed a higher uptake in tumor cells compared to normal cells, suggesting potential diagnostic applications in this field. In spite of this, no studies using labeled CUR have been performed in this direction, so far. Herein, 68Ga-labeled complexes with CUR and two curcuminoids, namely diacetyl-curcumin (DAC) and bis(dehydroxy)curcumin (bDHC), were synthesized and characterized by means of experimental and theoretical approaches. Moreover, a first evaluation of their affinity to synthetic β-amyloid fibrils and uptake by A549 lung cancer cells was performed to show the potential application of these new labeled curcuminoids in these diagnostic fields. The radiotracers were prepared by reacting 68Ga3+ obtained from a 68Ge/68Ga generator with 1 mg/mL curcuminoids solutions. Reaction parameters (precursor amount, reaction temperature, and pH) were optimized to obtain high and reproducible radiochemical yield and purity. Stoichiometry and formation of the curcuminoid complexes were investigated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, NMR, ultraviolet-visible, and fluorescence spectroscopy on the equivalent natGa-curcuminoids (nat = natural) complexes, and their structure was computed by theoretical density functional theory calculations. The analyses evidenced that CUR, DAC, and bDHC were predominantly in the keto-enol form and attested to Ga(L)2 + species formation. Identity of the 68Ga(L) 2 + complexes was confirmed by coelution with the equivalent natGa(L)2 + complexes in ultrahigh-performance liquid chromatography analyses.68Ga(CUR) 2 +, 68Ga(DAC)2 +, and 68Ga(bDHC)2 + were highly (87 ± 4, 90 ± 1%) and moderately (48 ± 2%), respectively, retained by synthetic β-amyloid fibrils in vitro. All the Ga-curcuminoid complexes showed an uptake in A549 lung cancer cells, at least equivalent to the respective free curcuminoids, confirming potential applications as cancer-detecting radiotracers. © 2014 American Chemical Society.",,"Kovacevic, Z., Kalinowski, S.D., Lovejoy, B.D., Yu, Y., Rahmanto, S.Y., Sharpe, C.P., Bernhardt, V.P., Richardson, R., (2011) Curr. Top. Med. Chem., 11, pp. 483-499; Zandi, K., Ramedani, E., Mohammadi, K., Tajbakhsh, S., Deilami, I., Rastian, Z., Fouladvand, M., Farshadpour, F., (2010) Nat. Prod. Commun., 5, pp. 1935-1938; Cheng, K.K., Yeung, C.F., Ho, S.W., Chow, S.F., Chow, A.H.L., Baum, L., (2013) AAPS J., 15, pp. 324-336; Ferrari, E., Asti, M., Benassi, R., Pignedoli, F., Saladini, M., (2013) Dalton Trans., 42, pp. 5304-5313; Sagnou, M., Benaki, D., Triantis, C., Tsotakos, T., Psycharis, V., Raptopoulou, C.P., Pirmettis, I., Pelecanou, M., (2011) Inorg. Chem., 50, pp. 1295-1303; Roesch, F., Riss, P.J., (2010) Curr. Top. Med. Chem., 10, pp. 1633-1668; Ferrari, E., Pignedoli, F., Imbriano, C., Marverti, G., Basile, V., Venturi, E., Saladini, M., (2011) J. Med. Chem., 54, pp. 8066-8077; Cai, X.Z., Huang, W.Y., Qiao, Y., Du, S.Y., Chen, Y., Chen, D., Yu, S., Jiang, Y., (2013) Phytomedicine, 20, pp. 495-505; Ostrowski, W., Śniecikowska, L., Hoffmann, M., Fransi, R., (2013) J. Spectrosc., 2103, pp. 1-8; Sagnou, M., Benaki, D., Triantis, C., Tsotakos, T., Psycharis, V., Raptopoulou, C.P., Pirmettis, I., Pelecanou, M., (2011) Inorg. Chem., 50, pp. 1295-1303; Benassi, R., Ferrari, E., Lazzari, S., Spagnolo, F., Saladini, M., (2008) J. Mol. Struct., 892, pp. 168-176; Mague, J.T., Alworth, W.L., Payton, F.L., (2004) Acta Crystallogr., Sect. C: Cryst. Struct. Commun., 60, pp. 608-o610; Xu, M., Dou, X., Bu, Y., Zhang, Y., (2012) Chem. Phys. Lett., 537, pp. 101-106; Kubícék, V., Havlíčková, J., Kotek, J., Tircsó, G., Hermann, P., Tóth, E., Lukeš, I., (2010) Inorg. Chem., 49, pp. 1060-10969; Chaves, S., Mendonca, A.C., Marques, S.M., Prata, M.I., Santos, A., Martins, A.F., Geraldes, C.F.G.C., Santos, M.A., (2011) J. Inorg. Biochem., 105, pp. 31-38; Kumar, A., Li, L., Chaturvedi, A., Brzostowski, J., Chittigori, J., Pierce, S., Samuelson, L.A., Kumar, J., (2012) Appl. Phys. Lett., 100, p. 203701; Kunwar, A., Barik, A., Pandey, R., Priyadarsini, K.I., (2006) Biochim. Biophys. Acta, 1760, pp. 1513-1520; Caselli, M., Ferrari, E., Imbriano, C., Pignedoli, F., Saladini, M., Ponterini, G., (2010) J. Photochem. Photobiol., A, 210, pp. 115-124; Kim, S.-H., Gwon, S.-Y., Burkinshaw, S.M., Son, Y.-A., (2010) Spectrochim. Acta, Part A, 76, pp. 384-387; Leung, M.H.M., Pham, D.-T., Lincoln, S.F., Kee, T.W., (2012) Phys. Chem. Chem. Phys., 14, pp. 13580-13587; Fages, F., Leroy, S., Soujanya, T., Sohna Sohna, J.-E., (2001) Pure Appl. Chem., 73, pp. 411-414; Salgin, S., Salgin, U., Bahadir, S., (2012) Int. J. Electrochem. Sci., 7, pp. 12404-12414; Basile, V., Ferrari, E., Lazzari, S., Belluti, S., Pignedoli, F., Imbriano, C., (2009) Biochem. Pharmacol., 78, pp. 1305-1315; Lee, I., Yang, J., Lee, J.H., Choe, Y.S., (2011) Bioorg. Med. Chem. Lett., 21, pp. 5765-5769; Ryu, E.K., Choe, Y.S., Lee, K.H., Choi, Y., Kim, B.T., (2006) J. Med. Chem., 49, pp. 6111-6119; Kunwar, A., Barik, A., Mishra, B., Rathinasamy, K., Pandey, R., Priyadarsini, K.I., (2008) Biochim. Biophys. Acta, 1780, pp. 673-679; Frisch, M.J., Trucks, G.W., Schlegel, H.B., (2004) GAUSSIAN 03, , Revision D.01; Gaussian, Inc. Wallingford, CT; Dennington, I.I.R., Keyth, T., Millam, J., Eppinnett, K., Hovell, W.L., Gilliand, R., (2003) Gaussview, , Version 3.0; Semichem, Inc. Shawnee Mission, KS; Stott, K., Stonehouse, J., Keeler, J., Hwang, T.L., Shaka, A.J., (1995) J. Am. Chem. Soc., 117, pp. 4199-4200; Asti, M., Iori, M., Erba, P.A., (2012) Nucl. Med. Commun., 33, pp. 1179-1187; Asti, M., Iori, M., Capponi, P.C., Atti, G., Rubagotti, S., Martin, R., Brennauer, A., Versari, A., (2014) Nucl. Med. Biol., 41, pp. 24-35; Klunk, W.E., Jacop, R.F., Mason, R.P., (1999) Anal. Biochem., 266, pp. 66-76; Agdeppa, E., Kepe, V., Liu, J., Torres, S.F., Satyamurthy, N., Petric, A., Cole, G.M., Barrio, J.R., (2001) J. Neurosci., 21, pp. 1-5",Article,Scopus,2-s2.0-84901058224
"Tiwari A.","Advanced Healthcare Materials",2014,"Advanced Healthcare Materials",,,,"1","532",,2,10.1002/9781118774205,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84920279622&partnerID=40&md5=e3d88b3e4e3f201aa3ea5b83a457a7e8","Biosensors and Bioelectronics Centre, Linköping UniversityLinköping, Sweden","Tiwari, A., Biosensors and Bioelectronics Centre, Linköping UniversityLinköping, Sweden","Advanced materials are attracting strong interest in the fundamental as well as applied sciences and are being extensively explored for their potential usage in a range of healthcare technological and biological applications. Advanced Healthcare Nanomaterials summarises the current status of knowledge in the fields of advanced materials for functional therapeutics, point-of-care diagnostics, translational materials, up and coming bio-engineering devices. The book highlights the key features which enable engineers to design stimuli-responsive smart nanoparticles, novel biomaterials, nano/micro-devices for diagnosis, therapy (theranostics).The leading contributor researchers cover the following topics: • State-of-the-art of biomaterials for human health • Micro- and nanoparticles and their application in biosensors • The role of immunoassays • Stimuli-responsive smart nanoparticles • Diagnosis and treatment of cancer • Advanced materials for biomedical application and drug delivery • Nanoparticles for diagnosis and/or treatment of Alzheimers disease • Hierarchical modelling of elastic behavior of human dental tissue • Biodegradable porous hydrogels • Hydrogels in tissue engineering, drug delivery and wound care • Modified natural zeolites • Supramolecular hydrogels based on cyclodextrin poly(pseudo)rotaxane • Polyhydroxyalkanoate-based biomaterials • Biomimetic molecularly imprinted polymers The book is written for readers from diverse backgrounds across chemistry, physics, materials science and engineering, medical science, pharmacy, biotechnology, and biomedical engineering. It offers a comprehensive view of cutting-edge research on advanced materials for healthcare technology and applications. © 2014 by Scrivener Publishing LLC. All rights reserved.",,,Book,Scopus,2-s2.0-84920279622
"Fehse S., Nowag S., Quadir M., Kim K.S., Haag R., Multhaup G.","Copper transport mediated by nanocarrier systems in a blood-brain barrier in vitro model",2014,"Biomacromolecules","15","5",,"1910","1919",,,10.1021/bm500400k,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900443924&partnerID=40&md5=44cba7cffee0f081d00113547d8fbf38","Freie Universität Berlin, Institut für Chemie und Biochemie, Thielallee 63, 14195 Berlin, Germany; Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, QC H3G 1Y6, Canada; Freie Universität Berlin, Institut für Chemie und Biochemie, Takustraße 3, 14195 Berlin, Germany; Johns Hopkins University, School of Medicine, Division of Pediatric Infectious Diseases, 200 North Wolfe St, Baltimore, MD 21287, United States","Fehse, S., Freie Universität Berlin, Institut für Chemie und Biochemie, Thielallee 63, 14195 Berlin, Germany, Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, QC H3G 1Y6, Canada; Nowag, S., Freie Universität Berlin, Institut für Chemie und Biochemie, Takustraße 3, 14195 Berlin, Germany; Quadir, M., Freie Universität Berlin, Institut für Chemie und Biochemie, Takustraße 3, 14195 Berlin, Germany; Kim, K.S., Johns Hopkins University, School of Medicine, Division of Pediatric Infectious Diseases, 200 North Wolfe St, Baltimore, MD 21287, United States; Haag, R., Freie Universität Berlin, Institut für Chemie und Biochemie, Takustraße 3, 14195 Berlin, Germany; Multhaup, G., Freie Universität Berlin, Institut für Chemie und Biochemie, Thielallee 63, 14195 Berlin, Germany, Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, QC H3G 1Y6, Canada","Copper (Cu) is a cofactor of various metalloenzymes and has a role in neurodegenerative diseases with disturbed Cu homeostasis, for example, in Alzheimers disease (AD) and Menkes disease. To address Cu imbalances, we synthesized two different dendritic nanoparticles (NP) for the transport of Cu(II) ions across the blood-brain barrier (BBB). The synthesized NPs show low toxicity and high water solubility and can stabilize high amounts of Cu(II). The Cu(II)-laden NPs crossed cellular membranes and increased the cellular Cu level. A human brain microvascular endothelial cell (HBMEC) model was established to investigate the permeability of the NPs through the BBB. By comparing the permeability × surface area product (PSe) of reference substances with those of NPs, we observed that NPs crossed the BBB model two times more effectively than 14C-sucrose and sodium fluorescein (NaFl) and up to 60× better than Evans Blue labeled albumin (EBA). Our results clearly indicate that NPs cross the BBB model effectively. Furthermore, Cu was shielded by the NPs, which decreased the Cu toxicity. The novel design of the core-shell NP enabled the complexation of Cu(II) in the outer shell and therefore facilitated the pH-dependent release of Cu in contrast to core-multishell NPs, where the Cu(II) ions are encapsulated in the core. This allows a release of Cu into the cytoplasm. In addition, by using a cellular detection system based on a metal response element with green fluorescent protein (MRE-GFP), we demonstrated that Cu could also be released intracellularly from NPs and is accessible for biological processes. Our results indicate that NPs are potential candidates to rebalance metal-ion homeostasis in disease conditions affecting brain and neuronal systems. © 2014 American Chemical Society.",,"Desai, V., Kaler, S.G., (2008) Am. J. Clin. Nutr., 88, pp. 855S-858S; Voskoboinik, I., Camakaris, J., (2002) J. Bioenerg. Biomembr., 34, pp. 363-371; Tümer, Z., Mller, L.B., (2010) Eur. J. Hum. Genet., 18, pp. 511-518; Deibel, M.A., Ehmann, W.D., Markesbery, W.R., (1996) J. Neurol. Sci., 143, pp. 137-142; Multhaup, G., Schlicksupp, A., Hesse, L., Beher, D., Ruppert, T., Masters, C.L., Beyreuther, K., (1996) Science, 271, pp. 1406-1409; Bush, A.I., Pettingell, W.H., Multhaup, G., Paradis, M.D., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Tanzi, R.E., (1994) Science, 265, pp. 1464-1467; Angeletti, B., Waldron, K.J., Freeman, K.B., Bawagan, H., Hussain, I., Miller, C.C.J., Lau, K.-F., Dingwall, C., (2005) J. Biol. Chem., 280, pp. 17930-17937; Munter, L.M., Sieg, H., Bethge, T., Liebsch, F., Bierkandt, F.S., Schleeger, M., Bittner, H.J., Multhaup, G., (2013) J. Am. Chem. Soc., 135, pp. 19354-19361; Southon, A., Greenough, M.A., Ganio, G., Bush, A.I., Burke, R., Camakaris, J., (2013) PLoS One, 8, p. 7; Treiber, C., Simons, A., Strauss, M., Hafner, M., Cappai, R., Bayer, T.A., Multhaup, G., (2004) J. Biol. Chem., 279, pp. 51958-51964; Barnham, K.J., McKinstry, W.J., Multhaup, G., Galatis, D., Morton, C.J., Curtain, C.C., Williamson, N.A., Cappai, R., (2003) J. Biol. Chem., 278, pp. 17401-17407; Hesse, L., Beher, D., Masters, C.L., Multhaup, G., (1994) FEBS Lett., 349, pp. 109-116; Kessler, H., Pajonk, F.-G., Bach, D., Schneider-Axmann, T., Falkai, P., Herrmann, W., Multhaup, G., Bayer, T., (2008) J. Neural Transm., 115, pp. 1651-1659; Borchardt, T., Camakaris, J., Cappai, R., Masters, C.L., Beyreuther, K., Multhaup, G., (1999) Biochem. J., 344, pp. 461-467; Crouch, P.J., Hung, L.W., Adlard, P.A., Cortes, M., Lal, V., Filiz, G., Perez, K.A., Barnham, K.J., (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 381-386; Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Bush, A.I., (2001) Neuron, 30, pp. 665-676; Schäfer, S., Pajonk, F.G., Multhaup, G., Bayer, T.A., (2007) J. Mol. Med., 85, pp. 405-413; Fleige, E., Quadir, M.A., Haag, R., (2012) Adv. Drug Delivery Rev., 64, pp. 866-884; Kozlovskaya, L., Stepensky, D., (2013) J. Controlled Release, 171, pp. 17-23; Treiber, C., Quadir, M.A., Voigt, P., Radowski, M., Xu, S.J., Munter, L.M., Bayer, T.A., Multhaup, G., (2009) Biochemistry, 48, pp. 4273-4284; Vincent, J.B., Love, S., (2012) Biochim. Biophys. Acta, Gen. Subj., 1820, pp. 362-378; Mainz, A., Bardiaux, B., Kuppler, F., Multhaup, G., Felli, I.C., Pierattelli, R., Reif, B., (2012) J. Biol. Chem., 287, pp. 1128-1138; Dandekar, D.H., Kumar, M., Ladha, J.S., Ganesh, K.N., Mitra, D., (2005) Anal. Biochem., 342, pp. 341-344; Stins, M.F., Badger, J., Sik Kim, K., (2001) Microb. Pathog., 30, pp. 19-28; Stins, M.F., Gilles, F., Kim, K.S., (1997) J. Neuroimmunol., 76, pp. 81-90; Deli, M.A., Abraham, C.S., Niwa, M., Falus, A., (2003) Inflamm. Res., 52, pp. 39-S40; Burakowska, E., Haag, R., (2009) Macromolecules, 42, pp. 5545-5550; Krämer, M., Kopaczynska, M., Krause, S., Haag, R., (2007) J. Polym. Sci., Polym. Chem., 45, pp. 2287-2303; Keilitz, J., Schwarze, M., Nowag, S., Schomäcker, R., Haag, R., (2010) ChemCatChem, 2, pp. 863-870; Keilitz, J., Radowski, M.R., Marty, J.D., Haag, R., Gauffre, F., Mingotaud, C., (2008) Chem. Mater., 20, pp. 2423-2425; Quadir, M.A., Radowski, M.R., Kratz, F., Licha, K., Hauff, P., Haag, R., (2008) J. Controlled Release, 132, pp. 289-294; Calderón, M., Quadir, M.A., Sharma, S.K., Haag, R., (2010) Adv. Mater., 22, pp. 190-218; Radowski, M.R., Shukla, A., Von Berlepsch, H., Böttcher, C., Pickaert, G., Rehage, H., Haag, R., (2007) Angew. Chem., Int. Ed., 46, pp. 1265-1269; Petersen, H., Fechner, P.M., Fischer, D., Kissel, T., (2002) Macromolecules, 35, pp. 6867-6874; Khandare, J., Mohr, A., Calderón, M., Welker, P., Licha, K., Haag, R., (2010) Biomaterials, 31, pp. 4268-4277; Kainthan, R.K., Janzen, J., Levin, E., Devine, D.V., Brooks, D.E., (2006) Biomacromolecules, 7, pp. 703-709; Huang, Y.-C., Royappa, A.T., Tundel, S., Tsukamoto, K., Sharma, V., (2009) J. Appl. Polym. Sci., 111, pp. 2275-2278; Di Vaira, M., Bazzicalupi, C., Orioli, P., Messori, L., Bruni, B., Zatta, P., (2004) Inorg. Chem., 43, pp. 3795-3797; Zysk, G., Schneider-Wald, B.K., Hwang, J.H., Bejo, L., Kim, K.S., Mitchell, T.J., Hakenbeck, R., Heinz, H.-P., (2001) Infect. Immun., 69, pp. 845-852; Odonohue, J.W., Reid, M.A., Varghese, A., Portmann, B., Williams, R., (1993) Eur. J. Gastroenterol. Hepatol., 5, pp. 561-562; Lippard, S.J., (1999) Science, 284, pp. 748-749; Broussard, G.J., Mytar, J., Li, R.C., Klapstein, G.J., (2012) Inflammopharmacology, 20, pp. 109-126; Li, Z., Wu, S., Han, J., Yang, L., Han, S., (2013) Talanta, 114, pp. 254-260; Balamurugan, K., Schaffner, W., (2006) Biochim. Biophys. Acta, Mol. Cell. Res., 1763, pp. 737-746; Günther, V., Lindert, U., Schaffner, W., (2012) Biochim. Biophys. Acta, Mol. Cell. Res., 1823, pp. 1416-1425; Bayer, T.A., Schafer, S., Simons, A., Kemmling, A., Kamer, T., Tepest, R., Eckert, A., Multhaup, G., (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 14187-14192; Pardridge, W.M., (2007) Drug Discovery Today, 12, pp. 54-61; Giese, H., Mertsch, K., Blasig, I.E., (1995) Neurosci. Lett., 191, pp. 169-172; Lundquist, S., Renftel, M., Brillault, J., Fenart, L., Cecchelli, R., Dehouck, M.P., (2002) Pharm. Res., 19, pp. 976-981; Muruganandam, A., Tanha, J., Narang, S., Stanimirovic, D., (2002) FASEB J., 16, pp. 240-242; Descamps, L., Coisne, C., Dehouck, B., Cecchelli, R., Torpier, G., (2003) Glia, 42, pp. 46-58; Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R.D., Lindmark, T., Österberg, T., (2005) Toxicol. in Vitro, 19, pp. 299-334; Gesuete, R., Zanier, E.R., Orsini, F., Garzetti, L., Deli, M., De Simoni, M.G., (2009) J. Cereb. Blood Flow Metab., 29, pp. 83-S84; Kato, H., Yoshimoto, K., Kobayashi, M., Sakabe, M., Funaki, H., Ikegaya, H., (2010) Eur. J. Pharmacol., 635, pp. 184-187; Abbott, N.J., Ronnback, L., Hansson, E., (2006) Nat. Rev. Neurosci., 7, pp. 41-53; Lu, W., Wan, J., She, Z., Jiang, X., (2007) J. Controlled Release, 118, pp. 38-53; Reddy, L.H., Sharma, R.K., Chuttani, K., Mishra, A.K., Murthy, R.R., (2004) AAPS J., 6, p. 23",Article,Scopus,2-s2.0-84900443924
"Lopez-Iglesias B., Perez C., Morales-Garcia J.A., Alonso-Gil S., Perez-Castillo A., Romero A., Lopez M.G., Villarroya M., Conde S., Rodriguez-Franco M.I.","New melatonin- N, N -dibenzyl(N -methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for alzheimers disease",2014,"Journal of Medicinal Chemistry","57","9",,"3773","3785",,8,10.1021/jm5000613,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900336722&partnerID=40&md5=7396c6a5fb0bae51dd3bc51386e02c24","Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain; Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, C/ Valderrebollo 5, 28031 Madrid, Spain; Instituto Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain; Departamento de Toxicología y Farmacologiá, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain","López-Iglesias, B., Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain; Pérez, C., Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain; Morales-García, J.A., Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, C/ Valderrebollo 5, 28031 Madrid, Spain; Alonso-Gil, S., Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, C/ Valderrebollo 5, 28031 Madrid, Spain; Pérez-Castillo, A., Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, C/ Valderrebollo 5, 28031 Madrid, Spain; Romero, A., Instituto Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain, Departamento de Toxicología y Farmacologiá, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain; López, M.G., Instituto Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain; Villarroya, M., Instituto Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid, Spain; Conde, S., Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain; Rodríguez-Franco, M.I., Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain","Here, we describe a new family of melatonin-N,N-dibenzyl(N-methyl)amine hybrids that show a balanced multifunctional profile covering neurogenic, antioxidant, cholinergic, and neuroprotective properties at low-micromolar concentrations. They promote maturation of neural stem cells into a neuronal phenotype and thus they could contribute to CNS repair. They also protect neural cells against mitochondrial oxidative stress, show antioxidant properties, and inhibit human acetylcholinesterase (AChE). Moreover, they displace propidium from the peripheral anionic site of AChE, preventing the β-amyloid aggregation promoted by AChE. In addition, they show low cell toxicity and can penetrate into the CNS. This multifunctional profile highlights these melatonin-N,N-dibenzyl(N-methyl)amine hybrids as useful prototypes in the research of innovative drugs for Alzheimers disease. © 2014 American Chemical Society.",,"Sloane, P.D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., Sudha, S., The public health impact of Alzheimers disease, 2000-2050: Potential implication of treatment advances (2002) Annu. Rev. Public Health, 23, pp. 213-231; Querfurth, H.W., Laferla, F.M., Alzheimers disease (2010) N. Engl. J. Med., 362, pp. 329-344; Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Hyde, C., The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease (review of technology appraisal no. 111): A systematic review and economic model (2012) Health Technol. Assess., 16, pp. 1-470; Wilkinson, D., Wirth, Y., Goebel, C., Memantine in patients with moderate to severe Alzheimers disease: Meta-analyses using realistic definitions of response (2013) Dementia Geriatr. Cognit. Disord., 37, pp. 71-85; Inestrosa, N.C., Dinamarca, M.C., Alvarez, A., Amyloid-cholinesterase interactions. Implications for Alzheimers disease (2008) FEBS J., 275, pp. 625-632; Rees, T., Hammond, P.I., Soreq, H., Younkin, S., Brimijoin, S., Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex (2003) Neurobiol. Aging, 24, pp. 777-787; De Ferrari, G.V., Canales, M.A., Shin, I., Weiner, L.M., Silman, I., Inestrosa, N.C., A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation (2001) Biochemistry, 40, pp. 10447-10457; Bartolini, M., Bertucci, C., Cavrini, V., Andrisano, V., Beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies (2003) Biochem. Pharmacol., 65, pp. 407-416; Viayna, E., Sabate, R., Muoz-Torrero, D., Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates (2013) Curr. Top. Med. Chem., 13, pp. 1820-1842; García-Palomero, E., Muoz, P., Usán, P., García, P., Delgado, E., De Austria, C., Valenzuela, R., Martinez, A., Potent beta-amyloid modulators (2008) Neurodegener. Dis., 5, pp. 153-156; Spuch, C., Antequera, D., Fernández-Bachiller, M.I., Rodríguez-Franco, M.I., Carro, E., A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimers disease (2010) Neurotoxic. Res., 17, pp. 421-431; Antequera, D., Bolos, M., Spuch, C., Pascual, C., Ferrer, I., Fernández- Bachiller, M.I., Rodríguez-Franco, M.I., Carro, E., Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Abeta accumulation and cell death: Involvement in hippocampal neuronal loss in Alzheimers disease (2012) Neurobiol. Dis., 46, pp. 682-691; Lorrio, S., Gómez-Rangel, V., Negredo, P., Egea, J., León, R., Romero, A., Dal-Cim, T., López, M.G., Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia (2013) Neuropharmacology, 67, pp. 403-411; Ansari, M.A., Scheff, S.W., Oxidative stress in the progression of Alzheimer disease in the frontal cortex (2010) J. Neuropathol. Exp. Neurol., 69, pp. 155-167; Gu, F., Zhu, M., Shi, J., Hu, Y., Zhao, Z., Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice (2008) Neurosci. Lett., 440, pp. 44-48; Caldeira, G.L., Ferreira, I.L., Rego, A.C., Impaired transcription in Alzheimers disease: Key role in mitochondrial dysfunction and oxidative stress (2013) J. Alzheimers Dis., 34, pp. 115-131; Huang, Q., Aluise, C.D., Joshi, G., Sultana, R., St Clair, D.K., Markesbery, W.R., Butterfield, D.A., Potential in vivo amelioration by N-acetyl- l -cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: Toward therapeutic modulation of mild cognitive impairment (2010) J. Neurosci. Res., 88, pp. 2618-2629; Altman, J., Are new neurons formed in the brains of adult mammals? (1962) Science, 135, pp. 1127-1128; Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, D.A., Gage, F.H., Neurogenesis in the adult human hippocampus (1998) Nat. Med., 4, pp. 1313-1317; Spalding, K.L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H.B., Boström, E., Frisén, J., Dynamics of hippocampal neurogenesis in adult humans (2013) Cell, 153, pp. 1219-1227; Abdipranoto, A., Wu, S., Stayte, S., Vissel, B., The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development (2008) CNS Neurol. Disord.: Drug Targets, 7, pp. 187-210; Bubenik, G.A., Konturek, S.J., Melatonin and aging: Prospects for human treatment (2011) J. Physiol. Pharmacol., 62, pp. 13-19; Reiter, R.J., Manchester, L.C., Tan, D.X., Neurotoxins: Free radical mechanisms and melatonin protection (2010) Curr. Neuropharmacol., 8, pp. 194-210; Reiter, R.J., Oxidative damage in the central nervous system: Protection by melatonin (1998) Prog. Neurobiol., 56, pp. 359-384; Pandi-Perumal, S.R., Bahammam, A.S., Brown, G.M., Spence, D.W., Bharti, V.K., Kaur, C., Hardeland, R., Cardinali, D.P., Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes (2013) Neurotoxic. Res., 23, pp. 267-300; Lin, L., Huang, Q.X., Yang, S.S., Chu, J., Wang, J.Z., Tian, Q., Melatonin in Alzheimers disease (2013) Int. J. Mol. Sci., 14, pp. 14575-14593; Ramírez-Rodríguez, G., Klempin, F., Babu, H., Benítez-King, G., Kempermann, G., Melatonin modulates cell survival of new neurons in the hippocampus of adult mice (2009) Neuropsychopharmacology, 34, pp. 2180-2191; Domínguez-Alonso, A., Ramírez-Rodríguez, G., Benítez-King, G., Melatonin increases dendritogenesis in the hilus of hippocampal organotypic cultures (2012) J. Pineal Res., 52, pp. 427-436; Liu, J., Somera-Molina, K.C., Hudson, R.L., Dubocovich, M.L., Melatonin potentiates running wheel-induced neurogenesis in the dentate gyrus of adult C3H/HeN mice hippocampus (2013) J. Pineal Res., 54, pp. 222-231; Morphy, R., Rankovic, Z., Designed multiple ligands. An emerging drug discovery paradigm (2005) J. Med. Chem., 48, pp. 6523-6543; Cavalli, A., Bolognesi, M.L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., Melchiorre, C., Multi-target-directed ligands to combat neurodegenerative diseases (2008) J. Med. Chem., 51, pp. 347-372; León, R., García, A.G., Marco-Contelles, J., Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimers disease (2013) Med. Res. Rev., 33, pp. 139-189; Cavalli, A., Bolognesi, M.L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Melchiorre, C., A small molecule targeting the multifactorial nature of Alzheimers disease (2007) Angew. Chem., Int. Ed., 46, pp. 3689-3692; Capurro, V., Busquet, P., Lopes, J.P., Bertorelli, R., Tarozzo, G., Bolognesi, M.L., Piomelli, D., Cavalli, A., Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimers disease (2013) PLoS One, 8, pp. 568701-e568708; Weinreb, O., Amit, T., Bar-Am, O., Youdim, M.B., Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimers disease treatment (2012) Curr. Drug Targets, 13, pp. 483-494; Viayna, E., Gómez, T., Galdeano, C., Ramírez, L., Ratia, M., Badía, A., Clos, M.V., Muoz-Torrero, D., Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates (2010) ChemMedChem., 5, pp. 1855-1870; Ratia, M., Giménez-Llort, L., Camps, P., Muoz-Torrero, D., Pérez, B., Clos, M.V., Badía, A., Huprine, X., And huperzine A improve cognition and regulate some neurochemical processes related with Alzheimers disease in triple transgenic mice (3xTg-AD) (2013) Neurodegener. Dis., 11, pp. 129-140; Fernández-Bachiller, M.I., Pérez, C., Monjas, L., Rademann, J., Rodríguez-Franco, M.I., New tacrine-4-oxo-4 H -chromene hybrids as multifunctional agents for the treatment of Alzheimers disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties (2012) J. Med. Chem., 55, pp. 1303-1317; Fernández-Bachiller, M.I., Pérez, C., González-Muoz, G.C., Conde, S., López, M.G., Villarroya, M., García, A.G., Rodríguez-Franco, M.I., Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties (2010) J. Med. Chem., 53, pp. 4927-4937; Arce, M.P., Rodríguez-Franco, M.I., González-Muoz, G.C., Pérez, C., López, B., Villarroya, M., López, M.G., Conde, S., Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimers disease (2009) J. Med. Chem., 52, pp. 7249-7257; Rodríguez-Franco, M.I., Fernández-Bachiller, M.I., Pérez, C., Hernández-Ledesma, B., Bartolomé, B., Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties (2006) J. Med. Chem., 49, pp. 459-462; Fernández-Bachiller, M.I., Pérez, C., Campillo, N.E., Páez, J.A., González-Muoz, G.C., Usán, P., García-Palomero, E., Rodríguez-Franco, M.I., Tacrine-melatonin hybrids as multifunctional agents for Alzheimers disease, with cholinergic, antioxidant, and neuroprotective properties (2009) ChemMedChem., 4, pp. 828-841; Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Recanatini, M., 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2 H -2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: A dual function lead for Alzheimers disease therapy (2003) J. Med. Chem., 46, pp. 2279-2282; Piazzi, L., Cavalli, A., Belluti, F., Bisi, A., Gobbi, S., Rizzo, S., Bartolini, M., Rampa, A., Extensive SAR and computational studies of 3-{4-[(benzylmethylamino) methyl]phenyl}-6,7-dimethoxy-2 H -2-chromenone (AP2238) derivatives (2007) J. Med. Chem., 50, pp. 4250-4254; Rizzo, S., Bartolini, M., Ceccarini, L., Piazzi, L., Gobbi, S., Cavalli, A., Recanatini, M., Rampa, A., Targeting Alzheimers disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238 (2010) Bioorg. Med. Chem., 18, pp. 1749-1760; Gilman, H., Bailie, J.C., Relative reactivities of organometallic compounds. XVII. the azo linkage (1937) J. Org. Chem., 2, pp. 84-94; Ellman, G.L., Courtney, K.D., Andres, Jr.V., Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity (1961) Biochem. Pharmacol., 7, pp. 88-95; Brunhofer, G., Fallarero, A., Karlsson, D., Batista-Gonzalez, A., Shinde, P., Gopi Mohan, C., Vuorela, P., Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine (2012) Bioorg. Med. Chem., 20, pp. 6669-6679; Di Pietro, O., Viayna, E., Vicente-García, E., Bartolini, M., Ramón, R., Juárez-Jiménez, J., Clos, M.V., Muoz-Torrero, D., 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: Synthesis, pharmacological evaluation and mechanistic studies (2014) Eur. J. Med. Chem., 73, pp. 141-152; Taylor, P., Lappi, S., Interaction of fluorescence probes with acetylcholinesterase. the site and specificity of propidium binding (1975) Biochemistry, 14, pp. 1989-1997; Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., High throughput artificial membrane permeability assay for blood-brain barrier (2003) Eur. J. Med. Chem., 38, pp. 223-232; Dávalos, A., Gómez-Cordovés, C., Bartolomé, B., Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay (2004) J. Agric. Food Chem., 52, pp. 48-54; Sofic, E., Rimpapa, Z., Kundurovic, Z., Sapcanin, A., Tahirovic, I., Rustembegovic, A., Cao, G., Antioxidant capacity of the neurohormone melatonin (2005) J. Neural Transm., 112, pp. 349-358; Egea, J., Rosa, A.O., Cuadrado, A., García, A.G., López, M.G., Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress (2007) J. Neurochem., 102, pp. 1842-1852; Maroto, R., De La Fuente, M.T., Artalejo, A.R., Abad, F., López, M.G., García-Sancho, J., García, A.G., Effects of Ca2+ channel antagonists on chromaffin cell death and cytosolic Ca2+ oscillations induced by veratridine (1994) Eur. J. Pharmacol., 270, pp. 331-339; Ferrón, S.R., Andreu-Agullo, C., Mira, H., Sánchez, P., Marqués-Torrejón, M.A., Farinas, I., A combined ex/in vivo assay to detect effects of exogenously added factors in neural stem cells (2007) Nat. Protoc., 2, pp. 849-859; Morales-García, J.A., Luna-Medina, R., Alfaro-Cervello, C., Cortes-Canteli, M., Santos, A., García-Verdugo, J.M., Pérez-Castillo, A., Peroxisome proliferator-activated receptor gamma ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo (2011) Glia, 59, pp. 293-307; Morales-García, J.A., Luna-Medina, R., Alonso-Gil, S., Sanz-Sancristóbal, M., Palomo, V., Gil, C., Santos, A., Pérez-Castillo, A., Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo (2012) ACS Chem. Neurosci., 3, pp. 963-971; Ou, B., Hampsch-Woodill, M., Prior, R.L., Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe (2001) J. Agric. Food Chem., 49, pp. 4619-4626; Denizot, F., Lang, R., Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability (1986) J. Immunol. Methods, 89, pp. 271-277",Article,Scopus,2-s2.0-84900336722
"Colomb J., Becker G., Fieux S., Zimmer L., Billard T.","Syntheses, radiolabelings, and in vitro evaluations of fluorinated pet radioligands of 5-HT6 serotoninergic receptors",2014,"Journal of Medicinal Chemistry","57","9",,"3884","3890",,2,10.1021/jm500372e,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900306946&partnerID=40&md5=2b1cd7fac45fe9601b583f6a0b51b1be","Institute of Chemistry and Biochemistry (ICBMS-UMR CNRS 5246), University of Lyon, CNRS, 43 Boulevard du 11 Novembre 1918, 69622 Lyon, France; Lyon Neuroscience Research Center (UMR 5292 U 1028), University of Lyon, INSERM, 59 Boulevard Pinel, 69003 Lyon, France; CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France; Hospices Civils de Lyon, Neurological Hospital, 59 Boulevard Pinel, 69003 Lyon, France","Colomb, J., Institute of Chemistry and Biochemistry (ICBMS-UMR CNRS 5246), University of Lyon, CNRS, 43 Boulevard du 11 Novembre 1918, 69622 Lyon, France, CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France; Becker, G., Lyon Neuroscience Research Center (UMR 5292 U 1028), University of Lyon, INSERM, 59 Boulevard Pinel, 69003 Lyon, France, CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France, Hospices Civils de Lyon, Neurological Hospital, 59 Boulevard Pinel, 69003 Lyon, France; Fieux, S., Lyon Neuroscience Research Center (UMR 5292 U 1028), University of Lyon, INSERM, 59 Boulevard Pinel, 69003 Lyon, France, CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France; Zimmer, L., Lyon Neuroscience Research Center (UMR 5292 U 1028), University of Lyon, INSERM, 59 Boulevard Pinel, 69003 Lyon, France, CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France, Hospices Civils de Lyon, Neurological Hospital, 59 Boulevard Pinel, 69003 Lyon, France; Billard, T., Institute of Chemistry and Biochemistry (ICBMS-UMR CNRS 5246), University of Lyon, CNRS, 43 Boulevard du 11 Novembre 1918, 69622 Lyon, France, CERMEP-In Vivo Imaging, Groupement Hospitalier Est, 59 Boulevard Pinel, 69003 Lyon, France","The 5-HT6 receptors are potent therapeutic targets for psychiatric and neurological diseases (schizophrenia, Alzheimers disease, etc.). However, with lack of specific radiopharmaceuticals, their pharmacology is still incomplete and their exploration is limited to animal models. In this context, we have designed a fluorinated PET radiotracer, [18F]2FNQ1P, that possesses a high affinity and selectivity for 5-HT6. In vitro PET autoradiographies in rat brain sections with this radiotracer were in accordance with the 5-HT6 distribution pattern. © 2014 American Chemical Society.",,"Monsma, Jr.F.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R., Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs (1993) Mol. Pharmacol., 43, pp. 320-327; Ruat, M., Traiffort, E., Arrang, J.M., Tardivel-Lacombe, J., Diaz, J., Leurs, R., Schwartz, J.C., A novel rat serotonin (5-HT6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation (1993) Biochem. Biophys. Res. Commun., 193, pp. 268-276; Kohen, R., Metcalf, M.A., Khan, N., Druck, T., Huebner, K., Lachowicz, J.E., Meltzer, H.Y., Hamblin, M.W., Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor (1996) J. Neurochem., 66, pp. 47-56; Boess, F.G., Riemer, C., Bos, M., Bentley, J., Bourson, A., Sleight, A.J., The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum (1998) Mol. Pharmacol., 54, pp. 577-583; Roberts, J.C., Reavill, C., East, S.Z., Harrison, P.J., Patel, S., Routledge, C., Leslie, R.A., The distribution of 5-HT(6) receptors in rat brain: An autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585 (2002) Brain Res., 934, pp. 49-57; East, S.Z., Burnet, P.W., Leslie, R.A., Roberts, J.C., Harrison, P.J., 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: Autoradiographic studies with [125I]SB-258585 (2002) Synapse, 45, pp. 191-199; Holenz, J., Pauwels, P.J., Díaz, J.L., Merc, R., Codony, X., Buschmann, H., Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents (2006) Drug Discovery Today, 11, pp. 283-299; Marazziti, D., Baroni, S., Borsini, F., Picchetti, M., Vatteroni, E., Falaschi, V., Catena-Dellosso, M., Serotonin receptors of type 6 (5-HT6): From neuroscience to clinical pharmacology (2013) Curr. Med. Chem., 20, pp. 371-377; Heckl, S., Pipkorn, R., Nagele, T., Vogel, U., Kuker, W., Voight, K., Molecular imaging: Bridging the gap between neuroradiology and neurohistology (2004) Histol. Histopathol., 19, pp. 651-668; Lancelot, S., Zimmer, L., Small-animal positron emission tomography as a tool for neuropharmacology (2010) Trends Pharmacol. Sci., 31, pp. 411-417; Zimmer, L., Luxen, A., PET radiotracers for molecular imaging in the brain: Past, present and future (2012) Neuroimage, 61, pp. 363-370; Lee, C.M., Farde, L., Using positron emission tomography to facilitate CNS drug development (2006) Trends Pharmacol. Sci., 27, pp. 310-316; Kim, H.J., Doddareddy, M.R., Choo, H., Cho, Y.S., No, K.T., Park, W.K., Pae, A.N., New serotonin 5-HT6 ligands from common feature pharmacophore hypotheses (2008) J. Chem. Inf. Model., 48, pp. 197-206; Shireman, B.T., Bonaventure, P., Carruthers, N.I., Recent advances on the 5-HT5A, 5-HT6 and 5-HT7 receptors (2008) Annu. Rep. Med. Chem., 43, pp. 25-42; Glennon, R.A., Higher-end serotonin receptors: 5-HT5, 5-HT6, and 5-HT7 (2003) J. Med. Chem., 46, pp. 2795-2812; Ivachtchenko, A.V., Ivanenkov, Y.A., Small molecule 5-HT6R ligands: A comprehensive insight into their selectivity and activity (2013) Curr. Bioact. Compd., 9, pp. 64-100; Vázquez-Villa, H., González-Vera, J.A., Benhamú, B., Viso, A., Fernández De La Pradilla, R., Junquera, E., Aicart, E., Ortega-Gutiérrez, S., Development of molecular probes for the human 5-HT6 receptor (2010) J. Med. Chem., 53, pp. 7095-7106; Johnson, C.N., Moss, S.F., Witty, D.R., (2005) Preparation of Piperazinyl-quinoline Derivatives Useful for the Treatment of CNS Disorders, , WO2005030724A1; Gee, A.D., Martarello, L., Johnson, C.N., Witty, D.R., (2006) Preparation of Isotopomeric Piperazine-containing Ligands Labeling and Diagnostic Imaging of 5-HT6 Receptors, , WO2006053785A1; Martarello, L., Ahmed, M., Chuang, A.T., Cunningham, V.J., Jakobsen, S., Johnson, C.N., Matthews, J.C., Gee, A.D., Radiolabelling and in vivo evaluation of [11C]GSK215083 as a potential 5-HT6 pet radioligand in the porcine brain (2005) J. Labelled Compd. Radiopharm., 48, p. 7; Ward, R.P., Dorsa, D.M., Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum (1996) J. Comp. Neurol., 370, pp. 405-414; Parker, C.A., Gunn, R.N., Rabiner, E.A., Slifstein, M., Comley, R., Salinas, C., Johnson, C.N., Martarello, L., Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor (2012) J. Nucl. Med., 53, pp. 295-303; Liu, F., Majo, V.J., Prabhakaran, J., Milak, M.S., John Mann, J., Parsey, R.V., Kumar, J.S., Synthesis and in vivo evaluation of [ O -methyl-11C] N -[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl) benzenesulfonamide as an imaging probe for 5-HT6 receptors (2011) Bioorg. Med. Chem., 19, pp. 5255-5259; Zhang, L., Villalobos, A., Anderson, D., Beck, E., Blumberg, L., Bocan, T., Bronk, B., Zasadny, K., Development of design and selection parameters to accelerate the discovery process of novel CNS PET ligands and their application in the identification of a potential 5HT6 PET ligand [11C]PF-1 (2011) J. Labelled Compd. Radiopharm., 54, p. 292; Rosse, G., Quinoline derivatives as 5-HT6 receptor PET ligands (2014) ACS Med. Chem. Lett., 5, pp. 275-276; Black, L.A., (2013) Radiolabeled 5-HT6 Ligands, , US20130343993A1; Tang, S., Verdurand, M., Joseph, B., Lemoine, L., Daoust, A., Billard, T., Fournet, G., Zimmer, L., Synthesis and biological evaluation in rat and cat of [ 18F]12ST05 as a potential 5-HT6 PET radioligand (2007) Nucl. Med. Biol., 34, pp. 995-1002; Bojarski, A.J., Pharmacophore models for metabotropic 5-HT receptor ligands (2006) Curr. Top. Med. Chem., 6, pp. 2005-2026; Ahmed, M., Johnson, C.N., Jones, M.C., Macdonald, G.J., Moss, S.F., Thompson, M., Wade, C.E., Witty, D., (2003) Preparation of Arylsulfonyl(diazacycloalkyl)quinolines for Treatment of CNS Disorders, , WO2003080580A2; Barillari, C., Brown, N., Classical Bioisosteres (2012) Bioisosteres in Medicinal Chemistry, pp. 15-29. , Brown, N. Wiley: Weinheim, Germany; Suzuki, H., Abe, H., Copper-assisted displacement reaction of nonactivated lodoarenes with arenesulfinates. Convenient alternative synthesis of unsymmetrical diaryl sulfones (1995) Tetrahedron Lett., 36, pp. 6239-6242; Baskin, J.M., Wang, Z., An efficient copper catalyst for the formation of sulfones from sulfinic acid salts and aryl iodides (2002) Org. Lett., 4, pp. 4423-4425; Zhu, W., Ma, D., Synthesis of aryl sulfones via l-proline-promoted CuI-catalyzed coupling reaction of aryl halides with sulfinic acid salts (2005) J. Org. Chem., 70, pp. 2696-2700; Cacchi, S., Fabrizi, G., Goggiamani, A., Parisi, L.M., An efficient palladium-catalyzed synthesis of unsymmetrical diaryl sulfones from aryl bromides/triflates and arenesulfinates (2003) Synlett, 2003, pp. 361-364; Colomb, J., Billard, T., Palladium-catalyzed desulfitative arylation of 3-haloquinolines with arylsulfinates (2013) Tetrahedron Lett., 54, pp. 1471-1474; Sperotto, E., Van Klink, G.P.M., De Vries, J.G., Van Koten, G., Ligand-free copper-catalyzed C-S coupling of aryl iodides and thiols (2008) J. Org. Chem., 73, pp. 5625-5628; Old, D.W., Wolfe, J.P., Buchwald, S.L., A highly active catalyst for palladium-catalyzed cross-coupling reactions: Room-temperature Suzuki couplings and amination of unactivated aryl chlorides (1998) J. Am. Chem. Soc., 120, pp. 9722-9723; Shen, Q., Ogata, T., Hartwig, J.F., Highly reactive, general and long-lived catalysts for palladium-catalyzed amination of heteroaryl and aryl chlorides, bromides, and iodides: Scope and structure-activity relationships (2008) J. Am. Chem. Soc., 130, pp. 6586-6596; Mitchell, E.S., Neumaier, J.F., 5-HT6 receptors: A novel target for cognitive enhancement (2005) Pharmacol. Ther., 108, pp. 320-333; Clark, D.E., In silico prediction of blood-brain barrier permeation (2003) Drug Discovery Today, 8, pp. 927-933; Norinder, U., Haeberlein, M., Computational approaches to the prediction of the blood-brain distribution (2002) Adv. Drug Delivery Rev., 54, pp. 291-313; Kelder, J., Grootenhuis, P.D.J., Bayada, D.M., Delbressine, L.P.C., Ploemen, J.-P., Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs (1999) Pharm. Res., 16, pp. 1514-1519; Andries, J., Lemoine, L., Le Bars, D., Zimmer, L., Billard, T., Synthesis and biological evaluation of potential 5-HT7 receptor PET radiotracers (2011) Eur. J. Med. Chem., 46, pp. 3455-3461; Le Bars, D., Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography (2006) J. Fluorine Chem., 127, pp. 1488-1493; Le Bars, D., Lemaire, C., Ginovart, N., Plenevaux, A., Aerts, J., Brihaye, C., Hassoun, W., Comar, D., High-yield radiosynthesis and preliminary in vivo evaluation of p-[ 18F]MPPF, a fluoro analog of WAY-100635 (1998) Nucl. Med. Biol., 25, pp. 343-350; Hirst, W.D., Minton, J.A.L., Bromidge, S.M., Moss, S.F., Latter, A.J., Riley, G., Routledge, C., Price, G.W., Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue (2000) Br. J. Pharmacol., 130, pp. 1597-1605; Sharman, J.L., Benson, H.E., Pawson, A.J., Lukito, V., Mpamhanga, C.P., Bombail, V., Davenport, A.P., Harmar, A.J., IUPHAR-DB: Updated database content and new features (2013) Nucleic Acids Res., 41, pp. 1083-D1088; Lemaire, C., Plenevaux, A., Aerts, J., Del Fiore, G., Brihaye, C., Le Bars, D., Comar, D., Luxen, A., Solid phase extraction - An alternative to the use of rotary evaporators for solvent removal in the rapid formulation of PET radiopharmaceuticals (1999) J. Labelled Compd. Radiopharm., 42, pp. 63-75",Article,Scopus,2-s2.0-84900306946
"Ali-Torres J., Mirats A., Marechal J.-D., Rodriguez-Santiago L., Sodupe M.","3D structures and redox potentials of Cu2+-Aβ(1-16) complexes at different pH: A computational study",2014,"Journal of Physical Chemistry B","118","18",,"4840","4850",,2,10.1021/jp5019718,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900296732&partnerID=40&md5=58c73faecc060ec6b12f22e06b44c0cc","Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain","Alí-Torres, J., Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain; Mirats, A., Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain; Maréchal, J.-D., Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain; Rodríguez-Santiago, L., Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain; Sodupe, M., Departament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain","Oxidative stress induced by redox-active metal cations such as Cu 2+ is a key event in the development of Alzheimers disease. A detailed knowledge of the structure of Cu2+-Aβ complex is thus important to get a better understanding of this critical process. In the present study, we use a computational approach that combines homology modeling with quantum-mechanics-based methods to determine plausible 3D structures of Cu 2+-Aβ(1-16) complexes that enclose the different metal coordination spheres proposed experimentally at different pH values. With these models in hand, we determine their standard reduction potential (SRP) with the aim of getting new insights into the relation between the structure of these complexes and their redox behavior. Results show that in all cases copper reduction induces CObackbone decoordination, which, for distorted square planar structures in the oxidized state (Ia-δδ, IIa-εδε, IIa-εεε, and IIc-ε), leads to tricoordinated species. For the pentacoordinated structural candidate Ib-δε with Glu11 at the apical position, the reduction leads to a distorted tetrahedral structure. The present results highlight the importance of the nature of the ligands on the SRP. The computed values (with respect to the standard hydrogen electrode) for complexes enclosing negatively charged ligands in the coordination sphere (from -0.81 to -0.12 V) are significantly lower than those computed for models involving neutral ligands (from 0.19 to 0.28 V). Major geometry changes induced by reduction, on both the metal site and the peptide configuration, are discussed as well as their possible influence in the formation of reactive oxygen species. © 2014 American Chemical Society.",,"(2014), http://www.alz.org/downloads/facts_figures_2014.pdf, Alzheimers Association, Alzheimers Disease Facts and Figures. (accessed 4/10/)Hardy, J., Selkoe, D.J., The Amyloid Hypothesis of Alzheimers Disease: Progress and Problems on the Road to Therapeutics (2002) Science, 297 (5580), pp. 353-356; Selkoe, D.J., Alzheimers Disease: Genes, Proteins, and Therapy (2001) Physiol. Rev., 81 (2), pp. 741-766; Markesbery, W.R., Oxidative Stress Hypothesis in Alzheimers Disease (1997) Free Radicals Biol. Med., 23 (1), pp. 134-147; Gaggelli, E., Kozlowski, H., Valensin, D., Valensin, G., Copper Homeostasis and Neurodegenerative Disorders (Alzheimers, Prion, and Parkinsons Diseases and Amyotrophic Lateral Sclerosis) (2006) Chem. Rev., 106 (6), pp. 1995-2044; Bush, A.I., The Metallobiology of Alzheimers Disease (2003) Neurosciences, 26 (4), pp. 207-214; Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Shimohama, S., Oxidative Damage is the Earliest Event in Alzheimer Disease (2001) J. Neuropathol. Exp. Neurol., 60 (8), pp. 759-767; Mecocci, P., Macgarvey, U., Kaufman, A.E., Koontz, D., Shoffner, J.M., Wallace, D.C., Beal, M.F., Oxidative Damage to Mitochondrial-DNA Shows Marked Age-dependent Increases in Human Brain (1993) Ann. Neurol., 34 (4), pp. 609-616; Huang, X.D., Cuajungco, M.P., Atwood, C.S., Hartshorn, M.A., Tyndall, J.D.A., Hanson, G.R., Stokes, K.C., Goldstein, L.E., Cu(II) Potentiation of Alzheimer A Beta Neurotoxicity -Correlation with Cell-free Hydrogen Peroxide Production and Metal Reduction (1999) J. Biol. Chem., 274 (52), pp. 37111-37116; Opazo, C., Huang, X., Cherny, R.A., Moir, R.D., Roher, A.E., White, A.R., Cappai, R., Inestrosa, N.C., Metalloenzyme-like Activity of Alzheimers Disease Beta -amyloid (2002) J. Biol. Chem., 277 (43), pp. 40302-40308; Barnham, K.J., Masters, C.L., Bush, A.I., Neurodegenerative Diseases and Oxidative Stress (2004) Nat. Rev. Drug Discovery, 3 (3), pp. 205-214; Hewitt, N., Rauk, A., Mechanism of Hydrogen Peroxide Production by Copper-Bound Amyloid Beta Peptide: A Theoretical Study (2009) J. Phys. Chem. B, 113 (4), pp. 1202-1209; Jiang, D.L., Li, X.J., Williams, R., Patel, S., Men, L.J., Wang, Y.S., Zhou, F.M., Ternary Complexes of Iron, Amyloid-beta, and Nitrilotriacetic Acid: Binding Affinities, Redox Properties, and Relevance to Iron-Induced Oxidative Stress in Alzheimers Disease (2009) Biochemistry, 48 (33), pp. 7939-7947; Jiang, D.L., Men, L.J., Wang, J.X., Zhang, Y., Chickenyen, S., Wang, Y.S., Zhou, F.M., Redox Reactions of Copper Complexes Formed with Different Beta-amyloid Peptides and their Neuropathalogical Relevance (2007) Biochemistry, 46 (32), pp. 9270-9282; Ali-Torres, J., Rodriguez-Santiago, L., Sodupe, M., Rauk, A., Structures and Stabilities of Fe(2+/3+) Complexes Relevant to Alzheimers Disease: An ab Initio Study (2011) J. Phys. Chem. A, 115 (45), pp. 12523-12530; Guilloreau, L., Combalbert, S., Sournia-Saquet, A., Mazarguil, H., Faller, P., Redox Chemistry of Copper-amyloid-beta: The Generation of Hydroxyl Radical in the Presence of Ascorbate is Linked to Redox-potentials and Aggregation State (2007) ChemBioChem., 8 (11), pp. 1317-1325; Balland, V., Hureau, C., Saveant, J.-M., Electrochemical and Homogeneous Electron Transfers to the Alzheimer Amyloid-beta Copper Complex Follow a Preorganization Mechanism (2010) Proc. Natl. Acad. Sci. U.S.A., 107 (40), pp. 17113-17118; Barnham, K.J., Haeffner, F., Ciccotosto, G.D., Curtain, C.C., Tew, D., Mavros, C., Beyreuther, K., Cherny, R.A., Tyrosine Gated Electron Transfer is Key to the Toxic Mechanism of Alzheimers Disease Beta -amyloid (2004) FASEB J., 18 (12), pp. 1427-1429; Sanaullah, G.S.W., Glass, R.S., The Effect of pH and Complexation of Amino Acid Functionality on the Redox Chemistry of Methionine and X-ray Structure of (Co(en)-2(L-Met))(ClO-4)-2. H-20 (1994) J. Inorg. Biochem., 55 (2), pp. 87-99; Nelson, D.L., Cox, M.M., (2005) Lehninger Principles of Biochemistry, , W. H. Freeman: New York; Azimi, S., Rauk, A., On the Involvement of Copper Binding to the N-terminus of the Amyloid Beta Peptide of Alzheimers Disease: A Computational Study on Model Systems (2011) Int. J. Alzheimers Dis., 2011, p. 539762; Liu, L., Jiang, D., Mcdonald, A., Hao, Y., Millhauser, G.L., Zhou, F., Copper Redox Cycling in the Prion Protein Depends Critically on Binding Mode (2011) J. Am. Chem. Soc., 133 (31), pp. 12229-12237; Hou, L.M., Zagorski, M.G., NMR Reveals Anomalous Copper(II) Binding to the Amyloid A Beta Peptide of Alzheimers Disease (2006) J. Am. Chem. Soc., 128 (29), pp. 9260-9261; Parthasarathy, S., Long, F., Miller, Y., Xiao, Y., Mcelheny, D., Thurber, K., Ma, B., Ishii, Y., Molecular-Level Examination of Cu2+ Binding Structure for Amyloid Fibrils of 40-Residue Alzheimers by Solid-State NMR Spectroscopy (2011) J. Am. Chem. Soc., 133 (10), pp. 3390-3400; Curtain, C.C., Ali, F., Volitakis, I., Cherny, R.A., Norton, R.S., Beyreuther, K., Barrow, C.J., Barnham, K.J., Alzheimers Disease Amyloid-beta Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits (2001) J. Biol. Chem., 276 (23), pp. 20466-20473; Drew, S.C., Masters, C.L., Barnham, K.J., Alanine-2 Carbonyl is an Oxygen Ligand in Cu2+ Coordination of Alzheimers Disease Amyloid-β Peptide -Relevance to N-Terminally Truncated Forms (2009) J. Am. Chem. Soc., 131 (25), pp. 8760-8761; Drew, S.C., Noble, C.J., Masters, C.L., Hanson, G.R., Barnham, K.J., Pleomorphic Copper Coordination by Alzheimers Disease Amyloid-beta Peptide (2009) J. Am. Chem. Soc., 131 (3), pp. 1195-1207; Guilloreau, L., Damian, L., Coppel, Y., Mazarguil, H., Winterhalter, M., Faller, P., Structural and Thermodynamical Properties of Cu-II Amyloid-beta 16/28 Complexes Associated with Alzheimers Disease (2006) J. Biol. Inorg. Chem., 11 (8), pp. 1024-1038; Karr, J.W., Akintoye, H., Kaupp, L.J., Szalai, V.A., N-Terminal Deletions Modify the Cu2+ Binding Site in Amyloid-beta (2005) Biochemistry, 44 (14), pp. 5478-5487; Miura, T., Suzuki, K., Kohata, N., Takeuchi, H., Metal Binding Modes of Alzheimers Amyloid beta -Peptide in Insoluble Aggregates and Soluble Complexes (2000) Biochemistry, 39 (23), pp. 7024-7031; Streltsov, V., X-ray Absorption and Diffraction Studies of the Metal Binding Sites in Amyloid Beta-peptide (2008) Eur. Biophys. J. Biophys. Lett., 37 (3), pp. 257-263; Streltsov, V.A., Titmuss, S.J., Epa, V.C., Barnham, K.J., Masters, C.L., Varghese, J.N., The Structure of the Amyloid-beta Peptide High-affinity Copper II Binding Site in Alzheimer Disease (2008) Biophys. J., 95 (7), pp. 3447-3456; Syme, C.D., Nadal, R.C., Rigby, S.E.J., Viles, J.H., Copper Binding to the Amyloid-beta (Abeta) Peptide Associated with Alzheimers Disease: Folding, coordination Geometry, pH Dependence, Stoichiometry, and Affinity of Abeta -(1-28): Insights from a Range of Complementary Spectroscopic Techniques (2004) J. Biol. Chem., 279 (18), pp. 18169-18177; Hureau, C., Coppel, Y., Dorlet, P., Solari, P.L., Sayen, S., Guillon, E., Sabater, L., Faller, P., Deprotonation of the Asp1Ala2 Peptide Bond Induces Modification of the Dynamic Copper(II) Environment in the Amyloid-β Peptide near Physiological pH (2009) Angew. Chem., Int. Ed., 48 (50), pp. 9522-9525; Dorlet, P., Gambarelli, S., Faller, P., Hureau, C., Pulse EPR Spectroscopy Reveals the Coordination Sphere of Copper(II) Ions in the 1-16 Amyloid-beta Peptide: A Key Role of the First Two N-Terminus Residues (2009) Angew. Chem., Int. Ed., 48 (49), pp. 9273-9276; Drew, S.C., Barnham, K.J., The Heterogeneous Nature of Cu2+ Interactions with Alzheimers Amyloid-beta Peptide (2011) Acc. Chem. Res., 44 (11), pp. 1146-1155; Faller, P., Hureau, C., Bioinorganic Chemistry of Copper and Zinc Ions Coordinated to Amyloid-beta Peptide (2009) Dalton Trans., (7), pp. 1080-1094; Faller, P., Hureau, C., Berthoumieu, O., Role of Metal Ions in the Self-assembly of the Alzheimers Amyloid-beta Peptide (2013) Inorg. Chem., 52 (21), pp. 12193-12206; Rickard, G.A., Gomez-Balderas, R., Brunelle, P., Raffa, D.F., Rauk, A., Binding Affinities for Models of Biologically Available Potential Cu(II) Ligands Relevant to Alzheimers Disease: An ab Initio Study (2005) J. Phys.Chem. A, 109 (37), pp. 8361-8370; Mantri, Y., Fioroni, M., Baik, M.H., Computational Study of the Binding of Cu-II to Alzheimers Amyloid-beta Peptide: Do A beta 42 and A beta 40 Bind Copper in Identical Fashion? (2008) J. Biolog. Inorg. Chem., 13 (8), pp. 1197-1204; Raffa, D.F., Rauk, A., Molecular Dynamics Study of the Beta Amyloid Peptide of Alzheimers Disease and Its Divalent Copper Complexes (2007) J. Phys. Chem. B, 111 (14), pp. 3789-3799; Minicozzi, V., Morante, S., Rossi, G.C., Stellato, F., Christian, N., Jansen, K., The Role of Metals in Amyloid Aggregation -Experiments and ab initio Simulations (2008) Int. J. Quantum Chem., 108 (11), pp. 1992-2015; Marino, T., Russo, N., Toscano, M., Pavelka, M., On the Metal Ion (Zn2+, Cu2+) Coordination with beta-amyloid Peptide: DFT Computational Study (2010) Interdiscip. Sci.: Comput. Life Sci., 2, pp. 57-69; Alí-Torres, J., Maréchal, J.-D., Rodríguez-Santiago, L., Sodupe, M., Three Dimensional Models of Cu2+-Aβ(1-16) Complexes from Computational Approaches (2011) J. Am. Chem. Soc., 133 (38), pp. 15008-15014; Furlan, S., Hureau, C., Faller, P., La Penna, G., Modeling Copper Binding to the Amyloid-beta Peptide at Different pH: Toward a Molecular Mechanism for Cu Reduction (2012) J. Phys.Chem. B, 116 (39), pp. 11899-11910; La Penna, G., Hureau, C., Andreussi, O., Faller, P., Identifying, By First-Principles Simulations, Cu Amyloid-beta Species Making Fenton-Type Reactions in Alzheimers Disease (2013) J. Phys. Chem. B, 117 (51), pp. 16455-16467; Zirah, S., Kozin, S.A., Mazur, A.K., Blond, A., Cheminant, M., Segalas-Milazzo, I., Debey, P., Rebuffat, S., Structural Changes of Region 1-16 of the Alzheimer Disease Amyloid beta -Peptide upon Zinc Binding and in Vitro Aging (2006) J. Biol. Chem., 281 (4), pp. 2151-2161; Sali, A., Webb, B., Madhusudhan, M.S., Shen, M.-Y., Marti-Renom, M.A., Eswar, N., Alber, F., Feyfant, E., (2007) MODELLER A Program for Protein Structure Modeling 9v5; Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera -A Visualization System for Exploratory Research and Analysis (2004) J. Comput. Chem., 25 (13), pp. 1605-1612; Colovos, C., Yeates, T.O., Verification of Protein Structures -Patterns of Nonbonded Atomic Interactions (1993) Protein Sci., 2 (9), pp. 1511-1519; Rios-Font, R., Sodupe, M., Rodriguez-Santiago, L., Taylor, P.R., The Role of Exact Exchange in the Description of Cu2+-(H2O)(n) (n=1-6) Complexes by Means of DFT Methods (2010) J. Phys. Chem. A, 114 (40), pp. 10857-10863; Georgieva, I., Trendafilova, N., Rodriguez-Santiago, L., Sodupe, M., Coordination Properties of the Oxime Analogue of Glycine to Cu(II) (2005) J. Phys. Chem. A, 109 (25), pp. 5668-5676; Zhao, Y., Truhlar, D.G., The M06 Suite of Density Functionals for Main Group Thermochemistry, Thermochemical Kinetics, Noncovalent Interactions, Excited States, and Transition Elements: Two New Functionals and Systematic Testing of Four M06-class Functionals and 12 Other Functionals (2008) Theor. Chem. Acc., 120 (13), pp. 215-241; (2014), http://physics.nist.gov/PhysRefData/Handbook/Tables/coppertable1.htm, National Institute of Standards and Technology. (accessed 04/10/)Hay, P.J., Wadt, W.R., Ab Initio Effective Core Potentials for Molecular Calculations. Potentials for K to Au Including the Outermost Core Orbitals (1985) J. Chem. Phys., 82 (1), pp. 299-310; Roy, L.E., Hay, P.J., Martin, R.L., Revised Basis Sets for the LANL Effective Core Potentials (2008) J. Chem. Theory Comput., 4 (7), pp. 1029-1031; Ehlers, A.W., Bohme, M., Dapprich, S., Gobbi, A., Hollwarth, A., Jonas, V., Kohler, K.F., Frenking, G., A Set of f Polarization Functions for Pseudo-potential Basis Sets of the Transition Metals Sc-Cu, Y-Ag and La-Au (1993) Chem. Phys. Lett., 208 (12), pp. 111-114; Marenich, A.V., Cramer, C.J., Truhlar, D.G., Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions (2009) J. Phys. Chem. B, 113 (18), pp. 6378-6396; Ali-Torres, J., Dannenberg, J.J., The Folding of Acetyl(Ala)(28)NH2 and Acetyl(Ala)(40)NH2 Extended Strand Peptides into Antiparallel beta-Sheets. A Density Functional Theory Study of beta-Sheets with beta-Turns (2012) J. Phys. Chem. B, 116 (48), pp. 14017-14022; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Petersson, G.A., (2009) Gaussian 09, , revision A.02; Gaussian, Inc. Wallingford, CT; Wagman, D.D., Parker, V.B., Schumm, R.H., Halow, I., Bailey, S.M., Churney, K.L., Nuttall, R.L., The NBS Tables of Chemical Thermodynamic Properties. Selected values for Inorganic and C-1 and C-2 organic substances in SI units (1982) J. Phys. Chem., 1, p. 11; El Khoury, Y., Dorlet, P., Faller, P., Hellwig, P., New Insights into the Coordination of Cu(II) by the Amyloid-B 16 Peptide from Fourier Transform IR Spectroscopy and Isotopic Labeling (2011) J. Phys. Chem. B, 115 (49), pp. 14812-14821; Bard, A.J., Parsons, R., Jordan, J., (1985) Standard Potentials in Aqueous Solutions, , Marcel Dekker: New York; Himes, R.A., Park, G.Y., Barry, A.N., Blackburn, N.J., Karlin, K.D., Synthesis and X-ray Absorption Spectroscopy Structural Studies of Cu(I) Complexes of HistidylHistidine Peptides: The Predominance of Linear 2-Coordinate Geometry (2007) J. Am. Chem. Soc., 129 (17), pp. 5352-5353; Himes, R.A., Park, G.Y., Siluvai, G.S., Blackburn, N.J., Karlin, K.D., Structural Studies of Copper(I) Complexes of Amyloid-beta Peptide Fragments: Formation of Two-Coordinate Bis(histidine) Complexes (2008) Angew. Chem., Int. Ed., 47 (47), pp. 9084-9087; Shearer, J., Szalai, V.A., The Amyloid-beta Peptide of Alzheimers Disease Binds Cu(I) in a Linear Bis-His Coordination Environment: Insight into a Possible Neuroprotective Mechanism for the Amyloid-beta Peptide (2008) J. Am. Chem. Soc., 130 (52), pp. 17826-17835; Raffa, D.F., Rickard, G.A., Rauk, A., Ab Initio Modelling of the Structure and Redox Behaviour of Copper(I) Bound to a His-His Model Peptide: Relevance to the beta-Amyloid Peptide of Alzheimers Disease (2007) J. Biol. Inorg. Chem., 12 (2), pp. 147-164; Rimola, A., Constantino, E., Rodriguez-Santiago, L., Sodupe, M., Binding Properties of Cu+/2+-(glycyl)nglycine Complexes (n = 1-3) (2008) J. Phys. Chem. A, 112 (15), pp. 3444-3453; Furlan, S., Hureau, C., Faller, P., La Penna, G., Modeling the Cu(+) Binding in the 1-16 Region of the Amyloid-beta Peptide Involved in Alzheimers Disease (2010) J. Phys. Chem. B, 114 (46), pp. 15119-15133; Cassagnes, L.-E., Herve, V., Nepveu, F., Hureau, C., Faller, P., Collin, F., The Catalytically Active Copper-amyloid-Beta State: Coordination Site Responsible for Reactive Oxygen Species Production (2013) Angew. Chem., Int. Ed., 52 (42), pp. 11110-11113; Peck, K.L., Clewett, H.S., Schmitt, J.C., Shearer, J., Copper Ligation to Soluble Oligomers of the English Mutant of the Amyloid-beta Peptide Yields a Linear Cu(I) Site that Is Resistant to O-2 Oxidation (2013) Chem. Commun., 49 (42), pp. 4797-4799; Dryhurst, G., Kadish, K.M., Scheller, F., Renneberg, R., (1982) Biol. Electrochem., 1. , Academic Press: New York; Wallace, D.C., Diseases of the Mitochondrial-DNA (1992) Annu. Rev. Biochem., 61, pp. 1175-1212; Conway, B.E., (1969) Electrochemical Data, , Greenwood Press: Westport, CT",Article,Scopus,2-s2.0-84900296732
"Attwood K., Tian L., Xiong C.","Diagnostic thresholds with three ordinal groups",2014,"Journal of Biopharmaceutical Statistics","24","3",,"608","633",,,10.1080/10543406.2014.888437,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898937193&partnerID=40&md5=eabc08624555659bcff135d959094abb","Department of Biostatistics, University at Buffalo, 703 Kimball Tower, 3435 Main St., Bldg. 26, Buffalo, NY 14214-3000, United States; Division of Biostatistics, Washington University, St. Louis, MO, United States","Attwood, K., Department of Biostatistics, University at Buffalo, 703 Kimball Tower, 3435 Main St., Bldg. 26, Buffalo, NY 14214-3000, United States; Tian, L., Department of Biostatistics, University at Buffalo, 703 Kimball Tower, 3435 Main St., Bldg. 26, Buffalo, NY 14214-3000, United States; Xiong, C., Division of Biostatistics, Washington University, St. Louis, MO, United States","In practice, there exist many disease processes with three ordinal disease classes; for example, in the detection of Alzheimers disease (AD) a patient can be classified as healthy (disease-free stage), mild cognitive impairment (early disease stage), or AD (full disease stage). The treatment interventions and effectiveness of such disease processes will depend on the disease stage. Therefore, it is important to develop diagnostic tests with the ability to discriminate between the three disease stages. Measuring the overall ability of diagnostic tests to discriminate between the three classes has been discussed extensively in the literature. However, there has been little proposed on how to select clinically meaningful thresholds for such diagnostic tests, except for a method based on the generalized Youden index by Nakas et al. (2010). In this article, we propose two new criteria for selecting diagnostic thresholds in the three-class setting. The numerical study demonstrated that the proposed methods may provide thresholds with less variability and more balance among the correct classification rates for the three stages. The proposed methods are applied to two real examples: the clinical diagnosis of AD from the Washington University Alzheimers Disease Research Center and the detection of liver cancer (LC) using protein segments. © 2014 Taylor and Francis Group, LLC.","Alzheimer's disease (AD); Generalized Youden index; Optimal threshold; ROC surface; Transitional stage","Alonzo, T.A., Nakas, C.T., Yiannoutsos, C.T., Bucher, S., A comparison of tests for restrictedorderings in the three-class case (2009) Statistics in Medicine, 28 (7), pp. 1144-1158; Bamber, D., The area above the ordinal dominance graph ans the area below the ROC graph (1975) Journal of Mathematical Psychology, 12, pp. 387-415; Coffin, M., Sukhatme, S., Receiver operating characteristic studies and measurement errors (1997) Biometrics, 53 (3), pp. 823-837; Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Madsdeu, J., Wolfson, L., Clinical, pathological and neurochemical changes indementia: Nondemented subjects with pathlogically confirmed Alzheimer's disease (1988) Neurology, 38, pp. 1682-1687; Delong, E., Delong, D., Clarke-Pearson, C., Comparing the area under two or morecorrelated ROC curves: A non-parametric approach (1988) Biometrics, 44, pp. 837-845; Dong, T., Tian, L., Hutson, A., Xiong, C., Parametric and non-parametric confidence intervalsof the probability of identifying early disease stage given sensitivity and specificity with threeordinal diagnostic groups (2011) Statistics in Medicine, 30, pp. 3532-3545; Egan, J., (1975) Signal Detection Theory and ROC Analysis, , New York, NY: Academic Press; Evans, D., Funkenstein, H., Albert, M., Scheer, P., Coook, N., Chown, M., Hennekensc, H.L., Taylor, J., Age-specific incidence of Alzheimer's disease in community population (1995) Journal of American Medical Association, 23, pp. 1354-1359; Faraggi, D., Reiser, B., Estimation of the area under the ROC curve (2002) Statistics in Medicine, 21, pp. 3093-3106; Fawcett, T., An introduction to ROC analysis (2006) Pattern Recognition Letters, 27, pp. 861-874; Fluss, R., Faraggi, D., Reiser, B., Estimation of the Youden Index and its associated cutoffpoint (2005) Biometrical Journal, 47 (4), pp. 458-472; Gail, M., Green, S., A generalization of the one-sided two-sample Kolmogorov-Smironovstatistic for evaluating diagnostic tests (1976) Biometrics, 32, pp. 561-570; Greiner, M., Pfeiffer, D., Smith, R., Principles and practical application of the receiveroperatingcharacteristic analysis for diagnostic tests (2000) Preventative Veterinary Medicine, 45, pp. 23-41; Gupta, S., Bent, S., Kohlwes, J., Test characteristics of alphafetoprotein for detecting hepatocellularcarcinoma in patients with hepatitis C. A systematic review and critical analysis (2003) Annals of Internal Medicine, 139 (1), pp. 46-50; He, X., Frey, E.C., Three-class ROC analysis-The equal error utility assumption and theoptimality of three-class ROC surface using the ideal observer (2006) IEEE Transactions on MedicalImaging, 25 (8), pp. 979-986; He, X., Frey, E., The meaning and use of the volume under a three-class ROC surface (VUS) (2008) IEEE Transactions on Medical Imaging, 27 (5), pp. 577-588; Kang, L., Xiong, C., Crane, P., Tian, L., Estimation of the volume under the ROC surface withthree ordinal diagnostic categories (2012) Statistics in Medicine, , doi:10.1002/sim.5542; Kanne, S., Balota, D., Storandt Jr., D.M., Morris, J., Relating anatomy to function inAlzheimer's disease: Neuropsychological profiles predict regional neuropathy 5 years later (1998) Neurology, 50, pp. 979-985; Lai, C.-Y., Tian, L., Schisterman, E., Exact confidence interval estimation for the Youdenindex and its corresponding optimal cut-point (2012) Computational Statistics and Data Analysis, 56, pp. 1103-1114; Leeflang, M., Moons, K.G.M., Reitsma, J., Zwinderman, Z., Bias in sensitivity and specificitycaused by data driven selection of optimal cutoff values: Mechanisms, magnitude andsolutions (2008) Clinical Chemistry, 58, pp. 729-737; Leton, E., Molanes, E., Adjusted empirical likelihood estimation of the Youden Index andassociated threshold for the bigamma model (2009) Statistics and Econometrics Series, 7; Li, C., Lao, C., Llu, J., A non-inferiority test for diagnostic accuracy based on the pairedpartial areas under ROC curves (2008) Statistics in Medicine, 27, pp. 1762-1776; Lloyd, C.J., Yong, Z., Kernal estimators of the ROC curve are better than empirical (1999) Statistics& Probability Letters, 44, pp. 221-228; Molodianovitch, K., Faraggi, D., Reiser, D., Comparing the areas under two correlated ROCcurves: Parametric and non-parametric approaches (2006) Biometrical Journal, 48, pp. 745-757; Morris, J., McKeel, D.W., Storandt, M., Rubin, E., Price, L., Grant, E., Ball, M., Berg, L., Verymild Alzheimer's disease: Informant-based clinical, psychometric and pathologic distinctionfrom normal aging (1991) Neurology, 41, pp. 469-478; Morris, J., The clinical dementia rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Mossman, D., Three-way ROCs (1999) Medical Decision Making, 19, pp. 78-89; Nakas, C.T., Alonzo, T.A., Yiannoutsos, C.T., Accuracy and cut-off point selection in threeclassclassification problems using a generalization of the Youden index (2010) Statistics in Medicine, 29, pp. 2946-2955; Obuchowski, N., Fundementals of clinical research for radiologists: ROC analysis (2005) AmericanJournal of Roentgenology, 184, pp. 364-372; Pepe, M., (2003) The Statistical Evaluation of Medical Tests for Classification and Prediction, , Oxford, UK: Oxford University Press; Perkins, N.J., Schisterman, E.F., The inconsistency of optimal cutpoints obtained using twocriteria based on receiver operating characteristic curve (2006) American Journal of Epidemiology, 163 (7), pp. 670-675; Phelps, C., Hutson, A., Estimating diagnostic test accuracy using a fuzzy gold standard (1995) Medical Decision Making, 15 (1), pp. 44-57; Reiser, B., Measuring the effectiveness of diagnostic markers in the presences of measurementerror through the use of ROC curves (2000) Statistics in Medicine, 19, pp. 2115-2129; Ressom, H., Varghese, R., Goldman, L., An, Y., Loffredo, C., Abdel-Hamid, M., Kyselova, Z., Goldman, R., Analysis of MALDI-TOF massspectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma (2008) Journal of Proteome Research, 7 (2), pp. 603-610; Rubin, E., Storandt, M., Miller, J., A prospective study of cognitive function and onset ofdementia in cognitivity healthy elders (1998) Archives of Neurology, 55, pp. 395-401; Sampat, M., Patel, A., Wang, Y., Gupta, S., Kan, C., Bovik, A., Markey, M., Indexes for threeclassclassification performance assessment-An empirical comparison (2009) IEEE Transactions OnInformation Technology in Biomedicine, 13 (3), pp. 300-312; Schafer, H., Constructing a cut-off point for a quantitative diagnostic test (1989) Statistics InMedicine, 8 (11), pp. 1381-1391; Schisterman, E.F., Perkins, N., Liu, A., Bondell, H., Confidence intervals for the YoudenIndex and corresponding optimal cut-point (2007) Communications in Statistics-Simulation AndComputation, 36, pp. 549-563; Shaposhnikova, G., Prokazova, N., Sadovskaia, V., Rozynov, B., Volgin, L., Gangliosides ofmouse liver and ascites hepatoma 22a (1981) Biokhimiia, 46 (12), pp. 2224-2233; Skaltsa, K., Jover, L., Fusterb, D., Carrascoa, J., Optimum threshold estimation based on costfunction in a multistate diagnostic setting (2012) Statistics in Medicine, 31, pp. 1098-1109; Tian, L., Xiong, C., Lai, C.-Y., Vexler, A., Exact confidence interval estimation for the differencein diagnostic accuracy with three ordinal diagnostic groups (2010) Journal of StatisticalPlanning and Inference, 141, pp. 549-558; Xiong, C., Belle, G.V., Miller, J.P., Morris, J.C., Measuring and estimating diagnostic accuracywhen there are three ordinal diagnostic groups (2006) Statistics in Medicine, 25 (7), pp. 1251-1273; Xiong, C., Belle, G.V., Miller, J., Yan, Y., Gao, F., Feng, S., Yu, K., Morris, J., A parametriccomparison of diagnostic accuracy with three ordinal diagnostic groups (2007) Biometrical Journal, 49, pp. 682-693; Youden, W., An index for rating diagnostic tests (1950) Cancer, 3, pp. 32-35; Zhang, D., Zhou, X., Freeman, D., Freeman, J., A Non-parametric Method for the Comparisonof Partial Area under ROC Curves and Its Application to Large Health Care Datasets (2002) Statistics InMedicine, 21, pp. 701-705; Zhang, Y., Li, J., Combining Multiple Markers for ulti-Category Classification: An ROCSurface Approach (2011) Australian & New Zealand Journal of Statistics, 53 (1), pp. 63-78; Zou, K., Hall, W., Shapiro, D., Smooth non-parametric receiver-operating characteristic(ROC) curves for continuous diagnostic tests (1997) Statistics in Medicine, 16, pp. 2143-2156",Article,Scopus,2-s2.0-84898937193
"Ghebretinsae A.H., Molenberghs G., Dmitrienko A., Offen W., Sethuraman G.","Assessment of type i error rate associated with dose-group switching in a longitudinal alzheimer trial",2014,"Journal of Biopharmaceutical Statistics","24","3",,"660","684",,,10.1080/10543406.2014.888570,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898998102&partnerID=40&md5=26d236828b6ff50cbbfd2f09dceefa24","I-BioStat, Universiteit Hasselt, Center for Statistics, Diepenbeek B-3590, Belgium; I-BioStat, Katholieke Universiteit Leuven, Leuven, Belgium; Quintiles Innovation, Overland Park, KS, United States; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States","Ghebretinsae, A.H., I-BioStat, Universiteit Hasselt, Center for Statistics, Diepenbeek B-3590, Belgium; Molenberghs, G., I-BioStat, Universiteit Hasselt, Center for Statistics, Diepenbeek B-3590, Belgium, I-BioStat, Katholieke Universiteit Leuven, Leuven, Belgium; Dmitrienko, A., Quintiles Innovation, Overland Park, KS, United States; Offen, W., Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States; Sethuraman, G., Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States","In clinical trials, there always is the possibility to use data-driven adaptation at the end of a study. There prevails, however, concern on whether the type I error rate of the trial could be inflated with such design, thus, necessitating multiplicity adjustment. In this project, a simulation experiment was set up to assess type I error rate inflation associated with switching dose group as a function of dropout rate at the end of the study, where the primary analysis is in terms of a longitudinal outcome. This simulation is inspired by a clinical trial in Alzheimers disease. The type I error rate was assessed under a number of scenarios, in terms of differing correlations between efficacy and tolerance, different missingness mechanisms, and different probabilities of switching. A collection of parameter values was used to assess sensitivity of the analysis. Results from ignorable likelihood analysis show that the type I error rate with and without switching was approximately the posited error rate for the various scenarios. Under last observation carried forward (LOCF), the type I error rate blew up both with and without switching. The type I error inflation is clearly connected to the criterion used for switching. While in general switching, in a way related to the primary endpoint, may impact the type I error, this was not the case for most scenarios in the longitudinal Alzheimer trial setting under consideration, where patients are expected to worsen over time. © 2014 Taylor and Francis Group, LLC.","Ignorable likelihood; LOCF; MAR; MNAR; Type I error.","Chang, M., (2008) Adaptive Design Theory and Implementation Using SAS and R, , Boca Raton, FL: Chapman & Hall/CRC; Chow, S.C., Chang, M., Adaptive design methods in clinical trials-A review (2008) OrphanetJournal of Rare Diseases, 3. , paper 11; Mallinckrodt, C.H., Sanger, T.M., Dub, S., Debrota, D.J., Molenberghs, G., Carroll, R.J., Potterw, Z., Tollefson, G.D., Assessing and interpreting treatment effects in longitudinalclinical trials with missing data (2003) Biological Psychiatry, 53, pp. 754-760; Molenberghs, G., Kenward, M.G., (2007) Missing Data in Clinical Studies, , Chichester, UK: JohnWiley & Sons; Molenberghs, G., Verbeke, G., (2005) Models for Discrete Longitudinal Data, , New York, NY: Springer; Verbeke, G., Molenberghs, G., (2000) Linear Mixed Models for Longitudinal Data, , New York, NY: Springer; Wang, M., Wu, Y.C., Tsai, G.F., A regulatory view of adaptive trial design (2008) Journal of TheFormos Medical Association, 107, pp. 3-8",Article,Scopus,2-s2.0-84898998102
"Pajoohesh-Ganji A., Burns M.P., Pal-Ghosh S., Tadvalkar G., Hokenbury N.G., Stepp M.A., Faden A.I.","Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury",2014,"Brain Research","1560",,,"73","82",,,10.1016/j.brainres.2014.02.049,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898020986&partnerID=40&md5=f7589bce277e42792e571f278ee57f43","George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States; Georgetown University, Washington, DC, United States; University of Maryland, Baltimore, United States","Pajoohesh-Ganji, A., George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States; Burns, M.P., Georgetown University, Washington, DC, United States; Pal-Ghosh, S., George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States; Tadvalkar, G., George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States; Hokenbury, N.G., George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States, Georgetown University, Washington, DC, United States, University of Maryland, Baltimore, United States; Stepp, M.A., George Washington University, Department of Anatomy and Regenerative Biology, Ross Hall, 2300 I St. NW, Washington, DC 20037, United States; Faden, A.I., University of Maryland, Baltimore, United States","Amyloid-β (Aβ) is produced through the enzymatic cleavage of amyloid precursor protein (APP) by β (Bace1) and γ-secretases. The accumulation and aggregation of Aβ as amyloid plaques is the hallmark pathology of Alzheimers disease and has been found in other neurological disorders, such as traumatic brain injury and multiple sclerosis. Although the role of Aβ after injury is not well understood, several studies have reported a negative correlation between Aβ formation and functional outcome. In this study we show that levels of APP, the enzymes cleaving APP (Bace1 and γ-secretase), and Aβ are significantly increased from 1 to 3 days after impact spinal cord injury (SCI) in mice. To determine the role of Aβ after SCI, we reduced or inhibited Aβ in vivo through pharmacological (using DAPT) or genetic (Bace1 knockout mice) approaches. We found that these interventions significantly impaired functional recovery as evaluated by white matter sparing and behavioral testing. These data are consistent with a beneficial role for Aβ after SCI. © 2014 Elsevier B.V.","Amyloid precursor protein; Amyloid-β; Bace1; Spinal cord injury; γ-Secretase","Ahlgren, S., Accumulation of beta-amyloid precursor protein and ubiquitin in axons after spinal cord trauma in humans: Immunohistochemical observations on autopsy material (1996) Acta Neuropathol., 92, pp. 49-55; Basso, D.M., Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains (2006) J. Neurotrauma, 23, pp. 635-659; Batchelor, P.E., Comparison of inflammation in the brain and spinal cord following mechanical injury (2008) J. Neurotrauma, 25, pp. 1217-1225; Blasko, I., Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimers disease beta-secretase (BACE-1) (2004) J. Neural Transm., 111, pp. 523-536; Brosnan, C.F., John, G.R., Revisiting Notch in remyelination of multiple sclerosis lesions (2009) J. Clin. Invest., 119, pp. 10-13; Bryson, J.B., Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis (2012) Hum. Mol. Genet., 21, pp. 3871-3882; Byrnes, K.R., Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury (2007) Brain, 130, pp. 2977-2992; Cai, H., BACE1 is the major beta-secretase for generation of Abeta peptides by neurons (2001) Nat. Neurosci., 4, pp. 233-234; Carlson, S.L., Acute inflammatory response in spinal cord following impact injury (1998) Exp. Neurol., 151, pp. 77-88; Chen, X.H., Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma (2004) Am. J. Pathol., 165, pp. 357-371; Choo, A.M., Secondary pathology following contusion, dislocation, and distraction spinal cord injuries (2008) Exp. Neurol., 212, pp. 490-506; Cornish, R., Topography and severity of axonal injury in human spinal cord trauma using amyloid precursor protein as a marker of axonal injury (2000) Spine (Phila Pa 1976), 25, pp. 1227-1233; Dsouza, B., The many facets of Notch ligands (2008) Oncogene, 27, pp. 5148-5167; De Strooper, B., Konig, G., Alzheimers disease: A firm base for drug development (1999) Nature, 402, pp. 471-472; Dominguez, D., Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice (2005) J. Biol. Chem., 280, pp. 30797-30806; Donnelly, D.J., An efficient and reproducible method for quantifying macrophages in different experimental models of central nervous system pathology (2009) J. Neurosci. Methods, 181, pp. 36-44; Farah, M.H., Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system (2011) J. Neurosci., 31, pp. 5744-5754; Gaiano, N., Radial glial identity is promoted by Notch1 signaling in the murine forebrain (2000) Neuron, 26, pp. 395-404; Gehrmann, J., Amyloid precursor protein (APP) expression in multiple sclerosis lesions (1995) Glia, 15, pp. 141-151; Grant, J.L., Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis (2012) Sci. Transl. Med., 4, pp. 145ra105; Hickman, S.E., Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimers disease mice (2008) J. Neurosci., 28, pp. 8354-8360; Hu, X., Bace1 modulates myelination in the central and peripheral nervous system (2006) Nat. Neurosci., 9, pp. 1520-1525; Hu, X., Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves (2008) FASEB J., 22, pp. 2970-2980; Hu, X., Reversing hypomyelination in BACE1-null mice with Akt-DD overexpression (2013) FASEB J., 27, pp. 1868-1873; Ikonomovic, M.D., Alzheimers pathology in human temporal cortex surgically excised after severe brain injury (2004) Exp. Neurol., 190, pp. 192-203; Iwata, A., Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes (2002) J. Neuropathol. Exp. Neurol., 61, pp. 1056-1068; Kigerl, K.A., Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord (2009) J. Neurosci., 29, pp. 13435-13444; Kobayashi, S., Temporal-spatial expression of presenilin 1 and the production of amyloid-beta after acute spinal cord injury in adult rat (2010) Neurochem. Int., 56, pp. 387-393; Li, G.L., Changes of beta-amyloid precursor protein after compression trauma to the spinal cord: An experimental study in the rat using immunohistochemistry (1995) J. Neurotrauma, 12, pp. 269-277; Loane, D.J., Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury (2009) Nat. Med., 15, pp. 377-379; Lu, J., Ashwell, K.W., Waite, P., Advances in secondary spinal cord injury: Role of apoptosis (2000) Spine (Phila Pa 1976), 25, pp. 1859-1866; Mandrekar, S., Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis (2009) J. Neurosci., 29, pp. 4252-4262; Mannix, R.C., Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice (2011) J. Neurotrauma, 28, pp. 1855-1861; Mannix, R.C., Whalen, M.J., Traumatic brain injury, microglia, and beta amyloid (2012) Int. J. Alzheimers Dis., 2012, p. 608732; Matsuoka, Y., Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimers disease (2001) Am. J. Pathol., 158, pp. 1345-1354; Nadler, Y., Increased expression of the gamma-secretase components presenlin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury (2008) Glia, 56, pp. 552-567; Pajoohesh-Ganji, A., A combined scoring method to assess behavioral recovery after mouse spinal cord injury (2010) Neurosci. Res., 67, pp. 117-125; Pajoohesh-Ganji, A., Byrnes, K.R., Novel neuroinflammatory targets in the chronically injured spinal cord (2011) Neurotherapeutics, 8, pp. 195-205; Pajoohesh-Ganji, A., Characterization of inflammatory gene expression and galectin-3 function after spinal cord injury in mice (2012) Brain Res., 1475, pp. 96-105; Panter, S.S., Faden, A.I., Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury (1992) Neurosci. Lett., 136, pp. 165-168; Raivich, G., Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function (1999) Brain Res. Brain Res. Rev., 30, pp. 77-105; Roberts, G.W., Beta A4 amyloid protein deposition in brain after head trauma (1991) Lancet, 338, pp. 1422-1423; Roberts, G.W., Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimers disease (1994) J. Neurol. Neurosurg. Psychiatry, 57, pp. 419-425; Saeidi, H., Effects of DAPT on serum vascular endothelial growth factor and its soluble receptor in obese BALB/C mice (2013) J. Isfahan Med. School, 30, pp. 1942-1948; Schnell, L., Acute inflammatory responses to mechanical lesions in the CNS: Differences between brain and spinal cord (1999) Eur. J. Neurosci., 11, pp. 3648-3658; Schnell, L., Cytokine-induced acute inflammation in the brain and spinal cord (1999) J. Neuropathol. Exp. Neurol., 58, pp. 245-254; Selkoe, D.J., Alzheimer disease: Mechanistic understanding predicts novel therapies (2004) Ann. Intern. Med., 140, pp. 627-638; Tanigaki, K., Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate (2001) Neuron, 29, pp. 45-55; Uryu, K., Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis (2002) J. Neurosci., 22, pp. 446-454; Uryu, K., Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans (2007) Exp. Neurol., 208, pp. 185-192; Velanac, V., Bace1 processing of NRG1 type III produces a myelin-inducing signal but is not essential for the stimulation of myelination (2012) Glia, 60, pp. 203-217; Wyss-Coray, T., Mucke, L., Inflammation in neurodegenerative disease - A double-edged sword (2002) Neuron, 35, pp. 419-432",Article,Scopus,2-s2.0-84898020986
"Yasuda N., Ishii T., Oyama D., Fukuta T., Agato Y., Sato A., Shimizu K., Asai T., Asakawa T., Kan T., Yamada S., Ohizumi Y., Oku N.","Neuroprotective effect of nobiletin on cerebral ischemia-reperfusion injury in transient middle cerebral artery-occluded rats",2014,"Brain Research","1559",,,"46","54",,2,10.1016/j.brainres.2014.02.007,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897490903&partnerID=40&md5=0dfcd30066068f353b96dbb87ebc8fd5","Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Department of Synthetic Organic and Medicinal Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Department of Anti-dementia Functional Food Development, Graduate School of Engineering, Tohoku University, Sendai, Japan; Yokohama College of Pharmacy, Yokohama, Japan","Yasuda, N., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Ishii, T., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Oyama, D., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Fukuta, T., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Agato, Y., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Sato, A., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Shimizu, K., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Asai, T., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Asakawa, T., Department of Synthetic Organic and Medicinal Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Kan, T., Department of Synthetic Organic and Medicinal Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Yamada, S., Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Ohizumi, Y., Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan, Department of Anti-dementia Functional Food Development, Graduate School of Engineering, Tohoku University, Sendai, Japan, Yokohama College of Pharmacy, Yokohama, Japan; Oku, N., Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan","Nobiletin, a citrus polymethoxylated flavone, is reported to possess various pharmacological activities such as anticancer, anti-inflammation, and antioxidant effects. Recently, nobiletin was shown to provide therapeutic benefit for the treatment of Alzheimers disease by activating cAMP-response element-binding protein (CREB). In the present study, we investigated whether nobiletin could protect the brain against ischemia-reperfusion (I/R) injury and improve functional outcome in cerebral I/R model rats, since CREB activation is known to protect neuronal cells in cerebral ischemia. Nobiletin was injected twice at 0 and 1 h after the start of reperfusion in transient middle cerebral artery occlusion (t-MCAO) rats. Cerebral I/R induced prominent brain damage in the ischemic hemisphere of t-MCAO rat brains; however, nobiletin treatment significantly reduced the infarct volume and suppressed the brain edema. Immunohistochemical and TUNEL staining indicated that nobiletin treatment significantly suppressed neutrophil invasion into the ischemic region and significantly decreased apoptotic brain cell death in ischemic hemisphere, suggesting that the anti-inflammatory effect and anti-apoptotic effect should be regarded as the neuroprotective mechanism of nobiletin. Moreover, nobiletin treatment ameliorated motor functional deficits in the ischemic rats compared with those deficits of the vehicle-treated group. These results indicate that nobiletin is a potential neuroprotectant for the treatment of cerebral I/R injury. © 2014 Elsevier B.V.","Citrus polymethoxylated flavone; Ischemic stroke; Motor function deficit; Neuroprotectant; Neutrophil infiltration; Nobiletin","Ali, S.M., Ahmad, A., Sheikh, S., Ahmad, M.U., Rane, R.C., Kale, P., Paithankar, M., Sehgal, A., Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant Tacrolimus: Pharmacokinetics, safety, and tolerability in rodents and humans (2010) Int. Immunopharmacol., 10, pp. 325-330; Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., Corasaniti, M.T., Post-ischemic brain damage: Pathophysiology and role of inflammatory mediators (2009) FEBS J., 276, pp. 13-26; Asakawa, T., Hiza, A., Nakayama, M., Inai, M., Oyama, D., Koide, H., Shimizu, K., Kan, T., PET imaging of nobiletin based on a practical total synthesis (2011) Chem. Commun. (Camb), 47, pp. 2868-2870; Cui, Y., Wu, J., Jung, S.C., Park, D.B., Maeng, Y.H., Hong, J.Y., Kim, S.J., Eun, S.Y., Anti-neuroinflammatory activity of nobiletin on suppression of microglial activation (2011) Biol. Pharm. Bull., 33, pp. 1814-1821; Eltzschig, H.K., Eckle, T., Ischemia and reperfusion - From mechanism to translation (2011) Nat. Med., 17, pp. 1391-1401; Ginsberg, M.D., Current status of neuroprotection for cerebral ischemia: Synoptic overview (2009) Stroke, 40, pp. 111-S114; Gursoy-Ozdemir, Y., Can, A., Dalkara, T., Reperfusion-induced oxidative/nitrativie injury to neurovascular unit after focal cerebral ischemia (2004) Stroke, 35 (6), pp. 1449-1453. , DOI 10.1161/01.STR.0000126044.83777.f4; Han, B.H., Holtzman, D.M., BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway (2000) Journal of Neuroscience, 20 (15), pp. 5775-5781; Hanawa, T., Endoh, N., Kazuno, F., Suzuki, M., Kobayashi, D., Tanaka, M., Kawano, K., Oguchi, T., Investigation of the release behavior of diethylhexyl phthalate from polyvinyl chloride tubing for intravenous administration based on HCO60 (2003) International Journal of Pharmaceutics, 267 (1-2), pp. 141-149. , DOI 10.1016/j.ijpharm.2003.08.009; Hishida, A., Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance (2007) Clinical and Experimental Nephrology, 11 (4), pp. 292-296. , DOI 10.1007/s10157-007-0495-2; Huang, J., Upadhyay, U.M., Tamargo, R.J., Inflammation in stroke and focal cerebral ischemia (2006) Surgical Neurology, 66 (3), pp. 232-245. , DOI 10.1016/j.surneu.2005.12.028, PII S0090301906001017; Hunter, A.J., Hatcher, J., Virley, D., Nelson, P., Irving, E., Hadingham, S.J., Parsons, A.A., Functional assessments in mice and rats after focal stroke (2000) Neuropharmacology, 39 (5), pp. 806-816. , DOI 10.1016/S0028-3908(99)00262-2, PII S0028390899002622; Ishii, T., Asai, T., Urakami, T., Oku, N., Accumulation of macromolecules in brain parenchyma in acute phase of cerebral infarction/reperfusion (2010) Brain Res., 1321, pp. 164-168; Ishiwa, J., Sato, T., Mimaki, Y., Sashida, Y., Yano, M., Ito, A., A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts (2000) Journal of Rheumatology, 27 (1), pp. 20-25; Kandaswami, C., Perkins, E., Soloniuk, D.S., Drzewiecki, G., Middleton, Jr.E., Antiproliferative effects of citrus flavonoids on a human squamous cell carcinoma in vitro (1991) Cancer Lett., 56, pp. 147-152; Kuller, L.H., Incidence rates of stroke in the eighties: The end of the decline in stroke (1989) Stroke, 20, pp. 841-843; Li, C., Jackson, R.M., Reactive species mechanisms of cellular hypoxia-reoxygenation injury (2002) Am. J. Physiol. Cell Physiol., 282, pp. 227-C241; Linnik, M.D., Zahos, P., Geschwind, M.D., Federoff, H.J., Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia (1995) Stroke, 26, pp. 1670-1674. , (discussion 1675); Lu, Y.H., Su, M.Y., Huang, H.Y., Lin, L., Yuan, C.G., Protective effects of the citrus flavanones to PC12 cells against cytotoxicity induced by hydrogen peroxide (2010) Neurosci. Lett., 484, pp. 6-11; Matsuzaki, K., Kenichi Miyazaki, Sakai, S., Yawo, H., Nakata, N., Moriguchi, S., Fukunaga, K., Ohizumi, Y., Nobiletin, a citrus flavonoid with neurotrophic action, augments protein kinase A-mediated phosphorylation of the AMPA receptor subunit, GluR1, and the postsynaptic receptor response to glutamate in murine hippocampus (2008) European Journal of Pharmacology, 578 (2-3), pp. 194-200. , DOI 10.1016/j.ejphar.2007.09.028, PII S0014299907010576; Nakajima, A., Yamakuni, T., Haraguchi, M., Omae, N., Song, S.-Y., Kato, C., Nakagawasai, O., Ohizumi, Y., Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice (2007) Journal of Pharmacological Sciences, 105 (1), pp. 122-126. , http://www.jstage.jst.go.jp/article/jphs/105/1/122/_pdf, DOI 10.1254/jphs.SC0070155; Olmez, I., Ozyurt, H., Reactive oxygen species and ischemic cerebrovascular disease (2012) Neurochem. Int., 60, pp. 208-212; Onozuka, H., Nakajima, A., Matsuzaki, K., Shin, R.W., Ogino, K., Saigusa, D., Tetsu, N., Ohizumi, Y., Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimers disease (2008) J. Pharmacol. Exp. Ther., 326, pp. 739-744; Riccio, A., Ahn, S., Davenport, C.M., Blendy, J.A., Ginty, D.D., Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons (1999) Science, 286 (5448), pp. 2358-2361. , DOI 10.1126/science.286.5448.2358; Sharkey, J., Butcher, S.P., Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia (1994) Nature, 371 (6495), pp. 336-339. , DOI 10.1038/371336a0; Tuma, R.F., Steffens, S., Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury (2012) Curr. Pharm. Biotechnol., 13, pp. 46-58; Tuttolomondo, A., Di Sciacca, R., Di Raimondo, D., Renda, C., Pinto, A., Licata, G., Inflammation as a therapeutic target in acute ischemic stroke treatment (2009) Curr. Top Med. Chem., 9, pp. 1240-1260; Ueno, M., Hayano, Y., Nakagawa, H., Yamashita, T., Intraspinal rewiring of the corticospinal tract requires target-derived brain-derived neurotrophic factor and compensates lost function after brain injury (2012) Brain, 135, pp. 1253-1267; Wong, C.H.Y., Crack, P.J., Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury (2008) Current Medicinal Chemistry, 15 (1), pp. 1-14. , http://www.ingentaconnect.com/content/ben/cmc/2008/00000015/00000001/ art00001, DOI 10.2174/092986708783330665; Yamamoto, Y., Shioda, N., Han, F., Moriguchi, S., Nakajima, A., Yokosuka, A., Mimaki, Y., Fukunaga, K., Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation (2009) Brain Res., 1295, pp. 218-229; Yang, Y., Estrada, E.Y., Thompson, J.F., Liu, W., Rosenberg, G.A., Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat (2007) Journal of Cerebral Blood Flow and Metabolism, 27 (4), pp. 697-709. , DOI 10.1038/sj.jcbfm.9600375, PII 9600375; Young, A.R., Ali, C., Duretete, A., Vivien, D., Neuroprotection and stroke: Time for a compromise (2007) Journal of Neurochemistry, 103 (4), pp. 1302-1309. , DOI 10.1111/j.1471-4159.2007.04866.x; Zhang, N., Komine-Kobayashi, M., Tanaka, R., Liu, M., Mizuno, Y., Urabe, T., Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain (2005) Stroke, 36 (10), pp. 2220-2225. , DOI 10.1161/01.STR.0000182241.07096.06",Article,Scopus,2-s2.0-84897490903
"Wang Y., Dan Y., Yang D., Hu Y., Zhang L., Zhang C., Zhu H., Cui Z., Li M., Liu Y.","The genus Anemarrhena Bunge: A review on ethnopharmacology, phytochemistry and pharmacology",2014,"Journal of Ethnopharmacology","153","1",,"42","60",,1,10.1016/j.jep.2014.02.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896948656&partnerID=40&md5=51d4a392d4d73367a722695edd5cf4da","Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China; Institute of Medicinal Plant Development, Chinese Academy of Medical Science, Beijing 100193, China; Baotou Medical College, Baotou, Inner-Mongolia 014060, China","Wang, Y., Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China, Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Dan, Y., Institute of Medicinal Plant Development, Chinese Academy of Medical Science, Beijing 100193, China; Yang, D., Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Hu, Y., Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Zhang, L., Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China, Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Zhang, C., Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Zhu, H., Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Cui, Z., Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China, Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Li, M., Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China, Baotou Medical College, Baotou, Inner-Mongolia 014060, China; Liu, Y., Institute of Medicinal Plant Development, Chinese Academy of Medical Science, Beijing 100193, China","Ethnopharmacological relevance Anemarrhena asphodeloides Bunge. (Asparagaceae) yields Anemarrhenae Rhizoma, which has a long history to be used as a traditional medicine to treat various ailments, like cold-induced febrile disease with arthralgia, hematochezia, tidal fever and night sweats by Yin deficiency, bone-steaming, cough, and hemoptysis. It is also used as an ingredient of healthy food, wine, tea, biological toothpaste. Its importance is demonstrated by large scale to treat kinds of diseases in eastern Asian countries. The aim of this review is to provide up-to-date information about phytochemistry, pharmacology, and toxicology of Anemarrhena asphodeloides based on scientific literatures. It will build up a new foundation for further study on mechanism and development of better therapeutic agent and healthy product from Anemarrhena asphodeloides. Material and methods All the available information on Anemarrhena asphodeloides was collected via electronic search (using PubMed, SciFinder Scholar, CNKI, TPL (www.theplantlist.org), Google Scholar, Baidu Scholar, and Web of Science). Results Comprehensive analysis of the literatures searched through sources available above confirmed that the ethnomedical uses of Anemarrhena asphodeloides had been recorded in China, Japan, and Korea for thousands of years. The phytochemical investigation revealed the presence of steroidal saponins, flavonoids, phenylpropanoids, alkaloids, steroids, organic acids, anthraquinones, and others. Crude extracts and pure compounds from Anemarrhena asphodeloides exhibited significant pharmacological effects on the nervous system and the blood system. They also showed valuable bioactivities, such as antitumor, anti-oxidation, anti-microbial, anti-virus, anti-inflammation, anti-osteoporosis, anti-skin aging and damage as well as other activities. Conclusions In light of long traditional use and modern phytochemical and pharmacological studies summarized, Anemarrhena asphodeloides has demonstrated a strong potential for therapeutic and health-maintaining purposes. Both the extracts and chemical components isolated from the plant showed a wide range of biological activities. Thus more pharmacological mechanisms on main active compounds (TBII, TAIII, mangiferin and other ingredients) are necessary to be explored. In addition, as a good source of the traditional medicine, clinical studies of main therapeutic aspects (e.g. diabetes, Alzheimers disease, Parkinsons disease, etc.), toxicity and adverse effect of Anemarrhena asphodeloides will also undoubtedly be the focus of future investigation. © 2014 Elsevier Ireland Ltd.","Anemarrhena asphodeloides; Ethnopharmacology; Pharmacology; Phytochemistry","Bae, G., Yu, J.R., Lee, J., Chang, J., Seo, E.K., Identification of nyasol and structurally related compounds as the active principles from Anemarrhena asphodeloides against respiratory syncytial virus (RSV) (2007) Chem. Biodivers., 4, pp. 2231-2235; Bao, W., Pan, H.F., Lu, M., Ni, Y., Zhang, R., Gong, X.G., The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cells (2007) Cell Biol. Int., 31, pp. 887-892; Bai, S.Q., Liu, Y.H., Pharmacologic study and clinical practice of Anemarrhena asphodeloides (2007) Chin. J. Mod. Drug Appl., 1, pp. 12-13; Bian, J., Xu, S.S., Advances in studies on chemical and pharmacological research in Anemarrhena asphodeloide (1993) J. Shenyang Coll. Pharm., 2, pp. 141-146; Bian, J., Xu, S.S., Huang, S., Wang, Z.X., A study on the chemical constituents of Anemarrhena asphodeloides Bge (1996) J. Shenyang Pharm. Univ., 13, pp. 34-40; Cai, F., Xu, W., Wei, H., Sun, L., Gao, S.H., Yang, Q., Feng, J., Chen, W.S., Simultaneous determination of active xanthone glycosides, timosaponins and alkaloids in rat plasma after oral administration of Zishen pill extract for the pharmacokinetic study by liquid chromatography tandem mass spectrometry (2010) J. Chromatogr. B, 878, pp. 1845-1854; Chae, S.W., Piao, M.J., Kang, K.A., Zhang, R., Kim, K.C., Youn, U.J., Nam, K.W., Hyun, J.W., Inhibition of Matrix Metalloproteinase-1 induced by oxidative stress in human keratinocytes by mangiferin isolated from Anemarrhena asphodeloides (2011) Biosci. Biotechnol. Biochem., 75, pp. 2321-2325; Chen, L.N., Cao, S.L., Li, B.H., Li, X.X., Study on biological activity and anitioxidative activity of anemaran in vitro (2013) Liaoning J. Tradit. Chin. Med., 40, pp. 309-312; Chen, Q., Xia, Z., Hu, Y.E., Effects of ZMS on deposition of β-Amyloid peptide and cholinergic function in rats with β-Amyloid injection into right (2002) Chin. Pharmacol. Bull., 18, pp. 390-393; Chen, Q., Xia, Z.Q., Hu, Y.E., Effect of ZMS on distribution of muscarinic receptor density in rats with β-Amyloid injection into right nucleus basalis (2003) Acta Laser Biol. Sin., 12, pp. 445-449; Chen, Q., Cao, Y.G., Lin, Y.M., Xia, Z.Q., Hu, Y.E., Effects of sapogenin from zhimu (ZMS) and its isomer on learning and memory ability and muscarinic subtype M1 receptor density in aged rat (2004) Chin. Pharmacol. Bull., 20, pp. 564-567; Chen, W.S., Sun, L.N., Lou, Z.Y., Zhang, C., (2004) Studies on Total Flavones from Anemarrhena Rhizome As A New Drug to Treat Type II Diabetes, , Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004, AGFD-132; Chen, Q.L., Ma, C.H., Wang, W.Q., Yu, M.M., Analysis of volatile constituents from Anemarrhena asphodeloides by GC-MS (2005) China J. Chin. Mater. Med., 30, pp. 1657-1659; Chen, Q.L., Shi, Z.Y., Ma, N.N., Wang, W.Q., Wei, S.L., Sun, W.J., Determination of two major xanthone glycosides in rhizome of Anemarrhena asphodeloides using high performance capillary electrophoresis (2012) J. Med. Plants Res., 9, pp. 1585-1589; Chen, X.Q., Nicholas, J.T., Lamiaceae (2000) Flora of China, 24 VOL.. , Z.Y. Wu, Science Press Beijing (pp. 136); Cheng, J.X., Cheng, G., (2010) Health Care Nano Fiber-Fabric Product Carrying Traditional Chinese Medicine and Selenium, , Germanium and Zinc Capable of Releasing Anion. CN 101703317A 20100512; Cheng, Z.F., Wang, Y.H., Zhang, G.Y., Xu, L.I., Effect of SAaB on Alzheimers model rats induced by l-glutamic acid (2008) Chin. J. Hosp. Pharm., 28, pp. 1997-1999; Chi, T.H., Chung hua Yao Hsuch Tsa chi (1988) Chin. Med. J., 40, p. 31; (2010) Pharmacopoeia of PR China. Part i, , Committee for the Pharmacopoeia of PR China Pharmacopoeia of PR China Peoples Health Publishing House, PR China Beijing; (2010) A Colored Identification Atlas of Chinese Material Medica and Plants As Specified in the Pharmacopocia of Peoples Republic of China, , Committee for the Pharmacopoeia of PR China Peoples Health Publishing House, PR China Beijing; Cong, Y., Liu, X.L., Yu, Z.Y., Kang, L.Y., Ma, B.P., Cong, Y.W., Screening of active ingredients of timosaponin for antiplatelet aggregation, and analysis of structure-Activity relationship (2010) Med. J.f Chin. Peoples Liberat. Army, 35, pp. 1370-1373; Corbiere, C., Liagre, B., Terro, F., Beneytout, J.L., Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells (2004) Cell Res., 14, pp. 188-196; Corbiere, C., Liagre, B., Bianchi, A., Bordji, K., Dauc, M., Netter, P., Beneytout, J.L., Different contribution of apoptosis to the antiproliferative effects of diosgenin and other plant steroids, hecogenin and tigogenin, on human 1547 osteosarcoma cells (2003) Int. J. Oncol., 22, pp. 899-905; Cui, Y., Dai, Y.X., Feng, J., (2007) Application of Timosaponin for Treating Anxiety, , CN 101002879A 20070725; Deng, J.G., Zheng, Z.W., Zeng, C.H., Pharmacodynamic studies on mangiferin (2002) Chin. Arch. Tradit. Chin. Med., 20, pp. 802-803; Dong, J.X., Han, G.Y., Active constituents of Anemarrhena asphodeloides Bunge (1992) Acta Pharm. Sin., 27, pp. 26-32; Duke, J.A., Bogenschutz-Godwin, M.J., Ducellier, J., Duke, P.A.K., (2002) Handbook of Medicinal Herbs, pp. 27-28. , 2nd ed. CRC Press New York; (1999) China Bencao, p. 56. , Editorial Board of China Bencao China Bencao Shanghai Science and Technology Press, PR China Shanghai; Fenteany, G., Standaert, R.F., Reichard, G.A., Corey, E.J., Schreiber, S.L., A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line (1994) Proc. Natl. Acad. Sci., 91, pp. 3358-3362; Fujii, K., Kawabe, T., Hosoe, K., Hidaka, T., (2003) Compositions for Diabetes, , US 0133459A1 20050526; Fujii, K., Kawabe, T., Kubo, H., Higuchi, K., (2005) Antiaging Composition, , US 0154066A1 20050714; Gao, J., Li, M., Liu, N., Antiviral effect of Chinonin on HBV in vivo and in vitro (2007) J. Shanxi Coll. Tradit. Chin., 8, pp. 16-17; (1999) Shanghai Science and Technology Press, pp. 22-24. , Health Department and National Chinese Medicine Management Office Zhong Hua Ben Cao, PR China Shanghai 56; Hikino, H., Study on the chemical constituents and pharmacological activity of Anemarrhena asphodeloides Bge (1992) World Phytomed., 7, pp. 59-61; Hoa, N.K., Phan, D.V., Thuan, N.D., Oestenson, C.G., Insulin secretion is stimulated by ethanol extract of Anemarrhena asphodeloides in isolated islet of healthy wistar and diabetic goto-kakizaki rats (2004) Exp. Clin. Endocrinol. Diabetes, 112, pp. 520-525; Hong, Y.F., Han, G.Y., Preliminary study on maniferin content in rhizoma anemrrhena of different collection time (1985) Chin. Tradit. Herb. Drugs, 16, pp. 31-33; Hu, Y., Xia, Z., Sun, Q., Orsi, A., Rees, D., A new approach to the pharmacological regulation of memory: Sarsasapogenin improves memory by elevating the low muscarini cacetylchol inereceptor density in brains of memory deficitratmodels (2005) Brain Re., 1060, pp. 26-39; Huang, C.Y., Xie, S.R., Huang, S.Y., Effect of anemam on rabbit blood glucose (2004) J. Dalian Univ., 25, pp. 98-99; Huang, F., Xu, L., Guo, J.M., Chen, T., Mao, C.P., Wu, J., Antidiabetic activity of compounds extracting from Anemarrhena asphodeloides (2005) Chin. J. Biochem. Pharm., 26, pp. 332-335; Huang, T.P., Chang, Y.H., Chen, S.H., Yang, S.L., Yen, H.R., Alternative therapy for persistent childhood immune thrombocytopenic purpura unresponsive to intravenous immunoglobulin (2013) Complement. Ther. Med., 21, pp. 525-528; Ichiki, H., Miura, T., Kubo, M., Ishihara, E., Komatsu, Y., Tanigawa, K., Okada, M., New antidiabetic compounds, mangiferin and its glucoside (1998) Biol. Pharm. Bull., 21, pp. 1389-1390; Iida, Y., Oh, K.B., Saito, M., Matsuoka, H., Kurata, H., Natsume, M., Abe, H., Detection of antifungal activity in Anemarrhena asphodeloides by sensitive BCT method and isolation of its active compound (1999) J. Agric. Food. Chem., 47, pp. 584-587; Iida, Y., Yonemura, H., Oh, K.B., Saito, M., Matsuoka, H., Sensitive screening of antifungal compounds from acetone extracts of medicinal plants with a biocell tracer (1999) Yakugaku. Zasshi., 119, pp. 964-971; Iida, Y., Oh, K.B., Saito, M., Matsuoka, H., Kurata, H., In vitro synergism between nyasol, an active compound isolated from Anemarrhena asphodeloides, and azole agents against Candida albicans (2000) Planta Med., 66, pp. 435-438; Jang, M.S., Kang, H.Y., Jang, T.H., (2008) Cosmetic Composition Containing Natural Complex Extracts with Excellent Antioxidation, , Whitening and Anti-Inflammatory Effects. KR 2008104672A 20081203; Jeong, S.J., Ahn, N.H., Kim, Y.C., Inagaki, M., Miyamoto, T., Higuchi, R., Norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides (1999) Planta Med., 65, pp. 367-368; Jeong, S.J., Higuchi, R., Ono, M., Kuwano, M., Kim, Y.C., Miyamoto, T., Cis-hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo (2003) Biol. Pharm. Bull., 26, pp. 1721-1724; Ji, D., Lu, T.L., Song, S., The study progress for the medicine of Anemarrhena asphodeloides (2005) Chin. J. Pract. Chin. Mod. Med., 18, pp. 260-262; Ji, X., Feng, Y.F., Advances in studies on saponins in Anemarrhena asphodeloides (2010) Chin. Tradit. Herb. Drugs, 41, pp. 12-15; Jiang, J., Xiang, J.Z., Study on activity of Chinonin against HSV-Iin vitro (2004) China Pharm., 7, pp. 666-670; Jigden, B., Wang, H.T., Samdan, N., Yang, D.C., Molecular identification of oriental medicinal plant Anemarrhena asphodeloides Bunge (Jimo) by multiplex PCR (2010) Mol. Biol. Rep., 37, pp. 955-960; Jo, Y.H., Kim, S.B., Ahn, J.H., Liu, Q., Hwang, B.Y., Lee, M.K., Inhibitory activity of benzophenones from Anemarrhena asphodeloides on pancreatic lipase (2013) Nat. Prod. Commun., 8, pp. 481-483; Ju, Y.H., Zhen, Q., Li, Y., Li, J., Li, J., Study on the antifungal effect of Anemarrhena asphodeloides Bunge extraction (2009) Spec. Wild Econ. Anim. Plant Res., 31, pp. 23-27; Jung, K., Lee, B., Han, S.J., Ryu, J.H., Kim, D.H., Mangiferin ameliorates scopolamine-induced learning deficits in mice (2009) Biol. Pharm. Bull., 32, pp. 242-246; Kaname, N., Zhang, J., Meng, Z., Effect of timosaponin E1 and E2 on superoxide generation induced by various stimuli in human neutrophils and on platelet aggregation in human blood (2000) Clin. Chim. Acta, 295, pp. 129-140; Kang, L.P., Zhang, J., Cong, Y., Li, B., Xiong, C.Q., Zhao, Y., Tan, D.W., Ma, B.P., Steroidal glycosides from the rhizomes of Anemarrhena asphodeloides and their antiplatelet aggregation activity (2012) Planta Med., 78, pp. 611-616; Kang, Y.J., Chung, H.J., Nam, J.W., Park, H.J., Seo, E.K., Kim, Y.S., Lee, D.H., Lee, S.K., Cytotoxic and antineoplastic activity of Timosaponin A-III for Human Colon Cancer Cells (2011) J. Nat. Prod., 74, pp. 701-706; Kawasaki, T., Komori, T., Miyahara, K., Nohara, T., Hosokawa, I., Mihashi, K., Furostanol bisglycosides corresponding to dioscin and gracillin (1974) Chem. Pharm. Bull. (Tokyo), 22, pp. 2164-2175; Kim, J.Y., Shin, J.S., Ryu, J.H., Anti-inflammatory effect of anemarsaponin B isolated from the rhizomes of Anemarrhena asphodeloides in LPS-induced RAW 264.7 macrophages is mediated by negative regulation of the nuclear factor [kappa] B and p38 pathways (2009) Food Chem. Toxicol., 47, pp. 1610-1617; Kim, H.S., Song, J.H., Youn, U.J., Hyun, J.W., Jeong, W.S., Lee, M.Y., Choi, H.J., Chae, S., Inhibition of UVB-induced wrinkle formation and MMP-9 expression by mangiferin isolated from Anemarrhena asphodeloides (2012) Eur. J. Pharmacol., 689, pp. 38-44; Kimura, M., Kimura, I., Matsura, H., (1992) Steroid Glycosides, Their Isolation from Anemarrhenae Rhizoma, and Hypoglycemic Containing Them, , JP 04054194A 19920221; King, F.W., Fong, S., Griffin, C., Shoemaker, M., Staub, R., Ling, Y., Shtivelman, E., Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER Stress (2009) PLoS One, 4, p. 7283; Kubo, H., Fujii, K., Hosoe, K., (2004) Composition Having Liver Function Protecting Effect, , US 0122044A1 20070531; Lai, X.L., (2011) Health-Care Pillow with Traditional Chinese Medicine Used for Deafness, , CN 102204766A 20111005; Lee, B., Jung, K.K., Kim, D.H., Timosaponin AIII, a saponin isolated from Anemarrhena asphodeloides, ameliorates learning and memory deficits in mice (2009) Pharmacol. Biochem. Behav., 93, pp. 121-127; Lee, D.H., Lee, W.C., (1998) Use of Extract of Anemarrhena Asphodeloides Bunge As Immunosuppressant, , KR 98008236A 19980430; Lee, H.J., Ryu, J.H., A novel inhibitor of LTB4 binding to the human neutrophils (1999) Planta Med., 65, p. 391; Lee, S.H., Ryu, S.Y., Choi, S.U., No, Z., Kim, S.K., Lee, C.O., Ahn, J.W., Antitumor agent from the rhizome of Anemarrhena asphodeloides (1995) Saengyak Hakhoechi, 26, pp. 47-50; Li, S.Y., Zhao, Z.H., Pei, H.Y., Xiong, C.Q., Han, Y., Ma, B.P., Mao, B.Z., Cong, Y.W., Effect of timosaponin-AIII on formation of thrombus (2006) Bull. Acad. Mil. Med. Sci., 30, pp. 340-342; Li, C., Lei, Q.Z., Liu, Z.F., Gao, Y.L., Shi, W.H., (2006) Application of Total Saponin of Anemarrhena Asphodeloides to Prepare the Medical Formulations for Treating Hyperlipemia and Arteriosclerosis, , CN 1778303A 20060531; Li, T.J., Qiu, Y., Yang, P.Y., Rui, Y.C., Chen, W.S., Timosaponin BII improvesmemory and learning dysfunction induced by cerebralisch emiain rats (2007) Neurosc. Lett., 421, pp. 147-151; Li, F.Z., Liu, J.X., Ma, L.R., Liu, F.Y., The Reserch of the teratogenic genetic experiments for Rhizoma Anemarrhenaes efficacious part in antifungal drugs (2007) J. Gannan Norm. Univ., 3, pp. 76-78; Li, H.B., Wong, C.C., Cheng, K.W., Chen, F., Antioxidant properties in vitro and total phenolic contents in methanol extracts from medicinal plants (2008) LWT - Food Sci. Technol., 41, pp. 385-390; Li, J., Li, M., Scavenging effect of Chinonin from Anemarrhena asphodeloides oxygen free radicals (1996) J. Xiamen Univ., 35, pp. 452-455; Li, P.M., Zhong, J.L., Chen, R.Q., Zhang, X.K., Ho, K.L., Chiu, J.F., Huang, D.P., Zhi-mu saponin inhibits alpha-fetoprotein gene expression in developing rat liver (1989) Int. J. Biochem., 21, pp. 15-22; Li, S., Zhen, H., Jiang, J., Xiang, J.Z., Anti-viral effects of Chinonin against HSV-II in vitro (2005) J. Huazhong Univ. Sci. Technol., 34, pp. 304-307; Li, S., Zheng, H., Anti-viral effects of Chinonin against influenza virus in vitro (2005) China Pharm., 4, pp. 267-270; Li, X., Cui, X.B., Sun, X.Y., Li, X.D., Zhu, Q., Li, W., Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats (2010) Phytother. Res., 24, pp. 893-899; Li, Z.S., Li, D.L., Huang, J., Ding, Y., Ma, B.P., Wang, S.Q., (2003) Acta Pharm. Sinica, 38, pp. 496-500; Liu, B., (2011) Method for Manufacturing Health Care Sweet Tea from Traditional Chinese Medicines, , CN 102144692A 20110810; Liu, Q.B., Peng, Y., Li, L.Z., Gao, P.Y., Sun, Y., Yu, L.H., Song, S.J., Steroidal saponins from Anemarrhena asphodeloides (2013) J. Asian. Nat. Prod. Res., 15, pp. 891-898; Liu, Q.B., Song, S.J., Peng, Y., Isolation and identification of lipophilic components of rhizome of Anemarrhena asphodeloides (2011) J. Shenyang Pharm. Univ., 28, pp. 276-278; Liu, Z., Jin, Y., Sui, H.J., Yan, E.Z., Effect and signaling mechanism of SAaB on the Aβ25-35 induced release of inflammatory mediators in cultured macrophages (2011) Chin. Pharmacol. Bull., 27, pp. 700-704; Liu, Z., Jin, Y., Yao, S., Zheng, D.Y., Guo, X.L., Qi, Z.M., Protection of saponins from Anemarrhena asphodeloides Bge on neurons from amyloid β-protein fragment 25-35-induced apoptosis (2006) Chin. J. Pharmacol. Toxicol., 20, pp. 295-304; Lou, Z.Y., Chen, W.S., (2005) Total Saponins Extract from Anemarrhena Asphodeloides, and Its Uses for Preparing Medicaments for Treating Myocardial Ischemia, , CN 1682873A 20051019; Lu, M.Z., Zhang, Z.Q., Yi, J., Chen, W.S., Hou, Z.H., Li, T.J., Study on the effect and mechanisms of timosaponin B-II on antidepressant (2010) J. Pharm. Pract., 4, pp. 283-287; Lu, W.Q., Qiu, Y., Li, T.J., Timosaponin B-II inhibits proinflammatory cytokine induction by lipopolysaccharide in BV2 cells (2009) Arch. Pharm. Res., 32, pp. 1301-1308; Lu, W.Q., Qiu, Y., Li, T.J., Tao, X., Sun, L.N., Chen, W.S., Antiplatelet and antithrombotic activities of timosaponin B-II, an extract of Anemarrhena asphodeloides (2011) Clin. Exp. Pharmacol. Physiol., 38, pp. 380-384; Ma, B.P., Cong, Y.W., Kang, L.P., Gao, Y., Tan, D.W., Xiong, C.Q., Zhao, Y., (2011) Pharmaceutical Composition Containing Timosaponin AIII and BII Extracted from Chinese Medicine Anemarrhena Used As Anti-thrombotic Agent, , WO 2011026259 A1 20110310; Ma, B.P., Dong, J.X., Wang, B.J., Yan, Z.S., Studies of furostanol saponins isolated from Anemarrhena asphodeloides (1996) Acta Pharm. Sin., 31, pp. 271-277; Ma, Y.K., Li, L., Liu, G.B., The effects of SAaB on Alzheimer s model rats induced by AlCl3 (2005) Qilu Pharm. Aff., 24, pp. 625-626; Matsuda, H., Sato, N., Yamazaki, M., Naruto, S., Kubo, M., Testosterone 5alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma (2001) Biol. Pharm. Bull., 24, pp. 586-587; Matsuoka, H., Wu, C.F., Iida, Y., (1999) Antifungal and Antibacterial Compounds Having 4',4''-(3-ethenyl-1- propene-1,3-diyl) Bisphenol Skeleton, and Their Use As Antimicrobial Agents, , JP 11171707A 19990629; Meng, Z.Y., Zhang, J.Y., Xu, S.X., Sagahara, K., Steroidal saponins from Anemarrhena asphodeloides and their effects on superoxide generation (1999) Planta Med., 65, pp. 661-663; Miura, T., Kako, M., Ishihara, E., Usami, M., Yano, H., Tanigawa, K., Sudo, K., Seino, Y., Antidiabetic effect of Seishin-kanro-to in KK-Ay mice (1997) Planta Med., 63, pp. 320-322; Miura, T., Ichiki, H., Hashimoto, I., Iwamoto, N., Kato, M., Kubo, M., Ishihara, E., Ishida, T., Antidiabetic activity of a xanthone compound, mangiferin (2001) Biol. Pharm. Bull., 8, pp. 85-87; Miura, T., Ichiki, H., Iwamoto, N., Kato, M., Kubo, M., Sasaki, H., Okada, M., Tanigawa, K., Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside (2001) Biol. Pharm. Bull., 24, pp. 1009-10011; Nakashima, N., Kimura, I., Kimura, M., Matsuura, H., Isolation of pseudoprototimosaponin AIII from rhizomes of Anemarrhena asphodeloides and its hypoglycemic activity in streptozotocin-induced diabetic mice (1993) J. Nat. Prod., 56, pp. 345-350; (1998) Natural Products Research Institute, Seoul National University, , Medicinal Plants in the Republic of Korea. Western Pacific Series no. 21. WHO Regional publications, Korea; Ni, Y., Gong, X.G., Lu, M., Chen, H.M., Wang, Y., Mitochondrial ROS burst as an early sign in sarsasapogenin-induced apoptosis in HepG2 cells (2008) Cell Biol. Int., 32, pp. 337-343; Nian, H., Qin, L., Chen, W., Protective effect of steroidal saponins from rhizome of Anemarrhena asphodeloides on ovariectomy induced bone loss in rats (2006) Acta. Pharmacol. Sin., 27, pp. 728-734; Nian, L.H., Qin, M.J., Advances in studies on chemical resources and pharmacological research in Anemarrhena asphodeloide (2005) Chin. Wild Plant Resour., 24, pp. 16-21; Niwa, A., Takeda, O., Ishimaru, M., Screening test for platelet aggregation inhibitor in natural products. The active principle of Anemarrhenae Rhizoma (1988) Yakugaku Zasshi, 108, pp. 555-561; Oh, J.K., Hyun, S.Y., Oh, H.R., Jung, J.W., Park, C., Lee, S.Y., Park, J.H., Kim, Y.K., Effects of Anemarrhena asphodeloides on focal ischemic brain injury induced by middle cerebral artery occlusion in rats (2007) Biol. Pharm. Bull., 30, pp. 38-43; Ouyang, S., Sun, L., Guo, S., Effects of timosaponins on learning and memory abilities of rats with dementia induced by lateral cerebral ventricular injection of amyloid beta-peptide (2005) J. First Mil. Med. Univ., 25, pp. 121-126; Ouyang, S., Sun, L.S., Xu, J.P., Effect of saponins from Anemarrhena asphodeloides Bge on activity of acetyl cholinesterase in cortices of rats (2006) Chin. Pharm. J., 41, pp. 1472-1474; Park, H.J., Lee, J.Y., Moon, S.S., Hwang, B.K., Isolation and antioomycete activity of nyasol from Anemarrhena asphodeloides rhizomes (2003) Phytochemistry, 64, pp. 997-1001; Park, J.H., Jung, Y.J., Choi, J.S., (2006) Composition for Controlling Anthracnose Caused by Colletotrichum Gloeosporioides in Environment-Friendly Manner Comprising Extract of Anemarrhena Asphodeloides Bunge Leaves or Compound Isolated from Leaves of Anemarrhena Asphodeloides, , KR 2006038420A 20060503; Park, S.Y., Kim, J.W., Isolation of cytotoxic compounds from Anemarrhena asphodeloides (1994) Soul Taehakkyo Yakhak Nonmunjip, 19, pp. 61-73; Peng, Z.G., Luo, J., Xia, L.H., Inhibitory effect of mangiferin on the proliferation of K562 Leukemia cells (2004) J. Guangxi Med. Univ., 21, pp. 168-170; Qin, L., Han, T., Zhang, Q., Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula (2008) J. Ethnopharmacol., 118, pp. 271-279; Ren, L.X., Luo, Y.F., Li, X., Zuo, D.Y., Wu, Y.L., Antidepressant-like effects of sarsasapogenin from Anemarrhena asphodeloides Bunge (Liliaceae) (2006) Biol. Pharm. Bull., 29, pp. 2304-2306; Ren, L.X., Luo, Y.F., Li, X., Wu, Y.L., Antidepressant activity of sarsasapogenin from Anemarrhena asphodeloides Bunge (Liliaceae) (2007) Pharmazie, 62, pp. 78-79; Ren, L.X., Luo, Y.F., Song, S.J., Zhu, J.H., Li, X., Wu, Y.L., Antidepressant effect of total saponins from Rhizoma Anemarrhenae on mice and its mechanism (2007) J. Shenyang Pharm. Univ., 24, pp. 172-176; Saiki, I., Basic research on kampo formulations used in allergic diseases (2002) Kampo Immuno. Allergy, 16, pp. 106-124; Sakaguchi, M., Goto, K., Ichiki, H., Hattori, N., Iizuka, A., Takeda, S., Ishige, A., Yamamoto, T., Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats (2005) J. Ethnopharmacol., 102, pp. 164-169; Sekiya, N., Hikiami, H., Sakai, S., Kainuma, M., Goto, H., Shibahara, N., Shimada, Y., Terasawa, K., Experimental application of jiin-koka-to to cases of bronchial asthma (2003) Jpn. J. Orient. Med., 54, pp. 1097-1101; Sekiya, N., Namiki, T., Kasahara, Y.J., Kogure, T., Tatsumi, T., Ono, K., Hayashi, K., Terasawa, K., Clinical Indications of Jiin-shiho-to (2006) Jpn. J. Orient. Med., 57, pp. 661-667; Seung, Y., Park, Y.H., Choi, W.L., Dangnyohwan improves glucose utilization and reduces insulin resistance by increasing the adipocyte-specific GLUT4 expression in Otsuka Long-evans Tokushima fatty rats (2008) J. Ethnopharmacol., 115, pp. 473-482; Shen, L., Dai, S.J., Zhao, D.Z., Studies on the alkaloids of Anemarrhena asphodeloides (2007) China J. Chin. Mater. Med., 32, pp. 39-41; Shin, I.S., Lee, M.Y., Lim, H.S., Seo, C.S., Ha, H.K., Shin, H.K., Shin, H.K., Jaeumganghwa-tang, a traditional herbal formula inhibits the development of benign prostatic hyperplasia in rats (2012) J. Korean Soc. Appl. Biol. Chem., 55, pp. 205-212; Shin, J.S., Noh, Y.S., Kim, D.H., Cho, Y.W., Lee, K.T., Mangiferin isolated from the rhizome of Anemarrhena asphodeloides inhibits the LPS-induced nitric oxide and prostaglandin E2 via the NF-κB inactivation in inflammatory macrophages (2008) Nat. Prod. Sci., 14, pp. 206-213; Sun, H., Li, T.J., Sun, L.N., Qiu, Y., Huang, B.B., Yi, B., Chen, W.S., Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats (2007) J. Ethnopharmacol., 115, pp. 203-208; Sun, H., Li, T.J., Sun, L.N., Qiu, Y., Huang, B.B., Yi, B., Chen, W.S., Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats (2008) J. Ethnopharmacol., 115, pp. 203-208; Sun, Y., Perry, G.N., Yu, J., Chen, B., Tian, Z.Z., Effect of nourishing ""yin"" removing ""fire"" Chinese herbal mixture on hypothalamic kisspeptin expression in female precocious rats (2010) J. Ethnopharmacol., 127, pp. 274-279; Sy, L.K., Yan, S.C., Lok, C.N., Man, R.Y.K., Che, C.M., Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells (2008) Cancer Res., 68, pp. 10229-10237; Takahashi, M., Konno, C., Hikino, H., Isolation and hypoglycemicivity of anemarans A, B, C and D, glycans of Anemarrhena asphodeloides rhizomes (1985) Planta Med., 2, pp. 100-102; Takeda, Y., Togashi, H., Matsuo, T., Shinzawa, H., Takeda, Y., Takahashi, T., Growth inhibition and apoptosis of gastric cancer cell lines by Anemarrhena asphodeloides Bunge (2001) J. Gastroenterol., 36, pp. 79-90; Tian, X.D., Tian, W., (2009) Method for Manufacturing Hypoglycemic and Hypolipidemic Food, , CN 101564163A 20091028; Trouillas, P., Corbière, C., Liagre, B., Durou, J.L., Beneytout, J.L., Structure function relationship for saponin effects on cell cycle arrest and apoptosis in the human 1547 osteosarcoma cells: A molecular modelling approach of natural molecules structurally close to diosgenin (2005) Bioorg. Med. Chem., 13, pp. 1141-1149; Tsukamoto, S., Wakana, T., Koimaru, K., Yoshida, T., Sato, M., Ohta, T., 7-Hydroxy-3-(4-hydroxybenzyl) chroman and broussonin B: Neurotrophic compounds, isolated from Anemarrhena asphodeloides Bunge, function as proteasome inhibitors (2005) Biol. Pharm. Bull., 28, pp. 1798-1800; Ushiroyama, T., The role of traditional Japanese medicine (Kampo) in the practice of psychosomatic medicine: The usefulness of Kampo in the treatment of the stress-related symptoms of women, especially those with peri-menopausal disorder (2013) Ushiroyama BioPsychoSoc. Med., 7, p. 16; Wang, C.D., Qiang, Y.Z., Lao, Q.H., Jiang, J.G., Effects on scavenging free radicals of Chinonin (1999) Chin. J. Wild Resour., 18, pp. 12-14; Wang, D.J., Li, J., Ju, Y.H., Yang, S., Li, J., Study on antioxidative activity of anemaran in vitro (2008) Res. Pract. Chin. Med., 22, pp. 31-32; Wang, D.Y., Chen, L., Li, J., Li, B.G., Effects of natural antioxidant chinonin on doxorubicin-induced cardiotoxicity and its antitumor activity (2000) Nat. Prod. Res. Dev., 12, pp. 8-11; Wang, G.J., Lin, L.C., Chen, C.F., Effect of timosaponin A-III from Anemarrhenae asphodeloides Bunge (Liliaceae) on calcium mobilization in vascular endothelial and smooth muscle cells and on vascular tension (2002) Life Sci., 71, pp. 1081-1090; Wang, L.J., Wang, Y., Chen, S.W., Ma, J.S., Fu, Q., Wang, B.X., The antitumor activity of diosgeninin vivo and in vitro (2002) China J. Chin. Mater. Med., 27, pp. 777-779; Wang, J., Ge, S.F., Chen, Q., Li, G.X., Hypoglycemic activity of polysaccharide of roots of common Anemarrhena (Anemarrhena asphodeloides) (1996) Chin. Tradit. Drug, 27, pp. 605-606; Wang, S.G., Xu, J.P., Regulation of saponins from Anemarrhena asphodeloides Bge on cerebral acetylcholine receptors in aged rats (2001) J. Chin. Peoples Liberat. Army, 17, pp. 71-73; Won, J.B., Ma, C.J., Neuroprotective activities of some medicinal plants against glutamate-induced neurotoxicity in primary cultures of rat cortical cells (2009) Nat. Prod. Sci., 15, pp. 125-129; Wu, X.M., Xu, T.T., Pan, Y., Liu, C.M., Microwave assisted extraction of mangiferin with anti-tumor activities from Anemarrhena Asphodeloides Bge (2007) J. Nanjing TCM Univ., 27, pp. 260-262; Xi, M.M., Hai, C.X., Tang, H.F., Chen, M.S., Fang, K.Q., Liang, X., Antioxidant and antiglycation properties of total saponins extracted from traditional Chinese medicine used to treat diabetes mellitus (2008) Phytother. Res., 22, pp. 228-237; Xiao, S.Z., Xu, M.E., Ge, Y.K., Xiao, G.F., Inhibitory effects of saponins from Anemarrhena asphodeloides Bunge on the growth ofvascular smooth muscle cells (2006) Biomed. Environ. Sci., 19, pp. 185-191; Xie, Z.K., Xu, G., Xia, Z.Q., Hu, Y., Protective effects of sapogenin from Rhizoma Anemarrhenae (ZMR) on chronic MPTP-lesioned mice (2009) J. Shanghai Jiaotong Univ. (Med. Sci.), 29, pp. 145-149; Xiong, Z.K., Xu, G., Chen, Z.P., Xia, Z.Q., Hu, Y.E., Regulation of a sapogenin from Rhizoma Anemarrhenae, ZMR on dopaminergic system in a chronic model of Parkinsons disease (2009) Chin. J. Nucl. Med., 29, pp. 331-334; Yang, J., (2009) Method for Manufacturing Health-care Beverage for Alleviating Diabetes, , CN 101589833A 20091202; Yang, M., Ji, H., Zhang, S.P., Jiang, W.G., Dai, S.J., Effects of sarsasapogenin on the activity of osteoblasts and the differentiation and the function of osteoclasts (2009) J. China Pharm. Univ., 40, pp. 544-548; Yang, M., Ji, H., Dai, S.J., Liu, K., Effect of sarsasapogenin on prevention and treatment of retinoic acid induced osteoporosis in mice (2006) Chin. J. Nat. Med., 4, pp. 219-223; Yang, M., Ji, J., Dai, S.J., Fu, F.H., Effects of sarsasapogenin on the endocrine hormones and anti-oxidation activities in ovaricetomized rats (2007) Chin. Tradit. Herb. Drugs, 38, pp. 245-247; Yang, M., Xiao, C.H., Wu, Q.F., Niue, M.C., Yao, Q., Li, K.Q., Chen, Y.Y., Xia, C., Anti -inflammatory effect of Sanshuibaihu decoction may be associated with nuclear factor-κB and p38 MAPKα in collagen-induced arthritis in rat (2010) J. Ethnopharmacol., 127, pp. 264-273; Yeum, H.S., Lee, Y.C., Kim, S.H., Roh, S.S., Lee, J.C., Seo, Y.B., Fritillaria cirrhosa, Anemarrhena asphodeloides, Lee-Mo-Tang and cyclosporine a inhibit ovalbumin-induced eosinophil accumulation and Th2-mediated bronchial hyperresponsiveness in a murine model of asthma (2007) Basic Clin. Pharmacol. Toxicol., 100, pp. 205-213; Yi, N.Y., Xia, Z.Q., Hu, Y.E., (1994) Extraction of β-Adrenergic Receptor and M Cholinergic Receptor-regulating (β,5β,25s)-spirostan-3-ol from Anemarrhena Asphodeloides Bunge, , CN 1096031A 19941207; You, G.B., You, G.N.N., Zhang, C.J., (2003) Biological Toothpaste, , CN 1436522A 20030820; Youn, U.J., Jang, J.E., Nam, J.W., Lee, Y.J., Son, Y.M., Shin, H.J., Han, A.R., Seo, E.K., Anti-respiratory syncytial virus (RSV) activity of timosaponin A-III from the rhizomes of Anemarrhena asphodeloides (2011) J. Med. Plants Res., 5, pp. 1062-1065; Youn, U.J., Lee, Y.J., Jeon, H.R., Shin, H.J., Son, Y.M., Nam, J.W., Han, A.R., Seo, E.K., A pyridyl alkaloid and benzoic acid derivatives from the rhizomes of Anemarrhena asphodeloides (2010) Nat. Prod. Sci., 16, pp. 203-206; Youn, U.J., Lee, Y.S., Jeong, H., Lee, J., Nam, J.W., Lee, Y.J., Hwang, E.S., Kang, S.S., Identification of antiadipogenic constituents of the rhizomes of Anemarrhena asphodeloides (2009) J. Nat. Prod., 72, pp. 1895-1898; Youn, U.J., Lee, Y.S., Jeong, H., Nam, J.W., Lee, Y.J., Son, Y.M., Hwang, E.S., Seo, E.K., Minor phenolic constituents of the Anemarrhenae Rhizoma (2009) Nat. Prod. Sci., 15, pp. 203-207; Yun, B.R., Ma, J.Y., Weon, J.B., Lee, B., Lee, J., Ma, C.J., Simultaneous determination of 12 bioactive compounds in 'Jaeumganghwa-tang' by HPLC-DAD (2012) Planta Med., 78, pp. 109-120; Zhang, H.Y., Wang, F.Y., Li, M., Zhang, Z.Y., Li, M.F., Studies of scavenging effects on active oxygens of chinonin (1997) J. Radiat. Res. Radiat. Proces., 15, pp. 224-228; Zhang, J.B., Yu, B., Hui, Y.Z., Recent progress in research of furostanol saponins (2000) Chin. J. Org. Chem, 20, pp. 663-668; Zhang, J.Y., Meng, Z.Y., Zhang, M.Y., Ma, D.S., Xu, S.X., Kodama, H., Effect of six steroidal saponins isolated from Anemarrhenae rhizoma on platelet aggregation and hemolysis in human blood (1999) Clin. Chim. Acta, 289, pp. 79-88; Zhang, J.Y., Zhang, M.Y., Sugahara, K., Sagara, Y., Meng, Z.Z., Xu, S.X., Kodama, H., Effect of steroidal saponins of Anemarrhenae Rhizoma on superoxide generation in human neutrophils (1999) Biochem. Biophys. Res. Commun., 259, pp. 636-639; Zhang, Y., Sun, H.M., He, X., Wang, Y.Y., Gao, Y.S., Wu, H.X., Xu, H., Guo, Z.Y., Da Bu Yin Wan and Qian Zheng San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinsons disease (2013) J. Ethnopharmacol., 146, pp. 363-371; Zhu, F.T., Huang, X.F., Kong, L., Steroidal saponins from Anemarrhena asphodeloides (2012) Nat. Prod. Res. Dev., 24, pp. 1497-1501",Review,Scopus,2-s2.0-84896948656
"Jung J.I., Ran Y., Cruz P.E., Rosario A.M., Ladd T.B., Kukar T.L., Koo E.H., Felsenstein K.M., Golde T.E.","Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators",2014,"Biochemistry","53","12",,"1947","1957",,1,10.1021/bi401521t,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898080760&partnerID=40&md5=444f6c45d9cfe6a4afc2007aa8b58dc5","Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Department of Pharmacology and Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States; Department of Neuroscience, University of California at San Diego, San Diego, CA 92093, United States; Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, United States","Jung, J.I., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Ran, Y., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Cruz, P.E., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Rosario, A.M., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Ladd, T.B., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Kukar, T.L., Department of Pharmacology and Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States; Koo, E.H., Department of Neuroscience, University of California at San Diego, San Diego, CA 92093, United States; Felsenstein, K.M., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States; Golde, T.E., Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32603, United States, Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, United States","γ-Secretase catalyzes the final cleavage of the amyloid precursor protein (APP), resulting in the production of amyloid-β (Aβ) peptides with different carboxyl termini. Presenilin (PSEN) and amyloid precursor protein (APP) mutations linked to early onset familial Alzheimers disease modify the profile of Aβ isoforms generated, by altering both the initial γ-secretase cleavage site and subsequent processivity in a manner that leads to increased levels of the more amyloidogenic Aβ42 and in some circumstances Aβ43. Compounds termed γ-secretase modulators (GSMs) and inverse GSMs (iGSMs) can decrease and increase levels of Aβ42, respectively. As GSMs lower the level of production of pathogenic forms of long Aβ isoforms, they are of great interest as potential Alzheimers disease therapeutics. The factors that regulate GSM modulation are not fully understood; however, there is a growing body of evidence that supports the hypothesis that GSM activity is influenced by the amino acid sequence of the γ-secretase substrate. We have evaluated whether mutations near the luminal border of the transmembrane domain (TMD) of APP alter the ability of both acidic, nonsteroidal anti-inflammatory drug-derived carboxylate and nonacidic, phenylimidazole- derived classes of GSMs and iGSMs to modulate γ-secretase cleavage. Our data show that point mutations can dramatically reduce the sensitivity to modulation of cleavage by GSMs but have weaker effects on iGSM activity. These studies support the concept that the effect of GSMs may be substrate selective; for APP, it is dependent on the amino acid sequence of the substrate near the junction of the extracellular domain and luminal segment of the TMD. © 2014 American Chemical Society.",,"Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Golde, T.E., Eckman, C.B., Younkin, S.G., Biochemical detection of Aβ isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimers disease (2000) Biochim. Biophys. Acta, 1502, pp. 172-187; Younkin, S.G., The role of Aβ42 in Alzheimers disease (1998) J. Physiol. Paris, 92, pp. 289-292; Jarret, J.T., The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implication for the pathogenesis of Alzheimers disease (1993) Biochemistry, 32, pp. 4693-4697; McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Golde, T., Aβ42 is essential for parenchymal and vascular amyloid deposition in mice (2005) Neuron, 47, pp. 191-199; Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D.W., McGowan, E., Aβ40 Inhibits Amyloid Deposition in Vivo (2007) J. Neurosci., 27, pp. 627-633; Wang, R., Wang, B., He, W., Zheng, H., Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology (2006) J. Biol. Chem., 281, pp. 15330-15336; Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, L., Younkin, L.H., Suzuki, N., Younkin, S.G., Amyloid β Protein (Aβ) in Alzheimers Disease Brain (1995) J. Biol. Chem., 270, pp. 7013-7016; Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) (1994) Neuron, 13, pp. 45-53; Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schenk, D., Isolation and quantification of soluble Alzheimers β-peptide from biological fluids (1992) Nature, 359, pp. 325-327; Moore, B.D., Chakrabarty, P., Levites, Y., Kukar, T.L., Baine, A.M., Moroni, T., Ladd, T.B., Golde, T.E., Overlapping profiles of Aβ peptides in the Alzheimers disease and pathological aging brains (2012) Alzheimers Res. Ther., 4, p. 18; Golde, T.E., Disease modifying therapy for AD (2006) J. Neurochem., 99, pp. 689-707; De Strooper, B., Vassar, R., Golde, T., The secretases: Enzymes with therapeutic potential in Alzheimer disease (2010) Nat. Rev. Neurol., 6, pp. 99-107; Golde, T.E., Petrucelli, L., Lewis, J., Targeting Aβ and tau in Alzheimers disease, an early interim report (2010) Exp. Neurol., 223, pp. 252-266; Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Koo, E.H., A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity (2001) Nature, 414, pp. 212-216; Eriksen, J.L., Sagi, S.A., Smith, T.E., Weggen, S., Das, P., McLendon, D.C., Ozols, V.V., Golde, T.E., NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo (2003) J. Clin. Invest., 112, pp. 440-449; Golde, T.E., Koo, E.H., Felsenstein, K.M., Osborne, B.A., Miele, L., γ-Secretase inhibitors and modulators (2013) Biochim. Biophys. Acta, 1828, pp. 2898-2907; Kukar, T., Golde, T.E., Possible mechanisms of action of NSAIDs and related compounds that modulate γ-secretase cleavage (2008) Curr. Top. Med. Chem., 8, pp. 47-53; Rivkin, A., Ahearn, S.P., Chichetti, S.M., Kim, Y.R., Li, C., Rosenau, A., Kattar, S.D., Shearman, M.S., Piperazinyl pyrimidine derivatives as potent γ-secretase modulators (2010) Bioorg. Med. Chem. Lett., 20, pp. 1269-1271; Page, R.M., Gutsmiedl, A., Fukumori, A., Winkler, E., Haass, C., Steiner, H., β-Amyloid Precursor Protein Mutants Respond to γ-Secretase Modulators (2010) J. Biol. Chem., 285, pp. 17798-17810; Loureiro, R.M., Dumin, J.A., McKee, T.D., Austin, W.F., Fuller, N.O., Hubbs, J.L., Shen, R., Tate, B., Efficacy of SPI-1865, a novel γ-secretase modulator, in multiple rodent models (2013) Alzheimers Res. Ther., 5, p. 19; Kukar, T., Murphy, M.P., Eriksen, J.L., Sagi, S.A., Weggen, S., Smith, T.E., Ladd, T., Golde, T.E., Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production (2005) Nat. Med., 11, pp. 545-550; Beel, A.J., Sanders, C.R., Substrate specificity of γ-secretase and other intramembrane proteases (2008) Cell. Mol. Life Sci., 65, pp. 1311-1334; De Strooper, B., Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex (2003) Neuron, 38, pp. 9-12; Wahrle, S., Das, P., Nyborg, A.C., McLendon, C., Shoji, M., Kawarabayashi, T., Younkin, L.H., Golde, T.E., Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains (2002) Neurobiol. Dis., 9, pp. 11-23; Lee, S.J., Liyanage, U., Bickel, P.E., Xia, W., Lansbury, P.T., Kosik, K.S., A detergent-insoluble membrane compartment contains Aβ in vivo (1998) Nat. Med., 4, pp. 730-734; De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J., Schroeter, E.H., Kopan, R., A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain (1999) Nature, 398, pp. 518-522; Taniguchi, Y., Kim, S.-H., Sisodia, S.S., Presenilin-dependent ""γ-Secretase"" Processing of Deleted in Colorectal Cancer (DCC) (2003) J. Biol. Chem., 278, pp. 30425-30428; Kopan, R., Ilagan, M.X.G., γ-Secretase: Proteasome of the membrane? (2004) Nat. Rev. Mol. Cell Biol., 5, pp. 499-504; Cupers, P., Orlans, I., Craessaerts, K., Annaert, W., De Strooper, B., The amyloid precursor protein (APP)-cytoplasmic fragment generated by γ-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture (2001) J. Neurochem., 78, pp. 1168-1178; Chavez-Gutierrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., De Strooper, B., The mechanism of γ-secretase dysfunction in familial Alzheimer disease (2012) EMBO J., 31, pp. 2261-2274; Murphy, M.P., Hickman, L.J., Eckman, C.B., Uljon, S.N., Wang, R., Golde, T.E., γ-Secretase, Evidence for Multiple Proteolytic Activities and Influence of Membrane Positioning of Substrate on Generation of Amyloid β Peptides of Varying Length (1999) J. Biol. Chem., 274, pp. 11914-11923; Kukar, T.L., Ladd, T.B., Robertson, P., Pintchovski, S.A., Moore, B., Bann, M.A., Ren, Z., Golde, T.E., Lysine 624 of the Amyloid Precursor Protein (APP) Is a Critical Determinant of Amyloid β Peptide Length (2011) J. Biol. Chem., 286, pp. 39804-39812; Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., Ihara, Y., γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment (2009) J. Neurosci., 29, pp. 13042-13052; Quintero-Monzon, O., Martin, M.M., Fernandez, M.A., Cappello, C.A., Krzysiak, A.J., Osenkowski, P., Wolfe, M.S., Dissociation between the Processivity and Total Activity of γ-Secretase: Implications for the Mechanism of Alzheimers Disease-Causing Presenilin Mutations (2011) Biochemistry, 50, pp. 9023-9035; Funamoto, S., Morishima-Kawashima, M., Tanimura, Y., Hirotani, N., Saido, T.C., Ihara, Y., Truncated Carboxyl-Terminal Fragments of β-Amyloid Precursor Protein Are Processed to Amyloid β-Proteins 40 and 42 (2004) Biochemistry, 43, pp. 13532-13540; Dimitrov, M., Alattia, J.-R., Lemmin, T., Lehal, R., Fligier, A., Houacine, J., Hussain, I., Fraering, P.C., Alzheimers disease mutations in APP but not γ-secretase modulators affect ε-cleavage-dependent AICD production (2013) Nat. Commun., 4, p. 2246; Ran, Y., Cruz, P.E., Ladd, T.B., Fauq, A.H., Jung, J.I., Matthews, J., Felsenstein, K.M., Golde, T.E., γ-Secretase Processing and Effects of γ-Secretase Inhibitors and Modulators on Long Aβ Peptides in Cells (2014) J. Biol. Chem., 289, pp. 3276-3287; Matsumura, N., Takami, M., Okochi, M., Wada-Kakuda, S., Fujiwara, H., Tagami, S., Funamoto, S., Morishima-Kawashima, M., γ-Secretase associated with lipid rafts: Multiple interactive pathways in the stepwise processing of β-carboxyl terminal fragment (2013) J. Biol. Chem., 289, pp. 5109-5121; Sagi, S.A., Lessard, C.B., Winden, K.D., Maruyama, H., Koo, J.C., Weggen, S., Kukar, T.L., Koo, E.H., Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein (2011) J. Biol. Chem., 286, pp. 39794-39803; Ousson, S., Saric, A., Baguet, A., Losberger, C., Genoud, S., Vilbois, F., Permanne, B., Beher, D., Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology (2013) J. Neurochem., 125, pp. 610-619; Page, R.M., Baumann, K., Tomioka, M., Pérez-Revuelta, B.I., Fukumori, A., Jacobsen, H., Flohr, A., Haass, C., Generation of Aβ38 and Aβ42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ-Secretase Modulation (2008) J. Biol. Chem., 283, pp. 677-683; Munter, L., Voigt, P., Harmeier, A., Kaden, D., Gottschalk, K., Weise, C., Pipkorn, R., Multhaup, G., GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Aβ42 (2007) EMBO J., 26, pp. 1702-1712; Zall, A., Kieser, D., Hottecke, N., Naumann, E.C., Thomaszewski, B., Schneider, K., Steinbacher, D.T., Schmidt, B., NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold (2011) Bioorg. Med. Chem., 19, pp. 4903-4909; Narlawar, R., Baumann, K., Czech, C., Schmidt, B., Conversion of the LXR-agonist TO-901317: From inverse to normal modulation of γ-secretase by addition of a carboxylic acid and a lipophilic anchor (2007) Bioorg. Med. Chem., 17, pp. 5428-5431; Richter, L., Munter, L.-M., Ness, J., Hildebrand, P.W., Dasari, M., Unterreitmeier, S., Bulic, B., Multhaup, G., Amyloid β42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization (2010) Proc. Natl. Acad. Sci. U.S.A., 107, pp. 14597-14602; Kukar, T.L., Ladd, T.B., Bann, M.A., Fraering, P.C., Narlawar, R., Maharvi, G.M., Healy, B., Golde, T.E., Substrate-targeting γ-secretase modulators (2008) Nature, 453, pp. 925-929; Carey, M.F., Peterson, C.L., Smale, S.T., PCR-Mediated Site-Directed Mutagenesis (2013) Cold Spring Harbor Protoc., 2013, pp. 738-742; Kim, S.-H., Leem, J.Y., Lah, J.J., Slunt, H.H., Levey, A.I., Thinakaran, G., Sisodia, S.S., Multiple Effects of Aspartate Mutant Presenilin 1 on the Processing and Trafficking of Amyloid Precursor Protein (2001) J. Biol. Chem., 276, pp. 43343-43350; Ren, Z., Schenk, D., Basi, G.S., Shapiro, I.P., Amyloid β-Protein Precursor Juxtamembrane Domain Regulates Specificity of γ-Secretase-dependent Cleavages (2007) J. Biol. Chem., 282, pp. 35350-35360; Raymond, C., Tom, R., Perret, S., Moussouami, P., Labbé, D., St-Laurent, G., Durocher, Y., A simplified polyethylenimine-mediated transfection process for large-scale and high-throughput applications (2011) Methods, 55, pp. 44-51; Wang, R., Sweeney, D., Gandy, S.E., Sisodia, S.S., The profile of soluble amyloid β protein in cultured cell media. Detection and quantification of amyloid β protein and variants by immunoprecipitation-mass spectrometry (1996) J. Biol. Chem., 271, pp. 31894-31902; Murphy, M.P., Uljon, S.N., Fraser, P.E., Fauq, A., Lookingbill, H.A., Findlay, K., Smith, T.E., Golde, T.E., Presenilin 1 regulates pharmacologically distinct γ-secretase activities. Implications for the role of presenilin in γ-secretase cleavage (2000) J. Biol. Chem., 275, pp. 26277-26284; Levites, Y., Das, P., Price, R.W., Rochette, M.J., Kostura, L.A., McGowan, E.M., Murphy, M.P., Golde, T.E., Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model (2006) J. Clin. Invest., 116, pp. 193-201; Jung, J.I., Ladd, T.B., Kukar, T., Price, A.R., Moore, B.D., Koo, E.H., Golde, T.E., Felsenstein, K.M., Steroids as γ-secretase modulators (2013) FASEB J., 27, pp. 3775-3785; Kimberly, W.T., Esler, W.P., Ye, W., Ostaszewski, B.L., Gao, J., Diehl, T., Selkoe, D.J., Wolfe, M.S., Notch and the Amyloid Precursor Protein Are Cleaved by Similar γ-Secretase(s) (2003) Biochemistry, 42, pp. 137-144; Esler, W.P., Kimberly, W.T., Ostaszewski, B.L., Ye, W., Diehl, T.S., Selkoe, D.J., Wolfe, M.S., Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate (2002) Proc. Natl. Acad. Sci. U.S.A., 99, pp. 2720-2725; Fraering, P.C., Ye, W., Lavoie, M.J., Ostaszewski, B.L., Selkoe, D.J., Wolfe, M.S., γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site (2005) J. Biol. Chem., 280, pp. 41987-41996; Alcaraz, C., De Diego, M., Pastor, M.J., Escribano, J.M., Comparison of a Radioimmunoprecipitation Assay to Immunoblotting and ELISA for Detection of Antibody to African Swine Fever Virus (1990) Journal of Veterinary Diagnostic Investigation, 2, pp. 191-196; Wanngren, J., Ottervald, J., Parpal, S., Portelius, E., Stromberg, K., Borgegard, T., Klintenberg, R., Karlstrom, H., Second Generation γ-Secretase Modulators Exhibit Different Modulation of Notch β and Aβ Production (2012) J. Biol. Chem., 287, pp. 32640-32650; Okochi, M., Fukumori, A., Jiang, J., Itoh, N., Kimura, R., Steiner, H., Haass, C., Takeda, M., Secretion of the Notch-1 Aβ-like Peptide during Notch Signaling (2006) J. Biol. Chem., 281, pp. 7890-7898; Li, X., Dang, S., Yan, C., Gong, X., Wang, J., Shi, Y., Structure of a presenilin family intramembrane aspartate protease (2013) Nature, 493, pp. 56-61; Wolfe, M.S., Toward the structure of presenilin/γ-secretase and presenilin homologs (2013) Biochim. Biophys. Acta, 1828, pp. 2886-2897; Levental, I., Grzybek, M., Simons, K., Greasing Their Way: Lipid Modifications Determine Protein Association with Membrane Rafts (2010) Biochemistry, 49, pp. 6305-6316; Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T.S., Mori, K., Nakayama, T., Takeda, M., γ-Secretase Modulators and Presenilin 1 Mutants Act Differently on Presenilin/γ-Secretase Function to Cleave Aβ42 and Aβ43 (2013) Cell Rep., 3, pp. 42-51; Ohki, Y., Higo, T., Uemura, K., Shimada, N., Osawa, S., Berezovska, O., Yokoshima, S., Iwatsubo, T., Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1 (2011) EMBO J., 30, pp. 4815-4824; Jumpertz, T., Rennhack, A., Ness, J., Baches, S., Pietrzik, C.U., Bulic, B., Weggen, S., Presenilin is the molecular target of acidic γ-secretase modulators in living cells (2012) PLoS One, 7, p. 30484; Ebke, A., Luebbers, T., Fukumori, A., Shirotani, K., Haass, C., Baumann, K., Steiner, H., Novel γ-Secretase Enzyme Modulators Directly Target Presenilin Protein (2011) J. Biol. Chem., 286, pp. 37181-37186; Pozdnyakov, N., Murrey, H.E., Crump, C.J., Pettersson, M., Ballard, T.E., Am Ende, C.W., Ahn, K., Johnson, D.S., γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin (2013) J. Biol. Chem., 288, pp. 9710-9720; Kounnas, M.Z., Danks, A.M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Wagner, S.L., Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimers Disease (2010) Neuron, 67, pp. 769-780; Holmes, O., Paturi, S., Ye, W., Wolfe, M.S., Selkoe, D.J., Effects of Membrane Lipids on the Activity and Processivity of Purified γ-Secretase (2012) Biochemistry, 51, pp. 3565-3575; Weggen, S., Beher, D., Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimers disease (2012) Alzheimers Res. Ther., 4, p. 9; Gijsen, H.J.M., Mercken, M., γ-Secretase Modulators: Can We Combine Potency with Safety? (2012) Int. J. Alzheimers Dis., 2012, p. 10; Puglielli, L., Ellis, B.C., Saunders, A., Kovacs, D.M., Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis (2003) J. Biol. Chem., 278, pp. 19777-19783",Article,Scopus,2-s2.0-84898080760
"Mesulam M.-M., Weintraub S., Rogalski E.J., Wieneke C., Geula C., Bigio E.H.","Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia",2014,"Brain","137","4",,"1176","1192",,14,10.1093/brain/awu024,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897827105&partnerID=40&md5=c2b4157a4a948e1f74098eabc6bda5ce","Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States","Mesulam, M.-M., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States; Weintraub, S., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States; Rogalski, E.J., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States; Wieneke, C., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States; Geula, C., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States; Bigio, E.H., Cognitive Neurology and Alzheimer's Disease Centre, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States","Fifty-eight autopsies of patients with primary progressive aphasia are reported. Twenty-three of these were previously described (Mesulam et al., 2008) but had their neuropathological diagnoses updated to fit current criteria. Thirty-five of the cases are new. Their clinical classification was guided as closely as possible by the 2011 consensus guidelines (Gorno-Tempini et al., 2011). Tissue diagnoses included Alzheimer's disease in 45% and frontotemporal lobar degeneration (FTLD) in the others, with an approximately equal split between TAR DNA binding protein 43 proteinopathies and tauopathies. The most common and distinctive feature for all pathologies associated with primary progressive aphasia was the asymmetric prominence of atrophy, neuronal loss, and disease-specific proteinopathy in the language-dominant (mostly left) hemisphere. The Alzheimer's disease pathology in primary progressive aphasia displayed multiple atypical features. Males tended to predominate, the neurofibrillary pathology was more intense in the language-dominant hemisphere, the Braak pattern of hippocampo-entorhinal prominence was tilted in favour of the neocortex, and the APOE e4 allele was not a risk factor. Mean onset age was under 65 in the FTLD as well as Alzheimer's disease groups. The FTLD-TAR DNA binding protein 43 group had the youngest onset and fastest progression whereas the Alzheimer's disease and FTLD-tau groups did not differ from each other in either onset age or progression rate. Each cellular pathology type had a preferred but not invariant clinical presentation. The most common aphasic manifestation was of the logopenic type for Alzheimer pathology and of the agrammatic type for FTLD-tau. The progressive supranuclear palsy subtype of FTLD-tau consistently caused prominent speech abnormality together with agrammatism whereas FTLD-TAR DNA binding protein 43 of type C consistently led to semantic primary progressive aphasia. The presence of agrammatism made Alzheimer's disease pathology very unlikely whereas the presence of a logopenic aphasia or word comprehension impairment made FTLD-tau unlikely. The association of logopenic primary progressive aphasia with Alzheimer's disease pathology was much more modest than has been implied by results of in vivo amyloid imaging studies. Individual features of the aphasia, such as agrammatism and comprehension impairment, were as informative of underlying pathology as more laborious subtype diagnoses. At the single patient level, no clinical pattern was pathognomonic of a specific neuropathology type, highlighting the critical role of biomarkers for diagnosing the underlying disease. During clinical subtyping, some patients were unclassifiable by the 2011 guidelines whereas others simultaneously fit two subtypes. Revisions of criteria for logopenic primary progressive aphasia are proposed to address these challenges. © 2013 The Author.","Alzheimers disease; aphasia; ApoE e4; frontotemporal lobar degeneration; hemispheric lateralization","Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., Focal cortical presentations of Alzheimer's disease (2007) Brain, 130, pp. 2636-2645; Bigio, E.H., Making the diagnosis of frontotemporal lobar degeneration (2013) Arch Pathol Lab Med, 137, pp. 314-325; Caselli, R.J., Beach, T.G., Sue, L.I., Connor, D.J., Sabbagh, M.N., Progressive aphasia with Lewy bodies (2002) Dement Geriatr Cogn Disord, 14, pp. 55-58; Deramecourt, V., Lebert, F., Debachy, B., Mackowiak-Cardoliani, M.A., Bombois, S., Kerdraon, O., Prediction of pathology in primary progressive language and speech disorders (2010) Neurology, 74, pp. 42-49; Dunn, L.A., Dunn, L.M., (2006) Peabody Picture Vocabulary test-4, , Minneapolis: Pearson;; Forman, M.S., Jennifer, F., Johnson, J.K., Clark, C.M., Arnold, S.E., Coslett, H.B., Frontotemporal dementia: Clinicopathological correlations (2006) Ann Neurol, 59, pp. 952-962; Gefen, T., Gasho, K., Rademaker, A., Lalehzari, M., Weintraub, S., Rogalski, E., Clinically concordant variations of Alzheimer pathology in apha-sic versus amnestic dementia (2012) Brain, 135, pp. 1554-1565; Gliebus, G., Bigio, E., Gasho, K., Mishra, M., Caplan, D., Mesulam, M.-M., Asymmetric TDP-43 distribution in primary progressive aphasia with progranulin mutation (2010) Neurology, 74, pp. 1607-1610; Goodglass, H., Kaplan, E., Barresi, B., (2001) Boston Diagnostic Aphasia Examination. 3rd Edn, , Austin: Pro-Ed;; Gorno-Tempini, M.L., Dronkers, N.F., Rankin, K.P., Ogar, J.M., Phengrasamy, L., Rosen, H.J., Cognition and anatomy in three variants of primary progressive aphasia (2004) Ann Neurol, 55, pp. 335-346; Gorno-Tempini, M.L., Hillis, A., Weintraub, S., Kertesz, A., Mendez, M.F., Cappa, S.F., Classification of primary progressive aphasia and its variants (2011) Neurology, 76, pp. 1006-1014; Grossman, M., The non-fluent/agrammatic variant of primary progressive aphasia (2012) Lancet Neurol, 11, pp. 545-555; Grossman, M., Xie, S.X., Djw, L., Massimo, L., Moore, P., Vesely, L., Longitudinal decline in autopsy-defined frontotemporal lobar degeneration (2008) Neurology, 70, pp. 2036-2045; Harris, J.M., Gall, C., Thompson, J.C., Amt, R., Neary, D., Du Plessis, D., Classification and pathology of primary progressive aphasia (2013) Neurology, 81, pp. 1-8; Hodges, J.R., Davies, R.R., Xuereb, J.H., Casey, B., Broe, M., Bak, T.H., Clinicopathological correlates in frontotemporal dementia (2004) Ann Neurol, 56, pp. 399-406; Hof, P.R., Vogt, B.A., Bouras, C., Morrison, J.H., Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: A review of lesion distribution and circuit disconnection in cortical visual pathways (1997) Vision Res, 37, pp. 3609-3625; Howard, D., Patterson, K., (1992) Pyramids and Palm Trees: A Test of Symantic Access from Pictures and Words, , Edmonds Suffolk UK: Thames Valley Test Company;; Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E., Cairns, N.J., Carillo, M.C., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach (2012) Alzheimers Dement, 8, pp. 1-13; Ito, S., Progressive supranuclear palsy and diffusion tensor imaging (2009) Eur Neurol Rev, 4, pp. 108-111; Johnson, J.K., Head, E., Kim, R., Starr, A., Cotman, C.W., Clinical and pathological evidence for a frontal variant of Alzheimer disease (1999) Arch Neurol, 56, pp. 1233-1239; Johnson, N., Barion, A., Rademaker, A., Rehkemper, G., Weintraub, S., The activities of daily living questionnaire (ADLQ): A validation study in patients with dementia (2004) Alzheimer Dis Assoc Disord, 18, pp. 223-230; Josephs, K.A., Duffy, R.J., Strand, E.A., Whitwell, J.L., Layton, K.F., Parisi, J.E., Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech (2006) Brain, 129, pp. 1385-1398; Kaplan, E., Goodglass, H., Weintraub, S., (1983) The Boston Naming Test, , Philadelphia: Lea & Febiger;; Kertesz, A., McMonagle, P., Blair, M., Davidson, W., Munoz, D.G., The evolution and pathology of frontotemporal dementia (2005) Brain, 128, pp. 1996-2005; Kertesz, A., (2006) WesternAphasia Battery-Revised (WAB-R), , Austin:Pro-Ed;; Knibb, J.A., Xuereb, J.H., Patterson, K., Hodges, J.R., Clinical and pathological characterization of progressive aphasia (2006) Ann Neurol, 59, pp. 156-165; Knopman, D.S., Mastri, A.R., Frey, W.H.I.I., Sung, J.H., Rustan, T., Dementia lacking distinctive histologic features: A common non-Alzheimer degenerative dementia (1990) Neurology, 40, pp. 251-256; Lehmann, M., Ghosh, P.M., Madison, C., Lafirce Jr., R., Corbetta-Rastelli, C., Weiner, M.W., Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease (2013) Brain, 136, pp. 844-858; Leyton, C.E., Villemange, V.L., Savage, S., Pike, K.E., Ballard, K.J., Piguet, O., Subtypes of progressive aphasia: Application of the international consensus criteria and validation using b-amyloid imaging (2011) Brain, 134, pp. 3030-3043; Mackenzie, I., Baborie, A., Pickering-Brown, S., Du Plessis, D., Jaros, E., Perry, R.H., Heterogeneity of ubiquitin pathology in frontotem-poral lobar degeneration: Classification and relation to clinical pheno-type (2006) Acta Neuropathol, 112, pp. 539-549; Mackenzie, I.R., Neumann, M., Bigio, E., Cairns, N.J., Alafuzoff, I., Krill, J., Nomenclature and nosology for neuropathologic subtypes of frontotem-poral lobar degeneration: An update (2010) Acta Neuropathol, 119, pp. 1-4; Mackenzie, I.R., Neumann, M., Baborie, A., Sampathu, D.M., Du Plessis, D., Jaros, E., A harmonized classification system for FTLD-TDP pathology (2011) Acta Neuropathol, 122, pp. 111-113; Mesulam, M., Weintraub, S., Is it time to revisit the classification of primary progressive aphasia? (2014) Neurology, , (Epub ahead of print.); Mesulam, M.M., Slowly progressive aphasia without generalized dementia (1982) Ann Neurol, 11, pp. 592-598; Mesulam, M.-M., Primary progressive aphasia (2001) Ann Neurol, 49, pp. 425-432; Mesulam, M.-M., Weintraub, S., Spectrum of primary progressive aphasia (1992) Unusual Dementias, pp. 583-609. , Rossor MN, editor, London: Baillière Tindall;; Mesulam, M.-M., Weintraub, S., Parrish, T., Gitelman, D.R., Primary progressive aphasia: Reversed asymmetry of atrophy and right hemisphere language dominance (2005) Neurology, 64, pp. 556-557; Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Leger, G.C., Rademaker, A., Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia (2008) Ann Neurol, 63, pp. 709-719; Mesulam, M., Wieneke, C., Rogalski, E., Cobia, D., Thompson, C., Weintraub, S., Quantitative template for subtyping primary progressive aphasia (2009) Arch Neurol, 66, pp. 1545-1551; Mesulam, M.-M., Wieneke, C., Thompson, C., Rogalski, E., Weintraub, S., Quantitative classification of primary progressive aphasia at early and mild impairment stages (2012) Brain, 135, pp. 1537-1553; Miller, Z.A., Mandelli, M.A., Rankin, K.P., Henry, M.L., Babiak, M.C., Frazier, D.T., Handedness and language learning disability differentially distribute in progressive aphasia variants (2013) Brain, 136, pp. 3461-3473; Mochizuki, A., Ueda, Y., Komatsuzaki, Y., Tsuchiya, K., Arai, T., Shoji, S., Progressive supranuclear palsy presenting with primary progressive aphasia-Clinicopathological report of an autopsy case (2003) Acta Neuropathol, 105, pp. 610-614; Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., National Institute on Aging-Alzheimer's Association guidelines for a neuropathologic assesment of Alzheimer's disease: A practical approach (2012) Acta Neuropathol, 123, pp. 1-11; Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria (1998) Neurology, 51, pp. 1546-1554; Perry, D.C., Lehmann, M., Yokoyama, J.S., Karydas, A.M., Lee, J.J., Coppola, G., Progranulin mutations as risk factors for Alzheimer disease (2013) JAMA Neurol, 70, pp. 774-778; Pinel, P., Fauchereau, F., Moreno, A., Barbot, A., Lathrop, M., Zelenika, D., Genetic variants of FOXP2 and KIAA0319/TTRAP/THEM2 locus are associated with altered brain activation in distinct language-related regions (2012) J Neurosci, 32, pp. 817-825; Premi, E., Pilotto, A., Alberici, A., Papetti, A., Archetti, S., Seripa, D., FOXP2, ApoE, and PRNP: New modulators in primary progressive aphasia (2012) J Alzheimers Dis, 28, pp. 941-950; Rogalski, E., Johnson, N., Weintraub, S., Mesulam, M.-M., Increased frequency of learning disability in patients with primary progressive aphasia and their first degree relatives (2008) Arch Neurol, 65, pp. 244-248; Rogalski, E., Rademaker, A., Helenewski, I., Johnson, N., Bigio, E., Mishra, M., APOE e4 is a susceptibility factor in amnestic but not aphasic dementias (2011) Am J Alzheimers Dis Other Demen, 25, pp. 159-163; Rogalski, E., Weintraub, S., Mesulam, M.-M., Are there susceptibility factors for primary progressive aphasia? (2013) Brain Lang, 127, pp. 135-138; Rohrer, J.D., Geser, F., Zhou, J., Gennatas, E.D., Sidhu, M., Trojanowski, J.Q., TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia (2010) Neurology, 75, pp. 2204-2211; Rohrer, J.D., Rossor, M.N., Warren, J., Alzheimer pathology in primary progressive aphasia (2012) Neurobiol Age, 33, pp. 744-752; Sajjadi, S.A., Patterson, K., Arnold, R.J., Watson, P.C., Nestor, P.J., Primary progressive aphasia: A tale of two syndromes and the rest (2012) Neurology, 78, pp. 1670-1677; Sun, T., Patoine, C., Abu-Khalil, A., Visvader, J., Sum, E., Cherry, T.J., Early asymmetry of gene transcription in embryonic human left and right cerebral cortex (2005) Science, 308, pp. 1794-1798; Thompson, C.K., Cho, S., Hsu, C.-J., Wieneke, C., Rademaker, A., Weitner, B.B., Dissociations between fluency and agrammatism in primary progressive aphasia (2012) Aphasiology, 26, pp. 20-43; Thompson, C.K., Shapiro, L.P., Tait, M.E., Jacobs, B., Schneider, S.L., Ballard, K., A system for the linguistic analysis of agrammatic language production (1995) Brain Lang, 51, pp. 124-129; Weintraub, S., Mesulam, M., With or without FUS, it is the anatomy that dictates the dementia phenotype (2009) Brain, 132, pp. 2906-2908; Weintraub, S., Mesulam, M.-M., Wieneke, C., Rademaker, A., Rogalski, E.J., Thompson, C.K., The Northwestern Anagram Test: Measuring sentence production in primary progressive aphasia (2009) Am J Alzheimers Dis Other Demen, 24, pp. 408-416; Weintraub, S., Rogalski, E., Shaw, E., Salwani, S., Rademaker, A., Wieneke, C., Verbal and nonverbal memory in primary progressive aphasia: The Three Words-Three Shapes Test (2012) Behav Neurol, 26, pp. 67-76; Weintraub, S., Rubin, N.P., Mesulam, M.M., Primary progressive aphasia. Longitudinal course, neuropsychological profile, and language features (1990) Arch Neurol, 47, pp. 1329-1335; Whitwell, J.L., Jack Jr., C.R., Boeve, B., Parisi, J.E., Ahlskog, J.E., Drubach, D.A., Imaging correlates of pathology in corticobasal syndrome (2010) Neurology, 75, pp. 1879-1887; Whitwell, J.L., Jack Jr., C.R., Parisi, J.E., Senjem, M.L., Knopman, D., Boeve, B., Does TDP-43 Type Confer A Distinct Pattern of Atrophy in Fron-totemporal Lobar Degeneration? Neurology 2010b, 75, pp. 2212-2220; Wicklund, A., Johnson, N., Weintraub, N., Preservation of reasoning in primary progressive aphasia: Further differentiation from Alzheimer's disease and the behavioral presentation of frontotemporal dementia (2004) J Clin Exper Neuropsychol, 26, pp. 347-355; Wicklund, M.R., Duffy, J.R., Strand, E.A., Machulda, M.M., Whitwell, J.L., Quantitative application of the primary progressive aphasia consensus criteria (2014) Neurology, , Epub ahead of print",Article,Scopus,2-s2.0-84897827105
"Joshi P., Turola E., Ruiz A., Bergami A., Libera D.D., Benussi L., Giussani P., Magnani G., Comi G., Legname G., Ghidoni R., Furlan R., Matteoli M., Verderio C.","Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles",2014,"Cell Death and Differentiation","21","4",,"582","593",,7,10.1038/cdd.2013.180,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903362492&partnerID=40&md5=453b5eb5d121e24c4d5b004c3aba43e1","Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy; Department of Medicine, CNR Institute of Neuroscience, via Vanvitelli 32, I-Milano-20129, Italy; INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni, Brescia 4 25125, Italy; SISSA, Department of Neuroscience, Via Bonomea 265, Trieste I-34136, Italy; IRCCS Humanitas, via Manzoni 56, Rozzano 20089, Italy","Joshi, P., Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy, Department of Medicine, CNR Institute of Neuroscience, via Vanvitelli 32, I-Milano-20129, Italy; Turola, E., Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy, Department of Medicine, CNR Institute of Neuroscience, via Vanvitelli 32, I-Milano-20129, Italy; Ruiz, A., Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy; Bergami, A., INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Libera, D.D., INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Benussi, L., Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni, Brescia 4 25125, Italy; Giussani, P., Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy; Magnani, G., INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Comi, G., INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Legname, G., SISSA, Department of Neuroscience, Via Bonomea 265, Trieste I-34136, Italy; Ghidoni, R., Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni, Brescia 4 25125, Italy; Furlan, R., INSPE, Division of Neuroscience, San Raffaele Scientific Institute, via Olgettina 60, I-Milano-20132, Italy; Matteoli, M., Department of Biotechnology and Translational Medicine, University of Milano, via Vanvitelli 32, I-Milano-20129, Italy, IRCCS Humanitas, via Manzoni 56, Rozzano 20089, Italy; Verderio, C., Department of Medicine, CNR Institute of Neuroscience, via Vanvitelli 32, I-Milano-20129, Italy, IRCCS Humanitas, via Manzoni 56, Rozzano 20089, Italy","Alzheimer's disease (AD) is characterized by extracellular amyloid-β (Aβ) deposition, which activates microglia, induces neuroinflammation and drives neurodegeneration. Recent evidence indicates that soluble pre-fibrillar Aβ species, rather than insoluble fibrils, are the most toxic forms of Aβ. Preventing soluble Aβ formation represents, therefore, a major goal in AD. We investigated whether microvesicles (MVs) released extracellularly by reactive microglia may contribute to AD degeneration. We found that production of myeloid MVs, likely of microglial origin, is strikingly high in AD patients and in subjects with mild cognitive impairment and that AD MVs are toxic for cultured neurons. The mechanism responsible for MV neurotoxicity was defined in vitro using MVs produced by primary microglia. We demonstrated that neurotoxicity of MVs results from (i) the capability of MV lipids to promote formation of soluble Aβ species from extracellular insoluble aggregates and (ii) from the presence of neurotoxic Aβ forms trafficked to MVs after Aβ internalization into microglia. MV neurotoxicity was neutralized by the Aβ-interacting protein PrP and anti-Aβ antibodies, which prevented binding to neurons of neurotoxic soluble Aβ species. This study identifies microglia-derived MVs as a novel mechanism by which microglia participate in AD degeneration, and suggest new therapeutic strategies for the treatment of the disease. © 2014 Macmillan Publishers Limited All rights reserved.","Abeta 1-42; Alzheimers disease; bioactive lipids; extracellular microvesicles; microglia; prion protein","Herring, A., Lewejohann, L., Panzer, A.L., Donath, A., Kroll, O., Sachser, N., Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms (2011) Neurobiol Dis, 42, pp. 530-538; Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G., On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) (2006) Biochemistry, 45, pp. 12393-12399; Bieschke, J., Herbst, M., Wiglenda, T., Friedrich, R.P., Boeddrich, A., Schiele, F., Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils (2012) Nat Chem Biol, 8, pp. 93-101; Winklhofer, K.F., Tatzelt, J., Haass, C., The two faces of protein misfolding: Gain- and loss-offunction in neurodegenerative diseases (2008) EMBO J, 27, pp. 336-349; Benilova, I., Karran, E., De Strooper, B., The toxic Abeta oligomer and Alzheimer's disease: An emperor in need of clothes (2012) Nat Neurosci, 15, pp. 349-357; Lue, L.F., Brachova, L., Civin, W.H., Rogers, J., Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration (1996) J Neuropathol Exp Neurol, 55, pp. 1083-1088; Haass, C., Mandelkow, E., Fyn-tau-amyloid: A toxic triad (2010) Cell, 142, pp. 356-358; Serrano-Pozo, A., Mielke, M.L., Gomez-Isla, T., Betensky, R.A., Growdon, J.H., Frosch, M.P., Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease (2011) Am J Pathol, 179, pp. 1373-1384; Serrano-Pozo, A., Mielke, M.L., Muzitansky, A., Gomez-Isla, T., Growdon, J.H., Bacskai, B.J., Stable size distribution of amyloid plaques over the course of Alzheimer disease (2012) J Neuropathol Exp Neurol, 71, pp. 694-701; Walsh, D.M., Selkoe, D.J., A beta oligomers - A decade of discovery (2007) J Neurochem, 101, pp. 1172-1184; McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease (1999) Ann Neurol, 46, pp. 860-866; Mielke, M.M., Haughey, N.J., Bandaru, V.V., Weinberg, D.D., Darby, E., Zaidi, N., Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease (2011) J Alzheimers Dis, 27, pp. 259-269; Martins, I.C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice (2008) EMBO J, 27, pp. 224-233; Johansson, A.S., Garlind, A., Berglind-Dehlin, F., Karlsson, G., Edwards, K., Gellerfors, P., Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloidbeta- induced neurotoxicity in vitro (2007) FEBS J, 274, pp. 990-1000; Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Regulation of NMDA receptor trafficking by amyloid-beta (2005) Nat Neurosci, 8, pp. 1051-1058; Lauren, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers (2009) Nature, 457, pp. 1128-1132; Um, J.W., Nygaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A., Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons (2012) Nat Neurosci, 15, pp. 1227-1235; Verdier, Y., Zarandi, M., Penke, B., Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease (2004) J Pept Sci, 10, pp. 229-248; Edison, P., Archer, H.A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F.E., Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study (2008) Neurobiol Dis, 32, pp. 412-419; Okello, A., Edison, P., Archer, H.A., Turkheimer, F.E., Kennedy, J., Bullock, R., Microglial activation and amyloid deposition in mild cognitive impairment: A PET study (2009) Neurology, 72, pp. 56-62; Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease (2011) Nat Genet, 43, pp. 429-435; Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., TREM2 variants in Alzheimer's disease (2013) N Engl J Med, 368, pp. 117-127; Giulian, D., Haverkamp, L.J., Yu, J.H., Karshin, W., Tom, D., Li, J., Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia (1996) J Neurosci, 16, pp. 6021-6037; Fuhrmann, M., Bittner, T., Jung, C.K., Burgold, S., Page, R.M., Mitteregger, G., Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease (2010) Nat Neurosci, 13, pp. 411-413; Tan, B., Choi, R.H., Chin, T.J., Kaur, C., Ling, E.A., Manipulation of microglial activity as a therapy for Alzheimer's disease (2012) Front Biosci, 4, pp. 1402-1412; Weitz, T.M., Town, T., Microglia in Alzheimer's Disease: It's all about context (2012) Int J Alzheimers Dis, 2012, p. 314185; Bianco, F., Pravettoni, E., Colombo, A., Schenk, U., Moller, T., Matteoli, M., Induces vesicle shedding and IL-1 beta release from microglia (2005) J Immunol, 174, pp. 7268-7277; Del Conde, I., Shrimpton, C.N., Thiagarajan, P., Lopez, J.A., Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation (2005) Blood, 106, pp. 1604-1611; Gonnord, P., Delarasse, C., Auger, R., Benihoud, K., Prigent, M., Cuif, M.H., Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts (2009) FASEB J, 23, pp. 795-805; Verderio, C., Muzio, L., Turola, E., Bergami, A., Novellino, L., Ruffini, F., Myeloid microvesicles are a marker and therapeutic target for neuroinflammation (2012) Ann Neurol, 72, pp. 610-624; Colombo, E., Borgiani, B., Verderio, C., Furlan, R., Microvesicles: Novel biomarkers for neurological disorders (2012) Front Physiol, 3, p. 63; Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., Alzheimer's disease beta-amyloid peptides are released in association with exosomes (2006) Proc Natl Acad Sci USA, 103, pp. 11172-11177; Perry, V.H., Nicoll, J.A., Holmes, C., Microglia in neurodegenerative disease (2010) Nat Rev Neurol, 6, pp. 193-201; Fukunaga, S., Ueno, H., Yamaguchi, T., Yano, Y., Hoshino, M., Matsuzaki, K., GM1 cluster mediates formation of toxic Abeta fibrils by providing hydrophobic environments (2012) Biochemistry, 51, pp. 8125-8131; Turola, E., Furlan, R., Bianco, F., Matteoli, M., Verderio, C., Microglial microvesicle secretion and intercellular signaling (2012) Front Physiol, 3, p. 149; Jana, A., Pahan, K., Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: Implications for Alzheimer's disease (2010) J Neurosci, 30, pp. 12676-12689; Alberdi, E., Sanchez-Gomez, M.V., Cavaliere, F., Perez-Samartin, A., Zugaza, J.L., Trullas, R., Amyloid beta oligomers induce Ca2 dysregulation and neuronal death through activation of ionotropic glutamate receptors (2010) Cell Calcium, 47, pp. 264-272; Bianco, F., Perrotta, C., Novellino, L., Francolini, M., Riganti, L., Menna, E., Acid sphingomyelinase activity triggers microparticle release from glial cells (2009) EMBO J, 28, pp. 1043-1054; Holtzman, D.M., CSF biomarkers for Alzheimer's disease: Current utility and potential future use (2011) Neurobiol Aging, 32 (1), pp. S4-S9; Yuyama, K., Sun, H., Mitsutake, S., Igarashi, Y., Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia (2012) J Biol Chem, 287, pp. 10977-10989; Thery, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses (2009) Nat Rev Immunol, 9, pp. 581-593; Mattei, V., Barenco, M.G., Tasciotti, V., Garofalo, T., Longo, A., Boller, K., Paracrine diffusion of PrP(C) and propagation of prion infectivity by plasma membrane-derived microvesicles (2009) PLoS One, 4, pp. e5057; Han, X., Fagan, A.M., Cheng, H., Morris, J.C., Xiong, C., Holtzman, D.M., Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (2003) Ann Neurol, 54, pp. 115-119; Malnar, M., Kosicek, M., Bene, R., Tarnik, I.P., Pavelin, S., Babic, I., Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting (2012) Acta Neurobiol Exp, 72, pp. 264-271; Ghidoni, R., Paterlini, A., Albertini, V., Glionna, M., Monti, E., Schiaffonati, L., Cystatin C is released in association with exosomes: A new tool of neuronal communication which is unbalanced in Alzheimer's disease (2011) Neurobiol Aging, 32, pp. 1435-1442; Vella, L.J., Sharples, R.A., Nisbet, R.M., Cappai, R., Hill, A.F., The role of exosomes in the processing of proteins associated with neurodegenerative diseases (2008) Eur Biophys J, 37, pp. 323-332; Vingtdeux, V., Hamdane, M., Begard, S., Loyens, A., Delacourte, A., Beauvillain, J.C., Intracellular pH regulates amyloid precursor protein intracellular domain accumulation (2007) Neurobiol Dis, 25, pp. 686-696; Yamamoto, M., Kiyota, T., Walsh, S.M., Liu, J., Kipnis, J., Ikezu, T., Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes (2008) J Immunol, 181, pp. 3877-3886; Aguzzi, A., Barres, B.A., Bennett, M.L., Microglia: Scapegoat saboteur or something else? (2013) Science, 339, pp. 156-161; Prinz, M., Priller, J., Sisodia, S.S., Ransohoff, R.M., Heterogeneity of CNS myeloid cells and their roles in neurodegeneration (2011) Nat Neurosci, 14, pp. 1227-1235; Paresce, D.M., Chung, H., Maxfield, F.R., Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells (1997) J Biol Chem, 272, pp. 29390-29397; Lee, C.Y., Landreth, G.E., The role of microglia in amyloid clearance from the AD brain (2010) J Neural Transm, 117, pp. 949-960; Rajendran, L., Annaert, W., Membrane trafficking pathways in Alzheimer's disease (2012) Traffic, 13, pp. 759-770; Ariga, T., Kobayashi, K., Hasegawa, A., Kiso, M., Ishida, H., Miyatake, T., Characterization of high-affinity binding between gangliosides and amyloid beta-protein (2001) Arch Biochem Biophys, 388, pp. 225-230; Kiyota, T., Yamamoto, M., Xiong, H., Lambert, M.P., Klein, W.L., Gendelman, H.E., CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction (2009) PLoS One, 4, pp. e6197; Shen, B., Wu, N., Yang, J.M., Gould, S.J., Protein targeting to exosomes/microvesicles by plasma membrane anchors (2011) J Biol Chem, 286, pp. 14383-14395; Sharples, R.A., Vella, L.J., Nisbet, R.M., Naylor, R., Perez, K., Barnham, K.J., Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes (2008) FASEB J, 22, pp. 1469-1478; Tamboli, I.Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion (2010) J Biol Chem, 285, pp. 37405-37414; Antonucci, F., Turola, E., Riganti, L., Caleo, M., Gabrielli, M., Perrotta, C., Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism (2012) EMBO J, 31, pp. 1231-1240; Klein, W.L., Abeta toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets (2002) Neurochem Int, 41, pp. 345-352; De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers (2008) Neurobiol Aging, 29, pp. 1334-1347; Frassoni, C., Inverardi, F., Coco, S., Ortino, B., Grumelli, C., Pozzi, D., Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ (2005) Neuroscience, 131, pp. 813-823; Paluzzi, S., Alloisio, S., Zappettini, S., Milanese, M., Raiteri, L., Nobile, M., Adult astroglia is competent for Na/Ca2 exchanger-operated exocytotic glutamate release triggered by mild depolarization (2007) J Neurochem, 103, pp. 1196-1207; Albertini, V., Bruno, A., Paterlini, A., Lista, S., Benussi, L., Cereda, C., Optimization protocol for amyloid-beta peptides detection in human cerebrospinal fluid using SELDI TOF MS (2010) Proteomics Clin Appl, 4, pp. 352-357",Article,Scopus,2-s2.0-84903362492
"Sepulveda-Falla D., Barrera-Ocampo A., Hagel C., Korwitz A., Vinueza-Veloz M.F., Zhou K., Schonewille M., Zhou H., Velazquez-Perez L., Rodriguez-Labrada R., Villegas A., Ferrer I., Lopera F., Langer T., De Zeeuw C.I., Glatzel M.","Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis",2014,"Journal of Clinical Investigation","124","4",,"1552","1567",,2,10.1172/JCI66407,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897504097&partnerID=40&md5=3f12503128a28b5a4a0cd69880e56533","Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany; Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands; Center for Research and Rehabilitation of Hereditary Ataxias, Holguin, Cuba; Neuroscience Group of Antioquia, Faculty of Medicine, University of Antioquia, Medellín, Colombia; Institute of Neuropathology, University Hospital Bellvitge, University of Barcelona, Hospitalet de LLobregat, Spain; Netherlands Institute for Neuroscience, Royal Dutch Academy of Arts and Sciences, Amsterdam, Netherlands","Sepulveda-Falla, D., Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany; Barrera-Ocampo, A., Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany; Hagel, C., Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany; Korwitz, A., Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Vinueza-Veloz, M.F., Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands; Zhou, K., Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands; Schonewille, M., Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands; Zhou, H., Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands; Velazquez-Perez, L., Center for Research and Rehabilitation of Hereditary Ataxias, Holguin, Cuba; Rodriguez-Labrada, R., Center for Research and Rehabilitation of Hereditary Ataxias, Holguin, Cuba; Villegas, A., Neuroscience Group of Antioquia, Faculty of Medicine, University of Antioquia, Medellín, Colombia; Ferrer, I., Institute of Neuropathology, University Hospital Bellvitge, University of Barcelona, Hospitalet de LLobregat, Spain; Lopera, F., Neuroscience Group of Antioquia, Faculty of Medicine, University of Antioquia, Medellín, Colombia; Langer, T., Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; De Zeeuw, C.I., Department of Neuroscience, Erasmus MC, PO Box 2040, NL-3000 CA Rotterdam, Netherlands, Netherlands Institute for Neuroscience, Royal Dutch Academy of Arts and Sciences, Amsterdam, Netherlands; Glatzel, M., Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany","Familial Alzheimer's disease (FAD) is characterized by autosomal dominant heritability and early disease onset. Mutations in the gene encoding presenilin-1 (PS1) are found in approximately 80% of cases of FAD, with some of these patients presenting cerebellar damage with amyloid plaques and ataxia with unclear pathophysiology. A Colombian kindred carrying the PS1-E280A mutation is the largest known cohort of PS1-FAD patients. Here, we investigated PS1-E280A-associated cerebellar dysfunction and found that it occurs early in PS1-E208A carriers, while cerebellar signs are highly prevalent in patients with dementia. Postmortem analysis of cerebella of PS1-E280A carrier revealed greater Purkinje cell (PC) loss and more abnormal mitochondria compared with controls. In PS1-E280A tissue, ER/mitochondria tethering was impaired, Ca 2+ channels IP3Rs and CACNA1A were downregulated, and Ca 2+-dependent mitochondrial transport proteins MIRO1 and KIF5C were reduced. Accordingly, expression of PS1-E280A in a neuronal cell line altered ER/mitochondria tethering and transport compared with that in cells expressing wild-type PS1. In a murine model of PS1-FAD, animals exhibited mild ataxia and reduced PC simple spike activity prior to cerebellar β-amyloid deposition. Our data suggest that impaired calcium homeostasis and mitochondrial dysfunction in PS1-FAD PCs reduces their activity and contributes to motor coordination deficits prior to Aβ aggregation and dementia. We propose that PS1-E280A affects both Ca2+ homeostasis and Aβ precursor processing, leading to FAD and neurodegeneration.",,"Querfurth, H.W., LaFerla, F.M., Alzheimer's disease (2010) N Engl J Med, 362 (14), pp. 329-344; Van Der Flier, W.M., Pijnenburg, Y.A., Fox, N.C., Scheltens, P., Early-onset versus late-onset Alzheimer's disease: The case of the missing APOE varepsilon4 allele (2011) Lancet Neurol, 10 (3), pp. 280-288; Larner, A.J., Doran, M., Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene (2006) Journal of Neurology, 253 (2), pp. 139-158. , DOI 10.1007/s00415-005-0019-5; Shepherd, C., McCann, H., Halliday, G.M., Variations in the neuropathology of familial Alzheimer's disease (2009) Acta Neuropathol, 118 (1), pp. 37-52; Sepulveda-Falla, D., Glatzel, M., Lopera, F., Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation (2012) J Alzheimers Dis, 32 (1), pp. 1-12; De Strooper, B., A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain (1999) Nature, 398 (6727), pp. 518-522; Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T., Selkoe, D.J., Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity (1999) Nature, 398 (6727), pp. 513-517; Chavez-Gutierrez, L., The mechanism of γ-secretase dysfunction in familial Alzheimer disease (2012) EMBO J, 31 (10), pp. 2261-2274; Wilson, C.A., Murphy, D.D., Giasson, B.I., Zhang, B., Trojanowski, J.Q., Lee, V.M.-Y., Degradative organelles containing mislocalized alpha- and beta-synuclein proliferate in presenilin-1 null neurons (2004) Journal of Cell Biology, 165 (3), pp. 335-346. , DOI 10.1083/jcb.200403061; Lee, J.H., Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations (2010) Cell, 141 (7), pp. 1146-1158; Bezprozvanny, I., Mattson, M.P., Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease (2008) Trends Neurosci, 31 (9), pp. 454-463; Sepulveda-Falla, D., Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease (2011) Brain Pathol, 21 (4), pp. 452-463; Matilla-Duenas, A., Corral-Juan, M., Volpini, V., Sanchez, I., The spinocerebellar ataxias: Clinical aspects and molecular genetics (2012) Adv Exp Med Biol, 724, pp. 351-374; Acosta-Baena, N., Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: A retrospective cohort study (2011) Lancet Neurol, 10 (3), pp. 213-220; Thal, D.R., Rub, U., Orantes, M., Braak, H., Phases of Aβ-deposition in the human brain and its relevance for the development of AD (2002) Neurology, 58 (12), pp. 1791-1800; Fleisher, A.S., Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional study (2012) Lancet Neurol, 11 (12), pp. 1057-1065; Chakrabarti, L., Eng, J., Ivanov, N., Garden, G.A., La Spada, A.R., Autophagy activation and enhanced mitophagy characterize the Purkinje cells of pcd mice prior to neuronal death (2009) Mol Brain, 2, p. 24; Area-Gomez, E., Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria (2009) Am J Pathol, 175 (5), pp. 1810-1816; Zampese, E., Fasolato, C., Kipanyula, M.J., Bortolozzi, M., Pozzan, T., Pizzo, P., Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk (2011) Proc Natl Acad Sci U S A, 108 (7), pp. 2777-2782; MacAskill, A.F., Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses (2009) Neuron, 61 (4), pp. 541-555; Sheng, Z.H., Cai, Q., Mitochondrial transport in neurons: Impact on synaptic homeostasis and neurodegeneration (2012) Nat Rev Neurosci, 13 (2), pp. 77-93; Zhang, H., Sun, S., Herreman, A., De Strooper, B., Bezprozvanny, I., Role of presenilins in neuronal calcium homeostasis (2010) J Neurosci, 30 (25), pp. 8566-8580; Rizzuto, R., De Stefani, D., Raffaello, A., Mammucari, C., Mitochondria as sensors and regulators of calcium signalling (2012) Nat Rev Mol Cell Biol, 13 (9), pp. 566-578; Bravo, R., Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress (2011) J Cell Sci, 124 (PART 13), pp. 2143-2152; Wang, X., Schwarz, T.L., The mechanism of Ca2+-dependent regulation of kinesin-mediated mitochondrial motility (2009) Cell, 136 (1), pp. 163-174; Duyckaerts, C., Potier, M.-C., Delatour, B., Alzheimer disease models and human neuropathology: Similarities and differences (2008) Acta Neuropathologica, 115 (1), pp. 5-38. , DOI 10.1007/s00401-007-0312-8; Van Der, G.R.S., Koekkoek, S.K., Van Dorp, S., De Gruijl, J.R., Cupido, A., Khosrovani, S., Dortland, B., De Zeeuw, C.I., Role of Olivary Electrical Coupling in Cerebellar Motor Learning (2008) Neuron, 58 (4), pp. 599-612. , DOI 10.1016/j.neuron.2008.03.016, PII S0896627308002626; Vinueza Veloz, M.F., The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice (2012) Genes Brain Behav, 11 (3), pp. 325-331; Coesmans, M., Sillevis, S.P.A., Linden, D.J., Shigemoto, R., Hirano, T., Yamakawa, Y., Van Alphen, A.M., De Zeeuw, C.I., Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies (2003) Annals of Neurology, 53 (3), pp. 325-336. , DOI 10.1002/ana.10451; De Zeeuw, C.I., Hoebeek, F.E., Bosman, L.W., Schonewille, M., Witter, L., Koekkoek, S.K., Spatiotemporal firing patterns in the cerebellum (2011) Nat Rev Neurosci, 12 (6), pp. 327-344; Ryan, N.S., Rossor, M.N., Correlating familial Alzheimer's disease gene mutations with clinical phenotype (2010) Biomark Med, 4 (1), pp. 99-112; Ehling, R., Cerebellar dysfunction in a family harboring the PSEN1 mutation co-segregating with a Cathepsin D variant p.A58V (2013) J Neurol Sci, 326 (1-2), pp. 75-82; Yu, J.T., Chang, R.C., Tan, L., Calcium dysregulation in Alzheimer's disease: From mechanisms to therapeutic opportunities (2009) Prog Neurobiol, 89 (3), pp. 240-255; Nelson, O., Supnet, C., Liu, H., Bezprozvanny, I., Familial Alzheimer's disease mutations in presenilins: Effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes (2010) J Alzheimers Dis, 21 (3), pp. 781-793; Marambaud, P., Wen, P.H., Dutt, A., Shioi, J., Takashima, A., Siman, R., Robakis, N.K., A CBP binding transcriptional repressor produced by the PS1/ epsilon-cleavage of N-Cadherin is inhibited by PS1 FAD mutations (2003) Cell, 114 (5), pp. 635-645. , DOI 10.1016/j.cell.2003.08.008; Cheung, K., Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating (2008) Neuron, 58 (6), pp. 871-883; Green, K.N., Demuro, A., Akbari, Y., Hitt, B.D., Smith, I.F., Parker, I., LaFerla, F.M., SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production (2008) Journal of Cell Biology, 181 (7), pp. 1107-1116. , http://www.jcb.org/cgi/reprint/181/7/1107, DOI 10.1083/jcb.200706171; Tu, H., Nelson, O., Bezprozvanny, A., Wang, Z., Lee, S.-F., Hao, Y.-H., Serneels, L., Bezprozvanny, I., Presenilins Form ER Ca2+ Leak Channels, a Function Disrupted by Familial Alzheimer's Disease-Linked Mutations (2006) Cell, 126 (5), pp. 981-993. , DOI 10.1016/j.cell.2006.06.059, PII S0092867406010257; Cheung, K., Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons (2010) Sci Signal, 3 (114), pp. ra22; Annaert, W., Novel research horizons for presenilins and gamma-secretases in cell biology and disease (2010) Annu Rev Cell Dev Biol, 26, pp. 235-260; Odero, G.L., Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer's disease (2010) Neuroscience, 169 (1), pp. 532-543; Hoebeek, F.E., Stahl, J.S., Van Alphen, A.M., Schonewille, M., Luo, C., Rutteman, M., Van Den, M.A.M.J.M., De Zeeuw, C.I., Increased noise level of Purkinje cell activities minimizes impact of their modulation during sensorimotor control (2005) Neuron, 45 (6), pp. 953-965. , DOI 10.1016/j.neuron.2005.02.012; Bezprozvanny, I., Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias (2011) Neurochem Res, 36 (7), pp. 1186-1197; Gao, Z., Cerebellar ataxia by enhanced Ca(V)2.1 currents is alleviated by Ca2+-dependent K+-channel activators in Cacna1a(S218L) mutant mice (2012) J Neurosci, 32 (44), pp. 15533-15546; Morotz, G.M., De Vos, K.J., Vagnoni, A., Ackerley, S., Shaw, C.E., Miller, C.C., Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria (2012) Hum Mol Genet, 21 (9), pp. 1979-1988; Dagda, R.K., Kulich, S.M., Tandon, A., Park, D., Chu, C.T., Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission (2009) J Biol Chem, 284 (20), pp. 13843-13855; Gottlieb, R.A., Carreira, R.S., Autophagy in health and disease. 5. Mitophagy as a way of life (2010) Am J Physiol Cell, 299 (2), pp. C203-C210; Zhang, X., A role for presenilins in autophagy revisited: Normal acidification of lysosomes in cells lacking PSEN1 and PSEN2 (2012) J Neurosci, 32 (25), pp. 8633-8648; Santos, R.X., Alzheimer's disease: Diverse aspects of mitochondrial malfunctioning (2010) Int J Clin Exp Pathol, 3 (6), pp. 570-581; Rhein, V., Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice (2009) Proc Natl Acad Sci U S A, 106 (47), pp. 20057-20062; Wang, X., Impaired balance of mitochondrial fission and fusion in Alzheimer's disease (2009) J Neurosci, 29 (28), pp. 9090-9103; Girard, M., Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (2012) Proc Natl Acad Sci U S A, 109 (5), pp. 1661-1666; Area-Gomez, E., Upregulated function of mitochondria-associated ER membranes in Alzheimer disease (2012) EMBO J, 31 (21), pp. 4106-4123; Hedskog, L., Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models (2013) Proc Natl Acad Sci U S A, 110 (19), pp. 7916-7921; Fernandez-Ruiz, J., Velasquez-Perez, L., Diaz, R., Drucker-Colin, R., Perez-Gonzalez, R., Canales, N., Sanchez-Cruz, G., Auburger, G., Prism adaptation in spinocerebellar ataxia type 2 (2007) Neuropsychologia, 45 (12), pp. 2692-2698. , DOI 10.1016/j.neuropsychologia.2007.04.006, PII S0028393207001509; Kasumu, A.W., Liang, X., Egorova, P., Vorontsova, D., Bezprozvanny, I., Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice (2012) J Neurosci, 32 (37), pp. 12786-12796; Velez-Pardo, C., Arellano, J.I., Cardona-Gomez, P., Jimenez, D.R.M.J., Lopera, F., De Felipe, J., CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy (2004) Epilepsia, 45 (7), pp. 751-756. , DOI 10.1111/j.0013-9580.2004.55403.x; Velez-Pardo, C., Arroyave, S.T., Lopera, F., Castano, A.D., Jimenez, D.R., Ultrastructure evidence of necrotic neural cell death in familial Alzheimer's disease brains bearing presenilin-1 E280A mutation (2001) J Alzheimers Dis, 3 (4), pp. 409-415; Lopera, F., Ardilla, A., Martinez, A., Madrigal, L., Arango-Viana, J.C., Lemere, C.A., Arango-Lasprilla, J.C., Kosik, K.S., Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation (1997) Journal of the American Medical Association, 277 (10), pp. 793-799; Manto, M., Marmolino, D., Cerebellar ataxias (2009) Curr Opin Neurol, 22 (4), pp. 419-429; Shanmugarajah, P., Phenytoin and cerebellar ataxia: Not all down to toxicity? (2013) J Neurol Neurosurg Psychiatry, 84, pp. e2; Wadman, M., US government sets out Alzheimer's plan (2012) Nature, 485 (7399), pp. 426-427; Pastor, P., Roe, C.M., Villegas, A., Bedoya, G., Chakraverty, S., Garcia, G., Tirado, V., Goate, A.M., Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred (2003) Annals of Neurology, 54 (2), pp. 163-169. , DOI 10.1002/ana.10636; Velazquez-Perez, L., Motor decline in clinically presymptomatic spinocerebellar ataxia type 2 gene carriers (2009) PLoS One, 4 (4), pp. e5398; Grice, K.O., Vogel, K.A., Le, V., Mitchell, A., Muniz, S., Vollmer, M.A., Adult norms for a commercially available nine hole peg test for finger dexterity (2003) American Journal of Occupational Therapy, 57 (5), pp. 570-573; Rouser, G., Fkeischer, S., Yamamoto, A., Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots (1970) Lipids, 5 (5), pp. 494-496; Altmeppen, H.C., Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo (2011) Mol Neurodegener, 6, p. 36; Dunkley, P.R., Jarvie, P.E., Robinson, P.J., A rapid Percoll gradient procedure for preparation of synaptosomes (2008) Nat Protoc, 3 (11), pp. 1718-1728; Jankowsky, J.L., Slunt, H.H., Gonzales, V., Jenkins, N.A., Copeland, N.G., Borchelt, D.R., APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1 (2004) Neurobiology of Aging, 25 (7), pp. 885-892. , DOI 10.1016/j.neurobiolaging.2003.09.008, PII S0197458003002367; Schonewille, M., Purkinje cell-specific knockout of the protein phosphatase PP2B impairs potentiation and cerebellar motor learning (2010) Neuron, 67 (4), pp. 618-628",Article,Scopus,2-s2.0-84897504097
"Russo M.J., Gustafson D., Vazquez S., Surace E., Guinjoan S., Allegri R.F., Sevlever G., Mendez P.C., Campos J., Martin M.E., Martinetto H., Ventrice F., Amengual A., Suarez M.F., Russo G., Cohen G., Clarens M.F., Harris P., Riudavets M.","Creation of the Argentina-Alzheimer's disease neuroimaging initiative",2014,"Alzheimer's and Dementia","10","1 SUPPL.",,"S84","S87",,,10.1016/j.jalz.2013.09.015,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897830879&partnerID=40&md5=53075afb5ae2c1556b00b8b15f4ecce6","Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Department of Neurology, Neuropsychiatric Epidemiology Unit, State University of New York, Brooklyn, NY, United States; Institute for Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden","Russo, M.J., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Gustafson, D., Department of Neurology, Neuropsychiatric Epidemiology Unit, State University of New York, Brooklyn, NY, United States, Institute for Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Vázquez, S., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Surace, E., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Guinjoan, S., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Allegri, R.F., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Sevlever, G., Aging and Memory Center, Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina; Méndez, P.C.; Campos, J.; Martin, M.E.; Martinetto, H.; Ventrice, F.; Amengual, A.; Suarez, M.F.; Russo, G.; Cohen, G.; Clarens, M.F.; Harris, P.; Riudavets, M.","The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite, longitudinal study that assesses clinical, imaging, genetic, and biospecimen biomarkers through the process of normal aging to mild cognitive impairment and dementia. We present the creation of the Argentina-ADNI - the first South American ADNI - and its effort to acquire data comparable with those gathered in other worldwide ADNI centers. © 2014 The Alzheimers Association. All rights reserved.","ADNI; Alzheimer's disease; Amyloid imaging; Biomarkers; Mild cognitive impairment","Carrillo, M.C., Bain, L.J., Frisoni, G.B., Weiner, M.W., Worldwide alzheimer's disease neuroimaging initiative (2012) Alzheimers Dement, 8, pp. 337-342; Weiner, M.W., Aisen, P.S., Jack Jr., C.R., Jagust, W.J., Trojanowski, J.Q., Shaw, L., The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) Alzheimers Dement, 6, pp. 202-211; Complete ADNI Study Schedule, , http://adni.loni.ucla.edu/wp-content/uploads/2012/10/adni-complete-study- schedule.pdf, (n.d). Accessed February 9, 2013; ADNI 2 Procedures Manual, , http://adni.loni.ucla.edu/wp-content/uploads/2008/07/adni2-procedures- manual.pdf, (n.d.). Accessed February 9, 2013; Bagnati, P., Russo, M.J., Bartoloni, L., Iturri, M., Allegri, R.F., Vision poblacional sobre la Enfermedad de Alzheimer y sus nuevos paradigmas diagnósticos y terapéuticos (2012) The XIII Pan-American Congress of Neurology, , Poster presented; Mar 4 -8; La Paz, Bolivia; Russo, M.J., Bartoloni, L., Iturri, M., Serrano, M.C., Bagnati, P., Allegri, R.F., Encuesta sobre la enfermedad de Alzheimer en el contexto de los nuevos paradigmas diagnósticos (2012) Neurol Arg, 4, pp. 118-125; Rosen, W.G., Terry, R.D., Field, P.A., Katzman, R., Peck, A., Pathological verification of ischemic score in differentiation of dementias (1980) Ann Neurol, 7, pp. 486-488; Folstein, M.F., Folstein, S.E., McHugh, P., ""mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) J Psychiatr Res, 12, pp. 189-198; Wechsler, D., (1987) WMS-RWechsler Memory Scale -Revised Manual, , The Psychological Corporation, Harcourt Brace Jovanovich New York; Sheikh, J.I., Yesavage, J.A., (1986) Geriatric Depression Scale (GDS): Recent Evidence and Development of A Shorter Version. Clinical Gerontology: A Guide to Assessment and Intervention, pp. 165-173. , Haworth Press New York; Berg, L., Clinical Dementia Rating (CDR) (1988) Psychopharmacol Bull, 24, pp. 637-639; Rosen, W.G., Mohs, R.C., Davis, K.L., A new rating scale for Alzheimer's disease (1984) Am J Psychiatry, 141, pp. 1356-1364; Kaplan, E.F., Goodglass, H., Weintraub, S., (1983) Boston Naming Test, , Lea & Febiger Philadelphia, PA; Butters, N., Granholm, E., Salmon, D.P., Grant, I., Wolfe, J., Episodic and semantic memory: A comparison of amnesic and demented patients (1987) J Clin Exp Neuropsychol, 9, pp. 479-497; Goodglass, H., Kaplan, E., (1983) The Assessment of Aphasia and Related Disorders, , Lea & Febiger Philadelphia, PA; Wechsler, D., (1981) Manual for the Wechsler Adult Intelligence Scale, , Rev. edition The Psychological Corporation, Harcourt Brace Jovanovich New York; Rey, A., (1964) L'Examen Clinique en Psychologie, , Presses Universitaires de France Paris; Reitan, R.M., Validity of the Trail Making Test as an indicator of organic brain damage (1958) Percept Motor Skills, 8, pp. 271-276; Pfeffer, R.I., Kurosaki, T.T., Harrah Jr., C.H., Chance, J.M., Filos, S., Measurement of functional activities in older adults in the community (1982) J Gerontol, 37, pp. 323-329; Kaufer, D.I., Cummings, J.L., Ketchel, P., Smith, V., Macmillan, A., Shelley, T., Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory (2000) J Neuropsychiatry Clin Neurosci, 12, pp. 233-239; Leon, I., Garcia, J., Roldan-Tapia, L., Development of the scale of cognitive reserve in Spanish population: A pilot study (2011) Rev Neurol, 52, pp. 653-660; ADNI 3T MRI Technical Procedures Manual, , http://adni.loni.usc.edu/wp-content/uploads/2010/05/ ADNIGO_MRI_Training_Manual_07292010.pdf, (n.d.). Accessed September 10, 2013; Hixson, J.E., Vernier, D.T., Restriction isotyping of human apolipoprotein e by gene amplification and cleavage with HhaI (1990) J Lipid Res, 31, pp. 545-548",Article,Scopus,2-s2.0-84897830879
"Valasani K.R., Vangavaragu J.R., Day V.W., Yan S.S.","Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors",2014,"Journal of Chemical Information and Modeling","54","3",,"902","912",,6,10.1021/ci5000196,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896928887&partnerID=40&md5=cfe40491913ee2f0c6af838011713f90","Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS 66047, United States; Department of Chemistry, University of Kansas, Lawrence, KS 66045, United States","Valasani, K.R., Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS 66047, United States; Vangavaragu, J.R., Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS 66047, United States; Day, V.W., Department of Chemistry, University of Kansas, Lawrence, KS 66045, United States; Yan, S.S., Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS 66047, United States","Cyclophilin D (CypD) is a peptidyl prolyl isomerase F that resides in the mitochondrial matrix and associates with the inner mitochondrial membrane during the mitochondrial membrane permeability transition. CypD plays a central role in opening the mitochondrial membrane permeability transition pore (mPTP) leading to cell death and has been linked to Alzheimers disease (AD). Because CypD interacts with amyloid beta (Aβ) to exacerbate mitochondrial and neuronal stress, it is a potential target for drugs to treat AD. Since appropriately designed small organic molecules might bind to CypD and block its interaction with Aβ, 20 trial compounds were designed using known procedures that started with fundamental pyrimidine and sulfonamide scaffolds know to have useful therapeutic effects. Two-dimensional (2D) quantitative structure-activity relationship (QSAR) methods were applied to 40 compounds with known IC50 values. These formed a training set and were followed by a trial set of 20 designed compounds. A correlation analysis was carried out comparing the statistics of the measured IC50 with predicted values for both sets. Selectivity-determining descriptors were interpreted graphically in terms of principle component analyses. These descriptors can be very useful for predicting activity enhancement for lead compounds. A 3D pharmacophore model was also created. Molecular dynamics simulations were carried out for the 20 trial compounds with known IC50 values, and molecular descriptors were determined by 2D QSAR studies using the Lipinski rule-of-five. Fifteen of the 20 molecules satisfied all 5 Lipinski rules, and the remaining 5 satisfied 4 of the 5 Lipinski criteria and nearly satisfied the fifth. Our previous use of 2D QSAR, 3D pharmacophore models, and molecular docking experiments to successfully predict activity indicates that this can be a very powerful technique for screening large numbers of new compounds as active drug candidates. These studies will hopefully provide a basis for efficiently designing and screening large numbers of more potent and selective inhibitors for CypD treatment of AD. © 2014 American Chemical Society.",,"Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W., Xu, H.W., Yan, S.D., Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimers disease (2005) FASEB J., 19, pp. 2040-2041; Reddy, P.H., Beal, M.F., Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimers disease (2008) Trends in Mol. Med., 14, pp. 45-53; Du, H., Guo, L., Yan, S., Sosunov, A.A., McKhann, G.M., Yan, S.S., Early deficits in synaptic mitochondria in an Alzheimers disease mouse model (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 18670-18675; Lunnon, K., Ibrahim, Z., Proitsi, P., Lourdusamy, A., Newhouse, S., Sattlecker, M., Furney, S., Addneuromed, C., Mitochondrial dysfunction and immune activation are detectable in early Alzheimers disease blood (2012) J. Alzheimers Disease: JAD, 30, pp. 685-710; Valasani, K.R., Sun, Q., Hu, G., Li, J., Du, F., Guo, Y., Carlson, E.A., Yan, S.S., Identification of Human ABAD Inhibitors for Rescuing Abeta-Mediated Mitochondrial Dysfunction (2014) Curr. Alzheimer Res., , 10.2174/1567205011666140130150108; Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A.A., McKhann, G.M., Yan, Y., Yan, S.D., Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimers disease (2008) Nature Med., 14, pp. 1097-1105; Manczak, M., Anekonda, T.S., Henson, E., Park, B.S., Quinn, J., Reddy, P.H., Mitochondria are a direct site of A beta accumulation in Alzheimers disease neurons: Implications for free radical generation and oxidative damage in disease progression (2006) Human Mol. Genetics, 15, pp. 1437-1449; Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Wu, H., ABAD directly links Abeta to mitochondrial toxicity in Alzheimers disease (2004) Science, 304, pp. 448-452; Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K.L., Jendrach, M., Leuner, K., Muller, W.E., Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice (2009) Neurobiol. Aging, 30, pp. 1574-1586; Yao, J., Irwin, R.W., Zhao, L., Nilsen, J., Hamilton, R.T., Brinton, R.D., Mitochondrial bioenergetic deficit precedes Alzheimers pathology in female mouse model of Alzheimers disease (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 14670-14675; Yan, S.D., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F., Collison, K., Stern, D., An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimers disease (1997) Nature, 389, pp. 689-695; Valasani, K.R., Hu, G., Chaney, M.O., Yan, S.S., Structure-Based Design and Synthesis of Benzothiazole Phosphonate Analogues with Inhibitors of Human ABAD-A beta for Treatment of Alzheimers Disease (2013) Chem. Biol. Drug Des., 81, pp. 238-249; Stains, C.I., Mondal, K., Ghosh, I., Molecules that target beta-amyloid (2007) ChemMedChem, 2, pp. 1674-1692; Ghosh, A.K., Venkateswara Rao, K., Yadav, N.D., Anderson, D.D., Gavande, N., Huang, X., Terzyan, S., Tang, J., Structure-Based Design of Highly Selective beta-Secretase Inhibitors: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Crystal Structure (2012) J. Med. Chem., 55, pp. 9195-9207; Gravenfors, Y., Viklund, J., Blid, J., Ginman, T., Karlstrom, S., Kihlstrom, J., Kolmodin, K., Rahm, F., Correction to New Aminoimidazoles as beta-Secretase (BACE-1) Inhibitors Showing Amyloid-beta (Abeta) Lowering in Brain (2012) J. Med. Chem., 55, pp. 9297-9311; Ogura, A., Morizane, A., Nakajima, Y., Miyamoto, S., Takahashi, J., Gamma-Secretase Inhibitors Prevent Overgrowth of Transplanted Neural Progenitors Derived from Human-Induced Pluripotent Stem Cells (2013) Stem Cells Dev., 22, pp. 374-382; Parker, M.F., Barten, D.M., Bergstrom, C.P., Bronson, J.J., Corsa, J.A., Dee, M.F., Gai, Y., Macor, J.E., 2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as gamma-secretase inhibitors (2012) Bioorg. Med. Chem. Lett., 22, pp. 6828-6831; Ozudogru, S.N., Lippa, C.F., Disease modifying drugs targeting beta-amyloid (2012) Am. J. Alzheimers Disease Other Dementias, 27, pp. 296-300; Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B.P., Capurso, C., Dintrono, A., Colacicco, A.M., Pilotto, A., Beyond the neurotransmitter-focused approach in treating Alzheimers disease: Drugs targeting beta-amyloid and tau protein (2009) Aging Clin. Exp. Res., 21, pp. 386-406; Frisardi, V., Solfrizzi, V., Imbimbo, P.B., Capurso, C., Dintrono, A., Colacicco, A.M., Vendemiale, G., Panza, F., Towards disease-modifying treatment of Alzheimers disease: Drugs targeting beta-amyloid (2010) Curr. Alzheimer Res., 7, pp. 40-55; Orlando, R.A., Gonzales, A.M., Royer, R.E., Deck, L.M., Vander Jagt, D.L., A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization (2012) PloS One, 7, p. 31869; Park, S.K., Pegan, S.D., Mesecar, A.D., Jungbauer, L.M., Ladu, M.J., Liebman, S.W., Development and validation of a yeast high-throughput screen for inhibitors of Abeta(4)(2) oligomerization (2011) Disease Models Mech., 4, pp. 822-831; Walsh, D.M., Townsend, M., Podlisny, M.B., Shankar, G.M., Fadeeva, J.V., El Agnaf, O., Hartley, D.M., Selkoe, D.J., Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation (2005) J. Neurosci., 25, pp. 2455-2462; Du, H., Guo, L., Zhang, W., Rydzewska, M., Yan, S., Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model (2011) Neurobiol. Aging, 32, pp. 398-406; Takuma, K., Yao, J., Huang, J., Xu, H., Chen, X., Luddy, J., Trillat, A.C., Yan, S.S., ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction (2005) FASEB J., 19, pp. 597-598; Tanveer, A., Virji, S., Andreeva, L., Totty, N.F., Hsuan, J.J., Ward, J.M., Crompton, M., Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress (1996) Eur. J. Biochem./FEBS, 238, pp. 166-172; Griffiths, E.J., Halestrap, A.P., Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin (1991) Biochem. J., 274 (PART 2), pp. 611-614; Galat, A., Metcalfe, S.M., Peptidylproline cis/trans isomerases (1995) Progress Biophys. Molec. Biol., 63, pp. 67-118; Khaspekov, L., Friberg, H., Halestrap, A., Viktorov, I., Wieloch, T., Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4- cyclosporin A mitigate glucose/oxygen deprivation-induced damage to rat cultured hippocampal neurons (1999) Eur. J. Neurosci., 11, pp. 3194-3198; Nicolli, A., Basso, E., Petronilli, V., Wenger, R.M., Bernardi, P., Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel (1996) J. Biol. Chem., 271, pp. 2185-2192; Clarke, S.J., McStay, G.P., Halestrap, A.P., Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A (2002) J. Biol. Chem., 277, pp. 34793-34799; Azzolin, L., Antolini, N., Calderan, A., Ruzza, P., Sciacovelli, M., Marin, O., Mammi, S., Rasola, A., Antamanide, a derivative of Amanita phalloides, is a novel inhibitor of the mitochondrial permeability transition pore (2011) PloS One, 6, p. 16280; Guo, H.X., Wang, F., Yu, K.Q., Chen, J., Bai, D.L., Chen, K.X., Shen, X., Jiang, H.L., Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca2+ uptake/ release (2005) Acta Pharma. Sin., 26, pp. 1201-1211; Wang, F., Chen, J., Liu, X.J., Shen, X., He, X.C., Jiang, H.L., Bai, D.L., Synthesis and peptidyl-prolyl isomerase inhibitory activity of quinoxalines as ligands of cyclophilin A (2006) Chem. Pharm. Bull., 54, pp. 372-376; Guo, H.X., Wang, F., Yu, K.Q., Chen, Y., Bai, D.L., Chen, K.X., Shen, X., Jiang, H.L., Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca2+ uptake/release (2005) Acta Pharma. Sin., 26, pp. 1201-1211; Li, J., Chen, J., Zhang, L., Wang, F., Gui, C.S., Zhang, L., Qin, Y., Jiang, H.L., One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation (2006) Bioorg. Med. Chem., 14, pp. 5527-5534; Vilar, S., Cozza, G., Moro, S., Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery (2008) Curr. Top Med. Chem., 8, pp. 1555-1572; Vilar, S., Gonzalez-Diaz, H., Santana, L., Uriarte, E., QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks (2008) J. Comput. Chem., 29, pp. 2613-2622; Kajitani, K., Fujihashi, M., Kobayashi, Y., Shimizu, S., Tsujimoto, Y., Miki, K., Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96-A resolution (2008) Proteins, 70, pp. 1635-1639; Valasani, K.R., Chaney, M.O., Day, V.W., Yan, S.S., Acetylcholinesterase Inhibitors: Structure Based Design, Synthesis, Pharmacophore Modeling, and Virtual Screening (2013) J. Chem. Inf. Model., 53, pp. 2033-2046; Zhi, H., Chen, L.M., Zhang, L.L., Liu, S.J., Wan, D.C.C., Lin, H.Q., Hu, C., Design, synthesis, and biological evaluation of 5H-thiazolo[3,2-a] pyrimidine derivatives as a new type of acetylcholinesterase inhibitors (2008) Arkivoc, pp. 266-277; Rivkin, A., Ahearn, S.P., Chichetti, S.M., Kim, Y.R., Li, C.M., Rosenau, A., Kattar, S.D., Shearman, M.S., Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators (2010) Bioorg. Med. Chem. Lett., 20, pp. 1269-1271; Messer Jr., W.S., Rajeswaran, W.G., Cao, Y., Zhang, H.J., El-Assadi, A.A., Dockery, C., Liske, J., Peseckis, S.M., Design and development of selective muscarinic agonists for the treatment of Alzheimers disease: Characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors (2000) Pharma. Acta Helvetiae, 74, pp. 135-140; Kypta, R.M., GSK-3 inhibitors and their potential in the treatment of Alzheimers disease (2005) Expert Opin. Ther. Pat., 15, pp. 1315-1331",Article,Scopus,2-s2.0-84896928887
"Salazar R., Velez C.E., Royall D.R.","Telephone screening for mild cognitive impairment in hispanics using the Alzheimers Questionnaire",2014,"Experimental Aging Research","40","2",,"129","139",,,10.1080/0361073X.2014.882189,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896352107&partnerID=40&md5=7442dbe48238b016916202f4e0ecfd8f","Department of Psychiatry, Division of Aging and Geriatrics, University of Texas Health Science Center at San Antonio, Room 718E, 7703 Floyd Curl Drive MC 7792, San Antonio, TX 78229, USA, United States; Departments of Psychiatry, Medicine, Family and Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; South Texas Veterans Health Administration Geriatric Research Education and Clinical Care (GRECC), San Antonio, TX, United States","Salazar, R., Department of Psychiatry, Division of Aging and Geriatrics, University of Texas Health Science Center at San Antonio, Room 718E, 7703 Floyd Curl Drive MC 7792, San Antonio, TX 78229, USA, United States; Velez, C.E., Department of Psychiatry, Division of Aging and Geriatrics, University of Texas Health Science Center at San Antonio, Room 718E, 7703 Floyd Curl Drive MC 7792, San Antonio, TX 78229, USA, United States; Royall, D.R., Departments of Psychiatry, Medicine, Family and Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States, South Texas Veterans Health Administration Geriatric Research Education and Clinical Care (GRECC), San Antonio, TX, United States","Background/Study Context: There is a need for a simple and reliable screening test to detect individuals with mild cognitive impairment (MCI). The authors analyzed the relationship between performance of the Alzheimers Questionnaire (AQ), an informant-rated measure of dementia-related behaviors, relative to the Telephone Interview for Cognitive Status-modified (TICS-m), Memory Impairment Scale-telephone version (MIS-t), and the Telephone Executive Assessment (TEXAS) as predictors of MCI. Methods: Comparative cross-sectional design, with data collected from participants in the Texas Alzheimers Research and Care Consortiums (TARCC) San Antonio site. One-hundred percent of our sample was Hispanic. The San Antonio subset of TARCC sample is highly enriched with Mexican Americans (MAs). Fifty-five percent of the interviews were conducted in Spanish. Of the 184 persons enrolled, 124 were normal controls (NCs), and 60 participants had MCI. MCI status and Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) were determined through clinical consensus and performed blind to telephone assessments. Controlling for age, gender, education, and language of interview, the association between telephone measures and CDR-SOB was evaluated by multivariate regression. Results: AQ scores were not affected by education, gender, and language of interview, but subjects age did show a positive correlation with informant AQ ratings. The AQ predicted CDR-SOB independently of the cognitive measures, adding variance above and beyond demographics. The TICS-m and the TEXAS appear to have additive value in improving the detection of cognitively impaired patients. The MIS-t failed to contribute significantly to CDR-SOB, independent of the other measures. Conclusion: The AQ may have utility as a culture-fair telephone screening for MCI. The AQ was able to modestly distinguish MCI from NCs. The TEXAS adds variance to a model of dementia severity independent of the AQ, suggesting that the latter may weakly assess that cognitive domain (executive control function). On the other hand, the AQ attenuates the MIS-t effect. This suggests a prominent AQ bias in favor of detecting memory impairment. Additional studies are required to determine if the AQ can distinguish between amnestic and dysexecutive MCI subtypes, or between MCI and Alzheimers disease in Hispanics. © Copyright © Taylor & Francis Group, LLC.",,"(2000) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association (4th ed. rev.). Washington, DC: Author; Brandt, J., Aretouli, E., Neijstrom, E., Samek, J., Manning, K., Albert, M.S., Bandeen-Roche, K., Selectivity of executive function deficits in mild cognitive impairment (2009) Neuropsychology, 23, pp. 607-618. , doi:10.1037/a0015851; Brandt, J., Folstein, M.F., (2003) Telephone Interview for Cognitive Status: Professional Manual, , Odessa, FL: Psychological Assessment Resources; Brandt, J., Spencer, M., Folstein, M., The telephone interview for cognitive status (1988) Neuropsychiatry Neuropsycholology and Behavioral Neurology, 1, pp. 111-117; Chang, Y.-L., Bondi, M.W., McEvoy, L.K., Fennema-Notestine, C., Salmon, D.P., Galasko, D., Dale, A.M., Global clinical dementia rating of 0.5 in MCI masks variability related to level of function (2011) Neurology, 76, pp. 652-659. , doi:10.1212/WNL.0b013e31820ce6a5; Chin, A.L., Negash, S., Hamilton, R., Diversity and disparity in dementia: The impact of ethnoracial differences in Alzheimer disease (2001) Alzheimer Disease & Associated Disorders, 25, pp. 187-195. , doi:10.1097/WAD.0b013e318211c6c9; Ferrucci, I., Del Lungo, I., Guralnik, J.M., Bandinelli, S., Benvenuti, E., Salani, B., Baroni, A., Is the telephone interview for cognitive status a valid alternative in persons who cannot be evaluated by the Mini Mental State Examination? (1998) Aging: Clinical & Experimental Research, 10, pp. 332-338; Graff-Radford, N.R., Ferman, T.J., Lucas, J.A., Johnson, H.K., Parfitt, F.C., Heckman, M.G., Crook, J.E., A cost effective method of identifying and recruiting persons over 80 free of dementia or mild cognitive impairment (2006) Alzheimer Disease & Associated Disorders, 20, pp. 101-104. , doi:10.1097/01.wad.0000213813.35424.d2; Hughes, C.P., Berg, L., Danziger, W.L., Coben, L.A., Martin, R.L., A new clinical scale for the staging of dementia (1982) The British Journal of Psychiatry, 140, pp. 566-572. , doi:10.1192/bjp.140.6.566; Jorm, A.F., Scott, R., Cullen, J.S., Mackinnon, A.J., Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia (1991) Psychological Medicine, 21, pp. 785-790. , doi:10.1017/S0033291700022418; Kaufer, D.I., Williams, C.S., Braaten, A.J., Gill, K., Zimmerman, S., Sloane, P.D., Cognitive screening for dementia and mild cognitive impairment in assisted living: Comparison of 3 tests (2008) Journal of the American Medical Directors Association, 9, pp. 586-593. , doi:10.1016/j.jamda.2008.05.006; Knopman, D.S., Roberts, R.O., Geda, Y.E., Pankratz, V.S., Christianson, T.J., Petersen, R.C., Rocca, W.A., Validation of the Telephone Interview for Cognitive Status-modified in subjects with normal cognition, mild cognitive impairment, or dementia (2010) Neuroepidemiology, 34, pp. 34-42. , doi:10.1159/000255464; Lipton, R.B., Katz, M.J., Kuslansky, G., Sliwinski, M.J., Stewart, W.F., Verghese, J., Buschke, H., Screening for dementia by telephone using the Memory Impairment Screen (2003) Journal of the American Geriatrics Society, 51, pp. 1382-1390. , doi:10.1046/j.1532-5415.2003.51455.x; Malek-Ahmadi, M., Davis, K., Belden, C., Laizure, B., Jacobson, S., Yaari, R., Sabbagh, M.N., Validation and diagnostic accuracy of the Alzheimers questionnaire (2012) Age and Ageing, 0, pp. 1-4; Malek-Ahmadi, M., Davis, K., Belden, C.M., Jacobson, S., Sabbagh, M.N., Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment (2012) BMC Geriatrics, 12, p. 3. , www.biomedcentral.com/1471-2318/12/3, (online publication, provisional); Morris, J.C., Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia (2012) Archives of Neurology, 69, pp. 700-708. , doi:10.1001/archneurol.2011.3152; Obryant, S.E., Waring, S.C., Cullum, C.M., Hall, J., Lacritz, L., Massman, P.J., Doody, R., Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores (2008) Archives of Neurology, 65, pp. 1091-1095; Petersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) Journal of Internal Medicine, 256, pp. 183-194. , doi:10.1111/j.1365-2796.2004.01388.x; Petersen, R.C., Current concepts in mild cognitive impairment (2001) Archives of Neurology, 58, pp. 1985-1992. , doi:10.1001/archneur.58.12.1985; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: Clinical characterization and outcome (1999) Archives of Neurology, 56, pp. 303-308. , doi:10.1001/archneur.56.3.303; Royall, D.R., Mahurin, R.K., Gray, K.F., Bedside assessment of executive cognitive impairment: The executive interview (1992) Journal of the American Geriatrics Society, 40, pp. 1221-1226; Royall, D.R., Palmer, R., Chiodo, L.K., Polk, M.J., Normal rates of cognitive change in successful aging: The Freedom House study (2005) Journal of the International Neuropsychological Society, 11, pp. 899-909; Sabbagh, M.N., Malek-Ahmadi, M., Kataria, R., Belden, C.M., Connor, D.J., Pearson, C., Singh, U., The Alzheimers Questionnaire: A proof of concept study for a new informant-based dementia assessment (2010) Journal of Alzheimers Disease, 22, pp. 1015-1021; Smith, M.M., Tremont, G., Ott, B.R., A reviewed of telephone-administered screening tests for dementia (2009) American Journal of Alzheimers Disease & Other Dementias, 24, pp. 58-69. , doi:10.1177/1533317508327586; Van Uffelen, J.G.Z., Chin, A., Paw, M.J.M., Klein, M., Van Mechelen, W., Hopman-Rock, M., Detection of self memory impairment in the general population: Screening by questionnaire and telephone compared to subsequent face to face assessment (2007) International Journal of Geriatric Psychiatry, 22, pp. 203-210. , doi:10.1002/gps.1661; Waring, S.C., Obryant, S.E., Reisch, J., Diaz-Arrastia, R., Knebl, J., Doody, R.S., The Texas Alzheimers Research Consortium longitudinal research cohort: Study design and baseline characteristics (2008) Journal of Texas Public Health Association, 63, pp. 9-13",Article,Scopus,2-s2.0-84896352107
"Jakubik J., Santruckova E., Randakova A., Janickova H., Zimcik P., Rudajev V., Michal P., El-Fakahany E.E., Dolezal V.","Outline of therapeutic interventions with muscarinic receptor-mediated transmission",2014,"Physiological Research","63","SUPPL.",,"S177","S189",,1,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897640586&partnerID=40&md5=59bd5e67a59e0863211c6d7544cbc75f","Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, United States","Jakubík, J., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Šantrůcková, E., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Randáková, A., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Janíčková, H., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Zimčík, P., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Rudajev, V., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; Michal, P., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic; El-Fakahany, E.E., Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, United States; Doležal, V., Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic","Muscarinc receptor-mediated signaling takes part in many physiological functions ranging from complex higher nervous activity to vegetative responses. Specificity of action of the natural muscarinic agonist acetylcholine is effected by action on five muscarinic receptor subtypes with particular tissue and cellular localization, and coupling preference with different G-proteins and their signaling pathways. In addition to physiological roles it is also implicated in pathologic events like promotion of carcinoma cells growth, early pathogenesis of neurodegenerative diseases in the central nervous system like Alzheimeŕs disease and Parkinsońs disease, schizophrenia, intoxications resulting in drug addiction, or overactive bladder in the periphery. All of these disturbances demonstrate involvement of specific muscarinic receptor subtypes and point to the importance to develop selective pharmacotherapeutic interventions. Because of the high homology of the orthosteric binding site of muscarinic receptor subtypes there is virtually no subtype selective agonist that binds to this site. Activation of specific receptor subtypes may be achieved by developing allosteric modulators of acetylcholine binding, since ectopic binding domains on the receptor are less conserved compared to the orthosteric site. Potentiation of the effects of acetylcholine by allosteric modulators would be beneficial in cases where acetylcholine release is reduced due to pathological conditions. When presynaptic function is severly compromised, the utilization of ectopic agonists can be a thinkable solution. © 2014 Institute of Physiology v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic.","Allosteric modulators; Ectopic agonists; G-proteins; Muscarinic receptors; Selectivity","Bartus, R.T., On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis (2000) Exp Neurol, 163, pp. 495-529; Bartus, R.T., Emerich, D.F., Cholinergic markers in Alzheimer disease (1999) JAMA, 282, pp. 2208-2209; Bartus, R.T., Dean, R.L., Beer, B., Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction (1982) Science, 217, pp. 408-414; Basile, A.S., Fedorova, I., Zapata, A., Liu, X.G., Shippenberg, T., Duttaroy, A., Yamada, M., Wess, J., Deletion of the M-5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia (2002) Proc Natl Acad Sci USA, 99, pp. 11452-11457; Biel, J.H., Hoya, W.K., Abood, L.G., Leiser, H.A., Nuhfer, P.A., Cholinergic blockade as an approach to development of new psychotropic agents (1962) Ann NY Acad Sci, 96, pp. 251-262; Bonner, T.I., The molecular basis of muscarinic receptor diversity (1989) Trends Neurosci, 12, pp. 148-151; Bonner, T.I., New subtypes of muscarinic acetylcholine receptors (1989) Trends Pharmacol Sci Suppl, pp. 11-15; Bonner, T.I., Buckley, N.J., Young, A.C., Brann, M.R., Identification of a family of muscarinic acetylcholine receptor genes (1987) Science, 237, pp. 527-532; Bonner, T.I., Young, A.C., Brann, M.R., Buckley, N.J., Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes (1988) Neuron, 1, pp. 403-410; Bowen, D.M., Smith, C.B., White, P., Davison, A.N., Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies (1976) Brain, 99, pp. 459-496; Brady, A.E., Jones, C.K., Bridges, T.M., Kennedy, J.P., Thompson, A.D., Heiman, J.U., Breininger, M.L., Lindsley, C.W., Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats (2008) J Pharmacol Exp Ther, 327, pp. 941-953; Burstein, E.S., Ma, J., Wong, S., Gao, Y., Pham, E., Knapp, A.E., Nash, N.R., Brann, M.R., Intrinsic efficacy of antipsychotics at human D-2, D-3, and D-4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D-2/D-3 partial agonist (2005) J Pharmacol Exp Ther, 315, pp. 1278-1287; Buxbaum, J.D., Oishi, M., Chen, H.I., Pinkas-Kramarski, R., Jaffe, E.A., Gandy, S.E., Greengard, P., Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor (1992) Proc Natl Acad Sci USA, 89, pp. 10075-10078; Christopoulos, A., Pierce, T.L., Sorman, J.L., El-Fakahany, E.E., On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor (1998) Mol Pharmacol, 53, pp. 1120-1130; Conner, J.M., Darracq, M.A., Roberts, J., Tuszynski, M.H., Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation (2001) Proc Natl Acad Sci USA, 98, pp. 1941-1946; Crook, J.M., Dean, B., Pavey, G., Copolov, D., The binding of [H-3]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia (1999) Life Sci, 64, pp. 1761-1771; Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L., Dean, B., Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation (2000) Biol Psychiatry, 48, pp. 381-388; Crook, J.M., Tomaskovic-Crook, E., Copolov, D.L., Dean, B., Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8 9 10 and 46 and the effects of neuroleptic drug treatment (2001) Am J Psychiatry, 158, pp. 918-925; Davies, P., Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimer's disease (1976) Lancet, 2, p. 1403; Davies, M.A., Compton-Toth, B.A., Hufeisen, S.J., Meltzer, H.Y., Roth, B.L., The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M-1 agonism a pre-requisite for mimicking clozapine's actions? (2005) Psychopharmacology, 178, pp. 451-460; Davis, A.A., Fritz, J.J., Wess, J., Lah, J.J., Levey, A.I., Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo (2010) J Neurosci, 30, pp. 4190-4196; Dean, B., Scarr, E., Naylor, L., Pavey, G., Opeskin, K., Hill, C., Keks, N., Copolov, D.L., Neurochemical changes in the hippocampus from subjects with schizophrenia (1999) Schizophr Res, 36, pp. 70-71; Dean, B., Mcleod, M., Keriakous, D., Mckenzie, J., Scarr, E., Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia (2002) Mol Psychiatry, 7, pp. 1083-1091; Dolezal, V., Kasparova, J., Beta-amyloid and cholinergic neurons (2003) Neurochem Res, 28, pp. 499-506; Eglen, R.M., Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function (2006) Auton Autacoid Pharmacol, 26, pp. 219-233; Eglen, R.M., Overview of muscarinic receptor subtypes (2012) Handb Exp Pharmacol, 208, pp. 3-28; Ehlert, F.J., Roeske, W.R., Yamamura, H.I., Muscarinic receptors and novel strategies for the treatment of agerelated brain disorders (1994) Life Sci, 55, pp. 2135-2145; Francis, P.T., Palmer, A.M., Sims, N.R., Bowen, D.M., Davison, A.N., Esiri, M.M., Neary, D., Wilcock, G.K., Neurochemical studies of early-onset Alzheimer's disease (1985) Possible influence on treatment. N Engl J Med, 313, pp. 7-11; Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K., The cholinergic hypothesis of Alzheimer's disease: a review of progress (1999) J Neurol Neurosurg Psychiatry, 66, pp. 137-147; Fredriksson, R., Lagerstrom, M.C., Lundin, L.G., Schioth, H.B., The G-protein-coupled receptors in the human genome form five main families (2003) Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol, 63, pp. 1256-1272; Goldberg, T.E., Weinberger, D.R., The effects of clozapine on neurocognition - an overview (1994) J Clin Psychiatry, 55, pp. 88-90; Grant, M.K.O., El-Fakahany, E.E., Persistent binding and functional antagonism by xanomeline at the muscarinic M-5 receptor (2005) J Pharmacol Exp Ther, 315, pp. 313-319; Grant, M.K., Noetzel, M.J., De Lorme, K.C., Jakubik, J., Dolezal, V., El-Fakahany, E.E., Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor (2010) PLoS One, 5, pp. e15722; Grimm, M.O., Grimm, H.S., Patzold, A.J., Zinser, E.G., Halonen, R., Duering, M., Tschape, J.A., Hartman, T., Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin (2005) Nat Cell Biol, 7, pp. 1118-1123; Grimm, M.O., Grimm, H.S., Hartman, T., Amyloid beta as a regulator of lipid homeostasis (2007) Trends Mol Med, 13, pp. 337-344; Grimm, M.O., Grimm, H.S., Tomic, I., Beyreuther, K., Hartmann, T., Bergmann, C., Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels (2008) J Biol Chem, 283, pp. 11302-11311; Grimm, M.O., Kuchenbecker, J., Groesgen, S., Burg, V.K., Hundsdoerfer, B., Rothhaar, T.L., Friess, P., Hartmann, T., Docosahexaenoic acid reduces amyloid beta production via multiple, pleiotropic mechanisms (2011) J Biol Chem, 286, pp. 14028-14039; Hagger, C., Buckley, P., Kenny, J.T., Friedman, L., Ubogy, D., Meltzer, H.Y., Improvement in cognitive functions and psychiatric-symptoms in treatment-refractory schizophrenic-patients receiving clozapine (1993) Biol Psychiatry, 34, pp. 702-712; Hardy, J., Amyloid, the presenilins and Alzheimer's disease (1997) Trends Neurosci, 20, pp. 154-159; Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; Hegde, S.S., Muscarinic receptors in the bladder: from basic research to therapeutics (2006) Br J Pharmacol, 147 (SUPPL. 2), pp. S80-S87; Heinrich, J.N., Butera, J.A., Carrick, T., Kramer, A., Kowal, D., Lock, T., Marquis, K.L., Mayer, S.C., Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists (2009) Eur J Pharmacol, 605, pp. 53-56; Hicks, D.A., Nalivaeva, N.N., Turner, A.J., Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling (2012) Front Physiol, 3, p. 189; Hu, J., Wang, Y., Zhang, X., Lloyd, J.R., Li, J.H., Karpiak, J., Costanzi, S., Wess, J., Structural basis of G proteincoupled receptor-G protein interactions (2010) Nat Chem Biol, 6, pp. 541-548; Hulme, E.C., Birdsall, N.J., Buckley, N.J., Muscarinic receptor subtypes (1990) Annu Rev Pharmacol Toxicol, 30, pp. 633-673; Hulme, E.C., Kurtenbach, E., Curtis, C.A., Muscarinic acetylcholine receptors: structure and function (1991) Biochem Soc Trans, 19, pp. 133-138; Hulme, E.C., Lu, Z.L., Saldanha, J.W., Bee, M.S., Structure and activation of muscarinic acetylcholine receptors (2003) Biochem Soc Trans, 31, pp. 29-34; Isacson, O., Seo, H., Lin, L., Albeck, D., Granholm, A.C., Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh (2002) Trends Neurosci, 25, pp. 79-84; Jakubik, J., El-Fakahany, E.E., Allosteric modulation of acetylcholine receptors (2010) Pharmaceuticals, 3, pp. 2838-2860; Jakubik, J., Bacakova, L., El-Fakahany, E.E., Tucek, S., Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors (1995) J Pharmacol Exp Ther, 274, pp. 1077-1083; Jakubik, J., Bacakova, L., Lisa, V., El-Fakahany, E.E., Tucek, S., Activation of muscarinic acetylcholine receptors via their allosteric binding sites (1996) Proc Natl Acad Sci USA, 93, pp. 8705-8709; Jakubik, J., Bacakova, L., El-Fakahany, E.E., Tucek, S., Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors (1997) Mol Pharmacol, 52, pp. 172-179; Jakubik, J., Tucek, S., El-Fakahany, E.E., Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor (2002) J Pharmacol Exp Ther, 301, pp. 1033-1041; Jakubik, J., Tucek, S., El-Fakahany, E.E., Role of receptor protein and membrane lipids in xanomeline washresistant binding to muscarinic M1 receptors (2004) J Pharmacol Exp Ther, 308, pp. 105-110; Jakubik, J., Krejci, A., Dolezal, V., Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators (2005) J Pharmacol Exp Ther, 313, pp. 688-696; Jakubik, J., El-Fakahany, E.E., Dolezal, V., Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors (2006) Mol Pharmacol, 70, pp. 656-666; Janickova, H., Rudajev, V., Zimcik, P., Jakubik, J., Tanila, H., El-Fakahany, E.E., Dolezal, V., Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42) (2013) Neuropharmacology, 67, pp. 272-283; Jones, S.V., Heilman, C.J., Brann, M.R., Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells (1991) Mol Pharmacol, 40, pp. 242-247; Jope, R.S., Song, L., Powers, R.E., Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain (1997) Neurobiol Aging, 18, pp. 111-120; Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H., Clozapine in treatment-resistant schizophrenics (1988) Psychopharmacol Bull, 24, pp. 62-67; Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Muller-Hill, B., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor (1987) Nature, 325, pp. 733-736; Karam, C.S., Ballon, J.S., Bivens, N.M., Freyberg, Z., Girgis, R.R., Lizardi-Ortiz, J.E., Markx, S., Javitch, J.A., Signaling pathways in schizophrenia: emerging targets and therapeutic strategies (2010) Trends Pharmacol Sci, 31, pp. 381-390; Karran, E., Mercken, M., De Strooper, B., The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics (2011) Nat Rev Drug Discov, 10, pp. 698-712; Kawashima, K., Fujii, T., Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function (2004) Front Biosci, 9, pp. 2063-2085; Kawashima, K., Fujii, T., Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance (2008) J Pharmacol Sci, 106, pp. 167-173; Kelly, J.F., Furukawa, K., Barger, S.W., Rengen, M.R., Mark, R.J., Blanc, E.M., Roth, G.S., Mattson, M.P., Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons (1996) Proc Natl Acad Sci USA, 93, pp. 6753-6758; Kelly, J.F., Storie, K., Skamra, C., Bienias, J., Beck, T., Bennett, D.A., Relationship between Alzheimer's disease clinical stage and Gq/11 in subcellular fractions of frontal cortex (2005) J Neural Transm, 112, pp. 1049-1056; Koch, H.J., Haas, S., Jurgens, T., On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease (2005) Curr Med Chem, 12, pp. 2915-2921; Kojro, E., Gimpl, G., Lammich, S., Marz, W., Fahrenholz, F., Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10 (2001) Proc Natl Acad Sci U S A, 98, pp. 5815-5820; Koob, G.F., Volkow, N.D., Neurocircuitry of addiction (2010) Neuropsychopharmacology, 35, pp. 217-238; Kubo, T., Fukuda, K., Mikami, A., Maeda, A., Takahashi, H., Mishina, M., Haga, T., Numa, S., Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor (1986) Nature, 323, pp. 411-416; Kubo, T., Maeda, A., Sugimoto, K., Akiba, I., Mikami, A., Takahashi, H., Haga, T., Numa, S., Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence (1986) FEBS Lett, 209, pp. 367-372; Kukar, T., Murphy, M.P., Eriksen, J.L., Sagi, S.A., Weggen, S., Smith, T.E., Ladd, T., Golde, T.E., Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production (2005) Nat Med, 11, pp. 545-550; Lahiri, D.K., Rogers, J.T., Greig, N.H., Sambamurti, K., Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents (2004) Curr Pharm Des, 10, pp. 3111-3119; Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Et, A.L., Initial sequencing and analysis of the human genome (2001) Nature, 409, pp. 860-921; Langmead, C.J., Watson, J., Reavill, C., Muscarinic acetylcholine receptors as CNS drug targets (2008) Pharmacol Ther, 117, pp. 232-243; Lebois, E.P., Bridges, T.M., Lewis, L.M., Dawson, E.S., Kane, A.S., Xiang, Z., Jadhav, S.B., Lindsley, C.W., Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system (2010) ACS Chem Neurosci, 1, pp. 104-121; Lefkowitz, R.J., G protein-coupled receptors III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization (1998) J Biol Chem, 273, pp. 18677-18680; Lefkowitz, R.J., Shenoy, S.K., Transduction of receptor signals by beta-arrestins (2005) Science, 308, pp. 512-517; Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs memory (2006) Nature, 440, pp. 352-357; Lesne, S., Kotilinek, L., Ashe, K.H., Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function (2008) Neuroscience, 151, pp. 745-749; Lester, D.B., Miller, A.D., Blaha, C.D., Muscarinic receptor blockade in the ventral tegmental area attenuates cocaine enhancement of laterodorsal tegmentum stimulation-evoked accumbens dopamine efflux in the mouse (2010) Synapse, 64, pp. 216-223; Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C.E., Wang, K., Candidate gene for the chromosome 1 familial Alzheimer's disease locus (1995) Science, 269, pp. 973-977; Levy-Lahad, E., Wijsman, E.M., Nemens, E., Anderson, L., Goddard, K.A., Weber, J.L., Bird, T.D., Schellenberg, G.D., A familial Alzheimer's disease locus on chromosome 1 (1995) Science, 269, pp. 970-973; Machova, E., Jakubik, J., El-Fakahany, E.E., Dolezal, V., Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain (2007) J Pharmacol Exp Ther, 322, pp. 316-323; Machova, E., Jakubik, J., Michal, P., Oksman, M., Iivonen, H., Tanila, H., Dolezal, V., Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice (2008) Neurobiol Aging, 29, pp. 368-378; Machova, E., Rudajev, V., Smyckova, H., Koivisto, H., Tanila, H., Dolezal, V., Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice (2010) Neurobiol Dis, 38, pp. 27-35; Maezawa, I., Zimin, P.I., Wulff, H., Jin, L.W., Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity (2011) J Biol Chem, 286, pp. 3693-3706; Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N., Beyreuther, K., Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels (1985) EMBO J, 4, pp. 2757-2763; Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., Mcdonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome (1985) Proc Natl Acad Sci USA, 82, pp. 4245-4249; Mego, D.M., Omori, D.J.M., Hanley, J.F., Transdermal scopolamine as a cause of transient psychosis in two elderly patients (1988) South Med J, 81, pp. 394-395; Mesulam, M.M., Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles (1999) Neuron, 24, pp. 521-529; Michal, P., El-Fakahany, E.E., Dolezal, V., Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins (2007) J Pharmacol Exp Ther, 320, pp. 607-614; Michal, P., Rudajev, V., El-Fakahany, E.E., Dolezal, V., Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways (2009) Eur J Pharmacol, 606, pp. 50-60; Morales, M., Pickel, V.M., Insights to drug addiction derived from ultrastructural views of the mesocorticolimbic system (2012) Ann NY Acad Sci, 1248, pp. 71-88; Nitsch, R.M., Slack, B.E., Wurtman, R.J., Growdon, J.H., Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors (1992) Science, 258, pp. 304-307; Peralta, E.G., Ashkenazi, A., Winslow, J.W., Smith, D.H., Ramachandran, J., Capon, D.J., Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors (1987) EMBO J, 6, pp. 3923-3929; Peralta, E.G., Winslow, J.W., Ashkenazi, A., Smith, D.H., Ramachandran, J., Capon, D.J., Structural basis of muscarinic acetylcholine receptor subtype diversity (1988) Trends Pharmacol Sci SUPPL, pp. 6-11; Perry, E.K., Gibson, P.H., Blessed, G., Perry, R.H., Tomlinson, B.E., Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue (1977) J Neurol Sci, 34, pp. 247-265; Perry, E.K., Perry, R.H., Blessed, G., Tomlinson, B.E., Necropsy evidence of central cholinergic deficits in senile dementia (1977) Lancet, 1, p. 189; Perry, E.K., Kilford, L., Lees, A.J., Burn, D.J., Perry, R.H., Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs (2003) Ann Neurol, 54, pp. 235-238; Pike, C.J., Walencewicz, A.J., Glabe, C.G., Cotman, C.W., In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity (1991) Brain Res, 563, pp. 311-314; Proskocil, B.J., Sekhon, H.S., Jia, Y., Savchenko, V., Blakely, R.D., Lindstrom, J., Spindel, E.R., Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells (2004) Endocrinology, 145, pp. 2498-2506; Raffa, R.B., The M-5 muscarinic receptor as possible target for treatment of drug abuse (2009) J Clin Pharm Ther, 34, pp. 623-629; Reiter, E., Lefkowitz, R.J., GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling (2006) Trends Endocrinol Metab, 17, pp. 159-165; Rudajev, V., Novotny, J., Hejnova, L., Milligan, G., Svoboda, P., Dominant portion of thyrotropin-releasing hormone receptor is excluded from lipid domains Detergent-resistant and detergent-sensitive pools of TRH receptor and Gqalpha/G11alpha protein (2005) J Biochem, 138, pp. 111-125; Schneider, A., Schulz-Schaeffer, W., Hartmann, T., Schulz, J.B., Simons, M., Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons (2006) Neurobiol Dis, 23, pp. 573-577; Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S.W., Simons, M., Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons (2008) J Neurosci, 28, pp. 2874-2882; Schuller, H.M., Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? (2009) Nat Rev Cancer, 9, pp. 195-205; Selkoe, D.J., Alzheimer's disease: genes, proteins, and therapy (2001) Physiol Rev, 81, pp. 741-766; Selkoe, D.J., Alzheimer's disease is a synaptic failure (2002) Science, 298, pp. 789-791; Shankar, G.M., Welzel, A.T., Mcdonald, J.M., Selkoe, D.J., Walsh, D.M., Isolation of low-n amyloid betaprotein oligomers from cultured cells, CSF, and brain (2011) Methods Mol Biol, 670, pp. 33-44; Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., St George-Hyslop, P.H., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease (1995) Nature, 375, pp. 754-760; Shirey, J.K., Xiang, Z., Orton, D., Brady, A.E., Johnson, K.A., Williams, R., Ayala, J.E., Conn, P.J., An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission (2008) Nat Chem Biol, 4, pp. 42-50; Sims, N.R., Bowen, D.M., Davison, A.N., [14C]acetylcholine synthesis and carbon 14C dioxide production from [U-14C]glucose by tissue prisms from human neocortex (1981) Biochem J, 196, pp. 867-876; Smith, A.L., Wein, A.J., Recent advances in the development of antimuscarinic agents for overactive bladder (2010) Trends Pharmacol Sci, 31, pp. 470-475; Smith, D.E., Roberts, J., Gage, F.H., Tuszynski, M.H., Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy (1999) Proc Natl Acad Sci USA, 96, pp. 10893-10898; Song, P., Sekhon, H.S., Jia, Y., Keller, J.A., Blusztajn, J.K., Mark, G.P., Spindel, E.R., Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma (2003) Cancer Res, 63, pp. 214-221; Song, P., Sekhon, H.S., Proskocil, B., Blusztajn, J.K., Mark, G.P., Spindel, E.R., Synthesis of acetylcholine by lung cancer (2003) Life Sci, 72, pp. 2159-2168; Song, P., Sekhon, H.S., Lu, A., Arredondo, J., Sauer, D., Gravett, C., Mark, G.P., Spindel, E.R., M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion (2007) Cancer Res, 67, pp. 3936-3944; Stahl, E., Ellis, J., Novel allosteric effects of amiodarone at the muscarinic M(5) receptor (2010) J Pharmacol Exp Ther, 334, pp. 214-222; Sulzer, D., How addictive drugs disrupt presynaptic dopamine neurotransmission (2011) Neuron, 69, pp. 628-649; Sykes, D.A., Dowling, M.R., Leighton-Davies, J., Kent, T.C., Fawcett, L., Renard, E., Trifilieff, A., Charlton, S.J., The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium (2012) J Pharmacol Exp Ther, 343, pp. 520-528; Thathiah, A., De Strooper, B., G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease (2009) Sci Signal, 2, pp. re8; Tsang, S.W., Lai, M.K., Kirvell, S., Francis, P.T., Esiri, M.M., Hope, T., Chen, C.P., Wong, P.T., Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease (2006) Neurobiol Aging, 27, pp. 1216-1223; Turner, A.J., Nalivaeva, N.N., New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection (2007) Int Rev Neurobiol, 82, pp. 113-135; Tzavara, E.T., Bymaster, F.P., Davis, R.J., Wade, M.R., Perry, K.W., Wess, J., Mckinzie, D.L., Nomikos, G.G., M-4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies (2004) Faseb J, 18, pp. 1410-1412; Weiner, D.M., Meltzer, H.Y., Veinbergs, I., Donohue, E.M., Spalding, T.A., Smith, T.T., Mohell, N., Brann, M., The role of M1 muscarinic receptor agonism of N-desmethyl-clozapine in the unique clinical effects of clozapine (2004) Psychopharmacology, 177, pp. 207-216; Wess, J., Blin, N., Mutschler, E., Bluml, K., Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling (1995) Life Sci, 56, pp. 915-922; Wessler, I.K., Kirkpatrick, C.J., Activation of muscarinic receptors by non-neuronal acetylcholine (2012) Handb Exp Pharmacol, 208, pp. 469-491; Whitson, J.S., Selkoe, D.J., Cotman, C.W., Amyloid beta protein enhances the survival of hippocampal neurons in vitro (1989) Science, 243, pp. 1488-1490; Whitson, J.S., Glabe, C.G., Shintani, E., Abcar, A., Cotman, C.W., Beta-amyloid protein promotes neuritic branching in hippocampal cultures (1990) Neurosci Lett, 110, pp. 319-324; Wilkinson, D.G., Francis, P.T., Schwam, E., Payne-Parrish, J., Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy (2004) Drugs Aging, 21, pp. 453-478; Yamada, M., Lamping, K.G., Duttaroy, A., Zhang, W.L., Cui, Y.H., Bymaster, F.P., Mckinzie, D.L., Wess, J., Cholinergic dilation of cerebral blood vessels is abolished in M-5 muscarinic acetylcholine receptor knockout mice (2001) Proc Natl Acad Sci USA, 98, pp. 14096-14101; Yamada, M., Basile, A.S., Fedorova, I., Zhang, W., Duttaroy, A., Cui, Y., Lamping, K.G., Wess, J., Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology (2003) Life Sci, 74, pp. 345-353; Yankner, B.A., Duffy, L.K., Kirschner, D.A., Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides (1990) Science, 250, pp. 279-282",Review,Scopus,2-s2.0-84897640586
"Agostini S., Clerici M., Mancuso R.","How plausible is a link between HSV-1 infection and Alzheimer's disease?",2014,"Expert Review of Anti-Infective Therapy","12","3",,"275","278",,2,10.1586/14787210.2014.887442,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84894205406&partnerID=40&md5=994503ee8d83eb254bacd06e25c843ca","Don C. Gnocchi Foundation ONLUS-IRCCS, Milano, Italy; Department of Physiopathology and Transplantation, University of Milano, Milano, Italy","Agostini, S., Don C. Gnocchi Foundation ONLUS-IRCCS, Milano, Italy; Clerici, M., Don C. Gnocchi Foundation ONLUS-IRCCS, Milano, Italy, Department of Physiopathology and Transplantation, University of Milano, Milano, Italy; Mancuso, R., Don C. Gnocchi Foundation ONLUS-IRCCS, Milano, Italy",[No abstract available],"Alzheimers disease; HSV-1; humoral immunity; intravenous immunoglobulin; MRI","Ball, M.J., Lukiw, W.J., Kammerman, E.M., Hill, J.M., Intracerebral propagation of Alzheimer's disease: Strengthening evidence of a herpes simplex virus etiology (2013) Alzheimers Dement, 9 (2), pp. 169-175; Licastro, F., Carbone, I., Ianni, M., Porcellini, E., Gene signature in Alzheimer's disease and environmental factors: The virus chronicle (2011) J Alzheimers Dis, 27 (4), pp. 809-817; Honjo, K., Van Reekum, R., Verhoeff, N.P., Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease? (2009) Alzheimers Dement, 5 (4), pp. 348-360; Letenneur, L., Peres, K., Fleury, H., Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: A population-based cohort study (2008) PLoS One, 3 (11), pp. e3637; Kobayashi, N., Nagata, T., Shinagawa, S., Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease (2013) Biochem Biophys Res Commun, 430 (3), pp. 907-911; Jamieson, G.A., Maitland, N.J., Wilcock, G.K., Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains (1991) J Med Virol, 33 (4), pp. 224-227; Dedicoat, M., Muir, D., Viral meningitis- or encephalitis? (1998) Practitioner, 242 (1587), pp. 489-492; Wozniak, M.A., Itzhaki, R.F., Shipley, S.J., Dobson, C.B., Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation (2007) Neurosci Lett, 429 (2-3), pp. 95-100; De Chiara, G., Marcocci, M.E., Civitelli, L., APP processing induced by herpes simplex virus type 1 (HSV-1) yelds several APP fragments in human and rat neuronal cells (2010) PLoS One, 5 (11), pp. e13989; Alvarez, G., Aldudo, J., Alonso, M., Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells (2012) J Neurosci Res, 90 (5), pp. 1020-1029; Martin, C., Aguila, B., Araya, P., Inflammatory and neurodegeneration markers during asymptomatic HSV-1 reactivation (2013) J Alzheimers Dis, , Epub ahead of print; Cheng, S.B., Ferland, P., Webster, P., Bearer, E.L., Herpes simplex virus dances with amyloid precursor protein while exiting the cell (2011) PLoS One, 6 (3), pp. e17966; Santana, S., Recuero, M., Bullido, M.J., Herpes simplex virus type I induces the accumulation of intracellular b-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells (2012) Neurobiol Aging, 33 (2), pp. 430e19-33; Sokolov, A.A., Reincke, M., Herpes simplex encephalitis affecting the entire limbic system (2012) Mayo Clin Proc, 87 (9), pp. e69; Burgos, J.S., Ramirez, C., Sastre, I., Valdivieso, F., Apolipoprotein E genotype influences vertical transmission of herpes simplex virus type 1 in a gender specific manner (2007) Aging Cell, 6 (6), pp. 841-842; Saldanha, J., Sutton, R.N., Gannicliffe, A., Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression (1986) J Neurol Neurosurg Psychiatry, 49 (6), pp. 613-619; Stowe, R.P., Peek, M.K., Cutchin, M.P., Goodwin, J.S., Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age (2012) J Med Virol, 84 (11), pp. 1797-1802; Mancuso, R., Baglio, F., Cabinio, M., Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in alzheimer's disease (2014) J Alzheimers Dis, 38 (4), pp. 741-745; Del Valle, J., Duran-Vilaregut, J., Manich, G., Time-course of blood-brain barrier disruption in senescence-accelerated mouse prone 8 (SAMP8) mice (2009) Int J Dev Neurosci, 27 (1), pp. 47-52; Pelegri, C., Canudas, A.M., Del Valle, J., Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence (2007) Mech Ageing Dev, 128 (9), pp. 522-528; Whitwell, J.L., Dickson, D.W., Murray, M.E., Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study (2012) Lancet Neurol, 11 (10), pp. 868-877; Erlich, K.S., Mills, J., Passive immunotherapy for encephalitis caused by herpes simplex virus (1986) Rev Infect Dis, 8 (SUPPL. 4), pp. S439-S445; Fillit, H., Hess, G., Hill, J., IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders (2009) Neurology, 73 (3), pp. 180-185; Relkin, N.R., Szabo, P., Adamiak, B., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease (2009) Neurobiol Aging, 30 (11), pp. 1728-1736; Dodel, R.C., Du, Y., Depboylu, C., Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease (2004) J Neurol Neurosurg Psychiatry, 75 (10), pp. 1472-1474; Giacobini, E., Gold, G., Alzheimer disease therapy-moving from amyloid-beta to tau (2013) Nat Rev Neurol, 9 (12), pp. 677-686; Dodel, R., Rominger, A., Bartenstein, P., Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial (2013) Lancet Neurol, 12 (3), pp. 233-243; Wozniak, M.A., Itzhaki, R.F., Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1 (2013) J Neuroimmunol, 257 (1-2), pp. 7-12",Review,Scopus,2-s2.0-84894205406
"Suarez-Gonzalez A., Serrano-Pozo A., Arroyo-Anllo E.M., Franco-Macias E., Polo J., Garcia-Solis D., Gil-Neciga E.","Utility of neuropsychiatric tools in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease: Quantitative and qualitative findings",2014,"International Psychogeriatrics","26","3",,"453","461",,,10.1017/S1041610213002068,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84893721625&partnerID=40&md5=bd42ad85b1c7b46adfdfb61fd66e6940","Memory Disorders Unit, Department of Neurology, University Hospital Virgen Del Rocío, Seville, Spain; Department of Psychobiology, University of Salamanca, Salamanca, Spain; Department of Public Health and Preventive Medicine, University of Seville, Seville, Spain; Department of Nuclear Medicine, University Hospital Virgen Del Rocío, Seville, Spain; Department of Neurology of the University of Iowa Hospitals and Clinics, Iowa City, IA, United States","Suárez-González, A., Memory Disorders Unit, Department of Neurology, University Hospital Virgen Del Rocío, Seville, Spain; Serrano-Pozo, A., Memory Disorders Unit, Department of Neurology, University Hospital Virgen Del Rocío, Seville, Spain, Department of Neurology of the University of Iowa Hospitals and Clinics, Iowa City, IA, United States; Arroyo-Anlló, E.M., Department of Psychobiology, University of Salamanca, Salamanca, Spain; Franco-Macías, E., Memory Disorders Unit, Department of Neurology, University Hospital Virgen Del Rocío, Seville, Spain; Polo, J., Department of Public Health and Preventive Medicine, University of Seville, Seville, Spain; García-Solís, D., Department of Nuclear Medicine, University Hospital Virgen Del Rocío, Seville, Spain; Gil-Néciga, E., Memory Disorders Unit, Department of Neurology, University Hospital Virgen Del Rocío, Seville, Spain","ABSTRACT Background: Discerning dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) is one of the most common and challenging differential diagnoses at the memory clinic. Although the neuropsychiatric manifestations have been widely reported as one of the main key points in the differential diagnosis between these two diseases, to date no neuropsychiatric questionnaire has been specifically devised for this purpose. Methods: We administered the Neuropsychiatric Inventory (NPI) and the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) to a memory clinic sample of 80 patients with probable DLB and 85 age- and severity-matched patients with probable AD. Diagnosis of probable DLB was supported with a positive dopamine transporter SPECT scan. We examined the usefulness of these two neuropsychiatric tools designed for AD in the differential diagnosis between DLB and AD. We also investigated the correlations between psychotic symptoms and measures of cognitive and functional decline. Results: Auditory hallucinations were very specific of DLB and were usually preceded by visual hallucinations. Misinterpretation of real visual stimuli (illusions) was more frequent in DLB. Delusions were both quantitatively and qualitatively different between DLB and AD: delusional misidentifications were significantly more characteristic of DLB, while paranoid delusions did not show specificity for DLB. Conclusions: Neuropsychiatric tools are useful to discriminate DLB from AD. Hallucinations and delusions are not only more frequent in DLB than in AD but also have distinct qualitative characteristics and patterns of progression that can help clinicians to make a more accurate differential diagnosis. © International Psychogeriatric Association 2013.","Alzheimer's disease; Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD); Delusional misidentifications; Dementia with Lewy bodies; Hallucinations; Illusions; Neuropsychiatric Inventory (NPI)","Aarsland, D., Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: Frequency, profile and associated caregiver stress (2007) Journal of Neurology Neurosurgery and Psychiatry, 78, pp. 36-42; Auning, E., Early and presenting symptoms of dementia with Lewy bodies (2011) Dementia and Geriatric Cognitive Disorders, 32, pp. 202-208; Ballard, C.G., Lowery, K., Harrison, R., McKeith, I.G., Non-Cognitive symptoms in Lewy body dementia (1996) Dementia with Lewy Bodies, pp. 67-84. , In R. H. Perry I. G. McKeith and E. K. Perry (eds. Cambridge, UK: Cambridge University Press; Ballard, C.G., O'Brien, J.T., Swann, A.G., Thompson, P., Neill, D., McKeith, I.G., The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: Persistence and new cases over 1-year follow-up (2001) Journal of Clinical Psychiatry, 62, pp. 46-49; Ballard, C.G., The prevalence and phenomenology of psychotic symptoms in dementia sufferers (1995) International Journal of Geriatric Psychiatry, 10, pp. 477-485; Ballard, C.G., Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease (1999) American Journal of Psychiatry, 156, pp. 1039-1045; Böhm, P., Peña-Casanova, J., Aguilar, M., Hernandez, G., Sol, J.M., Blesa, R., Clinical validity and utility of the interview for deterioration of daily living in dementia for spanish-speaking communities normacodem group (1998) International Psychogeriatrics, 10, pp. 261-270; Burns, A., Jacoby, R., Levy, R., Psychiatric phenomena in Alzheimer's disease I: Disorders of thought content (1990) British Journal of Psychiatry, 157, pp. 72-76; Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia (1994) Neurology, 44, pp. 2308-2314; Del Ser, T., McKetih, I., Anand, R., Cicin-Sain, A., Ferrara, R., Spiegel, R., Dementia with Lewy bodies: Findings from an international multicentre study (2000) International Journal of Geriatric Psychiatry, 15, pp. 1034-1045; Devanand, D., The columbia university scale for psychopathology in alzheimer's disease (1992) Archives of Neurology, 49, pp. 371-376; Engelborghs, S., Neuropsychiatric symptoms of dementia: Cross-sectional analysis from a prospective, longitudinal Belgian study (2005) International Journal of Geriatric Psychiatry, 20, pp. 1028-1037; Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I., Zimmerman, R.A., MR signal abnormalities at 1.5 T in Alzheimeŕs dementia and normal aging (1987) American Journal of Roentgenology, 149, pp. 351-358; Ferman, T.J., DLB fluctuations: Specific features that reliably differentiate DLB from AD and normal aging (2004) Neurology, 62, pp. 181-187; Folstein, F.E., Folstein, S.E., McHugh, P.R., Mini-mental state A practical method for grading the cognitive state of patients for the clinicians (1975) Journal of Psychiatric Research, 12, pp. 189-198; Hirono, N., Distinctive neurobehavioral features among neurodegenerative dementias (1999) Journal of Neuropsychiatry and Clinical Neurosciences, 11, pp. 498-503; Lyketsos, C.G., Steinberg, M., Tschanz, J.T., Norton, M.C., Steffens, D.C., Breitner, J.C.S., Mental and behavioural disturbances in dementia: Findings form Cache County Study in Memory and Aging (2000) American Journal of Psychiatry, 157, pp. 708-714; McKeith, I.G., Dementia with Lewy bodies (2002) British Journal of Psychiatry, 180, pp. 144-147; McKeith, I.G., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy body diseases (DLB): Report of the consortium on DLB international workshop (1996) Neurology, 47, pp. 1113-1124; McKeith, I.G., Diagnosis and management of dementia with Lewy bodies Third report of the DLB consortium (2005) Neurology, 65, pp. 1863-1872; McKeith, I., Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in the diagnosis of dementia with Lewy bodies: A phase III, multicenter study (2007) Lancet Neurology, 6, pp. 305-313; McKhann, G., Clinical diagnosis of alzheimer's disease report of the nincds-Adra work group under the auspices of department of health and human services task force on alzheimer's disease (1984) Neurology, 34, pp. 939-944; National Institute for Clinical Excellence, p. 2011. , Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease March Technology appraisal guidance 217. Review of NICE technology appraisal guidance 111. London: NICE; O'Brien, J.T., Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies (2004) Archives of Neurology, 61, pp. 919-925; Rockwell, E., Choure, J., Galasko, D., Olichney, J., Jeste, D.V., Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer's disease: Comparison of matched groups with autopsy-Confirmed diagnoses (2000) International Journal of Geriatric Psychiatry, 15, pp. 819-823; Stavitsky, K., The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer's disease (2006) Archives of Neurology, 63, pp. 1450-1456; Teunisse, S., Derix, M.M., Crevel, H., Assessing the severity of dementia Patient and caregiver (1991) Archives of Neurology, 4, pp. 274-277; Tiraboschi, P., Salmon, D.P., Hansen, L.A., Hofstetter, R.C., Thal, L.J., Corey-Bloom, J., What best differentiates Lewy body from Alzheimer's disease in early stage dementia? (2006) Brain, 129, pp. 729-735; Walker, Z., Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy (2007) Journal of Neurology, Neurosurgery Psychiatry with Practical Neurology, 78, pp. 1176-1181; Weiner, M.F., Alzheimer's disease and its Lewy body variant: A clinical analysis of postmorten verified cases (1996) American Journal of Psychiatry, 153, pp. 1269-1273",Article,Scopus,2-s2.0-84893721625
"Croset S., Overington J.P., Rebholz-Schuhmann D.","The functional therapeutic chemical classification system",2014,"Bioinformatics","30","6",,"876","883",,,10.1093/bioinformatics/btt628,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897840898&partnerID=40&md5=a0064719abc5cb3cbd6906d77df33e71","European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom","Croset, S., European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom; Overington, J.P., European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom; Rebholz-Schuhmann, D., European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom","Motivation: Drug repositioning is the discovery of new indications for compounds that have already been approved and used in a clinical setting. Recently, some computational approaches have been suggested to unveil new opportunities in a systematic fashion, by taking into consideration gene expression signatures or chemical features for instance. We present here a novel method based on knowledge integration using semantic technologies, to capture the functional role of approved chemical compounds.Results: In order to computationally generate repositioning hypotheses, we used the Web Ontology Language to formally define the semantics of over 20 000 terms with axioms to correctly denote various modes of action (MoA). Based on an integration of public data, we have automatically assigned over a thousand of approved drugs into these MoA categories. The resulting new resource is called the Functional Therapeutic Chemical Classification System and was further evaluated against the content of the traditional Anatomical Therapeutic Chemical Classification System. We illustrate how the new classification can be used to generate drug repurposing hypotheses, using Alzheimers disease as a use-case. © 2013 The Author 2013. Published by Oxford University Press.",,"Andronis, C., Literature mining, ontologies and information visualization for drug repurposing (2011) Brief. Bioinform., 12, pp. 357-368; Ashburn, T.T., Thor, K.B., Drug repositioning: Identifying and developing new uses for existing drugs (2004) Nat. Rev. Drug Disc., 3, pp. 673-683; Ashburner, M., Gene ontology: Tool for the unification of biology (2000) The Gene Ontology Consortium. Nat. Genet., 25, pp. 25-29; Campillos, M., Drug target identification using side-effect similarity (2008) Science, 321, pp. 263-266; Croset, S., Brain: Biomedical knowledge manipulation (2013) Bioinformatics, 29, pp. 1238-1239; Dimmer, E.C., The UniProt-GO Annotation database in 2011 (2012) Nucleic Acids Res., 40, pp. D565-D570; Dudley, J.T., Exploiting drug-disease relationships for computational drug repositioning (2011) Brief. Bioinform., 12, pp. 303-311; Francis, P.T., The cholinergic hypothesis of Alzheimer's disease: A review of progress (1999) J. Neurol., Neurosurg. Psych., 67, pp. 137-147; Gruber, T., Toward principles for the design of ontologies used for knowledge sharing? (1995) Int. J. Human-Computer Stud., 43, pp. 907-928; Grundke-Iqbal, I., Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology (1986) Proc. Natl Acad. Sci. USA, 83, pp. 4913-4917; Hastings, J., The ChEBI reference database and ontology for biologically relevant chemistry: Enhancements for 2013 (2013) Nucleic Acids Res., 41, pp. D456-D463; Haupt, V.J., Schroeder, M., Old friends in new guise: Repositioning of known drugs with structural bioinformatics (2011) Brief. Bioinform., 12, pp. 312-326; Hoehndorf, R., Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics (2012) Bioinformatics, 28, pp. 2169-2175; Iorio, F., Discovery of drug mode of action and drug repositioning from transcriptional responses (2010) Proc. Natl Acad. Sci. USA, 107, pp. 14621-14626; Jones, G.M., (1992) Effects of Acute Subcutaneous Nicotine on Attention, Information Processing and Short-term Memory in Alzheimer's Disease, , Technical Report 4, Department of Psychiatry, Institute of Psychiatry; Kazakov, Y., Concurrent classification of Ontologies (2011) The Semantic Web-ISWC 2011, pp. 305-320. , In: Aroyo, L. et al. (eds). Springer-Verlag, Berlin Heidelberg; Kilgore, M., Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease (2010) Neuropsychopharmacol., 35, pp. 870-880; Knox, C., DrugBank 3.0: A comprehensive resource for 'omics' research on drugs (2011) Nucleic Acids Res., 39, pp. D1035-D1041; Kruger, F., Mapping small molecule binding data to structural domains (2012) BMC Bioinformatics, 13 (SUPPL. 17), pp. S11; Medina-Franco, J.L., Shifting from the single to the multitarget paradigm in drug discovery (2008) Curr. Comput. Aided Drug Des., 4, pp. 76-90; Nelson, S.J., The MeSH translation maintenance system: Structure, interface design, and implementation (2004) Stud. Health Technol. Inform., 107, pp. 67-69; Sanseau, P., Koehler, J., Editorial: Computational methods for drug repurposing (2011) Brief. Bioinform., 12, pp. 301-302; Teo, S.K., Thalidomide as a novel therapeutic agent: New uses for an old product (2005) Drug. Discov. Today, 10, pp. 107-114; Update on activities at the Universal Protein Resource (UniProt) in 2013 (2013) Nucleic Acids Res., 41, pp. D43-D47. , The Uniprot Consortium; Therapontos, C., Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation (2009) Proc. Natl Acad. Sci., 106, pp. 8573-8578; Wang, H.Y., Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity (2000) Implications for Alzheimer's Disease Pathology. J. Biol. Chem., 275, pp. 5626-5632; (2000) Anatomical Therapeutic Chemical (Atc) Classification Index with Defined Daily Doses (Ddd's), , WHO. WHO Collaborating Centre for Drug Statistics Methodology, Oslo; Williams, A.J., Open phacts: Semantic interoperability for drug discovery (2012) Drug. Discov. Today, 17, pp. 1188-1198; Wolozin, B., Cholesterol, statins and dementia (2004) Current Opinion in Lipidology, 15, pp. 667-672; Young, A.H., More good news about the magic ion: Lithium may prevent dementia (2011) Br. J. Psychiatry, 198, pp. 336-337",Article,Scopus,2-s2.0-84897840898
"Fayaz S.M., Kumar V.S.S., Rajanikant G.K.","Necroptosis: Who knew there were so many interesting ways to die?",2014,"CNS and Neurological Disorders - Drug Targets","13","1",,"42","51",,3,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896698526&partnerID=40&md5=c61edd8332cad9706d7ed87216ef3707","School of Biotechnology, National Institute of Technology Calicut, Calicut - 673601, India","Fayaz, S.M., School of Biotechnology, National Institute of Technology Calicut, Calicut - 673601, India; Kumar, V.S.S., School of Biotechnology, National Institute of Technology Calicut, Calicut - 673601, India; Rajanikant, G.K., School of Biotechnology, National Institute of Technology Calicut, Calicut - 673601, India","Conventional knowledge considered apoptosis as the sole form of programmed cell death during development, homeostasis and diseases, whereas necrosis was regarded as an unregulated and uncontrollable process. Recent revelations suggest that necrosis can also occur in a regulated, caspase-independent manner and shares characteristics with both necrosis and apoptosis. The major cell death processes namely apoptosis, autophagy and necrosis are interlinked and contain many common regulatory mechanisms. Mounting evidence indicates that necroptosis contributes to the pathogenesis of various diseases, including ischemic stroke, traumatic brain injury, neurodegenerative disorders and brain tumor. We present here an overview of the molecular mechanisms governing necroptosis and its connection with apoptosis and autophagy processes. Further, the necroptosis mechanisms underlying the neurodegeneration during ischemia reperfusion (I/R) injury are described, with an emphasis on the key proteins involved in this type of cell death. Knowledge regarding programmed cell death (PCD) with relevance to necroptosis may play a significant role in debilitating brain disorders. © 2014 Bentham Science Publishers.","Alzheimers disease; Brain disorders; Ischemia/reperfusion (I/R); Necroptosis; Neurodegeneration; Parkinson's disease; Programmed cell death (PCD)","Clarke, P.G., Developmental cell death: Morphological diversity and multiple mechanisms (1990) Anat Embryol, 181 (3), pp. 195-213; Guillot-Sestier, M.V., Sunyach, C., Druon, C., Scarzello, S., Checler, F., The alpha-secretase-derived N-terminal product of cellular prion, N1: Displays neuroprotective function in vitro and in vivo (2009) J Biol Chem, 284 (51), pp. 35973-35986; Shintani, T., Klionsky, D.J., Autophagy in health and disease: A double-edged sword (2004) Science, 306 (5698), pp. 990-995; Yamanaka, K., Saito, Y., Yamamori, T., Urano, Y., Noguchi, N., 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis (2011) J Biol Chem, 286 (28), pp. 24666-24673; Vercammen, D., Vandenabeele, P., Beyaert, R., Declercq, W., Fiers, W., Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells (1997) Cytokine, 9 (11), pp. 801-808; Vandenabeele, P., Declercq, W., van Herreweghe, F., Vanden Berghe, T., The role of the kinases RIP1 and RIP3 in TNF-induced necrosis (2010) Sci Signal, 3, pp. e4; Vercammen, D., Beyaert, R., Denecker, G., Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor (1998) J Exp Med, 187 (9), pp. 1477-1485; Degterev, A., Huang, Z., Boyce, M., Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury (2005) Nat Chem Biol, 1 (2), pp. 112-119; Willingham, S.B., Allen, I.C., Bergstralh, D.T., NLRP3 (NALP3: Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and independent pathways (2009) J Immunol, 183 (3), pp. 2008-2015; Cho, Y., Challa, S., Moquin, D., Phosphorylation-driven assembly of RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation (2009) Cell, 137 (6), pp. 1112-1123; Upton, J.W., Kaiser, W.J., Mocarski, E.S., Virus inhibition of RIP3-dependent necrosis (2010) Cell Host Microbe, 7 (4), pp. 302-313; Baines, C.P., Kaiser, R.A., Purcell, N.H., Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death (2005) Nature, 434 (7033), pp. 658-662; Nakagawa, T., Shimizu, S., Watanabe, T., Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death (2005) Nature, 434 (7033), pp. 652-658; Lou, M., Chen, Y., Ding, M., Eschenfelder, C.C., Deuschl, G., Involvement of the mitochondrial ATP sensitive potassium channel in the neuroprotective effect of hyperbaric oxygenation after cerebral ischemia (2006) Brain Res Bull, 69 (2), pp. 109-116; Moskowitz, M.A., Lo, E.H., Iadecola, C., The science of stroke: Mechanisms in search of treatments (2010) Neuron, 67 (2), pp. 181-198; Hitomi, J., Christofferson, D.E., Ng, A., Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway (2008) Cell, 135 (7), pp. 1311-1323; Welz, P.S., Wullaert, A., Vlantis, K., FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation (2011) Nature, 477 (7364), pp. 330-334; Kaiser, W.J., Upton, J.W., Long, A.B., RIP3 mediates the embryonic lethality of caspase-8-deficient mice (2011) Nature, 471 (7338), pp. 368-372; Ch'En, I.L., Tsau, J.S., Molkentin, J.D., Komatsu, M., Hedrick, S.M., Mechanisms of necroptosis in T cells (2011) J Exp Med, 208 (4), pp. 633-641; Zheng, L., Bidere, N., Staudt, D., Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1 (2006) Mol Cell Biol, 26 (9), pp. 3505-3513; Ea, C.K., Deng, L., Xia, Z.P., Pineda, G., Chen, Z.J., Activation of IKK by TNFa requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO (2006) Mol Cell, 22 (2), pp. 245-257; Li, H., Kobayashi, M., Blonska, M., You, Y., Lin, X., Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation (2006) J Biol Chem, 281 (19), pp. 13636-13643; Micheau, O., Tschopp, J., Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes (2003) Cell, 114 (2), pp. 181-190; Brenner, D., Mak, T.W., Mitochondrial cell death effectors (2009) Curr Opin Cell Biol, 21 (6), pp. 871-887; Chan, F.K., Shisler, J., Bixby, J.G., A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses (2003) J Biol Chem, 278 (51), pp. 51613-51621; Cho, Y.S., Challa, S., Moquin, D., Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation (2009) Cell, 137 (6), pp. 1112-1123; He, S., Wang, L., Miao, L., Receptor interacting protein kinase-3 determines cellular necrotic response to TNFalpha (2009) Cell, 137 (6), pp. 1100-1111; Zhang, D.W., Shao, J., Lin, J., RIP3: An energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis (2009) Science, 325 (5938), pp. 332-336; Kang, T.B., Oh, G.S., Scandella, E., Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice (2008) J Immunol, 181 (4), pp. 2522-2532; Simonson, S.J., Wu, Z.H., Miyamoto, S., CYLD: A DUB with many talents (2007) Dev Cell, 13 (5), pp. 601-603; Wright, A., Reiley, W.W., Chang, M., Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD (2007) Dev Cell, 13 (5), pp. 705-716; Oberst, A., Dillon, C.P., Weinlich, R., Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis (2011) Nature, 471 (7338), pp. 363-367; Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., Molecular mechanisms of necroptosis: An ordered cellular explosion (2010) Nat Rev Mol Cell Biol, 11 (10), pp. 700-714; Whelan, R.S., Kaplinskiy, V., Kitsis, R.N., Cell death in the pathogenesis of heart disease: Mechanisms and significance (2010) Annu Rev Physiol, 72, pp. 19-44; Lemasters, J.J., Theruvath, T.P., Zhong, Z., Nieminen, A.L., Mitochondrial calcium and the permeability transition in cell death (2009) Biochim Biophys Acta, 1787 (11), pp. 1395-1401; Tafani, M., Schneider, T.G., Pastorino, J.G., Farber, J.L., Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition (2000) Am J Pathol, 156 (6), pp. 2111-2121; Richter, C., Schweizer, M., Cossarizza, A., Franceschi, C., Control of apoptosis by the cellular ATP level (1996) FEBS Lett, 378 (2), pp. 107-110; Du, H., Guo, L., Fang, F., Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease (2008) Nat Med, 14 (10), pp. 1097-1105; Ichas, F., Mazat, J.P., From calcium signaling to cell death: Two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state (1998) Biochim Biophys Acta, 1366 (1-2), pp. 33-50; Schinder, A.F., Olson, E.C., Spitzer, N.C., Montal, M., Mitochondrial dysfunction is a primary event in glutamate neurotoxicity (1996) J Neurosci, 16 (19), pp. 6125-6133; White, R.J., Reynolds, I.J., Mitochondrial depolarization in glutamate-stimulated neurons: An early signal specific to excitotoxin exposure (1996) J Neurosci, 16 (18), pp. 5688-5697; Sayre, L.M., Perry, G., Smith, M.A., Oxidative stress and neurotoxicity (2008) Chem Res Tox, 21 (1), pp. 172-188; Lotharius, J., Brundin, P., Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein (2002) Nat Rev Neurosci, 3 (12), pp. 932-942; Izumi, Y., Sawada, H., Sakka, N., p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly (2005) J Neurosci Res, 79 (6), pp. 849-860; McCoy, M.K., Martinez, T.N., Ruhn, K.A., Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease (2006) J Neurosci, 26 (37), pp. 9365-9375; Sriram, K., Matheson, J.M., Benkovic, S.A., Mice deficient in TNFreceptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease (2002) FASEB J, 16 (11), pp. 1474-1476; He, P., Zhong, Z., Lindholm, K., Deletion of tumor necrosis factor death receptor inhibits amyloid b generation and prevents learning and memory deficits in Alzheimer's mice (2007) J Cell Biol, 178 (5), pp. 829-841; McGeer, E.G., McGeer, P.L., Neuroinflammation in Alzheimer's disease and mild cognitive impairment: A field in its infancy (2010) J Alzheimers Dis, 19 (1), pp. 355-361; Huang, X., Atwood, C.S., Hartshorn, M.A., The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction (1999) Biochemistry, 38 (24), pp. 7609-7916; Hayashi, T., Shishido, N., Nakayama, K., Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide (2007) Free Radic Biol Med, 43 (11), pp. 1552-1559; Nakamura, M., Shishido, N., Nunomura, A., Smith, M.A., Perry, G., Hayashi, Y., Nakayama, K., Hayashi, T., Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron (2007) Biochemistry, 46 (44), pp. 12737-12743; Ramos, E.M., Lin, M.T., Larson, E.B., Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease (2006) Arch Neurol, 63 (8), pp. 1165-1169; Ma, S.L., Tang, N.L.S., Association between tumor necrosis factor-α promoter polymorphism and Alzheimer's disease (2004) Neurology, 62 (2), pp. 307-309; Goossens, V., de Vos, K., Vercammen, D., Redox regulation of TNF signaling (1999) Biofactors, 10 (2-3), pp. 145-156; Lin, Y., Choksi, S., Shen, H.M., Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation (2004) J Biol Chem, 279 (11), pp. 10822-10828; Zhao, J., Jitkaew, S., Cai, Z., Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis (2012) Proc Natl Acad Sci USA, 109 (14), pp. 5322-5327; Wang, Z., Jiang, H., Chen, S., Du, F., Wang, X., The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways (2012) Cell, 148 (1-2), pp. 228-243; Basso, E., Fante, L., Fowlkes, J., Properties of the permeability transition pore in mitochondria devoid of cyclophilin D (2005) J Biol Chem, 280 (19), pp. 18558-18561; Schinzel, A.C., Takeuchi, O., Huang, Z., Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia (2005) Proc Natl Acad Sci USA, 102 (34), pp. 12005-12010; Bianchi, M.E., Manfredi, A., Chromatin and cell death (2004) Biochim Biophys Acta, 1677 (1-3), pp. 181-186; Oppenheim, R.W., Flavell, R.A., Vinsant, S., Programmed cell death of developing mammalian neurons after genetic deletion of caspases (2001) J Neurosci, 21 (13), pp. 4752-4760; West, T., Atzeva, M., Holtzman, D.M., Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways (2006) Neurobiol Dis, 22 (3), pp. 523-537; Mareninova, O.A., Sung, K.F., Hong, P., Cell death in pancreatitis: Caspases protect from necrotizing pancreatitis (2006) J Biol Chem, 281 (6), pp. 3370-3381; Degterev, A., Hitomi, J., Germscheid, M., Identification of RIP1 kinase as a specific cellular target of necrostatins (2008) Nat Chem Biol, 4 (5), pp. 313-321; Vanlangenakker, N., Bertrand, M.J., Bogaert, P., Vandenabeele, P., Vanden Berghe, T., TNF induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members (2011) Cell Death Dis, 2, pp. e230; Tsujimoto, Y., Shimizu, S., Role of the mitochondrial membrane permeability transition in cell death (2007) Apoptosis, 12 (5), pp. 835-840; Halestrap, A.P., What is the mitochondrial permeability transition pore? (2009) J Mol Cell Cardiol, 46 (6), pp. 821-831; Martin, L.J., An approach to experimental synaptic pathology using green fluorescent protein-transgenic mice and gene knockout mice to show mitochondrial permeability transition pore-driven excitotoxicity in interneurons and motoneurons (2011) Toxicol Pathol, 39 (1), pp. 220-233; O'Donnell, M.A., Perez-Jimenez, E., Oberst, A., Caspase 8 inhibits programmed necrosis by processing CYLD (2011) Nat Cell Biol, 13 (12), pp. 1437-1442; Tauriello, D.V., Haegebarth, A., Kuper, I., Loss of the tumor suppressor CYLD enhances Wnt/b-catenin signaling through K63-linked ubiquitination of Dvl (2010) Mol Cell, 37 (5), pp. 607-619; Yuan, J., Kroemer, G., Alternative cell death mechanisms in development and beyond (2010) Genes Dev, 24 (23), pp. 2592-2602; Watson, A.J., Askew, J.N., Benson, R.S., Poly(adenosine diphosphate ribose) polymerase inhibition prevents necrosis induced by H2O2 but not apoptosis (1995) Gastroenterology, 109 (2), pp. 472-482; Yu, S.W., Wang, H., Poitras, M.F., Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor (2002) Science, 297 (5579), pp. 259-263; Endres, M., Wang, Z.Q., Namura, S., Waeber, C., Moskowitz, M.A., Ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase (1997) J Cereb Blood Flow Metab, 17 (11), pp. 1143-1151; Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., Kuchler, A.M., Interleukin-33 - cytokine of dual function or novel alarmin? (2009) Trends Immunol, 30 (5), pp. 227-233; Yang, Q.W., Wang, J.Z., Li, J.C., High-mobility group protein box-1 and its relevance to cerebral ischemia (2010) J Cereb Blood Flow Metab, 30 (2), pp. 243-254; Faraco, G., Fossati, S., Bianchi, M.E., High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo (2007) J Neurochem, 103 (2), pp. 590-603; Wang, Q., Tang, X.N., Yenari, M.A., The inflammatory response in stroke (2007) J Neuroimmunol, 184 (1-2), pp. 53-68; Barone, F.C., Feuerstein, G.Z., Inflammatory mediators and stroke: New opportunities for novel therapeutics (1999) J Cereb Blood Flow Metab, 19 (8), pp. 819-834; Asahi, M., Wang, X., Mori, T., Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia (2001) J Neurosci, 21 (19), pp. 7724-7732; Asahi, M., Asahi, K., Jung, J.C., Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with bb-94 (2000) J Cereb Blood Flow Metab, 20 (12), pp. 1681-1689; Rosenberg, G.A., Matrix metalloproteinases in neuroinflammation (2002) Glia, 39 (3), pp. 279-291; Rosenberg, G.A., Estrada, E.Y., Mobashery, S., Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents (2007) Brain Res, 1133 (1), pp. 186-192; Qiu, J., Xu, J., Zheng, Y., High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia (2010) Stroke, 41 (9), pp. 2077-2082; Lo, E.H., Dalkara, T., Moskowitz, M.A., Mechanisms, challenges and opportunities in stroke (2003) Nat Rev Neurosci, 4 (5), pp. 399-415; Kim, J.B., Sig Choi, J., Yu, Y.M., Hmgb1: A novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain (2006) J Neurosci, 26 (24), pp. 6413-6421; Liu, K., Mori, S., Takahashi, H.K., Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats (2007) FASEB J, 21 (14), pp. 3904-3916; Qiu, J., Nishimura, M., Wang, Y., Sims, J.R., Early release of hmgb-1 from neurons after the onset of brain ischemia (2008) J Cereb Blood Flow Metab, 28 (5), pp. 927-938; Tsung, A., Sahai, R., Tanaka, H., The nuclear factor hmgb1 mediates hepatic injury after murine liver ischemiareperfusion (2005) J Exp Med, 201 (7), pp. 1135-1143; Germani, A., Limana, F., Capogrossi, M.C., Pivotal advances: High-mobility group box 1 protein - a cytokine with a role in cardiac repair (2007) J Leukoc Biol, 81 (1), pp. 41-45; Piot, C., Croisille, P., Staat, P., Effect of cyclosporine on reperfusion injury in acute myocardial infarction (2008) N Engl J Med, 359 (5), pp. 473-481; Lo, S.C., Hannink, M., PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria (2008) Exp Cell Res, 314 (8), pp. 1789-1803; Xu, X., Chua, C.C., Kong, J., Necrostatin-1 protects against glutamate- induced glutathione depletion and caspase-independent cell death in HT-22 cells (2007) J Neurochem, 103 (5), pp. 2004-2014; Li, Y., Yang, X., Ma, C., Qiao, J., Zhang, C., Necroptosis contributes to the NMDA-induced excitotoxicity in rat's cultured cortical neurons (2008) Neurosci Lett, 447 (2-3), pp. 120-123; Northington, F.J., Chavez-Valdez, R., Graham, E.M., Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI (2010) J Cereb Blood Flow Metab, 31 (1), pp. 178-189; Smith, C.C., Davidson, S.M., Lim, S.Y., Necrostatin: A potentially novel cardioprotective agent? (2007) Cardiovasc Drugs Ther, 21 (4), pp. 227-233; Xu, X., Chua, K.W., Chua, C.C., Synergistic protective effects of humanin and necrostatin-1 on hypoxia and iscemia/reperfusion injury (2010) Brain Res, 1355, pp. 189-194; Rosenbaum, D.M., Degterev, A., David, J., Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia reperfusion injury model (2010) J Neurosci Res, 88 (7), pp. 1569-1576; Byun, H.S., Park, K.A., Won, M., Phorbol 12-myristate 13-acetate protects against tumor necrosis factor (TNF)-induced necrotic cell death by modulating the recruitment of TNF receptor 1-associated death domain and receptor-interacting protein into the TNF receptor 1 signaling complex: Implication for the regulatory role of protein kinase C (2006) Mol Pharmacol, 70 (3), pp. 1099-1108; Teng, X., Keys, H., Jeevanandam, A., Structure-activity relationship study of [1: 2: 3]thiadiazole necroptosis inhibitors (2007) Bioorg Med Chem Lett, 17 (24), pp. 6836-6840; Teng, X., Keys, H., Yuan, J., Degterev, A., Cuny, G.D., Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors (2008) Bioorg Med Chem Lett, 18 (11), pp. 3219-3223; Jagtap, P.G., Degterev, A., Choi, S., Structure-activity relationship study of tricyclic necroptosis inhibitors (2007) J Med Chem, 50 (8), pp. 1886-1895; Pyo, J.O., Jang, M.H., Kwon, Y.K., Essential roles of Atg5 and FADD in autophagic cell death: Dissection of autophagic cell death into vacuole formation and cell death (2005) J Biol Chem, 280 (21), pp. 20722-20729; Chinnaiyan, A.M., O'Rourke, K., Tewari, M., Dixit, V.M., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis (1995) Cell, 81 (4), pp. 505-512; Thorburn, J., Moore, F., Rao, A., Selective inactivation of a Fas-associated death domain protein (FADD)- dependent apoptosis and autophagy pathway in immortal epithelial cells (2005) Mol Biol Cell, 16 (3), pp. 1189-1199; Vazquez, C.L., Colombo, M.I., Beclin 1 modulates the anti-apoptotic activity of Bcl-2: Insights from a pathogen infection system (2010) Autophagy, 6 (1), pp. 177-178; Liang, X.H., Kleeman, L.K., Jiang, H.H., Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2- interacting protein (1998) J Virol, 72 (11), pp. 8586-8596; Pattingre, S., Tassa, A., Qu, X., Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy (2005) Cell, 122 (6), pp. 927-939; Clarke, P.G., Labelling of dying neurones by peroxidase injected intravascularly in chick embryos (1982) Neurosci Lett, 30 (3), pp. 223-228; Clarke, P.G., Identical populations of phagocytes and dying neurons revealed by intravascularly injected horseradish peroxidase, and by endogenous glutaraldehyde-resistant acid phosphatase, in the brains of chick embryos (1984) Histochem J, 16 (9), pp. 955-969; Borsello, T., Bressoud, R., Mottier, V., Kainate-induced endocytosis in retinal amacrine cells (2003) J Comp Neurol, 465 (2), pp. 286-295; Yu, L., Alva, A., Su, H., Regulation of an ATG7- beclin 1 program of autophagic cell death by caspase-8 (2004) Science, 304 (5676), pp. 1500-1502; Gonzalez-Polo, R.A., Boya, P., Pauleau, A.L., The apoptosis/autophagy paradox: Autophagic vacuolization before apoptotic death (2005) J Cell Sci, 118 (PART 14), pp. 3091-3102; Pattingre, S., Levine, B., Bcl-2 inhibition of autophagy: A new route to cancer? (2006) Cancer Res, 66 (6), pp. 2885-2888; Yousefi, S., Perozzo, R., Schmid, I., Calpain mediated cleavage of Atg5 switches autophagy to apoptosis (2006) Nat Cell Biol, 8 (10), pp. 1124-1132; Wang, Y., Dong, X.X., Cao, Y., p53 induction contributes to excitotoxic neuronal death in rat striatum through apoptotic and autophagic mechanisms (2009) Eur J Neurosci, 30 (12), pp. 2258-2270; Yuan, J., Lipinski, M., Degterev, A., Diversity in the mechanisms of neuronal cell death (2003) Neuron, 40 (2), pp. 401-413; Xu, Y., Jagannath, C., Liu, X.D., Toll-like receptor 4 is a sensor for autophagy associated with innate immunity (2007) Immunity, 27 (1), pp. 134-144; Sanz, L., Sanchez, P., Lallena, M.J., Diaz-Meco, M.T., Moscat, J., The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation (1999) EMBO J, 18 (11), pp. 3044-3053; Moscat, J., Diaz-Meco, M.T., p62 at the crossroads of autophagy, apoptosis, and cancer (2009) Cell, 137 (6), pp. 1001-1004; Bell, B.D., Leverrier, S., Weist, B.M., FADD and caspase-8 control the outcome of autophagic signaling in T cells (2008) Proc Natl Acad Sci USA, 105 (43), pp. 16677-16682; Ch'En, I.L., Beisner, D.R., Degterev, A., Antigen-mediated T cell expansion regulated by parallel pathways of death (2008) Proc Natl Acad Sci USA, 105 (45), pp. 17463-17468; Ullman, E., Fan, Y., Stawowczyk, M., Autophagy promotes necrosis in poptosis-deficient cells in response to ER stress (2008) Cell Death Differ, 15 (2), pp. 422-425; Debnath, J., Baehrecke, E.H., Kroemer, G., Does autophagy contribute to cell death? (2005) Autophagy, 1 (2), pp. 66-74; Baehrecke, E.H., Autophagy: Dual roles in life and death? (2005) Nat Rev Mol Cell Biol, 6 (6), pp. 505-510; Xiao, J., Moon, M., Yan, L., Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction (2012) Basic Res Cardiol, 107 (1), p. 239; Schattenberg, J.M., Zimmermann, T., Wörns, M., Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo (2011) J Hepatol, 55 (6), pp. 1272-1280; Yu, L., Miao, H., Hou, Y., Zhang, B., Guo, L., Neuroprotective effect of A20 on TNF-induced postischemic apoptosis (2006) Neurochem Res, 31 (1), pp. 21-32; Jin, Z., Li, Y., Pitti, R., Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling (2009) Cell, 137 (4), pp. 721-735; Nakajima, A., Kojima, Y., Nakayama, M., Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells (2008) Oncogene, 27 (1), pp. 76-84; Oberst, A., Dillon, C.P., Weinlich, R., Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis (2011) Nature, 471 (7338), pp. 363-367; Storz, P., Döppler, H., Ferran, C., Grey, S.T., Toker, A., Functional dichotomy of A20 in apoptotic and necrotic cell death (2005) Biochem J, 387 (PART 1), pp. 47-55",Article,Scopus,2-s2.0-84896698526
"Harrison J., Rentz D.M., McLaughlin T., Niecko T., Gregg K.M., Black R.S., Buchanan J., Liu E., Grundman M.","Cognition in MCI and alzheimers disease: Baseline data from a longitudinal study of the NTB",2014,"Clinical Neuropsychologist","28","2",,"252","268",,,10.1080/13854046.2013.875595,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897659577&partnerID=40&md5=d6ab0f3f5ab6260b02a5c13cb4a0fd34","Metis Cognition Ltd., Park House, Kilmington Common, Warminster, Wiltshire, BA12 6QY, United Kingdom; Department of Medicine, Imperial College, London, United Kingdom; Department of Neurology, Brigham and Womens Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, United States; Niecko Health Economics, LLC, Naples, FL, United States; Pfizer Inc., Collegeville, PA, United States; Global RandD Partners Inc., San Diego, CA, United States","Harrison, J., Metis Cognition Ltd., Park House, Kilmington Common, Warminster, Wiltshire, BA12 6QY, United Kingdom, Department of Medicine, Imperial College, London, United Kingdom; Rentz, D.M., Department of Neurology, Brigham and Womens Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; McLaughlin, T., Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, United States; Niecko, T., Niecko Health Economics, LLC, Naples, FL, United States; Gregg, K.M., Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, United States; Black, R.S., Pfizer Inc., Collegeville, PA, United States; Buchanan, J., Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, United States; Liu, E., Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, CA, United States; Grundman, M., Global RandD Partners Inc., San Diego, CA, United States","Baseline data are summarized from a study examining the psychometric properties of the Neuropsychological Test Battery (NTB) and its subtests, and correlating the NTB with other cognitive and functional assessments. A multicenter, longitudinal, non-interventional study included mild to moderate Alzheimers disease (AD, n = 196), mild cognitive impairment (MCI, n = 70), or normal cognition participants (NC, n = 75). The NTB, other cognitive assessment tools, functional/behavioral questionnaires, and health outcome assessments were administered. At baseline composite NTB, NTB memory, and NTB executive function z-scores were significantly lower for participants with AD compared with MCI, and for participants with MCI compared with NC. The composite NTB z-score had high test-retest reliability between screening and baseline. The results of this study suggest that NTB exhibits good reliability in patients with mild to moderate AD and MCI. © 2014 Taylor & Francis.","Alzheimer's disease; Cognition; MCI; Neuropsychological Test Battery; Psychometric properties","Black, R.S., Harrison, J., Li, D., Yang, L., Booth, K., Barlas, S., A comparison of the Neuropsychological Test Battery (NTB) and ADAS-Cog performance in an Alzheimers disease clinical trial (2009) Alzheimer Dement, 5(suppl), pp. P457. , Abstract P4-087; Faux, N.G., Ritchie, C.W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Bush, A.I., PBT2 rapidly improves cognition in Alzheimers disease: Additional phase II analyses (2010) Journal of Alzheimers Disease, 20, pp. 509-516; Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Orgogozo, J.-M., Clinical effects of a immunization (AN1792) in patients with AD in an interrupted trial (2005) Neurology, 64 (9), pp. 1553-1562. , DOI 10.1212/01.WNL.0000159740.16984.3C; Grundman, M., Petersen, R.C., Ferris, S.H., Thomas, R.G., Aisen, P.S., Bennett, D.A., Foster, N.L., Thal, L.J., Mild Cognitive Impairment Can Be Distinguished from Alzheimer Disease and Normal Aging for Clinical Trials (2004) Archives of Neurology, 61 (1), pp. 59-66. , DOI 10.1001/archneur.61.1.59; Harrison, J., Caveney, A., 10 years of the Neuropsychological Test Battery (NTB) (2011) PRO Newsletter, 46, pp. 21-24; Harrison, J., Minassian, S.L., Jenkins, L., Black, R.S., Koller, M., Grundman, M., A neuropsychological test battery for use in alzheimer disease clinical trials (2007) Archives of Neurology, 64 (9), pp. 1323-1329. , http://archneur.ama-assn.org/cgi/reprint/64/9/1323, DOI 10.1001/archneur.64.9.1323; Karin, A., Hannesdottir, K., Jaeger, J., Annas, P., Segerdahl, M., Karlsson, P., Karlsson, A., Miller, F., Psychometric evaluation of ADAS-Cog and NTB for measuring drug response (2013) Acta Neurologica Scandinavica, 129, pp. 114-122; Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Ritchie, C.W., PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimers disease: A phase IIa, double-blind, randomised, placebo-controlled trial (2008) Lancet Neurology, 7, pp. 779-786; (2009) Lancet Neurology, 8, p. 981. , Erratum; Martyr, A., Clare, L., Executive function and activities of daily living in Alzheimers disease: A correlational meta-analysis (2012) Dementia and Geriatric Cognitive Disorders, 33, pp. 189-203; McKhann, G., Drachman, D., Folstein, M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease (1984) Neurology, 34 (7), pp. 939-944; Scheltens, P., Kamphuis, P.J., Verhey, F.R., Olde Rikkert, M.G., Wurtman, R.J., Wilkinson, D., Kurz, A., Efficacy of a medical food in mild Alzheimers disease: A randomized, controlled trial (2010) Journal of Alzheimers Disease, 6, pp. 1-10; Scheltens, P., Twisk, J., Blesa, R., Scarpini, E., Von Arnim, C., Bongers, A., Kamphuis, P.J., Souvenaid improves memory in drug-naive patients with mild Alzheimers disease: Results from a randomized, controlled, double-blind study (Souvenir II) (2011) Journal of Nutrition, Health & Aging, 15 (SUPPL. 1), pp. S13. , Abstract LB3; Sevigny, J.J., Peng, Y., Liu, L., Lines, C.R., Item analysis of ADAS-Cog: Effect of baseline cognitive impairment in a clinical AD trial (2010) American Journal of Alzheimer's Disease & Other Dementias, 25, pp. 119-124; Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G.K., Truyen, L., Nye, J.S., GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in participants with mild cognitive impairment (2008) Neurology, 70, pp. 2024-2035; Erratum (2010) Neurology, 75, p. 1485",Article,Scopus,2-s2.0-84897659577
"El Haj M., Moroni C., Luyat M., Omigie D., Allain P.","To what extent does destination recall induce episodic reliving? Evidence from Alzheimers disease",2014,"Journal of Clinical and Experimental Neuropsychology","36","2",,"127","136",,4,10.1080/13803395.2013.869309,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84894645415&partnerID=40&md5=0473bc75e32d740186b600e7de86579c","Laboratoire Epsylon, Université Paul-Valery, Montpellier III, Rue du Professeur Henri Serre, FR-34000 Montpellier, France; Neuropsychology and Auditory Cognition, Department of Psychology, University of Lille, Lille, France; Centre de Neuroimagerie de Recherche (CENIR), Paris, France; Centre de Recherche de LInstitut du Cerveau et de la Moëlle Épinière (ICM), UPMC-UMR 7225 CNRS-UMRS 975 INSERM, Paris, France; LUNAM Université, Université DAngers, Laboratoire de Psychologie des Pays de la Loire, Angers, France; Centre Mémoire de Ressources et de Recherches, CHU Angers, France","El Haj, M., Laboratoire Epsylon, Université Paul-Valery, Montpellier III, Rue du Professeur Henri Serre, FR-34000 Montpellier, France, Neuropsychology and Auditory Cognition, Department of Psychology, University of Lille, Lille, France; Moroni, C., Neuropsychology and Auditory Cognition, Department of Psychology, University of Lille, Lille, France; Luyat, M., Neuropsychology and Auditory Cognition, Department of Psychology, University of Lille, Lille, France; Omigie, D., Neuropsychology and Auditory Cognition, Department of Psychology, University of Lille, Lille, France, Centre de Neuroimagerie de Recherche (CENIR), Paris, France, Centre de Recherche de LInstitut du Cerveau et de la Moëlle Épinière (ICM), UPMC-UMR 7225 CNRS-UMRS 975 INSERM, Paris, France; Allain, P., LUNAM Université, Université DAngers, Laboratoire de Psychologie des Pays de la Loire, Angers, France, Centre Mémoire de Ressources et de Recherches, CHU Angers, France","We compared destination memory to source memory in patients with Alzheimers disease (AD), as the latter type of memory is believed to be severely deteriorated in AD. Control participants and AD patients were tested on two conditions, both of which had a study phase and a recognition phase. In the study phase of the first condition, participants had to tell a set of facts to the faces of a set of celebrities (destination memory). In the study phase of the second condition, they had to receive a different set of facts from a different set of celebrity faces (source memory). During the recognition phase, participants had to indicate, for destination memory, whether they had previously told a given fact to a given face (yes) or not (no) and, for source memory, whether they had previously received a given fact from a given face (yes) or not (no). In both conditions, they were asked to choose between ""remember"" or ""know"" options when answering ""yes."" AD patients showed reliable difficulties in destination recall, accompanied by a significant decrease in the number of ""remember"" responses they gave. AD-related destination memory decline may be attributed to the perturbation of episodic memory and its autonoetic reliving. The potential neural bases of this decline are discussed in terms of hippocampal failures. © 2014 © 2014 Taylor & Francis.","Alzheimers disease","Addis, D.R., Moscovitch, M., Crawley, A.P., McAndrews, M.P., Recollective qualities modulate hippocampal activation during autobiographical memory retrieval (2004) Hippocampus, 14 (6), pp. 752-762; Bäckman, L., Andersson, J.L., Nyberg, L., Winblad, B., Nordberg, A., Almkvist, O., Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease (1999) Neurology, 52, pp. 1861-1870; Clarys, D., Bugaiska, A., Tapia, G., Baudouin, A., Ageing, remembering, and executive function (2009) Memory, 17 (2), pp. 158-168; Craik, F.I.M., Lockhart, R.S., Levels of processing: A framework for memory research (1972) Journal of Verbal Learning and Verbal Behavior, 11, pp. 671-684; Dalla Barba, G., Recognition memory and recollective experience in Alzheimer's disease (1997) Memory, 5 (6), pp. 657-672; Dalla Barba, G., Nedjam, Z., Dubois, B., Confabulation, executive functions, and source memory in Alzheimer's disease (1999) Cognitive Neuropsychology, 16, pp. 385-398; Deltour, J.J., (1993) Adaptation française et normes comparées du Mill Hill et du Standard Pragressive Matrice, , Echelle de vocabulaire de Mill Hill de J. C. Raven. (PM 38). Manuel [J.C. Raven's Mill-Hill Vocabulary Scale: French adaptation and comparative norms of Mill-Hill and the Standard Progressive Matrix (PM 38). Manual]. Braine-le-Château: L'Application des Techniques Modernes; Dudukovic, N.M., Knowlton, B.J., Remember-know judgments and retrieval of contextual details (2006) Acta Psychologica, 122 (2), pp. 160-173; El Haj, M., Fasotti, L., Allain, P., The involuntary nature of music-evoked autobiographical memories in Alzheimer's disease (2012) Consciousness and Cognition, 21, pp. 238-246; El Haj, M., Fasotti, L., Allain, P., Source monitoring in Alzheimer's disease (2012) Brain and Cognition, 80, pp. 185-191; El Haj, M., Postal, V., Allain, P., Destination memory in Alzheimer's disease: When I imagine telling Ronald Reagan about Paris (2013) Cortex, 49 (1), pp. 82-89; El Haj, M., Postal, V., Le Gall, D., Allain, P., Destination memory in mild Alzheimer's disease (2013) Behavioural Neurology, 26 (3), pp. 215-216; Erngrund, K., Mantyla, T., Nilsson, L.G., Adult age differences in source recall: A populationbased study (1996) Journal of Gerontology, 51, pp. 335-345; Fairfield, B., Mammarella, N., The role of cognitive operations in reality monitoring: A study with healthy older adults and Alzheimer's-Type dementia (2009) Journal of General Psychology, 136, pp. 21-39; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Gardiner, J.M., Episodic memory and autonoetic consciousness: A first person approach (2001) The Royal Society, 356, pp. 1351-1361; Gardiner, J.M., Ramponi, C., Richardson-Klavehn, A., Experiences of remembering, knowing, and guessing (1998) Consciousness and Cognition, 7 (1), pp. 1-26; Gopie, N., Craik, F.I.M., Hasher, L., Destination memory impairment in older people (2010) Psychology and Aging, 25, pp. 922-928; Gopie, N., MacLeod, C.M., Destination memory: Stop me if I've told you this before (2009) Psychological Science, 20, pp. 1492-1499; Grober, E., Buschke, H., Genuine memory deficits in dementia (1987) Developmental Neuropsychology, 3, pp. 13-36; Hudon, C., Belleville, S., Gauthier, S., The assessment of recognition memory using the remember/ know procedure in amnestic mild cognitive impairment and probable Alzheimer's disease (2009) Brain and Cognition, 70 (1), pp. 171-179; Johnson, M.K., The relation between source memory and episodic memory: Comment on Siedlecki et al. 2005 (2005) Psychology and Aging, 20, pp. 529-531; Lee, I.A., Preacher, K.J., (2013) Calculation for the test of the difference between two dependent correlations with one variable in common [Computer software, , http://quantpsy.org, Retrieved from; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of alzheimer's disease: Report of the nincdsadrda work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944; McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Phelps, C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimer's and Dementia, 7 (3), pp. 263-269; Moscovitch, M., Theories of memory and consciousness (2000) The Oxford handbook of memory, pp. 609-625. , In E. Tulving & F. I. M. Craik (Eds). Oxford: Oxford University Press; Moscovitch, M., The hippocampus as a stupid,"" domain-specific module: Implications for theories of recent and remote memory, and of imagination (2008) Canadian Journal of Experimental Psychology, 62 (1), pp. 62-79; Moscovitch, M., Nadel, L., Winocur, G., Gilboa, A., Rosenbaum, S.R., The cognitive neuroscience of remote episodic, semantic and spatial memory (2006) Current Opinion in Neurobiology, 16, pp. 179-190; Multhaup, K.S., Balota, D.A., Generation effects and source memory in healthy older adults and in adults with dementia of the Alzheimer type (1997) Neuropsychology, 11, pp. 382-391; Piolino, P., Desgranges, B., Belliard, S., Matuszewski, V., Lalevee, C., De La Sayette, V., Eustache, F., Autobiographical memory and autonoetic consciousness: Triple dissociation in neurodegenerative diseases (2003) Brain, 126 (10), pp. 2203-2219; Rauchs, G., Piolino, P., Mezenge, F., Landeau, B., Lalevee, C., Pelerin, A., Desgranges, B., Autonoetic consciousness in Alzheimer's disease: Neuropsychological and PET findings using an episodic learning and recognition task (2007) Neurobiology of Aging, 28 (9), pp. 1410-1420; Schacter, D.L., Kaszniak, A.W., Kihlstrom, J.F., Valdiserri, M., The relation between source memory and aging (1991) Psychology and Aging, 6, pp. 559-568; Squire, L.R., Stark, C.E., Clark, R.E., The medial temporal lobe (2004) Annual Review of Neuroscience, 27, pp. 279-306; Tulving, E., Memory and consciousness (1985) Canadian Psychologist, 25, pp. 1-12; Tulving, E., Episodic memory: From mind to brain (2002) Annual Review of Psychology, 53, pp. 1-25; Van Der Linden, M., Adam, S., Agniel, A., Baisset-Mouly, C., Bardet, F., Coyette, F., L'évaluation des troubles de la mémoire: Présentation de quatre tests de mémoire épisodique (avec leur étalonnage) [Evaluation of memory deficits: Presentation of four tests of episodic memory (with standardization)]. (2004) Marseille: Solal Editeurs; Wheeler, M.A., Stuss, D.T., Tulving, E., Toward a theory of episodic memory: The frontal lobes and autonoetic consciousness (1997) Psychological Bulletin, 121, pp. 331-354",Article,Scopus,2-s2.0-84894645415
"Whiteley C.G.","Arginine metabolising enzymes as targets against Alzheimers' disease",2014,"Neurochemistry International","67","1",,"23","31",,,10.1016/j.neuint.2014.01.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84894483773&partnerID=40&md5=c5cb8e4637bdf722c0970a75a89ec324","Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei, Taiwan","Whiteley, C.G., Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei, Taiwan","Even though the accumulation of arginine and the deposit of aggregated Aβ-peptides (senile plaques) in the brain of an Alzheimer patient are classic points of evidence in the neuropathology of the disease considerable dispute remains on their method of formation. One acceptable mechanism to initiate events is a 'seed' aggregation of free monomeric peptides into toxic soluble amyloid oligomers and subsequently into deposits of insoluble fibrils. Since all of these events take place in the brain astrocytes it suggests an interference between arginine-metabolising enzymes and the Aβ-peptides. Through kinetic, fluorimetric and thermodynamic analyses two such enzymes - neuronal nitric oxide synthase and peptidyl arginine deiminase - are, not only inhibited by structural fragments of Aβ1-42 but are catalytic towards fibrillogenesis. The interaction of the peptide fragments with each enzyme is endothermic, non-spontaneous and involves hydrophobic-hydrophobic associations with a single binding site. The trigger for this series of events focusses in particularly on Aβ17-21 with two phenylalanines [Phe19; Phe20], the three glycine zipper motifs [Aβ25-29; Aβ29-33; Aβ33-37] and the triple sequence [Aβ25-37] that includes two isoleucine residues [Ile31; Ile32]. FRET studies show the Aβ-peptide fragments bind to the enzymes &lt;3.0 nm from a single surface tryptophan. Free Aβ monomers bind to an enzyme, formulate a nucleus, initiate their aggregation and subsequently become entrapped and couple to the existing aggregated monomers, leading to an elongated fibril. Silver and gold nanoparticles reverse fibrillogenesis! They are surrounded by the amyloid peptide molecules in vivo to effectively deplete their concentration. This does not allow any 'lag' time, nor prevent the formation of critical nuclei for the initial association phase and, inevitably, prevent fibril initiation and elongation. This review focusses on the function and action of arginine metabolising enzymes with respect to the formation of senile plaques and amyloid peptide aggregation to facilitate more of an understanding of neurodegeneration in Alzheimer disease. © 2014 Elsevier B.V.","Alzheimers disease; Arginine metabolizing enzymes; Fibrillogenesis; Inhibition; Mechanisms; Neuronal nitric oxide synthase; Peptidyl arginine deiminase","Akkermans, C., Venema, P., Rogers, S.S., Van Der Goot, A.J., Boom, R.M., Van Der Linden, E., Shear pulses nucleate fibril aggregation (2006) Food Biophysics, 1 (3), pp. 144-150. , DOI 10.1007/s11483-006-9012-5; Auer, S., Trovato, A., Vendruscolo, M., A condensation-ordering mechanism in nanoparticle-catalyzed peptide aggregation (2009) PLoS Comput. Biol., 5 (8), p. 1000458; Berharnu, W.M., Hansmann, U.H.E., Structure and dynamics of amyloid-b segmental polymorphism (2012) PLoS ONE, 7 (7). , 10.137/journal.pone 0041479; Bologa, L., Deugnier, M.-A., Joubert, R., Bisconte, J.-C., Myelin basic protein stimulates the proliferation of astrocytes: Possible explanation for multiple sclerosis plaque formation (1985) Brain Research, 346 (1), pp. 199-203. , DOI 10.1016/0006-8993(85)91117-5; Bruckdorfer, R., The basics about nitric oxide (2005) Molecular Aspects of Medicine, 26 (1), pp. 3-31. , DOI 10.1016/j.mam.2004.09.002; Caflisch, A., Pellarin, R., Interpreting the aggregation kinetics of amyloid peptides (2006) J. Mol. Biol., 360, pp. 882-892; Calzolai, L., Franchini, F., Gilliland, D., Rossi, F., Protein-nanoparticle interaction: Identification of the ubiquitin-gold nanoparticle interaction site (2010) Nano Lett., 10, pp. 3101-3105; Campos, K.L., Giovanelli, J., Kaufman, S., Characteristics of the nitric oxide synthase-catalyzed conversion of arginine to N-hydroxyarginine, the first oxygenation step in the enzymatic synthesis of nitric oxide (1995) J. Biol. Chem., 270, pp. 1721-1728; Carlo, M., Beta-amyloid peptide: From different aggregation forms to the activation of different biochemical pathways (2010) Eur. Biophys. J., 39, pp. 877-888; Cedervall, T., Lynch, I., Lindman, S., Berggard, T., Thulin, E., Nilsson, H., Dawson, K.A., Linse, S., Understanding the nanoparticle-protein corona using methods to quntify exchange rates and affinities of proteins for nanoparticles (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (7), pp. 2050-2055. , DOI 10.1073/pnas.0608582104; Chen, Y., Mills, J.D., Periasamy, A., Protein localization in living cells and tissues using FRET and FLIM (2003) Differentiation, 71, pp. 528-554; Clegg, R.M., Fluorescence resonance energy transfer (1995) Curr. Opin. Biotechnol., 6, pp. 103-110; Clegg, R.M., (1996) Fluorescence Resonance Energy Transfer, Chem Anal Ser, 137, , John Wiley & Sons New York pp 179-251; Cohen, S.I., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., Knowles, T.P., Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism (2013) Proc. Natl. Acad. Sci. USA, , 10.1073/pnas.1218402110; Dasilva, K.A., Shaw, J.E., McLaurin, J., Amyloid-β fibrillogenesis: Structural insight and therapeutic intervention (2010) Exp. Neurol., 223, pp. 311-321; Jans, D.M., Martinet, W., Van De Parre, T.J.L., Herman, A.G., Bult, H., Kockx, M.M., De Meyer, G.R.Y., Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease (2006) Cardiovascular and Hematological Disorders - Drug Targets, 6 (1), pp. 21-34. , http://www.ingentaconnect.com/content/ben/chddt/2006/00000006/00000001/ art00002; Dobson, C.M., Principles of protein folding, misfolding and aggregation (2004) Seminars in Cell and Developmental Biology, 15 (1), pp. 3-16. , DOI 10.1016/j.semcdb.2003.12.008; Dolphin, G.T., Chierici, S., Ouberai, M., Dumy, P., Garcia, J., A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation (2008) ChemBioChem, 9 (6), pp. 952-963; Estrada, L.D., Soto, C., Disrupting β-amyloid aggregation for Alzheimer disease treatment (2007) Current Topics in Medicinal Chemistry, 7 (1), pp. 115-126. , http://www.ingentaconnect.com/content/ben/ctmc/2007/00000007/00000001/ art00010, DOI 10.2174/156802607779318262; Evans, K.C., Berger, E.P., Cho, C., Weisgraber, K.H., Lansbury, Jr.P.T., Apolipoprotein e is a kinetic but not thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimers disease (1995) Proc. Natl. Acad. Sci. USA, 92, pp. 763-767; Fandrich, M., Forge, V., Buder, K., Kittler, M., Dobson, C.M., Diekmann, S., Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (26), pp. 15463-15468. , DOI 10.1073/pnas.0303758100; Fei, L., Perrett, S., Effect of nanoparticles on protein folding and fibrillogenesis (2009) Int. J. Mol. Sci., 10, pp. 646-655; Ferreira, S.T., De Felice, F.G., Protein dynamics, folding and misfolding: From basic physical chemistry to human conformational diseases (2001) FEBS Letters, 498 (2-3), pp. 129-134. , DOI 10.1016/S0014-5793(01)02491-7, PII S0014579301024917; Ferreira, N., Saraiva, M.J., Almeiuda, M.R., Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation (2011) FEBS Lett., 585 (15), pp. 2424-2430; Findeis, M.A., The role of amyloid β peptide 42 in Alzheimer's disease (2007) Pharmacology and Therapeutics, 116 (2), pp. 266-286. , DOI 10.1016/j.pharmthera.2007.06.006, PII S016372580700143X; Fonte, V., Dostal, V., Roberts, C.M., Gonzales, P., Lacor, P., Magrane, J., Dingwell, N., Link, C.D., A glycine zipper motif mediates the formation of toxic b-amyloid oligomers in vitro and in vivo (2011) Mol. Neurodegener., 6, p. 61. , 10.1186/1750-1326-6-61; Giordano, C., Masi, A., Pizzini, A., Sansone, A., Consalvi, V., Chiaraluce, R., Lucente, G., Synthesis and activity of fibrillogenesis peptide inhibitors related to 17-21 β-amyloid fibrillogenesis (2009) Eur. J. Med. Chem., 44, pp. 179-189; Glabe, C.G., Common mechanisms of amyloid oligomer pathogenesis in degenerative disease (2006) Neurobiology of Aging, 27 (4), pp. 570-575. , DOI 10.1016/j.neurobiolaging.2005.04.017, PII S0197458005002344, Protein Misfolding in Alzheimer's and Other Age-Related Neurodegenerative Diseases; Glabe, C.G., Structural classification of toxic amyloid oligomers (2008) J. Biol. Chem., 283, pp. 29639-29643; Girevic, P.D., Castano, E.M., Sarma, R., Frangione, B., Ten of fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern (1987) Biochemical and Biophysical Research Communications, 147 (2), pp. 854-862. , DOI 10.1016/0006-291X(87)91008-4; Gruden, M.A., Davidova, T.B., Malisauskas, M., Sewell, R.D.E., Voskresenskaya, N.I., Wilhelm, K., Elistratova, E.I., Morozova-Roche, L.A., Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25-35) oligomers, S100b and neurotransmitters (2007) Journal of Neuroimmunology, 186 (1-2), pp. 181-192. , DOI 10.1016/j.jneuroim.2007.03.023, PII S0165572807001129; Hao, J., Zhang, W., Zhang, P., Liu, R., Aβ20-29 peptide blocking apoE/Aβ interaction reduces full length Aβ42/40 fibril formation and cytotoxicity in vitro (2010) Neuropeptides, 44, pp. 305-313; Harris, J.R., (2012) Subcellular Biochemistry: Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease, 65 VOL.. , J.R. Harris, Springer Science+Business Media Dordrecht, Germany 10.1007/978-94-007-5416-4-13, ©; Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Saido, T.C., Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition (2000) Nature Medicine, 6 (2), pp. 143-150. , DOI 10.1038/72237; Iwata, K., Zhang, S., Lachenmann, M.J., Peng, J.W., Li, S., Stimson, E.R., Lu, Y., Lee, J.P., The Alzheimer's peptide Aβ adopts a collapsed coil structure in water (2000) J. Biol. Chem., 130 (23), pp. 130-141; Jones, O.G., Mezzenga, R., Inhibiting, promoting and preserving stability of functional protein fibrils (2012) Soft Matter, 8, pp. 876-879; Kallberg, Y., Gustafsson, M., Persson, B., Thyberg, J., Johansson, J., Prediction of amyloid fibril-forming proteins (2001) J. Biol. Chem., 276, pp. 12945-12950; Kammerer, R.A., Kostrewa, D., Zurdo, J., Detken, A., Garcia-Echeverria, C., Green, J.D., Muller, S.A., Steinmetz, M.O., Exploring amyloid formation by a de novo design (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (13), pp. 4435-4440. , DOI 10.1073/pnas.0306786101; Kanski, J., Aksenova, M., Allan Butterfield, D., The hydrophobic environment of Met35 of Alzheimer's Aβ(1-42) is important for the neurotoxic and oxidative properties of the peptide (2002) Neurotoxicity Research, 4 (3), pp. 219-223. , DOI 10.1080/10298420290023945; Khan, M.S., Al-Senaidy, A.M., Priyadarshini, M., Shah, A., Bano, B., Different conformation of thiol protease inhibitor during amyloid formation: Inhibition by curcumin and quercetin (2013) J. Fluoresc., 23 (3), pp. 451-457; Kim, S., Jeon, T.-J., Oberai, A., Yang, D., Schmidt, J.J., Bowie, J.U., Transmembrane glycine zippers: Physiological and pathological roles in membrane proteins (2005) Proceedings of the National Academy of Sciences of the United States of America, 102 (40), pp. 14278-14283. , DOI 10.1073/pnas.0501234102; Klunk, W.E., Pettegrew, J.W., Abraham, D.J., Two simple methods for quantifying low-affinity dye-substrate binding (1989) Journal of Histochemistry and Cytochemistry, 37 (8), pp. 1293-1297; Alderton, W.K., Cooper, C.E., Knowles, R.G., Nitric oxide synthases: Structure, function and inhibition (2001) Biochemical Journal, 357 (3), pp. 593-615. , DOI 10.1042/0264-6021:3570593; Le Vine, H., Thioflavin T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution (1993) Protein Sci., 2, pp. 404-410; Le Vine, H., Quantification of β-sheet amyloid fibril structures with thioflavin-T (1999) Methods Enzymol., 309, pp. 274-284; Lekshmi, N.C.J., Sumi, S.B., Viveka, S., Jeeva, S., Brindha, J.R., Antibacterial activity of nanoparticles from Allium sp (2012) J. Microbiol. Biotechnol. Res., 2, pp. 115-119; Louw, C., Gordon, A., Johnston, N., Mollatt, C., Bradley, G., Whiteley, C., Arginine deiminases: Therapeutic tools in the etiology and pathogenesis of Alzheimer's disease (2007) Journal of Enzyme Inhibition and Medicinal Chemistry, 22 (1), pp. 121-126. , DOI 10.1080/14756360600990829, PII 772438816; Lynch, I., Are there generic mechanisms governing interactions between nanoparticles and cells? Epitope mapping the outer layer of the protein-material interface (2007) Physica A: Statistical Mechanics and its Applications, 373, pp. 511-520. , DOI 10.1016/j.physa.2006.06.008, PII S0378437106007229; Lynch, I., Dawson, K.A., Protein-nanoparticle interactions (2008) Nano Today, 3 (1-2), pp. 40-47. , DOI 10.1016/S1748-0132(08)70014-8, PII S1748013208700148; Mohlake, P., Whiteley, C.G., Arginine metabolising enzymes as therapeutic tools for Alzheimer's disease: Peptidyl arginine deiminase catalyses fibrillogenesis of β-amyloid peptides (2010) Mol. Neurobiol., 41 (23), pp. 149-158; Mubarakali, D., Thajuddin, N., Jeganathan, K., Gunasekaran, M., Plant extract mediated synthesis of silver and gold nanoparticles and its antibacterial activity against clinically isolated pathogens (2011) Colloids Surf., B, 85, pp. 360-365; Musse, A.A., Zhen, L., Ackerley, C.A., Bienzle, D., Lei, H., Poma, R., Harauz, G., Mastronardi, F.G., Peptidylarginine deiminase II (PADII) overexpression in transgenic mice leads to myelin loss in the central nervous system (2008) Dis. Models Mech., 1 (45), pp. 229-240; Naiki, H., Higuchi, K., Nakakuki, K., Takeda, T., Kinetic analysis of amyloid fibril polymerisation in vitro (1991) Lab. Invest., 65, pp. 104-110; Ono, K., Hasegawa, K., Naiki, H., Yamada, M., Curcumin Has Potent Anti-Amyloidogenic Effects for Alzheimer's β-Amyloid Fibrils In Vitro (2004) Journal of Neuroscience Research, 75 (6), pp. 742-750. , DOI 10.1002/jnr.20025; Orlando, R.A., Gonzales, A.M., Rover, R.E., Deck, L.M., Van Der Jagt, D.L., A chemical analog of curcumin as an improved inhibitor of amyloid abeta oligomerization (2012) PLoS ONE, 7 (3), p. 31869; Padayachee, E.R., (2013) Personal Communication; Padayachee, E.R., Whiteley, C.G., Spectrofluorimetric analysis for the interaction of amyloid peptides with neuronal nitric oxide synthase: Implications in Alzheimers disease (2011) Biochem. Biophys. Acta, 1810 (12), pp. 1136-1140; Padayachee, E.R., Whiteley, C.G., Etiology of Alzheimer's disease: Kinetic, thermodynamic and fluorimetric analyses of interactions of pseudo Aβ-peptides with neuronal nitric oxide synthase (2013) Neuropeptides, 47, pp. 321-327; Padayachee, E.R., Whiteley, C.G., Interaction of glycine zipper fragments of Aβ-peptides with neuronal nitric oxide synthase: Kinetic, thermodynamic and spectrofluorimetric analysis (2013) Neuropeptides, 47, pp. 171-178; Padayachee, E.R., Ngqwala, N.P., Whiteley, C.G., Association of β-amyloid peptide fragments with neuronal nitric oxide synthase: Implications in the etiology of Alzheimers disease (2012) J. Enzyme Inhib. Med. Chem., 27 (3), pp. 356-364; Padayachee, E.R., Sennuga, A., Whiteley, C.G., Nanomedicine: Action of metal nanoparticles on neuronal nitric oxide synthase. Fluorimetric analysis on the mechanism for fibrillogenesis (2013) Neurochem. Res., , 10.1007/s11064-013-1206-x; Pike, C.J., Walencewicz-Wasserman, A.J., Kosmoski, J., Cribbs, D.H., Glabe, C.G., Cotman, C.W., Structure-activity analyses of β-amyloid peptides: Contribution of the Aβ25-35 region to aggregation and neurotoxicity (1995) J. Neurochem., 64, pp. 253-265; Porat, Y., Abramowitz, A., Gazit, E., Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism (2006) Chemical Biology and Drug Design, 67 (1), pp. 27-37. , DOI 10.1111/j.1747-0285.2005.00318.x; Poulos, T.L., Li, H., Shimizu, H., Flinspach, M., Jamal, J., Yang, W., Xian, M., Wang, P.G., The novel binding mode of N-alkyl-N′-hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis (2002) Biochemistry, 41, pp. 3868-13875; Pritzker, L.B., Joshi, S., Gowan, J.J., Harauz, G., Moscarello, M.A., Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D (2000) Biochemistry, 39 (18), pp. 5374-5381. , DOI 10.1021/bi9925569; Pritzker, L.B., Joshi, S., Harauz, G., Moscarello, M.A., Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase (2000) Biochemistry, 39 (18), pp. 5382-5388. , DOI 10.1021/bi9925571; Rochet, J.-C., Lansbury Jr., P.T., Amyloid fibrillogenesis: Themes and variations (2000) Current Opinion in Structural Biology, 10 (1), pp. 60-68. , DOI 10.1016/S0959-440X(99)00049-4; Ross, P.D., Subramanian, S., Thermodynamics of protein association reactions: Forces contributing to stability (1981) Biochemistry, 20, pp. 3096-3102; Saengkhae, C., Salerno, M., Ades, D., Siove, A., Le Moyec, L., Migonney, V., Garnier-Suillerot, A., Ability of carbazole salts, inhibitors of Alzheimer β-amyloid fibril formation, to cross cellular membranes (2007) European Journal of Pharmacology, 559 (2-3), pp. 124-131. , DOI 10.1016/j.ejphar.2007.01.005, PII S0014299907000180; Salma, A.A., Amer, H.A., Shaemaa, H.A., Abdulrahman, K.A., The effects of gold and silver nanoparticles on transaminase enzymes activities (2011) Int. J. Chem. Res., 1, pp. 1-11; Sambasivam, D., Sivanesan, S., Ashok, B.S., Structural preferences of Aβ fragments in different micellar environments (2011) Neuropeptides, 45, pp. 369-373; Sennuga, A., Van Marwijk, J., Whiteley, C.G., Ferroxidase activity of apoferritin is increased in the presence of platinum nanoparticles (2012) Nanotechnology, 23, p. 035102. , 10.1088/0957-4484/23/3/035102; Sennuga, A., Van Marwijk, J., Boshoff, A., Whiteley, C.G., Enhanced activity of chaperonin GroEL in the presence of platinum nanoparticles (2012) J. Nanopart. Res., 14, pp. 824-835; Serpell, L.C., Alzheimer's amyloid fibrils: Structure and assembly (2000) Biochimica et Biophysica Acta - Molecular Basis of Disease, 1502 (1), pp. 16-30. , DOI 10.1016/S0925-4439(00)00029-6, PII S0925443900000296; Sklar, L.A., Hudson, B.S., Simoni, R.D., Conjugated polyene fatty acids as fluorescent probes: Binding to bovine serum albumin (1977) Biochemistry, 16 (23), pp. 5100-5108; Soreghan, B., Kosmoski, J., Glabe, C., Surfactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation (1994) Journal of Biological Chemistry, 269 (46), pp. 28551-28554; Soto, C., Plaque busters: Strategies to inhibit amyloid formation in Alzheimer's disease (1999) Molecular Medicine Today, 5 (8), pp. 343-350. , DOI 10.1016/S1357-4310(99)01508-7, PII S1357431099015087; Soto, C., Protein misfolding and disease; protein refolding and therapy (2001) FEBS Letters, 498 (2-3), pp. 204-207. , DOI 10.1016/S0014-5793(01)02486-3, PII S0014579301024863; Soto, C., Branes, M.C., Alvarez, J., Inestrosa, N.C., Structural determinants of the Alzheimer's amyloid β-peptide (1994) Journal of Neurochemistry, 63 (4), pp. 1191-1198; Soto, C., Castano, E., Frangione, B., Inestrosa, N.C., The α-helical to β-strand transition in the N-terminal fragment of the amyloid β-peptide modulates amyloid formation (1995) J. Biol. Chem., 266, pp. 4025-4028; Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M., Frangione, B., β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy (1998) Nature Medicine, 4 (7), pp. 822-826. , DOI 10.1038/nm0798-822; Soto, P., Griffin, M.A., Shea, J.-E., New insights into the mechanism of Alzheimer amyloid-β fibrillogenesis inhibition by N-methylated peptides (2007) Biophysical Journal, 93 (9), pp. 3015-3025. , http://www.biophysj.org/cgi/reprint/93/9/3015, DOI 10.1529/biophysj.107.112086; Srivastava, M., Singh, S., Self, W.T., Exposure to silver nanoparticles inhibits selenoprotein synthesis and the activity of thioredoxin reductase (2011) Environ. Health Perspect., 120, pp. 56-61; Strazza, S., Hunter, R., Walker, E., Darnall, D.W., The thermodynamics of bovine and porcine insulin and proinsulin association determined by concentration difference spectroscopy (1985) Archives of Biochemistry and Biophysics, 238 (1), pp. 30-42. , DOI 10.1016/0003-9861(85)90137-7; Takahashi, A., Masuda, A., Sun, M., Centonze, V.E., Herman, B., Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm) (2004) Brain Research Bulletin, 62 (6), pp. 497-504. , DOI 10.1016/j.brainresbull.2003.07.009; Thapa, A., Woo, E.R., Chi, E.Y., Sharoar, M.G., Jin, H.G., Shin, S.Y., Park, I.S., Biflavonoids are superior to monoflavonoids in inhibiting amyloid-β toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures (2011) Biochemistry, 50 (13), pp. 2445-2455; Wang, S.S.-S., Liu, K.-N., Lee, W.-H., Effect of cucurmin on the amyloid fibrillogenesis of hen egg-white lysozyme (2009) Biophys. Chem., 144 (12), pp. 78-87; Wigginton, N.S., Titta, A., Piccapietra, F., Dobias, J., Nesatyy, V.J., Suter, M.J.F., Bernier-Latmani, B., Binding of silver nanoparticles to bacterial proteins depends on surface modifications and inhibits enzymatic activity (2010) Environ. Sci. Technol., 44, pp. 2163-2168; Woo, H., Baik, S., Park, J.S., Gwon, A., Yang, S., Yun, Y., Secretases as therapeutic targets for Alzheimer's disease (2011) Biochem. Biophys. Res. Commun., 404, pp. 10-15; Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P., Cole, G.M., Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo (2005) Journal of Biological Chemistry, 280 (7), pp. 5892-5901. , DOI 10.1074/jbc.M404751200; Yi, J., Horky, L.H., Friedlich, A.L., Shi, Y., Rogers, J.T., Huang, Y., L-Arginine and Alzheimer's disease (2009) Int. J. Clin. Pathol., 3, pp. 211-238",Review,Scopus,2-s2.0-84894483773
"Park S.J., Shin J.H., Jeong J.I., Song J.H., Jo Y.K., Kim E.S., Lee E.H., Hwang J.J., Lee E.K., Chung S.J., Koh J.-Y., Jo D.-G., Cho D.-H.","Down-regulation of mortalin exacerbates aβ-mediated mitochondrial fragmentation and dysfunction",2014,"Journal of Biological Chemistry","289","4",,"2195","2204",,7,10.1074/jbc.M113.492587,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84893146602&partnerID=40&md5=4f7c6a6c4c6bde3d0a0ea0c5c55ef66d","Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; School of Pharmacy, Sungkyunkwan University, Suwon 440-746, South Korea; Asan Institute for Life Science, Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Seoul 138-736, South Korea; Department of Neurology, Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Seoul 138-736, South Korea; Department of Biochemistry, College of Medicine, Catholic University of Korea, Seoul 137-701, South Korea","Park, S.J., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; Shin, J.H., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; Jeong, J.I., School of Pharmacy, Sungkyunkwan University, Suwon 440-746, South Korea; Song, J.H., Asan Institute for Life Science, Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Seoul 138-736, South Korea; Jo, Y.K., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; Kim, E.S., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; Lee, E.H., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea; Hwang, J.J., Asan Institute for Life Science, Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Seoul 138-736, South Korea; Lee, E.K., Department of Neurology, Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Seoul 138-736, South Korea; Chung, S.J., Department of Biochemistry, College of Medicine, Catholic University of Korea, Seoul 137-701, South Korea; Koh, J.-Y., Department of Biochemistry, College of Medicine, Catholic University of Korea, Seoul 137-701, South Korea; Jo, D.-G., School of Pharmacy, Sungkyunkwan University, Suwon 440-746, South Korea; Cho, D.-H., Department of East-West Medical Science, Graduate School of East-West Medical Science, Kyung Hee University, 1, Seocheon-Dong, Yongin 446-701, South Korea","Background: Mitochondrial dysfunction is associated with neuronal disorders, and mitochondrial dynamics are altered in neurodegenerative diseases. Results: Inhibition of mortalin potentiates amyloid-β-mediated mitochondrial dysfunction and cytotoxicity. Conclusion: Inhibition of mortalin could lead to mitochondrial dysfunction through mitochondrial fragmentation. Significance: Activation of mortalin may antagonize the progression of Aβ-mediated neuronal injury in which mitochondrial dysfunction has a key role. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.",,"Cho, D.H., Nakamura, T., Lipton, S.A., Mitochondrial dynamics in cell death and neurodegeneration (2010) Cell Mol. Life Sci., 67, pp. 3435-3447; Westermann, B., Mitochondrial fusion and fission in cell life and death (2010) Nat. Rev. Mol. Cell Biol., 11, pp. 872-884; Chan, D.C., Mitochondria. Dynamic organelles in disease, aging, and development (2006) Cell, 125, pp. 1241-1252; Chen, H., Chan, D.C., Mitochondrial dynamics-fusion, fission, movement, and mitophagy in neurodegenerative diseases (2009) Hum. Mol. Genet., 18, pp. R169-R176; Liesa, M., Palacín, M., Zorzano, A., Mitochondrial dynamics in mammalian health and disease (2009) Physiol. Rev., 89, pp. 799-845; Knott, A.B., Perkins, G., Schwarzenbacher, R., Bossy-Wetzel, E., Mitochondrial fragmentation in neurodegeneration (2008) Nat. Rev. Neurosci., 9, pp. 505-518; Barsoum, M.J., Yuan, H., Gerencser, A.A., Liot, G., Kushnareva, Y., Gräber, S., Kovacs, I., Bossy-Wetzel, E., Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons (2006) EMBO J., 25, pp. 3900-3911; Wang, X., Zuo, X., Kucejova, B., Chen, X.J., Reduced cytosolic protein synthesis suppresses mitochondrial degeneration (2008) Nat. Cell Biol., 10, pp. 1090-1097; Cho, D.H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., Lipton, S.A., S-Nitrosylation of Drp1 mediates β-amyloid-related mitochondrial fission and neuronal injury (2009) Science, 324, pp. 102-105; Alexander, C., Votruba, M., Pesch, U.E., Thiselton, D.L., Mayer, S., Moore, A., Rodriguez, M., Wissinger, B., OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant atrophy linked to chromosome 3q28 (2000) Nat. Genet., 26, pp. 211-215; Züchner, S., Mersiyanova, I.V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E.L., Zappia, M., Vance, J.M., Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A (2004) Nat. Genet., 36, pp. 449-451; Chang, C.R., Manlandro, C.M., Arnoult, D., Stadler, J., Posey, A.E., Hill, R.B., Blackstone, C., A lethal de novo mutation in the middle domain of the dynamin-related GTPase Drp1 impairs higher order assembly and mitochondrial division (2010) J. Biol. Chem., 285, pp. 32494-32503; Gawlowski, T., Suarez, J., Scott, B., Torres-Gonzalez, M., Wang, H., Schwappacher, R., Han, X., Dillmann, W., Modulation of dynamin-related protein 1 (DRP1) function by increased O-linked-β-N-acetylglucosamine modification (O-GlcNAc) in cardiac myocytes (2012) J. Biol. Chem., 287, pp. 30024-30034; Palmer, C.S., Osellame, L.D., Laine, D., Koutsopoulos, O.S., Frazier, A.E., Ryan, M.T., MiD49 and MiD51, new components of the mitochondrial fission machinery (2011) EMBO Rep., 12, pp. 565-573; Chen, Y., Dorn, G.W., PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria (2013) Science, 340, pp. 471-475; Taguchi, N., Ishihara, N., Jofuku, A., Oka, T., Mihara, K., Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission (2007) J. Biol. Chem., 282, pp. 11521-11529; Chang, C.R., Blackstone, C., Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology (2007) J. Biol. Chem., 282, pp. 21583-21587; Cribbs, J.T., Strack, S., Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death (2007) EMBO Rep., 8, pp. 939-944; Han, X.J., Lu, Y.F., Li, S.A., Kaitsuka, T., Sato, Y., Tomizawa, K., Nairn, A.C., Matsushita, M., CaM kinase i α-induced phosphorylation of Drp1 regulates mitochondrial morphology (2008) J. Cell Biol., 182, pp. 573-585; Meuer, K., Suppanz, I.E., Lingor, P., Planchamp, V., Göricke, B., Fichtner, L., Braus, G.H., Weishaupt, J.H., Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis (2007) Cell Death Differ., 14, pp. 651-661; Cereghetti, G.M., Stangherlin, A., Martins De Brito, O., Chang, C.R., Blackstone, C., Bernardi, P., Scorrano, L., Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria (2008) Proc. Natl. Acad. Sci. U.S.A., 105, pp. 15803-15808; Harder, Z., Zunino, R., McBride, H., Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission (2004) Curr. Biol., 14, pp. 340-345; Figueroa-Romero, C., Iñiguez-Lluhí, J.A., Stadler, J., Chang, C.R., Arnoult, D., Keller, P.J., Hong, Y., Feldman, E.L., SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle (2009) FASEB J., 23, pp. 3917-3927; Zunino, R., Schauss, A., Rippstein, P., Andrade-Navarro, M., McBride, H.M., The SUMO protease SENP5 is required to maintain mitochondrial morphology and function (2007) J. Cell Sci., 120, pp. 1178-1188; Braschi, E., Zunino, R., McBride, H.M., MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission (2009) EMBO Rep., 10, pp. 748-754; Yonashiro, R., Ishido, S., Kyo, S., Fukuda, T., Goto, E., Matsuki, Y., Ohmura-Hoshino, M., Yanagi, S., A novel mitochondrial ubiquitin ligase plays a critical role in mitochondrial dynamics (2006) EMBO J., 25, pp. 3618-3626; Karbowski, M., Neutzner, A., Youle, R.J., The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division (2007) J. Cell Biol., 178, pp. 71-84; Niemann, A., Ruegg, M., La Padula, V., Schenone, A., Suter, U., Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network. New implications for Charcot-Marie-Tooth disease (2005) J. Cell Biol., 170, pp. 1067-1078; Tondera, D., Czauderna, F., Paulick, K., Schwarzer, R., Kaufmann, J., Santel, A., The mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells (2005) J. Cell Sci., 118, pp. 3049-3059; Otera, H., Wang, C., Cleland, M.M., Setoguchi, K., Yokota, S., Youle, R.J., Mihara, K., Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells (2010) J. Cell Biol., 191, pp. 1141-1158; Palmer, C.S., Osellame, L.D., Stojanovski, D., Ryan, M.T., The regulation of mitochondrial morphology. Intricate mechanisms and dynamic machinery (2011) Cell Signal., 23, pp. 1534-1545; Eura, Y., Ishihara, N., Oka, T., Mihara, K., Identification of a novel protein that regulates mitochondrial fusion by modulating mitofusin (Mfn) protein function (2006) J. Cell Sci., 119, pp. 4913-4925; Merkwirth, C., Dargazanli, S., Tatsuta, T., Geimer, S., Löwer, B., Wunderlich, F.T., Von Kleist-Retzow, J.C., Langer, T., Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria (2008) Genes Dev., 22, pp. 476-488; Tondera, D., Grandemange, S., Jourdain, A., Karbowski, M., Mattenberger, Y., Herzig, S., Da Cruz, S., Martinou, J.C., SLP-2 is required for stress-induced mitochondrial hyperfusion (2009) EMBO J., 28, pp. 1589-1600; Ishihara, N., Nomura, M., Jofuku, A., Kato, H., Suzuki, S.O., Masuda, K., Otera, H., Mihara, K., Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice (2009) Nat. Cell Biol., 11, pp. 958-966; Yoon, Y.S., Yoon, D.S., Lim, I.K., Yoon, S.H., Chung, H.Y., Rojo, M., Malka, F., Yoon, G., Formation of elongated giant mitochondria in DFO-induced cellular senescence. Involvement of enhanced fusion process through modulation of Fis1 (2006) J. Cell Physiol., 209, pp. 468-480; Wadhwa, R., Takano, S., Robert, M., Yoshida, A., Nomura, H., Reddel, R.R., Mitsui, Y., Kaul, S.C., Inactivation of tumor suppressor p53 by mot-2, an hsp70 family member (1998) J. Biol. Chem., 273, pp. 29586-29591; Wadhwa, R., Sugihara, T., Yoshida, A., Nomura, H., Reddel, R.R., Simpson, R., Maruta, H., Kaul, S.C., Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function (2000) Cancer Res., 60, pp. 6818-6821; Park, S.J., Shin, J.H., Kim, E.S., Jo, Y.K., Kim, J.H., Hwang, J.J., Kim, J.C., Cho, D.H., Mitochondrial fragmentation caused by phenanthroline promotes mitophagy (2012) FEBS Lett., 586, pp. 4303-4310; Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., Laferla, F.M., Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease (2003) Neurobiol. Aging, 24, pp. 1063-1070; Consensus recommendations for the postmortem diagnosis of Alzheimer's disease (1997) Neurobiol. Aging, 18, pp. S1-S2. , The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease, NIARI; Jo, D.G., Arumugam, T.V., Woo, H.N., Park, J.S., Tang, S.C., Mughal, M., Hyun, D.H., Mattson, M.P., Evidence that γ-secretase mediates oxidative stress-induced β-secretase expression in Alzheimer's disease (2010) Neurobiol. Aging, 31, pp. 917-925; Taylor, S.W., Fahy, E., Zhang, B., Glenn, G.M., Warnock, D.E., Wiley, S., Murphy, A.N., Ghosh, S.S., Characterization of the human heart mitochondrial proteome (2003) Nat. Biotechnol., 21, pp. 281-286; Walker, C., Böttger, S., Low, B., Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model (2006) Am. J. Pathol., 168, pp. 1526-1530; Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction (2006) J. Neurosci., 26, pp. 9057-9068; Shi, M., Jin, J., Wang, Y., Beyer, R.P., Kitsou, E., Albin, R.L., Gearing, M., Zhang, J., Mortalin. A protein associated with progression of Parkinson disease? (2008) J. Neuropathol. Exp. Neurol., 67, pp. 117-124; Burbulla, L.F., Schelling, C., Kato, H., Rapaport, D., Woitalla, D., Schiesling, C., Schulte, C., Krüger, R., Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease. Functional impact of disease-related variants on mitochondrial homeostasis (2010) Hum. Mol. Genet., 19, pp. 4437-4452; Su, B., Wang, X., Zheng, L., Perry, G., Smith, M.A., Zhu, X., Abnormal mitochondrial dynamics and neurodegenerative diseases (2010) Biochim. Biophys. Acta, 1802, pp. 135-142; Tamai, S., Iida, H., Yokota, S., Sayano, T., Kiguchiya, S., Ishihara, N., Hayashi, J., Oka, T., Characterization of the mitochondrial protein LETM1, which maintains the mitochondrial tubular shapes and interacts with the AAA-ATPase BCS1L (2008) J. Cell Sci., 121, pp. 2588-2600; Park, J., Kim, Y., Choi, S., Koh, H., Lee, S.H., Kim, J.M., Chung, J., Drosophila Porin/VDAC affects mitochondrial morphology (2010) PLoS One, 5, pp. e13151; Kim, N.C., Tresse, E., Kolaitis, R.M., Molliex, A., Thomas, R.E., Alami, N.H., Wang, B., Taylor, J.P., VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations (2013) Neuron, 78, pp. 65-80; Wadhwa, R., Kaul, S.C., Ikawa, Y., Sugimoto, Y., Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype (1993) J. Biol. Chem., 268, pp. 6615-6621; Bhattacharyya, T., Karnezis, A.N., Murphy, S.P., Hoang, T., Freeman, B.C., Phillips, B., Morimoto, R.I., Cloning and subcellular localization of human mitochondrial hsp70 (1995) J. Biol. Chem., 270, pp. 1705-1710; Kaul, S.C., Deocaris, C.C., Wadhwa, R., Three faces of mortalin. A housekeeper, guardian and killer (2007) Exp. Gerontol., 42, pp. 263-274; Schneider, H.C., Berthold, J., Bauer, M.F., Dietmeier, K., Guiard, B., Brunner, M., Neupert, W., Mitochondrial Hsp70/MIM44 complex facilitates protein import (1994) Nature, 371, pp. 768-774; Kampinga, H.H., Craig, E.A., The HSP70 chaperone machinery. J proteins as drivers of functional specificity (2010) Nat. Rev. Mol. Cell Biol., 11, pp. 579-592; Jin, J., Hulette, C., Wang, Y., Zhang, T., Pan, C., Wadhwa, R., Zhang, J., Proteomic identification of a stress protein, mortalin/mthsp70/ GRP75. Relevance to Parkinson disease (2006) Mol. Cell Proteomics, 5, pp. 1193-1204; Chiasserini, D., Tozzi, A., De Iure, A., Tantucci, M., Susta, F., Orvietani, P.L., Koya, K., Calabresi, P., Mortalin inhibition in experimental Parkinson's disease (2011) Mov. Disord., 26, pp. 1639-1647; Yang, H., Zhou, X., Liu, X., Yang, L., Chen, Q., Zhao, D., Zuo, J., Liu, W., Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin (2011) Biochem. Biophys. Res. Commun., 410, pp. 114-120; Qu, M., Zhou, Z., Xu, S., Chen, C., Yu, Z., Wang, D., Mortalin overexpression attenuates β-amyloid-induced neurotoxicity in SH-SY5Y cells (2011) Brain Res., 1368, pp. 336-345; Qu, M., Zhou, Z., Chen, C., Li, M., Pei, L., Yang, J., Wang, Y., Wang, D., Inhibition of mitochondrial permeability transition pore opening is involved in the protective effects of mortalin overexpression against β-amyloid-induced apoptosis in SHSY5Y cells (2012) Neurosci. Res., 72, pp. 94-102; Choi, J., Forster, M.J., McDonald, S.R., Weintraub, S.T., Carroll, C.A., Gracy, R.W., Proteomic identification of specific oxidized proteins in ApoE-knockout mice. Relevance to Alzheimer's disease (2004) Free Radic. Biol. Med., 36, pp. 1155-1162; Osorio, C., Sullivan, P.M., He, D.N., Mace, B.E., Ervin, J.F., Strittmatter, W.J., Alzate, O., Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice (2007) Neurobiol. Aging, 28, pp. 1853-1862; Kawai, A., Nishikawa, S., Hirata, A., Endo, T., Loss of the mitochondrial Hsp70 functions causes aggregation of mitochondria in yeast cells (2001) J. Cell Sci., 114, pp. 3565-3574; Takano, S., Wadhwa, R., Yoshii, Y., Nose, T., Kaul, S.C., Mitsui, Y., Elevated levels of mortalin expression in human brain tumors (1997) Exp. Cell Res., 237, pp. 38-45; Yokoyama, K., Fukumoto, K., Murakami, T., Harada, S., Hosono, R., Wadhwa, R., Mitsui, Y., Ohkuma, S., Extended longevity of Caenorhabditis elegans by knocking in extra copies of hsp70F, a homolog of mot-2 (mortalin)/mthsp70/Grp75 (2002) FEBS Lett., 516, pp. 53-57; Kaul, S.C., Yaguchi, T., Taira, K., Reddel, R.R., Wadhwa, R., Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts (2003) Exp. Cell Res., 286, pp. 96-101; Dundas, S.R., Lawrie, L.C., Rooney, P.H., Murray, G.I., Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival (2005) J. Pathol., 205, pp. 74-81; Deocaris, C.C., Widodo, N., Shrestha, B.G., Kaur, K., Ohtaka, M., Yamasaki, K., Kaul, S.C., Wadhwa, R., Mortalin sensitizes human cancer cells to MKT-077-induced senescence (2007) Cancer Lett., 252, pp. 259-269; Hooper, C., Chapple, J.P., Lovestone, S., Killick, R., The Notch-1 intracellular domain is found in sub-nuclear bodies in SH-SY5Y neuroblastomas and in primary cortical neurons (2007) Neurosci. Lett., 415, pp. 135-139; Buizza, L., Cenini, G., Lanni, C., Ferrari-Toninelli, G., Prandelli, C., Govoni, S., Buoso, E., Uberti, D., Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease (2012) PLoS One, 7, pp. e29789; Wang, A.M., Miyata, Y., Klinedinst, S., Peng, H.M., Chua, J.P., Komiyama, T., Li, X., Lieberman, A.P., Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation (2013) Nat. Chem. Biol., 9, pp. 112-118",Article,Scopus,2-s2.0-84893146602
"Smits R., Fischer S., Hiller A., Deuther-Conrad W., Wenzel B., Patt M., Cumming P., Steinbach J., Sabri O., Brust P., Hoepping A.","Synthesis and biological evaluation of both enantiomers of [ 18F]flubatine, promising radiotracers with fast kinetics for the imaging of α4β2-nicotinic acetylcholine receptors",2014,"Bioorganic and Medicinal Chemistry","22","2",,"804","812",,4,10.1016/j.bmc.2013.12.011,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84892374228&partnerID=40&md5=90cc1c16a3edfdad4be944782d833f98","ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, D-01454 Radeberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103 Leipzig, Germany","Smits, R., ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, D-01454 Radeberg, Germany; Fischer, S., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Hiller, A., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Deuther-Conrad, W., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Wenzel, B., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Patt, M., Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103 Leipzig, Germany; Cumming, P., ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, D-01454 Radeberg, Germany; Steinbach, J., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Sabri, O., Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103 Leipzig, Germany; Brust, P., Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmacy, Permoserstrasse-15, D-04318 Leipzig, Germany; Hoepping, A., ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, D-01454 Radeberg, Germany","Both enantiomers of the epibatidine analogue flubatine display high affinity towards the α4β2 nicotinic acetylcholine receptor (nAChR) in vitro, accompanied by negligible interactions with diverse off-target proteins. Extended single dose toxicity studies in rodent indicated a NOEL (No Observed Effect Level) of 6.2 μg/kg for (-)-flubatine and 1.55 μg/kg for (+)-flubatine. We developed syntheses for both flubatine enantiomers and their corresponding precursors for radiolabeling. The newly synthesized trimethylammonium precursors allowed for highly efficient 18F- radiolabelling in radiochemical yields &gt;60% and specific activities &gt;750 GBq/μmol, thus making the radioligands practical for clinical investigation. © 2013 Elsevier Ltd. All rights reserved.","Alzheimers's disease (AD); Flubatine; Fluorine-18; Nicotinic acetylcholine receptor (nAChR); PET","Joshi, A.D., Pontecorvo, M.J., Clark, C.M., Carpenter, A.P., Jennings, D.L., Sadowsky, C.H., Adler, L.P., Skovronsky, D.M., (2012) J. Nucl. Med., 53, p. 378; Herholz, K., Ebmeier, K., (2011) Lancet Neurol., 10, p. 667; Kurz, A., Perneczky, R., (2011) J. Alzheimers Dis., 24, p. 61; Graef, S., Schönknecht, P., Sabri, O., Hegerl, U., (2011) Psychopharmacology (Berlin, Ger.), 215, p. 205; Lindstrom, J., Anand, R., Peng, X., Gerzanich, V., Wang, F., Li, Y., (1995) Ann. N.Y. Acad. Sci., 757, p. 100; Baddick, C.G., Marks, M.J., (2011) Biochem. Pharmacol., 82, p. 828; Perry, E.K., Martin-Ruiz, C.M., Court, J.A., (2001) Alcohol, 24, p. 63; Perry, E., Martin-Ruiz, C., Lee, M., Griffiths, M., Johnson, M., Piggott, M., Haroutunian, V., Court, J., (2000) Eur. J. Pharmacol., 393, p. 215; Kadir, A., Almkvist, O., Wall, A., Langström, B., Nordberg, A., (2006) Psychopharmacology (Berlin, Ger.), 188, p. 509; O'Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., McKeith, I.G., Williams, E.D., (2007) J. Neurol. Neurosurg. Psychiatry, 78, p. 356; Kendziorra, K., Wolf, H., Meyer, P.M., Barthel, H., Hesse, S., Becker, G.A., Luthardt, J., Sabri, O., (2011) Eur. J. Nucl. Med. Mol. Imaging, 38, p. 515; Valette, H., Dolle, F., Saba, W., Roger, G., Hinnen, F., Coulon, C., Ottaviani, M., Bottlaender, M., (2007) Synapse, 61, p. 764; Kuwabara, H., Wong, D.F., Gao, Y., Valentine, H., Holt, D.P., Ravert, H.T., Dannals, R.F., Horti, A.G., (2012) J. Nucl. Med., 53, p. 121; Deuther-Conrad, W., Patt, J.T., Feuerbach, D., Wegner, F., Brust, P., Steinbach, J., (2004) Farmaco, 59, p. 785; Deuther-Conrad, W., Patt, J.T., Lockman, P.R., Allen, D.D., Patt, M., Schildan, A., Ganapathy, V., Brust, P., (2008) Eur. Neuropsychopharmacol., 18, p. 222; Brust, P., Patt, J.T., Deuther-Conrad, W., Becker, G., Patt, M., Schildan, A., Sorger, D., Sabri, O., (2008) Synapse, 62, p. 205; Hockley, B.G., Stewart, M.N., Sherman, P., Quesada, C., Kilbourn, M.R., Albin, R.L., Scott, P.J.H., (2013) J. Labelled Compd. Radiopharm., 56, p. 595; Patt, J.T., Deuther-Conrad, W., Wohlfahrt, K., Feuerbach, D., Brust, P., Steinbach, J., (2003) J. Labelled Compd. Radiopharm., 46, p. 168; Bai, D., Xu, R., Chu, G., Zhu, X., (1996) J. Org. Chem., 61, p. 4600; Patt, J.T., Deuther-Conrad, W., Brust, P., (2003) [18F]Norchloro-Fluoro-Homoepibatidine: Synthesis, Radiosynthesis, Evaluation in Vitro and Comparison of the Biodistribution with 2-[18F]Fluoro-A-85380 in Mice, , Institute of Interdisciplinary Isotope Research Leipzig Annual Report; Kim, H., Hoffmann, H.M.R., (2000) Eur. J. Org. Chem., p. 2195; Drew, M.G.B., George, A.V., Isaacs, N.S., (1985) J. Chem. Soc., Perkin Trans. 1, p. 1277; Mann, J., De Almeida Barbosa, L.-C., (1992) J. Chem. Soc., Perkin Trans. 1, p. 787; Cramer, N., Laschat, S., Baro, A., Frey, W., (2003) Synlett, p. 2175; Hodgson, D.M., Paruch, E., (2004) Tetrahedron, 60, p. 5158; Larock, R.C., Johnson, P.L., (1989) J. Chem. Soc., Chem. Commun., p. 1368; Arcadi, A., Marinelli, F., Bernocchi, E., Cacchi, S., Ortar, G., (1989) J. Organomet. Chem., 368, p. 249; Wu, X.-Y., Xu, H.-D., Zhou, Q.-L., Chan, A.S.C., (2000) Tetrahedron: Asymmetry, 11, p. 1255; Wu, X.-Y., Xu, H.-D., Tang, F.-Y., Zhou, Q.-L., (2001) Tetrahedron: Asymmetry, 12, p. 2565; Namyslo, J.C., Kaufmann, D.E., (1999) Synlett, p. 804; Clayton, S.C., Regan, A.C., (1993) Tetrahedron Lett., 34, p. 7493; Herrmann, W.A., Broßmer, C., Öfele, K., Reisinger, C.-P., Priermeier, T., Beller, M., Fischer, H., (1995) Angew. Chem., Int. Ed., 34, p. 1844; Kim, Y.H., Won, D.Y., Oh, C.Y., Lee, K.Y., Jeong, J.H., Jung, Y.H., Ham, W.H., (1999) Arch. Pharmacol. Res., 22, p. 435; Moreno-Vargas, A.J., Vogel, P., (2003) Tetrahedron: Asymmetry, 14, p. 3173; Liang, F., Navarro, H.A., Abraham, P., Kotian, P., Ding, Y.-S., Fowler, J., Volkow, N., Carroll, F.I., (1997) J. Med. Chem., 40, p. 2293; Fischer, S., Hiller, A., Smits, R., Hoepping, A., Funke, U., Wenzel, B., Cumming, P., Brust, P., (2013) Appl. Radiat. Isot., 74, p. 128; Patt, M., Schildan, A., Habermann, B., Fischer, S., Hiller, A., Deuther-Conrad, W., Wilke, S., Sabri, O., (2013) Appl. Radiat. Isot., 80, p. 7; Deuther-Conrad, W., Wevers, A., Becker, G., Schildan, A., Patt, M., Sabri, O., Steinbach, J., Brust, P., (2006) Synapse, 59, p. 201; Gatley, S.J., Ding, Y.S., Brady, D., Gifford, A.N., Dewey, S.L., Carroll, F.I., Fowler, J.S., Volkow, N.D., (1998) Nucl. Med. Biol., 25, p. 449; Han, Z.Y., Zoli, M., Cardona, A., Bourgeois, J.P., Changeux, J.P., Le Novere, N., (2003) J. Comp. Neurol., 461, p. 49; Sihver, W., Gillberg, P.G., Nordberg, A., (1998) Neuroscience, 85, p. 1121; Moser, N., Mechawar, N., Jones, I., Gochberg-Sarver, A., Orr-Urtreger, A., Plomann, M., Salas, R., Wevers, A., (2007) J. Neurochem., 102, p. 479; Gallezot, J.D., Bottlaender, M.A., Delforge, J., Valette, H., Saba, W., Dolle, F., Coulon, C.M., Gregoire, M.C., (2008) J. Cereb. Blood Flow Metab., 28, p. 172; Pimlott, S.L., Piggott, M., Owens, J., Greally, E., Court, J.A., Jaros, E., Perry, R.H., Wyper, D., (2004) Neuropsychopharmacology, 29, p. 108",Article,Scopus,2-s2.0-84892374228
"Rushing N.C., Sachs-Ericsson N., Steffens D.C.","Neuropsychological indicators of preclinical Alzheimers disease among depressed older adults",2014,"Aging, Neuropsychology, and Cognition","21","1",,"99","128",,1,10.1080/13825585.2013.795514,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84888628946&partnerID=40&md5=1c573b6ba28891a4e18fdac6547ad543","Department of Psychology, Florida State University, 1107 West Call St., Tallahassee, FL 32306, United States; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States","Rushing, N.C., Department of Psychology, Florida State University, 1107 West Call St., Tallahassee, FL 32306, United States; Sachs-Ericsson, N., Department of Psychology, Florida State University, 1107 West Call St., Tallahassee, FL 32306, United States; Steffens, D.C., Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States","Older adults with major depressive disorder (MDD) may also have preclinical Alzheimers disease (AD). Differential diagnosis is quite challenging due to the overlapping symptoms of MDD and AD. In the current study, we predicted that impaired long-term memory (an area most affected in early AD), but not executive function (an area affected in MDD and AD), would distinguish older depressed patients who developed AD from those who did not. Patients (N = 120) assessed as having MDD but not dementia at baseline were administered tests of cognitive function and followed longitudinally for subsequent diagnosis of AD. Using structural equation modeling we found a latent construct of long-term memory to be associated with AD to a greater extent than executive functioning. Additional analyses to enhance clinical utility of findings indicated that individual tests of episodic memory were most predictive of AD status. Tests of long-term memory can be utilized by the clinician when assessing for preclinical AD among depressed elderly. © 2014 Taylor & Francis.","Alzheimer's disease; Dementia; Depression; Neuropsychological assessment","Alexopoulos, G.S., Meyers, B.S., Young, R.C., Mattis, S., Kakuma, T., The course of geriatric depression with reversible dementia: A controlled study (1993) American Journal of Psychiatry, 150, pp. 1693-1699; Amieva, H., Le Goff, M., Millet, X., Orgogozo, J.M., Peres, K., Barberger-Gateau, P., Dartigues, J.F., Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms (2008) Annals of Neurology, 64, pp. 492-498; Andreescu, C., Butters, M.A., Begley, A., Rajji, T., Wu, M., Meltzer, C.C., Aizenstein, H., Gray matter changes in late life depression-A structural MRI analysis (2008) Neuropsychopharmacology, 33, pp. 2566-2572; Arnaiz, E., Almkvist, O., Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease (2003) Acta Neurologica Scandinavica, 107, pp. 34-41; Austin, M., Mitchell, P., Goodwin, G.M., Cognitive deficits in depression. Possible implications for functional neuropathology (2001) British Journal of Psychiatry, 178, pp. 200-206; Backman, L., Cognition in preclinical dementia: Current knowledge and future prospects (2009) Acta Psychologica Sinica, 41, pp. 1040-1048; Backman, L., Jones, S., Berger, A., Laukka, E.J., Small, B.J., Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis (2005) Neuropsychology, 19, pp. 520-531; Backman, L., Small, B.J., Fratiglioni, L., Stability of the preclinical episodic memory deficit in Alzheimer's disease (2001) Brain, 124, pp. 96-102; Bastos-Leite, A.J., Van Der Flier, W.M., Van Straaten, E.C.W., Staekenborg, S.S., Scheltens, P., Barkhof, F., The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia (2007) Stroke, 38, pp. 3182-3185; Beekman, A.T., De Beurs, E., Van Balkom, A.J., Deeg, D.G., Van Dyck, R., Van Tilburg, W., Anxiety and depression in later life: Co-occurrence and communality of risk factors (2000) American Journal of Psychiatry, 157, pp. 89-95; Benton, A., (1974) Revised Visual Retention Test, , (4th ed.). New York, NY: Psychological Corporation; Blacker, D., Albert, M.S., Bassett, S.S., Go, R.C., Harrell, L.E., Folstein, M.F., Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease (1994) Archives of Neurology, 51, pp. 1198-1204. , The National Institute of Mental Health Genetics Initiative; Bondi, M.W., Jak, A.J., Delano-Wood, L., Jacobson, M.W., Delis, D.C., Salmon, D.P., Neuropsychological contributions to the early identification of Alzheimer's disease (2008) Neuropsychology Review, 18, pp. 73-90; Brommelhoff, J.A., Gatz, M., Johansson, B., McArdle, J.J., Fratiglioni, L., Pedersen, N.L., Depression as a risk factor or prodomal feature for dementia? Findings in a population-based sample of Swedish twins (2009) Psychology and Aging, 24, pp. 373-384; Butters, M.A., Becker, J.T., Nebes, R.D., Zmuda, M.D., Mulsant, B.H., Pollock, B.G., Reynolds, C.F., Changes in cognitive functioning following treatment of late-life depression (2000) American Journal of Psychiatry, 157, pp. 1949-1954; Chapman, L.J., Chapman, J.P., Problems in the measurement of cognitive deficit (1973) Psychological Bulletin, 79, pp. 380-385; Christensen, H., Griffiths, K., Mackinnon, A., Jacomb, P., A quantitative review of cognitive deficits in depression and Alzheimer-type dementia (1997) Journal of the International Neuropsychological Society, 3, pp. 631-651; Devanand, D.P., Dwork, A.J., Hutchinson, E.R., Bolwig, T.G., Sackeim, H.A., Does ECT alter brain structure? (1994) American Journal of Psychiatry, 151, pp. 957-970; Devanand, D.P., Pelton, G.H., Marston, K., Camacho, Y., Roose, S.P., Stern, Y., Sackeim, H.A., Sertraline treatment of elderly patients with depression and cognitive impairment (2003) International Journal of Geriatric Psychiatry, 18, pp. 123-130; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Fratiglioni, L., Viitanen, M., Von Strauss, E., Tontodonati, V., Herlitz, A., Winblad, B., Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm (1997) Neurology, 48, pp. 132-138; Gauthier, S.G., Alzheimer's disease: The benefits of early treatment (2005) European Journal of Neurology, 12, pp. 11-16; Giannakopoulos, P., Gold, G., Duc, M., Michel, J.P., Hof, P.R., Bouras, C., Neural substrates of spatial and temporal disorientation in Alzheimer's disease (2000) Acta Neuropathologica, 100, pp. 189-195; Guarch, J., Marcos, T., Salamero, M., Gasto, C., Blesa, R., Mild cognitive impairment: A risk indicator of later dementia or a preclinical phase of the disease? (2008) International Journal of Geriatric Psychiatry, 23, pp. 257-265; Halloran, E., Prentice, N., Murray, C.L., O'Carroll, R.E., Glabus, M.F., Goodwin, G.M., Ebmeier, K.P., Follow-up study of depression in the elderly. Clinical and SPECT data (1999) British Journal of Psychiatry, 175, pp. 252-258; Helzer, J.E., Robins, L.N., McEvoy, L.T., Spitznagel, E.L., Stoltzman, R.K., Farmer, A., Brockington, I.F., A comparison of clinical and Diagnostic Interview Schedule diagnoses: Physician reexamination of lay-interviewed cases in the general population (1985) Archives of General Psychiatry, 42, pp. 657-666; Ihl, R., Frolich, L., Dierks, T., Martin, E.-M., Maurer, K., Differential validity of psychometric tests in dementia of the Alzheimer type (1992) Psychiatry Research, 44, pp. 93-106; Janssen, J., Hulshoff Pol, H.E., De Leeuw, F.-E., Schnack, H.G., Lampe, I.K., Kok, R.M., Heeren, T.J., Hippocampal volume and subcortical white matter lesions in late life depression: Comparison of early and late onset depression (2007) Journal of Neurology, Neurosurgery and Psychiatry, 78, pp. 638-640; Jean, L., Simard, M., Van Reekum, R., Clarke, D.E., Differential cognitive impairment in subjects with geriatric depression who will develop Alzheimer's disease and other dementias: A retrospective study (2005) International Psychogeriatrics, 17, pp. 289-301; Johnson, J.J., Head, E., Kim, R., Starr, A., Cotman, C.W., Clinical and pathological evidence for a frontal variant of Alzheimer disease (1999) Archives of Neurology, 56, pp. 1233-1239; Jorm, A.F., History of depression as a risk factor for dementia: An updated review (2001) Australian and New Zealand Journal of Psychiatry, 35, pp. 776-781; Kaplan, E.F., Goodglass, H., Weintraub, S., (1978) The Boston Naming Test: Experimental, , edition. Boston, MA: Kaplan & Goodglass; Kawas, C., Katzman, R., Epidemiology of dementia and Alzheimer disease (1999) Alzheimer Disease, pp. 95-116. , R. D. Terry, R. Katzman, K. L. Bick, & S. S. Sisodia (Eds.). New York, NY: Raven Press; Kline, R.B., (2005) Principles and Practice of Structural Equation Modeling, , (2nd ed.). New York NY: Guildord Publications; Kunig, G., Jager, M., Stief, V., Kaldune, A., Urbaniok, F., Endrass, J., The impact of the CERAD-NP on diagnosis of cognitive deficiencies in late onset depression and Alzheimer's disease (2006) International Journal of Geriatric Psychiatry, 21, pp. 911-916; Lee, J.S., Potter, G.G., Wagner, H.R., Welsh-Bohmer, K.A., Steffens, C.C., Persistent mild cognitive impairment in geriatric depression (2007) International Psychogeriatrics, 19, pp. 125-135; Lezak, M.D., Howieson, D.B., Loring, D.W., (2004) Neuropsychological Assessment, , (4th ed.). New York, NY: Oxford University Press; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944; Mendard, S., (2010) Logistic Regression: From Introductory to Advanced Concepts and Applications, , Thousand Oaks, CA: Sage Publications; Mitchell, A.J., Shiri-Feshki, M., Temporal trends in the long term risk of progression of mild cognitive impairment: A pooled analysis (2008) Journal of Neurology, Neurosurgery, and Psychiatry, 79, pp. 1386-1391; Mitchell, A.J., Shiri-Feshki, M., Rate of progression of mild cognitive impairment to dementia-Meta- analysis of 41 robust inception cohort studies (2009) Acta Psychiatrica Scandinavica, 119, pp. 252-265; Morris, J.C., Heyman, A., Mohs, R.C., Hughes, J.P., Van Belle, G., Fillenbaum, G., Clark, C., The consortium to establish a registry for alzheimer's disease (CERAD) Part I: Clinical and neuropsychological assessment of Alzheimer's disease (1989) Neurology, 39, pp. 159-1165; Muthén, L., Muthén, B., (2004) MPlus User's Guide, , Los Angeles, CA: Muthén & Muthén; Nebes, R.D., Pollock, B.G., Houck, P.R., Butters, M.A., Mulsant, B.H., Zmuda, M.D., Reynolds, C.F., Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine (2003) Journal of Psychiatric Research, 37, pp. 99-108; Ott, A., Breteler, M.M.B., Van Harskamp, F., Claus, J.J., Van Der Cammen, T.J.M., Grobbee, D.E., Hofman, A., Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study (1995) BMJ, 310, pp. 910-973; Peterson, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Winblad, B., Current concepts in mild cognitive impairment (2001) Archives of Neurology, 58, pp. 1985-1992; Pfennig, A., Littman, E., Bauer, M., Neurocognitive impairment and dementia in mood disorders (2007) Journal of Neuropsychiatry and Clinical Neurosciences, 19, pp. 373-382; Potter, G.G., Kittinger, J.D., Wagner, H.R., Steffens, D.C., Krishnan, K.R., Prefrontal neuropsychological predictors of treatment remission in late-life depression (2004) Neuropsychopharmacology, 29, pp. 2266-2271; Reischies, F.M., Neu, P., Comorbidity of mild cognitive disorder and depression-A neuropsychological analysis (2000) European Archives of Psychiatry and Clinical Neuroscience, 250, pp. 186-193; Reitan, R.M., Wolfson, D., (1985) The Halstead-Reitan Neuropsychological Test Battery, , Tucson, AZ: Neuropsychology Press; Robins, L.N., Helzer, J.E., Croughan, J., Ratcliff, K.S., National Institute of Mental Health Diagnostic Interview Schedule: Its history, characteristics, and validity (1981) Archives of General Psychiatry, 38, pp. 381-389; Robins, L.N., Helzer, J.E., Croughan, J.L., Williams, J.B.W., Sptizer, R.L., (1981) NIMH Diagnostic Interview Schedule (DIS), Version III, , St. Louis, MO: Department of Psychiatry, Washington University School of Medicine; Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., Hofman, A., Vascular dementia: Diagnostic criteria for research studies (1993) Neurology, 43, pp. 250-260. , Reports of the NINDS AIREN International Workshop; Rypma, B., Berger, J.S., Prabhakaran, V., Bly, B.M., Kimberg, D.Y., Biswal, B.B., D'Esposito, M., Neural correlates of cognitive efficiency (2006) NeuroImage, 33, pp. 969-979; Sachs-Ericsson, N., Blazer, D.G., Racial differences in cognitive decline in a sample of community-dwelling older adults: The mediating role of education and literacy (2005) American Journal of Geriatric Psychiatry, 13, pp. 968-975; Sair, H.I., Welsh-Bohmer, K.A., Wagner, H.R., Steffens, D.C., Ascending Digits Task as a measure of executive function in geriatric depression (2006) Journal of Neuropsychiatry and Clinical Neuroscience, 18, pp. 117-120; Sapolsky, R.M., Krey, L.C., McEwan, B.S., The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis (1986) Endocrine Reviews, 7, pp. 284-301; Sawrie, S.M., Martin, R.G., Gilliam, F.G., Faught, R.E., Mato, B., Hugg, J.W., Kuziecky, R.I., Visual confrontation naming and hippocampus function: A neural network study using quantitative 1H magnetic resonance spectroscopy (2000) Brain, 123, pp. 770-780; Small, B.J., Fratiglioni, L., Viitanen, M., Winblad, B., Backman, L., The course of cognitive impairment in preclinical Alzheimer disease: Three and 6-year follow-up of a population-based sample (2000) Archives of Neurology, 57, pp. 839-844; Smith, A., (1982) Symbol Digit Modalities Test Manual, , Los Angeles, CA: Western Psychological Services; Steffens, D.C., Potter, G.G., McQuoid, D.R., Macfall, J.R., Payne, M.E., Burke, J.R., Welsh-Bohmer, K.A., Longitudinal magnetic resonance imaging vascular changes, apolipoprotein e genotype, and development of dementia in the Neurocognitive Outcomes of Depression in the Elderly Study (2007) American Journal of Geriatric Psychiatry, 15, pp. 839-849; Steffens, D.C., Welsh-Bohmer, K.A., Burke, J.R., Plassman, B.L., Beyer, J.L., Gersing, K.R., Potter, G.G., Methodology and preliminary results from the Neurocognitive Outcomes of Depression in the Elderly Study (2004) Journal of Geriatric Psychiatry and Neurology, 17, pp. 202-211; Strauss, E., Sherman, E.M.S., Spreen, O., (2006) A Compendium of Neuropsychological Tests: Administration Norms, and Commentary, , (3rd ed.). New York, NY: Oxford University Press; Tapiola, T., Pennanen, C., Tapiola, M., Tervo, S., Kivipelto, M., Hanninen, T., Soininen, H., MRI of hippocampus and entorhinal cortex in mild cognitive impairment: A follow-up study (2008) Neurobiology of Aging, 29, pp. 31-38; Tierney, M.C., Szalai, J.P., Snow, W.G., Fisher, R.H., Nores, A., Nadon, G., George-Hyslop, P.H., Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study (1996) Neurology, 46, pp. 661-665; Tierney, M.C., Yao, C., Kiss, I., McDowell, I., Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years (2005) Neurology, 64, pp. 1853-1859; Twamley, E.W., Ropacki, S.A.L., Bondi, M.W., Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease (2006) Journal of the International Neuropsychological Society, 12, pp. 707-735; Unverzagt, F.W., Hall, K.S., Torke, A.M., Rediger, J.D., Mercado, N., Gureje, O., Hendrie, H.C., Effects of age, education, and gender on CERAD neuropsychological test performance in an African American sample (1996) The Clinical Neuropsychologist, 10, pp. 180-190; Vandiver, T., Sher, K.J., Temporal stability of the Diagnostic Interview Schedule (1991) Psychological Assessment, 3, pp. 277-281; Visser, P.J., Verhey, F.R.J., Ponds, R.W.H.M., Kester, A., Jolles, J., Distinction between preclinical Alzheimer's disease and depression (2000) Journal of the American Geriatrics Society, 48, pp. 479-484; Wechsler, D., (1981) The Wechsler Adult Intelligence Scale Revised, , New York, NY: Psychological Corporation; Wechsler, D., (1987) Wechsler Memory Scale-revised Manual, , San Antonio, TX: Psychological Corporation; Yuspeh, R.L., Vanderploeg, R.D., Kershaw, A.J., CERAD praxis memory and recognition in relation to other measures of memory (1998) The Clinical Neuropsychologist, 12, pp. 648-474",Review,Scopus,2-s2.0-84888628946
"Gilleen J., Greenwood K., David A.S.","The role of memory in awareness of memory deficits in Alzheimers disease, schizophrenia, and brain injury",2014,"Journal of Clinical and Experimental Neuropsychology","36","1",,"43","57",,,10.1080/13803395.2013.863835,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84893829859&partnerID=40&md5=e9e2d7fb634c2ccdd3e3052b08c1e813","Department of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom; School of Psychology, University of Sussex, Falmer-Sussex, United Kingdom; Early Intervention in Psychosis Service, Sussex Partnership NHS Foundation Trust Sussex, United Kingdom","Gilleen, J., Department of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom; Greenwood, K., School of Psychology, University of Sussex, Falmer-Sussex, United Kingdom, Early Intervention in Psychosis Service, Sussex Partnership NHS Foundation Trust Sussex, United Kingdom; David, A.S., Department of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom","Patients with neuropsychiatric disorders such as Alzheimers disease (AD), schizophrenia (Sz), and brain injury (BI) often show memory deficits and lack of awareness of those deficits. This study aimed to investigate the role of memory in awareness of memory deficits and illness in multiple patient groups. Comparison of awareness profiles between groups can reveal common or distinct patterns of awareness and predictors, which may inform theories about the structure of awareness. Using the same standardized measures, AD (N = 27) Sz (N = 31), and BI (N = 26) patients were compared on memory functioning, awareness of illness, and awareness of memory deficits - measured by discrepancy of pretest estimate and actual test scores. All groups were poor at pretest estimation of memory functioning, particularly the AD and BI groups. In AD, patients with the lowest memory functioning rated their performance highest. The BI group and to a lesser extent the AD group showed improved estimations of performance following the memory test. Those with the poorest memory showed the greatest improvement in ratings accuracy post test. The relationship between memory and awareness of memory was stronger than the association between memory and awareness of illness. There was a double dissociation between awareness of memory and awareness of illness across patient groups. The study shows that awareness of memory is linked to memory functioning, while memory is only modestly related to awareness of illness. Dissociations in the role of memory in different domains of awareness and ""online"" awareness of performance provide information to refine cognitive models of awareness. However, the results should be interpreted with caution given the heterogeneous nature of the sample. © 2013 © Taylor & Francis.","Awareness; Insight; Memory; Metacognition; Metamemory.","Agnew, S.K., Morris, R.G., The heterogeneity of anosognosia for memory impairment in Alzheimer's disease: A review of the literature and a proposed model (1998) Aging and Mental Health, 2 (1), pp. 7-19. , DOI 10.1080/13607869856876; Aleman, A., Agrawal, N., Morgan, K.D., David, A.S., Insight in psychosis and neuropsychological function: Meta-analysis (2006) British Journal of Psychiatry, 189 (SEP.), pp. 204-212. , DOI 10.1192/bjp.189.3.204; Amador, X.F., Strauss, D.H., Yale, S.A., Gorman, J.M., Awareness of illness in schizophrenia (1991) Schizophrenia Bulletin, 17 (1), pp. 113-132; (1994) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association (4th ed.). Washington, DC: Author; Anderson, S.W., Tranel, D., Awareness of disease states following cerebral infarction, dementia, and head trauma: Standardized assessment (1989) Clinical Neuropsychologist, 3 (4), pp. 327-339; Ansell, E.L., Bucks, R.S., Mnemonic anosognosia in Alzheimers disease: A test of Agnew and Morris (1998) (2006) Neuropsychologia, 44 (7), pp. 1095-1102; Beck, A.T., Steer, R.A., Brown, G.K., (1996) Beck Depression Inventory-II, , San Antonio, TX: The Psychological Corporation; Boake, C., Freeland, J., Ringholz, G., Nance, M., Edwards, K., Awareness of memory loss after severe closed-head injury (1995) Brain Injury, 9 (3), pp. 273-283; Bogod, N.M., Mateer, C.A., MacDonald, S.W.S., Self-awareness after traumatic brain injury: A comparison of measures and their relationship to executive functions (2003) Journal of the International Neuropsychological Society, 9 (3), pp. 450-458. , DOI 10.1017/S1355617703930104; Chen, K.C., Chu, C.L., Yang, Y.K., Yeh, T.L., Lee, I.H., Chen, P.S., Lu, R.B., The relationship among insight, cognitive function of patients with schizophrenia and their relatives' perception (2005) Psychiatry and Clinical Neurosciences, 59 (6), pp. 657-660; Clare, L., Awareness in early-stage Alzheimer's disease: A review of methods and evidence (2004) British Journal of Clinical Psychology, 43 (2), pp. 177-196. , DOI 10.1348/014466504323088042; Clare, L., Nelis, S.M., Martyr, A., Roberts, J., Whitaker, C.J., Markova, I.S., Morris, R.G., The influence of psychological, social and contextual factors on the expression and measurement of awareness in early-stage dementia: Testing a biopsychosocial model (2012) International Journal of Geriatric Psychiatry, 27 (2), pp. 167-177; Clare, L., Nelis, S.M., Martyr, A., Roberts, J., Whitaker, C.J., Markova, I.S., Morris, R.G., Longitudinal trajectories of awareness in early-stage dementia (2012) Alzheimer Disease & Associated Disorders, 26 (2), pp. 140-147; Clare, L., Whitaker, C.J., Nelis, S.M., Appraisal of memory functioning and memory performance in healthy ageing and early-stage Alzheimers disease (2010) Aging, Neuropsychology, and Cognition, 17 (4), pp. 462-491; Clare, L., Whitaker, C.J., Roberts, J.L., Nelis, S.M., Martyr, A., Marková, I.S., Morris, R.G., Memory awareness profiles differentiate mild cognitive impairment from early-stage dementia: Evidence from assessments of performance monitoring and evaluative judgement (2012) Dementia and Geriatric Cognitive Disorders, 35 (56), pp. 266-279; Clare, L., Wilson, B.A., Carter, G., Roth, I., Hodges, J.R., Assessing awareness in early-stage Alzheimer's disease: Development and piloting of the memory awareness rating scale (2002) Neuropsychological Rehabilitation, 12 (4), pp. 341-362. , DOI 10.1080/09602010244000129; David, A., Buchanan, A., Reed, A., Almeida, O., The assessment of insight in psychosis (1992) British Journal of Psychiatry, 161 (5), pp. 599-602; Derouesne, C., Thibault, S., Lagha-Pierucci, S., Baudouin-Madec, V., Ancri, D., Lacomblez, L., Decreased awareness of cognitive deficits in patients with mild dementia of the Alzheimer type (1999) International Journal of Geriatric Psychiatry, 14 (12), pp. 1019-1030. , DOI 10.1002/(SICI)1099-1166(199912)14: 12<1019::AID-GPS61>3.0.CO;2- F; Dixon, R.A., (1989) Everyday Cognition in Adulthood and Late Life, pp. 394-415. , Questionnaire research on metamemory and aging: Issues of structure and function. In L. W. Poon, D. C. Rubin, & B. A. Wilson (Eds.),. New York, NY: Cambridge University Press; Donohoe, G., Corvin, A., Robertson, I.H., Are the cognitive deficits associated with impaired insight in schizophrenia specific to executive task performance? (2005) Journal of Nervous and Mental Disease, 193 (12), pp. 803-808. , DOI 10.1097/01.nmd.0000190587.01950.72; Duke, L.M., Seltzer, B., Seltzer, J.E., Vasterling, J.J., Cognitive components of deficit awareness in Alzheimer's disease (2002) Neuropsychology, 16 (3), pp. 359-369. , DOI 10.1037; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12 (3), pp. 189-198; Gilleen, J., Greenwood, K., Archer, N., Lovestone, S., David, A., The role of premorbid personality and cognitive factors in awareness of illness, memory, and behavioural functioning in Alzheimers disease (2012) Cognitive Neuropsychiatry, 17 (3), pp. 227-245; Gilleen, J., Greenwood, K., David, A.S., (2010) The Study of Anosognosia, pp. 255-290. , Anosognosia in schizophrenia and other neuropsychiatric disorders: Similarities and differences. In G. P. Prigatano (Ed.),. New York, NY: Oxford University Press; Gilleen, J., Greenwood, K., David, A.S., (2010) Neuropsychiatric Disorders, pp. 33-50. , Lack of insight and awareness in schizophrenia and neuropsychiatric disorders. In K. Miyoshi, Y. Morimura, & K. Maeda (Eds.), Tokyo: Springer; Gilleen, J., Greenwood, K., David, A.S., Domains of awareness in schizophrenia (2011) Schizophrenia Bulletin, 37 (1), pp. 61-72; Goldstein, G., McCue, M., Differences between patient and informant functional outcome ratings in head-injured individuals (1995) International Journal of Rehabilitation and Health, 1 (1), pp. 25-35; González-Suárez, B., Gomar, J., Pousa, E., Ortiz-Gil, J., García, A., Salvador, R., McKenna, P.J., Awareness of cognitive impairment in schizophrenia and its relationship to insight into illness (2011) Schizophrenia Research, 133 (1), pp. 187-192; Goodman, C., Knoll, G., Isakov, V., Silver, H., Insight into illness in schizophrenia (2005) Comprehensive Psychiatry, 46 (4), pp. 284-290. , DOI 10.1016/j.comppsych.2004.11.002, PII S0010440X04001774; Graham, D.P., Kunik, M.E., Doody, R., Snow, A.L., Self-reported awareness of performance in dementia (2005) Cognitive Brain Research, 25 (1), pp. 144-152. , DOI 10.1016/j.cogbrainres.2005.05.001, PII S0926641005001217; Ham, T., Bonnelle, V., Barber, T., Leech, R., Kinnunen, K., De Boissezon, X., Sharp, D.J., The neural basis of impaired self-awareness after traumatic brain injury (2012) Journal of Neurology, Neurosurgery & Psychiatry, 83 (3), p. 1; Hannesdottir, K., Morris, R.G., Primary and secondary anosognosia for memory impairment in patients with Alzheimer's disease (2007) Cortex, 43 (7), pp. 1020-1030. , DOI 10.1016/S0010-9452(08)70698-1; Hart, T., Sherer, M., Whyte, J., Polansky, M., Novack, T.A., Awareness of behavioral, cognitive, and physical deficits in acute traumatic brain injury (2004) Archives of Physical Medicine and Rehabilitation, 85 (9), pp. 1450-1456. , DOI 10.1016/j.apmr.2004.01.030, PII S0003999304002941; Hoerold, D., Pender, N.P., Robertson, I.H., Metacognitive and online error awareness deficits after prefrontal cortex lesions (2012) Neuropsychologia, 51, pp. 385-391; Jamora, C.W., Young, A., Ruff, R.M., Comparison of subjective cognitive complaints with neuropsychological tests in individuals with mild vs more severe traumatic brain injuries (2012) Brain Injury, 26 (1), pp. 36-47; Johnson, I., Tabbane, K., Dellagi, L., Kebir, O., Self-perceived cognitive functioning does not correlate with objective measures of cognition in schizophrenia (2011) Comprehensive Psychiatry, 52 (6), pp. 688-692; Kaszniak, A.W., Edmonds, E., (2010) The Study of Anosognosia, pp. 189-228. , Anosognosia and Alzheimers disease: Behavioral studies. In G. P. Prigatano (Ed.), New York, NY: Oxford University Press; Kazui, H., Hirono, N., Hashimoto, M., Nakano, Y., Matsumoto, K., Takatsuki, Y., Mori, E., Takeda, M., Symptoms underlying unawareness of memory impairment in patients with mild Alzheimer's disease (2006) Journal of Geriatric Psychiatry and Neurology, 19 (1), pp. 3-12. , DOI 10.1177/0891988705277543; Keefe, R.S.E., Poe, M., Walker, T.M., Kang, J.W., Harvey, P.D., The schizophrenia cognition rating scale: An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity (2006) American Journal of Psychiatry, 163 (3), pp. 426-432. , DOI 10.1176/appi.ajp.163.3.426; Kotler-Cope, S., Camp, C.J., Anosognosia in Alzheimer disease (1995) Alzheimer Disease & Associated Disorders, 9 (1), pp. 52-56; Lecardeur, L., Briand, C., Prouteau, A., Lalonde, P., Nicole, L., Lesage, A., Stip, E., Preserved awareness of their cognitive deficits in patients with schizophrenia: Convergent validity of the SSTICS (2009) Schizophrenia Research, 107 (23), pp. 303-306; Leonesio, R.J., Nelson, T.O., Do different metamemory judgments tap the same underlying aspects of memory? (1990) Journal of Experimenta1 Psychology: Learning. Memory, and Cognition, 16 (3), pp. 464-470; Lin, F., Wharton, W., Dowling, N.M., Ries, M.L., Johnson, S.C., Carlsson, C.M., Gleason, C.E., Awareness of memory abilities in community-dwelling older adults with suspected dementia and mild cognitive impairment (2010) Dementia and Geriatric Cognitive Disorders, 30 (1), pp. 83-92; Lukoff, D., Nuechterlein, K.H., Ventura, J., Manual for the expanded brief psychiatric rating scale (1986) Schizophrenia Bulletin, 12, pp. 594-602; Marks, K.A., Fastenau, P.S., Lysaker, P.H., Bond, G.R., Self-Appraisal of Illness Questionnaire (SAIQ): Relationship to researcher-rated insight and neuropsychological function in schizophrenia (2000) Schizophrenia Research, 45 (3), pp. 203-211; McGlynn, S.M., Schacter, D.L., Unawareness of deficits in neuropsychological syndromes (1989) Journal of Clinical and Experimental Neuropsychology, 11 (2), pp. 143-205; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., (1984) Neurology, 34 (7), p. 939. , Clinical diagnosis of Alzheimers disease report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimers disease; Medalia, A., Lim, R.W., Self-awareness of cognitive functioning in schizophrenia (2004) Schizophrenia Research, 71 (2-3), pp. 331-338. , DOI 10.1016/j.schres.2004.03.003, PII S0920996404000970; Medalia, A., Thysen, J., Insight into neurocognitive dysfunction in schizophrenia (2008) Schizophrenia Bulletin, 34 (6), pp. 1221-1230; Medalia, A., Thysen, J., A comparison of insight into clinical symptoms versus insight into neuro-cognitive symptoms in schizophrenia (2010) Schizophrenia Research, 118, pp. 134-139; Medalia, A., Thysen, J., Freilich, B., Do people with schizophrenia who have objective cognitive impairment identify cognitive deficits on a self report measure? (2008) Schizophrenia Research, 105 (13), pp. 156-164; Michon, A., Deweer, B., Pillon, B., Agid, Y., Dubois, B., Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease (1994) Journal of Neurology Neurosurgery and Psychiatry, 57 (7), pp. 805-809; Mimura, M., Yano, M., Memory impairment and awareness of memory deficits in early-stage Alzheimers disease (2006) Reviews in the Neurosciences, 17 (12), pp. 253-266; Moritz, S., Ferahli, S., Naber, D., Memory and attention performance in psychiatric patients: Lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results (2004) Journal of the International Neuropsychological Society, 10 (4), pp. 623-633. , DOI 10.1017/S1355617704104153; Morris, R., Hannesdottir, K., (2004) Cognitive Neuropsychology of Alzheimers Disease, pp. 275-296. , Loss of ""awareness"" in Alzheimers disease. In R. Morris & J. Becker (Eds.),. New York, NY: Oxford University Press; Naylor, E., Clare, L., Awareness of memory functioning, autobiographical memory and identity in early-stage dementia (2008) Neuropsychological Rehabilitation, 18 (56), pp. 590-606; Nelson, H.E., (1991) The Revised National Adult Reading Scale (NART-R), , Windsor: Nelson; Nelson, T.O., Narens, L., (1990) Metamemory A Theoretical Framework and New Findings. The Psychology of Learning and Motivation, 26, pp. 125-141; Nelson, T.O., Narens, L., (1994) Metacognition: Knowing about Knowing, pp. 1-25. , Why investigate metacognition? In J. Metcalfe & A. P. Shimamura (Eds.),. Cambridge, MA: MIT Press; Noe, E., Ferri, J., Caballero, M.C., Villodre, R., Sanchez, A., Chirivella, J., Self-awareness after acquired brain injury: Predictors and rehabilitation (2005) Journal of Neurology, 252 (2), pp. 168-175. , DOI 10.1007/s00415-005-0625-2; Oyebode, J.R., Telling, A.L., Hardy, R.M., Austin, J., Awareness of memory functioning in early Alzheimer's disease: Lessons from a comparison with healthy older people and young adults (2007) Aging and Mental Health, 11 (6), pp. 761-767. , DOI 10.1080/13607860701366277, PII 788296040; Pinon, K., Allain, P., Kefi, M.Z., Dubas, F., Le Gall, D., Monitoring processes and metamemory experience in patients with dysexecutive syndrome (2005) Brain and Cognition, 57 (2), pp. 185-188. , DOI 10.1016/j.bandc.2004.08.042; Prigatano, G.P., Disturbances of self-awareness and rehabilitation of patients with traumatic brain injury: A 20-year perspective (2005) Journal of Head Trauma Rehabilitation, 20 (1), pp. 19-29; Reed, B.R., Jagust, W.J., Coulter, L., Anosognosia in Alzheimer's disease: Relationships to depression, cognitive function, and cerebral perfusion (1993) Journal of Clinical and Experimental Neuropsychology, 15 (2), pp. 231-244; Roche, N.L., Fleming, J.M., Shum, D.H.K., Self-awareness of prospective memory failure in adults with traumatic brain injury (2002) Brain Injury, 16 (11), pp. 931-945. , DOI 10.1080/02699050210138581; Sbordone, R.J., Seyranian, G.D., Ruff, R.M., Are the subjective complaints of traumatically brain injured patients reliable? (1998) Brain Injury, 12 (6), pp. 505-515. , DOI 10.1080/026990598122467; Schmitter-Edgecombe, M., Woo, E., Memory self-awareness and memory self-monitoring following severe closed-head injury (2004) Brain Injury, 18 (10), pp. 997-1016. , DOI 10.1080/02699050410001719934; Sevush, S., Leve, N., Denial of memory deficit in Alzheimers disease (1995) American Journal of Psychiatry, 150, pp. 748-751; Shad, M.U., Muddasani, S., Keshavan, M.S., Prefrontal subregions and dimensions of insight in first-episode schizophrenia - A pilot study (2006) Psychiatry Research - Neuroimaging, 146 (1), pp. 35-42. , DOI 10.1016/j.pscychresns.2005.11.001, PII S092549270500199X; Shimamura, A.P., Toward a cognitive neuroscience of metacognition (2000) Consciousness and Cognition, 9, pp. 313-323; Shimamura, A.P., (2008) Handbook of Memory and Metacognition, pp. 373-390. , A neurocognitive approach to metacognitive monitoring and control. In J. Dunlosky & R. Bjork (Eds.), Mahwah, NJ: Lawrence Erlbaum Associates; Souchay, C., Isingrini, M., Gil, R., Alzheimer's disease and feeling-of-knowing in episodic memory (2002) Neuropsychologia, 40 (13), pp. 2386-2396. , DOI 10.1016/S0028-3932(02)00075-1, PII S0028393202000751; Starkstein, S.E., Sabe, L., Chemerinski, E., Jason, L., Leiguarda, R., Two domains of anosognosia in Alzheimers disease (1996) British Medical Journal, 61 (5), p. 485; Stip, E., Caron, J., Renaud, S., Pampoulova, T., Lecomte, Y., Exploring cognitive complaints in schizophrenia: The Subjective Scale to Investigate Cognition in Schizophrenia (2003) Comprehensive Psychiatry, 44 (4), pp. 331-340. , DOI 10.1016/S0010-440X(03)00086-5; Trudel, T.M., Tryon, W.W., Purdum, C.M., Awareness of disability and long-term outcome after traumatic brain injury (1998) Rehabilitation Psychology, 43 (4), pp. 267-281. , DOI 10.1037//0090-5550.43.4.267; Tulving, E., What is episodic memory? (1993) Current Directions in Psychological Science, 2 (3), pp. 67-70; Upthegrove, R., Oyebode, F., George, M., Haque, M.S., Insight, social knowledge and working memory in schizophrenia (2002) Psychopathology, 35 (6), pp. 341-346. , DOI 10.1159/000068595; Van Den Bosch, R.J., Rombouts, R.P., Causal mechanisms of subjective cognitive dysfunction in schizophrenic and depressed patients (1998) Journal of Nervous and Mental Disease, 186 (6), pp. 364-368. , DOI 10.1097/00005053-199806000-00007; Varga, M., Magnusson, A., Flekkoy, K., David, A.S., Opjordsmoen, S., Clinical and neuropsychological correlates of insight in schizophrenia and bipolar I disorder: Does diagnosis matter? (2007) Comprehensive Psychiatry, 48 (6), pp. 583-591. , DOI 10.1016/j.comppsych.2007.06.003, PII S0010440X07000879; Vasterling, J.J., Seltzer, B., Watrous, W.E., Longitudinal assessment of deficit unawareness in Alzheimer's disease (1997) Neuropsychiatry, Neuropsychology and Behavioral Neurology, 10 (3), pp. 197-202; Williamson, C., Alcantar, O., Rothlind, J., Cahn-Weiner, D., Miller, B.L., Rosen, H.J., Standardised measurement of self-awareness deficits in FTD and AD (2010) Journal of Neurology, Neurosurgery & Psychiatry, 81 (2), pp. 140-145; Wilson, B., Cockburn, J., Baddeley, A., (1985) The Rivermead Behavioural Memory Test (RBMT), , Reading: Thames Valley Test Company",Article,Scopus,2-s2.0-84893829859
"Freitas S., Prieto G., Simoes M.R., Santana I.","Psychometric properties of the montreal cognitive assessment (MoCA): An analysis using the Rasch Model",2014,"Clinical Neuropsychologist","28","1",,"65","83",,1,10.1080/13854046.2013.870231,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84893919349&partnerID=40&md5=3e78a0a80d01987a3a14304538b76d9b","Centre for Neuroscience and Cell Biology (CNC), University of Coimbra, Largo Marquês de Pombal, 3004-517 Coimbra, Portugal; Centro de Investigacao Do Nucleo de Estudos e Intervencao Cognitivo Comportamental, University of Coimbra, Portugal; Departamento de Psicología Básica, Psicobiología y Metodología de Las Ciencias Del Comportamiento, Universidad de Salamanca, Spain; Psychological Assessment Lab., Faculty of Psychology and Educational Sciences, University of Coimbra, Portugal; Neurology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal","Freitas, S., Centre for Neuroscience and Cell Biology (CNC), University of Coimbra, Largo Marquês de Pombal, 3004-517 Coimbra, Portugal, Centro de Investigacao Do Nucleo de Estudos e Intervencao Cognitivo Comportamental, University of Coimbra, Portugal; Prieto, G., Departamento de Psicología Básica, Psicobiología y Metodología de Las Ciencias Del Comportamiento, Universidad de Salamanca, Spain; Simões, M.R., Centro de Investigacao Do Nucleo de Estudos e Intervencao Cognitivo Comportamental, University of Coimbra, Portugal, Psychological Assessment Lab., Faculty of Psychology and Educational Sciences, University of Coimbra, Portugal; Santana, I., Centre for Neuroscience and Cell Biology (CNC), University of Coimbra, Largo Marquês de Pombal, 3004-517 Coimbra, Portugal, Neurology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, Faculty of Medicine, University of Coimbra, Portugal","In the present study we analyzed the psychometric characteristics of the MoCA (Portuguese version) using the Rasch model for dichotomous items. The total sample comprised of 897 participants distributed between two main subgroups: (I) healthy group that was comprised of 650 cognitively healthy community dwellers and (II) clinical group that was comprised of 90 patients with Mild Cognitive Impairment, 90 patients with Alzheimers disease, 33 patients with frontotemporal dementia, and 34 patients with vascular dementia recruited at a reference dementia clinic. All patients were investigated through a comprehensive neuropsychological assessment, laboratory tests essential to exclude a reversible form of dementia, imaging studies (CT or MRI and SPECT or FDG-PET), Apolipoprotein E allele genotyping and CSF biomarker (Aβ42,Tau, and P-tau) analyses. The clinical diagnosis was established through the consensus of a multidisciplinary team, based on international criteria. The results demonstrated an overall good fit of both items and the persons values, a high variability on cognitive performance level, and a good quality of the measurements. The MoCA scores also demonstrated adequate discriminant validity, with high diagnostic value. DIF analyses indicated the generalized validity of the MoCA scores. In conclusion, the results of this study show the overall psychometric adequacy of the MoCA and verify the discriminant and generalized validity of the obtained results. © 2013 Taylor and Francis.","Assessment; Cognitive impairment; MoCA; Rasch model","Alves, L., Simões, M.R., Martins, C., (2009) Teste de Leitura de Palavras Irregulares (TeLPI) [Reading Word Irregular Test], , Coimbra, Portugal: Serviço de Avaliação Psicológica da Faculdade de Psicologia e de Ciências da Educação da Universidade de Coimbra [Psychological Assessment Department, Faculty of Psychology and Educational Sciences, University of Coimbra]; (2000) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association 4th ed., text revised). Washington, DC: American Psychiatric Association Press; Andrich, D., (1988) Rasch Models for Measurement, , London: Sage; Arnold, J.M.O., Howlett, J.G., Dorian, P., Ducharme, A., Giannetti, N., Haddad, H., Heckman, G.A., White, M., Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers (2007) Canadian Journal of Cardiology, 23 (1), pp. 21-45; Barreto, J., Leuschner, A., Santos, F., Sobral, M., Escala de Depressão Geriátrica [Geriatric Depression Scale] (2008) Escalas e Testes Na Demência [Scales and Tests in Dementia], pp. 69-72. , Grupo de Estudos de Envelhecimento Cerebral e Demências [Study Group on Brain Aging and Dementia] (Ed.) Lisbon: GEECD; Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing (1995) Journal of the Royal Statistical Society B, 57 (1), pp. 289-300; Chen, J., Lin, K., Chen, Y., Risk factors for dementia (2009) Journal of Formosan Medical Association, 108 (10), pp. 754-764; Chou, Y., Wang, W., Checking dimensionality in item response models with principal component analysis on standardized residuals (2010) Educational and Psychological Measurement, 70, pp. 717-731; Cohen, J., (1988) Statistical Power Analysis for the Behavioural Sciences, , 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; Comas-Herrera, A., Northey, S., Wittenberg, R., Knapp, M., Bhattacharyya, S., Burns, A., Future costs of dementia-related long-term care: Exploring future scenarios (2011) International Psychogeriatrics, 23 (1), pp. 20-30; Conrad, K.J., Smith, E.V., International conference on objective measurement: Applications of Rasch analysis in health care (2004) Medical Care, 42, pp. 1-6; Cullen, B., O'Neill, B., Evans, J.J., Coen, R.F., Lawlor, B.A., A review of screening tests for cognitive impairment (2007) Journal of Neurology, Neurosurgery and Psychiatry, 78 (8), pp. 790-799. , DOI 10.1136/jnnp.2006.095414; Damian, A.M., Jacobson, S.A., Hentz, J.G., Belden, C.M., Shill, H.A., Sabbagh, M.N., Adler, C.H., The Montreal Cognitive Assessment and the Mini-Mental State Examination as screening instruments for cognitive impairment: Item analyses and threshold scores (2011) Dementia and Geriatric Cognitive Disorders, 31 (2), pp. 126-131; Dorans, N.J., Holland, P.W., DIF detection and description: Mantel-Haenszel and standardization (1993) Differential Item Functioning, pp. 35-66. , P. W. Holland, & H. Wainer (Eds.) Hillsdale, NJ: Erlbaum; Drasgow, F., Study of measurement bias of two standardized psychological tests (1987) Journal of Applied Psychology, 72, pp. 19-29; Fabrigoule, C., Barberger-Gateau, P., Dartigues, J.F., The PAQUID study (2006) Mild Cognitive Impairment: International Perspectives, pp. 31-56. , H. A. Tuokko, & D. F. Hultsch (Eds.) New York, NY: Taylor & Francis; (2010) Older Americans 2010: Key Indicators of Well-being, , http://www.agingstats.gov/agingstatsdotnet/Main_Site/Data/2010_Documents/ Docs/OA_2010.pdf, Federal Interagency Forum on Aging-Related Statistics Retrieved from:; Folstein, M., Folstein, S., McHugh, P., Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12 (3), pp. 189-198; Freitas, S., Simões, M.R., Alves, L., Duro, D., Santana, I., Montreal Cognitive Assessment (MoCA): Validation study for frontotemporal dementia (2012) Journal of Geriatric Psychiatry and Neurology, 25 (3), pp. 146-154; Freitas, S., Simões, M.R., Alves, L., Santana, I., Montreal Cognitive Assessment (MoCA): Normative study for the Portuguese population (2011) Journal of Clinical and Experimental Neuropsychology, 33 (9), pp. 989-996; Freitas, S., Simões, M.R., Alves, L., Santana, I., Montreal Cognitive Assessment (MoCA): Influence of sociodemographic and health variables (2012) Archives of Clinical Neuropsychology, 27, pp. 165-175; Freitas, S., Simões, M.R., Alves, L., Santana, I., Montreal Cognitive Assessment (MoCA): Validation study for Mild Cognitive Impairment and Alzheimer's disease (2013) Alzheimer Disease and Associated Disorders, 21 (1), pp. 37-43; Freitas, S., Simões, M.R., Alves, L., Vicente, M., Santana, I., Montreal Cognitive Assessment (MoCA): Validation study for vascular dementia (2012) Journal of International Neuropsychology Society, 18 (6), pp. 1031-1040; Freitas, S., Simões, M.R., Marôco, J., Alves, L., Santana, I., Construct validity of the Montreal Cognitive Assessment (MoCA (2012) Journal of International Neuropsychology Society, 18, pp. 242-250; Freitas, S., Simões, M.R., Martins, C., Vilar, M., Santana, I., Estudos de adaptação do Montreal Cognitive Assessment (MoCA) para a população portuguesa [Montreal Cognitive Assessment (MoCA): Adaptation studies for the Portuguese population] (2010) Avaliação Psicológica, 9 (3), pp. 345-357; Fujiwara, Y., Suzuki, H., Yasunaga, M., Sugiyama, M., Ijuin, M., Sakuma, N., Shinkai, S., Brief screening tool for mild cognitive impairment in older Japanese: Validation of the Japanese version of the Montreal Cognitive Assessment (2010) Geriatrics & Gerontology International, 10, pp. 225-232; Gardizi, E., Millis, S.R., Hanks, R., Axelrod, B., Rasch analysis of the Postconcussive Symptom Questionnaire: Measuring the core construct of brain injury symptomatology (2012) The Clinical Neuropsychologist, 26, pp. 135-156; Garret, C., Santos, F., Tracana, I., Barreto, J., Sobral, M., Fonseca, R., Avaliação Clínica da Demência [Clinical Dementia Rating Scale] (2008) Escalas e Testes Na Demência [Scales and Tests in Dementia], pp. 17-32. , In Grupo de Estudos de Envelhecimento Cerebral e Demências [Study Group on Brain Aging and Dementia] (Ed.) Lisbon: GEECD; Gauthier, S., Patterson, C., Gordon, M., Soucy, J., Schubert, F., Leuzy, A., Commentary on Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) A Canadian Perspective. Alzheimer's & Dementia, 7, pp. 330-332; Ginó, S., Mendes, T., Ribeiro, F., Mendonça, A., Guerreiro, M., Garcia, C., Escala de Queixas de Memória [Memory Complaints Scale] (2008) Escalas e Testes Na Demência [Scales and Tests in Dementia], pp. 117-120. , In Grupo de Estudos de Envelhecimento Cerebral e Demências [Study Group on Brain Aging and Dementia] (Ed.) Lisbon: GEECD; Guerreiro, M., Silva, A.P., Botelho, M., Leitão, O., Castro-Caldas, A., Garcia, C., Adaptação à população portuguesa da tradução do Mini Mental State Examination [Adaptation of the Mini Mental State Examination translation for the Portuguese population] (1994) Revista Portuguesa de Neurologia, 1, p. 9; Hachinski, V., Iadecola, C., Petersen, R.C., Breteler, M.M., Nyenhuis, D.L., Black, S.E., Powers, W.J., Leblanc, G.G., National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards (2006) Stroke, 37 (9), pp. 2220-2241. , DOI 10.1161/01.STR.0000237236.88823.47, PII 0000767020060900000021; Herdman, M., Fox-Rushby, J., Badia, X., A model of equivalence in the cultural adaptation of HRQoL instruments: The universalist approach (1998) Quality of Life Research, 7 (4), pp. 323-335. , DOI 10.1023/A:1008846618880; Holland, P., Thayer, D., Differential item performance and the Mantel-Haenszel procedure (1988) Test Validity, pp. 129-145. , H. Wainer, & H. I. Braun (Eds. Hillsdale, NJ: Erlbaum; Hughes, C.P., Berg, L., Danziger, W.L., A new clinical scale for the staging of dementia (1982) British Journal of Psychiatry, 140 (6), pp. 566-572; Ismail, Z., Shulman, K., Avaliação cognitiva breve para a demência [Cognitive screening assessment for dementia] (2006) Psicogeriatria [Psychogeriatry], pp. 513-530. , In H. Firmino (Ed.) Coimbra: Psiquiatria Clínica; Konsztowicz, S., Xie, H., Higgins, J., Mayo, N., Koski, L., Development of a method for quantifying cognitive ability in the elderly through adaptive test administration (2011) International Psychogeriatrics, 23, 7, pp. 1116-1123; Koski, L., Xie, H., Finch, L., Measuring cognition in a geriatric outpatients clinic: Rasch analysis of the Montreal Cognitive Assessment (2009) Journal of Geriatric Psychiatry and Neurology, 32 (3), pp. 151-160; Koski, L., Xie, H., Konsztowicz, S., Improving precision in the quantification of cognition using the Montreal Cognitive Assessment and the Mini-Mental State Examination (2011) International Psychogeriatrics, 23 (7), pp. 1107-1115; Lee, J.-Y., Dong Woo Lee, Cho, S.-J., Na, D.L., Hong Jin Jeon, Kim, S.-K., You Ra Lee, Maeng Je Cho, Brief screening for mild cognitive impairment in elderly outpatient clinic: Validation of the Korean version of the Montreal Cognitive Assessment (2008) Journal of Geriatric Psychiatry and Neurology, 21 (2), pp. 104-110. , DOI 10.1177/0891988708316855; Linacre, J.M., (2011) A User's Guide to WINSTEPS & MINISTEPS: Rasch Model Computer Programs, , Chicago IL: Winsteps.com; McKhann, G., Drachman, D., Folstein, M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease (1984) Neurology, 34 (7), pp. 939-944; Nandakumar, R., Simultaneous DIF amplification and cancellation: Shealy-Stouts's Test for DIF (1993) Journal of Educational Measurement, 30 (4), pp. 293-311; Nasreddine, Z.S., Phillips, N.A., Bedirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.L., Chertkow, H., The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment (2005) Journal of the American Geriatrics Society, 53 (4), pp. 695-699. , DOI 10.1111/j.1532-5415.2005.53221.x; Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Benson, D.F., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria (1998) Neurology, 51, pp. 1546-1554; Padilla, J.L., Hidalgo, M.D., Benítez, I., Gómez-Benito, J., Comparison if three software programs for evaluating DIF by means of the Mantel-Haenszel procedure: EASY-DIF, DIFAS and EZDIF (2012) Psicológica, 33, pp. 135-156; Petersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) Journal of Internal Medicine, 256 (3), pp. 183-194. , DOI 10.1111/j.1365-2796.2004.01388.x; Petersen, R.C., Mild cognitive impairment (2007) CONTINUUM Lifelong Learning in Neurology, 13 (2), pp. 15-38. , DOI 10.1212/01.CON.0000267234.69379.4e, PII 0013297920070400000003; Potenza, M., Dorans, N., DIF assessment for politomously scored items: A framework for classification and evaluation (1995) Applied Psychological Measurement, 19, pp. 23-37; Prieto, G., Contador, I., Tapias-Merino, E., Mitchell, A.J., Bermejo-Pareja, F., The Mini-Mental-37 Test for dementia screening in the Spanish population: An analysis using the Rasch model (2012) The Clinical Neuropsychologist, 26 (6), pp. 1003-1018; Prieto, G., Delgado, A.R., Perea, M.V., Ladera, V., Scoring neuropsychological tests using the Rasch model: An illustrative example with the Rey-Osterreith Complex Figure (2010) The Clinical Neuropsychologist, 24, pp. 45-56; Rasch, G., (1960) Probabilistic Models for Some Intelligence and Attainment Tests, , Copenhagen: Danish Institute for Educational Research. [Expanded edition 1980. Chicago: University of Chicago Press.]; Reckase, M.D., Unifactor latent trait models applied to multifactor tests: Results and implications (1979) Journal of Educational Statistics, 4, pp. 207-230; Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., Amaducci, L., Kokmen, E., Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop (1993) Neurology, 43 (2), pp. 250-260; Roznowski, M., Use of tests manifesting sex differences as measure of intelligence: Implications for measurement bias (1987) Journal of Applied Psychology, 72, pp. 480-483; Schmand, B., Jonker, C., Hooijer, C., Lindeboom, J., Subjective memory complaints may announce dementia (1996) Neurology, 46 (1), pp. 121-125; Schumacker, R.E., Rasch measurement using dichotomous scoring (2004) Journal of Applied Measurement, 5 (3), pp. 328-349; Smith, R.M., Fit analysis in latent trait measurement models (2000) Journal of Applied Measurement, 1, pp. 199-218; Wright, B.D., Mok, M.M., An overview of the family of Rasch measurement models (2004) Introduction to Rasch Measurement, pp. 1-24. , E. V. Smith Jr, & R. M. Smith (Eds.) Maple Grove, MN: JAM Press; Yesavage, J.A., Brink, T.L., Rose, T.L., Development and validation of a geriatric depression screening scale: A preliminary report (1982) Journal of Psychiatric Research, 17 (1), pp. 37-49. , DOI 10.1016/0022-3956(82)90033-4; Zickar, M.J., Broadfoot, A.A., The partial revival of a dead horse? Comparing classical test theory and item response theory (2009) Statistical and Methodological Myths and Urban Legends, pp. 37-61. , C. E. Lance, & R. J. Vandenberg (Eds.) New York, NY: Routledge; Zwick, R., Ercikan, K., Analysis of differential item functioning in the NAEP history assessment (1989) Journal of Educational Measurement, 26, pp. 55-66",Article,Scopus,2-s2.0-84893919349
"Bai B., Chen P.-C., Hales C.M., Wu Z., Pagala V., High A.A., Levey A.I., Lah J.J., Peng J.","Integrated approaches for analyzing U1-70K cleavage in Alzheimers disease",2014,"Journal of Proteome Research","13","11",,"4526","4534",,1,10.1021/pr5003593,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908888137&partnerID=40&md5=7ccf8ed53a53589cec09a6817e12ba8e","Departments of Structural Biology and Developmental NeurobiologyMemphis, TN, United States; St. Jude Proteomics Facility, St. Jude Childrens Research HospitalMemphis, TN, United States; Department of Neurology, Center for Neurodegenerative Diseases, Emory UniversityAtlanta, GA, United States","Bai, B., Departments of Structural Biology and Developmental NeurobiologyMemphis, TN, United States; Chen, P.-C., Departments of Structural Biology and Developmental NeurobiologyMemphis, TN, United States; Hales, C.M., Department of Neurology, Center for Neurodegenerative Diseases, Emory UniversityAtlanta, GA, United States; Wu, Z., Departments of Structural Biology and Developmental NeurobiologyMemphis, TN, United States; Pagala, V., St. Jude Proteomics Facility, St. Jude Childrens Research HospitalMemphis, TN, United States; High, A.A., St. Jude Proteomics Facility, St. Jude Childrens Research HospitalMemphis, TN, United States; Levey, A.I., Department of Neurology, Center for Neurodegenerative Diseases, Emory UniversityAtlanta, GA, United States; Lah, J.J., Department of Neurology, Center for Neurodegenerative Diseases, Emory UniversityAtlanta, GA, United States; Peng, J., Departments of Structural Biology and Developmental NeurobiologyMemphis, TN, United States, St. Jude Proteomics Facility, St. Jude Childrens Research HospitalMemphis, TN, United States","The accumulation of pathologic protein fragments is common in neurodegenerative disorders. We have recently identified in Alzheimers disease (AD) the aggregation of the U1-70K splicing factor and abnormal RNA processing. Here, we present that U1-70K can be cleaved into an N-terminal truncation (N40K) in ∼50% of AD cases, and the N40K abundance is inversely proportional to the total level of U1-70K. To map the cleavage site, we compared tryptic peptides of N40K and stable isotope labeled U1-70K by liquid chromatography-tandem mass spectrometry (MS), revealing that the proteolysis site is located in a highly repetitive and hydrophilic domain of U1-70K. We then adapted Western blotting to map the cleavage site in two steps: (i) mass spectrometric analysis revealing that U1-70K and N40K share the same N-termini and contain no major modifications; (ii) matching N40K with a series of six recombinant U1-70K truncations to define the cleavage site within a small region (Arg300 ± 6 residues). Finally, N40K expression led to substantial degeneration of rat primary hippocampal neurons. In summary, we combined multiple approaches to identify the U1-70K proteolytic site and found that the N40K fragment might contribute to neuronal toxicity in Alzheimers disease. © 2014 American Chemical Society.","Alzheimers disease; LC-MS/MS; mass spectrometry; neurodegenerative disease; proteolytic cleavage; proteomics; RNA splicing; stable isotope labeling; U1 snRNP; U1-70K","Alzheimers disease facts and figures (2012) Alzheimer's Dementia, 8 (2), pp. 131-168. , 2012; Tanzi, R.E., The genetics of Alzheimer disease (2012) Cold Spring Harbor Perspect. Med., 2 (10); Liu, C.C., Kanekiyo, T., Xu, H., Bu, G., Apolipoprotein e and Alzheimer disease: Risk, mechanisms and therapy (2013) Nat. Rev. Neurol., 9 (2), pp. 106-118; Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Stefansson, K., Variant of TREM2 associated with the risk of Alzheimers disease (2013) N. Engl. J. Med., 368 (2), pp. 107-116; Neumann, H., Daly, M.J., Variant TREM2 as risk factor for Alzheimers disease (2013) N. Engl. J. Med., 368 (2), pp. 182-184; Taylor, J.P., Hardy, J., Fischbeck, K.H., Toxic proteins in neurodegenerative disease (2002) Science, 296 (5575), pp. 1991-1995; Glenner, G.G., Wong, C.W., Alzheimers disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein (1984) Biochem. Biophys. Res. Commun., 120 (3), pp. 885-890; Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome (1985) Proc. Natl. Acad. Sci. U. S. A., 82 (12), pp. 4245-4249; Lee, V.M., Balin, B.J., Otvos, L., Jr., Trojanowski, J.Q., A68: A major subunit of paired helical filaments and derivatized forms of normal Tau (1991) Science, 251 (4994), pp. 675-678; Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics (2002) Science, 297 (5580), pp. 353-356; Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimers disease and related disorders (2007) Nat. Rev. Neurosci., 8 (9), pp. 663-672; Pimplikar, S.W., Nixon, R.A., Robakis, N.K., Shen, J., Tsai, L.H., Amyloid-independent mechanisms in Alzheimers disease pathogenesis (2010) J. Neurosci., 30 (45), pp. 14946-14954; Aebersold, R., Mann, M., Mass spectrometry-based proteomics (2003) Nature, 422 (6928), pp. 198-207; Peng, J., Gygi, S.P., Proteomics: The move to mixtures (2001) J. Mass Spectrom., 36 (10), pp. 1083-1091; Cravatt, B.F., Simon, G.M., Yates, J., III, The biological impact of mass-spectrometry-based proteomics (2007) Nature, 450 (7172), pp. 991-1000; Mann, M., Kulak, N.A., Nagaraj, N., Cox, J., The coming age of complete, accurate, and ubiquitous proteomes (2013) Mol. Cell, 49 (4), pp. 583-590; Zhou, J.Y., Jones, D.R., Duong, D.M., Levey, A.I., Lah, J.J., Peng, J., Proteomic Analysis of Postsynaptic Density in Alzheimer Disease (2013) Clin. Chim. Acta, 420, pp. 62-68; Gozal, Y.M., Duong, D.M., Gearing, M., Cheng, D., Hanfelt, J.J., Funderburk, C., Peng, J., Levey, A.I., Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimers disease (2009) J. Proteome Res., 8 (11), pp. 5069-5079; Gozal, Y.M., Dammer, E.B., Duong, D.M., Cheng, D., Gearing, M., Rees, H.D., Peng, J., Levey, A.I., Proteomic analysis of hippocampal dentate granule cells in frontotemporal lobar degeneration: Application of laser capture technology (2011) Front. Neurol., 2, p. 24; Gozal, Y.M., Seyfried, N.T., Gearing, M., Glass, J.D., Heilman, C.J., Wuu, J., Duong, D.M., Lah, J.J., Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration (2011) Mol. Neurodegener., 6, p. 82; Dammer, E.B., Na, C.H., Xu, P., Seyfried, N.T., Duong, D.M., Cheng, D., Gearing, M., Peng, J., Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease (2011) J. Biol. Chem., 286 (12), pp. 10457-10465; Xia, Q., Cheng, D., Duong, D.M., Gearing, M., Lah, J.J., Levey, A.I., Peng, J., Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry (2008) J. Proteome Res., 7 (7), pp. 2845-2851; Liao, L., Cheng, D., Wang, J., Duong, D.M., Losik, T.G., Gearing, M., Rees, H.D., Peng, J., Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection (2004) J. Biol. Chem., 279 (35), pp. 37061-37068; Seyfried, N.T., Gozal, Y.M., Dammer, E.B., Xia, Q., Duong, D.M., Cheng, D., Lah, J.J., Peng, J., Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains (2010) Mol. Cell. Proteomics, 9 (4), pp. 705-718; Zhou, J.Y., Afjehi-Sadat, L., Asress, S., Duong, D.M., Cudkowicz, M., Glass, J.D., Peng, J., Galectin-3 is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics Approach (2010) J. Proteome Res., 9 (10), pp. 5133-5141; Bai, B., Hales, C.M., Chen, P.C., Gozal, Y., Dammer, E.B., Fritz, J.J., Wang, X., Peng, J., U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimers disease (2013) Proc. Natl. Acad. Sci. U. S. A., 110 (41), pp. 16562-16567; Hales, C.M., Dammer, E.B., Diner, I., Yi, H., Seyfried, N.T., Gearing, M., Glass, J.D., Lah, J.J., Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimers disease (2014) Brain Pathol.; Staley, J.P., Guthrie, C., Mechanical devices of the spliceosome: Motors, clocks, springs, and things (1998) Cell, 92 (3), pp. 315-326; Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease (2004) Nat. Med., 10 (SUPPL), pp. 10-17; Hyman, B.T., Trojanowski, J.Q., Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease (1997) J. Neuropathol. Exp. Neurol., 56 (10), pp. 1095-1097; Xu, P., Duong, D.M., Peng, J., Systematical optimization of reverse-phase chromatography for shotgun proteomics (2009) J. Proteome Res., 8 (8), pp. 3944-3950; Peng, J., Elias, J.E., Thoreen, C.C., Licklider, L.J., Gygi, S.P., Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: The yeast proteome (2003) J. Proteome Res., 2, pp. 43-50; Elias, J.E., Gygi, S.P., Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry (2007) Nat. Methods, 4 (3), pp. 207-214; Seyfried, N.T., Xu, P., Duong, D.M., Cheng, D., Hanfelt, J., Peng, J., Systematic approach for validating the ubiquitinated proteome (2008) Anal. Chem., 80 (11), pp. 4161-4169; Bonissone, S., Gupta, N., Romine, M., Bradshaw, R.A., Pevzner, P.A., N-terminal protein processing: A comparative proteogenomic analysis (2013) Mol. Cell. Proteomics, 12 (1), pp. 14-28; Kuchibhotla, K.V., Goldman, S.T., Lattarulo, C.R., Wu, H.Y., Hyman, B.T., Bacskai, B.J., Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks (2008) Neuron, 59 (2), pp. 214-225; Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., Selkoe, D.J., Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration (2011) Proc. Natl. Acad. Sci. U. S. A., 108 (14), pp. 5819-5824; Nikolaev, A., McLaughlin, T., Oleary, D.D., Tessier-Lavigne, M., APP binds DR6 to trigger axon pruning and neuron death via distinct caspases (2009) Nature, 457 (7232), pp. 981-989; Lobner, D., Comparison of the LDH and MTT assays for quantifying cell death: Validity for neuronal apoptosis? (2000) J. Neurosci. Methods, 96 (2), pp. 147-152; Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Lee, V.M., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (2006) Science, 314 (5796), pp. 130-133; Nonaka, T., Kametani, F., Arai, T., Akiyama, H., Hasegawa, M., Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43 (2009) Hum. Mol. Genet., 18 (18), pp. 3353-3364; Kambach, C., Mattaj, I.W., Intracellular distribution of the U1A protein depends on active transport and nuclear binding to U1 snRNA (1992) J. Cell Biol., 118 (1), pp. 11-21; Gervais, F.G., Xu, D., Robertson, G.S., Vaillancourt, J.P., Zhu, Y., Huang, J., Leblanc, A., Nicholson, D.W., Involvement of caspases in proteolytic cleavage of Alzheimers amyloid-beta precursor protein and amyloidogenic A beta peptide formation (1999) Cell, 97 (3), pp. 395-406; Saito, K., Elce, J.S., Hamos, J.E., Nixon, R.A., Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration (1993) Proc. Natl. Acad. Sci. U. S. A., 90 (7), pp. 2628-2632; Cataldo, A.M., Nixon, R.A., Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain (1990) Proc. Natl. Acad. Sci. U. S. A., 87 (10), pp. 3861-3865; Casciola-Rosen, L., Nicholson, D.W., Chong, T., Rowan, K.R., Thornberry, N.A., Miller, D.K., Rosen, A., Apopain/CPP32 cleaves proteins that are essential for cellular repair: A fundamental principle of apoptotic death (1996) J. Exp. Med., 183 (5), pp. 1957-1964; Casciola-Rosen, L., Andrade, F., Ulanet, D., Wong, W.B., Rosen, A., Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity (1999) J. Exp. Med., 190 (6), pp. 815-826; Casciola-Rosen, L., Wigley, F., Rosen, A., Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis (1997) J. Exp. Med., 185 (1), pp. 71-79; Lee, E.B., Lee, V.M., Trojanowski, J.Q., Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration (2012) Nat. Rev. Neurosci., 13 (1), pp. 38-50; Yuan, J., Yankner, B.A., Apoptosis in the nervous system (2000) Nature, 407 (6805), pp. 802-809",Article,Scopus,2-s2.0-84908888137
"Alkadhi K.A., Tran T.T.","Chronic psychosocial stress impairs early LTP but not late LTP in the dentate gyrus of at-risk rat model of Alzheimers disease",2014,"Brain Research","1588",,,"150","158",,,10.1016/j.brainres.2014.09.014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84909989276&partnerID=40&md5=7fdded722325868270b15ba904da1d85","Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of HoustonHouston, TX, United States","Alkadhi, K.A., Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of HoustonHouston, TX, United States; Tran, T.T., Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of HoustonHouston, TX, United States","The CA1 and dentate gyrus regions of the hippocampus are physically and functionally closely related but they react differently to insults. This study examined the effect of chronic psychosocial stress on the dentate gyrus of an at-risk (preclinical) rat model of Alzheimers disease (subAβ rats). Chronic psychosocial stress was produced using a rat intruder model. The at-risk rat model of Alzheimers disease was created by osmotic pump infusion of sub-pathological dose of Aβ (160 pmol Aβ1-42/day i.c.v) for 14 days. Electrophysiological methods were used to evoke and record early and late phase LTP in the dentate gyrus of anesthetized rats, and immunoblotting was used to measure levels of memory-related signaling molecules in the same region. Electrophysiological and molecular tests in the dentate gyrus showed that subAβ rats or stressed rats were not different from control rats. However, when the subAβ rats were chronically stressed, the combined treatments severely suppressed early phase LTP without affecting the late phase LTP of dentate gyrus. Additionally, in the chronically stressed subAβ rats the expected elevation of levels of phosphorylated CaMKII did not materialize after expression of early phase LTP suggesting impaired phosphorylation, which may explain the severely blocked early phase LTP. © 2014 Elsevier B.V.","Alzheimers disease; Beta amyloid; CA1; Electrophysiology; Hippocampus; Late-phase long-term potentiation; Radial arm water maze; Stress","Abrahám, H., Veszprémi, B., Kravják, A., Kovács, K., Gömöri, E., Seress, L., Ontogeny of calbindin immunoreactivity in the human hippocampal formation with a special emphasis on granule cells of the dentate gyrus (2009) Int. J. Dev. Neurosci., 27 (2), pp. 115-127; Abrahám, H., Richter, Z., Gyimesi, C., Horváth, Z., Janszky, J., Dóczi, T., Seress, L., Degree and pattern of calbindin immunoreactivity in granule cells of the dentate gyrus differ in mesial temporal sclerosis, cortical malformation- and tumor-related epilepsies (2011) Brain Res., 1399, pp. 66-78; Aleisa, A.M., Alzoubi, K.H., Alkadhi, K.A., Chronic but not acute nicotine treatment reverses stress-induced impairment of LTP in anesthetized rats (2006) Brain Res., 1097, pp. 78-84; Aleisa, A.M., Alzoubi, K.H., Alkadhi, K.A., Nicotine prevents stress-induced enhancement of long-term depression in hippocampal area CA1, electrophysiological and molecular studies (2006) J. Neurosci. Res., 83, pp. 309-317; Alkadhi, K.A., Alzoubi, K.H., Aleisa, A.M., Tanner, F.L., Nimer, A.S., Psychosocial stress-induced hypertension results from in vivo expression of long-term potentiation in rat sympathetic ganglia (2005) Neurobiol. Dis., 20, pp. 849-857; Alzoubi, K.H., Gerges, N.Z., Alkadhi, K.A., Levothyroxin restores hypothyroidism-induced impairment of LTP of hippocampal CA1, electrophysiological and molecular studies (2005) Exp. Neurol., 195, pp. 330-341; Barria, A., Muller, D., Derkach, V., Griffith, L.C., Soderling, T.R., Regulatory phosphorylation of AMPA-type glutamate receptors by CaMKII during long-term potentiation (1997) Science, 276, pp. 2042-2045; Bramham, C.R., Southard, T., Ahlers, S.T., Sarvey, J.M., Acute cold stress leading to elevated corticosterone neither enhances synaptic efficacy nor impairs LTP in the dentate gyrus of freely moving rats (1998) Brain Res., 789, pp. 245-255; Castellani, R.J., Lee, H.G., Zhu, X., Perry, G., Smith, M.A., Alzheimer disease pathology as a host response (2008) J. Neuropathol. Exp. Neurol., 67, pp. 523-531; Davies, K.J., Ermak, G., Rothermel, B.A., Pritchard, M., Heitman, J., Ahnn, J., Henrique-Silva, F., Estivill, X., Renaming the DSCR1/Adapt78 gene family as RCAN, regulators of calcineurin (2007) FASEB J., 12, pp. 3023-3028; Davis, S., Laroche, S., Activation of metabotropic glutamate receptors induces differential effects on synaptic transmission in the dentate gyrus and CA1 of the hippocampus in the anaesthetized rat (1996) Neuropharmacology, 35, pp. 337-346; Diamond, D.M., Bennett, M.C., Fleshner, M., Rose, G.M., Inverted-U relationship between the level of peripheral corticosterone and the magnitude of hippocampal primed burst potentiation (1992) Hippocampus, 2, pp. 421-430; Dringenberg, H.C., Oliveira, D., Habib, D., Predator,cat hair-induced enhancement of hippocampal long-term potentiation in rats: Involvement of acetylcholine (2008) Learn. Mem., 15, pp. 112-116; Effraimidis, G., Tijssen, J.G., Brosschot, J.F., Wiersinga, W.M., Involvement of stress in the pathogenesis of autoimmune thyroid disease: A prospective study (2012) Psychoneuroendocrinology, 37 (8), pp. 1191-1198; Frantz, G.D., Tobin, A.J., Cellular distribution of calbindin D28K mRNAs in the adult mouse brain (1994) J. Neurosci. Res., 37, pp. 287-302; Froc, D.J., Chapman, C.A., Trepel, C., Racine, R.J., Long-term depression and depotentiation in the sensorimotor cortex of the freely moving rat (2000) J. Neurosci., 20, pp. 438-445; Garcia, R., Stress, hippocampal plasticity, and spatial learning (2001) Synapse, 40, pp. 180-183; Gerges, N.Z., Alkadhi, K.A., Hypothyroidism impairs late LTP in CA1 region but not in dentate gyrus of the intact rat hippocampus, MAPK involvement (2004) Hippocampus, 14, pp. 40-45; Gerges, N.Z., Alzoubi, K.H., Alkadhi, K.A., Role of phosphorylated CaMKII and calcineurin in the differential effect of hypothyroidism on LTP of CA1 and dentate gyrus (2005) Hippocampus, 15, pp. 480-490; Gerges, N.Z., Stringer, J.L., Alkadhi, K.A., Combination of hypothyroidism and stress abolishes early LTP in the CA1 but not dentate gyrus of hippocampus of adult rats (2001) Brain Res., 922, pp. 250-260; Gilbert, P.E., Kesner, R.P., Lee, I., Dissociating hippocampal subregions, double dissociation between dentate gyrus and CA1 (2001) Hippocampus, 11, pp. 626-636; Glazewski, S., Bejar, R., Mayford, M., Fox, K., The effect of autonomous alpha-CaMKII expression on sensory responses and experience-dependent plasticity in mouse barrel cortex (2001) Neuropharmacology, 41, pp. 771-778; Halpain, S., Hipolito, A., Saffer, L., Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin (1998) J. Neurosci., 18, pp. 9835-9844; Hsu, J.C., Zhang, Y., Takagi, N., Gurd, J.W., Wallace, M.C., Zhang, L., Eubanks, J.H., Decreased expression and functionality of NMDA receptor complexes persist in the CA1, but not in the dentate gyrus after transient cerebral ischemia (1998) J. Cereb. Blood Flow Metab., 18, pp. 768-775; Izaki, Y., Arita, J., Long-term potentiation in the rat hippocampal CA1 region is inhibited selectively at the acquisition stage of discriminatory avoidance learning (1996) Brain Res., 723, pp. 162-168; Klee, C.B., Crouch, T.H., Krinks, M.H., Calcineurin, a calcium- and calmodulin-binding protein of the nervous system (1979) Proc. Natl. Acad. Sci. USA, 76, pp. 6270-6273; Liu, J., Fukunaga, K., Yamamoto, H., Nishi, K., Miyamoto, E., Differential roles of Ca2./calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal longterm potentiation (1999) J. Neurosci., 19, pp. 8292-8299; Lynch, M.A., Bliss, T.V., Noradrenaline modulates the release of [14C]glutamate from dentate but not from CA1/CA3 slices of rat hippocampus (1986) Neuropharmacology, 25, pp. 493-498; Malgaroli, A., Malinow, R., Schulman, H., Tsien, R.W., Persistent signalling and changes in presynaptic function in long-term potentiation (1992) Ciba F. Symp., 164, pp. 176-191. , (discussion 192-176); Malinow, R., Schulman, H., Tsien, R.W., Inhibition of postsynaptic PKC or CaMKII blocks induction but not expression of LTP (1989) Science, 245, pp. 862-866; Mansuy, I.M., Winder, D.G., Moallem, T.M., Osman, M., Mayford, M., Hawkins, R.D., Kandel, E.R., Inducible and reversible gene expression with the rtTA system for the study of memory (1998) Neuron, 21, pp. 257-265; Matthies, H., Schroeder, H., Becker, A., Loh, H., Hollt, V., Krug, M., Lack of expression of long-term potentiation in the dentate gyrus but not in the CA1 region of the hippocampus of mu-opioid receptor-deficient mice (2000) Neuropharmacology, 39, pp. 952-960; McEwen, B.S., Central effects of stress hormones in health and disease, understanding the protective and damaging effects of stress and stress mediators (2008) Eur. J. Pharmacol., 583, pp. 174-185; McEwen, B.S., Sapolsky, R.M., Stress and cognitive function (1995) Curr. Opin. Neurobiol., 5, pp. 205-216; Morioka, M., Nagahiro, S., Fukunaga, K., Miyamoto, E., Ushio, Y., Calcineurin in the adult rat hippocampus, different distribution in CA1 and CA3 subfields (1997) Neuroscience, 78, pp. 673-684; Müller, A., Kukley, M., Stausberg, P., Beck, H., Muller, W., Dietrich, D., Endogenous Ca2+ buffer concentration and Ca2+ microdomains in hippocampal neurons (2005) J. Neurosci., 25, pp. 558-565; Otmakhov, N., Griffith, L.C., Lisman, J.E., Postsynaptic inhibitors of calcium/calmodulin-dependent protein kinase type II block induction but not maintenance of pairing-induced long-term potentiation (1997) J. Neurosci., 17, pp. 5357-5365; Ouyang, Y., Kantor, D., Harris, K.M., Schuman, E.M., Kennedy, M.B., Visualization of the distribution of autophosphorylated calcium/calmodulin-dependent protein kinase II after tetanic stimulation in the CA1 area of the hippocampus (1997) J. Neurosci., 17, pp. 5416-5427; Parfitt, K.D., Doze, V.A., Madison, D.V., Browning, M.D., Isoproterenol increases the phosphorylation of the synapsins and increases synaptic transmission in dentate gyrus, but not in area CA1, of the hippocampus (1992) Hippocampus, 2, pp. 59-64; Pavlides, C., Ogawa, S., Kimura, A., McEwen, B.S., Role of adrenal steroid mineralocorticoid and glucocorticoid receptors in long-term potentiation in the CA1 field of hippocampal slices (1996) Brain Res., 738, pp. 229-235; Pavlides, C., Watanabe, Y., McEwen, B.S., Effects of glucocorticoids on hippocampal long-term potentiation (1993) Hippocampus, 3, pp. 183-192; Paxinos, G., Watson, C., The Rat Brain in Stereotaxic Coordinates, second (1986) Edition, , Academic Press Sydney; New York; Pettit, D.L., Perlman, S., Malinow, R., Potentiated transmission and prevention of further LTP by increased CaMKII activity in postsynaptic hippocampal slice neurons (1994) Science, 266, pp. 1881-1885; Pu, Z., Krugers, H.J., Joëls, M., Corticosterone time-dependently modulates beta-adrenergic effects on long-term potentiation in the hippocampal dentate gyrus (2007) Learn. Mem, 14, pp. 359-367; Sandi, C., Pinelo-Nava, M.T., Stress and memory, behavioral effects and neurobiological mechanisms (2007) Neural. Plast., 2007, p. 78970; Scharfman, H.E., Schwartzkroin, P.A., Protection of dentate hilar cells from prolonged stimulation by intracellular calcium chelation (1989) Science, 246 (4927), pp. 257-260; Schwaller, B., Cytosolic Ca2+ buffers (2010) Cold Spring Harb.Perspect. Biol, 2 (11), p. 004051; Selkoe, D.J., Alzheimer disease, mechanistic understanding predicts novel therapies (2004) Ann. Intern. Med., 140, pp. 627-638; Sik, A., Hajos, N., Gulacsi, A., Mody, I., Freund, T.F., The absence of a major Ca2. Signaling pathway in GABAergic neurons of the hippocampus (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 3245-3250; Silva, A.J., Paylor, R., Wehner, J.M., Tonegawa, S., Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice (1992) Science, 257, pp. 206-211; Silva, A.J., Stevens, C.F., Tonegawa, S., Wang, Y., Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice (1992) Science, 257, pp. 201-206; Silva, A.J., Wang, Y., Paylor, R., Wehner, J.M., Stevens, C.F., Tonegawa, S., Alpha calcium/calmodulin kinase II mutant mice, deficient long-term potentiation and impaired spatial learning (1992) Cold Spring Harb. Symp. Quant. Biol., 57, pp. 527-539; Song, D., Xie, X., Wang, Z., Berger, T.W., Differential effect of TEA on long-term synaptic modification in hippocampal CA1 and dentate gyrus in vitro (2001) Neurobiol. Learn Mem., 76, pp. 375-387; Srivareerat, M., Tran, T.T., Alzoubi, K.H., Alkadhi, K.A., Chronic psychosocial stress exacerbates impairment of cognition and long-term potentiation in beta-amyloid rat model of Alzheimers disease (2009) Biol. Psychiat., 65, pp. 918-926; Stabel, J., Ficker, E., Heinemann, U., Young CA1 pyramidal cells of rats, but not dentate gyrus granule cells, express a delayed inward rectifying current with properties of IQ (1992) Neurosci. Lett., 135, pp. 231-234; Stanton, P.K., Gage, A.T., Distinct synaptic loci of Ca2+/calmodulindependent protein kinase II necessary for long-term potentiation and depression (1996) J. Neurophysiol., 76, pp. 2097-2101; Steiner, J.P., Dawson, T.M., Fotuhi, M., Glatt, C.E., Snowman, A.M., Cohen, N., Snyder, S.H., High brain densities of the immunophilin FKBP colocalized with calcineurin (1992) Nature, 358, pp. 584-587; Tanzi, R.E., Bertram, L., Twenty years of the Alzheimers disease amyloid hypothesis, a genetic perspective (2005) Cell, 120, pp. 545-555; Thiels, E., Kanterewicz, B.I., Knapp, L.T., Barrionuevo, G., Klann, E., Protein phosphatase-mediated regulation of protein kinase C during long-term depression in the adult hippocampus in vivo (2000) J. Neurosci., 20, pp. 7199-7207; Tran, T.T., Srivareerat, M., Alhaider, I.A., Alkadhi, K.A., Chronic psychosocial stress enhances long-term depression in a subthreshold amyloid-beta rat model of Alzheimers disease (2011) J. Neurochem., 119, pp. 408-416; Tran, T.T., Srivareerat, M., Alkadhi, K.A., Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimers disease (2010) Neurobiol. Dis., 37, pp. 756-763; Tran, T.T., Srivareerat, M., Alkadhi, K.A., Chronic psychosocial stress accelerates impairment of long-term memory and late-phase long-term potentiation in an at-risk model of Alzheimers disease (2011) Hippocampus, 21, pp. 724-732; Tsatali, M., Papaliagkas, V., Damigos, D., Mavreas, V., Gouva, M., Tsolaki, M., Depression and anxiety levels increase chronic musculoskeletal pain in patients with Alzheimers disease (2014) Curr. Alzheimer Res., 11 (6), pp. 574-579; Vouimba, R.M., Muñoz, C., Diamond, D.M., Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala (2006) Stress, 9, pp. 29-40; Vouimba, R.M., Richter-Levin, G., Different patterns of amygdala priming differentially affect dentate gyrus plasticity and corticosterone, but not CA1 plasticity (2013) Front Neural Circuits, 7, p. 80; Walker, E., Mittal, V., Tessner, K., Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia (2008) Annu. Rev. Clin. Psychol., 4, pp. 189-216; Wang, J.H., Kelly, P.T., Attenuation of paired-pulse facilitation associated with synaptic potentiation mediated by postsynaptic mechanisms (1997) J. Neurophysiol., 78, pp. 2707-2716; Westerink, R.H., Beekwilder, J.P., Wadman, W.J., Differential alterations of synaptic plasticity in dentate gyrus and CA1 hippocampal area of Calbindin-D28K knockout mice (2012) Brain Res., 1450, pp. 1-10; Whitworth, J.A., Mangos, G.J., Kelly, J.J., Cushing, cortisol, and cardiovascular disease (2000) Hypertension, 36, pp. 912-916; Wikstrom, M.A., Matthews, P., Roberts, D., Collingridge, G.L., Bortolotto, Z.A., Parallel kinase cascades are involved in the induction of LTP at hippocampal CA1 synapses (2003) Neuropharmacology, 45, pp. 828-836; Williamson, J., Goldman, J., Marder, K.S., Genetic aspects of Alzheimer disease (2009) Neurologist, 15, pp. 80-86; Winder, D.G., Mansuy, I.M., Osman, M., Moallem, T.M., Kandel, E.R., Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin (1998) Cell, 92, pp. 25-37; Xiong, Z.Q., Stringer, J.L., Extracellular pH responses in CA1 and the dentate gyrus during electrical stimulation, seizure discharges, and spreading depression (2000) J. Neurophysiol., 83, pp. 3519-3524; Xu, L., Holscher, C., Anwyl, R., Rowan, M.J., Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 3204-3208; Yamada, K., McEwen, B.S., Pavlides, C., Site and time dependent effects of acute stress on hippocampal long-term potentiation in freely behaving rats (2003) Exp. Brain Res., 152, pp. 52-59; Yao, H., Huang, Y.H., Liu, Z.W., Wan, Q., Ding, A.S., Zhao, B., Fan, M., Wang, F.Z., The different responses to anoxia in cultured CA1 and DG neurons from newborn rats (1998) Sheng Li Xue Bao, 50, pp. 61-66; Zagaar, M., Alhaider, I., Dao, A., Levine, A., Alkarawi, A., Alzubaidy, M., Alkadhi, K., The beneficial effects of regular exercise on cognition in REM sleep deprivation, behavioral, electrophysiological and molecular evidence (2012) Neurobiol. Dis., 45, pp. 1153-1162; Zagaar, M., Dao, A., Levine, A., Alhaider, I., Alkadhi, K., Regular exercise prevents sleep deprivation associated impairment of long-term memory and synaptic plasticity in the CA1 area of the hippocampus (2013) Sleep, 36, pp. 751-761",Article,Scopus,2-s2.0-84909989276
"Vasange M.","Assay suitability for natural product screening: Searching for leads to fight alzheimers disease",2014,"Planta Medica","80","14",,"1200","1209",,,10.1055/s-0034-1383063,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84928610509&partnerID=40&md5=e85f471d73f60715f972a0441cc8f72c","Department of Biosciences, Pharmaceutical Sciences, Åbo Akademi University, Biocity Artillerigatan 6Turku, Finland","Vasänge, M., Department of Biosciences, Pharmaceutical Sciences, Åbo Akademi University, Biocity Artillerigatan 6Turku, Finland","Phenotypic and target-based approaches represent two principal strategies for identifying new bioactive compounds. In this review, differences between these approaches, as well as strengths and limitations thereof, are described by examples from the therapeutic area of Alzheimers disease. Some of the central mechanisms of the disease that today are targets of screening campaigns are described. These mechanisms include acetylcholinesterase inhibition, amyloid-based approaches, and oxidative stress. Examples of assays using natural products, either as isolated pure compounds, unpurified or partially purified extracts, are given for each mechanism. Further, the article presents and discusses the pros and cons of both target-based and phenotypic approaches for the chosen mechanisms. In most cases, a thoroughly biology-driven selection of the used assays can be recommended, especially when taking into account the complexity of the disease in question. However, target-based assays also have their justification as long as there is an awareness of what the assay read-out stands for. A clear recommendation is thus for every researcher to critically consider the aim of their bioactivity screening efforts and to adopt the screening strategies most appropriate for the goals set.","acetylcholinesterase; Alzheimers disease; amyloid; oxidative stress; phenotypic assay; reductionistic; target-based assay","Swinney, D.C., Anthony, J., How were new medicines discovered (2011) Nat Rev Drug Discov, 10, pp. 507-519; Kell, D.B., Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: Where drug discovery went wrong and how to fix it (2013) FEBS J, 280, pp. 5957-5980; Hughes, J.P., Rees, S., Kalindjian, S.B., Philpott, K.L., Principles of early drug discovery (2011) Brit J Pharmacol, 162, pp. 1239-1249; Cragg, G.M., Newman, D.J., Natural products: A continuing source of novel drug leads (2013) Biochim Biophys Acta, 1830, pp. 3670-3695; Mishra, B.B., Tiwari, V.K., Natural products: An evolving role in future drug discovery (2011) Eur J Med Chem, 46, pp. 4769-4807; Barker, A., Kettle, J.G., Nowak, T., Pease, J.E., Expanding medicinal chemistry space (2013) Drug Discov Today, 18, pp. 298-304; López-Vallejo, F., Giulianotti, M.A., Houghten, R.A., Medina-Franco, J.L., Expanding the medicinally relevant chemical space with compound libraries (2012) Drug Discov Today, 17, pp. 718-726; Beutler, J.A., Natural products as a foundation for drug discovery (2009) Curr Protoc Pharmacol, 46, pp. 1-9; Schmitt, E.K., Moore, C.M., Krastel, P., Petersen, F., Natural products as catalysts for innovation: A pharmaceutical industry perspective (2011) Curr Opin Chem Biol, 15, pp. 497-504; Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Scazufca, M., Global prevalence of dementia: A Delphi consensus study (2005) Lancet, 366, pp. 2112-2117; Bendlin, B.B., Carlsson, C.M., Gleason, C.E., Johnson, S.C., Sodhi, A., Gallagher, C.L., Puglielli, L., Asthana, S., Midlife predictors of Alzheimers disease (2010) Maturitas, 65, pp. 131-137; Skape, S.D., Alzheimers disease and amyloid: Culprit or coincidence (2012) Int Rev Neurobiol, 102, pp. 277-316; Cummings, J.L., Banks, S.J., Gary, R.K., Kinney, J.W., Lombardo, J.M., Ryan, R., Walsh, R.R., Zhong, K., Alzheimers disease drug development: Translational neuroscience strategies (2013) CNS Spectr, 18, pp. 128-138; Misra, S., Bikash, B., Drug development status for Alzheimers disease: Present scenario (2013) Neurol Sci, 34, pp. 831-839; Hardy, J.A., Higgins, G.A., Alzheimers disease: The amyloid cascade hypothesis (1992) Science, 256, pp. 184-185; De Strooper, B., Vassar, R., Golde, T., The secretases: Enzymes with therapeutic potential in Alzheimer disease (2010) Nat Rev Neurol, 6, pp. 99-107; Masters, C.L., Selkoe, D.J., Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease (2012) Cold Spring Harb Perspect Med, 2, pp. 1-24; Krstic, D., Knuesel, I., Deciphering the mechanism underlying late-onset Alzheimer disease (2013) Nat Rev Neurol, 9, pp. 25-34; Anand, R., Gill, K.D., Mahdi, A.A., Therapeutics of Alzheimers disease: Past, present and future (2014) Neuropharmacol, 76, pp. 27-50; Davies, P., Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimers disease (1976) Lancet, 8000, p. 1403; Mufson, E.J., Counts, S.E., Perez, S.E., Ginsberg, S.D., Cholinergic system during the progressing of Alzheimers disease: Therapeutic implications (2008) Expert Rev Neurother, 8, pp. 1703-1718; Munoz-Torrero, D., Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimers disease (2008) Curr Med Chem, 15, pp. 2433-2455; Tayeb, H.O., Yang, H.D., Price, B.H., Tazari, F.I., Pharmacotherapies for Alzheimers disease: Beyond cholinesterase inhibitors (2012) Pharmacol Ther, 134, pp. 8-25; Sun, X., Jin, L., Ling, P., Review of drugs for Alzheimers disease (2012) Drug Discov Ther, 6, pp. 285-290; Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., Somogyi, M., A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimers disease (2013) Prim Care Companion CNS Disord, p. 15; Ellman, G.L., Courtney, K.D., Anders, V., Jr., Feather-Stone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity (1961) Biochem Pharmacol, 7, pp. 88-95; Järvinen, P., Vuorela, P., Hatakka, A., Fallarero, A., Potency determinations of acetylcholinesterase inhibitors using Ellmans reaction based assay in screening: Effect of assay variants (2011) Anal Biochem, 408, pp. 166-168; Marston, A., Kissling, J., Hostettmann, K., A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase inhibitors in plants (2002) Phytochem Anal, 13, pp. 51-54; Di Giovannia, S., Borlozb, A., Urbainb, A., Marston, A., Hostettmann, K., Carrupta, P.A., Reista, M., In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: Thin layer chromatography versus microplate methods (2008) Eur J Pharm Sci, 33, pp. 109-119; Karlsson, D., Fallarero, A., Brunhofer, G., Guzik, P., Prinz, M., Holzgrabe, U., Erker, T., Vuorela, P., Identifying and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fiblil formation (2012) Eur J Pharm Sci, 45, pp. 169-183; Ingkaninan, K., De Best, C.M., Van Der Heijden, R., Hofte, A.J., Karabatak, B., Irth, H., Tjaden, U.R., Verpoorte, R., High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products (2000) J Chromatog A, 872, pp. 61-73; Mukherjee, P.K., Kumar, V., Mal, M., Houghton, P.J., Acetylcholinesterase inhibitors from plants (2007) Phytomedicine, 14, pp. 289-300; Orhan, I., Sener, B., Choudhary, I.M., Khalid, A., Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants (2004) J Ethnopharmacol, 91, pp. 57-60; Andersen, A., Gauguin, B., Gudiksen, L., Jäger, A.K., Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity (2006) J Ethnopharmacol, 104, pp. 418-422; Ferreira, A., Proença, C., Serralheiro, M.L., Araujo, M.E., The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal (2006) J Ethnopharmacol, 108, pp. 31-37; Mukherjee, P.K., Kumar, V., Houghton, P.J., Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity (2007) Phytother Res, 21, pp. 1142-1145; Loizzo, M.R., Tundis, R., Conforti, F., Menichini, F., Bonesi, M., Nadjafi, F., Frega, N.G., Menchini, F., Salvia leriifolia Benth (Laminaceae) extract demonstrates antioxidant properties and cholinesterase inhibitory activity (2010) Nutr Res, 30, pp. 823-830; Khan, M., Elhussein, S.A., Khan, M.M., Khan, N., Anti-acetylcholinesterase activity of Piper sarmentosum by a continuous immobilized-enzyme assay (2012) APCBEE Procedia, 2, pp. 199-204; Cespedes, C.L., Muñoz, E., Salazar, J.R., Yamaguchi, L., Werner, E., Alarcon, J., Kubo, I., Inhibition of cholinesterase activity by extracts, fractions and compounds from Calceolaria talcana and C. Integrifolia (Calceolariaceae: Scrophulariaceae) (2013) Food Chem Toxicol, 62, pp. 919-926; Lai, D.H., Yang, Z.D., Xue, W.W., Sheng, J., Shi, Y., Yao, X.J., Isolation, characterization and acetylcholinesterase inhibitory activity of alkaloids from roots of Stemona sessilifolia (2013) Fitoterapia, 89, pp. 257-264; Dvira, H., Silmanb, I., Harela, M., Rosenberryc, T.L., Sussmana, J.L., Acetylcholinesterase: From 3D?structure to function (2010) Chem Biol Interact, 187, pp. 10-22; Ryšlavá, H., Doubnerová, V., Kavan, D., Vaněk, O., Effect of posttranslational modifications on enzyme function and assembly (2013) J Proteomics, 92, pp. 80-109; Massoulié, J., Perrier, N., Noureddine, H., Liang, D., Bon, S., Old and new questions about cholinesterases (2008) Chemical Biol Interact, 75, pp. 30-44; Ramachandran, S., Rami, B.R., Udgaonkar, J.B., Measurements of cysteine reactivity during protein unfolding suggest the presence of competing pathways (2000) J Mol Biol, 297, pp. 733-745; Sakurada, K., Ikegaya, H., Ohta, H., Akutsu, T., Takatori, T., Hydrolysis of an acetylthiocholine by pralidoxime iodide (2-PAM) (2006) Toxicol Lett, 166, pp. 255-260; Veloso, A.J., Nagy, P.M., Zhang, B., Dhar, D., Liang, A., Ibrahim, T., Mikhaylichenko, S., Kerman, K., Miniaturized electrochemical system for cholinesterase inhibitor detection (2013) Anal Chim Acta, 774, pp. 73-78; Min, W., Wang, W., Chen, J., Wang, A., Hu, Z., On-line immobilized acetylcholinesterase microreactor for screening of inhibitors from natural extracts by capillary electrophoresis (2012) Anal Bioanal Chem, 404, pp. 2397-2405; Yang, Z.D., Song, Z.W., Ren, J., Yang, M.J., Li, S., Improved thin-layer chromatography bioautographic assay for the detection of actylcholinesterase inhibitors in plants (2011) Phytochem Anal, 22, pp. 509-515; Mullane, K., Williams, M., Alzheimers therapeutics: Continued clinical failures question the validity of the amyloid hypothesis - But what lies beyond (2013) Biochem Pharmacol, 85, pp. 289-305; Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A.K., Zhang, X.C., Tang, J., Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor (2000) Science, 290, pp. 150-153; Wang, H., Li, R., Shen, Y., β-Secretase: Its biology as a therapeutic target in diseases (2013) TIPS, 34, pp. 215-225; Golde, T.E., Koo, E.H., Felsenstein, K.M., Osborne, B.A., Miele, L., γ-Secretase inhibitors and modulators (2013) Biochim Biophys Acta, 1828, pp. 2898-2907; Jeon, S.Y., Kwon, S.H., Seong, Y.H., Bae, K., Hur, J.M., Lee, Y.Y., Suh, D.Y., Song, K.S., β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma (2007) Phytomedicine, 14, pp. 403-408; Sasaki, H., Miki, K., Kinoshita, K., Koyama, K., Juliawaty, L.D., Achmad, S.A., Hakim, E.H., Takahashi, K., β-secretase (BACE-1) inhibitory effect of bioflavonoids (2010) Bioorg Med Chem Lett, 20, pp. 4558-4560; Zhu, Z., Li, C., Wang, X., Yang, Z., Chen, J., Hu, L., Jiang, H., Shen, X., 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice (2010) J Neurochem, 114, pp. 374-385; Tao, J., Zhao, J., Zhao, Y., Cui, Y., Fang, W., BACE inhibitory flavanones from Balanophora involucrata Hook (2012) Fitoterapia, 83, pp. 1386-1390; Hwang, E.M., Ryu, Y.B., Kim, H.Y., Kim, D.G., Hong, S.G., Lee, J.H., Curtis-Long, M.J., Park, J.Y., BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens (2008) Bioorg Med Chem, 16, pp. 6669-6674; Vassar, R., Kovacs, D.M., Yan, R., Wong, P.C., The β-Secretase enzyme BACE in health and Alzheimers disease: Regulation, cell biology, function, and therapeutic potential (2009) J Neurosci, 29, pp. 12787-12794; Small, S.A., Gandy, S., Sorting through the cell biology of Alzheimers disease: Intracellular pathways to pathogenesis (2006) Neuron, 52, pp. 15-31; Axelman, K., Basun, H., Winblad, B., Lannfelt, L., A large Swedish family with Alzheimers disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation (1994) Arch Neurol, 51, pp. 1193-1197; Zhu, F., Wu, F., Ma, Y., Liu, G., Li, Z., Sun, Y., Pei, Z., Decrease in the production of beta-amyloid by berberine inhibition of the expression of betasecretase in HEK293 cells (2011) BMC Neuroscience, p. 12; Kang, I.J., Jeon, Y.E., Yin, X.F., Nam, J.S., You, S.G., Hong, M.S., Jang, B.G., Kim, M.J., Butanol extract of Ecklonia cava prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death (2011) Food Chem Toxicol, 49, pp. 2252-2259; Cecchi, C., Stefani, M., The amyloid-cell membrane system. the interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity (2013) Biophys Chem, 182, pp. 30-43; Vepsäläinen, S., Koivisto, H., Pekkarinen, E., Mäkinen, P., Dobson, G., McDougall, G.J., Stewart, D., Hiltunen, M., Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimers disease (2013) J Nutr Biochem, 24, pp. 360-370; Hage, S., Kleinlen-Campard, P., Octave, J.N., Quetin-Leclerq, J., In vitro screening on β-amyloid peptide production of plants used in traditional medicine for cognitive disorders (2010) J Ethnopharmacol, 131, pp. 585-591; Lee, T.H., Part, Y.I., Han, Y.H., Effect of mycelial extract of Clavicorona pyxidata on the production of amyloid β-peptide and the inhibition of endogenous β-secretase activity (2006) J Microbiol, 44, pp. 665-670; Findeis, M.A., Schroeder, F., McKee, T.D., Yager, D., Fraering, P.C., Creaser, S.P., Austin, W.F., Eckman, C.B., Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa (2012) ACS Chem Neurosci, 21, pp. 941-951; Hall, A., Patel, T.R., γ-Secretase modulators: Current status and future directions (2014) Prog Med Chem, 53, pp. 101-145; Liu, L.F., Durairajan, S.S., Lu, J.H., Koo, I., Li, M., In vitro screening on amyloid precursor protein modulation of plants used in ayurvedic and traditional Chinese medicine for memory improvement (2012) J Ethnopharmacol, 141, pp. 754-760; Bignante, E.A., Heredia, F., Morfini, G., Lorenzo, A., Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimers disease (2013) Neurobiol Aging, 34, pp. 2525-2537; Haugabook, S.J., Yager, D.M., Eckman, E.A., Golde, T.E., Younkin, S.G., Eckman, C.B., High throughput screens for the identification of compounds that alter the accumulation of the Alzheimers amyloid peptide (Aβ) (2001) J Neurosci Meth, 108, pp. 171-179; Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features (2008) Biochim Biophys Acta, 1780, pp. 819-825; Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., Alzheimers disease: Clinical trials and drug development (2010) Lancet Neurol, 9, pp. 702-716; Dumont, M., Flint Beal, M., Neuroprotective strategies involving ROS in Alzheimer disease (2011) Free Radical Biology Medicine, 51, pp. 1014-1026; Sutherland, G.T., Chami, B., Youssef, P., Witting, P.K., Oxidative stress in Alzheimers disease: Primary villain or physiological by-product (2013) Redox Report, 18, pp. 134-141; López-Alarcón, C., Denicola, A., Evaluating the antioxidant capacity of natural products: A review on chemical and cellular based assays (2013) Anal Chim Acta, 763, pp. 1-10; Magalhães, L.M., Segundo, M.A., Reis, S., Lima, J.L., Methodological aspects about in vitro evaluation of antioxidant properties (2008) Anal Chim Acta, 613, pp. 1-19; Niki, E., Assessment of antioxidant capacity in vitro and in vivo (2010) Free Radical Biol Med, 49, pp. 503-515; Kamdem, J.P., Adeniran, A., Boligon, A.A., Klimaczewski, C.V., Elekofehinti, O.O., Hassan, W., Ibrahim, M., Athayde, M.L., Antioxidant activity, genotoxicity and cytotoxicity evaluation of lemon balm (Melissa officinalis L.) ethanolic extract: Its potential role in neuroprotection (2013) Ind Crops Prod, 51, pp. 26-34; Venkatachalam, R.N., Singh, K., Marar, T., Phytochemical screening and in vitro antioxidant activity of Psidium guaja (2012) Free Rad Antiox, 2, pp. 31-36; Arruda, M., Viana, H., Rainha, N., Neng, N.R., Rosa, J.S., Nogueira, J.M., Do Carmo Barreto, M., Anti-acetylcholinesterase and antioxidant activity of essential oils from Hedychium gardnerianum Sheppard ex Ker-Gawl (2012) Molecules, 17, pp. 3082-3092; Orhan, I.E., Suntar, I.P., Akkol, E.K., In vitro neuroprotective effects of the leaf and fruit extracts of Juglans regia L. (walnut) through enzymes linked to Alzheimers disease and antioxidant activity (2011) Int J Food Sci Nutr, 62, pp. 781-786; Wong, D.Z., Kadir, H.A., Ling, S.K., Bio-assay guided isolation of neuroprotective compounds from Loranthus parasiticus against H<inf>2</inf>O<inf>2</inf>-induced oxidative damage in NG108-15 cells (2012) J Ethnopharmacol, 139, pp. 256-264; Zhao, Y., Dou, J., Wu, T., Aisa, H.A., Investigating the antioxidant and acetylcholinesterase inhibition activities of Gossypium herbaceam (2013) Molecules, 18, pp. 951-962; Xiao, Z., Huang, C., Wu, J., Sun, L., Hao, W., Leung, L.K., Huang, J., The neuroprotective effects of ipriflavone against H<inf>2</inf>O<inf>2</inf> and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells (2013) Eur J Pharmacol, 721, pp. 286-293; Custódio, L., Patarra, J., Alberício, F., Neng, N.R., Nogueira, J.M., Romano, A., Extracts from Quercus sp. Acorns exhibit in vitro neuroprotective features through inhibition of cholinesterase and protection of the human dopaminergic cell line SH-SY5Y from hydrogen peroxide-induced cytotoxicity (2013) Ind Corps Prod, 45, pp. 114-120; Ha, S.K., Moon, E., Ju, M.S., Kim, D.H., Ryu, J.H., Oh, M.S., Kim, S.Y., 6-shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection (2012) Neuropharmacol, 63, pp. 211-223; Figuera-Losasa, M., Rojas, C., Slusher, B.S., Inhibition of microglia activation as a phenotypic assay in early drug discovery (2014) JBS, 19, pp. 17-31; Masters, C.L., Simms, G., Weinman, N.A., Multhaupt, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome (1985) Proc Natl Acad Sci, 83, pp. 4245-4249; Hardy, J., Framing β-amyloid (1992) Nat Gen, 1, pp. 233-234; Imtiaz, B., Tolppanen, A.M., Kivipelto, M., Soininen, H., Future directions in Alzheimers disease from risk factors to prevention (2014) Biochem Pharmacol, 88, pp. 661-670; Macarrón, R., Hertzberg, R.P., Design and implementation of high throughput screening assays (2011) Mol Biotechnol, 47, pp. 270-285; Lee, J.A., Uhlik, M.T., Moxham, C.M., Tomandl, D., Sall, D.L., Modern phenotypic drug discovery is a viable, neoclassic strategy (2012) J Med Chem, 55, pp. 4527-4538; Butera, J., Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents (2013) J Med Chem, 56, pp. 7715-7718; Swinney, D.C., The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines (2013) J Biomol Screen, 18, pp. 1186-1192; Lee, L.A., Berg, E.L., Neoclassic drug discovery: The case for lead generation using phenotypic and functional approaches (2013) J Biomol Screen, 18, pp. 1145-1155; Winquist, R.J., Mullane, K., Williams, M., The fall and rise of pharmacology - (Re)defining the discipline (2014) Biochem Pharmacol, 87, pp. 4-24",Review,Scopus,2-s2.0-84928610509
"Oeckl P., Steinacker P., Von Arnim C.A.F., Straub S., Nagl M., Feneberg E., Weishaupt J.H., Ludolph A.C., Otto M.","Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in alzheimers disease and frontotemporal lobar degeneration",2014,"Journal of Proteome Research","13","11",,"4518","4525",,1,10.1021/pr5006058,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908888835&partnerID=40&md5=884b89d53a079cb2a28d83fe3b4a3836","Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany","Oeckl, P., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Steinacker, P., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Von Arnim, C.A.F., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Straub, S., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Nagl, M., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Feneberg, E., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Weishaupt, J.H., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Ludolph, A.C., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany; Otto, M., Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45Ulm, Germany","The impairment of the ubiquitin-proteasome system (UPS) is thought to be an early event in neurodegeneration, and monitoring UPS alterations might serve as a disease biomarker. Our aim was to establish an alternate method to antibody-based assays for the selective measurement of free monoubiquitin in cerebrospinal fluid (CSF). Free monoubiquitin was measured with liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MS/MS) in CSF of patients with Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), behavioral variant of frontotemporal dementia (bvFTD), Creutzfeldt-Jakob disease (CJD), Parkinsons disease (PD), primary progressive aphasia (PPA), and progressive supranuclear palsy (PSP). The LC-MS/MS method showed excellent intra-and interassay precision (4.4-7.4% and 4.9-10.3%) and accuracy (100-107% and 100-106%). CSF ubiquitin concentration was increased compared with that of controls (33.0 ± 9.7 ng/mL) in AD (47.5 ± 13.1 ng/mL, p < 0.05) and CJD patients (171.5 ± 103.5 ng/mL, p < 0.001) but not in other neurodegenerative diseases. Receiver operating characteristic curve (ROC) analysis of AD vs control patients revealed an area under the curve (AUC) of 0.832, and the specificity and sensitivity were 75 and 75%, respectively. ROC analysis of AD and FTLD patients yielded an AUC of 0.776, and the specificity and sensitivity were 53 and 100%, respectively. In conclusion, our LC-MS/MS method may facilitate ubiquitin determination to a broader community and might help to discriminate AD, CJD, and FTLD patients. © 2014 American Chemical Society.","Alzheimers disease; amyotrophic lateral sclerosis; biomarker; cerebrospinal fluid; Creutzfeldt-Jakob disease; frontotemporal lobar degeneration; mass spectrometry; MRM; Parkinsons disease; Ubiquitin","Kimura, Y., Tanaka, K., Regulatory mechanisms involved in the control of ubiquitin homeostasis (2010) J. Biochem., 147, pp. 793-798; Mukhopadhyay, D., Riezman, H., Proteasome-independent functions of ubiquitin in endocytosis and signaling (2007) Science, 315, pp. 201-205; Hegde, A.N., Upadhya, S.C., Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease (2011) Biochim. Biophys. Acta, 1809, pp. 128-140; Wang, G.P., Iqbal, K., Bucht, G., Winblad, B., Wisniewski, H.M., Grundke-Iqbal, I., Alzheimers disease: Paired helical filament immunoreactivity in cerebrospinal fluid (1991) Acta Neuropathol., 82, pp. 6-12; Kudo, T., Iqbal, K., Ravid, R., Swaab, D.F., Grundke-Iqbal, I., Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels (1994) Brain Res., 639, pp. 1-7; Blennow, K., Davidsson, P., Wallin, A., Gottfries, C.G., Svennerholm, L., Ubiquitin in cerebrospinal fluid in Alzheimers disease and vascular dementia (1994) Int. Psychogeriatr., 6, pp. 13-22; Steinacker, P., Rist, W., Swiatek-De-Lange, M., Lehnert, S., Jesse, S., Pabst, A., Tumani, H., Kretzschmar, H.A., Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease (2010) Proteomics, 10, pp. 81-89; Constantinescu, R., Andreasson, U., Li, S., Podust, V.N., Mattsson, N., Anckarsäter, R., Anckarsäter, H., Blennow, K., Proteomic profiling of cerebrospinal fluid in parkinsonian disorders (2010) Parkinsonism Relat. Disord., 16, pp. 545-549; Iqbal, K., Flory, M., Khatoon, S., Soininen, H., Pirttila, T., Lehtovirta, M., Alafuzoff, I., Vanmechelen, E., Subgroups of Alzheimers disease based on cerebrospinal fluid molecular markers (2005) Ann. Neurol., 58, pp. 748-757; Kandimalla, R.J., Bk, B., Wani, W.Y., Sharma, D.R., Grover, V.K., Bhardwaj, N., Jain, K., Gill, K.D., Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimers disease patients (2011) Neurosci. Lett., 487, pp. 134-138; Manaka, H., Kato, T., Kurita, K., Katagiri, T., Shikama, Y., Kujirai, K., Kawanami, T., Sasaki, H., Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease (1992) Neurosci. Lett., 139, pp. 47-49; Skoog, I., Vanmechelen, E., Andreasson, L.A., Palmertz, B., Davidsson, P., Hesse, C., Blennow, K., A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele (1995) Neurodegeneration, 4, pp. 433-442; Jesse, S., Brettschneider, J., Süssmuth, S.D., Landwehrmeyer, B.G., Von Arnim, C.A.F., Ludolph, A.C., Tumani, H., Otto, M., Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases (2011) J. Neurol., 258, pp. 1034-1041; Pradat, P.-F., Bruneteau, G., Clinical characteristics of amyotrophic lateral sclerosis subsets (2006) Rev. Neurol. (Paris)., 162, pp. 4S29-4S33; McKeith, I.G., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop (2006) J. Alzheimers Dis., 9, pp. 417-423; Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., Van Swieten, J.C., Onyike, C.U., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011) Brain, 134, pp. 2456-2477; Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Ogar, J.M., Boeve, B.F., Classification of primary progressive aphasia and its variants (2011) Neurology, 76, pp. 1006-1014; (1998) Consensus on Criteria for Sporadic CJD, , World Health Organization: Geneva, Switzerland; Hahne, H., Pachl, F., Ruprecht, B., Maier, S.K., Klaeger, S., Helm, D., Médard, G., Kuster, B., DMSO enhances electrospray response, boosting sensitivity of proteomic experiments (2013) Nat. Methods, 10, pp. 989-991; Majetschak, M., King, D.R., Krehmeier, U., Busby, L.T., Thome, C., Vajkoczy, S., Proctor, K.G., Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: Clinical and experimental findings (2005) Crit. Care Med., 33, pp. 1589-1594; Ohe, Y., Ishikawa, K., Itoh, Z., Tatemoto, K., Cultured leptomeningeal cells secrete cerebrospinal fluid proteins (1996) J. Neurochem., 67, pp. 964-971; Sandoval, J.A., Hoelz, D.J., Woodruff, H.A., Powell, R.L., Jay, C.L., Grosfeld, J.L., Hickeyd, R.J., Malkas, L.H., Novel peptides secreted from human neuroblastoma: Useful clinical tools? (2006) J. Pediatr. Surg., 41, pp. 245-251; Majetschak, M., Extracellular ubiquitin: Immune modulator and endogenous opponent of damage-associated molecular pattern molecules (2011) J. Leukocyte Biol., 89, pp. 205-219; Reiber, H., Peter, J.B., Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs (2001) J. Neurol. Sci., 184, pp. 101-122; Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (2010) Nat. Rev. Neurol., 6, pp. 131-144; Rosen, K.M., Moussa, C.E.-H., Lee, H.-K., Kumar, P., Kitada, T., Qin, G., Fu, Q., Querfurth, H.W., Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function (2010) J. Neurosci. Res., 88, pp. 167-178; Choi, J., Levey, A.I., Weintraub, S.T., Rees, H.D., Gearing, M., Chin, L.-S., Li, L., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinsons and Alzheimers diseases (2004) J. Biol. Chem., 279, pp. 13256-13264; Rabinovici, G.D., Miller, B.L., Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management (2010) CNS Drugs, 24, pp. 375-398",Article,Scopus,2-s2.0-84908888835
"Fernandez G., Laubrock J., Mandolesi P., Colombo O., Agamennoni O.","Registering eye movements during reading in Alzheimers disease: Difficulties in predicting upcoming words",2014,"Journal of Clinical and Experimental Neuropsychology","36","3",,"302","316",,2,10.1080/13803395.2014.892060,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84899439108&partnerID=40&md5=2b3695391a0c53664c742a4be8601f71","Agencia Nacional de Promoción Científica y Técnica, Instituto de Investigaciones en Ingeniería Eléctrica, Universidad Nacional Del sur, Alem 1253, Bahía Blanca 8000, Argentina; Department of Psychology, University of Potsdam, Potsdam, Germany; Departamento de Ingeniería Eléctrica y de Computadoras, Instituto de Investigaciones en Ingeniería Eléctrica, Universidad Nacional Del sur, Bahía Blanca, Argentina; Departamento de Neurología, Hospital Municipal de Agudos de Bahía Blanca, Bahía Blanca, Argentina","Fernández, G., Agencia Nacional de Promoción Científica y Técnica, Instituto de Investigaciones en Ingeniería Eléctrica, Universidad Nacional Del sur, Alem 1253, Bahía Blanca 8000, Argentina; Laubrock, J., Department of Psychology, University of Potsdam, Potsdam, Germany; Mandolesi, P., Departamento de Ingeniería Eléctrica y de Computadoras, Instituto de Investigaciones en Ingeniería Eléctrica, Universidad Nacional Del sur, Bahía Blanca, Argentina; Colombo, O., Departamento de Neurología, Hospital Municipal de Agudos de Bahía Blanca, Bahía Blanca, Argentina; Agamennoni, O., Departamento de Ingeniería Eléctrica y de Computadoras, Instituto de Investigaciones en Ingeniería Eléctrica, Universidad Nacional Del sur, Bahía Blanca, Argentina","Reading requires the fine integration of attention, ocular movements, word identification, and language comprehension, among other cognitive parameters. Several of the associated cognitive processes such as working memory and semantic memory are known to be impaired by Alzheimers disease (AD). This study analyzes eye movement behavior of 18 patients with probable AD and 40 age-matched controls during Spanish sentence reading. Controls focused mainly on word properties and considered syntactic and semantic structures. At the same time, controls knowledge and prediction about sentence meaning and grammatical structure are quite evident when we consider some aspects of visual exploration, such as word skipping, and forward saccades. By contrast, in the AD group, the predictability effect of the upcoming word was absent, visual exploration was less focused, fixations were much longer, and outgoing saccade amplitudes were smaller than those in controls. The altered visual exploration and the absence of a contextual predictability effect might be related to impairments in working memory and long-term memory retrieval functions. These eye movement measures demonstrate considerable sensitivity with respect to evaluating cognitive processes in Alzheimers disease. They could provide a user-friendly marker of early disease symptoms and of its posterior progression. © 2014 Taylor and Francis.","Alzheimer's disease; Eye movements; Fixation duration; Reading; Word predictability","(1994) Diagnosticand Statistical Manual of Mental Disorders, , American Psychiatric Association (4th ed. Washington, DC: Author; Arnáiz, E., Almkvist, O., Neuropsychologicalfeatures of mild cognitive impairment and preclinicalAlzheimer's disease (2003) Acta Neurologica ScandinavicaSupplementum, 179, pp. 34-41; Bäckman, L., Jones, S., Berger, A., Laukka, E., Small, B., Multiple cognitive deficits duringthe transition to Alzheimer's disease (2005) Journal OfInternal Medicine, 256 (3), pp. 195-204; Ball, K., Beard, B., Roenker, D., Miller, R., Griggs, D., Age and visual search: Expanding theuseful field of view (1998) Journal of the Optical Society OfAmerica, 5, pp. 2210-2219; Bates, D., Maechler, M., (2013) Lme4: Linearmixed-effectmodels Using S4 Classes (R Package Version 0.9999990)[Computer Software], , http://CRAN, Retrieved from; Hale, J., Vasishth, S., Kliegl, R., Parallelism and syntactic processes in reading difficulty (2011) Language and Cognitive Processes, 26, pp. 301-341; Braskie, M., Klunder, A., Hayashi, K., Kepev, P.H., Miller, K., Thompson, P., Plaque andtangle imaging and cognition in normal aging andAlzheimer's disease (2010) Neurobiology of Aging, 31 (10), pp. 1669-1678; Cohen, J., Cohen, P., (1975) Applied Multiple Regressionand Correlation Analysis for the Behavioral Sciences, , Hillsdale, NJ: Lawrence Erlbaum Associates; Cummings, J., Houlihan, J., Hill, M., Thepattern or reading deterioration in dementia of theAlzheimer's type: Observations and implications (1986) Brain and Language, 29, pp. 315-323; Daffne, K., Scinto, L., Weintraub, S., Guinessey, J., Mesulam, M., Diminished curiosity in patientswith Alzheimer's disease as measured by exploratoryeye movements (1992) Neurology, 42, pp. 320-328; Dambacher, M., Kliegl, R., Hofmann, M., Jacobs, A.M., Frequency and predictability effects on eventrelatedpotentials during reading (2006) Brain Research, 1084, pp. 89-103. , http://dx.doi.org/10.1016/j.bbr.2011.03.031; Drieghe, D., Brysbaert, M., Desmet, T., Parafoveal-on-foveal effects on eye movements intext reading: Does an extra space make a difference? (2005) Vision Research, 45, pp. 1693-1706; Fernández, G., Shalom, D., Kliegl, R., Sigman, M., Eye movements during reading proverbs andregular sentences: The incoming word predictabilityeffect (2013) Language and Cognitive Processes, 29, pp. 260-273. , doi:10.1080/01690065.2012.760745; Filoteo, J., Delis, D., Massman, Buttersn, P.T., Salmon, D., Directed and divided attentionin Alzheimer's disease: Impairment in shifting ofattention to global and local stimuli (1992) Journal of Clinicaland Experimental Neuropsychology, 14, pp. 871-883; Folstein, M., Folstein, S., McHugh, P., Minimentalstate"". A practical method for grading thecognitive state of patients for the clinician (1975) Journalof Psychiatric Research, 12, pp. 189-198; Förstl, H., Kurz, A., Clinical features ofAlzheimer's disease (1999) European Archives of Psychiatryand Clinical Neuroscience, 249 (6), pp. 288-290; Frank, E., Effect of Alzheimer's disease on communicationfunction (1994) Journal of the South CarolinaMedical Association, 90 (9), pp. 417-423; Hampel, H., Bürger, K., Teipel, S., Bokde, A., Zetterberg, H., Blennow, K., Core candidate neurochemicaland imaging biomarkers of Alzheimer's disease (2008) Alzheimer's & Dementia, 4 (1), pp. 38-48; Hardy, J., Allsop, D., Amyloid deposition asthe central event in the etiology of Alzheimer's disease (1991) Trends in Pharmacological Sciences, 12 (10), pp. 383-388; Hayhoe, M., Ballard, D., Eye movements innatural behavior (2005) Trends in Cognitive Sciences, 9 (4), pp. 188-193; Hoffman, J., Visual attention and eye movements (1998) Attention, pp. 119-154. , H. Pashler (Ed.) Hove: Psychology Press; Hogson, T., Bajwa, A., Owen, A., Kennard, C., The strategic control of gaze direction in theTower-of-London task (2000) Journal of CognitiveNeurosciences, 12, pp. 894-907; Hogson, T., Tiesman, B., Owen, A., Kennard, C., Abnormal gaze strategies during problem solvingin Parkinson's disease (2002) Neuropsychologia, 40, pp. 441-422; Itoh, N., Fukuda, T., Comparative study of eyemovement in extent of central and peripheral visionand use by young and elderly walkers (2002) PerceptualMotor Skills, 94 (3 PART. 2), pp. 1283-1291; Just, M., Carpenter, P., A theory of reading:From eye fixations to comprehension (1980) PsychologicalReview, 87 (4), pp. 329-354; Kennedy, A., The influence of parafoveal wordson foveal inspection time: Evidence for a processingtrade-off (1998) Eye Guidance Inreading and Scene Perception, pp. 149-179. , G. Underwood (Ed.) Oxford: Elsevier; Kennedy, A., Pynte, J., Parafoveal-on-fovealeffects in normal reading (2005) Vision Research, 45 (2), pp. 153-168; Kennedy, A., Pynte, J., Murray, W., Paul, S., Frequency and predictability effects in the Dundeecorpus (2012) Quarterly Journal of ExperimentalPsychology, 66 (3), pp. 601-618. , doi:10.1080/17470218.2012.676054; Kliegl, R., Nuthmann, A., Engbert, R., Trackingthe mind during reading: The influence of past, present,and future words on fixation durations (2006) Journal OfExperimental Psychology: General, 135 (1), pp. 12-35; Kuperman, V., Dambacher, M., Nuthmann, A., Kliegl, R., The effect of word position on eyemovements in sentence and paragraph reading (2010) Quarterly Journal of Experimental Psychology, 63 (9), pp. 1838-1857. , doi:10.1080/17470211003602412; Land, M., Mennie, N., Rusted, J., The roles ofvision and eye movements in control of activities ofdaily living (1999) Perception, 28, pp. 1311-1328; Landes, A., Sperry, S., Strauss, M., Geldmacher, D., Apathy in Alzheimer's disease (2001) Journal of TheAmerican Geriatric Society, 49 (12), pp. 1700-1707; Lee, H.G., Perry, G., Moreira, P., Garrett, M., Liu, Q., Zhu, X.W., Smith, M., Tau phosphorylationin Alzheimer's disease: Pathogen or protector? (2005) Trendsin Molecular Medicine, 11 (4), pp. 164-169; Lueck, K., Mendez, M., Perryman, M., Eye movementsabnormalities during reading in patients withAlzheimer disease (2000) Neuropsychiatry, Neuropsychology,and Behavioral Neurology, 13 (2), pp. 77-82; Miela, D., Lobel, E., Lehericy, S., Pierrot-Deseilligny, C., Berthoz, A., Cortical mechanisms of saccadicgeneration from execution to decision (2005) Annals NewYork Academy of Sciences, 1039, pp. 232-238; Moan, R., FMRI software accurately IDs preclinicalAlzheimer's disease (2009) Diagnostic Imaging, , http://www.diagnosticimaging.com/mri/mri-software-accurately-ids- preclinical-alzheimer%E2%80%99s-disease; Moser, A., Köompf, D., Olshinka, J., Eyemovements dysfunction in dementia of theAlzheimer type (1995) Dementia, 6, pp. 264-268; Mosimann, U., Felblinger, J., Ballinari, P., Hess, C., Müri, R., Visual exploration behavior duringclock reading in Alzheimer'sdisease (2004) Brain, 127, pp. 431-438; Mudher, A., Lovestone, S., Alzheimer's disease-Do tauists and baptists finally shake hands? (2002) Trendsin Neurosciences, 25 (1), pp. 22-26; Parasuraman, R., Greenwood, P., Alexander, G., Alzheimer's disease constricts the dynamicrange of spatial attention in visual search (2000) Neuropsychologia, 38, pp. 1126-1135; Posner, M., Orienting of attention (1980) QuarterlyJournal of Experimental Psychology, 32, pp. 3-25; Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H., Herms, J., Synapse formationand function is modulated by the amyloid precursorprotein (2006) Journal of Neurosciences, 26 (27), pp. 7212-7221; Prull, M., Gabrieli, J., Bunge, S., Age-relatedchanges in memory: A cognitive neuroscience perspective (2000) Thehandbook of Aging and Cognition, , F. I.M. Craik & T. A. Salthouse (Eds.) Mahwah, NJ: Lawrence Erlbaum Associates; R: A language andenvironment for statistical computing (2013) Vienna: RFoundation for Statistical Computing, , R Development Core Team; Rayner, K., Eye movements in reading and informationprocessing: 20 years of research (1998) Psychological Bulletin, 124 (3), pp. 372-422; Rayner, K., Eye movements in reading: Modelsand data (2009) Journal of Eye Movement Research, 2 (5), pp. 1-10; Rayner, K., Warren, T., Juhasz, B.J., Liversedge, S.P., The effect of plausibility on eye movementsin reading (2004) Journal of Experimental Psychology:Learning, Memory, and Cognition, 30, pp. 1290-1301; Rayner, K., Well, A.D., Effects of contextualconstraint on eye movements in reading:Afurther examination (1996) Psychonomic Bulletin & Review, 3, pp. 504-509; Rayner, K., White, S.J., Kambe, G., Miller, B., Liversedge, S.P., On the processing of meaningfrom parafoveal vision during eye fixations inreading (2003) Cognitive and Applied Aspects of Eye Movementresearch, pp. 213-234. , J. Hyöna, R. Radach, & H. Deubel(Eds.) Amsterdam: Elsevier; Rizzo, M., Anderson, S., Dawson, J., Myers, R., Ball, K., Visual attention impairments inAlzheimer's disease (2000) Neurology, 54, pp. 1954-1959; Rizzo, M., Anderson, S., Dawson, J., Nawrot, M., Vision and cognition in Alzheimer's disease (2000) Neuropsychologia, 38, pp. 1157-1169; Rösler, A., Mapstone, M., Hays, A., Mesulam, M., Rademaker, A., Gitelman, D., Weintraub, S., Alterations of visual search strategy inAlzheimer's disease and aging (2000) Neuropsychology, 14, pp. 398-408; Sebastián-Gallés, N., Martí, M., Cuetos, F., Carreiras, M., (1998) LEXESP: Léxico Informatizadodel Español [Lexicon Computerized in Spanish], , Barcelona: Ediciones de la Universidad de Barcelona; Slavin, M., Mattingley, J., Brandshaw, J., Storey, E., Local-global processing in Alzheimer'sdisease: An examination of interference, inhibitionand priming (2002) Neuropsychologia, 40, pp. 1173-1186; Taler, V., Phillips, N., Language performancein Alzheimer's disease and mild cognitive impairment:A comparative review (2008) Journal of Clinical AndExperimental Neuropsychology, 30 (5), pp. 501-511; Taylor, W., Cloze procedure: A new tool formeasuring read ability (1953) Journalism Quarterly, 30, pp. 415-433; Tiraboschi, P., Hansen, L., Thal, L., Corey-Bloom, J., The importance of neuritic plaques and tanglesto the development and evolution of AD (2004) Neurology, 62 (11), pp. 1984-1989; Ungerleider, L., Haxby, J., What"" and""where in the human brain. [Review] (1994) CurrentOpinion Neurobiology, 4, pp. 157-165; Van Broeck, B., Van Broeckhoven, C., Kumar-Singh, S., Current insights into molecular mechanisms ofAlzheimer disease and their implications for therapeuticapproaches (2007) Neurodegenerative Disease, 4 (5), pp. 349-365; Van Petten, C., Kutas, M., Interactions betweensentence context and word frequency in event-relatedbrain potentials (1990) Memory and Cognition, 18 (4), pp. 380-393; Vitu, F., Brysbaert, M., Lancelin, D., A test ofparafoveal-on-foveal effects with pairs of orthographicallyrelated words (2004) European Journal OfCognitive Psychology, 16, pp. 154-177; Waldemar, G., Recommendations for the diagnosisand management of Alzheimer's disease andother disorders associated with dementia: EFNSguideline (2007) European Journal of Neurology, 14 (1), pp. 1-26; Wenk, G., Neuropathologic changes in Alzheimer'sdisease (2003) Journal of Clinical Psychiatry, 64 (SUPPL. 9), pp. 7-10; Yarbus, A., (1967) Eye Movements and Vision, , NewYork, NY: Plenum",Article,Scopus,2-s2.0-84899439108
"Fargo K.","Alzheimer's Association Report: 2014 Alzheimers disease facts and figures",2014,"Alzheimer's and Dementia","10","2",,"e47","e92",,33,10.1016/j.jalz.2014.02.001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897481309&partnerID=40&md5=161e3a8e89f7e7f339bb85064ddb7c87",,"Fargo, K.","This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. It also examines the impact of AD on women compared with men. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million are age 65 years or older. By mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to grow by about 9 million. Today, someone in the country develops AD every 67 seconds. By 2050, one new case of AD is expected to develop every 33 seconds, or nearly a million new cases per year, and the total estimated prevalence is expected to be 13.8 million. In 2010, official death certificates recorded 83,494 deaths from AD, making AD the sixth leading cause of death in the United States and the fifth leading cause of death in Americans aged 65 years or older. Between 2000 and 2010, the proportion of deaths resulting from heart disease, stroke, and prostate cancer decreased 16%, 23%, and 8%, respectively, whereas the proportion resulting from AD increased 68%. The actual number of deaths to which AD contributes (or deaths with AD) is likely much larger than the number of deaths from AD recorded on death certificates. In 2014, an estimated 700,000 older Americans will die with AD, and many of them will die from complications caused by AD. In 2013, more than 15 million family members and other unpaid caregivers provided an estimated 17.7 billion hours of care to people with AD and other dementias, a contribution valued at more than $220 billion. Average per-person Medicare payments for services to beneficiaries aged 65 years and older with AD and other dementias are more than two and a half times as great as payments for all beneficiaries without these conditions, and Medicaid payments are 19 times as great. Total payments in 2014 for health care, long-term care, and hospice services for people aged 65 years and older with dementia are expected to be $214 billion. AD takes a stronger toll on women than men. More women than men develop the disease, and women are more likely than men to be informal caregivers for someone with AD or another dementia. As caregiving responsibilities become more time consuming and burdensome or extend for prolonged durations, women assume an even greater share of the caregiving burden. For every man who spends 21 to more than 60 hours per week as a caregiver, there are 2.1 women. For every man who lives with the care recipient and provides around-the-clock care, there are 2.5 women. In addition, for every man who has provided caregiving assistance for more than 5 years, there are 2.3 women. © 2014 The Alzheimers Association. All rights reserved.","Alzheimer's disease; Caregivers; Caregiving burden; Dementia; Diagnostic criteria; Family caregiver; Health-care costs; Health-care expenditures; Incidence; Long-term care costs; Medicaid spending; Medicare spending; Morbidity; Mortality; Prevalence; Spouse caregiver; Women caregivers","(2013) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association 5th edition American Psychiatric Publishing Arlington, Va; Viswanathan, A., Rocca, W.A., Tzourio, C., Vascular risk factors and dementia: How to move forward? (2009) Neurology, 72, pp. 368-374; Schneider, J.A., Arvanitakis, Z., Bang, W., Bennett, D.A., Mixed brain pathologies account for most dementia cases in community-dwelling older persons (2007) Neurology, 69, pp. 2197-2204; Schneider, J.A., Arvanitakis, Z., Leurgans, S.E., Bennett, D.A., The neuropathology of probable Alzheimer disease and mild cognitive impairment (2009) Ann Neurol, 66, pp. 200-208; Jellinger, K.A., Attems, J., Neuropathological evaluation of mixed dementia (2007) J Neurol Sci, 257, pp. 80-87; Jellinger, K.A., The enigma of mixed dementia (2007) Alzheimers Dement, 3, pp. 40-53; Clarfield, A.M., The decreasing prevalence of reversible dementias: An updated meta-analysis (2003) Arch Intern Med, 163, pp. 2219-2229; Fernando, M.S., Ince, P.G., Vascular pathologies and cognition in a population-based cohort of elderly people (2004) J Neurol Sci, 226, pp. 13-17. , MRC Cognitive Function and Ageing Neuropathology Study Group; Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study (2013) Lancet Neurol, 12, pp. 357-367; Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., Chen, K., Velez-Pardos, C., Jimenez-Del-Rio, M., Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study (2012) Lancet Neurol, 11, pp. 1048-1056; Jack, C.R., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease (2009) Brain, 132, pp. 1355-1365; Bekris, L.M., Yu, C.E., Bird, T.D., Tsuang, D.W., Genetics of Alzheimer disease (2010) J Geriatr Psychiatry Neurol, 23, pp. 213-227; Green, R.C., Cupples, L.A., Go, R., Benke, K.S., Edeki, T., Griffith, P.A., Risk of dementia among white and African American relatives of patients with Alzheimer disease (2002) JAMA, 287, pp. 329-336; Fratiglioni, L., Ahlbom, A., Viitanen, M., Winblad, B., Risk factors for late-onset Alzheimer's disease: A population-based, case-control study (1993) Ann Neurol, 33, pp. 258-266; Mayeux, R., Sano, M., Chen, J., Tatemichi, T., Stern, Y., Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders (1991) Arch Neurol, 48, pp. 269-273; Lautenschlager, N.T., Cupples, L.A., Rao, V.S., Auerbach, S.A., Becker, R., Burke, J., Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE Study: What is in store for the oldest old? (1996) Neurology, 46, pp. 641-650; (2011) Alzheimer's Disease Genetics: Fact Sheet, , Alzheimer's Disease Education and Referral Center National Institutes of Health Bethesda, Md Publication 11-6424; Raber, J., Huang, Y., Ashford, J.W., ApoE genotype accounts for the vast majority of AD risk and AD pathology (2004) Neurobiol Aging, 25, pp. 641-650; Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Association of apolipoprotein e allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease (1993) Neurology, 43, pp. 1467-1472; Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and Alzheimer disease: A meta-analysis (1997) JAMA, 278, pp. 1349-1356; Jack, C.R., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 257-262; McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 263-269; Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 270-279; Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 280-292; Anstey, K.J., Von Sanden, C., Salim, A., O'Kearney, R., Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies (2007) Am J Epidemiol, 166, pp. 367-378; Rusanen, M., Kivipelto, M., Quesenberry, C.P., Zhou, J., Whitmer, R.A., Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia (2010) Arch Intern Med, 171, pp. 333-339; Pendlebury, S.T., Rothwell, P.M., Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis (2009) Lancet Neurol, 8, pp. 1006-1018; Whitmer, R.A., Gustafson, D.R., Barrett-Connor, E., Haan, M.N., Gunderson, E.P., Yaffe, K., Central obesity and increased risk of dementia more than three decades later (2008) Neurology, 71, pp. 1057-1064; Raji, C.A., Ho, A.J., Parikshak, N.N., Becker, J.T., Lopez, O.L., Kuller, L.H., Brain structure and obesity (2010) Hum Brain Mapp, 31, pp. 353-364; Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease (2005) Arch Neurol, 62, pp. 1556-1560; Xu, W.L., Atti, A.R., Gatz, M., Pedersen, N.L., Johansson, B., Fratiglioni, L., Midlife overweight and obesity increase late-life dementia risk: A population-based twin study (2011) Neurology, 76, pp. 1568-1574. , 3; Fitzpatrick, A.L., Kuller, L.H., Lopez, O.L., Diehr, P., O'Meara, E.S., Longstreth, W.T., Midlife and late-life obesity and the risk of dementia: Cardiovascular Health Study (2009) Arch Neurol, 66, pp. 336-342; Rönnemaa, E., Zethelius, B., Lannfelt, L., Kilander, L., Vascular risk factors and dementia: 40-year follow-up of a population-based cohort (2011) Dement Geriatr Cogn Disord, 31, pp. 460-466; Luchsinger, J.A., Cheng, D., Tang, M.X., Schupf, N., Mayeux, R., Central obesity in the elderly is related to late-onset Alzheimer disease (2012) Alzheimer Dis Assoc Disord, 26, pp. 101-105; Wu, W., Brickman, A.M., Luchsinger, J., Ferrazzano, P., Pichiule, P., Yoshita, M., The brain in the age of old: The hippocampal formation is targeted differentially by diseases of late life (2008) Ann Neurol, 64, pp. 698-706; Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Glucose tolerance status and risk of dementia in the community: The Hisayama Study (2011) Neurol, 77, pp. 1126-1134; Reitz, C., Brayne, C., Mayeux, R., Epidemiology of Alzheimer disease (2011) Nat Rev Neurol, 7, pp. 137-152; Ahtiluoto, S., Polvikoski, T., Peltonen, M., Solomon, A., Tuomilehto, J., Winblad, B., Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study (2010) Neurology, 75, pp. 1195-1202; Cheng, D., Noble, J., Tang, M.X., Schupf, N., Mayeux, R., Luchsinger, J.A., Type 2 diabetes and late-onset Alzheimer's disease (2011) Dement Geriatr Cogn Disord, 31, pp. 424-430; Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., Whitmer, R.A., Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later (2009) Dement and Geriatr Disord, 28, pp. 75-80; Launer, L.J., Ross, G.W., Petrovitch, H., Masaki, K., Foley, D., White, L.R., Midlife blood pressure and dementia: The Honolulu-Asia Aging Study (2000) Neurobiol Aging, 21, pp. 49-55; Ninomiya, T., Ohara, T., Hirakawa, Y., Yoshida, D., Doi, Y., Hata, J., Midlife and late-life blood pressure and dementia in Japanese elderly: The Hisayama Study (2011) Hypertension, 58, pp. 22-28; Debette, S., Seshadri, S., Beiser, A., Au, R., Himali, J.J., Palumbo, C., Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline (2011) Neurology, pp. 461-468; Willis, B.L., Gao, A., Leonard, D., Defina, L.F., Berry, J.D., Midlife fitness and the development of chronic conditions in later life (2012) Arch Intern Med, 172, pp. 1333-1340; Larson, E.B., Wang, L., Bowen, J.D., McCormick, W.C., Teri, L., Crane, P., Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older (2006) Ann Intern Med, 144, pp. 73-81; Laurin, D., Verreault, R., Lindsay, J., Macpherson, K., Rockwood, K., Physical activity and risk of cognitive impairment and dementia in elderly persons (2001) Arch Neurol, 58, pp. 498-504; Wang, H.-X., Xu, W., Pei, J.-J., Leisure activities, cognition and dementia (2012) BBA - Mol Basis Dis, 1822, pp. 482-491; Wang, H.X., Karp, A., Winblad, B., Fratiglioni, L., Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: A longitudinal study from the Kungsholmen Project (2002) Am J Epidemiol, 155, pp. 1081-1087; Saczynski, J.S., Pfeifer, L.A., Masaki, K., Korf, E.S., Laurin, D., White, L., The effect of social engagement on incident dementia: The Honolulu-Asia Aging Study (2006) Am J Epidemiol, 163, pp. 433-440; Karp, A., Paillard-Borg, S., Wang, H.X., Silverstein, M., Winblad, B., Fratiglioni, L., Mental, physical and social components in leisure activities equally contribute to decrease dementia risk (2005) Dement Geriatr Cogn Disord, 21, pp. 65-73; Fabrigoule, C., Letenneur, L., Dartigues, J.F., Zarrouk, M., Commenges, D., Barberger-Gateau, P., Social and leisure activities and risk of dementia: A prospective longitudinal study (1995) J Am Ger Soc, 43, pp. 485-490; Krueger, K.R., Wilson, R.S., Kamenetsky, J.M., Barnes, L.L., Bienias, J.L., Bennett, D.A., Social engagement and cognitive function in old age (2009) Exp Aging Res, 35, pp. 45-60; Sharp, E.S., Reynolds, C.A., Pedersen, N.L., Gatz, M., Cognitive engagement and cognitive aging: Is openness protective? (2010) Psychol Aging, 25, pp. 60-73; Fratiglioni, L., Paillard-Borg, S., Winblad, B., An active and socially integrated lifestyle in late life might protect against dementia (2004) Lancet Neurol, 3, pp. 343-353; Wilson, R.S., Boyle, P.A., Yu, L., Barnes, L.L., Schneider, J.A., Bennett, D.A., Life-span cognitive activity, neuropathologic burden, and cognitive aging (2013) Neurology, 81, pp. 314-321; Ball, K., Berch, D.B., Helmers, K.F., Jobe, J.B., Leveck, M.D., Marsiske, M., Effects of cognitive training interventions with older adults: A randomized controlled trial (2002) JAMA, 288, pp. 2271-2281; Hall, C.B., Lipton, R.B., Sliwinski, M., Katz, M.J., Derby, C.A., Verghese, J., Cognitive activities delay onset of memory decline in persons who develop dementia (2009) Neurology, 73, pp. 356-361; Wilson, R.S., Mendes De Leon, C.F., Barnes, L.L., Schneider, J.A., Bienias, J.L., Evans, D.A., Participation in cognitively stimulating activities and risk of incident Alzheimer disease (2002) JAMA, 287, pp. 742-748; Wilson, R.S., Bennett, D.A., Bienias, J.L., Aggarwal, N.T., Mendes De Leon, C.F., Morris, M.C., Cognitive activity and incident AD in a population-based sample of older persons (2002) Neurology, 59, pp. 1910-1914; Fitzpatrick, A.L., Kuller, L.H., Ives, D.G., Lopez, O.L., Jagust, W., Breitner, J.C., Incidence and prevalence of dementia in the Cardiovascular Health Study (2004) J Am Geriatr Soc, 52, pp. 195-204; Kukull, W.A., Higdon, R., Bowen, J.D., McCormick, W.C., Teri, L., Schellenberg, G.D., Dementia and Alzheimer disease incidence: A prospective cohort study (2002) Arch Neurol, 59, pp. 1737-1746; Evans, D.A., Bennett, D.A., Wilson, R.S., Bienias, J.L., Morris, M.C., Scherr, P.A., Incidence of Alzheimer disease in a biracial urban community: Relation to apolipoprotein e allele status (2003) Arch Neurol, 60, pp. 185-189; Stern, Y., Gurland, B., Tatemichi, T.K., Tang, M.X., Wilder, D., Mayeux, R., Influence of education and occupation on the incidence of Alzheimer's disease (1994) JAMA, 271, pp. 1004-1010; Evans, D.A., Hebert, L.E., Beckett, L.A., Scherr, P.A., Albert, M.S., Chown, M.J., Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons (1997) Arch Neurol, 54, pp. 1399-1405; Roe, C.M., Xiong, C., Miller, J.P., Morris, J.C., Education and Alzheimer disease without dementia: Support for the cognitive reserve hypothesis (2007) Neurology, 68, pp. 223-228; Stern, Y., Cognitive reserve in ageing and Alzheimer's disease (2012) Lancet Neurol, 11, pp. 1006-1012; Stern, Y., Cognitive reserve and Alzheimer disease (2006) Alzheimer Dis Assoc Disord, 20, pp. 112-117; McDowell, I., Xi, G., Lindsay, J., Tierney, M., Mapping the connections between education and dementia (2007) J Clin Exp Neuropsychol, 29, pp. 127-141; Lye, T.C., Shores, E.A., Traumatic brain injury as a risk factor for Alzheimer's disease: A review (2000) Neuropsychol Rev, 10, pp. 115-129; http://www.nlm.nih.gov/medlineplus/traumaticbraininjury.html, National Institutes of Health. Traumatic brain injury Accessed October 10, 2012Plassman, B.L., Havlik, R.J., Steffens, D.C., Helms, M.J., Newman, T.N., Drosdick, D., Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias (2000) Neurology, 55, pp. 1158-1166; Crawford, F.C., Vanderploeg, R.D., Freeman, M.J., Singh, S., Waisman, M., Michaels, L., APOE genotype influences acquisition and recall following traumatic brain injury (2002) Neurology, 58, pp. 1115-1118; Roberts, G.W., Allsop, D., Bruton, C., The occult aftermath of boxing (1990) J Neurol, Neurosurg Psychiatry, 53, pp. 373-378; Guskiewicz, K.M., Association between recurrent concussion and late-life cognitive impairment in retired professional football players (2005) Neurosurgery, 57, pp. 719-726; (2009) National Football League Player Care Foundation Study of NFL Retired Players, , Institute for Social Research University of Michigan Ann Arbor, Mich; Groswasser, Z., Reider-Groswasser, I.I., Schwab, K., Ommaya, A.K., Pridgen, A., Brown, H.R., Quantitative imaging in late TBI. Part II: Cognition and work after closed and penetrating head injury: A report of the Vietnam Head Injury Study (2002) Brain Inj, 16, pp. 681-690; Salazar, A.M., Warden, D.L., Schwab, K., Spector, J., Braverman, S., Walter, J., Cognitive rehabilitation for traumatic brain injury: A randomized trial. Defense and Veterans Head Injury Program (DVHIP) Study Group (2000) JAMA, 283, pp. 3075-3081; Lehman, E.J., Hein, M.J., Baron, S.L., Gersic, C.M., Neurodegenerative causes of death among retired National Football League players (2012) Neurology, 79, pp. 1970-1974; Omalu, B.I., Dekosky, S.T., Minster, R.L., Kamboh, M.I., Hamilton, R.L., Wecht, C.H., Chronic traumatic encephalopathy in a National Football League player (2005) Neurosurgery, 57, pp. 128-134; McKee, A.C., Stern, R.A., Nowinski, C.J., Stein, T.D., Alvarez, V.E., Daneshvar, D.H., The spectrum of disease in chronic traumatic encephalopathy (2013) Brain, 136 (PART 1), pp. 43-64; Monti, J.M., Voss, M.W., Pence, A., McAuley, E., Kramer, A.F., Cohen, N.J., History of mild traumatic brain injury is associated with deficits in relational memory, reduced hippocampal volume, and less neural activity later in life (2013) Front Aging Neurosci, 5, p. 41; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease (1984) Neurology, pp. 939-944; Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., National Institute on Aging-Alzheimer's Association guidelines on neuropathologic assessment of Alzheimer's disease (2012) Alzheimers Dement, 8, pp. 1-13; Lopez, O.L., Jagust, W.J., Dekosky, S.T., Becker, J.T., Fitzpatrick, A., Dulberg, C., Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study (2003) Arch Neurol, 60, pp. 1385-1389; Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics (2008) Neuroepidemiology, 30, pp. 58-69; Hanninen, T., Hallikainen, M., Tuomainen, S., Vanhanen, M., Soininen, H., Prevalence of mild cognitive impairment: A population-based study in elderly subjects (2002) Acta Neurol Scand, 106, pp. 148-154; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: Clinical characterization and outcome (1999) Arch Neurol, 56, pp. 303-308; Manly, J.J., Tang, M.X., Schupf, N., Stern, Y., Vonsattel, J.P., Mayeux, R., Frequency and course of mild cognitive impairment in a multiethnic community (2008) Ann Neurol, 63, pp. 494-506; Ganguli, M., Snitz, B.E., Saxton, J.A., Chang, C.H., Lee, C., Vanderbilt, J., Outcomes of mild cognitive impairment by definition: A population study (2011) Arch Neurol, 68, pp. 761-767; Bloudek, L.M., Spackman, E.D., Blankenburg, M., Sullivan, S.D., Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease (2011) J Alzheimers Dis, 26, pp. 627-645; Rami, L., Solé-Padullés, C., Fortea, J., Bosch, B., Lladó, A., Antonell, A., Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD (2012) Int J Geriatr Psychiatry, 27, pp. 127-134; Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio-Chiavetto, L., Bonetti, M., Bonvicini, C., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD (2013) J Neurol, 260, pp. 640-650; Roe, C.M., Fagan, A.M., Grant, E.A., Hassenstab, J., Moulder, K.L., Maue, D., Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later (2013) Neurology, 80, pp. 1784-1791; Douaud, G., Menke, R.A., Gass, A., Monsch, A.U., Rao, A., Whitcher, B., Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease (2013) J Neurosci, 33, pp. 2147-2155; Johnson, K.A., Minoshima, S., Bohnen, N.I., Donohoe, K.J., Foster, N.L., Herscovitch, P., Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association (2013) Alzheimer's Dement, 9, pp. 1-E16; Yang, X., Tan, M.Z., Qiu, A., CSF and brain structural imaging markers of the Alzheimer's pathological cascade (2012) PLoS One, 7, p. 47406; Shaffer, J.L., Petrella, J.R., Sheldon, F.C., Choudhury, K.R., Calhoun, V.D., Coleman, R.E., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging and PET biomarkers (2013) Radiology, 266, pp. 583-591; Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N Engl J Med, 367, pp. 795-804; Bendlin, B.B., Carlsson, C.M., Johnson, S.C., Zetterberg, H., Blennow, K., Willette, A.A., CSF T-tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease (2012) PLoS One, 7, p. 37720; Honea, R.A., Vidoni, E.D., Swerdlow, R.H., Burns, J.M., Maternal family history is associated with Alzheimer's disease biomarkers (2012) J Alzheimers Dis, 31, pp. 659-668. , Alzheimer's Disease Neuroimaging Initiative; Stricker, N.H., Dodge, H.H., Dowling, N.M., Han, S.D., Erosheva, E.A., Jagust, W.J., CSF biomarker associations with change in hippocampal volume and precuneus thickness: Implications for the Alzheimer's pathological cascade (2012) Brain Imaging Behav, 6, pp. 599-609. , Alzheimer's Disease Neuroimaging Initiative; Schmand, B., Eikelenboom, P., Van Gool, W.A., Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment (2012) J Alzheimers Dis, 29, pp. 641-648. , Alzheimer's Disease Neuroimaging Initiative; Vos, S., Van Rossum, I., Burns, L., Knol, D., Scheltens, P., Soininen, H., Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI (2012) Neurobiol Aging, 33, pp. 2272-2281; Dickerson, B.C., Wolk, D.A., MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults (2012) Neurology, 78, pp. 84-90. , Alzheimer's Disease Neuroimaging Initiative; Wang, L., Fagan, A.M., Shah, A.R., Beg, M.F., Csernansky, J.G., Morris, J.C., Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type (2012) Alzheimer Dis Assoc Disord, 26, pp. 314-321; Furney, S.J., Kronenberg, D., Simmons, A., Güntert, A., Dobson, R.J., Proitsi, P., Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease - Cytokines and MRI measures together predict disease progression (2011) J Alzheimers Dis, 26 (SUPPL. 3), pp. 395-405; Schmand, B., Eikelenboom, P., Van Gool, W.A., Value of neuropsychological tests, neuroimaging and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts (2011) J Am Geriatr Soc, 59, pp. 1705-1710. , Alzheimer's Disease Neuroimaging Initiative; Vickrey, B.G., Mittman, B.S., Connor, K.I., Pearson, M.L., Della Penna, R.D., Ganiats, T.G., The effect of a disease management intervention on quality and outcomes of dementia care: A randomized, controlled trial (2006) Ann Intern Med, 145, pp. 713-726; Voisin, T., Vellas, B., Diagnosis and treatment of patients with severe Alzheimer's disease (2009) Drugs Aging, 26, pp. 135-144; Grossberg, G.T., Christensen, D.D., Griffith, P.A., Kerwin, D.R., Hunt, G., Hall, E.J., The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: Recommendations of an expert consensus panel (2010) Prim Care Companion J Clin Psychiatry, 12. , PCC.09cs00833; http://dementia.cochrane.org/our-reviews, Dementia and chronic cognitive impairment; rehabilitation and care. National Institute for Health Research. Accessed October 21, 2013Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., Del Ser, T., Nonpharmacological therapies in Alzheimer's disease: A systematic review of efficacy (2010) Dement Geriatr Cogn Disord, 30, pp. 161-178; Brodaty, H., Arasaratnam, C., Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia (2012) Am J Psychiatry, 169, pp. 946-953; Hebert, L.E., Weuve, J., Scherr, P.A., Evans, D.A., Alzheimer disease in the United States (2010-2050) estimated using the 2010 Census (2013) Neurology, 80, pp. 1778-1783; (2006) Early-onset Dementia: A National Challenge, A Future Crisis, , Alzheimer's Association Alzheimer's Association Washington, D.C; Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B., Prevalence of dementia in the United States: The Aging, Demographics, and Memory Study (2007) Neuroepidemiology, 29, pp. 125-132; Wilson, R.S., Weir, D.R., Leurgans, S.E., Evans, D.A., Hebert, L.E., Langa, K.M., Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States (2011) Alzheimers Dement, 7, pp. 74-79; Boustani, M., Peterson, B., Hanson, L., Harris, R., Lohr, K.N., Screening for dementia in primary care: A summary of the evidence for the U.S. Preventive Services Task Force (2003) Ann Intern Med, 138, pp. 927-937; Reisberg, B., Gauthier, S., Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease (2008) Int Psychogeriatr, 20, pp. 1-16; Jessen, F., Wiese, B., Bachmann, C., Prediction of dementia by subjective memory impairment: Effects of severity and temporal association with cognitive impairment (2010) Arch Gen Psychiatry, 67, pp. 414-422; Reisberg, B., Shulman, M.B., Torossian, C., Leng, L., Zhu, W., Outcome over seven years of healthy adults with and without subjective cognitive impairment (2010) Alzheimers Dement, 6, pp. 11-24; Self-reported increased confusion or memory loss and associated functional difficulties among adults aged >/= 60 years - 21 States, 2011 (2013) MMWR Morb Mortal Wkly Rep, 62, pp. 347-350. , Centers for Disease Control and Prevention; Seshadri, S., Wolf, P.A., Beiser, A., Au, R., McNulty, K., White, R., Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study (1997) Neurology, 49, pp. 1498-1504; Hebert, L.E., Scherr, P.A., McCann, J.J., Beckett, L.A., Evans, D.A., Is the risk of developing Alzheimer's disease greater for women than for men? (2001) Am J Epidemiol, 153, pp. 132-136; Bachman, D.L., Wolf, P.A., Linn, R.T., Knoefel, J.E., Cobb, J.L., Belanger, A.J., Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study (1993) Neurology, 43 (3 PART 1), pp. 515-519; Rocca, W.A., Cha, R.H., Waring, S.C., Kokmen, E., Incidence of dementia and Alzheimer's disease: A reanalysis of data from Rochester, Minn., 1975-1984 (1998) Am J Epidemiol, 148, pp. 51-62; Barnes, L.L., Wilson, R.S., Schneider, J.A., Bienias, J.L., Evans, D.A., Bennett, D.A., Gender, cognitive decline, and risk of AD in older persons (2003) Neurology, 60, pp. 1777-1781; Miech, R.A., Breitner, J.C., Zandi, P.P., Khachaturian, A.S., Anthony, J.C., Mayer, L., Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study (2002) Neurology, 58, pp. 209-218; Fillenbaum, G.G., Heyman, A., Huber, M.S., Woodbury, M.A., Leiss, J., Schmader, K.E., The prevalence and 3-year incidence of dementia in older black and white community residents (1998) J Clin Epidemiol, 51, pp. 587-595; Dilworth-Anderson, P., Hendrie, H.C., Manly, J.J., Khachaturian, A.S., Fazio, S., Diagnosis and assessment of Alzheimer's disease in diverse populations (2008) Alzheimers Dement, 4, pp. 305-309; Manly, J., Mayeux, R., Ethnic differences in dementia and Alzheimer's disease (2004) Critical Perspectives on Racial and Ethnic Differentials in Health in Late Life, pp. 95-141. , N. Anderson, R. Bulatao, B. Cohen, National Academies Press Washington, D.C; Potter, G.G., Plassman, B.L., Burke, J.R., Kabeto, M.U., Langa, K.M., Llewellyn, D.J., Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites (2009) Alzheimers Dement, 5, pp. 445-453; Gurland, B.J., Wilder, D.E., Lantigua, R., Stern, Y., Chen, J., Killeffer, E.H., Rates of dementia in three ethnoracial groups (1999) Int J Geriatr Psychiatry, 14, pp. 481-493; Reitz, C., Jun, G., Naj, A., Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein e 4, and the risk of late-onset Alzheimer disease in African Americans (2013) JAMA, 309, pp. 1483-1492; Chin, A.L., Negash, S., Hamilton, R., Diversity and disparity in dementia: The impact of ethnoracial differences in Alzheimer disease (2011) Alzheimer Dis Assoc Disord, 25, pp. 187-195; Yaffe, K., Falvey, C., Harris, T.B., Newman, A., Satterfield, S., Koster, A., Effect of socioeconomic disparities on incidence of dementia among biracial older adults: Prospective study (2013) BMJ, 347, p. 7051; Clark, P.C., Kutner, N.G., Goldstein, F.C., Peterson-Hazen, S., Garner, V., Zhang, R., Impediments to timely diagnosis of Alzheimer's disease in African Americans (2005) J Am Geriatr Soc, 53, pp. 2012-2017; Fitten, L.J., Ortiz, F., Ponton, M., Frequency of Alzheimer's disease and other dementias in a community outreach sample of Hispanics (2001) J Am Geriatr Soc, 49, pp. 1301-1308; Unpublished Tabulations Based on Data from the National 20% Sample Medicare Fee-for-Service Beneficiaries for 2009, , Prepared under contract by Julie Bynum, M.D., M.P.H., Dartmouth Institute for Health Policy and Clinical Care, Dartmouth Medical School, November 2011; Hebert, L.E., Beckett, L.A., Scherr, P.A., Evans, D.A., Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050 (2001) Alzheimer Dis Assoc Disord, 15, pp. 169-173; Corrada, M.M., Brookmeyer, R., Paganini-Hill, A., Berlau, D., Kawas, C.H., Dementia incidence continues to increase with age in the oldest old: The 90+ Study (2010) Ann Neurol, 67, pp. 114-121; Seshadri, S., Beiser, A., Kelly-Hayes, M., Kase, C.S., Au, R., Kannel, W.B., The lifetime risk of stroke: Estimates from the Framingham Study (2006) Stroke, 37, pp. 345-350; Vincent, G.K., Velkof, V.A., (2010) The Next Four Decades: The Older Population in the United States: 2010 to 2050, , U.S. Census Bureau Washington, D.C; Hebert, L.S., Scherr, P.A., Bienias, J.L., Bennett, D.A., Evans, D.A., Alzheimer's disease in the US population: Prevalence estimates using the 2000 census (2003) Arch Neurol, 60, pp. 1119-1122; Murphy, S.L., Xu, J.Q., Kochanek, K.D., (2013) Deaths: Final Data for 2010. National Vital Statistics Reports, 61. , http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf, National Center for Health Statistics Hyattsville, Md Available at Accessed Dec 12, 2013; (2004) International Statistical Classification of Diseases and Related Health Problems, , World Health Organization 10th revision. 2nd edition. Geneva, Switzerland; Ives, D.G., Samuel, P., Psaty, B.M., Kuller, L.H., Agreement between nosologist and Cardiovascular Health Study review of deaths: Implications of coding differences (2009) J Am Geriatr Soc, 57, pp. 133-139; Macera, C.A., Sun, R.K., Yeager, K.K., Brandes, D.A., Sensitivity and specificity of death certificate diagnoses for dementing illnesses, 1988-1990 (1992) J Am Geriatr Soc, 40, pp. 479-481; Olichney, J.M., Hofstetter, C.R., Galasko, D., Thal, L.J., Katzman, R., Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort (1995) J Am Geriatr Soc, 43, pp. 890-893; Burns, A., Jacoby, R., Luthert, P., Levy, R., Cause of death in Alzheimer's disease (1990) Age Ageing, 19, pp. 341-344; Brunnstrom, H.R., Englund, E.M., Cause of death in patients with dementia disorders (2009) Eur J Neurol, 16, pp. 488-492; Ganguli, M., Rodriguez, E.G., Reporting of dementia on death certificates: A community study (1999) J Am Geriatr Soc, 47, pp. 842-849; Weuve, J., Hebert, L.E., Scherr, P.A., Evans, D.A., Deaths in the United States among persons with Alzheimer's disease (2010-2050) Alzheimer Dement, , In press; James, B.D., Leurgans, S., Hebert, L.E., Scherr, P.A., Yaffe, K., Bennett, D.A., The contribution of Alzheimer's disease to mortality in the United States Neurology, , Published online ahead of print Mar 5 2014. DOI: 10.1212/WNL. 0000000000000240; (2011) Unpublished Tabulations Based on Data from the Medicare Current Beneficiary Survey for 2008, , Prepared under contract by Julie Bynum, M.D., M.P.H., Dartmouth Institute for Health Policy and Clinical Care, Dartmouth Medical School; November; Tinetti, M.E., McAvay, G.J., Murphy, T.E., Gross, C.P., Lin, H., Allore, H.G., Contribution of individual diseases to death in older adults with multiple diseases (2012) J Am Geriatr Soc, 60, pp. 1448-1456; Arrighi, H.M., Neumann, P.J., Lieberburg, I.M., Townsend, R.J., Lethality of Alzheimer disease and its impact on nursing home placement (2010) Alzheimer Dis Assoc Disord, 24, pp. 90-95; (2002) Deaths: Final Data for 2000. National Vital Statistics Reports, , National Center for Health Statistics National Center for Health Statistics Hyattsville, Md; Aguero-Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., Winblad, B., Mortality from dementia in advanced age: A 5-year follow-up study of incident dementia cases (1999) J Clin Epidemiol, 52, pp. 737-743; Ganguli, M., Dodge, H.H., Shen, C., Pandav, R.S., Dekosky, S.T., Alzheimer disease and mortality: A 15-year epidemiological study (2005) Arch Neurol, 62, pp. 779-784; Tejada-Vera, B., (2013) Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. National Center for Health Statistics Data Brief, No. 116, , National Center for Health Statistics Hyattsville, Md; Waring, S.C., Doody, R.S., Pavlik, V.N., Massman, P.J., Chan, W., Survival among patients with dementia from a large multi-ethnic population (2005) Alzheimer Dis Assoc Disord, 19, pp. 178-183; Brookmeyer, R., Corrada, M.M., Curriero, F.C., Kawas, C., Survival following a diagnosis of Alzheimer disease (2002) Arch Neurol, 59, pp. 1764-1767; Larson, E.B., Shadlen, M.F., Wang, L., McCormick, W.C., Bowen, J.D., Teri, L., Survival after initial diagnosis of Alzheimer disease (2004) Ann Intern Med, 140, pp. 501-509; Helzner, E.P., Scarmeas, N., Cosentino, S., Tang, M.X., Schupf, N., Stern, Y., Survival in Alzheimer disease: A multiethnic, population-based study of incident cases (2008) Neurology, 71, pp. 1489-1495; Xie, J., Brayne, C., Matthews, F.E., Survival times in people with dementia: Analysis from a population based cohort study with 14-year follow-up (2008) BMJ, 336, pp. 258-262; Mitchell, S.L., Teno, J.M., Miller, S.C., Mor, V., A national study of the location of death for older persons with dementia (2005) J Am Geriatr Soc, 53, pp. 299-305; The state of U.S. Health, 1990-2010: Burden of diseases, injuries, and risk factors (2013) JAMA, 310, pp. 591-608. , U.S. Burden of Disease Collaborators; Gaugler, J.E., Kane, R.L., Kane, R.A., Family care for older adults with disabilities: Toward more targeted and interpretable research (2002) Int J Aging Hum Dev, 54, pp. 205-231; Schulz, R., Quittner, A.L., Caregiving through the life-span: Overview and future directions (1998) Health Psychol, 17, pp. 107-111; Wal-Mart Sales Report 2012, , http://www.walmartstores.com/sites/annual-report/2012/WalMart_AR.pdf, Accessed February 21, 2014; McDonald's Corporation Report, , https://www.google.com/finance?fstype=ii%26q=nyse:mcd, Accessed February 21, 2014; Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J., Langa, K.M., Monetary costs of dementia in the United States (2013) N Engl J Med, 368, pp. 1326-1334; Gitlin, L.N., Schulz, R., Family caregiving of older adults (2012) Public Health for An Aging Society, pp. 181-204. , R.T. Prohaska, L.A. Anderson, R.H. Binstock, The Johns Hopkins University Press Baltimore, Md; Bouldin, E.D., Andresen, E., Caregiving across the United States: Caregivers of persons with Alzheimer's disease or dementia in 8 states and the District of Columbia Data from the 2009 & 2010 Behavioral Risk Factor Surveillance System, , http://www.alz.org/documents_custom/public-health/2009-2010-combined- caregiving.pdf, Accessed February 21, 2014; Langa, K.M., Plassman, B.L., Wallace, R.B., Herzog, A.R., Heeringa, S.G., Ofstedal, M.B., The Aging, Demographics, and Memory Study: Study design and methods (2005) Neuroepidemiol, 25, pp. 181-191; Fisher, G.G., Franks, M.M., Plassman, B.L., Brown, S.L., Potter, G.G., Llewellyn, D., Caring for individuals with dementia and cognitive impairment, not dementia: Findings from the Aging, Demographics, and Memory Study (2011) J Am Ger Soc, 59, pp. 488-494; (2009) National Alliance for Caregiving and AARP. Caregiving in the U.S. Unpublished Data Analyzed under Contract for the Alzheimer's Association; Brody, E.M., ""Women in the middle"" and family help to older people (1981) Gerontologist, 21, pp. 471-480; Riley, L.D., Bowen, C.P., The sandwich generation: Challenges and coping strategies of multigenerational families (2005) The Family Journal, 13, pp. 52-58; Schumacher, L.A.P., Macneil, R., Mobily, K., Teague, M., Butcher, H., The leisure journey for sandwich generation caregivers (2012) Ther Recreation J, 46, pp. 42-60; Spitze, G., Logan, J., More evidence on women (and men) in the middle (1990) Res Aging, 12, pp. 182-198; Hammer, L.B., Neal, M.B., Working sandwiched-generation caregivers: Prevalence, characteristics, and outcomes (2008) Psychol-Manager J, 11, pp. 93-112; http://assets.aarp.org/rgcenter/il/caregiving_09_fr.pdf, National Alliance for Caregiving and AARP, Caregiving in the U.S., November 2009. Accessed February 21, 2014Loomis, L.S., Booth, A., Multigenerational caregiving and well-being (1995) J Fam Issues, 16, pp. 131-148; Rubin, R., White-Means, S., Informal caregiving: Dilemmas of sandwiched caregivers (2009) J Fam Econ Issues, 30, pp. 252-267; Boustani, M., Perkins, A.J., Fox, C., Unverzagt, F., Austrom, M.G., Fultz, B., Who refuses the diagnostic assessment for dementia in primary care? (2006) Int J Geriatr Psych, 21, pp. 556-563; Garity, J., Caring for a family member with Alzheimer's disease: Coping with caregiver burden post-nursing home placement (2006) J Gerontol Nurs, 32, pp. 39-48; Port, C.L., Zimmerman, S., Williams, C.S., Dobbs, D., Preisser, J.S., Williams, S.W., Families filling the gap: Comparing family involvement for assisted living and nursing home residents with dementia (2005) Gerontologist, 45 (1), pp. 87-95; Schulz, R., Belle, S.H., Czaja, S.J., McGinnis, K.A., Stevens, A., Zhang, S., Long-term care placement of dementia patients and caregiver health and well-being (2004) JAMA, 292, pp. 961-967; Gaugler, J.E., Mittelman, M.S., Hepburn, K., Newcomer, R., Clinically significant changes in burden and depression among dementia caregivers following nursing home admission (2010) BMC Medicine, 8, p. 85; Ornstein, K., Gaugler, J.E., The problem with ""problem behaviors"": A systematic review of the association between individual patient behavioral and psychological symptoms and caregiver depression and burden within the dementia patient-caregiver dyad (2012) Int Psychogeriatr, 24, pp. 1536-1552; Kiecolt-Glaser, J.K., Glaser, R., Gravenstein, S., Malarkey, W.B., Sheridan, J., Chronic stress alters the immune response to influenza virus vaccine in older adults (1996) Proc Natl Acad Sci USA, 93, pp. 3043-3047; Schulz, R., Beach, S.R., Caregiving as a risk factor for mortality: The Caregiver Health Effects Study (1999) JAMA, 282, pp. 2215-2260; Vitaliano, P.P., Zhang, J., Scanlan, J.M., Is caregiving hazardous to one's physical health? A meta-analysis (2003) Psychol Bull, 129, pp. 946-972; Liu, W., Gallagher-Thompson, D., Impact of dementia caregiving: Risks, strains, and growth (2009) Aging Families and Caregiving, pp. 85-112. , S.H. Qualls, S.H. Zarit, John Wiley & Sons, Inc. Hoboken, N.J; Pinquart, M., Sörensen, S., Associations of stressors and uplifts of caregiving with caregiver burden and depressive mood: A meta-analysis (2003) J Gerontol B Psychol Sci Soc Sci, 58, pp. 112-128; Sörensen, S., Duberstein, P., Gill, D., Pinquart, M., Dementia care: Mental health effects, intervention strategies, and clinical implications (2006) Lancet Neurol, 5, pp. 961-973; Zarit, S., Positive aspects of caregiving: More than looking on the bright side (2012) Aging Ment Health, 16, pp. 673-674; Schulz, R., O'Brien, A.T., Bookwala, J., Fleissner, K., Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes (1995) Gerontologist, 35, pp. 771-791; Baumgarten, M., Battista, R.N., Infante-Rivard, C., Hanley, J.A., Becker, R., Gauthier, S., The psychological and physical health of family members caring for an elderly person with dementia (1992) J Clin Epidemiol, 45, pp. 61-70; Seeher, K., Low, L.-F., Reppermund, S., Brodaty, H., Predictors and outcomes for caregivers of people with mild cognitive impairment: A systematic literature review (2013) Alzheimers Dement, 9, pp. 346-355; Kessler, R.C., Chiu, W.T., Demler, O., Merikangas, K.R., Walters, E.E., Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication (2005) Arch Gen Psychiatry, 62, pp. 617-627; Epstein-Lubow, G., Gaudiano, B., Darling, E., Hinckley, M., Tremont, G., Kohn, R., Differences in depression severity in family caregivers of hospitalized individuals with dementia and family caregivers of outpatients with dementia (2012) Am J Geriatr Psychiatry, 20, pp. 815-819; Gaugler, J.E., Yu, F., Krichbaum, K., Wyman, J.F., Predictors of nursing home admission for persons with dementia (2009) Med Care, 47, pp. 191-198; Marziali, E., Shulman, K., Damianakis, T., Persistent family concerns in long-term care settings: Meaning and management (2006) J Am Med Dir Assoc, 7, pp. 154-162; Strang, V.R., Koop, P.M., Dupuis-Blanchard, S., Nordstrom, M., Thompson, B., Family caregivers and transition to long-term care (2006) Clin Nurs Res, 15, pp. 27-45; Peacock, S.C., The experience of providing end-of-life care to a relative with advanced dementia: An integrative literature review (2013) Palliat Support Care, 11, pp. 155-168; Schulz, R., Mendelsohn, A.B., Haley, W.E., Mahoney, D., Allen, R.S., Zhang, S., End-of-life care and the effects of bereavement on family caregivers of persons with dementia (2003) N Engl J Med, 349, pp. 1936-1942; Peng, H.-L., Chang, Y.-P., Sleep disturbance in family caregivers of individuals with dementia: A review of the literature (2012) Perspect Psychiatr Care, 49, pp. 135-146; The MetLife Study of Alzheimer's Disease: The Caregiving Experience, , https://www.metlife.com/assets/cao/mmi/publications/studies/ mmi-alzheimers-disease-caregiving-experience-study.pdf, MetLife Mature Market Institute Aug. 2006. Accessed December 8, 2013; Fredman, L., Bertrand, R.M., Martire, L.M., Hochberg, M., Harris, E.L., Leisure-time exercise and overall physical activity in older women caregivers and non-caregivers from the Caregiver-SOF Study (2006) Prev Med, 43, pp. 226-229; Roepke, S.K., Allison, M., Von Kanel, R., Mausbach, B.T., Chattillion, E.A., Harmell, A.L., Relationship between chronic stress and carotid intima-media thickness (IMT) in elderly Alzheimer's disease caregivers (2012) Stress, 15, pp. 121-129; Gouin, J., Glaser, R., Malarkey, W.B., Beversdorf, D., Kiecolt-Glaser, J., Chronic stress, daily stressors, and circulating inflammatory markers (2012) Health Psychol, 31, pp. 264-268; Von Kanel, R., Mills, P.J., Mausbach, B.T., Dimsdale, J.E., Patterson, T.L., Ziegler, M.G., Effect of Alzheimer caregiving on circulating levels of C-reactive protein and other biomarkers relevant to cardiovascular disease risk: A longitudinal study (2012) Gerontology, 58, pp. 354-365; Von Kanel, R., Mausbach, B.T., Dimsdale, J.E., Mills, P.J., Patterson, T.L., Ancoli-Israel, S., Effect of chronic dementia caregiving and major transitions in the caregiving situation on kidney function: A longitudinal study (2012) Psychosom Med, 74, pp. 214-220; Mausbach, B.T., Chattillion, E., Roepke, S.K., Ziegler, M.G., Milic, M., Von Kanel, R., A longitudinal analysis of the relations among stress, depressive symptoms, leisure satisfaction, and endothelial function in caregivers (2012) Health Psychol, 31, pp. 433-440; Chattillion, E.A., Mausbach, B.T., Roepke, S.K., Von Kanel, R., Mills, P.J., Dimsdale, J.E., Leisure activities, caregiving demands and catecholamine levels in dementia caregivers (2012) Psychol Health, 27, pp. 1134-1149; Von Kanel, R., Dimsdale, J.E., Mills, P.J., Ancoli-Israel, S., Patterson, T.L., Mausback, B.T., Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer (2006) J Gerontol A Biol Sci Med Sci, 61, pp. 963-969; Kiecolt-Glaser, J.K., Dura, J.R., Speicher, C.E., Trask, O.J., Galser, R., Spousal caregivers of dementia victims: Longitudinal changes in immunity and health (1991) Psychosom Med, 53, pp. 345-362; Kiecolt-Glaser, J.K., Marucha, P.T., Mercado, A.M., Malarkey, W.B., Glaser, R., Slowing of wound healing by psychological stress (1995) Lancet, 346, pp. 1194-1196; Shaw, W.S., Patterson, T.L., Ziegler, M.G., Dimsdale, J.E., Semple, S.J., Grant, I., Accelerated risk of hypertensive blood pressure recordings among Alzheimer caregivers (1999) J Psychosom Res, 46, pp. 215-227; Vitaliano, P.P., Scanlan, J.M., Zhang, J., Savage, M.V., Hirsch, I.B., Siegler, I., A path model of chronic stress, the metabolic syndrome, and coronary heart disease (2002) Psychosom Med, 64, pp. 418-435; Mausbach, B.T., Roepke, S.K., Ziegler, M.G., Milic, M., Von Kanel, R., Dimsdale, J.E., Association between chronic caregiving stress and impaired endothelial function in the elderly (2010) J Am Coll Cardiol, 55, pp. 2599-2606; Schubert, C.C., Boustani, M., Callahan, C.M., Perkins, A.J., Hui, S., Hendrie, H.C., Acute care utilization by dementia caregivers within urban primary care practices (2008) J Gen Intern Med, 23, pp. 1736-1740; Christakis, N.A., Allison, P.D., Mortality after the hospitalization of a spouse (2006) N Engl J Med, 354, pp. 719-730; Brown, S.L., Smith, D.M., Schulz, R., Kabeto, M.U., Ubel, P.A., Poulin, M., Caregiving behavior is associated with decreased mortality risk (2009) Psychol Sci, 20, pp. 488-494; Fredman, L., Cauley, J.A., Hochberg, M., Ensrud, K.E., Doros, G., Mortality associated with caregiving, general stress, and caregiving-related stress in elderly women: Results of Caregiver Study of Osteoporotic Fractures (2010) J Am Ger Soc, 58, pp. 937-943; Aneshensel, C.S., Pearlin, L.I., Mullan, J.T., Zarit, S.H., Whitlatch, C.J., (1995) Profiles in Caregiving: The Unexpected Career, , Academic Press San Diego, Calif; Sörensen, S., Pinquart, M., Duberstein, P., How effective are interventions with caregivers? An updated meta-analysis (2002) Gerontologist, 42, pp. 356-372; Mittelman, M., Psychosocial interventions to address the emotional needs of caregivers of individuals with Alzheimer's disease (2013) Caregiving for Alzheimer's Disease and Related Disorders, pp. 17-34. , S.H. Zarit, R.C. Talley, Springer New York, N.Y; Logsdon, R.G., Dementia: Psychosocial interventions for family caregivers (2008) Lancet, 372, pp. 182-183; Logsdon, R.G., McCurry, S.M., Teri, L., Evidence-based psychological treatments for disruptive behaviors in individuals with dementia (2007) Psychol and Aging, 22, pp. 28-36; Zarit, S.H., Empirically supported treatment for family caregivers (2009) Aging Families and Caregiving, pp. 131-154. , S.H. Qualls, S.H. Zarit, John Wiley & Sons, Inc. Hoboken, N.J; Mittelman, M.S., Haley, W.E., Clay, O.J., Roth, D.L., Improving caregiver well-being delays nursing home placement of patients with Alzheimer's disease (2006) Neurology, 67, pp. 1592-1599; Mittelman, M.S., Epstein, C., Pierzchala, A., (2003) Counseling the Alzheimer's Caregiver: A Resource for Health Care Professionals, , AMA Press Chicago; Gaugler, J.E., (2008) Dementia and Families: Interventions That Work, , http://www.mngero.org/downloads/dementiawebinar.pdf, Accessed October 22, 2008; Belle, S.H., Burgio, L., Burns, R., Coon, D., Czaja, S.J., Gallagher-Thompson, D., Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: A randomized, controlled trial (2006) Ann Intern Med, 145, pp. 727-738. , Resources for Enhancing Alzheimer's Caregiver Health (REACH) II Investigators; Acton, G.J., Kang, J., Interventions to reduce the burden of caregiving for an adult with dementia: A meta-analysis (2001) Res Nurs Health, 24, pp. 349-360; Ostwald, S.K., Hepburn, K.W., Caron, W., Burns, T., Mantell, R., Reducing caregiver burden: A randomized psychoeducational intervention for caregivers of persons with dementia (1999) Gerontologist, 39, pp. 299-309; Hepburn, K.W., Tornatore, J., Center, B., Ostwald, S.W., Dementia family caregiver training: Affecting beliefs about caregiving and caregiver outcomes (2001) J Am Geriatr Soc, 49, pp. 450-457; Hepburn, K.W., Lewis, M., Sherman, C.W., Tornatore, J., The Savvy Caregiver Program: Developing and testing a transportable dementia family caregiver training program (2003) Gerontologist, 43, pp. 908-915; Bass, D.M., Judge, K.S., Snow, L.A., Wilson, N.L., Morgan, R., Looman, W.J., Caregiver outcomes of partners in dementia care: Effect of a care coordination program for veterans with dementia and their family members and friends (2013) J Am Geriatr Soc, 61, pp. 1377-1386; Judge, K.S., Yarry, S.J., Looman, W.J., Bass, D.M., Improved strain and psychosocial outcomes for caregivers of individuals with dementia: Findings from project ANSWERS (2013) Gerontologist, 53, pp. 280-292; Levy, K., Lanctot, K.L., Farber, S.B., Li, A., Herrmann, N., Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? (2012) Drug Aging, 29, pp. 167-179; Whitebird, R.R., Kreitzer, M., Crain, A.L., Lewis, B.A., Hanson, L.R., Enstad, C.J., Mindfulness-based stress reduction for family caregivers: A randomized controlled trial (2013) Gerontologist, 53, pp. 676-686; Zarit, S.H., Reamy, A.M., Developmentally appropriate long-term care for people with Alzheimer's disease and related disorders (2013) Caregiving for Alzheimer's Disease and Related Disorders, pp. 51-69. , S.H. Zarit, R.C. Talley, Springer New York, N.Y; Gaugler, J.E., Gallagher-Winker, K., Kehrberg, K., Lunde, A.M., Marsolek, C.M., Ringham, K., The memory club: Providing support to persons with early-stage dementia and their care partners (2011) Am J Alzheimers Dis Other Demen, 26, pp. 218-226; Logsdon, R.G., Pike, K.C., McCurry, S.M., Hunter, P., Maher, J., Snyder, L., Early-stage memory loss support groups: Outcomes from a randomized controlled clinical trial (2010) J Gerontol B Psychol Sci Soc Sci, 65, pp. 691-697; Schulz, R., Lustig, A., Handler, S., Martire, L.M., Technology-based caregiver intervention research: Current status and future directions (2002) Gerontol Tech J, 2, pp. 15-47; Elliott, A.F., Burgio, L.D., Decoster, J., Enhancing caregiver health: Findings from the Resources for Enhancing Alzheimer's Caregiver Health II Intervention (2010) J Am Ger Soc, 58, pp. 30-37; Gitlin, L.N., Winter, L., Dennis, M.P., Hodgson, N., Hauck, W.W., Targeting and managing behavioral symptoms in individuals with dementia: A randomized trial of a nonpharmacological intervention (2010) J Am Ger Soc, 58, pp. 1465-1474; Gitlin, L.N., Winter, L., Dennis, M.P., A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: The COPE randomized trial (2010) JAMA, 304, pp. 983-991; Lee, C.C., Czaja, S.J., Schultz, R., The moderating influence of demographic characteristics, social support, and religious coping on the effectiveness of a multicomponent psychosocial caregiver intervention in three racial ethnic groups (2010) J Gerontol B Psychol Sci Soc Sci, 65, pp. 185-194; Gaugler, J.E., Roth, D.L., Haley, W.E., Mittelman, M.S., Can counseling and support reduce burden and depressive symptoms in caregivers of people with Alzheimer's disease during the transition to institutionalization? Results from the New York University Caregiver Intervention Study (2008) J Am Ger Soc, 56, pp. 421-428; Llanque, S.M., Enriquez, M., Interventions for Hispanic caregivers of patients with dementia: A review of the literature (2012) Am J Alzheimers Dis Other Demen, 27, pp. 23-32; Brodaty, H., Green, A., Koschera, A., Meta-analysis of psychosocial interventions for caregivers of people with dementia (2003) J Am Geriatr Soc, 51, pp. 657-664; Smits, C.H., De Lange, J., Dröes, R.M., Meiland, F., Vernooij-Dassen, M., Pot, A.M., Effects of combined intervention programmes for people with dementia living at home and their caregivers: A systematic review (2007) Int J Geriatr Psychiatry, 22, pp. 1181-1193; Griffin, J.M., Meis, L., Greer, N., Jensen, A., Macdonald, R., Rutks, I., (2013) Effectiveness of Family and Caregiver Interventions on Patient Outcomes among Adults with Cancer or Memory-related Disorders: A Systematic Review, , http://www.hsrd.research.va.gov/publications/esp/caregiver-interventions. cfm#.Ui5DMD89X2w, VA ESP Project. Accessed February 21, 2014; Pinquart, M., Sörensen, S., Helping caregivers of persons with dementia: Which interventions work and how large are their effects? (2006) Int Psychogeriatr, 18, pp. 577-595; Jones, A.L., Dwyer, L.L., Bercovitz, A.R., Strahan, G.W., The National Nursing Home Survey: 2004 overview (2009) Vital Health Stat 13, 167, pp. 1-155; Kramer, N.A., Smith, M.C., Training nursing assistants to care for nursing home residents with dementia (2000) Professional Psychology in Long Term Care, pp. 227-256. , V. Molinari, Hatherleigh Press New York, NY; McCabe, M.P., Davison, T.E., George, K., Effectiveness of staff training programs for behavioral problems among older people with dementia (2007) Aging Ment Health, 11, pp. 505-519; Beck, C., Ortigara, A., Mercer, S., Shue, V., Enabling and empowering certified nursing assistants for quality dementia care (1999) Int J Geriatr Psychiatry, 14, pp. 197-211; (2008) Retooling for An Aging America: Building the Health Care Workforce, , http://www.nap.edu, Institute of Medicine The National Academies Press Washington, D.C. Available at; Cohen-Mansfield, J., Nonpharmacologic interventions for inappropriate behaviors in dementia: A review, summary, and critique (2001) Am J Geriatr Psychiatry, 9, pp. 361-381; Lawrence, V., Fossey, J., Ballard, C., Moniz-Cook, E., Murray, J., Improving quality of life for people with dementia in care homes: Making psychosocial interventions work (2012) Br J Psychiatry, 201, pp. 344-351; (2012) Geriatrics Workforce Shortage: A Looming Crisis for Our Families, , Eldercare Workforce Alliance Eldercare Workforce Alliance Washington, D.C; 2012 Physician Specialty Data Book, , https://members.aamc.org/eweb/upload/ 2012%20Physician%20Specialty%20Data%20Book.pdf, Association of American Medical Colleges Accessed February 21, 2014; Brody, A.A., Galvin, J.E., A review of interprofessional dissemination and education interventions for recognizing and managing dementia (2013) Gerontol Geriatr Educ, 34, pp. 225-256; Yang, Z., Zhang, K., Lin, P.J., Clevenger, C., Atherly, A., A longitudinal analysis of the lifetime cost of dementia (2012) Health Serv Res, 47, pp. 1660-1678; Rudolph, J.L., Zanin, N.M., Jones, R.N., Marcantonio, E.R., Fong, T.G., Yang, F.M., Hospitalization in community-dwelling persons with Alzheimer's disease: Frequency and causes (2010) J Am Geriatr Soc, 58, pp. 1542-1548; Medicare: The Official U.S. Government Site for Medicare, , http://www.medicare.gov/HomeHealthCompare/Resources/Glossary.html, Medicare. Glossary Accessed December 8, 2013; Suehs, B.T., Davis, C.D., Alvir, J., Van Amerongen, D., Patel, N.C., Joshi, A.V., The clinical and economic burden of newly diagnosed Alzheimer's disease in a Medicare Advantage population (2013) Am J Alzheimers Dis Other Dement, 28, pp. 384-392; Lin, P.J., Fillit, H.M., Cohen, J.T., Neumann, P.J., Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders (2013) Alzheimers Dement, 9, pp. 30-38; (2012) Market Survey of Long-term Care Costs: The 2012 MetLife Market Survey of Nursing Home, Assisted Living, Adult Day Services, and Home Care Costs, , MetLife Mature Market Institute Metropolitan Life Insurance Company New York, N.Y; Johnson, R.W., Wiener, J.M., (2006) A Profile of Frail Older Americans and Their Caregivers, , Urban Institute Washington, D.C; Fortinsky, R.H., Fenster, J.R., Judge, J.O., Medicare and Medicaid home health and Medicaid waiver services for dually eligible older adults: Risk factors for use and correlates of expenditures (2004) Gerontologist, 44, pp. 739-749; Hirdes, J.P., Fries, B.E., Morris, J.N., Home care quality indicators (HCQIs) based on the MDS-HC (2004) Gerontologist, 44, pp. 665-679; Mitchell, G., Salmon, J.R., Polivka, L., Soberon-Ferrer, H., The relative benefits and cost of Medicaid home- and community-based services in Florida (2006) Gerontologist, 46, pp. 483-494; (2002) A National Study of Adult Day Services, 2001-2002, , Partners in Caregiving Wake Forest University School of Medicine Winston-Salem, N.C; O'Keeffe, J., Siebenaler, K., (2006) Adult Day Services: A Key Community Service for Older Adults. Office of the Assistant Secretary for Planning and Evaluation, , U.S. Department of Health and Human Services Washington, D.C; Mollica, R., Houser, A., Ujvari, K., (2012) Assisted Living and Residential Care in the States in 2010, , AARP Public Policy Institute; (2013) LTC Stats: Nursing Facility Operational Characteristics Report, , American Health Care Association Table 5: nursing facility beds in dedicated special care units, June; Callahan, C.M., Arling, G., Tu, W., Rosenman, M.B., Counsell, S.R., Stump, T.E., Transitions in care among older adults with and without dementia (2012) J Am Geriatr Soc, 60, pp. 813-820; Gozalo, P., Teno, J.M., Mitchell, S.L., End-of-life transitions among nursing home residents with cognitive issues (2011) N Engl J Med, 365, pp. 1212-1221; Teno, J.M., Mitchell, S.L., Skinner, J., Churning: The association between health care transitions and feeding tube insertion for nursing home residents with advanced cognitive impairment (2009) J Palliat Med, 12, pp. 359-362; Teno, J.M., Gozalo, P.L., Bynum, J.P., Change in end-of-life care for Medicare beneficiaries: Site of death, place of care, and health care transitions in 2000, 2005, and 2009 (2013) JAMA, 309, pp. 470-477; (2012) Report to the Congress: Medicare Payment Policy. Chapter 10: Long-term Care Hospital Services, , Medicare Payment Advisory Commission (MedPAC) MedPAC Washington, D.C; (2012) What Are Long-term Care Hospitals?, , Centers for Medicare and Medicaid Services CMS Publication No. 11347; (2008) Moratorium on Classification of Long-term Care Hospitals or Satellites/increase in Certified LTCH Beds, , Centers for Medicare and Medicaid Services MLN Matters. Medicare Learning Network. MLN Matters Number MM6172; (2012) Certificate of Need: State Health Laws and Programs, , http://www.ncsl.org/issues-research/health/con-certificate-of-need-state- laws.aspx#moratoria, National Conference of State Legislatures Updated March. Available at. Accessed December 16, 2012; Poverty Thresholds by Size of Family and Number of Children, , http://www.census.gov/hhes/www/poverty/data/threshld/, U.S. Census Bureau yAccessed February 21, 2014; (2011) Projecting Income and Assets: What Might the Future Hold for the Next Generation of Medicare Beneficiaries? Menlo Park, CA, , Kaiser Family Foundation Program on Medicare Policy Henry J. Kaiser Family Foundation; The 2011 Sourcebook for Long-term Care Insurance Information, , American Association for Long-Term Care Insurance Westlake Village, Calif; (2012) Medicaid and Long-term Care Services and Supports No. 2168-09, , Kaiser Commission on Medicaid and the Uninsured Henry J. Kaiser Family Foundation Washington, D.C; Special Comment: Long-term Care Insurance: Sector Profile, , Moody's Investors Service September 18, 2012; Gilligan, A.M., Malone, D.C., Warholak, T.L., Armstrong, E.P., Health disparities in cost of care in patients with Alzheimer's disease: An analysis across 4 state Medicaid populations (2013) Am J Alzheimers Dis Other Demen, 28, pp. 84-92; http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Hospice/ Medicare_Hospice_Data.html, U.S. Centers for Medicare and Medicaid Services. Hospice Center. Accessed February 21, 2014Shriver, M., (2010) The Shriver Report: A Woman's Nation Takes on Alzheimer's, , Alzheimer's Association Chicago, Ill; Chene, G., Beiser, A., Au, R., Preis, S.R., Wolf, P.A., Dufouil, C., Gender and incidence of dementia in the Framingham Heart Study from mid-adult life (2014) Alzheimers Dement, , Epub ahead of print; Carter, C.L., Resnick, E.M., Mallampalli, M., Kalbarczyk, A., Sex and gender differences in Alzheimer's disease: Recommendations for future research (2012) J Womens Health, 21, pp. 1018-1023; Ott, B.R., Tate, C.A., Gordon, N.M., Heindel, W.C., Gender differences in the behavioral manifestations of Alzheimer's disease (1996) J Am Geriatr Soc, 44, pp. 583-587; (2012) Researchers Discover Gender-based Differences in Alzheimer's Disease, , http://www2.rsna.org/timssnet/media/pressreleases/pr_target.cfm?id=634, Radiological Society of North America Oak Brook, Ill.; Available at. Accessed February 21, 2014; Ungar, L., Altmann, A., Greicius, M.D., Apolipoprotein E, gender, and Alzheimer's disease: An overlooked, but potent and promising interaction (2013) Brain Imaging Behav, , Epub ahead of print; Skup, M., Zhu, H., Wang, Y., Giovanello, K.S., Lin, J.A., Shen, D., Sex differences in grey matter atrophy patterns among AD and aMCI patients: Results from ADNI (2011) Neuroimage, 56, pp. 890-906; Cranswick, K., Dosman, D., (2008) Eldercare: What We Know Today. Statistics Canada, , http://www.statcan.gc.ca/pub/11-008-x/2008002/article/10689-eng.pdf, Accessed February 21, 2014; Bouldin, E.D., Andresen, E., Caregiving across the United States: Caregivers of persons with Alzheimer's disease or dementia in Connecticut, New Hampshire, New Jersey, New York, and Tennessee (2010) Data from the 2010 Behavioral Risk Factor Surveillance System, , Seattle, Wash; http://www.caregiving.org/data/04finalreport.pdf, National Alliance for Caregiving and AARP. Caregiving in the U.S., April 2004. Accessed February 21, 2014Campbell, P., Wright, J., Oyebode, J., Job, D., Crome, P., Bentham, P., Determinants of burden in those who care for someone with dementia (2008) Int J Geriatr Psychiatry, 23, pp. 1078-1085; Pope, N.D., Kolomer, S., Glass, A.P., How women in late midlife become caregivers for their aging parents (2012) J Women Aging, 24, pp. 242-261; Bedard, M., Raney, D., Molloy, D.W., Lever, J., Pedlar, D., Dubois, S., The experience of primary and secondary caregivers caring for the same adult with Alzheimer's disease (2001) J Mental Health Aging, 7, p. 287; Brazil, K., Thabane, L., Foster, G., Bédard, M., Gender differences among Canadian spousal caregivers at the end of life (2009) Health Soc Care Community, 17, pp. 159-166; Bedard, M., Kuzik, R., Chambers, L., Molloy, D.W., Dubois, S., Lever, J.A., Understanding burden differences between men and women caregivers: The contribution of care-recipient problem behaviors (2005) Int Psychogeriatr, 17, pp. 99-118; Gibbons, C., Creese, J., Tran, M., Brazil, K., Chambers, L., Weaver, B., The psychological and health consequences of caring for a spouse with dementia: A critical comparison of husbands and wives (2014) J Women Aging, 26, pp. 3-21; Feld, S., Dunkle, R.E., Schroepfer, T., Shen, H.W., Does gender moderate factors associated with whether spouses are the sole providers of IADL care to their partners? (2010) Res Aging, 32, pp. 499-526; Nagatomo, I., Akasaki, Y., Uchida, M., Tominaga, M., Hashiguchi, W., Takigawa, M., Gender of demented patients and specific family relationship of caregiver to patients influence mental fatigue and burdens on relatives as caregivers (1999) Int J Geriatr Psychiatry, 14, pp. 618-625; Gaugler, J.E., Davey, A., Pearlin, L.I., Zarit, S.H., Modeling caregiver adaptation over time: The longitudinal impact of behavior problems (2000) Psychol Aging, 15, pp. 437-450; (2012), http://www.dol.gov/wb/stats/Occupations.htm#Lofw, U.S. Department of Labor. 20 Leading occupations for employed women, 2012. Washington, D.C. Accessed February 21, 2014Occupational Employment and Wages, , http://www.bls.gov/oes/current/oes311011.htm, U.S. Department of Labor, Bureau of Labor Statistics May 2012: 31-1011 Home health aides. Accessed on February 14, 2014; (2012) Occupational Employment and Wages, pp. 39-9021. , http://www.bls.gov/oes/current/oes399021.htm, U.S. Department of Labor, Bureau of Labor Statistics Personal care aides. Accessed on February 14, 2014; Hebert, L.E., Bienias, J.L., Aggarwal, N.T., Change in risk of Alzheimer disease over time (2010) Neurology, 75, pp. 786-791; Brookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset (1998) Am J Public Health, 88, pp. 1337-1342; Amo, P.S., Levine, C., Memmott, M.M., The economic value of informal caregiving (1999) Health Aff, 18, pp. 182-188; (2013) Employment, Hours, and Earnings from the Current Employment Statistics Survey, , http://www.bls.gov/ces, U.S. Department of Labor, Bureau of Labor Statistics Series 10-CEU 6562160008, Home Health Care Services (NAICS code 6216), average hourly earnings, July. Accessed on November 23, 2013; Albert, S.M., Schulz, R., (2010) The MetLife Study of Working Caregivers and Employer Health Care Costs, , MetLife Mature Market Institute New York, N.Y; http://www.cms.gov/Research-Statistics-Data-and-Systems/ Statistics-Trends-and-Reports/NationalHealthExpendData/ NationalHealthAccountsStateHealthAccountsResidence.html, Centers for Medicare and Medicaid Services, Center for Strategic Planning, Health Expenditures by State of Residence 1991-2009",Article,Scopus,2-s2.0-84897481309
"Roy K., Chakrabarti O., Mukhopadhyay D.","Interaction of Grb2 SH3 domain with UVRAG in an Alzheimers disease-like scenario",2014,"Biochemistry and Cell Biology","92","3",,"219","225",,,10.1139/bcb-2014-0001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901976076&partnerID=40&md5=ac2c44037db7d59436426f33c1f2b928","Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhan Nagar, Kolkata 700 064, India","Roy, K., Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhan Nagar, Kolkata 700 064, India; Chakrabarti, O., Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhan Nagar, Kolkata 700 064, India; Mukhopadhyay, D., Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhan Nagar, Kolkata 700 064, India","Growth factor receptor-bound protein 2 (Grb2) is an adaptor protein which participates in trafficking pathways alongside its role in signaling. Proteins important for actin remodeling and cellular compartmentalization contain SRC Homology 3 (SH3) binding motifs that interact with Grb2. While studying the Grb2-amyloid precursor protein (APP) intracellular domain (AICD) interaction in Alzheimers disease cell line models, it was seen that Grb2 colocalized to compartments that mature into autophagosomes. The entrapping of AICD in the Grb2 vesicles and its clearance via autophagosomes was a survival contrivance on the part of the cell. Here, we report that Grb2, when in excess, interacts with ultraviolet radiation resistance-associated gene protein (UVRAG) under excess conditions of AICD-Grb2 or Grb2. The N-terminal SH3 domain of Grb2 specifically interacts with UVRAG, unlike the C-terminal SH3 domain. This interaction helps to understand the role of Grb2 in the autophagic maturation of vesicles. © 2014 Published by NRC Research Press.","Autophagy; Beclin 1; Endophilin B1; Grb2; UVRAG","Arencibia, M.G., Hochfeld, W.E., Toh, P.P., Rubinsztein, D.C., Autophagy, a guardian against neurodegeneration (2010) Semin. Cell Dev. Biol., 21 (7), pp. 691-698. , 10.1016/j.semcdb.2010.02.008. 20188203; Castino, R., Davies, J., Beaucourt, S., Isidoro, C., Murphy, D., Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene (2005) FASEB Journal, 19 (8), pp. 1021-1023. , DOI 10.1096/fj.04-3162fje; Chen, Z., Kolokoltsov, A.A., Wang, J., Adhikary, S., Lorinczi, M., Elferink, L.A., Daveya, R.A., GRB2 interaction with the ecotropic murine leukemia virus receptor, mCAT-1, controls virus entry and is stimulated by virus binding (2012) J. Virol., 86 (3), pp. 1421-1432. , 10.1128/JVI.05993-11. 22090132; Cheung, Z.H., Nancy, Y., Endophilin B1 guarding the gate to destruction (2009) Commun. Integr. Biol., 2 (2), pp. 130-132. , 19704909; Codogno, P., Meijer, A.J., Autophagy and signaling: Their role in cell survival and cell death (2005) Cell Death and Differentiation, 12 (SUPPL. 2), pp. 1509-1518. , DOI 10.1038/sj.cdd.4401751, PII 4401751; Ghosal, K., Vogt, D.L., Lianga, M., Shenb, Y., Lamba, B.T., Pimplikara, S.W., Alzheimers disease-like pathological features in transgenic mice expressing the APP intracellular domain (2009) Proc. Natl. Acad. Sci. U.S.A., 106 (43), pp. 18367-18377. , 10.1073/pnas.0907652106. 19837693; Giubellino, A., Battaro, T.R., Bottaro, D.P., Grb2 signaling in cell motility and cancer (2008) Expert Opin. Ther. Targets, 12 (8), pp. 1021-1033. , 10.1517/14728222.12.8.1021. 18620523; Jaeger, P.A., Wyss-Coray, T., Beclin 1 complex in autophagy and Alzheimer disease (2010) Arch. Neurol., 67 (10), pp. 1181-1184. , 10.1001/archneurol.2010.258. 20937944; Jeong, H., Then, F., Melia, Jr.T.J., Mazzulli, J.R., Cui, L., Savas, N.J., Acetylation targets mutant huntingtin to autophagosomes for degradation (2009) Cell, 137 (1), pp. 60-72. , 10.1016/j.cell.2009.03.018. 19345187; Jiang, X., Sorkin, A., Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells (2002) Molecular Biology of the Cell, 13 (5), pp. 1522-1535. , DOI 10.1091/mbc.01-11-0552; Jiang, X., Huang, F., Marusyk, A., Sorkin, A., Grb2 regulates internalization of EGF receptors through clathrin-coated pits (2003) Molecular Biology of the Cell, 14 (3), pp. 858-870. , DOI 10.1091/mbc.E02-08-0532; Kaneko, T., Li, L., Li, S.S.-C., The SH3 domain- A family of versatile peptide- and protein-recognition module (2008) Frontiers in Bioscience, 13 (13), pp. 4938-4952. , DOI 10.2741/3053; Kang, R., Zeh, H.J., Lotze, M.T., Tang, D., The Beclin 1 network regulates autophagy and apoptosis (2011) Cell Death Differ., 18, pp. 571-580. , 10.1038/cdd.2010.191. 21311563; Kirkin, V., McEwan, D.G., Novak, I., Dikic, I., A Role for Ubiquitin in Selective Autophagy (2009) Mol. Cell, 34 (3), pp. 259-269. , 10.1016/j.molcel.2009.04.026. 19450525; Lee, J.A., Neuronal autophagy: A housekeeper or a fighter in neuronal cell survival? (2012) Exp. Neurobiol., 21 (1), pp. 1-8. , 10.5607/en.2012.21.1.1. 22438673; Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B.H., Jung, J.U., Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG (2006) Nat. Cell Biol., 8 (7), pp. 688-699. , 10.1038/ncb1426. 16799551; Feng, C., Feng, P., Ku, B., Oh, B.-H., Jung, J.U., UVRAG: A new player in autophagy and tumor cell growth (2007) Autophagy, 3 (1), pp. 69-71; Liang, C., Lee, J.-S., Inn, K.-S., Gack, M.U., Li, Q., Roberts, E.A., Vergne, I., Jung, J.U., Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking (2008) Nature Cell Biology, 10 (7), pp. 776-787. , DOI 10.1038/ncb1740, PII NCB1740; Longatti, A., Tooze, S.A., Vesicular trafficking and autophagosome formation (2009) Cell Death Differ., 16 (7), pp. 956-965. , 10.1038/cdd.2009.39. 19373247; McShea, A., Zelasko, D.A., Gerst, J.L., Smith, M.A., Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli (1999) Brain Research, 815 (2), pp. 237-242. , DOI 10.1016/S0006-8993(98)01135-4, PII S0006899398011354; Noboru, M., Autophagy: Process and function (2007) Genes Dev., 21 (22), pp. 2861-2873. , 10.1101/gad.1599207. 18006683; Passer, B., Pellegrini, L., Russo, C., Siegel, R.M., Lenardo, M.J., Schettini, G., Bachmann, M., D'Adamio, L., Generation of an apoptotic intracellular peptide by γ-secretase cleavage of Alzheimer's amyloid β protein precursor (2000) Journal of Alzheimer's Disease, 2 (3-4), pp. 289-301; Ravikumar, B., Moreau, K., Jahreiss, L., Puri, C., Rubinsztein, D.C., Plasma membrane contributes to the formation of pre-autophagosomal structures (2010) Nat. Cell Biol., 12 (8), pp. 747-757. , 10.1038/ncb2078. 20639872; Raychaudhuri, M., Mukhopadhyay, D., AICD and its adaptors - In search of new players (2007) Journal of Alzheimer's Disease, 11 (3), pp. 343-358; Raychaudhuri, M., Mukhopadhyay, D., Grb2-mediated alteration in the trafficking of AbetaPP: Insights from Grb2-AICD interaction (2010) J. Alzheimers Dis., 20 (1), pp. 275-292. , 10.3233/JAD-2010-1371. 20164575; Raychaudhuri, M., Roy, K., Das, S., Mukhopadhyay, D., The N-terminal SH3 domain of Grb2 is required for endosomal localization of AβPP (2012) J. Alzheimers Dis., 32 (2), pp. 479-493. , 10.3233/JAD-2012-120388. 22785391; Roy, K., Raychaudhuri, M., Chakrabarti, O., Mukhopadhyay, D., Growth factor receptor-bound protein 2 promotes autophagic removal of amyloid-β protein precursor intracellular domain overload in neuronal cells (2014) J. Alzheimers Dis., 38 (4), pp. 881-895. , 10.3233/JAD-130929. 24100123; Salminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J., Haapasalo, A., Soininen, H., Hiltunen, M., Impaired autophagy and APP processing in Alzheimers disease: The potential role of Beclin 1 interactome (2013) Prog. Neurobiol., 106-107, pp. 33-54. , 10.1016/j.pneurobio.2013.06.002. 23827971; Sun, Q., Fan, W., Chen, K., Ding, X., Chen, S., Zhong, Q., Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase (2008) Proc. Natl. Acad. Sci. U.S.A., 105 (49), pp. 19211-19216. , 10.1073/pnas.0810452105. 19050071; Thies, W., Bleiler, L., Alzheimers disease facts and figures (2011) Alzheimers Dement., 7 (2), pp. 208-244. , 10.1016/j.jalz.2011.02.004. 21414557; Tonikian, R., Xin, X., Toret, C.P., Gfeller, D., Landgraf, C., Panni, S., Bayesian modeling of the yeast SH3 domain interactome predicts spatiotemporal dynamics of endocytosis proteins (2009) PloS Biol., 7 (10), p. 1000218. , 10.1371/journal.pbio.1000218. 19841731; Tsujimoto, Y., Shimizu, S., Another way to die: Autophagic programmed cell death (2005) Cell Death and Differentiation, 12 (SUPPL. 2), pp. 1528-1534. , DOI 10.1038/sj.cdd.4401777, PII 4401777; Martinez-Vicente, M., Cuervo, A.M., Autophagy and neurodegeneration: When the cleaning crew goes on strike (2007) Lancet Neurology, 6 (4), pp. 352-361. , DOI 10.1016/S1474-4422(07)70076-5, PII S1474442207700765; Vidal, M., Goudreau, N., Cornille, F., Cussac, D., Gincel, E., Garbay, C., Molecular and cellular analysis of Grb2 SH3 domain mutants: Interaction with Sos and dynamin (1999) Journal of Molecular Biology, 290 (3), pp. 717-730. , DOI 10.1006/jmbi.1999.2899; Waterman, H., Katz, M., Rubin, C., Shtiegman, K., Lavi, S., Elson, A., Jovin, T., Yarden, Y., A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling (2002) EMBO Journal, 21 (3), pp. 303-313. , DOI 10.1093/emboj/21.3.303; Yamazaki, T., Zaal, K., Hailey, D., Presley, J., Lippincott-Schwartz, J., Samelson, L.E., Role of Grb2 in EGF-stimulated EGFR internalization (2002) Journal of Cell Science, 115 (9), pp. 1791-1802; Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H.D., Sun, M., Sato, Y., Liang, C., Wang, H.-G., Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis (2007) Nature Cell Biology, 9 (10), pp. 1142-1151. , DOI 10.1038/ncb1634, PII NCB1634; Zhou, D., Noviello, C., D'Ambrosio, C., Scaloni, A., D'Adamio, L., Growth factor receptor-bound protein 2 interaction with the tyrosine-phosphorylated tail of amyloid β precursor protein is mediated by its Src homology 2 domain (2004) Journal of Biological Chemistry, 279 (24), pp. 25374-25380. , DOI 10.1074/jbc.M400488200",Article,Scopus,2-s2.0-84901976076
"Cheng X.-L., Li M.-K.","Effect of topiramate on apoptosis-related protein expression of hippocampus in model rats with Alzheimers Disease",2014,"European Review for Medical and Pharmacological Sciences","18","6",,"761","768",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902086705&partnerID=40&md5=900eef381b0dbb278613e3de1561a4e3","Department of Neurology, Hospital of Yangtze University, Hubei, China","Cheng, X.-L., Department of Neurology, Hospital of Yangtze University, Hubei, China; Li, M.-K., Department of Neurology, Hospital of Yangtze University, Hubei, China","OBJECTIVES: Alzheimer's disease is an age-related neurodegenerative disease and a synaptic function defect disease, the clinical symptoms are mainly progressive cognitive impairment, affecting patient's social function. Aim of this report was to investigate the effect of topiramate on apoptosis-related protein expression (Bcl-2, Survivin, Fas, Bax and Caspase-3) in the hippocampus of a rat model with Alzheimers Disease (AD). MATERIALS AND METHODS: Thirty-six adult Wistar rats were randomly divided into a control group, a model group and a test group. A dose of amyloid beta-protein 1-40 (Aβ1-40) was injected into the hippocampus of the rats in the model and test groups, and the control rats are injected with same amount of saline. After AD model was successfully established, the rats in each group were administrated with an i.p. injection of topiramate (20 mg/kg/d) for 30 days. The effect of topiramate on the apoptosis-related protein levels in hippocampus neurons was studied by immunohistochemistry. RESULTS: The number of Bcl-2 and Survivin positive cells and optical density in hippocampus of rats in test group was more than those of rats in model groups, but less than those of rats in control group (p < 0.01); Fas, Bax and Caspase-3 positive cells and optical density in hippocampus of rats in test group was less than those of rats in the model group, but more than those of rats in control group (p < 0.01). CONCLUSIONS: Alzheimer's disease can induce apoptosis of hippocampus neurons in rats. Topiramate can prevent apoptosis of hippocampus neurons, at least in part, by increasing expression of Bcl-2 and Survivin and decreasing expression of Fas, Bax and Caspase-3.","Alzheimer's disease; Bax; Bcl-2; Caspase-3; Fas; Survivin; Topiramate","Querfurth, H.W., Laferla, F.M., Alzheimer's disease (2010) N Engl J Med, 362, pp. 329-344; Davies, C.A., Mann, D.M., Sumpter, P.Q., Yates, P.O., A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease (1987) J Neurol Sci, 78, pp. 151-164; Selkoe, D.J., Alzheimer's disease is a synaptic failure (2002) Science, 298, pp. 789-791; Masliah, E., Mallory, M., Alford, M., Deteresa, R., Hansen, L.A., McKeel, D.W., Morris, J.C., Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease (2001) Neurology, 56, pp. 127-129; Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., Deteresa, R., Hill, R., Hansen, L.A., Katzman, R., Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment (1991) Ann Neurol, 30, pp. 572-580; Bamberger, M.E., Landreth, G.E., Inflammation, apoptosis, and Alzheimer's disease (2002) Neuroscientist, 8, pp. 276-283; Castellani, R.J., Rolston, R.K., Smith, M.A., Alzheimer disease (2010) Dis Mon, 56, pp. 484-546; Butterfield, D.A., Griffin, S., Munch, G., Pasinetti, G.M., Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists (2002) J Alzheimers Dis, 4, pp. 193-201; Cummings, J.L., Alzheimer's disease: From molecular biology to neuropsychiatry (2003) Semin Clin Neuropsychiatry, 8, pp. 31-36; Calissano, P., Matrone, C., Amadoro, G., Apoptos is and in vitro Alzheimer disease neuronal models (2009) Commun Integr Biol, 2, pp. 163-169; De Kosky, St., Pathology and pathways of Alzheimer's disease with an update on new developments in treatment (2003) J Am Geriatr Soc, 51 (SUPPL. 1), pp. 314-320; Doraiswamy, P.M., Alzheimer's disease and the glutamate NMDA receptor (2003) Psychopharmacol Bull, 37, pp. 41-49; Doraiswamy, P.M., The role of the N-methyl-Daspartate receptor in Alzheimer's disease: Therapeutic potential (2003) Curr Neurol Neurosci Rep, 3, pp. 373-378; Sastre, M., Walter, J., Gentleman, S.M., Interactions between APP secretases and inflammatory mediators (2008) J Neuroinflamm, 5, p. 25; Lx, L.I., Dai, J.P., Lq, R.U., Yin, G.F., Zhao, B., Effects of tanshinone on neuropathological changes induced by amyloid beta-peptide( 1-40) injection in rat hippocampus (2004) Acta Pharmacol Sin, 25, pp. 861-868; Laferla, F.M., Tinkle, B.T., Bieberich, C.J., Haudenschild, C.C., Jay, G., The Alzheimer's Abeta peptide induces neurogegeneration and apoptotic cell death in transgenic mice (1995) Nat Genet, 9, pp. 12-30; Jh, S.U., Anderson, A.J., Cummings, B.J., Cotman, C.W., Immunohistochemical evidence for apoptosis in Alzheimer's disease (1994) Neuroreport, 5, pp. 2529-2533; Calissano, P., Matrone, C., Amadoro, G., Apoptosis and in vitro Alzheimer disease neuronal models (2009) Commun Integr Biol, 2, pp. 163-169; Yang, Y., Varvel, N.H., Lamb, B.T., Herrup, K., Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models (2006) J Neurosci, 26, pp. 775-784; Never, R.L., McPhie, D.L., Dysfunction of amy oid precursor protein signaling in neurons leads to DNA synthesis and apoptosis (2007) Biochim Biophys Acta, 1772, pp. 430-437; Bisaglia, M., Venezia, V., Piccioli, P., Stanzione, S., Porcile, C., Russo, C., Mancini, F., Schettini, G., Acetaminophen protects hippoeampal neurols and PCI2 cultures from amyloid beta-peptides induced oxidative stress and reduces NF-kappaB activation (2002) Neurochem Int, 41, pp. 43-54; Hardy, J., Sclkoo, D.J., The amyloid hypothesis of Alzheimer' B disease: Progress and problems on the road to therapeutics (2002) Science, 297, pp. 353-356; Galindo, M.F., Ikuta, I., Zhu, X., Casadesus, G., Jordán, J., Mitochondrial biology in Alzheimer's disease pathngenesis (2010) J Neurochem, 114, pp. 933-945; Buenz, E.J., Sauer, B.M., Lafrance-Corey, R.G., Deb, C., Denic, A., German, C.L., Howe, C.L., Apoptosis of hippocampal pyramidal neurons is virus independent in a in a mouse model of acute neurovirulent picornavirus infection (2009) Am J Pathol, 175, pp. 668-684; Broughton, B.R., Reutens, D.C., Sobey, C.G., Apoptotic mechanisms after cerebral ischemia (2009) Stroke, 40, pp. 331-339; Chen, Y., McPhie, D.L., Hirschberg, J., Neve, R.L., The amyloid precursor protein-binding protein APPBPI drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons (2000) J Biol Chem, 275, pp. 8929-8935; Shaked, G.M., Kummer, M.P., Dc, L.U., Galvan, V., Bredesen, D.E., Koo, E.H., Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624) (2006) FASEB J, 20, pp. 1254-1256; Rovelet Lecrux, A., Hannequin, P., Ranx, G., Meur N, L.E., Laquerrière, A., Vital, A., Dumanchin, C., Campion, D., APP locus duplication cause autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy (2006) Nat Genet, 38, pp. 24-26; Kuo, M.H., Allis, C.D., Roles of histone acetyltransferases and deacetylases in gene regulation (1998) Bioessays, 20, pp. 615-626; Cyr, A.R., Domann, F.E., The redox basis of epigenetic modifications: From mechanisms to functional consequences (2011) Antioxid Redox Signal, 15, pp. 551-589; Wade, P.A., Pruss, D., Wolffe, A.P., Histone acetylation: Chromatin in action (1997) Trends Biochem Sci, 22, pp. 128-132; Banerjee, A., Trivedi, C.M., Damera, G., Jiang, M., Jester, W., Hoshi, T., Trichostatin A abrogates airway constriction, but not inflammation in mouse and human asthma models (2012) Am J Respir Cell Mol Biol, 46, pp. 132-138; Choi, J.H., Sw, O.H., Kang, M.S., Kwon, H.J., Gt, O.H., Kim, D.Y., Trichostatin A attenuates airway inflammation in mouse asthma model (2005) Clin Exp Allergy, 35, pp. 89-96; Antos, C.L., McKinsey, T.A., Dreitz, M., Hollingsworth, L.M., Zhang, C.L., Schreiber, K., Rindt, H., Olson, E.N., Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors (2003) J Biol Chem, 278, pp. 28930-28937; Backs, J., Olson, E.N., Control of cardiac growth by histone acetylation/deacetylation (2006) Circ Res, 98, pp. 15-24; Haberland, M., Montgomery, R.L., Olson, E.N., The many roles of histone deacetylases in development and physiology: Implications for disease and therapy (2009) Nat Rev Genet, 10, pp. 32-42; Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B.A., Olson, E.N., Hill, J.A., Suppression of class i and II histone deacetylases blunts pressure-overload cardiac hypertrophy (2006) Circulation, 113, pp. 2579-2588; McKinsey, T.A., Olson, E.N., Dual roles of histone deacetylases in the control of cardiac growth (2004) Novartis Found Symp, 259, pp. 132-1341. , discussion 141-145, 163-169; Chuang, D.M., Leng, Y., Marinova, Z., Kim, H.J., Chiu, C.T., Multiple roles of HDAC inhibition in neurodegenerative conditions (2009) Trends Neurosci, 32, pp. 591-601; Royce, S.G., Dang, W., Ververis, K., De Sampayo, N., Elosta, A., Tang, M.L.K., Karaggiannis, T.C., Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease (2011) Epigenetics, 6, pp. 1463-1470; Francis, Y.I., Fa, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D.S., Arancio, O., Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease (2009) J Alzheimers Dis, 18, pp. 131-139; Kilgore, M., Miller, C.A., Fass, D.M., Hennig, K.M., Haggarty, S.J., Sweatt, J.D., Rumbaugh, G., Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease (2010) Neuropsychopharmacology, 35, pp. 870-880; Park, H.J., Kim, H.J., Park, H.J., Ra, J., Zheng, L.T., Yim, S.V., Chung, J.H., Protective effect of topiramate on kainic acid-induced cell death in mice hippocampus (2008) Epilepsia, 49, pp. 163-167; Shi, J.Q., Wang, B.R., Tian, Y.Y., Xu, J., Gao, L., Zhao, S.L., Jiang, T., Zhang, Y.D., Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice (2013) CNS Neurosci Ther, 19, pp. 871-881; Mowla, A., Pani, A., Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: A double-blind, randomized clinical trial (2010) J Clin Psychopharmacol, 30, pp. 40-43; Ohkawara, T., Nagase, H., Koh, C.S., Nakayama, K., The amyloid precursor protein intracellular domain alaters gene expression and induces neuron-specific apoptosis (2011) Gene, 475, pp. 1-9; Kurul, S.H., Yi, U., Kumral, A., Yan K, T.U., Cilaker, S., Kolatan, E., Yilmaz, O., Genç, S., Protective effects of topiramate against hyperoxic brain injury in the developing brain (2009) Neuropediatrics, 40, pp. 22-27; Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M., Bialer, M., The activity of antiepileptic drugs as histone deacetylase inhibitors (2004) Epilepsia, 45, pp. 737-744; Ziemann, U., Pharmacology of TMS (2003) Suppl Clin Neurophysiol, 56, pp. 226-231",Article,Scopus,2-s2.0-84902086705
"Yu Y., Zhang L., Li C., Sun X., Tang D., Shi G.","A method for evaluating the level of soluble β-Amyloid(1-40/1-42) in alzheimers disease based on the binding of gelsolin to β-amyloid peptides",2014,"Angewandte Chemie - International Edition","53","47",,"12832","12835",,1,10.1002/anie.201405001,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911417363&partnerID=40&md5=c7ca46ba9c8f1532bf8d932af2e29a5c","Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Department of Chemistry, East China Normal University, 500 Dongchuan RoadShanghai, China","Yu, Y., Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Zhang, L., Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Li, C., Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Sun, X., Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Tang, D., Department of Pharmaceutical Analysis, Xuzhou Medical CollegeXuzhou, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical CollegeXuzhou, China; Shi, G., Department of Chemistry, East China Normal University, 500 Dongchuan RoadShanghai, China","In the present work, a new electrochemical strategy for the sensitive and specific detection of soluble β-amyloid Aβ(1-40/1-42) peptides in a rat model of Alzheimers disease (AD) is described. In contrast to previous antibody-based methods, β-amyloid(1-40/1-42) was quantified based on its binding to gelsolin, a secretory protein present in the cerebrospinal fluid (CSF) and plasma. The level of soluble β-amyloid peptides in the CSF and various brain regions were found with this method to be lower in rats with AD than in normal rats. © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.","Aggregation; Alzheimer's disease; Biosensors; Electrochemistry; β-amyloid peptides","Hardy, J., Selkoe, D.J., (2002) Science, 297, pp. 353-356; Glenner, G.G., Wong, C.W., (1984) Biochem. Biophys. Res. Commun., 120, pp. 885-890; Goedert, M., Spillantini, M.G., (2006) Science, 314, pp. 777-781; Hamley, I.W., (2007) Angew. Chem. Int. Ed., 46, pp. 8128-8147; (2007) Angew. Chem., 119, pp. 8274-8295; Irvine, G.B., El-Agnaf, O.M.A., Shankar, G.M., Walsh, D.M., (2008) Mol. Med., 14, pp. 451-464; Glabe, C.G., (2006) Neurobiol. Aging, 27, pp. 570-575; Masters, C.L., Simms, G., Weinman, N.A., Maulthaup, G., McDonald, B.L., Beyreuther, K., (1985) Proc. Natl. Acad. Sci. USA, 82, pp. 4245-4249; Stine, W.B., Jr., Dahigren, K.N., Krafft, G.A., Ladu, M.J., (2003) J. Biol. Chem., 278, pp. 11612-11622; Szab-, Z., Klement, E., Jost, K., Zarandi, M., Soos, K., Penke, B., (1999) Biochem. Biophys. Res. Commun., 265, pp. 297-300; Shen, C.L., Murphy, R.M., (1995) Biophys. J., 69, pp. 640-651; Vestergaard, M., Kerman, K., Saito, M., Nagatani, N., Takamura, Y., Tamiya, E., (2005) J. Am. Chem. Soc., 127, pp. 11892-11893; Nordberg, A., (2008) Neuropsychologia, 46, pp. 1636-1641; Karen, M.R., Kristen, M.K., Denise, C.P., (2009) Neuropsychol. Rev., 19, pp. 436-450; Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., (1994) Neuron, 13, pp. 45-53; Miller, D.L., Papayannopoulos, I.A., Styles, J., Bobin, S.A., Lin, Y.Y., Biemann, L.K., Iqbal, K., (1993) Arch. Biochem. Biophys., 301, pp. 41-52; Fukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., Yanagisawa, K., (2000) Eur Neurol., 43, pp. 155-160; Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., Blennow, K., (2007) Dementia Geriatr. Cognit. Disord., 23, pp. 316-320; N-Slund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., (2000) JAMAJ. Am. Med. Assoc., 283, pp. 1571-1577; Liu, L., He, Q.G., Zhao, F., Xia, N., Liu, H.J., Li, S.J., Liu, R.L., Zhan, H., (2014) Biosens. Bioelectron., 51, pp. 208-212; Tamaoka, A., Fraser, P.E., Ishii, K., (1998) Brain Res. Mol Brain Res., 56, pp. 178-185; Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., (2006) Neurology, 66, pp. 1837-1844; Thal, D.R., Capetillo-Zarate, E., Del Tredici, K., Braak, H., (2006) Science of Aging Knowledge Environment: SA GE KE, (6). , re1; Mustafa, M.K., Nabok, A., Parkinson, D., Tothill, I.E., Salam, F., Tsargorodskaya, A., (2010) Biosens. Bioelectron., 26, pp. 1332-1336; Chauhan, V.P.S., Ray, I., Chauhan, A., Wisniewski, H.M., (1999) Biochem. Biophys. Res. Commun., 258, pp. 241-246; Zhang, X.A., Teng, Y.Q., Fu, Y., Xu, L.L., Zhang, S.P., He, B., Wang, C.G., Zhang, W., (2010) Anal. Chem., 82, pp. 9455-9460; Selkoe, D.J., (1996) J. Biol. Chem., 271, pp. 18295-18298; Olt, J., Mburu, P., Johnson, S.L., Parker, A., (2014) PLoS One, 9, pp. e87331-87337; Wang, Q., Xie, Y., Du, Q.S., Wu, X.J., (2003) J. Cell. Biol., 160, pp. 565-575; Kusano, H., Shimizu, S., Koya, R.C., Fujita, H., (2000) Oncogene, 19, pp. 4807-4814; Picou, R., Moses, J.P., Wellman, A.D., Kheterpal, I., Douglass Gilman, S., (2010) Analyst, 135, pp. 1631-1635; Wang, C., Liu, D., Wang, Z., (2012) Chem. Commun., 48, pp. 8392-8394; Xia, N., Liu, L., Harrington, M.G., Wang, J., Zhou, F., (2010) Anal. Chem., 82, pp. 10151-10157; Moir, R.D., Atwood, C.S., Romano, D.M., Laurans, M.H., Huang, X., Bush, A.I., Smith, J.D., Tanzi, R.E., (1999) Biochemistry, 38, pp. 4595-4603; Golde, T.E., Eckman, C.B., Younkin, S.G., (2000) Biochim. Biophys. Acta Mol. Basis Dis., 1502, pp. 172-187; Grimmer, T., Riemenschneider, M., Fçrstl, H., Henriksen, G., Klunk, W.E., Mathis, C.A., (2009) Biol. Psychiatry, 65, pp. 927-934; Strozyk, D., Blennow, K., White, L.R., Launer, L.J., (2003) Neurology, 60, pp. 652-656; Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Lopresti, B.J., Dekosky, S.T., (2008) Brain, 131, pp. 1630-1645; Satou, T., Cummings, B., Head, E., Nielson, K., Hahn, F., Milgram, N., (1997) Brain Res., 774, pp. 35-43; Echeverria, V., Cuello, A.C., (2002) Mol. Neurobiol., 26, pp. 299-316; Rofina, J., Van Andel, I., Van Ederen, A., Papaioannou, N., Yamaguchi, H., Guys, E., (2000) Amyloid, 10, pp. 86-96",Article,Scopus,2-s2.0-84911417363
"Rao A.K., Chou A., Bursley B., Smulofsky J., Jezequel J.","Systematic review of the effects of exercise on activities of daily living in people with alzheimers disease",2014,"American Journal of Occupational Therapy","68","1",,"50","56",,4,10.5014/ajot.2014.009035,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84892581466&partnerID=40&md5=b6cafed321a0e231b69d321924d503c9","Department of Rehabilitation and Regenerative Medicine and G. H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, 710 West 168th Street, New York, NY 10032, United States; Department of Rehabilitation and Regenerative Medicine (Program in Physical Therapy), College of Physicians and Surgeons, Columbia University, New York, United States","Rao, A.K., Department of Rehabilitation and Regenerative Medicine and G. H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, 710 West 168th Street, New York, NY 10032, United States; Chou, A., Department of Rehabilitation and Regenerative Medicine (Program in Physical Therapy), College of Physicians and Surgeons, Columbia University, New York, United States; Bursley, B., Department of Rehabilitation and Regenerative Medicine (Program in Physical Therapy), College of Physicians and Surgeons, Columbia University, New York, United States; Smulofsky, J., Department of Rehabilitation and Regenerative Medicine (Program in Physical Therapy), College of Physicians and Surgeons, Columbia University, New York, United States; Jezequel, J., Department of Rehabilitation and Regenerative Medicine (Program in Physical Therapy), College of Physicians and Surgeons, Columbia University, New York, United States","OBJECTIVE. Alzheimers disease (AD) results in a loss of independence in activities of daily living (ADLs), which in turn affects the quality of life of affected people and places a burden on caretakers. Limited research has examined the influence of physical training (aerobic, balance, and strength training) on ADL performance of people with AD. METHOD. Six randomized controlled trials (total of 446 participants) fit the inclusion criteria. For each study, we calculated effect sizes for primary and secondary outcomes. RESULTS. Average effect size (95% confidence interval) for exercise on the primary outcome (ADL performance) was 0.80 (p ≤ .001). Exercise had a moderate impact on the secondary outcome of physical function (effect size 5 0.53, p 5 .004). CONCLUSION. Occupational therapy intervention that includes aerobic and strengthening exercises may help improve independence in ADLs and improve physical performance in people with AD. Additional research is needed to identify specific components of intervention and optimal dosage to develop clinical guidelines.",,"Changing the trajectory of alzheimer's disease: A national imperative (2010) American Occupational Therapy Association (N.d.). AOTA Guide to Medicare Local Coverage Determinations, , www.alz.org/documents_custom/trajectory.pdf, Alzheimer's Association. http://www.aota.org/z/media/Corporate/Files/ Advocacy/ Reimb/Pay/Medicare/LCDs/Resources/LCD%20Advocacy% 20Packet1.ashx; Arbesman, M., Lieberman, D., Methodology for the systematic reviews on occupational therapy for adults with alzheimer's disease and related dementias (2011) American Journal of Occupational Therapy, 65, pp. 490-496. , http://dx.doi.org/10.5014/ajot.2011.002576; Brawley, E.C., Design innovations for aging and alzheimer's: Creating caring environments (2006) Hoboken, , http://ims.cochrane.org/revman/download, NJ: Wiley. Cochrane Collaboration. (2011). Review Manager (RevMan, Version 5.2.3); Coelho, F.G., Santos-Galduroz, R.F., Gobbi, S., Stella, F., Systematized physical activity and cognitive performance in elderly with alzheimer's dementia: A systematic review (2009) Revista Brasileira de Psiquiatria, 31, pp. 163-170. , http://dx.doi.org/10.1590/S1516-44462009000200014, (Sao Paulo, Brazil; Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., Evans, D.A., Alzheimer disease in the US population: Prevalence estimates using the 2000 census (2003) Archives of Neurology, 60 (8), pp. 1119-1122. , DOI 10.1001/archneur.60.8.1119; Robb, G., Heneghan, C., The gate frame: Critical appraisal with pictures (2006) Evidence-Based Medicine, 11, pp. 35-38. , http://dx.doi.org/10.1136/ebm.11.2.35; Jellinger, K.A., Attems, J., Neuropathological evaluation of mixed dementia (2007) Journal of the Neurological Sciences, 257 (1-2), pp. 80-87. , DOI 10.1016/j.jns.2007.01.045, PII S0022510X07000780, Vascular Dementia Proceedings of the Fourth International Congress on Vascular Dementia; Jensen, L.E., Padilla, R., Effectiveness of interventions to prevent falls in people with alzheimer's disease and related dementias (2011) American Journal of Occupational Therapy, 65, pp. 532-540. , http://dx.doi.org/10.5014/ajot.2011.002626; Kandel, E.R., Schwartz, J.H., Jessell, T.M., (2000) Principles of Neural Science, , (4th ed.). New York: McGraw-Hill; McGibbon Lammi, B., Law, M., The effects of Family-Centred Functional Therapy on the occupational performance of children with cerebral palsy (2003) Canadian Journal of Occupational Therapy, 70 (5), pp. 285-297; Letts, L., Edwards, M., Berenyi, J., Moros, K., O'Neill, C., O'Toole, C., McGrath, C., Using occupations to improve quality of life, health and wellness, and client and caregiver satisfaction for people with alzheimer's disease and related dementias (2011) American Journal of Occupational Therapy, 65, pp. 497-504. , http://dx.doi.org/10.5014/ajot.2011.002584; Mayeux, R., Clinical practice: Early alzheimer's disease (2010) New England Journal of Medicine, 362, pp. 2194-2201. , http://dx.doi.org/10.1056/NEJMcp0910236; Monin, J.K., Schulz, R., Interpersonal effects of suffering in older adult caregiving relationships (2009) Psychology and Aging, 24, pp. 681-695. , http://dx.doi.org/10.1037/a0016355; (2013) OCEBM Levels of Evidence System, , http://www.cebm.net/index.aspx?o55653, Oxford Centre for Evidence Based Medicine Levels of Evidence Working Group; Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B., Burke, J.R., Wallace, R.B., Prevalence of dementia in the United States: The aging, demographics, and memory study (2007) Neuroepidemiology, 29 (1-2), pp. 125-132. , DOI 10.1159/000109998; Roach, K.E., Tappen, R.M., Kirk-Sanchez, N., Williams, C.L., Loewenstein, D., A randomized controlled trial of an activity specific exercise program for individuals with alzheimer disease in long-term care settings (2011) Journal of Geriatric Physical Therapy, 34, pp. 50-56. , http://dx.doi.org/10.1519/JPT.0b013e31820aab9c; Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., Andrieu, S., Riviere, D., Vellas, B., Exercise program for nursing home residents with Alzheimer's disease: A 1-year randomized, controlled trial (2007) Journal of the American Geriatrics Society, 55 (2), pp. 158-165. , DOI 10.1111/j.1532-5415.2007.01035.x; Santana-Sosa, E., Barriopedro, M.I., López-Mojares, L.M., Pérez, M., Lucia, A., Exercise training is beneficial for alzheimer's patients (2008) International Journal of Sports Medicine, 29, pp. 845-850. , http://dx.doi.org/10.1055/s-2008-1038432; Schneider, J.A., Arvanitakis, Z., Bang, W., Bennett, D.A., Mixed brain pathologies account for most dementia cases in community-dwelling older persons (2007) Neurology, 69 (24), pp. 2197-2204. , DOI 10.1212/01.wnl.0000271090.28148.24, PII 0000611420071211000005; Schulz, R., Mendelsohn, A.B., Haley, W.E., Mahoney, D., Allen, R.S., Zhang, S., Thompson, L., Belle, S.H., End-of-Life Care and the Effects of Bereavement on Family Caregivers of Persons with Dementia (2003) New England Journal of Medicine, 349 (20), pp. 1936-1942. , DOI 10.1056/NEJMsa035373; Seshadri, S., Wolf, P.A., Beiser, A., Au, R., McNulty, K., White, R., D'Agostino, R.B., Lifetime risk of dementia and Alzheimer's disease: The impact of mortality on risk estimates in the Framingham Study (1997) Neurology, 49 (6), pp. 1498-1504; Teri, L., Gibbons, L.E., McCurry, S.M., Logsdon, R.G., Buchner, D.M., Barlow, W.E., Kukull, W.A., Larson, E.B., Exercise Plus Behavioral Management in Patients with Alzheimer Disease: A Randomized Controlled Trial (2003) Journal of the American Medical Association, 290 (15), pp. 2015-2022. , DOI 10.1001/jama.290.15.2015; Venturelli, M., Scarsini, R., Schena, F., Six-month walking program changes cognitive and adl performance in patients with alzheimer (2011) American Journal of Alzheimer's Disease and Other Dementias, 26, pp. 381-388. , http://dx.doi.org/10.1177/1533317511418956; Vreugdenhil, A., Cannell, J., Davies, A., Razay, G., A community-based exercise programme to improve functional ability in people with alzheimer's disease: A randomized controlled trial (2012) Scandinavian Journal of Caring Sciences, 26, pp. 12-19. , http://dx.doi.org/10.1111/j.1471-6712.2011.00895.x; Yaffe, K., Fox, P., Newcomer, R., Sands, L., Lindquist, K., Dane, K., Covinsky, K.E., Patient and caregiver characteristics and nursing home placement in patients with dementia (2002) Journal of the American Medical Association, 287 (16), pp. 2090-2097",Review,Scopus,2-s2.0-84892581466
"Tsao S., Gajawelli N., Zhou J., Shi J., Ye J., Wang Y., Lepore N.","Evaluating the predictive power of multivariate tensor-based morphometry in Alzheimer's disease progression via convex fused sparse group Lasso",2014,"Progress in Biomedical Optics and Imaging - Proceedings of SPIE","9034",, 90342L,"","",,,10.1117/12.2042720,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902095854&partnerID=40&md5=e082f600ae133a607e4176ef804df016","University of Washington, Seattle, WA, United States; Children's Hospital Los Angeles, Los Angeles, CA, United States; Arizona State University, Phoenix, AZ, United States","Tsao, S., University of Washington, Seattle, WA, United States; Gajawelli, N., Children's Hospital Los Angeles, Los Angeles, CA, United States; Zhou, J., Arizona State University, Phoenix, AZ, United States; Shi, J., Arizona State University, Phoenix, AZ, United States; Ye, J., Arizona State University, Phoenix, AZ, United States; Wang, Y., Arizona State University, Phoenix, AZ, United States; Lepore, N., Children's Hospital Los Angeles, Los Angeles, CA, United States","Prediction of Alzheimers disease (AD) progression based on baseline measures allows us to understand disease progression and has implications in decisions concerning treatment strategy. To this end we combine a predictive multi-task machine learning method1 with novel MR-based multivariate morphometric surface map of the hippocampus2 to predict future cognitive scores of patients. Previous work by Zhou et al.1 has shown that a multi-task learning framework that performs prediction of all future time points (or tasks) simultaneously can be used to encode both sparsity as well as temporal smoothness. They showed that this can be used in predicting cognitive outcomes of Alzheimers Disease Neuroimaging Initiative (ADNI) subjects based on FreeSurfer-based baseline MRI features, MMSE score demographic information and ApoE status. Whilst volumetric information may hold generalized information on brain status, we hypothesized that hippocampus specific information may be more useful in predictive modeling of AD. To this end, we applied Shi et al.2s recently developed multivariate tensor-based (mTBM) parametric surface analysis method to extract features from the hippocampal surface. We show that by combining the power of the multi-task framework with the sensitivity of mTBM features of the hippocampus surface, we are able to improve significantly improve predictive performance of ADAS cognitive scores 6, 12, 24, 36 and 48 months from baseline. © 2014 SPIE.","ADAS-Cog; Alzheimers Disease; Disease Progression; Feature Selection; Fused Lasso; Hippocampus; Multi-task learning; Tensor-based Morphometry","Zhou, J., Liu, J., Narayan, V.A., Ye, J., Modeling disease progression via multi-task learning (2013) NeuroImage; Shi, J., Thompson, P.M., Gutman, B., Andwang, Y., Surface uid registration of conformal representation: Application to detect disease burden and genetic inuence on hippocampus (2013) NeuroImage; Caselli, R.J., Locke, D.E.C., Dueck, A.C., Knopman, D.S., Woodru, B.K., Ho-man-Snyder, C., Rademakers, R., Reiman, E.M., The neuropsychology of normal aging and preclinical alzheimer's disease (2013) Alzheimers Dement, , Mar; Elias-Sonnenschein, L.S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S.-K., Laitinen, M., Hiltunen, M., Genetic loci associated with alzheimer's disease and cerebrospinal uid biomarkers in afinnish case-control cohort (2013) PLoS One, 8 (4), pp. e59676; Teipel, S.J., Grothe, M., Lista, S., Toschi, N., Garaci, F.G., Hampel, H., Relevance of magnetic resonance imaging for early detection and diagnosis of alzheimer disease (2013) Med Clin North Am, 97, pp. 399-424. , May; Becker, G.A., Ichise, M., Barthel, H., Luthardt, J., Patt, M., Seese, A., Schultze-Mosgau, M., Sabri, O., Pet quantification of 18f-orbetaben binding to-amyloid deposits in human brains (2013) J Nucl Med, , Mar; Blennow, K., Zetterberg, H., The application of cerebrospinal uid biomarkers in early diagnosis of alzheimer disease (2013) Med Clin North Am, 97, pp. 369-376. , May; Hajjar, I., Brown, L., Mack, W.J., Chui, H., Alzheimer pathology and angiotension receptor blockers (2013) JAMA Neurol, 70, p. 414. , Mar; Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C.R., Jagust, W., Trojanowski, J.Q., Beckett, L., Ways toward an early diagnosis in alzheimer's disease: The alzheimer's disease neuroimaging initiative (adni) (2005) Alzheimers Dement, 1, pp. 55-66. , Jul; Wang, Y., Yuan, L., Shi, J., Greve, A., Ye, J., Toga, A.W., Reiss, A.L., Thompson, P.M., Applying tensor-based morphometry to parametric surfaces can improve mri-based disease diagnosis (2013) Neuroimage, 74, pp. 209-230. , Jul; Jenkinson, M., Beckmann, C.F., Behrens, T.E.J., Woolrich, M.W., Smith, S.M., (2012) Neuroim-age, 62, pp. 782-790. , Aug",Conference Paper,Scopus,2-s2.0-84902095854
"Hanson E.A., Westlye E., Lundervold A.","A PCA-based thresholding strategy for group studies of brain connectivity - With applications to resting state fMRI",2014,"Proceedings of the IEEE Southwest Symposium on Image Analysis and Interpretation",,, 6806029,"61","64",,,10.1109/SSIAI.2014.6806029,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902278983&partnerID=40&md5=607a606fbf61d9e0a37642f32766e4fa","Department of Mathematics, University of Bergen, Norway; Neuroinformatics and Image Analysis Laboratory, University of Bergen, Norway; Department of Medicine, Volda Hospital, Norway; Department of Biomedicine, University of Bergen, Norway; Department of Radiology, Haukeland University Hospital, Norway","Hanson, E.A., Department of Mathematics, University of Bergen, Norway, Neuroinformatics and Image Analysis Laboratory, University of Bergen, Norway; Westlye, E., Department of Medicine, Volda Hospital, Norway; Lundervold, A., Neuroinformatics and Image Analysis Laboratory, University of Bergen, Norway, Department of Biomedicine, University of Bergen, Norway, Department of Radiology, Haukeland University Hospital, Norway","Functional brain connectivity can be measured from BOLD fMRI recordings using graph representations incorporating inter-regional similarity of time courses. The resulting binary graphs are commonly constructed using thresholding of correlation values between pairwise time series anchored at their corresponding brain locations, representing the nodes in the graph. In this work we propose a new data driven approach to the challenge of selecting correlation threshold levels in group studies. Our approach addresses a collection of subject-specific graphs, thresholded at different levels. It combines information such that variability is preserved, and detection of sub-groups in the sample, having specific properties, is facilitated. The method is illustrated on simple synthetic graphs, and also tested on data from a resting state fMRI study of healthy elderly people with varying genetic risk of Alzheimers disease. © 2014 IEEE.","Alzheimers disease; fMRI; Functional brain connectivity; Graph analysis; Graph thresholding","He, Y., Chen, Z.J., Evans, A.C., Small-world anatomical networks in the human brain revealed by cortical thickness from MRI (2007) Cerebral Cortex, 17 (10), pp. 2407-2419. , DOI 10.1093/cercor/bhl149; Rubinov, M., Sporns, O., Complex network measures of brain connectivity: Uses and interpretations (2010) NeuroImage, 52 (3), pp. 1059-1069. , computational Models of the Brain; Bullmore, E., Sporns, O., Complex brain networks: Graph theoretical analysis of structural and functional systems (2009) Nat Rev Neurosci, 10 (3), pp. 186-198; Smith, S.M., The future of fmri connectivity (2012) NeuroImage, 62 (2), pp. 1257-1266. , 20 YEARS OF fMRI; Westlye, E.T., Lundervold, A., Rootwelt, H., Lundervold, A.J., Westlye, L.T., Increased hippocampal default mode synchronization during rest in middle-aged and elderly apoe 4 carriers: Relationships with memory performance (2011) The Journal of Neuroscience, 31 (21), pp. 7775-7783; Brown, J.A., Terashima, K.H., Burggren, A.C., Ercoli, L.M., Miller, K.J., Small, G.W., Bookheimer, S.Y., Brain network local interconnectivity loss in aging apoe-4 allele carriers (2011) Proceedings of the National Academy of Sciences, 108 (51), pp. 20760-20765; Filippini, N., MacIntosh, B.J., Hough, M.G., Goodwin, G.M., Frisoni, G.B., Smith, S.M., Matthews, P.M., Mackay, C.E., Distinct patterns of brain activity in young carriers of the apoe-4 allele (2009) Proceedings of the National Academy of Sciences, 106 (17), pp. 7209-7214",Conference Paper,Scopus,2-s2.0-84902278983
"Pogue A.I., Hill J.M., Lukiw W.J.","MicroRNA (miRNA): Sequence and stability, viroid-like properties, and disease association in the CNS",2014,"Brain Research","1584",,,"73","79",,5,10.1016/j.brainres.2014.03.042,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904549036&partnerID=40&md5=42898984f67498f5a71c6c48f44d4b1c","Alchem BiotekToronto, ON, Canada; Departments of Neurology, Neuroscience and Ophthalmology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier StreetNew Orleans, LA, United States","Pogue, A.I., Alchem BiotekToronto, ON, Canada; Hill, J.M., Departments of Neurology, Neuroscience and Ophthalmology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier StreetNew Orleans, LA, United States; Lukiw, W.J., Alchem BiotekToronto, ON, Canada, Departments of Neurology, Neuroscience and Ophthalmology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier StreetNew Orleans, LA, United States","MicroRNAs (miRNAs) constitute a relatively recently-discovered class of small non-coding RNAs (sncRNAs) that are gaining considerable attention in the molecular-genetic regulatory mechanisms that contribute to human health and disease. As highly soluble and mobile entities, emerging evidence indicates that miRNAs posess a highly selected ribonucleotide sequence structure, are part of an evolutionary ancient genetic signaling system, resemble the plant pathogens known as viroids in their structure, mode of generation and function, and are very abundant in the physiological fluids that surround cells and tissues. Persistence and altered abundance of miRNAs in the extracellular fluid (ECF) or cerebrospinal fluid (CSF) may play a role in the intercellular spreading of disease systemically, and throughout functionally-linked cellular and tissue systems such as the central nervous system (CNS). This short communication will review some of the more fascinating features of these highly structured single stranded RNAs (ssRNAs) with emphasis on their presence and function in the human CNS, with particular reference to Alzheimers disease (AD) wherever possible. This article is part of a Special Issue entitled RNA Metabolism 2013. © 2014 Elsevier B.V.","Alzheimers disease; CSF; ECF; Endocrine; Evolution; MicroRNA (miRNA); Neurological disease; Paracrine; Stability; Translocation; Transmissibility; Viroids","Adams, M.J., Carstens, E.B., Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012) Arch. Virol., 157, pp. 1411-1422; Alexandrov, P.N., Pogue, A., Bhattacharjee, S., Retinal amyloid peptides and complement factor H in transgenic models of Alzheimers disease (2011) NeuroReport, 22, pp. 623-627; Alexandrov, P.N., Dua, P., Hill, J.M., MicroRNA (miRNA) speciation in Alzheimers disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF) (2012) Int. J. Biochem. Mol. Biol., 3, pp. 365-373; Ambros, V., The functions of animal microRNAs (2004) Nature, 431, pp. 350-355; Ambros, V., Bartel, B., Bartel, D.P., A uniform system for microRNA annotation (2003) RNA, 9, pp. 277-279; Aronica, E., Fluiter, K., Iyer, A., Expression pattern of miRNA-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy (2010) Eur. J. Neurosci., 31, pp. 1100-1107; Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma (2011) Proc. Natl. Acad. Sci. USA, 108, pp. 5003-5008; Arteaga-Vazquez, M., Caballero-Pérez, J., Vielle-Calzada, J.P., A family of miRNAs present in plants and animals (2006) Plant Cell, 18, pp. 3355-3369; Baulcombe, D., RNA silencing (2005) Trends Biochem. Sci., 30, pp. 290-293; Bhattacharjee, S., Lukiw, W.J., Alzheimer's disease and the microbiome (2013) Front Cell Neurosci, 7, p. 153. , (eCollection 2013. PubMed PMID: 24062644; PubMed Central PMCID: PMC3775450); Burmistrova, O.A., Goltsov, A.Y., Abramova, MicroRNA in schizophrenia: Genetic and expression analysis of miR-130b (22q11) (2007) Biochemistry (Mosc.), 72, pp. 578-582; Busch, S., Wu, L., Feng, Y., Alzheimers disease and retinal neurodegeneration share a consistent stress response of the neurovascular unit (2012) Cell Physiol. Biochem., 30, pp. 1436-1443; Chen, C.Y., Shyu, A.B., AU-rich elements: Characterization and importance in mRNA degradation (1995) Trends Biochem. Sci., 20, pp. 465-470; Cogswell, J.P., Ward, J., Taylor, I.A., Identification of miRNA changes in Alzheimers disease brain and CSF yields putative biomarkers and insights into disease pathways (2008) J. Alzheimers Dis., 14, pp. 27-41; Colangelo, V., Schurr, J., Ball, M.J., Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1 (2002) J. Neurosci. Res., 70, pp. 462-473; Cui, J.G., Zhao, Y., Lukiw, W.J., Isolation of high spectral quality RNA using run-on gene transcription; Application to gene expression profiling of human brain (2005) Cell Mol. Neurobiol., 25, pp. 789-794; Cui, J.G., Hill, J.M., Zhao, Y., Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimers disease (2007) NeuroReport, 18, pp. 115-119; Cui, J.G., Li, Y.Y., Zhao, Y., Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by miRNA-146a and NF-kB in stressed human astroglial cells and in Alzheimers disease (2010) J. Biol. Chem., 285, pp. 38951-38960; Ding, B., The biology of viroid-host interactions (2009) Ann. Rev. Phytopathol., 47, pp. 105-131; Diener, T.O., Subviral pathogens of plants: Viroids and viroidlike satellite RNAs (1991) FASEB J., 5, pp. 2808-2813; Diener, T.O., Discovering viroids - A personal perspective (2003) Nat. Rev. Microbiol., 1, pp. 75-80; Erickson, M.A., Banks, W.A., Blood-brain barrier dysfunction as a cause and consequence of Alzheimers disease (2013) J. Cereb. Blood Flow Metab., 33 (10), pp. 1500-1513. , Epub 2013 Aug 7. PubMed PMID: 23921899; PubMed Central PMCID: PMC3790938; Gallego, J.A., Gordon, M.L., Claycomb, K., In vivo microRNA detection and quantitation in cerebrospinal fluid (2012) J. Mol. Neurosci., 47, pp. 243-248; Ginsberg, S.D., Alldred, M.J., Che, S., Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimers disease (2012) Neurobiol. Dis., 45, pp. 99-107; Guo, H., Ingolia, N.T., Weissman, J.S., Mammalian microRNAs predominantly act to decrease target mRNA levels (2010) Nature, 466, pp. 835-840; Hammann, C., Steger, G., Viroid-specific small RNA in plant disease (2012) RNA Biol., 9, pp. 809-819; Hébert, S.S., De Strooper, B., Alterations of the microRNA network cause neurodegenerative disease (2009) Trends Neurosci., 32, pp. 199-206; Hedges, S.B., The origin and evolution of model organisms (2002) Nat. Rev. Genet., 3, pp. 838-849; Hill, J.M., Zhao, Y., Bhattacharjee, S., MiRNAs and viroids utilize common strategies in genetic signal transfer (2014) Front. J. Mol. Neurosci., 7, p. 10; http://www.ictvonline.org/, International Committee on the Taxonomy of Viruses)Jucker, M., Walker, L.C., Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders (2011) Ann. Neurol., 70, pp. 532-540; Krol, J., Krzyzosiak, W.J., Structure analysis of microRNA precursors (2006) Methods Mol. Biol., 342, pp. 19-32; Krol, J., Busskamp, V., Markiewicz, I., Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs (2010) Cell, 141, pp. 618-631; Lagos-Quintana, M., Rauhut, R., Lendeckel, W., Identification of novel genes coding for small expressed RNAs (2001) Science, 294, pp. 853-858; Lee, S.J., Lim, H.S., Masliah, E., Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives (2011) Neurosci. Res., 70, pp. 339-348; Li, Y.Y., Cui, J.G., Dua, P., Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells (2011) Neurosci. Lett., 499, pp. 109-113; Li, Y.Y., Cui, J.G., Hill, J.M., Bhattacharjee, S., Zhao, Y., Lukiw, W.J., Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models (2011) Neurosci Lett., 487 (1), pp. 94-98. , (Epub 2010 Oct 8. PubMed PMID: 20934487); Loring, J.F., Wen, X., Lee, J.M., A gene expression profile of Alzheimers disease (2001) DNA Cell Biol., 20, pp. 683-695; Lukiw, W.J., Handley, P., Wong, L., BC200 and other small RNAs RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD) (1992) Neurochem. Res., 17, pp. 591-597; Lukiw, W.J., Gordon, W.C., Rogaev, E.I., Thompson, H., Bazan, N.G., Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis (2001) Neuroreport, 12 (1), pp. 53-57. , (PubMed PMID: 11201091); Lukiw, W.J., Leblanc, H.J., Carver, L.A., McLachlan, D.R., Bazan, N.G., Run-on gene transcription in human neocortical nuclei. Inhibition by nanomolar aluminum and implications for neurodegenerative disease (1998) J Mol Neurosci., 11 (1), pp. 67-78. , (PubMed PMID: 9826787); Lukiw, W.J., Gene expression profiling in fetal, aged, and Alzheimer hippocampus: A continuum of stress-related signaling (2004) Neurochem. Res., 29, pp. 1287-1297; Lukiw, W.J., Pogue, A.I., Induction of specific microRNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells (2007) J. Inorg. Biochem., 101, pp. 1265-1269; Lukiw, W.J., Micro-RNA speciation in fetal, adult and Alzheimers disease hippocampus (2007) NeuroReport, 18, pp. 297-300; Lukiw, W.J., Zhao, Y., Cui, J.G., An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells (2008) J. Biol. Chem., 283, pp. 31315-31322; Lukiw, W.J., Dua, P., Pogue, A.I., Upregulation of microRNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome (2011) J. Toxicol. Environ. Health A, 74, pp. 1460-1468; Lukiw, W.J., NF-kB-regulated microRNAs (miRNAs) in primary human brain cells (2012) Exp. Neurol., 235, pp. 484-490; Lukiw, W.J., Evolution and complexity of microRNA in the human brain (2012) Front. Genet., 3, p. 166; Lukiw, W.J., Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimers disease (AD) (2013) Front. Cell Neurosci., 7, p. 133. , (Aug 27); Machida, A., Ohkubo, T., Yokota, T., Circulating microRNAs in the cerebrospinal fluid of patients with brain diseases (2013) Methods Mol. Biol., 1024, pp. 203-209; Madathil, S.K., Nelson, P.T., Saatman, K.E., Wilfred, B.R., MicroRNAs in CNS injury: Potential roles and therapeutic implications (2011) Bioessays, 33, pp. 21-26; Mehler, M.F., Mattick, J.S., Noncoding RNAs and RNA editing in brain development, functional diversification and neurological disease (2007) Physiol. Rev., 87, pp. 799-823; Müller, M., Kuiperij, H.B., Claassen, J.A., Küsters, B., Verbeek, M.M., MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid (2014) Neurobiol Aging., 35 (1), pp. 152-158. , (Epub 2013 Aug 17. PubMed PMID: 23962497); Na, Y.J., Kim, J.H., Understanding cooperativity of microRNAs via microRNA association networks (2013) BMC Genomics, 14 (SUPPL. 5), p. 17; Navarro, B., Gisel, A., Rodio, M.E., Viroids: How to infect a host and cause disease without encoding proteins (2012) Biochimie, 94, pp. 1474-1480; Neilson, J.R., Sharp, P.A., Small RNA regulators of gene expression (2008) Cell, 134, pp. 899-902; Pasquinelli, A.E., Ruvkun, G., Control of developmental timing by microRNAs and their targets (2002) Annu. Rev. Cell. Dev. Biol., 18, pp. 495-513; Perkel, J.M., Assume nothing: The tale of circular RNA (2013) Biotechniques, 55, pp. 55-57; Rao, P., Benito, E., Fischer, A., MicroRNAs as biomarkers for CNS disease (2013) Front Mol Neurosci., 6 (39). , (eCollection 2013. PubMed PMID: 24324397; PubMed Central PMCID: PMC3840814); Reijerkerk, A., Lopez-Ramirez, M.A., Van Het Hof, B., MiRNAs regulate human brain endothelial cell-barrier function in inflammation: Implications for multiple sclerosis (2013) J. Neurosci., 17, pp. 6857-6863; Ritchie, W., Legendre, M., Gautheret, D., RNA stem-loops: To be or not be cleaved by RNAse III (2007) RNA, 13, pp. 457-462; Rocheleau, L., Pelchat, M., The subviral RNA database: A toolbox for viroids, the hepatitis delta virus and satellite RNAs research (2006) BMC Microbiol., 6, p. 24; Saba, R., Gushue, S., Huzarewich, R.L., Manguiat, K., Medina, S., Robertson, C., MicroRNA 146a (miR-146a) is over-expressed during prion disease and modulates the innate immune response and the microglial activation state (2012) PLoS One, 7, p. 30832; Saetrom, P., Snøve, O., Nedland, M., Conserved microRNA characteristics in mammals (2006) Oligonucleotides, 16, pp. 115-144; Sagare, A.P., Bell, R.D., Zlokovic, B.V., Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimers disease (2013) J. Alzheimers Dis., 33, pp. 87-S100; Sarkies, P., Miska, E.A., Molecular biology is there social RNA? (2013) Science, 341, pp. 467-468; Sempere, L.F., Freemantle, S., Pitha-Rowe, I., Expression profiling of mammalian miRNAs uncovers a subset of brain-expressed miRNAs with possible roles in murine and human neuronal differentiation (2004) Genome Biol., 5, p. 13; Sethi, P., Lukiw, W.J., Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimers disease temporal lobe neocortex (2009) Neurosci. Lett., 459, pp. 100-104; Shi, B., Gao, W., Wang, J., Sequence fingerprints of microRNA conservation (2012) PLoS One, 7 (10), p. 48256; Sivak, J.M., The aging eye: Common degenerative mechanisms between the Alzheimer's brain and retinal disease (2013) Invest Ophthalmol Vis Sci., 54 (1), pp. 871-880. , (Review. PubMed PMID: 23364356); Taft, R.J., Pang, K.C., Mercer, T.R., Non-coding RNAs: Regulators of disease (2010) J. Pathol., 220, pp. 126-139; Taganov, K.D., Boldin, M.P., Chang, K.J., NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 12481-12486; Triboulet, R., Gregory, R.I., Autoregulatory mechanisms controlling the Microprocessor (2010) Adv Exp Med Biol., 700, pp. 56-66. , (Review. PubMed PMID: 21627030); Wang, D.Y., Kumar, S., Hedges, S.B., Divergence time estimates for the early history of animal phyla and the origin of plants, animals and fungi (1999) Proc. Biol. Sci., 266, pp. 163-171; Wang, K., Zhang, S., Weber, J., Export of microRNAs and microRNA-protective protein by mammalian cells (2010) Nucleic Acids Res., 38, pp. 7248-7259; Witkos, T.M., Koscianska, E., Krzyzosiak, W.J., Practical aspects of miRNA target prediction (2011) Curr. Mol. Med., 11, pp. 93-109; Yuva-Aydemir, Y., Simkin, A., Gascon, E., MicroRNA-9: Functional evolution of a conserved small regulatory RNA (2011) RNA Biol., 8, pp. 557-564; Zhang, L., Hou, D., Chen, X., Exogenous plant MIR168a specifically targets mammalian LDLRAP1: Evidence of cross-kingdom regulation by microRNA (2012) Cell Res., 22, pp. 107-126; Zhao, Y., Cui, J.G., Lukiw, W.J., Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic ""spreading"" and Alzheimers disease (2006) Mol. Neurobiol., 34, pp. 181-192; Zhao, Y., Bhattacharjee, S., Jones, B.M., Regulation of TREM2 expression by an NF-kB-sensitive miRNA-34a (2013) NeuroReport, 24, pp. 318-323; Zhou, R., Hu, G., Liu, J., NF-kB p65-dependent transactivation of miRNA genes following cryptosporidium parvum infection stimulates epithelial cell immune responses (2009) PLoS Pathol., 5, p. 1000681",Article,Scopus,2-s2.0-84904549036
"Roy S., He Q., Carass A., Jog A., Cuzzocreo J.L., Reich D.S., Prince J., Pham D.","Example based lesion segmentation",2014,"Progress in Biomedical Optics and Imaging - Proceedings of SPIE","9034",, 90341Y,"","",,,10.1117/12.2043917,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902094483&partnerID=40&md5=1a4cf76fd1f6b77d8d4f037546a64090","Center for Neuroscience and Regenerative Medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States; Department of Electrical and Computer Engineering, Johns Hopkins University, United States; Department of Radiology, Johns Hopkins School of Medicine, United States; Translational Neuroradiology Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, United States","Roy, S., Center for Neuroscience and Regenerative Medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States; He, Q., Center for Neuroscience and Regenerative Medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States; Carass, A., Department of Electrical and Computer Engineering, Johns Hopkins University, United States; Jog, A., Department of Electrical and Computer Engineering, Johns Hopkins University, United States; Cuzzocreo, J.L., Department of Radiology, Johns Hopkins School of Medicine, United States; Reich, D.S., Translational Neuroradiology Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, United States; Prince, J., Department of Electrical and Computer Engineering, Johns Hopkins University, United States; Pham, D., Center for Neuroscience and Regenerative Medicine, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States","Automatic and accurate detection of white matter lesions is a significant step toward understanding the progression of many diseases, like Alzheimers disease or multiple sclerosis. Multi-modal MR images are often used to segment T2 white matter lesions that can represent regions of demyelination or ischemia. Some automated lesion segmentation methods describe the lesion intensities using generative models, and then classify the lesions with some combination of heuristics and cost minimization. In contrast, we propose a patch-based method, in which lesions are found using examples from an atlas containing multi-modal MR images and corresponding manual delineations of lesions. Patches from subject MR images are matched to patches from the atlas and lesion memberships are found based on patch similarity weights. We experiment on 43 subjects with MS, whose scans show various levels of lesion-load. We demonstrate significant improvement in Dice coefficient and total lesion volume compared to a state of the art model-based lesion segmentation method, indicating more accurate delineation of lesions. © 2014 SPIE.","Lesion segmentation; Magnetic resonance imaging; MRI; MS; Patches","Fisher, E., Lee, J.-C., Rudick, K.N.R.A., Gray matter atrophy in multiple sclerosis: A longitudinal study (2008) Annals Neurol., 64 (3), pp. 255-265; Leemput, K.V., Maes, F., Vandermeulen, D., Colchester, A., Suetens, P., Automated segmentation of multiple sclerosis lesions by model outlier detection (2001) IEEE Trans. on Med. Imag., 20 (8), pp. 677-688; Ait-Ali, L.S., Prima, S., Hellier, P., Carsin, B., Edan, G., Barillot, C., STREM: A robust multidimensional parametric method to segment ms lesions in MRI (2005) Med. Image Comp. and Comp. Asst. Intervention (MICCAI), pp. 409-416; Shiee, N., Bazin, P.-L., Ozturk, A., Reich, D.S., Calabresi, P.A., Pham, D.L., A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions (2010) NeuroImage, 49 (2), pp. 1524-1535; Sweeney, E.M., Shinohara, R.T., Shiee, N., Mateen, F.J., Chudgar, A.A., Cuzzocreo, J.L., Calabresi, P.A., Crainiceanu, C.M., OASIS is automated statistical inference for segmentation, with applications to multiple sclerosis lesion segmentation in MRI (2013) NeuroImage Clinical, 2, pp. 402-413; Coupé, P., Manjon, J.V., Pruessner, J., Robles, M., Fonov, V., Collins, D.L., Patch-based segmentation using expert priors: Application to hippocampus and ventricle segmentation (2011) NeuroImage, 54 (2), pp. 940-954; Jog, A., Roy, S., Prince, J.L., Carass, A., MR brain segmentation using decision trees (2013) MICCAI Grand Challenge on MR Brain Image Segmentation; Lao, Z., Shen, D., Liu, D., Jawad, A.F., Melhem, E.R., Launer, L.J., Bryan, R.N., Davatzikos, C., Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine (2008) Academic Radiology, 15 (3), pp. 300-313; Eskildsen, S.F., Coupé, P., Fonov, V., Manjon, J.V., Leung, K.K., Guizard, N., Wassef, S.N., Collins, D.L., BEaST: Brain extraction based on nonlocal segmentation technique (2012) NeuroImage, 59 (3), pp. 2362-2373; Roy, S., Carass, A., Prince, J.L., Magnetic resonance image example-based contrast synthesis (2013) IEEE Trans. on Med. Imag., 32 (12), pp. 2348-2363; Roy, S., Carass, A., Prince, J.L., A compressed sensing approach for mr tissue contrast synthesis (2011) Inf. Proc. in Med. Imaging (IPMI), pp. 371-383; Hertzmann, A., Jacobs, C.E., Oliver, N., Curless, B., Salesin, D.H., Image analogies (2001) Proc. of 28th Ann. Conf. on Comp. Graphics and Interactive Techniques, SIGGRAPH '01, pp. 327-340; Roy, S., Carass, A., Shiee, N., Pham, D.L., Prince, J.L., MR contrast synthesis for lesion segmentation (2010) IEEE Intl. Symp. on Biomed. Imaging, pp. 932-935; Ye, D.H., Zikic, D., Glocker, B., Criminisi, A., Konukoglu, E., Modality propagation: Coherent synthesis of subject-specific scans with data-driven regularization (2013) Med. Image Comp. and Comp. Asst. Intervention (MICCAI), pp. 606-613; Wang, H., Yushkevich, P.A., Multi-atlas segmentation without registration: A supervoxel-based approach (2013) Med. Image Comp. and Comp. Asst. Intervention (MICCAI), 8151, pp. 535-542; Christensen, J.D., Normalization of brain magnetic resonance images using histogram even-order derivative analysis (2003) Magn. Resonance Imaging, 21 (7), pp. 817-820; Mairal, J., Bach, F., Ponce, J., Sapiro, G., Zisserman, A., Non-local sparse models for image restoration (2009) IEEE Intl. Conf. on Comp. Vision, pp. 2272-2279; Yang, J., Wright, J., Huang, T.S., Ma, Y., Image super-resolution via sparse representation (2010) IEEE Trans. Imag. Proc., 19, pp. 2861-2873. , November; Bazin, P.L., Pham, D.L., Topology-preserving tissue classification of magnetic resonance brain images (2007) IEEE Trans. on Medical Imaging, 26, pp. 487-496. , April; Donoho, D.L., Tsaig, Y., Drori, I., Starck, J.-L., Sparse solution of underdetermined systems of linear equations by stagewise orthogonal matching pursuit (2012) IEEE Trans. on Inf. Theory, 58 (2), pp. 1094-1121",Conference Paper,Scopus,2-s2.0-84902094483
"Moradi E., Tohka J., Gaser C.","Semi-supervised learning in MCI-to-ad conversion prediction - When is unlabeled data useful?",2014,"Proceedings - 2014 International Workshop on Pattern Recognition in Neuroimaging, PRNI 2014",,, 6858535,"","",,,10.1109/PRNI.2014.6858535,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84905717723&partnerID=40&md5=a4824ab36a5262cf17a201ab2a0a1676","Department of Signal Processing Tampere, University of Technology, Finland; Department of Psychiatry, University of Jena, Jena, Germany","Moradi, E., Department of Signal Processing Tampere, University of Technology, Finland; Tohka, J., Department of Signal Processing Tampere, University of Technology, Finland; Gaser, C., Department of Psychiatry, University of Jena, Jena, Germany","This paper investigates the use of semi-supervised learning (SSL) for predicting Alzheimers Disease (AD) conversion in Mild Cognitive Impairment (MCI) patients based on Magnetic Resonance Imaging (MRI). SSL methods differ from standard supervised learning methods in that they make use of unlabeled data - in this case data from MCI subjects whose final diagnosis is not yet known. We compare two widely used semi-supervised methods (low density separation (LDS) and semi-supervised discriminant analysis (SDA)) to the corresponding supervised methods using real and synthetic MRI data of MCI subjects. With simulated data, using SSL instead of supervised learning led to higher classification performance in certain cases, however, the applicability of semi-supervised methods depended strongly on the data distributions. With real MRI data, the SSL methods achieved significantly better classification performances over supervised methods. Moreover, even using a small number of unlabeled samples improved the AD conversion predictions. © 2014 IEEE.",,"Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., Initiative, A.D.N., BrainAGE in mild cognitive impaired patients: Predicting the conversion to alzheimers disease (2013) PloS ONE, 8 (6), pp. e67346; Eskildsen, S.F., Coupé, P., Garcia-Lorenzo, D., Fonov, V., Pruessner, J.C., Collins, D.L., Prediction of Alzheimers disease in subjects with mild cognitive impairment from the adni cohort using patterns of cortical thinning (2013) NeuroImage, 65, pp. 511-521; Chapelle, O., Schölkopf, B., Zien, A., (2006) Semi-Supervised Learning, , Cambridge MA: MIT Press; Batmanghelich, K.N., Ye, D.H., Pohl, K.M., Taskar, B., Davatzikos, C., Disease classification and prediction via semi-supervised dimensionality reduction (2011) ISBI IEEE, pp. 1086-1090; Ye, D.H., Pohl, K.M., Davatzikos, C., Semi-supervised pattern classification: Application to structural mri of alzheimers disease (2011) Pattern Recognition in NeuroImaging (PRNI), pp. 1-4. , IEEE; Filipovych, R., Davatzikos, C., Semi-supervised pattern classification of medical images: Application to mild cognitive impairment (MCI) (2011) NeuroImage, 55 (3), pp. 1109-1119; Friedman, J.H., Hastie, T., Tibshirani, R., Regularization paths for generalized linear models via coordinate descent (2010) J. Stat. Software, 33 (1), pp. 1-22; Huttunen, H., Manninen, T., Tohka, J., Bayesian error estimation and model selection in sparse logistic regression (2013) Machine Learning for Signal Processing (MLSP), pp. 1-6. , IEEE; Dalton, L.A., Dougherty, E.R., Bayesian minimum mean-square error estimation for classification errorpart II: The bayesian mmse error estimator for linear classification of gaussian distributions (2011) IEEE Trans. Signal Process, 59, pp. 130-144; Chapelle, O., Zien, A., Semi-supervised classification by low density separation (2005) AISTATS, pp. 57-64; Cai, D., He, X., Han, J., Semi-supervised discriminant analysis (2007) ICCV IEEE, pp. 1-7; Joachims, T., Transductive inference for text classification using support vector machines (1999) ICML, pp. 200-209; Chang, C.-C., Lin, C.-J., Libsvm: A library for support vector machines (2011) ACM Trans. Intell. Systems Tech, 2, p. 27; Friedman, J.H., Regularized discriminat analysis (1989) J. Am. Stat. Assoc, 84 (405), pp. 165-175; Bradley, A.P., The use of the area under the ROC curve in the evaluation of machine learning algorithms (1997) Patt. Recog, 30, pp. 1145-1159",Conference Paper,Scopus,2-s2.0-84905717723
"Boye M., Tran T.M., Grabar N.","NLP-oriented contrastive study of linguistic productions of alzheimer’s and control people",2014,"Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)","8686",,,"412","424",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921762460&partnerID=40&md5=1dde07f3720179f1f3d63a8ccd2f63ec","Institut d’Orthophonie, Universitè Lille 2Lille, France; CNRS UMR 8163 STL, Universitè Lille 3Villeneuve d’Ascq, France","Boyè, M., Institut d’Orthophonie, Universitè Lille 2Lille, France; Tran, T.M., Institut d’Orthophonie, Universitè Lille 2Lille, France, CNRS UMR 8163 STL, Universitè Lille 3Villeneuve d’Ascq, France; Grabar, N., CNRS UMR 8163 STL, Universitè Lille 3Villeneuve d’Ascq, France","The increase in Alzheimers disease is due to the aging of the population and is the first cause of neurodegenerative disorders. Progressive development of cognitive, emotional and behavior troubles leads to the loss of autonomy and to dependency of people, which corresponds to the dementia phase. Language disorders are among the first clinical cognitive signs of the disease. Our objective is to study verbal communication of people affected by the Alzheimer’s disease at early to moderate stages. One particularity of our approach is that we work in ecological conversation situation: people are faced to persons they know. We study verbal productions of five people affected by the Alzheimer’s disease and of five control people. The conversations are transcribed and processed with the NLP methods and tools. Over thirty features grouped in four categories are studied. Our results indicate that the Alzheimer’s patients present lexical and semantic deficit and that, in several ways, their conversation is notably poorer than the conversation of the control people. © Springer International Publishing Switzerland 2014.","Alzheimer’s disease; conversation; Linguistics; Natural Language Processing; Speech and language therapy","Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Scazufca, M., Global prevalence of dementia: A Delphi consensus study (2006) Alzheimer’s Disease International, 366 (9503), pp. 2112-2117; Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, M., Forecasting the global burden of Alzheimer’s disease (2007) Alzheimer’s and Dementia, 3 (3), pp. 186-191; Derouesnè, C., Maladie d’Alzheimer: Donnèes èpidèmiologiques, neuropathologiques et cliniques (2006) Actualitès Sur Les dèmences: Aspects Cliniques et Neuropsychologiques, pp. 25-34. , In: Belin, C., Ergis, S.,Moreaud, O. (eds.), Solal, Marseille; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E., Clinical diagnosis of Alzheimer’s disease: Report of the NINCDSADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease (1984) Neurology, 34, pp. 939-944; Dubois, B., Feldman, H., Jacova, C., Cummings, J., Dekosky, S., Barberger-Gateau, P., Delacourte, A., Scheltens, P., Revising the definition of Alzheimer’s disease: A new lexicon (2010) Lancet Neurology, 9 (11), pp. 1118-1127; McKhann, G., Knopman, D., Chertkow, H., Hyman, B., Jack, C., Kawash, C., Klunk, W., Phelps, C., The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the national institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease (2011) Alzheimer’s & Dementia, 7 (3), pp. 263-269; Mackenzie, C., Adult spoken discourse: The influences of age and education (2000) International Journal of Language and Communication Disorders, 35 (2), pp. 269-285; Nef, F., Hupet, M., Les manifestations du vieillissement normal dans le langage spontanè oral et ècrit (1992) L’annèe Psychologique, 9 (3), pp. 393-419; Rousseau, T., De Saint-Andrè, A., Gatignol, P., èvaluation pragmatique de la communication des personnes âgèes saines (2009) Neurologie Psychiatrie Gèriatrie, 9, pp. 271-280; Kynette, D., Kemper, S., Aging and the loss of grammatical forms: A crosssectional study of language performance (1986) Language and Communication, 6, pp. 65-72; Kemper, S., Rash, S., Kynette, D., Norman, S., Telling stories: The structure of adults’ narratives (1990) European Journal of Cognitive Psychology, 2, pp. 205-228; Croisile, B., Ska, B., Brabant, M., Duchene, A., Lepage, Y., Aimard, G., Trillet, M., Comparative study of oral and written picture description in patients with Alzheimer’s disease (1996) Brain and Language, 53, pp. 1-19; Duong, A., Tardif, A., Ska, B., Discourse about discourse: What is it and how does it progress in Alzheimer’s disease? (2003) Brain and cognition, 53, pp. 177-180; Berrewaerts, J., Hupet, M., Feyereisen, P., Langage et dèmence: examen des capacitès pragmatiques dans la maladie d’Alzheimer (2003) Revue de Neuropsychologie, 13 (2), pp. 165-207; Ska, B., Duong, A., Communication, discours et dèmence (2005) Psychologie et NeuroPsychiatrie du Vieillissement, 3 (2), pp. 125-133; Lee, H., Vieillissement normal et maladie d’Alzheimer: Analyse comparative de la narration semi-dirigèe au niveau lexical (2011) Mèthodes et Analyses Comparatives en Sciences du Langage; Barras, C., Geoffrois, E., Wu, Z., Liberman, M., Transcriber: A free tool for segmenting, labeling and transcribing speech (1998) Conference on Language Resources and Evaluation (LREC), pp. 1373-1376; Blanche-Benveniste, C., Bilger, M., Rouget, C., Van Den Eynde, K., Le français parlè (1991) Études grammaticales, , CNRS èditions, Paris; Schmid, H., Probabilistic part-of-speech tagging using decision trees (1994) ICNMLP, Manchester, pp. 44-49. , UK; Namer, F., FLEMM: Un analyseur flexionnel du français á base de règles (2000) Traitement Automatique des Langues (TAL), 41 (2), pp. 523-547; Namer, F., Morphologie, Lexique et TAL: L’analyseur DèriF (2009) TIC et Sciences cognitives, , Hermes Sciences Publishing, London; Pallaud, B., Les amorces de mots comme faits antonymiques en langage oral (2002) Recherches Sur le Français Parlè, 17, pp. 79-102; Henry, S., Pallaud, B., Amorces de mots et rèpètitions dans les ènoncès oraux (2004) Recherches Sur le Français Parlè, 18, pp. 201-229; Bove, R., Analyse syntaxique automatique de l’oral: ètude des disfluences (2008) Thèse de doctorat, , Universitè d’Aix-Marseille I, Marseille; Dewaele, J., Saisir l’insaisissable? Les mesures de longueur d’ènoncès en linguistique appliquèe (2009) International Review of Applied Linguistics in Language Teaching, 38, pp. 17-34; Blanche-Benveniste, C., (1997) Approches de la langue parlèe en français, , Ophrys, Paris; Gaspers, J., Thiele, K., Cimiano, P., Foltz, A., Stenneken, P., Tscherepanow, M., An evaluation of measures to dissociate language and communication disorders from healthy controls using machine learning techniques (2012) IHI 2012, pp. 209-218; Levin, B., (1993) English Verb Classes and Alternations: A Preliminary Investigation, , University of Chicago Press",Article,Scopus,2-s2.0-84921762460
"Rosness T.A.","Kan preklinisk Alzheimers sykdom oppdages hos friske eldre?",2014,"Tidsskrift for den Norske Laegeforening","134","1",,"23","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84892859744&partnerID=40&md5=ca72a6aab9c9c896461a5078f87abdfb",,"Rosness, T.A.",[No abstract available],,"Vos, S.J., Xiong, C., Visser, P.J., Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study (2013) Lancet Neurol, 12, pp. 957-965",Note,Scopus,2-s2.0-84892859744
"Benestad H.B.","Mulige biomarkører for Alzheimers sykdom",2014,"Tidsskrift for den Norske Laegeforening","134","17",,"1650","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907259436&partnerID=40&md5=332046587fdf6a9392d85abbc7b575b3","Universitetet i Oslo, Norway","Benestad, H.B., Universitetet i Oslo, Norway",[No abstract available],,"Mapstone, M., Cheema, A.K., Fiandaca, M.S., Plasma phospholipids identify antecedent memory impairment in older adults (2014) Nat Med, 20, pp. 415-418",Note,Scopus,2-s2.0-84907259436
"Lindqvist E.","Bensodiazepiner kopplas till alzheimers sjukdom",2014,"Lakartidningen","111","40",,"","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84907546199&partnerID=40&md5=78502aa4e728a4f35be51992391c8ded","Karolinska institutetStockholm, Sweden","Lindqvist, E., Karolinska institutetStockholm, Sweden",[No abstract available],,"Gage, B.D., (2014) BMJ, , Epub 9sep",Note,Scopus,2-s2.0-84907546199
"Bystad M., Pettersen K., Gronli O.K.","Depresjon eller demens av Alzheimers type?",2014,"Tidsskrift for den Norske Laegeforening","134","5",,"525","528",,1,10.4045/tidsskr.13.0364,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896329012&partnerID=40&md5=e4619bb2a6afaa9ddef10e52a04ac507","Alderspsykiatrisk avdeling, Universitetssykehuset Nord-Norge, Norway; Institutt for psykologi, Universitetet i Tromsø, Norway","Bystad, M., Alderspsykiatrisk avdeling, Universitetssykehuset Nord-Norge, Norway, Institutt for psykologi, Universitetet i Tromsø, Norway; Pettersen, K., Alderspsykiatrisk avdeling, Universitetssykehuset Nord-Norge, Norway; Grønli, O.K., Alderspsykiatrisk avdeling, Universitetssykehuset Nord-Norge, Norway",[No abstract available],,"(2009) Befolkningsframskrivningen 2009., , Oslo: Statistisk sentralbyrå; Rosenvinge, B.H., Rosenvinge, J.H., Forekomst av depresjon hos eldre-systematisk oversikt over 55 prevalensstudier fra 1990-2001 (2003) Tidsskr Nor Lægeforen, 123, pp. 928-929; Mayeux, R., Clinical practice (2010) Early Alzheimer's disease. N Engl J Med, 362, pp. 2194-2201; Herrmann, L.L., Goodwin, G.M., Ebmeier, K.P., The cognitive neuropsychology of depression in the elderly (2007) Psychol Med, 37, pp. 1693-1702; Elderkin-Thompson, V., Mintz, J., Haroon, E., Executive dysfunction and memory in older patients with major and minor depression (2006) Arch Clin Neuropsychol, 21, pp. 669-676; Thomas, A.J., Gallagher, P., Robinson, L.J., A comparison of neurocognitive impairment in younger and older adults with major depression (2009) Psychol Med, 39, pp. 725-733; Olin, J.T., Schneider, L.S., Katz, I.R., Provisional diagnostic criteria for depression of Alzheimer disease (2002) Am J Geriatr Psychiatry, 10, pp. 125-128; Thorpe, L., Depression vs (2009) dementia: how do we assess? The Canadian Review of Alzheimer's Disease and other Dementias, 9, pp. 17-21; Hestad, K., Reinvang, I., Normal og patologisk kognitiv aldring-kan de skilles (2008) Tidsskrift for Norsk Psykologforening, 45, pp. 1133-1142; Bäckman, L., Jones, S., Berger, A.K., Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis (2005) Neuropsychology, 19, pp. 520-531; Psykiske lidelser og atferdsforstyrrelser. (1993) Genève: World Health Organization, pp. 116-124. , ICD-10; Unützer, J., Clinical practice (2007) Late-life depression. N Engl J Med, 357, pp. 2269-2276; Lyketsos, C.G., Olin, J., Depression in Alzheimer's disease: overview and treatment (2002) Biol Psychiatry, 52, pp. 243-252; Engedal, K., Alderspsykiatri i praksis. (2008) Tønsberg: Forlaget Aldring og Helse, pp. 109-118; Alexopoulos, G.S., Depression in the elderly (2005) Lancet, 365, pp. 1961-1970; Saczynski, J.S., Beiser, A., Seshadri, S., Depressive symptoms and risk of dementia: the Framingham Heart Study (2010) Neurology, 75, pp. 35-41; Alexopoulos, G.S., Buckwalter, K., Olin, J., Comorbidity of late life depression: an opportunity for research on mechanisms and treatment (2002) Biol Psychiatry, 52, pp. 543-558; Karantzoulis, S., Galvin, J.E., Distinguishing Alzheimer's disease from other major forms of dementia (2011) Expert Rev Neurother, 11, pp. 1579-1591; Engedal, K.H., Haugen, P.K., Demens-fakta og utfordringer. (2009) Tønsberg: Forlaget Aldring og Helse, pp. 176-179; Jorm, A.F., The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review (2004) Int Psychogeriatr, 16, pp. 275-293; Howieson, D.B., Loring, D.W., Hannay, H.J., Neurobehavioral variables and diagnostic issues. (2004), I: Lezak MD, Howieson DB, Tranel D et al, red. Neuropsychological assessment. Oxford: Oxford University PressWright, S.L., Persad, C., Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates (2007) J Geriatr Psychiatry Neurol, 20, pp. 189-198; Dotson, V.M., Resnick, S.M., Zonderman, A.B., Differential association of concurrent, baseline, and average depressive symptoms with cognitive decline in older adults (2008) Am J Geriatr Psychiatry, 16, pp. 318-330; Folstein, M.F., Folstein, S.E., McHugh, P.R., «Minimental state» (1975) A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, pp. 189-198; Woo, B.K., Rice, V.A., Legendre, S.A., The clock drawing test as a measure of executive dysfunction in elderly depressed patients (2004) J Geriatr Psychiatry Neurol, 17, pp. 190-194; Samton, J.B., Ferrando, S.J., Sanelli, P., The clock drawing test: diagnostic, functional, and neuroimaging correlates in older medically ill adults (2005) J Neuropsychiatry Clin Neurosci, 17, pp. 533-540; Milian, M.L., Leiherr, A.M., Straten, G., The Mini-Cog, Clock Drawing Test, and the Mini-Mental State Examination in a German memory clinic: specificity of separation dementia from depression (2013) Int Psychogeriatr, 25, pp. 96-104; Vertesi, A., Lever, J.A., Molloy, D.W., Standardized Mini-Mental State examination (2001) Use and interpretation. Can Fam Physician, 47, pp. 2018-2023; Christensen, H., Griffiths, K., Mackinnon, A., A quantitative review of cognitive deficits in depression and Alzheimer-type dementia (1997) J Int Neuropsychol Soc, 3, pp. 631-651; O'Carroll, R.E., Conway, S., Ryman, A., Performance on the delayed word recall test (DWR) fails to differentiate clearly between depression and Alzheimer's disease in the elderly (1997) Psychol Med, 27, pp. 967-971; Dierckx, E., Engelborghs, S., De Raedt, R., Differentiation between mild cognitive impairment, Alzheimer's disease and depression by means of cued recall (2007) Psychol Med, 37, pp. 747-755; Dierckx, E., Engelborghs, S., De Raedt, R., The 10-word learning task in the differential diagnosis of early Alzheimer's disease and elderly depression: A cross-sectional pilot study (2011) Aging Ment Health, 15, pp. 113-121; Foldi, N.S., Brickman, A.M., Schaefer, L.A., Distinct serial position profiles and neuropsychological measures differentiate late life depression from normal aging and Alzheimer's disease (2003) Psychiatry Res, 120, pp. 71-84; Crowe, S.F., Hoogenraad, K., Differentiation of dementia of the Alzheimer's type from depression with cognitive impairment on the basis of a cortical versus subcortical pattern of cognitive deficit (2000) Arch Clin Neuropsychol, 15, pp. 9-19; Mazur-Mosiewicz, A., Trammell, B.A., Noggle, C.A., Differential diagnosis of depression and Alzheimer's disease using the Cattell-Horn-Carroll theory (2011) Appl Neuropsychol, 18, pp. 252-262; Dierckx, E., Engelborghs, S., De Raedt, R., Differentiation between dementia and depression among older persons: can the difference between actual and premorbid intelligence be useful (2008) J Geriatr Psychiatry Neurol, 21, pp. 242-249; Reis, T., Brandão, C.O., Freire Coutinho, E.S., Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil (2012) CNS Neurosci Ther, 18, pp. 524-529; Buerger, K., Zinkowski, R., Teipel, S.J., Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231 (2003) Am J Psychiatry, 160, pp. 376-379; Oksengard, A.R., Cavallin, L., Axelsson, R., Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative (2010) Dement Geriatr Cogn Disord, 30, pp. 374-380; O'Brien, J.T., Desmond, P., Ames, D., Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment (1997) Psychol Med, 27, pp. 1267-1275; Denihan, A., Wilson, G., Cunningham, C., CT measurement of medial temporal lobe atrophy in Alzheimer's disease, vascular dementia, depression and paraphrenia (2000) Int J Geriatr Psychiatry, 15, pp. 306-312; Olesen, P.J., Gustafson, D.R., Simoni, M., Temporal lobe atrophy and white matter lesions are related to major depression over 5 years in the elderly (2010) Neuropsychopharmacology, 35, pp. 2638-2645; Øksengård, A.R., Haakonsen, M., Dullerud, R., Bildediagnostiske metoder ved demensutredning (2002) Tidsskr Nor Lægeforen, 122, pp. 10-14",Article,Scopus,2-s2.0-84896329012
"Haugen T.B.","Benzodiazepinbruk øker risikoen for Alzheimers sykdom",2014,"Tidsskrift for den Norske Laegeforening","134","20",,"1937","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84910623808&partnerID=40&md5=681638ec14c85d967db93e6a69230b34",,"Haugen, T.B.",[No abstract available],,"de Gage, S.B., Moride, Y., Ducruet, T., Benzodiazepine use and risk of Alzheimer's disease: casecontrol study (2014) BMJ, 349",Note,Scopus,2-s2.0-84910623808
"Sahrim M., Nixon M.S., Carare R.O.","Blood vessel feature description for detection of Alzheimers disease",2014,"2014 13th International Conference on Control Automation Robotics and Vision, ICARCV 2014",,, 7064325,"317","322",,,10.1109/ICARCV.2014.7064325,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84927732691&partnerID=40&md5=8c87e32f5673ce6b169f01adcc4853f5","School of Electronic and Computer Science, University of SouthamptonSouthampton, United Kingdom; School of Medicine, University of SouthamptonSouthampton, United Kingdom","Sahrim, M., School of Electronic and Computer Science, University of SouthamptonSouthampton, United Kingdom; Nixon, M.S., School of Electronic and Computer Science, University of SouthamptonSouthampton, United Kingdom; Carare, R.O., School of Medicine, University of SouthamptonSouthampton, United Kingdom","We describe how image analysis can be used to detect the presence of Alzheimer's disease. The data are images of brain tissue collected from subjects with and without Alzheimer's disease. The analysis concentrates on the shape and structure of the blood vessels which are known to be affected by amyloid beta, whose drainage is affected by Alzheimer's disease. The structure is analysed by a new approach which measures the Influence of the blood vessels' branching structures. Their density and tortuosity are analysed in conjunction with a boundary description derived using Fourier descriptors. These measures form a feature vector which is derived from the images of brain tissue, and the discrimination capability shows that it is possible to detect the presence of Alzheimer's disease using these measures and in an automated way. These measures also show that shape information is influenced by the vessels' branching structure, as known to be consistent with Alzheimer's disease evolution. © 2014 IEEE.","Alzheimer's disease; medical image analysis; segmentation; shape description","Boscolo, E., Folin, M., Nico, B., Grandi, C., Mangieri, D., Longo, V., Beta amyloid angiogenic activity in vitro and in vivo (2007) International Journal of Molecular Medicine, 19, p. 581; Lemere, C., Blusztajn, J., Yamaguchi, H., Wisniewski, T., Saido, T., Selkoe, D., Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation (1996) Neurobiology of Disease, 3, p. 16; Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Decreased clearance of CNS β-amyloid in Alzheimer's disease (2010) Science, 330, pp. 1774-1774; Weller, R., Subash, M., Preston, S., Mazanti, I., Carare, R., Perivascular drainage of amyloid-b peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease (2008) Brain Pathology, 18, pp. 253-266; Wang, L., Beg, F., Ratnanather, T., Ceritoglu, C., Younes, L., Morris, J.C., Large deformation diffeomorphism and momentum based hippocampal shape discrimination in dementia of the Alzheimer type (2007) IEEE Trans Med Imaging, 26, pp. 462-470. , Apr; Freeborough, P.A., Fox, N.C., MR image texture analysis applied to the diagnosis and tracking of Alzheimer's disease (1998) IEEE Trans Med Imaging, 17, pp. 475-479. , Jun; Fischl, B., Dale, A.M., Measuring the thickness of the human cerebral cortex from magnetic resonance images (2000) Proc Natl Acad Sci U S A, 97, pp. 11050-11055. , Sep. 26; Kojda, G., Harrison, D., Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure (1999) Cardiovascular Research, 43, pp. 652-671; Droz, L., Bellaiche, G., Rhone deep-sea fan: Morphostructure and growth pattern (1985) Am. Assoc. Pet. Geol, Bull; (United States), 69; Biron, K.E., Dickstein, D.L., Gopaul, R., Jefferies, W.A., Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease (2011) PLoS One, 6, p. e23789; Lotmar, W., Freiburghaus, A., Bracher, D., Measurement of vessel tortuosity on fundus photographs (1979) Graefe's Archive for Clinical and Experimental Ophthalmology, 211, pp. 49-57; Nixon, M., Aguado, A.S., (2012) Feature Extraction & Image Processing for Computer Vision, , Academic Press; Granlund, G.H., Fourier preprocessing for hand print character recognition (1972) Computers, IEEE Transactions On, 100, pp. 195-201; Zahn, C.T., Roskies, R.Z., Fourier descriptors for plane closed curves (1972) Computers, IEEE Transactions On, 100, pp. 269-281; Jain, A., Zongker, D., Feature selection: Evaluation, application, and small sample performance (1997) Pattern Analysis and Machine Intelligence, IEEE Transactions On, 19, pp. 153-158",Conference Paper,Scopus,2-s2.0-84927732691
"Thyssen J.P.","E-vitamin forsinker udvikling af let til moderat Alzheimers demens",2014,"Ugeskrift for Laeger",,"7",,"","",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84921708990&partnerID=40&md5=6e0a74cf7fcf234d0fa25e965467be87",,"Thyssen, J.P.",[No abstract available],,,Note,Scopus,2-s2.0-84921708990
[No author name available],"Does vitamin E slow decline in mild to moderate Alzheimers disease?",2014,"Drug and Therapeutics Bulletin","52","3",,"29","",,,10.1136/dtb.2014.3.0239,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896103156&partnerID=40&md5=7042e6645e462a40cb43c57b70ad6258",,"",[No abstract available],,"Dysken, M.W., Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial (2014) JAMA, 11, pp. 33-44",Note,Scopus,2-s2.0-84896103156
"Altomare A., Capparelli E., Carrieri A., Colabufo N.A., Moliterni A., Rizzi R., Siliqi D.","Crystallographic study of PET radiotracers in clinical evaluation for early diagnosis of Alzheimers",2014,"Acta Crystallographica Section E: Structure Reports Online","70","11",,"o1149","o1150",,,10.1107/S1600536814021400,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908622704&partnerID=40&md5=7eb27d692b56850eaf05366e08b2e4c9","Istituto di Cristallografia, Via G. Amendola, 122/oBari, Italy; Dip. di Farmacia-Scienze Del Farmaco, Universita' Degli Studi di Bari, Via Orabona, 4Bari, Italy; Dip. di Farmacia-Scienze Del Farmaco, Biofordrug, Srl, Universita' Degli Studi di Bari, Via Orabona, 4Bari, Italy","Altomare, A., Istituto di Cristallografia, Via G. Amendola, 122/oBari, Italy; Capparelli, E., Dip. di Farmacia-Scienze Del Farmaco, Universita' Degli Studi di Bari, Via Orabona, 4Bari, Italy; Carrieri, A., Dip. di Farmacia-Scienze Del Farmaco, Universita' Degli Studi di Bari, Via Orabona, 4Bari, Italy; Colabufo, N.A., Dip. di Farmacia-Scienze Del Farmaco, Biofordrug, Srl, Universita' Degli Studi di Bari, Via Orabona, 4Bari, Italy; Moliterni, A., Istituto di Cristallografia, Via G. Amendola, 122/oBari, Italy; Rizzi, R., Istituto di Cristallografia, Via G. Amendola, 122/oBari, Italy; Siliqi, D., Istituto di Cristallografia, Via G. Amendola, 122/oBari, Italy","The title compound, C24H25NO3·2CH3OH, which crystallized as a methanol disolvate, has applications as a PET radiotracer in the early diagnosis of Alzheimer's disease. The dihedral angle between the biphenyl rings is 8.2 (2)° and the heterocyclic ring adopts a half-chair conformation with the N atom adopting a pyramidal geometry (bond-angle sum = 327.6°). The C atoms of both methoxy groups lie close to the plane of their attached ring [deviations = 0.107 (6) and 0.031 (6) Å]. In the crystal, the components are linked by O - H⋯O and O - H⋯N hydrogen bonds, generating [010] chains. C - H⋯O interactions are also observed.","crystal structure; hydrogen bonds; ligands; P-glycoprotein inhibitor; PET radiotracer","Altomare, A., Cuocci, C., Giacovazzo, C., Moliterni, A., Rizzi, R., Corriero, N., Falcicchio, A., (2013) J. Appl. Cryst., 46, pp. 1231-1235; Burla, M.C., Caliandro, R., Camalli, M., Carrozzini, B., Cascarano, G.L., Giacovazzo, C., Mallamo, M., Spagna, R., (2012) J. Appl. Cryst., 45, pp. 357-361; Colabufo, N.A., Berardi, F., Cantore, M., Perrone, M.G., Contino, M., Inglese, C., Niso, M., Paradiso, A., (2008) Bioorg. Med. Chem., 16, pp. 3732-3743; Colabufo, N.A., Berardi, F., Perrone, M.G., Cantore, M., Contino, M., Inglese, C., Niso, M., Perrone, R., (2009) ChemMedChem, 4, pp. 188-195; Duisenberg, A.J.M., (1992) J. Appl. Cryst., 25, pp. 92-96; Duisenberg, A.J.M., Hooft, R.W.W., Schreurs, A.M.M., Kroon, J., (2000) J. Appl. Cryst., 33, pp. 893-898; Duisenberg, A.J.M., Kroon-Batenburg, L.M.J., Schreurs, A.M.M., (2003) J. Appl. Cryst., 36, pp. 220-229; Farrugia, L.J., (2012) J. Appl. Cryst., 45, pp. 849-854; (2002) COLLECT and EVAL, , Nonius Nonius BV, Delft, The Netherlands; Sheldrick, G.M., (2008) SADABS, , University of Göttingen, Germany; Sheldrick, G.M., (2008) Acta Cryst. A, 64, pp. 112-122; Westrip, S.P., (2010) J. Appl. Cryst., 43, pp. 920-925",Article,Scopus,2-s2.0-84908622704
"Weiler M., Fukuda A., Massabki L.H.P., Lopes T.M., Franco A.R., Damasceno B.P., Cendes F., Balthazar M.L.F.","Default mode, executive function, and language functional connectivity networks are compromised in mild Alzheimeŕs disease",2014,"Current Alzheimer Research","11","3",,"274","282",,,10.2174/1567205011666140131114716,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897455607&partnerID=40&md5=1bd418e98b5cc5be2c7e661a3b28af96","Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Unit for Neuropsychology and Neurolinguistics, Department of Neurology, University of Campinas (Unicamp), Brazil; Brain Institute of Rio Grande do Sul, Catholic University of Rio Grande do Sul (PUCRS), Brazil","Weiler, M., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Fukuda, A., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Massabki, L.H.P., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Lopes, T.M., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Franco, A.R., Brain Institute of Rio Grande do Sul, Catholic University of Rio Grande do Sul (PUCRS), Brazil; Damasceno, B.P., Unit for Neuropsychology and Neurolinguistics, Department of Neurology, University of Campinas (Unicamp), Brazil; Cendes, F., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil; Balthazar, M.L.F., Neuroimaging Laboratory, Department of Neurology, University of Campinas (Unicamp), Brazil, Unit for Neuropsychology and Neurolinguistics, Department of Neurology, University of Campinas (Unicamp), Brazil","Alzheimer's disease (AD) is characterized by mental and cognitive problems, particularly with memory, language, visuospatial skills (VS), and executive functions (EF). Advances in the neuroimaging of AD have highlighted dysfunctions in functional connectivity networks (FCNs), especially in the memory related default mode network (DMN). However, little is known about the integrity and clinical significance of FNCs that process other cognitive functions than memory. We evaluated 22 patients with mild AD and 26 healthy controls through a resting state functional MRI scan. We aimed to identify different FCNs: the DMN, language, EF, and VS. Seed-based functional connectivity was calculated by placing a seed in the DMN (posterior cingulate cortex), language (Broca's and Wernicke's areas), EF (right and left dorsolateral prefrontal cortex), and VS networks (right and left associative visual cortex). We also performed regression analyses between individual connectivity maps for the different FCNs and the scores on cognitive tests. We found areas with significant decreases in functional connectivity in patients with mild AD in the DMN and Wernicke's area compared with controls. Increased connectivity in patients was observed in the EF network. Regarding multiple linear regression analyses, a significant correlation was only observed between the connectivity of the DMN and episodic memory (delayed recall) scores. In conclusion, functional connectivity alterations in mild AD are not restricted to the DMN. Other FCNs related to language and EF may be altered. However, we only found significant correlations between cognition and functional connectivity in the DMN and episodic memory performance. © 2014 Bentham Science Publishers.","Alzheimer's disease; Cognition; Default mode network; Functional connectivity; Functional networks; Resting-state networks","Guye, M., Bettus, G., Bartolomei, F., Cozzone, P.J., Graph theoretical analysis of structural and functional connectivity MRI in normal and pathological brain networks (2010) MAGMA, 23, pp. 409-421; Bozzali, M., Parker, G.J., Serra, L., Embleton, K., Gili, T., Perri, R., Anatomical connectivity mapping: A new tool to assess brain disconnection in Alzheimer's disease (2010) Neuroimage, 54, pp. 2045-2051; Bokde, A.L., Ewers, M., Hampel, H., Assessing neuronal networks: Understanding Alzheimer's disease (2009) Prog Neurobiol, 89, pp. 125-133; Celone, K.A., Calhoun, V.D., Dickerson, B.C., Atri, A., Chua, E.F., Miller, S.L., Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: An independent component analysis (2006) J Neurosci, 26, pp. 10222-10231; Wang, K., Liang, M., Wang, L., Tian, L., Zhang, X., Li, K., Altered functional connectivity in early Alzheimer's disease: A resting-state fMRI study (2007) Hum Brain Mapp, 28, pp. 967-978; Rombouts, S.A., Barkhof, F., Goekoop, R., Stam, C.J., Scheltens, P., Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study (2005) Hum Brain Mapp, 26, pp. 231-239; Matthews, P.M., Filippini, N., Douaud, G., Brain Structural and Functional Connectivity and the Progression of Neuropathology in Alzheimer's Disease (2013) J Alzheimers Dis, 33 (1), pp. S163-S172; Sorg, C., Riedl, V., Muhlau, M., Calhoun, V.D., Eichele, T., Laer, L., Selective changes of resting-state networks in individuals at risk for Alzheimer's disease (2007) Proc Natl Acad Sci USA, 104, pp. 18760-18765; Qi, Z., Wu, X., Wang, Z., Zhang, N., Dong, H., Yao, L., Impairment and compensation coexist in amnestic MCI default mode network (2010) Neuroimage, 50, pp. 48-55; Greicius, M.D., Srivastava, G., Reiss, A.L., Menon, V., Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI (2004) Proc Natl Acad Sci USA, 101, pp. 4637-4642; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Hachinski, V., Iadecola, C., Petersen, R.C., Breteler, M.M., Nyenhuis, D.L., Black, S.E., National Institute of Neurological Disorders and Stroke-Canadian Stroke Network (2006) Stroke, 37, pp. 2220-2241; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician (1975) J Psychiatr Res, 12, pp. 189-198; Malloy-Diniz, L.F., Lasmar, V.A., Gazinelli Lde, S., Fuentes, D., Salgado, J.V., The Rey Auditory-Verbal Learning Test: Applicability for the Brazilian elderly (2007) Rev Bras Psiquiatr, 29, pp. 324-329; Christensen, P., Guilford, J., (1959) Manual for the Christensen Guilford Fluency Tests, , (2nd ed.) Beverly Hills, California: Sheridan Supply; Ratcliff, G., Spatial thought, mental rotation and the right cerebral hemisphere (1979) Neuropsychologia, 17, pp. 49-54; Osterrieth, P., The test of copying a complex figure: A contribution to the study of perception and memory (1944) Arch Psychol, 30, pp. 206-356; Reitan, R., Validity of the Trail Making Test as an indicator of organic brain damage (1958) Percept Mot Skills, 8, pp. 271-276; Stroop, J., Studies of interference in serial verbal reactions (1935) J Exp Psychol, 18, pp. 643-662; Kaplan, E., Goodglass, H., Weintraub, S., (1983) The Boston Naming Test, , (2nd ed.) Philadelphia: Lea & Febiger; Wechsler, D., (1987) Manual for the Wechsler Memory Scale-Revised (WMS-R), , San Antonio: The Psychological Corporation; Nichols, T.E., Holmes, A.P., Nonparametric permutation tests for functional neuroimaging: A primer with examples (2002) Hum Brain Mapp, 15, pp. 1-25; Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory (2005) J Neurosci, 25, pp. 7709-7779; Villain, N., Desgranges, B., Viader, F., de la Sayette, V., Mezenge, F., Landeau, B., Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease (2008) J Neurosci, 28, pp. 6174-6181; Zhou, J., Greicius, M.D., Gennatas, E.D., Growdon, M.E., Jang, J.Y., Rabinovici, G.D., Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease (2010) Brain, 133, pp. 1352-1367; Buckner, R.L., Andrews-Hanna, J.R., Schacter, D.L., The brain's default network: Anatomy, function, and relevance to disease (2008) Ann N Y Acad Sci, 1124, pp. 1-38; Mason, M.F., Norton, M.I., Van Horn, J.D., Wegner, D.M., Grafton, S.T., McRae, C.N., Wandering minds: The default network and stimulusindependent thought (2007) Science, 315, pp. 393-395; Mevel, K., Chételat, G., Eustache, F., Desgranges, B., The default mode network in healthy aging and Alzheimer's disease (2011) Int J Alzheimers Dis, 2011, p. 535816; Pihlajamaki, M., Sperling, R.A., Functional MRI assessment of taskinduced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals (2009) Behav Neurol, 21, pp. 77-91; de Calignon, A., Polydoro, M., Suarez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Propagation of tau pathology in a model of early Alzheimer's disease (2012) Neuron, 73, pp. 685-697; Brier, M.R., Thomas, J.B., Snyder, A.Z., Benzinger, T.L., Zhang, D., Raichle, M.E., Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression (2012) J Neurosci, 32, pp. 8890-8899; Andrews-Hanna, J.R., Snyder, A.Z., Vincent, J.L., Lustig, C., Head, D., Raichle, M.E., Disruption of large-scale brain systems in advanced aging (2007) Neuron, 56, pp. 924-935; Pievani, M., de Haan, W., Wu, T., Seeley, W.W., Frisoni, G.B., Functional network disruption in the degenerative dementias (2011) Lancet Neurol, 10, pp. 829-843; Stebbins, G.T., Murphy, C.M., Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment (2009) Behav Neurol, 21, pp. 39-49; Agosta, F., Pievani, M., Geroldi, C., Copetti, M., Frisoni, G.B., Filippi, M., Resting state fMRI in Alzheimer's disease: Beyond the default mode network (2012) Neurobiol Aging, 33, pp. 1564-1578; Seeley, W.W., Menon, V., Schatzberg, A.F., Keller, J., Glover, G.H., Kenna, H., Dissociable intrinsic connectivity networks for salience processing and executive control (2007) J Neurosci, 27, pp. 2349-2356; Sridharan, D., Levitin, D.J., Menon, V., A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks (2008) Proc Natl Acad Sci USA, 105, pp. 12569-12574; Greicius, M.D., Krasnow, B., Reiss, A.L., Menon, V., Functional connectivity in the resting brain: A network analysis of the default mode hypothesis (2003) Proc Natl Acad Sci USA, 100, pp. 253-258; Balthazar, M.L., Pereira, F.R., Lopes, T.M., Campos, B.M., Coan, A.C., Duncan, N.W., (2013) Neuropsychiatric symptoms in AD are related to functional connectivity alterations in Salience network, , Human Brain Mapping [in press]; Gili, T., Cercignani, M., Serra, L., Perri, R., Giove, F., Maraviglia, B., Regional brain atrophy and functional disconnection across Alzheimer's disease evolution (2011) J Neurol Neurosurg Psychiatry, 82, pp. 58-66; McHulda, M.M., Jones, D.T., Vemuri, P., McDade, E., Avula, R., Przybelski, S., Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects (2011) Arch Neurol, 68, pp. 1131-1136",Article,Scopus,2-s2.0-84897455607
"Wang L.J., Du X.Q., Du Z.W., Yang Y.Y., Chen P., Tian Q., Shang X.L., Liu Z.C., Yao X.Q., Wang J.Z., Wang X.H., Cheng Y., Peng J., Shen A.G., Hu J.M.","Raman spectroscopy detection of platelet for Alzheimer's disease with predictive probabilities",2014,"Laser Physics","24","8", 085702,"","",,,10.1088/1054-660X/24/8/085702,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904985784&partnerID=40&md5=b483ca9150fdd1f43d6ebbb021d2d36c","Emergency Department, Tianjin Medical University Genenal Hospital, Tianjin 300000, China; Department of Science and Education, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, China; College of Computer Science and Technology, Jilin University, Changchun 130012, China; Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China","Wang, L.J., Emergency Department, Tianjin Medical University Genenal Hospital, Tianjin 300000, China; Du, X.Q., Department of Science and Education, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, China; Du, Z.W., College of Computer Science and Technology, Jilin University, Changchun 130012, China; Yang, Y.Y., College of Computer Science and Technology, Jilin University, Changchun 130012, China; Chen, P., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Tian, Q., Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China; Shang, X.L., Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China; Liu, Z.C., Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China; Yao, X.Q., Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China; Wang, J.Z., Department of Pathophysiology, National Education Ministry, Huazhong University of Science and Technology, Wuhan 430030, China; Wang, X.H., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Cheng, Y., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Peng, J., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Shen, A.G., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China; Hu, J.M., Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China","Alzheimer's disease (AD) is a common form of dementia. Early and differential diagnosis of AD has always been an arduous task for the medical expert due to the unapparent early symptoms and the currently imperfect imaging examination methods. Therefore, obtaining reliable markers with clinical diagnostic value in easily assembled samples is worthy and significant. Our previous work with laser Raman spectroscopy (LRS), in which we detected platelet samples of different ages of AD transgenic mice and non-transgenic controls, showed great effect in the diagnosis of AD. In addition, a multilayer perception network (MLP) classification method was adopted to discriminate the spectral data. However, there were disturbances, which were induced by noise from the machines and so on, in the data set; thus the MLP method had to be trained with large-scale data. In this paper, we aim to re-establish the classification models of early and advanced AD and the control group with fewer features, and apply some mechanism of noise reduction to improve the accuracy of models. An adaptive classification method based on the Gaussian process (GP) featured, with predictive probabilities, is proposed, which could tell when a data set is related to some kind of disease. Compared with MLP on the same feature set, GP showed much better performance in the experimental results. What is more, since the spectra of platelets are isolated from AD, GP has good expansibility and can be applied in diagnosis of many other similar diseases, such as Parkinson's disease (PD). Spectral data of 4 month and 12 month AD platelets, as well as control data, were collected. With predictive probabilities, the proposed GP classification method improved the diagnostic sensitivity to nearly 100%. Samples were also collected from PD platelets as classification and comparison to the 12 month AD. The presented approach and our experiments indicate that utilization of GP with predictive probabilities in platelet LRS detection analysis turns out to be more accurate for early and differential diagnosis of AD and has a wide application prospect. © 2014 Astro Ltd.","Alzheimers disease; predictive probability; Raman spectroscopy","Chen, P., Shen, A., Zhao, W., Baek, S., Yuan, H., Hu, J., Raman signature from brain hippocampus could aid Alzheimer's disease diagnosis (2009) Appl. Opt., 48, pp. 4743-4748. , 10.1364/AO.48.004743 0003-6935; Chen, P., Laser Raman detection of platelet as a non-invasive approach for early and differential diagnosis of Alzheimer's disease (2011) Laser Phys. Lett., 8 (7), pp. 547-552. , 10.1002/lapl.201110016 1612-202X 010; Darvin, M.E., Patzelt, A., Meinke, M., Sterry, W., Lademann, J., Influence of two different IR radiators on the antioxidative potential of the human skin (2009) Laser Phys. Lett., 6 (3), pp. 229-234. , 10.1002/lapl.200810124 1612-202X 009; Dauer, W., Przedborski, S., Parkinson's disease: Mechanisms and models (2003) Neuron, 39 (6), pp. 889-909. , DOI 10.1016/S0896-6273(03)00568-3; Mariani, M.M., Day, P., Deckert, V., Applications of modern micro-Raman spectroscopy for cell analyses (2010) Integr. Biol., 2, pp. 94-101. , 10.1039/b920572a 1093-4391; Raman, C., Krishnan, K., A new type of secondary radiation (1928) Nature, 121, pp. 501-502. , 10.1038/121501c0; Rasmussen, C.E., Williams, C.K.I., (2005) Gaussian Processes for Machine Learning, pp. 715-719; Reilly, J., Rodriguez, A.D., Lamy, M., Neils-Strunjas, J., Cognition, language, and clinical pathological features of non-Alzheimer's dementias: An overview (2010) J. Commun. Disord., 43, pp. 438-452. , 10.1016/j.jcomdis.2010.04.011 0021-9924; Richardson, J.R., Caudle, W.M., Guillot, T.S., Watson, J.L., Nakamaru-Ogiso, E., Seo, B.B., Sherer, T.B., Miller, G.W., Obligatory role for complex i inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (2007) Toxicological Sciences, 95 (1), pp. 196-204. , DOI 10.1093/toxsci/kfl133; Rong, X., Huang, S.S., Kuang, X.C., Liu, H., Real-time detection of single-living pancreatic beta-cell by laser tweezers Raman spectroscopy: High glucose stimulation (2010) Biopolymers, 93, pp. 587-594. , 10.1002/bip.21389; Samek, O., Al-Marashi, J.F.M., Telle, H.H., The potential of Raman spectroscopy for the identification of biofilm formation by Staphylococcus epidermidis (2010) Laser Phys. Lett., 7 (5), pp. 378-383. , 10.1002/lapl.200910154 1612-202X 010; Sato, H., Chiba, H., Tashiro, H., Ozaki, Y., Excitation wavelength-dependent changes in Raman spectra of whole blood and hemoglobin: Comparison of the spectra with 514.5-, 720-, and 1064-nm excitation (2001) Journal of Biomedical Optics, 6 (3), pp. 366-370. , DOI 10.1117/1.1380668; Seeger, M., Gaussian processes for machine learning (2004) Int. J. Neural Syst., 14, pp. 69-106. , 10.1142/S0129065704001899 0129-0657; Tiwari, V.S., Luanje, A.T., Kalluru, R.R., Yueh, F.Y., Singh, J.P., An integrated laser Raman optical sensor for fast detection of nitrogen and oxygen in a cryogenic mixture (2011) Rev. Sci. Instrum., 82. , 10.1063/1.3581336 043108",Article,Scopus,2-s2.0-84904985784
"Poza J., Gomez C., Garcia M., Corralejo R., Fernandez A., Hornero R.","Analysis of neural dynamics in mild cognitive impairment and Alzheimer's disease using wavelet turbulence",2014,"Journal of Neural Engineering","11","2", 026010,"","",,,10.1088/1741-2560/11/2/026010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897565406&partnerID=40&md5=0590121ab2aa98174516eafc00f0ba39","Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain; IMUVA, Instituto de Investigación en Matemáticas, University of Valladolid, Valladolid, Spain; INCYL, Instituto de Neurociencias de Castilla y León, Salamanca, Spain; Departamento de Psiquiatría y Psicología Médica, Facultad de Medicina, Complutense University of Madrid, Madrid, Spain","Poza, J., Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain, IMUVA, Instituto de Investigación en Matemáticas, University of Valladolid, Valladolid, Spain, INCYL, Instituto de Neurociencias de Castilla y León, Salamanca, Spain; Gómez, C., Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain; García, M., Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain; Corralejo, R., Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain; Fernández, A., Departamento de Psiquiatría y Psicología Médica, Facultad de Medicina, Complutense University of Madrid, Madrid, Spain; Hornero, R., Biomedical Engineering Group, Department TSCIT, University of Valladolid, Valladolid, Spain, IMUVA, Instituto de Investigación en Matemáticas, University of Valladolid, Valladolid, Spain, INCYL, Instituto de Neurociencias de Castilla y León, Salamanca, Spain","Objective. Current diagnostic guidelines encourage further research for the development of novel Alzheimer's disease (AD) biomarkers, especially in its prodromal form (i.e. mild cognitive impairment, MCI). Magnetoencephalography (MEG) can provide essential information about AD brain dynamics; however, only a few studies have addressed the characterization of MEG in incipient AD. Approach. We analyzed MEG rhythms from 36 AD patients, 18 MCI subjects and 27 controls, introducing a new wavelet-based parameter to quantify their dynamical properties: the wavelet turbulence. Main results. Our results suggest that AD progression elicits statistically significant regional-dependent patterns of abnormalities in the neural activity (p < 0.05), including a progressive loss of irregularity, variability, symmetry and Gaussianity. Furthermore, the highest accuracies to discriminate AD and MCI subjects from controls were 79.4% and 68.9%, whereas, in the three-class setting, the accuracy reached 67.9%. Significance. Our findings provide an original description of several dynamical properties of neural activity in early AD and offer preliminary evidence that the proposed methodology is a promising tool for assessing brain changes at different stages of dementia. © 2014 IOP Publishing Ltd.","Alzheimers disease; continuous wavelet transform; magnetoencephalogram; mild cognitive impairment; wavelet turbulence","Babiloni, C., Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease (2009) NeuroImage, 44, pp. 123-135. , 10.1016/j.neuroimage.2008.08.005; Blanco, S., García, H., Quiroga, R.Q., Romanelli, L., Rosso, O.A., Stationarity of the EEG series (1995) IEEE Eng. Med. Biol. Mag., 14, pp. 395-399. , 10.1109/51.395321 0739-5175; Bruña, R., Poza, J., Gómez, C., García, M., Fernández, A., Hornero, R., Analysis of spontaneous MEG activity in mild cognitive impairment and Alzheimer's disease using spectral entropies and statistical complexity measures (2012) J. Neural Eng., 9 (3). , 10.1088/1741-2560/9/3/036007 1741-2552 036007; De Haan, W., Van Der Flier, W.M., Koene, T., Smits, L.L., Scheltens, P., Stam, C.J., Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease (2012) NeuroImage, 59, pp. 3085-3093. , 10.1016/j.neuroimage.2011.11.055; Escudero, J., Sanei, S., Jarchi, D., Abásolo, D., Hornero, R., Regional coherence evaluation in mild cognitive impairment and Alzheimer's disease based on adaptively extracted magnetoencephalogram rhythms (2011) Physiol. Meas., 32 (8), pp. 1163-1180. , 10.1088/0967-3334/32/8/011 0967-3334 011; Ewers, M., Sperling, R.A., Klunk, W.E., Weiner, M.W., Hampel, H., Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia (2011) Trends Neurosci., 34, pp. 430-442. , 10.1016/j.tins.2011.05.005 0166-2236; Fernández, A., Hornero, R., Gómez, C., Turrero, A., Gil-Gregorio, P., Matías-Santos, J., Ortiz, T., Complexity analysis of spontaneous brain activity in Alzheimer's disease and mild cognitive impairment: An MEG study (2010) Alzheimer Dis. Assoc. Disord., 24, pp. 182-189. , 10.1097/WAD.0b013e3181c727f7 0893-0341; Fernández, A., Hornero, R., Mayo, A., Poza, J., Gil-Gregorio, P., Ortiz, T., MEG spectral profile in Alzheimer's disease and mild cognitive impairment (2006) Clin. Neurophysiol., 117, pp. 306-314. , 10.1016/j.clinph.2005.10.017 1388-2457; Fernández, A., Turrero, A., Zuluaga, P., Gil, P., Maestú, F., Campo, P., Ortiz, T., Magnetoencephalographic parietal delta dipole density in mild cognitive impairment: Preliminary results of a method to estimate the risk of developing Alzheimer disease (2006) Arch. Neurol., 63, pp. 427-430. , 10.1001/archneur.63.3.427; Ferrer, I., Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia (2012) Prog. Neurobiol., 97, pp. 38-51. , 10.1016/j.pneurobio.2012.03.005 0301-0082; Figliola, A., Serrano, E., Analysis of physiological time series using wavelet transforms (1997) IEEE Eng. Med. Biol. Mag., 16, pp. 74-79. , 10.1109/51.585521 0739-5175; Franciotti, R., Falasca, N.W., Bonanni, L., Anzellotti, F., Maruotti, V., Comani, S., Thomas, A., Onofrj, M., Default network is not hypoactive in dementia with fluctuating cognition: An Alzheimer disease/dementia with Lewy bodies comparison (2013) Neurobiol. Aging, 34, pp. 1148-1158. , 10.1016/j.neurobiolaging.2012.09.015 0197-4580; Georgopoulos, A.P., Synchronous neural interactions assessed by magnetoencephalography: A functional biomarker for brain disorders (2007) J. Neural Eng., 4 (4), pp. 349-355. , 10.1088/1741-2560/4/4/001 1741-2552 001; Ghuman, A.S., McDaniel, J.R., Martin, A., A wavelet-based method for measuring the oscillatory dynamics of resting-state functional connectivity in MEG (2011) NeuroImage, 56, pp. 69-77. , 10.1016/j.neuroimage.2011.01.046; Gómez, C., Stam, C.J., Hornero, R., Fernández, A., Maestú, F., Disturbed beta band functional connectivity in patients with mild cognitive impairment: A MEG study (2009) IEEE Trans. Biomed. Eng., 56, pp. 1683-1690. , 10.1109/TBME.2009.2018454 0018-9294; Hampel, H., Lista, S., Khachaturian, Z.S., Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot (2012) Alzheimers Dement., 8, pp. 312-336. , 10.1016/j.jalz.2012.05.2116; Hampel, H., The future of Alzheimer's disease: The next 10 years (2011) Prog. Neurobiol., 95, pp. 718-728. , 10.1016/j.pneurobio.2011.11.008 0301-0082; Jobson, J.D., (1991) Applied Multivariate Data Analysis: Regression and Experimental Design, 1. , 10.1007/978-1-4612-0955-3; Kelen, G.J., Henkin, R., Starr, A.M., Caref, E.B., Bloomfield, D., El-Sherif, N., Spectral turbulence analysis of the signal-averaged electrocardiogram and its predictive accuracy for inducible sustained monomorphic ventricular tachycardia (1991) Am. J. Cardiol., 67, pp. 965-975. , 10.1016/0002-9149(91)90169-L 0002-9149; Kendall, M.G., Gibbons, J.D., (1990) Rank Correlation Methods; Knyazeva, M.G., Carmeli, C., Khadivi, A., Ghika, J., Meuli, R., Frackowiak, R.S., Evolution of source EEG synchronization in early Alzheimer's disease (2013) Neurobiol. Aging, 34, pp. 694-705. , 10.1016/j.neurobiolaging.2012.07.012 0197-4580; Mallat, S.G., (1998) A Wavelet Tour of Signal Processing; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease (1984) Neurology, 34, pp. 939-944. , 10.1212/WNL.34.7.939; McKhann, G.M., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement., 7, pp. 263-269. , 10.1016/j.jalz.2011.03.005; Mufson, E.J., Binder, L., Counts, S.E., Dekosky, S.T., De Toledo-Morrell, L., Ginsberg, S.D., Ikonomovic, M.D., Scheff, S.W., Mild cognitive impairment: Pathology and mechanisms (2012) Acta Neuropathol., 123, pp. 13-30. , 10.1007/s00401-011-0884-1 0001-6322; Nakas, C.T., Yiannoutsos, C.T., Ordered multiple-class ROC analysis with continuous measurements (2004) Stat. Med., 23, pp. 3437-3449. , 10.1002/sim.1917; Nichols, T.E., Holmes, A.P., Nonparametric permutation tests for functional neuroimaging: A primer with examples (2001) Hum. Brain Mapp., 15, pp. 1-25. , 10.1002/hbm.1058; Osipova, D., Rantanen, K., Ahveninen, J., Ylikoski, R., Happola, O., Strandberg, T., Pekkonen, E., Source estimation of spontaneous MEG oscillations in mild cognitive impairment (2006) Neurosci. Lett., 405, pp. 57-61. , 10.1016/j.neulet.2006.06.045 0304-3940; Percival, D.B., On estimation of the wavelet variance (1995) Biometrika, 82, pp. 619-631. , 10.1093/biomet/82.3.619 0006-3444; Petersen, R.C., Alzheimer's disease: Progress in prediction (2010) Lancet Neurol., 9, pp. 4-5. , 10.1016/S1474-4422(09)70330-8; Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Ritchie, K., Winblad, B., Current concepts in mild cognitive impairment (2001) Arch. Neurol., 58, pp. 1985-1992. , 10.1001/archneur.58.12.1985; Poza, J., Gómez, C., García, M., Fernández, A., Hornero, R., Analysis of spontaneous MEG activity in mild cognitive impairment using the wavelet turbulence (2012) Proc. 4th Int. Joint Conf. on Computational Intelligence, pp. 721-726; Poza, J., Hornero, R., Abásolo, D., Fernández, A., García, M., Extraction of spectral based measures from MEG background oscillations in Alzheimer's disease (2007) Med. Eng. Phys., 29, pp. 1073-1083. , 10.1016/j.medengphy.2006.11.006 1350-4533; Poza, J., Hornero, R., Escudero, J., Fernández, A., Gómez, C., Analysis of spontaneous MEG activity in Alzheimer's disease using time-frequency parameters (2008) Conf. Proc. IEEE Engineering in Medicine and Biology Society, pp. 5712-5715. , 10.1109/IEMBS.2008.4650511; Poza, J., Hornero, R., Escudero, J., Fernández, A., Sánchez, C.I., Regional analysis of spontaneous MEG rhythms in patients with Alzheimer's disease using spectral entropies (2008) Ann. Biomed. Eng., 36, pp. 141-152. , 10.1007/s10439-007-9402-y; Rabinovich, M.I., Afraimovich, V.S., Bick, C., Varona, P., Information flow dynamics in the brain (2012) Phys. Life Rev., 9, pp. 51-73. , 10.1016/j.plrev.2011.11.002; Rampp, S., Stefan, H., On the opposition of EEG and MEG (2007) Clin. Neurophysiol., 118, pp. 1658-1659. , 10.1016/j.clinph.2007.04.021 1388-2457; Reitz, C., Brayne, C., Mayeux, R., Epidemiology of Alzheimer disease (2011) Nature Rev. Neurol., 7, pp. 137-152. , 10.1038/nrneurol.2011.2; Roach, B.J., Mathalon, B.H., Event-related EEG time-frequency analysis: An overview of measures and an analysis of early gamma band phase locking in schizophrenia (2008) Schizophr. Bull., 34, pp. 907-926. , 10.1093/schbul/sbn093 0586-7614; Sperling, R.A., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement., 7, pp. 280-292. , 10.1016/j.jalz.2011.03.003; Stam, C.J., Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders (2010) J. Neurol. Sci., 289, pp. 128-134. , 10.1016/j.jns.2009.08.028 0022-510X; Ward, A., Arrighi, H.M., Michels, S., Cedarbaum, J.M., Mild cognitive impairment: Disparity of incidence and prevalence estimates (2012) Alzheimers Dement., 8, pp. 14-21. , 10.1016/j.jalz.2011.01.002",Article,Scopus,2-s2.0-84897565406
"Nayebi A.M., Pourrabi S., Hossini S.","Testosterone ameliorates streptozotocin-induced memory impairment in male rats",2014,"Acta Pharmacologica Sinica","35","6",,"752","757",,1,10.1038/aps.2014.6,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902246225&partnerID=40&md5=f57495663245426475b22e7dc4a710d9","Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran; Department of Biology, Science and Research Branch, Islamic Azad University, Fars, Iran","Nayebi, A.M., Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51664, Iran; Pourrabi, S., Department of Biology, Science and Research Branch, Islamic Azad University, Fars, Iran; Hossini, S., Department of Biology, Science and Research Branch, Islamic Azad University, Fars, Iran","Aim:To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.Methods:Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 μg) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ. Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation. Testosterone (1 mg·kg -1 ·d -1, sc), the androgen receptor antagonist flutamide (10 mg·kg -1 ·d -1, ip), the estrogen receptor antagonist tamoxifen (1 mg·kg -1 ·d -1, ip) or the aromatase inhibitor letrozole (4 mg·kg -1 ·d -1, ip) were administered for 6 d after the first injection of STZ.Results:STZ administration and castration markedly decreased both STL1 (the short memory) and STL2 (the long memory) in passive avoidance tests. Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats. Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment. Conclusion:Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats. © 2014 CPS and SIMM All rights reserved.","Alzheimers disease; flutamide; Learning and memory; letrozole; streptozotocin; tamoxifen; testosterone","Pike, C.J., Nguyen, T.V., Ramsden, M., Yao, M., Murphy, M.P., Rosario, E.R., Androgen cell signaling pathways involved in neuroprotective actions (2008) Horm Behav, 53, pp. 693-705; Pike, C.J., Rosario, E.R., Nguyen, T.V., Androgens, aging, and alzheimer's disease (2006) Endocrine, 29, pp. 233-241; Rosario, E.R., Chang, L., Stanczyk, F.Z., Pike, C.J., Age-related testosterone depletion and the development of Alzheimer disease (2004) JAMA, 292, pp. 1431-1432; Compton, J., Van Amelsvoort, T., Murphy, D., Mood, cognition and alzheimer's disease (2002) Best Pract Res Clin Obstet Gynaecol, 16, pp. 357-370; Jaffe, A.B., Toran-Allerand, C.D., Greengard, P., Gandy, S.E., Estrogen regulates metabolism of alzheimer amyloid beta precursor protein (1994) J Biol Chem, 269, pp. 13065-13068; Levin-Allerhand, J.A., Lominska, C.E., Wang, J., Smith, J.D., 17alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in abeta ppswe transgenic mice (2002) J Alzheimers Dis, 4, pp. 449-457; Gouras, G.K., Xu, H., Gross, R.S., Greenfield, J.P., Hai, B., Wang, R., Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides (2000) Proc Natl Acad Sci USA, 97, pp. 1202-1205; Goodenough, S., Engert, S., Behl, C., Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen activated protein kinase pathway (2000) Neurosci Lett, 296, pp. 49-52; Gillett, M.J., Martins, R.N., Clarnette, R.M., Chubb, S.A., Bruce, D.G., Yeap, B.B., Relationship between testosterone sex hormone binding globulin and plasma amyloid beta peptide in older men with subjective memory loss or dementia (2003) J Alzheimers Dis, 5, pp. 267-269; Papasozomenos, S.C., The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: Implications for Alzheimer's disease (1997) Proc Natl Acad Sci USA, 94, pp. 6612-6617; Papasozomenos, S.C.H., Shanavas, A., Testosterone prevents the heat shock-ind uced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: Implications for Alzheimer's disease (2002) Proc Natl Acad Sci USA, 99, pp. 1140-1145; Weill-Engerer, S., David, J.P., Sazdovitch, V., Liere, P., Eychenne, B., Pianos, A., Neurosteroid quantification in human brain regions: Comparison between Alzheimer's and no demente d patients (2002) J Clin Endocrinol Metab, 87, pp. 5138-5143; Simpson, E.R., Davis, S.R., Minireview: Aromatase and the regulation of estrogen biosynthesis-some new perspectives (2001) Endocrinology, 142, pp. 4589-4594; Mooradian, A.D., Morley, J.E., Korenman, S.G., Biological actions of androgens (1987) Endocr Rev, 8, pp. 1-28; Leranth, C., Hajszan, T., Mac Lusky, N.J., Androgens increase spine synapse density in the CA1 hippocampal subfield of ovariectomized female rats (2004) J Neurosci, 24, pp. 495-499; Naftolin, F., Ryan, K.J., Petro, Z., Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats (1972) Endocrinology, 90, pp. 295-298; Jakab, R.L., Horvath, T.L., Leranth, C., Harada, N., Naftolin, F., Aromataseimmunoreactivity in the rat brain gonadectomy-sensitive hypothalamicneurons and an unresponsive limbic ring of the lateral septumbednucleus-amygdala complex (1993) J Steroid Biochem Mol Biol, 44, pp. 481-498; Kemppainen, J.A., Wilson, E.M., Agonist and antagonist activities of hydroxyflutamideand Casodex relate to androgen receptor stabilization (1996) Urology, 48, pp. 157-163; Singh, S.M., Gauthier, S., Labrie, F., Androgen receptor antagonists (anti androgens): Structure-activity relationships (2000) Curr Med Chem, 7, pp. 211-247; Berrevoets, C.A., Umar, A., Brinkmann, A.O., Anti-androgens: Selective androgen receptor modulators (2002) Mol Cell Endocrinol, 198, pp. 97-103; Paxinos, G., Watson, C., (1986) The Rat Brain in Stereotaxic Coordinates, , 2nd ed. San Diego Academic Press; Shingo, A.S., Kanabayashi, T., Murase, T., Kito, S., Cognitive decline in STZ-3V rats is largely due to dysfunctional i nsulin signalling through the dentate gyrus (2012) Behav Brain Res, 229, pp. 378-383; Seyedreza, P., Alireza, M.N., Seyedebrahim, H., Role of testosterone in memory impairment of Alzheimer's disease induced b y Streptozotocin in male rats (2012) Daru, 20, p. 98; Spritzer, M.D., Daviau, E.D., Coneeny, M.K., Engelman, S.M., Prince, W.T., Rodriguez-Wisdom, K.N., Effects of testosterone on spatial learning and memo ry in adult male rats (2011) Horm Behav, 59, pp. 484-496; Cherrier, M.M., Matsumoto, A.M., Amory, J.K., Ahmed, S., Bremner, W., Peskind, E.R., The role of aromatization in testosterone supplementation: Effect s on cognition in older men (2005) Neurology, 64, pp. 290-296; Gibbs, R.B., Testosterone and estradiol produce different effects on cognitive performance in male rats (2005) Horm Behav, 48, pp. 268-277; Packard, M.G., Kohlimaire, J.R., Alexander, G.M., Post training intrahippocampal estradiol injections enhance spatial memory in male rats: Interaction with cholinergic system (1996) Behav Neurosci, 110, pp. 626-632",Article,Scopus,2-s2.0-84902246225
"Buhler S., Laufer S.A.","P38 MAPK inhibitors: A patent review (2012-2013)",2014,"Expert Opinion on Therapeutic Patents","24","5",,"535","554",,3,10.1517/13543776.2014.894977,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898981377&partnerID=40&md5=5ba1867cb1734aff176ada79876b7708","Eberhard-Karls-University Tübingen, Department of Pharmaceutical/Medicinal Chemistry, Auf der Morgenstelle 8, 72076 Tübingen, Germany","Bühler, S., Eberhard-Karls-University Tübingen, Department of Pharmaceutical/Medicinal Chemistry, Auf der Morgenstelle 8, 72076 Tübingen, Germany; Laufer, S.A., Eberhard-Karls-University Tübingen, Department of Pharmaceutical/Medicinal Chemistry, Auf der Morgenstelle 8, 72076 Tübingen, Germany","Introduction: The p38 MAPK is a ubiquitous target in the research-based pharmaceutical industry. It plays a decisive role in the regulation of the production of proinflammatory cytokines. Since novel biological therapies have revolutionized the treatment of chronic inflammatory diseases, an intensive global search is underway for small molecules for the same application. Areas covered: Herein, the patents and the corresponding publications of international companies, which focus on the development and identification of a new generation of small-molecule p38 inhibitors, are summarized. Expert opinion: The most promising approach is the development of linear binders, which induce a glycine flip at Gly110 of the kinase hinge region by a carbonyl oxygen atom of the respective ligand. The major focus of the patent works was the application of molecules in new indications. Previous applications were in the treatment of rheumatoid arthritis; currently, there are several new applications, including pulmonary diseases, cancer and Alzheimer's disease. Targeting p38 upstream kinases and downstream effectors has also proved to be a very promising step in the development of more effective inhibitors. A further trend is drug combination, applied to a wide range of indications, such as chronic obstructive pulmonary disease and cancer. © Informa UK, Ltd.","Allosteric inhibitor; Alzheimer̀s disease; Asthma; BAY 73-4506; BMS-582949; Cancer; Chronic obstructive pulmonary disease; Competitive inhibitor; DFG-out; Downstream effectors; Drug combination; Dual action p38 inhibitor; Glycine flip; Inflammatory diseases; Linear binders; Non-small-cell lung carcinoma; P38 MAPK; P38/MK2 inhibitors; Proinflammatory cytokine; Pulmonary diseases; Rheumatoid arthritis; TNF-α; Upstream kinase; VX-745","Young, P.R., Perspective on the discovery and scientific impact of p38 MAP kinase (2013) J Biomol Screen, 18, pp. 1156-1163; Lee, J.C., Laydon, J.T., McDonnell, P.C., A protein kinase involved in the regulation of inflammatory cytokine biosynthesis (1994) Nature, 372, pp. 739-746; Cuadrado, A., Nebreda, A.R., Mechanisms and functions of p38 MAPK signaling (2010) Biochem J, 429, pp. 403-417; Jiang, Y., Chen, C., Li, Z., Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta) (1996) J Biol Chem, 271, pp. 17920-17926; Zhang, J., Shen, B., Lin, A., Novel strategies for inhibition of the p38 MAPK pathway (2007) Trends Pharmacol Sci, 28, pp. 286-295; Li, Z., Jiang, Y., Ulevitch, R.J., The primary structure of p38gamma: A new member of p38 group of MAP kinases (1996) Biochem Biophys Res Commun, 228, pp. 334-340; Fischer, S., Koeberle, S.C., Laufer, S.A., P38alpha mitogen-activated protein kinase inhibitors a patent review (2005-2011) (2011) Expert Opin Ther Pat, 21, pp. 1843-1866; Schett, G., Zwerina, J., Firestein, G., The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis (2008) Ann Rheum Dis, 67, pp. 909-916; Millan, D.S., Bunnage, M.E., Burrows, J.L., Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease (2011) J Med Chem, 54, pp. 7797-7814; Hammaker, D., Firestein, G.S., Go upstream, young man: Lessons learned from the p38 saga (2010) Ann Rheum Dis, p. 69. , i77-82; http://www.clinicaltrials.gov, ClinicalTrials.gov [Last accessed 23 November 2013]Flynn Gary, A., (2013) Preparation and Methods of Use for Ortho-aryl 5- Membered Heteroaryl-carboxamide Containing Multi-targeted Kinase Inhibitors. WO2013022766; Karcher, S.C., Laufer, S.A., Successful structure-based design of recent p38 MAP kinase inhibitors (2009) Curr Top Med Chem, 9, pp. 655-676; Lee, M.R., Dominguez, C., MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38alpha protein (2005) Curr Med Chem, 12 (25), pp. 2979-2994; Okram, B., Nagle, A., Adrian, F.J., A general strategy for creating inactiveconformation abl inhibitors (2006) Chem Biol, 13, pp. 779-786; Angell, R.M., Angell, T.D., Bamborough, P., Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes (2008) Bioorg Med Chem Lett, 18, pp. 4433-4437; Wrobleski, S.T., Lin, S., Hynes, J., Synthesis and SAR of new pyrrolo[2,1-f] [1,2,4]triazines as potent p38alpha MAP kinase inhibitors (2008) Bioorg Med Chem Lett, 18, pp. 2739-2744; Davis, M.I., Hunt, J.P., Herrgard, S., Comprehensive analysis of kinase inhibitor selectivity (2011) Nat Biotechnol, 29, pp. 1046-1051; Fitzgerald, C.E., Patel, S.B., Becker, J.W., Structural basis for p38alpha MAP kinase quinazolinone and pyridolpyrimidine inhibitor specificity (2003) Nat Struct Biol, 10, pp. 764-769; Last Accessed at 23 November 2013, , www.proqinase.com, Proqinase; Respivert., , www.respivert.com, Last accessed at 13 November 2013]; Respivert - Treatment of Asthma and COPD, , http://www.imperialinnovations.co.uk/ventures/casestudies/ respivert-treatment-asthma-andcopd/, Last accessed at 13 November 2013]; Ortho Biotech, C., (2010) Strengthens Pulmonary Focus, , http://www.prnewswire.com/newsreleases/centocor-ortho-biotech- incacquires-respivert-ltd-strengthenspulmonary-focus-95293879.html, Acquires Respivert Ltd Inc. [Last accessed at 13 November 2013]; (2013) 1-pyrazolyl-3-(4-((2 - anilinopyrimidin-4-yl)oxy)napththalen-1- Yl)ureas As P38 Map Kinase Inhibitors, , Respivert Ltd WO2013050756; (2013) P38 MAP Kinase Inhibitors, , Respivert Ltd. US20130012512; (2013) 1-Pyrazolyl-3-(4-((2- anilinopyrimidin-4-yl)oxy)naphthalen-1- Yl)ureas As p38 MAP Kinase Inhibitors, , Respivert Ltd. EP2578582; (2013) 1-pyrazolyl-3-(4-((2 - anilinopyrimidin-4-yl)oxy)napththalen-1- Yl)ureas As P38 MAP Kinase Inhibitors, , Respivert Ltd WO2013050757; (2013) Novel Compounds, , Respivert Ltd. US20130040995; (2013) P38 MAP Kinase Inhibitors, , Respivert Ltd. US20130040962; (2013) Pyrazole P38 MAP Kinase Inhibitors, , Respivert Ltd. US20130029990; Pargellis, C., Tong, L., Churchill, L., Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site (2011) Nat Struct Biol, 9, pp. 268-272; Irusen, E., Matthews, J.G., Takahashi, A., P38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma (2002) J Allergy Clin Immunol, 109, pp. 649-657; (2013) Pyrazole P38 MAP Kinase Inhibitors, , Respivert Ltd. EP2556065; (2013) P38 MAP Kinase Inhibitors, , Respivert Ltd. EP2556068; (2013) Pyrazolyl Ureas As P38 MAP Kinase Inhibitors, , Respivert Ltd. EP2556067; (2012) Confluence Life Sciences, , Inc. Substituted pyridine urea compounds. US20120142708; (2012) Confluence Life Sciences, , Inc. Substituted pyrimidine urea compounds. WO2012078687;; (2013) Substituted Pyrimidinone-phenyl-pyrimidinyl Compounds, , Confluence Life Sciences Inc. US20130143906; (2013) Substituted Pyrimidinone-phenyl-pyrimidinyl Compounds, , Confluence Life Sciences Inc. US20130143906; Goldstein, D.M., Kuglstatter, A., Lou, Y., Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders (2010) J Med Chem, 53, pp. 2345-2353; (2012) Substituted Indole/indazole-pyrimidinyl Compounds, , Confluence Life Sciences Inc. US20120142696; (2012) Substituted Pyridinone-pyridinyl Compounds, , Confluence Life Sciences Inc. US20120142709; Selness, S.R., Devraj, R.V., Devadas, B., Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase (2011) Bioorg Med Chem Lett, 21, pp. 4066-4071; Devadas, B., Selness, S.R., Xing, L., Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitors (2011) Bioorg Med Chem Lett, 21, pp. 3856-3860; Selness, S.R., Devraj, R.V., Monahan, J.B., Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase (2009) Bioorg Med Chem Lett, 19, pp. 5851-5856; Selness, S.R., Boehm, T.L., Walker, J.K., Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase (2011) Bioorg Med Chem Lett, 21, pp. 4059-4065; (2013) Methyl/ Difluorophenyl-methoxy Substituted Pyridinone-pyridinyl Compounds, Methyl-pyridinyl-methoxy Substituted Pyridinone-pyridinyl Compounds, and Methyl-pyrimidinyl-methoxy Substituted Pyridinone-pyridinyl Compounds, , Confluence Life Sciences Inc. US20130274272; (2013) Substituted Pyrimidinone-phenyl-pyrimidinyl Compounds, , Confluence Life Sciences Inc. US20130143906; Substituted Pyrimidinone-phenyl-pyrimidinyl Compounds, , Confluence Life Sciences Inc. US20130143906; 2013; Chiesi Farmaceutici S.P.A. Kinase inhibitors. WO2013083606 2013Chiesi Farmaceutici S.P.A. Kinase inhibitors. WO2013083604 2013(2013) Derivatives of 4-hydroxy-1, 2, 3,4-tetrahydronaphtalen-1- Yl Urea and Their Use in the Treatment Of, Inter Alia, Diseases of the Respiratory Tract. WO2013083206, , Chiesi Farmaceutici S.P.A; Chopra, P., Kanoje, V., Semwal, A., Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases (2008) Expert Opin Investig Drugs, 17, pp. 1411-1425; Millan, D.S., (2011) What Is the Potential for Inhaled p38 Inhibitors in the Treatment of Chronic Obstructive Pulmonary Disease? Future Med Chem, 3, pp. 1635-1645; (2010) Triazolopyridine Derivatives As P38 MAP Kinase Inhibitors, , Pulmagen Therapeutics Inflamma WO2010094956; (2012) Triazolopyridine Derivatives and Their Therapeutic Use, , Chiesi Farmaceutici S.P.A. US20120088763; Aiguade, J., Balague, C., Carranco, I., Novel triazolopyridylbenzamides as potent and selective p38alpha inhibitors (2012) Bioorg Med Chem Lett, 22, pp. 3431-3436; McClure, K.F., Abramov, Y.A., Laird, E.R., Theoretical and Experimental Design of Atypical Kinase Inhibitors: Application to p38 MAP Kinase (2005) J Med Chem, 48, pp. 5728-5737; (2012) Inhibition of P38 Kinase Activity Using Substituted Heterocyclic Ureas, , Bayer Healthcare LLC US20120149706; (2012) Inhibition of P38 Kinase Activity Using Substituted Heterocyclic Ureas, , Bayer Healthcare LLC. US20120046290; Dumas, J., Hatoum-Mokdad, H., Sibley, R.N., Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor (2002) Bioorg Med Chem Lett, 12, pp. 1559-1562; Dumas, J., Sibley, R., Riedl, B., Discovery of a new class of p38 kinase inhibitors (2000) Bioorg Med Chem Lett, 10, pp. 2047-2050; Dumas, J., Hatoum-Mokdad, H., Sibley, R., 1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors (2000) Bioorg Med Chem Lett, 10, pp. 2051-2054; Pargellis, C., Tong, L., Churchill, L., Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site (2002) Nat Struct Biol, 9, pp. 268-272; (2012) Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, , Bayer Healthcare LLC. US20120270878; (2005) Fluoro Substituted Omega-carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions, , Bayer Pharmaceuticals Corp. WO2005009961; (2013) Fluro Substituted Omega-carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions, , Bayer Healthcare LLC. US20130131122; (2012) Drug Combinations with Fluoro-substituted Omega-carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions, , Bayer Healthcare LLC WO2012012404; Wilhelm, S.M., Dumas, J., Adnane, L., Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (2011) Int J Cancer, 129, pp. 245-255; An Open-label, multi-center, nonrandomized Phase Ib study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 Regorafenib, administered in combination with Pemetrexed and Cisplatin in patients with Advanced Nonsquamous Non Small Cell Lung, , http://trialfinder.bayerscheringpharma.de/html/pdf/ 14458_Study_Synopsis_CTP.pdf, [Last accessed at 18 November 2013]; (2009) Pyrazinone Derivatives and Their Use in the Treatment of Lung Diseases, , Astrazeneca UK Ltd. WO2009001132; (2012) Pharmaceutical Product Comprising A P38 Kinase Inhibitor and A Second Active Ingredient, , Astrazeneca UK Ltd. US2012028941; (2012) Novel Combinations, , Astrazeneca UK Ltd. WO2012046050; (2012) Compound, , Astrazeneca UK Ltd. WO2012085582; (2012) New compound, , Astrazeneca UK Ltd. WO2012085583; (2003) Pyrrolo-triazine Aniline Compounds Useful As Kinase Inhibitors, , Bristol-Myers Squibb WO2003090912; (2012) Tablet Formulation for P38 Inhibitor and Method, , Bristol-Myers Squibb US20120035177; Liu, C., Lin, J., Wrobleski, S.T., Discovery of 4-(5- (cyclopropylcarbamoyl)-2- methylphenylamino)-5-methyl- Npropylpyrrolo[1,2-f][1,2,4]triazine-6- carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases (2010) J Med Chem, 53, pp. 6629-6639; (2012) BMS-582949 for the Treatment of Resistant Rheumatic Disease, , Bristol-Myers Squibb WO2012031057; Bonilla-Hernan, M.G., Miranda-Carus, M.E., Martin-Mola, E., New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors (2011) Rheumatology, 50, pp. 1542-1550; Schieven, G., Zhang, R., Pitt, S., BMS-582949 is a dual action p38 kinase inhibitor well suited to avoid resistance mechanisms that increase p38 activation in cells (2010) 2010 Congress American College of Rheumatology Arthritis Rheum, 62, pp. S629-S630; Emerging Oral Biologic Therapies for Rheumatoid Arthritis., , http://lmt.projectsinknowledge.com, Last accessed at 23 November 2013]; Novartis, A.G., (2012) 5-membered Heterocyclebased P38 Kinase Inhibitors, , US20120264801; Novartis, A.G., (2013) 5-Membered Heterocyclebased P38 Kinase Us20130172352 Inhibitors; Novartis, A.G., (2013) Use of Pyrazole Derivative in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease, , WO2013139809; (2005) Kinase Inhibitors, , Eli Lilly and Co WO2005075478; De Dios, A., Shih, C., Lopez De Uralde, B., Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy (2005) J Med Chem, 48, pp. 2270-2273; Mader, M., De Dios, A., Shih, C., (2008) Imidazolyl Benzimidazoles and Imidazo, 18, pp. 179-183. , 4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett; Lilly, E., (2012) 5, 4 -B] pyridin-5-yl Compounds and Their Use for the Treatment of Cancer, , Co. Oxazolo WO2012074761; EIP Pharma, LLC. Compositions and methods for treating Alzheimers disease. WO2012154814; 2012(2013) Compositions Process of Preparation of Said Compositions and Method of Treating Cancer, , Cellworks Research India Private Ltd. WO2013086002; (2013) Helmholtz-Zentrum für Infektionsforschung Gmbh. Medicament for Treatment of Liver Cancer, , WO2013007708; (2012) Methods of Treating Memory Loss and Enhancing Memory Performance, , Translational Genomics Research Institute US2012245188; (2012) Pharmasyntez. Compounds Pharmaceutical Compositions and A Method for the Prophylaxis and Treatment of the Adhesion Process, , Joint Stock Co. WO2012156938; The Trustees of Columbia University in the City of New York (2013) CaMKII, IP3R, Calcineurin, P38 and MK2/3 Inhibitors to Treat Metabolic Disturbances of Obesity, , WO2013033657; (2013) Drugs for Inhibiting P38 and Uses Thereof, , Universidad Autonóma de Madrid WO2013064714; Scott, L.J., Tofacitinib: A review of its use in adult patients with rheumatoid arthritis (2013) Drugs, 73, pp. 857-874; Alten, R., Intracellular targets - Current data on effectiveness and safety profile (2013) Z Rheumatol, 72, pp. 867-872; P38 MAPK Pathway, , http://www.novusbio.com/p38mapkpathway.html, [Last accessed 26 November 2013]",Review,Scopus,2-s2.0-84898981377
"Watanabe H., Iqbal M., Zheng J., Wines-Samuelson M., Shen J.","Partial loss of presenilin impairs age-dependent neuronal survival in the cerebral cortex",2014,"Journal of Neuroscience","34","48",,"15912","15922",,1,10.1523/JNEUROSCI.3261-14.2014,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911879080&partnerID=40&md5=d8ed6309ba2512747560df021b2204a1","Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States; Harvard Medical SchoolBoston, MA, United States","Watanabe, H., Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States; Iqbal, M., Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States; Zheng, J., Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States; Wines-Samuelson, M., Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States; Shen, J., Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s HospitalBoston, MA, United States, Harvard Medical SchoolBoston, MA, United States","Mutations in the presenilin (PSEN1 and PSEN2) genes are linked to familial Alzheimer’s disease (AD) and cause loss of its essential function. Complete inactivation of presenilins in excitatory neurons of the adult mouse cerebral cortex results in progressive memory impairment and age-dependent neurodegeneration, recapitulating key features of AD. In this study, we examine the effects of varying presenilin dosage on cortical neuron survival by generatingpresenilin-1 conditional knock-out (PS1 cKO) mice carrying two, one, or zero copies of the PS2 gene. We found that PS1 cKO;PS2+/- mice at 16 months exhibit marked neurodegeneration in the cerebral cortex with ~17% reduction of cortical volume and neuron number, as well as astrogliosis and microgliosis compared with ~50% reduction of cortical volume and neuron number in PS1 cKO;PS2-/- mice. Moreover, there are more apoptotic neurons labeled by activated caspase-3 immunoreactivity and TUNEL assay in PS1 cKO;PS2+/- mice at 16 months, whereas apoptotic neurons are increased in the PS1 cKO; PS2-/- cerebral cortex at 4 months. The accumulation of the C-terminal fragments of the amyloid precursor protein is inversely correlated with PS dosage. Interestingly, levels of PS2 are higher in the cerebral cortex of PS1 cKO mice, suggesting a compensatory upregulation that may provide protection against neurodegeneration in these mice. Together, our findings show that partial to complete loss of presenilin activity causes progressively more severe neurodegeneration in the mouse cerebral cortex during aging, suggesting that impaired presenilin function by PSEN mutations may lead to neurodegeneration and dementia in AD. © 2014 the authors.","Alzheimers disease; Conditional knockout; Dementia; Gamma-secretase; Neurodegeneration; Neuronal survival","Beglopoulos, V., Sun, X., Saura, C.A., Lemere, C.A., Kim, R.D., Shen, J., Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice (2004) J Biol Chem, 279, pp. 46907-46914; Dewachter, I., Reversé, D., Caluwaerts, N., Ris, L., Kuipéri, C., Van Den Haute, C., Spittaels, K., Van Leuven, F., Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice (2002) J Neurosci, 22, pp. 3445-3453; Donoviel, D.B., Hadjantonakis, A.K., Ikeda, M., Zheng, H., Hyslop, P.S., Bernstein, A., Mice lacking both presenilin genes exhibit early embryonic patterning defects (1999) Genes Dev, 13, pp. 2801-2810; Earnshaw, W.C., Martins, L.M., Kaufmann, S.H., Mammalian caspases: Structure, activation, substrates, and functions during apoptosis (1999) Annu Rev Biochem, 68, pp. 383-424; Feng, R., Wang, H., Wang, J., Shrom, D., Zeng, X., Tsien, J.Z., Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer’s presenilin-1 and presenilin-2 (2004) Proc Natl Acad Sci U S A, 101, pp. 8162-8167; Handler, M., Yang, X., Shen, J., Presenilin-1 regulates neuronal differentiation during neurogenesis (2000) Development, 127, pp. 2593-2606; Heilig, E.A., Xia, W., Shen, J., Kelleher, R.J., A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete lossofgamma-secretase activity (2010) Jbiol Chem, 285, p. 22359; Heneka, M.T., Rodríguez, J.J., Verkhratsky, A., Neuroglia in neurodegen-eration (2010) Brain Res Rev, 63, pp. 189-211; Ho, A., Shen, J., Presenilins in synaptic function and disease (2011) Trends Mol Med, 17, pp. 617-624; Jayadev, S., Case, A., Eastman, A.J., Nguyen, H., Pollak, J., Wiley, J.C., Moller, T., Garden, G.A., Presenilin 2 is the predominant gamma-secretase in microglia and modulates cytokine release (2010) Plos One, 5; Kim, W.Y., Shen, J., Presenilins are required for maintenance of neural stem cells in the developing brain (2008) Mol Neurodegener, 3, p. 2; Lai, M.T., Chen, E., Crouthamel, M.C., Dimuzio-Mower, J., Xu, M., Huang, Q., Price, E., Li, Y.M., Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities (2003) J Biol Chem, 278, pp. 22475-22481; Lee, S.H., Sharma, M., Südhof, T.C., Shen, J., Synaptic function of nicastrin in hippocampal neurons (2014) Proc Natl Acad Sci U S A, 111, pp. 8973-8978; Levitan, D., Doyle, T.G., Brousseau, D., Lee, M.K., Thinakaran, G., Slunt, H.H., Sisodia, S.S., Greenwald, I., Assessment of normal and mutant human pre-senilin function in Caenorhabditis elegans (1996) Proc Natl Acad Sci U S A, 93, pp. 14940-14944; Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C.E., Tanzi, R.E., Candidate gene for the chromosome 1 familial Alzheimer’s disease locus (1995) Science, 269, pp. 973-977; Li, Y.M., Xu, M., Lai, M.T., Huang, Q., Castro, J.L., Dimuzio-Mower, J., Harrison, T., Gardell, S.J., Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 (2000) Nature, 405, pp. 689-694; Lobsiger, C.S., Cleveland, D.W., Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease (2007) Nat Neurosci, 10, p. 1360; Moehlmann, T., Winkler, E., Xia, X., Edbauer, D., Murrell, J., Capell, A., Kaether, C., Steiner, H., Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracel-lular domains independent of their effect on Abeta 42 production (2002) Proc <Checkcomponent>Natl Acad Sci U S A</Checkcomponent>, 99, pp. 8025-8030; Naruse, S., Thinakaran, G., Luo, J.J., Kusiak, J.W., Tomita, T., Iwatsubo, T., Qian, X., Sisodia, S.S., Effects of PS1 deficiency on membrane protein trafficking in neurons (1998) Neuron, 21, pp. 1213-1221; Placanica, L., Zhu, L., Li, Y.M., Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease (2009) Plos One, 4; Qyang, Y., Chambers, S.M., Wang, P., Xia, X., Chen, X., Goodell, M.A., Zheng, H., Myeloproliferative disease in mice with reduced presenilin gene dosage: Effect of gamma-secretase blockage (2004) Biochemistry, 43, pp. 5352-5359; Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., St George-Hyslop, P.H., Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene (1995) Nature, 376, pp. 775-778; Saura, C.A., Choi, S.Y., Beglopoulos, V., Malkani, S., Zhang, D., Shankaranarayana Rao, B.S., Chattarji, S., Shen, J., Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegenera-tion (2004) Neuron, 42, pp. 23-36; Saura, C.A., Chen, G., Malkani, S., Choi, S.Y., Takahashi, R.H., Zhang, D., Gouras, G.K., Shen, J., Conditional inactivation of pre-senilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice (2005) J Neurosci, 25, pp. 6755-6764; Seidner, G.A., Ye, Y., Faraday, M.M., Alvord, W.G., Fortini, M.E., Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila (2006) Curr Biol, 16, pp. 1026-1033; Shen, J., Bronson, R.T., Chen, D.F., Xia, W., Selkoe, D.J., Tonegawa, S., Skeletal and CNS defects in Presenilin-1-deficient mice (1997) Cell, 89, pp. 629-639; Shen, J., Kelleher, R.J., III, The presenilin hypothesis of Alzheimer’s disease: Evidence for a loss-of-function pathogenic mechanism (2007) Proc Natl Acad Sci U S A, 104, pp. 403-409; Song, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., Yankner, B.A., Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations (1999) Proc Natl Acad Sci U S A, 96, pp. 6959-6963; Steiner, H., Duff, K., Capell, A., Romig, H., Grim, M.G., Lincoln, S., Hardy, J., Haass, C., A loss of function mutationof presenilin-2 interferes with amyloid beta-peptide production and notch signaling (1999) J Biol Chem, 274, pp. 28669-28673; Tabuchi, K., Chen, G., Südhof, T.C., Shen, J., Conditional forebrain inac-tivation of nicastrin causes progressive memory impairment and age-related neurodegeneration (2009) J Neurosci, 29, pp. 7290-7301; Tournoy, J., Bossuyt, X., Snellinx, A., Regent, M., Garmyn, M., Serneels, L., Saftig, P., Hartmann, D., Partial loss of prese-nilins causes seborrheic keratosis and autoimmune disease in mice (2004) Hum Mol Genet, 13, pp. 1321-1331; Wines-Samuelson, M., Shen, J., Presenilins in the developing, adult, and aging cerebral cortex (2005) Neuroscientist, 11, pp. 441-451; Wines-Samuelson, M., Handler, M., Shen, J., Role of presenilin-1 in cortical lamination and survival of Cajal-Retzius neurons (2005) Dev Biol, 277, p. 346; Wines-Samuelson, M., Schulte, E.C., Smith, M.J., Aoki, C., Liu, X., Kelleher, R.J., III, Shen, J., Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice (2010) Plos One, 5; Wu, B., Yamaguchi, H., Lai, F.A., Shen, J., Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hip-pocampal neurons (2013) Proc Natl Acad Sci U S A, 110, pp. 15091-15096; Yamaguchi, H., Shen, J., Histological analysis of neurodegeneration in the mouse brain (2013) Methods Mol Biol, 1004, pp. 91-113; Yonemura, Y., Futai, E., Yagishita, S., Suo, S., Tomita, T., Iwatsubo, T., Ishiura, S., Comparison of presenilin 1 and presenilin 2 gamma-secretase activities using a yeast reconstitution system (2011) J Biol Chem, 286, pp. 44569-44575; Yu, H., Saura, C.A., Choi, S.Y., Sun, L.D., Yang, X., Handler, M., Kawarabayashi, T., Shen, J., APP processing and synaptic plasticity in presenilin-1 conditional knockout mice (2001) Neuron, 31, pp. 713-726; Zhang, C., Wu, B., Beglopoulos, V., Wines-Samuelson, M., Zhang, D., Dragatsis, I., Südhof, T.C., Shen, J., Presenilins are essential for regulating neu-rotransmitter release (2009) Nature, 460, pp. 632-636; Zhang, D., Zhang, C., Ho, A., Kirkwood, A., Südhof, T.C., Shen, J., Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction (2010) J Neurochem, 115, pp. 1215-1221",Article,Scopus,2-s2.0-84911879080
"Chapman J.","Vitamin E and Alzheimer's disease",2014,"Australian Journal of Pharmacy","95","1126",,"92","93",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896919487&partnerID=40&md5=899fb565f886b5762228944358b9ac78",,"Chapman, J.",[No abstract available],,"Rowe, C.C., Bourgeat, P., Ellis, K.A., Brown, B., Lim, Y.Y., Mulligan, R., Predicting Alzheimer disease with beta-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing (2013) Ann Neurol, 74 (6), pp. 905-913. , doi:10.1002/ana.24040; Marin, M.F., Lord, C., Andrews, J., Juster, R.P., Sindi, S., Arsenault-Lapierre, G., Chronic stress, cognitive functioning and mental health (2011) Neurobiol Learn Mem, 96 (4), pp. 583-595. , doi:10.1016/j.nlm.2011-02-016. Epub2Mar2011; Landmark, K., Could intake of vitamins C and E inhibit development of Alzheimer dementia? (2006) Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række, 126 (2), pp. 159-161; Tabet, N., Birks, J., Grimley Evans, J., Vitamin E for Alzheimer's disease (2000) Cochrane Database Syst Rev, (4), pp. CD002854; Isaac, M.G., Quinn, R., Tabet, N., Vitamin E for Alzheimer's disease and mild cognitive impairment (2008) Cochrane Database Syst Rev, (3), pp. CD002854. , doi: 10.1002/14651858.CD002854.pub2; Farina, N., Isaac, M.G., Clark, A.R., Rusted, J., Tabet, N., Vitamin E for Alzheimer's dementia and mild cognitive impairment (2012) Cochrane Database Syst Rev, 11, pp. CD002854. , doi:10.1002/14651858.CD002854.pub3; Engelhart, M.J., Geerlings, M.I., Ruitenberg, A., Van Swieten, J.C., Hofman, A., Witteman, J.C.M., Breteler, M.M.B., Dietary intake of antioxidants and risk of Alzheimer disease (2002) Journal of the American Medical Association, 287 (24), pp. 3223-3229; Devore, E.E., Grodstein, F., Van Rooij, F.J., Hofman, A., Stampfer, M.J., Witteman, J.C., Dietary antioxidants and long-term risk of dementia (2010) Arch Neurol, 67 (7), pp. 819-825. , doi:10.1001/archneurol.2010.144; Dysken, M.W., Sano, M., Asthana, S., Vertrees, J.E., Pallaki, M., Llorente, M., Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial (2014) JAMA, 311 (1), pp. 33-44. , doi: 10.1001/jama.2013.282834; Miller III, E.R., Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E., Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality (2005) Annals of Internal Medicine, 142 (1), pp. 37-46",Short Survey,Scopus,2-s2.0-84896919487
"Lemos R., Duro D., Simoes M.R., Santana I.","The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease",2014,"Archives of Clinical Neuropsychology","29","7",,"670","679",,,10.1093/arclin/acu031,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911385641&partnerID=40&md5=50f753d988bf6f4788f0645809e479b9","Faculty of Psychology and Educational Sciences, University of Coimbra, Rua do Colégio Novo, Apartado 6153Coimbra, Portugal; Visual Neuroscience Laboratory, Faculty of Medicine, University of CoimbraCoimbra, Portugal; Faculty of Medicine, University of CoimbraCoimbra, Portugal; Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal","Lemos, R., Faculty of Psychology and Educational Sciences, University of Coimbra, Rua do Colégio Novo, Apartado 6153Coimbra, Portugal, Visual Neuroscience Laboratory, Faculty of Medicine, University of CoimbraCoimbra, Portugal; Duro, D., Faculty of Medicine, University of CoimbraCoimbra, Portugal, Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal; Simões, M.R., Faculty of Psychology and Educational Sciences, University of Coimbra, Rua do Colégio Novo, Apartado 6153Coimbra, Portugal; Santana, I., Faculty of Medicine, University of CoimbraCoimbra, Portugal, Neurology Department, Coimbra Hospital and University CenterCoimbra, Portugal","Memory impairment is often present in frontotemporal dementia (FTD) as a result of an inefficient use of learning strategies, sometimes leading to a misdiagnosis of Alzheimer's disease (AD). The Free and Cued Selective Reminding Test (FCSRT) is a memory test that controls attention and acquisition, by providing category cues in the learning process. The main goal of this study was to show the usefulness of the FCSRT in the distinction between behavioral (bv-) FTD and AD. Three matched subgroups of participants were considered: bv-FTD (n = 32), AD (n = 32), and a control group of healthy adults (n = 32). Results proved that while AD patients exhibited an overall impairment in FCSRT, bv-FTD subjects showed to benefit more from the controlled learning through category cues. AD patients were 25 times more likely to have an impaired FCSRT. The FCSRT has shown its utility in the distinction between bv-FTD and AD, therefore increasing the diagnostic accuracy. © 2014 © The Author 2014. Published by Oxford University Press. All rights reserved.","Alzheimers disease; Assessment; Frontotemporal dementia; Learning and memory","(2000) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (4th Ed., Text Revision), , American Psychiatric Association Washington, DC: The author; Barreto, J., Leuschner, A., Santos, F., Sobral, M., Escala de Depressao Geriatrica [Geriatric Depression Scale] (2008) Escalas e Testes Na Demencia [Scales and Tests in Dementia] Grupo de Estudos de Envelhecimento Cerebral e Demencia [Study Group on Brain Aging and Dementia], pp. 69-72. , A. de Mendonca, C. Garcia, & M. Guerreiro (Eds.) Lisbon: GEECD; Benedict, R., (1997) Brief Visuospatial Memory Test-revised, , Odessa, FL: Psychological Assessment Resources, Inc; Blumenfeld, R.S., Ranganath, C., Prefrontal cortex and long-term memory encoding: An integrative review of findings from neuropsychology and neuroimaging (2007) Neuroscientist, 13, pp. 280-291; Brown, L.B., Storandt, M., Sensitivity of category cued recall to very mild dementia of the Alzheimer type (2000) Archives of Clinical Neuropsychology, 15, pp. 529-534; Buschke, H., Cued recall in amnesia (1984) Journal of Clinical and Experimental Neuropsychology, 6, pp. 433-440; Buschke, H., Criteria for the identification of memory deficits: Implications for the design of memory tests (1987) Memory and Learning: The Ebbinghaus Centenial Conference, pp. 331-344. , D. S. Gorfein, & R. R. Hoffman (Eds.) Hillsdale, NJ: Lawrence Erlbaum; Buschke, H., Sliwinski, M.J., Kuslansky, G., Lipton, R.B., Diagnosis of early dementia by the Double Memory Test: Encoding specificity improves diagnostic sensitivity and specificity (1997) Neurology, 48, pp. 989-997; Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia (1994) Neurology, 44, pp. 2308-2314; Cummings, J.L., Miller, B.L., Conceptual and clinical aspects of the frontal lobes (2007) The Human Frontal Lobes: Functions and Disorders, pp. 25-43. , B.L. Miller, & J.L. Cummings (Eds.) New York: The Guilford Press; Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-Gateau, P., Revising the definition of Alzheimers disease: A new lexicon (2010) Lancet Neurology, 9, pp. 1118-1127; Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., Research criteria for the diagnosis of Alzheimers disease: Revising the NINCDS-ADRDA criteria (2007) Lancet Neurology, 6, pp. 734-746; Dubois, B., Slachevsky, A., Litvan, I., Pillon, B., The FAB: A Frontal Assessment Battery at bedside (2000) Neurology, 55, pp. 1621-1626; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-Mental State:Apractical methodfor grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Freitas, S., Simoes, M.R., Alves, L., Santana, I., Montreal cognitive assessment (MoCA): Validation study for mild cognitive impairment and alzheimers disease (2012) Alzheimers Disease and Associated Disorders, 27, pp. 37-43; Garcia, C., (1984) A Doenca de Alzheimer: Problemas de Diagnostico Cl?nico [Alzheimers Disease: Difficulties in Clinical Diagnosis], , (Unpublished doctoral dissertation thesis). Lisbon: Faculty of Medicine, University of Lisbon; Garrett, C., Santos, F., Tracana, I., Barreto, J., Sobral, M., Fonseca, R., (2008) Avaliacao Cl?nica DaDemencia [Clinical Dementia Rating], pp. 18-32. , A. de Mendonca, C. GarciaM. Guerreiro (Eds.), escalas e Testes na Demencia [Scales and tests in dementia] Grupo de Estudos de Envelhecimento Cerebral e Demencia [Study Group on Brain Aging and Dementia]. Lisbon: GEECD; Geerlings, M.I., Jonker, C., Bouter, L.M., Ader, H.J., Schmand, B., Association between memorycomplaints and incident Alzheimers disease in elderly people with normal baseline cognition (1999) The American Journal of Psychiatry, 156, pp. 531-537; Giovagnoli, A.R., Erbetta, A., Reati, F., Bugiani, O., Differential neuropsychological patterns of frontal variant frontotemporaldementia and Alzheimers disease in a study of diagnostic concordance (2008) Neuropsychologia, 46, pp. 1495-1504; Glosser, G., Gallo, J.L., Clark, C.M., Grossman, M., Memory encoding and retrieval in frontotemporal dementia and Alzheimers disease (2002) Neuropsychology, 16, pp. 190-196; Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Classification of primary progressive aphasia and its variants (2011) Neurology, (76), pp. 1006-1014; Gregory, C.A., Orrell, M., Sahakian, B., Hodges, J.R., Can frontotemporal dementia and Alzheimers disease be differentiated using a brief battery of tests? (1997) International Journal of Geriatric Psychiatry, 12, pp. 375-383; Grober, E., Buschke, H., Genuine memory deficits in dementia (1987) Developmental Neuropsychology, 3, pp. 13-36; Grober, E., Buschke, H., Crystal, H., Bang, S., Dresner, R., Screening for dementia by memory testing (1988) Neurology, 38, pp. 900-903; Grober, E., Gitlin, H., Bang, S., Buschke, H., Implicit and explicit memory in young, old and demented adults (1992) Journal of Clinical and Experimental Neuropsychology, 14, pp. 298-316; Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., Kawas, C., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimers disease (2008) Journal of the International Neuropsychology Society, 14, pp. 266-278; Grober, E., Hall, C., Sanders, A.E., Lipton, R.B., Free and cued selective reminding distinguishes Alzheimers disease from vasculardementia (2008) Journal of the American Geriatrics Society, 56, pp. 944-946; Grober, E., Kawas, C., Learning and retention in preclinical and early Alzheimers disease (1997) Psychology and Aging, 12, pp. 183-188; Grober, E., Sanders, A.E., Hall, C., Lipton, R.B., Free and cued selective reminding identifies very mild dementia in primary care (2010) Alzheimers Disease and Associated Disorders, 24, pp. 284-290; Guerreiro, M., (1998) Contributo da Neuropsicologia Para O Estudo das Demencias [Contribution of Neuropsychology to the Study of Dementia], , (Unpublished doctoral dissertation) Lisbon: University of Lisbon; Guerreiro, M., Fonseca, S., Barreto, J., Garcia, C., (2008) Escala de Avaliacao da Doenca de Alzheimer - EAda [Alzheimer Disease Assessment Scale - ADAS], pp. 42-58. , A. de Mendonca, C. Garcia, & M. Guerreiro (Eds.), escalas e Testes na Demencia [Scales and tests in dementia] Grupo de Estudos de Envelhecimento Cerebral e Demencia [Study Group on Brain Aging and Dementia] Lisbon: GEECD; Habert, M.O., Hornn, J.F., Sarazin, M., Lotterie, J.A., Puel, M., Onen, F., Brain perfusion SPECTwith an automated quantitative tool can identify prodromal Alzheimers disease among patients with mild cognitive impairment (2011) Neurobiology of Aging, 32 (1), pp. 15-23; Harvey, R.J., Skelton-Robinson, M., Rossor, M.N., The prevalence and causes of dementia in people under the age of 65 years (2003) Journal of Neurology, Neurosurgery And, Psychiatry, 74, pp. 1206-1209; Hodges, J.R., Patterson, K., Ward, R., Garrard, P., Bak, T., Perry, R., The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimers disease: A comparative neuropsychological study (1999) Neuropsychology, 13, pp. 31-40; Ivanoiu, A., Adam, S., Van Der Linden, M., Salmon, E., Juillerat, A.C., Mulligan, R., Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimers disease (2005) Journal of Neurology, 252, pp. 47-55; Johnson, J.K., Diehl, J., Mendez, M.F., Neuhaus, J., Shapira, J.S., Forman, M., Frontotemporal lobar degeneration demographic characteristics of 353 patients (2005) Archives of Neurology, 62, pp. 925-930; Kertesz, A., Nadkami, N., Davidson, W., Thomas, A.W., The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia (2000) Journal of the International Neuropsychological Society, 6, pp. 460-468; Lemos, R., Martins, C., Simoes, M.R., Santana, I., Estudo de adaptacao do Teste de Recordacao Selectiva Livre e Guiada para a populacao portuguesa [Adaptation Study of the Free and Cued Selective Reminding Test for the portuguese population] (2012) Avaliacao Psicologica, 11, pp. 49-61; Lemos, R., Simoes, M.R., Santiago, B., Santana, I., The Free and Cued Selective Reminding Test: Validation for Mild Cognitive Impairment and Alzheimers disease (2014) Journal of Neuropsychology; Lezak, M.D., Howieson, D.B., Loring, D.W., (2004) Neuropsychological Assessment, , New York: Oxford, University Press; Lindberg, O., Walterfang, M., Looi, J.C., Malykhin, N., Ostberg, P., Zandbelt, B., Hippocampal shape analysis in Alzheimers disease and frontotemporal lobar degeneration subtypes (2012) Journal of Alzheimers Disease, 30 (2), pp. 355-365; McKhann, G.M., Albert, M.S., Grossman, M., Miller, B., Dickson, D., Trojanowski, J.Q., Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Picks Disease (2001) Archives of Neurology, 58, pp. 1803-1809. , Work Group on Frontotemporal Dementia and Picks Disease; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease (1984) Neurology, 34, pp. 939-944; Mohs, R.C., Rosen, W.G., Davis, K.L., The AlzheimersDisease Assessment Scale: An instrument for assessing treatment efficacy (1983) Psychopharmacology Bulletin, 19, pp. 448-450; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Munoz-Ruiz, M.A., Hartikainen, P., Koikkalainen, J., Wolz, R., Julkunen, V., Niskanen, E., StructuralMRIin frontotemporal dementia:Comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry (2012) PLoS ONE, 7 (12), p. e52531; Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria (1998) Neurology, 51, pp. 1546-1554; Partington, J.E., Leiter, R.G., Partingtons Pathway Test (1949) The Psychological Service Center Bulletin, 1, pp. 9-20; Pasquier, F., Grymonprez, L., Lebert, F., Van Der Linden, M., Memory impairment differs in frontotemporal dementia and Alzheimers disease (2001) Neurocase, 7, pp. 161-171; Perri, R., Fadda, L., Caltagirone, C., Carlesimo, G.A., Word list and story recall elicit different patterns of memory deficit in patients with Alzheimers disease, frontotemporal dementia, subcortical ischemic vascular disease, and Lewy body dementia (2013) Journal of Alzheimers Disease, 37, pp. 99-107; Petersen, R.C., Smith, G.E., Ivnik, R.J., Kokmen, E., Tangalos, E.G., Memory function in very early Alzheimers disease (1994) Neurology, 44, pp. 867-872; Possin, K.L., Feigenbaum, D., Rankin, K.P., Smith, G.E., Boxer, A.L., Wood, K., Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias (2013) Neurology, 80, pp. 2180-2185; Rami, L., Fortea, J., Bosch, B., Sole-Padulles, C., Llado, A., Iranzo, A., Cerebrospinal fluid biomarkers and memorypresent distinct associations along the continuum from healthy subjects to AD patients (2011) Journal of Alzheimers Disease, 23, pp. 319-326; Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011) Brain, 134, pp. 2456-2477; Sanchez-Benavides, G., Gomez-Anson, B., Molinuevo, J.L., Blesa, R., Monte, G.C., Buschke, H., Medial temporal lobe correlates ofmemoryscreening measures in normal aging, MCI, and AD (2010) Journal of Geriatric Psychiatry and Neurology, 23, pp. 100-108; Sarazin, M., Chauvire, V., Gerardin, E., Colliot, O., Kinkingnehun, S., De Souza, L.C., The amnestic syndrome of hippocampal type in Alzheimers disease: An MRI study (2010) Journal of Alzheimers Disease, 22, pp. 285-294; Schaffer, S.G., Wisniewski, A., Dahdah, M., Froming, K.B., Emotion processing: The comprehensive affect testing system (2006) Users Manual, , Sanford, FL: Psychology Software Inc; Seelaar, H., Kamphorst, W., Rosso, S.M., Azmani, A., Masdjedi, R., De Koning, I., Distinct genetic forms of frontotemporal dementia (2008) Neurology, 71, pp. 1220-1226; Seelaar, H., Rohrer, J.D., Pijnenburg, Y.A., Fox, N.C., Van Swieten, J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review (2011) Journal of Neurology, Neurosurgery, and Psychiatry, 82, pp. 476-486; Squire, L.R., Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans (1992) Psychological Review, 99, pp. 195-231; Squire, L.R., Stark, C.E., Clark, R.E., The medial temporal lobe (2004) Annual Review Neuroscience, 27, pp. 279-306; Tulving, E., Osler, S., Effectiveness of retrieval cues in memory for words (1968) Journal of Experimental Psychology, 77, pp. 593-601; Tulving, E., Thomson, D.M., Encoding specificity and retrieval processes in episodic memory (1973) Psychological Review, 80, pp. 352-373; Van De Pol, L.A., Hensel, A., Van Der Flier, W.M., Visser, P.J., Pijnenburg, Y.A., Barkhof, F., Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimers disease (2006) Journal of Neurology, Neurosurgery, and Psychiatry, 77, pp. 439-442; Vogel, A., Mortensen, E.L., Gade, A., Waldemar, G., The category cued recall test in very mild Alzheimers disease: Discriminative validity and correlation with semantic memory functions (2007) European Journal of Neurology, 14, pp. 102-108; Wagner, M., Wolf, S., Reischies, F.M., Daerr, M., Wolfsgruber, S., Jessen, F., Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease (2012) Neurology, 78, pp. 379-386; Walker, A.J., Meares, S., Sachdev, P.S., Brodaty, H., The differentiation of mild frontotemporal dementia fromAlzheimers disease and healthy aging by neuropsychological tests (2005) International Psychogeriatrics, 17, pp. 57-68; Wang, P.-N., Miller, B.L., Clinical aspects of frontotemporal dementia (2007) The Human Frontal Lobes: Functions and Disorders, pp. 365-381. , B.L. Miller, & J.L. Cummings (Eds.) New York: The Guilford Press; Wechsler, D., (2008) Escala de Inteligencia de Wechsler Para Adultos-3 Ed, , [Wechsler Adult Intelligence Scale-3rd ed.] Lisbon: Cegoc-Tea; Weder, N.D., Aziz, R., Wilkins, K., Tampi, R.R., Frontotemporal dementias: A review (2007) Annals of General Psychiatry, 6, p. 15; Wittenberg, D., Possin, K.L., Rascovsky, K., Rankin, K.P., Miller, B.L., Kramer, J.H., The early neuropsychological and behavioral characteristics of frontotemporal dementia (2008) Neuropsychology Review, 18, pp. 91-102; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Development and validation of a geriatric depression screening scale: A preliminary report (1983) Journal of Psychiatric Research, 17, pp. 37-49",Article,Scopus,2-s2.0-84911385641
"Verdile G., Laws S.M., Henley D., Ames D., Bush A.I., Ellis K.A., Faux N.G., Gupta V.B., Li Q.-X., Masters C.L., Pike K.E., Rowe C.C., Szoeke C., Taddei K., Villemagne V.L., Martins R.N.","Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease",2014,"Molecular Psychiatry","19","1",,"69","75",,4,10.1038/mp.2012.147,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84891151697&partnerID=40&md5=031c71ba38425f766033161d9dafab31","Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia; Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia; Co-operative Research Centre for Mental Health, Australia; Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia; National Ageing Research Institute, Parkville, VIC, Australia; Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia; Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Department of Pathology, University of Melbourne, Parkville, VIC, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; School of Psychological Science, La Trobe University, Bundoora, VIC, Australia; CSIRO, Parkville, VIC, Australia","Verdile, G., Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia, Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia; Laws, S.M., Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia, Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia, Co-operative Research Centre for Mental Health, Australia; Henley, D., Co-operative Research Centre for Mental Health, Australia, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; Ames, D., Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia, National Ageing Research Institute, Parkville, VIC, Australia; Bush, A.I., Co-operative Research Centre for Mental Health, Australia, Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Ellis, K.A., School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia, Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia, National Ageing Research Institute, Parkville, VIC, Australia, Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia; Faux, N.G., Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Gupta, V.B., Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia, Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia; Li, Q.-X., Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Department of Pathology, University of Melbourne, Parkville, VIC, Australia; Masters, C.L., Co-operative Research Centre for Mental Health, Australia, Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia; Pike, K.E., Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Centre for Neuroscience, University of Melbourne, Parkville, VIC, Australia, Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia, School of Psychological Science, La Trobe University, Bundoora, VIC, Australia; Rowe, C.C., Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; Szoeke, C., National Ageing Research Institute, Parkville, VIC, Australia, CSIRO, Parkville, VIC, Australia; Taddei, K., Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia, Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia, Co-operative Research Centre for Mental Health, Australia; Villemagne, V.L., Mental Health Research Institute, University of Melbourne, Parkville, VIC, Australia, Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; Martins, R.N., Centre of Excellence for Alzheimers Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia, Sir James McCusker Alzheimers Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia, Co-operative Research Centre for Mental Health, Australia","Testosterone and gonadotropins have been associated with cognitive decline in men and the modulation of β amyloid (Aβ) metabolism. The relatively few studies that have investigated whether changes in one or a combination of these hormones influence Aβ levels have focused primarily on plasma Aβ 1-40 and not on the more pathogenic Aβ 1-42. Currently, no study has investigated whether these hormones are associated with an increase in brain amyloid deposition, ante mortem. Through the highly characterised Australian imaging, biomarkers and lifestyle study, we have determined the impact of these hormones on plasma Aβ levels and brain amyloid burden (Pittsburgh compound B (PiB) retention). Spearman's rank correlation and linear regression analysis was carried out across the cohort and within subclassifications. Luteinizing hormone (LH) was the only variable shown, in the total cohort, to have a significant impact on plasma Aβ 1-40 and Aβ 1-42 levels (beta=0.163, P<0.001; beta=0.446, P<0.001). This held in subjective memory complainers (SMC) (Aβ 1-40; beta=0.208, P=0.017; Aβ 1-42; beta=0.215, P=0.017) but was absent in mild cognitive impairment (MCI) and Alzheimer's disease (AD) groups. In SMC, increased frequency of the APOE-ε4 allele (beta=0.536, P<0.001) and increasing serum LH levels (beta=0.421, P=0.004) had a significant impact on PiB retention. Whereas in MCI, PiB retention was associated with increased APOE-ε4 allele copy number (beta=0.674, P<0.001) and decreasing calculated free testosterone (beta=-0.303, P=0.043). These findings suggest a potential progressive involvement of LH and testosterone in the early preclinical stages of AD. Furthermore, these hormones should be considered while attempting to predict AD at these earliest stages of the disease. © 2014 Macmillan Publishers Limited.","Alzheimers disease; b amyloid; luteinizing hormone; testosterone","Barrett-Connor, E., Goodman-Gruen, D., Patay, B., Endogenous sex hormones and cognitive function in older men (1999) J Clin Endocrinol Metab, 84, pp. 3681-3685; Burkhardt, M.S., Foster, J.K., Clarnette, R.M., Chubb, S.A., Bruce, D.G., Drummond, P.D., Interaction between testosterone and apolipoprotein e epsilon4 status on cognition in healthy older men (2006) J Clin Endocrinol Metab, 91, pp. 1168-1172; Bowen, R.L., Isley, J.P., Atkinson, R.L., An association of elevated serum gonadotropin concentrations and Alzheimer disease? (2000) J Neuroendocrinol, 12, pp. 351-354; Hogervorst, E., Combrinck, M., Smith, A.D., Testosterone and gonadotropin levels in men with dementia (2003) Neuro Endocrinol Lett, 24, pp. 203-208; Hogervorst, E., Williams, J., Budge, M., Barnetson, L., Combrinck, M., Smith, A.D., Serum total testosterone is lower in men with Alzheimer's disease (2001) Neuro Endocrinol Lett, 22, pp. 163-168; Moffat, S.D., Zonderman, A.B., Metter, E.J., Kawas, C., Blackman, M.R., Harman, S.M., Free testosterone and risk for Alzheimer disease in older men (2004) Neurology, 62, pp. 188-193; Paoletti, A.M., Congia, S., Lello, S., Tedde, D., Orru, M., Pistis, M., Low androgenization index in elderly women and elderly men with Alzheimer's disease (2004) Neurology, 62, pp. 301-303; Rosario, E.R., Chang, L., Stanczyk, F.Z., Pike, C.J., Age-related testosterone depletion and the development of Alzheimer disease (2004) JAMA, 292, pp. 1431-1432; Rosario, E.R., Chang, L., Head, E.H., Stanczyk, F.Z., Pike, C.J., Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease (2009) Neurobiol Aging, 32, pp. 604-613; Gouras, G.K., Xu, H., Gross, R.S., Greenfield, J.P., Hai, B., Wang, R., Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides (2000) Proc Natl Acad Sci USA, 97, pp. 1202-1205; Goodenough, S., Engert, S., Behl, C., Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway (2000) Neurosci Lett, 296, pp. 49-52; Pike, C.J., Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons (2001) Brain Res, 919, pp. 160-165; Gandy, S., Almeida, O.P., Fonte, J., Lim, D., Waterrus, A., Spry, N., Chemical andropause and amyloid-beta peptide (2001) JAMA, 285, pp. 2195-2196; Gillett, M.J., Martins, R.N., Clarnette, R.M., Chubb, S.A., Bruce, D.G., Yeap, B.B., Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia (2003) J Alzheimers Dis, 5, pp. 267-269; Almeida, O.P., Waterreus, A., Spry, N., Flicker, L., Martins, R.N., One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men (2004) Psychoneuroendocrinology, 29, pp. 1071-1081; Rosario, E.R., Carroll, J.C., Oddo, S., Laferla, F.M., Pike, C.J., Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease (2006) J Neurosci, 26, pp. 13384-13389; Ramsden, M., Nyborg, A.C., Murphy, M.P., Chang, L., Stanczyk, F.Z., Golde, T.E., Androgens modulate beta-amyloid levels in male rat brain (2003) J Neurochem, 87, pp. 1052-1055; Chakravarti, S., Collins, W.P., Forecast, J.D., Newton, J.R., Oram, D.H., Studd, J.W., Hormonal profiles after the menopause (1976) Br Med J, 2, pp. 784-787; Couzinet, B., Schaison, G., The control of gonadotrophin secretion by ovarian steroids (1993) Hum Reprod, 8 (SUPPL. 2), pp. 97-101; Veldhuis, J.D., Keenan, D.M., Liu, P.Y., Iranmanesh, A., Takahashi, P.Y., Nehra, A.X., The aging male hypothalamic-pituitary-gonadal axis: Pulsatility and feedback (2009) Mol Cell Endocrinol, 299, pp. 14-22; Yeap, B.B., Almeida, O.P., Hyde, Z., Norman, P.E., Chubb, S.A., Jamrozik, K., In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study (2007) Eur J Endocrinol, 156, pp. 585-594; Hogervorst, E., Bandelow, S., Combrinck, M., Smith, A.D., Low free testosterone is an independent risk factor for Alzheimer's disease (2004) Exp Gerontol, 39, pp. 1633-1639; Short, R.A., Bowen, R.L., O'Brien, P.C., Graff-Radford, N.R., Elevated gonadotropin levels in patients with Alzheimer disease (2001) Mayo Clin Proc, 76, pp. 906-909; Bowen, R.L., Smith, M.A., Harris, P.L., Kubat, Z., Martins, R.N., Castellani, R.J., Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology (2002) J Neurosci Res, 70, pp. 514-518; Bowen, R.L., Verdile, G., Liu, T., Parlow, A.F., Perry, G., Smith, M.A., Luteinizing hormone, a reproductive regulator that modulates the processing of amyloidbeta precursor protein and amyloid-beta deposition (2004) J Biol Chem, 279, pp. 20539-20545; Casadesus, G., Webber, K.M., Atwood, C.S., Pappolla, M.A., Perry, G., Bowen, R.L., Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice (2006) Biochim Biophys Acta, 1762, pp. 447-452; Verdile, G., Yeap, B.B., Clarnette, R.M., Dhaliwal, S., Burkhardt, M.S., Chubb, S.A., Luteinizing hormone levels are positively correlated with plasma amyloid-beta protein levels in elderly men (2008) J Alzheimers Dis, 14, pp. 201-208; Ellis, K.A., Bush, A.I., Darby, D., De Fazio, D., Foster, J., Hudson, P., The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease (2009) Int Psychogeriatr, 21, pp. 672-687; Mehta, P.D., Pirttila, T., Mehta, S.P., Sersen, E.A., Aisen, P.S., Wisniewski, H.M., Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease (2000) Arch Neurol, 57, pp. 100-105; Mehta, P.D., Pirttila, T., Patrick, B.A., Barshatzky, M., Mehta, S.P., Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease (2001) Neurosci Lett, 304, pp. 102-106; Lopez, O.L., Kuller, L.H., Mehta, P.D., Becker, J.T., Gach, H.M., Sweet, R.A., Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study (2008) Neurology, 70, pp. 1664-1671; Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease (2007) Brain, 130 (PART 11), pp. 2837-2844; Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Imaging betaamyloid burden in aging and dementia (2007) Neurology, 68, pp. 1718-1725; Box, G.E.P., Cox, D.R., An Analysis of Transformations (1964) J Roy Stat Soc B, 26, pp. 211-252; Ihaka, R., Gentleman, R.R., A Language for Data Analysis and Graphics (1996) J Comput Graph Stat, 5, pp. 299-314; Storey, J.D., A direct approach to false discovery rates (2002) J Roy Stat Soc B, 64, pp. 479-498; Storey, J.D., The positive false discovery rate: A Bayesian interpretation and the q-value (2003) Ann Stat, 31, pp. 2013-2035; Storey, J.D., Taylor, J.E., Siegmund, D., Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: A unified approach (2004) J Roy Stat Soc B, 66, pp. 187-205; Storey, J.D., Tibshirani, R., Statistical significance for genomewide studies (2003) P Natl Acad Sci USA, 100, pp. 9440-9445; Geerlings, M.I., Jonker, C., Bouter, L.M., Ader, H.J., Schmand, B., Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition (1999) Am J Psychiatry, 156, pp. 531-537; Jonker, C., Geerlings, M.I., Schmand, B., Are memory complaints predictive for dementia? A review of clinical and population-based studies (2000) Int J Geriatr Psychiatry, 15, pp. 983-991; Jorm, A.F., Christensen, H., Korten, A.E., Jacomb, P.A., Henderson, A.S., Memory complaints as a precursor of memory impairment in older people: A longitudinal analysis over 7-8 years (2001) Psychol Med, 31, pp. 441-449; Reid, L.M., Maclullich, A.M., Subjective memory complaints and cognitive impairment in older people (2006) Dement Geriatr Cogn Disord, 22, pp. 471-485; Dik, M.G., Jonker, C., Comijs, H.C., Bouter, L.M., Twisk, J.W., Van Kamp, G.J., Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly (2001) Neurology, 57, pp. 2217-2222; Bates, K.A., Sohrabi, H.R., Rodrigues, M., Beilby, J., Dhaliwal, S.S., Taddei, K., Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory complainers (2009) J Alzheimers Dis, 17, pp. 305-318; Barron, A.M., Verdile, G., Taddei, K., Bates, K.A., Martins, R.N., Effect of chronic hCG administration on Alzheimer's-related cognition and A beta accumulation in PS1KI mice (2010) Endocrinology, (151), pp. 5380-5388; Wahjoepramono, E.J., Wijaya, L.K., Taddei, K., Bates, K.A., Howard, M., Martins, G., Direct exposure of guinea pig CNS to human luteinizing hormone increases cerebrospinal fluid and cerebral beta amyloid levels (2011) Neuroendocrinology, 94, pp. 313-322; Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2010) Neurobiol Aging, 31, pp. 1275-1283; Tiraboschi, P., Hansen, L.A., Masliah, E., Alford, M., Thal, L.J., Corey-Bloom, J., Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease (2004) Neurology, 62, pp. 1977-1983; Gomez-Isla, T., West, H.L., Rebeck, G.W., Harr, S.D., Growdon, J.H., Locascio, J.J., Clinical and pathological correlates of apolipoprotein e epsilon 4 in Alzheimer's disease (1996) Ann Neurol, 39, pp. 62-70; Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein (1995) N Engl J Med, 333, pp. 1242-1247; Hyman, B.T., West, H.L., Rebeck, G.W., Buldyrev, S.V., Mantegna, R.N., Ukleja, M., Quantitative analysis of senile plaques in Alzheimer disease: Observation of lognormal size distribution and molecular epidemiology of differences associated with apolipoprotein e genotype and trisomy 21 (Down syndrome (1995) P Natl Acad Sci USA, 92, pp. 3586-3590; Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) Proc Natl Acad Sci USA, 106, pp. 6820-6825; Karmisholt, J., Andersen, S., Laurberg, P., Variation in thyroid function in subclinical hypothyroidism: Importance of clinical follow-up and therapy (2011) Eur J Endocrinol, 164, pp. 317-323",Article,Scopus,2-s2.0-84891151697
"Parasuraman P., Suresh R., Premnath D.","Balancing anti-amyloid and anti-cholinesterase capacity in a single chemical entity: InSilico drug design",2014,"International Journal of Pharmacy and Pharmaceutical Sciences","6","SUPPL. 2",,"571","574",,2,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896479158&partnerID=40&md5=cc04d11d482573afff0e275a274ee5b0","Department of Pharmacy, FEAT, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu 608002, India; Department of Bioinformatics, Karunya University, Karunya Nagar, Coimbatore, Tamil Nadu 641114, India","Parasuraman, P., Department of Pharmacy, FEAT, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu 608002, India; Suresh, R., Department of Pharmacy, FEAT, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu 608002, India; Premnath, D., Department of Bioinformatics, Karunya University, Karunya Nagar, Coimbatore, Tamil Nadu 641114, India","Objective: Alzheimer's disease is currently deliberation to be a complex, multi factorial syndrome, unlikely to take place from a single causal factor; instead, a number of allied biological alterations are thought to put in to its pathogenesis. This may clarify why the currently available drugs, developed according to the archetypal drug discovery paradigm of ""one-molecule-one-target,"" have turned out to be palliative. In light of this, drug combinations that can act at different levels of the neurotoxic cascade offer new avenues in the direction of curing Alzheimer's and other neurodegenerative diseases. In similar, a new strategy is promising that of developing a single chemical entity able to amend multiple targets simultaneously. This has lead to a new paradigm in medicinal chemistry, the ""multi-target-directed ligand"" design strategy, which has previously been successfully exploited at both academic and industrial levels. Method: Flavone fused thiazole moiety were docked against AChE and BACE enzyme Using Schrodinger software. Results and Conclusion: As a case study, we report here on 1-(5-(3, 5, 6, 7, 8-pentahydroxy-4-oxo-4H-chromen-2-yl) benzo[d]thiazol-2-yl)-3-(2-oxobutyl) urea (PS122), a new molecule developed following this strategy. The in-silico profile of 1-(5-(3, 5, 6, 7, 8-pentahydroxy-4-oxo-4H-chromen-2-yl) benzo[d]thiazol-2-yl)-3-(2-oxobutyl) urea demonstrates the suitability of the new strategy for obtaining innovative drug candidates for the treatment of neurodegenerative diseases as it inhibit both AChE and BACE enzyme through in-silico studies.","Alzheimers disease; Flavones; InSlico; Multi-targeted; Thiazole","Aurn, K.G., Nagaswamy, K., Jordan, T., Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimer's disease (2005) Curr Top Med Chem, 5, pp. 1609-1622; Tao, G., Doug, W.H., Development of BACE1 Inhibitors for Alzheimer's disease (2006) Curr Med Chem, 13, pp. 1811-1829; Morphy, R., Rankovic, Z., Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges (2009) Curr Pharm Design, 15, pp. 587-600; Bolognesi, M.L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., Melchiorre, C., Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease (2007) J Med Chem, 50, pp. 6446-6449; Zhu, Y.P., Xiao, K., Ma, L.P., Xiong, B., Fu, Y., Yu, H.P., Wang, W.D., Shen, J.K., Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase (2009) Bioorg Med Chem, 17, pp. 1600-1613; Marco-Contelles, J., León, R., de Ríos, C., Samadi, A., Bartolini, M., Andrisano, V., Huertas, O., Villarroya, M., Tacripyrines, the First Tacrine Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease (2009) J Med Chem, 9, pp. 2724-2732; John, V., Beck, J.P., Bienkowski, M.J., Sinha, S., Heinrikson, R.L., Human beta-secretase (BACE) and BACE inhibitors (2003) J Med Chem, 46, pp. 4625-4630; Kornilova, A.Y., Wolfe, M.S., Secretase inhibitors for Alzheimer's disease (2003) Annu Rep Med Chem, 38, pp. 41-50; Magdolna, P., János, K., Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease (2008) Neurochem Int, 53, p. 103; Toews, M.L., Bylund, D.B., Pharmacologic principles for combination therapy (2005) Proc Am Thorac Soc, 2, pp. 282-289. , discussion 290-291; Cavalli, A., Bolognesi, M.L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., Multi-target-directed ligands to combat neurodegenerative diseases (2008) J Med Chem, 51, pp. 347-372; Small, G., Dubois, B., A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch (2007) CurrMed Res Opin, 23, pp. 2705-2713; Van der Schyf, C.J., Mandel, S., Geldenhuys, W.J., Amit, T., Avramovich, Y., Zheng, H., Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties (2007) Curr Alzheimer Res, 4, pp. 522-536; Choi, M.M., Kim, E.A., Hahn, H.G., Nam, K.D., Yang, S.J., Choi, S.Y., Kim, T.U., Huh, J.W., Protective Effect of Benzothiazole Derivative KHG21834 On Amyloid -induced; Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features (2008) Biochim Biophys Acta, 1780, pp. 819-825; Joshi, A., Gadhwal, M.K., Patil, S., Mello, P.D., Homology Modeling of Aryl Hydrocarbon Receptor and Docking of Agonists and Antagonists (2013) Int J Pharm Pharm Sci, 5 (2), pp. 76-81",Article,Scopus,2-s2.0-84896479158
"Killick R., Ribe E.M., Al-Shawi R., Malik B., Hooper C., Fernandes C., Dobson R., Nolan P.M., Lourdusamy A., Furney S., Lin K., Breen G., Wroe R., To A.W.M., Leroy K., Causevic M., Usardi A., Robinson M., Noble W., Williamson R., Lunnon K., Kellie S., Reynolds C.H., Bazenet C., Hodges A., Brion J.-P., Stephenson J., Paul Simons J., Lovestone S.","Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway",2014,"Molecular Psychiatry","19","1",,"88","98",,13,10.1038/mp.2012.163,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84891149958&partnerID=40&md5=124a3db9c62050e5ab682bdc013cdc88","Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Division of Medicine and Centre for Biomedical Science, University College London, London, United Kingdom; MRC Harwell, Mammalian Genetics Unit, Harwell Science and Innovation Campus, Oxfordshire, United Kingdom; Universite Libre de Bruxelles, Faculte de Me Decine, Brussels, Belgium; University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, QLD, Australia","Killick, R., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Ribe, E.M., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Al-Shawi, R., Division of Medicine and Centre for Biomedical Science, University College London, London, United Kingdom; Malik, B., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Hooper, C., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Fernandes, C., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Dobson, R., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Nolan, P.M., MRC Harwell, Mammalian Genetics Unit, Harwell Science and Innovation Campus, Oxfordshire, United Kingdom; Lourdusamy, A., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Furney, S., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Lin, K., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Breen, G., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Wroe, R., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; To, A.W.M., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Leroy, K., Universite Libre de Bruxelles, Faculte de Me Decine, Brussels, Belgium; Causevic, M., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Usardi, A., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Robinson, M., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Noble, W., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Williamson, R., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Lunnon, K., Division of Medicine and Centre for Biomedical Science, University College London, London, United Kingdom; Kellie, S., University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, QLD, Australia; Reynolds, C.H., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Bazenet, C., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Hodges, A., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Brion, J.-P., Universite Libre de Bruxelles, Faculte de Me Decine, Brussels, Belgium; Stephenson, J., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom; Paul Simons, J., Division of Medicine and Centre for Biomedical Science, University College London, London, United Kingdom; Lovestone, S., Kings College London, Institute of Psychiatry, De Crespigny Park, London, SE58AF, United Kingdom","Although the mechanism of Aβ action in the pathogenesis of Alzheimer's disease (AD) has remained elusive, it is known to increase the expression of the antagonist of canonical wnt signalling, Dickkopf-1 (Dkk1), whereas the silencing of Dkk1 blocks Aβ neurotoxicity. We asked if clusterin, known to be regulated by wnt, is part of an Aβ/Dkk1 neurotoxic pathway. Knockdown of clusterin in primary neurons reduced Aβ toxicity and DKK1 upregulation and, conversely, Aβ increased intracellular clusterin and decreased clusterin protein secretion, resulting in the p53-dependent induction of DKK1. To further elucidate how the clusterin-dependent induction of Dkk1 by Aβ mediates neurotoxicity, we measured the effects of Aβ and Dkk1 protein on whole-genome expression in primary neurons, finding a common pathway suggestive of activation of wnt-planar cell polarity (PCP)-c-Jun N-terminal kinase (JNK) signalling leading to the induction of genes including EGR1 (early growth response-1), NAB2 (Ngfi-A-binding protein-2) and KLF10 (Krüppel-like factor-10) that, when individually silenced, protected against Aβ neurotoxicity and/or tau phosphorylation. Neuronal overexpression of Dkk1 in transgenic mice mimicked this Aβ-induced pathway and resulted in age-dependent increases in tau phosphorylation in hippocampus and cognitive impairment. Furthermore, we show that this Dkk1/wnt-PCP-JNK pathway is active in an Aβ-based mouse model of AD and in AD brain, but not in a tau-based mouse model or in frontotemporal dementia brain. Thus, we have identified a pathway whereby Aβ induces a clusterin/p53/Dkk1/wnt-PCP-JNK pathway, which drives the upregulation of several genes that mediate the development of AD-like neuropathologies, thereby providing new mechanistic insights into the action of Aβ in neurodegenerative diseases. © 2014 Macmillan Publishers Limited.","Alzheimers; amyloid; clusterin; Dickkopf-1; tau; wnt","Glenner, G.G., Wong, C.W., Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein (1984) Biochem Biophys Res Commun, 122, pp. 1131-1135; Brion, J.P., Flament-Durand, J., Dustin, P., Alzheimer's disease and tau proteins (1986) Lancet, 2, p. 1098; Hardy, J., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer's disease (1991) Trends Pharmacol Sci, 12, pp. 383-388; Hardy, J., The amyloid hypothesis for Alzheimer's disease: A critical reappraisal (2009) J Neurochem, 110, pp. 1129-1134; Kremer, A., Louis, J.V., Jaworski, T., Van Leuven, F., GSK3 and Alzheimer's disease: Facts and fiction (2011) Front Mol Neurosci, 4, p. 17; Kang, D.E., Soriano, S., Xia, X., Eberhart, C.G., De Strooper, B., Zheng, H., Presenilin couples the paired phosphorylation of beta-catenin independent of axin: Implications for beta-catenin activation in tumorigenesis (2002) Cell, 110, pp. 751-762; Alvarez, A.R., Godoy, J.A., Mullendorff, K., Olivares, G.H., Bronfman, M., Inestrosa, N.C., Wnt- 3a overcomes beta-amyloid toxicity in rat hippocampal neurons (2004) Exp Cell Res, 297, pp. 186-196; Caricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A.J., Caruso, A., Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain (2004) J Neurosci, 24, pp. 6021-6027; Toledo, E.M., Inestrosa, N.C., Activation of wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an appswepsen1deltae9 mouse model of alzheimer's disease (2010) Mol Psychiatry, 15 (272-285), p. 228; De Ferrari, G.V., Papassotiropoulos, A., Biechele, T., Wavrant De-Vrieze, F., Avila, M.E., Major, M.B., Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease (2007) Proc Natl Acad Sci USA, 104, pp. 9434-9439; Mudher, A., Chapman, S., Richardson, J., Asuni, A., Gibb, G., Pollard, C., Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase (2001) J Neurosci, 21, pp. 4987-4995; Killick, R., Pollard, C.C., Asuni, A.A., Mudher, A.K., Richardson, J.C., Rupniak, H.T., Presenilin 1 independently regulates beta-catenin stability and transcriptional activity (2001) J Biol Chem, 276, pp. 48554-48561; Rosen, E.Y., Wexler, E.M., Versano, R., Coppola, G., Gao, F., Winden, K.D., Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling (2011) Neuron, 71, pp. 1030-1042; Chen, S., Guttridge, D.C., You, Z., Zhang, Z., Fribley, A., Mayo, M.W., Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription (2001) J Cell Biol, 152, pp. 87-96; Purro, S.A., Dickins, E.M., Salinas, P.C., The Secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss (2012) J Neurosci, 32, pp. 3492-3498; Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer's disease (2009) Nat Genet, 41, pp. 1094-1099; Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) Nat Genet, 41, pp. 1088-1093; Koch-Brandt, C., Morgans, C., Clusterin: A role in cell survival in the face of apoptosis? (1996) Prog Mol Subcell Biol, 16, pp. 130-149; Rosi, M.C., Luccarini, I., Grossi, C., Fiorentini, A., Spillantini, M.G., Prisco, A., Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease (2010) J Neurochem, 112, pp. 1539-1551; Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease (2010) Arch Gen Psychiatry, 67, pp. 739-748; Schrijvers, E.M., Koudstaal, P.J., Hofman, A., Breteler, M.M., Plasma clusterin and the risk of Alzheimer disease (2011) JAMA, 305, pp. 1322-1326; Schepeler, T., Mansilla, F., Christensen, L.L., Orntoft, T.F., Andersen, C.L., Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling (2007) J Mol Signal, 2, p. 6; Gonzalez-Sancho, J.M., Aguilera, O., Garcia, J.M., Pendas-Franco, N., Pena, C., Cal, S., The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer (2005) Oncogene, 24, pp. 1098-1103; Theuns, J., Remacle, J., Killick, R., Corsmit, E., Vennekens, K., Huylebroeck, D., Alzheimer-associated C allele of the promoter polymorphism -22C4T causes a critical neuron-specific decrease of presenilin 1 expression (2003) Hum Mol Genet, 12, pp. 869-877; Tizon, B., Ribe, E.M., Mi, W., Troy, C.M., Levy, E., Cystatin C protects neuronal cells from amyloid-beta-induced toxicity (2010) J Alzheimers Dis, 19, pp. 885-894; Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S., Khvorova, A., Rational siRNA design for RNA interference (2004) Nat Biotechnol, 22, pp. 326-330; Davidson, T.J., Harel, S., Arboleda, V.A., Prunell, G.F., Shelanski, M.L., Greene, L.A., Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation (2004) J Neurosci, 24, pp. 10040-10046; Killick, R., Scales, G., Leroy, K., Causevic, M., Hooper, C., Irvine, E.E., Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice (2009) Biochem Biophys Res Commun, 386, pp. 257-262; Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) (2001) Method. Methods, 25, pp. 402-408; Trougakos, I.P., So, A., Jansen, B., Gleave, M.E., Gonos, E.S., Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress (2004) Cancer Res, 64, pp. 1834-1842; Bertram, L., Tanzi, R.E., Alzheimer disease: New light on an old CLU (2010) Nat Rev Neurol, 6, pp. 11-13; Hooper, C., Killick, R., Fernandes, C., Sugden, D., Lovestone, S., Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones (2011) J Neurochem, 118, pp. 512-520; Millucci, L., Ghezzi, L., Bernardini, G., Santucci, A., Conformations and biological activities of amyloid beta peptide 25-35 (2009) Curr Protein Pept Sci, 11, pp. 54-67; Abeti, R., Abramov, A.Y., Duchen, M.R., Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death (2011) Brain, 134 (PART 6), pp. 1658-1672; Lu, Y., Li, T., Qureshi, H.Y., Han, D., Paudel, H.K., Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain (2011) J Biol Chem, 286, pp. 20569-20581; Kumbrink, J., Kirsch, K.H., Johnson, J.P., EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin (2010) J Cell Biochem, 111, pp. 207-217; Svaren, J., Sevetson, B.R., Golda, T., Stanton, J.J., Swirnoff, A.H., Milbrandt, J., Novel mutants of NAB corepressors enhance activation by Egr transactivators (1998) EMBO J, 17, pp. 6010-6019; Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice (1996) Science, 274, pp. 99-102; Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K.L., Barde, Y.A., Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms (2003) J Neurochem, 86, pp. 582-590; Liang, W.S., Dunckley, T., Beach, T.G., Grover, A., Mastroeni, D., Ramsey, K., Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: A reference data set (2008) Physiol Genomics, 33, pp. 240-256; Huang, Y., Sun, X., Hu, G., An integrated genetics approach for identifying protein signal pathways of Alzheimer's disease (2011) Comput Methods Biomech Biomed Engin, 14, pp. 371-378; Webster, J.A., Gibbs, J.R., Clarke, J., Ray, M., Zhang, W., Holmans, P., Genetic control of human brain transcript expression in Alzheimer disease (2009) Am J Hum Genet, 84, pp. 445-458; Lockstone, H.E., Harris, L.W., Swatton, J.E., Wayland, M.T., Holland, A.J., Bahn, S., Gene expression profiling in the adult Down syndrome brain (2007) Genomics, 90, pp. 647-660; Ideker, T., Ozier, O., Schwikowski, B., Siegel, A.F., Discovering regulatory and signalling circuits in molecular interaction networks (2002) Bioinformatics, 18 (SUPPL. 1), pp. S233-S240; Bertrand, J., Plouffe, V., Senechal, P., Leclerc, N., The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons (2010) Neuroscience, 168, pp. 323-334; Korol, O., Gupta, R.W., Mercola, M., A novel activity of the Dickkopf-1 amino terminal domain promotes axial and heart development independently of canonical Wnt inhibition (2008) Dev Biol, 324, pp. 131-138; Krupnik, V.E., Sharp, J.D., Jiang, C., Robison, K., Chickering, T.W., Amaravadi, L., Functional and structural diversity of the human Dickkopf gene family (1999) Gene, 238, pp. 301-313; Bafico, A., Liu, G., Yaniv, A., Gazit, A., Aaronson, S.A., Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow (2001) Nat Cell Biol, 3, pp. 683-686; Mao, B., Wu, W., Li, Y., Hoppe, D., Stannek, P., Glinka, A., LDL-receptor-related protein 6 is a receptor for Dickkopf proteins (2001) Nature, 411, pp. 321-325; Semenov, M.V., Tamai, K., Brott, B.K., Kuhl, M., Sokol, S., He, X., Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6 (2001) Curr Biol, 11, pp. 951-961; Caneparo, L., Huang, Y.L., Staudt, N., Tada, M., Ahrendt, R., Kazanskaya, O., Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt/beta catenin and Wnt/PCP activities, through interaction with the Dally-like homolog Knypek (2007) Genes Dev, 21, pp. 465-480; Boutros, M., Paricio, N., Strutt, D.I., Mlodzik, M., Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling (1998) Cell, 94, pp. 109-118; Yamanaka, H., Moriguchi, T., Masuyama, N., Kusakabe, M., Hanafusa, H., Takada, R., JNK functions in the non-canonical Wnt pathway to regulate convergent extension movements in vertebrates (2002) EMBO Rep, 3, pp. 69-75; Pandur, P., Lasche, M., Eisenberg, L.M., Kuhl, M., Wnt-11 activation of a noncanonical Wnt signalling pathway is required for cardiogenesis (2002) Nature, 418, pp. 636-641; Checler, F., Dunys, J., Pardossi-Piquard, R., Alves Da Costa, C., P53 is regulated by and regulates members of the gamma-secretase complex (2010) Neurodegener Dis, 7, pp. 50-55; Macgibbon, G.A., Lawlor, P.A., Walton, M., Sirimanne, E., Faull, R.L., Synek, B., Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease (1997) Exp Neurol, 147, pp. 316-332; Gomez Ravetti, M., Rosso, O.A., Berretta, R., Moscato, P., Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease (2010) PLoS One, 5, pp. e10153; Criswell, T., Beman, M., Araki, S., Leskov, K., Cataldo, E., Mayo, L.D., Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr- 1 signaling regulates clusterin expression, a pro-survival factor (2005) J Biol Chem, 280, pp. 14212-14221; Tolias, K.F., Duman, J.G., Um, K., Control of synapse development and plasticity by Rho GTPase regulatory proteins (2011) Prog Neurobiol, 94, pp. 133-148; Montcouquiol, M., Crenshaw III, E.B., Kelley, M.W., Noncanonical Wnt signaling and neural polarity (2006) Annu Rev Neurosci, 29, pp. 363-386",Article,Scopus,2-s2.0-84891149958
"Moore R.A., Sturdevant D.E., Chesebro B., Priola S.A.","Proteomics analysis of amyloid and nonamyloid prion disease phenotypes reveals both common and divergent mechanisms of neuropathogenesis",2014,"Journal of Proteome Research","13","11",,"4620","4634",,2,10.1021/pr500329w,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908884094&partnerID=40&md5=543e698c1d703f3519c60090822f6f30","Laboratory of Persistent Viral DiseasesHamilton, MT, United States; Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious DiseasesHamilton, MT, United States","Moore, R.A., Laboratory of Persistent Viral DiseasesHamilton, MT, United States; Sturdevant, D.E., Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious DiseasesHamilton, MT, United States; Chesebro, B., Laboratory of Persistent Viral DiseasesHamilton, MT, United States; Priola, S.A., Laboratory of Persistent Viral DiseasesHamilton, MT, United States","Prion diseases are a heterogeneous group of neurodegenerative disorders affecting various mammals including humans. Prion diseases are characterized by a misfolding of the host-encoded prion protein (PrPC) into a pathological isoform termed PrPSc. In wild-type mice, PrPC is attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor and PrPSc typically accumulates in diffuse nonamyloid deposits with gray matter spongiosis. By contrast, when mice lacking the GPI anchor are infected with the same prion inoculum, PrPSc accumulates in dense perivascular amyloid plaques with little or no gray matter spongiosis. In order to evaluate whether different host biochemical pathways were implicated in these two phenotypically distinct prion disease models, we utilized a proteomics approach. In both models, infected mice displayed evidence of a neuroinflammatory response and complement activation. Proteins involved in cell death and calcium homeostasis were also identified in both phenotypes. However, mitochondrial pathways of apoptosis were implicated only in the nonamyloid form, whereas metal binding and synaptic vesicle transport were more disrupted in the amyloid phenotype. Thus, following infection with a single prion strain, PrPC anchoring to the plasma membrane correlated not only with the type of PrPSc deposition but also with unique biochemical pathways associated with pathogenesis. © 2014 American Chemical Society.","Alzheimers disease; amyloid; cerebral amyloid angiopathy; glycosylphosphatidylinositol; LC-MS/MS; prion disease; proteomics; transmissible spongiform encephalopathies","Chesebro, B., Introduction to the Transmissible Spongiform Encephalopathies or Prion Diseases (2003) Br. Med. Bull., 66, pp. 1-20; Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F., Caughey, W.S., Secondary Structure-Analysis of the Scrapie-Associated Protein Prp 27-30 in Water by Infrared-Spectroscopy (1991) Biochemistry, 30, pp. 7672-7680; Pan, K.-M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Prusiner, S.B., Conversion of Alpha-Helices into Beta-Sheets Features in the Formation of the Scrapie Prion Protein (1993) Proc. Natl. Acad. Sci. U. S. A., 90, pp. 10962-10966; Bruce, M.E., TSE Strain Variation (2003) Br. Med. Bull., 66, pp. 99-108; Kretzschmar, H., Tatzelt, J., Prion Disease: A Tale of Folds and Strains (2013) Brain Pathol., 23, pp. 321-332; Poggiolini, I., Saverioni, D., Parchi, P., Prion Protein Misfolding, Strains, and Neurotoxicity: An Update from Studies on Mammalian Prions (2013) Int. J. Cell Biol., 2013, p. 910314; Moore, R.A., Taubner, L.M., Priola, S.A., Prion Protein Misfolding and Disease (2009) Curr. Opin. Struct. Biol., 19, pp. 14-22; Wiltzius, J.J., Landau, M., Nelson, R., Sawaya, M.R., Apostol, M.I., Goldschmidt, L., Soriaga, A.B., Eisenberg, D., Molecular Mechanisms for Protein-Encoded Inheritance (2009) Nat. Struct. Mol. Biol., 16, pp. 973-978; Chesebro, B., Race, B., Meade-White, K., Lacasse, R., Race, R., Klingeborn, M., Striebel, J., Jeffrey, M., Fatal Transmissible Amyloid Encephalopathy: A New Type of Prion Disease Associated with Lack of Prion Protein Membrane Anchoring (2010) PLoS Pathog., 6, p. 1000800; Klingeborn, M., Race, B., Meade-White, K.D., Rosenke, R., Striebel, J.F., Chesebro, B., Crucial Role for Prion Protein Membrane Anchoring in the Neuroinvasion and Neural Spread of Prion Infection (2011) J. Virol., 85, pp. 1484-1494; Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., Lacasse, R., Raymond, L., Oldstone, M., Anchorless Prion Protein Results in Infectious Amyloid Disease Without Clinical Scrapie (2005) Science, 308, pp. 1435-1439; Stahl, N., Borchelt, D.R., Hsiao, K., Prusiner, S.B., Scrapie Prion Protein Contains a Phosphatidylinositol Glycolipid (1987) Cell, 51, pp. 229-240; Ghetti, B., Piccardo, P., Spillantini, M.G., Ichimiya, Y., Porro, M., Perini, F., Kitamoto, T., Tagliavini, F., Vascular Variant of Prion Protein Cerebral Amyloidosis with Tau-Positive Neurofibrillary Tangles: The Phenotype of the Stop Codon 145 Mutation in PRNP (1996) Proc. Natl. Acad. Sci. U. S. A., 93, pp. 744-748; Jansen, C., Parchi, P., Capellari, S., Vermeij, A.J., Corrado, P., Baas, F., Strammiello, R., Rozemuller, A.J., Prion Protein Amyloidosis with Divergent Phenotype Associated with Two Novel Nonsense Mutations in PRNP (2010) Acta Neuropathol., 119, pp. 189-197; Jayadev, S., Nochlin, D., Poorkaj, P., Steinbart, E.J., Mastrianni, J.A., Montine, T.J., Ghetti, B., Leverenz, J.B., Familial Prion Disease with Alzheimer Disease-Like Tau Pathology and Clinical Phenotype (2011) Ann. Neurol., 69, pp. 712-720; Mead, S., Gandhi, S., Beck, J., Caine, D., Gajulapalli, D., Carswell, C., Hyare, H., Collinge, J., A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy (2013) N. Engl. J. Med., 369, pp. 1904-1914; Tribouillard-Tanvier, D., Striebel, J.F., Peterson, K.E., Chesebro, B., Analysis of Protein Levels of 24 Cytokines in Scrapie Agent-Infected Brain and Glial Cell Cultures from Mice Differing in Prion Protein Expression Levels (2009) J. Virol., 83, pp. 11244-11253; Baron, G.S., Hughson, A.G., Raymond, G.J., Offerdahl, D.K., Barton, K.A., Raymond, L.D., Dorward, D.W., Caughey, B., Effect of Glycans and the Glycophosphatidylinositol Anchor on Strain Dependent Conformations of Scrapie Prion Protein: Improved Purifications and Infrared Spectra (2011) Biochemistry, 50, pp. 4479-4490; Sorensen, G., Medina, S., Parchaliuk, D., Phillipson, C., Robertson, C., Booth, S.A., Comprehensive Transcriptional Profiling of Prion Infection in Mouse Models Reveals Networks of Responsive Genes (2008) BMC Genomics, 9, p. 114; Skinner, P.J., Abbassi, H., Chesebro, B., Race, R.E., Reilly, C., Haase, A.T., Gene Expression Alterations in Brains of Mice Infected with Three Strains of Scrapie (2006) BMC Genomics, 7, p. 114; Booth, S., Bowman, C., Baumgartner, R., Sorensen, G., Robertson, C., Coulthart, M., Phillipson, C., Somorjai, R.L., Identification of Central Nervous System Genes Involved in the Host Response to the Scrapie Agent during Preclinical and Clinical Infection (2004) J. Gen. Virol., 85, pp. 3459-3471; Xiang, W., Windl, O., Wunsch, G., Dugas, M., Kohlmann, A., Dierkes, N., Westner, I.M., Kretzschmar, H.A., Identification of Differentially Expressed Genes in Scrapie-Infected Mouse Brains by Using Global Gene Expression Technology (2004) J. Virol., 78, pp. 11051-11060; Hwang, D., Lee, I.Y., Yoo, H., Gehlenborg, N., Cho, J.H., Petritis, B., Baxter, D., Hood, L.E., A Systems Approach to Prion Disease (2009) Mol. Syst. Biol., 5, p. 252; Benetti, F., Gasperini, L., Zampieri, M., Legname, G., Gene Expression Profiling to Identify Druggable Targets in Prion Diseases (2010) Expert. Opin. Drug Discovery, 5, pp. 177-202; Xiang, W., Windl, O., Westner, I.M., Neumann, M., Zerr, I., Lederer, R.M., Kretzschmar, H.A., Cerebral Gene Expression Profiles in Sporadic Creutzfeldt-Jakob Disease (2005) Ann. Neurol., 58, pp. 242-257; Gawinecka, J., Dieks, J., Asif, A.R., Carimalo, J., Heinemann, U., Streich, J.H., Dihazi, H., Zerr, I., Codon 129 Polymorphism Specific Cerebrospinal Fluid Proteome Pattern in Sporadic Creutzfeldt-Jakob Disease and the Implication of Glycolytic Enzymes in Prion-Induced Pathology (2010) J. Proteome. Res., 9, pp. 5646-5657; Brown, A.R., Webb, J., Rebus, S., Williams, A., Fazakerley, J.K., Identification of Up-Regulated Genes by Array Analysis in Scrapie-Infected Mouse Brains (2004) Neuropathol. Appl. Neurobiol., 30, pp. 555-567; Asuni, A.A., Gray, B., Bailey, J., Skipp, P., Perry, V.H., Oconnor, V., Analysis of the Hippocampal Proteome in ME7 Prion Disease Reveals a Predominant Astrocytic Signature and Highlights the Brain-Restricted Production of Clusterin in Chronic Neurodegeneration (2014) J. Biol. Chem., 289, pp. 4532-4545; Gawinecka, J., Nowak, M., Carimalo, J., Cardone, F., Asif, A.R., Wemheuer, W.M., Schulz-Schaeffer, W.J., Zerr, I., Subtype-Specific Synaptic Proteome Alterations in Sporadic Creutzfeldt-Jakob Disease (2013) J. Alzheimers Dis., 37, pp. 51-61; Campisi, E., Cardone, F., Graziano, S., Galeno, R., Pocchiari, M., Role of Proteomics in Understanding Prion Infection (2012) Expert Rev. Proteomics, 9, pp. 649-666; Barr, J.B., Watson, M., Head, M.W., Ironside, J.W., Harris, N., Hogarth, C., Fraser, J.R., Barron, R., Differential Protein Profiling As a Potential Multi-Marker Approach for TSE Diagnosis (2009) BMC Infect. Dis., 9, p. 188; Huzarewich, R.L., Siemens, C.G., Booth, S.A., Application of Omics to Prion Biomarker Discovery (2010) J. Biomed. Biotechnol., 2010, p. 613504; Rangel, A., Race, B., Phillips, K., Striebel, J., Kurtz, N., Chesebro, B., Distinct Patterns of Spread of Prion Infection in Brains of Mice Expressing Anchorless or Anchored Forms of Prion Protein (2014) Acta Neuropathol. Commun., 2, p. 8; Moore, R.A., Timmes, A., Wilmarth, P.A., Priola, S.A., Comparative Profiling of Highly Enriched 22L and Chandler Mouse Scrapie Prion Protein Preparations (2010) Proteomics, 10, pp. 2858-2869; Weatherly, D.B., Atwood, J.A., III, Minning, T.A., Cavola, C., Tarleton, R.L., Orlando, R., A Heuristic Method for Assigning a False-Discovery Rate for Protein Identifications from Mascot Database Search Results (2005) Mol. Cell Proteomics, 4, pp. 762-772; Nesvizhskii, A.I., Keller, A., Kolker, E., Aebersold, R., A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry (2003) Anal. Chem., 75, pp. 4646-4658; Old, W.M., Meyer-Arendt, K., Veline-Wolf, L., Pierce, K.G., Mendoza, A., Sevinsky, J.R., Resing, K.A., Ahn, N.G., Comparison of Label-Free Methods for Quantifying Human Proteins by Shotgun Proteomics (2005) Mol. Cell Proteomics, 4, pp. 1487-1502; Lundgren, D.H., Hwang, S.I., Wu, L., Han, D.K., Role of Spectral Counting in Quantitative Proteomics (2010) Expert Rev. Proteomics, 7, pp. 39-53; Benjamini, Y., Hochberg, Y., Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing (1995) J. R. Stat. Soc., Ser. B (Methodological), 57, pp. 289-300; Liu, H., Sadygov, R.G., Yates, J.R., III, A Model for Random Sampling and Estimation of Relative Protein Abundance in Shotgun Proteomics (2004) Anal. Chem., 76, pp. 4193-4201; Mueller, L.N., Brusniak, M.Y., Mani, D.R., Aebersold, R., An Assessment of Software Solutions for the Analysis of Mass Spectrometry Based Quantitative Proteomics Data (2008) J. Proteome Res., 7, pp. 51-61; Sofroniew, M.V., Vinters, H.V., Astrocytes: Biology and Pathology (2010) Acta Neuropathol., 119, pp. 7-35; Levin, E.C., Acharya, N.K., Sedeyn, J.C., Venkataraman, V., Dandrea, M.R., Wang, H.Y., Nagele, R.G., Neuronal Expression of Vimentin in the Alzheimers Disease Brain May Be Part of a Generalized Dendritic Damage-Response Mechanism (2009) Brain Res., 1298, pp. 194-207; Provansal, M., Roche, S., Pastore, M., Casanova, D., Belondrade, M., Alais, S., Leblanc, P., Lehmann, S., Proteomic Consequences of Expression and Pathological Conversion of the Prion Protein in Inducible Neuroblastoma N2a Cells (2010) Prion, 4, pp. 292-301; Pekny, M., Wilhelmsson, U., Bogestal, Y.R., Pekna, M., The Role of Astrocytes and Complement System in Neural Plasticity (2007) Int. Rev. Neurobiol., 82, pp. 95-111; Nezu, T., Hosomi, N., Aoki, S., Deguchi, K., Masugata, H., Ichihara, N., Ohyama, H., Matsumoto, M., Alpha2-Macroglobulin As a Promising Biomarker for Cerebral Small Vessel Disease in Acute Ischemic Stroke Patients (2013) J. Neurol., 260, pp. 2642-2649; Van, G. D., De, S. B., Van, L. F., Triau, E., Dom, R., Alpha 2-Macroglobulin Expression in Neuritic-Type Plaques in Patients with Alzheimers Disease (1993) Neurobiol. Aging, 14, pp. 233-237; Wang, H., Sama, A.E., Anti-Inflammatory Role of Fetuin-A in Injury and Infection (2012) Curr. Mol. Med., 12, pp. 625-633; Riemer, C., Gultner, S., Heise, I., Holtkamp, N., Baier, M., Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention (2009) CNS Neurol. Disord. Drug Targets, 8, pp. 329-341; Jahn, R., Fasshauer, D., Molecular Machines Governing Exocytosis of Synaptic Vesicles (2012) Nature, 490, pp. 201-207; Ostermeier, C., Brunger, A.T., Structural Basis of Rab Effector Specificity: Crystal Structure of the Small G Protein Rab3A Complexed with the Effector Domain of Rabphilin-3A (1999) Cell, 96, pp. 363-374; Norberg, E., Orrenius, S., Zhivotovsky, B., Mitochondrial Regulation of Cell Death: Processing of Apoptosis-Inducing Factor (AIF) (2010) Biochem. Biophys. Res. Commun., 396, pp. 95-100; Jang, B., Jin, J.K., Jeon, Y.C., Cho, H.J., Ishigami, A., Choi, K.C., Carp, R.I., Choi, E.K., Involvement of Peptidylarginine Deiminase-Mediated Post-Translational Citrullination in Pathogenesis of Sporadic Creutzfeldt-Jakob Disease (2010) Acta Neuropathol., 119, pp. 199-210; Gawinecka, J., Cardone, F., Asif, A.R., De, P. A., Wemheuer, W.M., Schulz-Schaeffer, W.J., Pocchiari, M., Zerr, I., Sporadic Creutzfeldt-Jakob Disease Subtype-Specific Alterations of the Brain Proteome: Impact on Rab3a Recycling (2012) Proteomics, 12, pp. 3610-3620; Riemer, C., Neidhold, S., Burwinkel, M., Schwarz, A., Schultz, J., Kratzschmar, J., Monning, U., Baier, M., Gene Expression Profiling of Scrapie-Infected Brain Tissue (2004) Biochem. Biophys. Res. Commun., 323, pp. 556-564; Gasque, P., Ischenko, A., Legoedec, J., Mauger, C., Schouft, M.T., Fontaine, M., Expression of the Complement Classical Pathway by Human Glioma in Culture. A Model for Complement Expression by Nerve Cells (1993) J. Biol. Chem., 268, pp. 25068-25074; Fabrizi, C., Colasanti, M., Persichini, T., Businaro, R., Starace, G., Lauro, G.M., Interferon Gamma Up-Regulates Alpha 2 Macroglobulin Expression in Human Astrocytoma Cells (1994) J. Neuroimmunol., 53, pp. 31-37; Moore, R.A., Timmes, A.G., Wilmarth, P.A., Safronetz, D., Priola, S.A., Identification and Removal of Proteins That Co-Purify with Infectious Prion Protein Improves the Analysis of Its Secondary Structure (2011) Proteomics, 11, pp. 3853-3865; Giorgi, A., Di, F.L., Principe, S., Mignogna, G., Sennels, L., Mancone, C., Alonzi, T., Schinina, M.E., Proteomic Profiling of PrP27-30-Enriched Preparations Extracted from the Brain of Hamsters with Experimental Scrapie (2009) Proteomics, 9, pp. 3802-3814; Graham, J.F., Kurian, D., Agarwal, S., Toovey, L., Hunt, L., Kirby, L., Pinheiro, T.J., Gill, A.C., Na+/K+-ATPase is Present in Scrapie-Associated Fibrils, Modulates PrP Misfolding in Vitro and Links PrP Function and Dysfunction (2011) PLoS ONE, 6, p. 26813; Yerbury, J.J., Poon, S., Meehan, S., Thompson, B., Kumita, J.R., Dobson, C.M., Wilson, M.R., The Extracellular Chaperone Clusterin Influences Amyloid Formation and Toxicity by Interacting with Prefibrillar Structures (2007) FASEB J., 21, pp. 2312-2322; Narita, M., Holtzman, D.M., Schwartz, A.L., Bu, G., Alpha2-Macroglobulin Complexes with and Mediates the Endocytosis of Beta-Amyloid Peptide Via Cell Surface Low-Density Lipoprotein Receptor-Related Protein (1997) J. Neurochem., 69, pp. 1904-1911; Rolyan, H., Feike, A.C., Upadhaya, A.R., Waha, A., Van, D. T., Haass, C., Birkenmeier, G., Thal, D.R., Amyloid-Beta Protein Modulates the Perivascular Clearance of Neuronal Apolipoprotein e in Mouse Models of Alzheimers Disease (2011) J. Neural Transm., 118, pp. 699-712; Zhang, H., Kim, J.K., Edwards, C.A., Xu, Z., Taichman, R., Wang, C.Y., Clusterin Inhibits Apoptosis by Interacting with Activated Bax (2005) Nat. Cell Biol., 7, pp. 909-915; Lashley, T., Holton, J.L., Verbeek, M.M., Rostagno, A., Bojsen-Mller, M., David, G., Van, H. J., Revesz, T., Molecular Chaperons, Amyloid and Preamyloid Lesions in the BRI2 Gene-Related Dementias: A Morphological Study (2006) Neuropathol. Appl. Neurobiol., 32, pp. 492-504; Desai, P.P., Ikonomovic, M.D., Abrahamson, E.E., Hamilton, R.L., Isanski, B.A., Hope, C.E., Klunk, W.E., Kamboh, M.I., Apolipoprotein D is a Component of Compact but Not Diffuse Amyloid-Beta Plaques in Alzheimers Disease Temporal Cortex (2005) Neurobiol. Dis., 20, pp. 574-582; Attems, J., Jellinger, K., Thal, D.R., Van, N. W., Review: Sporadic Cerebral Amyloid Angiopathy (2011) Neuropathol. Appl. Neurobiol., 37, pp. 75-93; Wong, B.S., Brown, D.R., Pan, T., Whiteman, M., Liu, T., Bu, X., Li, R., Sy, M.S., Oxidative Impairment in Scrapie-Infected Mice is Associated with Brain Metals Perturbations and Altered Antioxidant Activities (2001) J. Neurochem., 79, pp. 689-698; Clapham, D.E., Calcium Signaling (2007) Cell, 131, pp. 1047-1058; Torres, M., Castillo, K., Armisen, R., Stutzin, A., Soto, C., Hetz, C., Prion Protein Misfolding Affects Calcium Homeostasis and Sensitizes Cells to Endoplasmic Reticulum Stress (2010) PLoS ONE, 5, p. 15658; Trifilo, M.J., Sanchez-Alavez, M., Solforosi, L., Bernard-Trifilo, J., Kunz, S., McGavern, D., Oldstone, M.B., Scrapie-Induced Defects in Learning and Memory of Transgenic Mice Expressing Anchorless Prion Protein Are Associated with Alterations in the Gamma Aminobutyric Acid-Ergic Pathway (2008) J. Virol., 82, pp. 9890-9899; Ferrer, I., Rivera, R., Blanco, R., Marti, E., Expression of Proteins Linked to Exocytosis and Neurotransmission in Patients with Creutzfeldt-Jakob Disease (1999) Neurobiol. Dis., 6, pp. 92-100; Jeffrey, M., Halliday, W.G., Bell, J., Johnston, A.R., Macleod, N.K., Ingham, C., Sayers, A.R., Fraser, J.R., Synapse Loss Associated with Abnormal PrP Precedes Neuronal Degeneration in the Scrapie-Infected Murine Hippocampus (2000) Neuropathol. Appl. Neurobiol., 26, pp. 41-54; Siskova, Z., Reynolds, R.A., Oconnor, V., Perry, V.H., Brain Region Specific Pre-Synaptic and Post-Synaptic Degeneration Are Early Components of Neuropathology in Prion Disease (2013) PLoS ONE, 8, p. 55004; Siso, S., Puig, B., Varea, R., Vidal, E., Acin, C., Prinz, M., Montrasio, F., Ferrer, I., Abnormal Synaptic Protein Expression and Cell Death in Murine Scrapie (2002) Acta Neuropathol., 103, pp. 615-626; Moreno, J.A., Radford, H., Peretti, D., Steinert, J.R., Verity, N., Martin, M.G., Halliday, M., Mallucci, G.R., Sustained Translational Repression by EIF2alpha-P Mediates Prion Neurodegeneration (2012) Nature, 485, pp. 507-511; Kristiansen, M., Deriziotis, P., Dimcheff, D.E., Jackson, G.S., Ovaa, H., Naumann, H., Clarke, A.R., Tabrizi, S.J., Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome (2007) Mol. Cell, 26, pp. 175-188; Lin, Z., Zhao, D., Yang, L., Interaction between Misfolded PrP and the Ubiquitin-Proteasome System in Prion-Mediated Neurodegeneration (2013) Acta Biochim. Biophys. Sin. (Shanghai), 45, pp. 477-484; Choi, S.I., Ju, W.K., Choi, E.K., Kim, J., Lea, H.Z., Carp, R.I., Wisniewski, H.M., Kim, Y.S., Mitochondrial Dysfunction Induced by Oxidative Stress in the Brains of Hamsters Infected with the 263 K Scrapie Agent (1998) Acta Neuropathol., 96, pp. 279-286; Siskova, Z., Mahad, D.J., Pudney, C., Campbell, G., Cadogan, M., Asuni, A., Oconnor, V., Perry, V.H., Morphological and Functional Abnormalities in Mitochondria Associated with Synaptic Degeneration in Prion Disease (2010) Am. J. Pathol., 177, pp. 1411-1421; Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S.A., Mannella, C.A., Korsmeyer, S.J., A Distinct Pathway Remodels Mitochondrial Cristae and Mobilizes Cytochrome c during Apoptosis (2002) Dev. Cell, 2, pp. 55-67; Polster, B.M., Fiskum, G., Mitochondrial Mechanisms of Neural Cell Apoptosis (2004) J. Neurochem., 90, pp. 1281-1289; Linden, R., Martins, V.R., Prado, M.A., Cammarota, M., Izquierdo, I., Brentani, R.R., Physiology of the Prion Protein (2008) Physiol. Rev., 88, pp. 673-728",Article,Scopus,2-s2.0-84908884094
"Balouch S., Rusted J.M.","Error-monitoring in an everyday task in people with Alzheimer-type dementia: Observations over five years of performance decline",2014,"Journal of Clinical and Experimental Neuropsychology","36","7",,"773","786",,,10.1080/13803395.2014.943697,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911985583&partnerID=40&md5=fbd3e82b00710949faf2acc3b328e3aa","School of Psychology, University of SussexBrighton-East-Sussex, United Kingdom","Balouch, S., School of Psychology, University of SussexBrighton-East-Sussex, United Kingdom; Rusted, J.M., School of Psychology, University of SussexBrighton-East-Sussex, United Kingdom","Research suggests that, although everyday action errors increase significantly with dementia progression, accomplishment of the task remains high, even in severe dementia. We used archive observational data charting progressive decline in everyday task performance to explore error-monitoring over a 5-year period in four people with dementia. None of the participants showed effective error-monitoring during their execution of their established tea-making routine: Over 5 years and into more severe stages of dementia, errors increased, but there was no reactive increase from our participants in error-monitoring. Training to error-monitor routine tasks may be an appropriate target for further study. © 2014 Taylor & Francis.","Alzheimers disease; Dementia; Error; Error-monitoring; Everyday task","Association, A.P., (2013) Diagnostic and Statistical Manual of Mental Disorders, , (5th ed.). Arlington, VA: Author; Bailey, H.R., Kurby, C.A., Giovannetti, T., Zacks, J.M., Action perception predicts action performance (2013) Neuropsychologia, 51 (11), pp. 2294-2304; Balouch, S., Rusted, J.M., Age-related changes in error monitoring of an everyday task (2013) Journal of the International Neuropsychological Society: JINS, 19 (7), pp. 763-772; Band, G.P., Kok, A., Age effects on response monitoring in a mental-rotation task (2000) Biological Psychology, 51 (2-3), pp. 201-221; Bettcher, B.M., Giovannetti, T., From cognitive neuroscience to geriatric neuropsychology: What do current conceptualizations of the action error handling process mean for older adults? (2009) Neuropsychology Review, 19 (1), pp. 64-84; Bettcher, B.M., Giovannetti, T., Libon, D.J., Eppig, J., Wambach, D., Klobusicky, E., Improving everyday error detection, one picture at a time: A performance-based study of everyday task training (2011) Neuropsychology, 25 (6), pp. 771-783; Bettcher, B.M., Giovannetti, T., Macmullen, L., Libon, D.J., Error detection and correction patterns in dementia: A breakdown of error monitoring processes and their neuropsychological correlates (2008) Journal of the International Neuropsychological Society: JINS, 14 (2), pp. 199-208; Botvinick, M., Plaut, D.C., Representing task context: Proposals based on a connectionist model of action (2002) Psychological Research, 66 (4), pp. 298-311; Botvinick, M., Plaut, D.C., Doing without schema hierarchies: A recurrent connectionist approach to normal and impaired routine sequential action (2004) Psychological Review, 111 (2), pp. 395-429; Botvinick, M.M., Plaut, D.C., Such stuff as habits are made on: A reply to Cooper and Shallice (2006) (2006) Psychological Review, 113 (4), pp. 917-928; Brennan, L., Giovannetti, T., Libon, D.J., Bettcher, B.M., Duey, K., The impact of goal cues on everyday action performance in dementia (2009) Neuropsychological Rehabilitation, 19 (4), pp. 562-582; Buxbaum, L.J., Ideational apraxia and naturalistic action (1998) Cognitive Neuropsychology, 15 (6-8), pp. 617-643; Cohen, J., (1988) Statistical Power Analysis for the Behavioral Sciences, , (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates; Cooper, R., Shallice, T., Contention scheduling and the control of routine activities (2000) Cognitive Neuropsychology, 17 (4), pp. 297-338; Cooper, R.P., Shallice, T., Structured representations in the control of behavior cannot be so easily dismissed: A reply to Botvinick and Plaut (2006) (2006) Psychological Review, 113 (4), pp. 929-931; Falkenstein, M., Hoormann, J., Christ, S., Hohnsbein, J., ERP components on reaction errors and their functional significance: A tutorial (2000) Biological Psychology, 51 (2-3), pp. 87-107; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""Mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12 (3), pp. 189-198; Giovannetti, T., Bettcher, B.M., Brennan, L., Libron, D.J., Kessler, R.K., Duey, K., Coffee with jelly or unbuttered toast: Commissions and omissions are dissociable aspects of everyday action impairment in Alzheimers disease (2008) Neuropsychology, 22 (2), pp. 235-245; Giovannetti, T., Britnell, P., Brennan, L., Siderowf, A., Grossman, M., Libon, D.J., Seidel, G.A., Everyday action impairment in Parkinsons disease dementia (2012) Journal of the International Neuropsychological Society, 18 (5), pp. 787-798; Giovannetti, T., Libon, D.J., Buxbaum, L.J., Schwartz, M.F., Naturalistic action impairments in dementia (2002) Neuropsychologia, 40 (8), pp. 1220-1232; Giovannetti, T., Libon, D.J., Hart, T., Awareness of naturalistic action errors in dementia (2002) Journal of the International Neuropsychological Society, 8 (5), pp. 633-644; Giovannetti, T., Schwartz, M.F., Buxbaum, L.J., The coffee challenge: A new method for the study of everyday action errors (2007) Journal of Clinical and Experimental Neuropsychology, 29 (7), pp. 690-705; Hachinski, V., Iliff, L., Zilhka, E., Duboulay, G., McAllister, V., Marshall, J., Symon, L., Cerebral blood-flow in dementia (1975) Archives of Neurology, 32 (9), pp. 632-637; Hester, R., Foxe, J.J., Molholm, S., Shpaner, M., Garavan, H., Neural mechanisms involved in error processing: A comparison of errors made with and without awareness (2005) NeuroImage, 27 (3), pp. 602-608; Ito, J., Kitagawa, J., Error processing in patients with Alzheimers disease (2005) Pathophysiology: The Official Journal of the International Society for Pathophysiology/ISP, 12 (2), pp. 97-101; Kessler, R.K., Giovannetti, T., Macmullen, L.R., Everyday action in schizophrenia: Performance patterns and underlying cognitive mechanisms (2007) Neuropsychology, 21 (4), pp. 439-447; Kirk, R.E., Practical significance: A concept whose time has come (1996) Educational and Psychological Measurement, 56 (5), pp. 746-759; Klein, T.A., Endrass, T., Kathmann, N., Neumann, J., Von Cramon, D.Y., Ullsperger, M., Neural correlates of error awareness (2007) NeuroImage, 34 (4), pp. 1774-1781; Mathalon, D.H., Bennett, A., Askari, N., Gray, E.M., Rosenbloom, M.J., Ford, J.M., Response-monitoring dysfunction in aging and Alzheimers disease: An event-related potential study (2003) Neurobiology of Aging, 24 (5), pp. 675-685; Mathewson, K.J., Dywan, J., Segalowitz, S.J., Brain bases of error-related ERPs as influenced by age and task (2005) Biological Psychology, 70 (2), pp. 88-104; Nieuwenhuis, S., Ridderinkhof, K.R., Talsma, D., Coles, M.G.H., Holroyd, C.B., Kok, A., Van Der Molen, M.W., A computational account of altered error processing in older age: Dopamine and the error-related negativity (2002) Cognitive, Affective, & Behavioral Neuroscience, 2 (1), pp. 19-36; Nieuwenhuis-Mark, R.E., The death knoll for the MMSE: Has it outlived its purpose? (2010) Journal of Geriatric Psychiatry and Neurology, 23 (3), pp. 151-157; Noldus Information Technology, (2003) The Observer. Professional System for Collection, Analysis, Presentation and Management of Observational Data, , Wageningen: Author; Ramsden, C.M., Kinsella, G.J., Ong, B., Storey, E., Performance of everyday actions in mild Alzheimers disease (2008) Neuropsychology, 22 (1), pp. 17-26; Roth, M., Huppert, F., Tym, E., Mountjoy, C.Q., (1988) Cambridge Examination for Mental Disorders of the Elderly (CAMDEX), , Cambridge: Cambridge University Press; Rusted, J.M., Moniz-Cook, E., Neurorehabilitation strategies for people with neurodegenerative conditions (2013) Clinical Neuropsychology: A Practical Guide to Assessment and Management for Clinicians, pp. 549-566. , L. H. Goldstein & J. E. McNeil (Eds.), (2nd ed.) Chichester: John Wiley & Sons; Rusted, J., Sheppard, L., Action-based memory in Alzheimers disease: A longitudinal look at tea making (2002) Neurocase, 8 (1-2), pp. 111-126; Schwartz, M.F., The cognitive neuropsychology of everyday action and planning (2006) Cognitive Neuropsychology, 23 (1), pp. 202-221; Schwartz, M.F., Buxbaum, L.J., Montgomery, M.W., Fitzpatrick-Desalme, E., Hart, T., Ferraro, M., Coslett, H.B., Naturalistic action production following right hemisphere stroke (1999) Neuropsychologia, 37 (1), pp. 51-66; Schwartz, M., Montgomery, M., Fitzpatrick-Desalme, E., Ochipa, C., Coslett, H.B., Mayer, N., Analysis of a disorder of everyday action (1995) Cognitive Neuropsychology, 12 (8), pp. 863-892; Schwartz, M.F., Reed, E.S., Montgomery, M., Palmer, C., Mayer, N.H., The quantitative description of action disorganisation after brain damage: A case study (1991) Cognitive Neuropsychology, 8 (5), pp. 381-414; Schwartz, M.F., Segal, M., Veramonti, T., Ferraro, M., Buxbaum, L.J., The Naturalistic Action Test: A standardised assessment for everyday action impairment (2002) Neuropsychological Rehabilitation, 12 (4), pp. 311-339; Seidel, G.A., Giovannetti, T., Price, C.C., Tanner, J., Mitchell, S., Eppig, J., Libon, D.J., Neuroimaging correlates of everyday action in dementia (2013) Journal of Clinical and Experimental Neuropsychology, 35 (9), pp. 993-1005; Tombaugh, T.N., McIntyre, N.J., The Mini-Mental State Examination: A comprehensive review (1992) Journal of the American Geriatrics Society, 40 (9), pp. 922-935; Ullsperger, M., Harsay, H.A., Wessel, J.R., Ridderinkhof, K.R., Conscious perception of errors and its relation to the anterior insula (2010) Brain Structure & Function, 214 (5-6), pp. 629-643",Article,Scopus,2-s2.0-84911985583
"Zhang L.-L., Sui H.-J., Liang B., Wang H.-M., Qu W.-H., Yu S.-X., Jin Y.","Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway",2014,"Acta Pharmacologica Sinica","35","6",,"716","726",,1,10.1038/aps.2013.203,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902292304&partnerID=40&md5=e82e005a5e2376a9d22f1df5359d7298","Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China","Zhang, L.-L., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Sui, H.-J., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Liang, B., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Wang, H.-M., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Qu, W.-H., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Yu, S.-X., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China; Jin, Y., Department of Pharmacology, Liaoning Medical University, Jinzhou 121001, China","Aim:To investigate whether atorvastatin treatment could prevent Aβ 1-42 oligomer (AβO)-induced synaptotoxicity and memory dysfunction in rats, and to elucidate the mechanisms involved in the neuroprotective actions of atorvastatin.Methods:SD rats were injected with AβOs (5 nmol, icv). The rats were administrated with atorvastatin (10 mg·kg -1 ·d -1, po) for 2 consecutive weeks (the first dose was given 5 d before AβOs injection). The memory impairments were evaluated with Morris water maze task. The expression of inflammatory cytokines in the hippocampus was determined using ELISA assays. The levels of PSD-95 and p38MAPK proteins in rat hippocampus were evaluated using Western blot analysis. For in vitro experiments, cultured rat hippocampal neurons were treated with AβOs (50 nmol/L) for 48 h. The expression of MAP-2 and synaptophysin in the neurons was detected with immunofluorescence.Results:The AβO-treated rats displayed severe memory impairments in Morris water maze tests, and markedly reduced levels of synaptic proteins synaptophysin and PSD-95, increased levels of inflammatory cytokines (IL-1β, IL-6 and TNF-) and p38MAPK activation in the hippocampus. All these effects were prevented or substantially attenuated by atorvastatin administration. Pretreatment of cultured hippocampal neurons with atorvastatin (1 and 5 μmol/L) concentration-dependently attenuated the AβO-induced synaptotoxicity, including the loss of dendritic marker MAP-2, and synaptic proteins synaptophysin and PSD-95. Pretreatment of the cultured hippocampal neurons with the p38MAPK inhibitor SB203580 (5 μmol/L) blocked the AβO-induced loss of synaptophysin and PSD-95.Conclusion:Atorvastatin prevents AβO-induced synaptotoxicity and memory dysfunction through a p38MAPK-dependent pathway. © 2014 CPS and SIMM All rights reserved.","Alzheimers disease; amyloid-â peptide; atorvastatin; cytokine; hippocampus; learning and memory; p38 MAPK; PSD-95; synapse; synaptophysin","Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide (2007) Nat Rev Mol Cell Biol, 8, pp. 101-112; Cerpa, W., Dinamarca, M.C., Inestrosa, N.C., Structure-function implications in Alzheimer's disease: Effect of Abeta oligomers at central synapses (2008) Curr Alzheimer Res, 5, pp. 233-243; Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss (2003) Proc Natl Acad Sci USA, 100, pp. 10417-10422; Chang, L., Bakhos, L., Wang, Z., Venton, D.L., Klein, W.L., Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening (2003) J Mol Neurosci, 20, pp. 305-313; Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function (2005) Nat Neurosci, 8, pp. 79-84; Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539; Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Synaptic targeting by Alzheimer's-related amyloid beta oligomers (2004) J Neurosci, 24, pp. 10191-10200; Wei, W., Nguyen, L.N., Kessels, H.W., Hagiwara, H., Sisodia, S., Malinow, R., Amyloid beta from axons and dendrites reduces local spine number and plasticity (2010) Nat Neurosci, 13, pp. 190-196; Liu, J., Chang, L., Roselli, F., Almeida, O.F., Gao, X., Wang, X., Amyloidbeta induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors (2010) J Alzheimers Dis, 22, pp. 541-556; El-Husseini, A.E., Schnell, E., Chetkovich, D.M., Nicoll, R.A., Bredt, D.S., PSD-95 involvement in maturation of excitatory synapses (2000) Science, 290, pp. 1364-1368; Rao, A., Kim, E., Sheng, M., Craig, A.M., Heterogeneity in the molecular composition of excitatory postsynaptic sites during development of hippocampal neurons in culture (1998) J Neurosci, 18, pp. 1217-1229; Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Regulation of NMDA receptor trafficking by amyloid-beta (2005) Nat Neurosci, 8, pp. 1051-1058; Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway (2007) J Neurosci, 27, pp. 2866-2875; Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease (2007) J Neurosci, 27, pp. 796-807; Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., Selkoe, D.J., Soluble Abeta oligomers inhibit long-term poten tiation through a mechanism involving excessive activation of extrasynaptic NR2Bcontaining NMDA receptors (2011) J Neurosci, 31, pp. 6627-6638; Liao, J.K., Laufs, U., Pleiotropic effects of statins (2005) Annu Rev Pharmacol Toxicol, 45, pp. 89-118; Wang, C.Y., Liu, P.Y., Liao, J.K., Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results (2008) Trends Mol Med, 14, pp. 37-44; Hosaka, A., Araki, W., Oda, A., Tomidokoro, Y., Tamaoka, A., Statins reduce amyloid beta-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterolindependent mechanism in cultured neurons (2013) Neurochem Res, 38, pp. 589-600; Kurata, T., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., Ikeda, Y., Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: Protection by atorvastatin and pitavastatin (2011) Neuroscience, 197, pp. 358-368; Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., Drachman, D.A., Statins and the risk of dementia (2000) Lancet, 356, pp. 1627-1631; Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G.G., Siegel, G., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl c oenzyme A reductase inhibitors (2000) Arch Neurol, 57, pp. 1439-1443; Simons, M., Schwarzler, F., Lutjohann, D., Von Bergmann, K., Beyreuther, K., Dichgans, J., Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebocontrolled, double-blind trial (2002) Ann Neurol, 52, pp. 346-350; Sparks, D.L., Sabbagh, M., Connor, D., Soares, H., Lopez, J., Stankovic, G., Statin therapy in Alzheimer's disease (2006) Acta Neurol Scand Suppl, 185, pp. 78-86; Li, L., Cao, D., Kim, H., Lester, R., Fukuchi, K., Simvastatin enhances learning and memory independent of amyloid load in mice (2006) Ann Neurol, 60, pp. 729-739; Waters, D.D., Safety of high-dose atorvastatin therapy (2005) Am J Cardiol, 96, pp. 69F-75F; Clarke, R.M., O'Connell, F., Lyons, A., Lynch, M.A., The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo (2007) Neuropharmacology, 52, pp. 136-145; Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins (1998) Proc Natl Acad Sci USA, 95, pp. 6448-6453; Cao, C., Cirrito, J.R., Lin, X., Wang, L., Verges, D.K., Dickson, A., Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice (2009) J Alzheimers Dis, 17, pp. 681-697; Clarke, R.M., Lyons, A., Oconnell, F., Deighan, B.F., Barry, C.E., Anyakoha, N.G., A pivotal role for interleukin-4 in atorvast atin-associated neuroprotection in rat brain (2008) J Biol Chem, 283, pp. 1808-1817; Briones, T.L., Woods, J., Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications (2011) BMC Neurosci, 12, p. 124; Jin, Y., Sui, H.J., Dong, Y., Ding, Q., Qu, W.H., Yu, S.X., Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regu lating the Akt/mTOR and Akt/GSK-3beta signaling pathways (2012) Acta Pharmacol Sin, 33, pp. 861-872; Silva, C.G., Porciuncula, L.O., Canas, P.M., Oliveira, C.R., Cunha, R.A., Blockade of adenosine A(2A) recep tors prevents staurosporine-induced apoptosis of rat hippocampal neurons (2007) Neurobiol Dis, 27, pp. 182-189; Munoz, L., Ralay Ranaivo, H., Roy, S.M., Hu, W., Craft, J.M., McNamara, L.K., A nov el p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model (2007) J Neuroinflammation, 4, p. 21; Zhu, X., Mei, M., Lee, H.G., Wang, Y., Han, J., Perry, G., P38 activation mediates amyloid-beta cytotoxicity (2005) Neurochem Res, 30, pp. 791-796; Mc Donald, J.M., Savva, G.M., Brayne, C., Welzel, A.T., Forster, G., Shankar, G.M., The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia (2010) Brain, 133, pp. 1328-1341; Deshpande, A., Kawai, H., Metherate, R., Glabe, C.G., Busciglio, J., A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses (2009) J Neurosci, 29, pp. 400-415; Maezawa, I., Hong, H.S., Liu, R., Wu, C.Y., Cheng, R.H., Kung, M.P., Congo red and thioflavin-T analogs detect Abeta oligomers (2008) J Neurochem, 104, pp. 457-468; Wang, H.W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus (2002) Brain Res, 924, pp. 133-140; Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., Selkoe, D.J., Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers (2006) J Physiol, 572, pp. 477-492; Canas, P.M., Porciuncula, L.O., Cunha, G.M., Silva, C.G., Machado, N.J., Oliveira, J.M., Adenosine A2A receptor blockade prevents synaptotoxicity and memory dys function caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway (2009) J Neurosci, 29, pp. 14741-14751; Yamada, M., Chiba, T., Sasabe, J., Nawa, M., Tajima, H., Niikura, T., Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory (2005) Behav Brain Res, 164, pp. 139-146; Takeda, S., Sato, N., Niisato, K., Takeuchi, D., Kurinami, H., Shinohara, M., Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease (2009) Brain Res, 1280, pp. 137-147; Walsh, D.M., Selkoe, D.J., Deciphering the molecular basis of memory failure in Alzheimer's disease (2004) Neuron, 44, pp. 181-193; Lambert, M.P., Velasco, P.T., Chang, L., Viola, K.L., Fernandez, S., Lacor, P.N., Monoclonal antibodies that target pathological assemblies of Abeta (2007) J Neurochem, 100, pp. 23-35; Wolozin, B., Cholesterol, statins and dementia (2004) Curr Opin Lipidol, 15, pp. 667-672; Petanceska, S.S., Derosa, S., Olm, V., Diaz, N., Sharma, A., Thomas-Bryant, T., Statin therapy for Alzheimer's disease will it work (2002) J Mol Neurosci, 19, pp. 155-161; Cordle, A., Landreth, G., 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses (2005) J Neurosci, 25, pp. 299-307; Lee, S.T., Chu, K., Park, J.E., Hong, N.H., Im, W.S., Kang, L., Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways (2008) J Neurochem, 104, pp. 1190-1200; Wang, Q., Wu, J., Rowan, M.J., Anwyl, R., Beta-amyloid inhibition of longterm potentiation is mediated via tumor necrosis factor (2005) Eur J Neurosci, 22, pp. 2827-2832; Giuliani, F., Vernay, A., Leuba, G., Schenk, F., Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism (2009) Brain Res Bull, 80, pp. 302-308; Mc Alpine, F.E., Lee, J.K., Harms, A.S., Ruhn, K.A., Blurton-Jones, M., Hong, J., Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology (2009) Neurobiol Dis, 34, pp. 163-177; Tarkowski, E., Blennow, K., Wallin, A., Tarkowski, A., Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascu lar dementia (1999) J Clin Immunol, 19, pp. 223-230; Tarkowski, E., Andreasen, N., Tarkowski, A., Blennow, K., Intrathecal inflammation precedes development of Alzheimer's disease (2003) J Neurol Neurosurg P Sychiatry, 74, pp. 1200-1205; Woiciechowsky, C., Schoning, B., Stoltenburg-Didinger, G., Stockhammer, F., Volk, H.D., Brain-IL-1 beta triggers astrogliosis through induction of IL-6: Inhibition by propranol ol and IL-10 (2004) Med Sci Monit, 10, pp. BR325-BR330; Akama, K.T., Van Eldik, L.J., Beta-amyloid stimulation of inducible nitricoxide synthase in astrocytes is interleukin-1beta-and tumor necrosis factor-alpha (TNFalpha )-dependent, and involves a TNFalpha receptorassociated factor-and NFkappaB-inducing kinase-dependent signaling mechanism (2000) J Biol Chem, 275, pp. 7918-7924; Origlia, N., Righi, M., Capsoni, S., Cattaneo, A., Fang, F., Stern, D.M., Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-betamediated cortical synaptic dysfunction (2008) J Neurosci, 28, pp. 3521-3530; Sun, A., Liu, M., Nguyen, X.V., Bing, G., P38 MAP kinase is activated at early stages in Alzheimer's disease brain (2003) Exp Neurol, 183, pp. 394-405; Jin, Y., Yan, E.Z., Fan, Y., Zh, Z., Qi, Z.M., Li, Z., Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus (2005) Acta Pharmacol Sin, 26, pp. 943-951; Giovannini, M.G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M.G., Rosi, S., Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of th e p38MAPK pathway (2002) Neurobiol Dis, 11, pp. 257-274; Lee, Y.B., Schrader, J.W., Kim SU p38 map kinase regulates TNFalpha production in human astrocytes and microglia by multiple mechanisms (2000) Cytokine, 12, pp. 874-880; Sheng, J.G., Jones, R.A., Zhou, X.Q., Mc Ginness, J.M., Van Eldik, L.J., Mrak, R.E., Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's dis ease: Potential significance for tau protein phosphorylation (2001) Neurochem Int, 39, pp. 341-348; Li, Y., Liu, L., Barger, S.W., Griffin, W.S., Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway (2003) J Neurosci, 23, pp. 1605-1611",Article,Scopus,2-s2.0-84902292304
"Larrabee G.J.","Test validity and performance validity: Considerations in providing a framework for development of an ability-focused neuropsychological test battery",2014,"Archives of Clinical Neuropsychology","29","7",,"695","714",,,10.1093/arclin/acu049,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911393601&partnerID=40&md5=42d1eeece2374fe86acf93827121daa9","Independent Practice, 2650 Bahia Vista Street No 308Sarasota, FL, United States","Larrabee, G.J., Independent Practice, 2650 Bahia Vista Street No 308Sarasota, FL, United States","Literature on test validity and performance validity is reviewed to propose a framework for specification of an ability-focused battery (AFB). Factor analysis supports six domains of ability: first, verbal symbolic; secondly, visuoperceptual and visuospatial judgment and problem solving; thirdly, sensorimotor skills; fourthly, attention/working memory; fifthly, processing speed; finally, learning and memory (which can be divided into verbal and visual subdomains). The AFB should include at least three measures for each of the six domains, selected based on various criteria for validity including sensitivity to presence of disorder, sensitivity to severity of disorder, correlation with important activities of daily living, and containing embedded/derived measures of performance validity. Criterion groups should include moderate and severe traumatic brain injury, and Alzheimer's disease. Validation groups should also include patients with left and right hemisphere stroke, to determine measures sensitive to lateralized cognitive impairment and so that the moderating effects of auditory comprehension impairment and neglect can be analyzed on AFB measures. © 2014 © The Author 2014. Published by Oxford University Press. All rights reserved.","Alzheimers disease; Assessment; Cerebrovascular disease/accident and stroke; Head injury; Meta-analysis; Test construction; Traumatic brain injury","American Academy of Clinical Neuropsychology (AACN) practice guidelines for neuropsychological assessment and consultation (2007) The Clinical Neuropsychologist, 21, pp. 209-231. , American Academy of Clinical Neuropsychology; (2013) Diagnostic and Statistical Manual of Mental Disorders-text Revision, , American Psychiatric Association (5th ed.). Washington DC: Author; Ardolf, B.R., Denney, R.L., Houston, C.M., Base rates of negative response bias and malingered neurocognitive dysfunction among criminal defendants referred for neuropsychological evaluation (2007) The Clinical Neuropsychologist, 20, pp. 145-159; Arnold, G., Boone, K.B., Lu, P., Dean, A., Wen, J., Nitch, S., Sensitivity and specificity of finger tapping test scores for the detection of suspect effort (2005) The Clinical Neuropsychologist, 19 (1), pp. 105-120; Babikian, T., Boone, K.B., Lu, P., Arnold, G., Sensitivity and specificity of various digit span scores in the detection of suspect effort (2006) The Clinical Neuropsychologist, 20, pp. 145-159; Backman, L., Jones, S., Berger, A.-K., Laukka, E.J., Small, B.J., Cognitive impairment in preclinical Alzheimers disease: A meta-analysis (2005) Neuropsychology, 19, pp. 520-531; Baddeley, A., (2007) Working Memory, Thought and Action, , New York: Oxford; Barbey, A.K., Colom, R., Grafman, J., Dorsolateral prefrontal contributions to human intelligence (2013) Neuropsychologia, 51, pp. 1361-1369; Barrash, J., Suhr, J., Manzel, K., Detecting poor effort and malingering with an expanded version of the Auditory Verbal Learning Test (AVLTX): Validation with clinical samples (2004) Journal of the International Neuropsychological Society, 26, pp. 125-140; Bauer, R.M., The flexible battery approach to neuropsychologial assessment (2000) Clinician's Guide to Neuropsychological Assessment, pp. 419-448. , R.D. Vanderploeg (Ed.) (2nd ed.). Mahwah, NJ: Lawrence Erlbaum Associates; Belanger, H.G., Curtiss, G., Demery, J.A., Lebowitz, B.K., Vanderploeg, R.D., Factors moderating neuropsychological outcomes following mild traumatic brain injury: A meta-analysis (2005) Journal of the International Neuropsychological Society, 11, pp. 215-227; Benedict, R.H.B., (1997) Brief Visuospatial Memory Test-revised, , Odessa, FL: Psychological Assessment Resources; Ben-Porath, Y.S., (2012) Interpreting the MMPI-2-RF, , Minneapolis: University of Minnesota Press; Benton, A.L., Hamsher, K., De, S., Sivan, A.B., (1994) Multilingual Aphasia Examination, , (3rd ed.) Iowa City: AJA; Benton, A.L., Sivan Hamsher, B.A.K., De, S., Varney, N.R., Spreen, O., (1994) Contributions to Neuropsychological Assessment. A Clinical Manual, , (2nd ed.) New York: Oxford University Press; Binder, L.M., Rohling, M.L., Larrabee, G.J., A review of mild head trauma. Part I: Meta-analytic review of neuropsychological studies (1997) Journal of Clinical and Experimental Neuropsychology, 19, pp. 421-431; Blessed, G., Tomlinson, B.F., Roth, M., The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects (1968) British Journal of Psychiatry, 114, pp. 797-811; Boone, K.B., (2007) Assessment of Feigned Cognitive Impairment. A Neuropsychological Perspective, , New York: Guilford; Boone, K.B., Clinical Practice of Forensic Neuropsychology. An Evidence-based Approach, 2013. , New York: Guilford; Boone, K.B., Lu, P., Wen, J., Comparisons of various RAVLT scores in the detection of noncredible memory performance (2005) Archives of Clinical Neuropsychology, 20, pp. 301-319; Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., (2009) Introduction to Meta-analysis, , Chichester, West Sussex, UK: Wiley; Brandt, J., The Hopkins Verbal Learning Test: Development of a new verbal memory test with six equivalent forms (1991) The Clinical Neuropsychologist, 5, pp. 124-142; Brandt, J., Benedict, R.H.B., (2001) Hopkins Verbal Learning Test-revised, , Odessa, FL: Psychological Assessment Resources, Inc; Brown, F.C., Roth, R.M., Saykin, A.J., Beverly-Gibson, G., A new measure of visual location learning and memory: Development and psychometric properties for the Brown Location Test (BLT) (2007) The Clinical Neuropsychologist, 21, pp. 811-825; Brown, F.C., Tuttle, E., Westerveld, M., Ferraro, F.R., Chmieleowiec, T., Vandemore, M., Visual memory in patients after anterior right temporal lobectomy and adult normative data for the Brown Location Test (2010) Epilepsy & Behavior, 17, pp. 215-220; Brown, L.B., Stern, R.A., Cahn-Weiner, D.A., Rogers, B., Messer, M.A., Lannon, M.C., Driving Scenes Test of the Neuropsychological Assessment Battery (NAB) and on-road driving performance in aging and very mild dementia (2005) Archives of Clinical Neuropsychology, 20, pp. 209-215; Buschke, H., Selective reminding for analysis of memory and learning (1973) Journal of Verbal Learning and Verbal Behavior, 12, pp. 543-550; Bush, S.S., Ruff, R.M., Troster, A., Barth, J., Koffler, S.P., Pliskin, N.H., NAN position paper: Symptom validity assessment: Practice issues and medical necessity (2005) Archives of Clinical Neuropsychology, 20, pp. 419-426; Carroll, J.B., (1993) Human Cognitive Abilities: A Survey of Factor Analytic Studies, , New York, NY: Cambridge University Press; Chafetz, M., Malingering on the Social Security consultative exam: Predictors and base rates (2008) The Clinical Neuropsychologist, 22, pp. 529-546; Chelune, G.J., Evidence-based research and practice in clinical neuropsychology (2010) The Clinical Neuropsychologist, 24, pp. 454-467; Christensen, H., Griffiths, K., Mackinnon, A., Jacomb, P., Aquantitative reviewof cognitive deficits in depression and Alzheimer-type dementia (1997) Journal of the International Neuropsychological Society, 3, pp. 631-651; Cohen, J., (1988) Statistical Power Analysis for the Behavioral Sciences, , (2nd ed.) Mahwah, NJ: Lawrence Erlbaum Associates; Crook, T.H., Larrabee, G.J., Interrelationships among everyday memory tests: Stability of factor structure with age (1988) Neuropsychology, 2, pp. 1-12; Davis, J.J., Millis, S.R., Axelrod, B.N., Derivation of an embedded Rey Auditory Verbal Learning Test performance validity indicator (2012) The Clinical Neuropsychologist, 26, pp. 1397-1408; Delis, D.C., Jacobson, M., Bondi, M.W., Hamilton, J.M., Salmon, D.P., The myth of testing construct validity using factor analysis or correlations with normal or mixed clinical populations: Lessons from memory assessment (2003) Journal of the International Neuropsychological Society, 9, pp. 936-946; Delis, D.C., Kramer, J.H., Kaplan, E., Ober, B.A., (1987) California Verbal Learning Test (CVLT): Adult Version, , (Research ed.). San Antonio: Psychological Corporation; Delis, D.C., Kramer, J.H., Kaplan, E., Ober, B.A., (2000) California Verbal Learning Test, II, , San Antonio, TX: Psychological Corporation; Dikmen, S.S., Machamer, J.E., Winn, H.R., Temkin, N.R., Neuropsychological outcome at 1-year post head injury (1995) Neuropsychology, 9, pp. 80-90; Dikmen, S.S., Temkin, N.R., Machamer, J.E., Holubkov, A.L., Fraser, R.T., Winn, H.R., Employment following traumatic head injuries (1994) Archives of Neurology, 51, pp. 177-186; Donders, J., Axelrod, B.N., Two-subtest estimations of WAIS-III factor index scores (2002) Psychological Assessment, 14, pp. 360-364; Donders, J., Tulsky, D.S., Zhu, J., Criterion validity of new WAIS-III subtest scores after traumatic brain injury (2001) Journal of the International Neuropsychological Society, 7, pp. 892-898; Earnst, K.S., Wadley, V.G., Aldridge, T.M., Steenwyk, A.B., Hammond, A.E., Harrell, L.E., Loss of financial capacity in Alzheimers disease: The role of working memory (2001) Aging, Neuropsychology, and Cognition, 8, pp. 109-111; Evans, J.D., Bond, G.R., Meyer, P.S., Kim, H.W., Lysaker, P.H., Gibson, P.J., Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia (2004) Schizophrenia Research, 70, pp. 331-342; Fawcett, T., (2003) ROC Graphs: Notes and Practical Considerations for Data Mining Researchers, , Palo Alto: HP Laboratories; Frazier, T.W., Youngstrom, E.A., Chelune, G.J., Naugle, R.I., Lineweaver, T.T., Increasing the reliability of ipsative interpretations in neuropsychology: A comparison of reliable components analysis and other factor analytic methods (2004) Journal of the International Neuropsychological Society, 10, pp. 578-579; Frencham, K.A.R., Fox, A.M., Maybery, M.T., Neuropsychological studies of mild traumatic brain injury: A meta-analytic review of research since 1995 (2005) Journal of Clinical and Experimental Neuropsychology, 27, pp. 334-351; Gervais, R.O., Ben-Porath, Y.S., Wygant, D.B., Green, P., Differential sensitivity of the Response Bias Scale (RBS) and MMPI-2 validity scales to memory complaints (2008) Clinical Neuropsychologist, 22, pp. 1061-1079; Golden, C.J., (1978) Stroop Color and Word Test, , Chicago: Stoelting; Golden, C.J., Purisch, A.D., Hammeke, T.A., (1985) A Manual for the Luria-Nebraska Neuropsychological Battery, Forms i and Ii, , Los Angeles: Western Psychological Services; Green, P., The pervasive influence of effort on neuropsychological tests (2007) Physical Medicine and Rehabilitation Clinics of North America, 18, pp. 43-68; Green, P., Rohling, M.L., Iverson, G.L., Gervais, R.O., Relationships between olfactory discrimination and head injury severity (2003) Brain Injury, 17, pp. 479-496; Greiffenstein, M.F., Baker, W.J., Gola, T., Validation of malingered amnesia measures with a large clinical sample (1994) Psychological Assessment, 6, pp. 218-224; Greiffenstein, M.F., Baker, W.J., Gola, T., Motordysfunction profiles in traumatic brain injuryand postconcussion syndrome (1996) Journal of the International Neuropsychological Society, 2, pp. 477-485; Greve, K.W., Bianchini, K.J., Mathias, C.W., Houston, R.J., Crouch, J.A., Detecting malingered performance with the Wisconsin Card Sorting Test: A preliminary investigation in traumatic brain injury (2002) The Clinical Neuropsychologist, 16, pp. 179-191; Griffith, H.R., Netson, K.L., Harrell, L.E., Zamrini, E.Y., Brockington, J.C., Marson, D.C., Amnestic mild cognitive impairment: Diagnostic outcomes and clinical prediction over a two-year time period (2006) Journal of the International Neuropsychological Society, 12, pp. 166-175; Gronwall, D.M.A., Paced Auditory Serial Addition Task: A measure of recovery from concussion (1977) Perceptual and Motor Skills, 44, pp. 367-373; Hannay, H.J., Levin, H.S., Grossman, R.G., Impaired recognition memory after head injury (1979) Cortex, 15, pp. 269-283; Heaton, R.K., Chelune, G.J., Talley, J.L., Kay, G.G., Curtiss, G., (1993) The Wisconsin Card Sorting Test Manual: Revised and Expanded, , Odessa, FL: Psychological Assessment Resources, Inc; Heaton, R.K., Miller, S.W., Taylor, M.J., Grant, I., (2004) Revised Comprehensive Norms for An Expanded Halstead-Reitan Battery: Demographically Adjusted Norms for African American and Caucasian Adults (HRB), , Lutz FL: Psychological Assessment Resources; Heilbronner, R.L., Sweet, J.J., Morgan, J.E., Larrabee, G.J., Millis, S.R., Participants, C., American Academy of Clinical Neuropsychology consensus conference statement on the neuropsychological assessment of effort, response bias, and malingering (2009) The Clinical Neuropsychologist, 23, pp. 1093-1129; Heilman, K.M., Watson, R.T., Valenstein, E., Neglect and related disorders (2012) Clinical Neuropsychology, pp. 296-348. , K.M.Heilman, & E.Valenstein (Eds.) 5th ed. New York: Oxford University Press; Hill, B.D., Boettcher, A.C., Cary, B., Kline, J.S., Womble, M.N., Rohling, M.L., Much ado about norming: AComparison of the heaton demographically adjusted norms and the mitrushina meta-norms (2013) 41st Annual Conference of the International Neuropsychological Society in Waikoloa, , February HI; Hill, B.D., Rohling, M.L., Boettcher, A.C., Meyers, J.E., Cognitive intra-individual variability has a positive association with traumatic brain injury severity and suboptimal effort (2013) Archives of Clinical Neuropsychology, 28, pp. 640-648; Holdnack, J.A., Millis, S.R., Larrabee, G.J., Iverson, G.L., Assessing performance validity with the ACS (2013) WAIS-IV, WMS-IV, and ACS, pp. 331-365. , J. A. Holdnack, L.W. Drozdick L. G. Weiss & G. L. Iverson (Eds.) San Diego: Academic Press; Holdnack, J.A., Zhou, X., Larrabee, G.J., Millis, S.R., Salthouse, T.A., Confirmatory factor analysis of the WAIS-IV/WMS-IV (2011) Assessment, 18, pp. 178-191; Hosmer, D.W., Lemeshow, S., (2000) Applied Logistic Regression, , New York: Wiley Inter science; Hsaio, J.K., Bartko, J.J., Potter, W.Z., Diagnosing diagnoses:Receiver operating characteristics methods and psychiatry (1989) Archives of GeneralPsychiatry, 46, pp. 664-667; Hughes, C.P., Berg, L., Danziger, W.L., Coben, L.A., Martin, R.L., Anew clinical scale for the staging of dementia (1982) British Journal of Psychiatry, 140, pp. 566-572; Iverson, G.L., Can malingering be identified with the judgment of line orientation test? (2001) Applied Neuropsychology, 8 (3), p. 167; Jacobs, M.L., Donders, J., Criterion validity of the California Verbal Learning Test-Second Edition (CVLT-II) after traumatic brain injury (2007) Archives of Clinical Neuropsychology, 22, pp. 143-149; Jasinski, L.J., Berry, D.T.R., Shandera, A.L., Clark, J.A., Use of theWechsler Adult Intelligence Scale Digit Span subtest for malingering detection: A meta-analytic review (2011) Journal of Clinical and Experimental Neuropsychology, 33, pp. 300-314; Jastak, J., Wilkinson, G.S., (1984) The Wide Range Achievement Test-revised, , Wilmington, DE: Jastak Associates; Kaplan, E.F., Goodglass, H., Weintraub, S., (1983) The Boston Naming Test, , (2nd ed.) Philadelphia: Lea and Febiger; Keifer, E., Tranel, D., A neuropsychological investigation of the Delis-Kaplan Executive Function System (2013) Journal of Clinical and Experimental Neuropsychology, 35, pp. 1048-1059; Killgore, W.D.S., Dellapietra, L., Using the WMS-III to detect malingering: Empirical validation of the Rarely Missed Index (RMI) (2000) Journal of Clinical and Experimental Neuropsychology, 22, pp. 761-771; Langeluddecke, P.M., Lucas, S.K., Quantitative measures of memory malingering on theWechsler Memory Scale-Third Edition in mild head injury litigants (2003) Archives of Clinical Neuropsychology, 18, pp. 181-197; Larrabee, G.J., Another look at VIQ-PIQ scores and unilateral brain damage (1986) International Journal of Neuroscience, 29, pp. 141-148; Larrabee, G.J., Association between IQ and neuropsychological test performance: Commentary on Tremont, Hoffman, Scott, and Adams (1998) (2000) The Clinical Neuropsychologist, 14, pp. 139-145; Larrabee, G.J., Detection of malingering using atypical performance patterns on standard neuropsychological tests (2003) The Clinical Neuropsychologist, 17, pp. 410-425; Larrabee, G.J., Exaggerated pain report in litigants with malingered neurocognitive dysfunction (2003) The Clinical Neuropsychologist, 17, pp. 395-401; Larrabee, G.J., Detection of symptom exaggeration with the MMPI-2 in litigants with malingered neurocognitive dysfunction (2003) The Clinical Neuropsychologist, 17, pp. 54-68; Larrabee, G.J., Lessons on measuring construct validity: A commentary on Delis, Jacobson, Bondi, Hamilton, and Salmon (2003) Journal of the International Neuropsychological Society, 9, pp. 947-953; Larrabee, G.J., (2007) Assessment of Malingered Neuropsychological Deficits, , New York: Oxford University Press; Larrabee, G.J., Aggregation across multiple indicators improves the detection of malingering: Relationship to likelihood ratios (2008) The Clinical Neuropsychologist, 22, pp. 666-679; Larrabee, G.J., Malingering scales for the continuous recognition memory test and the continuous visual memory test (2009) The Clinical Neuropsychologist, 23, pp. 167-180; Larrabee, G.J., Performance validity and symptom validity in neuropsychological assessment (2012) Journal of the International Neuropsychological Society, 18, pp. 625-630; Larrabee, G.J., Assessment of malingering (2012) Forensic Neuropsychology. A Scientific Approach, pp. 116-159. , G. J. Larrabee (Ed.) NewYork: Oxford; Larrabee, G.J., False-positive rates associated with the use of multiple performance and symptom validity tests (2014) Archives of Clinical Neuropsychology, 29, pp. 364-373; Larrabee, G.J., Curtiss, G., Factor structure of an ability-focused neuropsychological battery (abstract) (1992) Journal of Clinical and Experimental Neuropsychology, 14, p. 65; Larrabee, G.J., Curtiss, G., Construct validity of various verbal and visual memory tests (1995) Journal of Clinical and Experimental Neuropsychology, 17, pp. 536-547; Larrabee, G.J., Kane, R.L., Schuck, J.R., Francis, D.J., The construct validity of various memory testing procedures (1985) Journal of Clinical and Experimental Neuropsychology, 7, pp. 239-250; Larrabee, G.J., Largen, J.W., Levin, H.S., Sensitivity of age-decline reistant (""Hold"")WAIS subtests to Alzheimers disease (1985) Journal of Clinical and Experimental Neuropsychology, 7, pp. 497-504; Larrabee, G.J., Millis, S.R., Meyers, J.E., Sensitivity to brain dysfunction of the Halstead Reitan vs. An ability-focused neuropsychological battery (2008) The Clinical Neuropsychologist, 22, pp. 813-825; Larrabee, G.J., Trahan, D.E., Curtiss, G., Levin, H.S., Normative data for the Verbal Selective Reminding Test (1988) Neuropsychology, 2, pp. 173-182; Leonberger, F.T., Nicks, S.D., Larrabee, G.J., Goldfader, P.R., Factor structure and construct validity of a comprehensive neuropsychological battery (1992) Neuropsychology, 6, pp. 239-249; Levin, H.S., Benton, A.L., Grossman, R.G., (1982) Neurobehavioral Consequences of Closed Head Injury, , New York: Oxford; Lezak, M.D., Howieson, D.E., Bigler, E.D., Tranel, D., (2012) Neuropsychological Assessment, , (5th ed.) New York, NY: Oxford University Press; Loewenstein, D.A., Mogosky, B., Functional assessment in the older adult patient (1999) Handbook of Assessment in Clinical Gerontology, pp. 529-554. , P. Lichtenberg (Ed.) New York: Wiley; Loring, D.W., Larrabee, G.J., Sensitivity of the Halstead and Wechsler test batteries to brain damage: Evidence fromReitans original validation sample (2006) The Clinical Neuropsychologist, 20, pp. 221-229; Loring, D.W., Strauss, E., Hermann, B.P., Barr, W.B., Perrine, K., Trenerry, M.R., Differential neuropsychological test sensitivity to left temporal lobe epilepsy (2008) Journal of the International Neuropsychological Society, 14, pp. 394-400; Lu, P.H., Boone, K.G., Cozolino, L., Mitchell, C., Effectiveness of the Rey-osterreith complex figure test and the Meyers and Meyers recognition trial in the detection of suspect effort (2003) The Clinical Neuropsychologist, 17, pp. 426-440; Machamer, J., Temkin, N., Fraser, R., Doctor, J.N., Dikmen, S.S., Stability of employment after traumatic brain injury (2005) Journal of the International Neuropsychological Society, 11, pp. 807-816; Malec, J.F., Kragness, M., Evans, R.W., Finlay, K.L., Kent, A., Lezak, M.D., Further psychometric evaluation and revision of the Mayo-Portland Adaptability Inventory in a national sample (2003) Journal of Head Trauma Rehabilitation, 18, pp. 479-492; Marson, D.C., Ingram, K.K., Cody, H.A., Harrell, L.E., Assessing the competency of patients with Alzheimers disease under different legal standards: A prototype instrument (1995) Archives of Neurology, 52, pp. 949-954; McGrew, K.S., CHC Theory and the human cognitive abilities project: Standing on the shoulders of the giants of psychometric intelligence research (2009) Intelligence, 37, pp. 1-10; McGurk, S.R., Mueser, K.T., Harvey, P.D., Lapuglia, R., Marder, J., Cognitive and symptompredictors of workoutcomefor clients with schizophrenia in supported employment (2003) Psychiatric Services, 54, pp. 1129-1135; Meyers, J.E., Galinsky, A.M., Volbrecht, M., Malingering and mild brain injury: How low is too low? (1999) Applied Neuropsychology, 6 (4), p. 208; Meyers, J.E., Meyers, K., (1995) The Meyers Scoring System for the Rey Complex Figure and the Recognition Trial: Professional Manual, , Odessa, FL: Psychological Assessment Resources; Meyers, J.E., Miller, R.M., Thompson, L.M., Scalese, A.M., Allred, B.C., Rupp, Z.W., Using likelihood ratios to detect invalid performance with performance validity measures (2014) Archives of Clinical Neuropsychology, 29, pp. 224-235; Meyers, J.E., Miller, R.M., Tuita, A.R.R., Using pattern analysis matching to differentiate TBI and PTSD in a military sample (2013) Applied Neuropsychology: Adult, 21, pp. 60-68; Meyers, J.E., Rohling, M.L., Validation of the Meyers Short Battery on mild TBI patients (2004) Archives of Clinical Neuropsychology, 19, pp. 637-651; Meyers, J.E., Volbrecht, M.E., Avalidation of multiple malingering detection methods in a large clinical sample (2003) Archives of Clinical Neuropsychology, 18, pp. 61-276; Miller, J.B., Fichtenberg, N.L., Millis, S.R., Diagnostic efficiency of an ability focused battery (2010) The Clinical Neuropsychologist, 24, pp. 678-688; Millis, S.R., Putnam, S.H., Adams, K.M., Ricker, J.H., The California Verbal Learning Test in the detection of incomplete effort in neuropsychological evaluation (1995) Psychological Assessment, 7, pp. 463-471; Millis, S.R., Volinksy, C.T., Assessment of response bias in mild head injury: Beyond malingering tests (2001) Journal of Clinical and Experimental Neuropsychology, 23, pp. 809-828; Mitrushina, M., Boone, K., Razani, J., Delia, L., (2005) Handbook of Normative Data for Neuropsychological Assessment, , (2nd ed.) New York: Oxford University Press; Mittenberg, W., Azrin, R., Millsaps, C., Heilbronner, R., Identification of malingered head injury on theWechslerMemoryScale-Revised (1993) Psychological Assessment, 5, pp. 34-40; Mittenberg, W., Patton, C., Canyock, E.M., Condit, D.C., Base rates of malingering and symptom exaggeration (2002) Journal of Clinical and Experimental Neuropsychology, 24, pp. 1094-1102; Mittenberg, W., Theroux-Fichera, S., Zielinski, R.E., Heilbronner, R.L., Identification of malingered head injury on theWechsler Adult Intelligence Scale-Revised (1995) Professional Psychology: Research and Practice, 26, pp. 491-498; Morgan, J.E., Sweet, J.J., (2009) Neuropsychology of Malingering Casebook, , Hove, East Sussex, UK: Psychology Press; Novack, T.A., Banos, J.H., Alderson, A.L., Schneider, J.J., Weed, W., Blankenship, J., UFOVperformance and driving ability following traumatic brain injury (2006) Brain Injury, 20, pp. 455-461; Osterrieth, P.A., Le test de copie dune figure complex: Contribution a letude de la perception et de la memoire (1944) Archives de Psychologie, 30, pp. 286-356; Pearson, (2009) Advanced Clinical Solutions for Use with WAIS-IV and WMS-IV, , San Antonio: Pearson Education; Powell, J.B., Cripe, L.I., Dodrill, C.B., Assessment of brain impairment with the Rey Auditory Verbal Learning Test: A comparison with other neuropsychological measures (1991) Archives of Clinical Neuropsychology, 6, pp. 241-249; Purves, D., Brannon, E.M., Cabeza, R., Huettel, S.A., Labar, K.S., Platt, M.L., (2008) Principles of Cognitive Neuroscience, , Sunderland, MA: Sinauer Associates; Rabin, L.A., Barr, W.B., Burton, L.A., Assessment practices of clinical neuropsychologists in the United States and Canada: Asurvey of INS, NAN, and APA Division 40 members (2005) Archives of Clinical Neuropsychology, 20, pp. 33-65; Rappaport, M., Hall, K., Hopkins, K., Belleza, T., Cope, D., Disability Rating Scale for severe head trauma: Coma to community (1982) Archives of Physical Medicine and Rehabilitation, 63, pp. 118-123; Reitan, R.M., Wolfson, D., (1993) The Halstead-Reitan Neuropsychological Test Battery Theory and Clinical Interpretation, , (3rd ed.). Tucson, AZ: Neuropsychology Press; Rey, A., Lexamen psychologique dans les cas dencephalopathie traumatique (1941) Archives de Psychologie, 28, pp. 286-340; Rey, A., (1964) Lexamen Clinique en Psychologie, , Paris: Presses Univeritaires de France; Rice, M.E., Harris, G.T., Comparing effect sizes in follow-up studies: ROC Area, Cohens d, and r (2005) Law and Human Behavior, 29, pp. 615-620; Rohling, M.L., Axelrod, B., Wall, J., What impact does co-norming have on Neuropsychological Test Scores: Myth vs. Reality? (2008) 6th Annual Conference of the American Academy of Clinical Neuropsychology in Boston, MA, , June; Rohling, M.L., Binder, L.M., Demakis, G.J., Larrabee, G.J., Ploetz, D.M., Langhinrichsen-Rohling, J., Ameta-analysis of neuropsychological outcome after mild traumatic brain injury: Re-analyses and reconsiderations of Binder et al. (1997), Frencham et al. (2005), and Pertab et al 2009) (2011) The Clinical Neuropsychologist, 25, pp. 608-623; Rohling, M.L., Larrabee, G.J., Greiffenstein, M.F., Ben Porath, Y.S., Lees-Haley, P., Green, P., Amisleading reviewof response bias: Commentary on McGrath, Mitchell, Kim, and Hough (2010) (2011) Psychological Bulletin, 137, pp. 708-712; Rohling, M.L., Meyers, J.E., Millis, S.R., Neuropsychological impairment following traumatic brain injury: A dose-response analysis (2003) The Clinical Neuropsychologist, 17, pp. 289-302; Rohling, M.L., Miller, L.S., Langhinrichsen-Rohling, J., Rohlings interpretive method for neuropsychological case data: A response to critics (2004) Neuropsychology Review, 14, pp. 155-169; Russell, E.W., Starkey, R.I., (1993) Halstead Russell Neuropsychological Evaluation System (Manual and Computer Program), , Los Angeles CA: Western Psychological Services; Salmon, D.P., Heindel, W.C., Lange, K.L., Differential decline in word generation from phonemic and semantic categories during the course of Alzheimers disease: Implications for the integrity of semantic memory (1999) Journal of the International Neuropsychological Society, 5, pp. 692-703; Salthouse, T.A., Relations between cognitive abilities and measures of executive function (2005) Neuropsychology, 19, pp. 532-545; Salthouse, T.A., Saklofske, D.H., DotheWAIS-IV tests measure the same aspects of cognitive functioning in adults under and over 65? (2010) WAIS-IV. Clinical Use and Interpretation, pp. 217-235. , L. G.Weiss, D. H. Saklofske, D. Coalson, & S. E. Raiford (Eds.) San Diego: Academic Press; Schmidt, M., (1996) Rey Auditory and Verbal Learning Test, , Los Angeles: Western Psychological Services; Schretlen, D.J., Shapiro, A.M., Aquantitative reviewof the effects of traumatic brain injury on cognitive functioning (2003) International Review of Psychiatry, 15, pp. 341-349; Sherod, M.G., Griffith, H.R., Copeland, J., Belue, K., Kryzwanski, S., Zamrini, E.Y., Neurocogntiive predictors of financial capacity across the dementia spectrum: Normal aging, MCI, and Alzheimers disease (2009) Journal of the International Neuropsychological Society, 15, pp. 258-267; Slick, D.J., Sherman, E.M.S., Iverson, G.L., Diagnostic criteria for malingered neurocognitive dysfunction: Proposed standards for clinical practice and research (1999) The Clinical Neuropsychologist, 13, pp. 545-561; Smith, A., (1983) The Symbol Digit Modalities Test (SDMT) Manual (Revised), , Los Angeles: Western Psychological Services; Stern, R., White, T.R., (2003) Neuropsychological Assessment Battery. Manual, , Lutz: Psychological Assessment Resources; Strauss, E., Spreen, O., Sherman, E.M.S., (2006) A Compendium of Neuropsychological Tests: Adminstration, Norms, and Commentary, , (3rd ed.) New York: Oxford University Press; Stuss, D.T., Stethem, L.L., Hugenholtz, H., Richard, M.T., Traumatic brain injury: A comparison of three clinical tests and analysis of recovery (1989) The Clinical Neuropsychologist, 3, pp. 145-156; Suhr, J.A., Boyer, D., Use of theWisconsin Card Sorting Test in the detection of malingering in student simulator and patient samples (1999) Journal of Clinical and Experimental Neuropsychology, 21, pp. 701-708; Sweet, J.J., Meyer, D.G., Nelson, N.W., Moberg, P.J., The TCN/AACN 2010 ""salary Survey"": Professional practices, beliefs, and incomes of U. S. Neuropsychologists (2011) The Clinical Neuropsychologist, 25, pp. 12-61; Swets, J.J., The relative operating characteristic in psychology (1973) Science, 182, pp. 990-1000; Tabachnick, B.G., Fidell, L., (2005) Using Multivariate Statistics, , (5th ed.). Boston MA: Allyn & Bacon; Tellegen, A., Ben-Porath, Y.S., (2008) MMPI-2-RF (Minnesota Multiphasic Personality Inventory-2Restructured Form) Technical Manual, , Minneapolis: University of Minnesota Press; Tenhula, W.N., Sweet, J.J., Double cross-validation of the Booklet Category Test in detecting malingered traumatic brain injury (1996) The Clinical Neuropsychologist, 10, pp. 104-116; Trahan, D.E., Larrabee, G.J., (1988) The Continuous Visual Memory Test, , Lutz, FL: Psychological Assessment Resources; Trahan, D.E., Larrabee, G.J., Quintana, J.W., Visual recognition memory in normal adults and patients with unilateral vascular lesions (1990) Journal of Clinical and Experimental Neuropsychology, 12, pp. 857-872; Trahan, D.E., Larrabee, G.J., Quintana, J.W., Goethe, K.E., Willingham, A.C., Development and clinical validation of an expanded paired associates test with delayed recall (1989) The Clinical Neuropsychologist, 3, pp. 169-183; Trenerry, M.R., Crosson, B., Deboe, J., Leber, W.R., (1989) The Stroop Neuropsychological Screening Test, , Lutz, FL: Psychological Assessment Resources, Inc; Tulsky, D.S., Price, L.R., The jointWAIS-III and WMS-IIIfactor structure:Development and cross-validation of a six factor model of cognitive functioning (2003) Psychological Assessment, 15, pp. 149-162; Victor, T.L., Boone, K.B., Serpa, J.G., Buehler, M.A., Ziegler, E.A., Interpreting the meaning of multiple symptom validity test failure (2009) The Clinical Neuropsychologist, 23, pp. 297-313; Vollbrecht, M.E., Meyers, J.E., Kaster-Bundgaard, J., Neuropsychological outcome of head injury using a short battery (2000) Archives of Clinical Neuropsychology, 15, pp. 251-264; Wechsler, D., (1981) Wechsler Adult Intelligence Scale, Revised. Manual, , New York: The Psychological Corporation; Wechsler, D., (1987) Wechsler Memory Scale-Revised Manual, , San Antonio: The Psychological Corporation; Wechsler, D., (1997) Wechsler Adult Intelligence Scale, III, Manual, , San Antonio, TX: Psychological Corporation; Wechsler, D., (1997) Wechsler Memory Scale III, Manual, , San Antonio, TX: Psychological Corporation; Wechsler, D., (1997) WAIS-III/WMS-III Technical Manual, , San Antonio, TX: Psychological Corporation; Wechsler, D., (2008) WAIS-IV. Technical and Interpretive Manual, , San Antonio: Pearson; Wechsler, D., (2009) WMS-IV. Technical and Interpretive Manual, , San Antonio: Pearson; Welsh, K.A., Butters, N., Mohs, R.C., Beekly, D., Edland, S., Fillenbaum, G., The consortium to establish a registry for Alzheimers disease (CERAD). Part V. A normative study of the neuropsychological battery (1994) Neurology, 44, pp. 609-614; Whelihan, W.M., Dicarlo, M.A., Paul, R.H., The relationship of neuropsychological functioning to driving competence in older persons with early cognitive decline (2005) Archives of Clinical Neuropsychology, 20, pp. 217-228; Williams, M.W., Rapport, L.J., Hanks, R.A., Millis, S.R., Greene, H.A., Incremental validity of neuropsychological evaluations to computed tomography in predicting long-term outcomes after traumatic brain injury (2013) The Clinical Neuropsychologist, 27, pp. 356-375; Wilkinson, G.S., (1993) WRAT-3: The Wide Range Achievement Test Administration Manual, , (3rd ed.).Wilmington, DE: Wide Range; Wilkinson, G.S., Robertson, G.J., (2006) Wide Range Achievment Test-4 (WRAT-4), , Lutz, FL: Psychological Assessment Resources, Inc; Wolfe, P.L., Millis, S.R., Hanks, R., Fichtenberg, N., Larrabee, G.J., Sweet, J.J., Effort indicators within the California Verbal Learning Test-II (CVLT-II) (2010) The Clinical Neuropsychologist, 24, pp. 153-168; Wygant, D.B., Sellbom, M., Ben-Porath, Y.S., Stafford, K.P., Freeman, D.B., Heilbronner, R.H., The relation between symptom validity testing and MMPI-2 scores as a function of forensic evaluation context (2007) Archives of Clinical Neuropsychology, 22, pp. 489-499; Zakzanis, K.K., Leach, L., Kaplan, E.F., (1999) Neuropsychological Differential Diagnosis, , New York, NY: Taylor & Francis",Article,Scopus,2-s2.0-84911393601
"Diniz B.S., Teixeira A.L., Machado-Vieira R., Talib L.L., Radanovic M., Gattaz W.F., Forlenza O.V.","Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression",2014,"Journals of Gerontology - Series B Psychological Sciences and Social Sciences","69","6",,"845","851",,1,10.1093/geronb/gbu096,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911446832&partnerID=40&md5=620165a5b7bfbbc82130cb7c90c4feb0","Department of Mental Health, Faculty of Medicine, Federal University of Minas Gerais School, Av. Alfredo Balena, 190Belo Horizonte, Minas Gerais, Brazil; Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil; National Institute of Science and Technology - Molecular Medicine (INCT-MM), Brazil; Department of Internal Medicine, Faculty of Medicine, Federal University of Minas GeraisBelo Horizonte, Brazil; National Institute of Mental Health (NIMH), National Institutes of HealthBethesda, MD, United States","Diniz, B.S., Department of Mental Health, Faculty of Medicine, Federal University of Minas Gerais School, Av. Alfredo Balena, 190Belo Horizonte, Minas Gerais, Brazil, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil, National Institute of Science and Technology - Molecular Medicine (INCT-MM), Brazil; Teixeira, A.L., Department of Internal Medicine, Faculty of Medicine, Federal University of Minas GeraisBelo Horizonte, Brazil; Machado-Vieira, R., Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil, National Institute of Mental Health (NIMH), National Institutes of HealthBethesda, MD, United States; Talib, L.L., Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil; Radanovic, M., Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil; Gattaz, W.F., Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil; Forlenza, O.V., Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil","Objectives. Late-life depression (LLD) is associated with reduced neurotrophic support and abnormalities in neurodegenerative cascades. The aim of the present study is to determine the concentrations of brain-derived neurotrophic factor (BDNF), amyloid-β42, total Tau, and phosphorylated Tau in the cerebrospinal fluid (CSF) of patients with LLD and cognitive impairment compared to healthy older adults.Method. We included 25 antidepressant-free patients with LLD (10 with mild cognitive impairment [LLD + MCI] and 15 with no cognitive decline [LLD + NCD]) and 25 healthy older adults as a comparison group. Depressive symptoms were assessed by the 21-item Hamilton Depression Rating Scale (HDRS-21) and cognitive performance by a comprehensive cognitive battery.Results. Patients with LLD + MCI showed significantly lower CSF BDNF levels compared to LLD + NCD and healthy controls (p =. 003). There were no significant differences in Alzheimer's disease-related CSF biomarkers between groups. CSF BDNF concentrations were positively correlated with Cambridge Cognitive Test (CAMCOG) scores (r =. 36, p =. 02).Discussion. The present study adds to the growing body of evidence that abnormalities in the BDNF system are involved in the pathophysiology of LLD. The reduction of the availability of BDNF in the central nervous system may indicate increased vulnerability to the development of several age-related neuropsychiatric disorders as well as to adverse cognitive outcomes. © The Author 2014. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.","Alzheimers disease; Amyloid-42; BDNF; Cerebrospinal fluid; Cognition; Late-life depression","Brunoni, A.R., Lopes, M., Fregni, F., A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression (2008) International Journal of Neuropsychopharmacology, 11, pp. 1169-1180; Butters, M.A., Klunk, W.E., Mathis, C.A., Price, J.C., Ziolko, S.K., Hoge, J.A., Meltzer, C.C., Imaging Alzheimer pathology in latelife depression with PET and Pittsburgh Compound-b (2008) Alzheimer Disease and Associated Disorders, 22, pp. 261-268; Butters, M.A., Whyte, E.M., Nebes, R.D., Begley, A.E., Dew, M.A., Mulsant, B.H., Becker, J.T., The nature and determinants of neuropsychological functioning in late-life depression (2004) Archives of General Psychiatry, 61, pp. 587-587; American Psychiatric Association, (2000) Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV), , Washington, DC American Psychiatric Association; Diniz, B.S., Butters, M.A., Albert, S.M., Dew, M.A., Reynolds, C.F., III, Late-life depression and risk of vascular dementia and Alzheimers disease: Systematic review and meta-analysis of community-based cohort studies (2013) British Journal of Psychiatry, 202, pp. 329-329; Diniz, B.S., Reynolds, C.F., Begley, A., Dew, M.A., Anderson, S.J., Lotrich, F., Butters, M.A., Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study (2014) Journal of Psychiatric Research, 49, pp. 96-96; Diniz, B.S., Talib, L.L., Joaquim, H.P., De Paula, V.R., Gattaz, W.F., Forlenza, O.V., Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment? (2011) World Journal of Biological Psychiatry, 12, pp. 216-216; Diniz, B.S., Teixeira, A.L., Machado-Vieira, R., Talib, L.L., Gattaz, W.F., Forlenza, O.V., Reduced serum nerve growth factor in patients with late-life depression (2013) The American Journal of Geriatric Psychiatry, 21, pp. 493-493; Diniz, B.S., Teixeira, A.L., Miranda, A.S., Talib, L.L., Gattaz, W.F., Forlenza, O.V., Circulating Glial-derived neurotrophic factor is reduced in late-life depression (2012) Journal of Psychiatric Research, 46, pp. 135-135; Diniz, B.S., Teixeira, A.L., Talib, L.L., Mendona, V.A., Gattaz, W.F., Forlenza, O.V., Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression (2010) Journal of Psychiatric Research, 44, pp. 917-917; Diniz, B.S., Teixeira, A.L., Talib, L.L., Mendona, V.A., Gattaz, W.F., Forlenza, O.V., Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression (2010) The World Journal of Biological Psychiatry, 11, pp. 550-550; Fernandes, B.S., Gama, C.S., Ceresér, K.M., Yatham, L.N., Fries, G.R., Colpo, G., Kapczinski, F., Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis (2011) Journal of Psychiatric Research, 45, pp. 995-1004; First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., (2002) Structured Clinical Interview for DSM-IV-TR Axis i Disorders, Research Version, , Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-189; Forlenza, O.V., Diniz, B.S., Talib, L.L., Radanovic, M., Yassuda, M.S., Ojopi, E.B., Gattaz, W.F., Clinical and biological predictors of Alzheimers disease in patients with amnestic mild cognitive impairment (2010) Revista Brasileira de Psiquiatria (São Paulo, Brazil: 1999), 32, pp. 216-216; Forlenza, O.V., Diniz, B.S., Teixeira, A.L., Ojopi, E.B., Talib, L.L., Mendona, V.A., Gattaz, W.F., Effect of brainderived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment (2010) World Journal of Biological Psychiatry, 11, pp. 774-774; Gudmundsson, P., Skoog, I., Waern, M., Blennow, K., Plsson, S., Rosengren, L., Gustafson, D., The relationship between cerebrospinal fluid biomarkers and depression in elderly women (2007) The American Journal of Geriatric Psychiatry, 15, pp. 832-832; Hamilton, M., A rating scale for depression (1960) Journal of Neurology Neurosurgery and Psychiatry, 23, pp. 56-56; Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimers disease in patients with mild cognitive impairment: A follow-up study (2006) Lancet Neurology, 5, pp. 228-228; Kumar, A., Kepe, V., Barrio, J.R., Siddarth, P., Manoukian, V., Elderkin- Thompson, V., Small, G.W., Protein binding in patients with late-life depression (2011) Archives of General Psychiatry, 68, pp. 1143-1143; McKinney, B.C., Sibille, E., The age-by-disease interaction hypothesis of late-life depression (2013) American Journal of Geriatric Psychiatry, 21, pp. 418-418; Modrego, P.J., Ferrndez, J., Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: A prospective cohort study (2004) Archives of Neurology, 61, pp. 1290-1290; Naismith, S.L., Norrie, L.M., Mowszowski, L., Hickie, I.B., The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological features (2012) Progress in Neurobiology, 98, pp. 99-143; Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L., Dekosky, S.T., Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) (2001) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56, pp. 1133-1133; Pomara, N., Bruno, D., Sarreal, A.S., Hernando, R.T., Nierenberg, J., Petkova, E., Blennow, K., Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder (2012) American Journal of Psychiatry, 169, pp. 523-523; Reiber, H., Dynamics of brain-derived proteins in cerebrospinal fluid (2001) Clinica Chimica Acta, 310, pp. 173-173; Reis, T., Brandão, C.O., Freire Coutinho, E.S., Engelhardt, E., Laks, J., Cerebrospinal fluid biomarkers in Alzheimers disease and geriatric depression: Preliminary findings from Brazil (2012) CNS Neuroscience and Therapeutics, 18, pp. 524-524; Roth, M., Tym, E., Mountjoy, C.Q., Huppert, F.A., Hendrie, H., Verma, S., Goddard, R., CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia (1986) The British Journal of Psychiatry, 149, pp. 698-698; Sibille, E., Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders (2013) Dialogues in Clinical Neurosciences, 15, pp. 53-53; Tsopelas, C., Stewart, R., Savva, G.M., Brayne, C., Ince, P., Thomas, A., Matthews, F.E., Neuropathological correlates of late-life depression in older people (2011) The British Journal of Psychiatry, 198, pp. 109-109. , Medical Research Council Cognitive Function and Ageing Study",Article,Scopus,2-s2.0-84911446832
"Bertola L., Mota N.B., Copelli M., Rivero T., Diniz B.S., Ribeiro M.A.R., Ribeiro S., Malloy-Diniz L.F.","Graph analysis of verbal fluency test discriminate between patients with Alzheimer's disease, Mild Cognitive Impairment and normal elderly controls",2014,"Frontiers in Aging Neuroscience","6","JUL", 185,"","",,,10.3389/fnagi.2014.00185,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84904619570&partnerID=40&md5=8b696711ac034708d211ce160d272aac","Laboratory of Clinical Neuroscience Investigations (LINC), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil; Physics Department, Federal University of Pernambuco, Recife, Pernambuco, Brazil; Mental Health Department, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; National Institute of Science and Technology- Molecular Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil","Bertola, L., Laboratory of Clinical Neuroscience Investigations (LINC), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Mota, N.B., Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil; Copelli, M., Physics Department, Federal University of Pernambuco, Recife, Pernambuco, Brazil; Rivero, T., Laboratory of Clinical Neuroscience Investigations (LINC), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Diniz, B.S., Laboratory of Clinical Neuroscience Investigations (LINC), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, Mental Health Department, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Ribeiro, M.A.R., Mental Health Department, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, National Institute of Science and Technology- Molecular Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Ribeiro, S., Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil; Malloy-Diniz, L.F., Laboratory of Clinical Neuroscience Investigations (LINC), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, Mental Health Department, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil","Verbal fluency is the ability to produce a satisfying sequence of spoken words during a given time interval. The core of verbal fluency lies in the capacity to manage the executive aspects of language. The standard scores of the semantic verbal fluency test are broadly used in the neuropsychological assessment of the elderly, and different analytical methods are likely to extract even more information from the data generated in this test. Graph theory, a mathematical approach to analyze relations between items, represents a promising tool to understand a variety of neuropsychological states. This study reports a graph analysis of data generated by the semantic verbal fluency test by cognitively healthy elderly (NC), patients with Mild Cognitive Impairment - subtypes amnestic (aMCI) and amnestic multiple domain (a+mdMCI) - and patients with Alzheimer's disease (AD). Sequences of words were represented as a speech graph in which every word corresponded to a node and temporal links between words were represented by directed edges. To characterize the structure of the data we calculated 13 speech graph attributes (SGAs). The individuals were compared when divided in three (NC - MCI - AD) and four (NC - aMCI - a+mdMCI - AD) groups. When the three groups were compared, significant differences were found in the standard measure of correct words produced, and three SGA: diameter, average shortest path, and network density. SGA sorted the elderly groups with good specificity and sensitivity. When the four groups were compared, the groups differed significantly in network density, except between the two MCI subtypes and NC and aMCI. The diameter of the network and the average shortest path were significantly different between the NC and AD, and between aMCI and AD. SGA sorted the elderly in their groups with good specificity and sensitivity, performing better than the standard score of the task. These findings provide support for a new methodological frame to assess the strength of semantic memory through the verbal fluency task, with potential to amplify the predictive power of this test. Graph analysis is likely to become clinically relevant in neurology and psychiatry, and may be particularly useful for the differential diagnosis of the elderly. © 2014 Bertola, Mota, Copelli, Rivero, Diniz, Romano-silva, Ribeiro and Malloy-diniz.","Alzheimeŕs disease; Elderly; Graph analysis; Mild cognitive impairment; Semantic verbal fluency","Adlam, A.-L., Bozeat, S., Arnold, R., Watson, P., Hodges, J.R., Semantic knowledge in mild cognitive impairment and mild Alzheimer's disease (2006) Cortex, 42, pp. 675-684. , doi: 10.1016/sOO 10-9452(08)70404-0; Amieva, H., Jacqmin-Gadda, H., Orgogozo, J.-M., Le Carret, N., Helmer, C., Dartigues, J.-F., The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study (2005) Brain, 128 (5), pp. 1093-1101. , doi:10.1093/brain/awh451; Aretouli, E., Okonkwo, C.O., Samek, J., Brandt, J., The fate of the 0.5s: predictors of 2-year outcome in mild cognitive impairment (2011) Journal of International Neuropsychology Society, 17 (2), pp. 277-288. , doi:10.1017/sl355617710001621; Bales, M.E., Johnson, S.B., Graph theoretic modeling of large-scale semantic networks (2006) Journal of BiomedicalInformatics, 39, pp. 451-464. , doi: 10.1016/j jbi.2005.10.007; Brucki, S.M.D., Malheiros, S.M.F., Okamoto, I.H., Bertolucci, P.H.F., Dados normativos para o teste de fluencia verbal categoria animais em nosso rneio (1997) Arquivos de Neuropsiquiatria, 55 (1), pp. 56-61; Butts, C.T., Revisiting the Foundations of Network Analysis (2009) Science, 325 (5939), pp. 414-416. , doi: 10.1126/science. 1171022; Craik, F.I.M., Bialystok, E., Cognition through the lifespan: mechanisms of change (2006) Trends in Cognitive Sciences, 10 (3), pp. 131-138. , doi:10.1016/j.tics.2006.01.007; De Deyne, S., Storms, G., Word Associations: networ and semantic properties (2008) Behavior Research Methods, 40 (1), pp. 213-231. , doi: 10.3758/BRM. 40.1213; de Paula, J.J., Bertola, L., Avila, R.T., Moreira, L., Coutinho, G., Moraes, E.N., Malloy-Diniz, L.F., Clinical Applicability and Cutoff Values for an Unstructured Neuropsychological Assessment Protocol for Older Adults With Low Formal Education (2013) Plos One, 8, pp. E73167. , doi: 10.1371/journal.pone.007316; Diniz, B.S.O., Yassuda, M.S., Nunes, P.V., Radanovic, M., Forlenza, O.V., Minimental State Examination performance in mild cognitive impairment subtypes (2007) International Psychogeriatrics, 19 (4), pp. 647-656. , doi: 10.1590/S1516-44462008000400003; Garrard, P., Lambon Ralph, M.A., Patterson, K., Pratt, K.H., Hodges, J.R., Semantic feature knowledge and picture naming in dementia of Alzheimer's type: a new approach (2005) Brain and Language, 93, pp. 79-94. , doi:10.1016/j.bandl.2004.08.003; Griffiths, T.L., Steyvers, M., Tenenbaum, J.B., Topics in semantic representation (2007) Psychological Review, 114 (2), pp. 211-244. , doi: 10.1037/0033-295X. 114.2.211; Goni, J., Arrondo, G., Sepulcre, J., Martincorena, I., Mendizabal, N.V., Corominas-Murtra, B., Bejarano, B., Villoslada, P., The semantic organization of the animal category: evidence from semantic verbal fluency and network theory (2010) Cognitive Processing, , doi: 10.1007/s 103 3 9-010-03 72-x; Henry, J.D., Crawford, J.R., Phillips, L.H., Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis (2004) Neuropsychologia, 42, pp. 1212-1222. , doi: 10.1016/j.neuropsychologia.2004.02.001; Hodges, J.R., Erzinclioglu, S., Patterson, K., Evolution of Cognitive Defi cits and Conversion to Dementia in Patients with Mild Cognitive Impairment: A Very-Long-Term Follow-Up Study (2006) Dementia and Geriatric Cognitive Disorders, 21, pp. 380-391. , doi: 10.1159/000092534; Holler, Y., Trinka, E., What do temporal lobe epilepsy and progressive mild cognitive impairment have in common? (2014) Frontiers in System Neuroscience, p. 8. , doi:10.3389/fnsys.2014.00058; Huntley, J.D., Howard, R.J., Working memory in early Alzheimer's disease: a neuropsychological review (2010) International Journal of Geriatric Psychiatry, 25, pp. 121-132. , doi: 10.1002/gps.2314; Kotsiantis, S.B., (2007) Supervised machine learning: a review of classification techniques, pp. 3-24. , Emerging artificial intelligence applications in computer engineering: real word AI systems with applications IOS Press; Lezak, M., Howieson, D.B., Loring, D.W., (2004) Neuropsychological Assessment, , Oxford University Press, New York, 4th ed; Lerner, A.J., Ogrocki, P.K., Thomas, P.T., Network Graph Analysis of Category Fluency Testing (2009) Cognitive Behavioral Neurology, 22, pp. 45-52. , doi:10.1097/wnn.0b013e318192ccaf; McClelland, J.L., Rogers, T.T., The parallel distributed processing approach to semantic cognition (2003) Nature Review Neuroscience, 4, pp. 310-323. , doi: 10.1038/nrnl076; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's (1984) Neurology, 34, pp. 939-944. , doi: 10.1212/WNL.34.7.939; Mota, N.B., Vasconcelos, N.A.P., Lemos, N., Pieretti, A.C., Kinouchi, O., Cecchi, G.A., Ribeiro, S., Speech graphs provide a quantitative measure of thought disorder in psychosis (2012) Plos One, 7 (4), pp. 1-9. , doi:10.1371/journal.pone.0034928; Mota, M.B., Furtado, R., Maia, P.P.C., Copelli, M., Ribeiro, S., Graph analysis of dream reports is especially informative about psychosis (2014) Scientific Reports, 4, p. 3691. , doi: 10.1038/srep03691; Nickles, L., (2001) Spoken Word Production, , Rapp, B. (Ed.) What Deficits Reveal about the Human Mind/Brain: A Handbook of Cognitive Neuropsychology. Philadelphia: Psychology Press; Nutter-Upham, K.E., Saykin, A., Rabin, L.A., Roth, R.M., Wishart, H.A., Pare, N., Flashman, L.A., Verbal fluency performance in amnestic MCI and older adults with cognitive complaints (2008) Achieves in Clinical Neuropsychology, 1 (3), pp. 229-241. , doi: 10.10170S1355617706060590; Patterson, K., Nestor, P.J., Rogers, T.T., Where do you know what you know? The representation of semantic knowledge in the human brain (2007) Nature Reviews Neuroscience, 8, pp. 976-988. , doi:10.1038/nrn2277; Radanovic, M., Diniz, B.S., Mirandez, R.M., Novaretti, T.M.S., Flacks, M.K., Yassuda, M.S., Forlenza, O.V., Verbal fluency in the detection of mild cognitive impairment and Alzheimer's disease among Brazilian Portuguese speakers: the influence of education (2009) International Psychogeriatrics, pp. 1-7. , doi: 10.1017/S104161020999063 9; Salmon, D.P., Thomas, R.G., Pay, M.M., Booth, A., Hofstetter, C.R., Thai, L.J., Katzman, R., Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals (2002) Neurology, 59, pp. 1022-1028. , doi: 10.1212/wnl.59.7.1022; Saxton, J., Lopez, O.L., Ratcliff, G., Dulberg, C., Fried, L.P., Carlson, M.C., Kuller, L., Preclinical Alzheimer disease: Neuropsychological test performance 1 5 to 8 years prior to onset (2004) Neurology, 63, pp. 2341-2347. , doi: 10.1017/S1041610208007631; Singh, M., Provan, G.M., (1995) A comparison of induction algorithms for selective and nonselective Bayesian classifiers, pp. 497-505. , Proc. 12th International Conference on Machine Learning; Strauss, E., Sherman, E.M.S., Spreen, O., (2006) A Compendium of Neuropsychological Tests: Administration, , Norms, and Commentary. United Kigdom: Oxford University Press; Taler, V., Phillips, N.A., Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review (2008) Journal of Clinical and Experimental Neuropsychology, 30 (5), pp. 501-556. , doi: 10.1080/13803390701550128; Unsworth, N., Spillers, G.J., Brewer, G.A., Variation in verbal fluency: A latent variable analysis of clustering, switching, and overall performance (2011) The Quarterly Journal of Experimental Psychology, 64 (3), pp. 447-466. , doi: 10.1080/17470218.2010.505292; Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., Petersen, R.C., Mild Cognitive Impairment - beyond controversies, towards a consensus: reports of the international working group on Mild Cognitive Impairment (2004) Journal of International Medicine, 256, pp. 240-246. , doi: 10.1111/j.l365-2796.2004.01380.x",Article,Scopus,2-s2.0-84904619570
"Wei H.-J., Xu J.-H., Li M.-H., Tang J.-P., Zou W., Zhang P., Wang L., Wang C.-Y., Tang X.-Q.","Hydrogen sulfide inhibits homocysteine-induced endoplasmic reticulum stress and neuronal apoptosis in rat hippocampus via upregulation of the BDNF-TrkB pathway",2014,"Acta Pharmacologica Sinica","35","6",,"707","715",,3,10.1038/aps.2013.197,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84902244912&partnerID=40&md5=a764a6ba6fae28724f4aff7768a13fef","Institute of Neuroscience, Medical College, University of South China, Hengyang 421001, China; Laboratory Center of Biochemistry and Molecular Biology, University of South China, Hengyang 421001, China; Department of Neurology, Nanhua Affiliated Hospital, University of South China, Hengyang 421001, China; Department of Anthropotomy, Medical College, University of South China, Hengyang 421001, China; Department of Pathophysiology, Medical College, University of South China, Hengyang 421001, China","Wei, H.-J., Institute of Neuroscience, Medical College, University of South China, Hengyang 421001, China; Xu, J.-H., Laboratory Center of Biochemistry and Molecular Biology, University of South China, Hengyang 421001, China; Li, M.-H., Institute of Neuroscience, Medical College, University of South China, Hengyang 421001, China, Department of Neurology, Nanhua Affiliated Hospital, University of South China, Hengyang 421001, China; Tang, J.-P., Institute of Neuroscience, Medical College, University of South China, Hengyang 421001, China, Department of Neurology, Nanhua Affiliated Hospital, University of South China, Hengyang 421001, China; Zou, W., Department of Neurology, Nanhua Affiliated Hospital, University of South China, Hengyang 421001, China; Zhang, P., Department of Neurology, Nanhua Affiliated Hospital, University of South China, Hengyang 421001, China; Wang, L., Department of Anthropotomy, Medical College, University of South China, Hengyang 421001, China; Wang, C.-Y., Department of Pathophysiology, Medical College, University of South China, Hengyang 421001, China; Tang, X.-Q., Institute of Neuroscience, Medical College, University of South China, Hengyang 421001, China","Aim:Homocysteine (Hcy) can elicit neuronal cell death, and hyperhomocysteinemia is a strong independent risk factor for Alzheimer's disease. The aim of this study was to examine the effects of hydrogen sulfide (H 2 S) on Hcy-induced endoplasmic reticulum (ER) stress and neuronal apoptosis in rat hippocampus.Methods:Adult male SD rats were intracerebroventricularly (icv) injected with Hcy (0.6 μmol/d) for 7 d. Before Hcy injection, the rats were treated with NaHS (30 or 100 μmol·kg -1 ·d -1, ip) and/or k252a (1 μg/d, icv) for 2 d. The apoptotic neurons were detected in hippocampal coronal slices with TUNEL staining. The expression of glucose regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), cleaved caspase-12, and BDNF in the hippocampus were examined using Western blotting assays. The generation of H 2 S in the hippocampus was measured with the NNDPD method.Results:Hcy markedly inhibited the production of endogenous H 2 S and increased apoptotic neurons in the hippocampus. Furthermore, Hcy induced ER stress responses in the hippocampus, as indicated by the upregulation of GRP78, CHOP, and cleaved caspase-12. Treatment with the H 2 S donor NaHS increased the endogenous H 2 S production and BDNF expression in a dose-dependent manner, and significantly reduced Hcy-induced neuronal apoptosis and ER stress responses in the hippocampus. Treatment with k252a, a specific inhibitor of TrkB (the receptor of BDNF), abolished the protective effects of NaHS against Hcy-induced ER stress in the hippocampus.Conclusion:H 2 S attenuates ER stress and neuronal apoptosis in the hippocampus of Hcy-treated rats via upregulating the BDNF-TrkB pathway. © 2014 CPS and SIMM All rights reserved.","Alzheimers disease; apoptosis; BDNF; ER stress; hippocampus; homocysteine; Hydrogen sulfide; neurotoxicity; tyrosine protein kinase B","Prudova, A., Bauman, Z., Braun, A., Vitvitsky, V., Lu, S.C., Banerjee, R., S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity (2006) Proc Natl Acad Sci USA, 103, pp. 6489-6494; Selhub, J., Homocysteine metabolism (1999) Annu Rev Nutr, 19, pp. 217-246; Kim, J.H., Cho, S.Y., Lee, J.H., Jeong, S.M., Yoon, I.S., Lee, B.H., Neuroprotective effects of ginsenoside Rg3 agai nst homocysteine-induced excitotoxicity in rat hippocampus (2007) Brain Res, 1136, pp. 190-199; Loureiro, S.O., Heimfarth, L., Pelaez Pde, L., Vanzin, C.S., Viana, L., Wyse, A.T., Homocysteine act ivates calcium-mediated cell signaling mechanisms targeting the cytoskeleton in rat hippocampus (2008) Int J Dev Neurosci, 26, pp. 447-455; Ho, Y.S., Yu, M.S., Yang, X.F., So, K.F., Yuen, W.H., Chang, R.C., Ne uroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons (2010) J Alzheimers Dis, 19, pp. 813-827; Oldreive, C.E., Doherty, G.H., Neurotoxic effects of homocysteine on cerebellar Purkinje neurons in vitro (2007) Neurosci Lett, 413, pp. 52-57; Kuszczyk, M., Gordon-Krajcer, W., Lazarewicz, J.W., Homocysteine-induced acute excitotoxicity in cerebellar granule cells in vitro is accompanied by PP2A-mediated dephosphorylation of tau (2009) Neurochem Int, 55, pp. 174-180; Kim, H.J., Cho, H.K., Kwon, Y.H., Synergistic induction of ER stress by homocysteine and beta-amyloid in SH-SY5Y cells (2008) J Nutr Biochem, 19, pp. 754-761; Park, Y.J., Jang, Y., Kwon, Y.H., Protective effect of isoflavones against homocysteine-mediated neuronal degeneration in SH-SY5Y cells (2010) Amino Acids, 39, pp. 785-794; Van Dam, F., Van Gool, W.A., Hyperhomocysteinemia and Alzheimer's disease: A systematic review (2009) Arch Gerontol Geriatr, 48, pp. 425-430; Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., Dagostino, R.B., Plasma homocys teine as a risk factor for dementia and Alzheimer's disease (2002) N Engl J Med, 346, pp. 476-483; Miller, J.W., Homocysteine and Alzheimer's disease (1999) Nutr Rev, 57, pp. 126-129; Clarke, R., Smith, A.D., Jobst, K.A., Refsum, H., Sutton, L., Ueland, P.M., Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease (1998) Arch Neurol, 55, pp. 1449-1455; Dwyer, B.E., Raina, A.K., Perry, G., Smith, M.A., Homocysteine and Alzheimer's disease: A modifiable risk (2004) Free Radic Biol Med, 36, pp. 1471-1475; Hoozemans, J.J., Veerhuis, R., Van Haastert, E.S., Rozemuller, J.M., Baas, F., Eikelenboom, P., The unfolded protein response is activated in Alzheimer's disease (2005) Acta Neuropathol, 110, pp. 165-172; Salminen, A., Kauppinen, A., Suuronen, T., Kaarnir Anta, K., Ojala, J., ER stress in Alzheimer's disease: A novel neuronal trigger for inflammation and Alzheimer's pathology (2009) J Neuroinflammation, 6, p. 41; Cornejo, V.H., Hetz, C., The unfolded protein response in Alzheimer's disease (2013) Semin Immunopathol, 35, pp. 277-292; Pizzo, P., Pozzan, T., Mitochondria-endoplasmic reticulum choreography: Structure and signaling dynamics (2007) Trends Cell Biol, 17, pp. 511-517; Kim, I., Xu, W., Reed, J.C., Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities (2008) Nat Rev Drug Discov, 7, pp. 1013-1030; Schroder, M., Kaufman, R.J., ER stress and the unfolded protein response (2005) Mutat Res, 569, pp. 29-63; Wei, H., Zhang, R., Jin, H., Liu, D., Tang, X., Tang, C., Hydrogen sulfide attenuates hyperhomocysteinemia-induced cardiomyocytic endoplasmic reticulum stress in rats (2010) Antioxid Redox Signal, 12, pp. 1079-1091; Outinen, P.A., Sood, S.K., Pfeifer, S.I., Pamidi, S., Podor, T.J., Li, J., Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in h uman vascular endothelial cells (1999) Blood, 94, pp. 959-967; Chigurupati, S., Wei, Z., Belal, C., Vandermey, M., Kyriazis, G.A., Arumugam, T.V., The homocysteine-inducible endoplasmic reticul um stress protein counteracts calcium store depletion and induction of CCAAT enhancer-binding protein homologous protein in a neurotoxin model of Parkinson disease (2009) J Biol Chem, 284, pp. 18323-18333; Zhang, C., Cai, Y., Adachi, M.T., Oshiro, S., Aso, T., Kaufman, R.J., Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response (2001) J Biol Chem, 276, pp. 35867-35874; Yu, X., Lv, J., Zhu, Y., Duan, L., Ma, L., Homocysteine inhibits hepatocyte proliferation via endoplasmic reticulum stress (2013) PLoS One, 8, pp. e54265; Kimura, H., Hydrogen sulfide as a neuromodulator (2002) Mol Neurobiol, 26, pp. 13-19; Kimura, H., Shibuya, N., Kimura, Y., Hydrogen sulfide is a signaling molecule and a cytoprotectant (2012) Antioxid Redox Signal, 17, pp. 45-57; Hu, L.F., Lu, M., Hon Wong, P.T., Bian, J.S., Hydrogen sulfide: Neurophysiology and neuropathology (2011) Antioxid Redox Signal, 15, pp. 405-419; Zhou, C.F., Tang, X.Q., Hydrogen sulfide and nervous system regulation (2011) Chin Med J (Engl), 124, pp. 3576-3582; Tang, X.Q., Shen, X.T., Huang, Y.E., Chen, R.Q., Ren, Y.K., Fang, H.R., Inhibitio n of endogenous hydrogen sulfide generation is associated with homocysteine-induced neurotoxicity: Role of ERK1/2 activation (2011) J Mol Neurosci, 45, pp. 60-67; Tang, X.Q., Shen, X.T., Huang, Y.E., Ren, Y.K., Chen, R.Q., Hu, B., Hydrogen sulfide antagonizes homocysteine-induced neurotoxicity in PC12 cells (2010) Neurosci Res, 68, pp. 241-249; Chen, Z.F., Zhao, B., Tang, X.Y., Li, W., Zhu, L.L., Tang, C.S., Hydrogen sulfide regulates vascular endoplasmic reticulum stress in apolipoprotein e knockout mice (2011) Chin Med J (Engl), 124, pp. 3460-3467; Wang, X.Y., Yang, C.T., Zheng, D.D., Mo, L.Q., Lan, A.P., Yang, Z.L., Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress (2012) Mol Cell Biochem, 363, pp. 419-426; Xie, L., Tiong, C.X., Bian, J.S., Hydrogen sulfide protects SH-SY5Y cells against 6-hydroxydopamine-induced endoplasmic reticulum stress (2012) Am J Physiol Cell Physiol, 303, pp. C81-91; Chen, G., Fan, Z., Wang, X., Ma, C., Bower, K.A., Shi, X., Brain-derived neurotrophic factor suppresses tunicamycin-induced upregulation of CHOP in neurons (2007) J Neurosci Res, 85, pp. 1674-1684; Shimoke, K., Utsumi, T., Kishi, S., Nishimura, M., Sasaya, H., Kudo, M., Prevention of endoplasmic reticulum stress-induced cell death by brain-derived neurotrophic factor in cultured cerebral cortical neurons (2004) Brain Res, 1028, pp. 105-111; Zhu, W., Bijur, G.N., Styles, N.A., Li, X., Regulation of FOXO3a by brainderived neurotrophic f actor in differentiated human SH-SY5Y neuroblastoma cells (2004) Brain Res Mol Brain Res, 126, pp. 45-56; Li, Y., Zhang, H., Jiang, C., Xu, M., Pang, Y., Feng, J., Hyperhomocysteinemia promo tes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue (2013) J Biol Chem, 288, pp. 9583-9592; Park, S.J., Kim, K.J., Kim, W.U., Oh, I.H., Cho, C.S., Involvement of endoplasmic retic ulum stress in homocysteine-induced apoptosis of osteoblastic cells (2012) J Bone Miner Metab, 30, pp. 474-484; Zbidi, H., Redondo, P.C., Lopez, J.J., Bartegi, A., Salido, G.M., Rosado, J.A., Homocysteine induces caspase activation by endoplasmic reticulum stress in platelets from type 2 diabetics and healthy donors (2010) Thromb Haemost, 103, pp. 1022-1032; Werstuck, G.H., Lentz, S.R., Dayal, S., Hossain, G.S., Sood, S.K., Shi, Y.Y., Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways (2001) J Clin Invest, 107, pp. 1263-1273; Stipanu, K.M.H., Sulfur amino acid metabolism: Pathways for production and removal of homocysteine and cysteine (2004) Annu Rev Nutr, 24, pp. 539-577; White, A.R., Huang, X., Jobling, M.F., Barrow, C.J., Beyreuther, K., Masters, C.L., Homocysteine potentiates copper-and amyloid beta peptidemediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer's-type neurodegenerative pathways (2001) J Neurochem, 76, pp. 1509-1520; Ho, P.I., Collins, S.C., Dhitavat, S., Ortiz, D., Ashline, D., Rogers, E., Homocysteine potentiates beta-amyloid neurotoxicity: Role of oxidative stress (2001) J Neurochem, 78, pp. 249-253; Kimura, Y., Kimura, H., Hydrogen sulfide protects neurons from oxidative stress (2004) FASEB J, 18, pp. 1165-1167; Tang, X.Q., Yang, C.T., Chen, J., Yin, W.L., Tian, S.W., Hu, B., Effect of hydrogen sulphide on beta-amyloid-induced damage in PC12 cells (2008) Clin Exp Pharmacol Physiol, 35, pp. 180-186; Whiteman, M., Armstrong, J.S., Chu, S.H., Jia-Ling, S., Wong, B.S., Cheung, N.S., The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite scavenger (2004) J Neurochem, 90, pp. 765-768; Whiteman, M., Cheung, N.S., Zhu, Y.Z., Chu, S.H., Siau, J.L., Wong, B.S., Hydrogen sulphide: A novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain (2005) Biochem Biophys Res Commun, 326, pp. 794-798; Eto, K., Asada, T., Arima, K., Makifuchi, T., Kimura, H., Brain hydrogen sulfide is severely decreased in Alzheimer's disease (2002) Biochem Biophys Res Commun, 293, pp. 1485-1488; Tang, X.Q., Ren, Y.K., Zhou, C.F., Yang, C.T., Gu, H.F., He, J.Q., Hydrogen sulfide prevents formaldehyde-induced neurotoxicity to PC12 cells by attenuation of mitochondrial dysfunction and pro-apoptotic potential (2012) Neurochem Int, 61, pp. 16-24; Hu, L.F., Lu, M., Wu, Z.Y., Wong, P.T., Bian, J.S., Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function (2009) Mol Pharmacol, 75, pp. 27-34; Xu, C., Bailly-Maitre, B., Reed, J.C., Endoplasmic reticulum stress: Cell life and death decisions (2005) J Clin Invest, 115, pp. 2656-2664; Binder, D.K., Scharfman, H.E., Brain-d erived neurotrophic factor (2004) Growth Factors, 22, pp. 123-131; Huang, E.J., Reichardt, L.F., Neurotrophins: Roles in neuronal development and function (2001) Annu Rev Neurosci, 24, pp. 677-736; Zuccato, C., Cattaneo, E., Brain-derived neurotrophic factor in neurodegenerative diseases (2009) Nat Rev Neurol, 5, pp. 311-322; Pezet, S., Malcangio, M., Brain-derived neurotrophic factor as a drug target for CNS disorders (2004) Expert Opin Ther Targets, 8, pp. 391-399",Article,Scopus,2-s2.0-84902244912
"Yi Y., Wu S., Ye M., Zeng Y., Zhang P., Xie Y.","Effect of Aβ1-42 injection on hippocampus cells in rats and protective role of polygona-polysaccharose for Alzheimer's disease",2014,"Journal of Central South University (Medical Sciences)","39","4",,"344","348",,,10.11817/j.issn.1672-7347.2014.04.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901750233&partnerID=40&md5=5a5e85abb1cd0c50c07cbb885561f2d1","Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China","Yi, Y., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China; Wu, S., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China; Ye, M., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China; Zeng, Y., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China; Zhang, P., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China; Xie, Y., Department of Gerontology, Second Xiangya Hospital, Central South University, Changsha 410011, China","Objective: To determine the effect of polygona-polysaccharose (PP) on learning and memory ability in rats with Alzheimer's disease (AD). Methods: Forty five Sprague-Dawley rats were assigned into 3 groups. Rats in the sham-operated group were injected with normal saline. Rats in the group were injected with Apl-42. Rats in the PP group were injected with 16% PP solution for 45 days consecutively. The Morris water maze was used to investigate the ability of learning and memory in the rats. Ihe effect of and PP on the hippocampus cells was observed by HE and Congo red staining of methanol. Results: Rats in the sham-operated group had no obvious morphological change; and morphology of rats in the PP group was basicaly normal. The layer of pyramidal cells in the Ap group was decreased. The cells appeared sparse and irregular and became smaller. Karyopyknosis and vacuolar degeneration cells were also found. More positive staining materials aggradated in the Aβ group compared with the PP group by Congo red staining (P<0.05). Conclusion: Aβ infusion into the hippocampus results in the impairment of the neuronal degeneration in the rats, which shows similar characterizations of AD. PP can reduce the deposition of Ap in the hippocampus.","Alzheimers disease; Cognitive handicap; Polygona-polysaccharose; β-amyloid peptide","Feld, M., Krawczyk, M.C., Sol Fustifiana, M., Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease[J] (2014) J Alzheimers Dis, 40 (1), pp. 69-82; Nagarathinam, A., Hdflinger, P., Biihler, A., Membrane-anchored Ap accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice[J] (2013) J Neurosci, 33 (49), pp. 19284-19294; Liu, H., Chen, J., Tian, S., Intrahippocampal injection of β-amyloid 1-40 induces neurotoxicity in rats in vivo injury of hippocampal injection of amyloid beta protein on learning and memory and local neurons in rats[J] (2000) Chinese Journal of Neurology, 33 (3), pp. 150-152; Lee, S., Zemianek, J., Shea, T.B., Rapid, reversible impairment of synaptic signaling in cultured cortical neurons by exogenously-applied amyloidp[J] (2013) J Alzheimers Dis, 35 (2), pp. 395-402; Vecreshwarayya, V., Kumar, P., Rosen, K.M., Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular β-amyloid-induced inhibition of complex IV and limit apoptosis[J] (2006) J Biol Chem, 281 (40), pp. 29468-29478; Jia, J., Kang, L., Li, S., Amelioratory effects of testosterone treatment on cognitive performance deficits induced by soluble Aβ1-42 oligomers injected into the hippocampus [J] (2013) Horm Behav, 64 (3), pp. 477-486; Frozza, R.L., Bernardi, A., Hoppe, J.B., Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules[J] (2013) Mol Neurobiol, 47 (3), pp. 1066-1080; Zhong, S., Ma, S., Hong, Z., Antiinflammation effect of danggui shaoyao san on Alzheimer's diseases[J] (2011) China Jotimal of Chinese Materia Medica, 36 (22), pp. 3155-3160; Xue, C., Ren, H., Xue, R., Experimental study of polygonatum sibiricum polysaccharide induced antioxidation mice model for thermal medicine[J] (2006) Henan Journal of Traditional Chinese Medicine, 26 (3), pp. 24-26; Chen, J., Chen, S., Wang, X., Effect of polygonatum oral liquid on acute exercise mice of oxygen free radical metabolism and blood creatine kinase[J] (1996) Journal of Integrated Traditional Chinese and Western Medicine, (S1), pp. 258-259; Wang, H., Lin, Y., Qi, M., Effect of polygonatum multiflorum effective part of the uniform design combined anti-lipid peroxidation in hyperlipidemia rats[J] (2005) Chinese Journal of Traditional Chinese Medicine, 20 (8), pp. 502-504; Lei, Z., Yang, G., Ye, F., Overview of research and clinical application of polygonatum polysaccharide pharmacology [J] (2012) China Pharmacists, 15 (1), pp. 114-115",Article,Scopus,2-s2.0-84901750233
"Lardner A.L.","Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders",2014,"Nutritional Neuroscience","17","4",,"145","155",,1,10.1179/1476830513Y.0000000079,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901323138&partnerID=40&md5=adfc9afaf020b6b126ee53a24596dcf7","St Vincents University Hospital, Elm Park, Dublin 4, Ireland","Lardner, A.L., St Vincents University Hospital, Elm Park, Dublin 4, Ireland","Theanine (n-ethylglutamic acid), a non-proteinaceous amino acid component of green and black teas, has received growing attention in recent years due to its reported effects on the central nervous system. It readily crosses the blood-brain barrier where it exerts a variety of neurophysiological and pharmacological effects. Its most well-documented effect has been its apparent anxiolytic and calming effect due to its up-regulation of inhibitory neurotransmitters and possible modulation of serotonin and dopamine in selected areas. It has also recently been shown to increase levels of brain-derived neurotrophic factor. An increasing number of studies demonstrate a neuroprotective effects following cerebral infarct and injury, although the exact molecular mechanisms remain to be fully elucidated. Theanine also elicits improvements in cognitive function including learning and memory, in human and animal studies, possibly via a decrease in NMDA-dependent CA1 long-term potentiation (LTP) and increase in NMDA-independent CA1-LTP. Furthermore, theanine administration elicits selective changes in alpha brain wave activity with concomitant increases in selective attention during the execution of mental tasks. Emerging studies also demonstrate a promising role for theanine in augmentation therapy for schizophrenia, while animal models of depression report positive improvements following theanine administration. A handful of studies are beginning to examine a putative role in attention deficit hyperactivity disorder, and theoretical extrapolations to a therapeutic role for theanine in other psychiatric disorders such as anxiety disorders, panic disorder, obsessive compulsive disorder (OCD), and bipolar disorder are discussed. © W. S. Maney & Son Ltd 2014.","Alpha-wave; Alzheimers; Anti-Psychotic; Anxiety; Central nervous system; Depression; Neuroprotection; Selective attention; Theanine","Sakato, Y., The chemical constituents of tea:111. A new amide theanine (1949) Nippon Nogeikagaku Kaishi, 23, pp. 261-267; Kai-Yang, S., Chih-Li, L., Syu, K.Y., Lin, C.L., Hsiu-Chen, H., Lin, J.K., Determination of theanine, GABA, and other amino acids in green, oolong, black, and pu-erh teas with dabsylation and high-performance liquid chromatography (2008) J Agric Food Chem, 56, pp. 7637-7643; Unno, T., Suzuki, Y., Kakuda, T., Hayakawa, T., Tsuge, H., Metabolism of theanine, gamma-glutamylethylamide, in rats (1999) J Agric Food Chem, 47, pp. 1593-1596; Terashima, T., Takido, J., Yokogoshi, H., Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine (1999) Biosci Biotechnol Biochem, 63, pp. 615-618; Tsuge, H., Sano, S., Hayakawa, T., Kakuda, T., Unno, T., Theanine, gamma-glutamylethylamide, is metabolized by renal phosphate-independent glutaminase (2003) Biochim Biophys Acta, 1620, pp. 47-53; Yokogoshi, H., Mochizuki, M., Saitoh, K., Theanine-induced reduction of brain serotonin concentration in rats (1998) Biosc Biotechnol Biochem, 62, pp. 816-817; Kimura, R., Murata, T., Influence of alkylamides of glutamic acid and related compounds on the central nervous system. 1. Central depressant effect of theanine (1971) Chem Pharm Bull, 19, pp. 1257-1261; Yamada, T., Terashima, T., Okubo, T., Junega, L.R., Yokogoshi, R., Effects of theanine-glutamyl ethylamide, on neurotransmitter release and its relationship with glutamic acid neurotransmission (2005) Nutr Neurosci, 8, pp. 219-226; Yadid, G., Pacak, K., Golomb, E., Harvey-White, D.J., Lieberman, M.D., Kopin, J.I., Glycine stimulates striatal dopamine release in conscious rats (1993) Br J Pharmacol, 110, pp. 50-53; Kakuda, T., Abe, A., Ogura, M., Yoneda, Y., Theanine, an ingredient of green tea, inhibits [3H]glutamine transport in neurons and astroglia in rat brain (2008) J Neurosci Res, 86, pp. 1846-1856; Egashira, N., Hayakawa, K., Mishima, K., Iwasaki, K., Fijiwara, M., Neuroprotective effect of gamma-glutamylethylamide (theanine) on cerebral infarction in mice (2004) Neurosci Lett, 363, pp. 58-61; Yamada, T., Terashima, T., Wada, K., Ueda, S., Ito, M., Okubo, T., Theanine, γ-glutamylethylamide, increases neurotransmission concentrations and neurotrophin mRNA levels in the brain during lactation (2007) Life Sci, 81, pp. 1247-1255; Ganguly, K., Schinger, F.A., Wong, T.S., Poo, M.M., GABA itself promotes the developmental switch of neuronal GABAergic neurons from excitation to inhibition (2001) Cell, 105, pp. 521-532; Yokogoshi, H., Kobayashi, M., Mochizuki, M., Terashima, T., Effect of theanine, γ-glutamylethylamide, on brain monoamines and striatal dopaomine release in conscious rats (1998) Neurochem Res, 23, pp. 667-673; Wakabayashi, C., Numakawa, T., Ninomiya, M., Chiba, S., Kunugi, H., Behavioural and molecular evidence for psychotropic effects in L-theanine (2012) Psychopharmol, 219, pp. 1099-1109; Yokogoshi, H., Mochizuki, M., Saitoh, K., Theanine-induced reduction of brain serotonin concentration in rats (1998) Biosci Biotechonol Biochem, 62, pp. 816-817; Yokogoshi, H., Terashima, T., Effect of theanine, γ-glutamylethylamide, on brain monoamines, striatal dopamine release and some kinds of behaviour in rats (2000) Nutrition, 16, pp. 776-781; Shen, H., Shen, X., Wang, R., Wu, M., Effects of theanine on cereberal ishaemia-reperfusion injury in rats (abstract only) (2011) Wei Sheng Yan Jiu, 40, pp. 684-687; Schallier, A., Vermoesen, K., Loyens, E., Liefferinge, J.V., Michotte, Y., Smolders, I., L-theanine intake increases threshold for limbic seizures but decreases threshold for generalised seizures (2013) Nutr Neurosci, 16, pp. 78-82; Yamada, T., Terashima, T., Honma, H., Nagata, S., Okubo, T., Juneja, L.R., Effects of theanine, a unique amino acid in tea leaves, on memory in a rat behavioural test (2008) Biosci Biotech Biochem, 72, pp. 1356-1359; Takeda, A., Sakamoto, K., Tamano, H., Fukura, K., Inui, N., Suh, S.W., Facilitated neurogenesis in the developing hippocampus after intake of theanine, an amino acid in tea-leaves, and object recognition memory (2011) Cell Mol Neurobiol, 31, pp. 1079-1088; Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Serum levels of brain-derived neurotrophic factor and cortisol to sulphate of dehydroiepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation therapy of antipsychotic therapy in schizophrenia and schizoaffectve disorder in patients (2011) Clin Neuropharmac, 34, pp. 155-160; Di, X., Yan, J., Zhao, Y., Chang, Y., Zhao, B., L-theanine inhibits nicotine-induced dependence via regulation of the nicotine acetylcholine receptor-dopamine reward pathway (2012) Sci China Life Sci., 55, pp. 1064-1074; Cho, H.S., Kim, S., Lee, S.Y., Kim, S.J., Chun, H.S., Protective effect of he green tea component L-theanine on environmental toxininduced neuronal cell death (2008) Neurobiology, 29, pp. 656-662; Gomez-Ramirez, M., Kelly, S.P., Montesi, J.L., Fox, J.J., The effect of L-theanine on alpha-band oscillatory brain activity during a visuo-spatial attention task (2009) Brain Topogr, 22, pp. 44-51; Walton, H.S., Dodd, P.R., Glutamate-glutamine cycling in Alzheimers disease (2007) Neurochem Int, 50, pp. 1052-1066; Egashira, N., Hayakawa, K., Osajima, M., Mishima, K., Iwasaki, K., Involvement of GABAA receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice (2007) Pharmac Sci, 105, pp. 211-214; Kakuda, T., Neuroprotective effects of the green tea compounds theanine and catechins (2002) Biol Pharm Bull, 25, pp. 1513-1518; Nagasawa, K., Aoki, H., Yasuda, E., Nagai, K., Shimohama, S., Fugimoto, S., Possible involvement of group 1 mGluRs in neuroprotective effects of theanine (2004) Biochem Biophys Res Comm, 320, pp. 116-122; Kakuda, T., Nozawa, A., Sugimoto, A., Nino, H., Inhibition by theanine of binding of [3H] AMPA, [3H] Kainate, and [3H] MDL 105 519 to glutamate receptors (2002) Biosci Biotechnol Biochem, 66, pp. 2683-2686; Zukhurova, M., Prosvirnina, M., Daineko, A., Simanenkova, A., Petrishchev, N., Sonin, D., L-theanine administration results in neuroprotection and prevents glutamate receptor agonist-mediated injury in the rat model of cerebral ishaemiareperfusion (2012) Phytother Res, , (epub ahead of print); Di, X., Yan, J., Zhao, Y., Zhang, J., Shi, Z., Chang, Y., L-theanine protects the APP (Swedish mutation) transgenic SH-SY5Y cell against glutamate-induced excitotoxicity via inhibition of the NMDA receptor pathway (2010) Nueroscience, 168, pp. 778-786; Nagasawa, K., Aoki, H., Yasuda, E., Nagai, K., Shimohama, S., Fujimoto, S., Possible involvement of group 1 mGLuRs in neuroprotective effect of theanine (2004) Biochem Biophys Res Commun, 320, pp. 116-122; Kim, T.I., Lee, Y.K., Park, S.G., Choi, I.S., Ban, J.O., Park, H.K., Ltheanine, an amino acid in green tea, attenuates β-amyloidinduced cognitive dysfunction and neurotoxicity: Reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-κB pathways (2009) Free Rad Biol Med, 47, pp. 1601-1610; Kakuda, T., Neuroprotective effects of theanine and its preventive effects on cognitive function (2011) Pharm Res, 64, pp. 162-168; Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., Green tea consumption and cognitive function: A cross-sectional study from the Tsurgaya project (2006) Am J Clin Nutr, 83, pp. 355-361; Kataoka, Y., Utsunomiya, K., Kimbara, A., Fukushima, K., Mori, T., Shiba, J., Preventative effect of green tea containing theanine at a high concentration on dementia in aged volunteers (2009) J Jpn Mibyou Syst Assoc, 15, pp. 17-23; Eschenauer, G., Sweet, B.V., Pharmacology and therapeutic uses of theanine (2006) Am J Health Syst Pharm, 63, pp. 26-30; Kobayashi, T., Nagato, Y., Aon, N., Juneja, L.R., Kim, M., Yamamoto, T., Effects of L-theanine on the release of α-brain waves in human volunteers (1998) Nippon Nogei Kagakukaishi, 72, pp. 153-157; Song, C.H., Jung, H.J., Oh, S.J., Kim, S.K., Effects of theanine on the release of brain alpha wave in adult males (2003) J Korean Nutr Soc (abstract only in English)., 36, pp. 918-923; Gomez-Ramirez, M., Higgins, B.A., Rycroft, J.A., Owen, G.N., Mahoney, J., The deployment of intersensory selective attention: A high-density electrical mapping study of the effects of theanine (2007) Clin Neuropharmac, 30, pp. 25-38; Owen, G.N., Parnell, H., De Bruin, E.A., Rycroft, J.A., The combined effect of L-theanine and caffeine on cognitive performance and mood (2008) Nutr Neuro, 11, pp. 93-98; Nobre, A.C., Rao, A., Owen, G.N., L-theanine, a natural constituent in tea, and its effect on mental state (2008) Asia Pac J Clin Nutr, 17 (SUPPL. 1), pp. 167-168; Fox, J.J., Morie, K.P., Laud, P.J., Rowson, M.J., de Bruin, E.A., Kelly, S.P., Assessing the effects of caffeine and theanine on the maintenance of vigilance on a sustained attention task (2012) Neuropharmacol, 62, pp. 2319-2326; Kimura, R., Murata, T., Influence of alkylamides of glutamic acid and related compounds on the central nervous system. 1 V Effect of theanine on 3′, 5′-monophosphate formation in rat cerebral cortex (1980) Chem Pharm Bulletin, 80, pp. 661-666; Kakuda, T., Nozawa, A., Unno, T., Okamuaa, N., Okai, O., Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat (2000) Biosci Biotech Biochem, 64, pp. 287-293; Rogers, P.J., Smith, J.E., Heatherley, S.V., Pleydell-Pearce, C.W., Time for tea: Mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together (2008) Psychopharmacology, 195, pp. 569-577; Kimura, R., Kurita, M., Murata, T., Influence of glutamic acid and related compounds on the central nervous system. 111. Effect of theanine on spontaneous activity in mice (1975) Yakugaku Zasshi, 95, pp. 892-895; Sagesaka, Y., Kakuda, T., Kawamura, K., Pharmacological effect of theanine (1991) Proc of the Internat Symposium on Tea Science, 7, pp. 362-365; Jang, H.S., Jung, J.Y., Jang, I.S., Jang, K.H., Kim, S.H., Hah, J.H., Ltheanine partially counteracts caffeine-induced sleep disturbance in rats (2012) Pharmac Biochem Behav, 101, pp. 217-221; Owen, G.N., Parnell, H., De Bruin, W.A., Rycroft, J.A., The combined effects of L-theanine and caffeine on cognitive performance and mood (2008) Nutr Neurosci, 11, pp. 193-198; Einother, S.J., Martens, V.E., Rycroft, J.A., De Bruin, E.A., L-theanine and caffeine improve task switching but not intersensory attention or subjective alertness (2010) Appetite, 54, pp. 406-409; Abdou, A.M., Higashiguchi, S., Horie, K., Kim, M., Hatta, H., Yokogoshi, H., Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans (2006) Biofactors, 26, pp. 201-208; Yoto, A., Murao, S., Motoki, M., Yokoyama, Y., Horie, N., Takeshima, K., Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks (2012) Amino Acids, 43, pp. 1331-1337; Takeda, A., Tamano, H., Suzuki, M., Sakamoto, K., Oku, N., Yokogoshi, H., Unique Induction of CA1 LTP components after intake of theanine, an amino acid in tea leaves and its effect on stress response (2012) Cell Mol Neurobiol, 32, pp. 41-48; Yamin, G., NMDA receptor-dependent signalling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus (2009) J Neurosci Res, 87, pp. 1729-1736; Tian, X., Sun, L., Gou, L., Ling, X., Feng, Y., Wang, L., Protective effect of L-theanine on chronic restraint stress-induced cognitive impairments in mice (2013) Brain Res, 1503, pp. 24-32; Lu, K., Gray, M.A., Oliver, C., Liley, D.T., Harrison, B.J., Bartholomuesz, C.F., The acute effects of L-theanine in comparison with alprezolam on anticipatory anxiety in humans (2004) Hum Psychopharmacol, 19, pp. 457-465; Kimura, K., Ozeki, M., Juneja, L.R., Ohira, H., L-theanine reduces psychological and physiological stress responses (2007) Biol Psychol, 74, pp. 39-45; Hease, T., Jenkinson, J., Love, C., Milam, R., Perkins, L., Adams, C., Anxiolytic effects of L-theanine-a component of green tea-when combined with midazolam, in the male Sprague-Dawley rat (2009) AANA J, 77, pp. 445-449; Ritsner, M.S., Miodownik, C., Ratner, Y., Schleifer, T., Mar, M., Pintov, L., L theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: An 8-week, randomised, double-blind, placebocontrolled, 2-center study (2011) Clin Psych, 72, pp. 34-42; Wise, L.E., Premaratne, I.D., Gamage, T.F., Lichtman, A.H., Hughes, L.D., Harris, L.S., L-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like behaviour in mice (2012) Pharm Bioch Behav, 103, pp. 245-252; Yin, C., Liu, Y., Yin, X., Xhang, L., Jia, G., Zhuang, X., Antidepressant-like effects of L-theanine in the forced-swim and tail suspension tests in mice (2011) Phytother Res, 25, pp. 1636-1639; Dwivedi, Y., Brain derived neurotrophic factor: Role in depression and suicide (2009) Neuropsychiatr Dis Treat, 5, pp. 4433-4449; Yoshiumura, R., Ikenouchi-Sugita, A., Hori, H., Umene-Nakano, W., Katsuki, A., Havashi, K., (Abstract only) Brain derived neurotrophic factor (BDNF) and mood disorder (2010) Nihon Shinkei Seishin Yakuriqaku Zasshi, 30, pp. 181-184; Hashimoto, K., Shimizu, E., Ivo, M., Critical role of brain-derived neurotrophic factor in mood disorders (2004) Brain Res Brain Res Rev, 45, pp. 104-114; Dean, B., The neurobiology of bipolar disorder: Findings using human post-mortem central nervous system tissue (2004) Aust NZ J Psychiatry, 38, pp. 135-140; Brampilla, P., Jerez, J., Barale, F., Schettini, G., Soares, J.C., GABAergic dysfunction in mood disorders (2003) Mol Psychiatry, 8, pp. 721-737; Shiah, I.S., Yatham, L.N., GABA function in mood disorders; an update and critical review (1998) Life Sci, 63, pp. 1289-1303; Cross, D.R., Kellerman, G., McKenzie, L.B., Purvis, K.B., Hills, G.J., Huisman, H., A randomised targeted amino acid therapy with behaviourally at-risk adapted children (2011) Child Care Health Dev, 37, pp. 671-678; Lyon, M.R., Kapoor, M.P., Juneja, L.R., The effects of L-theanine (suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): A randomized, doubleblind, placebo-controlled clinical trial (2011) Altern Med Rev, 16, pp. 348-354; Mandel, S.A., Amit, T., Kalafon, L., Reznichenko, L., Youdim, M., Targetting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins (2008) J. Nutr, 138, pp. 1578S-1583S; Weinreb, O., Amit, T., Mandel, S., Youdim, M., Neuroprotective molecular mechanisms of epigallocatechin-3-gallate: A reflective outcome of its antioxidant, iron chelating and neuritogenic properties (2009) Genes Nutr, 4, pp. 283-296; Moosemang, S., Haider, N., Klugbauer, N., Adelsberger, H., Langwieser, N., Muller, J., Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory (2005) J Neurosci, 25, pp. 9883-9889; Allen, S.J., Watson, J.J., Dawbarn, D., The neurotrophins and their role in Alzheimer's disease (2011) Curr Neuropharmacol, 9, pp. 559-573; Maina, G., Rosso, G., Zanardini, R., Bogetto, F., Genarrelli, M., Bochio-Chiavetto, L., Serum levels of brain-derived neurotrophic factor in drug-naive obsessive-compulsive patients: A case control study (2010) J Affect Disord, 122, pp. 174-178; Mercader, J.M., Fernández-Aranda, F., Gratacòs, M., Ribasés, M., Badía, A., Villarejo, C., Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients (2007) Neuropsychobiology, 56, pp. 185-190",Review,Scopus,2-s2.0-84901323138
"Mirsra M., Kiruba Thangam R., Febin Prabhu Dass J.","Prediction of novel drug target involved in psychosis in alzheimer disease: A computational network study",2014,"International Journal of Drug Development and Research","6","3",,"147","152",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84908207950&partnerID=40&md5=b88c87f20b1f44067bb6da0cb9658d07","Bioinformatics Division, School of Biosciences and Technology, VIT UniversityVellore, Tamil Nadu, India; Enterprise and Cloud Computing, School of Information Technology and Engineering, VIT UniversityVellore, Tamil Nadu, India","Mirsra, M., Bioinformatics Division, School of Biosciences and Technology, VIT UniversityVellore, Tamil Nadu, India; Kiruba Thangam, R., Enterprise and Cloud Computing, School of Information Technology and Engineering, VIT UniversityVellore, Tamil Nadu, India; Febin Prabhu Dass, J., Bioinformatics Division, School of Biosciences and Technology, VIT UniversityVellore, Tamil Nadu, India","Alzheimer (AD) disease is the most frequent form of dementia. Several structural and functional genomic factors are strongly associated with AD candidate genes, including age of onset, cognitive decline and amyloid depositions. Serotonin (5- TH) receptors play an important role in psychosis in AD with cognitive impairment. This study is based on insilco identification and prioritization of the differentially expressed genes of the genetic network involved in AD. Fourteen 5-HT candidate genes interaction network associated with AD was generated using agilent literature search cytoscape plugin. The organic layout shows cross-interaction between the genes set. On merging the genetic network with gene expression profile data, notable changes in interaction patterns were observed. These changes revealed 5-HTR2A, 5-HTR2C and 5-HTR4 as important genes in AD. Further refinement with Enrichment Map indicated 5-HTR2C as novel candidate gene that showed high functional significance in correlation to Alzheimer's disease. Our result will be a crucial factor for better understanding of the genetic pathways involved in causing psychosis in AD and will form a future landmark in developing target based drug therapies against this disease. © 2014 By IYPF. All rights reserved.","Co-expression; Major target, computational network analysis of alzheimers; Within family interaction","C1, Q., Kivipelto, M., Von Strauss, E., Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention (2009) Dialogues Clin Neurosci, 11 (2), pp. 111-128; Meneses, A., Physiological, Pathophysiological and Therapeutic Roles of 5-HT Systems in Learning and Memory (1998) Reviews in the Neurosciences, 9, pp. 275-289; Salmon, E., A review of the literature on neuroimaging of serotoninergic function in Alzheimer's disease and related disorders (2007) J Neural Transm, 114 (9), pp. 1179-1185; Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Ideker, T., Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks (2003) Genome Res, 13, pp. 2498-2504; Vailaya, A., Bluvas, P., Kincaid, R., Kuchinsky, A., Creech, M., Adler, A., An architecture for biological information extraction and representation (2005) Bioinformatics, 21 (4), pp. 430-438; Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.-L., Ideker, T., Cytoscape 2.8: New features for data integration and network visualization (2011) Bioinformatics, 27 (3), pp. 431-432; Merico, D., Isserlin, R., Stueker, O., Emili, A., Bader, G.D., Enrichment map: A network-based method for gene-set enrichment visualization and interpretation (2010) PLoS One, 5 (11); Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Pahwa, J.S., Williams, J., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) Nat Genet, 41 (10), pp. 1088-1093; Hu, X., Pickering, E., Liu, Y.C., Hall, S., Fournier, H., Katz, E., Dechairo, B., Soares, H., Alzheimer's Disease Neuroimaging Initiative. Metaanalysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease (2011) PLoS One, 6 (2); Courtney, C., Babbitt,Jesse S. Silverman,Ralph Haygood,Jennifer M. Reininga,Matthew V. Rockman, Gregory A. Wray. Multiple Functional Variants in cis Modulate PDYN Expression (2010) Mol Biol Evol, 27 (2), pp. 465-479; Kim, W.S., Guillemin, G.J., Glaros, E.N., Lim, C.K., Garner, B., Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells (2006) Neuroreport, 17 (9), pp. 891-896; Casas, S., Gomis, R., Gribble, F.M., Altirriba, J., Knuutila, S., Novials, A., Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis (2007) Diabetes, 56 (9), pp. 2284-2294; Zherebtsova, A.L., Shadrina, M.I., Semenova, E.V., Levitskiĭ, G.N., Alekhin, A.V., Slominskiĭ, P.A., Skvortsova, V.I., Limborskaia, S.A., Analysis of the possible involvement of the glutamate transporter gene EAAT2 and the glutamate receptor genes GRIA1 and GRIA2 in pathogenesis of motor neuron disease in the Russian population (2006) Genetika, 42 (1), pp. 104-109; Sabo, S.L., Ikin, A.F., Buxbaum, J.D., Greengard, P., The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo (2003) J Neurosci, 23 (13), pp. 5407-5415; Ly, P.T., Song, W., Loss of activated CaMKII at the synapse underlies Alzheimer's disease memory loss (2011) J Neurochem, 119 (4), pp. 673-675; Deane, R., Sagare, A., Zlokovic, B.V., The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease (2008) Curr Pharm Des, 14 (16), pp. 1601-1605; Rocca, W.A., Shuster, L.T., Grossardt, B.R., Maraganore, D.M., Gostout, B.S., Geda, Y.E., Melton, L.J., Long-term effects of bilateral oophorectomy on brain aging: Unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging (2009) Womens Health (Lond Engl), 5 (1), pp. 39-48; Yokota, T., Mishra, M., Akatsu, H., Tani, Y., Miyauchi, T., Yamamoto, T., Kosaka, K., Heese, K., Brain site-specific gene expression analysis in Alzheimer's disease patients (2006) Eur J Clin Invest, 36 (11), pp. 820-830; Heredia, L., Helguera, P., Olmos, S.D., Kedikian, G., Solá Vigo, F., Laferla, F., Staufenbiel, M., Lorenzo, A., Phosphorylation of Actin- Depolymerizing Factor/Cofilin by LIM-Kinase Mediates Amyloid -Induced Degeneration: A Potential Mechanism of Neuronal Dystrophy in Alzheimer's Disease (2006) J. Neurosci, 26 (24), pp. 6533-6542; Johnson, F., Giulivi, C., Superoxide dismutases and their impact upon human health (2005) Mol Aspects Med, 26 (4-5), pp. 340-352",Article,Scopus,2-s2.0-84908207950
"Van Groen T., Miettinen P., Kadish I.","Axonal tract tracing for delineating interacting brain regions: Implications for Alzheimer's disease-associated memory",2014,"Future Neurology","9","1",,"89","98",,2,10.2217/fnl.13.67,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84890938561&partnerID=40&md5=1c126a5bf5f1ca6c0886907047117e95","Department of Cell Developmental and Integrative Biology, University of Alabama at Birmingham, 1900 University Boulevard, THT 912, Birmingham, AL 35294-0006, United States; Department of Neuroscience, University of Eastern Finland, FIN 70211, Kuopio, Finland","Van Groen, T., Department of Cell Developmental and Integrative Biology, University of Alabama at Birmingham, 1900 University Boulevard, THT 912, Birmingham, AL 35294-0006, United States; Miettinen, P., Department of Neuroscience, University of Eastern Finland, FIN 70211, Kuopio, Finland; Kadish, I., Department of Cell Developmental and Integrative Biology, University of Alabama at Birmingham, 1900 University Boulevard, THT 912, Birmingham, AL 35294-0006, United States","We are studying the projections from the entorhinal cortex to the hippocampal formation in the mouse. The dentate gyrus is innervated by the lateral entorhinal cortex (lateral perforant path) and medial entorhinal cortex (medial perforant path). The entorhinal cortex also projects to hippocampal areas CA3 and CA1, and to the subiculum. In young transgenic Alzheimers disease mouse models (before amyloid- pathology), the connections are not different from normal mice. In Alzheimers disease mice with pathology, two changes occur: first, dystrophic axon endings appear near amyloid- plaques, and second, there are sparse aberrant axon terminations not in the appropriate area or lamina of the hippocampus. Furthermore, MRI-diffusion tensor imaging analysis indicates a decrease in the quality of the white matter tracts connecting the hippocampus to the brain; in other words, the fimbria/fornix and perforant path. Similar changes in white matter integrity have been found in Alzheimers disease patients and could potentially be used as early indicators of disease onset. © 2014 Future Medicine Ltd.","entorhinal cortex; hippocampus; limbic system; perforant path; tractography","Witter, M.P., Groenewegen, H.J., Lopes Da Silva, F.H., Lohman, A.H., Functional organization of the extrinsic and intrinsic circuitry of the parahippocampal region (1989) Prog. Neurobiol., 33 (3), pp. 161-253; Ramon, Y., Cajal, S., Notes on the fine anatomy of the large brain (1893) Z. Wissensch. Zool., 56, pp. 615-672; Van Hoesen, G.W., Pandya, D.N., Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. III. Efferent connections (1975) Brain Res., 95 (1), pp. 39-59; Steward, O., Scoville, S.A., Cells of origin of entorhinal cortical afferents to the hippocampus and fascia dentata of the rat (1976) J. Comp. Neurol., 169 (3), pp. 347-370; Witter, M.P., Groenewegen, H.J., Laminar origin and septotemporal distribution of entorhinal and perirhinal projections to the hippocampus in the cat (1984) J. Comp. Neurol., 224 (3), pp. 371-385; Amaral, D.G., Witter, M.P., The three-dimensional organization of the hippocampal formation: A review of anatomical data (1989) Neuroscience, 31 (3), pp. 571-591; Van Groen, T., Miettinen, P., Kadish, I., The entorhinal cortex of the mouse: Organization of the projection to the hippocampal formation (2003) Hippocampus, 13 (1), pp. 133-149; Pohle, W., Ott, T., Muller-Welde, P., Identification of neurons of origin providing the dopaminergic innervation of the hippocampus (1984) J. Hirnforsch., 25 (1), pp. 1-10; Dolorfo, C.L., Amaral, D.G., Entorhinal cortex of the rat: Topographic organization of the cells of origin of the perforant path projection to the dentate gyrus (1998) J. Comp. Neurol., 398 (1), pp. 25-48; Ruth, R.E., Collier, T.J., Routtenberg, A., Topography between the entorhinal cortex and the dentate septotemporal axis in rats: I. Medial and intermediate entorhinal projecting cells (1982) J. Comp. Neurol., (209), pp. 69-78; Ruth, R.E., Collier, T.J., Routtenberg, A., Topographical relationship between the entorhinal cortex and the septotemporal axis of the dentate gyrus in rats: II. Cells projecting from lateral entorhinal subdivisions (1988) J. Comp. Neurol., 270 (4), pp. 506-516; Hjorth-Simonsen, A., Jeune, B., Origin and termination of the hippocampal perforant path in the rat studied by silver impregnation (1972) J. Comp. Neurol., 144 (2), pp. 215-232; Deller, T., Haas, C.A., Frotscher, M., Sprouting in the hippocampus after entorhinal cortex lesion is layer-specific but not translaminar: Which molecules may be involved? (2001) Restor. Neurol. Neurosci., 19 (3-4), pp. 159-167; Von Gunten, A., Kovari, E., Bussiere, T., Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease (2006) Neurobiol. Aging, 27 (2), pp. 270-277; Kadish, I., Van Groen, T., Low levels of estrogen significantly diminish axonal sprouting after entorhinal cortex lesions in the mouse (2002) J. Neurosci., 22 (10), pp. 4095-4102; Deller, T., Haas, C.A., Frotscher, M., Reorganization of the rat fascia dentata after a unilateral entorhinal cortex lesion. Role of the extracellular matrix (2000) Ann. NY Acad. Sci., 911, pp. 207-220; Van Groen, T., Entorhinal cortex of the mouse: Cytoarchitectonical organization (2001) Hippocampus, 11 (4), pp. 397-407; De Nó, L., Studies on the structure of the cerebral cortex. II. Continuation of the study of the ammonic system (1934) J. Psychol. Neurol., 46, pp. 113-177; Blackstad, T.W., Commissural connections of the hippocampal region in the rat, with special reference to their mode of termination (1956) J. Comp. Neurol., 105 (3), pp. 417-537; West, M.J., Andersen, A.H., An allometric study of the area dentata in the rat and mouse (1980) Brain Res., 2 (3), pp. 317-348; Van Groen, T., Kadish, I., Wyss, J.M., Species differences in the projections from the entorhinal cortex to the hippocampus (2002) Brain Res. Bull., 57 (3), pp. 553-556; Suzuki, W.A., Amaral, D.G., Topographic organization of the reciprocal connections between the monkey entorhinal cortex and the perirhinal and parahippocampal cortices (1994) J. Neurosci., 14 (3 PART 2), pp. 1856-1877; Witter, M.P., Amaral, D.G., Entorhinal cortex of the monkey: V. Projections to the dentate gyrus, hippocampus, and subicular complex (1991) J. Comp. Neurol., (307), pp. 437-459; Van Groen, T., Van Haren, F.J., Witter, M.P., Groenewegen, H.J., The organization of the reciprocal connections between the subiculum and the entorhinal cortex in the cat: I. A neuroanatomical tracing study (1986) J. Comp. Neurol., 250 (4), pp. 485-497; Phinney, A.L., Deller, T., Stalder, M., Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice (1999) J. Neurosci., 19 (19), pp. 8552-8559; Amaral, D.G., Insausti, R., Cowan, W.M., The commissural connections of the monkey hippocampal formation (1984) J. Comp. Neurol., 224 (3), pp. 307-336; Kondo, H., Lavenex, P., Amaral, D.G., Intrinsic connections of the macaque monkey hippocampal formation: II. CA3 connections (2009) J. Comp. Neurol., 515 (3), pp. 349-377; Swanson, L.W., Sawchenko, P.E., Cowan, W.M., Evidence for collateral projections by neurons in Ammon's horn, the dentate gyrus, and the subiculum: A multiple retrograde labeling study in the rat (1981) J. Neurosci., 1 (5), pp. 548-559; Laurberg, S., Commissural and intrinsic connections of the rat hippocampus (1979) J. Comp. Neurol., 184 (4), pp. 685-708; Witter, M.P., Van Hoesen, G.W., Amaral, D.G., Topographical organization of the entorhinal projection to the dentate gyrus of the monkey (1989) J. Neurosci., 9 (1), pp. 216-228; Kadish, I., Van Groen, T., Lesion-induced hippocampal plasticity in transgenic Alzheimer's disease mouse models: Influences of age, genotype, and estrogen (2009) J. Alzheimers Dis., 18 (2), pp. 429-445; De La Monte, S.M., Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease (1989) Ann. Neurol., 25 (5), pp. 450-459; Laakso, M.P., Vaurio, O., Savolainen, L., A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism (2000) Behav. Brain Res., 109 (2), pp. 177-186; Laakso, M.P., Frisoni, G.B., Kononen, M., Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: A morphometric MRI study (2000) Biol. Psychiatry, 47 (12), pp. 1056-1063; Stranahan, A.M., Mattson, M.P., Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer's disease (2010) Neural Plast., 2010, p. 108190; Kordower, J.H., Chu, Y., Stebbins, G.T., Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (2001) Ann. Neurol., 49 (2), pp. 202-213; Gomez-Isla, T., Price, J.L., Mckeel Jr., D.W., Morris, J.C., Growdon, J.H., Hyman, B.T., Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease (1996) J. Neurosci., 16 (14), pp. 4491-4500; Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone (1987) Ann. Neurol., 22 (1), pp. 37-40; Cabalka, L.M., Hyman, B.T., Goodlett, C.R., Ritchie, T.C., Van Hoesen, G.W., Alteration in the pattern of nerve terminal protein immunoreactivity in the perforant pathway in Alzheimer's disease and in rats after entorhinal lesions (1992) Neurobiol. Aging, 13 (2), pp. 283-291; Mielke, M.M., Okonkwo, O.C., Oishi, K., Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease (2012) Alzheimer's Dement., 8 (2), pp. 105-113; Oishi, K., Mielke, M.M., Albert, M., Lyketsos, C.G., Mori, S., The fornix sign: A potential sign for Alzheimer's disease based on diffusion tensor imaging (2012) J. Neuroimaging, 22 (4), pp. 365-374; Schmued, L.C., Raymick, J., Paule, M.G., Dumas, M., Sarkar, S., Characterization of myelin pathology in the hippocampal complex of a transgenic mouse model of Alzheimer's disease (2013) Curr. Alzheimers Res., 10 (1), pp. 30-37; Yassa, M.A., Muftuler, L.T., Stark, C.E., Ultrahigh-resolution microstructural diffusion tensor imaging reveals perforant path degradation in aged humans in vivo (2010) Proc. Natl Acad. Sci. USA, 107 (28), pp. 12687-12691; Hyman, B.T., Kromer, L.J., Van Hoesen, G.W., Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease (1987) Ann. Neurol., 21 (3), pp. 259-267; Cotman, C.W., Anderson, K.J., Synaptic plasticity and functional stabilization in the hippocampal formation: Possible role in Alzheimer's disease (1988) Adv. Neurol., 47, pp. 313-335; Hyman, B.T., Van Hoesen, G.W., Kromer, L.J., Damasio, A.R., Perforant pathway changes and the memory impairment of Alzheimer's disease (1986) Ann. Neurol., 20 (4), pp. 472-481; Deller, T., Del Turco, D., Rappert, A., Bechmann, I., Structural reorganization of the dentate gyrus following entorhinal denervation: Species differences between rat and mouse (2007) Prog. Brain Res., 163, pp. 501-528; Van Groen, T., Liu, L., Ikonen, S., Kadish, I., Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions (2003) Neuroscience, 119 (4), pp. 1185-1197; Arendt, T., Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer's disease (2001) Int. J. Dev. Neurosci., 19 (3), pp. 231-245; Arendt, T., Synaptic degeneration in Alzheimer's disease (2009) Acta Neuropathol., 118 (1), pp. 167-179; Spires-Jones, T.L., Meyer-Luehmann, M., Osetek, J.D., Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model (2007) Am. J. Pathol., 171 (4), pp. 1304-1311; Shankar, G.M., Li, S., Mehta, T.H., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008) Nat. Med., 14 (8), pp. 837-842; Arendt, T., Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization (2001) Neuroscience, 102 (4), pp. 723-765; Holtmaat, A., Svoboda, K., Experience-dependent structural synaptic plasticity in the mammalian brain (2009) Nat. Rev. Neurosci., 10 (9), pp. 647-658; Swaab, D.F., Brain Aging and Alzheimer's Disease 'wear and tear' versus 'use it or lose it' (1991) Neurobiol. Aging, 12 (4), pp. 317-324; Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes (1991) Acta Neuropathol., 82 (4), pp. 239-259; Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes (1995) Neurobiol. Aging, 16 (3), pp. 271-278. , discussion 278-284; Arendt, T., Bruckner, M.K., Gertz, H.J., Marcova, L., Cortical distribution of neurofibrillary tangles in Alzheimer's disease matches the pattern of neurons that retain their capacity of plastic remodelling in the adult brain (1998) Neuroscience, 83 (4), pp. 991-1002; Small, S.A., Schobel, S.A., Buxton, R.B., Witter, M.P., Barnes, C.A., A pathophysiological framework of hippocampal dysfunction in ageing and disease (2011) Nat. Rev. Neurosci., 12 (10), pp. 585-601; Hardy, J., Revesz, T., The spread of neurodegenerative disease (2012) N. Engl. J. Med., 366 (22), pp. 2126-2128; Walker, L.C., Diamond, M.I., Duff, K.E., Hyman, B.T., Mechanisms of protein seeding in neurodegenerative diseases (2013) JAMA Neurol., 70 (3), pp. 304-310; Wu, J.W., Herman, M., Liu, L., Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons (2013) J. Biol. Chem., 288 (3), pp. 1856-1870; Van Hoesen, G.W., Hyman, B.T., Hippocampal formation: Anatomy and the patterns of pathology in Alzheimer's disease (1990) Prog. Brain Res., 83, pp. 445-457; Matthews, P.M., Filippini, N., Douaud, G., Brain structural and functional connectivity and the progression of neuropathology in Alzheimer's disease (2013) J. Alzheimers Dis., 33 (SUPPL. 1), pp. S163-S172; Agosta, F., Pievani, M., Geroldi, C., Copetti, M., Frisoni, G.B., Filippi, M., Resting state fMRI in Alzheimer's disease: Beyond the default mode network (2012) Neurobiol. Aging, 33 (8), pp. 1564-1578; Filippi, M., Agosta, F., Structural and functional network connectivity breakdown in Alzheimer's disease studied with magnetic resonance imaging techniques (2011) J. Alzheimers Dis., 24 (3), pp. 455-474; Huang, H., Fan, X., Weiner, M., Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization (2012) Neurobiol. Aging, 33 (9), pp. 2029-2045; Fieremans, E., Benitez, A., Jensen, J.H., Novel white matter tract integrity metrics sensitive to Alzheimer disease progression (2013) AJNR Am. J. Neuroradiol., 34 (11), pp. 2105-2112; Zerbi, V., Kleinnijenhuis, M., Fang, X., Gray and white matter degeneration revealed by diffusion in an Alzheimer mouse model (2013) Neurobiol. Aging, 34 (5), pp. 1440-1450; Johnson, D.K., Barrow, W., Anderson, R., Diagnostic utility of cerebral white matter integrity in early Alzheimer's disease (2010) Int. J. Neurosci., 120 (8), pp. 544-550; Chao, L.L., Decarli, C., Kriger, S., Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI (2013) PLoS ONE, 8 (6), pp. e65175; Clerx, L., Visser, P.J., Verhey, F., Aalten, P., New MRI markers for Alzheimer's disease: A meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements (2012) J. Alzheimers Dis., 29 (2), pp. 405-429",Review,Scopus,2-s2.0-84890938561
"Marchewka A., Kherif F., Krueger G., Grabowska A., Frackowiak R., Draganski B.","Influence of magnetic field strength and image registration strategy on voxel-based morphometry in a study of Alzheimer's disease",2014,"Human Brain Mapping","35","5",,"1865","1874",,3,10.1002/hbm.22297,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897991077&partnerID=40&md5=cc4a0a8049aee774e7f7657800aebfb6","LREN, Département des Neurosciences Cliniques, CHUV, University of Lausanne, Lausanne, Switzerland; Laboratory of Brain Imaging, Neurobiology Centre, Nencki Institute of Experimental Biology, Warsaw, Poland; Healthcare Sector IM andWS S, Siemens Schweiz AG, Renens, VD, Switzerland; Laboratory of Psychophysiology, Department of Neurophysiology, Nencki Institute of Experimental Biology, Warsaw, Poland; Max-Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany","Marchewka, A., LREN, Département des Neurosciences Cliniques, CHUV, University of Lausanne, Lausanne, Switzerland, Laboratory of Brain Imaging, Neurobiology Centre, Nencki Institute of Experimental Biology, Warsaw, Poland; Kherif, F., LREN, Département des Neurosciences Cliniques, CHUV, University of Lausanne, Lausanne, Switzerland; Krueger, G., Healthcare Sector IM andWS S, Siemens Schweiz AG, Renens, VD, Switzerland; Grabowska, A., Laboratory of Psychophysiology, Department of Neurophysiology, Nencki Institute of Experimental Biology, Warsaw, Poland; Frackowiak, R., LREN, Département des Neurosciences Cliniques, CHUV, University of Lausanne, Lausanne, Switzerland; Draganski, B., LREN, Département des Neurosciences Cliniques, CHUV, University of Lausanne, Lausanne, Switzerland, Max-Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany","Multi-centre data repositories like the Alzheimer's Disease Neuroimaging Initiative (ADNI) offer a unique research platform, but pose questions concerning comparability of results when using a range of imaging protocols and data processing algorithms. The variability is mainly due to the non-quantitative character of the widely used structural T1-weighted magnetic resonance (MR) images. Although the stability of the main effect of Alzheimer's disease (AD) on brain structure across platforms and field strength has been addressed in previous studies using multi-site MR images, there are only sparse empirically-based recommendations for processing and analysis of pooled multi-centre structural MR data acquired at different magnetic field strengths (MFS). Aiming to minimise potential systematic bias when using ADNI data we investigate the specific contributions of spatial registration strategies and the impact of MFS on voxel-based morphometry in AD. We perform a whole-brain analysis within the framework of Statistical Parametric Mapping, testing for main effects of various diffeomorphic spatial registration strategies, of MFS and their interaction with disease status. Beyond the confirmation of medial temporal lobe volume loss in AD, we detect a significant impact of spatial registration strategy on estimation of AD related atrophy. Additionally, we report a significant effect of MFS on the assessment of brain anatomy (i) in the cerebellum, (ii) the precentral gyrus and (iii) the thalamus bilaterally, showing no interaction with the disease status. We provide empirical evidence in support of pooling data in multi-centre VBM studies irrespective of disease status or MFS. © 2013 Wiley Periodicals, Inc.","Diffeomorphic registration; Disease-specific template; Multi-centre study; Voxel-based morphometry","Ashburner, J., Friston, K.J., Voxel-based morphometry - The methods (2000) NeuroImage, 11, pp. 805-821; Ashburner, J., Friston, K.J., Unified segmentation (2005) NeuroImage, 26, pp. 839-851; Ashburner, J., A fast diffeomorphic image registration algorithm (2007) Neuroimage, 38, pp. 95-113; Bastos-Leite, A.J., van Waesberghe, J.H., Oen, A.L., van der Flier, W.M., Scheltens, P., Barkhof, F., Hippocampal sulcus width and cavities: Comparison between patients with Alzheimer disease and nondemented elderly subjects (2006) AJNR Am J Neuroradiol, 27, pp. 2141-2145; Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes (1991) Acta Neuropathol, 82 (4), pp. 239-259; Briellmann, R.S., Syngeniotis, A., Jackson, G.D., Comparison of hippocampal volumetry at 1.5 Tesla and 3 Tesla (2001) Epilepsia, 42, pp. 1021-1024; Deoni, S.C.L., Catani, M., Visualization of the deep cerebellar nuclei using quantitative T1 and rho magnetic resonance imaging at 3 Tesla (2007) NeuroImage, 37, pp. 1260-1266; Dickerson, B.C., Fenstermacher, E., Salat, D.H., Wolk, D.A., Maguire, R.P., Desikan, R., Pacheco, J., Fischl, B., Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths (2008) NeuroImage, 39, pp. 10-18; Di Perri, C., Dwyer, M.G., Wack, D.S., Cox, J.L., Hashmi, K., Saluste, E., Hussein, S., Zivadinov, R., Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study (2009) Neuroimage, 47, pp. 1352-1362; Focke, N.K., Helms, G., Kaspar, S., Diederich, C., Tóth, V., Dechent, P., Mohr, A., Paulus, W., Multi-site voxel-based morphometry - Not quite there yet (2011) Neuroimage, 56 (3), pp. 1164-1170; Frisoni, G.B., Fox, N.C., Jack, C.R., Scheltens, P., Thompson, P.M., The clinical use of structural MRI in Alzheimer disease (2010) Nat Rev Neurol, 6, pp. 67-77; Friston, K., Penny, W., Phillips, C., Kiebel, S., Hinton, G., Ashburner, J., Classical and Bayesian inference in neuroimaging: Theory (2002) NeuroImage, 16, pp. 465-483; Gitelman, D.R., Ashburner, J., Friston, K.J., Tyler, L.K., Price, C.J., Voxel-based morphometry of herpes simplex encephalitis (2001) NeuroImage, 13, pp. 623-631; Goodro, M., Sameti, M., Patenuade, B., Fein, G., Age effect on subcortical structures in healthy adults (2012) Psychiatry Res. Neuroimaging, 203 (1), pp. 38-45; Han, X., Jovicich, J., Salat, D., Van der Kouwe, A., Quinn, B., Czanner, S., Busa, E., Fischl, B., Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer (2006) NeuroImage, 32, pp. 180-194; Hua, X., Leow, A.D., Lee, S., Klunder, A.D., Toga, A.W., Lepore, N., Chou, Y.Y., Thompson, P.M., 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry (2008) Neuroimage, 41, pp. 19-34. , Alzheimer's Disease Neuroimaging Initiative : :-; Hyman, B.T., The neuropathological diagnosis of Alzheimer's disease: Clinical-pathological studies (1997) Neurobiol Aging, 18, pp. S27-S32; Jack, C.R., Bernstein, M.A., Fox, C., Thompson, P.M., Alexander, G., Harvey, D., Borowski, B., Weiner, M.W., The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods (2008) J Magn Reson Imag, 27, pp. 685-691; Klein, A., Andersson, J., Ardekani, B.A., Ashburner, J., Avants, B., Chiang, M.-C., Christensen, G.E., Parsey, R.V., Evaluation of 15 nonlinear deformation algorithms applied to human brain MRI registration (2009) NeuroImage, 46, pp. 786-802; Lepore, N., Brun, C., Yi-Yu, C., Lee, A.D., Barysheva, M., Pennec, X., Mcmahon, K.L., Thompson, P.M., Best individual template selection from deformation tensor minimization (2008) Proceedings of the 5th IEEE International Symposium on Biomedical Imaging (ISBI), , Paris, France, May 14-17; Lotjonen, J., Wolz, R., Koikkalainen, J., Julkunen, V., Thurfjell, L., Lundqvist, R., Waldemar, G., Rueckert, D., Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease (2011) NeuroImage, 56, pp. 185-196. , Alzheimer's Disease Neuroimaging Initiative : :-; Mandal, P.K., Mahajan, R., Dinov, I.D., Structural Brain Atlases: Design, rationale, and applications in normal and pathological cohorts (2012) J Alzheimers Dis, 31 (0), pp. S169-S188; Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C., Jagust, W., Trojanowski, J.Q., Beckett, L., The Alzheimer's Disease Neuroimaging Initiative (2005) Neuroimaging Clin N Am, 15, pp. 869-877; Nestor, S.M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J.L., Fogarty, J., Bartha, R., Alzheimer's Disease Neuroimaging Initiative ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's Disease Neuroimaging Initiative database (2008) Brain, 131, pp. 2443-2454; Pardoe, H., Pell, G.S., Abbott, D.F., Berg, A.T., Jackson, G.D., Multi-site voxel-based morphometry: Methods and a feasibility demonstration with childhood absence epilepsy (2008) NeuroImage, 42, pp. 611-666; Pereira, J.M., Nestor, P.J., Williams, G.B., Impact of inconsistent resolution on VBM studies (2008) Neuroimage, 40, pp. 1711-1717; Pereira, J.M.S., Xiong, L., Acosta-Cabronero, J., Pengas, G., Williams, G.B., Nestor, P.J., Registration accuracy for VBM studies varies according to region and degenerative disease grouping (2010) NeuroImage, 49, pp. 2205-2215; Pfefferbaum, A., Rohlfing, T., Rosenbloom, M.J., Sullivan, E.V., Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 T and 3.0 T field strengths (2012) Neuroimage, 60, pp. 940-951; Raz, N., Lindenberger, U., Rodrigue, K.M., Kennedy, K.M., Head, D., Williamson, A., Dahle, C., Acker, J.D., Regional brain changes in aging healthy adults: General trends, individual differences and modifiers (2005) Cereb Cortex, 15, pp. 1676-1689; Scorzin, J.E., Kaaden, S., Quesada, C.M., Muller, C.A., Fimmers, R., Urbach, H., Schramm, J., Volume determination of amygdala and hippocampus at 1.5 and 3.0 T MRI in temporal lobe epilepsy (2008) Epilepsy Res, 82, pp. 29-37; Stonnington, C.M., Tan, G., Klöppel, S., Chu, C., Draganski, B., Jack, C.R., Chen, K., Frackowiak, R.S., Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease (2008) Neuroimage, 39, pp. 1180-1185; Takahashia, R., Ishiice, K., Miyamotoc, N., Yoshikawac, T., Shimadad, K., Ohkawa, S., Kakigi, T., Yokoyama, K., Measurement of grey and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated Lie Algebra: A Comparison with conventional voxel-based morphometry (2010) AJNR Am J Neuroradiol, 31, pp. 1873-1878; Tanenbaum, L.N., Clinical 3T MR imaging: Mastering the challenges (2006) Magn Reson Imag Clin N Am, 14, pp. 1-15; Tardif, C.L., Collins, D.L., Pike, G.B., Regional impact of field strength on voxel-based morphometry results (2010) Hum Brain Mapp, 31, pp. 943-957",Article,Scopus,2-s2.0-84897991077
"Jeong J.-K., Lee J.-H., Moon J.-H., Lee Y.-J., Park S.-Y.","Melatonin-mediated β-catenin activation protects neuron cells against prion protein-induced neurotoxicity",2014,"Journal of Pineal Research","57","4",,"427","434",,,10.1111/jpi.12182,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84918793692&partnerID=40&md5=2703a26cdc64c68c3e070fa584a7f5d1","Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea","Jeong, J.-K., Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea; Lee, J.-H., Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea; Moon, J.-H., Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea; Lee, Y.-J., Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea; Park, S.-Y., Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National UniversityJeonju, Jeonbuk, South Korea","Activation of β-catenin in neurons regulates mitochondrial function and protects against protein misfolding disorders, including Alzheimers disease and Huntingtons disease. Melatonin, a natural secretory product of the pineal gland, exerts neuroprotective effects through the activation of β-catenin. In this study, melatonin increased β-catenin protein expression and activation in human neuroblastoma cell lines SH-SY5Y cells. Melatonin also inhibited PrP (106126)-induced neurotoxicity and the inhibition attenuated by treatment of β-catenin inhibitor ICG-001. Activation of β-catenin blocked PrP (106126)-mediated downregulation of anti-apoptotic protein survivin and Bcl-2. Reduction of mitochondrial membrane potential, translocation of Bax, and cytochrome c release which induced by PrP (106126) treatment were inhibited by β-catenin activation, which contributed to prevented PrP (106 126)-induced neuronal cell death. In conclusion, β-catenin activation by melatonin prevented PrP (106126)-induced neuronal cell death through regulating anti-apoptotic proteins and mitochondrial pathways. These results also suggest the therapeutic value of Wnt/b-catenin signaling in prion-related disorders as influenced by melatonin.","Melatonin; Prion disease; PrP 106126; β-catenin","Prusiner, S.B., (1998) Prions. Proc Natl Acad Sci USA, 95, pp. 13363-13383; Wickner, R.B., Prion diseases: Infectivity versus toxicity (2011) Nature, 470, pp. 470-471; Freixes, M., Rodriguez, A., Dalfo, E., Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in creutzfeldt-jakob disease (2006) Neurobiol Aging, 27, pp. 1807-1815; Avrahami, D., Gabizon, R., Age-related alterations affect the susceptibility of mice to prion infection (2011) Neurobiol Aging, 32, pp. 2006-2015; Hara, H., Okemoto-Nakamura, Y., Shinkai-Ouchi, F., Mouse prion protein (prp) segment 100 to 104 regulates conversion of prpc to prpsc in prion-infected neuroblastoma cells (2012) J Virol, 86, pp. 5626-5636; Siskova, Z., Mahad, D.J., Pudney, C., Morphological and functional abnormalities in mitochondria associated with synaptic degeneration in prion disease (2010) Am J Pathol, 177, pp. 1411-1421; Jeong, J.-K., Moon, M.-H., Bae, B.-C., Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity (2012) Neurosci Res, 73, pp. 99-105; Jeong, J.-K., Moon, M.-H., Lee, Y.-J., Autophagy induced by the class iii histone deacetylase sirt1 prevents prion peptide neurotoxicity (2013) Neurobiol Aging, 34, pp. 146-156; Jeong, J.-K., Moon, M.-H., Lee, Y.-J., Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity (2012) J Pineal Res, 53, pp. 138-146; Lehwald, N., Tao, G.Z., Jang, K.Y., B-catenin regulates hepatic mitochondrial function and energy balance in mice (2012) Gastroenterology, 143, pp. 754-764; Maeda, K., Takahashi, N., Kobayashi, Y., Roles of wnt signals in bone resorption during physiological and pathological states (2013) J Mol Med, 91, pp. 15-23; Flaherty, M.P., Kamerzell, T.J., Dawn, B., Chapter 7-wnt signaling and cardiac differentiation (2012) Progress in Molecular Biology and Translational Science, pp. 153-174. , YAOLIANG T, ed. Academic Press New York; Wiedau-Pazos, M., Wong, E., Solomon, E., Wnt-pathway activation during the early stage of neurodegeneration in ftdp-17 mice (2009) Neurobiol Aging, 30, pp. 14-21; Wei, L., Sun, C., Lei, M., Activation of wnt/b-catenin pathway by exogenous wnt1 protects sh-sy5y cells against 6-hydroxydopamine toxicity (2013) J Mol Neurosci, 49, pp. 105-115; Hsu, H.-C., Liu, Y.-S., Tseng, K.-C., Lgr5 regulates survival through mitochondria-mediated apoptosis and by targeting the wnt/b-catenin signaling pathway in colorectal cancer cells (2014) Cell Signal, 26, pp. 2333-2342; Santos, M.J., Quintanilla, R.A., Toro, A., Peroxisomal proliferation protects from b-amyloid neurodegeneration (2005) J Biol Chem, 280, pp. 41057-41068; Arendt, J., Melatonin and the pineal gland: Influence on mammalian seasonal and circadian physiology (1998) Rev Reprod, 3, pp. 13-22; Csernus, V., Mess, B., Biorhythms and pineal gland (2003) Neuro Endocrinol Lett, 24, pp. 404-411; Pevet, P., Melatonin and biological rhythms (2000) Biol Signals Recept, 9, pp. 203-212; Takaesu, Y., Komada, Y., Inoue, Y., Melatonin profile and its relation to circadian rhythm sleep disorders in angelman syndrome patients (2012) Sleep Med, 13, pp. 1164-1170; Crowley, S., Eastman, C., Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance (2013) Psychopharmacology, 225, pp. 825-837; Münch, M., Knoblauch, V., Blatter, K., Age-related attenuation of the evening circadian arousal signal in humans (2005) Neurobiol Aging, 26, pp. 1307-1319; Mauriz, J.L., Collado, P.S., Veneroso, C., A review of the molecular aspects of melatonin's anti-inflammatory actions: Recent insights and new perspectives (2013) J Pineal Res, 54, pp. 1-14; Calvo, J.R., Gonzalez-Yanes, C., Maldonado, M.D., The role of melatonin in the cells of the innate immunity: A review (2013) J Pineal Res, 55, pp. 103-120; Galano, A., Tan, D.X., Reiter, R.J., On the free radical scavenging activities of melatonin's metabolites, afmk and amk (2013) J Pineal Res, 54, pp. 245-257; Dragicevic, N., Copes, N., O'Neal-Moffitt, G., Melatonin treatment restores mitochondrial function in alzheimer's mice: A mitochondrial protective role of melatonin membrane receptor signaling (2011) J Pineal Res, 51, pp. 75-86; Wang, X., Sirianni, A., Pei, Z., The melatonin mt1 receptor axis modulates mutant huntingtin-mediated toxicity (2011) J Neurosci, 31, pp. 14496-14507; Rosales-Corral, S.A., Acuna-Castroviejo, D., Coto-Montes, A., Alzheimer's disease: Pathological mechanisms and the beneficial role of melatonin (2012) J Pineal Res, 52, pp. 167-202; Zhang, H.-M., Zhang, Y., Melatonin: A well-documented antioxidant with conditional pro-oxidant actions (2014) J Pineal Res, 57, pp. 131-146; Park, K.-H., Kang, J., Lee, E.-M., Melatonin promotes osteoblastic differentiation through the bmp/erk/wnt signaling pathways (2011) J Pineal Res, 51, pp. 187-194; Luchetti, F., Canonico, B., Bartolini, D., Melatonin regulates mesenchymal stem cell differentiation: A review (2014) J Pineal Res, 56, pp. 382-397; Gutierrez-Cuesta, J., Tajes, M., Jim-Enez, A., Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model (2008) J Pineal Res, 45, pp. 497-505; O'Donovan, C.N., Tobin, D., Cotter, T.G., Prion protein fragment prp-106-126) induces apoptosis via mitochondrial disruption in human neuronal sh-sy5y cells (2001) J Biol Chem, 276, pp. 43516-43523; Kim, B.-H., Kim, I.I.J., Carp, R., Oxidative stress and mitochondrial dysfunction in neurodegeneration of transmissible spongiform encephalopathies (tses) (2005) Neurodegeneration and Prion Disease, pp. 195-216. , BROWN D, ed. Springer New York; Thellung, S., Villa, V., Corsaro, A., P38 map kinase mediates the cell death induced by prp106-126 in the shsy5y neuroblastoma cells (2002) Neurobiol Dis, 9, pp. 69-81; Giese, K.P., Gsk-3: A key player in neurodegeneration and memory (2009) IUBMB Life, 61, pp. 516-521; Dun, Y., Li, G., Yang, Y., Inhibition of the canonical wnt pathway by dickkopf-1 contributes to the neurodegeneration in 6-ohda-lesioned rats (2012) Neurosci Lett, 525, pp. 83-88; Go, H.S., Kim, K.C., Choi, C.S., Prenatal exposure to valproic acid increases the neural progenitor cell pool and induces macrocephaly in rat brain via a mechanism involving the gsk-3b/b-catenin pathway (2012) Neuropharmacology, 63, pp. 1028-1041; Liang, J., Liu, L., Xing, D., Photobiomodulation by low-power laser irradiation attenuates ab-induced cell apoptosis through the akt/gsk3b/b-catenin pathway (2012) Free Radic Biol Med, 53, pp. 1459-1467; Zhang, X., Yin, W.-K., Shi, X.-D., Curcumin activates wnt/b-catenin signaling pathway through inhibiting the activity of gsk-3b in appswe transfected sy5y cells (2011) Eur J Pharm Sci, 42, pp. 540-546; L'Episcopo, F., Tirolo, C., Testa, N., Plasticity of subventricular zone neuroprogenitors in mptp (1-methyl-4-phenyl-1 2,3,6-tetrahydropyridine) mouse model of parkinson's disease involves cross talk between inflammatory and wnt/beta-catenin signaling pathways: Functional consequences for neuroprotection and repair (2012) J Neurosci, 32, pp. 2062-2085; Helfer, G., Ross, A.W., Russell, L., Photoperiod regulates vitamin a and wnt/b-catenin signaling in f344 rats (2012) Endocrinology, 153, pp. 815-824; Ming, M., Wang, S., Wu, W., Activation of wnt/b-catenin protein signaling induces mitochondria-mediated apoptosis in hematopoietic progenitor cells (2012) J Biol Chem, 287, pp. 22683-22690; Liu, S., Yeh, T.-H., Singh, V.P., B-catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice (2012) Hepatology, 55, pp. 931-940",Article,Scopus,2-s2.0-84918793692
"Toledano A., Alvarez M.I., Lopez-Rodriguez A.B., Toledano-Diaz A., Fernandez-Verdecia C.I.","Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II) [¿Existe la enfermedad de Alzheimer en todos los primates? Patología Alzheimer en primates no humanos y sus implicaciones fisiopatológicas (II)]",2014,"Neurologia","29","1",,"42","55",,1,10.1016/j.nrl.2011.05.004,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84895067148&partnerID=40&md5=723f9e7190096675c953e7b3aa2c82ff","Instituto Cajal, CSIC, Madrid, Spain; Departamento de Reproducción Animal, INIA, Madrid, Spain; Centro Internacional de Restauración Neurológica (CIREN), Cubanacán, La Habana, Cuba","Toledano, A., Instituto Cajal, CSIC, Madrid, Spain; Álvarez, M.I., Instituto Cajal, CSIC, Madrid, Spain; López-Rodríguez, A.B., Instituto Cajal, CSIC, Madrid, Spain; Toledano-Díaz, A., Departamento de Reproducción Animal, INIA, Madrid, Spain; Fernández-Verdecia, C.I., Centro Internacional de Restauración Neurológica (CIREN), Cubanacán, La Habana, Cuba","Introduction: In the ageing process there are some species of non-human primates which can show some of the defining characteristics of the Alzheimer's disease (AD) of man, both in neuropathological changes and cognitive-behavioural symptoms. The study of these species is of prime importance to understand AD and develop therapies to combat this neurodegenerative disease. Development: In this second part of the study, these AD features are discussed in the most important non-experimental AD models (Mouse Lemur - Microcebus murinus, Caribbean vervet - Chlorocebus aethiops, and the Rhesus and stump-tailed macaque - Macaca mulatta and M. arctoides) and experimental models (lesional, neurotoxic, pharmacological, immunological, etc.) non-human primates. In all these models cerebral amyloid neuropathology can occur in senility, although with different levels of incidence (100% in vervets; < 30% in macaques). The differences between normal and pathological (Alzheimer's) senility in these species are difficult to establish due to the lack of cognitive-behavioural studies in the many groups analysed, as well as the controversy in the results of these studies when they were carried out. However, in some macaques, a correlation between a high degree of functional brain impairment and a large number of neuropathological changes (""possible AD"") has been found. Conclusions: In some non-human primates, such as the macaque, the existence of a possible continuum between ""normal"" ageing process, ""normal"" ageing with no deep neuropathological and cognitive-behavioural changes, and ""pathological ageing"" (or ""Alzheimer type ageing""), may be considered. In other cases, such as the Caribbean vervet, neuropathological changes are constant and quite marked, but its impact on cognition and behaviour does not seem to be very important. This does assume the possible existence in the human senile physiological regression of a stable phase without dementia even if neuropathological changes appeared. © 2011 Sociedad Española de Neurología.","Ageing; Alzheimer models; Alzheimeŕs Disease; Amyloid; Behaviour; Cognitive functions; Non-human primates; Senility; Tau protein","Toledano, A., Álvarez, M.I., López-Rodríguez, A.B., Toledano-Díaz, A., Fernández-Verdecia, C.I., doi:10.1016/j.neurobiolaging.2010.06.003, ¿Existe la enfermedad de alzheimer en todos los primates? Patología alzheimer en primates no humanos y sus implicaciones fisiopatológicas (I). NeurologíaBons, N., Rieger, F., Prudhomme, D., Fisher, A., Krause, K.-H., Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? (2006) Genes, Brain and Behavior, 5, pp. 120-130; Silhol, S., Calenda, A., Jallageas, V., Mestre-Frances, N., Bellis, M., Bons, N., Beta-amyloid protein precursor in Microcebus murinus: genotyping and brain localization (1996) Neurobiol Dis, 3, pp. 169-182; Giannakopoulos, P., Silhol, S., Jallageas, V., Mallet, J., Bons, N., Bouras, C., Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus (1997) Acta Neuropathol (Berl), 94, pp. 131-139; Bons, N., Mestre, N., Ritchie, K., Petter, A., Podlisny, M., Selkoe, D., Identification of amyloid beta protein in the brain of the small, short-lived lemurian primate Microcebus murinus (1994) Neurobiol Aging, 15, pp. 215-220; Calenda, A., Mestre-Frances, N., Czech, C., Pradier, L., Petter, A., Perret, M., Bons, N., Cloning of the presenilin 2 cDNA and its distribution in brain of the primate, Microcebus murinus: coexpression with betaAPP and Tau proteins (1998) Neurobiol Dis, 5, pp. 323-333; Trouche, S.G., Maurice, T., Rouland, S., Verdier, J.M., Mestre-Francés, N., The three-panel runway maze adapted to Microcebus murinus reveals age-related differences in memory and perseverance performances (2010) Neurobiol Learn Mem, 94, pp. 100-106; Trouche, S.G., Asuni, A., Rouland, S., Wisniewski, T., Frangione, B., Verdier, J.M., Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives (2009) Vaccine, 27, pp. 957-964; Kanemaru, K., Iwatsubo, T., Ihara, Y., Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain (1996) Neurosci Lett, 214, pp. 196-198; McGuire, M.T., The St Kitts vervet (cercopithecus aethiops) (1974) J Med Primatol, 3, pp. 285-297; Palmour, R.M., Mulligan, J., Howbert, J.J., Ervin, F., Of monkeys and men: vervets and the genetics of human-like behaviors (1997) Am J Hum Genet, 61, pp. 481-488; Lemere, C.A., Beierschmitt, A., Iglesias, M., Spooner, E.T., Bloom, J.K., Leverone, J.F., Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a non-human primate, the Caribbean vervet (2004) Am J Pathol, 165, pp. 83-97; Voytko, M.L., Tinker, G.P., Cognitive function and its neural mechanism in nonhuman primate models of aging, Alzheimer's diseases, and menopause (2004) Front Biosci, 9, pp. 1899-1914; Bachevalier, J., Landis, L.S., Walker, L.C., Brickson, M., Mishkin, M., Price, D.L., Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction (1991) Neurobiol Aging, 12, pp. 99-111; Uno, H., Walker, L.C., The age of biosenescence and the incidence of cerebral beta-amyloidosis in aged captive Rhesus monkeys (1993) Ann N Y Acad Sci, 695, pp. 232-235; (1986) The Cayo Santiago macaques. History, behavior and biology, , State University of New York Press, Albany, R.G. Rawlins, M.J. Kessler (Eds.); Sani, S., Traul, D., Klink, A., Niaraki, N., Gonzalo-Ruiz, A., Wu, C.K., Distribution, progression and chemical composition of cortical amyloid-beta deposits in aged Rhesus monkeys: similarities to the human (2003) Acta Neuropathol (Berl), 105, pp. 145-156; Nakamura, S., Nakayama, H., Goto, N., Ono, F., Sakakibara, I., Yoshikawa, Y., Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys (1998) J Med Primatol, 27, pp. 244-252; Kimura, N., Tanemura, K., Nakamura, S., Takashima, A., Ono, F., Sakakibara, I., Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains (2003) Biochem Biophys Res Commun, 310, pp. 303-311; Voytko, M.L., Impairements in acquisition and reversal of two-choice discriminations by aged Rhesus monkeys (1999) Neurobiol Aging, 20, pp. 617-627; Gearing, M., Tigges, J., Mori, H., Mirra, S., Abeta40 is a major form of beta-amyloid in nonhuman primates (1996) Neurobiol Aging, 17, pp. 903-908; Toledano, A., Alvarez, M.I., Lesions and dysfunctions of the nucleus basalis as Alzheimer's disease models: general and critical overview and analysis of the long-term changes in several excitotoxic models (2004) Curr Alz Res, 1, pp. 189-214; Toledano, A., Álvarez, M.I., Lesion-induced vertebrate models of Alzheimer dementia (2010) Animal models of dementia, pp. 295-345. , Humana Press, New York, P.P. Deyn, D. Van Dam (Eds.); Ramirez, M.J., Ridley, R.M., Baker, H.F., Maclean, C.J., Honer, W.G., Francis, P.T., Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions (2001) J Neural Transm, 108, pp. 809-826; Aigner, T.G., Mitchell, S.J., Aggleton, J.P., DeLong, M.R., Struble, R.G., Price, D.L., Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert (1987) Psychopharmacology, 92, pp. 292-300; Aigner, T.G., Mitchell, S.J., Aggleton, J.P., DeLong, M.R., Struble, R.G., Price, D.L., Transient impairment of recognition memory following ibotenic-acid lesions of the basal forebrain in macaques (1991) Exp Brain Res, 86, pp. 18-26; Irle, E., Markowitsch, H.J., Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory (1987) Ann Neurol, 22, pp. 735-743; Ridley, R.M., Baker, H.F., Drewwtt, B., Johnson, J.A., Effects of ibotenic acid leisons of the basal forebrain on serial reversal learning in marmosets (1985) Psychopharmacology, 86, pp. 438-443; Ridley, R.M., Murray, T.K., Johnson, J.A., Baker, H.F., Learning impairment following lesion of the nucleus of Meynert in marmoset: modification by cholinergic drugs (1986) Brain Res, 376, pp. 108-116; Li, W., Wu, Y., Min, F., Li, Z., Huang, J., Huang, R., A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan (2010) Metab Brain Dis, 25, pp. 277-284; Wenk, G.L., A primate model of Alzheimer's disease (1993) Behav Brain Res, 57, pp. 117-122; McKee, A.C., Kowall, N.W., Schumacher, J.S., Beal, M.F., The neurotoxicity of amyloid beta protein in aged primates (1998) Amyloid, 5, pp. 1-9; Podlisny, M.B., Stephenson, D.T., Frosch, M.P., Tolan, D.R., Lieberburg, I., Clemens, J.A., Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity (1993) Am J Pathol, 142, pp. 17-24; Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J., Bruton, C.J., Evidence for the experimental transmission of cerebral beta-amyloidosis to primates (1993) Int J Exp Pathol, 74, pp. 441-454; Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J., Bruton, C.J., Experimental induction of beta-amyloid plaques and cerebral angiopathy in primates (1993) Ann N Y Acad Sci, 695, pp. 228-231; Maclean, C.J., Baker, H.F., Ridley, R.M., Mori, H., Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (Callithrix jacchus) (2000) J Neural Transm, 107, pp. 799-814; Ridley, R.M., Baker, H.F., Windle, C.P., Cummings, R.M., Very long term studies of the seeding of beta-amyloidosis in primates (2006) J Neural Transm, 113, pp. 1243-1251; Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J., Bruton, C.J., Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy (1994) Mol Neurobiol, 8, pp. 25-39; McArthur, R.A., Gray, J., Schreiber, R., Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials (2010) Curr Opin Investig Drugs, 11, pp. 740-760; Toyohara, J., Ishiwata, K., Sakata, M., Wu, J., Nishiyama, S., Tsukada, H., In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys (2010) PLoS One, 5, pp. e8961; Asai, M., Fujikawa, A., Noda, A., Miyoshi, S., Matsuoka, N., Nishimura, S., Donepezil- and scopolamine-induced rCMRglu changes assessed by PET in conscious Rhesus monkeys (2009) Ann Nucl Med, 23, pp. 877-882; Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) Nat Med, 15, pp. 331-337; Cook, J.J., Wildsmith, K.R., Gilberto, D.B., Holahan, M.A., Kinney, G.G., Mathers, P.D., Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound (2010) J Neurosci, 30, pp. 6743-6750; Sankaranarayanan, S., Holahan, M.A., Colussi, D., Crouthamel, M.C., Devanarayan, V., Ellis, J., First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates (2009) J Pharmacol Exp Ther, 328, pp. 131-140; Gandy, S., DeMattos, R.B., Lemere, C.A., Heppner, F.L., Leverone, J., Aguzzi, A., Alzheimer A beta vaccination of Rhesus monkeys (Macaca mulatta) (2004) Alzheimer Dis Assoc Disord, 18, pp. 44-46; Gandy, S., DeMattos, R.B., Lemere, C.A., Heppner, F.L., Leverone, J., Aguzzi, A., Alzheimer's Abeta vaccination of Rhesus monkeys (Macaca mulatta) (2004) Mech Ageing Dev, 125, pp. 149-151; Lemere, C.A., Beierschmitt, A., Iglesias, M., Spooner, E.T., Bloom, J.K., Leverone, J.F., Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a non-human primate, the Caribbean vervet (2004) Am J Pathol, 165, pp. 283-297; Li, S.B., Wang, H.Q., Lin, X., Xu, J., Xie, Y., Yuan, Q.F., Specific humoral immune responses in Rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine (2005) Chin Med J (Engl), 118, pp. 660-664; Lemere, C.A., Maier, M., Jiang, L., Peng, Y., Seabrook, T.J., Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans (2006) Rejuvenation Res, 9, pp. 77-84; Britschgi, M., Olin, C.E., Johns, H.T., Takeda-Uchimura, Y., LeMieux, M.C., Rufibach, K., Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease (2009) Proc Natl Acad Sci U S A, 106, pp. 12145-12150; Qin, W., Chachich, M., Lane, M., Roth, G., Bryant, M., De Cabo, R., Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus) (2006) J Alzheimers Dis, 10, pp. 417-422; Willette, A.A., Gallagher, C., Bendlin, B.B., McLaren, D.G., Kastman, E.K., Canu, E., Homocysteine, neural atrophy, and the effect of caloric restriction in Rhesus monkeys (2010) Neurobiol Aging, , (En prensa); Wu, J., Basha, M.R., Brock, B., Cox, D.P., Cardozo-Pelaez, F., McPherson, C.A., Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD (2008) J Neurosci, 28, pp. 3-9; Basha, M.R., Wei, W., Bakheet, S.A., Benitez, N., Siddiqi, H.K., Ge, Y.W., The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and -amyloid in the aging brain (2005) J Neurosci, 25, pp. 823-829; Niklowitz, W.J., Mandybur, T.I., Neurofibrillary changes following childhood lead encephalopathy (1985) J Neuropathol Exp Neurol, 34, pp. 445-455; Barker, D.J., Winter, P.D., Osmond, C., Margetts, B., Simmonds, S.J., Weight in infancy and death from ischaemic heart disease (1989) Lancet, 2, pp. 577-580; Osmond, C., Barker, D.J., Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women (2000) Environ Health Perspect, 108, pp. 545-553; Guilarte, T.R., APLP1, Alzheimer's-like pathology and neurodegeneration in the frontal cortex of manganese-exposed non-human primates (2010) Neurotoxicology, 31, pp. 572-574; Price, D.L., Martin, L.J., Sisodia, S.S., Wagster, M.V., Koo, E.H., Walker, L.C., Aged non-human primates: an animal model of age-associated neurodegenerative disease (1991) Brain Pathol, 1, pp. 287-296; Gearing, M., Rebeck, G.W., Hyman, B.T., Tigges, J., Mirra, S.S., Neuropathology and apolipoprotein E profile of aging chimpanzees: implications for Alzheimer disease (1994) Proc Natl Acad Sci U S A, 91, pp. 9382-9386; Selkoe, D.J., Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior (2008) Behav Brain Res, 192, pp. 106-113; Cork, L.C., Powers, R.E., Selkoe, D.J., Davies, P., Geyer, J.J., Price, D.L., Neurofibrillary tangles and senile plaques in aged bears (1988) J Neuropathol Exp Neurol, 47, pp. 629-641; Pawlik, M., Fuchs, E., Walker, L.C., Levy, E., Primate-like amyloid-beta sequence but no cerebral amyloidosis in aged tree shrews (1999) Neurobiol Aging, 20, pp. 47-51; Gearing, M., Tigges, J., Mori, H., Mirra, S.S., Beta-Amyloid (A beta) deposition in the brains of aged orangutans (1997) Neurobiol Aging, 18, pp. 139-146; Lemere, C.A., Oh, J., Stanish, H.A., Peng, Y., Pepivani, I., Fagan, A.M., Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? (2008) Rejuvenation Res, 11, pp. 321-332; Rosen, R.F., Farberg, A.S., Gearing, M., Dooyema, J., Long, P.M., Anderson, D.C., Tauopathy with paired helical filaments in an aged chimpanzee (2008) J Comp Neurol, 509, pp. 259-270; Walker, L.C., Rosen, R.F., Levine, H., Diversity of Abeta deposits in the aged brain: a window on molecular heterogenity? (2008) Rom J Morphol Embryol, 49, pp. 5-11; Chambers, J.K., Kuribayashi, H., Ikeda, S., Une, Y., Distribution of neprilysin and deposit patterns of Abeta subtypes in the brains of aged squirrel monkeys (Saimiri sciureus) (2010) Amyloid, 17, pp. 75-82; Kraska, A., Dorieux, O., Picq, J.L., Petit, F., Bourrin, E., Chenu, E., Age-associated cerebral atrophy in mouse lemur primates (2011) Neurobiol Aging, 32, pp. 894-906; Ichinohe, N., Hayashi, M., Wakabayashi, K., Rockland, K.S., Distribution and progression of amyloid-beta deposits in the amygdala of the aged macaque monkey, and parallels with zinc distribution (2009) Neuroscience, 159, pp. 1374-1383; Oikawa, N., Kimura, N., Yanagisawa, K., Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition (2010) Brain Res, 1315, pp. 137-149; Shah, P., Lal, N., Leung, E., Traul, D.E., Gonzalo-Ruiz, A., Geula, C., Neuronal and axonal loss are selectively linked to fibrillar amyloid-{beta} within plaques of the aged primate cerebral cortex (2010) Am J Pathol, 177, pp. 325-333; Cai, Y., Xiong, K., Zhang, X.M., Cai, H., Luo, X.G., Feng, J.C., Beta-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and beta-amyloid accumulation (2010) Eur J Neurosci, 18, pp. 1223-1238; Brizee, K.R., Ordy, J.M., Bartus, R.T., Localization of cellular changes within multimodal sensory regions in aged monkey brain: possible implications for aged-related cognitive less (1980) Neurobiol Aging, 1, pp. 45-52; Cupp, C.J., Uemura, E., Aged-related changes in prefrontal cortex of Maccaca mulatta: quantitative analysis of dendritic branching patterns (1980) Exp Neurol, 69, pp. 143-163; Keuker, J.I., Luiten, P.G., Fuchs, E., Preservation of hippocampal neuron numbers in aged Rhesus monkeys (2003) Neurobiol Aging, 24, pp. 157-165; Rapp, P.R., Amaral, D.G., Evidence for task-dependent memory dysfunction in the aged monkey (1989) J Neurosci, 9, pp. 3568-3576; Craik, F.I.M., Byrd, M., Swanson, J.M., Patterns of memory loss in three elderly samples (1987) Psychol Aging, 2, pp. 79-86; Capitanio, J.P., Emborg, M.E., Contributions of non-human primates to neuroscience research (2008) Lancet, 371, pp. 1126-1135; Nagahara, A.H., Bernot, T., Tuszynski, M.H., Age-related cognitive deficits in Rhesus monkeys mirror human deficits on an automated test battery (2010) Neurobiol Aging, 31, pp. 1020-1031; Buccafusco, J.J., Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders (2008) J Alzheimers Dis, 15, pp. 709-720; Moss, M.B., Moore, T.L., Schettler, S.P., Killiany, R., Rosene, D., Successful vs. unsuccessful aging in the Rhesus monkey (2007) Brain aging: models, methods, and mechanisms. Frontiers in neuroscience, , CRC Press, Boca Raton, D.R. Riddle (Ed.); Rosen, R.F., Walker, L.C., Levine, H., PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer's disease (2011) Neurobiol Aging, 32, pp. 223-234; Rapoport, S.I., Hypothesis: Alzheimer's disease is a phylogenetic disease (1989) Med Hypotheses, 29, pp. 147-150; Albert, M.S., Neuropsychological and neurophysiological changes in healthy adult humans across the age range (1993) Neurobiol Aging, 14, pp. 623-625; Forlenza, O.V., Diniz, B.S., Gattaz, W.F., Diagnosis and biomarkers of predementia in Alzheimer's disease (2010) BMC Med, 8, p. 89; Perls, T.T., The different paths to 100 (2006) Am J Clin Nutr, 83, pp. 485S-487S; Nelson, P.T., Stefansson, K., Gulcher, J., Saper, C.B., Molecular evolution of tau protein: implications for Alzheimer's disease (1996) J Neurochem, 67, pp. 1622-1632; Wallace, D.C., Sequence variation in human evolution and disease (1994) Proc Natl Acad Sci U S A, 91, pp. 8739-8746. , Mitochondrial DNA; Bufill, E., Blesa, R., Enfermedad de Alzheimer y evolución cerebral. ¿Es la enfermedad de Alzheimer un ejemplo de pleiotropía antagonística? (2006) Rev Neurol, 42, pp. 25-33; Vamathevan, J.J., Hasan, S., Emes, R.D., Amrine-Madsen, H., Rajagopalan, D., Topp, S.D., The role of positive selection in determining the molecular cause of species differences in disease (2008) BMC Evol Biol, 8, p. 273; Finnerty, J.R., Wang, W.X., Hébert, S.S., Wilfred, B.R., Mao, G., Nelson, P.T., The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases (2010) J Mol Biol, 402, pp. 491-509",Short Survey,Scopus,2-s2.0-84895067148
"Okita M., Kusakabe A., Akiba R., Yagi H., Tamura Y.","A case of an elderly woman with dementia in whom nutrition via gastrostomy was discontinued after considerable discussion according to the guidelines",2014,"Japanese Journal of Geriatrics","51","6",,"560","563",,,,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84924338809&partnerID=40&md5=b8d70d1b5323e42ceb585838a1efe671","Mirai Zaitaku Clinic, Japan; Yu Zaitaku Clinic, Japan","Okita, M., Mirai Zaitaku Clinic, Japan; Kusakabe, A., Mirai Zaitaku Clinic, Japan; Akiba, R., Mirai Zaitaku Clinic, Japan; Yagi, H., Yu Zaitaku Clinic, Japan; Tamura, Y., Yu Zaitaku Clinic, Japan","A 94-year-old woman with Alzheimers disease had been receiving nourishment via gastrostomy for three years and in a state in which communication was not possible. Upon the familyʼs request for consultation and advice, and after a considerable discussion according to the guidelines, the decision was made to stop the gastrostomy feeding. The patient subsequently coincidentally contracted influenza one week later and died due to pneumonia. Based on our experience of making the decision to stop nutritional supplementation via gastrostomy according to the guidelines, there are various issues, such as the psychological distress of the family, which cannot be resolved based on the guidelines. © 2015, Japan Geriatrics Society. All rights reserved.","Dementia; Dignity; Gastrostomy; Guideline; Stop",,Article,Scopus,2-s2.0-84924338809
"Knight R.G., Tsui H.S.L., Abraham W.C., Skeaff C.M., McMahon J.A., Cutfield N.J.","Lack of effect of the apolipoprotein e ε4 genotype on cognition during healthy aging",2014,"Journal of Clinical and Experimental Neuropsychology","36","7",,"742","750",,,10.1080/13803395.2014.935706,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911990048&partnerID=40&md5=61c09b3721629c7c8862f8c5438ca98a","Department of Psychology, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Department of Human Nutrition, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Department of Medicine, Brain Health Research Centre, University of OtagoDunedin, New Zealand","Knight, R.G., Department of Psychology, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Tsui, H.S.L., Department of Psychology, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Abraham, W.C., Department of Psychology, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Skeaff, C.M., Department of Human Nutrition, Brain Health Research Centre, University of OtagoDunedin, New Zealand; McMahon, J.A., Department of Human Nutrition, Brain Health Research Centre, University of OtagoDunedin, New Zealand; Cutfield, N.J., Department of Medicine, Brain Health Research Centre, University of OtagoDunedin, New Zealand","Background: The apolipoprotein E (APOE) ε4 genotype is associated with an increased risk of Alzheimers disease. In community surveys, older adults with this genotype have been found to have lower scores on neuropsychological tests than those who do not. It is possible that this is the consequence of subclinical changes in cognition in those persons who later develop dementia. The aim of this research was to determine whether the effect of APOE genotype on cognition would remain if those who subsequently became demented were retrospectively removed from the analysis of the baseline test data from a sample of healthy adults.Method: A sample of 241 nondemented persons over the age of 65 for whom APOE genotyping was available were administered a range of neuropsychological tests at baseline and were followed up 10 years later.Results: Significant differences between the ε4-present and ε4-absent groups were found for the delayed recall trial of the Rey Auditory Verbal Learning Test and the Trail Making Test. When those participants known to have developed dementia during the follow-up period were excluded from the analysis of the baseline data these differences disappeared. A total of 113 nondemented survivors from the original sample were retested, and no difference was found in the rate of decline on any measure between the ε4-present and ε4-absent groups.Conclusions: It is likely that the reported effect of the ε4 APOE genotype on cognition is the consequence of the ε4-present group containing persons whose cognition is subtly affected by the early stages of a dementing process. It is also unlikely that the presence of the ε4 allele by itself leads to a significantly accelerated rate of cognitive decline in the nondemented elderly. © 2014 Taylor & Francis.","Apolipoprotein E; Cognition; Older adult; Rey Auditory Verbal Learning Test; Trail Making Test","Brainerd, C.J., Reyna, V.F., Petersen, R.C., Smith, G.E., Kenney, A.E., Gross, C.J., Fisher, G.G., The apolipoprotein-E genotype predicts longitudinal transitions to mild cognitive impairment but not Alzheimers dementia: Findings from a national representative study (2013) Neuropsychology, 27, pp. 86-94; Broadbent, D.E., Cooper, P.F., Fitzgerald, P., Parkes, K.R., The Cognitive Failures Questionnaire (CFQ) and its correlates (1982) British Journal of Clinical Psychology, 21 (1), pp. 1-16; Buschke, H., Fuld, P.A., Evaluating storage, retention and retrieval in disordered memory and learning (1974) Neurology, 24, pp. 1019-1025; Dik, M.G., Jonker, C., Bouter, L.M., Geerlings, M.I., Van Kamp, G.J., Deeg, D.J., APOE-epsilon 4 is associated with memory decline in cognitively impaired elderly (2000) Neurology, 54, pp. 1492-1497; Farrer, L.A., Cupples, A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Van Duijn, C.M., Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and Alzheimer disease: A meta-analysis (1997) JAMA, 278 (16), pp. 1349-1356; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""Mini-Mental State"": A practical method for grading the cognitive scale of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198. , doi.org/ 10.1016/0022-3956(75)90026-6; Fox, N.C., Warrington, E.K., Seiffer, A.L., Agnew, S.K., Rossor, M.N., Presymptomatic cognitive deficits in individuals at risk of familial Alzheimers disease. A longitudinal prospective study (1998) Brain, 121, pp. 1631-1639; Goodglass, H., Kaplan, E., (1983) The Assessment of Aphasia and Related Disorders, , (2nd ed.). Philadelphia, PA: Lea and Febiger; Hixson, J.E., Vernier, D.T., Restriction isotyping of human apolipoprotein e by gene amplification and cleavage with Hha i (1990) Journal of Lipid Research, 31 (3), pp. 545-548; Hom, J., Reitan, R.M., Generalised cognitive function after stroke (1990) Journal of Clinical and Experimental Neuropsychology, 12, pp. 644-654; Horsburgh, K., McCarron, M.O., White, F., Nicholl, J.A., The role of apolipoprotein e in Alzheimers disease, acute brain injury and cerebrovascular disease: Evidence of common mechanisms and utility of animal models (2000) Neurobiology of Aging, 21 (2), pp. 245-255; Ivnik, R.J., Malec, J.F., Tangalos, E.G., Petersen, R.C., Kokmen, E., Kurland, L.T., The Auditory Verbal Learning Test (AVLT): Norms for age 55 and older (1990) Psychological Assessment; A Journal of Consulting and Clinical Psychology, 2 (3), pp. 304-312; Jordan, J., Galindo, M.F., Miller, J.J., Reardon, C.A., Getz, G.S., Ladu, M.J., (1997) Journal of Neuroscience, 18 (1), pp. 195-204; Jorm, A.F., Mather, K.A., Butterworth, P., Anstey, K.J., Christensen, H., Eastel, S., APOE genotype and cognitive functioning in a large age-stratified population sample (2007) Neuropsychology, 21, pp. 1-8; Knight, R.G., McMahon, J., Green, T.J., Skeaff, C.M., Regression equations for predicting scores of persons over 65 on the Rey AVLT, the MMSE, the Trail Making Test, and semantic fluency measures (2006) British Journal of Clinical Psychology, 45, pp. 393-402; Lezak, M.D., Howieson, D.B., Loring, D.W., (2004) Neuropsychological Assessment, , New York, NY: Oxford University Press; Mayeux, R., Small, S.S., Tang, M.-X., Tyco, B., Stern, Y., Memory performance in healthy elderly without Alzheimers disease: Effects of time and apolipoprotein-E (2001) Neurobiology of Aging, 22 (4), pp. 683-689; McMahon, J.A., Green, T.J., Skeaff, C.M., Knight, R.G., Mann, J.I., Williams, S.M., A controlled trial of homocysteine lowering and cognitive performance (2006) New England Journal of Medicine, 354, pp. 14-22; Nelson, H.E., Willison, J., (1991) National Adult Reading Test (NART): Test Manual, , (2nd ed.). Windsor: NFER-Nelson; Pachana, N.A., Bryne, G.J., Siddle, H., Koloski, N., Harley, E., Arnold, E., Development and validation of the Geriatric Anxiety Inventory (2007) International Psychogeriatrics, 19, pp. 103-114; Peila, R., Rodriguez, B.L., Launer, L.J., Type 2 diabetes, APOE gene, and the risk of dementia and related pathologies: The Honolulu-Asia aging study (2002) Diabetes, 51, pp. 1256-1262; Praetorius, M., Thorvaldsson, V., Hassing, L.B., Johansson, B., Substantial effects of apolipoprotein-E ε4 on memory decline in very old age: Longitudinal findings from a population-based sample (2013) Neurobiology of Aging, 34, pp. 2734-2739; Reitan, R.M., The relation of the Trail Making Test to organic brain damage (1955) Journal of Consulting Psychology, 19 (5), pp. 393-394; Salmon, D.P., Ferris, S.H., Thomas, R.G., Sano, M., Cummings, J.L., Sperling, R.A., Aisen, P.S., Age and apolipoprotein e genotype influence rate of cognitive decline in nondemented elderly (2013) Neuropsychology, 27, pp. 391-401; Savage, R.M., Grouvier, W.D., Rey-Auditory Verbal Learning Test: The effects of age and gender, and norms for delayed recall and story recognition trials (1992) Archives of Clinical Neuropsychology, 7, pp. 407-414. , doi.org/ 10.1016/0887-6177(92)90153-E; Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Roses, A.D., Increased amyloid beta-peptide deposition in the cerebral cortex as a consequence of apolipoprotein e genotype in late onset Alzheimer disease (1993) Proceedings of the National Academy of Sciences USA, 90 (20), pp. 9649-9653; Small, B.J., Basun, H., Bäckman, L., Three-year changes in cognitive performance as a function of apolipoprotein e genotype: Evidence from very old adults without dementia (1998) Psychology and Aging, 13, pp. 80-87; Small, B.J., Rosnick, C.B., Fratiglioni, L., Bäckman, L., Apolipoprotein e and cognitive performance: A meta-analysis (2004) Psychology and Aging, 19, pp. 592-600; Strauss, E., Sherman, E.M.S., Spreen, O., (2006) A Compendium of Neuropsychological Tests, , (3rd ed.). New York, NY: Oxford University Press; Tombaugh, T., Trail Making Test A and B: Normative data stratified by age and education (2004) Archives of Clinical Neuropsychology, 19, pp. 203-214. , doi.org/ 10.1016/S0887-6177(03)00039-8; Van Gerven, P.W.M., Van Boxtel, B.P.J., Ausems, E.E.B., Bekers, O., Jolles, J., Do apolipoprotein e genotype and educational attainment predict the rate of cognitive decline in normal aging? A 12-year follow-up of the Maastricht aging study (2012) Neuropsychology, 26, pp. 459-472; Wisdom, N.M., Callahan, J.L., Hawkins, K.A., The effects of apolipoprotein e on non-impaired cognitive functioning: A meta-analysis (2011) Neurobiology of Aging, 32, pp. 63-74; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V.O., Development and validation of a geriatric depression screening scale: A preliminary report (1983) Journal of Psychiatric Research, 17 (1), pp. 37-49; Yin, Y.-W., Li, J.-C., Wang, J.-Z., Li, B.-H., Pi, Y., Yang, Q.-W., Zhang, L.-L., Association between apolipoprotein e gene polymorphism and the risk of vascular dementia: A meta-analysis (2012) Neuroscience Letters, 514, pp. 6-11",Article,Scopus,2-s2.0-84911990048
"Prigent S., Haffaf H.W., Banks H.T., Hoffmann M., Rezaei H., Doumic M.","Size distribution of amyloid fibrils. Mathematical models and experimental data",2014,"International Journal of Pure and Applied Mathematics","93","6",,"845","878",,1,10.12732/ijpam.v93i6.10,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903169009&partnerID=40&md5=92c4dc36d8202dc37ce357649a3fb25f","Inria, Institut National de Recherche en Informatique et AutomatiqueRocquencourt, France; Pierre et Marie Curie University, Paris-Diderot University, CNRS UMR 7598Paris, France; Center for Research in Scientific Computation (CRSC), North Carolina State UniversityRaleigh, NC, United States; CEREMADE (Centre de REcherche en MAthmatique de la DEcision), CNRS-UMR 7534 and CREST, University Paris-DauphineParis, France; Institut National de Recherche AgronomiqueJouy-en-Josas, France","Prigent, S., Inria, Institut National de Recherche en Informatique et AutomatiqueRocquencourt, France, Pierre et Marie Curie University, Paris-Diderot University, CNRS UMR 7598Paris, France; Haffaf, H.W., Inria, Institut National de Recherche en Informatique et AutomatiqueRocquencourt, France, Pierre et Marie Curie University, Paris-Diderot University, CNRS UMR 7598Paris, France; Banks, H.T., Center for Research in Scientific Computation (CRSC), North Carolina State UniversityRaleigh, NC, United States; Hoffmann, M., CEREMADE (Centre de REcherche en MAthmatique de la DEcision), CNRS-UMR 7534 and CREST, University Paris-DauphineParis, France; Rezaei, H., Institut National de Recherche AgronomiqueJouy-en-Josas, France; Doumic, M., Inria, Institut National de Recherche en Informatique et AutomatiqueRocquencourt, France, Pierre et Marie Curie University, Paris-Diderot University, CNRS UMR 7598Paris, France","More than twenty types of proteins can adopt misfolded conformations, which can co-aggregate into amyloid fibrils, and are related to pathologies such as Alzheimers disease. This article surveys mathematical models for aggregation chain reactions, and discuss the ability to use them to understand amyloid distributions. Numerous reactions have been proposed to play a role in their aggregation kinetics, though the relative importance of each reaction in vivo is unclear: these include activation steps, with nucleation compared to initiation, disaggregation steps, with depolymerization compared to fragmentation, and additional processes such as filament coalescence or secondary nucleation. We have statistically analysed the shape of the size distribution of prion fibrils, with the specific example of truncated data due to the experimental technique (electron microscopy). A model of polymerization and depolymer-ization succeeds in explaining this distribution. It is a very plausible scheme though, as evidenced in the review of other mathematical models, other types of reactions could also give rise to the same type of distributions. © 2014 Academic Publications, Ltd.","Becker-döring system; Kernel density estimation; Protein aggregation; PrP fiber; Statistical test","Alper, T., Cramp, W.A., Haig, D.A., Clarke, M.C., Does the agent of scrapie replicate without nucleic acid? (1967) Nature, 214, pp. 764-766; Anderson, M., Bocharova, O.V., Makarava, N., Breydo, L., Salnikov, V.V., Baskakov, I.V., Polymorphism and ultrastructural organization of prion protein amyloid fibrils: An insight from high resolution atomic force microscopy (2006) Journal of Molecular Biology, 358 (2), pp. 580-596; Andreoletti, O., Litaise, L., Simmons, H., Corbiere, F., Lugan, S., Costes, F., Schelcher, F., Lacroux, C., Highly efficient prion transmission by blood transfusion (2012) PLoS Path, 8, p. e1002782; Balagué, D., Cañizo, J., Gabriel, P., Fine asymptotics of profiles and relaxation to equilibrium for growth-fragmentation equations with variable drift rates (2013) Kinetic Related Models, , in press; Ball, J.M., Carr, J., Asymptotic behaviour of solutions to the beckerdring equations for arbitrary initial data (1988) Proc. Roy. Soc. Edinburgh Sect., A, 108, pp. 109-116; Ball, J.M., Carr, J., Penrose, O., The becker-dring cluster equations: Basic properties and asymptotic behaviour of solutions (1986) Commun. Math. Phys., 104, pp. 657-692; Becker, R., Dring, W., Kinetische Behandlung der Keimbildung in berst-tigten Dmpfern (1935) Ann. Phys., 24, pp. 719-752; Beringue, V., Herzog, L., Jaumain, E., Reine, F., Sibille, P., Le Dur, A., Vilotte, J.-L., Laude, H., Facilitated cross-species transmission of prions in extraneural tissue (2012) Science, 335, pp. 472-475; Brown, W.-B., Szwarc, M., Molecular weight distribution of ""living"" polymers (1958) Trans. Faraday Soc., 54, pp. 416-419; Burton, J.J., (1977) Nucleation Theory. Statistical Mechanics, Part A: Equilibrium Techniques, , Springer US; Cohen, S., Vendruscolo, M., Welland, M.E., Dobson, C.M., Terentjev, E.M., Knowles, T.P.J., Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments (2011) The Journal of Chemical Physics, 135 (6), p. 065105; Cohen, S.I., Vendruscolo, M., Dobson, C.M., Knowles, T.P.J., Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations (2011) The Journal of Chemical Physics, 135 (6), p. 065107; Collins, S.R., Douglass, A., Vale, R.D., Weissman, J.S., Mechanism of prion propagation: Amyloid growth occurs by monomer addition (2004) PLOS Biology, 2, p. e321; DePace, A.H., Weissman, J.S., Origins and kinetic consequences of diversity in sup35 yeast prion fibers (2002) Nature Structural Biology, 9 (5), pp. 389-396; Doumic, M., Gabriel, P., Eigenelements of a general aggregation-fragmentation model (2009) Mathematical Models and Methods in Applied Sciences, 20 (5), p. 757; Doumic, M., Hoffmann, M., Krell, N., Robert, L., (2014) Statistical Estimation of a Growth-fragmentation Model Observed on a Genealogical Tree, , Bernoulli, under revision; Doumic, M., Hoffmann, M., Reynaud, P., Rivoirard, V., Nonparametric estimation of the division rate of a size-structured population (2012) SIAM J. on Numer. Anal., 50 (2), pp. 925-950; Doumic, M., Perthame, B., Zubelli, J.P., Numerical solution of an inverse problem in size-structured population dynamics (2009) Inverse Problems, 25 (4), p. 045008; El Moustaine, D., Perrier, V., Acquatella-Tran Van Va., I., Meersman, F., Ostapchenko, V.G., Baskakov, I.V., Lange, R., Torrent, J., Amyloid features and neuronal toxicity of mature prion fibrils are highly sensitive to high pressure (2011) Journal of Biological Chemistry, 286, pp. 13448-13459; Flory, P.J., (1953) Principles of Polymer Chemistry, , Cornell University Press; Furukawa, Y., Nukina, N., Functional diversity of protein fibrillar aggregates from physiology to rna granules to neurodegenerative diseases (2013) Biochimica et Biophysica Acta, 1832, pp. 1271-1278; Gill, N., Spence, Y., Richard-Loendt, A., Kelly, A., Dabaghian, R., Boyes, L., Linehan, J., Brandner, S., Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: Large scale survey (2013) BMJ, 347, p. f5675; Gillam, J.E., MacPhee, C.E., Modelling amyloid fibril formation kinetics: Mechanisms of nucleation and growth (2013) J. Phys. Condens. Matter, 25, p. 373101; Goldenshluger, A., Lepski, O., Bandwidth selection in kernel density estimation: Oracle inequalities and adaptive minimax optimality (2011) Ann. Statist., 39, pp. 1608-1632; Goldenshluger, A., Lepski, O., Uniform bounds for norms of sums of independent random functions (2011) Ann. Probab., 39, pp. 2318-2384; Greer, S.C., Reversible polymerizations and aggregations (2002) Annual Review of Physical Chemistry, 53, pp. 173-200; Inoue, Y., Kishimoto, A., Hirao, J., Yoshida, M., Taguchi, H., Strong growth polarity of yeast prion fiber revealed by single fiber imaging (2001) The Journal of Biological Chemistry, 276 (38), pp. 35227-35230; Koch, I., Reisig, W., (2011) Modeling in Systems Biology - The Petri Net Approach, , Springer; Liu, T., Bitan, G., Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: Strategies and mechanisms (2012) Chem Med Chem, 7, pp. 359-374; Meersman, F., Dobson, C.M., Probing the pressure-temperature stability of amyloid fibrils provides new insights into their molecular properties (2006) Biochimica et Biophysica Acta, 1764, pp. 452-460; Miyake, A., Stockmayer, W.H., Theoretical reaction kinetics of reversible living polymerization (1965) Die Makromolekulare Chemie, 88, pp. 90-116; Mostaert, A.S., Giordani, C., Crockett, R., Karsten, U., Schumann, R., Parvis, S.P., Characterisation of amyloid nanostructures in the natural adhesive of unicellular subaerial algae (2009) Journal of Adhesion, 85, pp. 465-485; Necula, M., Kuret, J., Electron microscopy as a quantitative method for investigating tau fibrillization (2004) Analytical Biochemistry, 329 (2), pp. 238-246; Oosawa, F., Size distribution of protein polymers (1970) Journal of Theoretical Biology, 27 (1), pp. 69-86; Pallitto, M.M., Murphy, R.M., A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state (2001) Biophysical Journal, 81 (3), pp. 1805-1822; Penrose, O., The becker-dring equations for the kinetics of phase transitions Math. Proc. Camb. Phil. Soc., 96, p. 2001; Penrose, O., Lebowitz, J.L., (1979) Towards a Rigorous Molecular Theory of Metastability, , Gauthier-Villars; Petkova, A.T., Leapman, R.D., Guo, Z., Yau, W.M., Mattson, M.P., Tycko, R., Self-propagating, molecular-level polymorphism in alzheimerss beta-amyloid fibrils (2005) Science, 307, pp. 262-265; Prigent, S., Ballesta, A., Charles, F., Lenuzza, N., Gabriel, P., Tine, L.-M., Rezaei, H., Doumic, M., An efficient kinetic model for assemblies of amyloid fibrils and its application to polyglutamine aggregation (2012) Plos One, 7, p. 0043273; Rezaei, H., Marc, D., Choiset, Y., Takahashi, M., Hui Bon Hoa, G., Haertle, T., Grosclaude, J., Debey, P., High yield purification and physico-chemical properties of full-length recombinant allelic variants of sheep prion protein linked to scrapie susceptibility (2000) European Journal of Biochemistry, 267, pp. 2833-2839; Schwartz, K., Boles, B.R., Microbial amyloids functions and interactions within the host (2012) Current Opinion in Microbiology, 2012, pp. 93-99; Silverman, B., Density estimation for statistics and data analysis (1986) Monographs on Statistics and Applied Probability, , Chapman and Hall, London; Sipe, J.D., Cohen, A., Review: History of the amyloid fibril (2000) Journal of Structural Biology, 130, pp. 88-98; Smith, J.F., Knowles, T.P.J., Dobson, C.M., Macphee, C.E., Welland, M.E., Characterization of the nanoscale properties of individual amyloid fibrils (2006) Proceedings of the National Academy of Sciences of the United States of America, 103 (43), pp. 15806-15811; Sun, Y., Makarava, N., Lee, C.I., Laksanalamai, P., Robb, F.T., Baskakov, I.V., Conformational stability of prp amyloid fibrils controls their smallest possible fragment size (2008) J Mol Biol., 376, pp. 1155-1167; Sweers, K.K.M., Bennink, M.L., Subramaniam, V., Nanomechanical properties of single amyloid fibrils (2012) J. Phys.: Condens. Matter, 24, p. 243101; (2013) National CJD Surveillance Unit, , http://www.cjd.ed.ac.uk/; Wasserman, L., All of statistics: A concise course in statistical inference brief contents (2004) Simulation, 100 (1), p. 461; Xue, W.-F., Homans, S.W., Radford, S.E., Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (26), pp. 8926-8931; Xue, W.-F., Homans, S.W., Radford, S.E., Amyloid fibril length distribution quantified by atomic force microscopy single-particle image analysis (2009) Protein Engineering, Design & Selection: Peds, 22 (8), pp. 489-496; Xue, W.-F., Radford, S.E., An imaging and systems modeling approach to fibril breakage enables prediction of amyloid behavior (2013) Biophysical Journal, 105 (12), pp. 2811-2819",Article,Scopus,2-s2.0-84903169009
"Rafii M.S., Taylor C.S., Kim H.T., Desikan R.S., Fleisher A.S., Katibian D., Brewer J.B., Dale A.M., Aisen P.S.","Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and alzheimer's disease",2014,"American Journal of Alzheimer's Disease and other Dementias","29","2",,"159","165",,1,10.1177/1533317513507373,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84898940271&partnerID=40&md5=58359cbc6bc6ed14584eedc9dffd6341","Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States; Department of Radiology, University of California, San Diego, CA, United States; Banner Alzheimer's Institute, Phoenix, AZ, United States","Rafii, M.S., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States; Taylor, C.S., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States; Kim, H.T., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States; Desikan, R.S., Department of Radiology, University of California, San Diego, CA, United States; Fleisher, A.S., Banner Alzheimer's Institute, Phoenix, AZ, United States; Katibian, D., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States; Brewer, J.B., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States, Department of Radiology, University of California, San Diego, CA, United States; Dale, A.M., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States, Department of Radiology, University of California, San Diego, CA, United States; Aisen, P.S., Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, #0949, San Diego, CA 92093, United States","Background: To assess the relationship between regional neocortical atrophy and psychotic symptoms in adults with mild cognitive impairment (MCI) and Alzheimers disease (AD). Methods: Rates of change in regional neocortical atrophy as measured by longitudinal magnetic resonance imaging scans and the occurrence of psychotic symptoms and/or the long-term use of antipsychotic medications in 389 outpatients with MCI or AD in Alzheimers Disease Neuroimaging Initiative. Results: Atrophy rate of 3 specific neocortical regions, lateral frontal, lateral parietal, and anterior cingulate gyrus, was significantly associated with the onset of psychosis including delusions, agitation, wandering, and hallucinations and/or the need for chronic antipsychotic medications. Atrophy rate of the lateral frontal lobe correlated most significantly with onset of psychotic symptoms or need for chronic antipsychotic medications. Conclusions: Psychosis was associated with volume loss in specific regions of the lateral frontal and parietal lobes as well as anterior cingulate gyrus. © The Author(s) 2013.","Alzheimer's disease; dementia; neuroimaging; psychosis","Cummings, J.L., (2003) The Neuropsychiatry of Alzheimer's Disease and Related Dementias, , London: Martin Dunitz;; Jeste, D.V., Finkel, S.I., Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome (2000) Am J Geriatr Psychiatry, 8 (1), pp. 29-34; Schneider, L.S., Dagerman, K.S., Psychosis of Alzheimer's disease: Clinical characteristics and history (2004) J Psychiatr Res, 38 (1), pp. 105-111; Paulsen, J.S., Salmon, D.P., Thal, L.J., Incidence of and risk factors for hallucinations and delusions in patients with probable AD (2000) Neurology, 54 (10), pp. 1965-1971; Steele, C., Rovner, B., Chase, G.A., Folstein, M., Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease (1990) Am J Psychiatry, 147 (8), pp. 1049-1051; Hebert, R., Dubois, M.F., Wolfson, C., Chambers, L., Cohen, C., Factors associated with long-term institutionalization of older people with dementia: Data from the Canadian study of health and aging (2001) J Gerontol A Biol Sci Med Sci, 56 (11), pp. 693-M699; Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., Dekosky, S., Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study (2002) JAMA, 288 (12), pp. 1475-1483; Kovacevic, S., Rafii, M.S., Brewer, J.B., Alzheimer's disease neuroimaging initiative. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment (2009) Alzheimer Dis Assoc Disord, 23 (2), pp. 139-145; Borgwardt, S.J., McGuire, P.K., Aston, J., Reductions in frontal, temporal and parietal volume associated with the onset of psychosis (2008) Schizophr Res, 106 (23), pp. 108-114; Lagopoulos, J., Hermens, D.F., Naismith, S.L., Scott, E.M., Hickie, I.B., Frontal lobe changes occur early in the course of affective disorders in young people (2012) BMC Psychiatry, 12, p. 4; Whitwell, J.L., Przybelski, S.A., Weigand, S.D., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study (2009) Brain, 132 (PART 11), pp. 2932-2946; Grady, C.L., Haxby, J.V., Schapiro, M.B., Subgroups in dementia of the Alzheimer's type identified using positron emission tomography (1990) J Neuropsychiatry Clin Neurosci, 2 (4), pp. 373-384; Kotrla, K.J., Chacko, R.C., Harper, R.G., Jhingran, S., Doody, R., SPECT findings on psychosis in Alzheimer's disease (1995) Am J Psychiatry, 152 (10), pp. 1470-1475; Sultzer, D.L., Mahler, M.E., Mandelkern, M.A., The relationship between psychiatric symptoms and regional neocortical metabolism in Alzheimer's disease (1995) J Neuropsychiatry Clin Neurosci, 7 (4), pp. 476-484; Jack, C.R., Bernstein, M.A., Fox, N.C., The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods (2008) J Magn Reson Imaging, 27 (4), pp. 685-691; Jovicich, J., Czanner, S., Greve, D., Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data (2006) Neuroimage, 30 (2), pp. 436-443; Sled, J.G., Zijdenbos, A.P., Evans, A.C., A nonparametric method for automatic correction of intensity nonuniformity in MRI data (1998) IEEE Trans Med Imaging, 17 (1), pp. 87-97; Dale, A.M., Fischl, B., Sereno, M.I., Neocortical surface-based analysis. I. Segmentation and surface reconstruction (1999) Neuroimage, 9 (2), pp. 179-194; Fischl, B., Sereno, M.I., Dale, A.M., Neocortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system (1999) Neuroimage, 9 (2), pp. 195-207; Desikan, R.S., Ségonne, F., Fischl, B., An automated labeling system for subdividing the human cerebral neocortex on MRI scans into gyral based regions of interest (2006) Neuroimage, 31 (3), pp. 968-980; Holland, D., Brewer, J.B., Hagler, D.J., Fennema-Notestine, C., Dale, A.M., Alzheimer's Disease Neuroimaging Initiative. Subregional neuroanatomical change as a biomarker for Alzheimer's disease (2009) Proc Natl Acad Sci USA, 106 (49), pp. 20954-20959; Holland, D., Dale, A.M., Alzheimer's Disease Neuroimaging Initiative. Nonlinear registration of longitudinal images and measurement of change in regions of interest (2011) Med Image Anal, 15 (4), pp. 489-497; Rosen, W.G., Mohs, R.C., Davis, K.L., A new rating scale for Alzheimer's disease (1984) Am J Psychiatry, 141 (11), pp. 1356-1364; Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia (1994) Neurology, 44 (12), pp. 2308-2314; Arango, C., Rapado-Castro, M., Reig, S., Progressive brain changes in children and adolescents with first-episode psychosis (2012) Arch Gen Psychiatry, 69 (1), pp. 16-26; Fusar-Poli, P., Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis (2012) J Psychiatry Neurosci, 37 (2), pp. 106-112; Mega, M.S., Lee, L., Dinov, I.D., Mishkin, F., Toga, A.W., Cummings, J.L., Cerebral correlates of psychotic symptoms in Alzheimer's disease (2000) J Neurol Neurosurg Psychiatry, 69 (2), pp. 167-171; Devinsky, O., Morrell, M.J., Vogt, B.A., Contributions of anterior cingulate neocortex to behaviour (1995) Brain, 118 (PART 1), pp. 279-306; Allman, J.M., Hakeem, A., Erwin, J.M., Nimchinsky, E., Hof, P., The anterior cingulate neocortex. The evolution of an in-terface between emotion and cognition (2001) Ann N y Acad Sci, 935, pp. 107-117; Zamboni, G., Huey, E.D., Krueger, F., Nichelli, P.F., Grafman, J., Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates (2008) Neurology, 71 (10), pp. 736-742; Chui, H.C., Lyness, S.A., Sobel, E., Schneider, L.S., Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease (1994) Arc Neurol, 51 (7), pp. 676-681; Stern, Y., Albert, M., Brandt, J., Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: Prospective analyses from the predictors study (1994) Neurology, 44 (12), pp. 2300-2307; Grundman, M., Petersen, R.C., Ferris, S.H., Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials (2004) Arch Neurol, 61 (1), pp. 59-66; Apostolova, L.G., Cummings, J.L., Neuropsychiatric manifestations in mild cognitive impairment: A systematic review of the literature (2008) Dement Geriatr Cogn Disord, 25 (2), pp. 115-126",Article,Scopus,2-s2.0-84898940271
"Davatzikos C., Da X., Toledo J.B., Zee J., Wolk D.A., Xie S.X., Ou Y., Shacklett A., Parmpi P., Shaw L., Trojanowski J.Q.","Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers",2014,"NeuroImage: Clinical","4",,,"164","173",,5,10.1016/j.nicl.2013.11.010,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84890903550&partnerID=40&md5=750d00abd52d57e91d5fb3d94eeffb9e","Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA, United States; Memory Center, University of Pennsylvania, Philadelphia, PA, United States; Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States","Davatzikos, C., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Da, X., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Toledo, J.B., Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA, United States; Zee, J., Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States; Wolk, D.A., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States, Memory Center, University of Pennsylvania, Philadelphia, PA, United States; Xie, S.X., Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States; Ou, Y., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Shacklett, A., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Parmpi, P., Department of Radiology, Center for Biomedical Image Computing and Analytics, University of Pennsylvania, 3600 Market Street, Philadelphia, PA 19104, United States; Shaw, L., Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA, United States; Trojanowski, J.Q., Department of Pathology and Laboratory Medicine, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA, United States","This study evaluates the individual, as well as relative and joint value of indices obtained from magnetic resonance imaging (MRI) patterns of brain atrophy (quantified by the SPARE-AD index), cerebrospinal fluid (CSF) biomarkers, APOE genotype, and cognitive performance (ADAS-Cog) in progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) within a variable follow-up period up to 6 years, using data from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI-1). SPARE-AD was first established as a highly sensitive and specific MRI-marker of AD vs. cognitively normal (CN) subjects (AUC = 0.98). Baseline predictive values of all aforementioned indices were then compared using survival analysis on 381 MCI subjects. SPARE-AD and ADAS-Cog were found to have similar predictive value, and their combination was significantly better than their individual performance. APOE genotype did not significantly improve prediction, although the combination of SPARE-AD, ADAS-Cog and APOE ε4 provided the highest hazard ratio estimates of 17.8 (last vs. first quartile). In a subset of 192 MCI patients who also had CSF biomarkers, the addition of Aβ1-42, t-tau, and p-tau181p to the previous model did not improve predictive value significantly over SPARE-AD and ADAS-Cog combined. Importantly, in amyloid-negative patients with MCI, SPARE-AD had high predictive power of clinical progression. Our findings suggest that SPARE-AD and ADAS-Cog in combination offer the highest predictive power of conversion from MCI to AD, which is improved, albeit not significantly, by APOE genotype. The finding that SPARE-AD in amyloid-negative MCI patients was predictive of clinical progression is not expected under the amyloid hypothesis and merits further investigation. © 2013 The Authors.","Amyloid; Biomarkers of AD; Cerebrospinal fluid; Dementia; Early Alzheimer's disease; Magnetic resonance imaging; Mild cognitive impairment","Adaszewski, S., Dukart, J., Kherif, F., Frackowiak, R., Draganski, B., How early can we predict Alzheimer's disease using computational anatomy? (2013) Neurobiol. Aging, 34, pp. 2815-2826; Aguilar, C., Westman, E., Muehlboeck, J., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Spenger, C., Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment (2013) Psychiatry Res. Neuroimaging, 212, pp. 89-98; Aksu, Y., Miller, D.J., Kesidis, G., Bigler, D.C., Yang, Q.X., An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients (2011) PLoS ONE, 6, p. 25074; Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement., 7, pp. 270-279; Becker, J.T., Mintun, M.A., Aleva, K., Wiseman, M., Nichols, T., Dekosky, S.T., Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease (1996) Neurology, 46, pp. 692-700; Clark, C.M., Pontecorvo, M.J., Beach, T.G., Bedell, B.J., Coleman, R.E., Doraiswamy, P.M., Fleisher, A.S., Skovronsky, D.M., Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study (2012) Lancet Neurol., 11, pp. 669-678; Clark, V.H., Resnick, S.M., Doshi, J., Beason-Held, L.L., Zhou, Y., Ferrucci, L., Wong, D.F., Davatzikos, C., Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults (2012) Neurobiol. Aging, 33, pp. 2733-2745; Costafreda, S.G., Dinov, I.D., Tu, Z., Shi, Y., Liu, C.-Y., Kloszewska, I., Mecocci, P., Simmons, A., Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment (2011) Neuroimage, 56, pp. 212-219; Davatzikos, C., Genc, A., Xu, D., Resnick, S.M., Voxel-based morphometry using the RAVENS maps: Methods and validation using simulated longitudinal atrophy (2001) Neuroimage, 14, pp. 1361-1369; Davatzikos, C., Fan, Y., Wu, X., Shen, D., Resnick, S.M., Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging (2008) Neurobiol. Aging, 29, pp. 514-523; Davatzikos, C., Resnick, S., Wu, X., Parmpi, P., Clark, C., Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI (2008) Neuroimage, 41, p. 1220; Davatzikos, C., Borthakur, A., Xu, F., Wu, X., Parmpi, E., Sochor, M., Clark, C.M., (2008) Integration of MRI Measures of Atrophy and Protein Aggregation with CSF Biomarkers of AD Pathology in Individuals with Mild Cognitive Impairment, , International Conference on Alzheimer's Disease Chicago, IL; Davatzikos, C., Xu, F., An, Y., Fan, Y., Resnick, S., Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: The SPARE-AD index (2009) Brain, 132, pp. 2026-2035; Davatzikos, C., Bhatt, P., Shaw, L.M., Batmanghelich, K.N., Trojanowski, J.Q., Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification (2011) Neurobiol. Aging, 32, pp. 2322e2319-2322e2327; Dickerson, B.C., Wolk, D.A., MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults (2012) Neurology, 78, pp. 84-90; Dickerson, B.C., Bakkour, A., Salat, D.H., Feczko, E., Pacheco, J., Greve, D.N., Grodstein, F., Rosas, H.D., The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals (2009) Cereb. Cortex, 19, pp. 497-510; Driscoll, I., Davatzikos, C., An, Y., Wu, X., Shen, D., Kraut, M., Resnick, S.M., Longitudinal pattern of regional brain volume change differentiates normal aging from MCI (2009) Neurology, 72, pp. 1906-1913; Driscoll, I., Zhou, Y., An, Y., Sojkova, J., Davatzikos, C., Kraut, M.A., Ye, W., Resnick, S.M., Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals (2011) Neurobiol. Aging, 32, pp. 2123-2130; Duchesne, S., Caroli, A., Geroldi, C., Barillot, C., Frisoni, G.B., Collins, D.L., MRI-based automated computer classification of probable AD versus normal controls (2008) IEEE Trans. Med. Imaging, 27, pp. 509-520; Eskildsen, S.F., Coupé, P., García-Lorenzo, D., Fonov, V., Pruessner, J.C., Collins, D.L., Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning (2013) Neuroimage, 65, pp. 511-521; Fagan, A.M., Mintun, M.A., Shah, A.R., Aldea, P., Roe, C.M., Mach, R.H., Marcus, D., Holtzman, D.M., Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease (2009) EMBO Mol. Med., 1, pp. 371-380; Fan, Y., Shen, D., Gur, R.C., Gur, R.E., Davatzikos, C., COMPARE: Classification of morphological patterns using adaptive regional elements (2007) IEEE Trans. Med. Imaging, 26, pp. 93-105; Fan, Y., Batmanghelich, N., Clark, C.M., Davatzikos, C., Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline (2008) Neuroimage, 39, pp. 1731-1743. , one of the top 10 cited papers of 2008; Fjell, A.M., Walhovd, K.B., Fennema-Notestine, C., McEvoy, L.K., Hagler, D.J., Holland, D., Brewer, J.B., Dale, A.M., CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease (2010) J. Neurosci., 30, pp. 2088-2101; Fleisher, A.S., Chen, K., Quiroz, Y.T., Jakimovich, L.J., Gomez, M.G., Langois, C.M., Langbaum, J.B., Reiman, E.M., Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional study (2012) Lancet Neurol., 11, pp. 1057-1065; Foster, J.K., Albrecht, M.A., Savage, G., Lautenschlager, N.T., Ellis, K.A., Maruff, P., Szoeke, C., Masters, C.L., Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: Findings from the Australian Imaging, Biomarkers and Lifestyle Study (2013) Brain, 136, pp. 2201-2216; Fox, N., Schott, J., Imaging cerebral atrophy: Normal ageing to Alzheimer's disease (2004) Lancet, 363, pp. 392-394; Fox, N., Warrington, E., Freeborough, P., Hartikainen, P., Kennedy, A., Stevens, J., Rossor, M., Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study (1996) Brain, 119, pp. 2001-2007; Gomar, J.J., Bobes-Bascaran, M.T., Conejero-Goldberg, C., Davies, P., Goldberg, T.E., Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative (2011) Arch. Gen. Psychiatry, 68, p. 961; Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., Witten, I.H., The WEKA data mining software: An update (2009) ACM SIGKDD Explor. Newsl., 11, pp. 10-18; Hampel, H., Blennow, K., Shaw, L.M., Hoessler, Y.C., Zetterberg, H., Trojanowski, J.Q., Total and phosphorylated tau protein as biological markers of Alzheimer's disease (2010) Exp. Gerontol., 45, pp. 30-40; Hampel, H., Shen, Y., Walsh, D.M., Aisen, P., Shaw, L.M., Zetterberg, H., Trojanowski, J.Q., Blennow, K., Biological markers of amyloid β-related mechanisms in Alzheimer's disease (2010) Exp. Neurol., 223, pp. 334-346; Hinrichs, C., Singh, V., Mukherjee, L., Xu, G., Chung, M.K., Johnson, S.C., Spatially augmented LPBoosting for AD classification with evaluations on the ADNI dataset (2009) Neuroimage, 48, pp. 138-149; Hinrichs, C., Singh, V., Xu, G., Johnson, S.C., Predictive markers for AD in a multi-modality framework: An analysis of MCI progression in the ADNI population (2011) Neuroimage, 55, pp. 574-589; Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J., Langa, K.M., Monetary costs of dementia in the United States (2013) N. Engl. J. Med., 368, pp. 1326-1334; Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Lopresti, B.J., Dekosky, S.T., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) Brain, 131, pp. 1630-1645; Jack, C.J., Petersen, R., O'Brien, P., Tangalos, E., MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease (1992) Neurology, 42, pp. 183-188; Jack, C.J., Slomkowski, M., Gracon, S., Hoover, T., Felmlee, J., Stewart, K., Xu, Y., Petersen, R., MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD (2003) Neurology, 60, pp. 253-260; Jack, C.R., Lowe, V.J., Senjem, M.L., Weigand, S.D., Kemp, B.J., Shiung, M.M., Knopman, D.S., Mathis, C.A., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment (2008) Brain, 131, pp. 665-680; Jack, C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Weiner, M.W., The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods (2008) J. Magn. Reson. Imaging, 27, pp. 685-691; Jack Jr., C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol., 9, pp. 119-128; Jack Jr., C.R., Wiste, H.J., Vemuri, P., Weigand, S.D., Senjem, M.L., Zeng, G., Bernstein, M.A., Knopman, D.S., Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease (2010) Brain, 133, pp. 3336-3348; Jack, C.R., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Petersen, R.C., An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease (2012) Ann. Neurol., 71, pp. 765-775; Jack, C.R., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., Pankratz, V.S., Mielke, M.M., Brain β-amyloid load approaches a plateau (2013) Neurology, 80, pp. 890-896; Jack Jr., C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Weigand, S.D., Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers (2013) Lancet Neurol., 12, pp. 207-216; Kloppel, S., Stonnington, C.M., Chu, C., Draganski, B., Scahill, R.I., Rohrer, J.D., Fox, N.C., Frackowiak, R.S.J., Automatic classification of MR scans in Alzheimer's disease (2008) Brain, 131, pp. 681-689; Landau, S.M., Harvey, D., Madison, C.M., Reiman, E.M., Foster, N.L., Aisen, P.S., Petersen, R.C., Jagust, W.J., Comparing predictors of conversion and decline in mild cognitive impairment (2010) Neurology, 75, pp. 230-238; Liu, Y., Teverovskiy, L., Carmichael, O., Kikinis, R., Shenton, M., Carter, C., Stenger, V., Becker, J., Discriminative MR image feature analysis for automatic schizophrenia and alzheimer's disease classification (2004) Med. Image Comput. Comput. Assist. Interv., pp. 393-401; Manly, J.J., Tang, M.X., Schupf, N., Stern, Y., Vonsattel, J.P., Mayeux, R., Frequency and course of mild cognitive impairment in a multiethnic community (2008) Ann. Neurol., 63, pp. 494-506; McEvoy, L.K., Fennema-Notestine, C., Roddey, J.C., Hagler Jr., D.J., Holland, D., Karow, D.S., Pung, C.J., Dale, A.M., Alzheimer disease: Quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment (2009) Radiology, 251, pp. 195-205; McEvoy, L.K., Holland, D., Hagler, D.J., Fennema-Notestine, C., Brewer, J.B., Dale, A.M., Mild cognitive impairment: Baseline and longitudinal structural MR imaging measures improve predictive prognosis (2011) Radiology, 259, pp. 834-843; McMillan, C.T., Avants, B., Irwin, D.J., Toledo, J.B., Wolk, D.A., Van Deerlin, V.M., Shaw, L.M., Grossman, M., Can MRI screen for CSF biomarkers in neurodegenerative disease? (2013) Neurology, 80, pp. 132-138; Misra, C., Fan, Y., Davatzikos, C., Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI (2009) Neuroimage, 44, pp. 1415-1422; Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Del Tredici, K., Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature (2012) J. Neuropathol. Exp. Neurol., 71, p. 362; Petersen, R.C., Roberts, R.O., Knopman, D.S., Boeve, B.F., Geda, Y.E., Ivnik, R.J., Smith, G.E., Jack Jr., C.R., Mild cognitive impairment: Ten years later (2009) Arch. Neurol., 66, pp. 1447-1455; Plant, C., Teipel, S.J., Oswald, A., Böhm, C., Meindl, T., Mourao-Miranda, J., Bokde, A.W., Ewers, M., Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease (2010) Neuroimage, 50, p. 162; Schneider, J.A., Arvanitakis, Z., Leurgans, S.E., Bennett, D.A., The neuropathology of probable Alzheimer disease and mild cognitive impairment (2009) Ann. Neurol., 66, pp. 200-208; Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L.M., Trojanowski, J.Q., Thompson, P.M., Weiner, M.W., MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers (2009) Brain, 132, pp. 1067-1077; Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Trojanowski, J.Q., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) Ann. Neurol., 65, pp. 403-413; Silverman, D.H., Small, G.W., Chang, C.Y., Lu, C.S., De Aburto, M.A.K., Chen, W., Czernin, J., Alexander, G.E., Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome (2001) JAMA, 286, pp. 2120-2127; Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., Pirttila, T., Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain (2009) Arch. Neurol., 66, p. 382; Toledo, J.B., Vanderstichele, H., Figurski, M., Aisen, P.S., Petersen, R.C., Weiner, M.W., Jack Jr., C.R., Shaw, L.M., Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI (2011) Acta Neuropathol., 122, pp. 401-413; Toledo, J.B., Brettschneider, J., Grossman, M., Arnold, S.E., Hu, W.T., Xie, S.X., Lee, V.M., Trojanowski, J.Q., CSF biomarkers cutoffs: The importance of coincident neuropathological diseases (2012) Acta Neuropathol., 124, pp. 23-35; Toledo, J.B., Cairns, N.J., Da, X., Chen, K., Carter, D., Fleisher, A., Householder, E., Bauer, R.J., Clinical and multimodal biomarker correlates of ADNI neuropathological findings (2013) Acta Neuropathol. Commun., 1, p. 65; Toledo, J.B., Da, X., Bhatt, P., Wolk, D.A., Arnold, S.E., Shaw, L.M., Trojanowski, J.Q., Davatzikos, C., Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI (2013) PLoS ONE, 8, p. 55531; Toledo, J.B., Xie, S.X., Trojanowski, J.Q., Shaw, L.M., Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI (2013) Acta Neuropathol., 126, pp. 659-670; Tosun, D., Schuff, N., Mathis, C.A., Jagust, W., Weiner, M.W., Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment (2011) Brain, 134, pp. 1077-1088; Vapnik, V.N., (1998) Statistical Learning Theory, , Wiley New York; Vemuri, P., Gunter, J.L., Senjem, M.L., Whitwell, J.L., Kantarci, K., Knopman, D.S., Boeve, B.F., Jack Jr., C.R., Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies (2008) Neuroimage, 39, pp. 1186-1197; Vemuri, P., Wiste, H.J., Weigand, S.D., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., Knopman, D.S., Jack Jr., C.R., MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations (2009) Neurology, 73, pp. 287-293; Vemuri, P., Wiste, H.J., Weigand, S.D., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., Knopman, D.S., Adni, J., MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical changes (2009) Neurology, 73, pp. 294-301; Walhovd, K., Fjell, A., Brewer, J., McEvoy, L., Fennema-Notestine, C., Hagler, D., Jennings, R., Dale, A., Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease (2010) Am. J. Neuroradiol., 31, pp. 347-354; Weesie, J., Sg121: Seemingly unrelated estimation and the cluster-adjusted sandwich estimator (1999) Stata Tech. Bull., 52, pp. 34-47; Westman, E., Muehlboeck, J., Simmons, A., Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion (2012) Neuroimage, 62, pp. 229-238; Whitwell, J.L., Shiung, M.M., Przybelski, S., Weigand, S.D., Knopman, D.S., Boeve, B.F., Petersen, R.C., Jack, C., MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment (2008) Neurology, 70, pp. 512-520; Wirth, M., Madison, C.M., Rabinovici, G.D., Oh, H., Landau, S.M., Jagust, W.J., Alzheimer's Disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals (2013) J. Neurosci., 33, pp. 5553-5563; Wolk, D.A., Dickerson, B.C., Apolipoprotein e (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease (2010) Proc. Natl. Acad. Sci. U. S. A., 107, pp. 10256-10261; Wolz, R., Julkunen, V., Koikkalainen, J., Niskanen, E., Zhang, D.P., Rueckert, D., Soininen, H., Lötjönen, J., Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease (2011) PLoS ONE, 6, p. 25446; Zhang, T., Davatzikos, C., ODVBA: Optimally-discriminative voxel-based analysis (2011) IEEE Trans. Med. Imaging, 30, pp. 1441-1454",Article,Scopus,2-s2.0-84890903550
"Tsao S., Gajawelli N., Hwang D.H., Kriger S., Law M., Chui H., Weiner M., Lepore N.","Mapping of ApoE4 related white matter damage using diffusion MRI",2014,"Progress in Biomedical Optics and Imaging - Proceedings of SPIE","9039",, 90390H,"","",,,10.1117/12.2043925,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84901783404&partnerID=40&md5=148a3918bc071897065244008d384fc3","University of Washington, Seattle, WA, United States; University of Southern California, Los Angeles, CA, United States; Children's Hospital Los Angeles, Los Angeles, CA, United States; Center for Neurodegenerative Disease, San Francisco VA Medical Center, San Francisco, CA, United States","Tsao, S., University of Washington, Seattle, WA, United States; Gajawelli, N., University of Southern California, Los Angeles, CA, United States, Children's Hospital Los Angeles, Los Angeles, CA, United States; Hwang, D.H., University of Southern California, Los Angeles, CA, United States; Kriger, S., Center for Neurodegenerative Disease, San Francisco VA Medical Center, San Francisco, CA, United States; Law, M., University of Southern California, Los Angeles, CA, United States; Chui, H., University of Southern California, Los Angeles, CA, United States; Weiner, M., Center for Neurodegenerative Disease, San Francisco VA Medical Center, San Francisco, CA, United States; Lepore, N., University of Southern California, Los Angeles, CA, United States, Children's Hospital Los Angeles, Los Angeles, CA, United States","ApoliopoproteinE 4 (ApoE-4) polymorphism is the most well known genetic risk factor for developing Alzheimers Disease. The exact mechanism through which ApoE 4 increases AD risk is not fully known, but may be related to decreased clearance and increased oligomerization of Aβ. By making measurements of white matter integrity via diffusion MR and correlating the metrics in a voxel-based statistical analysis with ApoE-4 genotype (whilst controlling for vascular risk factor, gender, cognitive status and age) we are able to identify changes in white matter associated with carrying an ApoE 4 allele. We found potentially significant regions (Puncorrected &lt; 0:05) near the hippocampus and the posterior cingulum that were independent of voxels that correlated with age or clinical dementia rating (CDR) status suggesting that ApoE may affect cognitive decline via a pathway in dependent of normal aging and acute insults that can be measured by CDR and Framingham Coronary Risk Score (FCRS). © 2014 SPIE.","Alzheimer's Disease; ApoE; Dementia; Diusion MRI; DTI; MRI; Neuroimaging","Bagepally, B.S., Halahalli, H.N., John, J.P., Kota, L., Purushottam, M., Mukherjee, O., Sivakumar Bharath T P, S., Varghese, M., Apolipoprotein e4 and brain white matter integrity in alzheimer'sdisease: Tract-based spatial statistics study under 3-tesla mri (2012) Neurodegener Dis, 10 (1-4), pp. 145-148",Conference Paper,Scopus,2-s2.0-84901783404
"Gong H., Feng L.","Probabilistic verification of ER stress-induced signaling pathways",2014,"Proceedings - 2014 IEEE International Conference on Bioinformatics and Biomedicine, IEEE BIBM 2014",,, 6999149,"182","187",,,10.1109/BIBM.2014.6999149,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84922827530&partnerID=40&md5=8fb4ea3bad18ca85e6079d5410a896c5","Department of Mathematics and Computer Science, Saint Louis UniversitySt. Louis, MO, United States","Gong, H., Department of Mathematics and Computer Science, Saint Louis UniversitySt. Louis, MO, United States; Feng, L., Department of Mathematics and Computer Science, Saint Louis UniversitySt. Louis, MO, United States","Endoplasmic reticulum (ER) is a communication hub for several signaling and secretory pathways that regulate the cell cycle progression. Recent studies revealed that deregulation of ER stress-induced signaling pathways are involved in the patho-genesis of cancer and Alzheimers disease. Computational analysis and verification of these pathways will provide insights into the mechanism linking ER stress with different diseases. Based on the experimental observation and our recent bioinformatics studies, we construct a quantitative model to systematically study the ER stress-induced apoptosis and survival signaling pathways. To overcome the limitations of traditional simulation techniques, a formal verification method, called Probabilistic Model Checking, was introduced and applied to formally analyze the temporal logic properties of the stochastic model, which is written in the PRISM language. Compared with the symbolic model verification method, this PRISM verification technique can not only qualitatively verify the signaling pathway model using sequential probability ratio test (SPRT), but also provide a quantitative estimation of the temporal properties using confidence interval estimation method. The probabilistic verification studies show that, overexpressed ER transmembrane proteins will promote the expression of Cyclin D, Amyloid-β and MDM2, leading to the pathogenesis of cancer and other diseases in the long term, and inhibit the apoptosis. Our work also verified that, varying IKK's expression level will influence the number of NFκB molecules in the nucleus, which explained why IKK inhibitor could inhibit tumorigenesis. The proposed signaling pathway model and PRISM method can help our understanding of the mechanisms that link ER stress with cancer and other diseases. © 2014 IEEE.","Alzheimer's disease; cancer; confidence Interval; ER stress; PRISM; Probabilistic verification; sequential probability ratio test; signaling pathway","Kadowaki, H., Nishitoh, H., Signaling pathways from the endoplasmic reticulum and their roles in disease (2013) Genes; Wlodkowic, D., Skommer, J., Er-golgi network-a future target for anti-cancer therapy (2009) Leuk Res; Wu, T.T., Gong, H., Clarke, E.M., A transcriptome analysis by lasso penalized cox regression for pancreatic cancer survival (2011) Journal of Bioinformatics and Computational Biology, 9, p. 63; Gong, H., Wu, T.T., Clarke, E.M., Pathway-gene identification for pancreatic cancer survival via doubly regularized cox regression (2014) BMC Systems Biology, 8; Statnikov, A., Aliferis, C.F., Tsamardinos, I., Hardin, D., Levy, S., A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis (2005) Bioinformatics, 21, pp. 631-643; Luan, Y., Li, H., Group additive regression models for genomic data analysis (2008) Biostatistics, 9, pp. 100-113; Wu, T.T., Chen, Y.F., Hastie, T., Sobel, E., Lange, K., Genomewide association analysis by lasso penalized logistic regression (2009) Bioinformatics, 25, pp. 714-721; Ma, S., Song, X., Huang, J., Supervised group lasso with applications to microarray data analysis (2007) BMC Bioinformatics, 8, pp. 60-76; Wu, T.T., Wang, S., Doubly regularized cox regression for highdimensional survival data with group structures (2013) Statisstics and Its Interface, 6, pp. 175-186; Yuan, M., Lin, Y., Model selection and estimation in regression with grouped variables (2006) J. R. Statist. Soc. B, 68, pp. 49-67; Gong, H., Wang, Q., Zuliani, P., Lotze, M.T., Faeder, J.R., Clarke, E.M., Symbolic model checking of the signaling pathway in pancreatic cancer (2011) Proceedings of the International Conference on Bioinformatics and Computational Biology (BICoB); Zuliani, P., Platzer, A., Clarke, E.M., Bayesian statistical model checking with application to simulink/stateflow verification (2010) HSCC, pp. 243-252; Gong, H., Zuliani, P., Clarke, E., Model checking of a diabetescancer model (2011) 3rd International Symposium on Computational Models for Life Sciences; Clarke, E.M., Faeder, J.R., Harris, L.A., Langmead, C.J., Legay, A., Jha, S.K., (2008) Statistical Model Checking in Biolab: Applications to the Automated Analysis of T-cell Receptor Signaling Pathway, 5307, pp. 231-250; Gong, H., Analysis of intercellular signal transduction in the tumor microenvironment (2013) BMC Systems Biology, 7, p. S5; Gong, H., Feng, L., Computational analysis of the roles of er-golgi network in the cell cycle (2014) BMC Bioinformatics, 15, pp. S12-S18; Gillespie, D.T., A general method for numerically simulating the stochastic time evolution of coupled chemical reactions (1976) J. Comp. Phys., 22 (4), pp. 403-434; Gong, H., Sengupta, H., Linstedt, A., Schwartz, R., Simulated de novo assembly of golgi compartments by selective cargo capture during vesicle budding and targeted vesicle fusion (2008) Biophysical Journal, 95, pp. 1674-1688; Gong, H., Guo, Y., Linstedt, A., Schwartz, R., Discrete, continuous, and stochastic models of protein sorting in the golgi apparatus (2010) Physical Review e, 81 (1), p. 011914; Gong, H., Zuliani, P., Komuravelli, A., Faeder, J.R., Clarke, E.M., Analysis and verification of the HMGB1 signaling pathway (2010) BMC Bioinformatics, 11 (7); Gong, H., Zuliani, P., Komuravelli, A., Faeder, J., Clarke, E., Computational modeling and verification of signaling pathways in cancer (2012) Proceedings of Algebraic and Numeric Biology, LNCS, 6479; Hotamisligil, G., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease (2010) Cell, 140; Breckenridge, D.G., Regulation of apoptosis by endoplasmic reticulum pathways (2003) Oncogene, 22; Rutkowski, D.T., Kaufman, R.J., A trip to the er: Coping with stress (2004) Trends in Cell Biology, 14; Pereira, C., Crosstalk between endoplasmic reticulum stress and protein misfolding in neurodegenerative diseases (2013) ISRN Cell Biology; Salminen, A., Er stress in alzheimer's disease: A novel neuronal trigger for inflammation and alzheimer's pathology (2009) Journal of Neuroinflammation, 6; Yagi, A., Gadd34 induces p53 phosphorylation and p21/waf1 transcription (2003) J Cell Biochem, 90 (6), pp. 1242-1249; De La Vega C, M., Possible mechanisms involved in the downregulation of translation during transient global ischaemia in the rat brain (2001) Biochem J., 357; Van Beijnum, J.R., Buurman, W.A., Griffioen, A.W., Convergence and amplification of toll-like receptor (tlr) and receptor for advanced glycation end products (rage) signaling pathways via high mobility group b1 (2008) Angiogenesis, 11, pp. 91-99; Hoffmann, A., Levchenko, A., Scott, M., Baltimore, D., The IBNF B signaling module: Temporal control and selective gene activation (2002) Science, 298, pp. 1241-1245; Clarke, E.M., Grumberg, O., Peled, D.A., (1999) Model Checking, , MIT Press; Kwiatkowska, M., Norman, G., Sproston, J., Probabilistic model checking of deadline properties in the ieee1394 firewire root contention protocol (2003) Formal Aspects of Computing, 14, pp. 295-318; Kwiatkowska, M., Norman, G., Parker, D., Probabilistic model checking in practice: Case studies with prism (2005) ACM SIGMETRICS Performance Evaluation Review, 32, pp. 16-21; Prism Code for Er Stress-induced Pathway Model, , http://cs.slu.edu/gong/research/ERprism.zip; Mokhtar, S., The beta-amyloid protein of alzheimers disease: Communication breakdown by modifying the neuronal cytoskeleton (2013) International Journal of Alzheimers Disease, 2013; Liu, B., Endoplasmic reticulum stress promotes amyloid-beta peptides production in rgc-5 cells (2014) Cell Stress and Chaperones",Conference Paper,Scopus,2-s2.0-84922827530
"Choi M.-H., Alquzi M.B., Hong M.","Assessment of human perceptual sensitivity to physically non-conforming motion in virtual environments",2014,"Journal of Supercomputing","69","3",,"1311","1323",,,10.1007/s11227-014-1169-y,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84919905213&partnerID=40&md5=255f7a1ec93a09699e38a2afd2a22dc9","Department of Computer Science and Engineering, The University of Colorado DenverDenver, CO, United States; Department of Computer Software Engineering, Soonchunhyang UniversityAsan, South Korea","Choi, M.-H., Department of Computer Science and Engineering, The University of Colorado DenverDenver, CO, United States; Alquzi, M.B., Department of Computer Science and Engineering, The University of Colorado DenverDenver, CO, United States; Hong, M., Department of Computer Software Engineering, Soonchunhyang UniversityAsan, South Korea","Recent advances in neuroscience have shown that the neuropathological disorders are closely related with diseases such as Alzheimers. Those damages are particularly associated with the intermediate visual perceptual processing which can cause the motion perception defects and abnormal visuospatial functions in daily living of patients. In this paper, we propose virtual reality-based assessment tools for measuring human perceptual sensitivity to dynamic erroneous motions, particularly designed to assess possible early stage of brain damages and its associated visual dysfunctions. The main thrust of this paper is on perceptually tuned virtual reality system that can produce realistic natural behavior. The proposed method contains multiple assessment layers to check the awareness of erroneous motion in natural scenes at various severities. Our VR-based game-type environment provides an effective test bed for various dynamic motion-based perceptual sensitivity experiments. Our initial human subject tests show that game-based test environment produces more coherent and consistent data, preferable to survey-based methods. © 2014, Springer Science+Business Media New York.","3D simulation; Perceptual sensitivity; Physically-based modeling","Bro-Nielsen, M., Surgery simulation using fast finite elements. In: Proceedings of visualization in biomedical computing (1996) pp 529–534; Beer, G., Smith, I., Duenser, C., (2008) The boundary element method with programming: for engineers and scientists, , Springer, Berlin:; Cotin, S., Delingette, H., Ayache, N., A hybrid elastic model for real-time cutting, deformations, and force feedback for surgery training and simulation (2000) Vis Comput, 16 (7), pp. 437-452; Kim, J., Yoon, S., Lee, Y., Trivariate B-spline approximation of spherical solid objects (2014) J Inf Process Syst, 10 (1), pp. 23-35; Jeon, J., Choi, M.-H., Hong, M., Enhanced FFD-AABB collision algorithm for deformable objects (2012) J Inf Process Syst, 8 (4), pp. 713-720; O’Sullivan, J., Dingliana, T., Giang, M., Kaiser, K., Evaluating the visual fidelity of physically based animations (2003) ACM Trans Graph, 22 (3), pp. 527-536; Riva, G., Virtual reality as assessment tool in psychology (1997) Virtual reality in neuro-psycho-physiology, pp. 71-80; Theeuwes, J., Kramer, A.F., Kingstone, A., Attentional capture modulates perceptual sensitivity (2004) Psychon Bull Rev, 11 (3), pp. 551-554; Kovcs, I., Julesz, B., Perceptual sensitivity maps within globally defined visual shapes (1994) Nature, 370 (6491), pp. 644-646; Clement, J., Students’ preconceptions in introductory mechanics (1982) Am J Phys, 50 (1), pp. 66-71; Abraham, S., Choi, M.-H., Optimization of collision handling based on differential thresholds of human perception (2011) In: Proceedings of international conference on computer graphics and virtual reality; Choi, M., Yu, S., Pelak, V., Assessment of visual dysfunction using virtual reality game environment (2011) J Future Game Technol, 1 (2), pp. 81-82; Popovic, J., Seitz, S.M., Erdmann, M., Witkin, A., Interactive manipulation of rigid body simulations (2000) Proceedings of SIGGRAPH, 2000, pp. 209-218; Popovic, J., Seitz, S.M., Erdmann, M., Motion sketching for control of rigid body simulations (2003) ACM Trans Graph, 22 (4), pp. 1034-1054; James, D.L., Fatahalian, K., Precomputing interactive dynamic deformable scenes (2003) Proceedings of SIGGRAPH, 2003, pp. 879-887; Harvey, L.O., Jr., Efficient estimation of sensory thresholds with ML-PEST (1997) Spat Vis, 11 (1), pp. 121-128; Tetewsky, S.J., Duffy, C.J., Visual loss and getting lost in Alzheimer’s disease (1999) Neurology, 52 (5), pp. 958-965; UNreal Development Kit (UDK), , http://www.unrealengine.com; Crane, K., Llamas, I., Tariq, S., Crane, K., Llamas, I., Tariq, S., Real-time simulation and rendering of 3D fluids (2007) Nguyen H, p. 3. , Addison-Wesley Professional; Diener, J., Reveret, L., Fiume, E., (2006) (2006) Hierarchical retargetting of 2D motion fields to the animation of 3D plant models. In, , Proceedings of the: ACM SIGGRAPH/Eurographics symposium on computer, animation; Van Haevre, W., Di Fiore, F., Van Reeth, F., (2006) Physically-based driven tree animations, , In: Proceedings of Eurographics/ACM SIGGRAPH symposium on computer, animation; Sechrest, M., Maher, M., Bordes, J., NVidia apex: high definition physics with clothing and vegetation (2009) In: Game developer conference; Twigg, C.D., James, D.L., Many-worlds browsing for control of multibody dynamics (2007) ACM Trans Graph 26(3):14, 8, pp. 1-14; Jeon, H., Choi, M.H., Controllable simulation of deformable objects using heuristic optimal control (2007) J Geom Graph, 2 (1), pp. 59-71; Cotin, S., Delingette, H., Clement, J., Soler, L., Ayache, N., Marescaux, J., (1996) Geometrical and physical representation for a simulator of hepatic surgery, , In, Proceedings of medicine meets virtual reality IV:; Posner, M.I., Orienting of attention (1980) Q J Exp Psychol, 32 (1), p. 325; Walter, H., Ehrenstein and Addie Ehrenstein psychophysical methods (1995) Psychology Software News, 5; Ihm, S.-Y., Lee, K.-E., Nasridinov, A., Huh, J.-S., Park, Y.-H., Approximate convex skyline: a partitioned layer-based index for efficient processing top-k queries (2014) Knowledge-Based Syst, 61, pp. 13-28",Article,Scopus,2-s2.0-84919905213
"Morris J.C., Blennow K., Froelich L., Nordberg A., Soininen H., Waldemar G., Wahlund L.-O., Dubois B.","Harmonized diagnostic criteria for Alzheimer's disease: Recommendations",2014,"Journal of Internal Medicine","275","3",,"204","213",,12,10.1111/joim.12199,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84895727628&partnerID=40&md5=6a301cd43b6f5131309b2cb7d48abe7f","Department of Neurology, Washington University, St. Louis, MO, United States; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry, University of Gothenburg, Sahlgrenska University Hospital, Molndal Campus, Mölndal, Sweden; Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany; Karolinska Institutet, Alzheimer Neurobiology Center, Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Neurology, Kuopio University Hospital, Kuopio, Finland; Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Section for Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié Salpêtriére, Paris, France; Université Pierre et Marie Curie, Paris, France","Morris, J.C., Department of Neurology, Washington University, St. Louis, MO, United States; Blennow, K., Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry, University of Gothenburg, Sahlgrenska University Hospital, Molndal Campus, Mölndal, Sweden; Froelich, L., Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany; Nordberg, A., Karolinska Institutet, Alzheimer Neurobiology Center, Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Soininen, H., Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland, Department of Neurology, Kuopio University Hospital, Kuopio, Finland; Waldemar, G., Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Wahlund, L.-O., Section for Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Dubois, B., Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié Salpêtriére, Paris, France, Université Pierre et Marie Curie, Paris, France","Background: Two major sets of criteria for the clinical diagnosis of Alzheimer's disease (AD) recently have been published, one from an International Working Group (IWG) and the other from working groups convened by the National Institute on Aging (NIA) and the Alzheimer's Association (AA) in the United States. These criteria both aim to support a clinical diagnosis with in vivo evidence of AD pathology, using imaging methods and detection of biofluid biomarkers, and emphasize an aetiological diagnosis even in the prodromal stages of the disorder. Nonetheless, there are substantial differences in these two sets of criteria. Methods: An international group of investigators with experience in the clinical diagnosis of AD met at the Key Symposium in Stockholm, Sweden on 6 & 7 December 2012, to develop recommendations to harmonize these criteria. The group was led by individuals who were integral to the development of both the IWG and the NIA-AA criteria. The similarities and differences between the two sets of criteria were identified and open discussion focused on ways to resolve the differences and thus yield a harmonized set of criteria. Results: Based on both published evidence as well as the group's collective clinical experience, the group was tasked with achieving consensus, if not unanimity, as it developed recommendations for harmonized clinical diagnostic criteria for AD. Conclusion: The recommendations are to: (i) define AD as a brain disorder, regardless of clinical status; (ii) refer to the clinically expressed disorder, including its prodromal stages, as symptomatic AD; (iii) after the successful completion of standardization efforts, consider incorporating biomarkers into diagnostic algorithms for AD; and (iv) allow nonamnestic, atypical presentations to be included as symptomatic AD, especially when there is supportive biomarker evidence. © 2014 The Association for the Publication of the Journal of Internal Medicine.","Alzheimer biomarkers; Alzheimer's disease; Clinical diagnostic criteria; Preclinical Alzheimer's disease","Dubois, B., Feldman, H.H., Jacova, C., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria (2007) Lancet Neurol, 6, pp. 734-746; Dubois, B., Feldman, H., Jacova, C., Revising the definition of Alzheimer's disease: a new lexicon (2010) Lancet Neurol, 9, pp. 1118-1127; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease (1984) Neurology, 34, pp. 939-944; Sperling, R.A., Aisen, P.S., Beckett, L.A., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 280-292. , PMCID: PMC3220946; Albert, M.S., DeKosky, S.T., Dickson, D., The diagnosis of mild cognitive impairment due to Alzheimer disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 270-279. , PMCID: PMC3312027; McKhann, G.M., Knopman, D.S., Chertkow, H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging and the Alzheimer's association workgroup (2011) Alzheimers Dement, 7, pp. 263-269. , PMCID: PMC3312024; Holtzman, D.M., Morris, J.C., Goate, A.M., Alzheimer's disease: the challenge of the second century (2011) Sci Transl Med, 77, pp. 1-17. , PMC3130546; Clark, C.M., Xie, S., Chittams, J., CSF tau and β-amyloid: how well do these biomarkers reflect autopsy confirmed dementia diagnoses? (2003) Arch Neurol, 60, pp. 1696-1702; Tapiola, T., Alafuzoff, I., Herukka, S.-K., Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain (2009) Arch Neurol, 66, pp. 382-389; Klunk, W.E., Engler, H., Nordberg, A., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (2004) Ann Neurol, 55, pp. 306-319; Clark, C.M., Schneider, J.A., Bedell, B.J., Use of florbetapir-PET for imaging β-amyloid pathology (2011) JAMA, 305, pp. 275-283; Vandenberghe, R., Van Laere, K., Ivanoiu, A., 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment a phase 2 trial (2010) Ann Neurol, 68, pp. 319-329; Barthel, H., Gertz, H.J., Dresel, S., Cerebral amyloid-B PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study (2011) Lancet Neurol, 10, pp. 424-435. , Florbetaben Study Group; Cselenyi, Z., Jonhagen, M.E., Forsberg, A., Clinical validation of 18F-AZD4694, and amyloid-B-specific PET radioligand (2012) J Nucl Med, 53, pp. 415-424; Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Post-mortem correlates of in-vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) Brain, 131, pp. 1630-1645; Dickerson, B.C., Bakkour, A., Salat, D.H., The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals (2009) Cereb Cortex, 19, pp. 497-510; Wang, L., Brier, M.R., Snyder, A.Z., Cerebrospinal fluid AB42, phosphorylated tau181, and resting-state functional connectivity (2013) JAMA Neurol, 70, pp. 1242-1248; Beason-Held, L.L., Goh, J.O., An, Y., Changes in brain function occur years before the onset of cognitive impairment (2013) J Neurosci, 33, pp. 18008-18014; Jack Jr., C.R., Albert, M.S., Knopman, D.S., Introduction to the recommendations from the national institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 257-262; Frisoni, G.B., Galluzzi, S., Signorini, M., Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis; report of 2 cases (2010) Alzheimer Dis Assoc Disord, 24, pp. 108-114; Bouwman, F.H., Verwey, N.A., Klein, M., New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population (2010) Dement Geriatr Cogn Disord, 30, pp. 1-7; Galluzzi, S., Geroldi, C., Ghidoni, R., The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment (2010) J Neurol, 257, pp. 2004-2014. , Translational Outpatient Memory Clinic Working Group; Oksengard, A.R., Cavallin, L., Axelsson, R., Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative (2010) Dement Geriatr Cogn Disord, 30, pp. 374-380; Jack, C.R., Knopman, D.S., Weigand, S.D., An operational approach to national institute on aging-Alzheimer's association criteria for preclinical Alzheimer disease (2012) Ann Neurol, 71, pp. 765-775; Knopman, D.S., Jack Jr., C.R., Wiste, H.J., Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease (2012) Neurol, 78, pp. 1576-1582; Vos, S.J.B., Xiong, C., Visser, P.J., Prevalence and outcome of preclinical Alzheimer's disease (2013) Lancet Neurol, 12, pp. 957-965. , NIHMS:MIHMSID 525894; Roe, C.M., Fagan, A.M., Grant, E.A., Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later (2013) Neurology, 80, pp. 1784-1791; Lim, Y.Y., Maruff, P., Pietrzak, R.H., Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease (2014) Brain, 137, pp. 221-231. , for the AIBL Research Group; National Research Council of the National Academies. Toward Precision Medicine; Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Committee on a Framework for Developing a New Taxonomy of Disease, Board of Life Sciences, Division on Earth and Life Studies, editors. 1-128. 2011. Washington, DC, The National Academies PressBateman, R.J., Xiong, C., Benzinger, T.L.S., Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012) N Engl J Med, 367, pp. 795-804. , for the Dominantly Inherited Alzheimer Network. PMCID: PMC3474597; Fagan, A.M., Roe, C.M., Xiong, C., Morris, J.C., Holtzman, D.M., Cerebrospinal fluid tau/ß-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults (2007) Arch Neurol, 64, pp. 343-349; Morris, J.C., Roe, C.M., Grant, E.A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer's disease (2009) Arch Neurol, 66, pp. 1469-1475. , PMC2798814; Griffith, H.R., Belue, K., Sicola, A., Impaired financial abilities in mild cognitive impairment (2003) Neurology, 60, pp. 449-457; Farias, S.T., Mungas, D., Reed, B.R., Harvey, D., Cahn-Weiner, D., DeCarli, C., MCI is associated with deficits in everyday functioning (2006) Alzheimer Dis Assoc Disord, 20, pp. 217-223; Peres, K., Chrysostome, V., Fabrigoule, C., Orgogozo, J.M., Dartigues, J.-F., Barberger-Gateau, P., Restriction in complex activities of daily living in MCI; impact on outcome (2006) Neurology, 67, pp. 461-466; Berg, L., McKeel Jr., D.W., Miller, J.P., Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype (1998) Arch Neurol, 55, pp. 326-335; Storandt, M., Grant, E.A., Miller, J.P., Morris, J.C., Longitudinal course and neuropathological outcomes in original versus revised MCI and in PreMCI (2006) Neurology, 67, pp. 467-473; Chiu, H.F.K., Brodaty, H., Arguments against the biomarker-driven diagnosis of AD (2013) Int Psychogeriatr, 25, pp. 177-181; Draper, B., Peisah, C., Snowdon, J., Brodaty, H., Early dementia diagnosis and the risk of suicide and euthanasia (2010) Alzheimers Dement, 6, pp. 75-92; Rohde, K., Peskind, E.R., Raskind, M.A., Suicide in two patients with Alzheimer's disease (1995) J Am Geriatr Soc, 43, pp. 187-189; Lim, W.S., Rubin, E.H., Coats, M., Morris, J.C., Early stage Alzheimer disease represents increased suicidal risk in relation to later stages (2005) Alzheimer Dis Assoc Disord, 19, pp. 214-219; Erlangsen, A., Zarit, S.H., Conwell, Y., Hospital-diagnosed dementia and suicide: a longitudinal study using prospective, nationwide register data (2008) Am J Geriatr Psychiatry, 16, pp. 220-228; Carpenter, B.D., Xiong, C., Porensky, E.K., Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment (2008) J Am Geriatr Soc, 56, pp. 405-412; Tarek, M.E., Segers, K., Van Nechel, C., What Belgian neurologists and neuropsychiatrists tell their patients with Alzheimer disease and why: a national survey (2009) Alzheimer Dis Assoc Disord, 23, pp. 33-37; Connell, C.M., Gallant, M.P., Spouse caregivers' attitudes toward obtaining a diagnosis of a dementing illness (1996) J Am Geriatr Soc, 44, pp. 1003-1009; Lin, K.N., Liao, Y.C., Wang, P.N., Liu, H.C., Family members favor disclosing the diagnosis of Alzheimer's disease (2005) Int Psychogeriatr, 17, pp. 679-688; Morris, J.C., The clinical dementia rating (CDR): current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Morris, J.C., Selkoe, D.J., Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview (2011) Neurobiol Aging, 32, pp. S1-S3; Alladi, S., Xuereb, J., Bak, T., Focal cortical presentations of Alzheimer's disease (2007) Brain, 130, pp. 2636-2645; Fagan, A.M., Perrin, R.J., Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease (2012) Biomark Med, 6, pp. 455-476. , NIHMS406854",Article,Scopus,2-s2.0-84895727628
"Wardlow L., Ivanova I., Gollan T.H.","The cognitive mechanisms underlying perspective taking between conversational partners: Evidence from speakers with Alzheimer[U+05F3]s disease",2014,"Neuropsychologia","56","1",,"184","195",,1,10.1016/j.neuropsychologia.2014.01.013,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84896341376&partnerID=40&md5=055cab21e8cd2aa36fb169d512a56820","University of California, Department of Psychology, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0109, United States; University of California, Department of Psychiatry, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0948, United States","Wardlow, L., University of California, Department of Psychology, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0109, United States; Ivanova, I., University of California, Department of Psychiatry, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0948, United States; Gollan, T.H., University of California, Department of Psychiatry, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0948, United States","Successful communication requires speakers to consider their listeners'perspectives. Little is known about how this ability changes in Alzheimer's Disease (AD) although such knowledge could reveal the cognitive mechanisms fundamental to perspective-taking ability, and reveal which cognitive deficits are fundamental to communication disorders in AD. Patients with mild to moderate AD and age and education matched controls were tested in a communicative perspective-taking task, and on measures of executive control, general cognitive functioning, and lexical retrieval. Patients[U+05F3] ability to perform the perspective-taking task was significantly correlated with performance on measures of general cognitive functioning, visual scanning and construction, response conflict and attention. Measures of lexical retrieval tended not to be correlated with performance on the communication task with one exception: semantic but not letter fluency predicted a derived score of perspective-taking ability. These findings broaden our understanding of the cognitive mechanisms underlying perspective taking, and suggest that impairments in perspective taking in AD occur during utterance planning, and at a relatively early processing stage which involves rapid visual scanning and problem solving, rather than during retrieval of lexical items needed to speak. More broadly, these data reveal executive function and semantic deficits, but not problems with lexical retrieval, as more fundamental to the basis of cognitive changes associated with AD. © 2014 Elsevier Ltd.","Alzheimer's disease; Communication; Executive function; Language production","Ahmet, F.S., Miller, L.S., Relationship between theory of mind and functional independence is mediated by executive function (2013) Psychology and Aging, 28, pp. 293-303; Amieva, H., Philips, L.H., Della Sala, S., Henry, J.D., Inhibitory functioning in Alzheimer[U+05F3]s disease (2004) Brain, 127, pp. 949-964; Baayen, R.H., (2008) Analyzing linguistic data: A practical introduction to statistics using R, , Cambridge University Press, Cambridge; Baayen, R.H., Davidson, D.J., Bates, D.M., Mixed-effects modelling with crossed random effects for subjects and items (2008) Journal of Memory and Language, 59, pp. 390-412; Bates, D., Maechler, M., Bolker, B., (2012), http://CRAN.R-project.org/package=lme4, lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-0Barr, D.J., Levy, R., Scheepers, C., Tily, H.J., Random effects structure for confirmatory hypothesis testing: Keep it maximal (2013) Journal of Memory and Language, 68 (3), pp. 255-278; Belleville, S., Rouleau, N., Van der Linden, M., Use of the Hayling task to measure inhibition of prepotent responses in normal aging and Alzheimer[U+05F3]s disease (2006) Brain and Cognition, 62 (2), pp. 113-119; Blanken, G., Dittmann, J., Haas, J.C., Wallesch, C.W., Spontaneous speech in senile dementia and aphasia: Implication for a neurolinguistic model of language production (1987) Cognition, 27, pp. 247-274; Brown-Schmidt, S., The role of executive function in perspective taking during online language comprehension (2009) Psychonomic Bulletin and Review, 16, pp. 893-900; Bucks, R.S., Singh, S., Cuerden, J.M., Wilcock, G.K., Analysis of spontaneous, conversational speech in dementia of Alzheimer type: Evaluation of an objective technique for analysing lexical performance (2000) Aphasiology, 14, pp. 71-91; Burgess, P.W., Shallice, T., Bizarre responses, rule detection and frontal lobe lesions. (1996) Cortex, 32.2, pp. 241-259; Burgess, P.W., Shallice, T., (1997) The Hayling and Brixton tests, , Harcourt Assessment, London; Bush, G., Luu, P., Posner, M.I., Cognitive and emotional influences in anterior cingulate cortex (2000) Trends in Cognitive Sciences, 4 (6), pp. 215-222; Butters, N., Granholm, E., Salmon, D.P., Grant, I., Wolfe, J., Episodic and semantic memory: A comparison of amnesic and demented patients (1987) Journal of Clinical and Experimental Neuropsychology, 9 (5), pp. 479-497; Carlomagno, S., Santoro, A., Menditti, A., Pandolfi, M., Marinia, A., Referential communication in Alzheimer[U+05F3]s type dementia (2005) Cortex, 41, pp. 520-534; Clark, H.H., Marshall, C.R., Definite reference and mutual knowledge (1981) Elements of discourse understanding, , Cambridge University Press, Cambridge, A.K. Joshi, B. Webber, I.A. Sag (Eds.); Cohen, J., MacWhinney, B., Flatt, M., Provost, J., PsyScope: An interactive graphical system for designing and controlling experiments in the psychology laboratory using Macintosh computers (1993) Behavioral Research Methods, Instrumentation and Computation, 25, pp. 257-271; Collette, F., Van der Linden, M., Delfiore, G., Degueldre, C., Luxen, A., Salmon, E., The functional anatomy of inhibition processes investigated with the Hayling task (2001) Neuroimage, 14 (2), pp. 258-267; Demakis, G.J., Frontal lobe damage and tests of executive processing: A meta-analysis of the category test, stroop test, and trail-making test (2004) Journal of Clinical and Experimental Neuropsychology, 26 (3), pp. 441-450; Dixon, P., Models of accuracy in repeated-measures designs (2008) Journal of Memory and Language, 59, pp. 447-496; Fan, J., Flombaum, J.I., McCandliss, B.D., Thomas, K.M., Posner, M.I., Cognitive and brain consequences of conflict (2003) Neuroimage, 18 (1), pp. 42-57; Fan, J., McCandliss, B.D., Sommer, T., Raz, A., Posner, M.I., Testing the efficiency and independence of attentional networks (2002) Journal of Cognitive Neuroscience, 14, pp. 340-347; Feyereisen, P., Berrewaerts, J., Hupet, M., Pragmatic skills in the early stages of Alzheimer[U+05F3]s disease: An analysis by means of a referential communication task (2007) International Journal of Language and Communicative Disorders, 21 (1), pp. 1-17; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state: A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Hao, J., Li, K., Li, K., Zhang, D., Wang, W., Yang, Y., Visual attention deficits in Alzheimer[U+05F3]s disease: An fMRI study (2005) Neuroscience Letters, 385 (1), pp. 18-23; Hodges, J.R., Patterson, K., Oxbury, S., Funnell, E., Semantic dementia progressive fluent aphasia with temporal lobe atrophy (1992) Brain, 115 (6), pp. 1783-1806; Jaeger, T.F., Categorical data analysis: Away from ANOVAs (transformation or not) and towards logit mixed models (2008) Journal of Memory and Language, 59, pp. 434-446; Kaplan, E., Goodglass, H., Weintraub, S., (1983) The Boston naming test, , Lea and Febiger, Philadelphia; Keysar, B., Unconfounding common ground (1997) Discourse Processes, 24 (2-3), pp. 253-270; Kirshner, H.S., Webb, W.G., Kelly, M.P., The naming disorder of dementia (1984) Neuropsychologia, 22 (1), pp. 23-30; Lin, S., Keysar, B., Epley, N., Reflexively mindblind: Using theory of mind to interpret behavior requires effortful attention (2010) Journal of Experimental Social Psychology, 46 (3), pp. 551-556; MacDonald, A.W., Cohen, J.D., Stenger, V.A., Carter, C.S., Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control (2000) Science, 288 (5472), pp. 1835-1838; Mattis, S., (1988) Dementia rating scale: Professional manual, , Psychological Assessment Resources, Odessa, FL; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer[U+05F3]s disease: Report of the NINCDS-ADRDA work group (1984) Neurology, 34, pp. 939-944; Menard, S.W., (2002) Applied logistic regression analysis. In Sage University papers series on quantitative applications in the social sciences, 07 106, , Sage, Thousand Oaks, CA; Mickes, L., Wixted, J.T., Fennema-Notestine, C., Galasko, D., Bondi, M.W., Thal, L.J., Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer[U+05F3]s disease (2007) Neuropsychology-New York, 21 (6), p. 696; Moll, J., Oliveira-Souza, R.D., Moll, F.T., Bramati, I.E., Andreiuolo, P.A., The cerebral correlates of set-shifting: An fMRI study of the trail making test (2002) Arquivos de neuro-psiquiatria, 60 (4), pp. 900-905; Monsch, A.U., Bondi, M.W., Butters, N., Paulsen, J.S., Salmon, D.P., Brugger, P., A comparison of category and letter fluency in Alzheimer[U+05F3]s disease and Huntington[U+05F3]s disease (1994) Neuropsychology, 8 (1), pp. 25-30; Moran, J.M., Lifespan development: The effects of typical aging on theory of mind (2013) Behavioral Brain Research, 237, pp. 32-40; Nadig, A.S., Sedivy, J.C., Evidence of perspective-taking constraints in children[U+05F3]s on-line reference resolution (2002) Psychological Science, 13 (4), pp. 329-336; Nebes, R.D., Brady, C.B., Preserved organization of semantic attributes in Alzheimer[U+05F3]s disease (1990) Psychology and Aging, 5 (4), pp. 574-579; Nebes, R.D., Martin, D.C., Horn, L.C., Sparing of semantic memory in Alzheimer[U+05F3]s disease (1984) Journal of Abnormal Psychology, 93 (3), pp. 321-330; Nilsen, E.S., Graham, S., The relations between children[U+05F3]s communicative perspective-taking and executive functioning (2009) Cognitive Psychology, 58, pp. 220-249; Nilsen, E.S., Fecica, A.M., A model of communicative perspective-taking for typical and atypical populations of children (2011) Developmental Review, 31, pp. 55-78; Ober, B.A., Shenaut, G.K., Lexical decision and priming in Alzheimer[U+05F3]s disease (1988) Neuropsychologia, 26 (2), pp. 273-286; Oosterman, J.M., Vogels, R.L., van Harten, B., Gouw, A.A., Poggesi, A., Scheltens, P., Assessing mental flexibility: Neuroanatomical and neuropsychological correlates of the Trail Making Test in elderly people (2010) The Clinical Neuropsychologist, 24 (2), pp. 203-219; Orange, J.B., Colton-Hudson, A., Enhancing communication in dementia of the Alzheimer[U+05F3]s type (1998) Topics in Geriatric Rehabilitation, 14 (2), pp. 56-75; Perry, R.J., Hodges, J.R., Attention and executive deficits in Alzheimer[U+05F3]s disease: A critical review (1999) Brain, 122, pp. 383-404; Petersen, R.C., Jack, C.R., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Memory and MRI-based hippocampal volumes in aging and AD (2000) Neurology, 54 (3), p. 581. , (581); Pinheiro, J.C., Bates, D.M., (2000) Mixed-effects models in S and S-PLUS, , Springer Verlag, Berlin; Reitan, R.M., Validity of the Trail Making Test to organic brain damage (1958) Perceptual Motor Skills, 8, pp. 271-276; Richter, T., What is wrong With ANOVA and multiple regression? Analyzing sentence reading times With hierarchical linear models (2006) Discourse Processes, 41 (3), pp. 221-250; Robinson, G., Shallice, T., Bozzali, M., Cipolotti, L., The differing roles of the frontal cortex in fluency tests (2012) Brain, 135 (7), pp. 2202-2214; Salmon, D.P., Butters, N., Chan, A.S., The deterioration of semantic memory in Alzheimer[U+05F3]s disease (1999) Canadian Journal of Experimental Psychology, 53 (1), pp. 108-117; Salmon, D.P., Thomas, R.G., Pay, M.M., Booth, A., Hofstetter, C.R., Thal, L.J., Alzheimer[U+05F3]s disease can be accurately diagnosed in very mildly impaired individuals (2002) Neurology, 59 (7), pp. 1022-1028; Sattler, J.M., (1974) Assessment of children[U+05F3]s intelligence, , Saunders, Philadelphia; Small, J.A., Geldart, K., Gutman, G., Clarke Scott, M., The discourse of self in dementia (1998) Aging and Society, 18, pp. 291-316; Small, J.A., Montoro, J., Kemper, S., (1996), Discourse styles of conflict resolution in a nursing home setting. Poster presented at the third international conference on communication, aging and health, May 16-18, 1996. Kansas City: MOStalnaker, R.C., (1978) Syntax and semantics 9: Pragmatics, pp. 315-332. , Academic Press, New York, P. Cole (Ed.); Thompson-Schill, S.L., D'Esposito, M., Kan, I.P., Effects of repetition and competition on activity in left prefrontal cortex during word generation (1999) Neuron, 23 (3), pp. 513-522; Thurstone, L.L., Thurstone, T.G., Factorial studies of intelligence (1941) Psychometric Monographs, 2, p. 94; Wardlow, L., Individual differences in speakers[U+05F3] perspective taking: The roles of executive control and working memory (2013) Psychonomic Bulletin and Review, 20, pp. 766-772; Wardlow Lane, L., Groisman, M., Ferreira, V.S., Don[U+05F3]t Talk About Pink Elephants! Speakers[U+05F3] control over leaking private information during language production (2006) Psychological Science, 17, pp. 273-277; Wardlow Lane, L., Ferreira, V.S., Speaker-external versus speaker-internal forces on utterance form: Do cognitive demands override threats to referential success? (2008) Journal of Experimental Psychology: Learning, Memory, and Cognition, 34 (6), pp. 1466-1481; Wechsler, D., Manual for the Wechsler Intelligence Scale for children, revised (1974) Psychological Corporation; Wechsler, D., (1997) Wechsler adult intelligence scale, , The Psychological Corporation, San Antonio, TX; Coping with specific stressors in Alzheimer[U+05F3]s disease caregiving (1993) The Gerontologist, 33 (6), pp. 747-755. , Williamson Shultz; Zakzanis, K.K., Mraz, R., Graham, S.J., An fMRI study of the trail making test (2005) Neuropsychologia, 43 (13), pp. 1878-1886",Article,Scopus,2-s2.0-84896341376
"Caramelli P., Laks J., Palmini A.L.F., Nitrini R., Chaves M.L.F., Forlenza O.V., de Assis Carvalho do Vale F., Barbosa M.T., de Campos Bottino C.M., Machado J.C., Charchat-Fichman H., Lawson F.L.","Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: A 24- week, randomized, placebo-controlled exploratory trial (the REMIX study) [Efeitos da galantamina e da galantamina combinada à nimodipina sobre a velocidade de processamento cognitivo e qualidade de vida na demência mista: Ensaio clínico exploratório, randomizado e controlado com placebo (estudo REMIX)]",2014,"Arquivos de Neuro-Psiquiatria","72","6",,"411","417",,1,10.1590/0004-282X20140055,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903309697&partnerID=40&md5=6d6470ca020ca374ee6b93c8de5f2073","Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil; Centro de Doença de Alzheimer e outras Desordens Mentais na Velhice, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil; Serviço de Neurologia, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brazil; Departamento de Neurologia, Universidade de São Paulo, Sao Paulo SP, Brazil; Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil; Laboratório de Neurociências LIM-27, Departamento e Instituto de Psiquiatria, Universidade de São Paulo, Sao Paulo SP, Brazil; Liga de Neurologia Cognitiva e Comportamental, Universidade Federal de São Carlos, Sao Carlos SP, Brazil; Instituto de Ensino e Pesquisa do Envelhecimento, Departamento de Medicina Geriátrica, Hospital Mater Dei, Belo Horizonte MG, Brazil; Departamento e Instituto de Psiquiatria, Universidade de São Paulo, Sao Paulo SP, Brazil; Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro RJ, Brazil; Janssen-Cilag Farmacêutica Ltda., Sao Paulo SP, Brazil","Caramelli, P., Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil; Laks, J., Centro de Doença de Alzheimer e outras Desordens Mentais na Velhice, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil; Palmini, A.L.F., Serviço de Neurologia, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brazil; Nitrini, R., Departamento de Neurologia, Universidade de São Paulo, Sao Paulo SP, Brazil; Chaves, M.L.F., Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil; Forlenza, O.V., Laboratório de Neurociências LIM-27, Departamento e Instituto de Psiquiatria, Universidade de São Paulo, Sao Paulo SP, Brazil; de Assis Carvalho do Vale, F., Liga de Neurologia Cognitiva e Comportamental, Universidade Federal de São Carlos, Sao Carlos SP, Brazil; Barbosa, M.T., Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil, Instituto de Ensino e Pesquisa do Envelhecimento, Departamento de Medicina Geriátrica, Hospital Mater Dei, Belo Horizonte MG, Brazil; de Campos Bottino, C.M., Departamento e Instituto de Psiquiatria, Universidade de São Paulo, Sao Paulo SP, Brazil; Machado, J.C., Instituto de Ensino e Pesquisa do Envelhecimento, Departamento de Medicina Geriátrica, Hospital Mater Dei, Belo Horizonte MG, Brazil; Charchat-Fichman, H., Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro RJ, Brazil; Lawson, F.L., Janssen-Cilag Farmacêutica Ltda., Sao Paulo SP, Brazil","The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored. Method: Double-blind, placebo-controlled, multicenter Brazilian trial, studying the effects of GAL/NIM vs. GAL/placebo (PLA) in mild to moderate mixed dementia. Patients were randomized to receive GAL/NIM or GAL/PLA for 24 weeks. Primary efficacy measures were changes on a computerized neuropsychological battery (CNTB) and QoL Scale in Alzheimer's Disease (QoL-AD) from baseline to week 24. Results: Twenty-one patients received at least one drug dose (9 GAL/NIM and 12 GAL/PLA). Groups were matched for age, sex, education, cognitive and QoL scores at baseline. No significant differences were observed between groups on primary or secondary measures. QoL and cognitive performance showed significant improvement (p<0.05) from baseline when all GAL-treated patients were analyzed. Adverse events were predominantly mild to moderate. Conclusion: GAL treatment improved QoL in mixed dementia, in addition to its previously known cognitive benefits. The combination GAL/NIM was not advantageous. However, the small sample size precludes any definitive conclusions. Trial registered at ClinicalTrials.gov:NCT00814658.","Alzheimer disease; Cerebrovascular disorders; Galantamine; Nimodipine","Korczyn, A.D., Mixed dementia - the most common cause of dementia (2002) Ann New York Acad Sci, 977, pp. 129-134; Herrera, E., Caramelli, P., Silveira, A.S.B., Nitrini, R., Epidemiologic survey of dementia in a community-dwelling Brazilian population (2002) Alzheimer Dis Assoc Disord, 16, pp. 103-108; López-Arrieta, J.M., Birks, J., Nimodipine for primary degenerative, mixed and vascular dementia (2002) Cochrane Database Syst Rev, 3. , CD000147; Craig, D., Birks, J., Galantamine for vascular cognitive impairment (2006) Cochrane Database Syst Rev, 1. , CD004746; Loy, C., Schneider, L., Galantamine for Alzheimer's disease and mild cognitive impairment (2006) Cochrane Database Syst Rev, 1. , CD001747; Gold, G., Giannakopoulos, P., Herrmann, F.R., Bouras, C., Kövari, E., Identification of Alzheimer and vascular lesion thresholds for mixed dementia (2007) Brain, 130, pp. 2830-2836; Erkinjuntti, T., Gauthier, S., Bullock, R., Galantamine treatment in Alzheimer's disease with cerebrovascular disease: Responder analyses from a randomized, controlled trial (GAL-INT-6) (2008) J Psychopharmacol, 22, pp. 761-768; Kumar, V., Anand, R., Messina, J., Hartman, R., Veach, J., An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors (2000) Eur J Neurol, 7, pp. 159-169; Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., Damaraju, C.V., Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial (2002) Lancet, 359, pp. 1283-1290; Kurz, A., Galantamine improves cognitive and global abilities in Alzheimer's disease with cerebrovascular components and probable vascular dementia: Preliminary results (2001) Neurology, 56 (SUPPL.), pp. S340; Tomassoni, D., Lanari, A., Silvestrelli, G., Traini, E., Amenta, F., Nimodipine and its use in cerebrovascular disease: Evidence from recent preclinical and controlled clinical studies (2008) Clin Exp Hypertens, 30, pp. 744-766; (1994) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association, Washington, DC: American Psychiatric Association; Román, G.C., Tatemichi, T.K., Erkinjuntti, T., Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop (1993) Neurology, 43, pp. 250-260; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state. A practical method for grading the cognitive state of patients for the clinician (1975) J Psychiatr Res, 12, pp. 189-198; Charchat, H., (1999) Desenvolvimento De Uma Bateria De Testes Neuropsicológicos Computadorizados Para O Diagnóstico Precoce Da Doença De Alzheimer, , Dissertação de Mestrado, Universidade de São Paulo; Caramelli, P., Chaves, M.L., Engelhardt, E., Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: Results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01) (2004) Arq Neuropsiquiatr, 62, pp. 379-384; Logsdon, R.G., Gibbons, L.E., McCurry, S.M., Teri, L., Quality of life in Alzheimer's disease: Patient and caregiver reports (1999) J Mental Health Aging, 5, pp. 21-32; Novelli, M.M., Rovere, H.H.D., Nitrini, R., Caramelli, P., Cross-cultural adaptation of the quality of life assessment scale on Alzheimer disease (2005) Arq Neuropsiquiatr, 63, pp. 201-206; Rosen, W.G., Mohs, R.C., Davis, K.L., A new rating scale for Alzheimer's disease (1984) Am J Psychiatry, 141, pp. 1356-1364; Schultz, R.R., Siviero, M.O., Bertolucci, P.H., The cognitive subscale of the ""Alzheimer's Disease Assessment Scale"" in a Brazilian sample (2001) Braz J Med Biol Res, 34, pp. 1295-1302; Guy, W., E.C.D.E.U. assessment manual for psychopharmacology. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health (1976) Psychopharmacology Research Branch, Division of Extramural Research Programs; Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia (1994) Neurology, 44, pp. 2214-2308; Camozzato, A.L., Kochhann, R., Simeoni, C., Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer's disease and their caregivers (2008) Int Psychogeriatr, 20, pp. 383-393; Brucki, S.M.D., Nitrini, R., Caramelli, P., Bertolucci, P.H., Okamoto, I.H., Suggestions for utilization of the Mini-Mental State Examination in Brazil (2003) Arq Neuropsiquiatr, 61, pp. 777-781; Rodda, J., Morgan, S., Walker, Z., Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine (2009) Int Psychogeriatr, 21, pp. 813-824; Lockhart, I.A., Mitchell, S.A., Kelly, S., Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the ""real-world"" evidence (2009) Dement Geriatr Cogn Disord, 28, pp. 389-403; Auchus, A.P., Brashear, H.R., Salloway, S., Korczyn, A.D., de Deyn, P.P., Gassmann-Mayer, C., Galantamine treatment of vascular dementia: A randomized trial (2007) Neurology, 69, pp. 448-458; Kurz, A.F., Erkinjuntti, T., Small, G.W., Lilienfeld, S., Damaraju, C.R.V., Longterm safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease (2003) Eur J Neurol, 10, pp. 633-640; Kavanagh, S., Howe, I., Brashear, H.R., Long-term response to galantamine in relation to short-term efficacy data: Pooled analysis in patients with mild to moderate Alzheimer's disease (2011) Curr Alzheimer Res, 8, pp. 175-186",Article,Scopus,2-s2.0-84903309697
"Tay L., Chua K.C., Chan M., Lim W.S., Ang Y.Y., Koh E., Chong M.S.","Differential perceptions of quality of life (QoL) in community-dwelling persons with mild-to-moderate dementia",2014,"International Psychogeriatrics","26","8",,"1273","1282",,,10.1017/S1041610214000660,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903640737&partnerID=40&md5=ceabe93ab20f0582f7fbbd4d998384f2","Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore; Institute of Psychiatry, King's College London, London, United Kingdom; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore","Tay, L., Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore, Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore; Chua, K.C., Institute of Psychiatry, King's College London, London, United Kingdom; Chan, M., Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore, Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore; Lim, W.S., Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore, Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore; Ang, Y.Y., Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; Koh, E., Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Chong, M.S., Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore, Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore","Background: Discordance between patient- and caregiver-reported quality of life (QoL) is well recognized. This study sought to (i) identify predictors of discrepancy between patient- and caregiver-rated QoL amongst community-dwelling persons with mild-to-moderate dementia, and (ii) differentiate between patients who systematically rate their QoL lower versus those who rate their QoL higher relative to their caregiver ratings. Methods: We recruited 165 patient-caregiver dyads with mild-to-moderate dementia. Quality of life in Alzheimer's disease (QoL-AD) scale was administered separately to patients and caregivers. Data on socio-demographics, interpersonal relationship, and disease-related characteristics (cognitive performance, mood, neuropsychiatric symptoms, functional ability, and caregiver burden) were collected. Patient-caregiver dyads were categorized based on whether patient-rated QoL was lower or higher than their respective caregiver ratings. Univariate analyses and multiple regression models were performed to identify predictors of dyadic rating discrepancy. Results: Mean patient-rated QoL was significantly higher than caregiver rating (mean difference: 3.8 ± 7.1, p < 0.001). Majority (111 (67.2%)) of patients had more positive self-perceived QoL (QoL-ADp (QoL-AD self rated by the patient) > QoL-ADc (QoL-AD proxy-rated by a caregiver)), compared with those (44 (26.7%)) with poorer self-perceived QoL (QoL-ADp < QoL-ADc). Patient's education level, depressive symptoms, and severity of neuropsychiatric symptoms predicted magnitude of discrepancy. Depression (OR = 1.17, 95% CI = 1.02-1.35) and being cared for by other relative (non-spouse/adult child; OR = 7.54, 95% CI = 1.07-53.03) predicted poorer self-perceived QoL. Conclusions: Dyadic rating discrepancy in QoL should draw the clinician's attention to patient depression and neuropsychiatric symptoms. Consideration should also be given to nature of patient-caregiver relationship when discordance between patient and caregiver assessments of QoL is observed. © International Psychogeriatric Association 2014.","agreement; caregivers; dementia; quality of life","Alexopoulos, G.S., Abrams, R.C., Young, R.C., Shamoian, C.A., Cornell scale for depression in Dementia (1988) Biological Psychiatry, 23, pp. 271-284; Banerjee, S., What do we know about quality of life in Dementia?. A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia (2009) International Journal of Geriatric Psychiatry, 24, pp. 15-24; Brod, M., Stewart, A.L., Sands, L., Walton, P., Conceptualization and measurement of quality of life in Dementia: The dementia quality of life instrument (DQoL (1999) The Gerontologist, 39, pp. 25-35; Buckley, T., Predictors of quality of life ratings for persons with demenita simultaneously reorted by patients and their caregivers: The Cache County (Utah) study (2012) International Psychogeriatrics, 24, pp. 1094-1102; Bucks, R.S., Ashworth, D.L., Wilcock, G.K., Siegfried, K., Assessment of activities of daily living in Dementia: Development of the bristol activities of daily living scale (1996) Age and Ageing, 25 (2), pp. 113-120. , DOI 10.1093/ageing/25.2.113; Carr, A.J., Gibson, B., Robinson, P.G., Measuring quality of life: Is quality of life determined by expectations or experience? (2001) British Medical Journal, 322, pp. 1240-1243; Cheah, W.K., Han, H.C., Chong, M.S., Anthony, P.V., Lim, W.S., Multidimensionality of the Zarit Burden Interview across the severity spectrum of cognitive impairment: An Asian perspective (2012) International Psychogeriatrics, 24, pp. 1846-1854; Conde-Sala, J.L., Garre-Olmo, J., Turro-Garriga, O., Lopez-Pousa, S., Vilalta-Franch, J., Factors related to perceived quality of life in patients with Alzheimers disease: The patients perception compared with that of caregivers (2009) International Journal of Geriatric Psychiatry, 24, pp. 585-594; Conde-Sala, J.L., Severity of dementia, anosognosia, and depression in relation to the quality of life of patients with Alzheimer disease: Discrepancies between patients and caregivers (2014) The American Journal of Geriatric Psychiatry, 22, pp. 138-147; Feldman, H.H., Van Baelen, B., Kavanagh, S.M., Torfs, K.E., Cognition function and caregiving time patterns in patients with mild to moderate Alzheimers disease: A 12 month analysis (2005) Alzheimer Disease & Associated Disorders, 19, pp. 29-36; Huang, H.L., Chang, M.Y., Tang, J.S.H., Chiu, Y.C., Weng, L.C., Determinants of the discrepancy in patient- and caregiver-rated quality of life for persons with dementia (2009) Journal of Clinical Nursing, 18, pp. 3107-3118; Hurt, C.S., Insight, cognition and quality of life in Alzheimers disease (2010) Journal of Neurology, Neurosurgery & Psychiatry, 81, pp. 331-336; Karttunen, K., Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimers disease (2011) International Journal of Geriatric Psychiatry, 26, pp. 473-482; Kashiwa, Y., Kitabayashi, Y., Narumoto, J., Nakamura, K., Ueda, H., Fukui, K., Anosognosia in alzheimers disease: Association with patient characteristics, psychiatric symptoms and cognitive deficits (2005) Psychiatry and Clinical Neurosciences, 59 (6), pp. 697-704; Kaufer, D.I., Cummings, J.L., Ketchel, P., Smith, V., MacMillan, A., Shelley, T., Lopez, O.L., Dekosky, S.T., Validation of the npi-q, a brief clinical form of the neuropsychiatric inventory (2000) Journal of Neuropsychiatry and Clinical Neurosciences, 12 (2), pp. 233-239. , DOI 10.1176/appi.neuropsych.12.2.233; Lawton, M.P., Quality of life in alzheimer disease (1994) Alzheimer Disease & Associated Disorders, 8, pp. 138-150; Li, X.J., The comparison of dementia patients quality of life and influencing factors in two cities (2012) Journal of Clinical Nursing, 22, pp. 2132-2140; Lim, W.S., Chin, J.J., Lam, C.K., Lim, P.P.J., Sahadevan, S., Clinical dementia rating: Experience of a multi-racial asian population (2005) Alzheimer Disease and Associated Disorders, 19 (3), pp. 135-142. , DOI 10.1097/01.wad.0000174991.60709.36; Logsdon, R.G., Gibbons, L.E., McCurry, S.M., Teri, L., Assessing quality of life in older adults with cognitive impairment (2002) Psychosomatic Medicine, 64 (3), pp. 510-519; MacK, J.L., Whitehouse, P.J., Quality of life in Dementia: State of the art-report of the international working group for harmonization of dementia drug guidelines and the Alzheimers society satellite meeting (2001) Alzheimer Disease and Associated Disorders, 15 (2), pp. 69-71. , DOI 10.1097/00002093-200104000-00005; Matsui, T., Nakaaki, S., Murata, Y., Sato, J., Shinagawa, Y., Tatsumi, H., Furukawa, T.A., Determinants of the quality of life in Alzheimers disease patients as assessed by the Japanese version of the quality of life - Alzheimers disease scale (2006) Dementia and Geriatric Cognitive Disorders, 21 (3), pp. 182-191. , DOI 10.1159/000090744; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Naglie, G., Quality of life in Dementia (2007) The Canadian Journal of Neurological Sciences, 34, pp. S57-S61; Pfeifer, L., Drobetz, R., Fankhauser, S., Mortby, M.E., Maercker, A., Forstmeier, S., Caregiver rating bias in mild cognitive impairment and mild Alzheimers disease: Impact of caregiver burden and depression on Dyadic rating discrepancy across domains (2013) International Psychogeriatrics, 25, pp. 1345-1355; Sahadevan, S., Lim, P.P.J., Tan, N.J.L., Chan, S.P., Diagnostic performance of two mental status tests in the older chinese: Influence of education and age on cut-off values (2000) International Journal of Geriatric Psychiatry, 15 (3), pp. 234-241. , DOI 10.1002/(SICI)1099-1166(200003)15:3<234::AID-GPS99>3.0.CO;2-G; Sousa, M.F.B., Quality of life in Dementia: The role of non-cognitive factors in ratings of people with dementia and family caregivers (2013) International Psychogeriatrics, 25, pp. 1097-1105; Vogel, A., Mortensen, E.L., Hasselbalch, S.G., Andersen, B.B., Waldemar, G., Patient versus informant reported quality of life in the earliest phases of Alzheimers disease (2006) International Journal of Geriatric Psychiatry, 21 (12), pp. 1132-1138. , DOI 10.1002/gps.1619; Vogel, A., Waldorff, F., Waldemar, G., Impaired awareness of deficits and neuropsychiatric symptoms in early Alzheimers disease: The Danish Alzheimer Intervention Study (DAISY (2010) Journal of Neuropsychiatry and Clinical Neurosciences, 22, pp. 93-99; Zarit, S.H., Reever, K.E., Bach-Peterson, J., Relatives of the impaired elderly: Correlates of feelings of burden (1980) Gerontologist, 20 (6), pp. 649-655; Zhao, H., Factors associated with caregivers underestimation of life in patients with Alzheimers disease (2012) Dementia and Geriatric Cognitive Disorders, 33, pp. 11-17",Article,Scopus,2-s2.0-84903640737
"Lendel C., Bjerring M., Dubnovitsky A., Kelly R.T., Filippov A., Antzutkin O.N., Nielsen N.C., Hard T.","A hexameric peptide barrel as building block of amyloid-b protofibrils",2014,"Angewandte Chemie - International Edition","53","47",,"12756","12760",,1,10.1002/anie.201406357,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84911413890&partnerID=40&md5=05ccc0724c197bba437592243588ee6c","Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences (SLU), Box 7015Uppsala, Sweden; Center for Insoluble Protein Structures (InSPIN), Department of Chemistry, Aarhus UniversityAarhus, Denmark; Department of Physics, Warwick UniversityCoventry, United Kingdom; Chemistry of Interfaces, Lulea University of TechnologyLulea, Sweden; Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska InstitutetStockholm, Sweden","Lendel, C., Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences (SLU), Box 7015Uppsala, Sweden; Bjerring, M., Center for Insoluble Protein Structures (InSPIN), Department of Chemistry, Aarhus UniversityAarhus, Denmark; Dubnovitsky, A., Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences (SLU), Box 7015Uppsala, Sweden, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska InstitutetStockholm, Sweden; Kelly, R.T., Department of Physics, Warwick UniversityCoventry, United Kingdom; Filippov, A., Chemistry of Interfaces, Lulea University of TechnologyLulea, Sweden; Antzutkin, O.N., Department of Physics, Warwick UniversityCoventry, United Kingdom, Chemistry of Interfaces, Lulea University of TechnologyLulea, Sweden; Nielsen, N.C., Center for Insoluble Protein Structures (InSPIN), Department of Chemistry, Aarhus UniversityAarhus, Denmark; Härd, T., Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences (SLU), Box 7015Uppsala, Sweden","Oligomeric and protofibrillar aggregates formed by the amyloid-b peptide (Ab) are believed to be involved in the pathology of Alzheimers disease. Central to Alzheimer pathology is also the fact that the longer Ab42 peptide is more prone to aggregation than the more prevalent Ab40. Detailed structural studies of Ab oligomers and protofibrils have been impeded by aggregate heterogeneity and instability. We previously engineered a variant of Ab that forms stable protofibrils and here we use solid-state NMR spectroscopy and molecular modeling to derive a structural model of these. NMR data are consistent with packing of residues 16 to 42 of Ab protomers into hexameric barrel-like oligomers within the protofibril. The core of the oligomers consists of all residues of the central and C-terminal hydrophobic regions of Ab, and hairpin loops extend from the core. The model accounts for why Ab42 forms oligomers and protofibrils more easily than Ab40. © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.","Alzheimer's disease; Amyloid β-peptides; Neurotoxicity; Oligomers; Protein structures","Haass, C., Selkoe, D.J., (2007) Nat. Rev. Mol. Cell Biol., 8, pp. 101-112; Lansbury, P., Lashuel, H., (2006) Nature, 443, pp. 774-779; Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T., Younkin, S., (1996) Nat. Med., 2, pp. 864-870; Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., De Strooper, B., (2010) EMBO J., 29, pp. 3408-3420; Bitan, G., Kirkitadze, M.D., Lomakin, A., Vollers, S.S., Benedek, G.B., Teplow, D.B., (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 330-335; Nilsberth, C., Westlind-Danielsson, A., Eckman, C., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Lannfelt, L., (2001) Nat. Neurosci., 4, pp. 887-893; O-Nuallain, B., Freir, D.B., Nicoll, A.J., Risse, E., Ferguson, N., Herron, C.E., Collinge, J., Walsh, D.M., (2010) J. Neurosci., 30, pp. 14411-14419; Walsh, D., Lomakin, A., Benedek, G., Condron, M., Teplow, D., (1997) J. Biol. Chem., 272, pp. 22364-22372; Harper, J., Wong, S., Lieber, C., Lansbury, P., (1997) Chem. Biol., 4, pp. 119-125; Caughey, B., Lansbury, P., (2003) Annu. Rev. Neurosci., 26, pp. 267-298; Moores, B., Drolle, E., Attwood, S., Simons, J., Leonenko, Z., (2011) PLoS One, 6, p. e25954; Dubnovitsky, A., Sandberg, A., Rahman, M.M., Benilova, I., Lendel, C., H-Rd, T., (2013) PLoS One, 8, p. e66101; Sandberg, A., Luheshi, L.M., Sçllvander, S., De Barros, T.P., Macao, B., Knowles, T.P., Biverst-L, H., H-Rd, T., (2010) Proc. Natl. Acad. Sci. USA, 107, pp. 15595-15600; Lewandowski, J.R., De Paepe, G., Griffin, R.G., (2007) J. Am. Chem. Soc., 129, pp. 728-729; Leaver-Fay, A., Tyka, M., Lewis, S., Lange, O., Thompson, J., Jacak, R., Kaufman, K., Bradley, P., (2011) Methods Enzymol., 487, pp. 545-574; Urbanc, B., Cruz, L., Yun, S., Buldyrev, S.V., Bitan, G., Teplow, D.B., Stanley, H.E., (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 17345-17350; Rosenman, D., Connors, C., Chen, W., Wang, C., Garc-A, A., (2013) J. Mol. Biol., 425, pp. 3338-3359; Lu, J.-X., Qiang, W., Yau, W.-M., Schwieters, C., Meredith, S., Tycko, R., (2013) Cell, 154, pp. 1257-1268; Bernstein, S.L., Dupuis, N.F., Lazo, N.D., Wyttenbach, T., Condron, M.M., Bitan, G., Teplow, D.B., Bowers, M.T., (2009) Nat. Chem., 1, pp. 326-331; Jarrett, J., Berger, E., Lansbury, P., (1993) Biochemistry, 32, pp. 4693-4697; Lazo, N.D., Grant, M.A., Condron, M.C., Rigby, A.C., Teplow, D.B., (2005) Protein Sci., 14, pp. 1581-1596; Sciarretta, K., Gordon, D., Petkova, A., Tycko, R., Meredith, S., (2005) Biochemistry, 44, pp. 6003-6014; Yu, L., Edalji, R., Harlan, J.E., Holzman, T.F., Lopez, A.P., Labkovsky, B., Hillen, H., Olejniczak, E.T., (2009) Biochemistry, 48, pp. 1870-1877; Hoyer, W., Grçnwall, C., Jonsson, A., St-Hl, S., H-Rd, T., (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 5099-5104; Scheidt, H.A., Morgado, I., Rothemund, S., Huster, D., F-Ndrich, M., (2011) Angew. Chem. Int. Ed., 50, pp. 2837-2840; (2011) Angew. Chem., 123, pp. 2889-2892; Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J., Smith, S.O., (2010) Nat. Struct. Mol. Biol., 17, pp. 561-567; Lawrence, M., Colman, P., (1993) J. Mol. Biol., 234, pp. 946-950; Wishart, D.S., Sykes, B.D., (1994) J. Biomol. NMR, 4, pp. 171-180",Article,Scopus,2-s2.0-84911413890
"McLennon S.M., Bakas T., Habermann B., Meuser T.M.","Content and Face Validity of the Marwit-Meuser Caregiver Grief Inventory (Short Form) in African American Caregivers",2014,"Death Studies","38","6",,"365","373",,,10.1080/07481187.2013.766657,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84897090102&partnerID=40&md5=1ae588b512ee95faddc4bc285af7c529","School of Nursing, Indiana University, Indianapolis, IN, United States; Gerontology Program, School of Social Work, University of Missouri-St. Louis, St. Louis, MO, United States","McLennon, S.M., School of Nursing, Indiana University, Indianapolis, IN, United States; Bakas, T., School of Nursing, Indiana University, Indianapolis, IN, United States; Habermann, B., School of Nursing, Indiana University, Indianapolis, IN, United States; Meuser, T.M., Gerontology Program, School of Social Work, University of Missouri-St. Louis, St. Louis, MO, United States","There may be cultural differences in the experience of predeath grief in African American (AA)/Black caregivers for persons with Alzheimers disease (AD). The most commonly used screening tool, the Marwit and Meuser Caregiver Grief Inventory-Short Form (MMCGI-SF), was developed from focus groups with primarily Caucasian/White caregivers. Interviews were held with 19 AA spouse and adult child caregivers for persons with mild, moderate, and severe AD, and data were coded and compared with scale items on the MCMGI-SF to assess validity. Results from this study provide evidence for content and face validity of the MMCGI-SF for use in AA caregivers. © 2014 Copyright Taylor & Francis Group, LLC.",,"Adams, K.B., McClendon, M.J., Smyth, K.A., Personal losses and relationship quality in dementia caregiving (2008) Dementia, 7, pp. 301-319; Adams, K.B., Sanders, S., Alzheimer's caregiver differences in experience of loss, grief reactions, and depressive symptoms across stage of disease (2004) Dementia, 3, pp. 195-210; (2012) Alzheimer's Association, 2012 Alzheimer's disease facts and figures, , http://www.alz.org/downloads/Facts_Figures_2012.pdf, Retrieved from; Bass, D.M., Judge, K.S., Snow, A.L., Wilson, N.L., Looman, W.J., McCarthy, C., Kunik, M.E., Negative caregiving effects among caregivers of veterans with dementia (2012) American Journal of Geriatric Psychiatry, 20, pp. 239-247; Broome, B.A., Culture counts (2004) Journal of Cultural Diversity, 11, pp. 1-2. , Fall; Burke, W.J., Miller, J.P., Rubin, E.H., Morris, J.C., Coben, L.A., Duchek, J., Berg, L., Reliability of the Washington University Clinical Dementia Rating (1988) Archives of Neurology, 45, pp. 31-32; Chadiha, L.A., Morrow-Howell, N., Darkwa, O., McGillick, J., Targeting the Black church and clergy for disseminating knowledge about Alzheimer's disease and caregiver's support services (1994) American Journal of Alzheimer's Care and Related Disorders & Research, 9, pp. 17-20; Chan, D., Livingston, G., Jones, L., Sampson, E.L., Grief reactions in dementia carers: A systematic review (2012) International Journal of Geriatric Psychiatry, 28, pp. 1-17; Daviglus, M.L., Bell, C.C., Berrettini, W., Bowen, P.E., Connolly Jr., E.S., Cox, N.J., Trevisan, M., NIH state-of-the-science conference statement: Preventing Alzheimer's Disease and cognitive decline (2010) Annals of Internal Medicine, 153, pp. W65; Devellis, R., (2003) Scale development: Theory and applications, , Thousand Oaks, CA, Sage; Diwan, S., Hougham, G.W., Sachs, G.A., Chronological patterns and issues precipitating grieving over the course of caregiving among family caregivers of persons with dementia (2009) Clinical Gerontologist: The Journal of Aging And Mental Health, 32, pp. 358-370; Doka, K.J., Culture, ethnicity, and dementia (2004) Living with grief: Alzheimers disease, , In: Doka K. J., editors Washington, DC, Hospice Foundation of America; Doka, K.J., Aber, R., Psychosocial loss and grief (1989) Disenfranchised grief: Recognizing hidden sorrow, pp. 187-211. , In: Doka K. J., editors Lexington, MA, Lexington Books; Elo, S., Kyngäs, H., The qualitative content analysis (2007) Journal of Advanced Nursing, 62, pp. 107-115; Frank, J.B., Evidence for grief as the major barrier faced by Alzheimer's caregivers: A qualitative analysis (2008) American Journal of Alzheimer's Disease and Other Dementias, 22, pp. 516-527; Givens, J.L., Prigerson, H.G., Kiely, D.K., Shaffer, M.L., Mitchell, S.L., Grief among family members of nursing home residents with advanced dementia (2011) American Journal of Geriatric Psychiatry, 19, pp. 543-550; Goldsmith, B., Morrison, R.S., Vanderweker, L.C., Prigerson, H.G., Elevated rates of prolonged grief disorder in African Americans (2008) Death Studies, 32, pp. 352-365; Grant, J.S., Davis, L.L., Selection and use of content experts for instrument development (1997) Research in Nursing and Health, 20, pp. 269-274; Hebert, R.S., Dang, Q., Schulz, R., Preparedness for the death of a loved one and mental health in bereaved caregivers of patients with dementia: Findings from the REACH study (2006) Journal of Palliative Medicine, 9, pp. 683-693; Hebert, R.S., Koenig, H.G., Arnold, R.M., Schulz, R., Caregiver intervention research: An opportunity for collaboration between caregiving investigators and African-American faith communities (2006) Journal of the National Medical Association, 98, pp. 1510-1514; Holley, C.K., Mast, B.T., The impact of anticipatory grief on caregiver burden in dementia caregivers (2009) The Gerontologist, 49, pp. 388-396; Johnson, E.A., Bakas, T., Lyon, B.L., Cognitive appraisal of health scale (2008) Clinical Nurse Specialist, 22 (1), pp. 12-18; Kissane, D., Bloch, S., (2002) Family focused grief therapy: A model of family-centered care during palliative care and bereavement, , Philadelphia, PA, Open University Press; Krippendorff, K., (2004) Content analysis: An introduction to its methodology (), , 2nd ed., Thousand Oaks, CA, Sage; Liang, J., Assessing cross-cultural comparability in mental health among older adults (2002) Multicultural measurement in older populations, pp. 11-21. , In:, In:, In:, In:, In: Skinner J. H., editorsTeresi J. A., editorsHolmes D., editorsStahl S. M., editorsStewart A. L., editors, New York, NY, Springer; Lichtenthal, W.G., Cruess, D.G., Prigerson, H.G., A case for establishing complicated grief as a distinct mental disorder in DSM-V (2004) Clinical Psychology Review, 24, pp. 637-662; Lynn, M.R., Determination and quantification of content validity (1986) Nursing Research, 35, pp. 382-385; Marwit, S.J., Chibnall, J.T., Dougherty, R., Jenkins, C., Shawgo, J., Assessing pre-death grief in cancer caregivers using the Marwit-Meuser Caregiver Grief Inventory (MMCGI) (2008) Psycho-Oncology, 17, pp. 300-303; Marwit, S.J., Kaye, P.N., Measuring grief in caregivers of persons with acquired brain injury (2006) Brain Injury, 20, pp. 1419-1429; Marwit, S.J., Meuser, T.M., Development and initial validation of an inventory to assess grief in caregivers of persons with Alzheimer's Disease (2002) Gerontologist, 42, pp. 751-765; Marwit, S.J., Meuser, T.M., Development of a short form inventory to assess grief in caregivers of dementia patients (2005) Death Studies, 29, pp. 191-205; Mausbach, B.T., Roepke, S.K., Chattillion, E.A., Harmell, A.L., Moore, R., Romero-Moreno, R., Grant, I., Multiple mediators of the relations between caregiving stress and depressive symptoms (2012) Aging & Mental Health, 16, pp. 27-38; McLennon, S.M., Habermann, B., Accruing the sample: Strategies for recruiting older adult and African American caregivers for persons with Alzheimer's Disease (2012) Applied Nursing Research, 25, pp. e1-e6; Meuser, T.M., Marwit, S.J., A comprehensive, stage-sensitive model of grief in dementia caregiving (2001) The Gerontologist, 41, pp. 658-670; Meuser, T.M., Marwit, S.J., Sanders, S., Assessing grief in family caregivers (2004) Living with grief: Alzheimer's disease, pp. 170-195. , In: Doka K., editors Washington, DC, Hospice Foundation of America; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Morris, J.C., Berg, L., Cohen, L.A., Rubin, E.H., Deuel, R., Wittenborn, R., Norton, J., (1995) Treating Alzheimer's and other dementias: Clinical application of recent research advances, pp. 338-346. , In:, In: Bergener M., editorsFinkel S. I., editors In, New York, NY, Springer Publishing; Neighbors, H.W., Musick, M.A., Williams, D.R., The African American minister as a source of help for serious personal crises: Bridge or barriers to mental health care? (1998) Health Education & Behavior, 25, pp. 759-777; Ory, M.G., Hoffman, R.R., Yee, J.L., Tennstedt, S., Schulz, R., Prevalence and impact of caregiving: A detailed comparison between dementia and nondementia caregivers (1999) Gerontologist, 39, pp. 177-185; Owen, J.E., Goode, K.T., Haley, W.E., End of life care and reactions to death in African-American and white family caregivers of relatives with Alzheimer's disease (2001) Omega-Journal of Death and Dying, 43, pp. 349-361; Pittman, J., Bakas, T., Measurement and instrument design (2010) Journal of Wound, Ostomy, and Continence Nurses, 37, pp. 603-607; Prigerson, H.G., Bierhals, A.J., Kasl, S.V., Reynolds, C.F., Shear, K., Day, N., Jacobs, S., Traumatic grief as a risk factor for mental and physical morbidity (1997) American Journal of Psychiatry, 154, pp. 616-623; Prigerson, H.G., Horowitz, M.J., Jacobs, S.C., Parkes, C.M., Aslan, M., Goodkin, K., Maciejewski, P.K., Prolonged grief disorder: Psychometric validation of criteria proposed for DSM-V and ICD-11 (2009) Public Library of Science Medicine, 6, pp. e1000121; Ramirez, M., Teresi, J.A., Silver, S., Holmes, D., Gurland, B., Langtigua, R., Cognitive assessment among minority elderly: Possible test bias (2002) Multicultural measurement in older populations, pp. 97-128. , In:, In:, In:, In:, In: Skinner J. H., editorsTeresi J. A., editorsHolmes D., editorsStahl S. M., editorsStewart A. L., editors, New York, NY, Springer; Rando, T.A., A comprehensive analysis of anticipatory grief: Perspectives, processes, promises, and problems (1986) Loss and anticipatory grief, pp. 3-37. , In: Rando T. A., editors Lexington, MA, Lexington Books; Rosenblatt, P.C., Grief: What we have learned from cross-cultural studies (2007) Living with grief: Before and after the death, pp. 123-136. , In: Doka K. J., editors, Washington, DC, Hospice Foundation of America; Ross, A., Dagley, J.C., An assessment of anticipatory grief as experienced by family caregivers of individuals with dementia (2009) Alzheimer's Care Today, 10, pp. 8-21; Sahadevan, S., Rockwood, K., Morris, J.C., Global assessment measures in dementia (1999) Clinical diagnosis and management of Alzheimer's disease (, pp. 167-177. , In: Gauthier S., editors 2nd ed., London, UK, Martin Dunitz; Sandelowski, M., Sample size in qualitative research (1995) Research in Nursing and Health, 18, pp. 179-183; Sanders, S., Adams, K.B., Grief reactions and depression in caregivers of individuals with Alzheimer's Disease: Results from a pilot study in an urban setting (2005) Health and Social Work, 30, pp. 287-295; Sanders, S., Marwit, S.J., Meuser, T.M., Harrington, P., Caregiver grief in end-stage dementia: Using the Marwit and Meuser Caregiver Grief Inventory for assessment and intervention in social work practice (2007) Social Work Health Care, 46, pp. 47-65; Sanders, S., Ott, C.H., Kelber, S.T., Noonan, P., The experience of high levels of grief in caregivers of persons with Alzheimer's disease and related dementia (2008) Death Studies, 32, pp. 495-523; Schulz, R., Boerner, K., Shear, K., Zhang, S., Gitlin, L.N., Predictors of complicated grief in dementia caregivers: A prospective study of bereavement (2006) American Journal of Geriatric Psychiatry, 14, pp. 650-658; Tang, M., Stern, Y., Marder, K., Bell, K., Gurland, B., Lantigua, R., Mayeux, R., The APOE-j{cyrillic, ukrainian}4 allele and the risk of Alzheimer Disease among African Americans, Whites, and Hispanics (1998) Journal of the American Medical Association, 279, pp. 751-755; Taylor, R.J., Ellison, C.G., Chatters, L.M., Levin, J.S., Lincoln, K.D., Mental health services in faith communities: The role of clergy in black churches (2000) Social Work, 45, pp. 73-86; Tomarken, A., Holland, J., Schachter, S., Vanderwerker, L., Zuckerman, E., Nelson, C., Prigerson, H., Factors of complicated grief pre-death in caregivers of cancer patients (2008) Psycho-Oncology, 17, pp. 105-111; Welsh, K.A., Butters, N., Hughes, J.P., Mohs, R.C., Heyman, A., Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease (1992) Archives of Neurology, 49, pp. 448-452; (2011) CDR Overview & Abstracts, , http://alzheimer.wustl.edu/cdr/aboutcdr.htm, Washington University School of Medicine in St. Louis, Knight Alzheimers Disease Research Center. Retrieved from",Article,Scopus,2-s2.0-84897090102
"Edwards M., Johnson L., Mauer C., Barber R., Hall J., Obryant S.","Regional specific groundwater arsenic levels and neuropsychological functioning: A cross-sectional study",2014,"International Journal of Environmental Health Research","24","6",,"546","557",,1,10.1080/09603123.2014.883591,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84926116863&partnerID=40&md5=df8714f6ca41de969a0f24f839e88761","Department of Psychology, University of North TexasFort Worth, TX, United States; Department of Internal Medicine, University of North Texas Health Sciences CenterFort Worth, TX, United States; Department of Institute for Aging and Alzheimers Disease Research, University of North Texas Health Science CenterFort Worth, TX, United States; Department of Psychology, Texas Tech UniversityLubbock, TX, United States; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences CenterFort Worth, TX, United States; Department of Psychiatry, University of North Texas Health Sciences CenterFort Worth, TX, United States","Edwards, M., Department of Psychology, University of North TexasFort Worth, TX, United States; Johnson, L., Department of Internal Medicine, University of North Texas Health Sciences CenterFort Worth, TX, United States, Department of Institute for Aging and Alzheimers Disease Research, University of North Texas Health Science CenterFort Worth, TX, United States; Mauer, C., Department of Psychology, Texas Tech UniversityLubbock, TX, United States; Barber, R., Department of Pharmacology and Neuroscience, University of North Texas Health Sciences CenterFort Worth, TX, United States; Hall, J., Department of Psychiatry, University of North Texas Health Sciences CenterFort Worth, TX, United States; Obryant, S., Department of Internal Medicine, University of North Texas Health Sciences CenterFort Worth, TX, United States, Department of Institute for Aging and Alzheimers Disease Research, University of North Texas Health Science CenterFort Worth, TX, United States","Background: The purpose of the study was to examine the link between geographic information system (GIS)-estimated regional specific groundwater levels and neuropsychological functioning in a sample of individuals with and without cognitive impairment. Methods: This cross-sectional study design analyzed data from 1390 participants (733 Alzheimers disease, 127 Mild Cognitive Impairment, and 530 with normal cognition) enrolled in the Texas Alzheimers Research and Care Consortium. GISs analyses were used to estimate regional specific groundwater arsenic concentrations using the Environmental Systems Research Institute and arsenic concentrations from the Texas Water Development Board. Results: In the full cohort, regional specific arsenic concentrations were positively associated with language abilities (p = 0.008), but associated with poorer verbal memory, immediate (p = 0.008), and delayed (p < 0.001), as well as poorer visual memory, immediate (p = 0.02), and delayed (p < 0.001). The findings varied by diagnostic category with arsenic being related with cognition most prominently among mild cognitive impairment cases. Conclusions: Overall, estimated regional specific groundwater arsenic levels were negatively associated with neuropsychological performance. © 2014 © 2014 Taylor & Francis.","Alzheimer's disease; arsenic; Groundwater; Mild cognitive impairment; Neuropsychology","Andersen, O., Nielsen, J.B., Effects of simultaneous low level supplementation with inorganic and organic selenium on whole-body, blood and organ levels of toxic metals in mice (1994) Environ Health Perspect, 102, pp. 321-324; Avruskin, G.A., Jacquez, G.M., Meliker, J.R., Slotnick, M.J., Kaufmann, A.M., Nriagu, J.O., Visualization and exploratory analysis of epidemiologic data using a novel space time information system (2004) Int J Health Geogr, 3, p. 26; Babiker, I.S., Mohamed, M.A.A., Hiyama, T., Assessing groundwater quality using gis (2007) Water Resour Manage, 21, pp. 699-715; Baum, L., Chan, I.H.S., Cheung, S.K.K., Goggins, W.B., Mok, V., Lam, L., Leung, V., Woo, J., Serum zinc is decreased in alzheimer's disease and serum arsenic correlates positively with cognitive ability (2010) Biometals, 23, pp. 173-179; Biswas, S., Talukder, G., Sharma, A., Prevention of cytotoxic effects of arsenic by short-term dietary supplementation with selenium in mice in vivo (1999) Mutat Res, 441, pp. 155-160; Bolla-Wilson, K., Bleecker, M.L., Neuropsychological impairment following inorganic arsenic exposure (1987) J Occup Med, 29, pp. 500-503; Darvesh, A.S., Carroll, R.T., Bishayee, A., Geldenhuys, W.J., Van Der Schyf, C.J., Oxidative stress and alzheimer's disease: Dietary polyphenols as potential therapeutic agents (2010) Expert Rev Neurother, 10, pp. 729-745; Dewji, N.N., Do, C., Bayney, R.M., Transcriptional activation of alzheimer's β-amyloid precursor protein gene by stress (1995) Brain Res. Mol. Brain Res, 33, pp. 245-253; Dho, S., Camusso, W., Mucciarelli, M., Fusconi, A., Arsenate toxicity on the apices of pisum sativum l seedling roots: Effects on mitotic activity, chromatin integrity and microtubules (2010) Environ Exp Bot, 69, pp. 17-23; Engström, K.S., Vahter, M., Johansson, G., Lindh, C.H., Teichert, F., Singh, R., Kippler, M., Broberg, K., Chronic exposure to cadmium and arsenic strongly influences concentrations of 8-oxo-7,8-dihydro-2'-deoxyguanosine in urine (2010) Free Radic Biol Med, 48, pp. 1211-1217; Fatmi, Z., Azam, I., Ahmed, F., Kazi, A., Gill, A.B., Kadir, M.M., Ahmed, M., Janjua, N.Z., Health burden of skin lesions at low arsenic exposure through groundwater in pakistan. Is river the source? (2009) Environ Res, 109, pp. 575-581; Focazio, M., Welch, A.H., Watkins, S.A., Helsel, D.R., Horn, M.A., (2000) A Retrospective Analysis on the Occurrence of Arsenic in Ground-water Resources of the United States and Limitations in Drinking-water-supply Characterizations, , Water-Resources Investigations Report 99-4279. Washington (DC): U.S. Geological Survey; Folstein, M.F., Folstein, S.E., McHugh, P.R., Mini-mental state"": A practical method for grading the cognitive state of patients for the clinician (1975) J Psych Res, 12, pp. 189-198; Fry, R.C., Navasumrit, P., Valiathan, C., Svensson, J.P., Hogan, B.J., Luo, M., Bhattacharya, S., Nookabkaew, S., Activation of inflammation/nf-κb signaling in infants born to arsenic-exposed mothers (2007) PLoS Genet, 3, pp. 2180-2189; Fytianos, K., Christophoridis, C., Nitrate, arsenic and chloride pollution of drinking water in northern greece. Elaboration by applying gis (2004) Environ Monit Assess, 93, pp. 55-67; Garelick, H., Jones, H., Dybowska, A., Valsami-Jones, E., Arsenic pollution sources (2008) Rev Environ Contam Toxicol, 197, pp. 17-60; Gong, G., Hargrave, K.A., Hobson, V., Spallholz, J., Boylan, M., Lefforge, D., O'Bryant, S.E., Low-level groundwater arsenic exposure impacts cognition: A project frontier study (2011) J Environ Health, 74, pp. 16-22; Gong, G., O'Bryant, S.E., The arsenic exposure hypothesis for alzheimer disease (2010) Alzheimer Dis Assoc Disord, 24, pp. 311-316; Grandjean, P., Landrigan, P., Developmental neurotoxicity of industrial chemicals (2006) Lancet, 368, pp. 2167-2178; Hobson, V.L., Hall, J.R., Harvey, M., Cullum, C.M., Lacritz, L., Massman, P.J., Waring, S.C., O'Bryant, S.E., An examination of the boston naming test: Calculation of ""estimated"" 60-item score from 30- and 15-item scores in a cognitively impaired population (2011) Int J Geriatr Psychiatry, 26, pp. 351-355; Ivnik, R., Malec, J.F., Smith, G.E., Tangalos, E.G., Petersen, R.C., Kokmen, E., Kurkland, L.T., Mayo's older americans normative studies: Wais-r norms for age 56 to 97 (1992) The Clin Neuropsych, 6, pp. 1-30; Ivnik, R.J., Malec, J.F., Smith, G.E., Tangalos, E.G., Petersen, R.C., Neuropsychological tests' norms above age 55: Cowat, bnt, mae token, wrat-r reading, amnart, stroop, tmt, and jlo (1996) Clin Neuropsychol, 10, pp. 262-278; Kapaj, S., Peterson, H., Liber, K., Bhattacharya, P., Human health effects from chronic arsenic poisoning - A review (2006) J Environ Sci Health A Tox Hazard Subst Environ Eng, 41, pp. 2399-2428; Khan, N.I., Owens, G., Bruce, D., Naidu, R., Human arsenic exposure and risk assessment at the landscape level: A review (2009) Environ Geochem Health, 31, pp. 143-166; Lezak, M.D., Howieson, D.B., Loring, D.W., (2004) Neuropsychological Assessment, , 4th ed. Oxford: Oxford University Press; Liao, C., Shen, H.H., Chen, C.L., Li, H., Lin, T.L., Chen, S.C., Chen, C.J., Risk assessment of arsenic-induced internal cancer at long-term low dose exposure (2009) J. Hazard. Mater, 165, pp. 652-663; Luo, J.H., Qiu, Z.Q., Shu, W.Q., Zhang, Y.Y., Zhang, L., Chen, J.A., Effects of arsenic exposure from drinking water on spatial memory, ultra-structures and nmdar gene expression of hippocampus in rats (2009) Toxicol Lett, 184, pp. 121-125; Martinez-Finley, E.J., Ali, A.M.S., Allan, A.M., Learning deficits in c57bl/6j mice following perinatal arsenic exposure: Consequence of lower corticosterone receptor levels? (2009) Pharmacol Biochem Behav, 94, pp. 271-277; McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of alzheimer's disease: Report of the nincds-adrda work group under the auspices of department of health and human services task force on alzheimer's disease (1984) Neurology, 34, pp. 939-939; Meng, D., Wang, X., Chang, Q., Hitron, A., Zhang, Z., Xu, M., Chen, G., Shi, X., Arsenic promotes angiogenesis in vitro via a heme oxygenase-1-dependent mechanism (2010) Toxicol Appl Pharmacol, 244, pp. 291-299; Morris, J.C., The clinical dementia rating (cdr): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2412; (1999) Subcommittee on Arsenic in Drinking Water. Arsenic in Drinking Water, , National Research Council., Washington, DC: National Academies Press; (2001) Arsenic in Drinking Water: 2001 Update, , National Research Council., Washington, DC: The National Academies Press; Navas-Acien, A., Silbergeld, E.K., Pastor-Barriuso, R., Guallar, E., Arsenic exposure and prevalence of type 2 diabetes in us adults (2008) JAMA, 300, pp. 814-822; O'Bryant, S., Edwards, M., Menon, C.V., Gong, G., Barber, R., Long-term low-level arsenic exposure is associated with poorer neuropsychological functioning: A project frontier study (2011) Int J Environ Res Public Health, 8, pp. 861-874; O'Bryant, S.E., Hobson, V., Hall, J.R., Waring, S.C., Chan, W., Massman, P., Lacritz, L., Diaz-Arrastia, R., Brain-derived neurotrophic factor levels in alzheimer's disease (2009) J Alzheimer's Dis, 17, pp. 337-341; Petersen, R.C., (2003) Mild Cognitive Impairment: Aging to Alzheimer's Disease, , New York (NY): Oxford University Press; Rosado, J.L., Ronquillo, D., Kordas, K., Rojas, O., Alatorre, J., Lopez, P., Garcia-Vargas, G., Stoltzfus, R.J., Arsenic exposure and cognitive performance in mexican school children (2007) Environ Health Perspect, 115, pp. 1371-1375; Samadder, S.R., Subbarao, C., GIS approach of delineation and risk assessment of areas affected by arsenic pollution in drinking water (2007) J Environl Eng, 133, pp. 742-749; Strauss, E., Sherman, E.M.S., Spreen, O., (2006) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, , 3rd ed. Oxford: Oxford University Press; Su, C.C., Lin, Y.Y., Chang, T.K., Chiang, C.T., Chung, J.A., Hsu, Y.Y., Lian, I.B., Incidence of oral cancer in relation to nickel and arsenic concentrations in farm soils of patients' residential areas in taiwan (2010) BMC Public Health, 10, p. 67; Tan, Z.S., Seshadri, S., Beiser, A., Wilson, P.W.F., Kiel, D.P., Tocco, M., D'Agostino, R.B., Wolf, P.A., Plasma total cholesterol level as a risk factor for alzheimer disease (2003) Arch Intern Med, 163, pp. 1053-1057; (1997) WAIS-III - WMS-III Technical Manual, , The Psychological Corporation., San Antonio (TX): The Psychological Corporation; Thies, W., Bleiler, L., 2013 alzheimer's disease facts and figures alzheimer's association (2013) Alzheimers Dement, 9, pp. 208-245; Tsai, S.Y., Chou, H.Y., The, H.W., Chen, C.M., Chen, C.J., The effects of chronic arsenic exposure from drinking water on the neurobehavioral development in adolescence (2003) NeuroToxicology, 24, pp. 747-753; Usali, N., Ismail, M.H., Use of remote sensing and gis in monitoring water quality (2010) J Sustainable Dev, 3, pp. 228-238; Vahidnia, A., Van Der Straaten, R.J.H.M., Romijn, F., Van Pelt, J., Van Der Voet, G.B., De Wolff, F.A., Arsenic metabolites affect expression of the neurofilament and tau genes: An in vitro study into the mechanism of arsenic neurotoxicity (2007) Toxicology in Vitro, 21, pp. 1104-1112; Vega, L., Styblo, M., Patterson, R., Cullen, W., Wang, C., Germolec, D., Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes (2001) Toxicol Appl Pharmacol, 172, pp. 225-232; Wang, Y., Li, S., Piao, F., Hong, Y., Liu, P., Zhao, Y., Arsenic down-regulates the expression of camk4, an important gene related to cerebellar ltd in mice (2009) Neurotoxicol Teratol, 31, pp. 318-322; Waring, S., O'Bryant, S.E., Reisch, J.S., Diaz-Arrastia, R., Knebl, J., Doody, R., The texas alzheimer's research consortium longitudinal research cohort: Study design and baseline characteristics (2008) Texas Public Health J, 60, pp. 9-13. , for the Texas Alzheimer's Research Consortium; Wasserman, G.A., Liu, X., Parvez, F., Ahsan, H., Factor-Litvak, P., Van Geen, A., Slavkovich, V., Hussain, I., Water arsenic exposure and children's intellectual function in araihazar, bangladesh (2004) Environ Health Perspects, 112, pp. 1329-1333; Wasserman, G.A., Liu, X., Parvez, F., Ahsan, H., Factor-Litvak, P., Kline, J., Van Geen, A., Levy, D., Water arsenic exposure and intellectual function in 6-yearold children in araihazar (2007) Bangladesh Environ Health Perspect, 115, pp. 285-289; Wechsler, D., (1997) Wechsler Memory Scale Third Edition Manual, , San Antonio (TX): The Psychological Corporation; Wright, R.O., Amarasiriwardena, C., Woolf, A.D., Jim, R., Bellinger, D.C., Neuropsychological correlates of hair arsenic, manganese, and cadmium levels in school-age children residing near a hazardous waste site (2006) NeuroToxicology, 27, pp. 210-216; Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., Leirer, V.O., Development and validation of a geriatric depression screening scale: A preliminary report (1983) J Psych Res, 17, pp. 37-49; Yin, X., Wright, J., Wall, T., Grammas, P., Brain endothelial cells synthesize neurotoxic thrombin in alzheimer's disease (2010) Am J Pathol, 176, pp. 1600-1606",Article,Scopus,2-s2.0-84926116863
"Klekociuk S.Z., Summers M.J.","Exploring the validity of mild cognitive impairment (MCI) subtypes: Multiple-domain amnestic MCI is the only identifiable subtype at longitudinal follow-up",2014,"Journal of Clinical and Experimental Neuropsychology","36","3",,"290","301",,,10.1080/13803395.2014.890699,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84899412386&partnerID=40&md5=49355bc4b2473c25a69cd767e0207e16","School of Psychology, University of Tasmania, Locked Bag 1342, Launceston, TAS 7250, Australia; Wicking Dementia Research and Education Centre, School of Medicine, University of Tasmania, Hobart, TAS, Australia","Klekociuk, S.Z., School of Psychology, University of Tasmania, Locked Bag 1342, Launceston, TAS 7250, Australia; Summers, M.J., School of Psychology, University of Tasmania, Locked Bag 1342, Launceston, TAS 7250, Australia, Wicking Dementia Research and Education Centre, School of Medicine, University of Tasmania, Hobart, TAS, Australia","Background: Epidemiological research exploring risk factors for Alzheimers dementia resulted in the identification of the mild cognitive impairment (MCI) profile. Subsequently, distinct subtypes of MCI have been proposed; however, the validity of these as diagnostic entities remains uncertain. Design and participants: The aim of the present study was to examine the longitudinal neuropsychological profiles of MCI subtypes. A total of 118 adults aged 60-90 years were classified at screening as amnestic (a-MCI), nonamnestic (na-MCI), and multiple-domain amnestic (a-MCI+) and were assessed at two time points across 20 months on a comprehensive neuropsychological assessment battery. Results: The a-MCI+ group displayed the poorest performance of all groups in terms of episodic memory, working memory, attention, and executive functioning. Conclusions: These findings suggest that the a-MCI+ subtype is the only variant that is recognizable via neuropsychological testing. In contrast, the differentiation between single-domain subtypes and healthy controls is difficult and may not be achievable through current neuropsychological assessment practices. © 2014 Taylor and Francis.","Amnesti; Longitudinal; Mild cognitive impairment; Multiple-domain; Neuropsychological","Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Phelps, C.H., The diagnosis of mild cognitive impairment due toAlzheimer's disease: Recommendations from theNational Institute on Aging-Alzheimer'sAssociation workgroups on diagnostic guidelines forAlzheimer's disease (2011) Alzheimer's & Dementia, 7 (3), pp. 270-279. , doi:10.1016/j.jalz.2011.03.008; Alladi, S., Arnold, R., Mitchell, J., Nestor, P.J., Hodges, J.R., Mild cognitive impairment:Applicability of research criteria in a memory clinicand characterisation of cognitive profile (2006) Psychological Medicine, 36, pp. 507-515; Artero, S., Petersen, R., Touchon, J., Ritchie, K., Revised criteria for mild cognitive impairment:Validation within a longitudinal populationstudy (2006) Dementia and Geriatric Cognitive Disorders, 22 (5-6), pp. 465-470. , doi:10.1159/000096287; Baddeley, A., Logie, R., Bressi, S., Dellasala, S., Spinnler, H., Dementia and working memory (1986) Quarterly Journal of Experimental PsychologySection A: Human Experimental Psychology, 38 (4), pp. 603-618; Belleville, S., Chertkow, H., Gauthier, S., Working memory and control of attention in personswith Alzheimer's disease and mild cognitive impairment (2007) Neuropsychology, 21 (4), pp. 458-469; Brainerd, C.J., Reyna, V.F., Petersen, R.C., Smith, G.E., Kenney, A.E., Gross, C.J., Fisher, G.G., The apolipoprotein e genotype predicts longitudinaltransitions to mild cognitive impairment butnot to Alzheimer's dementia: Findings from a nationallyrepresentative study (2013) Neuropsychology, 27 (1), pp. 86-94. , doi:10.1037/a0030855; Brodaty, H., Heffernan, M., Kochan, N.A., Draper, B., Trollor, J.N., Reppermund, S., Sachdev, P.S., Mild cognitive impairment in a communitysample: The Sydney Memory and Ageing Study (2013) Alzheimer's & Dementia, 9 (3), pp. 310-317; Brooks, B.L., Iverson, G.L., Holdnack, J.A., Feldman, H.H., Potential for misclassificationof mild cognitive impairment: A study of memoryscores on the Wechsler Memory Scale-III in healthyolder adults (2008) Journal of the InternationalNeuropsychological Society, 14 (3), pp. 463-478; Brooks, B.L., Iverson, G.L., White, T., Substantial risk of ""accidental MCI"" in healthyolder adults: Base rates of low memory scores inneuropsychological assessment (2007) Journal of TheInternational Neuropsychological Society, 13 (3), pp. 490-500; Busse, A., Hensel, A., Guhne, U., Angermeyer, M.C., Riedel-Heller, S.G., Mild cognitive impairment:Long-term course of four clinical subtypes (2006) Neurology, 67 (12), pp. 2176-2185; Clark, L.R., Delano-Wood, L., Libon, D.J., McDonald, C.R., Nation, D.A., Bangen, K.J., Bondi, M.W., Are empirically-derived subtypesof mild cognitive impairment consistent withconventional subtypes? (2013) Journal of the InternationalNeuropsychological Society, 19 (6), pp. 635-645. , doi:10.1017/S1355617713000313; Delano-Wood, L., Bondi, M.W., Sacco, J., Abeles, N., Jak, A.J., Libon, D.J., Bozoki, A., Heterogeneity in mild cognitive impairment:Differences in neuropsychological profile and associatedwhite matter lesion pathology (2009) Journal of TheInternational Neuropsychological Society, 15 (6), pp. 906-914; Duff, K., Evidence-based indicators of neuropsychologicalchange in the individual patient: Relevantconcepts and methods (2012) Archives of ClinicalNeuropsychology, 27 (3), pp. 248-261. , doi:10.1093/arclin/acr120; Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Tragl, K.H., Conversion from subtypes of mild cognitiveimpairment to Alzheimer dementia [Article] (2007) Neurology, 68 (4), pp. 288-291; Forlenza, O.V., Diagnostic transitions in mild cognitive impairmentsubtypes (2009) International Psychogeriatrics, 21 (6), pp. 1088-1095. , doi:10.1017/S1041610209990792; Han, J.W., Kim, T.H., Lee, S.B., Park, J.H., Lee, J.J., Huh, Y., Kim, K.W., Predictive validityand diagnostic stability of mild cognitive impairmentsubtypes (2012) Alzheimer's & Dementia, 8 (6), pp. 553-559; Howell, D.C., (2002) Statistical Methods for Psychology, , (5th ed.). Pacific Grove, CA: Thomson Learning; Hughes, T.F., Snitz, B.E., Ganguli, M., Should mild cognitive impairment be subtyped? (2011) Current Opinion in Psychiatry, 24 (3), pp. 237-242. , doi:10.197/YCO.1090b1013e328344696b; Jurica, P.J., Leitten, C.L., Mattis, S., (2001) Dementia Rating Scale-2 (DRS-2): Professionalmanual, , Odessa, FL: Psychological AssessmentResources; Kendell, R., Jablensky, A., Distinguishingbetween the validity and utility of psychiatric diagnoses (2003) American Journal of Psychiatry, 160 (1), pp. 4-12; Klekociuk, S.Z., Summers, M.J., The self-fulfillingprophecy of episodicmemory impairment in mildcognitive impairment: Do episodic memory deficitsidentified at classification remain evident when laterexamined with different memory tests? (2013) NeurologyResearch International, p. 6. , http://www.hindawi.com/journals/nri/2013/437013, Advance online publication. Retrieved from doi:10.1155/2013/437013; Kramer, J.H., Nelson, A., Johnson, J.K., Yaffe, K., Glenn, S., Rosen, H.J., Miller, B.L., Multiple cognitive deficits in amnestic mild cognitiveimpairment (2006) Dementia and Geriatric CognitiveDisorders, 22 (4), pp. 306-311. , doi:10.1159/000095303; Lenehan, M.E., Klekociuk, S.Z., Summers, M.J., Absence of a relationship between subjectivememory complaint and objective memory impairmentin mild cognitive impairment (MCI): Is it time to abandonsubjective memory complaint as an MCI diagnosticcriterion? (2012) International Psychogeriatrics, 24 (9), pp. 1505-1514. , doi:10.1017/S1041610212000695; Libon, D.J., Xie, S.X., Eppig, J., Wicas, G., Lamar, M., Lippa, C., Wambach, D.M., Theheterogeneity of mild cognitive impairment: A neuropsychologicalanalysis (2010) Journal of the InternationalNeuropsychological Society, 16 (1), pp. 84-93. , doi:10.1017/S1355617709990993; Lopez, O.L., Becker, J.T., Jagust, W.J., Fitzpatrick, A., Carlson, M.C., Dekosky, S.T., Kuller, L.H., Neuropsychological characteristics of mildcognitive impairment subgroups (2006) Journal OfNeurology, Neurosurgery & Psychiatry, 77 (2), pp. 159-165. , doi:10.1136/jnnp.2004.045567; Mitchell, A.J., Shiri-Feshki, M., Rate of progressionof mild cognitive impairment to dementia-Meta-analysis of 41 robust inception cohortstudies (2009) Acta Psychiatrica Scandinavica, 119 (4), pp. 252-265; Palmer, K., Mild cognitive impairment in the generalpopulation: Occurrence and progression toAlzheimer disease (2008) American Journal of GeriatricPsychiatry, 16 (7), pp. 603-611; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Kokmen, E., Tangelos, E.G., Aging, memory,and mild cognitive impairment (1997) InternationalPsychogeriatrics, 9 (SUPPL. 1), pp. 65-69; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitiveimpairment: Clinical characterization and outcome (1999) Archives of Neurology, 56 (3), pp. 303-308; Price, S.E., Kinsella, G.J., Ong, B., Mullaly, E., Phillips, M., Pangnadasa-Fox, L., Storey, E., Learning and memory in amnestic mild cognitiveimpairment: Contribution of working memory (2010) Journal of the International NeuropsychologicalSociety, 16 (2), pp. 342-351. , doi:10.1017/S1355617709991391; Ritchie, K., Touchon, J., Mild cognitiveimpairment: Conceptual basis and current nosologicalstatus (2000) The Lancet, 355, pp. 225-228; Ritchie, L.J., Tuokko, H., Patterns of cognitivedecline, conversion rates, and predictive validityfor 3 models of MCI (2010) American Journal OfAlzheimer's Disease and Other Dementias, 25 (7), pp. 592-603. , doi:10.1177/1533317510382286; Saunders, N.L.J., Summers, M.J., Attentionand working memory deficits in mild cognitiveimpairment (2010) Journal of Clinical and ExperimentalNeuropsychology, 32 (4), pp. 350-357; Saunders, N.L.J., Summers, M.J., Longitudinal deficits to attention, executive, andworking memory in subtypes of mild cognitiveimpairment (2011) Neuropsychology, 25 (2), pp. 237-248. , doi:10.1037/a0021134; Snaith, R.P., Zigmond, A.S., (1994) The HospitalAnxiety and Depression Scale (HADS): Manual, , London: GL Assessment; Summers, M.J., Saunders, N.L., Neuropsychological measures predict decline toAlzheimer's dementia from mild cognitive impairment (2012) Neuropsychology, 26 (4), pp. 498-508. , doi:10.1037/a0028576; (2001) Wechsler Test OfAdult Reading, , The Psychological Corporation San Antonio, TX: HarcourtAssessment; Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., Petersen, R.C., Mild cognitive impairment-Beyond controversies,towards a consensus: Report of theInternational Working Group on Mild CognitiveImpairment (2004) Journal of Internal Medicine, 256 (3), pp. 240-246. , doi:10.1111/j.1365-2796.2004.01380.x",Article,Scopus,2-s2.0-84899412386
"Suarez V.M., Fernandez Y., Lopez E.D.C.R., Clarke D.H., Bobes M.A., Riveron A.M., Lopez-Canovas L.","Apolipoprotein e alleles in cuban patients with mild cognitive impairment",2014,"American Journal of Alzheimer's Disease and other Dementias","29","3",,"236","241",,,10.1177/1533317513517037,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84900430871&partnerID=40&md5=4eb314cbb23e1aae7a8003b2d98974ae","Molecular Biology Department, Cuban Neurosciences Center, La Habana, Cuba; Cognitive Neurosciences Department, Cuban Neurosciences Center, La Habana, Cuba","Suárez, V.M., Molecular Biology Department, Cuban Neurosciences Center, La Habana, Cuba; Fernández, Y., Cognitive Neurosciences Department, Cuban Neurosciences Center, La Habana, Cuba; López, E.D.C.R., Cognitive Neurosciences Department, Cuban Neurosciences Center, La Habana, Cuba; Clarke, D.H., Molecular Biology Department, Cuban Neurosciences Center, La Habana, Cuba; Bobes, M.A., Cognitive Neurosciences Department, Cuban Neurosciences Center, La Habana, Cuba; Riverón, A.M., Molecular Biology Department, Cuban Neurosciences Center, La Habana, Cuba; López-Cánovas, L., Molecular Biology Department, Cuban Neurosciences Center, La Habana, Cuba","Background: Apolipoprotein E (ApoE) ε4 genotype is the most clearly documented risk factor for Alzheimers disease (AD). Epidemiological studies demonstrate an accelerated rate of progression to dementia and AD in patients with mild cognitive impairment (MCI). We assessed the ApoE allele and genotypes frequencies in Cuban patients with MCI. Methods: We performed ApoE genotyping of 74 Cuban patients more than 65 years old. Cognitive assessments included the Mini-Mental State Examination (MMSE) and a cognitive battery for evaluating memory, attention, perception, and executive function. Results: Cognitive impairments were characterized by amnesia and executive deficits in patients with MCI. The Apo ε4 allele frequency was 0.196 in patients with MCI, 10-fold higher than that in the controls. Patients carrying the ε4 allele exhibited poorer performance in MMSE and tests assessing executive function and short-term memory than noncarriers. Conclusions: The patients exhibited amnestic MCI multiple domains. Cognitive performance was worse in patients who carried the ApoE e4 allele. © The Author(s) 2013.","Alzheimer's disease; apolipoprotein E; cognitive domain; cognitive impairment; gen polymorphism","Petersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) J Intern Med, 256 (3), pp. 183-194; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: Clinical characterization and outcome (1999) Arch Neurol, 56 (3), pp. 303-308; Winblad, B., Palmer, K., Kivipelto, M., Mild cognitive impairment - Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment (2004) J Intern Med, 256 (3), pp. 240-246; Albert, M.S., Dekosky, S.T., Dickson, D., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7 (3), pp. 270-279; Morris, J.C., Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia (2012) Arch Neurol, 69 (6), pp. 700-708; Portet, F., Ousset, P.J., Visser, P.J., Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease (2006) J Neurol Neurosurg Psychiatry, 77 (6), pp. 714-718; Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Kokmen, E., Tangelos, E.G., Aging, memory, and mild cognitive impairment (1997) Int Psychogeriatr, 9 (SUPPL. 1), pp. 65-69; Bartres-Faz, D., Junque, C., Lopez-Alomar, A., Neuropsychological and genetic differences between age-associated memory impairment and mild cognitive impairment entities (2001) J Am Geriatr Soc, 49 (7), pp. 985-990; Grundman, M., Petersen, R.C., Ferris, S.H., Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials (2004) Arch Neurol, 61 (1), pp. 59-66; Corder, E.H., Saunders, A.M., Strittmatter, W.J., Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families (1993) Science, 261 (5123), pp. 921-923; Small, B.J., Rosnick, C.B., Fratiglioni, L., Backman, L., Apolipoprotein e and cognitive performance: A meta-analysis (2004) Psychol Aging, 19 (4), pp. 592-600; Greenwood, P.M., Lambert, C., Sunderland, T., Parasuraman, R., Effects of apolipoprotein e genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: Results from the National Institute of Mental Health's BIOCARD study (2005) Neuropsychology, 19 (2), pp. 199-211; Farlow, M.R., He, Y., Tekin, S., Xu, J., Lane, R., Charles, H.C., Impact of APOE in mild cognitive impairment (2004) Neurology, 63 (10), pp. 1898-1901; Negash, S., Petersen, L.E., Geda, Y.E., Effects of ApoE genotype and mild cognitive impairment on implicit learning (2007) Neurobiol Aging, 28 (6), pp. 885-893; Parasuraman, R., Greenwood, P.M., Sunderland, T., The apolipoprotein e gene, attention, and brain function (2002) Neuropsychology, 16 (2), pp. 254-274; Marcheco, B., Llibre, J., McKeigue, P., Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; A crosssectional population survey and nested case-control study (2013) BMC Med Genet, 12, p. 43; Sevush, S., Peruyera, G., Crawford, F., Mullan, M., Apolipoprotein-E epsilon 4 allele frequency and conferred risk for Cuban Americans with Alzheimer's disease (2000) Am J Geriatr Psychiatry, 8 (3), pp. 254-256; Llibre, J., Fernández, Y., Marcheco, B., Prevalence of dementia and Alzheimer's disease in a Havana municipality: A community-based study among elderly residents (2009) MEDICC Rev, 11 (2), pp. 29-35; Gonzalez, H.M., Mungas, D., Reed, B.R., Marshall, S., Haan, M.N., A new verbal learning and memory test for English- and Spanish-speaking older people (2001) J Int Neuropsychol Soc, 7 (5), pp. 544-555; Osterrieth, P.A., Le test de copie d'une figure complex: Contribution a l'etude de la perception et de la memoire [The test of copying a complex figure: A contribution to the study of perception and memory] (1944) Arch Psychol, 30, pp. 286-356; Wechsler, D., (1981) Weschler Adult Intelligence Scale-Revised, , San Antonio, TX: Psychological Corporation;; Milner, B., Interhemispheric differences in the localization of psychological processes in man (1971) Br Med Bull, 27 (3), pp. 272-277; De Re, Faglioni, P., Normative data and screening power of a shortened version of the Token Test (1978) Cortex, 14 (1), pp. 41-49; De Re, Scotti, G., Spinnlier, H., Perceptual and associative disorders of visual recognition. Relationship to the side of the cerebral lesion (1969) Neurology, 19 (7), pp. 634-642; Carlesimo, G.A., Caltagirone, C., Gainotti, G., The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery (1996) Eur Neurol, 36 (6), pp. 378-384; Giovagnoli, A.R., Del, P.M., Mascheroni, S., Simoncelli, M., Laiacona, M., Capitani, E., Trail making test: Normative values from 287 normal adult controls (1996) Ital J Neurol Sci, 17 (4), pp. 305-309; Spinnler, H., Tognoni, G., Standardizzazione e taratura italiana di test neuropsicologici (1987) Ital J Neurol Sci, 6 (SUPPL. 8), pp. 1-120; Arrigoni, C., De, R.E., Constructional apraxia and hemispheric locus of lesion (1964) Cortex, 1 (2), pp. 170-197; Suárez, V.M., Clarke, D.H., López-Canovas, L., Riverón, A.M., PCR of immobilized DNA molecules isolated from human blood cells by a non-enzymatic method (2008) Prep Biochem Biotechnol, 38 (1), pp. 40-50; Wenham, P.R., Price, W.H., Blandell, G., Apolipoprotein e genotyping by one-stage PCR (1991) Lancet, 337 (8750), pp. 1158-1159; Stern, C., The Hardy-Weinberg law (1943) Science, 97 (2510), pp. 137-138; Cohen, J., (1988) Statistical Power Analysis for the Behavioral Sciences, , 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. Hillsdale, NJ: Lawrence Erlbaum Associates;; Farrer, L.A., Cupples, L.A., Haines, J.L., Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium (1997) JAMA, 278 (16), pp. 1349-1356; Lewis, C.M., Knight, J., Introduction to genetic association studies (2012) Cold Spring Harb Protoc, 2012 (3), pp. 297-306; Schwartz, S., Susser, E., The use of well controls: An unhealthy practice in psychiatric research (2011) Psychol Med, 41 (6), pp. 1127-1131; Cedazo-Minguez, A., Cowburn, R.F., Apolipoprotein E: A major piece in the Alzheimer's disease puzzle (2001) J Cell Mol Med, 5 (3), pp. 254-266; Petersen, R.C., Mild cognitive impairment: Current research and clinical implications (2007) Semin Neurol, 27 (1), pp. 22-31; Jorm, A.F., Mather, K.A., Butterworth, P., Anstey, K.J., Christensen, H., Easteal, S., APOE genotype and cognitive functioning in a large age-stratified population sample (2007) Neuropsychology, 21 (1), pp. 1-8; Small, B.J., Graves, A.B., McEvoy, C.L., Crawford, F.C., Mullan, M., Mortimer, J.A., Is APOE - Epsilon4 a risk factor for cognitive impairment in normal aging? (2000) Neurology, 54 (11), pp. 2082-2088; Sun, X., Nicholas, J., Walker, A., Wagner, M.T., Bachman, D., APOE genotype in the diagnosis of Alzheimer's disease in patients with cognitive impairment (2012) Am J Alzheimers Dis Other Demen, 27 (5), pp. 315-320",Article,Scopus,2-s2.0-84900430871
"Nguyen V.Q., Gillen D.L., Dick M.B.","Memory for unfamiliar faces differentiates mild cognitive impairment from normal aging",2014,"Journal of Clinical and Experimental Neuropsychology","36","6",,"607","620",,,10.1080/13803395.2014.919992,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84903784956&partnerID=40&md5=7df70923cef193e5580af9d5553a53d9","Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Gottschalk Medical Plaza, Irvine, CA 92697-4585, United States","Nguyen, V.Q., Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Gottschalk Medical Plaza, Irvine, CA 92697-4585, United States; Gillen, D.L., Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Gottschalk Medical Plaza, Irvine, CA 92697-4585, United States; Dick, M.B., Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Gottschalk Medical Plaza, Irvine, CA 92697-4585, United States","Memory for unfamiliar faces has received little attention in the effort to identify neuropsychological measures that could differentiate mild cognitive impairment (MCI) from normal aging and/or predict conversion from MCI to dementia. We used the Wechsler Memory Scale-III Faces test to investigate facial memory in normal aging (n = 58), MCI (n = 74), and mild Alzheimers disease (n = 22). After adjustment for age, gender, and years of education, MCI patients demonstrated significantly poorer memory for unfamiliar faces than their healthy peers. Lower scores were also associated with worsening cognition and functional abilities but not an increased risk of dementia. © 2014 Taylor & Francis.","Alzheimer's disease; Conversion; Facial memory; Mild cognitive impairment","Ahmed, S., Arnold, R., Thompson, S.A., Graham, K.S., Hodges, J.R., Naming of objects, faces, and buildings in mild cognitive impairment (2008) Cortex, 44 (6), pp. 746-752. , doi: 10.1016/j.cortex.2007.02.002; Albert, M.S., Blacker, D., Moss, M.B., Tanzi, R., McArdle, J.J., Longitudinal change in cognitive performance among individuals with mild cognitive impairment (2007) Neuropsychology, 21, pp. 158-169. , doi: 10.1037/0894-4105.21.2.158; Barense, M.D., Groen, I.I.A., Lee, A.C.H., Yeung, L.-K., Brady, S.M., Gregori, M., Henson, R.N.A., Intact memory for irrelevant information impairs perception in amnesia (2012) Neuron, 75, pp. 157-167. , doi: 10.1016/j.neuron.2012.05.014; Benton, A.L., Hamsher, K.D.S., (1989) Multilingual Aphasia Examination: Manual, , Iowa City, IA: AJA Associates; Brooks, B.L., Weaver, L.E., Scialfa, C.T., Does impaired executive functioning differentially impact verbal memory measures in older adults with suspected dementia? (2006) The Clinical Neuropsychologist, 20, pp. 230-242. , doi: 10.1080/13854040590947461; Bucks, R.S., Ashworth, D.L., Wilcock, G.K., Siegfried, K., Assessment of activities of daily living in dementia: Development of the Bristol Activities of Daily Living Scale (1996) Age and Ageing, 25, pp. 113-120; Chapman, R.M., Mapstone, M., McCrary, J.W., Gardner, M.N., Porsteinsson, A., Sandoval, T.C., Reilly, L.A., Predicting conversion from mild cognitive impairment to Alzheimers disease using neuropsychological tests and multivariate methods (2011) Journal of Clinical and Experimental Neuropsychology, 33 (2), pp. 187-199. , doi: 10.1080/13803395.2010.499356; Dade, L.A., Jones-Gotman, M., Face learning and memory: The Twins test (2001) Neuropsychology, 15 (4), pp. 525-534. , doi: 10.1037//0894-4105.15.4.525; Doss, R.C., Chelune, G.J., Naugle, R.I., WMS-III performance in epilepsy patients following temporal lobectomy (2004) Journal of the International Neuropsychological Society, 10, pp. 173-179. , doi: 10.1017/S1355617704102026; Estévez-González, A., Garcia-Sánchez, C., Boles, A., Otermin, P., Pascual-Sedano, B., Gironell, A., Kulisevsky, J., Semantic knowledge of famous people in mild cognitive impairment and progression to Alzheimers disease (2004) Dementia and Geriatric Cognitive Disorders, 17 (3), pp. 188-195. , doi: 10.1159/000076355; Farah, M.J., Wilson, K.D., Drain, M., Tanaka, J.N., What is ""special"" about face perception? (1998) Psychological Review, 105, pp. 482-498; Folstein, M.F., Folstein, S.E., McHugh, P.R., ""mini-mental state."" A practical method for grading the cognitive state of patients for the clinician (1975) Journal of Psychiatric Research, 12, pp. 189-198; Gibson, A.J., Kendrick, D.C., (1979) The Kendrick Battery for the Detection of Dementia in the Elderly, , Windsor: NFER Publishing; Goren, C.C., Sarty, M., Wu, R.W.K., Visual following and pattern discrimination of face-like stimuli by newborn infants (1975) Pediatrics, 65, pp. 544-549; Gorno-Tempini, M.L., Price, C.J., Identification of famous faces and buildings: A functional neuroimaging study of semantically unique items (2001) Brain, 124 (10), pp. 2087-2097. , doi: 10.1093/brain/124.10.2087; Grabowski, T.J., Damasio, H., Tranel, D., Ponto, L.L., Hichwa, R.D., Damasio, A.R., (2001) Human Brain Mapping, 13 (4), pp. 199-212. , doi: 10.1002/hbm.1033; Hildebrandt, A., Wilhelm, O., Schmiedek, F., Herzmann, G., Sommer, W., On the specificity of face cognition compared with general cognitive functioning across adult age (2011) Psychology and Aging, 26, pp. 701-715. , doi: 10.1037/a0023056; Holdnack, J.A., Delis, D.C., Parsing the recognition memory components of the WMS-III face memory subtest: Normative data and clinical findings in dementia groups (2004) Journal of Clinical and Experimental Neuropsychology, 26, pp. 459-483. , doi: 10.1080/13803390490496687; Holm, S., A simple sequentially rejective multiple test procedure (1979) Scandinavian Journal of Statistics, 6, pp. 65-70; Kaplan, E., Goodglass, H., Weintraub, S., (1983) The Boston Naming Test, , Philadelphia, PA: Lea and Febiger; Levy, B., About the power for detecting severe impairment in older adults with the Faces test from Wechsler Memory Scale-III: Simply guess and save face (2003) Journal of Clinical and Experimental Neuropsychology, 25 (3), pp. 376-381. , doi: 10.1076/jcen.25.3.376.13804; Liang, K.-Y., Zeger, S.L., Longitudinal data analysis using generalized linear models (1986) Biometrika, 73 (1), pp. 13-22. , doi: 10.1093/biomet/73.1.13; Lin, D.Y., Wei, L.J., The robust inference for the Cox proportional hazards model (1989) Journal of the American Statistical Association, 84 (408), pp. 1074-1078; McCarthy, R.A., Warrington, E.K., (1990) Cognitive Neuropsychology, , San Diego, CA: Academic Press; McKhann, G., Drachmann, D., Folstein, M., Katzman, R., Price, D., Stadian, E.M., Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Service Task Force on Alzheimers disease (1984) Neurology, 34, pp. 939-944; Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules (1993) Neurology, 43, pp. 2412-2414; Morris, J.C., Heyman, A., Mohs, R.C., The Consortium to Establish a Registry for Alzheimers Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheimers disease (1989) Neurology, 39, pp. 1159-1165; Newsome, R.N., Duarte, A., Barense, M.D., Reducing perceptual interference improves visual discrimination in mild cognitive impairment: Implications for a model of perirhinal cortex function (2012) Hippocampus, 22, pp. 1990-1999. , doi: 10.1002/hipo.22071; Osterrieth, P.A., The test for copying a complex figure (1944) Archives de Psychologie, 30, pp. 206-356; Petersen, R.C., Mild cognitive impairment as a diagnostic entity (2004) Journal of Internal Medicine, 256, pp. 183-194. , doi: 10.1111/j.1365-2796.2004.01388.x; Petersen, R.C., Smith, G.E., Warings, S.C., Ivink, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: Clinical characterization and outcome (1999) Archives of Neurology, 56, pp. 303-308; Pfeffer, R.I., Kurosaki, T.T., Harrah Jr., C.H., Chance, J.M., Filos, S., Measurement of functional activities in older adults in the community (1982) Journals of Gerontology, 37, pp. 323-329; Rabin, I.A., Pare, N., Saykin, A.J., Brown, M.J., Wishart, H.A., Flashman, L.A., Santulli, R.B., Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimers disease (2009) Aging, Neuropsychology, and Cognition, 16, pp. 357-376. , doi: 10.1080/13825580902825220; Reitan, R.M., Validity of the trail making test as an indicator of organic brain damage (1958) Perceptual and Motor Skills, 8, pp. 271-276; Rey, A., Psychological testing in the case of traumatic encephalopathy (1941) Archives de Psychologie, 28, pp. 286-340; Schiltz, C., Dricot, L., Goebel, R., Rossion, B., Holistic perception of individual faces in the right middle fusiform gyrus as evidenced by the composite face illusion (2010) Journal of Vision, 10 (2), pp. 1-16. , doi: 10.1167/10.2.25; Schmitter-Edgecombe, M., Woo, E., Greeley, D.R., Characterizing multiple memory deficits and their relation to everyday functioning in individuals with mild cognitive impairment (2009) Neuropsychology, 23 (2), pp. 168-177. , doi: 10.1037/a0014186oi; Seelye, A.M., Howieson, D.B., Wild, K.V., Moore, M.M., Kaye, J.A., Wechsler Memory Scale-III Faces test performance in patients with mild cognitive impairment and mild Alzheimers disease (2009) Journal of Clinical and Experimental Neuropsychology, 31 (6), pp. 682-688. , doi: 10.1080/13803390802484763; Sergent, J., An investigation into component and configural processes underlying face perception (1984) British Journal of Psychology, 75, pp. 221-242; Smith, A., (1982) Symbol Digits Modality Test: Manual, , Los Angeles, CA: Western Psychological Services; Tabert, M.H., Albert, S.M., Borukhova-Milov, L., Camacho, Y., Pelton, G., Liu, X., Devanand, D.P., (2002) Neurology, 58, pp. 758-764; Tremont, G., Miele, A., Smith, M.M., Westervelt, H.J., Comparison of verbal memory impairment rates in mild cognitive impairment (2010) Journal of Clinical and Experimental Neuropsychology, 32 (6), pp. 630-636. , doi: 10.1080/13803390903401328; Tulsky, D.S., Chiaravalloti, N.D., Palmer, B.W., Chelune, G.J., The Wechsler Memory Scale-Third Edition: A new perspective (2003) Clinical Interpretation of the WAIS-III and WMS-III, pp. 93-139. , D. S. Tulsky, D. H. Saklofske, G. J. Chelune, R. K. Heaton, R. J. Ivnik, R. Bornstein, A. Prifitera, & M. Ledbetter (Eds.), San Diego, CA: Academic Press; Warrington, E.K., (1984) Recognition Memory Test: Manual, , Windsor: NFER-Nelson Publishing Company; Wechsler, D., (1981) Manual for the Wechsler Adult Intelligence Scale-Revised, , New York, NY: Psychological Corporation; Wechsler, D., (1987) Wechsler, , Memory Scale-Revised Edition: Administration and scoring manual. San Antonio, TX: The Psychological Corporation; Wechsler, D., (1997) The Wechsler Adult Intelligence Scale-III Manual, , San Antonio, TX: The Psychological Corporation; Wechsler, D., (1997) Wechsler, , Memory Scale-Third Edition: Administration and scoring manual. San Antonio, TX: The Psychological Corporation; Wechsler, D., (2009) Wechsler Memory Scale-Fourth Edition, , San Antonio, TX: The Psychological Corporation; White, H., A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity (1980) Econometrica, 48, pp. 817-830; Wilmer, J.B., Germine, L., Chabris, C.F., Chatterjee, G., Gerbasi, M., Nakayama, K., Capturing specific abilities as a window into human individuality: The example of face recognition (2012) Cognitive Neuropsychology, 2956, pp. 360-392. , doi: 10.1080/02643294.2012.753433; Yan, J.H., Dick, M.B., Practice effects on motor control in healthy seniors and patients with mild cognitive impairment or mild Alzheimers disease (2006) Aging, Neuropsychology, and Cognition, 13, pp. 385-410. , doi: 10.1080/138255890969609oi; Yan, J.H., Rountree, S., Massman, P., Doody, R.S., Li, H., Alzheimers disease and mild cognitive impairment deteriorate fine motor control (2008) Journal of Psychiatric Research, 42, pp. 1203-1212. , doi: 10.1016/j.psychires.2008.01.006",Article,Scopus,2-s2.0-84903784956
